{"generated":"2026-09-04T11:36:38Z","content_changed":"2026-09-03T17:37:17Z","count":8499,"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","note":"Auteurs (minstens twee artikelen) en sprekers, afgeleid uit de inhoud; titels van hun artikelen staan in articles.json; dutch_institution = affiliatie bij een Nederlands instituut voor zover bekend (title).","people":[{"id":"scott-d-solomon","type":"person","url":"https://hartvaat.nl/mensen/scott-d-solomon/","name":"Scott D Solomon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":141,"articles":[{"url":"https://hartvaat.nl/2026/08/26/vutrisiran-stabiliseert-rechterventrikel-functie-bij-attr-cardiomyopathie-helios/","published":"2026-09-03"},{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/06/26/finerenone-verlaagt-hart-en-vaatrisico-via-vroege-daling-van-uacr-en-systolische/","published":"2026-08-06"},{"url":"https://hartvaat.nl/2026/05/11/finearts-hf-subanalyse-virale-luchtweginfecties-triggeren-hartfalen-verslechteri/","published":"2026-05-12"},{"url":"https://hartvaat.nl/2026/05/09/meta-analyse-decision-digit-hf-dig-digitalisglycosiden-reduceren-verslechterende/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/05/10/hf-revert-antisense-mirna-remmer-cdr132l-mist-primair-eindpunt-na-infarct-met-ve/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2026/03/05/aficamten-veilig-en-effectief-bij-langdurige-behandeling-van-obstructieve-hcm/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2026/01/05/magnesium-en-uitkomsten-bij-hfref-galactic-hf-subanalyse/","published":"2026-01-05"},{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/10/28/rsv-vaccin-vermindert-cv-hospitalisaties-bij-ouderen/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/02/25/ambulante-hf-verslechtering-bij-attr-cm-attr-act-subanalyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/02/25/ambulante-hartfalenverslechtering-bij-attr-cardiomyopathie-attr-act-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/nudge-flu-subanalyse-griepvaccinatie-nudges-bij-mi-langetermijn/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/01/plotse-dood-na-mi-inzichten-uit-valiant-en-paradise-mi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","published":"2024-09-21"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/07/09/selectieve-aldosereductaseremmer-bij-diabetische-cardiomyopathie-rct/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/07/02/upgrade-rv-naar-crt-pacing-bij-hartfalen-met-af-voordelen-bevestigd/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/06/25/raas-blokkade-bij-hartfalen-voordeel-onafhankelijk-van-etniciteit-jama-meta-anal/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2024/06/18/mra-bij-hartfalen-met-nierfunctiestoornissen-veiligheid-en-effectiviteit/","published":"2024-06-18"},{"url":"https://hartvaat.nl/2024/06/04/sacubitril-valsartan-bij-hartfalen-over-het-nierfunctiespectrum/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/06/01/invested-griepvaccin-immuunrespons-bij-hoog-risico-cv-patienten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/05/27/nudge-flu-elektronische-nudges-verhogen-griepvaccinatie-na-mi/","published":"2024-05-27"},{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/10/21/upgrade-van-rv-pacing-naar-crt-bij-hartfalen-gerandomiseerde-trial/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/04/sacubitril-valsartan-bij-hfmref-hfpef-met-verslechterend-hartfalen/","published":"2023-07-04"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/dosisrespons-van-sacubitril-valsartan-bij-hfref/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","published":"2022-09-03"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-niet-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/12/01/sacubitril-valsartan-uitgebreide-fda-labeling-jama-cardiology-implicaties/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2021/02/01/polsdruk-prognose-en-sacubitril-valsartan-bij-hfpef-paragon-hf/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/07/antisense-tegen-microrna-132-bij-hartfalen-fase-1b-resultaten/","published":"2021-01-07"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"deepak-l-bhatt","type":"person","url":"https://hartvaat.nl/mensen/deepak-l-bhatt/","name":"Deepak L Bhatt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":139,"articles":[{"url":"https://hartvaat.nl/2026/04/16/pcsk9-remmers-verlagen-events-bij-ascvd-zonder-eerder-infarct-of-beroerte-real-w/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2026/05/26/odyssey-outcomes-post-hoc-hscrp-en-il-6-zijn-complementaire-prognostische-marker/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2026/02/27/nieuwe-aldosteronsynthase-remmers-bij-hypertensie-bayesiaanse-meta-analyse/","published":"2026-03-08"},{"url":"https://hartvaat.nl/2026/02/19/evolocumab-en-doorgankelijkheid-van-veneuze-bypasses-na-cabg-newton-cabg-cardiol/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","published":"2025-09-20"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/01/07/optimale-strategie-voor-complete-revascularisatie-bij-stemi-met-meervatslijden-m/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/12/01/korte-dapt-na-des-bij-acs-ipd-meta-analyse-bevestigt-veiligheid/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/11/12/renale-denervatie-bij-hypertensie-uitgebreide-meta-analyse-van-alle-trials/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/06/01/invested-griepvaccin-immuunrespons-bij-hoog-risico-cv-patienten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","published":"2024-04-30"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/23/lp-a-en-cv-risicoreductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/04/01/lp-a-en-hscrp-als-cv-risicofactoren-primaire-en-secundaire-preventie/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/04/01/icosapent-ethyl-na-acs-reduce-it-subanalyse/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/12/05/intravasculaire-beeldvorming-versus-functionele-versus-angiografische-pci-begele/","published":"2023-12-05"},{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/04/15/inflammatie-en-cholesterol-als-cv-voorspellers-onder-statinetherapie-lancet-anal/","published":"2023-04-15"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/02/baxdrostat-aldosteronsynthaseremmer-bij-resistente-hypertensie-nejm-fase-2/","published":"2023-02-02"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2022/10/22/symplicity-htn-3-langetermijn-follow-up-renale-denervatie-bij-resistente-hyperte/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2022/10/18/asundexian-factor-xia-remmer-na-acs-fase-2-dosisfindingsstudie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/09/15/polypill-voor-secundaire-cardiovasculaire-preventie-secure-trial-in-nejm/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2022/09/01/collaterale-schade-van-covid-19-aan-cardiovasculaire-zorg-meta-analyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/09/01/dapagliflozine-effectief-ongeacht-cv-achtergrondmedicatie-declare-subanalyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","published":"2022-08-02"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/10/12/overbrugging-van-antiplaatjestherapie-na-pci-jacc-review/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/07/01/cv-gevolgen-van-stoppen-met-laaggedoseerd-rivaroxaban-bij-chronisch-vaatlijden/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2021/02/09/2020-acc-consensus-anticoagulatie-en-antiplaatjestherapie-bij-af-of-vte/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/11/01/klinische-toepassing-van-hs-troponine-in-het-ascvd-raamwerk-jama-cardiology/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/10/21/icosapent-ethyl-en-coronaire-atheroscleroseprogressie-bij-verhoogde-triglyceride/","published":"2020-10-21"},{"url":"https://hartvaat.nl/2020/10/13/dapt-na-pci-met-des-netwerkmeta-analyse-van-duur-en-intensiteit/","published":"2020-10-13"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2020/06/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-acs-trials-jama-cardiology/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/19/pav-en-vte-na-acs-rol-van-lp-a-en-modificatie-door-alirocumab/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/05/12/management-van-stabiel-coronairlijden-bij-diabetes-type-2-aha-scientific-stateme/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/05/01/optimaal-antitrombotisch-regime-bij-af-na-pci-jama-cardiology-netwerkmeta-analys/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/02/04/aanhoudende-ldl-verlaging-met-alirocumab-in-odyssey-outcomes/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/19/empagliflozine-en-lv-massa-bij-diabetes-type-2-met-coronairlijden-empa-heart/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/11/01/themis-en-themis-pci-editorial-perspectief/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/13/rivaroxaban-met-of-zonder-aspirine-bij-hf-met-coronair-of-perifeer-vaatlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/08/01/antitrombotische-strategieen-bij-af-na-pci-jama-cardiology-veiligheids-en-werkza/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/14/dabigatran-duale-therapie-met-ticagrelor-of-clopidogrel-na-pci-bij-af-re-dual-pc/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/04/09/sham-gecontroleerde-rct-s-van-renale-denervatie-meta-analyse/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2019/01/10/endoscopische-versus-open-veneoogst-bij-cabg-nejm-regroup/","published":"2019-01-10"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"},{"url":"https://hartvaat.nl/2019/01/03/icosapent-ethyl-en-cardiovasculaire-uitkomsten-bij-hypertriglyceridemie-nejm-red/","published":"2019-01-03"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-cv-uitkomsten-met-of-zonder-eerder-mi-leader/","published":"2018-12-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-j-v-mcmurray","type":"person","url":"https://hartvaat.nl/mensen/john-j-v-mcmurray/","name":"John J V McMurray","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":136,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2026/01/06/sacubitril-valsartan-versus-enalapril-bij-chagas-hartfalen/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2026/01/05/magnesium-en-uitkomsten-bij-hfref-galactic-hf-subanalyse/","published":"2026-01-05"},{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/11/18/2025-acc-scientific-statement-obesitasmanagement-bij-hartfalen/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/11/14/nierfunctietrajecten-voor-en-na-hospitalisatie-voor-hfref/","published":"2025-11-14"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/01/plotse-dood-na-mi-inzichten-uit-valiant-en-paradise-mi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","published":"2024-09-21"},{"url":"https://hartvaat.nl/2024/08/01/candesartan-dosering-bij-mannen-versus-vrouwen-met-chronisch-hartfalen/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/25/raas-blokkade-bij-hartfalen-voordeel-onafhankelijk-van-etniciteit-jama-meta-anal/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2024/06/18/mra-bij-hartfalen-met-nierfunctiestoornissen-veiligheid-en-effectiviteit/","published":"2024-06-18"},{"url":"https://hartvaat.nl/2024/06/04/sacubitril-valsartan-bij-hartfalen-over-het-nierfunctiespectrum/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","published":"2024-04-21"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/10/01/pa-drukmonitoring-bij-chronisch-hartfalen-meta-analyse-van-drie-rct-s/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/08/08/glp-1-agonisten-met-en-zonder-sglt2-remmers-bij-type-2-diabetes-jacc-analyse/","published":"2023-08-08"},{"url":"https://hartvaat.nl/2023/08/01/mondiale-vergelijking-van-heropnamepercentages-bij-hartfalen/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/05/15/implanteerbare-hemodynamische-monitoring-bij-hartfalen-meta-analyse-over-ef-spec/","published":"2023-05-15"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/04/01/natriumzirconiumcyclosilicaat-bij-hyperkaliemie-en-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/14/dal-gene-farmacogenetica-geleide-dalcetrapib-na-acs/","published":"2022-10-14"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","published":"2022-09-03"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-niet-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/12/01/sacubitril-valsartan-uitgebreide-fda-labeling-jama-cardiology-implicaties/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/03/31/dapagliflozine-en-mortaliteit-bij-ckd-dapa-ckd-pre-gespecificeerde-analyse/","published":"2021-03-31"},{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2021/02/01/polsdruk-prognose-en-sacubitril-valsartan-bij-hfpef-paragon-hf/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/10/08/dapagliflozine-bij-chronische-nierziekte-nejm-dapa-ckd/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/09/29/arni-en-renale-uitkomsten-bij-hfpef-paragon-hf/","published":"2020-09-29"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/07/11/levenslang-voordeel-van-uitgebreide-hfref-farmacotherapie-lancet-schatting/","published":"2020-07-11"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/04/14/systolische-bloeddruk-bij-hfpef-behandeld-met-sacubitril-valsartan-paragon-hf/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/28/eerdere-hf-hospitalisatie-en-sacubitril-valsartan-versus-valsartan-bij-hfpef-par/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"}],"videos":[{"url":"https://hartvaat.nl/video/aldosteron-ontregeling-hypertensie-esc/nieuwe-data-in-praktijk-mcmurray/","title":"Wat betekent nieuwe data voor de praktijk? — John JV McMurray"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philippe-gabriel-steg","type":"person","url":"https://hartvaat.nl/mensen/philippe-gabriel-steg/","name":"Philippe Gabriel Steg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":120,"articles":[{"url":"https://hartvaat.nl/2026/05/26/odyssey-outcomes-post-hoc-hscrp-en-il-6-zijn-complementaire-prognostische-marker/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/10/23/aspirine-bij-chronisch-coronairsyndroom-plus-oac-wel-of-niet/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2024/10/01/plotse-dood-na-mi-inzichten-uit-valiant-en-paradise-mi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","published":"2024-04-30"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/23/lp-a-en-cv-risicoreductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/04/01/icosapent-ethyl-na-acs-reduce-it-subanalyse/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","published":"2022-08-02"},{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","published":"2021-08-03"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/11/01/klinische-toepassing-van-hs-troponine-in-het-ascvd-raamwerk-jama-cardiology/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/08/25/carotisatherosclerose-evolutie-bij-ldl-streefwaarde-70-na-ischemisch-cva-tst-sub/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2020/05/19/pav-en-vte-na-acs-rol-van-lp-a-en-modificatie-door-alirocumab/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2020/03/17/klinische-en-farmacologische-effecten-van-apixaban-dosisaanpassing-aristotle/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2020/02/25/polygene-risicoscore-en-voordeel-van-alirocumab-bij-coronairlijden-odyssey-outco/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2020/02/04/aanhoudende-ldl-verlaging-met-alirocumab-in-odyssey-outcomes/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2020/01/02/vergelijking-van-twee-ldl-streefwaarden-na-ischemisch-cva-nejm-tst/","published":"2020-01-02"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/11/01/themis-en-themis-pci-editorial-perspectief/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/05/14/dabigatran-duale-therapie-met-ticagrelor-of-clopidogrel-na-pci-bij-af-re-dual-pc/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2019/01/03/icosapent-ethyl-en-cardiovasculaire-uitkomsten-bij-hypertriglyceridemie-nejm-red/","published":"2019-01-03"},{"url":"https://hartvaat.nl/2018/12/07/laesiecomplexiteit-en-periprocedurele-events-bij-potente-iv-antiplaatjestherapie/","published":"2018-12-07"},{"url":"https://hartvaat.nl/2018/12/01/multipele-biomarkers-en-mortaliteitsrisico-na-acs-jama-cardiology/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/08/14/adma-en-sdma-voorspellen-uitkomsten-bij-af-aristotle-substudie/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/05/14/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-meta-analyse/","published":"2018-05-14"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2018/02/01/cv-uitkomsten-naar-albumin-en-nierziekte-bij-diabetes-type-2-met-hoog-cv-risico/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/11/14/timing-van-angiografie-bij-hoogrisico-nstemi-acuity-analyse/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/10/31/laesiecomplexiteit-en-uitkomsten-van-verlengde-dapt-na-pci/","published":"2017-10-31"},{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","published":"2017-10-19"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-bij-stabiel-coronairlijden-stability-inzic/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2017/08/01/kosteneffectiviteit-van-langdurig-ticagrelor-na-mi-pegasus-timi-54/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/07/01/1-jaarsmortaliteit-bivalirudine-versus-heparine-in-de-ambulance-bij-stemi-matrix/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/02/01/cangrelor-versus-gpiib-iiia-remmers-ischemie-en-bloedingsrisico-s-vergeleken/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/01/17/cangrelor-met-en-zonder-gpiib-iiia-remmers-bij-pci/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/11/29/presentatie-buiten-kantoortijden-versus-tijdens-kantoortijden-bij-stemi-champion/","published":"2016-11-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gregg-w-stone","type":"person","url":"https://hartvaat.nl/mensen/gregg-w-stone/","name":"Gregg W Stone","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":107,"articles":[{"url":"https://hartvaat.nl/2025/09/23/pci-versus-cabg-en-gezondheidsstatus-bij-stabiel-coronairlijden/","published":"2025-09-23"},{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2025/07/15/oct-gebaseerde-post-pci-fysiologiebeoordeling-voorspelt-klinische-uitkomsten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/04/12/orbitale-atherectomie-versus-ballonangioplastie-voor-des-bij-ernstig-verkalkte-l/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2025/01/07/optimale-strategie-voor-complete-revascularisatie-bij-stemi-met-meervatslijden-m/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/01/korte-dapt-na-des-bij-acs-ipd-meta-analyse-bevestigt-veiligheid/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/01/opt-birisk-clopidogrel-monotherapie-bij-acs-met-hoog-ischemisch-en-bloedingsrisi/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/05/11/ivus-acs-ivus-geleide-pci-bij-acs-superieur-lancet/","published":"2024-05-11"},{"url":"https://hartvaat.nl/2024/05/11/ticagrelor-monotherapie-versus-dapt-na-1-maand-bij-acs-lancet-rct/","published":"2024-05-11"},{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","published":"2024-05-04"},{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2024/03/02/intravasculaire-beeldvorming-bij-des-implantatie-lancet-netwerk-meta-analyse/","published":"2024-03-02"},{"url":"https://hartvaat.nl/2023/12/05/intravasculaire-beeldvorming-versus-functionele-versus-angiografische-pci-begele/","published":"2023-12-05"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/18/bioresorbeerbare-coronaire-scaffolds-vijfjaarsuitkomsten-met-verbeterde-techniek/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2022/11/26/bivalirudine-versus-heparine-bij-primaire-pci-voor-stemi-lancet-trial/","published":"2022-11-26"},{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","published":"2022-11-15"},{"url":"https://hartvaat.nl/2022/05/01/nierdisfunctie-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2022/01/18/magnetisch-gecontroleerde-capsule-endoscopie-voor-antiplaatjestherapie-gi-schade/","published":"2022-01-18"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2021/07/15/ultradunne-versus-conventionele-2e-generatie-des-langetermijn-meta-analyse/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2021/04/01/ero-lvedv-ratio-en-respons-op-mitraclip-jama-cardiology/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/10/13/dapt-na-pci-met-des-netwerkmeta-analyse-van-duur-en-intensiteit/","published":"2020-10-13"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/09/07/des-versus-cabg-bij-hoofdstamlijden-mortaliteits-meta-analyse/","published":"2020-09-07"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/09/01/routine-revascularisatie-versus-medicamenteus-bij-stabiel-coronairlijden-meta-an/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2020/05/05/gezondheidsstatus-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/23/gezondheidsstatus-na-invasieve-of-conservatieve-zorg-bij-coronairlijden-met-gevo/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/14/langetermijnuitkomsten-bij-vrouwen-en-mannen-na-pci/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/12/17/echo-uitkomsten-na-mitraclip-bij-secundaire-mr-coapt-echocardiografisch/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/12/01/absorb-scaffold-5-jaarsresultaten-systematische-meta-analyse/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/08/13/off-pump-versus-on-pump-cabg-bij-hoofdstamcoronairlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/05/07/gezondheidsstatus-na-mitraclip-bij-hf-met-secundaire-mr-coapt/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/04/23/hedendaagse-uitkomsten-na-cabg-voor-hoofdstamlijden/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"},{"url":"https://hartvaat.nl/2018/12/07/laesiecomplexiteit-en-periprocedurele-events-bij-potente-iv-antiplaatjestherapie/","published":"2018-12-07"},{"url":"https://hartvaat.nl/2018/11/13/ultradunne-versus-dikkere-drug-eluting-stents-systematische-review/","published":"2018-11-13"},{"url":"https://hartvaat.nl/2018/10/27/absorb-iv-bioresorbeerbare-scaffold-30-daags-en-1-jaarsresultaten/","published":"2018-10-27"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/07/31/bnp-bij-linker-hoofdstamrevascularisatie-excel-analyse/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2018/02/13/richtlijngetrouwe-medicamenteuze-therapie-in-contemporaine-revascularisatietrial/","published":"2018-02-13"},{"url":"https://hartvaat.nl/2018/01/30/absorb-bioresorbeerbare-scaffold-3-jaarsresultaten-ipd-meta-analyse/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"},{"url":"https://hartvaat.nl/2017/12/12/implantatiechniek-en-uitkomsten-van-bioresorbeerbare-scaffolds-absorb-analyses/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/12/12/3-jaarsresultaten-van-bioresorbeerbare-scaffolds-absorb-iii-trial/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"},{"url":"https://hartvaat.nl/2017/10/10/dagelijks-ischemie-en-bloedingsrisico-na-primaire-pci-voor-stemi/","published":"2017-10-10"},{"url":"https://hartvaat.nl/2017/10/03/ridaforolimus-versus-zotarolimus-eluting-stents-gerandomiseerde-primaire-resulta/","published":"2017-10-03"},{"url":"https://hartvaat.nl/2017/08/19/absorb-bioresorbeerbare-scaffold-lancet-2-jaars-systematische-review-en-meta-ana/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2017/06/01/korte-procedureduur-met-bivalirudine-en-risico-op-acute-stenttrombose-bij-stemi/","published":"2017-06-01"},{"url":"https://hartvaat.nl/2017/05/09/ranolazine-na-incomplete-pci-bij-diabetes-versus-zonder-diabetes-river-pci/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2017/02/01/cangrelor-versus-gpiib-iiia-remmers-ischemie-en-bloedingsrisico-s-vergeleken/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/01/17/cangrelor-met-en-zonder-gpiib-iiia-remmers-bij-pci/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/12/20/bloedingen-voor-coronairangiografie-bij-nste-acs/","published":"2016-12-20"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"},{"url":"https://hartvaat.nl/2016/11/29/presentatie-buiten-kantoortijden-versus-tijdens-kantoortijden-bij-stemi-champion/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/11/26/oct-versus-ivus-versus-angiografie-bij-coronaire-stentimplantatie-lancet-ilumien/","published":"2016-11-26"},{"url":"https://hartvaat.nl/2016/09/06/consistente-reductie-in-periprocedureel-mi-met-cangrelor-champion-analyses/","published":"2016-09-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"javed-butler","type":"person","url":"https://hartvaat.nl/mensen/javed-butler/","name":"Javed Butler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":105,"articles":[{"url":"https://hartvaat.nl/2026/08/21/lipidparadox-bij-kanker-ldl-c-dekt-de-lading-niet-voor-cardiovasculair-risico/","published":"2026-08-30"},{"url":"https://hartvaat.nl/2026/08/18/c-mic-apparaat-vermindert-hartfalen-ernst-onafhankelijk-van-gdmt-aanpassingen-c-/","published":"2026-08-25"},{"url":"https://hartvaat.nl/2026/05/05/apture-shunt-verlaagt-hartfalen-heropnames-bij-patienten-met-hfpef-hfmref-alt-fl/","published":"2026-07-30"},{"url":"https://hartvaat.nl/2026/04/07/confident-hfpef-machine-learning-voorspelt-sterfte-en-opname-beter-dan-bestaande/","published":"2026-07-20"},{"url":"https://hartvaat.nl/2026/04/21/jacc-beschouwing-placebo-in-trials-met-incretine-therapie-bij-hartfalen-wetensch/","published":"2026-07-18"},{"url":"https://hartvaat.nl/2026/03/03/tien-jaar-real-world-sacubitril-valsartan-mortaliteitsreductie-bevestigd-maar-sl/","published":"2026-04-20"},{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/03/03/c-mic-ii-hartfunctie-inspanningscapaciteit-en-kwaliteit-van-leven-zijn-verwante-/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2025/01/01/hartfalenpreventie-bewijsgeneratie-trialontwerp-en-regulatoire-trajecten/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/16/farmacologische-behandeling-van-hfref-geactualiseerde-systematische-review/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/12/01/hfpef-fenotypen-in-device-en-chirurgische-trials-karakterisatie/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/05/13/empagliflozine-erytropoese-en-ijzermobilisatie-bij-hartfalen/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/04/01/vericiguat-voordeel-geprojecteerd-op-paradigm-hf-en-dapa-hf-populaties/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/04/01/cardiale-akoestische-biomarkers-bij-hartfalenmonitoring-systematische-review/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/11/12/sglt2-remming-en-proteomische-handtekeningen-bij-hartfalen-bevestiging/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/af-en-semaglutide-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/05/iv-ferricarboxymaltose-en-inspanningscapaciteit-bij-hfpef-met-ijzerdeficientie/","published":"2024-10-05"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/24/2024-acc-beslispad-klinische-beoordeling-en-trajectmanagement-bij-hfpef/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","published":"2024-08-27"},{"url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/07/09/selectieve-aldosereductaseremmer-bij-diabetische-cardiomyopathie-rct/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2024/04/16/2024-acc-expert-consensus-behandeling-van-hfref-beslispad-geactualiseerd/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2023/12/21/iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-ipd-meta-analyse/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2023/09/26/geblindeerde-stopstudie-voordelen-empagliflozine-verdwijnen-na-staken-bij-hf/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2023/09/14/heart-fid-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-nejm/","published":"2023-09-14"},{"url":"https://hartvaat.nl/2023/07/18/sglt2-remmers-verbeteren-kwaliteit-van-leven-gelijk-bij-zwarte-en-witte-hartfale/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2022/12/21/empagliflozine-en-het-circulerend-proteoom-bij-hartfalen-emperor-mechanismen/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/11/01/empagliflozine-vermindert-albuminurie-bij-hartfalen-emperor-pooled-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/dosisrespons-van-sacubitril-valsartan-bij-hfref/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/04/06/nierfunctiebeoordeling-en-eindpuntbepaling-in-klinische-trials-ehj/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2022/04/01/robuustheid-van-sglt2-remmer-hf-trials-evaluatie/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2022/02/08/stress-cardiale-biomarkers-en-cv-renale-uitkomsten-bij-canagliflozine/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/10/19/diabetes-met-cardiomyopathie-in-de-community-prevalentie-en-prognose/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-en-renale-uitkomsten-bij-hartfalen-nejm-emperor-reduced-renal/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/09/28/nt-probnp-prognose-en-empagliflozine-effect-bij-emperor-reduced/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2021/07/13/finerenon-vermindert-nieuw-onset-af-bij-ckd-met-diabetes-fidelio-dkd/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/04/27/2021-acc-aha-kerngegevenselementen-voor-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/03/23/mra-en-empagliflozine-interactie-bij-hf-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/03/23/empagliflozine-bij-hfref-met-volume-overbelasting-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/02/16/2021-acc-hf-behandeloptimalisatie-update-antwoorden-op-10-cruciale-vragen/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/02/01/zelfzorginterventie-en-90-daags-uitkomsten-bij-acuut-hf-na-seh-ontslag-jama-card/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/12/01/sglt2-remmers-bij-hartfalen-systematische-review-en-meta-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/11/03/canagliflozine-en-nt-probnp-implicaties-voor-cv-risicoreductie/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/09/19/sglt2-remmers-bij-hfref-meta-analyse-van-emperor-reduced-en-dapa-hf/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2020/09/15/empagliflozine-bij-hartfalen-diuretische-en-cardiorenale-effecten/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/06/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-acs-trials-jama-cardiology/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2018/10/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-hf-trials-jama-cardiology-review/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/02/01/empagliflozine-en-cv-dood-en-hf-hospitalisatie-over-het-hf-spectrum-empa-reg-out/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/11/01/raas-blokkade-bij-hfpef-systematische-review-en-meta-analyse/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/08/08/canagliflozine-en-cardiovasculaire-biomarkers-bij-oudere-diabetespatienten/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/07/trv027-biased-ligand-van-de-angiotensine-ii-receptor-bij-acuut-hartfalen-gerando/","published":"2017-08-07"},{"url":"https://hartvaat.nl/2017/06/27/hospitalisatie-voor-nieuw-gediagnosticeerd-versus-verslechterend-chronisch-hartf/","published":"2017-06-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marc-s-sabatine","type":"person","url":"https://hartvaat.nl/mensen/marc-s-sabatine/","name":"Marc S Sabatine","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":105,"articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2026/01/13/effectiviteit-en-veiligheid-van-zeer-laag-bereikt-ldl-na-ischemisch-cva/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","published":"2025-10-02"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/05/20/intensieve-ldl-verlaging-met-evolocumab-bij-auto-immuunziekten-rct/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/02/11/langetermijn-evolocumab-bij-ouderen-effectiviteit-en-veiligheid/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-hypertriglyceridemie-en-hoog-cv-risico-nejm/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/04/01/lp-a-en-hscrp-als-cv-risicofactoren-primaire-en-secundaire-preventie/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/11/17/olpasiran-sirna-verlaagt-lipoproteine-a-spectaculair-in-fase-2-trial/","published":"2022-11-17"},{"url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","published":"2022-10-11"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/09/01/dapagliflozine-effectief-ongeacht-cv-achtergrondmedicatie-declare-subanalyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/08/30/biomarkers-voorspellen-complexe-coronaire-revascularisatie-in-fourier/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2022/05/03/vupanorsen-en-non-hdl-cholesterol-bij-statinebehandelde-patienten-translate-timi/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/10/12/baseline-ldl-en-klinische-uitkomsten-van-ezetimibe-plus-statine-improve-it/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/02/01/evolocumab-bij-metabool-syndroom-na-acs-fourier/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/11/21/ldl-verlaging-bij-ouderen-lancet-meta-analyse-werkzaamheid-en-veiligheid/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/11/01/klinische-toepassing-van-hs-troponine-in-het-ascvd-raamwerk-jama-cardiology/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/08/11/veiligheid-van-aspirinestaken-met-p2y12-achtergrond-na-pci-meta-analyse/","published":"2020-08-11"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/12/cognitie-na-ldl-verlaging-met-evolocumab-fourier-follow-up/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/03/17/non-culprit-mi-na-pci-bij-acs/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2020/02/25/genetische-risicoscore-voorspelt-voordeel-van-evolocumab-fourier/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2020/01/28/morfine-en-cv-uitkomsten-bij-nste-acs-jacc-analyse/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/12/17/uitkomsten-van-vrouwen-versus-mannen-na-nste-acs/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/29/langetermijn-werkzaamheid-en-veiligheid-van-evolocumab-bij-hypercholesterolemie/","published":"2019-10-29"},{"url":"https://hartvaat.nl/2019/10/15/triglyceridenverlaging-en-cv-risicoreductie-over-therapeutische-klassen-meta-ana/","published":"2019-10-15"},{"url":"https://hartvaat.nl/2019/09/01/persisterende-arteriele-wandinflammatie-bij-verhoogd-lp-a-ondanks-lage-ldl/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/01/evolocumab-en-totale-cv-events-bij-cardiovasculaire-ziekte-fourier-analyse/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/18/evolocumab-bij-ckd-werkzaamheid-en-veiligheid-in-de-fourier-trial/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"},{"url":"https://hartvaat.nl/2019/01/01/interindividuele-variatie-in-ldl-verlaging-met-evolocumab-fourier-analyse/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2018/09/01/verdere-ldl-verlaging-bij-reeds-zeer-lage-niveaus-jama-cardiology-meta-analyse/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/08/21/klinisch-voordeel-van-evolocumab-naar-ernst-van-coronairlijden-fourier/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/07/10/inflammatie-en-cholesterol-in-de-fourier-trial/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/06/01/fgf-23-en-recidiverende-cv-events-na-acs/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/12/01/evolocumab-bij-hoogrisicopatienten-met-laag-ldl-op-statine-fourier-subanalyse/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2017/11/14/timing-van-angiografie-bij-hoogrisico-nstemi-acuity-analyse/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2017/08/17/cognitieve-functie-in-de-fourier-trial-met-evolocumab-nejm-ebbinghaus/","published":"2017-08-17"},{"url":"https://hartvaat.nl/2017/08/01/kosteneffectiviteit-van-langdurig-ticagrelor-na-mi-pegasus-timi-54/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/05/04/evolocumab-en-klinische-uitkomsten-bij-cardiovasculaire-ziekte-nejm-fourier/","published":"2017-05-04"},{"url":"https://hartvaat.nl/2016/09/27/ldl-c-verlaging-en-cardiovasculaire-risicoreductie-jama-systematische-review-en-/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/09/20/cva-preventie-met-ticagrelor-na-myocardinfarct-pegasus-timi-54-inzichten/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/07/26/atherotrombotische-risicostratificatie-en-vorapaxar-bij-stabiel-ischemisch-hartl/","published":"2016-07-26"},{"url":"https://hartvaat.nl/2016/07/19/serieel-cardiaal-troponine-met-hoog-sensitieve-assay-bij-stabiel-ischemisch-hart/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/06/14/reductie-van-ischemische-events-met-ticagrelor-bij-diabetes-na-myocardinfarct-pe/","published":"2016-06-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-nicolas-van-mieghem","type":"person","url":"https://hartvaat.nl/mensen/prof-nicolas-van-mieghem/","name":"Nicolas Van Mieghem","title":"Hoogleraar Interventiecardiologie","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":2,"articles":[{"url":"https://hartvaat.nl/2026/04/16/pandora-register-supra-versus-intra-annulaire-kleppen-bij-tavr-in-tavr/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-trials-to-watch-gesprek/","title":"ESC 2026 Trials to Watch: het volledige gesprek"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-acacia-hcm/","title":"ACACIA-HCM: kan aficamten slagen waar andere myosineremmers faalden?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-staree/","title":"STAREE: verbeteren statines gezond ouder worden?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-amundsen/","title":"AMUNDSEN: verandert vroege PCSK9-remming de zorg na een infarct?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-premium/","title":"PREMIUM: is een aspirinevrije STEMI-behandeling de toekomst?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-a-close/","title":"A-CLOSE: is clopidogrel alleen genoeg na PCI?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-pvi-sham-af/","title":"PVI-SHAM-AF: presteert AF-ablatie beter dan placebo?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-single-af/","title":"SINGLE-AF: hebben AF-patiënten met intermediair risico antistolling nodig?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-laacs-2/","title":"LAACS-2: het linkerhartoor sluiten tijdens hartchirurgie?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-popular-ace-tavi/","title":"POPular ACE TAVI: protamine routinematig na TAVI?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-tavi-pci/","title":"TAVI PCI: revascularisatie vóór of na TAVI?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-notion-4-acasa-tavi/","title":"NOTION-4 en ACASA-TAVI: doet HALT ertoe?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-poet-ii/","title":"POET-II: kan de antibioticakuur bij endocarditis korter?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-prague-26/","title":"PRAGUE-26: verbetert kathetergerichte therapie de uitkomst bij longembolie?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-cmr-guide/","title":"CMR GUIDE: kan cardiale MRI de ICD-selectie verbeteren?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-syncope-stopper/","title":"Syncope-Stopper: vroege pacing voor sommige syncopepatiënten?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-tric-i-hf/","title":"TRIC-I-HF: verbetert tricuspidalisinterventie de uitkomsten?"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/hi-peitho-katheter-trombolyse-longembolie/","title":"HI-PEITHO: Kathetergeleide trombolyse bij intermediair-risico longembolie"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/champion-af-hartoorocclusie-versus-doacs/","title":"CHAMPION-AF: Linker hartoorocclusie versus DOAC's bij atriumfibrilleren"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/spirrit-hfpef-spironolacton-hartfalen/","title":"SPIRRIT-HFpEF: Spironolacton bij hartfalen met behouden en licht verlaagde ejectiefractie"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/stemi-dtu-ontlading-voor-primaire-pci/","title":"STEMI-DTU: Ontladingsstrategie vóór primaire PCI bij anterieur STEMI"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/chip-bcis3-impella-hoog-risico-pci/","title":"CHIP-BCIS3: Impella-ondersteuning bij hoog-risico PCI"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/orbita-cto-gecontroleerde-cto-pci/","title":"ORBITA-CTO: Placebogecontroleerde PCI bij chronische totaalocclusie"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/all-rise-fast-iii-ffrangio-vffr/","title":"ALL-RISE & FAST III: Angiografie-gebaseerde FFR versus draadgebaseerde FFR"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/optimal-beeldgeleide-pci-complex/","title":"OPTIMAL: Intravasculaire beeldgeleide PCI bij complexe coronairziekte"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/ivus-chip-echogeleide-hoog-risico-pci/","title":"IVUS-CHIP: Intravasculaire echogeleide hoog-risico PCI"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/dkcrush-viii-ivus-bifurcatie/","title":"DKCRUSH-VIII: IVUS-geleide DK Crush-techniek bij complexe bifurcatielaesies"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/pro-tavi-pci-versus-uitstel-bij-tavi/","title":"PRO-TAVI: Routinematige PCI versus uitstel bij patiënten die TAVI ondergaan"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/protect-h2h-cerebrale-bescherming-tavi/","title":"Protect H2H: Directe vergelijking van emboliebescherming tijdens TAVI"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/trifr-transcatheter-tricuspidalisreparatie/","title":"Tri.Fr: Transcatheter tricuspidalisreparatie"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/triscend-ii-evoque-tricuspidalisklepvervanging/","title":"TRISCEND II: Evoque transcatheter tricuspidalisklepvervanging bij ernstige regurgitatie"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-faiez-zannad","type":"person","url":"https://hartvaat.nl/mensen/prof-faiez-zannad/","name":"Prof. Faiez Zannad","title":"Hoogleraar cardiologie, Université de Lorraine, Nancy, Frankrijk","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":90,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/06/26/finerenone-verlaagt-hart-en-vaatrisico-via-vroege-daling-van-uacr-en-systolische/","published":"2026-08-06"},{"url":"https://hartvaat.nl/2026/05/05/sterftecijfers-in-controle-armen-van-hartfalen-rcts-dalen-niet-ondanks-betere-ac/","published":"2026-07-30"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/01/01/hartfalenpreventie-bewijsgeneratie-trialontwerp-en-regulatoire-trajecten/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/16/farmacologische-behandeling-van-hfref-geactualiseerde-systematische-review/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/11/14/nierfunctietrajecten-voor-en-na-hospitalisatie-voor-hfref/","published":"2025-11-14"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/08/05/sglt2-remmer-met-en-zonder-mra-bij-hartfalen-gecombineerde-analyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/05/13/empagliflozine-erytropoese-en-ijzermobilisatie-bij-hartfalen/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/11/12/sglt2-remming-en-proteomische-handtekeningen-bij-hartfalen-bevestiging/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","published":"2024-09-21"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/07/09/selectieve-aldosereductaseremmer-bij-diabetische-cardiomyopathie-rct/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/06/18/mra-bij-hartfalen-met-nierfunctiestoornissen-veiligheid-en-effectiviteit/","published":"2024-06-18"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2023/09/26/geblindeerde-stopstudie-voordelen-empagliflozine-verdwijnen-na-staken-bij-hf/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2023/08/01/mondiale-vergelijking-van-heropnamepercentages-bij-hartfalen/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2022/12/21/empagliflozine-en-het-circulerend-proteoom-bij-hartfalen-emperor-mechanismen/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/11/01/empagliflozine-vermindert-albuminurie-bij-hartfalen-emperor-pooled-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/04/19/therapeutische-doelen-voor-hf-via-proteomics-en-mendeliaanse-randomisatie/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2022/04/06/nierfunctiebeoordeling-en-eindpuntbepaling-in-klinische-trials-ehj/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-en-renale-uitkomsten-bij-hartfalen-nejm-emperor-reduced-renal/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/09/28/nt-probnp-prognose-en-empagliflozine-effect-bij-emperor-reduced/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/03/23/mra-en-empagliflozine-interactie-bij-hf-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/03/23/empagliflozine-bij-hfref-met-volume-overbelasting-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/02/01/polsdruk-prognose-en-sacubitril-valsartan-bij-hfpef-paragon-hf/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/09/29/arni-en-renale-uitkomsten-bij-hfpef-paragon-hf/","published":"2020-09-29"},{"url":"https://hartvaat.nl/2020/09/19/sglt2-remmers-bij-hfref-meta-analyse-van-emperor-reduced-en-dapa-hf/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/07/11/levenslang-voordeel-van-uitgebreide-hfref-farmacotherapie-lancet-schatting/","published":"2020-07-11"},{"url":"https://hartvaat.nl/2020/07/07/baroreflexactivatietherapie-bij-hfref-beat-hf/","published":"2020-07-07"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/04/14/systolische-bloeddruk-bij-hfpef-behandeld-met-sacubitril-valsartan-paragon-hf/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/04/01/biomarkers-bij-hf-met-centrale-slaapapneu-serve-hf/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2019/11/21/rivaroxaban-en-cva-tia-bij-hf-met-coronairlijden-en-sinusritme-commander-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/06/01/rivaroxaban-en-trombo-embolische-events-bij-hf-met-coronairlijden-en-sinusritme-/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/02/01/spironolacton-en-collageenmetabolisme-biomarkers-bij-ongecontroleerde-hypertensi/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/11/01/aldosteronblokkade-bij-myocardinfarct-ipd-analyse-van-twee-trials/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/10/04/rivaroxaban-bij-hartfalen-met-sinusritme-en-coronairlijden-nejm-commander-hf/","published":"2018-10-04"},{"url":"https://hartvaat.nl/2018/02/20/cva-risico-bij-verminderde-ef-na-mi-zonder-af/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/05/16/serieel-hoog-sensitief-troponine-i-en-cv-uitkomsten-bij-diabetes-type-2-examine/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2017/03/01/24-uurs-bloeddrukmonitoring-bij-renale-denervatie-denerhtn-studie/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/09/20/medicatietrouw-en-bloeddrukeffecten-van-renale-denervatie-rsd-pathway-2-analyse/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/09/01/ace-remmers-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-met-dpp-4-remmers/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/07/14/finerenon-versus-eplerenon-bij-hartfalen-met-diabetes-en-verslechterende-nierfun/","published":"2016-07-14"},{"url":"https://hartvaat.nl/2016/04/26/vroege-aldosteronblokkade-bij-acuut-myocardinfarct-de-albatross-trial/","published":"2016-04-26"}],"videos":[{"url":"https://hartvaat.nl/video/hfa-2026-late-breaking-science/masterclass-globalising-hf-zannad-van-spall/","title":"Masterclass — Hartfalen-evidence wereldwijd inclusiever maken"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"renato-d-lopes","type":"person","url":"https://hartvaat.nl/mensen/renato-d-lopes/","name":"Renato D Lopes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":92,"articles":[{"url":"https://hartvaat.nl/2026/03/17/answer-hf-sacubitril-valsartan-versus-enalapril-bij-chagas-hf-primaire-resultate/","published":"2026-03-17"},{"url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2026/01/06/sacubitril-valsartan-versus-enalapril-bij-chagas-hartfalen/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/03/25/antitrombotische-therapie-bij-af-na-acs-pci-augustus-gecombineerde-inzichten/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/12/01/korte-dapt-na-des-bij-acs-ipd-meta-analyse-bevestigt-veiligheid/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/11/26/artesia-subanalyse-cva-risico-naar-frequentie-en-duur-van-subclinisch-af/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/11/19/screening-op-niet-gediagnosticeerd-af-voor-cva-preventie-gerandomiseerde-trial/","published":"2024-11-19"},{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2024/09/10/tact-2-chelatietherapie-na-mi-bij-diabetes-negatieve-trial/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/09/03/augustus-4-weg-vergelijking-antitrombotische-strategieen-bij-af-na-acs-pci/","published":"2024-09-03"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/07/16/interventie-voor-evidence-based-zorg-bij-diabetes-en-cv-risico/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/03/26/doac-s-bij-device-gedetecteerd-af-meta-analyse-noah-afnet-6-en-artesia/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/04/18/gecoordineerde-zorg-optimaliseert-cv-preventie-bij-type-2-diabetes-jama-rct/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2023/03/28/amplitude-o-dosisrespons-van-efpeglenatide-op-cv-uitkomsten-bij-diabetes/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/12/06/apixaban-bij-af-op-hemodialyse-eerste-gerandomiseerde-trial/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"},{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/02/08/antitrombotische-therapie-bij-af-na-acs-of-pci-jacc-overzicht/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-niet-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/11/30/voorspellers-van-af-ontwikkeling-bij-embolic-stroke-of-undetermined-source-re-sp/","published":"2021-11-30"},{"url":"https://hartvaat.nl/2021/09/02/efpeglenatide-en-cv-en-renale-uitkomsten-bij-diabetes-type-2-nejm-amplitude-o/","published":"2021-09-02"},{"url":"https://hartvaat.nl/2021/05/01/vroegtijdig-permanent-staken-van-apixaban-of-warfarine-bij-af/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2021/01/19/stoppen-versus-doorgaan-met-ace-remmers-arb-s-bij-gehospitaliseerde-patienten-ja/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/11/26/rivaroxaban-bij-af-met-bioprothese-mitralisklep-nejm-river/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/11/01/ace2-niveaus-en-covid-19-risicofactoren-bij-af-patienten/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/05/01/optimaal-antitrombotisch-regime-bij-af-na-pci-jama-cardiology-netwerkmeta-analys/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/04/28/apixaban-versus-warfarine-bij-af-met-gevorderde-ckd/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2020/03/17/klinische-en-farmacologische-effecten-van-apixaban-dosisaanpassing-aristotle/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2020/01/07/nsaid-s-en-oac-bij-af-aristotle-analyse/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/01/antitrombotische-strategieen-bij-af-na-pci-jama-cardiology-veiligheids-en-werkza/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/05/14/verlaagde-dosis-doac-bij-af-werkzaamheid-en-veiligheid-meta-analyse/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-en-evidence-based-prescriptie-bij-hoog-cv-risico-jama-card/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/12/25/cv-en-ledemaat-uitkomsten-bij-diabetes-met-pav-euclid/","published":"2018-12-25"},{"url":"https://hartvaat.nl/2018/11/01/timing-van-atorvastatine-oplaaddosis-voor-pci-bij-acs-jama-cardiology/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/10/02/periprocedurele-uitkomsten-van-doac-versus-warfarine-bij-niet-valvulair-af/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2018/08/14/adma-en-sdma-voorspellen-uitkomsten-bij-af-aristotle-substudie/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/08/01/uitkomsten-bij-af-met-oac-bij-mitralis-of-aortakleplijden/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/03/13/digoxine-en-mortaliteit-bij-patienten-met-atriumfibrilleren/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2018/03/01/doac-plus-antiplaatjestherapie-voor-secundaire-preventie-na-acs-meta-analyse/","published":"2018-03-01"},{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","published":"2018-02-07"},{"url":"https://hartvaat.nl/2017/10/14/multifacet-interventie-voor-oac-gebruik-bij-af-lancet-impact-af/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2017/04/01/niet-ernstige-bloedingen-met-apixaban-versus-warfarine-bij-af/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/11/29/biomarkergebaseerde-cva-risicoscore-bij-atriumfibrilleren-validatie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/09/01/apixaban-5-mg-bij-af-met-hoge-leeftijd-laag-gewicht-of-hoog-creatinine-aristotle/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/07/01/apixaban-versus-warfarine-bij-af-in-relatie-tot-nierfunctie-aristotle-analyse/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","published":"2016-06-04"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"},{"url":"https://hartvaat.nl/2016/04/19/trends-in-behandeling-en-uitkomsten-bij-nste-acs-naar-leeftijd/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/04/01/biomarkers-van-inflammatie-en-cardiovasculair-risico-bij-patienten-met-atriumfib/","published":"2016-04-01"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brian-l-claggett","type":"person","url":"https://hartvaat.nl/mensen/brian-l-claggett/","name":"Brian L Claggett","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":91,"articles":[{"url":"https://hartvaat.nl/2026/08/26/vutrisiran-stabiliseert-rechterventrikel-functie-bij-attr-cardiomyopathie-helios/","published":"2026-09-03"},{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/05/11/finearts-hf-subanalyse-virale-luchtweginfecties-triggeren-hartfalen-verslechteri/","published":"2026-05-12"},{"url":"https://hartvaat.nl/2026/05/12/massieve-lvh-bij-pediatrische-hcm-vroeger-diagnose-vaker-sarcomere-variant-driev/","published":"2026-05-12"},{"url":"https://hartvaat.nl/2026/05/09/meta-analyse-decision-digit-hf-dig-digitalisglycosiden-reduceren-verslechterende/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2026/03/28/lp-a-verhoogt-risico-op-veneuze-trombo-embolie-bij-premenopauzale-vrouwen-en-hor/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/01/01/aficamten-bij-obstructieve-hcm-multidomeinanalyse-van-maple-hcm/","published":"2026-03-14"},{"url":"https://hartvaat.nl/2025/01/01/aficamten-versus-metoprolol-betere-levenskwaliteit-bij-obstructieve-hcm/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2025/01/01/timing-van-cardiovasculaire-en-renale-voordelen-van-finerenon-bij-hartfalen-en-c/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/10/28/rsv-vaccin-vermindert-cv-hospitalisaties-bij-ouderen/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/10/07/nieuwe-inspanningsherstelpatronen-als-maat-voor-cardiale-prestatie/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/nudge-flu-subanalyse-griepvaccinatie-nudges-bij-mi-langetermijn/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/01/plotse-dood-na-mi-inzichten-uit-valiant-en-paradise-mi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","published":"2024-09-21"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/04/sacubitril-valsartan-bij-hartfalen-over-het-nierfunctiespectrum/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/06/01/invested-griepvaccin-immuunrespons-bij-hoog-risico-cv-patienten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/05/27/nudge-flu-elektronische-nudges-verhogen-griepvaccinatie-na-mi/","published":"2024-05-27"},{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","published":"2022-09-03"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/12/01/sacubitril-valsartan-uitgebreide-fda-labeling-jama-cardiology-implicaties/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2021/02/01/polsdruk-prognose-en-sacubitril-valsartan-bij-hfpef-paragon-hf/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/09/29/arni-en-renale-uitkomsten-bij-hfpef-paragon-hf/","published":"2020-09-29"},{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/07/11/levenslang-voordeel-van-uitgebreide-hfref-farmacotherapie-lancet-schatting/","published":"2020-07-11"},{"url":"https://hartvaat.nl/2020/05/01/langetermijnvoordeel-van-intensieve-bloeddrukcontrole-op-resterende-levensduur-s/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/04/14/systolische-bloeddruk-bij-hfpef-behandeld-met-sacubitril-valsartan-paragon-hf/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/28/eerdere-hf-hospitalisatie-en-sacubitril-valsartan-versus-valsartan-bij-hfpef-par/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2019/12/10/echocardiografische-kenmerken-bij-hfpef/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/03/26/bnp-tijdens-sacubitril-valsartan-paradigm-hf/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2019/02/26/sacubitril-valsartan-en-biomarkers-van-extracellulaire-matrixregulatie-bij-hfref/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/12/01/number-needed-to-treat-met-arni-voor-preventie-van-cv-dood-of-hf-hospitalisatie/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/10/01/natriuretische-peptiden-en-cardiovasculaire-prognose-bij-hfpef-topcat/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/06/01/sacubitril-valsartan-en-fysieke-en-sociale-activiteitsbeperkingen-bij-hf-paradig/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/04/10/geen-verband-tussen-hartfalen-en-kankerincidentie/","published":"2018-04-10"},{"url":"https://hartvaat.nl/2017/09/12/lichamelijke-activiteit-en-prognose-bij-hfpef-topcat-analyse/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2017/03/07/cva-risico-bij-chronisch-hartfalen-met-behouden-ef-zonder-af-charm-analyse/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2017/01/01/verminderd-hyperkaliemierisico-met-mra-door-sacubitril-valsartan-bij-hartfalen/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/12/06/prognostische-implicaties-van-nt-probnp-veranderingen-bij-hartfalen/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/11/29/bmi-en-nauwkeurigheid-van-nt-probnp-en-bnp-voor-diagnose-van-acuut-hartfalen/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/07/19/sacubitril-valsartan-en-30-daagse-heropname-na-hartfalenhospitalisatie/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/02/01/regionale-hartdisfunctie-en-prognose-na-myocardinfarct-met-lv-disfunctie-of-hart/","published":"2016-02-01"},{"url":"https://hartvaat.nl/2016/02/01/invloed-van-ejectiefractie-op-uitkomsten-van-spironolacton-bij-hfpef/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"akshay-s-desai","type":"person","url":"https://hartvaat.nl/mensen/akshay-s-desai/","name":"Akshay S Desai","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":87,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2026/05/09/meta-analyse-decision-digit-hf-dig-digitalisglycosiden-reduceren-verslechterende/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/01/01/ai-voorspelt-hartfalen-op-basis-van-12-afleidingen-ecg-in-grote-cohortanalyse/","published":"2026-03-17"},{"url":"https://hartvaat.nl/2025/01/01/timing-van-cardiovasculaire-en-renale-voordelen-van-finerenon-bij-hartfalen-en-c/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/kardia-2-zilebesiran-als-toevoeging-bij-ongecontroleerde-hypertensie-rct/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","published":"2024-09-21"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/04/sacubitril-valsartan-bij-hartfalen-over-het-nierfunctiespectrum/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/13/implanteerbare-hemodynamische-monitoren-verbeteren-overleving-bij-hfref/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/20/zilebesiran-rna-interferentietherapie-voor-hypertensie-nejm/","published":"2023-07-20"},{"url":"https://hartvaat.nl/2023/07/04/sacubitril-valsartan-bij-hfmref-hfpef-met-verslechterend-hartfalen/","published":"2023-07-04"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/04/01/natriumzirconiumcyclosilicaat-bij-hyperkaliemie-en-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","published":"2022-09-03"},{"url":"https://hartvaat.nl/2022/07/14/guide-hf-en-de-impact-van-covid-19-op-hartfalenuitkomsten/","published":"2022-07-14"},{"url":"https://hartvaat.nl/2021/09/11/hemodynamisch-geleid-hf-management-lancet-guide-hf/","published":"2021-09-11"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/28/eerdere-hf-hospitalisatie-en-sacubitril-valsartan-versus-valsartan-bij-hfpef-par/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/07/sacubitril-valsartan-of-enalapril-bij-acuut-gedecompenseerd-hf-pioneer-hf-klinis/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/03/26/bnp-tijdens-sacubitril-valsartan-paradigm-hf/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2019/01/08/hfref-differentiele-impact-op-mannen-en-vrouwen/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/12/01/number-needed-to-treat-met-arni-voor-preventie-van-cv-dood-of-hf-hospitalisatie/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/10/01/natriuretische-peptiden-en-cardiovasculaire-prognose-bij-hfpef-topcat/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/06/01/maatschappelijk-werker-palliatieve-zorg-bij-hoogrisico-hf-swap-hf-pilot/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/06/01/sacubitril-valsartan-en-fysieke-en-sociale-activiteitsbeperkingen-bij-hf-paradig/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/11/14/af-type-en-uitkomsten-bij-hfref/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/01/01/verminderd-hyperkaliemierisico-met-mra-door-sacubitril-valsartan-bij-hartfalen/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/12/06/prognostische-implicaties-van-nt-probnp-veranderingen-bij-hartfalen/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/11/29/bmi-en-nauwkeurigheid-van-nt-probnp-en-bnp-voor-diagnose-van-acuut-hartfalen/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/07/19/sacubitril-valsartan-en-30-daagse-heropname-na-hartfalenhospitalisatie/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/06/11/ixmyelocel-t-bij-ischemisch-hartfalen-lancet-dubbelblinde-gerandomiseerde-trial/","published":"2016-06-11"},{"url":"https://hartvaat.nl/2016/04/21/aliskiren-enalapril-of-de-combinatie-bij-hartfalen-nejm-atmosphere-trial/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/03/19/serca2a-gentherapie-bij-hartfalen-de-cupid-2-trial/","published":"2016-03-19"},{"url":"https://hartvaat.nl/2016/02/01/invloed-van-ejectiefractie-op-uitkomsten-van-spironolacton-bij-hfpef/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-roxana-mehran","type":"person","url":"https://hartvaat.nl/mensen/prof-roxana-mehran/","name":"Prof. Roxana Mehran","title":"Icahn School of Medicine at Mount Sinai, New York, VS","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":81,"articles":[{"url":"https://hartvaat.nl/2026/05/26/esc-consensus-vrouwenhartcentra-whc-als-nieuw-zorgmodel-in-europa/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2026/02/24/yellow-iii-intracoronaire-beeldvorming-en-genexpressie-na-maximale-lipideverlagi/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2025/11/18/cv-effecten-en-verdraagbaarheid-van-glp-1-agonisten-meta-analyse/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","published":"2025-07-21"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2025/03/25/antitrombotische-therapie-bij-af-na-acs-pci-augustus-gecombineerde-inzichten/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2025/01/07/optimale-strategie-voor-complete-revascularisatie-bij-stemi-met-meervatslijden-m/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/12/01/korte-dapt-na-des-bij-acs-ipd-meta-analyse-bevestigt-veiligheid/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/09/03/augustus-4-weg-vergelijking-antitrombotische-strategieen-bij-af-na-acs-pci/","published":"2024-09-03"},{"url":"https://hartvaat.nl/2024/06/06/smart-zelf-expanderend-versus-ballonexpandeerbaar-tavr-bij-kleine-annulus-nejm/","published":"2024-06-06"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/12/05/intravasculaire-beeldvorming-versus-functionele-versus-angiografische-pci-begele/","published":"2023-12-05"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/01/mitraclip-bij-secundaire-mitralisklepinsufficientie-meta-analyse-ischemisch-vs-n/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2022/08/09/ticagrelor-dapt-en-veneuze-graftfalen-na-cabg-systematische-review/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","published":"2022-03-07"},{"url":"https://hartvaat.nl/2022/02/08/antitrombotische-therapie-bij-af-na-acs-of-pci-jacc-overzicht/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2022/01/18/2021-acc-aha-scai-richtlijn-voor-coronaire-revascularisatie-executive-summary/","published":"2022-01-18"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/10/12/overbrugging-van-antiplaatjestherapie-na-pci-jacc-review/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2021/02/09/2020-acc-consensus-anticoagulatie-en-antiplaatjestherapie-bij-af-of-vte/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2021/01/21/korte-dapt-gevolgd-door-p2y12-mono-versus-verlengde-dapt-meta-analyse/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/08/04/2020-acc-bloedingsmanagement-bij-oac-expert-consensus-decision-pathway/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/08/01/seksegerelateerde-uitkomsten-bij-hoog-bloedingsrisico-na-pci-leaders-free/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/08/01/complete-versus-culprit-only-revascularisatie-bij-stemi-jama-cardiology-meta-ana/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/06/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-acs-trials-jama-cardiology/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/01/optimaal-antitrombotisch-regime-bij-af-na-pci-jama-cardiology-netwerkmeta-analys/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/04/14/langetermijnuitkomsten-bij-vrouwen-en-mannen-na-pci/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2020/02/18/ticagrelor-met-of-zonder-aspirine-na-pci-twilight-plaatjessubstudie/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2019/08/01/antitrombotische-strategieen-bij-af-na-pci-jama-cardiology-veiligheids-en-werkza/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/07/07/orbusneich-combo-stent-japan-usa-harmonee-gerandomiseerde-multicenter-trial/","published":"2018-07-07"},{"url":"https://hartvaat.nl/2017/10/10/dagelijks-ischemie-en-bloedingsrisico-na-primaire-pci-voor-stemi/","published":"2017-10-10"},{"url":"https://hartvaat.nl/2017/06/01/korte-procedureduur-met-bivalirudine-en-risico-op-acute-stenttrombose-bij-stemi/","published":"2017-06-01"},{"url":"https://hartvaat.nl/2017/05/30/polygene-risicoscore-en-relatief-voordeel-van-statinetherapie-primaire-preventie/","published":"2017-05-30"},{"url":"https://hartvaat.nl/2017/01/24/heropnames-bij-af-patienten-na-stenting-twee-antitromboticastrategieen-vergeleke/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/12/22/preventie-van-bloedingen-bij-af-patienten-die-pci-ondergaan-nejm-pioneer-af-pci/","published":"2016-12-22"},{"url":"https://hartvaat.nl/2016/12/20/bloedingen-voor-coronairangiografie-bij-nste-acs/","published":"2016-12-20"},{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"},{"url":"https://hartvaat.nl/2016/02/16/ticagrelor-versus-clopidogrel-bij-troponine-negatieve-laagrisico-acs-met-ad-hoc-/","published":"2016-02-16"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/expert-acc26-overzicht-mehran/","title":"Expertinterview: ACC.26 overzicht met Roxana Mehran"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pardeep-s-jhund","type":"person","url":"https://hartvaat.nl/mensen/pardeep-s-jhund/","name":"Pardeep S Jhund","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":83,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/01/01/kwaliteit-van-hartfalenzorg-bij-aziatische-patienten-in-de-vs/","published":"2026-04-08"},{"url":"https://hartvaat.nl/2025/01/01/timing-van-cardiovasculaire-en-renale-voordelen-van-finerenon-bij-hartfalen-en-c/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/05/magnesium-en-uitkomsten-bij-hfref-galactic-hf-subanalyse/","published":"2026-01-05"},{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","published":"2024-09-21"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/25/raas-blokkade-bij-hartfalen-voordeel-onafhankelijk-van-etniciteit-jama-meta-anal/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2024/06/18/mra-bij-hartfalen-met-nierfunctiestoornissen-veiligheid-en-effectiviteit/","published":"2024-06-18"},{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/10/01/pa-drukmonitoring-bij-chronisch-hartfalen-meta-analyse-van-drie-rct-s/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/05/15/implanteerbare-hemodynamische-monitoring-bij-hartfalen-meta-analyse-over-ef-spec/","published":"2023-05-15"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","published":"2022-09-03"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2021/12/01/hartfalen-en-atriumflutter-systematische-review/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/29/arni-en-renale-uitkomsten-bij-hfpef-paragon-hf/","published":"2020-09-29"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/07/11/levenslang-voordeel-van-uitgebreide-hfref-farmacotherapie-lancet-schatting/","published":"2020-07-11"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2019/01/08/hfref-differentiele-impact-op-mannen-en-vrouwen/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/10/01/associatie-is-geen-causaliteit-behandeleffecten-bij-hartfalen-en-observationele-/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/11/14/af-type-en-uitkomsten-bij-hfref/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/04/14/systolische-bloeddruk-en-werkzaamheid-van-sacubitril-valsartan-bij-chronisch-hfr/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/03/07/cva-risico-bij-chronisch-hartfalen-met-behouden-ef-zonder-af-charm-analyse/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2017/02/21/diabetesstatus-en-cardiovasculaire-uitkomsten-bij-hfpef-klinische-en-echocardiog/","published":"2017-02-21"},{"url":"https://hartvaat.nl/2016/11/01/tienjaarsuitkomsten-na-cabg-naar-leeftijd-bij-hartfalen-met-lv-systolische-disfu/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/06/07/klinische-verslechtering-van-poliklinisch-behandeld-hartfalen-paradigm-hf-analys/","published":"2016-06-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"muthiah-vaduganathan","type":"person","url":"https://hartvaat.nl/mensen/muthiah-vaduganathan/","name":"Muthiah Vaduganathan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":79,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/06/26/finerenone-verlaagt-hart-en-vaatrisico-via-vroege-daling-van-uacr-en-systolische/","published":"2026-08-06"},{"url":"https://hartvaat.nl/2026/05/19/sglt2-remmers-bij-oudere-patienten-opgenomen-voor-hfref-24-sterfte-en-16-heropna/","published":"2026-06-15"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2026/03/29/confidence-analyse-acute-egfr-daling-bij-empagliflozin-finerenone-is-reversibel-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/02/27/sglt2-remmers-bij-ernstig-verminderde-nierfunctie-data-uit-credence/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2025/01/01/hartfalenpreventie-bewijsgeneratie-trialontwerp-en-regulatoire-trajecten/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/nudge-flu-subanalyse-griepvaccinatie-nudges-bij-mi-langetermijn/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/11/26/glp-1-agonisten-alleen-en-met-sglt2-remmers-cv-renale-en-veiligheidsuitkomsten/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","published":"2024-09-21"},{"url":"https://hartvaat.nl/2024/06/18/mra-bij-hartfalen-met-nierfunctiestoornissen-veiligheid-en-effectiviteit/","published":"2024-06-18"},{"url":"https://hartvaat.nl/2024/06/04/sacubitril-valsartan-bij-hartfalen-over-het-nierfunctiespectrum/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/27/nudge-flu-elektronische-nudges-verhogen-griepvaccinatie-na-mi/","published":"2024-05-27"},{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/22/symplicity-htn-3-langetermijn-follow-up-renale-denervatie-bij-resistente-hyperte/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","published":"2022-09-03"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/04/01/robuustheid-van-sglt2-remmer-hf-trials-evaluatie/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2022/02/08/stress-cardiale-biomarkers-en-cv-renale-uitkomsten-bij-canagliflozine/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/12/01/sacubitril-valsartan-uitgebreide-fda-labeling-jama-cardiology-implicaties/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/10/19/diabetes-met-cardiomyopathie-in-de-community-prevalentie-en-prognose/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/08/01/gdf-15-en-liraglutide-behandeling-bij-hf-patienten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/12/01/sglt2-remmers-bij-hartfalen-systematische-review-en-meta-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/07/11/levenslang-voordeel-van-uitgebreide-hfref-farmacotherapie-lancet-schatting/","published":"2020-07-11"},{"url":"https://hartvaat.nl/2020/06/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-acs-trials-jama-cardiology/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/01/langetermijnvoordeel-van-intensieve-bloeddrukcontrole-op-resterende-levensduur-s/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/04/14/systolische-bloeddruk-bij-hfpef-behandeld-met-sacubitril-valsartan-paragon-hf/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/28/eerdere-hf-hospitalisatie-en-sacubitril-valsartan-versus-valsartan-bij-hfpef-par/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/21/rivaroxaban-en-cva-tia-bij-hf-met-coronairlijden-en-sinusritme-commander-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/05/21/vroegtijdig-staken-van-ticagrelor-bij-secundaire-cv-preventie-jacc-review/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2019/03/26/bnp-tijdens-sacubitril-valsartan-paradigm-hf/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2018/10/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-hf-trials-jama-cardiology-review/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/10/01/natriuretische-peptiden-en-cardiovasculaire-prognose-bij-hfpef-topcat/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/02/07/doodsoorzaken-bij-hartfalen-met-behouden-ejectiefractie/","published":"2017-02-07"},{"url":"https://hartvaat.nl/2017/02/01/cangrelor-versus-gpiib-iiia-remmers-ischemie-en-bloedingsrisico-s-vergeleken/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/01/17/cangrelor-met-en-zonder-gpiib-iiia-remmers-bij-pci/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/04/12/protonpompremmers-verminderen-gastro-intestinale-events-ongeacht-aspirinedosis-b/","published":"2016-04-12"}],"videos":[{"url":"https://hartvaat.nl/video/aldosteron-ontregeling-hypertensie-esc/nieuwe-data-in-praktijk-vaduganathan/","title":"Wat betekent nieuwe data voor de praktijk? — Muthiah Vaduganathan"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-p-giugliano","type":"person","url":"https://hartvaat.nl/mensen/robert-p-giugliano/","name":"Robert P Giugliano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":82,"articles":[{"url":"https://hartvaat.nl/2026/08/25/extracraniale-bloedingen-komen-bij-26-van-af-patienten-op-antistolling-voor-comb/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/24/systemische-embolieen-bij-af-ipd-mega-meta-analyse-van-71-683-patienten/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2026/01/13/effectiviteit-en-veiligheid-van-zeer-laag-bereikt-ldl-na-ischemisch-cva/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","published":"2025-10-02"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/05/20/intensieve-ldl-verlaging-met-evolocumab-bij-auto-immuunziekten-rct/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/02/11/langetermijn-evolocumab-bij-ouderen-effectiviteit-en-veiligheid/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2024/09/01/eldercare-af-subanalyse-dosisreductie-edoxaban-bij-80-jarigen-met-af/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-hypertriglyceridemie-en-hoog-cv-risico-nejm/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/04/01/lp-a-en-hscrp-als-cv-risicofactoren-primaire-en-secundaire-preventie/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","published":"2023-05-21"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/12/01/serieel-hoog-sensitief-troponine-t-voorspelt-cv-events-na-acs-odyssey-analyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","published":"2022-10-11"},{"url":"https://hartvaat.nl/2022/08/30/biomarkers-voorspellen-complexe-coronaire-revascularisatie-in-fourier/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/10/12/baseline-ldl-en-klinische-uitkomsten-van-ezetimibe-plus-statine-improve-it/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/03/09/halve-versus-volle-dosis-edoxaban-bij-af-gerandomiseerde-vergelijking/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2021/02/01/evolocumab-bij-metabool-syndroom-na-acs-fourier/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/11/21/ldl-verlaging-bij-ouderen-lancet-meta-analyse-werkzaamheid-en-veiligheid/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/12/cognitie-na-ldl-verlaging-met-evolocumab-fourier-follow-up/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/02/25/genetische-risicoscore-voorspelt-voordeel-van-evolocumab-fourier/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/28/morfine-en-cv-uitkomsten-bij-nste-acs-jacc-analyse/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2019/12/17/uitkomsten-van-vrouwen-versus-mannen-na-nste-acs/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/10/29/langetermijn-werkzaamheid-en-veiligheid-van-evolocumab-bij-hypercholesterolemie/","published":"2019-10-29"},{"url":"https://hartvaat.nl/2019/10/15/triglyceridenverlaging-en-cv-risicoreductie-over-therapeutische-klassen-meta-ana/","published":"2019-10-15"},{"url":"https://hartvaat.nl/2019/09/01/simvastatine-ezetimibe-versus-simvastatine-na-acs-bij-75-plussers-jama-cardiolog/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/09/01/edoxaban-versus-warfarine-naar-gemiddelde-bloeddruk-bij-af-met-hypertensie/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/16/edoxaban-versus-warfarine-bij-af-met-leverziekte-engage-af-timi-48/","published":"2019-07-16"},{"url":"https://hartvaat.nl/2019/07/01/evolocumab-en-totale-cv-events-bij-cardiovasculaire-ziekte-fourier-analyse/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/18/evolocumab-bij-ckd-werkzaamheid-en-veiligheid-in-de-fourier-trial/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/05/14/bmi-en-uitkomsten-bij-af-behandeld-met-edoxaban-of-warfarine-engage-af-timi-48/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/05/14/verlaagde-dosis-doac-bij-af-werkzaamheid-en-veiligheid-meta-analyse/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/05/14/edoxaban-bij-aziatische-af-patienten-concentraties-en-anti-xa-activiteit/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2019/02/05/abc-scores-voor-cva-en-bloedingsrisico-bij-af-prestatieverbetering/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2019/02/01/edoxaban-en-implanteerbare-cardiale-devices-engage-af-timi-48/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2019/01/01/interindividuele-variatie-in-ldl-verlaging-met-evolocumab-fourier-analyse/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/10/30/endogene-factor-xa-activiteit-en-edoxaban-farmacodynamische-marker-en-klinische-/","published":"2018-10-30"},{"url":"https://hartvaat.nl/2018/09/25/edoxaban-versus-warfarine-bij-latijns-amerikaanse-af-patienten-engage-af-timi-48/","published":"2018-09-25"},{"url":"https://hartvaat.nl/2018/09/01/verdere-ldl-verlaging-bij-reeds-zeer-lage-niveaus-jama-cardiology-meta-analyse/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/08/21/klinisch-voordeel-van-evolocumab-naar-ernst-van-coronairlijden-fourier/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/07/10/inflammatie-en-cholesterol-in-de-fourier-trial/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/04/10/ezetimibe-bij-diabetes-versus-zonder-diabetes-improve-it-subanalyse/","published":"2018-04-10"},{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/12/19/cva-preventie-met-ezetimibe-bij-acs-improve-it-analyse/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/12/01/evolocumab-bij-hoogrisicopatienten-met-laag-ldl-op-statine-fourier-subanalyse/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2017/08/17/cognitieve-functie-in-de-fourier-trial-met-evolocumab-nejm-ebbinghaus/","published":"2017-08-17"},{"url":"https://hartvaat.nl/2017/05/04/evolocumab-en-klinische-uitkomsten-bij-cardiovasculaire-ziekte-nejm-fourier/","published":"2017-05-04"},{"url":"https://hartvaat.nl/2017/05/01/langetermijnveiligheid-van-zeer-lage-ldl-cholesterolniveaus-improve-it-analyse/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2017/03/28/edoxaban-bij-af-met-bioprothese-hartkleppen-trombo-emboliepreventie/","published":"2017-03-28"},{"url":"https://hartvaat.nl/2017/03/21/kleplijden-en-edoxaban-versus-warfarine-bij-af-engage-af-timi-48/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2017/03/21/doac-s-bij-af-met-kleplijden-jacc-review/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2017/03/21/nieuwe-risicovoorspellingsscore-bij-af-voor-netto-klinisch-resultaat-engage-af-t/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/12/21/ezetimibe-bij-post-cabg-patienten-met-acs-improve-it-subanalyse/","published":"2016-12-21"},{"url":"https://hartvaat.nl/2016/09/27/ldl-c-verlaging-en-cardiovasculaire-risicoreductie-jama-systematische-review-en-/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/09/13/edoxaban-versus-warfarine-bij-af-patienten-met-valrisico-engage-af-timi-48-analy/","published":"2016-09-13"},{"url":"https://hartvaat.nl/2016/07/05/nierfunctie-en-uitkomsten-met-edoxaban-in-de-engage-af-timi-48-trial/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/04/21/mtp-131-bij-reperfusieschade-na-stemi-de-embrace-stemi-fase-2a-trial/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/04/19/trends-in-behandeling-en-uitkomsten-bij-nste-acs-naar-leeftijd/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/02/02/reductie-in-totale-cardiovasculaire-events-met-ezetimibe-simvastatine-na-acs-imp/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"piotr-ponikowski","type":"person","url":"https://hartvaat.nl/mensen/piotr-ponikowski/","name":"Piotr Ponikowski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":79,"articles":[{"url":"https://hartvaat.nl/2026/06/26/machine-learning-voorspelt-diureticumrespons-bij-acuut-hartfalen-drc-ahf/","published":"2026-08-06"},{"url":"https://hartvaat.nl/2026/05/26/adipokineprofiel-bij-acuut-hartfalen-voorspelt-natriuretische-respons-en-mortali/","published":"2026-05-30"},{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/12/01/gelijktijdige-griep-en-rsv-vaccinatie-bij-hoogrisico-hartfalenpatienten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/04/01/vericiguat-voordeel-geprojecteerd-op-paradigm-hf-en-dapa-hf-populaties/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/02/01/transveneuze-frenische-zenuwstimulatie-bij-centraal-slaapapneu-en-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/02/01/finerenon-en-lvh-bij-ckd-en-diabetes/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/05/iv-ferricarboxymaltose-en-inspanningscapaciteit-bij-hfpef-met-ijzerdeficientie/","published":"2024-10-05"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2023/12/21/iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-ipd-meta-analyse/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2023/11/01/beta3-lvh-mirabegron-bij-linkerventrikel-hypertrofie-fase-2b-rct/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/14/heart-fid-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-nejm/","published":"2023-09-14"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2022/12/01/vericiguat-en-nt-probnp-bij-hfref-victoria-subanalyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/15/polypill-voor-secundaire-cardiovasculaire-preventie-secure-trial-in-nejm/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/04/01/lv-longitudinale-systolische-functieparameters-als-voorspellers-bij-hfpef/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/12/01/hepatorenale-disfunctie-identificeert-hoogrisico-acuut-hf-relax-ahf/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2019/08/01/ijzercarboxymaltose-en-plasmavolumestatus-bij-hf-fair-hf-substudie/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/04/01/icd-mortaliteit-naar-hartfalenetiologie-propensity-matched-analyse/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/10/01/linkeratriumvolume-en-cv-uitkomsten-bij-systolisch-hf-antitromboticaeffect/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/08/07/trv027-biased-ligand-van-de-angiotensine-ii-receptor-bij-acuut-hartfalen-gerando/","published":"2017-08-07"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/04/14/vericiguat-bij-verslechterend-chronisch-hfpef-socrates-preserved-resultaten/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2016/12/10/omecamtiv-mecarbil-bij-chronisch-hartfalen-lancet-cosmic-hf-fase-2-trial/","published":"2016-12-10"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"},{"url":"https://hartvaat.nl/2016/07/14/finerenon-versus-eplerenon-bij-hartfalen-met-diabetes-en-verslechterende-nierfun/","published":"2016-07-14"},{"url":"https://hartvaat.nl/2016/03/29/omecamtiv-mecarbil-bij-acuut-hartfalen-de-atomic-ahf-studie/","published":"2016-03-29"},{"url":"https://hartvaat.nl/2016/03/19/serca2a-gentherapie-bij-hartfalen-de-cupid-2-trial/","published":"2016-03-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefan-d-anker","type":"person","url":"https://hartvaat.nl/mensen/stefan-d-anker/","name":"Stefan D Anker","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":79,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/08/18/c-mic-apparaat-vermindert-hartfalen-ernst-onafhankelijk-van-gdmt-aanpassingen-c-/","published":"2026-08-25"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/03/03/c-mic-ii-hartfunctie-inspanningscapaciteit-en-kwaliteit-van-leven-zijn-verwante-/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/05/13/empagliflozine-erytropoese-en-ijzermobilisatie-bij-hartfalen/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/02/01/finerenon-en-lvh-bij-ckd-en-diabetes/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/11/12/sglt2-remming-en-proteomische-handtekeningen-bij-hartfalen-bevestiging/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/10/05/iv-ferricarboxymaltose-en-inspanningscapaciteit-bij-hfpef-met-ijzerdeficientie/","published":"2024-10-05"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2023/12/21/iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-ipd-meta-analyse/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2023/09/26/geblindeerde-stopstudie-voordelen-empagliflozine-verdwijnen-na-staken-bij-hf/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2023/08/01/atrial-flow-regulator-en-overleving-bij-hartfalen-voorspelde-impact/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2022/12/21/empagliflozine-en-het-circulerend-proteoom-bij-hartfalen-emperor-mechanismen/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/12/01/finerenon-bloeddrukeffecten-en-cardiorenale-uitkomsten-bij-ckd-en-diabetes/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/12/01/hartfalen-tijdens-de-covid-19-pandemie-klinische-en-organisatorische-dilemma-s/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/empagliflozine-vermindert-albuminurie-bij-hartfalen-emperor-pooled-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/04/06/nierfunctiebeoordeling-en-eindpuntbepaling-in-klinische-trials-ehj/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2022/04/01/robuustheid-van-sglt2-remmer-hf-trials-evaluatie/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2022/02/10/finerenon-cv-en-renale-uitkomsten-bij-diabetes-met-ckd-fidelity-gepoolde-analyse/","published":"2022-02-10"},{"url":"https://hartvaat.nl/2022/02/08/finerenon-vermindert-incident-hf-bij-ckd-met-diabetes-fidelity/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/12/09/finerenon-bij-nierziekte-met-diabetes-type-2-nejm-figaro-dkd/","published":"2021-12-09"},{"url":"https://hartvaat.nl/2021/12/01/sglt2-remmers-en-cardiale-remodellering-meta-analyse-van-mri-trials/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/lv-dimensies-en-cv-uitkomsten-bij-systolisch-hf-warcef/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-en-renale-uitkomsten-bij-hartfalen-nejm-emperor-reduced-renal/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/09/28/nt-probnp-prognose-en-empagliflozine-effect-bij-emperor-reduced/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/07/13/finerenon-vermindert-nieuw-onset-af-bij-ckd-met-diabetes-fidelio-dkd/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/03/23/mra-en-empagliflozine-interactie-bij-hf-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/03/23/empagliflozine-bij-hfref-met-volume-overbelasting-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/02/09/finerenon-en-cardiovasculaire-uitkomsten-bij-ckd-met-diabetes-type-2-fidelio-dkd/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/12/01/sglt2-remmers-bij-hartfalen-systematische-review-en-meta-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/09/19/sglt2-remmers-bij-hfref-meta-analyse-van-emperor-reduced-en-dapa-hf/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/04/14/systolische-bloeddruk-bij-hfpef-behandeld-met-sacubitril-valsartan-paragon-hf/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/28/eerdere-hf-hospitalisatie-en-sacubitril-valsartan-versus-valsartan-bij-hfpef-par/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2019/11/21/rivaroxaban-en-cva-tia-bij-hf-met-coronairlijden-en-sinusritme-commander-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2019/08/01/ijzercarboxymaltose-en-plasmavolumestatus-bij-hf-fair-hf-substudie/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/01/rivaroxaban-en-trombo-embolische-events-bij-hf-met-coronairlijden-en-sinusritme-/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/04/01/icd-mortaliteit-naar-hartfalenetiologie-propensity-matched-analyse/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2019/03/05/canakinumab-ter-preventie-van-hartfalen-hospitalisatie-cantos-analyse/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2018/10/04/rivaroxaban-bij-hartfalen-met-sinusritme-en-coronairlijden-nejm-commander-hf/","published":"2018-10-04"},{"url":"https://hartvaat.nl/2018/10/01/linkeratriumvolume-en-cv-uitkomsten-bij-systolisch-hf-antitromboticaeffect/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/09/22/telemedische-interventie-bij-hartfalen-lancet-tim-hf2/","published":"2018-09-22"},{"url":"https://hartvaat.nl/2017/11/01/raas-blokkade-bij-hfpef-systematische-review-en-meta-analyse/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/06/07/dagelijkse-telemonitoring-van-icd-s-gepoolde-analyse-van-drie-gerandomiseerde-tr/","published":"2017-06-07"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"},{"url":"https://hartvaat.nl/2016/07/14/finerenon-versus-eplerenon-bij-hartfalen-met-diabetes-en-verslechterende-nierfun/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carolyn-s-p-lam","type":"person","url":"https://hartvaat.nl/mensen/carolyn-s-p-lam/","name":"Carolyn S P Lam","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":78,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2026/03/05/ai-echocardiografie-door-niet-specialisten-kosteneffectiviteitsanalyse-uit-singa/","published":"2026-04-08"},{"url":"https://hartvaat.nl/2026/03/06/kdigo-consensusconferentie-uitdagingen-bij-gecombineerd-hartfalen-en-nierziekte/","published":"2026-03-15"},{"url":"https://hartvaat.nl/2025/01/01/timing-van-cardiovasculaire-en-renale-voordelen-van-finerenon-bij-hartfalen-en-c/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/01/geografische-variatie-in-hfref-patientkenmerken-en-behandeling/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/04/01/vericiguat-voordeel-geprojecteerd-op-paradigm-hf-en-dapa-hf-populaties/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","published":"2024-09-21"},{"url":"https://hartvaat.nl/2024/08/20/tadalafil-bij-gecombineerde-post-en-precapillaire-ph-en-hfpef/","published":"2024-08-20"},{"url":"https://hartvaat.nl/2024/08/01/coronaire-microvasculaire-disfunctie-bij-hfpef-meta-analyse/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/07/09/selectieve-aldosereductaseremmer-bij-diabetische-cardiomyopathie-rct/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/03/28/amplitude-o-dosisrespons-van-efpeglenatide-op-cv-uitkomsten-bij-diabetes/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","published":"2022-09-03"},{"url":"https://hartvaat.nl/2022/08/01/sekseverschillen-in-effectiviteit-van-hartfalenmedicatie-meta-analyse/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/10/19/diabetes-met-cardiomyopathie-in-de-community-prevalentie-en-prognose/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/09/02/efpeglenatide-en-cv-en-renale-uitkomsten-bij-diabetes-type-2-nejm-amplitude-o/","published":"2021-09-02"},{"url":"https://hartvaat.nl/2021/07/13/finerenon-vermindert-nieuw-onset-af-bij-ckd-met-diabetes-fidelio-dkd/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2020/04/14/systolische-bloeddruk-bij-hfpef-behandeld-met-sacubitril-valsartan-paragon-hf/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2019/12/10/echocardiografische-kenmerken-bij-hfpef/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2019/11/21/rivaroxaban-en-cva-tia-bij-hf-met-coronairlijden-en-sinusritme-commander-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2019/06/01/rivaroxaban-en-trombo-embolische-events-bij-hf-met-coronairlijden-en-sinusritme-/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/10/04/rivaroxaban-bij-hartfalen-met-sinusritme-en-coronairlijden-nejm-commander-hf/","published":"2018-10-04"},{"url":"https://hartvaat.nl/2018/06/12/sglt2-remmers-en-cardiovasculaire-events-de-cvd-real-2-real-world-studie/","published":"2018-06-12"},{"url":"https://hartvaat.nl/2018/04/01/eenmalig-intraveneus-ijzer-bij-hartfalen-in-zuidoost-azie-practice-asia-hf-pilot/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2017/04/14/vericiguat-bij-verslechterend-chronisch-hfpef-socrates-preserved-resultaten/","published":"2017-04-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gerasimos-s-filippatos","type":"person","url":"https://hartvaat.nl/mensen/gerasimos-s-filippatos/","name":"Gerasimos S Filippatos","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":78,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/01/01/timing-van-cardiovasculaire-en-renale-voordelen-van-finerenon-bij-hartfalen-en-c/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/05/13/empagliflozine-erytropoese-en-ijzermobilisatie-bij-hartfalen/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/02/01/finerenon-en-lvh-bij-ckd-en-diabetes/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/11/12/sglt2-remming-en-proteomische-handtekeningen-bij-hartfalen-bevestiging/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/11/01/beta3-lvh-mirabegron-bij-linkerventrikel-hypertrofie-fase-2b-rct/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/09/30/adaptresponse-adaptieve-versus-conventionele-crt-bij-hartfalen-lancet/","published":"2023-09-30"},{"url":"https://hartvaat.nl/2023/09/26/geblindeerde-stopstudie-voordelen-empagliflozine-verdwijnen-na-staken-bij-hf/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","published":"2023-06-09"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/12/21/empagliflozine-en-het-circulerend-proteoom-bij-hartfalen-emperor-mechanismen/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2022/12/01/finerenon-bloeddrukeffecten-en-cardiorenale-uitkomsten-bij-ckd-en-diabetes/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/empagliflozine-vermindert-albuminurie-bij-hartfalen-emperor-pooled-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","published":"2022-09-29"},{"url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/04/01/robuustheid-van-sglt2-remmer-hf-trials-evaluatie/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2022/02/10/finerenon-cv-en-renale-uitkomsten-bij-diabetes-met-ckd-fidelity-gepoolde-analyse/","published":"2022-02-10"},{"url":"https://hartvaat.nl/2022/02/08/finerenon-vermindert-incident-hf-bij-ckd-met-diabetes-fidelity/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/12/09/finerenon-bij-nierziekte-met-diabetes-type-2-nejm-figaro-dkd/","published":"2021-12-09"},{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-en-renale-uitkomsten-bij-hartfalen-nejm-emperor-reduced-renal/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/09/28/nt-probnp-prognose-en-empagliflozine-effect-bij-emperor-reduced/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/07/13/finerenon-vermindert-nieuw-onset-af-bij-ckd-met-diabetes-fidelio-dkd/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/03/23/mra-en-empagliflozine-interactie-bij-hf-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/03/23/empagliflozine-bij-hfref-met-volume-overbelasting-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/02/09/finerenon-en-cardiovasculaire-uitkomsten-bij-ckd-met-diabetes-type-2-fidelio-dkd/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/12/01/sglt2-remmers-bij-hartfalen-systematische-review-en-meta-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/10/01/sekseverschillen-in-kenmerken-en-qol-bij-crt-patienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/09/19/sglt2-remmers-bij-hfref-meta-analyse-van-emperor-reduced-en-dapa-hf/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2019/12/01/hepatorenale-disfunctie-identificeert-hoogrisico-acuut-hf-relax-ahf/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2019/08/01/ijzercarboxymaltose-en-plasmavolumestatus-bij-hf-fair-hf-substudie/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/06/01/geindividualiseerd-patiromer-doseringsregime-bij-hf-met-ckd-en-hyperkaliemie/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/07/trv027-biased-ligand-van-de-angiotensine-ii-receptor-bij-acuut-hartfalen-gerando/","published":"2017-08-07"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/04/14/vericiguat-bij-verslechterend-chronisch-hfpef-socrates-preserved-resultaten/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/07/14/finerenon-versus-eplerenon-bij-hartfalen-met-diabetes-en-verslechterende-nierfun/","published":"2016-07-14"},{"url":"https://hartvaat.nl/2016/03/29/omecamtiv-mecarbil-bij-acuut-hartfalen-de-atomic-ahf-studie/","published":"2016-03-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sanjiv-j-shah","type":"person","url":"https://hartvaat.nl/mensen/sanjiv-j-shah/","name":"Sanjiv J Shah","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":75,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/humain-hfpef-nieuwe-metabole-accelerator-bij-obesitas-hfpef-rct/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/nierfunctie-en-dapagliflozine-effect-op-gezondheidsstatus-define-hf/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/03/01/kaliumnitraat-bij-hfpef-gerandomiseerde-trial/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/01/splanchnische-zenuwablatie-bij-hfpef-endovasculaire-benadering/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/af-en-semaglutide-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/01/amethyst-verinurad-plus-allopurinol-bij-hfpef-negatieve-trial/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","published":"2024-09-21"},{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","published":"2024-08-27"},{"url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2024/01/01/tafamidis-en-cardiale-functie-bij-attr-cm-post-hoc-attr-act-analyse/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2023/07/18/sglt2-remmers-verbeteren-kwaliteit-van-leven-gelijk-bij-zwarte-en-witte-hartfale/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","published":"2022-09-03"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/11/16/sacubitril-valsartan-versus-standaardtherapie-op-nt-probnp-en-inspanningscapacit/","published":"2021-11-16"},{"url":"https://hartvaat.nl/2021/04/01/canagliflozine-naar-diureticagebruik-canvas-post-hoc-analyse/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2021/02/01/polsdruk-prognose-en-sacubitril-valsartan-bij-hfpef-paragon-hf/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/10/20/praliciguat-en-piek-vo2-bij-hfpef-jama-capacity-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/09/22/sekse-specifieke-cv-risicofactoren-en-biomarkers-bij-incident-hartfalen/","published":"2020-09-22"},{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/06/01/variatie-in-uitkomsten-tussen-complexe-hfpef-fenotypen/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2019/12/10/echocardiografische-kenmerken-bij-hfpef/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2019/11/26/interatriale-shunt-en-pulmonale-vaatfunctie-bij-hfpef/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/07/23/ag10-transthyretinestabilisator-bij-symptomatische-attr-cardiomyopathie/","published":"2019-07-23"},{"url":"https://hartvaat.nl/2019/06/04/neladenoson-bialanaat-en-inspanningscapaciteit-bij-hfpef-jama-panache/","published":"2019-06-04"},{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","published":"2018-11-06"},{"url":"https://hartvaat.nl/2018/10/01/transcatheter-interatriale-shunt-bij-hfpef-1-jaarsresultaten/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/10/01/natriuretische-peptiden-en-cardiovasculaire-prognose-bij-hfpef-topcat/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/09/13/tafamidis-bij-transthyretine-amyloid-cardiomyopathie-nejm-attr-act/","published":"2018-09-13"},{"url":"https://hartvaat.nl/2018/04/10/geen-verband-tussen-hartfalen-en-kankerincidentie/","published":"2018-04-10"},{"url":"https://hartvaat.nl/2018/01/23/transcatheter-interatriale-shunt-bij-hfpef-reduce-lap-hf-i/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/09/12/lichamelijke-activiteit-en-prognose-bij-hfpef-topcat-analyse/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2017/04/14/vericiguat-bij-verslechterend-chronisch-hfpef-socrates-preserved-resultaten/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/02/07/doodsoorzaken-bij-hartfalen-met-behouden-ejectiefractie/","published":"2017-02-07"},{"url":"https://hartvaat.nl/2016/02/01/invloed-van-ejectiefractie-op-uitkomsten-van-spironolacton-bij-hfpef/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stuart-j-pocock","type":"person","url":"https://hartvaat.nl/mensen/stuart-j-pocock/","name":"Stuart J Pocock","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":74,"articles":[{"url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/02/11/reboot-betablokkers-na-mi-sekseverschillen/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/11/25/amphilimus-versus-zotarolimus-eluting-stent-bij-diabetes-en-coronairlijden/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2025/11/14/nierfunctietrajecten-voor-en-na-hospitalisatie-voor-hfref/","published":"2025-11-14"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","published":"2025-09-13"},{"url":"https://hartvaat.nl/2025/05/13/empagliflozine-erytropoese-en-ijzermobilisatie-bij-hartfalen/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/11/12/sglt2-remming-en-proteomische-handtekeningen-bij-hartfalen-bevestiging/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/07/invasieve-strategie-bij-ouderen-met-mi-gerandomiseerde-trial-nejm/","published":"2024-11-07"},{"url":"https://hartvaat.nl/2024/06/14/invasief-versus-conservatief-bij-ouderen-met-nste-acs-ipd-meta-analyse/","published":"2024-06-14"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","published":"2023-11-23"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2023/09/26/geblindeerde-stopstudie-voordelen-empagliflozine-verdwijnen-na-staken-bij-hf/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2022/12/21/empagliflozine-en-het-circulerend-proteoom-bij-hartfalen-emperor-mechanismen/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","published":"2022-11-15"},{"url":"https://hartvaat.nl/2022/11/01/empagliflozine-vermindert-albuminurie-bij-hartfalen-emperor-pooled-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/15/polypill-voor-secundaire-cardiovasculaire-preventie-secure-trial-in-nejm/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2022/03/31/amphilimus-versus-zotarolimus-stents-bij-diabetes-sugar-gerandomiseerde-trial/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-en-renale-uitkomsten-bij-hartfalen-nejm-emperor-reduced-renal/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/09/28/nt-probnp-prognose-en-empagliflozine-effect-bij-emperor-reduced/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/09/07/hartfrequentie-en-uitkomsten-van-renale-denervatie-bij-ongecontroleerde-hyperten/","published":"2021-09-07"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2021/03/23/mra-en-empagliflozine-interactie-bij-hf-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/03/23/empagliflozine-bij-hfref-met-volume-overbelasting-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/09/19/sglt2-remmers-bij-hfref-meta-analyse-van-emperor-reduced-en-dapa-hf/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2020/04/07/yoga-gebaseerde-hartrevalidatie-na-acuut-mi-gerandomiseerde-trial/","published":"2020-04-07"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-ballonexpandeerbare-klep-bij-laagrisicopatienten-nejm-partner-3/","published":"2019-05-02"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2019/03/01/ambulante-hartfrequentiereductie-na-renale-denervatie-bij-hypertensie-zonder-med/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/09/29/langetermijnmortaliteit-na-bloeddruk-en-lipidenverlaging-bij-hypertensie-ascot-l/","published":"2018-09-29"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/06/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-6-maandsresultat/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2017/10/10/dagelijks-ischemie-en-bloedingsrisico-na-primaire-pci-voor-stemi/","published":"2017-10-10"},{"url":"https://hartvaat.nl/2017/04/01/polymeervrije-biolimus-stent-bij-hoog-bloedingsrisico-met-acs-leaders-free-subst/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/12/20/bloedingen-voor-coronairangiografie-bij-nste-acs/","published":"2016-12-20"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"},{"url":"https://hartvaat.nl/2016/07/28/liraglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-leader-trial/","published":"2016-07-28"},{"url":"https://hartvaat.nl/2016/06/09/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-atriumfibrilleren-nejm-/","published":"2016-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eugene-braunwald","type":"person","url":"https://hartvaat.nl/mensen/eugene-braunwald/","name":"Eugene Braunwald","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":73,"articles":[{"url":"https://hartvaat.nl/2026/02/24/systemische-embolieen-bij-af-ipd-mega-meta-analyse-van-71-683-patienten/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2024/10/01/plotse-dood-na-mi-inzichten-uit-valiant-en-paradise-mi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/01/eldercare-af-subanalyse-dosisreductie-edoxaban-bij-80-jarigen-met-af/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/04/01/lp-a-en-hscrp-als-cv-risicofactoren-primaire-en-secundaire-preventie/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/04/sacubitril-valsartan-bij-hfmref-hfpef-met-verslechterend-hartfalen/","published":"2023-07-04"},{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/12/01/serieel-hoog-sensitief-troponine-t-voorspelt-cv-events-na-acs-odyssey-analyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/10/12/baseline-ldl-en-klinische-uitkomsten-van-ezetimibe-plus-statine-improve-it/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/03/09/halve-versus-volle-dosis-edoxaban-bij-af-gerandomiseerde-vergelijking/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2020/11/21/ldl-verlaging-bij-ouderen-lancet-meta-analyse-werkzaamheid-en-veiligheid/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/11/01/klinische-toepassing-van-hs-troponine-in-het-ascvd-raamwerk-jama-cardiology/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/09/01/arni-naar-hf-voorgeschiedenis-en-raas-antagonistgebruik/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/03/17/non-culprit-mi-na-pci-bij-acs/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2020/02/01/arni-initiatie-na-acuut-gedecompenseerd-hf-pioneer-hf-open-label-extensie/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/12/17/uitkomsten-van-vrouwen-versus-mannen-na-nste-acs/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/10/21/cv-biomarkers-bij-acuut-gedecompenseerd-hf-met-sacubitril-valsartan-pioneer-hf/","published":"2019-10-21"},{"url":"https://hartvaat.nl/2019/09/01/simvastatine-ezetimibe-versus-simvastatine-na-acs-bij-75-plussers-jama-cardiolog/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/09/01/edoxaban-versus-warfarine-naar-gemiddelde-bloeddruk-bij-af-met-hypertensie/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/16/edoxaban-versus-warfarine-bij-af-met-leverziekte-engage-af-timi-48/","published":"2019-07-16"},{"url":"https://hartvaat.nl/2019/05/14/bmi-en-uitkomsten-bij-af-behandeld-met-edoxaban-of-warfarine-engage-af-timi-48/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/05/14/edoxaban-bij-aziatische-af-patienten-concentraties-en-anti-xa-activiteit/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/05/07/sacubitril-valsartan-of-enalapril-bij-acuut-gedecompenseerd-hf-pioneer-hf-klinis/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/02/07/angiotensine-neprilysineremming-bij-acuut-gedecompenseerd-hf-nejm-pioneer-hf/","published":"2019-02-07"},{"url":"https://hartvaat.nl/2019/02/05/abc-scores-voor-cva-en-bloedingsrisico-bij-af-prestatieverbetering/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2019/02/01/edoxaban-en-implanteerbare-cardiale-devices-engage-af-timi-48/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","published":"2018-11-06"},{"url":"https://hartvaat.nl/2018/10/30/endogene-factor-xa-activiteit-en-edoxaban-farmacodynamische-marker-en-klinische-/","published":"2018-10-30"},{"url":"https://hartvaat.nl/2018/09/25/edoxaban-versus-warfarine-bij-latijns-amerikaanse-af-patienten-engage-af-timi-48/","published":"2018-09-25"},{"url":"https://hartvaat.nl/2018/07/10/fatale-of-irreversibele-bloedingen-en-ischemische-events-met-rivaroxaban-bij-acs/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/06/01/fgf-23-en-recidiverende-cv-events-na-acs/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/04/10/ezetimibe-bij-diabetes-versus-zonder-diabetes-improve-it-subanalyse/","published":"2018-04-10"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2018/02/01/cv-uitkomsten-naar-albumin-en-nierziekte-bij-diabetes-type-2-met-hoog-cv-risico/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/12/19/cva-preventie-met-ezetimibe-bij-acs-improve-it-analyse/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/09/28/anacetrapib-bij-atherosclerotisch-vaatlijden-nejm-hps3-timi55-reveal/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/08/01/kosteneffectiviteit-van-langdurig-ticagrelor-na-mi-pegasus-timi-54/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/05/16/oraal-ijzer-bij-hfref-met-ijzerdeficientie-jama-ironout-hf/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2017/05/01/langetermijnveiligheid-van-zeer-lage-ldl-cholesterolniveaus-improve-it-analyse/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2017/03/21/kleplijden-en-edoxaban-versus-warfarine-bij-af-engage-af-timi-48/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2017/03/21/nieuwe-risicovoorspellingsscore-bij-af-voor-netto-klinisch-resultaat-engage-af-t/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/12/21/ezetimibe-bij-post-cabg-patienten-met-acs-improve-it-subanalyse/","published":"2016-12-21"},{"url":"https://hartvaat.nl/2016/09/27/ldl-c-verlaging-en-cardiovasculaire-risicoreductie-jama-systematische-review-en-/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/09/20/cva-preventie-met-ticagrelor-na-myocardinfarct-pegasus-timi-54-inzichten/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/09/13/edoxaban-versus-warfarine-bij-af-patienten-met-valrisico-engage-af-timi-48-analy/","published":"2016-09-13"},{"url":"https://hartvaat.nl/2016/08/02/liraglutide-en-klinische-stabiliteit-bij-gevorderd-hartfalen-met-verminderde-ef-/","published":"2016-08-02"},{"url":"https://hartvaat.nl/2016/07/26/atherotrombotische-risicostratificatie-en-vorapaxar-bij-stabiel-ischemisch-hartl/","published":"2016-07-26"},{"url":"https://hartvaat.nl/2016/07/19/serieel-cardiaal-troponine-met-hoog-sensitieve-assay-bij-stabiel-ischemisch-hart/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/07/05/nierfunctie-en-uitkomsten-met-edoxaban-in-de-engage-af-timi-48-trial/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/06/14/reductie-van-ischemische-events-met-ticagrelor-bij-diabetes-na-myocardinfarct-pe/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/03/15/plaatjesremming-met-ticagrelor-60-mg-versus-90-mg-in-de-pegasus-timi-54-trial/","published":"2016-03-15"},{"url":"https://hartvaat.nl/2016/03/08/acute-ledischemie-en-vorapaxar-bij-perifeer-arterieel-vaatlijden-tra-2p-timi-50-/","published":"2016-03-08"},{"url":"https://hartvaat.nl/2016/02/02/reductie-in-totale-cardiovasculaire-events-met-ezetimibe-simvastatine-na-acs-imp/","published":"2016-02-02"},{"url":"https://hartvaat.nl/2016/01/21/doodsoorzaken-bij-langdurige-dapt-na-coronaire-stents/","published":"2016-01-21"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"},{"url":"https://hartvaat.nl/2016/01/21/langdurige-duale-antiplaatjestherapie-bij-patienten-met-eerder-myocardinfarct-me/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"patrick-w-j-c-serruys","type":"person","url":"https://hartvaat.nl/mensen/patrick-w-j-c-serruys/","name":"Patrick W J C Serruys","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":73,"articles":[{"url":"https://hartvaat.nl/2026/02/25/hemodynamische-en-bloedviscositeitsprofielen-van-culprit-versus-non-culprit-coro/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2026/02/24/invloed-van-coronaire-ziekte-patronen-op-klinische-uitkomsten-pullback-pressure-/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2026/02/05/driejaarsuitkomsten-van-linker-hartoorsluiting-met-of-zonder-ablatie-record-stud/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2025/01/01/ffr-versus-ifr-bij-coronaire-revascularisatie-vijfjaars-follow-up/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2022/04/19/externe-validatie-van-de-freedom-score-voor-pci-versus-cabg/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/31/syntax-score-ii-herontwikkeling-voor-gepersonaliseerde-revascularisatiebeslissin/","published":"2020-10-31"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/04/14/langetermijnuitkomsten-bij-vrouwen-en-mannen-na-pci/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/12/01/absorb-scaffold-5-jaarsresultaten-systematische-meta-analyse/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/08/13/off-pump-versus-on-pump-cabg-bij-hoofdstamcoronairlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/07/01/lokale-hemodynamische-krachten-en-fenotype-van-coronaire-plaques/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/04/23/hedendaagse-uitkomsten-na-cabg-voor-hoofdstamlijden/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2018/11/01/ct-coronairangiografie-voor-heart-team-besluitvorming-bij-multivatenlijden/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/07/31/bnp-bij-linker-hoofdstamrevascularisatie-excel-analyse/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/05/07/esc-eapci-taskforce-rapport-over-bioresorbeerbare-scaffolds-executive-summary/","published":"2018-05-07"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2018/02/13/richtlijngetrouwe-medicamenteuze-therapie-in-contemporaine-revascularisatietrial/","published":"2018-02-13"},{"url":"https://hartvaat.nl/2018/02/03/sirolimus-eluting-bioabsorbeerbare-stent-versus-everolimus-eluting-stent-na-mi-l/","published":"2018-02-03"},{"url":"https://hartvaat.nl/2018/01/30/absorb-bioresorbeerbare-scaffold-3-jaarsresultaten-ipd-meta-analyse/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"},{"url":"https://hartvaat.nl/2017/12/12/implantatiechniek-en-uitkomsten-van-bioresorbeerbare-scaffolds-absorb-analyses/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/09/01/late-trombotische-events-na-bioresorbeerbare-scaffold-meta-analyse-van-gerandomi/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/08/19/absorb-bioresorbeerbare-scaffold-lancet-2-jaars-systematische-review-en-meta-ana/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"},{"url":"https://hartvaat.nl/2017/07/01/syntax-scores-en-uitkomsten-bij-diabetes-met-multivatenlijden-gepoolde-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2017/04/25/kwaliteit-van-leven-na-chirurgie-of-des-bij-drienvaten-of-hoofdstamlijden/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"},{"url":"https://hartvaat.nl/2016/09/06/pci-versus-cabg-bij-onbeschermde-hoofdstamziekte-uitkomsten/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/01/23/everolimus-eluting-stent-versus-bare-metal-stent-bij-stemi-5-jaarsresultaten-exa/","published":"2016-01-23"},{"url":"https://hartvaat.nl/2016/01/14/bioresorbeerbare-versus-metallic-everolimus-eluting-stent-bij-stemi-gerandomisee/","published":"2016-01-14"},{"url":"https://hartvaat.nl/2016/01/05/doodsoorzaken-na-pci-versus-cabg-bij-complex-coronairlijden-5-jaarsfollow-up-van/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"subodh-verma","type":"person","url":"https://hartvaat.nl/mensen/subodh-verma/","name":"Subodh Verma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":70,"articles":[{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/03/05/semaglutide-bij-perifeer-arterieel-vaatlijden-en-diabetes-stride-trial/","published":"2026-03-20"},{"url":"https://hartvaat.nl/2026/03/09/semaglutide-stimuleert-anti-inflammatoire-stamcelflux-vanuit-beenmerg/","published":"2026-03-09"},{"url":"https://hartvaat.nl/2026/02/19/evolocumab-en-doorgankelijkheid-van-veneuze-bypasses-na-cabg-newton-cabg-cardiol/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/02/01/cagrisema-verlaagt-bloeddruk-bij-overgewicht-obesitas-redefine-1/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/11/18/sekseverschillen-in-semaglutide-effect-bij-pad-stride-subanalyse/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","published":"2025-09-20"},{"url":"https://hartvaat.nl/2025/05/03/solbinsiran-langwerkend-sirna-tegen-angptl3-duurzaamheid-en-effectiviteit/","published":"2025-05-03"},{"url":"https://hartvaat.nl/2025/05/03/semaglutide-en-loopafstand-bij-perifeer-vaatlijden-en-diabetes/","published":"2025-05-03"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/af-en-semaglutide-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","published":"2024-08-27"},{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","published":"2024-08-24"},{"url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2023/06/01/igfbp7-en-lv-massaregressie-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/nlr-en-cardiale-remodelling-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/diabetesduur-beinvloedt-lv-massaregressie-met-empagliflozine/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/05/03/vupanorsen-en-non-hdl-cholesterol-bij-statinebehandelde-patienten-translate-timi/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/04/01/sglt2-remmers-bij-hfref-of-hfpef-meta-analyse/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2022/03/01/bloeddruk-hypertensie-en-risico-op-aortadissectie-j-sch-en-uk-biobank/","published":"2022-03-01"},{"url":"https://hartvaat.nl/2021/12/01/sglt2-remmers-en-cardiale-remodellering-meta-analyse-van-mri-trials/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/10/19/diabetes-met-cardiomyopathie-in-de-community-prevalentie-en-prognose/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/nt-probnp-prognose-en-empagliflozine-effect-bij-emperor-reduced/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/12/01/eerste-en-recidiverende-cv-events-met-liraglutide-bij-diabetes-type-2-leader/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/11/19/empagliflozine-en-lv-massa-bij-diabetes-type-2-met-coronairlijden-empa-heart/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/06/04/microvasculaire-ziekte-en-cv-events-bij-diabetes-type-2/","published":"2019-06-04"},{"url":"https://hartvaat.nl/2019/02/21/laaggedoseerd-methotrexaat-voor-preventie-van-atherosclerotische-events-nejm-cir/","published":"2019-02-21"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-cv-uitkomsten-met-of-zonder-eerder-mi-leader/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/09/27/6-maandsuitkomsten-van-restrictieve-versus-liberale-transfusie-bij-hartchirurgie/","published":"2018-09-27"},{"url":"https://hartvaat.nl/2018/07/10/inflammatie-en-cholesterol-in-de-fourier-trial/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/05/15/liraglutide-bij-diabetes-type-2-met-polyvasculaire-ziekte-leader-analyse/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2018/01/23/empagliflozine-bij-diabetes-type-2-met-perifeer-vaatlijden-empa-reg-outcome/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/12/19/chirurgische-versus-percutane-revascularisatie-bij-diabetes-met-acs/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/11/30/restrictieve-versus-liberale-bloedtransfusie-bij-hartchirurgie-nejm-trics-iii/","published":"2017-11-30"},{"url":"https://hartvaat.nl/2017/01/17/dapt-versus-aspirine-monotherapie-bij-diabetes-met-multivatenlijden-na-cabg-free/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lars-v-kober","type":"person","url":"https://hartvaat.nl/mensen/lars-v-kober/","name":"Lars V Køber","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":68,"articles":[{"url":"https://hartvaat.nl/2026/10/01/voorgebruik-van-opioiden-verhoogt-sterfte-en-ziekenhuisopnames-na-tavi-deens-coh/","published":"2026-08-21"},{"url":"https://hartvaat.nl/2026/01/20/af-screening-naar-genetisch-risico-loop-subanalyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/15/hypokaliemie-en-af-gedetecteerd-door-implanteerbare-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2025/12/15/circadiaanse-patronen-van-af-en-ziekteprogressie-via-implanted-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2025/10/28/rsv-vaccin-vermindert-cv-hospitalisaties-bij-ouderen/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/09/01/af-en-icd-bij-niet-ischemische-hfref-impliciaties-voor-devicetherapie/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/04/22/thoracentese-bij-acuut-hartfalen-gerandomiseerde-trial/","published":"2025-04-22"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/01/01/nudge-flu-subanalyse-griepvaccinatie-nudges-bij-mi-langetermijn/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/10/01/plotse-dood-na-mi-inzichten-uit-valiant-en-paradise-mi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/05/27/nudge-flu-elektronische-nudges-verhogen-griepvaccinatie-na-mi/","published":"2024-05-27"},{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/06/13/loop-substudie-nt-probnp-verbetert-af-screeningsopbrengst/","published":"2023-06-13"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/02/23/ct-coronairangiografie-bij-75-jarigen-met-nste-acs/","published":"2023-02-23"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/09/01/bloeddruk-beinvloedt-opbrengst-van-af-screening-loop-substudie/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/04/01/icd-bij-niet-ischemisch-systolisch-hf-met-coronaire-atherosclerose-danish/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/07/01/empagliflozine-en-lv-volumes-en-functie-bij-hfref-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/06/01/metabole-effecten-van-empagliflozine-bij-hf-empire-hf-metabolic-gerandomiseerde-/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2020/12/08/empagliflozine-en-hemodynamiek-bij-hfref/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/05/12/ritme-monitoringstrategieen-voor-af-screening-uitgebreide-evaluatie/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/12/03/natuurlijk-beloop-van-subklinisch-af-gedetecteerd-door-implanteerbare-looprecord/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/01/08/hfref-differentiele-impact-op-mannen-en-vrouwen/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/11/14/af-type-en-uitkomsten-bij-hfref/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2017/02/21/diabetesstatus-en-cardiovasculaire-uitkomsten-bij-hfpef-klinische-en-echocardiog/","published":"2017-02-21"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"},{"url":"https://hartvaat.nl/2016/07/14/finerenon-versus-eplerenon-bij-hartfalen-met-diabetes-en-verslechterende-nierfun/","published":"2016-07-14"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"},{"url":"https://hartvaat.nl/2016/04/21/aliskiren-enalapril-of-de-combinatie-bij-hartfalen-nejm-atmosphere-trial/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/02/01/regionale-hartdisfunctie-en-prognose-na-myocardinfarct-met-lv-disfunctie-of-hart/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-b-granger","type":"person","url":"https://hartvaat.nl/mensen/christopher-b-granger/","name":"Christopher B Granger","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":67,"articles":[{"url":"https://hartvaat.nl/2026/08/25/extracraniale-bloedingen-komen-bij-26-van-af-patienten-op-antistolling-voor-comb/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/02/24/systemische-embolieen-bij-af-ipd-mega-meta-analyse-van-71-683-patienten/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2025/03/25/antitrombotische-therapie-bij-af-na-acs-pci-augustus-gecombineerde-inzichten/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2025/01/01/dialysaat-kalium-3-0-mmol-l-met-natriumzirconiumcyclosilicaat-bij-dialyse/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/11/26/artesia-subanalyse-cva-risico-naar-frequentie-en-duur-van-subclinisch-af/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/10/01/plotse-dood-na-mi-inzichten-uit-valiant-en-paradise-mi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/03/augustus-4-weg-vergelijking-antitrombotische-strategieen-bij-af-na-acs-pci/","published":"2024-09-03"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/07/16/interventie-voor-evidence-based-zorg-bij-diabetes-en-cv-risico/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/06/25/raas-blokkade-bij-hartfalen-voordeel-onafhankelijk-van-etniciteit-jama-meta-anal/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2024/03/26/doac-s-bij-device-gedetecteerd-af-meta-analyse-noah-afnet-6-en-artesia/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/08/08/glp-1-agonisten-met-en-zonder-sglt2-remmers-bij-type-2-diabetes-jacc-analyse/","published":"2023-08-08"},{"url":"https://hartvaat.nl/2023/07/13/traverse-testosteronsubstitutie-cardiovasculair-veilig-bij-hypogonadisme/","published":"2023-07-13"},{"url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","published":"2023-05-21"},{"url":"https://hartvaat.nl/2023/04/18/gecoordineerde-zorg-optimaliseert-cv-preventie-bij-type-2-diabetes-jama-rct/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/12/06/apixaban-bij-af-op-hemodialyse-eerste-gerandomiseerde-trial/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/02/08/antitrombotische-therapie-bij-af-na-acs-of-pci-jacc-overzicht/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/11/30/voorspellers-van-af-ontwikkeling-bij-embolic-stroke-of-undetermined-source-re-sp/","published":"2021-11-30"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/11/01/antiplaatjestherapie-bij-mi-zonder-obstructief-coronairlijden-minoca/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2021/06/01/continue-cardiale-monitoring-versus-standaardzorg-bij-cryptogeen-cva-jama/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/05/01/vroegtijdig-permanent-staken-van-apixaban-of-warfarine-bij-af/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/01/19/stoppen-versus-doorgaan-met-ace-remmers-arb-s-bij-gehospitaliseerde-patienten-ja/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2020/11/01/ace2-niveaus-en-covid-19-risicofactoren-bij-af-patienten/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/11/01/invloed-van-acs-trials-buiten-de-primaire-hypothese-systematische-review/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/05/01/optimaal-antitrombotisch-regime-bij-af-na-pci-jama-cardiology-netwerkmeta-analys/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/04/28/apixaban-versus-warfarine-bij-af-met-gevorderde-ckd/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2020/03/17/klinische-en-farmacologische-effecten-van-apixaban-dosisaanpassing-aristotle/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2020/01/07/nsaid-s-en-oac-bij-af-aristotle-analyse/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2019/08/01/antitrombotische-strategieen-bij-af-na-pci-jama-cardiology-veiligheids-en-werkza/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/11/01/timing-van-atorvastatine-oplaaddosis-voor-pci-bij-acs-jama-cardiology/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/10/27/albiglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-harmony-ou/","published":"2018-10-27"},{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/08/14/adma-en-sdma-voorspellen-uitkomsten-bij-af-aristotle-substudie/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/08/01/uitkomsten-bij-af-met-oac-bij-mitralis-of-aortakleplijden/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/07/31/antitrombotische-therapie-bij-af-met-oac-na-pci-aha-scientific-statement/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/03/13/digoxine-en-mortaliteit-bij-patienten-met-atriumfibrilleren/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","published":"2018-02-07"},{"url":"https://hartvaat.nl/2017/10/14/multifacet-interventie-voor-oac-gebruik-bij-af-lancet-impact-af/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/04/01/niet-ernstige-bloedingen-met-apixaban-versus-warfarine-bij-af/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/11/29/biomarkergebaseerde-cva-risicoscore-bij-atriumfibrilleren-validatie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/09/01/apixaban-5-mg-bij-af-met-hoge-leeftijd-laag-gewicht-of-hoog-creatinine-aristotle/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/07/01/apixaban-versus-warfarine-bij-af-in-relatie-tot-nierfunctie-aristotle-analyse/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","published":"2016-06-04"},{"url":"https://hartvaat.nl/2016/04/12/infarctgrootte-en-uitkomsten-na-primaire-pci-patientanalyse-uit-10-trials/","published":"2016-04-12"},{"url":"https://hartvaat.nl/2016/04/01/biomarkers-van-inflammatie-en-cardiovasculair-risico-bij-patienten-met-atriumfib/","published":"2016-04-01"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mikhail-n-kosiborod","type":"person","url":"https://hartvaat.nl/mensen/mikhail-n-kosiborod/","name":"Mikhail N Kosiborod","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":67,"articles":[{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/06/01/nierfunctie-en-dapagliflozine-effect-op-gezondheidsstatus-define-hf/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/af-en-semaglutide-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/flow-semaglutide-vermindert-hartfalen-bij-diabetes-en-ckd/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","published":"2024-08-27"},{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","published":"2024-08-24"},{"url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","published":"2024-04-30"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2023/07/18/sglt2-remmers-verbeteren-kwaliteit-van-leven-gelijk-bij-zwarte-en-witte-hartfale/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","published":"2022-09-03"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/04/27/empagliflozine-en-pulmonalisdruk-bij-hf-embrace-hf/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/03/31/dapagliflozine-en-mortaliteit-bij-ckd-dapa-ckd-pre-gespecificeerde-analyse/","published":"2021-03-31"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/09/01/2020-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/05/12/management-van-stabiel-coronairlijden-bij-diabetes-type-2-aha-scientific-stateme/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"},{"url":"https://hartvaat.nl/2019/02/05/glycemische-controle-en-cardiale-auto-immuniteit-bij-diabetes-type-1-en-langeter/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/12/18/2018-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/06/12/sglt2-remmers-en-cardiovasculaire-events-de-cvd-real-2-real-world-studie/","published":"2018-06-12"},{"url":"https://hartvaat.nl/2017/07/18/sglt2-remmers-en-lager-risico-op-hartfalen-en-sterfte-versus-andere-glucoseverla/","published":"2017-07-18"},{"url":"https://hartvaat.nl/2016/12/06/comorbiditeiten-bij-hartfalen-hypertensie-obesitas-diabetes-hyperlipidemie-en-me/","published":"2016-12-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephan-windecker","type":"person","url":"https://hartvaat.nl/mensen/stephan-windecker/","name":"Stephan Windecker","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":67,"articles":[{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/03/25/antitrombotische-therapie-bij-af-na-acs-pci-augustus-gecombineerde-inzichten/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2025/03/25/amulet-ide-vijfjaarsresultaten-laa-occlusie-met-amulet/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2024/12/01/korte-dapt-na-des-bij-acs-ipd-meta-analyse-bevestigt-veiligheid/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/09/03/augustus-4-weg-vergelijking-antitrombotische-strategieen-bij-af-na-acs-pci/","published":"2024-09-03"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/11/25/biodegradeerbare-versus-duurzame-polymeer-des-bij-stemi-langetermijndata/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2023/08/02/peri-device-lekkage-bij-laa-occluders-mechanismen-en-voorspellers/","published":"2023-08-02"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2022/02/08/antitrombotische-therapie-bij-af-na-acs-of-pci-jacc-overzicht/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/10/01/paroxetine-grk2-remming-versus-placebo-bij-anterieur-mi-jama-cardiology/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/02/02/dalend-hemoglobine-en-prognose-bij-acs-hospitalisatie/","published":"2021-02-02"},{"url":"https://hartvaat.nl/2020/08/04/cangrelor-tirofiban-en-prasugrel-bij-stemi-primaire-resultaten/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/11/19/evolocumab-voor-vroege-ldl-verlaging-bij-acs-evopacs/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/05/biodegradeerbare-versus-duurzame-polymer-des-bij-stemi-gerandomiseerde-trial/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/07/01/lokale-hemodynamische-krachten-en-fenotype-van-coronaire-plaques/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/12/21/culprit-shock-integratie-in-2017-esc-stemi-richtlijn-richtlijncommissie-standpun/","published":"2018-12-21"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/09/01/ultradunne-biodegradeerbare-versus-dunne-duurzame-stents-lancet-gerandomiseerde-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/08/07/adenosine-en-ticagrelorspiegels-bij-patienten-met-en-zonder-ticagrelor-dyspneu/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2018/05/07/esc-eapci-taskforce-rapport-over-bioresorbeerbare-scaffolds-executive-summary/","published":"2018-05-07"},{"url":"https://hartvaat.nl/2018/04/07/statines-en-niet-statine-ldl-verlagers-en-cardiovasculaire-uitkomsten-meta-analy/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2018/03/20/effecten-van-ticagrelor-prasugrel-of-clopidogrel-op-endotheelfunctie/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"},{"url":"https://hartvaat.nl/2017/05/23/stralingsblootstelling-en-vasculaire-toegang-bij-acs-rad-matrix-trial/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2016/12/01/tienjaarsuitkomsten-van-eerste-generatie-drug-eluting-stents-ses-versus-pes/","published":"2016-12-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/01/langere-versus-korte-dapt-na-pci-met-en-zonder-periprocedureel-mi-jama-cardiolog/","published":"2016-10-01"},{"url":"https://hartvaat.nl/2016/08/16/intracoronair-abciximab-bij-diabetespatienten-met-primaire-pci-1-jaarsresultaten/","published":"2016-08-16"},{"url":"https://hartvaat.nl/2016/01/21/doodsoorzaken-bij-langdurige-dapt-na-coronaire-stents/","published":"2016-01-21"},{"url":"https://hartvaat.nl/2016/01/14/bioresorbeerbare-versus-metallic-everolimus-eluting-stent-bij-stemi-gerandomisee/","published":"2016-01-14"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"milton-packer","type":"person","url":"https://hartvaat.nl/mensen/milton-packer/","name":"Milton Packer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":63,"articles":[{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/09/09/summit-tirzepatide-effect-bij-hfpef-met-en-zonder-diabetes/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/07/29/summit-bmi-centrale-adipositas-en-gewichtsverlies-beinvloeden-tirzepatide-effect/","published":"2025-07-29"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/05/13/empagliflozine-erytropoese-en-ijzermobilisatie-bij-hartfalen/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/05/13/summit-tirzepatide-en-ckd-interactie-bij-hfpef-met-obesitas/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/03/11/summit-tirzepatide-en-klinisch-traject-bij-hfpef-met-obesitas-langetermijn/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/02/25/summit-tirzepatide-vermindert-lv-massa-en-paracardiaal-vetweefsel-bij-hfpef/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/01/30/summit-tirzepatide-bij-hfpef-met-obesitas-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/12/sglt2-remming-en-proteomische-handtekeningen-bij-hartfalen-bevestiging/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/04/sacubitril-valsartan-bij-hartfalen-over-het-nierfunctiespectrum/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2023/09/26/geblindeerde-stopstudie-voordelen-empagliflozine-verdwijnen-na-staken-bij-hf/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/12/21/empagliflozine-en-het-circulerend-proteoom-bij-hartfalen-emperor-mechanismen/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/11/01/empagliflozine-vermindert-albuminurie-bij-hartfalen-emperor-pooled-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/04/06/nierfunctiebeoordeling-en-eindpuntbepaling-in-klinische-trials-ehj/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-en-renale-uitkomsten-bij-hartfalen-nejm-emperor-reduced-renal/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/09/28/nt-probnp-prognose-en-empagliflozine-effect-bij-emperor-reduced/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/03/23/mra-en-empagliflozine-interactie-bij-hf-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/03/23/empagliflozine-bij-hfref-met-volume-overbelasting-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/09/29/arni-en-renale-uitkomsten-bij-hfpef-paragon-hf/","published":"2020-09-29"},{"url":"https://hartvaat.nl/2020/09/19/sglt2-remmers-bij-hfref-meta-analyse-van-emperor-reduced-en-dapa-hf/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2020/07/11/levenslang-voordeel-van-uitgebreide-hfref-farmacotherapie-lancet-schatting/","published":"2020-07-11"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/01/28/eerdere-hf-hospitalisatie-en-sacubitril-valsartan-versus-valsartan-bij-hfpef-par/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/03/26/bnp-tijdens-sacubitril-valsartan-paradigm-hf/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2019/02/26/sacubitril-valsartan-en-biomarkers-van-extracellulaire-matrixregulatie-bij-hfref/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2019/01/08/hfref-differentiele-impact-op-mannen-en-vrouwen/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/12/01/number-needed-to-treat-met-arni-voor-preventie-van-cv-dood-of-hf-hospitalisatie/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/06/01/sacubitril-valsartan-en-fysieke-en-sociale-activiteitsbeperkingen-bij-hf-paradig/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/11/14/af-type-en-uitkomsten-bij-hfref/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/06/20/hartfrequentie-en-ritme-en-het-voordeel-van-betablokkers-bij-hartfalen/","published":"2017-06-20"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/04/14/systolische-bloeddruk-en-werkzaamheid-van-sacubitril-valsartan-bij-chronisch-hfr/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/01/01/verminderd-hyperkaliemierisico-met-mra-door-sacubitril-valsartan-bij-hartfalen/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/12/06/prognostische-implicaties-van-nt-probnp-veranderingen-bij-hartfalen/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/11/29/bmi-en-nauwkeurigheid-van-nt-probnp-en-bnp-voor-diagnose-van-acuut-hartfalen/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/07/19/sacubitril-valsartan-en-30-daagse-heropname-na-hartfalenhospitalisatie/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/06/07/klinische-verslechtering-van-poliklinisch-behandeld-hartfalen-paradigm-hf-analys/","published":"2016-06-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bela-merkely","type":"person","url":"https://hartvaat.nl/mensen/bela-merkely/","name":"Béla Merkely","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":62,"articles":[{"url":"https://hartvaat.nl/2026/05/21/eplerenon-halveert-recidief-ventriculaire-tachycardie-versus-spironolacton-bij-h/","published":"2026-06-08"},{"url":"https://hartvaat.nl/2025/01/01/aficamten-bij-obstructieve-hcm-multidomeinanalyse-van-maple-hcm/","published":"2026-03-14"},{"url":"https://hartvaat.nl/2025/01/01/aficamten-versus-metoprolol-betere-levenskwaliteit-bij-obstructieve-hcm/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","published":"2025-09-20"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/af-en-semaglutide-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/07/02/upgrade-rv-naar-crt-pacing-bij-hartfalen-met-af-voordelen-bevestigd/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/closed-loop-stimulatie-vermindert-ahre-s-versus-conventionele-rate-adaptieve-pac/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/10/21/upgrade-van-rv-pacing-naar-crt-bij-hartfalen-gerandomiseerde-trial/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2023/09/26/biodegradeerbare-versus-duurzame-polymeer-stents-bij-hoog-bloedingsrisico/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2023/04/01/natriumzirconiumcyclosilicaat-bij-hyperkaliemie-en-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/asundexian-factor-xia-remmer-na-acs-fase-2-dosisfindingsstudie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/09/15/polypill-voor-secundaire-cardiovasculaire-preventie-secure-trial-in-nejm/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/11/08/closed-loop-stimulatie-en-cardiopulmonale-variabelen-bij-chronisch-hf-met-chrono/","published":"2021-11-08"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/11/01/determinanten-van-linkeratriumtrombi-bij-geplande-cardioversie-ensure-af/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2018/09/01/cer-001-hdl-mimeticum-en-coronaire-atherosclerose-na-acs-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/08/01/inhalatie-stikstofoxide-bij-stemi-nomi-gerandomiseerde-trial/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/02/01/katheterablatie-bij-af-met-hartfalen-nejm-castle-af/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/11/01/klinische-presentatie-bij-eerste-hartfalenhospitalisatie-voorspelt-geen-heropnam/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","published":"2017-10-19"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2017/09/01/budapest-crt-upgrade-study-studieontwerp-voor-crt-upgrade/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"},{"url":"https://hartvaat.nl/2016/10/22/edoxaban-versus-enoxaparine-warfarine-bij-cardioversie-van-af-ensure-af-trial/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/04/21/mtp-131-bij-reperfusieschade-na-stemi-de-embrace-stemi-fase-2a-trial/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shaun-g-goodman","type":"person","url":"https://hartvaat.nl/mensen/shaun-g-goodman/","name":"Shaun G Goodman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":62,"articles":[{"url":"https://hartvaat.nl/2026/05/26/odyssey-outcomes-post-hoc-hscrp-en-il-6-zijn-complementaire-prognostische-marker/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/03/25/antitrombotische-therapie-bij-af-na-acs-pci-augustus-gecombineerde-inzichten/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2024/09/03/augustus-4-weg-vergelijking-antitrombotische-strategieen-bij-af-na-acs-pci/","published":"2024-09-03"},{"url":"https://hartvaat.nl/2024/07/09/bempedoinezuur-versus-statines-vergelijking-van-cv-voordelen/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2022/02/08/antitrombotische-therapie-bij-af-na-acs-of-pci-jacc-overzicht/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","published":"2021-08-03"},{"url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2021/03/01/objectieve-risicobeoordeling-versus-standaardzorg-bij-acs-jama-cardiology/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/08/25/genotype-geleide-p2y12-selectie-versus-clopidogrel-na-pci-jama-tailor-pci/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/05/19/pav-en-vte-na-acs-rol-van-lp-a-en-modificatie-door-alirocumab/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2020/02/04/aanhoudende-ldl-verlaging-met-alirocumab-in-odyssey-outcomes/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/11/19/empagliflozine-en-lv-massa-bij-diabetes-type-2-met-coronairlijden-empa-heart/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/11/01/interventies-voor-statinevoorschrijving-bij-primaire-cv-preventie-meta-analyse/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"},{"url":"https://hartvaat.nl/2018/07/31/antitrombotische-therapie-bij-af-met-oac-na-pci-aha-scientific-statement/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/08/01/voorspelling-van-bloedingsrisico-tijdens-dapt-na-acs/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/05/25/levosimendan-bij-lv-disfunctie-voor-hartchirurgie-nejm-levo-cts/","published":"2017-05-25"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/01/17/dapt-versus-aspirine-monotherapie-bij-diabetes-met-multivatenlijden-na-cabg-free/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marco-valgimigli","type":"person","url":"https://hartvaat.nl/mensen/marco-valgimigli/","name":"Marco Valgimigli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":61,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/07/08/amulet-versus-watchman-flx-driejaarsresultaten-laa-sluiting/","published":"2025-07-08"},{"url":"https://hartvaat.nl/2024/12/01/korte-dapt-na-des-bij-acs-ipd-meta-analyse-bevestigt-veiligheid/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","published":"2024-02-06"},{"url":"https://hartvaat.nl/2024/01/01/verkorte-dapt-bij-hoog-bloedingsrisico-geen-sekseverschillen/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/09/26/biodegradeerbare-versus-duurzame-polymeer-stents-bij-hoog-bloedingsrisico/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/02/02/dalend-hemoglobine-en-prognose-bij-acs-hospitalisatie/","published":"2021-02-02"},{"url":"https://hartvaat.nl/2021/01/21/korte-dapt-gevolgd-door-p2y12-mono-versus-verlengde-dapt-meta-analyse/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2020/12/22/fentanyl-versus-morfine-op-ticagrelor-plaatjesremming-bij-stemi/","published":"2020-12-22"},{"url":"https://hartvaat.nl/2020/12/14/edoxaban-bij-af-met-pci-naar-acute-versus-chronische-coronaire-presentatie-entru/","published":"2020-12-14"},{"url":"https://hartvaat.nl/2020/08/04/cangrelor-tirofiban-en-prasugrel-bij-stemi-primaire-resultaten/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/05/26/subcutaan-selatogrel-remt-plaatjesaggregatie-bij-acuut-mi/","published":"2020-05-26"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2020/01/01/weglaten-van-aspirine-bij-gecombineerde-antitrombotische-therapie-voor-af-acs-he/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/12/07/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-veiligheid-en-werk/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/12/edoxaban-versus-vka-gebaseerd-antitrombotisch-regime-na-stenting-bij-af-lancet-e/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/10/05/biodegradeerbare-versus-duurzame-polymer-des-bij-stemi-gerandomiseerde-trial/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2019/04/14/aki-en-bloedingen-en-mortaliteit-na-radiale-versus-femorale-toegang-bij-acs/","published":"2019-04-14"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2019/01/29/microvasculaire-schade-bij-gerevasculariseerde-stemi-met-ticagrelor-versus-prasu/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/08/07/adenosine-en-ticagrelorspiegels-bij-patienten-met-en-zonder-ticagrelor-dyspneu/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2018/03/20/effecten-van-ticagrelor-prasugrel-of-clopidogrel-op-endotheelfunctie/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2018/01/07/2017-esc-richtlijn-voor-stemi-management/","published":"2018-01-07"},{"url":"https://hartvaat.nl/2017/05/23/stralingsblootstelling-en-vasculaire-toegang-bij-acs-rad-matrix-trial/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2017/03/14/afweging-myocardinfarct-versus-bloedingstype-en-mortaliteit-na-acs-tra-2p-timi-5/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/10/01/langere-versus-korte-dapt-na-pci-met-en-zonder-periprocedureel-mi-jama-cardiolog/","published":"2016-10-01"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"},{"url":"https://hartvaat.nl/2016/01/23/everolimus-eluting-stent-versus-bare-metal-stent-bij-stemi-5-jaarsresultaten-exa/","published":"2016-01-23"},{"url":"https://hartvaat.nl/2016/01/21/langdurige-duale-antiplaatjestherapie-bij-patienten-met-eerder-myocardinfarct-me/","published":"2016-01-21"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mark-c-petrie","type":"person","url":"https://hartvaat.nl/mensen/mark-c-petrie/","name":"Mark C Petrie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":59,"articles":[{"url":"https://hartvaat.nl/2026/04/21/jacc-beschouwing-placebo-in-trials-met-incretine-therapie-bij-hartfalen-wetensch/","published":"2026-07-18"},{"url":"https://hartvaat.nl/2026/05/21/find-af-biomarker-stratificeert-prognose-bij-hfref-met-atriale-cardiomyopathie-z/","published":"2026-06-08"},{"url":"https://hartvaat.nl/2026/05/09/subcut-hf-ii-subcutane-furosemide-thuis-verlaagt-opnameduur-met-5-5-dagen-na-har/","published":"2026-05-11"},{"url":"https://hartvaat.nl/2026/03/25/meta-analyse-glp-1-agonisten-voorkomen-hartfalen-in-type-2-diabetes-sterkste-eff/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/01/01/hartfalenpreventie-bewijsgeneratie-trialontwerp-en-regulatoire-trajecten/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/03/semaglutide-versus-tirzepatide-bij-patienten-met-obesitas-en-hfpef/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/af-en-semaglutide-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","published":"2024-08-27"},{"url":"https://hartvaat.nl/2024/07/23/anatomische-versus-viabiliteitsgerichte-completeness-van-revascularisatie/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/05/15/implanteerbare-hemodynamische-monitoring-bij-hartfalen-meta-analyse-over-ef-spec/","published":"2023-05-15"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/10/13/revived-bcis2-pci-verbetert-overleving-niet-bij-ischemische-lv-disfunctie/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/12/01/hartfalen-en-atriumflutter-systematische-review/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/05/01/pci-versus-medicamenteus-bij-angina-met-ffr-in-de-grijze-zone/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/01/08/hfref-differentiele-impact-op-mannen-en-vrouwen/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/10/01/transcatheter-interatriale-shunt-bij-hfpef-1-jaarsresultaten/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/10/01/associatie-is-geen-causaliteit-behandeleffecten-bij-hartfalen-en-observationele-/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/01/23/transcatheter-interatriale-shunt-bij-hfpef-reduce-lap-hf-i/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/02/21/diabetesstatus-en-cardiovasculaire-uitkomsten-bij-hfpef-klinische-en-echocardiog/","published":"2017-02-21"},{"url":"https://hartvaat.nl/2016/12/15/infarctgrootte-en-linkerkamerremodellering-na-preventieve-pci/","published":"2016-12-15"},{"url":"https://hartvaat.nl/2016/11/01/tienjaarsuitkomsten-na-cabg-naar-leeftijd-bij-hartfalen-met-lv-systolische-disfu/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/21/coronaire-bypasschirurgie-bij-ischemische-cardiomyopathie-nejm-stich-trial/","published":"2016-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sabina-a-murphy","type":"person","url":"https://hartvaat.nl/mensen/sabina-a-murphy/","name":"Sabina A Murphy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":58,"articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","published":"2025-10-02"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/05/20/intensieve-ldl-verlaging-met-evolocumab-bij-auto-immuunziekten-rct/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/02/11/langetermijn-evolocumab-bij-ouderen-effectiviteit-en-veiligheid/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2024/09/01/eldercare-af-subanalyse-dosisreductie-edoxaban-bij-80-jarigen-met-af/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-hypertriglyceridemie-en-hoog-cv-risico-nejm/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/11/17/olpasiran-sirna-verlaagt-lipoproteine-a-spectaculair-in-fase-2-trial/","published":"2022-11-17"},{"url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","published":"2022-10-11"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/08/30/biomarkers-voorspellen-complexe-coronaire-revascularisatie-in-fourier/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2022/05/03/vupanorsen-en-non-hdl-cholesterol-bij-statinebehandelde-patienten-translate-timi/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/03/09/halve-versus-volle-dosis-edoxaban-bij-af-gerandomiseerde-vergelijking/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2021/02/01/evolocumab-bij-metabool-syndroom-na-acs-fourier/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/08/11/veiligheid-van-aspirinestaken-met-p2y12-achtergrond-na-pci-meta-analyse/","published":"2020-08-11"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/03/17/non-culprit-mi-na-pci-bij-acs/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/07/16/edoxaban-versus-warfarine-bij-af-met-leverziekte-engage-af-timi-48/","published":"2019-07-16"},{"url":"https://hartvaat.nl/2019/07/01/evolocumab-en-totale-cv-events-bij-cardiovasculaire-ziekte-fourier-analyse/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/02/01/edoxaban-en-implanteerbare-cardiale-devices-engage-af-timi-48/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2019/01/01/interindividuele-variatie-in-ldl-verlaging-met-evolocumab-fourier-analyse/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/09/01/verdere-ldl-verlaging-bij-reeds-zeer-lage-niveaus-jama-cardiology-meta-analyse/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/08/21/klinisch-voordeel-van-evolocumab-naar-ernst-van-coronairlijden-fourier/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/07/10/fatale-of-irreversibele-bloedingen-en-ischemische-events-met-rivaroxaban-bij-acs/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/07/10/inflammatie-en-cholesterol-in-de-fourier-trial/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/12/19/cva-preventie-met-ezetimibe-bij-acs-improve-it-analyse/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/12/01/evolocumab-bij-hoogrisicopatienten-met-laag-ldl-op-statine-fourier-subanalyse/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2017/05/04/evolocumab-en-klinische-uitkomsten-bij-cardiovasculaire-ziekte-nejm-fourier/","published":"2017-05-04"},{"url":"https://hartvaat.nl/2017/05/01/langetermijnveiligheid-van-zeer-lage-ldl-cholesterolniveaus-improve-it-analyse/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/12/21/ezetimibe-bij-post-cabg-patienten-met-acs-improve-it-subanalyse/","published":"2016-12-21"},{"url":"https://hartvaat.nl/2016/09/13/edoxaban-versus-warfarine-bij-af-patienten-met-valrisico-engage-af-timi-48-analy/","published":"2016-09-13"},{"url":"https://hartvaat.nl/2016/07/26/atherotrombotische-risicostratificatie-en-vorapaxar-bij-stabiel-ischemisch-hartl/","published":"2016-07-26"},{"url":"https://hartvaat.nl/2016/07/19/serieel-cardiaal-troponine-met-hoog-sensitieve-assay-bij-stabiel-ischemisch-hart/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/07/05/nierfunctie-en-uitkomsten-met-edoxaban-in-de-engage-af-timi-48-trial/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/06/14/reductie-van-ischemische-events-met-ticagrelor-bij-diabetes-na-myocardinfarct-pe/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/03/08/acute-ledischemie-en-vorapaxar-bij-perifeer-arterieel-vaatlijden-tra-2p-timi-50-/","published":"2016-03-08"},{"url":"https://hartvaat.nl/2016/02/02/reductie-in-totale-cardiovasculaire-events-met-ezetimibe-simvastatine-na-acs-imp/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"harvey-d-white","type":"person","url":"https://hartvaat.nl/mensen/harvey-d-white/","name":"Harvey D White","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":56,"articles":[{"url":"https://hartvaat.nl/2026/05/26/odyssey-outcomes-post-hoc-hscrp-en-il-6-zijn-complementaire-prognostische-marker/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/23/pci-versus-cabg-en-gezondheidsstatus-bij-stabiel-coronairlijden/","published":"2025-09-23"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2024/07/10/intracoronaire-trombolyse-bij-stemi-meta-analyse/","published":"2024-07-10"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/10/14/dal-gene-farmacogenetica-geleide-dalcetrapib-na-acs/","published":"2022-10-14"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","published":"2021-08-03"},{"url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/05/19/pav-en-vte-na-acs-rol-van-lp-a-en-modificatie-door-alirocumab/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2020/02/04/aanhoudende-ldl-verlaging-met-alirocumab-in-odyssey-outcomes/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/12/07/laesiecomplexiteit-en-periprocedurele-events-bij-potente-iv-antiplaatjestherapie/","published":"2018-12-07"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/12/19/cva-preventie-met-ezetimibe-bij-acs-improve-it-analyse/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-bij-stabiel-coronairlijden-stability-inzic/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/08/01/voorspelling-van-bloedingsrisico-tijdens-dapt-na-acs/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/03/14/afweging-myocardinfarct-versus-bloedingstype-en-mortaliteit-na-acs-tra-2p-timi-5/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2017/02/01/cangrelor-versus-gpiib-iiia-remmers-ischemie-en-bloedingsrisico-s-vergeleken/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/01/17/cangrelor-met-en-zonder-gpiib-iiia-remmers-bij-pci/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/11/29/presentatie-buiten-kantoortijden-versus-tijdens-kantoortijden-bij-stemi-champion/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/11/01/tienjaarsuitkomsten-na-cabg-naar-leeftijd-bij-hartfalen-met-lv-systolische-disfu/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/09/13/edoxaban-versus-warfarine-bij-af-patienten-met-valrisico-engage-af-timi-48-analy/","published":"2016-09-13"},{"url":"https://hartvaat.nl/2016/09/06/consistente-reductie-in-periprocedureel-mi-met-cangrelor-champion-analyses/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/08/01/eerder-clopidogrelgebruik-en-uitkomsten-bij-conservatief-behandeld-acs/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/07/19/serieel-cardiaal-troponine-met-hoog-sensitieve-assay-bij-stabiel-ischemisch-hart/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/04/19/trends-in-behandeling-en-uitkomsten-bij-nste-acs-naar-leeftijd/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/04/07/cangrelor-en-toegangsplaats-effect-op-ischemische-en-bloedingsevents-champion-ph/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"},{"url":"https://hartvaat.nl/2016/03/01/cyp2c19-metaboliseerdersstatus-en-uitkomsten-bij-acs-prasugrel-versus-clopidogre/","published":"2016-03-01"},{"url":"https://hartvaat.nl/2016/01/21/neoplasiedetectie-bij-langdurige-dapt-met-prasugrel-versus-clopidogrel-triton-ti/","published":"2016-01-21"},{"url":"https://hartvaat.nl/2016/01/19/werkzaamheid-en-veiligheid-van-cangrelor-bij-vrouwen-versus-mannen-tijdens-pci-c/","published":"2016-01-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adriaan-a-voors","type":"person","url":"https://hartvaat.nl/mensen/adriaan-a-voors/","name":"Adriaan A Voors","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":54,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/05/28/atriumfibrilleren-en-hartfalen-versterken-elkaar-en-verhogen-sterfte-aanzienlijk/","published":"2026-07-28"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/16/farmacologische-behandeling-van-hfref-geactualiseerde-systematische-review/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/01/vericiguat-voordeel-geprojecteerd-op-paradigm-hf-en-dapa-hf-populaties/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/01/amethyst-verinurad-plus-allopurinol-bij-hfpef-negatieve-trial/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","published":"2024-09-21"},{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2024/08/01/candesartan-dosering-bij-mannen-versus-vrouwen-met-chronisch-hartfalen/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"},{"url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2019/12/01/hepatorenale-disfunctie-identificeert-hoogrisico-acuut-hf-relax-ahf/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2019/06/04/neladenoson-bialanaat-en-inspanningscapaciteit-bij-hfpef-jama-panache/","published":"2019-06-04"},{"url":"https://hartvaat.nl/2017/08/07/trv027-biased-ligand-van-de-angiotensine-ii-receptor-bij-acuut-hartfalen-gerando/","published":"2017-08-07"},{"url":"https://hartvaat.nl/2017/06/27/hospitalisatie-voor-nieuw-gediagnosticeerd-versus-verslechterend-chronisch-hartf/","published":"2017-06-27"},{"url":"https://hartvaat.nl/2016/12/10/omecamtiv-mecarbil-bij-chronisch-hartfalen-lancet-cosmic-hf-fase-2-trial/","published":"2016-12-10"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"},{"url":"https://hartvaat.nl/2016/07/14/finerenon-versus-eplerenon-bij-hartfalen-met-diabetes-en-verslechterende-nierfun/","published":"2016-07-14"},{"url":"https://hartvaat.nl/2016/03/19/serca2a-gentherapie-bij-hartfalen-de-cupid-2-trial/","published":"2016-03-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bertram-pitt","type":"person","url":"https://hartvaat.nl/mensen/bertram-pitt/","name":"Bertram Pitt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":53,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/12/01/supar-en-uitkomsten-bij-hfpef-topcat-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/11/14/nierfunctietrajecten-voor-en-na-hospitalisatie-voor-hfref/","published":"2025-11-14"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/02/01/finerenon-en-lvh-bij-ckd-en-diabetes/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","published":"2024-09-21"},{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2024/06/18/mra-bij-hartfalen-met-nierfunctiestoornissen-veiligheid-en-effectiviteit/","published":"2024-06-18"},{"url":"https://hartvaat.nl/2024/02/01/transform-hf-torsemide-versus-furosemide-bij-nieuw-vs-chronisch-hartfalen/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/07/18/sglt2-remmers-verbeteren-kwaliteit-van-leven-gelijk-bij-zwarte-en-witte-hartfale/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2023/07/11/transform-hf-torsemide-versus-furosemide-geen-verschil-in-symptomen/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/01/17/transform-hf-torsemide-biedt-geen-overlevingsvoordeel-boven-furosemide/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/12/01/finerenon-bloeddrukeffecten-en-cardiorenale-uitkomsten-bij-ckd-en-diabetes/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/02/10/finerenon-cv-en-renale-uitkomsten-bij-diabetes-met-ckd-fidelity-gepoolde-analyse/","published":"2022-02-10"},{"url":"https://hartvaat.nl/2022/02/08/finerenon-vermindert-incident-hf-bij-ckd-met-diabetes-fidelity/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/12/09/finerenon-bij-nierziekte-met-diabetes-type-2-nejm-figaro-dkd/","published":"2021-12-09"},{"url":"https://hartvaat.nl/2021/07/13/finerenon-vermindert-nieuw-onset-af-bij-ckd-met-diabetes-fidelio-dkd/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/01/kbp-5074-en-bloeddruk-bij-gevorderde-ckd-block-ckd/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2021/02/09/finerenon-en-cardiovasculaire-uitkomsten-bij-ckd-met-diabetes-type-2-fidelio-dkd/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/07/01/mra-bij-hypertensie-met-gevorderde-ckd-block-ckd-trial/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2018/11/01/aldosteronblokkade-bij-myocardinfarct-ipd-analyse-van-twee-trials/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/10/01/natriuretische-peptiden-en-cardiovasculaire-prognose-bij-hfpef-topcat/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/08/01/langetermijn-patiromer-bij-hyperkaliemie-met-mild-hf-en-diabetische-nefropathie/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/06/01/geindividualiseerd-patiromer-doseringsregime-bij-hf-met-ckd-en-hyperkaliemie/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/02/20/cva-risico-bij-verminderde-ef-na-mi-zonder-af/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/09/12/lichamelijke-activiteit-en-prognose-bij-hfpef-topcat-analyse/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2016/07/14/finerenon-versus-eplerenon-bij-hartfalen-met-diabetes-en-verslechterende-nierfun/","published":"2016-07-14"},{"url":"https://hartvaat.nl/2016/02/01/invloed-van-ejectiefractie-op-uitkomsten-van-spironolacton-bij-hfpef/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kenneth-w-mahaffey","type":"person","url":"https://hartvaat.nl/mensen/kenneth-w-mahaffey/","name":"Kenneth W Mahaffey","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":53,"articles":[{"url":"https://hartvaat.nl/2026/02/23/semaglutide-vermindert-infectierisico-bij-diabetes-en-chronische-nierziekte/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","published":"2025-03-24"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/10/22/flow-semaglutide-vermindert-hartfalen-bij-diabetes-en-ckd/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/07/11/flow-semaglutide-beschermt-nieren-bij-type-2-diabetes-en-ckd-nejm-gerelateerd/","published":"2024-07-11"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/12/06/apixaban-bij-af-op-hemodialyse-eerste-gerandomiseerde-trial/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/02/08/stress-cardiale-biomarkers-en-cv-renale-uitkomsten-bij-canagliflozine/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2021/04/01/canagliflozine-naar-diureticagebruik-canvas-post-hoc-analyse/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/11/03/canagliflozine-en-nt-probnp-implicaties-voor-cv-risicoreductie/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/08/04/2020-acc-bloedingsmanagement-bij-oac-expert-consensus-decision-pathway/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/02/01/geschiktheid-voor-sglt2-remmers-bij-diabetespatienten-opgenomen-met-hartfalen/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"},{"url":"https://hartvaat.nl/2019/05/28/canagliflozine-en-hf-uitkomsten-bij-behouden-versus-verminderde-ef-canvas/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2019/01/01/mi-bij-pav-patienten-incidentie-en-uitkomsten-euclid/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/12/25/cv-en-ledemaat-uitkomsten-bij-diabetes-met-pav-euclid/","published":"2018-12-25"},{"url":"https://hartvaat.nl/2018/12/07/laesiecomplexiteit-en-periprocedurele-events-bij-potente-iv-antiplaatjestherapie/","published":"2018-12-07"},{"url":"https://hartvaat.nl/2018/12/01/ras-etniciteit-en-oac-gebruik-bij-af-orbit-af/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/12/01/multipele-biomarkers-en-mortaliteitsrisico-na-acs-jama-cardiology/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"},{"url":"https://hartvaat.nl/2018/07/31/canagliflozine-en-hartfalen-bij-diabetes-type-2-canvas-programma/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/01/23/canagliflozine-voor-primaire-en-secundaire-cardiovasculaire-preventie-canvas/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/08/17/canagliflozine-en-cardiovasculaire-en-renale-events-bij-diabetes-type-2-nejm-can/","published":"2017-08-17"},{"url":"https://hartvaat.nl/2017/08/01/voorspelling-van-bloedingsrisico-tijdens-dapt-na-acs/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/03/14/afweging-myocardinfarct-versus-bloedingstype-en-mortaliteit-na-acs-tra-2p-timi-5/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2017/02/01/cangrelor-versus-gpiib-iiia-remmers-ischemie-en-bloedingsrisico-s-vergeleken/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/01/17/cangrelor-met-en-zonder-gpiib-iiia-remmers-bij-pci/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/12/20/off-label-doac-dosering-en-ongunstige-uitkomsten-orbit-af-ii-register/","published":"2016-12-20"},{"url":"https://hartvaat.nl/2016/11/29/presentatie-buiten-kantoortijden-versus-tijdens-kantoortijden-bij-stemi-champion/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/09/06/consistente-reductie-in-periprocedureel-mi-met-cangrelor-champion-analyses/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/08/01/hospitalisaties-bij-atriumfibrilleren-analyse-uit-rocket-af/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/07/05/verslechterende-nierfunctie-en-uitkomsten-met-rivaroxaban-versus-warfarine-rocke/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/07/01/natief-kleplijden-bij-af-patienten-op-warfarine-of-rivaroxaban/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/04/19/trends-in-behandeling-en-uitkomsten-bij-nste-acs-naar-leeftijd/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/04/07/cangrelor-en-toegangsplaats-effect-op-ischemische-en-bloedingsevents-champion-ph/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/01/26/polyfarmacie-en-werkzaamheid-van-rivaroxaban-versus-warfarine-bij-atriumfibrille/","published":"2016-01-26"},{"url":"https://hartvaat.nl/2016/01/19/werkzaamheid-en-veiligheid-van-cangrelor-bij-vrouwen-versus-mannen-tijdens-pci-c/","published":"2016-01-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-bohm","type":"person","url":"https://hartvaat.nl/mensen/michael-bohm/","name":"Michael Böhm","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":53,"articles":[{"url":"https://hartvaat.nl/2026/03/04/leeftijd-en-geslacht-beinvloeden-verband-tussen-ambulante-bloeddruk-en-cardiovas/","published":"2026-03-22"},{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/02/23/immunoadsorptie-bij-gedilateerde-cardiomyopathie-de-iaso-dcm-trial/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/09/25/digitoxine-bij-hfref-gerandomiseerde-trial-nejm/","published":"2025-09-25"},{"url":"https://hartvaat.nl/2025/07/14/hartfrequentieverlagende-middelen-en-uitkomsten-bij-hypertensie-cvd-meta-analyse/","published":"2025-07-14"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2024/11/12/renale-denervatie-bij-hypertensie-uitgebreide-meta-analyse-van-alle-trials/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/10/05/iv-ferricarboxymaltose-en-inspanningscapaciteit-bij-hfpef-met-ijzerdeficientie/","published":"2024-10-05"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/08/20/tadalafil-bij-gecombineerde-post-en-precapillaire-ph-en-hfpef/","published":"2024-08-20"},{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2023/10/01/ivabradine-bij-hoogrisico-hartfalenpatienten-shift-analyse/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/08/01/empagliflozine-vermindert-nierletselmarkers-bij-acuut-hartfalen/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"},{"url":"https://hartvaat.nl/2022/07/01/pulsatiele-hemodynamiek-voorspelt-bloeddrukrespons-op-renale-denervatie/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/10/01/apothekerzorg-bij-poliklinisch-hf-meta-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/09/07/hartfrequentie-en-uitkomsten-van-renale-denervatie-bij-ongecontroleerde-hyperten/","published":"2021-09-07"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/04/14/systolische-bloeddruk-bij-hfpef-behandeld-met-sacubitril-valsartan-paragon-hf/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/03/10/overleving-na-revascularisatie-met-paclitaxel-gecoate-ballonnen/","published":"2020-03-10"},{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/03/01/ambulante-hartfrequentiereductie-na-renale-denervatie-bij-hypertensie-zonder-med/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/10/09/24-uurs-ambulante-bloeddrukreductie-na-renale-denervatie-spyral-htn-off-med/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2018/09/01/bereikte-diastolische-bloeddruk-en-polsdruk-bij-streef-sbp-en-cv-uitkomsten-bij-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/06/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-6-maandsresultat/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2017/11/01/gemiddelde-bloeddruk-en-visit-to-visit-variabiliteit-als-gecombineerde-voorspell/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/06/20/hartfrequentie-en-ritme-en-het-voordeel-van-betablokkers-bij-hartfalen/","published":"2017-06-20"},{"url":"https://hartvaat.nl/2017/06/03/bereikte-bloeddruk-en-cv-uitkomsten-bij-hoogrisicopatienten-ontarget-transcend/","published":"2017-06-03"},{"url":"https://hartvaat.nl/2017/04/14/systolische-bloeddruk-en-werkzaamheid-van-sacubitril-valsartan-bij-chronisch-hfr/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/01/07/verminderd-bloeddrukverlagend-effect-van-renale-denervatie-bij-geisoleerde-systo/","published":"2017-01-07"},{"url":"https://hartvaat.nl/2016/11/01/vochtstatustelemonitoring-bij-hartfalen-gerandomiseerde-trial/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/07/14/finerenon-versus-eplerenon-bij-hartfalen-met-diabetes-en-verslechterende-nierfun/","published":"2016-07-14"},{"url":"https://hartvaat.nl/2016/06/28/escitalopram-bij-hartfalen-en-depressie-de-mood-hf-trial/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lawrence-a-leiter","type":"person","url":"https://hartvaat.nl/mensen/lawrence-a-leiter/","name":"Lawrence A Leiter","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":52,"articles":[{"url":"https://hartvaat.nl/2026/05/19/peulvruchten-in-de-voeding-verlagen-ldl-en-non-hdl-dose-response-meta-analyse-va/","published":"2026-06-13"},{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/02/19/evolocumab-en-doorgankelijkheid-van-veneuze-bypasses-na-cabg-newton-cabg-cardiol/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","published":"2025-09-20"},{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","published":"2024-04-30"},{"url":"https://hartvaat.nl/2023/08/08/glp-1-agonisten-met-en-zonder-sglt2-remmers-bij-type-2-diabetes-jacc-analyse/","published":"2023-08-08"},{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2022/12/21/orion-11-inclisiran-verlaagt-ldl-effectief-bij-primaire-preventie/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2022/09/01/dapagliflozine-effectief-ongeacht-cv-achtergrondmedicatie-declare-subanalyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/05/12/management-van-stabiel-coronairlijden-bij-diabetes-type-2-aha-scientific-stateme/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-bij-heterozygote-familiaire-hypercholesterolemie-nejm-orion-9/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-fase-3-bij-verhoogd-ldl-nejm-orion-10-en-orion-11/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2019/11/19/empagliflozine-en-lv-massa-bij-diabetes-type-2-met-coronairlijden-empa-heart/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/11/12/bempedoinezuur-toegevoegd-aan-statines-bij-hoog-cv-risico-jama-clear-harmony/","published":"2019-11-12"},{"url":"https://hartvaat.nl/2019/11/01/inclisiran-1-of-2-dosis-en-ldl-cholesterol-orion-1-1-jaarsfollow-up/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-cv-uitkomsten-met-of-zonder-eerder-mi-leader/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/10/27/albiglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-harmony-ou/","published":"2018-10-27"},{"url":"https://hartvaat.nl/2018/09/25/sirna-tegen-pcsk9-en-atherogene-lipoproteinen-orion-1-secundaire-eindpunten/","published":"2018-09-25"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2018/07/10/inflammatie-en-cholesterol-in-de-fourier-trial/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/05/15/liraglutide-bij-diabetes-type-2-met-polyvasculaire-ziekte-leader-analyse/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2018/02/01/lipoproteine-a-en-recidiverende-ischemische-events-na-acs-dal-outcomes-analyse/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/04/13/inclisiran-bij-patienten-met-hoog-cv-risico-en-verhoogd-ldl-nejm-orion-1/","published":"2017-04-13"},{"url":"https://hartvaat.nl/2017/04/01/fenofibraat-en-langetermijn-cardiovasculair-risico-bij-statinebehandelde-diabete/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/12/06/dalcetrapib-wijzigt-de-relatie-tussen-hdl-cholesterol-en-crp/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/11/10/semaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-sustain-6/","published":"2016-11-10"},{"url":"https://hartvaat.nl/2016/10/14/geen-effect-van-pcsk9-remmer-alirocumab-op-diabetes-incidentie-odyssey-analyse/","published":"2016-10-14"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-philippe-bertrand","type":"person","url":"https://hartvaat.nl/mensen/dr-philippe-bertrand/","name":"Philippe Bertrand","title":"Cardioloog, Ziekenhuis Oost-Limburg, Genk","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":1,"articles":[{"url":"https://hartvaat.nl/2026/03/25/inspanningsecho-identificeert-hcm-patienten-die-baat-hebben-bij-mavacamten/","published":"2026-03-25"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-trials-to-watch-gesprek/","title":"ESC 2026 Trials to Watch: het volledige gesprek"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-acacia-hcm/","title":"ACACIA-HCM: kan aficamten slagen waar andere myosineremmers faalden?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-staree/","title":"STAREE: verbeteren statines gezond ouder worden?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-amundsen/","title":"AMUNDSEN: verandert vroege PCSK9-remming de zorg na een infarct?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-premium/","title":"PREMIUM: is een aspirinevrije STEMI-behandeling de toekomst?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-a-close/","title":"A-CLOSE: is clopidogrel alleen genoeg na PCI?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-pvi-sham-af/","title":"PVI-SHAM-AF: presteert AF-ablatie beter dan placebo?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-single-af/","title":"SINGLE-AF: hebben AF-patiënten met intermediair risico antistolling nodig?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-laacs-2/","title":"LAACS-2: het linkerhartoor sluiten tijdens hartchirurgie?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-popular-ace-tavi/","title":"POPular ACE TAVI: protamine routinematig na TAVI?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-tavi-pci/","title":"TAVI PCI: revascularisatie vóór of na TAVI?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-notion-4-acasa-tavi/","title":"NOTION-4 en ACASA-TAVI: doet HALT ertoe?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-poet-ii/","title":"POET-II: kan de antibioticakuur bij endocarditis korter?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-prague-26/","title":"PRAGUE-26: verbetert kathetergerichte therapie de uitkomst bij longembolie?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-cmr-guide/","title":"CMR GUIDE: kan cardiale MRI de ICD-selectie verbeteren?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-syncope-stopper/","title":"Syncope-Stopper: vroege pacing voor sommige syncopepatiënten?"},{"url":"https://hartvaat.nl/video/esc26-preview-trials-to-watch/esc26-tric-i-hf/","title":"TRIC-I-HF: verbetert tricuspidalisinterventie de uitkomsten?"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adrian-f-hernandez","type":"person","url":"https://hartvaat.nl/mensen/adrian-f-hernandez/","name":"Adrian F Hernandez","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":51,"articles":[{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2024/09/01/aspirinedosering-voor-secundaire-preventie-bij-mannen-versus-vrouwen/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/12/21/iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-ipd-meta-analyse/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/10/03/vericiguat-bij-hfref-is-kosteneffectief-victoria-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2023/09/14/heart-fid-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-nejm/","published":"2023-09-14"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/08/08/glp-1-agonisten-met-en-zonder-sglt2-remmers-bij-type-2-diabetes-jacc-analyse/","published":"2023-08-08"},{"url":"https://hartvaat.nl/2023/07/04/sacubitril-valsartan-bij-hfmref-hfpef-met-verslechterend-hartfalen/","published":"2023-07-04"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","published":"2022-09-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/08/01/gdf-15-en-liraglutide-behandeling-bij-hf-patienten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2020/04/28/open-label-drop-in-van-glucoseverlagende-medicatie-en-exscel-uitkomsten/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2020/02/01/geschiktheid-voor-sglt2-remmers-bij-diabetespatienten-opgenomen-met-hartfalen/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/03/01/ziekenhuisgebaseerde-kwaliteitsinterventies-bij-hartfalen-systematische-review/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/12/01/liraglutide-en-gewicht-bij-gevorderd-hfref-fight-trial-inzichten/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","published":"2018-11-06"},{"url":"https://hartvaat.nl/2018/10/27/albiglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-harmony-ou/","published":"2018-10-27"},{"url":"https://hartvaat.nl/2018/05/08/nierfunctieverslechtering-bij-acuut-hartfalen-met-agressieve-diurese-geen-tubula/","published":"2018-05-08"},{"url":"https://hartvaat.nl/2017/09/28/exenatide-eenmaal-per-week-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-ne/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/06/27/hospitalisatie-voor-nieuw-gediagnosticeerd-versus-verslechterend-chronisch-hartf/","published":"2017-06-27"},{"url":"https://hartvaat.nl/2017/05/16/oraal-ijzer-bij-hfref-met-ijzerdeficientie-jama-ironout-hf/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/08/02/liraglutide-en-klinische-stabiliteit-bij-gevorderd-hartfalen-met-verminderde-ef-/","published":"2016-08-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-azeem-latib","type":"person","url":"https://hartvaat.nl/mensen/dr-azeem-latib/","name":"Dr. Azeem Latib","title":"Hoofd Interventiecardiologie, Montefiore Medical Center, VS","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/04/16/pandora-register-supra-versus-intra-annulaire-kleppen-bij-tavr-in-tavr/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2025/08/19/paclitaxel-gecoate-ballon-bij-multilayer-in-stent-restenose-agent-ide-subgroep/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/05/02/paclitaxel-gecoate-ballonnen-versus-des-bij-kleine-vaten-ipd-meta-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2021/08/24/de-escalatie-van-dapt-bij-acs-jacc-review/","published":"2021-08-24"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2020/03/10/overleving-na-revascularisatie-met-paclitaxel-gecoate-ballonnen/","published":"2020-03-10"}],"videos":[{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/hi-peitho-katheter-trombolyse-longembolie/","title":"HI-PEITHO: Kathetergeleide trombolyse bij intermediair-risico longembolie"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/champion-af-hartoorocclusie-versus-doacs/","title":"CHAMPION-AF: Linker hartoorocclusie versus DOAC's bij atriumfibrilleren"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/spirrit-hfpef-spironolacton-hartfalen/","title":"SPIRRIT-HFpEF: Spironolacton bij hartfalen met behouden en licht verlaagde ejectiefractie"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/stemi-dtu-ontlading-voor-primaire-pci/","title":"STEMI-DTU: Ontladingsstrategie vóór primaire PCI bij anterieur STEMI"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/chip-bcis3-impella-hoog-risico-pci/","title":"CHIP-BCIS3: Impella-ondersteuning bij hoog-risico PCI"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/orbita-cto-gecontroleerde-cto-pci/","title":"ORBITA-CTO: Placebogecontroleerde PCI bij chronische totaalocclusie"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/all-rise-fast-iii-ffrangio-vffr/","title":"ALL-RISE & FAST III: Angiografie-gebaseerde FFR versus draadgebaseerde FFR"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/optimal-beeldgeleide-pci-complex/","title":"OPTIMAL: Intravasculaire beeldgeleide PCI bij complexe coronairziekte"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/ivus-chip-echogeleide-hoog-risico-pci/","title":"IVUS-CHIP: Intravasculaire echogeleide hoog-risico PCI"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/dkcrush-viii-ivus-bifurcatie/","title":"DKCRUSH-VIII: IVUS-geleide DK Crush-techniek bij complexe bifurcatielaesies"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/pro-tavi-pci-versus-uitstel-bij-tavi/","title":"PRO-TAVI: Routinematige PCI versus uitstel bij patiënten die TAVI ondergaan"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/protect-h2h-cerebrale-bescherming-tavi/","title":"Protect H2H: Directe vergelijking van emboliebescherming tijdens TAVI"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/trifr-transcatheter-tricuspidalisreparatie/","title":"Tri.Fr: Transcatheter tricuspidalisreparatie"},{"url":"https://hartvaat.nl/video/acc26-preview-latib-van-mieghem/triscend-ii-evoque-tricuspidalisklepvervanging/","title":"TRISCEND II: Evoque transcatheter tricuspidalisklepvervanging bij ernstige regurgitatie"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-h-alexander","type":"person","url":"https://hartvaat.nl/mensen/john-h-alexander/","name":"John H Alexander","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":50,"articles":[{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/03/25/antitrombotische-therapie-bij-af-na-acs-pci-augustus-gecombineerde-inzichten/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2024/09/03/augustus-4-weg-vergelijking-antitrombotische-strategieen-bij-af-na-acs-pci/","published":"2024-09-03"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2022/10/18/asundexian-factor-xia-remmer-na-acs-fase-2-dosisfindingsstudie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/02/08/antitrombotische-therapie-bij-af-na-acs-of-pci-jacc-overzicht/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/05/01/vroegtijdig-permanent-staken-van-apixaban-of-warfarine-bij-af/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/01/19/stoppen-versus-doorgaan-met-ace-remmers-arb-s-bij-gehospitaliseerde-patienten-ja/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2020/11/26/rivaroxaban-bij-af-met-bioprothese-mitralisklep-nejm-river/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2020/05/01/optimaal-antitrombotisch-regime-bij-af-na-pci-jama-cardiology-netwerkmeta-analys/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/04/28/apixaban-versus-warfarine-bij-af-met-gevorderde-ckd/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2020/03/17/klinische-en-farmacologische-effecten-van-apixaban-dosisaanpassing-aristotle/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2020/01/07/nsaid-s-en-oac-bij-af-aristotle-analyse/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/08/01/antitrombotische-strategieen-bij-af-na-pci-jama-cardiology-veiligheids-en-werkza/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/11/01/timing-van-atorvastatine-oplaaddosis-voor-pci-bij-acs-jama-cardiology/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/08/14/adma-en-sdma-voorspellen-uitkomsten-bij-af-aristotle-substudie/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/08/01/uitkomsten-bij-af-met-oac-bij-mitralis-of-aortakleplijden/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/03/13/digoxine-en-mortaliteit-bij-patienten-met-atriumfibrilleren/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2018/03/01/doac-plus-antiplaatjestherapie-voor-secundaire-preventie-na-acs-meta-analyse/","published":"2018-03-01"},{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","published":"2018-02-07"},{"url":"https://hartvaat.nl/2017/05/25/levosimendan-bij-lv-disfunctie-voor-hartchirurgie-nejm-levo-cts/","published":"2017-05-25"},{"url":"https://hartvaat.nl/2017/04/01/niet-ernstige-bloedingen-met-apixaban-versus-warfarine-bij-af/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/11/29/biomarkergebaseerde-cva-risicoscore-bij-atriumfibrilleren-validatie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/09/01/apixaban-5-mg-bij-af-met-hoge-leeftijd-laag-gewicht-of-hoog-creatinine-aristotle/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/07/01/apixaban-versus-warfarine-bij-af-in-relatie-tot-nierfunctie-aristotle-analyse/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","published":"2016-06-04"},{"url":"https://hartvaat.nl/2016/04/19/trends-in-behandeling-en-uitkomsten-bij-nste-acs-naar-leeftijd/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/04/01/biomarkers-van-inflammatie-en-cardiovasculair-risico-bij-patienten-met-atriumfib/","published":"2016-04-01"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"salim-yusuf","type":"person","url":"https://hartvaat.nl/mensen/salim-yusuf/","name":"Salim Yusuf","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":48,"articles":[{"url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2024/06/25/raas-blokkade-bij-hartfalen-voordeel-onafhankelijk-van-etniciteit-jama-meta-anal/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2023/10/24/laaos-iii-laa-occlusie-en-anticoagulatiegebruik/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2023/08/24/vaste-dosiscombinatietherapie-voor-primaire-cv-preventie-ipd-meta-analyse/","published":"2023-08-24"},{"url":"https://hartvaat.nl/2023/02/01/aspirine-en-cardiovasculaire-uitkomsten-bij-chronische-nierziekte/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/09/15/invictus-rivaroxaban-versus-warfarine-bij-reumatische-hartziekte-en-af/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2021/11/01/antiplaatjestherapie-bij-mi-zonder-obstructief-coronairlijden-minoca/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/07/01/cv-gevolgen-van-stoppen-met-laaggedoseerd-rivaroxaban-bij-chronisch-vaatlijden/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","published":"2021-06-03"},{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2021/01/01/rivaroxaban-plus-aspirine-bij-symptomatisch-pav-compass-subanalyse/","published":"2021-01-01"},{"url":"https://hartvaat.nl/2020/11/01/ace2-niveaus-en-covid-19-risicofactoren-bij-af-patienten/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2019/10/21/digoxine-en-mortaliteit-gerandomiseerd-versus-observationeel-in-de-dig-trial/","published":"2019-10-21"},{"url":"https://hartvaat.nl/2019/10/05/uitgebreide-community-interventie-bij-hypertensie-lancet-hope-4/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2019/08/13/rivaroxaban-met-of-zonder-aspirine-bij-hf-met-coronair-of-perifeer-vaatlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/07/01/hospitalisatieredenen-en-mortaliteitsrisico-bij-af-met-dabigatran-versus-warfari/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/05/14/rivaroxaban-plus-aspirine-bij-vaatlijden-met-nierdisfunctie-compass/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2018/09/01/bereikte-diastolische-bloeddruk-en-polsdruk-bij-streef-sbp-en-cv-uitkomsten-bij-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/07/17/oac-plus-nsaid-bij-af-risico-op-ernstige-bloedingen/","published":"2018-07-17"},{"url":"https://hartvaat.nl/2018/06/09/dabigatran-bij-myocardschade-na-niet-cardiale-chirurgie-lancet-manage-trial/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","published":"2018-02-07"},{"url":"https://hartvaat.nl/2018/02/01/dabigatran-versus-warfarine-bij-af-met-linkerventrikelhypertrofie-re-ly/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2018/01/09/risico-s-van-overinterpretatie-van-interimdata-lessen-uit-de-total-trial/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/11/01/gemiddelde-bloeddruk-en-visit-to-visit-variabiliteit-als-gecombineerde-voorspell/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/07/01/dabigatran-naar-leeftijd-bij-atriumfibrilleren-re-ly-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/06/03/bereikte-bloeddruk-en-cv-uitkomsten-bij-hoogrisicopatienten-ontarget-transcend/","published":"2017-06-03"},{"url":"https://hartvaat.nl/2017/05/16/statines-voor-primaire-preventie-bij-ouderen-meta-analyse-van-jupiter-en-hope-3/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2017/03/07/cva-risico-bij-chronisch-hartfalen-met-behouden-ef-zonder-af-charm-analyse/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2017/01/10/trombusaspiratie-bij-stemi-individuele-patientdata-meta-analyse/","published":"2017-01-10"},{"url":"https://hartvaat.nl/2016/12/15/off-pump-versus-on-pump-cabg-5-jaarsresultaten-nejm-coronary-trial/","published":"2016-12-15"},{"url":"https://hartvaat.nl/2016/11/29/biomarkergebaseerde-cva-risicoscore-bij-atriumfibrilleren-validatie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/11/01/intensieve-bloeddrukbehandeling-120-80-mmhg-antagonist-standpunt/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/08/23/dabigatran-versus-warfarine-bij-af-met-kleplijden-re-ly-analyse/","published":"2016-08-23"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnevaluatie-van-dabigatran-150-versus-110-mg-bij-niet-valvulair-af/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","published":"2016-06-04"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"silvio-e-inzucchi","type":"person","url":"https://hartvaat.nl/mensen/silvio-e-inzucchi/","name":"Silvio E Inzucchi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":48,"articles":[{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/06/01/nierfunctie-en-dapagliflozine-effect-op-gezondheidsstatus-define-hf/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","published":"2025-05-29"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/03/26/grade-cv-uitkomsten-van-glucoseverlagende-middelen-bij-type-2-diabetes/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/10/21/prompt-ahf-epd-alerts-verbeteren-hartfalenmedicatie-bij-ontslag/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","published":"2022-09-03"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/06/07/elektronische-alerts-verbeteren-hartfalenbehandeling-in-de-polikliniek/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/09/15/empagliflozine-bij-hartfalen-diuretische-en-cardiorenale-effecten/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/05/12/management-van-stabiel-coronairlijden-bij-diabetes-type-2-aha-scientific-stateme/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/07/hypoglykemie-cv-uitkomsten-en-empagliflozine-empa-reg-outcome/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/08/01/empagliflozine-voorkomt-progressie-van-ckd-empa-reg-outcome-renale-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/03/12/empagliflozine-vermindert-mortaliteit-en-hf-hospitalisatie-over-het-cv-risicospe/","published":"2019-03-12"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2018/09/18/hartfalen-na-cva-tia-bij-insulineresistente-patienten-behandeld-met-pioglitazon/","published":"2018-09-18"},{"url":"https://hartvaat.nl/2018/02/01/empagliflozine-en-cv-dood-en-hf-hospitalisatie-over-het-hf-spectrum-empa-reg-out/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2018/01/23/empagliflozine-bij-diabetes-type-2-met-perifeer-vaatlijden-empa-reg-outcome/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2018/01/09/empagliflozine-bij-diabetes-type-2-met-cardiovasculaire-ziekte-en-ckd-empa-reg-o/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2016/07/28/empagliflozine-en-progressie-van-nierziekte-bij-diabetes-type-2-nejm-empa-reg-re/","published":"2016-07-28"},{"url":"https://hartvaat.nl/2016/04/07/pioglitazon-na-ischemisch-cva-of-tia-gerandomiseerde-nejm-trial/","published":"2016-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-p-cannon","type":"person","url":"https://hartvaat.nl/mensen/christopher-p-cannon/","name":"Christopher P Cannon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":47,"articles":[{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2024/06/25/vasculair-zorgteam-versus-educatie-bij-perifeer-arterieel-vaatlijden/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2024/06/04/drive-remote-management-verbetert-richtlijnmedicatie-bij-hartfalen/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/12/01/serieel-hoog-sensitief-troponine-t-voorspelt-cv-events-na-acs-odyssey-analyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/10/12/baseline-ldl-en-klinische-uitkomsten-van-ezetimibe-plus-statine-improve-it/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/04/01/canagliflozine-naar-diureticagebruik-canvas-post-hoc-analyse/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2021/02/09/2020-acc-consensus-anticoagulatie-en-antiplaatjestherapie-bij-af-of-vte/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2021/02/01/sglt2-remmers-en-cv-renale-uitkomsten-bij-diabetes-type-2-jama-cardiology-meta-a/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/12/08/ertugliflozine-en-hf-events-bij-diabetes-met-atherosclerotische-cvd-vertis-cv/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/11/21/ldl-verlaging-bij-ouderen-lancet-meta-analyse-werkzaamheid-en-veiligheid/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/10/08/ertugliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-vertis-cv/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/07/14/vergelijking-van-orale-p2y12-remmers-bij-acs-netwerkmeta-analyse-van-52-816-pati/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2020/05/01/zelfgerapporteerde-versus-apotheekgeregistreerde-medicatietrouw-compass-analyse/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/05/01/optimaal-antitrombotisch-regime-bij-af-na-pci-jama-cardiology-netwerkmeta-analys/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/01/p2y12-copay-reductie-en-therapietrouw-aan-andere-secundaire-preventiemiddelen/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/12/17/uitkomsten-van-vrouwen-versus-mannen-na-nste-acs/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/09/01/simvastatine-ezetimibe-versus-simvastatine-na-acs-bij-75-plussers-jama-cardiolog/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/08/01/antitrombotische-strategieen-bij-af-na-pci-jama-cardiology-veiligheids-en-werkza/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"},{"url":"https://hartvaat.nl/2019/05/14/dabigatran-duale-therapie-met-ticagrelor-of-clopidogrel-na-pci-bij-af-re-dual-pc/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/03/12/empagliflozine-vermindert-mortaliteit-en-hf-hospitalisatie-over-het-cv-risicospe/","published":"2019-03-12"},{"url":"https://hartvaat.nl/2019/01/01/medicatie-copay-vouchers-en-p2y12-gebruik-en-cv-events-na-mi-jama/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/12/01/multipele-biomarkers-en-mortaliteitsrisico-na-acs-jama-cardiology/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/07/31/antitrombotische-therapie-bij-af-met-oac-na-pci-aha-scientific-statement/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/07/14/ldl-verlaging-en-cv-events-met-pcsk9-remmers-meta-analyse-van-gerandomiseerde-tr/","published":"2018-07-14"},{"url":"https://hartvaat.nl/2018/06/01/fgf-23-en-recidiverende-cv-events-na-acs/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/05/14/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-meta-analyse/","published":"2018-05-14"},{"url":"https://hartvaat.nl/2018/04/10/ezetimibe-bij-diabetes-versus-zonder-diabetes-improve-it-subanalyse/","published":"2018-04-10"},{"url":"https://hartvaat.nl/2017/12/19/cva-preventie-met-ezetimibe-bij-acs-improve-it-analyse/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","published":"2017-10-19"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-bij-stabiel-coronairlijden-stability-inzic/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/09/28/anacetrapib-bij-atherosclerotisch-vaatlijden-nejm-hps3-timi55-reveal/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/05/16/serieel-hoog-sensitief-troponine-i-en-cv-uitkomsten-bij-diabetes-type-2-examine/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2017/05/01/langetermijnveiligheid-van-zeer-lage-ldl-cholesterolniveaus-improve-it-analyse/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/12/21/ezetimibe-bij-post-cabg-patienten-met-acs-improve-it-subanalyse/","published":"2016-12-21"},{"url":"https://hartvaat.nl/2016/12/13/alirocumab-en-reductie-in-atherogene-lipiden-en-cardiovasculaire-events-10-odyss/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/12/01/empagliflozine-en-bloeddruk-bij-diabetes-type-2-met-hypertensie-naar-achtergrond/","published":"2016-12-01"},{"url":"https://hartvaat.nl/2016/09/01/ace-remmers-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-met-dpp-4-remmers/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/07/19/serieel-cardiaal-troponine-met-hoog-sensitieve-assay-bij-stabiel-ischemisch-hart/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/04/12/protonpompremmers-verminderen-gastro-intestinale-events-ongeacht-aspirinedosis-b/","published":"2016-04-12"},{"url":"https://hartvaat.nl/2016/02/02/reductie-in-totale-cardiovasculaire-events-met-ezetimibe-simvastatine-na-acs-imp/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gregory-y-h-lip","type":"person","url":"https://hartvaat.nl/mensen/gregory-y-h-lip/","name":"Gregory Y H Lip","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":47,"articles":[{"url":"https://hartvaat.nl/2026/08/25/risicogestuurde-af-screening-met-machine-learning-verhoogt-detectiegraad-find-af/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/05/19/salamander-register-95-5-technisch-succes-bij-stand-alone-linker-hartoor-occlusi/","published":"2026-06-10"},{"url":"https://hartvaat.nl/2026/05/21/find-af-biomarker-stratificeert-prognose-bij-hfref-met-atriale-cardiomyopathie-z/","published":"2026-06-08"},{"url":"https://hartvaat.nl/2026/03/07/lancet-seminar-atriumfibrilleren-in-2026/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/02/27/prognose-takotsubo-syndroom-versus-hartfalen-op-de-lange-termijn/","published":"2026-03-09"},{"url":"https://hartvaat.nl/2026/02/27/van-vitamine-k-antagonist-naar-doac-bij-kwetsbare-ouderen-met-af/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2026/02/03/lichamelijke-activiteit-en-risico-op-complicaties-bij-atriumfibrilleren/","published":"2026-03-06"},{"url":"https://hartvaat.nl/2026/02/19/cardiovasculair-renaal-metabool-samenspel-bij-patienten-met-atriumfibrilleren/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/02/03/mortaliteit-en-hospitalisaties-bij-hfpef-versus-hfref-vergelijkende-analyse/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/12/01/comorbiditeitsbelasting-en-uitkomsten-van-ablatie-versus-medicatie-bij-af/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/10/01/piek-vo2-en-prognose-bij-hartfalen-meta-analyse/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/08/01/opnameduur-en-eerdere-hf-opnames-bij-frailteit-en-hartfalen-systematische-review/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/05/optimale-timing-van-anticoagulatie-na-ischemisch-cva-en-af-collaboratief-project/","published":"2025-07-05"},{"url":"https://hartvaat.nl/2025/04/01/ambulante-behandeling-van-gedecompenseerd-hartfalen-meta-analyse/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2025/03/15/doac-s-versus-geen-anticoagulatie-na-intracraniele-bloeding-bij-af-meta-analyse/","published":"2025-03-15"},{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/10/01/natriuretische-peptiden-en-crp-bij-hartfalen-en-ondervoeding-systematische-revie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2023/10/05/rivaroxaban-dosering-bij-af-on-label-versus-off-label-in-azie-en-niet-azie/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2022/06/01/edoxaban-15-mg-bij-zeer-oude-patienten-met-atriumfibrilleren-eldercare-subanalys/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2022/03/02/kenmerken-van-patienten-met-atriale-high-rate-episodes-bij-icd-crt/","published":"2022-03-02"},{"url":"https://hartvaat.nl/2022/01/04/sglt2-remmers-en-plotse-hartdood-ventriculaire-aritmie-meta-analyse/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2021/09/14/copd-bij-af-prevalentie-management-en-impact-meta-analyse/","published":"2021-09-14"},{"url":"https://hartvaat.nl/2020/12/22/digoxine-versus-bisoprolol-voor-frequentiecontrole-bij-af-en-qol-jama-rate-af/","published":"2020-12-22"},{"url":"https://hartvaat.nl/2020/10/29/laaggedoseerd-edoxaban-bij-zeer-oude-af-patienten-nejm-eldercare-af/","published":"2020-10-29"},{"url":"https://hartvaat.nl/2020/04/07/mobiele-gezondheidstechnologie-voor-af-zorg/","published":"2020-04-07"},{"url":"https://hartvaat.nl/2020/01/01/weglaten-van-aspirine-bij-gecombineerde-antitrombotische-therapie-voor-af-acs-he/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/01/determinanten-van-linkeratriumtrombi-bij-geplande-cardioversie-ensure-af/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/05/14/dabigatran-duale-therapie-met-ticagrelor-of-clopidogrel-na-pci-bij-af-re-dual-pc/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/04/01/icd-mortaliteit-naar-hartfalenetiologie-propensity-matched-analyse/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/12/01/edoxaban-verhoogt-behandeltevredenheid-en-vermindert-zorggebruik-engage-af-timi-/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/10/01/linkeratriumvolume-en-cv-uitkomsten-bij-systolisch-hf-antitromboticaeffect/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/05/14/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-meta-analyse/","published":"2018-05-14"},{"url":"https://hartvaat.nl/2018/03/13/doac-s-bij-af-met-ckd-systematische-review-werkzaamheid-en-veiligheid/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2018/02/01/dabigatran-versus-warfarine-bij-af-met-linkerventrikelhypertrofie-re-ly/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/11/01/bloeddrukvariabiliteit-en-uitkomsten-bij-af-affirm-studie/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","published":"2017-10-19"},{"url":"https://hartvaat.nl/2017/10/01/korte-dabigatran-onderbreking-voor-device-implantatie-re-ly-multicenterervaring/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/03/07/cva-risico-bij-chronisch-hartfalen-met-behouden-ef-zonder-af-charm-analyse/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/01/24/heropnames-bij-af-patienten-na-stenting-twee-antitromboticastrategieen-vergeleke/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/12/22/preventie-van-bloedingen-bij-af-patienten-die-pci-ondergaan-nejm-pioneer-af-pci/","published":"2016-12-22"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/22/edoxaban-versus-enoxaparine-warfarine-bij-cardioversie-van-af-ensure-af-trial/","published":"2016-10-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marc-p-bonaca","type":"person","url":"https://hartvaat.nl/mensen/marc-p-bonaca/","name":"Marc P Bonaca","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":46,"articles":[{"url":"https://hartvaat.nl/2026/03/05/semaglutide-bij-perifeer-arterieel-vaatlijden-en-diabetes-stride-trial/","published":"2026-03-20"},{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/11/18/sekseverschillen-in-semaglutide-effect-bij-pad-stride-subanalyse/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/05/03/semaglutide-en-loopafstand-bij-perifeer-vaatlijden-en-diabetes/","published":"2025-05-03"},{"url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2024/06/25/vasculair-zorgteam-versus-educatie-bij-perifeer-arterieel-vaatlijden/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","published":"2024-04-30"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/12/12/voyager-pad-rivaroxaban-plus-aspirine-na-endovasculaire-revascularisatie-voor-pa/","published":"2023-12-12"},{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/11/01/klinische-toepassing-van-hs-troponine-in-het-ascvd-raamwerk-jama-cardiology/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/03/17/non-culprit-mi-na-pci-bij-acs/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2017/08/01/kosteneffectiviteit-van-langdurig-ticagrelor-na-mi-pegasus-timi-54/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/09/20/cva-preventie-met-ticagrelor-na-myocardinfarct-pegasus-timi-54-inzichten/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/07/26/atherotrombotische-risicostratificatie-en-vorapaxar-bij-stabiel-ischemisch-hartl/","published":"2016-07-26"},{"url":"https://hartvaat.nl/2016/07/19/serieel-cardiaal-troponine-met-hoog-sensitieve-assay-bij-stabiel-ischemisch-hart/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/06/14/reductie-van-ischemische-events-met-ticagrelor-bij-diabetes-na-myocardinfarct-pe/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/03/15/plaatjesremming-met-ticagrelor-60-mg-versus-90-mg-in-de-pegasus-timi-54-trial/","published":"2016-03-15"},{"url":"https://hartvaat.nl/2016/03/08/acute-ledischemie-en-vorapaxar-bij-perifeer-arterieel-vaatlijden-tra-2p-timi-50-/","published":"2016-03-08"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"},{"url":"https://hartvaat.nl/2016/01/21/langdurige-duale-antiplaatjestherapie-bij-patienten-met-eerder-myocardinfarct-me/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marco-metra","type":"person","url":"https://hartvaat.nl/mensen/marco-metra/","name":"Marco Metra","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":46,"articles":[{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/05/25/pah-met-renaal-diabetische-overlap-komt-vaak-voor-en-geeft-tweemaal-zo-hoog-mort/","published":"2026-06-01"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2026/03/28/gestandaardiseerd-stappenplan-voor-tricuspidalisinsufficientie-van-verwijzing-to/","published":"2026-04-19"},{"url":"https://hartvaat.nl/2026/03/25/meta-analyse-glp-1-agonisten-voorkomen-hartfalen-in-type-2-diabetes-sterkste-eff/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2026/02/03/geslachtsverschillen-bij-patienten-met-gevorderd-hartfalen/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2026/01/05/magnesium-en-uitkomsten-bij-hfref-galactic-hf-subanalyse/","published":"2026-01-05"},{"url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2024/08/01/coronaire-microvasculaire-disfunctie-bij-hfpef-meta-analyse/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2022/12/01/hartfalen-tijdens-de-covid-19-pandemie-klinische-en-organisatorische-dilemma-s/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/10/01/sacubitril-valsartan-in-real-life-europese-hfref-meta-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2019/12/01/hoogtepunten-in-hartfalen-2019/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/12/01/hepatorenale-disfunctie-identificeert-hoogrisico-acuut-hf-relax-ahf/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2018/06/01/geindividualiseerd-patiromer-doseringsregime-bij-hf-met-ckd-en-hyperkaliemie/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/08/07/trv027-biased-ligand-van-de-angiotensine-ii-receptor-bij-acuut-hartfalen-gerando/","published":"2017-08-07"},{"url":"https://hartvaat.nl/2017/06/27/hospitalisatie-voor-nieuw-gediagnosticeerd-versus-verslechterend-chronisch-hartf/","published":"2017-06-27"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/12/10/omecamtiv-mecarbil-bij-chronisch-hartfalen-lancet-cosmic-hf-fase-2-trial/","published":"2016-12-10"},{"url":"https://hartvaat.nl/2016/03/29/omecamtiv-mecarbil-bij-acuut-hartfalen-de-atomic-ahf-studie/","published":"2016-03-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christie-m-ballantyne","type":"person","url":"https://hartvaat.nl/mensen/christie-m-ballantyne/","name":"Christie M Ballantyne","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":42,"articles":[{"url":"https://hartvaat.nl/2026/03/25/mendeliaanse-randomisatie-lp-a-verhoogt-coronarialijden-onafhankelijk-van-ldl-c-/","published":"2026-04-20"},{"url":"https://hartvaat.nl/2026/02/05/orale-pcsk9-remmer-enlicitide-verlaagt-ldl-met-57-placebogecontroleerde-trial/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2026/01/13/enlicitide-orale-pcsk9-remmer-bij-heterozygote-fh-fase-3/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2025/10/07/obicetrapib-en-mace-bij-hoogrisicopatienten-gepoolde-analyse/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2025/05/20/plozasiran-en-lipoproteine-deeltjesgrootte-bij-hypertriglyceridemie/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2024/09/12/zodasiran-sirna-tegen-angptl3-bij-gemengde-hyperlipidemie-nejm/","published":"2024-09-12"},{"url":"https://hartvaat.nl/2024/09/12/plozasiran-sirna-tegen-apoc3-bij-gemengde-hyperlipidemie-nejm/","published":"2024-09-12"},{"url":"https://hartvaat.nl/2024/09/01/troponine-nt-probnp-en-cognitieve-uitkomsten-in-sprint/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/07/01/plozasiran-sirna-tegen-apoc3-bij-ernstige-hypertriglyceridemie-shasta-2/","published":"2024-07-01"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-familiaire-chylomicronemie-nejm-fase-3/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2024/04/23/lp-a-en-cv-risicoreductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/04/01/icosapent-ethyl-na-acs-reduce-it-subanalyse/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2023/05/02/gepersonaliseerde-beslisondersteuning-verhoogt-statinegebruik-bij-ascvd/","published":"2023-05-02"},{"url":"https://hartvaat.nl/2023/04/25/mk-0616-eerste-orale-pcsk9-remmer-in-fase-2b/","published":"2023-04-25"},{"url":"https://hartvaat.nl/2022/10/18/intensieve-bloeddrukverlaging-bij-maligne-linkerventrikel-hypertrofie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/2022-acc-expert-consensus-niet-statine-therapieen-voor-ldl-verlaging-bij-ascvd/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","published":"2022-08-02"},{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/08/31/2021-acc-consensus-ascvd-risicoreductie-bij-persistente-hypertriglyceridemie/","published":"2021-08-31"},{"url":"https://hartvaat.nl/2021/05/01/mcp-1-en-cardiovasculaire-mortaliteit-populatie-gebaseerde-meta-analyse/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/03/14/bempedoinezuur-voor-ldl-verlaging-nejm-veiligheid-en-werkzaamheid/","published":"2019-03-14"},{"url":"https://hartvaat.nl/2019/01/03/icosapent-ethyl-en-cardiovasculaire-uitkomsten-bij-hypertriglyceridemie-nejm-red/","published":"2019-01-03"},{"url":"https://hartvaat.nl/2018/10/23/evolocumab-en-coronaire-plaquesamenstelling-glagov-beeldvorming/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/09/01/hdl-mimeticum-met-recombinant-apoa-i-milano-en-coronairlijden-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/02/01/lipoproteine-a-en-recidiverende-ischemische-events-na-acs-dal-outcomes-analyse/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/10/03/2017-acc-gerichte-update-niet-statinetherapie-voor-ldl-verlaging/","published":"2017-10-03"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/12/06/dalcetrapib-wijzigt-de-relatie-tussen-hdl-cholesterol-en-crp/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/04/19/evolocumab-versus-ezetimibe-bij-statine-intolerante-patienten-de-gauss-3-trial/","published":"2016-04-19"}],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/ldl-cholesterol/","title":"Sessie 2: LDL-cholesterol"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"darren-k-mcguire","type":"person","url":"https://hartvaat.nl/mensen/darren-k-mcguire/","name":"Darren K McGuire","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":44,"articles":[{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2025/12/01/dapagliflozine-na-mi-naar-ef-cardiometabole-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/06/01/nierfunctie-en-dapagliflozine-effect-op-gezondheidsstatus-define-hf/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","published":"2025-05-29"},{"url":"https://hartvaat.nl/2025/05/17/tandem-obicetrapib-plus-ezetimibe-voor-ldl-verlaging-lancet-fase-3/","published":"2025-05-17"},{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2024/07/16/interventie-voor-evidence-based-zorg-bij-diabetes-en-cv-risico/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","published":"2024-04-30"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/04/18/gecoordineerde-zorg-optimaliseert-cv-preventie-bij-type-2-diabetes-jama-rct/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/09/01/dapagliflozine-effectief-ongeacht-cv-achtergrondmedicatie-declare-subanalyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/10/19/diabetes-met-cardiomyopathie-in-de-community-prevalentie-en-prognose/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2021/02/01/sglt2-remmers-en-cv-renale-uitkomsten-bij-diabetes-type-2-jama-cardiology-meta-a/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/12/08/ertugliflozine-en-hf-events-bij-diabetes-met-atherosclerotische-cvd-vertis-cv/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/10/08/ertugliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-vertis-cv/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/03/12/empagliflozine-vermindert-mortaliteit-en-hf-hospitalisatie-over-het-cv-risicospe/","published":"2019-03-12"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"},{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2018/02/01/cv-uitkomsten-naar-albumin-en-nierziekte-bij-diabetes-type-2-met-hoog-cv-risico/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/11/01/hypertensiecontrole-bij-diabetes-met-recidiverende-cv-events-tecos-globale-resul/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/26/secundaire-cardiovasculaire-preventie-bij-diabetes-type-2-tecos-internationale-i/","published":"2017-09-26"},{"url":"https://hartvaat.nl/2017/08/24/degludec-versus-glargine-bij-diabetes-type-2-nejm-devote-werkzaamheid-en-veiligh/","published":"2017-08-24"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-r-zile","type":"person","url":"https://hartvaat.nl/mensen/michael-r-zile/","name":"Michael R Zile","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":44,"articles":[{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/09/09/summit-tirzepatide-effect-bij-hfpef-met-en-zonder-diabetes/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/07/29/summit-bmi-centrale-adipositas-en-gewichtsverlies-beinvloeden-tirzepatide-effect/","published":"2025-07-29"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/05/13/summit-tirzepatide-en-ckd-interactie-bij-hfpef-met-obesitas/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/03/11/summit-tirzepatide-en-klinisch-traject-bij-hfpef-met-obesitas-langetermijn/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/02/25/summit-tirzepatide-vermindert-lv-massa-en-paracardiaal-vetweefsel-bij-hfpef/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/01/30/summit-tirzepatide-bij-hfpef-met-obesitas-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/04/sacubitril-valsartan-bij-hartfalen-over-het-nierfunctiespectrum/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/02/13/implanteerbare-hemodynamische-monitoren-verbeteren-overleving-bij-hfref/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/07/14/guide-hf-en-de-impact-van-covid-19-op-hartfalenuitkomsten/","published":"2022-07-14"},{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/09/11/hemodynamisch-geleid-hf-management-lancet-guide-hf/","published":"2021-09-11"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/10/20/praliciguat-en-piek-vo2-bij-hfpef-jama-capacity-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/07/07/baroreflexactivatietherapie-bij-hfref-beat-hf/","published":"2020-07-07"},{"url":"https://hartvaat.nl/2019/12/10/echocardiografische-kenmerken-bij-hfpef/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2019/03/26/bnp-tijdens-sacubitril-valsartan-paradigm-hf/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2019/02/26/sacubitril-valsartan-en-biomarkers-van-extracellulaire-matrixregulatie-bij-hfref/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2019/01/08/hfref-differentiele-impact-op-mannen-en-vrouwen/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/12/01/number-needed-to-treat-met-arni-voor-preventie-van-cv-dood-of-hf-hospitalisatie/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/06/01/sacubitril-valsartan-en-fysieke-en-sociale-activiteitsbeperkingen-bij-hf-paradig/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/11/14/af-type-en-uitkomsten-bij-hfref/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/04/14/systolische-bloeddruk-en-werkzaamheid-van-sacubitril-valsartan-bij-chronisch-hfr/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/03/07/cva-risico-bij-chronisch-hartfalen-met-behouden-ef-zonder-af-charm-analyse/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2017/02/21/diabetesstatus-en-cardiovasculaire-uitkomsten-bij-hfpef-klinische-en-echocardiog/","published":"2017-02-21"},{"url":"https://hartvaat.nl/2017/01/01/verminderd-hyperkaliemierisico-met-mra-door-sacubitril-valsartan-bij-hartfalen/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/12/06/prognostische-implicaties-van-nt-probnp-veranderingen-bij-hartfalen/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/11/29/bmi-en-nauwkeurigheid-van-nt-probnp-en-bnp-voor-diagnose-van-acuut-hartfalen/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/07/19/sacubitril-valsartan-en-30-daagse-heropname-na-hartfalenhospitalisatie/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/06/07/klinische-verslechtering-van-poliklinisch-behandeld-hartfalen-paradigm-hf-analys/","published":"2016-06-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michele-senni","type":"person","url":"https://hartvaat.nl/mensen/michele-senni/","name":"Michele Senni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":44,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/01/01/timing-van-cardiovasculaire-en-renale-voordelen-van-finerenon-bij-hartfalen-en-c/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/11/26/panorama-hf-sacubitril-valsartan-bij-pediatrisch-hartfalen-nejm/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","published":"2024-09-21"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/11/01/beta3-lvh-mirabegron-bij-linkerventrikel-hypertrofie-fase-2b-rct/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2023/02/01/diabetes-en-sacubitril-valsartan-titratie-bij-hartfalen-na-opname/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/12/01/vericiguat-en-nt-probnp-bij-hfref-victoria-subanalyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/10/01/sacubitril-valsartan-in-real-life-europese-hfref-meta-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/09/29/arni-en-renale-uitkomsten-bij-hfpef-paragon-hf/","published":"2020-09-29"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2017/02/07/doodsoorzaken-bij-hartfalen-met-behouden-ejectiefractie/","published":"2017-02-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c-michael-gibson","type":"person","url":"https://hartvaat.nl/mensen/c-michael-gibson/","name":"C Michael Gibson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":43,"articles":[{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","published":"2022-03-07"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2021/01/19/stoppen-versus-doorgaan-met-ace-remmers-arb-s-bij-gehospitaliseerde-patienten-ja/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/01/optimaal-antitrombotisch-regime-bij-af-na-pci-jama-cardiology-netwerkmeta-analys/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/02/18/ticagrelor-met-of-zonder-aspirine-na-pci-twilight-plaatjessubstudie/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/12/17/uitkomsten-van-vrouwen-versus-mannen-na-nste-acs/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/22/implanteerbare-monitor-voor-snellere-behandeling-bij-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/08/01/antitrombotische-strategieen-bij-af-na-pci-jama-cardiology-veiligheids-en-werkza/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/04/23/implanteerbaar-cardiaal-alertsysteem-voor-vroege-herkenning-van-stemi/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2018/12/07/laesiecomplexiteit-en-periprocedurele-events-bij-potente-iv-antiplaatjestherapie/","published":"2018-12-07"},{"url":"https://hartvaat.nl/2018/07/31/antitrombotische-therapie-bij-af-met-oac-na-pci-aha-scientific-statement/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/07/10/fatale-of-irreversibele-bloedingen-en-ischemische-events-met-rivaroxaban-bij-acs/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2017/06/01/korte-procedureduur-met-bivalirudine-en-risico-op-acute-stenttrombose-bij-stemi/","published":"2017-06-01"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2017/02/01/cangrelor-versus-gpiib-iiia-remmers-ischemie-en-bloedingsrisico-s-vergeleken/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/01/24/heropnames-bij-af-patienten-na-stenting-twee-antitromboticastrategieen-vergeleke/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2017/01/17/cangrelor-met-en-zonder-gpiib-iiia-remmers-bij-pci/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/12/22/preventie-van-bloedingen-bij-af-patienten-die-pci-ondergaan-nejm-pioneer-af-pci/","published":"2016-12-22"},{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/11/29/presentatie-buiten-kantoortijden-versus-tijdens-kantoortijden-bij-stemi-champion/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/09/06/consistente-reductie-in-periprocedureel-mi-met-cangrelor-champion-analyses/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/08/16/bio-absorbeerbare-intracoronaire-matrix-ter-preventie-van-ventriculaire-remodell/","published":"2016-08-16"},{"url":"https://hartvaat.nl/2016/04/21/mtp-131-bij-reperfusieschade-na-stemi-de-embrace-stemi-fase-2a-trial/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/04/07/cangrelor-en-toegangsplaats-effect-op-ischemische-en-bloedingsevents-champion-ph/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/01/19/werkzaamheid-en-veiligheid-van-cangrelor-bij-vrouwen-versus-mannen-tijdens-pci-c/","published":"2016-01-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lars-wallentin","type":"person","url":"https://hartvaat.nl/mensen/lars-wallentin/","name":"Lars Wallentin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":43,"articles":[{"url":"https://hartvaat.nl/2026/08/25/extracraniale-bloedingen-komen-bij-26-van-af-patienten-op-antistolling-voor-comb/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/02/24/systemische-embolieen-bij-af-ipd-mega-meta-analyse-van-71-683-patienten/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2025/11/25/abc-af-risicoscores-voor-gepersonaliseerde-af-behandeling/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2025/01/07/euroheart-definities-van-klinische-studie-eindpunten-voor-cvd/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/10/01/neurofilament-light-chain-en-cva-risico-bij-af/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","published":"2023-05-21"},{"url":"https://hartvaat.nl/2022/06/14/euroheart-datastandaarden-voor-hartfalenregistraties/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/05/01/vroegtijdig-permanent-staken-van-apixaban-of-warfarine-bij-af/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2020/11/01/ace2-niveaus-en-covid-19-risicofactoren-bij-af-patienten/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/07/14/vergelijking-van-orale-p2y12-remmers-bij-acs-netwerkmeta-analyse-van-52-816-pati/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2020/04/28/apixaban-versus-warfarine-bij-af-met-gevorderde-ckd/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2020/03/17/klinische-en-farmacologische-effecten-van-apixaban-dosisaanpassing-aristotle/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2020/01/07/nsaid-s-en-oac-bij-af-aristotle-analyse/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/12/01/multipele-biomarkers-en-mortaliteitsrisico-na-acs-jama-cardiology/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/08/14/adma-en-sdma-voorspellen-uitkomsten-bij-af-aristotle-substudie/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/08/01/uitkomsten-bij-af-met-oac-bij-mitralis-of-aortakleplijden/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/07/17/oac-plus-nsaid-bij-af-risico-op-ernstige-bloedingen/","published":"2018-07-17"},{"url":"https://hartvaat.nl/2018/04/01/fibrinestoleigenschappen-en-klinische-uitkomsten-na-acs-plato-substudie/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2018/03/13/digoxine-en-mortaliteit-bij-patienten-met-atriumfibrilleren/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","published":"2018-02-07"},{"url":"https://hartvaat.nl/2018/02/01/dabigatran-versus-warfarine-bij-af-met-linkerventrikelhypertrofie-re-ly/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-bij-stabiel-coronairlijden-stability-inzic/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/07/01/dabigatran-naar-leeftijd-bij-atriumfibrilleren-re-ly-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/04/01/niet-ernstige-bloedingen-met-apixaban-versus-warfarine-bij-af/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2017/03/14/afweging-myocardinfarct-versus-bloedingstype-en-mortaliteit-na-acs-tra-2p-timi-5/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/11/29/biomarkergebaseerde-cva-risicoscore-bij-atriumfibrilleren-validatie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/10/15/vroeg-invasief-versus-conservatief-bij-nste-acs-15-jaarsfollow-up-frisc-ii/","published":"2016-10-15"},{"url":"https://hartvaat.nl/2016/09/01/apixaban-5-mg-bij-af-met-hoge-leeftijd-laag-gewicht-of-hoog-creatinine-aristotle/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/08/23/dabigatran-versus-warfarine-bij-af-met-kleplijden-re-ly-analyse/","published":"2016-08-23"},{"url":"https://hartvaat.nl/2016/07/01/apixaban-versus-warfarine-bij-af-in-relatie-tot-nierfunctie-aristotle-analyse/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnevaluatie-van-dabigatran-150-versus-110-mg-bij-niet-valvulair-af/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","published":"2016-06-04"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/04/21/gdf-15-voorspelt-bloedingen-en-cardiovasculaire-events-bij-acuut-coronair-syndro/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/04/01/veiligheid-en-werkzaamheid-van-ticagrelor-versus-clopidogrel-bij-primaire-pci-vo/","published":"2016-04-01"},{"url":"https://hartvaat.nl/2016/04/01/biomarkers-van-inflammatie-en-cardiovasculair-risico-bij-patienten-met-atriumfib/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rafael-diaz","type":"person","url":"https://hartvaat.nl/mensen/rafael-diaz/","name":"Rafael Díaz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":43,"articles":[{"url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","published":"2021-08-03"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/08/cv-uitkomsten-bij-diabetes-met-vastgesteld-of-hoog-risico-coronairlijden-dulaglu/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2020/05/19/pav-en-vte-na-acs-rol-van-lp-a-en-modificatie-door-alirocumab/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/02/04/aanhoudende-ldl-verlaging-met-alirocumab-in-odyssey-outcomes/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"},{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jose-c-nicolau","type":"person","url":"https://hartvaat.nl/mensen/jose-c-nicolau/","name":"José C Nicolau","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":42,"articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2022/11/01/vip-acs-dubbele-dosis-griepvaccinatie-na-acs-verbetert-uitkomsten-niet/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/03/16/plaatjesreactiviteit-bij-acs-in-afwachting-van-chirurgische-revascularisatie/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/28/morfine-en-cv-uitkomsten-bij-nste-acs-jacc-analyse/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/06/11/sonotrombolyse-bij-stemi-behandeld-met-primaire-pci/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/09/25/edoxaban-versus-warfarine-bij-latijns-amerikaanse-af-patienten-engage-af-timi-48/","published":"2018-09-25"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/04/10/ezetimibe-bij-diabetes-versus-zonder-diabetes-improve-it-subanalyse/","published":"2018-04-10"},{"url":"https://hartvaat.nl/2018/02/20/sekseverschillen-bij-ischemisch-hartfalen-na-cabg-stich-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/03/21/plotse-hartdood-bij-ischemisch-hartfalen-na-cabg-stich-resultaten/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/05/31/diagnostische-ultrageluidspulsen-verbeteren-microvasculaire-flow-bij-stemi-met-m/","published":"2016-05-31"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephen-d-wiviott","type":"person","url":"https://hartvaat.nl/mensen/stephen-d-wiviott/","name":"Stephen D Wiviott","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":42,"articles":[{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/08/24/reprieve-pitavastatine-vermindert-cv-events-bij-hiv-nejm/","published":"2023-08-24"},{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","published":"2022-10-11"},{"url":"https://hartvaat.nl/2022/09/01/dapagliflozine-effectief-ongeacht-cv-achtergrondmedicatie-declare-subanalyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2022/05/03/vupanorsen-en-non-hdl-cholesterol-bij-statinebehandelde-patienten-translate-timi/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/11/01/klinische-toepassing-van-hs-troponine-in-het-ascvd-raamwerk-jama-cardiology/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/03/17/non-culprit-mi-na-pci-bij-acs/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/12/17/uitkomsten-van-vrouwen-versus-mannen-na-nste-acs/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/10/29/langetermijn-werkzaamheid-en-veiligheid-van-evolocumab-bij-hypercholesterolemie/","published":"2019-10-29"},{"url":"https://hartvaat.nl/2019/10/15/triglyceridenverlaging-en-cv-risicoreductie-over-therapeutische-klassen-meta-ana/","published":"2019-10-15"},{"url":"https://hartvaat.nl/2019/07/01/evolocumab-en-totale-cv-events-bij-cardiovasculaire-ziekte-fourier-analyse/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2018/09/01/verdere-ldl-verlaging-bij-reeds-zeer-lage-niveaus-jama-cardiology-meta-analyse/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/08/21/klinisch-voordeel-van-evolocumab-naar-ernst-van-coronairlijden-fourier/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2017/12/19/cva-preventie-met-ezetimibe-bij-acs-improve-it-analyse/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/11/14/timing-van-angiografie-bij-hoogrisico-nstemi-acuity-analyse/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/09/28/anacetrapib-bij-atherosclerotisch-vaatlijden-nejm-hps3-timi55-reveal/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/05/04/evolocumab-en-klinische-uitkomsten-bij-cardiovasculaire-ziekte-nejm-fourier/","published":"2017-05-04"},{"url":"https://hartvaat.nl/2017/05/01/langetermijnveiligheid-van-zeer-lage-ldl-cholesterolniveaus-improve-it-analyse/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/09/27/ldl-c-verlaging-en-cardiovasculaire-risicoreductie-jama-systematische-review-en-/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/05/31/dapt-score-validatie-bij-patienten-met-en-zonder-eerder-myocardinfarct/","published":"2016-05-31"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/01/21/neoplasiedetectie-bij-langdurige-dapt-met-prasugrel-versus-clopidogrel-triton-ti/","published":"2016-01-21"},{"url":"https://hartvaat.nl/2016/01/21/doodsoorzaken-bij-langdurige-dapt-na-coronaire-stents/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephen-j-nicholls","type":"person","url":"https://hartvaat.nl/mensen/stephen-j-nicholls/","name":"Stephen J Nicholls","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":42,"articles":[{"url":"https://hartvaat.nl/2026/08/18/semaglutide-verlaagt-hscrp-en-ontstekingsactiviteit-bij-ascvd-patienten-met-over/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/uk-biobank-na-ischemisch-cva-of-tia-is-het-risico-op-hartfalen-groter-dan-dat-op/","published":"2026-06-29"},{"url":"https://hartvaat.nl/2026/05/24/lp-a-japan-verhoogd-lp-a-blijft-risicovol-ondanks-ldl-onder-55-mg-dl/","published":"2026-06-05"},{"url":"https://hartvaat.nl/2026/05/25/obicetrapib-verlaagt-naast-ldl-en-apob-ook-lipoproteine-a/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2026/05/25/verve-102-eenmalige-base-editing-schakelt-pcsk9-blijvend-uit-fase-1/","published":"2026-05-25"},{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/02/19/evolocumab-en-doorgankelijkheid-van-veneuze-bypasses-na-cabg-newton-cabg-cardiol/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2025/10/07/obicetrapib-en-mace-bij-hoogrisicopatienten-gepoolde-analyse/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","published":"2025-09-20"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2025/05/20/solbinsiran-angptl3-remming-van-preklinisch-tot-eerste-humane-studies/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/05/17/tandem-obicetrapib-plus-ezetimibe-voor-ldl-verlaging-lancet-fase-3/","published":"2025-05-17"},{"url":"https://hartvaat.nl/2025/05/03/solbinsiran-langwerkend-sirna-tegen-angptl3-duurzaamheid-en-effectiviteit/","published":"2025-05-03"},{"url":"https://hartvaat.nl/2025/01/21/muvalaplin-orale-lp-a-verlaging-nejm-gerandomiseerde-trial/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/09/12/zodasiran-sirna-tegen-angptl3-bij-gemengde-hyperlipidemie-nejm/","published":"2024-09-12"},{"url":"https://hartvaat.nl/2024/07/09/bempedoinezuur-versus-statines-vergelijking-van-cv-voordelen/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/07/01/plozasiran-sirna-tegen-apoc3-bij-ernstige-hypertriglyceridemie-shasta-2/","published":"2024-07-01"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/03/01/clear-outcomes-bempedoinezuur-vermindert-totale-cv-events-bij-statine-intolerant/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/10/01/crp-op-lp-a-geassocieerd-cv-risico-bij-optimaal-behandelde-hoogrisicopatienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/04/28/apabetalone-en-cv-events-bij-acs-met-diabetes-type-2-jama-betonmace/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/04/01/initieel-en-serieel-crp-en-cv-events-en-dood-na-acs-jama-cardiology/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/10/23/evolocumab-en-coronaire-plaquesamenstelling-glagov-beeldvorming/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/09/01/hdl-mimeticum-met-recombinant-apoa-i-milano-en-coronairlijden-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/09/01/cer-001-hdl-mimeticum-en-coronaire-atherosclerose-na-acs-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/02/01/lipoproteine-a-en-recidiverende-ischemische-events-na-acs-dal-outcomes-analyse/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/12/06/dalcetrapib-wijzigt-de-relatie-tussen-hdl-cholesterol-en-crp/","published":"2016-12-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-a-morrow","type":"person","url":"https://hartvaat.nl/mensen/david-a-morrow/","name":"David A Morrow","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":40,"articles":[{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/bestaande-cv-data-benutten-voor-hypertensiedetectie-en-behandeling-vital-trial/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/25/omega-3-biomarkers-en-incident-af-ipd-analyse/","published":"2023-07-25"},{"url":"https://hartvaat.nl/2023/07/04/sacubitril-valsartan-bij-hfmref-hfpef-met-verslechterend-hartfalen/","published":"2023-07-04"},{"url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","published":"2023-05-21"},{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/12/01/serieel-hoog-sensitief-troponine-t-voorspelt-cv-events-na-acs-odyssey-analyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/08/30/biomarkers-voorspellen-complexe-coronaire-revascularisatie-in-fourier/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2020/11/01/klinische-toepassing-van-hs-troponine-in-het-ascvd-raamwerk-jama-cardiology/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/09/01/arni-naar-hf-voorgeschiedenis-en-raas-antagonistgebruik/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/03/17/non-culprit-mi-na-pci-bij-acs/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2020/03/17/2020-acc-hfsa-ishlt-verklaring-voor-gevorderd-hf-en-transplantatiespecialisten/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2020/02/01/arni-initiatie-na-acuut-gedecompenseerd-hf-pioneer-hf-open-label-extensie/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/12/17/uitkomsten-van-vrouwen-versus-mannen-na-nste-acs/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/10/21/cv-biomarkers-bij-acuut-gedecompenseerd-hf-met-sacubitril-valsartan-pioneer-hf/","published":"2019-10-21"},{"url":"https://hartvaat.nl/2019/05/07/sacubitril-valsartan-of-enalapril-bij-acuut-gedecompenseerd-hf-pioneer-hf-klinis/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/02/07/angiotensine-neprilysineremming-bij-acuut-gedecompenseerd-hf-nejm-pioneer-hf/","published":"2019-02-07"},{"url":"https://hartvaat.nl/2019/02/05/abc-scores-voor-cva-en-bloedingsrisico-bij-af-prestatieverbetering/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/06/01/fgf-23-en-recidiverende-cv-events-na-acs/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/05/16/serieel-hoog-sensitief-troponine-i-en-cv-uitkomsten-bij-diabetes-type-2-examine/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/09/20/cva-preventie-met-ticagrelor-na-myocardinfarct-pegasus-timi-54-inzichten/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/07/26/atherotrombotische-risicostratificatie-en-vorapaxar-bij-stabiel-ischemisch-hartl/","published":"2016-07-26"},{"url":"https://hartvaat.nl/2016/07/19/serieel-cardiaal-troponine-met-hoog-sensitieve-assay-bij-stabiel-ischemisch-hart/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"},{"url":"https://hartvaat.nl/2016/03/08/acute-ledischemie-en-vorapaxar-bij-perifeer-arterieel-vaatlijden-tra-2p-timi-50-/","published":"2016-03-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"holger-thiele","type":"person","url":"https://hartvaat.nl/mensen/holger-thiele/","name":"Holger Thiele","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":40,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/25/palliatieve-zorg-in-de-cardiologie-een-state-of-the-art-overzicht/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/03/03/4-eiwitmodel-voor-cardiogene-shock-prognose-danger-substudie/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/02/19/delirium-in-de-cardiovasculaire-geneeskunde/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/12/01/scai-shockklassen-en-prognose-bij-ami-cardiogene-shock-danger-substudie/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2024/12/16/gp-iib-iiia-remmers-bij-acuut-mi-en-microvasculaire-obstructie-meta-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2024/10/01/galectine-3-en-langetermijnuitkomsten-bij-hartfalen-meta-analyse/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/07/12/nste-acs-na-cabg-meta-analyse-van-behandelstrategieen/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2023/03/28/culprit-interventie-bij-cardiogene-shock-met-hartstilstand/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2021/01/19/residuele-syntax-score-bij-cardiogene-shock/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/04/21/morfine-met-metoclopramide-en-ticagrelor-plaatjesremming-bij-acuut-mi/","published":"2020-04-21"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2020/03/01/slagvolumeveranderingen-na-renale-denervatie-cardiale-mri-inzichten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/08/01/renale-denervatie-bij-geisoleerde-systolische-hypertensie-vergelijking-van-kathe/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2019/01/29/drie-armen-vergelijkende-renale-denervatie-radiosound-htn/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2019/01/22/milde-hypothermie-bij-cardiogene-shock-complicerend-mi/","published":"2019-01-22"},{"url":"https://hartvaat.nl/2018/12/21/culprit-shock-integratie-in-2017-esc-stemi-richtlijn-richtlijncommissie-standpun/","published":"2018-12-21"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/12/14/mechanische-ondersteuning-bij-cardiogene-shock-systematische-review-en-meta-anal/","published":"2017-12-14"},{"url":"https://hartvaat.nl/2017/08/19/optimale-timing-van-invasieve-strategie-bij-nste-acs-lancet-meta-analyse/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2017/08/01/des-versus-bms-bij-acuut-mi-met-cardiogene-shock/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/04/18/risicostratificatie-bij-cardiogene-shock-na-acuut-myocardinfarct/","published":"2017-04-18"},{"url":"https://hartvaat.nl/2016/08/16/intracoronair-abciximab-bij-diabetespatienten-met-primaire-pci-1-jaarsresultaten/","published":"2016-08-16"},{"url":"https://hartvaat.nl/2016/08/01/cabg-versus-pci-en-risico-op-myocardinfarct-en-revascularisatie-bij-ckd-patiente/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/04/12/infarctgrootte-en-uitkomsten-na-primaire-pci-patientanalyse-uit-10-trials/","published":"2016-04-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yoshinobu-onuma","type":"person","url":"https://hartvaat.nl/mensen/yoshinobu-onuma/","name":"Yoshinobu Onuma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":40,"articles":[{"url":"https://hartvaat.nl/2026/02/24/invloed-van-coronaire-ziekte-patronen-op-klinische-uitkomsten-pullback-pressure-/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/04/19/externe-validatie-van-de-freedom-score-voor-pci-versus-cabg/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/31/syntax-score-ii-herontwikkeling-voor-gepersonaliseerde-revascularisatiebeslissin/","published":"2020-10-31"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/12/01/absorb-scaffold-5-jaarsresultaten-systematische-meta-analyse/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/04/23/hedendaagse-uitkomsten-na-cabg-voor-hoofdstamlijden/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2018/11/01/ct-coronairangiografie-voor-heart-team-besluitvorming-bij-multivatenlijden/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/05/07/esc-eapci-taskforce-rapport-over-bioresorbeerbare-scaffolds-executive-summary/","published":"2018-05-07"},{"url":"https://hartvaat.nl/2018/02/03/sirolimus-eluting-bioabsorbeerbare-stent-versus-everolimus-eluting-stent-na-mi-l/","published":"2018-02-03"},{"url":"https://hartvaat.nl/2018/01/30/absorb-bioresorbeerbare-scaffold-3-jaarsresultaten-ipd-meta-analyse/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2017/12/12/implantatiechniek-en-uitkomsten-van-bioresorbeerbare-scaffolds-absorb-analyses/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/09/01/late-trombotische-events-na-bioresorbeerbare-scaffold-meta-analyse-van-gerandomi/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/08/19/absorb-bioresorbeerbare-scaffold-lancet-2-jaars-systematische-review-en-meta-ana/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"},{"url":"https://hartvaat.nl/2017/07/01/syntax-scores-en-uitkomsten-bij-diabetes-met-multivatenlijden-gepoolde-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/09/06/pci-versus-cabg-bij-onbeschermde-hoofdstamziekte-uitkomsten/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/01/14/bioresorbeerbare-versus-metallic-everolimus-eluting-stent-bij-stemi-gerandomisee/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joao-pedro-ferreira","type":"person","url":"https://hartvaat.nl/mensen/joao-pedro-ferreira/","name":"João Pedro Ferreira","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":39,"articles":[{"url":"https://hartvaat.nl/2026/05/10/porthos-nt-probnp-afkapwaarden-onbetrouwbaar-bij-obese-patienten-risico-op-gemis/","published":"2026-05-11"},{"url":"https://hartvaat.nl/2025/01/01/hartfalenpreventie-bewijsgeneratie-trialontwerp-en-regulatoire-trajecten/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/11/14/nierfunctietrajecten-voor-en-na-hospitalisatie-voor-hfref/","published":"2025-11-14"},{"url":"https://hartvaat.nl/2025/08/05/sglt2-remmer-met-en-zonder-mra-bij-hartfalen-gecombineerde-analyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/05/13/empagliflozine-erytropoese-en-ijzermobilisatie-bij-hartfalen/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/11/12/sglt2-remming-en-proteomische-handtekeningen-bij-hartfalen-bevestiging/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/09/26/geblindeerde-stopstudie-voordelen-empagliflozine-verdwijnen-na-staken-bij-hf/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2023/08/08/glp-1-agonisten-met-en-zonder-sglt2-remmers-bij-type-2-diabetes-jacc-analyse/","published":"2023-08-08"},{"url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/21/empagliflozine-en-het-circulerend-proteoom-bij-hartfalen-emperor-mechanismen/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/11/01/empagliflozine-vermindert-albuminurie-bij-hartfalen-emperor-pooled-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/19/therapeutische-doelen-voor-hf-via-proteomics-en-mendeliaanse-randomisatie/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-en-renale-uitkomsten-bij-hartfalen-nejm-emperor-reduced-renal/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/09/28/nt-probnp-prognose-en-empagliflozine-effect-bij-emperor-reduced/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/03/23/mra-en-empagliflozine-interactie-bij-hf-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/03/23/empagliflozine-bij-hfref-met-volume-overbelasting-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/09/19/sglt2-remmers-bij-hfref-meta-analyse-van-emperor-reduced-en-dapa-hf/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2020/07/11/levenslang-voordeel-van-uitgebreide-hfref-farmacotherapie-lancet-schatting/","published":"2020-07-11"},{"url":"https://hartvaat.nl/2020/04/01/biomarkers-bij-hf-met-centrale-slaapapneu-serve-hf/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2019/11/21/rivaroxaban-en-cva-tia-bij-hf-met-coronairlijden-en-sinusritme-commander-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/02/01/spironolacton-en-collageenmetabolisme-biomarkers-bij-ongecontroleerde-hypertensi/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/04/17/nt-probnp-geleide-therapie-bij-acuut-gedecompenseerd-hartfalen-prima-ii/","published":"2018-04-17"},{"url":"https://hartvaat.nl/2018/02/20/cva-risico-bij-verminderde-ef-na-mi-zonder-af/","published":"2018-02-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kausik-k-ray","type":"person","url":"https://hartvaat.nl/mensen/kausik-k-ray/","name":"Kausik K Ray","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":39,"articles":[{"url":"https://hartvaat.nl/2026/05/19/ehj-review-dyslipidemie-bij-kankerpatienten-verhoogd-ascvd-risico-beperkte-data-/","published":"2026-06-14"},{"url":"https://hartvaat.nl/2026/05/24/lp-a-japan-verhoogd-lp-a-blijft-risicovol-ondanks-ldl-onder-55-mg-dl/","published":"2026-06-05"},{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/24/eas-consensus-wereldwijde-harmonisatie-van-lipidenklinieken/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/25/obicetrapib-verlaagt-naast-ldl-en-apob-ook-lipoproteine-a/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2026/04/24/santorini-uk-ldl-doel-onbereikt-bij-meerderheid-van-hoogrisicopatienten-na-1-jaa/","published":"2026-05-08"},{"url":"https://hartvaat.nl/2026/01/16/non-hdl-c-doelen-halen-in-de-eerste-en-tweede-lijn-een-da-vinci-deelanalyse/","published":"2026-01-16"},{"url":"https://hartvaat.nl/2026/01/11/zeventien-jaar-voor-verandering-doorbreken-de-2025-esc-eas-dyslipidemierichtlijn/","published":"2026-01-11"},{"url":"https://hartvaat.nl/2025/10/07/obicetrapib-en-mace-bij-hoogrisicopatienten-gepoolde-analyse/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2025/05/20/solbinsiran-angptl3-remming-van-preklinisch-tot-eerste-humane-studies/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/05/03/solbinsiran-langwerkend-sirna-tegen-angptl3-duurzaamheid-en-effectiviteit/","published":"2025-05-03"},{"url":"https://hartvaat.nl/2024/07/09/bempedoinezuur-versus-statines-vergelijking-van-cv-voordelen/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/03/01/clear-outcomes-bempedoinezuur-vermindert-totale-cv-events-bij-statine-intolerant/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2022/12/21/orion-11-inclisiran-verlaagt-ldl-effectief-bij-primaire-preventie/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2022/05/03/korte-interfererende-rna-tegen-lp-a-jama-fase-1-dosisstudie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/06/02/prevalentie-van-fh-bij-atherosclerotische-cv-ziekte-meta-analyse/","published":"2020-06-02"},{"url":"https://hartvaat.nl/2020/04/28/apabetalone-en-cv-events-bij-acs-met-diabetes-type-2-jama-betonmace/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-bij-heterozygote-familiaire-hypercholesterolemie-nejm-orion-9/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-fase-3-bij-verhoogd-ldl-nejm-orion-10-en-orion-11/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2019/11/01/inclisiran-1-of-2-dosis-en-ldl-cholesterol-orion-1-1-jaarsfollow-up/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"},{"url":"https://hartvaat.nl/2019/03/14/bempedoinezuur-voor-ldl-verlaging-nejm-veiligheid-en-werkzaamheid/","published":"2019-03-14"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/10/01/geschat-individueel-levensvoordeel-van-pcsk9-remming-bij-statinebehandelde-cad-p/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/09/25/sirna-tegen-pcsk9-en-atherogene-lipoproteinen-orion-1-secundaire-eindpunten/","published":"2018-09-25"},{"url":"https://hartvaat.nl/2018/09/01/cer-001-hdl-mimeticum-en-coronaire-atherosclerose-na-acs-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/07/14/ldl-verlaging-en-cv-events-met-pcsk9-remmers-meta-analyse-van-gerandomiseerde-tr/","published":"2018-07-14"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2017/11/14/ldl-verlaging-voor-primaire-preventie-bij-mannen-met-primaire-ldl-verhoging/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/04/13/inclisiran-bij-patienten-met-hoog-cv-risico-en-verhoogd-ldl-nejm-orion-1/","published":"2017-04-13"},{"url":"https://hartvaat.nl/2016/12/13/alirocumab-en-reductie-in-atherogene-lipiden-en-cardiovasculaire-events-10-odyss/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/11/08/residueel-vasculair-risico-bij-secundaire-preventie-verdeling-van-10-jaarsrisico/","published":"2016-11-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-a-harrington","type":"person","url":"https://hartvaat.nl/mensen/robert-a-harrington/","name":"Robert A Harrington","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":39,"articles":[{"url":"https://hartvaat.nl/2026/05/26/odyssey-outcomes-post-hoc-hscrp-en-il-6-zijn-complementaire-prognostische-marker/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2024/09/01/aspirinedosering-voor-secundaire-preventie-bij-mannen-versus-vrouwen/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","published":"2024-04-30"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2020/02/04/aanhoudende-ldl-verlaging-met-alirocumab-in-odyssey-outcomes/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/12/07/laesiecomplexiteit-en-periprocedurele-events-bij-potente-iv-antiplaatjestherapie/","published":"2018-12-07"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"},{"url":"https://hartvaat.nl/2017/05/25/levosimendan-bij-lv-disfunctie-voor-hartchirurgie-nejm-levo-cts/","published":"2017-05-25"},{"url":"https://hartvaat.nl/2017/03/14/afweging-myocardinfarct-versus-bloedingstype-en-mortaliteit-na-acs-tra-2p-timi-5/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2017/02/01/cangrelor-versus-gpiib-iiia-remmers-ischemie-en-bloedingsrisico-s-vergeleken/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/01/17/cangrelor-met-en-zonder-gpiib-iiia-remmers-bij-pci/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/11/29/presentatie-buiten-kantoortijden-versus-tijdens-kantoortijden-bij-stemi-champion/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/09/06/consistente-reductie-in-periprocedureel-mi-met-cangrelor-champion-analyses/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/04/19/trends-in-behandeling-en-uitkomsten-bij-nste-acs-naar-leeftijd/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/04/07/cangrelor-en-toegangsplaats-effect-op-ischemische-en-bloedingsevents-champion-ph/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/04/01/veiligheid-en-werkzaamheid-van-ticagrelor-versus-clopidogrel-bij-primaire-pci-vo/","published":"2016-04-01"},{"url":"https://hartvaat.nl/2016/01/19/werkzaamheid-en-veiligheid-van-cangrelor-bij-vrouwen-versus-mannen-tijdens-pci-c/","published":"2016-01-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"felix-mahfoud","type":"person","url":"https://hartvaat.nl/mensen/felix-mahfoud/","name":"Felix Mahfoud","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":38,"articles":[{"url":"https://hartvaat.nl/2026/06/02/pulsfield-ablatie-levert-betere-vrijwaring-van-recidief-dan-cryoballoon-bij-paro/","published":"2026-08-12"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/07/aldosteronsynthaseremming-bij-resistente-hypertensie-beloften-en-onzekerheden/","published":"2026-03-20"},{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/05/02/paclitaxel-gecoate-ballonnen-versus-des-bij-kleine-vaten-ipd-meta-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2025/04/17/pfa-versus-cryoballon-bij-paroxysmaal-af-gerandomiseerde-trial/","published":"2025-04-17"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2024/11/12/renale-denervatie-bij-hypertensie-uitgebreide-meta-analyse-van-alle-trials/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/12/rf-renale-denervatie-bij-ongecontroleerde-hypertensie-in-china-gerandomiseerde-t/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/06/11/target-bp-i-alcohol-gemedieerde-renale-denervatie-bij-hypertensie/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2023/10/01/ivabradine-bij-hoogrisico-hartfalenpatienten-shift-analyse/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/08/01/atrial-flow-regulator-en-overleving-bij-hartfalen-voorspelde-impact/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/07/01/pulsatiele-hemodynamiek-voorspelt-bloeddrukrespons-op-renale-denervatie/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/09/07/hartfrequentie-en-uitkomsten-van-renale-denervatie-bij-ongecontroleerde-hyperten/","published":"2021-09-07"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2020/03/10/overleving-na-revascularisatie-met-paclitaxel-gecoate-ballonnen/","published":"2020-03-10"},{"url":"https://hartvaat.nl/2020/03/01/slagvolumeveranderingen-na-renale-denervatie-cardiale-mri-inzichten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/03/01/ambulante-hartfrequentiereductie-na-renale-denervatie-bij-hypertensie-zonder-med/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/10/09/24-uurs-ambulante-bloeddrukreductie-na-renale-denervatie-spyral-htn-off-med/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2018/09/08/drug-coated-balloons-bij-kleine-coronairarterien-lancet-basket-small-2/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/09/01/bereikte-diastolische-bloeddruk-en-polsdruk-bij-streef-sbp-en-cv-uitkomsten-bij-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2018/06/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-6-maandsresultat/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2017/06/03/bereikte-bloeddruk-en-cv-uitkomsten-bij-hoogrisicopatienten-ontarget-transcend/","published":"2017-06-03"},{"url":"https://hartvaat.nl/2017/01/07/verminderd-bloeddrukverlagend-effect-van-renale-denervatie-bij-geisoleerde-systo/","published":"2017-01-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefan-k-james","type":"person","url":"https://hartvaat.nl/mensen/stefan-k-james/","name":"Stefan K James","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":38,"articles":[{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2025/12/11/ticagrelor-plus-aspirine-versus-aspirine-na-cabg-voor-acs-gerandomiseerde-trial/","published":"2025-12-11"},{"url":"https://hartvaat.nl/2025/12/01/dapagliflozine-na-mi-naar-ef-cardiometabole-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/10/07/help-mi-helicobacter-pylori-screening-na-acuut-mi-cluster-rct/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/01/07/euroheart-definities-van-klinische-studie-eindpunten-voor-cvd/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2024/11/02/bioadaptor-implantaat-versus-drug-eluting-stent-bij-stabiel-coronairlijden/","published":"2024-11-02"},{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/10/18/asundexian-factor-xia-remmer-na-acs-fase-2-dosisfindingsstudie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/03/15/5-jaars-ifr-versus-ffr-geleide-pci-define-flair-ifr-swedeheart/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2020/08/01/complete-versus-culprit-only-revascularisatie-bij-stemi-jama-cardiology-meta-ana/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/07/14/vergelijking-van-orale-p2y12-remmers-bij-acs-netwerkmeta-analyse-van-52-816-pati/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"},{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/12/21/culprit-shock-integratie-in-2017-esc-stemi-richtlijn-richtlijncommissie-standpun/","published":"2018-12-21"},{"url":"https://hartvaat.nl/2018/12/11/langetermijneffecten-van-zuurstof-op-sterfte-of-hf-hospitalisatie-na-verdenking-/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/12/01/multipele-biomarkers-en-mortaliteitsrisico-na-acs-jama-cardiology/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/10/01/zuurstof-bij-verdenking-acuut-mi-meta-analyse-van-gerandomiseerde-trials/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/08/01/zuurstoftherapie-bij-stemi-overzichtsartikel/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/05/07/esc-eapci-taskforce-rapport-over-bioresorbeerbare-scaffolds-executive-summary/","published":"2018-05-07"},{"url":"https://hartvaat.nl/2018/04/01/fibrinestoleigenschappen-en-klinische-uitkomsten-na-acs-plato-substudie/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2018/01/07/2017-esc-richtlijn-voor-stemi-management/","published":"2018-01-07"},{"url":"https://hartvaat.nl/2017/09/28/zuurstoftherapie-bij-vermoedelijk-acuut-myocardinfarct-nejm-deto2x-ami/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/05/11/instantaneous-wave-free-ratio-versus-ffr-voor-pci-indicatie-nejm-ifr-swedeheart/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2017/05/09/ranolazine-na-incomplete-pci-bij-diabetes-versus-zonder-diabetes-river-pci/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2017/01/10/trombusaspiratie-bij-stemi-individuele-patientdata-meta-analyse/","published":"2017-01-10"},{"url":"https://hartvaat.nl/2016/04/21/gdf-15-voorspelt-bloedingen-en-cardiovasculaire-events-bij-acuut-coronair-syndro/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/04/01/veiligheid-en-werkzaamheid-van-ticagrelor-versus-clopidogrel-bij-primaire-pci-vo/","published":"2016-04-01"},{"url":"https://hartvaat.nl/2016/01/09/ranolazine-bij-incomplete-revascularisatie-na-pci-de-river-pci-trial/","published":"2016-01-09"},{"url":"https://hartvaat.nl/2016/01/05/ranolazine-bij-angina-en-kwaliteit-van-leven-na-pci-met-incomplete-revascularisa/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-engstrm","type":"person","url":"https://hartvaat.nl/mensen/thomas-engstrm/","name":"Thomas Engstrøm","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":38,"articles":[{"url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","published":"2026-04-09"},{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2026/02/03/coronaire-vaatspasmen-bij-overlevenden-van-hartstilstand/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/12/29/functionele-en-morfologische-karakterisering-van-coronaire-atherosclerose/","published":"2025-12-29"},{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/06/01/ffr-geleide-pci-versus-cabg-bij-diffuus-coronairlijden/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/11/01/ifr-versus-ffr-en-vijfjaarsmortaliteit-swedeheart-en-define-flair/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/02/23/ct-coronairangiografie-bij-75-jarigen-met-nste-acs/","published":"2023-02-23"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2020/08/01/complete-versus-culprit-only-revascularisatie-bij-stemi-jama-cardiology-meta-ana/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/02/14/danami-2-16-jaarsfollow-up-primaire-pci-versus-fibrinolyse/","published":"2020-02-14"},{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-j-cohen","type":"person","url":"https://hartvaat.nl/mensen/david-j-cohen/","name":"David J Cohen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":37,"articles":[{"url":"https://hartvaat.nl/2026/05/25/1-op-5-oudere-patienten-heeft-hartfalen-opname-binnen-jaar-na-tavr-1-jaarsmortal/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/09/16/ischemia-anginatrajecten-na-invasieve-versus-conservatieve-strategie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/01/01/kccq-interpretatie-bij-hartfalen-patient-ankering/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","published":"2023-11-23"},{"url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","published":"2022-11-15"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/04/19/externe-validatie-van-de-freedom-score-voor-pci-versus-cabg/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2020/10/31/syntax-score-ii-herontwikkeling-voor-gepersonaliseerde-revascularisatiebeslissin/","published":"2020-10-31"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/05/gezondheidsstatus-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/05/01/zelfgerapporteerde-versus-apotheekgeregistreerde-medicatietrouw-compass-analyse/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/01/01/p2y12-copay-reductie-en-therapietrouw-aan-andere-secundaire-preventiemiddelen/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/22/individualisering-van-revascularisatiestrategie-bij-diabetes-met-multivatenlijde/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/05/07/gezondheidsstatus-na-mitraclip-bij-hf-met-secundaire-mr-coapt/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-ballonexpandeerbare-klep-bij-laagrisicopatienten-nejm-partner-3/","published":"2019-05-02"},{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","published":"2019-02-19"},{"url":"https://hartvaat.nl/2019/01/01/medicatie-copay-vouchers-en-p2y12-gebruik-en-cv-events-na-mi-jama/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"},{"url":"https://hartvaat.nl/2017/08/01/kosteneffectiviteit-van-langdurig-ticagrelor-na-mi-pegasus-timi-54/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/04/25/kwaliteit-van-leven-na-chirurgie-of-des-bij-drienvaten-of-hoofdstamlijden/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2016/04/26/predictieregel-voor-voordeel-en-schade-van-dapt-na-1-jaar-pci-jama-validatiestud/","published":"2016-04-26"},{"url":"https://hartvaat.nl/2016/01/21/doodsoorzaken-bij-langdurige-dapt-na-coronaire-stents/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"felipe-a-martinez","type":"person","url":"https://hartvaat.nl/mensen/felipe-a-martinez/","name":"Felipe A Martinez","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":37,"articles":[{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","published":"2022-09-03"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-j-p-kastelein","type":"person","url":"https://hartvaat.nl/mensen/john-j-p-kastelein/","name":"John J P Kastelein","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":34,"articles":[{"url":"https://hartvaat.nl/2026/05/14/mendeliaanse-randomisatie-hmgcr-remming-verhoogt-diabetesrisico-andere-lipidendo/","published":"2026-06-20"},{"url":"https://hartvaat.nl/2026/05/25/obicetrapib-verlaagt-naast-ldl-en-apob-ook-lipoproteine-a/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2025/10/07/obicetrapib-en-mace-bij-hoogrisicopatienten-gepoolde-analyse/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2025/05/17/tandem-obicetrapib-plus-ezetimibe-voor-ldl-verlaging-lancet-fase-3/","published":"2025-05-17"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/01/30/orion-5-inclisiran-bij-homozygote-fh/","published":"2024-01-30"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/10/01/evolocumab-bij-pediatrische-heterozygoot-fh-nejm-hauser-rct/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/08/20/evinacumab-bij-homozygoot-familiaire-hypercholesterolemie-nejm/","published":"2020-08-20"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2020/07/14/alirocumab-bij-homozygoot-fh-odyssey-hofh/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-bij-heterozygote-familiaire-hypercholesterolemie-nejm-orion-9/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-fase-3-bij-verhoogd-ldl-nejm-orion-10-en-orion-11/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2019/11/01/inclisiran-1-of-2-dosis-en-ldl-cholesterol-orion-1-1-jaarsfollow-up/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/04/01/initieel-en-serieel-crp-en-cv-events-en-dood-na-acs-jama-cardiology/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/10/23/evolocumab-en-coronaire-plaquesamenstelling-glagov-beeldvorming/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/01/geschat-individueel-levensvoordeel-van-pcsk9-remming-bij-statinebehandelde-cad-p/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/09/25/sirna-tegen-pcsk9-en-atherogene-lipoproteinen-orion-1-secundaire-eindpunten/","published":"2018-09-25"},{"url":"https://hartvaat.nl/2018/09/01/hdl-mimeticum-met-recombinant-apoa-i-milano-en-coronairlijden-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/09/01/cer-001-hdl-mimeticum-en-coronaire-atherosclerose-na-acs-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/11/14/ldl-verlaging-voor-primaire-preventie-bij-mannen-met-primaire-ldl-verhoging/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/08/29/rosuvastatine-bij-kinderen-met-homozygote-familiaire-hypercholesterolemie/","published":"2017-08-29"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/04/20/ldl-reductievariabiliteit-en-antilichaamvorming-bij-bococizumab-nejm/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/04/13/inclisiran-bij-patienten-met-hoog-cv-risico-en-verhoogd-ldl-nejm-orion-1/","published":"2017-04-13"},{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/11/08/residueel-vasculair-risico-bij-secundaire-preventie-verdeling-van-10-jaarsrisico/","published":"2016-11-08"},{"url":"https://hartvaat.nl/2016/05/01/ly3015014-een-nieuw-monoklonaal-pcsk9-antilichaam-gerandomiseerde-fase-2-trial/","published":"2016-05-01"}],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/ldl-cholesterol/","title":"Sessie 2: LDL-cholesterol"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aldo-p-maggioni","type":"person","url":"https://hartvaat.nl/mensen/aldo-p-maggioni/","name":"Aldo P Maggioni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":36,"articles":[{"url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-vasculaire-preventie-meta-analyse-van-lange-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2025/01/07/euroheart-definities-van-klinische-studie-eindpunten-voor-cvd/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/28/g-csf-voor-stamcelmobilisatie-na-acuut-mi-meta-analyse/","published":"2024-10-28"},{"url":"https://hartvaat.nl/2024/10/01/plotse-dood-na-mi-inzichten-uit-valiant-en-paradise-mi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/25/raas-blokkade-bij-hartfalen-voordeel-onafhankelijk-van-etniciteit-jama-meta-anal/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/06/01/betablokkers-bij-systolisch-hartfalen-en-pacemakerritme-mortaliteitseffect/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/03/10/mondiale-prevalentie-uitkomsten-en-kosten-van-hartfalen-careme-studie/","published":"2023-03-10"},{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/10/14/dal-gene-farmacogenetica-geleide-dalcetrapib-na-acs/","published":"2022-10-14"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/06/14/euroheart-datastandaarden-voor-hartfalenregistraties/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/08/13/rivaroxaban-met-of-zonder-aspirine-bij-hf-met-coronair-of-perifeer-vaatlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2017/09/28/exenatide-eenmaal-per-week-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-ne/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/04/14/vericiguat-bij-verslechterend-chronisch-hfpef-socrates-preserved-resultaten/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2016/07/14/finerenon-versus-eplerenon-bij-hartfalen-met-diabetes-en-verslechterende-nierfun/","published":"2016-07-14"},{"url":"https://hartvaat.nl/2016/02/02/ciclosporine-a-bij-gereperfuseerd-myocardinfarct-de-multicenter-cycle-trial/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dominick-j-angiolillo","type":"person","url":"https://hartvaat.nl/mensen/dominick-j-angiolillo/","name":"Dominick J Angiolillo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":36,"articles":[{"url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2025/11/18/cv-effecten-en-verdraagbaarheid-van-glp-1-agonisten-meta-analyse/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2024/12/01/korte-dapt-na-des-bij-acs-ipd-meta-analyse-bevestigt-veiligheid/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/06/01/opt-birisk-clopidogrel-monotherapie-bij-acs-met-hoog-ischemisch-en-bloedingsrisi/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/08/09/ticagrelor-dapt-en-veneuze-graftfalen-na-cabg-systematische-review/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","published":"2022-03-07"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/10/12/overbrugging-van-antiplaatjestherapie-na-pci-jacc-review/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2021/04/17/geleide-versus-standaard-antiplaatjestherapie-na-pci-lancet-meta-analyse/","published":"2021-04-17"},{"url":"https://hartvaat.nl/2020/12/15/prehospitaal-gemalen-prasugrel-bij-stemi-gerandomiseerde-trial/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/10/13/laaggedoseerd-ticagrelor-versus-standaard-clopidogrel-bij-diabetes-farmacodynami/","published":"2020-10-13"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/02/18/ticagrelor-met-of-zonder-aspirine-na-pci-twilight-plaatjessubstudie/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2019/04/02/cangrelor-en-gemalen-ticagrelor-bij-stemi-met-primaire-pci/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/07/31/antitrombotische-therapie-bij-af-met-oac-na-pci-aha-scientific-statement/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2016/09/13/prasugrel-versus-ticagrelor-bij-diabetes-type-2-met-coronairlijden-optimus-4-stu/","published":"2016-09-13"},{"url":"https://hartvaat.nl/2016/06/14/reductie-van-ischemische-events-met-ticagrelor-bij-diabetes-na-myocardinfarct-pe/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/05/03/gemalen-prasugrel-bij-stemi-met-primaire-pci-de-crush-studie/","published":"2016-05-03"},{"url":"https://hartvaat.nl/2016/04/01/veiligheid-en-werkzaamheid-van-ticagrelor-versus-clopidogrel-bij-primaire-pci-vo/","published":"2016-04-01"},{"url":"https://hartvaat.nl/2016/03/15/plaatjesremming-met-ticagrelor-60-mg-versus-90-mg-in-de-pegasus-timi-54-trial/","published":"2016-03-15"},{"url":"https://hartvaat.nl/2016/02/16/ticagrelor-versus-clopidogrel-bij-troponine-negatieve-laagrisico-acs-met-ad-hoc-/","published":"2016-02-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jean-l-rouleau","type":"person","url":"https://hartvaat.nl/mensen/jean-l-rouleau/","name":"Jean L Rouleau","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":36,"articles":[{"url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/10/01/plotse-dood-na-mi-inzichten-uit-valiant-en-paradise-mi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/04/sacubitril-valsartan-bij-hartfalen-over-het-nierfunctiespectrum/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2024/01/18/raft-langetermijn-crt-d-bij-hartfalen-nejm-14-jaarsresultaten/","published":"2024-01-18"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/04/01/natriumzirconiumcyclosilicaat-bij-hyperkaliemie-en-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/03/26/bnp-tijdens-sacubitril-valsartan-paradigm-hf/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2019/02/26/sacubitril-valsartan-en-biomarkers-van-extracellulaire-matrixregulatie-bij-hfref/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2019/01/08/hfref-differentiele-impact-op-mannen-en-vrouwen/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/12/01/number-needed-to-treat-met-arni-voor-preventie-van-cv-dood-of-hf-hospitalisatie/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/10/01/natriuretische-peptiden-en-cardiovasculaire-prognose-bij-hfpef-topcat/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/06/01/sacubitril-valsartan-en-fysieke-en-sociale-activiteitsbeperkingen-bij-hf-paradig/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/11/14/af-type-en-uitkomsten-bij-hfref/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/04/14/systolische-bloeddruk-en-werkzaamheid-van-sacubitril-valsartan-bij-chronisch-hfr/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/03/21/plotse-hartdood-bij-ischemisch-hartfalen-na-cabg-stich-resultaten/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2017/01/01/verminderd-hyperkaliemierisico-met-mra-door-sacubitril-valsartan-bij-hartfalen/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/12/06/prognostische-implicaties-van-nt-probnp-veranderingen-bij-hartfalen/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/11/29/bmi-en-nauwkeurigheid-van-nt-probnp-en-bnp-voor-diagnose-van-acuut-hartfalen/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/11/01/tienjaarsuitkomsten-na-cabg-naar-leeftijd-bij-hartfalen-met-lv-systolische-disfu/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/07/19/sacubitril-valsartan-en-30-daagse-heropname-na-hartfalenhospitalisatie/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/06/07/klinische-verslechtering-van-poliklinisch-behandeld-hartfalen-paradigm-hf-analys/","published":"2016-06-07"},{"url":"https://hartvaat.nl/2016/04/21/coronaire-bypasschirurgie-bij-ischemische-cardiomyopathie-nejm-stich-trial/","published":"2016-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-w-eikelboom","type":"person","url":"https://hartvaat.nl/mensen/john-w-eikelboom/","name":"John W Eikelboom","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":36,"articles":[{"url":"https://hartvaat.nl/2026/08/25/extracraniale-bloedingen-komen-bij-26-van-af-patienten-op-antistolling-voor-comb/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/02/24/systemische-embolieen-bij-af-ipd-mega-meta-analyse-van-71-683-patienten/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2024/10/01/neurofilament-light-chain-en-cva-risico-bij-af/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2023/11/04/colchicine-vermindert-perioperatief-af-na-thoraxchirurgie-lancet-rct/","published":"2023-11-04"},{"url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","published":"2023-05-21"},{"url":"https://hartvaat.nl/2022/10/18/asundexian-factor-xia-remmer-na-acs-fase-2-dosisfindingsstudie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/08/31/colchicine-bij-chronisch-coronairlijden-met-versus-zonder-eerder-acs/","published":"2021-08-31"},{"url":"https://hartvaat.nl/2021/07/21/laaggedoseerd-colchicine-bij-coronairlijden-meta-analyse-van-gerandomiseerde-tri/","published":"2021-07-21"},{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/07/01/cv-gevolgen-van-stoppen-met-laaggedoseerd-rivaroxaban-bij-chronisch-vaatlijden/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/01/01/rivaroxaban-plus-aspirine-bij-symptomatisch-pav-compass-subanalyse/","published":"2021-01-01"},{"url":"https://hartvaat.nl/2020/11/01/ace2-niveaus-en-covid-19-risicofactoren-bij-af-patienten/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/08/04/2020-acc-bloedingsmanagement-bij-oac-expert-consensus-decision-pathway/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2019/12/07/individueel-levenslang-voordeel-en-bloedingsrisico-van-rivaroxaban-plus-aspirine/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2019/08/13/rivaroxaban-met-of-zonder-aspirine-bij-hf-met-coronair-of-perifeer-vaatlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/05/14/rivaroxaban-plus-aspirine-bij-vaatlijden-met-nierdisfunctie-compass/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2018/11/21/voortzetten-versus-onderbreken-doac-bij-device-chirurgie-bruise-control-2/","published":"2018-11-21"},{"url":"https://hartvaat.nl/2018/07/31/antitrombotische-therapie-bij-af-met-oac-na-pci-aha-scientific-statement/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/07/17/oac-plus-nsaid-bij-af-risico-op-ernstige-bloedingen/","published":"2018-07-17"},{"url":"https://hartvaat.nl/2018/06/09/dabigatran-bij-myocardschade-na-niet-cardiale-chirurgie-lancet-manage-trial/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","published":"2018-02-07"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2017/07/01/dabigatran-naar-leeftijd-bij-atriumfibrilleren-re-ly-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/11/29/biomarkergebaseerde-cva-risicoscore-bij-atriumfibrilleren-validatie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnevaluatie-van-dabigatran-150-versus-110-mg-bij-niet-valvulair-af/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","published":"2016-06-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"justin-a-ezekowitz","type":"person","url":"https://hartvaat.nl/mensen/justin-a-ezekowitz/","name":"Justin A Ezekowitz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":36,"articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/16/farmacologische-behandeling-van-hfref-geactualiseerde-systematische-review/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/01/geografische-variatie-in-hfref-patientkenmerken-en-behandeling/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/04/01/vericiguat-voordeel-geprojecteerd-op-paradigm-hf-en-dapa-hf-populaties/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","published":"2024-08-27"},{"url":"https://hartvaat.nl/2024/07/09/selectieve-aldosereductaseremmer-bij-diabetische-cardiomyopathie-rct/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2023/09/14/heart-fid-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-nejm/","published":"2023-09-14"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"},{"url":"https://hartvaat.nl/2022/04/09/natriumreductie-100-mmol-bij-hartfalen-lancet-sodium-hf/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2020/03/10/routine-versus-selectieve-cardiale-mri-bij-niet-ischemisch-hf-outsmart-hf/","published":"2020-03-10"},{"url":"https://hartvaat.nl/2020/02/01/geschiktheid-voor-sglt2-remmers-bij-diabetespatienten-opgenomen-met-hartfalen/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/08/01/hoog-versus-laag-zuurstof-bij-acuut-hartfalen-hilo-hf-pilot/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/11/27/economische-en-qol-uitkomsten-van-nt-probnp-geleide-hf-therapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/10/01/zuurstof-bij-verdenking-acuut-mi-meta-analyse-van-gerandomiseerde-trials/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/08/22/natriuretisch-peptide-geleide-therapie-bij-hoogrisico-hartfalen-jama-guide-it/","published":"2017-08-22"},{"url":"https://hartvaat.nl/2017/08/07/trv027-biased-ligand-van-de-angiotensine-ii-receptor-bij-acuut-hartfalen-gerando/","published":"2017-08-07"},{"url":"https://hartvaat.nl/2017/06/27/hospitalisatie-voor-nieuw-gediagnosticeerd-versus-verslechterend-chronisch-hartf/","published":"2017-06-27"},{"url":"https://hartvaat.nl/2016/12/10/omecamtiv-mecarbil-bij-chronisch-hartfalen-lancet-cosmic-hf-fase-2-trial/","published":"2016-12-10"},{"url":"https://hartvaat.nl/2016/09/01/apixaban-5-mg-bij-af-met-hoge-leeftijd-laag-gewicht-of-hoog-creatinine-aristotle/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/03/29/omecamtiv-mecarbil-bij-acuut-hartfalen-de-atomic-ahf-studie/","published":"2016-03-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stuart-j-connolly","type":"person","url":"https://hartvaat.nl/mensen/stuart-j-connolly/","name":"Stuart J Connolly","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":36,"articles":[{"url":"https://hartvaat.nl/2024/11/26/artesia-subanalyse-cva-risico-naar-frequentie-en-duur-van-subclinisch-af/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/01/af-ablatie-bij-hfref-versus-hfpef-meta-analyse/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/05/16/annexa-i-andexanet-alfa-bij-factor-xa-remmer-geassocieerde-intracerebrale-bloedi/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2024/03/26/doac-s-bij-device-gedetecteerd-af-meta-analyse-noah-afnet-6-en-artesia/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/10/24/laaos-iii-laa-occlusie-en-anticoagulatiegebruik/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","published":"2023-05-21"},{"url":"https://hartvaat.nl/2022/09/15/invictus-rivaroxaban-versus-warfarine-bij-reumatische-hartziekte-en-af/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2022/04/09/asundexian-factor-xia-remmer-versus-apixaban-bij-af-lancet-pacific-af/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/07/01/cv-gevolgen-van-stoppen-met-laaggedoseerd-rivaroxaban-bij-chronisch-vaatlijden/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/06/15/prevalentie-van-linkeratriumtrombus-bij-geanticoaguleerde-af-patienten/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","published":"2021-06-03"},{"url":"https://hartvaat.nl/2021/05/01/screening-op-af-bij-ouderen-jama-cardiology-gerandomiseerde-trial/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2019/08/13/rivaroxaban-met-of-zonder-aspirine-bij-hf-met-coronair-of-perifeer-vaatlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/07/01/hospitalisatieredenen-en-mortaliteitsrisico-bij-af-met-dabigatran-versus-warfari/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/05/14/rivaroxaban-plus-aspirine-bij-vaatlijden-met-nierdisfunctie-compass/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/02/26/patientgerichte-transitional-care-bij-hf-hospitalisatie-jama-pact-hf/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/11/21/voortzetten-versus-onderbreken-doac-bij-device-chirurgie-bruise-control-2/","published":"2018-11-21"},{"url":"https://hartvaat.nl/2018/07/17/oac-plus-nsaid-bij-af-risico-op-ernstige-bloedingen/","published":"2018-07-17"},{"url":"https://hartvaat.nl/2018/06/09/dabigatran-bij-myocardschade-na-niet-cardiale-chirurgie-lancet-manage-trial/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","published":"2018-02-07"},{"url":"https://hartvaat.nl/2018/02/01/dabigatran-versus-warfarine-bij-af-met-linkerventrikelhypertrofie-re-ly/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2017/10/01/korte-dabigatran-onderbreking-voor-device-implantatie-re-ly-multicenterervaring/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/07/01/dabigatran-naar-leeftijd-bij-atriumfibrilleren-re-ly-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/02/01/reductie-van-onnodige-ventriculaire-pacing-en-klinische-uitkomsten-bij-behouden-/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2016/11/29/biomarkergebaseerde-cva-risicoscore-bij-atriumfibrilleren-validatie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/08/23/dabigatran-versus-warfarine-bij-af-met-kleplijden-re-ly-analyse/","published":"2016-08-23"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnevaluatie-van-dabigatran-150-versus-110-mg-bij-niet-valvulair-af/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","published":"2016-06-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-t-ruff","type":"person","url":"https://hartvaat.nl/mensen/christian-t-ruff/","name":"Christian T Ruff","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":35,"articles":[{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/24/systemische-embolieen-bij-af-ipd-mega-meta-analyse-van-71-683-patienten/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2024/09/01/eldercare-af-subanalyse-dosisreductie-edoxaban-bij-80-jarigen-met-af/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2023/01/11/inadequate-noac-dosering-bij-af-uitkomsten-en-oorzaken-meta-analyse/","published":"2023-01-11"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/03/09/halve-versus-volle-dosis-edoxaban-bij-af-gerandomiseerde-vergelijking/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/02/25/genetische-risicoscore-voorspelt-voordeel-van-evolocumab-fourier/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2019/09/01/edoxaban-versus-warfarine-naar-gemiddelde-bloeddruk-bij-af-met-hypertensie/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/16/edoxaban-versus-warfarine-bij-af-met-leverziekte-engage-af-timi-48/","published":"2019-07-16"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/14/bmi-en-uitkomsten-bij-af-behandeld-met-edoxaban-of-warfarine-engage-af-timi-48/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/05/14/edoxaban-bij-aziatische-af-patienten-concentraties-en-anti-xa-activiteit/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/02/05/abc-scores-voor-cva-en-bloedingsrisico-bij-af-prestatieverbetering/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2019/02/01/edoxaban-en-implanteerbare-cardiale-devices-engage-af-timi-48/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/10/30/endogene-factor-xa-activiteit-en-edoxaban-farmacodynamische-marker-en-klinische-/","published":"2018-10-30"},{"url":"https://hartvaat.nl/2018/09/25/edoxaban-versus-warfarine-bij-latijns-amerikaanse-af-patienten-engage-af-timi-48/","published":"2018-09-25"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2017/03/28/edoxaban-bij-af-met-bioprothese-hartkleppen-trombo-emboliepreventie/","published":"2017-03-28"},{"url":"https://hartvaat.nl/2017/03/21/kleplijden-en-edoxaban-versus-warfarine-bij-af-engage-af-timi-48/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2017/03/21/nieuwe-risicovoorspellingsscore-bij-af-voor-netto-klinisch-resultaat-engage-af-t/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/09/13/edoxaban-versus-warfarine-bij-af-patienten-met-valrisico-engage-af-timi-48-analy/","published":"2016-09-13"},{"url":"https://hartvaat.nl/2016/07/05/nierfunctie-en-uitkomsten-met-edoxaban-in-de-engage-af-timi-48-trial/","published":"2016-07-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dalane-w-kitzman","type":"person","url":"https://hartvaat.nl/mensen/dalane-w-kitzman/","name":"Dalane W Kitzman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":35,"articles":[{"url":"https://hartvaat.nl/2025/06/01/humain-hfpef-nieuwe-metabole-accelerator-bij-obesitas-hfpef-rct/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/bloeddrukcontrole-en-arteriele-stijfheidsmechanismen-in-sprint/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/nierfunctie-en-dapagliflozine-effect-op-gezondheidsstatus-define-hf/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/af-en-semaglutide-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/01/amethyst-verinurad-plus-allopurinol-bij-hfpef-negatieve-trial/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","published":"2024-08-27"},{"url":"https://hartvaat.nl/2024/08/01/sarcopenie-en-intensieve-bloeddrukbehandeling-sprint-subanalyse/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2023/07/18/sglt2-remmers-verbeteren-kwaliteit-van-leven-gelijk-bij-zwarte-en-witte-hartfale/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2023/04/18/aha-scientific-statement-gestructureerde-inspanningstraining-bij-hfpef/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2023/02/01/fysieke-revalidatie-bij-fragiele-ouderen-met-acuut-hartfalen/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/10/18/intensieve-bloeddrukverlaging-bij-maligne-linkerventrikel-hypertrofie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/07/12/frailteit-beinvloedt-effect-van-inspanningstraining-bij-hartfalen-hf-action-anal/","published":"2022-07-12"},{"url":"https://hartvaat.nl/2022/02/01/economische-uitkomsten-van-revalidatie-bij-ouderen-met-acuut-hf-rehab-hf/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/07/15/fysieke-revalidatie-bij-oudere-gehospitaliseerde-hf-patienten-nejm-rehab-hf/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2021/05/05/intensieve-bloeddruk-en-aortastijfheid-sprint-heart/","published":"2021-05-05"},{"url":"https://hartvaat.nl/2020/12/22/lichaamssamenstelling-en-risico-op-hartfalen-en-mi-prospectieve-analyse/","published":"2020-12-22"},{"url":"https://hartvaat.nl/2019/06/04/neladenoson-bialanaat-en-inspanningscapaciteit-bij-hfpef-jama-panache/","published":"2019-06-04"},{"url":"https://hartvaat.nl/2018/06/01/geindividualiseerd-patiromer-doseringsregime-bij-hf-met-ckd-en-hyperkaliemie/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/01/09/diastolische-bloeddruk-en-intensieve-bloeddrukcontrole-sprint-analyse/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/04/04/inspanningstraining-bij-chronisch-hartfalen-met-atriumfibrilleren/","published":"2017-04-04"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"},{"url":"https://hartvaat.nl/2016/03/01/voorschrijfpatronen-van-thiazidediuretica-in-de-sprint-trial/","published":"2016-03-01"},{"url":"https://hartvaat.nl/2016/01/05/calorierestrictie-of-aerobe-training-bij-obese-ouderen-met-hfpef-effect-op-vo2-p/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"james-l-januzzi","type":"person","url":"https://hartvaat.nl/mensen/james-l-januzzi/","name":"James L Januzzi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":35,"articles":[{"url":"https://hartvaat.nl/2025/12/09/aspree-cardiale-stress-en-bloeddrukmanagement-bij-ouderen/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/11/18/2025-acc-scientific-statement-obesitasmanagement-bij-hartfalen/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/07/01/bestaande-cv-data-benutten-voor-hypertensiedetectie-en-behandeling-vital-trial/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/05/13/empagliflozine-erytropoese-en-ijzermobilisatie-bij-hartfalen/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2024/11/12/sglt2-remming-en-proteomische-handtekeningen-bij-hartfalen-bevestiging/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/07/09/selectieve-aldosereductaseremmer-bij-diabetische-cardiomyopathie-rct/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/16/2024-acc-expert-consensus-behandeling-van-hfref-beslispad-geactualiseerd/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2023/08/08/stop-ca-atorvastatine-beschermt-tegen-antracycline-cardiotoxiciteit/","published":"2023-08-08"},{"url":"https://hartvaat.nl/2023/07/18/sglt2-remmers-verbeteren-kwaliteit-van-leven-gelijk-bij-zwarte-en-witte-hartfale/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2023/05/09/2023-acc-expert-consensus-management-van-hfpef/","published":"2023-05-09"},{"url":"https://hartvaat.nl/2022/12/21/empagliflozine-en-het-circulerend-proteoom-bij-hartfalen-emperor-mechanismen/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/10/18/dosisrespons-van-sacubitril-valsartan-bij-hfref/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/02/08/stress-cardiale-biomarkers-en-cv-renale-uitkomsten-bij-canagliflozine/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/nt-probnp-prognose-en-empagliflozine-effect-bij-emperor-reduced/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/08/01/klinische-fenotypen-zijn-effectiever-dan-ef-categorieen-voor-hf-uitkomsten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2021/02/16/2021-acc-hf-behandeloptimalisatie-update-antwoorden-op-10-cruciale-vragen/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2020/11/03/canagliflozine-en-nt-probnp-implicaties-voor-cv-risicoreductie/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/09/22/sekse-specifieke-cv-risicofactoren-en-biomarkers-bij-incident-hartfalen/","published":"2020-09-22"},{"url":"https://hartvaat.nl/2020/09/01/2020-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2018/12/18/2018-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/11/27/economische-en-qol-uitkomsten-van-nt-probnp-geleide-hf-therapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2018/01/16/hoog-sensitief-troponine-t-bij-chronisch-hartfalen-individuele-patientdata-meta-/","published":"2018-01-16"},{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","published":"2017-10-19"},{"url":"https://hartvaat.nl/2017/08/22/natriuretisch-peptide-geleide-therapie-bij-hoogrisico-hartfalen-jama-guide-it/","published":"2017-08-22"},{"url":"https://hartvaat.nl/2017/08/08/canagliflozine-en-cardiovasculaire-biomarkers-bij-oudere-diabetespatienten/","published":"2017-08-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-g-f-cleland","type":"person","url":"https://hartvaat.nl/mensen/john-g-f-cleland/","name":"John G F Cleland","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":35,"articles":[{"url":"https://hartvaat.nl/2026/05/04/congestie-bij-chronisch-hartfalen-echografie-vult-klinisch-onderzoek-aan-en-voor/","published":"2026-07-01"},{"url":"https://hartvaat.nl/2026/02/23/ijzertekort-bij-chronische-nierziekte-en-hartfalen-expertperspectieven/","published":"2026-03-04"},{"url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2025/04/01/ambulante-behandeling-van-gedecompenseerd-hartfalen-meta-analyse/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","published":"2024-04-21"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/06/14/euroheart-datastandaarden-voor-hartfalenregistraties/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/10/01/thuismonitoring-met-technologie-ondersteund-management-bij-chronisch-hf-gerandom/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2019/12/01/orale-morfine-bij-dyspneu-bij-chronisch-hartfalen-gerandomiseerde-placebogecontr/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/11/21/rivaroxaban-en-cva-tia-bij-hf-met-coronairlijden-en-sinusritme-commander-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2019/06/01/rivaroxaban-en-trombo-embolische-events-bij-hf-met-coronairlijden-en-sinusritme-/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/02/01/spironolacton-en-collageenmetabolisme-biomarkers-bij-ongecontroleerde-hypertensi/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2019/01/05/staken-van-hf-medicatie-bij-herstelde-dilaterende-cardiomyopathie-lancet-tred-hf/","published":"2019-01-05"},{"url":"https://hartvaat.nl/2018/10/04/rivaroxaban-bij-hartfalen-met-sinusritme-en-coronairlijden-nejm-commander-hf/","published":"2018-10-04"},{"url":"https://hartvaat.nl/2018/10/01/transcatheter-interatriale-shunt-bij-hfpef-1-jaarsresultaten/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/06/20/hartfrequentie-en-ritme-en-het-voordeel-van-betablokkers-bij-hartfalen/","published":"2017-06-20"},{"url":"https://hartvaat.nl/2017/03/21/plotse-hartdood-bij-ischemisch-hartfalen-na-cabg-stich-resultaten/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/12/10/omecamtiv-mecarbil-bij-chronisch-hartfalen-lancet-cosmic-hf-fase-2-trial/","published":"2016-12-10"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"},{"url":"https://hartvaat.nl/2016/03/29/omecamtiv-mecarbil-bij-acuut-hartfalen-de-atomic-ahf-studie/","published":"2016-03-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-j-mentz","type":"person","url":"https://hartvaat.nl/mensen/robert-j-mentz/","name":"Robert J Mentz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":35,"articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2026/02/03/intraveneus-ijzer-bij-hartfalen-met-ijzertekort-meta-analyse-met-trial-sequentie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/04/01/vericiguat-voordeel-geprojecteerd-op-paradigm-hf-en-dapa-hf-populaties/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/10/01/amethyst-verinurad-plus-allopurinol-bij-hfpef-negatieve-trial/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/02/01/transform-hf-torsemide-versus-furosemide-bij-nieuw-vs-chronisch-hartfalen/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/12/21/iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-ipd-meta-analyse/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2023/09/14/heart-fid-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-nejm/","published":"2023-09-14"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/11/transform-hf-torsemide-versus-furosemide-geen-verschil-in-symptomen/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/07/04/sacubitril-valsartan-bij-hfmref-hfpef-met-verslechterend-hartfalen/","published":"2023-07-04"},{"url":"https://hartvaat.nl/2023/04/01/intraveneus-ijzer-bij-hartfalen-meta-analyse-op-studieniveau/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/02/01/fysieke-revalidatie-bij-fragiele-ouderen-met-acuut-hartfalen/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2023/01/17/transform-hf-torsemide-biedt-geen-overlevingsvoordeel-boven-furosemide/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/07/12/frailteit-beinvloedt-effect-van-inspanningstraining-bij-hartfalen-hf-action-anal/","published":"2022-07-12"},{"url":"https://hartvaat.nl/2022/02/01/economische-uitkomsten-van-revalidatie-bij-ouderen-met-acuut-hf-rehab-hf/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2021/08/01/gdf-15-en-liraglutide-behandeling-bij-hf-patienten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2021/07/15/fysieke-revalidatie-bij-oudere-gehospitaliseerde-hf-patienten-nejm-rehab-hf/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2020/04/28/open-label-drop-in-van-glucoseverlagende-medicatie-en-exscel-uitkomsten/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2018/12/01/liraglutide-en-gewicht-bij-gevorderd-hfref-fight-trial-inzichten/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/03/01/poliklinische-verslechtering-van-hartfalen-als-therapiedoel-jama-cardiology-revi/","published":"2018-03-01"},{"url":"https://hartvaat.nl/2017/09/28/exenatide-eenmaal-per-week-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-ne/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/07/18/palliatieve-zorg-bij-hartfalen-de-pal-hf-gerandomiseerde-trial/","published":"2017-07-18"},{"url":"https://hartvaat.nl/2017/06/27/hospitalisatie-voor-nieuw-gediagnosticeerd-versus-verslechterend-chronisch-hartf/","published":"2017-06-27"},{"url":"https://hartvaat.nl/2017/04/04/inspanningstraining-bij-chronisch-hartfalen-met-atriumfibrilleren/","published":"2017-04-04"},{"url":"https://hartvaat.nl/2017/03/21/werkzaamheid-en-veiligheid-van-tolvaptan-bij-gehospitaliseerd-acuut-hartfalen/","published":"2017-03-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"barry-a-borlaug","type":"person","url":"https://hartvaat.nl/mensen/barry-a-borlaug/","name":"Barry A Borlaug","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":34,"articles":[{"url":"https://hartvaat.nl/2026/04/27/nierfunctiestoornis-verergert-pulmonale-vaatziekte-bij-hfpef/","published":"2026-07-16"},{"url":"https://hartvaat.nl/2025/09/09/summit-tirzepatide-effect-bij-hfpef-met-en-zonder-diabetes/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/07/29/summit-bmi-centrale-adipositas-en-gewichtsverlies-beinvloeden-tirzepatide-effect/","published":"2025-07-29"},{"url":"https://hartvaat.nl/2025/06/01/humain-hfpef-nieuwe-metabole-accelerator-bij-obesitas-hfpef-rct/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/nierfunctie-en-dapagliflozine-effect-op-gezondheidsstatus-define-hf/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/05/13/summit-tirzepatide-en-ckd-interactie-bij-hfpef-met-obesitas/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/03/11/summit-tirzepatide-en-klinisch-traject-bij-hfpef-met-obesitas-langetermijn/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/02/25/summit-tirzepatide-vermindert-lv-massa-en-paracardiaal-vetweefsel-bij-hfpef/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/01/30/summit-tirzepatide-bij-hfpef-met-obesitas-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2024/12/01/splanchnische-zenuwablatie-bij-hfpef-endovasculaire-benadering/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/11/12/ketonester-bij-type-2-diabetes-en-hartfalen-cross-over-trial/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/af-en-semaglutide-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/09/24/dapagliflozine-verbetert-arteriele-en-veneuze-compliantie-bij-hfpef/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/09/01/dapagliflozine-en-rv-pulmonale-interactie-bij-hfpef/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","published":"2024-08-27"},{"url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/05/07/orale-ketonester-bij-hfref-gerandomiseerde-trial/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2023/09/05/cameo-dapa-cardiale-en-metabole-effecten-van-dapagliflozine-bij-hfpef/","published":"2023-09-05"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/08/01/gdf-15-en-liraglutide-behandeling-bij-hf-patienten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2020/12/08/empagliflozine-en-hemodynamiek-bij-hfref/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2019/11/26/interatriale-shunt-en-pulmonale-vaatfunctie-bij-hfpef/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2018/12/01/liraglutide-en-gewicht-bij-gevorderd-hfref-fight-trial-inzichten/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","published":"2018-11-06"},{"url":"https://hartvaat.nl/2017/07/11/arteriele-verstijving-bij-inspanning-bij-hfpef/","published":"2017-07-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gregg-c-fonarow","type":"person","url":"https://hartvaat.nl/mensen/gregg-c-fonarow/","name":"Gregg C Fonarow","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":34,"articles":[{"url":"https://hartvaat.nl/2026/05/19/sglt2-remmers-bij-oudere-patienten-opgenomen-voor-hfref-24-sterfte-en-16-heropna/","published":"2026-06-15"},{"url":"https://hartvaat.nl/2026/02/03/intraveneus-ijzer-bij-hartfalen-met-ijzertekort-meta-analyse-met-trial-sequentie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/02/01/iv-ijzer-bij-hartfalen-en-ijzerdeficientie-geactualiseerde-meta-analyse-van-rct-/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/04/16/2024-acc-expert-consensus-behandeling-van-hfref-beslispad-geactualiseerd/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2024/04/01/interventies-voor-optimalisatie-van-richtlijnmedicatie-bij-hartfalen-systematisc/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/04/06/nierfunctiebeoordeling-en-eindpuntbepaling-in-klinische-trials-ehj/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2022/04/01/robuustheid-van-sglt2-remmer-hf-trials-evaluatie/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2021/12/01/sacubitril-valsartan-uitgebreide-fda-labeling-jama-cardiology-implicaties/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2021/04/01/eiwitrijk-versus-standaard-dieet-bij-obees-hf-met-diabetes/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2021/02/16/2021-acc-hf-behandeloptimalisatie-update-antwoorden-op-10-cruciale-vragen/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2021/01/26/2020-acc-aha-kwaliteitsmaten-voor-af-geactualiseerd/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/11/24/2020-acc-aha-prestatie-en-kwaliteitsmaten-voor-hartfalen/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/07/11/levenslang-voordeel-van-uitgebreide-hfref-farmacotherapie-lancet-schatting/","published":"2020-07-11"},{"url":"https://hartvaat.nl/2020/06/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-acs-trials-jama-cardiology/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/01/zelfgerapporteerde-versus-apotheekgeregistreerde-medicatietrouw-compass-analyse/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/02/01/geschiktheid-voor-sglt2-remmers-bij-diabetespatienten-opgenomen-met-hartfalen/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2020/01/01/p2y12-copay-reductie-en-therapietrouw-aan-andere-secundaire-preventiemiddelen/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/01/01/medicatie-copay-vouchers-en-p2y12-gebruik-en-cv-events-na-mi-jama/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/12/01/number-needed-to-treat-met-arni-voor-preventie-van-cv-dood-of-hf-hospitalisatie/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/12/01/ras-etniciteit-en-oac-gebruik-bij-af-orbit-af/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/10/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-hf-trials-jama-cardiology-review/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/11/01/raas-blokkade-bij-hfpef-systematische-review-en-meta-analyse/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/06/01/primaire-preventie-icd-bij-niet-ischemische-cardiomyopathie-meta-analyse/","published":"2017-06-01"},{"url":"https://hartvaat.nl/2016/12/20/off-label-doac-dosering-en-ongunstige-uitkomsten-orbit-af-ii-register/","published":"2016-12-20"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/02/23/inspanningstestvariabelen-als-mortaliteitsvoorspellers-bij-chronisch-systolisch-/","published":"2016-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joann-lindenfeld","type":"person","url":"https://hartvaat.nl/mensen/joann-lindenfeld/","name":"JoAnn Lindenfeld","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":34,"articles":[{"url":"https://hartvaat.nl/2026/05/05/apture-shunt-verlaagt-hartfalen-heropnames-bij-patienten-met-hfpef-hfmref-alt-fl/","published":"2026-07-30"},{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/01/draadloos-ultrasound-gebaseerd-crt-systeem-bij-hartfalen/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/04/16/2024-acc-expert-consensus-behandeling-van-hfref-beslispad-geactualiseerd/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2024/04/09/dapagliflozine-bij-acuut-hartfalen-effectiviteit-en-veiligheid/","published":"2024-04-09"},{"url":"https://hartvaat.nl/2024/02/13/implanteerbare-hemodynamische-monitoren-verbeteren-overleving-bij-hfref/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","published":"2022-11-15"},{"url":"https://hartvaat.nl/2022/07/14/guide-hf-en-de-impact-van-covid-19-op-hartfalenuitkomsten/","published":"2022-07-14"},{"url":"https://hartvaat.nl/2022/05/01/nierdisfunctie-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2021/09/11/hemodynamisch-geleid-hf-management-lancet-guide-hf/","published":"2021-09-11"},{"url":"https://hartvaat.nl/2021/04/01/ero-lvedv-ratio-en-respons-op-mitraclip-jama-cardiology/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2021/02/16/2021-acc-hf-behandeloptimalisatie-update-antwoorden-op-10-cruciale-vragen/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/02/01/zelfzorginterventie-en-90-daags-uitkomsten-bij-acuut-hf-na-seh-ontslag-jama-card/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/07/07/baroreflexactivatietherapie-bij-hfref-beat-hf/","published":"2020-07-07"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/05/05/gezondheidsstatus-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/12/17/echo-uitkomsten-na-mitraclip-bij-secundaire-mr-coapt-echocardiografisch/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"},{"url":"https://hartvaat.nl/2018/10/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-hf-trials-jama-cardiology-review/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/03/28/adaptieve-servoventilatie-bij-hartfalen-de-cat-hf-trial/","published":"2017-03-28"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kevin-j-anstrom","type":"person","url":"https://hartvaat.nl/mensen/kevin-j-anstrom/","name":"Kevin J Anstrom","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":34,"articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/04/01/vericiguat-voordeel-geprojecteerd-op-paradigm-hf-en-dapa-hf-populaties/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/10/tact-2-chelatietherapie-na-mi-bij-diabetes-negatieve-trial/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2024/02/01/transform-hf-torsemide-versus-furosemide-bij-nieuw-vs-chronisch-hartfalen/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/10/03/vericiguat-bij-hfref-is-kosteneffectief-victoria-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/07/11/transform-hf-torsemide-versus-furosemide-geen-verschil-in-symptomen/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/01/17/transform-hf-torsemide-biedt-geen-overlevingsvoordeel-boven-furosemide/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","published":"2022-08-16"},{"url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/07/28/langetermijn-icd-uitkomsten-scd-heft/","published":"2020-07-28"},{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2020/05/01/zelfgerapporteerde-versus-apotheekgeregistreerde-medicatietrouw-compass-analyse/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/01/01/p2y12-copay-reductie-en-therapietrouw-aan-andere-secundaire-preventiemiddelen/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-medicamenteus-bij-af-en-kwaliteit-van-leven-jama-cabana-q/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/01/01/medicatie-copay-vouchers-en-p2y12-gebruik-en-cv-events-na-mi-jama/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/11/27/economische-en-qol-uitkomsten-van-nt-probnp-geleide-hf-therapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","published":"2018-11-06"},{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/08/22/natriuretisch-peptide-geleide-therapie-bij-hoogrisico-hartfalen-jama-guide-it/","published":"2017-08-22"},{"url":"https://hartvaat.nl/2017/07/18/palliatieve-zorg-bij-hartfalen-de-pal-hf-gerandomiseerde-trial/","published":"2017-07-18"},{"url":"https://hartvaat.nl/2017/05/25/levosimendan-bij-lv-disfunctie-voor-hartchirurgie-nejm-levo-cts/","published":"2017-05-25"},{"url":"https://hartvaat.nl/2017/05/16/oraal-ijzer-bij-hfref-met-ijzerdeficientie-jama-ironout-hf/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2017/05/09/ranolazine-na-incomplete-pci-bij-diabetes-versus-zonder-diabetes-river-pci/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2017/03/28/adaptieve-servoventilatie-bij-hartfalen-de-cat-hf-trial/","published":"2017-03-28"},{"url":"https://hartvaat.nl/2016/08/02/liraglutide-en-klinische-stabiliteit-bij-gevorderd-hartfalen-met-verminderde-ef-/","published":"2016-08-02"},{"url":"https://hartvaat.nl/2016/01/05/ranolazine-bij-angina-en-kwaliteit-van-leven-na-pci-met-incomplete-revascularisa/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-j-mack","type":"person","url":"https://hartvaat.nl/mensen/michael-j-mack/","name":"Michael J Mack","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":34,"articles":[{"url":"https://hartvaat.nl/2025/01/01/mitralisklepherstel-bij-degeneratief-mr-met-matige-tricuspidalisinsufficientie-2/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","published":"2023-11-23"},{"url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","published":"2022-11-15"},{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2022/05/01/nierdisfunctie-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/04/01/ero-lvedv-ratio-en-respons-op-mitraclip-jama-cardiology/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/05/05/gezondheidsstatus-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/12/17/echo-uitkomsten-na-mitraclip-bij-secundaire-mr-coapt-echocardiografisch/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2019/05/07/gezondheidsstatus-na-mitraclip-bij-hf-met-secundaire-mr-coapt/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-ballonexpandeerbare-klep-bij-laagrisicopatienten-nejm-partner-3/","published":"2019-05-02"},{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","published":"2019-02-19"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"},{"url":"https://hartvaat.nl/2016/01/05/doodsoorzaken-na-pci-versus-cabg-bij-complex-coronairlijden-5-jaarsfollow-up-van/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-szarek","type":"person","url":"https://hartvaat.nl/mensen/michael-szarek/","name":"Michael Szarek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":34,"articles":[{"url":"https://hartvaat.nl/2026/05/25/obicetrapib-verlaagt-naast-ldl-en-apob-ook-lipoproteine-a/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2026/05/26/odyssey-outcomes-post-hoc-hscrp-en-il-6-zijn-complementaire-prognostische-marker/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2026/02/19/evolocumab-en-doorgankelijkheid-van-veneuze-bypasses-na-cabg-newton-cabg-cardiol/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/10/07/obicetrapib-en-mace-bij-hoogrisicopatienten-gepoolde-analyse/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","published":"2025-09-20"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2024/06/25/vasculair-zorgteam-versus-educatie-bij-perifeer-arterieel-vaatlijden/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2024/04/23/lp-a-en-cv-risicoreductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","published":"2021-08-03"},{"url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2020/05/19/pav-en-vte-na-acs-rol-van-lp-a-en-modificatie-door-alirocumab/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/05/05/atorvastatine-vermindert-eerste-en-volgende-vasculaire-events-sparcl/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/02/25/polygene-risicoscore-en-voordeel-van-alirocumab-bij-coronairlijden-odyssey-outco/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2020/02/04/aanhoudende-ldl-verlaging-met-alirocumab-in-odyssey-outcomes/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pascal-vranckx","type":"person","url":"https://hartvaat.nl/mensen/pascal-vranckx/","name":"Pascal Vranckx","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":34,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/07/08/amulet-versus-watchman-flx-driejaarsresultaten-laa-sluiting/","published":"2025-07-08"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","published":"2024-02-06"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/02/02/dalend-hemoglobine-en-prognose-bij-acs-hospitalisatie/","published":"2021-02-02"},{"url":"https://hartvaat.nl/2020/12/14/edoxaban-bij-af-met-pci-naar-acute-versus-chronische-coronaire-presentatie-entru/","published":"2020-12-14"},{"url":"https://hartvaat.nl/2020/08/04/cangrelor-tirofiban-en-prasugrel-bij-stemi-primaire-resultaten/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/05/01/optimaal-antitrombotisch-regime-bij-af-na-pci-jama-cardiology-netwerkmeta-analys/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/12/07/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-veiligheid-en-werk/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/12/edoxaban-versus-vka-gebaseerd-antitrombotisch-regime-na-stenting-bij-af-lancet-e/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/04/14/aki-en-bloedingen-en-mortaliteit-na-radiale-versus-femorale-toegang-bij-acs/","published":"2019-04-14"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/12/21/culprit-shock-integratie-in-2017-esc-stemi-richtlijn-richtlijncommissie-standpun/","published":"2018-12-21"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/08/01/inhalatie-stikstofoxide-bij-stemi-nomi-gerandomiseerde-trial/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2018/01/07/2017-esc-richtlijn-voor-stemi-management/","published":"2018-01-07"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-juni","type":"person","url":"https://hartvaat.nl/mensen/peter-juni/","name":"Peter Jüni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":34,"articles":[{"url":"https://hartvaat.nl/2026/06/02/pulsfield-ablatie-levert-betere-vrijwaring-van-recidief-dan-cryoballoon-bij-paro/","published":"2026-08-12"},{"url":"https://hartvaat.nl/2026/02/19/evolocumab-en-doorgankelijkheid-van-veneuze-bypasses-na-cabg-newton-cabg-cardiol/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","published":"2025-09-20"},{"url":"https://hartvaat.nl/2025/06/09/tino-stents-versus-des-bij-acs-ipd-meta-analyse/","published":"2025-06-09"},{"url":"https://hartvaat.nl/2025/04/17/pfa-versus-cryoballon-bij-paroxysmaal-af-gerandomiseerde-trial/","published":"2025-04-17"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2020/10/01/natuurlijk-beloop-van-asymptomatische-ernstige-aortastenose-jama-cardiology-meta/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/19/empagliflozine-en-lv-massa-bij-diabetes-type-2-met-coronairlijden-empa-heart/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/10/05/biodegradeerbare-versus-duurzame-polymer-des-bij-stemi-gerandomiseerde-trial/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2019/09/24/asymptomatische-patienten-met-abnormale-ffr-medicamenteus-versus-pci/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2019/04/14/aki-en-bloedingen-en-mortaliteit-na-radiale-versus-femorale-toegang-bij-acs/","published":"2019-04-14"},{"url":"https://hartvaat.nl/2019/04/01/restrictieve-versus-liberale-transfusie-bij-hartchirurgie-meta-analyse/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/09/27/6-maandsuitkomsten-van-restrictieve-versus-liberale-transfusie-bij-hartchirurgie/","published":"2018-09-27"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/09/01/ultradunne-biodegradeerbare-versus-dunne-duurzame-stents-lancet-gerandomiseerde-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2018/05/07/esc-eapci-taskforce-rapport-over-bioresorbeerbare-scaffolds-executive-summary/","published":"2018-05-07"},{"url":"https://hartvaat.nl/2018/01/30/kosteneffectiviteit-van-ffr-geleide-pci-bij-stabiele-coronairlijden/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2017/11/30/restrictieve-versus-liberale-bloedtransfusie-bij-hartchirurgie-nejm-trics-iii/","published":"2017-11-30"},{"url":"https://hartvaat.nl/2017/05/23/stralingsblootstelling-en-vasculaire-toegang-bij-acs-rad-matrix-trial/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2016/12/01/tienjaarsuitkomsten-van-eerste-generatie-drug-eluting-stents-ses-versus-pes/","published":"2016-12-01"},{"url":"https://hartvaat.nl/2016/11/29/natuurlijk-beloop-van-coronaire-atherosclerose-met-ffr-prospectieve-studie/","published":"2016-11-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dirk-j-van-veldhuisen","type":"person","url":"https://hartvaat.nl/mensen/dirk-j-van-veldhuisen/","name":"Dirk J van Veldhuisen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":33,"articles":[{"url":"https://hartvaat.nl/2026/05/10/decision-trial-digoxine-staken-bij-hartfalen-leidt-tot-zevenvoudige-stijging-in-/","published":"2026-06-25"},{"url":"https://hartvaat.nl/2026/05/10/decision-onttrekkingssubstudie-stoppen-van-digoxine-na-lange-behandeling-leidt-t/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/03/13/tubulaire-nierschade-hangt-samen-met-natriumretentie-en-diureticarespons-bij-acu/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2025/11/14/nierfunctietrajecten-voor-en-na-hospitalisatie-voor-hfref/","published":"2025-11-14"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/18/mra-bij-hartfalen-met-nierfunctiestoornissen-veiligheid-en-effectiviteit/","published":"2024-06-18"},{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/12/21/iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-ipd-meta-analyse/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/07/15/race-3-langetermijnresultaten-gerichte-behandeling-bij-vroeg-persisterend-af-en-/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2022/05/21/bariatrische-chirurgie-en-cardiovasculaire-ziekte-meta-analyse/","published":"2022-05-21"},{"url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/10/05/ketonlichamen-en-functionele-uitkomsten-na-stemi/","published":"2021-10-05"},{"url":"https://hartvaat.nl/2021/09/08/antiaritmica-bij-vroeg-persisterend-af-met-hf-race-3/","published":"2021-09-08"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/09/29/arni-en-renale-uitkomsten-bij-hfpef-paragon-hf/","published":"2020-09-29"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2019/11/21/rivaroxaban-en-cva-tia-bij-hf-met-coronairlijden-en-sinusritme-commander-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/06/01/rivaroxaban-en-trombo-embolische-events-bij-hf-met-coronairlijden-en-sinusritme-/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/04/01/upstream-therapie-verbetert-qol-bij-persisterend-af-arrest-af/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/12/01/pro-gastrin-releasing-peptide-en-uitkomsten-bij-hf-met-anemie-red-hf/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/10/04/rivaroxaban-bij-hartfalen-met-sinusritme-en-coronairlijden-nejm-commander-hf/","published":"2018-10-04"},{"url":"https://hartvaat.nl/2018/08/21/behandeling-van-onderliggende-aandoeningen-verbetert-sinusritme-na-af-arrest-af/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/06/20/hartfrequentie-en-ritme-en-het-voordeel-van-betablokkers-bij-hartfalen/","published":"2017-06-20"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2016/07/12/nervus-vagus-stimulatie-bij-hartfalen-de-inovate-hf-trial/","published":"2016-07-12"},{"url":"https://hartvaat.nl/2016/03/22/zelfmanagementinterventies-bij-hartfalen-individuele-patientdata-meta-analyse/","published":"2016-03-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"j-wouter-jukema","type":"person","url":"https://hartvaat.nl/mensen/j-wouter-jukema/","name":"J Wouter Jukema","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":33,"articles":[{"url":"https://hartvaat.nl/2026/05/26/odyssey-outcomes-post-hoc-hscrp-en-il-6-zijn-complementaire-prognostische-marker/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2022/10/14/dal-gene-farmacogenetica-geleide-dalcetrapib-na-acs/","published":"2022-10-14"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","published":"2021-08-03"},{"url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/19/pav-en-vte-na-acs-rol-van-lp-a-en-modificatie-door-alirocumab/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/02/04/aanhoudende-ldl-verlaging-met-alirocumab-in-odyssey-outcomes/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/07/01/evolocumab-en-totale-cv-events-bij-cardiovasculaire-ziekte-fourier-analyse/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/04/profylactische-icd-bij-dialysepatienten-ter-preventie-van-plotse-hartdood/","published":"2019-06-04"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"},{"url":"https://hartvaat.nl/2018/11/27/metabolome-consequenties-van-pcsk9-remming-versus-statinetherapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2018/09/01/hdl-mimeticum-met-recombinant-apoa-i-milano-en-coronairlijden-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/04/20/ldl-reductievariabiliteit-en-antilichaamvorming-bij-bococizumab-nejm/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2016/07/19/visit-to-visit-ldl-cholesterolvariabiliteit-en-cognitieve-functie/","published":"2016-07-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"naveed-sattar","type":"person","url":"https://hartvaat.nl/mensen/naveed-sattar/","name":"Naveed Sattar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":33,"articles":[{"url":"https://hartvaat.nl/2026/09/01/tirzepatide-zorgt-voor-sterk-gewichtsverlies-bij-vrouwen-met-pcos-en-obesitas/","published":"2026-08-31"},{"url":"https://hartvaat.nl/2026/04/07/kosteneffectiviteit-van-stapsgewijze-lipidenverlaging-na-coronaire-bypasschirurg/","published":"2026-07-18"},{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/05/13/empagliflozine-erytropoese-en-ijzermobilisatie-bij-hartfalen/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/03/25/leeftijds-en-sekseverschillen-in-effectiviteit-van-diabetesbehandeling-netwerk-m/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2024/11/12/sglt2-remming-en-proteomische-handtekeningen-bij-hartfalen-bevestiging/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/09/16/tirzepatide-en-bloeddrukverlaging-surmount-1-gestratificeerde-analyse/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2024/09/01/troponine-nt-probnp-en-cognitieve-uitkomsten-in-sprint/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/03/28/amplitude-o-dosisrespons-van-efpeglenatide-op-cv-uitkomsten-bij-diabetes/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2022/12/21/empagliflozine-en-het-circulerend-proteoom-bij-hartfalen-emperor-mechanismen/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/02/08/stress-cardiale-biomarkers-en-cv-renale-uitkomsten-bij-canagliflozine/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/nt-probnp-prognose-en-empagliflozine-effect-bij-emperor-reduced/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/09/02/efpeglenatide-en-cv-en-renale-uitkomsten-bij-diabetes-type-2-nejm-amplitude-o/","published":"2021-09-02"},{"url":"https://hartvaat.nl/2021/03/23/empagliflozine-bij-hfref-met-volume-overbelasting-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/11/03/canagliflozine-en-nt-probnp-implicaties-voor-cv-risicoreductie/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2020/03/31/laaggedoseerde-alteplase-bij-primaire-pci-naar-ischemietijd/","published":"2020-03-31"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2019/02/01/spironolacton-en-collageenmetabolisme-biomarkers-bij-ongecontroleerde-hypertensi/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/11/27/metabolome-consequenties-van-pcsk9-remming-versus-statinetherapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2017/08/08/canagliflozine-en-cardiovasculaire-biomarkers-bij-oudere-diabetespatienten/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/05/30/polygene-risicoscore-en-relatief-voordeel-van-statinetherapie-primaire-preventie/","published":"2017-05-30"},{"url":"https://hartvaat.nl/2016/10/04/ldl-cholesterolverlagende-genetische-varianten-en-risico-op-diabetes-type-2-jama/","published":"2016-10-04"},{"url":"https://hartvaat.nl/2016/08/01/2016-europese-richtlijnen-voor-cardiovasculaire-preventie-in-de-klinische-prakti/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/04/19/evolocumab-versus-ezetimibe-bij-statine-intolerante-patienten-de-gauss-3-trial/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prashanthan-sanders","type":"person","url":"https://hartvaat.nl/mensen/prashanthan-sanders/","name":"Prashanthan Sanders","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":33,"articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/01/27/decaf-cafeinehoudende-koffie-en-af-gerandomiseerde-trial/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/12/01/arrest-af-agressieve-risicofactorreductie-en-ablatie-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/10/21/dieet-en-af-risico-systematische-review/","published":"2024-10-21"},{"url":"https://hartvaat.nl/2024/10/01/draadloos-ultrasound-gebaseerd-crt-systeem-bij-hartfalen/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","published":"2024-02-16"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/07/14/vroege-versus-late-af-ablatie-impact-op-aritmierecidief/","published":"2023-07-14"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2022/12/01/langetermijnmortaliteit-bij-hfmref-systematische-review-en-meta-analyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/06/21/mri-geleide-fibroseablatie-versus-conventionele-ablatie-bij-persisterend-af/","published":"2022-06-21"},{"url":"https://hartvaat.nl/2021/10/09/klinische-risicofactoren-voor-cva-bij-anticoagulantie-naieve-af-meta-analyse/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2021/07/18/procedurevolume-en-complicaties-bij-af-ablatie-meta-analyse/","published":"2021-07-18"},{"url":"https://hartvaat.nl/2020/01/01/obesitas-opzettelijk-gewichtsverlies-en-hartfalen-meta-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/12/01/geintegreerde-gespecialiseerde-af-poliklinieken-verlagen-totale-mortaliteit-post/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/09/24/interne-versus-externe-cardioversie-bij-atriale-aritmieen-met-icd/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2019/01/01/slokdarmletsel-bij-af-ablatie-prevalentie-en-preventie-meta-analyse/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/11/01/uitkomsten-van-ablatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/07/01/rotorablatie-bij-atriumfibrilleren-systematische-review/","published":"2018-07-01"},{"url":"https://hartvaat.nl/2018/04/21/subklinisch-device-gedetecteerd-af-en-cva-risico-meta-analyse/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2018/02/01/katheterablatie-bij-af-met-hartfalen-nejm-castle-af/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/12/01/geintegreerde-zorg-bij-atriumfibrilleren-systematische-review-en-meta-analyse/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2016/05/21/af-type-en-risico-op-trombo-embolie-mortaliteit-en-bloedingen-systematische-revi/","published":"2016-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-gilles-montalescot","type":"person","url":"https://hartvaat.nl/mensen/prof-gilles-montalescot/","name":"Prof. Gilles Montalescot","title":"Cardioloog, Hôpital Pitié-Salpêtrière, Parijs","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":30,"articles":[{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/10/23/aspirine-bij-chronisch-coronairsyndroom-plus-oac-wel-of-niet/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2024/11/19/afloat-flecainide-voorkomt-af-na-pfo-sluiting-rct/","published":"2024-11-19"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2024/04/16/postprocedurale-anticoagulatie-na-primaire-pci-voor-stemi-multicenter-studie/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2023/03/28/culprit-interventie-bij-cardiogene-shock-met-hartstilstand/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2021/01/19/residuele-syntax-score-bij-cardiogene-shock/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2020/12/15/prehospitaal-gemalen-prasugrel-bij-stemi-gerandomiseerde-trial/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"},{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/03/05/timing-van-prasugrel-start-en-coronairangiografie-bij-nstemi/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/11/01/aldosteronblokkade-bij-myocardinfarct-ipd-analyse-van-twee-trials/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2017/08/19/optimale-timing-van-invasieve-strategie-bij-nste-acs-lancet-meta-analyse/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/04/26/vroege-aldosteronblokkade-bij-acuut-myocardinfarct-de-albatross-trial/","published":"2016-04-26"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/01/21/langdurige-duale-antiplaatjestherapie-bij-patienten-met-eerder-myocardinfarct-me/","published":"2016-01-21"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-amundsen-lbct/","title":"AMUNDSEN: evolocumab vóór de PCI, het gesprek"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rudolf-a-de-boer","type":"person","url":"https://hartvaat.nl/mensen/rudolf-a-de-boer/","name":"Rudolf A de Boer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":33,"articles":[{"url":"https://hartvaat.nl/2026/05/22/epicardiaal-vetweefsel-voorspelt-aritmieen-en-hartfalen-events-bij-genotype-posi/","published":"2026-06-06"},{"url":"https://hartvaat.nl/2026/02/28/hartfalen-bij-ouderen-van-epidemiologie-tot-behandeling/","published":"2026-03-06"},{"url":"https://hartvaat.nl/2025/08/14/hartfalen-mondiale-economische-ziektelast/","published":"2025-08-14"},{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/04/01/socio-economische-ongelijkheid-en-hartfalenuitkomsten-systematische-review/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/08/21/pa-drukmonitoring-bij-chronisch-hartfalen-effecten-over-klinische-subgroepen/","published":"2024-08-21"},{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/10/01/pa-drukmonitoring-bij-chronisch-hartfalen-meta-analyse-van-drie-rct-s/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/08/14/telemonitoring-bij-hartfalen-meta-analyse-van-alle-strategieen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/06/24/monitor-hf-pa-drukmonitoring-bij-hartfalen-effectief-in-europa-lancet-rct/","published":"2023-06-24"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/10/01/bloedbiomerkers-voor-prognose-bij-hypertrofische-cardiomyopathie-meta-analyse/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","published":"2022-09-03"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/05/21/bariatrische-chirurgie-en-cardiovasculaire-ziekte-meta-analyse/","published":"2022-05-21"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/22/sekse-specifieke-cv-risicofactoren-en-biomarkers-bij-incident-hartfalen/","published":"2020-09-22"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2018/01/16/hoog-sensitief-troponine-t-bij-chronisch-hartfalen-individuele-patientdata-meta-/","published":"2018-01-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shamir-r-mehta","type":"person","url":"https://hartvaat.nl/mensen/shamir-r-mehta/","name":"Shamir R Mehta","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":33,"articles":[{"url":"https://hartvaat.nl/2026/01/27/intracoronair-lage-dosis-rtpa-bij-primaire-pci-voor-stemi-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","published":"2024-04-30"},{"url":"https://hartvaat.nl/2023/05/18/triluminate-transcatheter-tricuspidaliskleprepair-bij-ernstige-tr-nejm/","published":"2023-05-18"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/11/01/antiplaatjestherapie-bij-mi-zonder-obstructief-coronairlijden-minoca/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/08/01/complete-versus-culprit-only-revascularisatie-bij-stemi-jama-cardiology-meta-ana/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2017/11/14/timing-van-angiografie-bij-hoogrisico-nstemi-acuity-analyse/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/08/19/optimale-timing-van-invasieve-strategie-bij-nste-acs-lancet-meta-analyse/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"},{"url":"https://hartvaat.nl/2016/01/05/varenicline-voor-stoppen-met-roken-bij-patienten-opgenomen-met-acuut-coronair-sy/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steven-e-nissen","type":"person","url":"https://hartvaat.nl/mensen/steven-e-nissen/","name":"Steven E Nissen","title":"Cleveland Clinic, Ohio, VS","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":30,"articles":[{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2025/05/17/tandem-obicetrapib-plus-ezetimibe-voor-ldl-verlaging-lancet-fase-3/","published":"2025-05-17"},{"url":"https://hartvaat.nl/2025/05/08/lorundrostat-bij-ongecontroleerde-hypertensie-fase-3-nejm/","published":"2025-05-08"},{"url":"https://hartvaat.nl/2025/01/21/muvalaplin-orale-lp-a-verlaging-nejm-gerandomiseerde-trial/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/09/bempedoinezuur-versus-statines-vergelijking-van-cv-voordelen/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/03/01/clear-outcomes-bempedoinezuur-vermindert-totale-cv-events-bij-statine-intolerant/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/07/13/traverse-testosteronsubstitutie-cardiovasculair-veilig-bij-hypogonadisme/","published":"2023-07-13"},{"url":"https://hartvaat.nl/2023/04/15/inflammatie-en-cholesterol-als-cv-voorspellers-onder-statinetherapie-lancet-anal/","published":"2023-04-15"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2023/01/03/rosuvastatine-versus-voedingssupplementen-voor-lipidenmanagement/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/05/03/korte-interfererende-rna-tegen-lp-a-jama-fase-1-dosisstudie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/01/28/cryoballonablatie-als-initiele-therapie-voor-af-nejm-early-af/","published":"2021-01-28"},{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/10/01/crp-op-lp-a-geassocieerd-cv-risico-bij-optimaal-behandelde-hoogrisicopatienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/04/01/initieel-en-serieel-crp-en-cv-events-en-dood-na-acs-jama-cardiology/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/10/23/evolocumab-en-coronaire-plaquesamenstelling-glagov-beeldvorming/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/09/01/hdl-mimeticum-met-recombinant-apoa-i-milano-en-coronairlijden-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/09/01/cer-001-hdl-mimeticum-en-coronaire-atherosclerose-na-acs-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/11/21/bloeddrukeffecten-van-ibuprofen-naproxen-en-celecoxib-bij-artritis-precision-abp/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/04/20/ldl-reductievariabiliteit-en-antilichaamvorming-bij-bococizumab-nejm/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/02/16/bariatrische-chirurgie-versus-intensieve-medicamenteuze-therapie-bij-diabetes-5-/","published":"2017-02-16"},{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/09/01/ace-remmers-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-met-dpp-4-remmers/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/07/28/liraglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-leader-trial/","published":"2016-07-28"},{"url":"https://hartvaat.nl/2016/05/01/ly3015014-een-nieuw-monoklonaal-pcsk9-antilichaam-gerandomiseerde-fase-2-trial/","published":"2016-05-01"},{"url":"https://hartvaat.nl/2016/04/19/evolocumab-versus-ezetimibe-bij-statine-intolerante-patienten-de-gauss-3-trial/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/03/08/naltrexon-bupropion-en-cardiovasculaire-events-bij-obesitas-gerandomiseerde-tria/","published":"2016-03-08"}],"videos":[{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/expert-surpass-cvot-tirzepatide-nissen/","title":"Expertinterview: SURPASS-CVOT — tirzepatide versus dulaglutide met Steven Nissen"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"arie-pieter-kappetein","type":"person","url":"https://hartvaat.nl/mensen/arie-pieter-kappetein/","name":"Arie Pieter Kappetein","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":32,"articles":[{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/31/syntax-score-ii-herontwikkeling-voor-gepersonaliseerde-revascularisatiebeslissin/","published":"2020-10-31"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/10/01/natuurlijk-beloop-van-asymptomatische-ernstige-aortastenose-jama-cardiology-meta/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/08/13/off-pump-versus-on-pump-cabg-bij-hoofdstamcoronairlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/04/23/hedendaagse-uitkomsten-na-cabg-voor-hoofdstamlijden/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/07/31/bnp-bij-linker-hoofdstamrevascularisatie-excel-analyse/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2018/02/13/richtlijngetrouwe-medicamenteuze-therapie-in-contemporaine-revascularisatietrial/","published":"2018-02-13"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"},{"url":"https://hartvaat.nl/2017/04/25/kwaliteit-van-leven-na-chirurgie-of-des-bij-drienvaten-of-hoofdstamlijden/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"},{"url":"https://hartvaat.nl/2016/01/05/doodsoorzaken-na-pci-versus-cabg-bij-complex-coronairlijden-5-jaarsfollow-up-van/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dik-heg","type":"person","url":"https://hartvaat.nl/mensen/dik-heg/","name":"Dik Heg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":32,"articles":[{"url":"https://hartvaat.nl/2026/06/02/pulsfield-ablatie-levert-betere-vrijwaring-van-recidief-dan-cryoballoon-bij-paro/","published":"2026-08-12"},{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/12/09/gepersonaliseerde-versus-standaard-dapt-duur-na-pci-gerandomiseerde-trial/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/04/17/pfa-versus-cryoballon-bij-paroxysmaal-af-gerandomiseerde-trial/","published":"2025-04-17"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","published":"2024-02-06"},{"url":"https://hartvaat.nl/2024/01/01/verkorte-dapt-bij-hoog-bloedingsrisico-geen-sekseverschillen/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2023/11/25/biodegradeerbare-versus-duurzame-polymeer-des-bij-stemi-langetermijndata/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/10/01/paroxetine-grk2-remming-versus-placebo-bij-anterieur-mi-jama-cardiology/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/08/04/cangrelor-tirofiban-en-prasugrel-bij-stemi-primaire-resultaten/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2019/11/19/evolocumab-voor-vroege-ldl-verlaging-bij-acs-evopacs/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/10/05/biodegradeerbare-versus-duurzame-polymer-des-bij-stemi-gerandomiseerde-trial/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2019/07/01/lokale-hemodynamische-krachten-en-fenotype-van-coronaire-plaques/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/04/14/aki-en-bloedingen-en-mortaliteit-na-radiale-versus-femorale-toegang-bij-acs/","published":"2019-04-14"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/09/01/ultradunne-biodegradeerbare-versus-dunne-duurzame-stents-lancet-gerandomiseerde-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/05/23/stralingsblootstelling-en-vasculaire-toegang-bij-acs-rad-matrix-trial/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2016/12/01/tienjaarsuitkomsten-van-eerste-generatie-drug-eluting-stents-ses-versus-pes/","published":"2016-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"g-michael-felker","type":"person","url":"https://hartvaat.nl/mensen/g-michael-felker/","name":"G Michael Felker","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":32,"articles":[{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2026/01/05/magnesium-en-uitkomsten-bij-hfref-galactic-hf-subanalyse/","published":"2026-01-05"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2023/09/30/adaptresponse-adaptieve-versus-conventionele-crt-bij-hartfalen-lancet/","published":"2023-09-30"},{"url":"https://hartvaat.nl/2022/10/18/dosisrespons-van-sacubitril-valsartan-bij-hfref/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/08/01/gdf-15-en-liraglutide-behandeling-bij-hf-patienten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2020/02/01/geschiktheid-voor-sglt2-remmers-bij-diabetespatienten-opgenomen-met-hartfalen/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/12/01/hepatorenale-disfunctie-identificeert-hoogrisico-acuut-hf-relax-ahf/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2018/12/01/liraglutide-en-gewicht-bij-gevorderd-hfref-fight-trial-inzichten/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/11/27/economische-en-qol-uitkomsten-van-nt-probnp-geleide-hf-therapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","published":"2018-11-06"},{"url":"https://hartvaat.nl/2018/05/08/nierfunctieverslechtering-bij-acuut-hartfalen-met-agressieve-diurese-geen-tubula/","published":"2018-05-08"},{"url":"https://hartvaat.nl/2018/03/01/poliklinische-verslechtering-van-hartfalen-als-therapiedoel-jama-cardiology-revi/","published":"2018-03-01"},{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/08/22/natriuretisch-peptide-geleide-therapie-bij-hoogrisico-hartfalen-jama-guide-it/","published":"2017-08-22"},{"url":"https://hartvaat.nl/2017/08/07/trv027-biased-ligand-van-de-angiotensine-ii-receptor-bij-acuut-hartfalen-gerando/","published":"2017-08-07"},{"url":"https://hartvaat.nl/2017/05/16/oraal-ijzer-bij-hfref-met-ijzerdeficientie-jama-ironout-hf/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2017/03/21/werkzaamheid-en-veiligheid-van-tolvaptan-bij-gehospitaliseerd-acuut-hartfalen/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/12/10/omecamtiv-mecarbil-bij-chronisch-hartfalen-lancet-cosmic-hf-fase-2-trial/","published":"2016-12-10"},{"url":"https://hartvaat.nl/2016/08/02/liraglutide-en-klinische-stabiliteit-bij-gevorderd-hartfalen-met-verminderde-ef-/","published":"2016-08-02"},{"url":"https://hartvaat.nl/2016/03/29/omecamtiv-mecarbil-bij-acuut-hartfalen-de-atomic-ahf-studie/","published":"2016-03-29"},{"url":"https://hartvaat.nl/2016/03/19/serca2a-gentherapie-bij-hartfalen-de-cupid-2-trial/","published":"2016-03-19"},{"url":"https://hartvaat.nl/2016/01/26/langketen-acylcarnitines-bij-hartfalen-prognostische-waarde-en-reversibiliteit-m/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gregory-g-schwartz","type":"person","url":"https://hartvaat.nl/mensen/gregory-g-schwartz/","name":"Gregory G Schwartz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":32,"articles":[{"url":"https://hartvaat.nl/2026/05/26/odyssey-outcomes-post-hoc-hscrp-en-il-6-zijn-complementaire-prognostische-marker/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/01/28/lp-a-en-ldl-cholesterol-onafhankelijke-cv-risicopaden/","published":"2025-01-28"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2022/12/21/orion-11-inclisiran-verlaagt-ldl-effectief-bij-primaire-preventie/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","published":"2021-08-03"},{"url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/05/19/pav-en-vte-na-acs-rol-van-lp-a-en-modificatie-door-alirocumab/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/04/28/apabetalone-en-cv-events-bij-acs-met-diabetes-type-2-jama-betonmace/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2020/02/25/polygene-risicoscore-en-voordeel-van-alirocumab-bij-coronairlijden-odyssey-outco/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2020/02/04/aanhoudende-ldl-verlaging-met-alirocumab-in-odyssey-outcomes/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/04/01/initieel-en-serieel-crp-en-cv-events-en-dood-na-acs-jama-cardiology/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"},{"url":"https://hartvaat.nl/2018/10/13/lp-a-baseline-en-on-statin-voor-cv-eventvoorspelling-lancet-ipd-meta-analyse/","published":"2018-10-13"},{"url":"https://hartvaat.nl/2018/09/18/hartfalen-na-cva-tia-bij-insulineresistente-patienten-behandeld-met-pioglitazon/","published":"2018-09-18"},{"url":"https://hartvaat.nl/2018/09/01/cer-001-hdl-mimeticum-en-coronaire-atherosclerose-na-acs-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/02/01/lipoproteine-a-en-recidiverende-ischemische-events-na-acs-dal-outcomes-analyse/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/12/06/dalcetrapib-wijzigt-de-relatie-tussen-hdl-cholesterol-en-crp/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/04/07/pioglitazon-na-ischemisch-cva-of-tia-gerandomiseerde-nejm-trial/","published":"2016-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"keith-a-a-fox","type":"person","url":"https://hartvaat.nl/mensen/keith-a-a-fox/","name":"Keith A A Fox","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":32,"articles":[{"url":"https://hartvaat.nl/2024/11/07/invasieve-strategie-bij-ouderen-met-mi-gerandomiseerde-trial-nejm/","published":"2024-11-07"},{"url":"https://hartvaat.nl/2024/06/14/invasief-versus-conservatief-bij-ouderen-met-nste-acs-ipd-meta-analyse/","published":"2024-06-14"},{"url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/04/09/asundexian-factor-xia-remmer-versus-apixaban-bij-af-lancet-pacific-af/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/07/08/grace-2-0-score-bij-type-1-en-type-2-mi/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/07/01/cv-gevolgen-van-stoppen-met-laaggedoseerd-rivaroxaban-bij-chronisch-vaatlijden/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/01/01/rivaroxaban-plus-aspirine-bij-symptomatisch-pav-compass-subanalyse/","published":"2021-01-01"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/12/07/individueel-levenslang-voordeel-en-bloedingsrisico-van-rivaroxaban-plus-aspirine/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/08/13/rivaroxaban-met-of-zonder-aspirine-bij-hf-met-coronair-of-perifeer-vaatlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/05/14/rivaroxaban-plus-aspirine-bij-vaatlijden-met-nierdisfunctie-compass/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/01/24/heropnames-bij-af-patienten-na-stenting-twee-antitromboticastrategieen-vergeleke/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/12/22/preventie-van-bloedingen-bij-af-patienten-die-pci-ondergaan-nejm-pioneer-af-pci/","published":"2016-12-22"},{"url":"https://hartvaat.nl/2016/08/01/eerder-clopidogrelgebruik-en-uitkomsten-bij-conservatief-behandeld-acs/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/08/01/hospitalisaties-bij-atriumfibrilleren-analyse-uit-rocket-af/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/07/05/verslechterende-nierfunctie-en-uitkomsten-met-rivaroxaban-versus-warfarine-rocke/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/07/01/natief-kleplijden-bij-af-patienten-op-warfarine-of-rivaroxaban/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"},{"url":"https://hartvaat.nl/2016/03/01/cyp2c19-metaboliseerdersstatus-en-uitkomsten-bij-acs-prasugrel-versus-clopidogre/","published":"2016-03-01"},{"url":"https://hartvaat.nl/2016/01/26/polyfarmacie-en-werkzaamheid-van-rivaroxaban-versus-warfarine-bij-atriumfibrille/","published":"2016-01-26"},{"url":"https://hartvaat.nl/2016/01/21/neoplasiedetectie-bij-langdurige-dapt-met-prasugrel-versus-clopidogrel-triton-ti/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"manesh-r-patel","type":"person","url":"https://hartvaat.nl/mensen/manesh-r-patel/","name":"Manesh R Patel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":32,"articles":[{"url":"https://hartvaat.nl/2026/08/25/extracraniale-bloedingen-komen-bij-26-van-af-patienten-op-antistolling-voor-comb/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/04/07/confident-hfpef-machine-learning-voorspelt-sterfte-en-opname-beter-dan-bestaande/","published":"2026-07-20"},{"url":"https://hartvaat.nl/2026/04/01/prevent-risicoscore-presteert-robuust-in-de-dagelijkse-ehr-praktijk/","published":"2026-07-15"},{"url":"https://hartvaat.nl/2026/02/24/systemische-embolieen-bij-af-ipd-mega-meta-analyse-van-71-683-patienten/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2026/01/13/risicofactoren-en-plaquevolume-op-coronaire-ct-angiografie-lessen-uit-het-advanc/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2025/01/01/ffr-versus-ifr-bij-coronaire-revascularisatie-vijfjaars-follow-up/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/01/splanchnische-zenuwablatie-bij-hfpef-endovasculaire-benadering/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2023/12/12/voyager-pad-rivaroxaban-plus-aspirine-na-endovasculaire-revascularisatie-voor-pa/","published":"2023-12-12"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","published":"2023-05-21"},{"url":"https://hartvaat.nl/2022/04/09/asundexian-factor-xia-remmer-versus-apixaban-bij-af-lancet-pacific-af/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2022/02/01/ccta-afgeleide-ffr-prognostische-waarde-meta-analyse/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/05/14/verlaagde-dosis-doac-bij-af-werkzaamheid-en-veiligheid-meta-analyse/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/03/01/ambulante-hartfrequentiereductie-na-renale-denervatie-bij-hypertensie-zonder-med/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2019/01/01/mi-bij-pav-patienten-incidentie-en-uitkomsten-euclid/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/12/25/cv-en-ledemaat-uitkomsten-bij-diabetes-met-pav-euclid/","published":"2018-12-25"},{"url":"https://hartvaat.nl/2018/10/09/24-uurs-ambulante-bloeddrukreductie-na-renale-denervatie-spyral-htn-off-med/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2018/10/02/cv-uitkomsten-na-endovasculaire-versus-chirurgische-revascularisatie-onderste-le/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2017/02/07/acc-aats-aha-2016-criteria-voor-gepaste-coronaire-revascularisatie-bij-acs-en-st/","published":"2017-02-07"},{"url":"https://hartvaat.nl/2016/08/01/hospitalisaties-bij-atriumfibrilleren-analyse-uit-rocket-af/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/07/05/verslechterende-nierfunctie-en-uitkomsten-met-rivaroxaban-versus-warfarine-rocke/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/07/01/natief-kleplijden-bij-af-patienten-op-warfarine-of-rivaroxaban/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/04/12/infarctgrootte-en-uitkomsten-na-primaire-pci-patientanalyse-uit-10-trials/","published":"2016-04-12"},{"url":"https://hartvaat.nl/2016/01/26/polyfarmacie-en-werkzaamheid-van-rivaroxaban-versus-warfarine-bij-atriumfibrille/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-m-ridker","type":"person","url":"https://hartvaat.nl/mensen/paul-m-ridker/","name":"Paul M Ridker","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":29,"articles":[{"url":"https://hartvaat.nl/2026/08/18/semaglutide-verlaagt-hscrp-en-ontstekingsactiviteit-bij-ascvd-patienten-met-over/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2025/01/28/lp-a-en-ldl-cholesterol-onafhankelijke-cv-risicopaden/","published":"2025-01-28"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/12/05/inflammatie-cholesterol-lp-a-en-30-jaars-cv-uitkomsten-bij-vrouwen/","published":"2024-12-05"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2023/04/15/inflammatie-en-cholesterol-als-cv-voorspellers-onder-statinetherapie-lancet-anal/","published":"2023-04-15"},{"url":"https://hartvaat.nl/2023/01/03/rosuvastatine-versus-voedingssupplementen-voor-lipidenmanagement/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","published":"2022-08-02"},{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/08/14/il-6-crp-en-ldl-als-biomarkers-van-residueel-risico-vergelijking/","published":"2020-08-14"},{"url":"https://hartvaat.nl/2020/05/05/triglyceriderijk-lipoproteinecholesterol-small-dense-ldl-en-cv-events/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/02/01/il-1-remming-en-bloeddruk-hypertensie-en-residueel-inflammatoir-risico-cantos/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/03/05/canakinumab-ter-preventie-van-hartfalen-hospitalisatie-cantos-analyse/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2019/02/21/laaggedoseerd-methotrexaat-voor-preventie-van-atherosclerotische-events-nejm-cir/","published":"2019-02-21"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2018/10/13/lp-a-baseline-en-on-statin-voor-cv-eventvoorspelling-lancet-ipd-meta-analyse/","published":"2018-10-13"},{"url":"https://hartvaat.nl/2018/07/10/residueel-inflammatoir-risico-bij-pcsk9-remming-plus-statine/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2017/12/21/lilrb5-variant-geassocieerd-met-statine-intolerantie-en-myalgie/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/10/21/canakinumab-en-longkankerincidentie-bij-atherosclerose-lancet-cantos-exploratief/","published":"2017-10-21"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/06/20/cholesteroleffluxcapaciteit-hdl-deeltjesaantal-en-cv-events-jupiter-analyse/","published":"2017-06-20"},{"url":"https://hartvaat.nl/2017/05/16/statines-voor-primaire-preventie-bij-ouderen-meta-analyse-van-jupiter-en-hope-3/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/04/20/ldl-reductievariabiliteit-en-antilichaamvorming-bij-bococizumab-nejm/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2016/05/01/lipoproteinen-insulineresistentie-en-rosuvastatine-bij-incident-type-2-diabetes/","published":"2016-05-01"},{"url":"https://hartvaat.nl/2016/05/01/procentuele-ldl-verlaging-bij-hoogintensieve-statinetherapie-implicaties-voor-ri/","published":"2016-05-01"}],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/implementatie-lipidenmanagement/","title":"Sessie 4: Implementatie van lipidenmanagement — praktische uitdagingen"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ulf-landmesser","type":"person","url":"https://hartvaat.nl/mensen/ulf-landmesser/","name":"Ulf Landmesser","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":32,"articles":[{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2025/07/15/oct-gebaseerde-post-pci-fysiologiebeoordeling-voorspelt-klinische-uitkomsten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","published":"2024-11-09"},{"url":"https://hartvaat.nl/2024/10/01/oraal-butyraat-verlaagt-bloeddruk-bij-hypertensie-rct/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/03/02/intravasculaire-beeldvorming-bij-des-implantatie-lancet-netwerk-meta-analyse/","published":"2024-03-02"},{"url":"https://hartvaat.nl/2024/01/14/residuele-lekkage-na-laa-occlusie-en-uitkomsten-meta-analyse/","published":"2024-01-14"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2022/12/21/orion-11-inclisiran-verlaagt-ldl-effectief-bij-primaire-preventie/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2022/02/10/propionaat-vermindert-atherosclerose-via-immuunregulatie-van-intestinaal-cholest/","published":"2022-02-10"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/11/08/closed-loop-stimulatie-en-cardiopulmonale-variabelen-bij-chronisch-hf-met-chrono/","published":"2021-11-08"},{"url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","published":"2021-08-03"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2019/11/01/inclisiran-1-of-2-dosis-en-ldl-cholesterol-orion-1-1-jaarsfollow-up/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/09/25/sirna-tegen-pcsk9-en-atherogene-lipoproteinen-orion-1-secundaire-eindpunten/","published":"2018-09-25"},{"url":"https://hartvaat.nl/2018/07/14/ldl-verlaging-en-cv-events-met-pcsk9-remmers-meta-analyse-van-gerandomiseerde-tr/","published":"2018-07-14"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/04/13/inclisiran-bij-patienten-met-hoog-cv-risico-en-verhoogd-ldl-nejm-orion-1/","published":"2017-04-13"},{"url":"https://hartvaat.nl/2016/10/14/2016-esc-eas-richtlijn-voor-het-management-van-dyslipidemieen/","published":"2016-10-14"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"william-t-abraham","type":"person","url":"https://hartvaat.nl/mensen/william-t-abraham/","name":"William T Abraham","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":32,"articles":[{"url":"https://hartvaat.nl/2025/02/01/transveneuze-frenische-zenuwstimulatie-bij-centraal-slaapapneu-en-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/02/13/implanteerbare-hemodynamische-monitoren-verbeteren-overleving-bij-hfref/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2023/10/01/pa-drukmonitoring-bij-chronisch-hartfalen-meta-analyse-van-drie-rct-s/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","published":"2022-11-15"},{"url":"https://hartvaat.nl/2022/05/01/nierdisfunctie-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2021/04/01/ero-lvedv-ratio-en-respons-op-mitraclip-jama-cardiology/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/07/07/baroreflexactivatietherapie-bij-hfref-beat-hf/","published":"2020-07-07"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/05/05/gezondheidsstatus-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/12/17/echo-uitkomsten-na-mitraclip-bij-secundaire-mr-coapt-echocardiografisch/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/05/07/gezondheidsstatus-na-mitraclip-bij-hf-met-secundaire-mr-coapt/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/01/08/hfref-differentiele-impact-op-mannen-en-vrouwen/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"},{"url":"https://hartvaat.nl/2018/03/27/crt-bij-hartfalen-met-smal-qrs-complex/","published":"2018-03-27"},{"url":"https://hartvaat.nl/2017/11/14/af-type-en-uitkomsten-bij-hfref/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/10/10/pulmonalisdrukgeleide-therapie-bij-hfref/","published":"2017-10-10"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/03/07/lv-global-longitudinal-strain-en-prognose-bij-hartfalen-met-smal-qrs-en-crt/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2016/04/21/aliskiren-enalapril-of-de-combinatie-bij-hartfalen-nejm-atmosphere-trial/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/01/30/hemodynamische-telemonitoring-bij-chronisch-hartfalen-volledige-champion-resulta/","published":"2016-01-30"},{"url":"https://hartvaat.nl/2016/01/01/persisterende-echocardiografische-dyssynchronie-voorspelt-ongunstige-uitkomsten-/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marie-claude-morice","type":"person","url":"https://hartvaat.nl/mensen/marie-claude-morice/","name":"Marie-Claude Morice","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":31,"articles":[{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2025/03/04/stapsgewijze-provisionale-versus-systematische-dualstent-bij-ware-linker-hoofdst/","published":"2025-03-04"},{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/10/01/ebc-hoofdstam-stentstudie-provisional-versus-systematisch-dubbel-stenten/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/08/01/seksegerelateerde-uitkomsten-bij-hoog-bloedingsrisico-na-pci-leaders-free/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"},{"url":"https://hartvaat.nl/2017/04/25/kwaliteit-van-leven-na-chirurgie-of-des-bij-drienvaten-of-hoofdstamlijden/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2017/04/01/polymeervrije-biolimus-stent-bij-hoog-bloedingsrisico-met-acs-leaders-free-subst/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"},{"url":"https://hartvaat.nl/2016/01/05/doodsoorzaken-na-pci-versus-cabg-bij-complex-coronairlijden-5-jaarsfollow-up-van/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martina-brueckmann","type":"person","url":"https://hartvaat.nl/mensen/martina-brueckmann/","name":"Martina Brueckmann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":31,"articles":[{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2023/09/26/geblindeerde-stopstudie-voordelen-empagliflozine-verdwijnen-na-staken-bij-hf/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/11/01/empagliflozine-vermindert-albuminurie-bij-hartfalen-emperor-pooled-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2021/11/30/voorspellers-van-af-ontwikkeling-bij-embolic-stroke-of-undetermined-source-re-sp/","published":"2021-11-30"},{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-en-renale-uitkomsten-bij-hartfalen-nejm-emperor-reduced-renal/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/03/23/mra-en-empagliflozine-interactie-bij-hf-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/03/23/empagliflozine-bij-hfref-met-volume-overbelasting-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/09/19/sglt2-remmers-bij-hfref-meta-analyse-van-emperor-reduced-en-dapa-hf/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2019/07/01/hospitalisatieredenen-en-mortaliteitsrisico-bij-af-met-dabigatran-versus-warfari/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/05/14/dabigatran-duale-therapie-met-ticagrelor-of-clopidogrel-na-pci-bij-af-re-dual-pc/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2018/07/17/oac-plus-nsaid-bij-af-risico-op-ernstige-bloedingen/","published":"2018-07-17"},{"url":"https://hartvaat.nl/2018/03/13/doac-s-bij-af-met-ckd-systematische-review-werkzaamheid-en-veiligheid/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2018/02/01/dabigatran-versus-warfarine-bij-af-met-linkerventrikelhypertrofie-re-ly/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/08/23/dabigatran-versus-warfarine-bij-af-met-kleplijden-re-ly-analyse/","published":"2016-08-23"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnevaluatie-van-dabigatran-150-versus-110-mg-bij-niet-valvulair-af/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"william-c-cushman","type":"person","url":"https://hartvaat.nl/mensen/william-c-cushman/","name":"William C Cushman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":31,"articles":[{"url":"https://hartvaat.nl/2026/04/25/bloeddrukverlaging-beschermt-over-het-hele-spectrum-van-chronische-nierschade-la/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukcontrole-en-cerebrale-small-vessel-disease-markers/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2023/11/01/sekseverschillen-in-effect-van-bloeddrukverlaging-ipd-meta-analyse/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/08/01/combinatietabletten-voor-intensieve-bloeddrukbehandeling-sprint-analyse/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/12/29/chloortalidon-versus-hydrochloorthiazide-geen-verschil-in-cv-events/","published":"2022-12-29"},{"url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/07/08/cv-uitkomsten-bij-diabetes-met-vastgesteld-of-hoog-risico-coronairlijden-dulaglu/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2021/04/27/patientselectie-voor-intensieve-bloeddrukbehandeling-naar-voordeel-en-bijwerking/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/03/01/kdigo-2021-bloeddruk-bij-ckd-executive-summary/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2021/02/01/therapietrouw-aan-single-pill-versus-vrije-combinatietherapie-bij-hypertensie-me/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/03/01/orthostatische-hypotensie-cv-uitkomsten-en-adverse-events-sprint-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2020/02/01/bloeddrukcontrole-en-diabetes-incidentie-sprint-resultaten/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2018/06/01/intensieve-versus-standaard-bloeddruk-naar-tertielen-in-sprint/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/01/09/diastolische-bloeddruk-en-intensieve-bloeddrukcontrole-sprint-analyse/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/08/01/intensieve-bloeddrukverlaging-en-linkerventrikelhypertrofie-sprint-echocardiogra/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/05/16/serieel-hoog-sensitief-troponine-i-en-cv-uitkomsten-bij-diabetes-type-2-examine/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2017/01/01/intensieve-versus-standaard-bloeddrukcontrole-op-ambulante-bloeddruk-sprint-resu/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/10/01/orthostatische-hypotensie-in-de-accord-bloeddruk-trial-prevalentie-en-klinische-/","published":"2016-10-01"},{"url":"https://hartvaat.nl/2016/09/01/ace-remmers-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-met-dpp-4-remmers/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/07/01/medicatie-non-adherentie-en-visit-to-visit-bloeddrukvariabiliteit-target-bp-stud/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/03/01/voorschrijfpatronen-van-thiazidediuretica-in-de-sprint-trial/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anna-maria-langkilde","type":"person","url":"https://hartvaat.nl/mensen/anna-maria-langkilde/","name":"Anna Maria Langkilde","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":30,"articles":[{"url":"https://hartvaat.nl/2025/12/01/dapagliflozine-na-mi-naar-ef-cardiometabole-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/03/31/dapagliflozine-en-mortaliteit-bij-ckd-dapa-ckd-pre-gespecificeerde-analyse/","published":"2021-03-31"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jan-g-p-tijssen","type":"person","url":"https://hartvaat.nl/mensen/jan-g-p-tijssen/","name":"Jan G P Tijssen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":30,"articles":[{"url":"https://hartvaat.nl/2026/05/10/decision-trial-digoxine-staken-bij-hartfalen-leidt-tot-zevenvoudige-stijging-in-/","published":"2026-06-25"},{"url":"https://hartvaat.nl/2026/05/10/decision-onttrekkingssubstudie-stoppen-van-digoxine-na-lange-behandeling-leidt-t/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/10/12/castle-htx-af-ablatie-bij-eindstadium-hartfalen-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2022/07/15/race-3-langetermijnresultaten-gerichte-behandeling-bij-vroeg-persisterend-af-en-/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2022/03/02/frequentiecontrolemiddelen-verschillen-in-preventie-van-af-progressie/","published":"2022-03-02"},{"url":"https://hartvaat.nl/2021/12/07/gold-force-multi-elektrode-rf-versus-irrigated-rf-bij-af-gerandomiseerde-trial/","published":"2021-12-07"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/09/08/antiaritmica-bij-vroeg-persisterend-af-met-hf-race-3/","published":"2021-09-08"},{"url":"https://hartvaat.nl/2021/08/31/colchicine-bij-chronisch-coronairlijden-met-versus-zonder-eerder-acs/","published":"2021-08-31"},{"url":"https://hartvaat.nl/2021/07/21/laaggedoseerd-colchicine-bij-coronairlijden-meta-analyse-van-gerandomiseerde-tri/","published":"2021-07-21"},{"url":"https://hartvaat.nl/2020/12/14/edoxaban-bij-af-met-pci-naar-acute-versus-chronische-coronaire-presentatie-entru/","published":"2020-12-14"},{"url":"https://hartvaat.nl/2020/11/10/ticagrelor-plus-aspirine-en-safeneuze-graft-patency-na-cabg/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2020/02/01/verpleegkundig-geleide-versus-standaard-af-zorg/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/12/07/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-veiligheid-en-werk/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/12/edoxaban-versus-vka-gebaseerd-antitrombotisch-regime-na-stenting-bij-af-lancet-e/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/04/18/vroege-of-uitgestelde-cardioversie-bij-recent-onset-af-nejm-race-7-acwas/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2019/04/01/upstream-therapie-verbetert-qol-bij-persisterend-af-arrest-af/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/09/01/langetermijnimpact-van-cto-rekanalisatie-bij-stemi-patienten/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/08/21/behandeling-van-onderliggende-aandoeningen-verbetert-sinusritme-na-af-arrest-af/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/04/17/nt-probnp-geleide-therapie-bij-acuut-gedecompenseerd-hartfalen-prima-ii/","published":"2018-04-17"},{"url":"https://hartvaat.nl/2017/06/15/bioresorbeerbare-scaffolds-versus-metallic-stents-bij-routine-pci-nejm-aida/","published":"2017-06-15"},{"url":"https://hartvaat.nl/2017/04/18/vroeg-invasief-versus-selectieve-strategie-bij-nste-acs-ictus-trial-langetermijn/","published":"2017-04-18"},{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-circulatoire-ondersteuning-versus-iabp-bij-cardiogene-shoc/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/10/11/pci-van-chronische-totale-occlusie-bij-stemi-met-multivatenlijden-explore-trial/","published":"2016-10-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeff-s-healey","type":"person","url":"https://hartvaat.nl/mensen/jeff-s-healey/","name":"Jeff S Healey","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":30,"articles":[{"url":"https://hartvaat.nl/2026/04/08/vision-postoperatief-atriumfibrilleren-na-hartchirurgie-verhoogt-sterfte-na-een-/","published":"2026-07-15"},{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/04/03/laa-sluiting-na-af-ablatie-gerandomiseerde-trial-nejm/","published":"2025-04-03"},{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2025/02/20/vanish2-catheterablatie-versus-antiaritmica-bij-ventriculaire-tachycardie-nejm/","published":"2025-02-20"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/11/26/artesia-subanalyse-cva-risico-naar-frequentie-en-duur-van-subclinisch-af/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/01/af-ablatie-bij-hfref-versus-hfpef-meta-analyse/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/03/07/mra-s-verminderen-af-risico-meta-analyse-van-klinische-trials/","published":"2024-03-07"},{"url":"https://hartvaat.nl/2024/01/18/raft-langetermijn-crt-d-bij-hartfalen-nejm-14-jaarsresultaten/","published":"2024-01-18"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/11/04/colchicine-vermindert-perioperatief-af-na-thoraxchirurgie-lancet-rct/","published":"2023-11-04"},{"url":"https://hartvaat.nl/2023/10/24/laaos-iii-laa-occlusie-en-anticoagulatiegebruik/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2023/02/16/technieken-om-cardioversiesucces-bij-af-te-verbeteren-meta-analyse/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2022/10/13/voorbehandeling-met-antiaritmica-voor-cardioversie-bij-af-netwerk-meta-analyse/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2021/08/06/orale-antiaritmica-voor-cardioversie-van-recent-onset-af-netwerkmeta-analyse/","published":"2021-08-06"},{"url":"https://hartvaat.nl/2021/06/15/prevalentie-van-linkeratriumtrombus-bij-geanticoaguleerde-af-patienten/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","published":"2021-06-03"},{"url":"https://hartvaat.nl/2021/05/01/screening-op-af-bij-ouderen-jama-cardiology-gerandomiseerde-trial/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2019/08/01/vernakalant-voor-cardioversie-van-recent-onset-af-meta-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/07/01/hospitalisatieredenen-en-mortaliteitsrisico-bij-af-met-dabigatran-versus-warfari/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/01/amiodaron-voor-en-na-electrische-cardioversie-van-af-meta-analyse/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/11/21/voortzetten-versus-onderbreken-doac-bij-device-chirurgie-bruise-control-2/","published":"2018-11-21"},{"url":"https://hartvaat.nl/2018/05/08/vasopressine-plus-catecholamines-en-af-bij-distributieve-shock-jama-meta-analyse/","published":"2018-05-08"},{"url":"https://hartvaat.nl/2017/10/01/korte-dabigatran-onderbreking-voor-device-implantatie-re-ly-multicenterervaring/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/02/01/reductie-van-onnodige-ventriculaire-pacing-en-klinische-uitkomsten-bij-behouden-/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2016/07/14/ablatie-versus-escalatie-van-antiaritmica-bij-ventriculaire-tachycardie-nejm-van/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"julia-f-kuder","type":"person","url":"https://hartvaat.nl/mensen/julia-f-kuder/","name":"Julia F Kuder","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":30,"articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/11/17/olpasiran-sirna-verlaagt-lipoproteine-a-spectaculair-in-fase-2-trial/","published":"2022-11-17"},{"url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","published":"2022-10-11"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/08/30/biomarkers-voorspellen-complexe-coronaire-revascularisatie-in-fourier/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2022/05/03/vupanorsen-en-non-hdl-cholesterol-bij-statinebehandelde-patienten-translate-timi/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/14/bmi-en-uitkomsten-bij-af-behandeld-met-edoxaban-of-warfarine-engage-af-timi-48/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2019/01/01/interindividuele-variatie-in-ldl-verlaging-met-evolocumab-fourier-analyse/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2018/08/21/klinisch-voordeel-van-evolocumab-naar-ernst-van-coronairlijden-fourier/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/06/01/fgf-23-en-recidiverende-cv-events-na-acs/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/05/04/evolocumab-en-klinische-uitkomsten-bij-cardiovasculaire-ziekte-nejm-fourier/","published":"2017-05-04"},{"url":"https://hartvaat.nl/2016/07/05/nierfunctie-en-uitkomsten-met-edoxaban-in-de-engage-af-timi-48-trial/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/03/15/plaatjesremming-met-ticagrelor-60-mg-versus-90-mg-in-de-pegasus-timi-54-trial/","published":"2016-03-15"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-f-storey","type":"person","url":"https://hartvaat.nl/mensen/robert-f-storey/","name":"Robert F Storey","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":30,"articles":[{"url":"https://hartvaat.nl/2026/03/05/doac-of-vka-bij-kwetsbare-ouderen-met-atriumfibrilleren/","published":"2026-03-20"},{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/12/01/dapagliflozine-na-mi-naar-ef-cardiometabole-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2024/11/07/invasieve-strategie-bij-ouderen-met-mi-gerandomiseerde-trial-nejm/","published":"2024-11-07"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2020/11/01/klinische-toepassing-van-hs-troponine-in-het-ascvd-raamwerk-jama-cardiology/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/08/01/complete-versus-culprit-only-revascularisatie-bij-stemi-jama-cardiology-meta-ana/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2018/12/01/multipele-biomarkers-en-mortaliteitsrisico-na-acs-jama-cardiology/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/04/01/fibrinestoleigenschappen-en-klinische-uitkomsten-na-acs-plato-substudie/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2017/08/01/kosteneffectiviteit-van-langdurig-ticagrelor-na-mi-pegasus-timi-54/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/09/20/cva-preventie-met-ticagrelor-na-myocardinfarct-pegasus-timi-54-inzichten/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/06/14/reductie-van-ischemische-events-met-ticagrelor-bij-diabetes-na-myocardinfarct-pe/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/04/21/gdf-15-voorspelt-bloedingen-en-cardiovasculaire-events-bij-acuut-coronair-syndro/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/04/01/veiligheid-en-werkzaamheid-van-ticagrelor-versus-clopidogrel-bij-primaire-pci-vo/","published":"2016-04-01"},{"url":"https://hartvaat.nl/2016/03/15/plaatjesremming-met-ticagrelor-60-mg-versus-90-mg-in-de-pegasus-timi-54-trial/","published":"2016-03-15"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-e-kandzari","type":"person","url":"https://hartvaat.nl/mensen/david-e-kandzari/","name":"David E Kandzari","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":29,"articles":[{"url":"https://hartvaat.nl/2025/04/12/orbitale-atherectomie-versus-ballonangioplastie-voor-des-bij-ernstig-verkalkte-l/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/12/renale-denervatie-bij-hypertensie-uitgebreide-meta-analyse-van-alle-trials/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/06/11/target-bp-i-alcohol-gemedieerde-renale-denervatie-bij-hypertensie/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2022/10/22/symplicity-htn-3-langetermijn-follow-up-renale-denervatie-bij-resistente-hyperte/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2022/07/01/pulsatiele-hemodynamiek-voorspelt-bloeddrukrespons-op-renale-denervatie/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/07/hartfrequentie-en-uitkomsten-van-renale-denervatie-bij-ongecontroleerde-hyperten/","published":"2021-09-07"},{"url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2019/03/01/ambulante-hartfrequentiereductie-na-renale-denervatie-bij-hypertensie-zonder-med/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/10/09/24-uurs-ambulante-bloeddrukreductie-na-renale-denervatie-spyral-htn-off-med/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/06/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-6-maandsresultat/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2017/10/21/ultradunne-bioresorbeerbare-versus-dunne-duurzame-polymer-stents-lancet-bioscien/","published":"2017-10-21"},{"url":"https://hartvaat.nl/2017/10/03/ridaforolimus-versus-zotarolimus-eluting-stents-gerandomiseerde-primaire-resulta/","published":"2017-10-03"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"george-l-bakris","type":"person","url":"https://hartvaat.nl/mensen/george-l-bakris/","name":"George L Bakris","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":29,"articles":[{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","published":"2025-03-24"},{"url":"https://hartvaat.nl/2025/02/01/finerenon-en-lvh-bij-ckd-en-diabetes/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/10/22/flow-semaglutide-vermindert-hartfalen-bij-diabetes-en-ckd/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/07/11/flow-semaglutide-beschermt-nieren-bij-type-2-diabetes-en-ckd-nejm-gerelateerd/","published":"2024-07-11"},{"url":"https://hartvaat.nl/2023/07/20/zilebesiran-rna-interferentietherapie-voor-hypertensie-nejm/","published":"2023-07-20"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2022/12/03/precision-aprocitentan-bij-resistente-hypertensie-eerste-endothelineantagonist/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2022/12/01/finerenon-bloeddrukeffecten-en-cardiorenale-uitkomsten-bij-ckd-en-diabetes/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/10/22/symplicity-htn-3-langetermijn-follow-up-renale-denervatie-bij-resistente-hyperte/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2022/04/06/nierfunctiebeoordeling-en-eindpuntbepaling-in-klinische-trials-ehj/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2022/02/10/finerenon-cv-en-renale-uitkomsten-bij-diabetes-met-ckd-fidelity-gepoolde-analyse/","published":"2022-02-10"},{"url":"https://hartvaat.nl/2022/02/08/finerenon-vermindert-incident-hf-bij-ckd-met-diabetes-fidelity/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/12/09/finerenon-bij-nierziekte-met-diabetes-type-2-nejm-figaro-dkd/","published":"2021-12-09"},{"url":"https://hartvaat.nl/2021/07/13/finerenon-vermindert-nieuw-onset-af-bij-ckd-met-diabetes-fidelio-dkd/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/01/kbp-5074-en-bloeddruk-bij-gevorderde-ckd-block-ckd/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/02/09/finerenon-en-cardiovasculaire-uitkomsten-bij-ckd-met-diabetes-type-2-fidelio-dkd/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/07/01/mra-bij-hypertensie-met-gevorderde-ckd-block-ckd-trial/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"},{"url":"https://hartvaat.nl/2018/11/01/therapieresistente-hypertensie-aha-scientific-statement-over-detectie-evaluatie-/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/08/01/langetermijn-patiromer-bij-hyperkaliemie-met-mild-hf-en-diabetische-nefropathie/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/05/16/serieel-hoog-sensitief-troponine-i-en-cv-uitkomsten-bij-diabetes-type-2-examine/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2017/05/01/aanhoudende-bloeddrukreductie-met-baroreceptoractivatietherapie-6-jaarsfollow-up/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2017/02/01/bereikte-bloeddruk-en-cardiovasculaire-uitkomsten-bij-oudere-patienten-met-geiso/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/01/07/verminderd-bloeddrukverlagend-effect-van-renale-denervatie-bij-geisoleerde-systo/","published":"2017-01-07"},{"url":"https://hartvaat.nl/2016/09/01/ace-remmers-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-met-dpp-4-remmers/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/09/01/patiromer-verlaagt-aldosteron-bij-ckd-patienten-met-hyperkaliemie-op-raas-remmer/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/03/08/naltrexon-bupropion-en-cardiovasculaire-events-bij-obesitas-gerandomiseerde-tria/","published":"2016-03-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kurt-huber","type":"person","url":"https://hartvaat.nl/mensen/kurt-huber/","name":"Kurt Huber","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":29,"articles":[{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/03/28/culprit-interventie-bij-cardiogene-shock-met-hartstilstand/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/08/21/klinisch-voordeel-van-evolocumab-naar-ernst-van-coronairlijden-fourier/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/01/16/hoog-sensitief-troponine-t-bij-chronisch-hartfalen-individuele-patientdata-meta-/","published":"2018-01-16"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/12/01/evolocumab-bij-hoogrisicopatienten-met-laag-ldl-op-statine-fourier-subanalyse/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2016/09/01/apixaban-5-mg-bij-af-met-hoge-leeftijd-laag-gewicht-of-hoog-creatinine-aristotle/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paulus-kirchhof","type":"person","url":"https://hartvaat.nl/mensen/paulus-kirchhof/","name":"Paulus Kirchhof","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":29,"articles":[{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/03/28/athena-post-hoc-dronedaron-als-effectieve-vroege-ritmecontrole/","published":"2025-03-28"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2024/03/26/doac-s-bij-device-gedetecteerd-af-meta-analyse-noah-afnet-6-en-artesia/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2023/05/19/east-afnet-4-vroege-ritmecontrole-bij-af-is-kosteneffectief/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2023/01/24/axadia-afnet-8-apixaban-versus-vka-bij-af-op-hemodialyse/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","published":"2022-09-13"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2020/12/22/digoxine-versus-bisoprolol-voor-frequentiecontrole-bij-af-en-qol-jama-rate-af/","published":"2020-12-22"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/01/predictie-van-af-recidief-na-ablatie-systematische-review-van-prognostische-mode/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2018/10/16/doac-s-halveren-trombo-embolische-events-na-af-cardioversie-versus-warfarine/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/10/01/ononderbroken-doac-versus-vka-bij-af-ablatie-meta-analyse/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-versus-heparine-vka-bij-cardioversie-voor-af-emanate-trial/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2017/01/01/axafa-afnet-5-apixaban-versus-vka-bij-af-ablatie-studieprotocol/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/07/de-tien-geboden-van-de-2016-esc-af-richtlijn/","published":"2016-10-07"},{"url":"https://hartvaat.nl/2016/10/07/2016-esc-richtlijn-voor-atriumfibrilleren-in-samenwerking-met-eacts/","published":"2016-10-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"evald-hoj-christiansen","type":"person","url":"https://hartvaat.nl/mensen/evald-hoj-christiansen/","name":"Evald Høj Christiansen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":28,"articles":[{"url":"https://hartvaat.nl/2025/12/29/functionele-en-morfologische-karakterisering-van-coronaire-atherosclerose/","published":"2025-12-29"},{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","published":"2024-11-09"},{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2024/03/02/intravasculaire-beeldvorming-bij-des-implantatie-lancet-netwerk-meta-analyse/","published":"2024-03-02"},{"url":"https://hartvaat.nl/2023/11/01/ifr-versus-ffr-en-vijfjaarsmortaliteit-swedeheart-en-define-flair/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/03/15/5-jaars-ifr-versus-ffr-geleide-pci-define-flair-ifr-swedeheart/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","published":"2020-01-18"},{"url":"https://hartvaat.nl/2019/01/07/bioresorbeerbare-scaffold-versus-ees-bij-stabiel-coronairlijden-prospectieve-tri/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/12/04/ffr-versus-angiografie-geleide-cabg/","published":"2018-12-04"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/07/07/revascularisatie-versus-optimale-medicamenteuze-therapie-bij-cto-gerandomiseerde/","published":"2018-07-07"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2017/05/11/instantaneous-wave-free-ratio-versus-ffr-voor-pci-indicatie-nejm-ifr-swedeheart/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"},{"url":"https://hartvaat.nl/2016/02/23/everolimus-versus-sirolimus-eluting-stents-5-jaarsresultaten-sort-out-iv/","published":"2016-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gerhard-hindricks","type":"person","url":"https://hartvaat.nl/mensen/gerhard-hindricks/","name":"Gerhard Hindricks","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":28,"articles":[{"url":"https://hartvaat.nl/2026/04/20/stopstorm-stereotactische-bestraling-reduceert-refractaire-vt-met-80/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2026/02/03/upgrade-van-draadloze-pacemaker-van-enkelvoudig-naar-tweekamersysteem/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/03/05/biventriculair-versus-rv-pacing-bij-patienten-met-verwachte-frequente-pacing/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/10/21/upgrade-van-rv-pacing-naar-crt-bij-hartfalen-gerandomiseerde-trial/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2023/10/12/castle-htx-af-ablatie-bij-eindstadium-hartfalen-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/02/16/p-golfduur-voorspelt-af-recidief-na-catheterablatie-meta-analyse/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2022/06/21/mri-geleide-fibroseablatie-versus-conventionele-ablatie-bij-persisterend-af/","published":"2022-06-21"},{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2021/05/21/firm-ablatie-versus-pvi-bij-paroxysmaal-af-gerandomiseerde-resultaten/","published":"2021-05-21"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/10/01/slokdarmsonde-bij-rf-ablatie-voor-af-opera-prospectieve-gerandomiseerde-trial/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/01/01/weglaten-van-aspirine-bij-gecombineerde-antitrombotische-therapie-voor-af-acs-he/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/11/01/individueel-aangepaste-versus-gestandaardiseerde-substraatmodificatie-bij-rf-abl/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/01/07/2017-esc-richtlijn-voor-stemi-management/","published":"2018-01-07"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/supraventriculaire-ectopie-na-af-ablatie-voorspelt-recidief/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/09/01/budapest-crt-upgrade-study-studieontwerp-voor-crt-upgrade/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/06/07/dagelijkse-telemonitoring-van-icd-s-gepoolde-analyse-van-drie-gerandomiseerde-tr/","published":"2017-06-07"},{"url":"https://hartvaat.nl/2017/03/01/katheterablatie-als-eerstelijnsbehandeling-bij-paroxysmaal-af-5-jaarsresultaten/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2017/01/01/axafa-afnet-5-apixaban-versus-vka-bij-af-ablatie-studieprotocol/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/07/2016-esc-richtlijn-voor-atriumfibrilleren-in-samenwerking-met-eacts/","published":"2016-10-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"inder-s-anand","type":"person","url":"https://hartvaat.nl/mensen/inder-s-anand/","name":"Inder S Anand","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":28,"articles":[{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/25/raas-blokkade-bij-hartfalen-voordeel-onafhankelijk-van-etniciteit-jama-meta-anal/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/02/01/polsdruk-prognose-en-sacubitril-valsartan-bij-hfpef-paragon-hf/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/04/14/systolische-bloeddruk-bij-hfpef-behandeld-met-sacubitril-valsartan-paragon-hf/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2018/10/01/natriuretische-peptiden-en-cardiovasculaire-prognose-bij-hfpef-topcat/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/02/01/autonome-regulatietherapie-bij-hfpef-anthem-hfpef/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2018/01/16/hoog-sensitief-troponine-t-bij-chronisch-hartfalen-individuele-patientdata-meta-/","published":"2018-01-16"},{"url":"https://hartvaat.nl/2017/09/12/lichamelijke-activiteit-en-prognose-bij-hfpef-topcat-analyse/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2017/02/21/diabetesstatus-en-cardiovasculaire-uitkomsten-bij-hfpef-klinische-en-echocardiog/","published":"2017-02-21"},{"url":"https://hartvaat.nl/2016/02/01/invloed-van-ejectiefractie-op-uitkomsten-van-spironolacton-bij-hfpef/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jens-cosedis-nielsen","type":"person","url":"https://hartvaat.nl/mensen/jens-cosedis-nielsen/","name":"Jens Cosedis Nielsen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":28,"articles":[{"url":"https://hartvaat.nl/2026/02/03/klinische-impact-van-veiligheidswaarschuwingen-voor-implanteerbare-pacemakers-en/","published":"2026-04-05"},{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/01/af-en-icd-bij-niet-ischemische-hfref-impliciaties-voor-devicetherapie/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/10/21/minimalisatie-van-atriale-pacing-bij-sinusknoopziekte-vermindert-af/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2023/08/02/gerichte-lv-leadplaatsing-bij-crt-meta-analyse-van-beeldvorming-en-elektrisch-ge/","published":"2023-08-02"},{"url":"https://hartvaat.nl/2022/05/03/multimodaliteitsbeeldvorming-geleide-lv-leadplaatsing-bij-crt-langetermijn/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/04/01/icd-bij-niet-ischemisch-systolisch-hf-met-coronaire-atherosclerose-danish/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/09/01/elektrisch-versus-beeldvorming-geleide-lv-leadplaatsing-bij-crt-gerandomiseerde-/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/supraventriculaire-ectopie-na-af-ablatie-voorspelt-recidief/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/12/01/enkelvoudige-versus-tweekamer-pacing-bij-sick-sinus-syndroom-danpace-langetermij/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2017/03/01/katheterablatie-als-eerstelijnsbehandeling-bij-paroxysmaal-af-5-jaarsresultaten/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2017/01/01/axafa-afnet-5-apixaban-versus-vka-bij-af-ablatie-studieprotocol/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kyungah-im","type":"person","url":"https://hartvaat.nl/mensen/kyungah-im/","name":"KyungAh Im","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":28,"articles":[{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","published":"2022-10-11"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/11/21/ldl-verlaging-bij-ouderen-lancet-meta-analyse-werkzaamheid-en-veiligheid/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/05/12/cognitie-na-ldl-verlaging-met-evolocumab-fourier-follow-up/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/01/28/morfine-en-cv-uitkomsten-bij-nste-acs-jacc-analyse/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2019/12/17/uitkomsten-van-vrouwen-versus-mannen-na-nste-acs/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/10/15/triglyceridenverlaging-en-cv-risicoreductie-over-therapeutische-klassen-meta-ana/","published":"2019-10-15"},{"url":"https://hartvaat.nl/2019/07/01/evolocumab-en-totale-cv-events-bij-cardiovasculaire-ziekte-fourier-analyse/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/18/evolocumab-bij-ckd-werkzaamheid-en-veiligheid-in-de-fourier-trial/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2018/09/01/verdere-ldl-verlaging-bij-reeds-zeer-lage-niveaus-jama-cardiology-meta-analyse/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/06/01/fgf-23-en-recidiverende-cv-events-na-acs/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2018/02/01/cv-uitkomsten-naar-albumin-en-nierziekte-bij-diabetes-type-2-met-hoog-cv-risico/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2017/08/17/cognitieve-functie-in-de-fourier-trial-met-evolocumab-nejm-ebbinghaus/","published":"2017-08-17"},{"url":"https://hartvaat.nl/2016/09/27/ldl-c-verlaging-en-cardiovasculaire-risicoreductie-jama-systematische-review-en-/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/14/reductie-van-ischemische-events-met-ticagrelor-bij-diabetes-na-myocardinfarct-pe/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/02/02/reductie-in-totale-cardiovasculaire-events-met-ezetimibe-simvastatine-na-acs-imp/","published":"2016-02-02"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-p-lefkowitz","type":"person","url":"https://hartvaat.nl/mensen/martin-p-lefkowitz/","name":"Martin P Lefkowitz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":28,"articles":[{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/04/sacubitril-valsartan-bij-hartfalen-over-het-nierfunctiespectrum/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/02/01/polsdruk-prognose-en-sacubitril-valsartan-bij-hfpef-paragon-hf/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/09/29/arni-en-renale-uitkomsten-bij-hfpef-paragon-hf/","published":"2020-09-29"},{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/04/14/systolische-bloeddruk-bij-hfpef-behandeld-met-sacubitril-valsartan-paragon-hf/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/28/eerdere-hf-hospitalisatie-en-sacubitril-valsartan-versus-valsartan-bij-hfpef-par/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/03/26/bnp-tijdens-sacubitril-valsartan-paradigm-hf/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2019/02/26/sacubitril-valsartan-en-biomarkers-van-extracellulaire-matrixregulatie-bij-hfref/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/06/01/sacubitril-valsartan-en-fysieke-en-sociale-activiteitsbeperkingen-bij-hf-paradig/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/04/14/systolische-bloeddruk-en-werkzaamheid-van-sacubitril-valsartan-bij-chronisch-hfr/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/01/01/verminderd-hyperkaliemierisico-met-mra-door-sacubitril-valsartan-bij-hartfalen/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/11/29/bmi-en-nauwkeurigheid-van-nt-probnp-en-bnp-voor-diagnose-van-acuut-hartfalen/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/07/19/sacubitril-valsartan-en-30-daagse-heropname-na-hartfalenhospitalisatie/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/06/07/klinische-verslechtering-van-poliklinisch-behandeld-hartfalen-paradigm-hf-analys/","published":"2016-06-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexander-n-parkhomenko","type":"person","url":"https://hartvaat.nl/mensen/alexander-n-parkhomenko/","name":"Alexander N Parkhomenko","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":27,"articles":[{"url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2016/07/01/apixaban-versus-warfarine-bij-af-in-relatie-tot-nierfunctie-aristotle-analyse/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bjorn-redfors","type":"person","url":"https://hartvaat.nl/mensen/bjorn-redfors/","name":"Björn Redfors","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":27,"articles":[{"url":"https://hartvaat.nl/2026/05/25/1-op-5-oudere-patienten-heeft-hartfalen-opname-binnen-jaar-na-tavr-1-jaarsmortal/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2025/04/12/orbitale-atherectomie-versus-ballonangioplastie-voor-des-bij-ernstig-verkalkte-l/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/02/18/lage-dosis-sirolimus-bdp-stent-versus-tweede-generatie-des-non-inferioriteit/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","published":"2022-11-15"},{"url":"https://hartvaat.nl/2022/08/09/ticagrelor-dapt-en-veneuze-graftfalen-na-cabg-systematische-review/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/05/01/nierdisfunctie-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2021/07/15/ultradunne-versus-conventionele-2e-generatie-des-langetermijn-meta-analyse/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2021/04/01/ventriculaire-aritmie-of-overlijden-na-stemi-versus-takotsubo/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/04/14/langetermijnuitkomsten-bij-vrouwen-en-mannen-na-pci/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/07/31/bnp-bij-linker-hoofdstamrevascularisatie-excel-analyse/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/10/10/dagelijks-ischemie-en-bloedingsrisico-na-primaire-pci-voor-stemi/","published":"2017-10-10"},{"url":"https://hartvaat.nl/2016/12/20/bloedingen-voor-coronairangiografie-bij-nste-acs/","published":"2016-12-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-w-hamm","type":"person","url":"https://hartvaat.nl/mensen/christian-w-hamm/","name":"Christian W Hamm","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":27,"articles":[{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/03/05/timing-van-prasugrel-start-en-coronairangiografie-bij-nstemi/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2018/12/07/laesiecomplexiteit-en-periprocedurele-events-bij-potente-iv-antiplaatjestherapie/","published":"2018-12-07"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/11/01/aldosteronblokkade-bij-myocardinfarct-ipd-analyse-van-twee-trials/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/06/01/fgf-23-en-recidiverende-cv-events-na-acs/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/10/01/langetermijnmortaliteit-en-prehospitale-tirofibanbehandeling-bij-stemi/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/02/01/cangrelor-versus-gpiib-iiia-remmers-ischemie-en-bloedingsrisico-s-vergeleken/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/01/17/cangrelor-met-en-zonder-gpiib-iiia-remmers-bij-pci/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/11/29/presentatie-buiten-kantoortijden-versus-tijdens-kantoortijden-bij-stemi-champion/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/09/06/consistente-reductie-in-periprocedureel-mi-met-cangrelor-champion-analyses/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/04/07/cangrelor-en-toegangsplaats-effect-op-ischemische-en-bloedingsevents-champion-ph/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"},{"url":"https://hartvaat.nl/2016/01/19/werkzaamheid-en-veiligheid-van-cangrelor-bij-vrouwen-versus-mannen-tijdens-pci-c/","published":"2016-01-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-m-o-connor","type":"person","url":"https://hartvaat.nl/mensen/christopher-m-o-connor/","name":"Christopher M O'Connor","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":27,"articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/01/geografische-variatie-in-hfref-patientkenmerken-en-behandeling/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/04/01/vericiguat-voordeel-geprojecteerd-op-paradigm-hf-en-dapa-hf-populaties/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2023/10/03/vericiguat-bij-hfref-is-kosteneffectief-victoria-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2022/07/12/frailteit-beinvloedt-effect-van-inspanningstraining-bij-hartfalen-hf-action-anal/","published":"2022-07-12"},{"url":"https://hartvaat.nl/2021/07/15/fysieke-revalidatie-bij-oudere-gehospitaliseerde-hf-patienten-nejm-rehab-hf/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/04/02/inspanningsrevalidatie-bij-hf-ipd-meta-analyse-van-inspanningscapaciteit-en-qol/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/11/27/economische-en-qol-uitkomsten-van-nt-probnp-geleide-hf-therapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2018/10/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-hf-trials-jama-cardiology-review/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/05/08/nierfunctieverslechtering-bij-acuut-hartfalen-met-agressieve-diurese-geen-tubula/","published":"2018-05-08"},{"url":"https://hartvaat.nl/2017/08/22/natriuretisch-peptide-geleide-therapie-bij-hoogrisico-hartfalen-jama-guide-it/","published":"2017-08-22"},{"url":"https://hartvaat.nl/2017/07/18/palliatieve-zorg-bij-hartfalen-de-pal-hf-gerandomiseerde-trial/","published":"2017-07-18"},{"url":"https://hartvaat.nl/2017/06/27/hospitalisatie-voor-nieuw-gediagnosticeerd-versus-verslechterend-chronisch-hartf/","published":"2017-06-27"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/04/04/inspanningstraining-bij-chronisch-hartfalen-met-atriumfibrilleren/","published":"2017-04-04"},{"url":"https://hartvaat.nl/2017/03/28/adaptieve-servoventilatie-bij-hartfalen-de-cat-hf-trial/","published":"2017-03-28"},{"url":"https://hartvaat.nl/2017/03/21/werkzaamheid-en-veiligheid-van-tolvaptan-bij-gehospitaliseerd-acuut-hartfalen/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/02/23/inspanningstestvariabelen-als-mortaliteitsvoorspellers-bij-chronisch-systolisch-/","published":"2016-02-23"},{"url":"https://hartvaat.nl/2016/01/26/langketen-acylcarnitines-bij-hartfalen-prognostische-waarde-en-reversibiliteit-m/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giuseppe-boriani","type":"person","url":"https://hartvaat.nl/mensen/giuseppe-boriani/","name":"Giuseppe Boriani","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":27,"articles":[{"url":"https://hartvaat.nl/2026/05/19/esc-atlas-2025-3-miljoen-cvd-doden-per-jaar-in-europa-middeninkomenlanden-hebben/","published":"2026-06-13"},{"url":"https://hartvaat.nl/2026/03/07/lancet-seminar-atriumfibrilleren-in-2026/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/02/27/prognose-takotsubo-syndroom-versus-hartfalen-op-de-lange-termijn/","published":"2026-03-09"},{"url":"https://hartvaat.nl/2026/02/03/lichamelijke-activiteit-en-risico-op-complicaties-bij-atriumfibrilleren/","published":"2026-03-06"},{"url":"https://hartvaat.nl/2026/02/25/alcoholgebruik-en-het-ontstaan-van-atriumfibrilleren-dosis-risico-en-dogma-herov/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2026/02/03/aanbesteding-van-cardiale-implanteerbare-devices-in-europa-waarde-of-kosten/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2026/02/03/atriumfibrilleren-bij-kankerpatienten-de-esc-richtlijn-2025-in-de-praktijk/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/08/04/lbbap-versus-rv-pacing-tweejaarsresultaten-bij-pacemakergeindiceerde-patienten/","published":"2025-08-04"},{"url":"https://hartvaat.nl/2025/06/03/multipoint-pacing-vermindert-hf-hospitalisaties-en-sterfte-bij-crt-non-responder/","published":"2025-06-03"},{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2024/11/26/artesia-subanalyse-cva-risico-naar-frequentie-en-duur-van-subclinisch-af/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/08/03/device-algoritmen-voor-rv-pacingminimalisatie-meta-analyse-van-uitkomsten/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2024/08/03/dagontslag-versus-overnachting-na-af-ablatie-uitgebreide-meta-analyse/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2024/08/01/alcohol-en-hypertensierisico-dosis-respons-meta-analyse-van-niet-experimentele-s/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/10/01/alcoholconsumptie-en-bloeddruk-dosis-respons-meta-analyse/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2021/10/01/katheterablatie-als-eerstelijns-paf-therapie-meta-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/09/14/copd-bij-af-prevalentie-management-en-impact-meta-analyse/","published":"2021-09-14"},{"url":"https://hartvaat.nl/2019/05/14/bmi-en-uitkomsten-bij-af-behandeld-met-edoxaban-of-warfarine-engage-af-timi-48/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/04/01/pr-interval-en-pacingmodus-en-af-incidentie-bij-tweekamer-pacemaker/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/06/01/preventie-van-atriumfibrilleren-beoordeling-van-huidig-bewijs/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/05/01/risicostratificatie-met-geintegreerde-devicediagnostiek-bij-hartfalen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/03/01/vaste-versus-responsieve-pacingfrequentie-bij-permanent-af-met-pacemakerindicati/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/02/01/reductie-van-onnodige-ventriculaire-pacing-en-klinische-uitkomsten-bij-behouden-/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"harry-j-g-m-crijns","type":"person","url":"https://hartvaat.nl/mensen/harry-j-g-m-crijns/","name":"Harry J G M Crijns","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":27,"articles":[{"url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/03/28/athena-post-hoc-dronedaron-als-effectieve-vroege-ritmecontrole/","published":"2025-03-28"},{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2024/08/03/anticoagulatie-bij-postoperatief-af-na-geisoleerde-cabg-meta-analyse/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2023/11/10/rate-control-bij-af-calciumantagonisten-versus-betablokkers/","published":"2023-11-10"},{"url":"https://hartvaat.nl/2023/10/12/castle-htx-af-ablatie-bij-eindstadium-hartfalen-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/05/19/east-afnet-4-vroege-ritmecontrole-bij-af-is-kosteneffectief/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","published":"2022-09-13"},{"url":"https://hartvaat.nl/2022/07/15/race-3-langetermijnresultaten-gerichte-behandeling-bij-vroeg-persisterend-af-en-/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2022/03/02/frequentiecontrolemiddelen-verschillen-in-preventie-van-af-progressie/","published":"2022-03-02"},{"url":"https://hartvaat.nl/2021/11/08/preoperatieve-tte-voor-voorspelling-van-postoperatief-af-meta-analyse/","published":"2021-11-08"},{"url":"https://hartvaat.nl/2021/09/08/antiaritmica-bij-vroeg-persisterend-af-met-hf-race-3/","published":"2021-09-08"},{"url":"https://hartvaat.nl/2020/12/01/coronairangiografie-na-hartstilstand-zonder-st-elevatie-coact-1-jaarsuitkomsten/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/02/01/verpleegkundig-geleide-versus-standaard-af-zorg/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/12/01/geintegreerde-gespecialiseerde-af-poliklinieken-verlagen-totale-mortaliteit-post/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/11/19/beeldvorming-geleide-versus-routinezorg-bij-nstemi-jacc/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/04/18/vroege-of-uitgestelde-cardioversie-bij-recent-onset-af-nejm-race-7-acwas/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2019/04/11/coronairangiografie-na-hartstilstand-zonder-st-elevatie-nejm-coact/","published":"2019-04-11"},{"url":"https://hartvaat.nl/2019/04/01/upstream-therapie-verbetert-qol-bij-persisterend-af-arrest-af/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/08/21/behandeling-van-onderliggende-aandoeningen-verbetert-sinusritme-na-af-arrest-af/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jonas-oldgren","type":"person","url":"https://hartvaat.nl/mensen/jonas-oldgren/","name":"Jonas Oldgren","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":27,"articles":[{"url":"https://hartvaat.nl/2026/08/25/extracraniale-bloedingen-komen-bij-26-van-af-patienten-op-antistolling-voor-comb/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2025/12/01/dapagliflozine-na-mi-naar-ef-cardiometabole-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/11/25/abc-af-risicoscores-voor-gepersonaliseerde-af-behandeling/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2025/07/05/optimale-timing-van-anticoagulatie-na-ischemisch-cva-en-af-collaboratief-project/","published":"2025-07-05"},{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/11/02/bioadaptor-implantaat-versus-drug-eluting-stent-bij-stabiel-coronairlijden/","published":"2024-11-02"},{"url":"https://hartvaat.nl/2024/10/01/neurofilament-light-chain-en-cva-risico-bij-af/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2022/10/04/timing-vroege-versus-late-noac-start-na-ischemisch-cva-bij-af/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/04/09/asundexian-factor-xia-remmer-versus-apixaban-bij-af-lancet-pacific-af/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2020/11/01/ace2-niveaus-en-covid-19-risicofactoren-bij-af-patienten/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2019/05/14/dabigatran-duale-therapie-met-ticagrelor-of-clopidogrel-na-pci-bij-af-re-dual-pc/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-versus-heparine-vka-bij-cardioversie-voor-af-emanate-trial/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/08/01/2018-ehra-praktische-gids-doac-s-bij-af-europace-editie/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/07/17/oac-plus-nsaid-bij-af-risico-op-ernstige-bloedingen/","published":"2018-07-17"},{"url":"https://hartvaat.nl/2018/05/14/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-meta-analyse/","published":"2018-05-14"},{"url":"https://hartvaat.nl/2018/04/21/2018-ehra-praktische-gids-voor-doac-gebruik-bij-af/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","published":"2018-02-07"},{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","published":"2017-10-19"},{"url":"https://hartvaat.nl/2017/10/01/korte-dabigatran-onderbreking-voor-device-implantatie-re-ly-multicenterervaring/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/07/01/dabigatran-naar-leeftijd-bij-atriumfibrilleren-re-ly-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/11/29/biomarkergebaseerde-cva-risicoscore-bij-atriumfibrilleren-validatie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/07/2016-esc-richtlijn-voor-atriumfibrilleren-in-samenwerking-met-eacts/","published":"2016-10-07"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnevaluatie-van-dabigatran-150-versus-110-mg-bij-niet-valvulair-af/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","published":"2016-06-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marc-a-pfeffer","type":"person","url":"https://hartvaat.nl/mensen/marc-a-pfeffer/","name":"Marc A Pfeffer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":27,"articles":[{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2024/10/01/plotse-dood-na-mi-inzichten-uit-valiant-en-paradise-mi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/06/25/raas-blokkade-bij-hartfalen-voordeel-onafhankelijk-van-etniciteit-jama-meta-anal/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/04/01/natriumzirconiumcyclosilicaat-bij-hyperkaliemie-en-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/10/14/dal-gene-farmacogenetica-geleide-dalcetrapib-na-acs/","published":"2022-10-14"},{"url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2021/02/01/polsdruk-prognose-en-sacubitril-valsartan-bij-hfpef-paragon-hf/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/09/29/arni-en-renale-uitkomsten-bij-hfpef-paragon-hf/","published":"2020-09-29"},{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2018/10/01/natriuretische-peptiden-en-cardiovasculaire-prognose-bij-hfpef-topcat/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/02/20/cva-risico-bij-verminderde-ef-na-mi-zonder-af/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/09/12/lichamelijke-activiteit-en-prognose-bij-hfpef-topcat-analyse/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2017/03/07/cva-risico-bij-chronisch-hartfalen-met-behouden-ef-zonder-af-charm-analyse/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2016/02/01/regionale-hartdisfunctie-en-prognose-na-myocardinfarct-met-lv-disfunctie-of-hart/","published":"2016-02-01"},{"url":"https://hartvaat.nl/2016/02/01/invloed-van-ejectiefractie-op-uitkomsten-van-spironolacton-bij-hfpef/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marcus-d-flather","type":"person","url":"https://hartvaat.nl/mensen/marcus-d-flather/","name":"Marcus D Flather","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":27,"articles":[{"url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","published":"2025-01-25"},{"url":"https://hartvaat.nl/2024/11/07/invasieve-strategie-bij-ouderen-met-mi-gerandomiseerde-trial-nejm/","published":"2024-11-07"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/03/12/rapid-nstemi-zeer-vroege-invasieve-strategie-bij-hoger-risico-nstemi/","published":"2024-03-12"},{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2022/09/01/timing-van-invasieve-strategie-bij-nste-acs-meta-analyse-van-rct-s/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/11/01/antiplaatjestherapie-bij-mi-zonder-obstructief-coronairlijden-minoca/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/10/16/betablokker-respons-bij-hf-met-sinusritme-en-af-machine-learning-clusteranalyse/","published":"2021-10-16"},{"url":"https://hartvaat.nl/2021/01/05/leeftijd-en-10-jaarsuitkomsten-na-cabg-art-trial/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/06/postoperatief-af-en-langetermijn-cva-risico-na-geisoleerde-cabg/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/01/31/bilaterale-versus-enkele-mammaria-interna-grafts-na-10-jaar-nejm-art/","published":"2019-01-31"},{"url":"https://hartvaat.nl/2018/11/01/aldosteronblokkade-bij-myocardinfarct-ipd-analyse-van-twee-trials/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","published":"2018-09-06"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/08/01/radiale-arterie-graft-als-aanvulling-op-mammaria-interna-grafts-bij-cabg/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/06/20/hartfrequentie-en-ritme-en-het-voordeel-van-betablokkers-bij-hartfalen/","published":"2017-06-20"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2016/12/29/bilaterale-versus-enkelvoudige-a-mammaria-interna-grafts-nejm-art-trial/","published":"2016-12-29"},{"url":"https://hartvaat.nl/2016/06/07/ischemie-en-infarct-bij-stemi-met-multivatenlijden-cvlprit-nucleaire-substudie/","published":"2016-06-07"},{"url":"https://hartvaat.nl/2016/04/19/ct-coronairangiografie-voor-het-sturen-van-beleid-bij-coronairlijden/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-a-weber","type":"person","url":"https://hartvaat.nl/mensen/michael-a-weber/","name":"Michael A Weber","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":27,"articles":[{"url":"https://hartvaat.nl/2026/02/01/aprocitentan-bij-ckd-en-resistente-hypertensie/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/04/01/aprocitentan-bij-zwarte-patienten-met-hypertensie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/07/01/value-trial-cv-uitkomsten-bij-hypertensie-met-perifeer-vaatlijden/","published":"2024-07-01"},{"url":"https://hartvaat.nl/2024/06/11/target-bp-i-alcohol-gemedieerde-renale-denervatie-bij-hypertensie/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/03/precision-aprocitentan-bij-resistente-hypertensie-eerste-endothelineantagonist/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/07/01/pulsatiele-hemodynamiek-voorspelt-bloeddrukrespons-op-renale-denervatie/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/09/07/hartfrequentie-en-uitkomsten-van-renale-denervatie-bij-ongecontroleerde-hyperten/","published":"2021-09-07"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2020/06/01/arb-versus-calciumantagonist-bloeddrukprofiel-en-klinische-effecten-vergelijking/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/03/01/ambulante-hartfrequentiereductie-na-renale-denervatie-bij-hypertensie-zonder-med/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/10/09/24-uurs-ambulante-bloeddrukreductie-na-renale-denervatie-spyral-htn-off-med/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2018/09/01/bereikte-diastolische-bloeddruk-en-polsdruk-bij-streef-sbp-en-cv-uitkomsten-bij-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2018/06/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-6-maandsresultat/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2017/06/03/bereikte-bloeddruk-en-cv-uitkomsten-bij-hoogrisicopatienten-ontarget-transcend/","published":"2017-06-03"},{"url":"https://hartvaat.nl/2017/01/07/verminderd-bloeddrukverlagend-effect-van-renale-denervatie-bij-geisoleerde-systo/","published":"2017-01-07"},{"url":"https://hartvaat.nl/2016/03/21/cardiovasculaire-uitkomsten-bij-verschillende-bereiktestreefdrukken-in-de-value-/","published":"2016-03-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-pordy","type":"person","url":"https://hartvaat.nl/mensen/robert-pordy/","name":"Robert Pordy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":27,"articles":[{"url":"https://hartvaat.nl/2025/12/22/evinacumab-bij-kinderen-van-5-17-jaar-met-homozygote-familiaire-hypercholesterol/","published":"2025-12-22"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2023/11/01/evinacumab-bij-refractaire-hypercholesterolemie-langetermijn-effectiviteit-en-ve/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","published":"2021-08-03"},{"url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/12/10/evinacumab-bij-refractaire-hypercholesterolemie-nejm/","published":"2020-12-10"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/08/20/evinacumab-bij-homozygoot-familiaire-hypercholesterolemie-nejm/","published":"2020-08-20"},{"url":"https://hartvaat.nl/2020/07/14/alirocumab-bij-homozygoot-fh-odyssey-hofh/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2020/05/19/pav-en-vte-na-acs-rol-van-lp-a-en-modificatie-door-alirocumab/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/02/25/polygene-risicoscore-en-voordeel-van-alirocumab-bij-coronairlijden-odyssey-outco/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/06/angptl3-remming-met-monoklonaal-antilichaam-verlaagt-triglyceriden/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"},{"url":"https://hartvaat.nl/2017/07/20/genetische-en-farmacologische-inactivatie-van-angptl3-en-cardiovasculaire-ziekte/","published":"2017-07-20"},{"url":"https://hartvaat.nl/2016/12/13/alirocumab-en-reductie-in-atherogene-lipiden-en-cardiovasculaire-events-10-odyss/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/10/14/geen-effect-van-pcsk9-remmer-alirocumab-op-diabetes-incidentie-odyssey-analyse/","published":"2016-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"seung-jung-park","type":"person","url":"https://hartvaat.nl/mensen/seung-jung-park/","name":"Seung-Jung Park","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":27,"articles":[{"url":"https://hartvaat.nl/2026/03/06/debat-preventieve-pci-bij-kwetsbare-plaques-als-standaardbehandeling/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/12/05/edoxaban-bij-af-en-stabiel-coronairlijden-antitrombotische-monotherapie/","published":"2024-12-05"},{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","published":"2024-05-04"},{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/11/22/ees-versus-cabg-bij-meervatslijden-langetermijn-follow-up-van-rct-s/","published":"2022-11-22"},{"url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","published":"2022-09-08"},{"url":"https://hartvaat.nl/2022/04/19/externe-validatie-van-de-freedom-score-voor-pci-versus-cabg/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2020/10/31/syntax-score-ii-herontwikkeling-voor-gepersonaliseerde-revascularisatiebeslissin/","published":"2020-10-31"},{"url":"https://hartvaat.nl/2020/05/05/des-versus-cabg-bij-linker-hoofdstam-10-jaarsresultaten-excel-extended/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/12/03/klinisch-significante-bloedingen-met-ticagrelor-versus-clopidogrel-bij-koreaanse/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2018/02/13/richtlijngetrouwe-medicamenteuze-therapie-in-contemporaine-revascularisatietrial/","published":"2018-02-13"},{"url":"https://hartvaat.nl/2017/11/07/stentontwerp-en-dapt-duur-effect-op-ischemie-en-bloedingen-netwerkmeta-analyse/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2017/07/01/syntax-scores-en-uitkomsten-bij-diabetes-met-multivatenlijden-gepoolde-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2016/09/06/pci-versus-cabg-bij-onbeschermde-hoofdstamziekte-uitkomsten/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/04/19/statinebehandeling-en-plaquesamenstelling-dubbelblinde-gerandomiseerde-studie/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/01/21/langdurige-duale-antiplaatjestherapie-bij-patienten-met-eerder-myocardinfarct-me/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anthony-c-keech","type":"person","url":"https://hartvaat.nl/mensen/anthony-c-keech/","name":"Anthony C Keech","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":26,"articles":[{"url":"https://hartvaat.nl/2026/01/13/effectiviteit-en-veiligheid-van-zeer-laag-bereikt-ldl-na-ischemisch-cva/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2025/05/20/intensieve-ldl-verlaging-met-evolocumab-bij-auto-immuunziekten-rct/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/02/11/langetermijn-evolocumab-bij-ouderen-effectiviteit-en-veiligheid/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2024/07/10/intracoronaire-trombolyse-bij-stemi-meta-analyse/","published":"2024-07-10"},{"url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","published":"2022-10-11"},{"url":"https://hartvaat.nl/2022/08/30/biomarkers-voorspellen-complexe-coronaire-revascularisatie-in-fourier/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2021/07/21/laaggedoseerd-colchicine-bij-coronairlijden-meta-analyse-van-gerandomiseerde-tri/","published":"2021-07-21"},{"url":"https://hartvaat.nl/2021/02/01/evolocumab-bij-metabool-syndroom-na-acs-fourier/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/11/21/ldl-verlaging-bij-ouderen-lancet-meta-analyse-werkzaamheid-en-veiligheid/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/12/cognitie-na-ldl-verlaging-met-evolocumab-fourier-follow-up/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/02/25/genetische-risicoscore-voorspelt-voordeel-van-evolocumab-fourier/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2019/07/01/evolocumab-en-totale-cv-events-bij-cardiovasculaire-ziekte-fourier-analyse/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/18/evolocumab-bij-ckd-werkzaamheid-en-veiligheid-in-de-fourier-trial/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2019/01/01/interindividuele-variatie-in-ldl-verlaging-met-evolocumab-fourier-analyse/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2018/08/21/klinisch-voordeel-van-evolocumab-naar-ernst-van-coronairlijden-fourier/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/07/10/inflammatie-en-cholesterol-in-de-fourier-trial/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/12/01/evolocumab-bij-hoogrisicopatienten-met-laag-ldl-op-statine-fourier-subanalyse/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2017/08/17/cognitieve-functie-in-de-fourier-trial-met-evolocumab-nejm-ebbinghaus/","published":"2017-08-17"},{"url":"https://hartvaat.nl/2017/05/04/evolocumab-en-klinische-uitkomsten-bij-cardiovasculaire-ziekte-nejm-fourier/","published":"2017-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bruce-neal","type":"person","url":"https://hartvaat.nl/mensen/bruce-neal/","name":"Bruce Neal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":26,"articles":[{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2026/01/01/consistentie-van-bloeddrukrespons-op-kaliumverrijkt-zout-ssass-subanalyse/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/04/11/heterogeniteit-in-bloeddrukrespons-op-antihypertensiva-jama-cross-over-rct/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2022/09/26/zoutvervangers-verminderen-cardiovasculaire-events-systematische-review/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2022/05/17/kosteneffectiviteit-van-zoutsubstitutie-ssass-analyse/","published":"2022-05-17"},{"url":"https://hartvaat.nl/2022/02/08/stress-cardiale-biomarkers-en-cv-renale-uitkomsten-bij-canagliflozine/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","published":"2021-09-18"},{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","published":"2021-09-16"},{"url":"https://hartvaat.nl/2021/04/01/canagliflozine-naar-diureticagebruik-canvas-post-hoc-analyse/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/11/03/canagliflozine-en-nt-probnp-implicaties-voor-cv-risicoreductie/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"},{"url":"https://hartvaat.nl/2019/05/28/canagliflozine-en-hf-uitkomsten-bij-behouden-versus-verminderde-ef-canvas/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/01/01/acute-creatininestijging-bij-start-ace-remmer-en-effecten-van-voortzetting-analy/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2019/01/01/polypil-en-cardiovasculaire-preventie-meta-analyse-van-gerandomiseerde-trials/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/07/31/canagliflozine-en-hartfalen-bij-diabetes-type-2-canvas-programma/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/01/23/canagliflozine-voor-primaire-en-secundaire-cardiovasculaire-preventie-canvas/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/08/17/canagliflozine-en-cardiovasculaire-en-renale-events-bij-diabetes-type-2-nejm-can/","published":"2017-08-17"},{"url":"https://hartvaat.nl/2017/07/11/positieve-luchtwegdruk-en-cv-events-bij-slaapapneu-jama-meta-analyse/","published":"2017-07-11"},{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"},{"url":"https://hartvaat.nl/2016/11/22/plasma-lipidomiek-verbetert-cardiovasculaire-risicovoorspelling-bij-diabetes-typ/","published":"2016-11-22"},{"url":"https://hartvaat.nl/2016/01/30/intensieve-bloeddrukverlaging-en-cardiovasculaire-en-renale-uitkomsten-systemati/","published":"2016-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christoph-wanner","type":"person","url":"https://hartvaat.nl/mensen/christoph-wanner/","name":"Christoph Wanner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":26,"articles":[{"url":"https://hartvaat.nl/2026/03/03/cardiovasculaire-mortaliteit-bij-chronische-nierziekte-en-dialyse-een-tweestappe/","published":"2026-04-08"},{"url":"https://hartvaat.nl/2026/02/23/van-internationale-richtlijnen-naar-nationale-implementatie-bij-cardio-renaal-me/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/01/21/patientgerapporteerde-uitkomsten-verbeteren-voorspelling-van-mortaliteit-bij-dia/","published":"2026-01-21"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/01/28/lp-a-en-ldl-cholesterol-onafhankelijke-cv-risicopaden/","published":"2025-01-28"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2023/01/24/axadia-afnet-8-apixaban-versus-vka-bij-af-op-hemodialyse/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2022/04/06/nierfunctiebeoordeling-en-eindpuntbepaling-in-klinische-trials-ehj/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-niet-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-en-renale-uitkomsten-bij-hartfalen-nejm-emperor-reduced-renal/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/01/07/hypoglykemie-cv-uitkomsten-en-empagliflozine-empa-reg-outcome/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/08/01/empagliflozine-voorkomt-progressie-van-ckd-empa-reg-outcome-renale-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/04/microvasculaire-ziekte-en-cv-events-bij-diabetes-type-2/","published":"2019-06-04"},{"url":"https://hartvaat.nl/2019/04/01/spironolacton-en-lv-massa-bij-hemodialysepatienten-gerandomiseerde-trial/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/10/13/lp-a-baseline-en-on-statin-voor-cv-eventvoorspelling-lancet-ipd-meta-analyse/","published":"2018-10-13"},{"url":"https://hartvaat.nl/2018/02/01/empagliflozine-en-cv-dood-en-hf-hospitalisatie-over-het-hf-spectrum-empa-reg-out/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2018/01/09/empagliflozine-bij-diabetes-type-2-met-cardiovasculaire-ziekte-en-ckd-empa-reg-o/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2016/07/28/empagliflozine-en-progressie-van-nierziekte-bij-diabetes-type-2-nejm-empa-reg-re/","published":"2016-07-28"},{"url":"https://hartvaat.nl/2016/06/01/langetermijneffecten-van-atorvastatine-bij-diabetes-type-2-op-hemodialyse-4d-tri/","published":"2016-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-b-mark","type":"person","url":"https://hartvaat.nl/mensen/daniel-b-mark/","name":"Daniel B Mark","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":26,"articles":[{"url":"https://hartvaat.nl/2025/09/23/pci-versus-cabg-en-gezondheidsstatus-bij-stabiel-coronairlijden/","published":"2025-09-23"},{"url":"https://hartvaat.nl/2025/09/16/ischemia-anginatrajecten-na-invasieve-versus-conservatieve-strategie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2024/09/10/tact-2-chelatietherapie-na-mi-bij-diabetes-negatieve-trial/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2023/10/03/vericiguat-bij-hfref-is-kosteneffectief-victoria-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","published":"2022-08-16"},{"url":"https://hartvaat.nl/2022/03/15/leeftijd-en-uitkomsten-van-katheterablatie-versus-medicatie-bij-af-cabana/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/07/13/ablatie-versus-medicatie-bij-af-naar-ras-en-etniciteit/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2020/07/28/langetermijn-icd-uitkomsten-scd-heft/","published":"2020-07-28"},{"url":"https://hartvaat.nl/2020/06/30/af-recidief-na-ablatie-versus-antiaritmica-in-cabana/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/23/gezondheidsstatus-na-invasieve-of-conservatieve-zorg-bij-coronairlijden-met-gevo/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-medicamenteus-bij-af-en-kwaliteit-van-leven-jama-cabana-q/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/03/05/inspanningstest-versus-ccta-bij-diabetes-met-verdenking-coronairlijden/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2018/11/27/economische-en-qol-uitkomsten-van-nt-probnp-geleide-hf-therapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2017/08/22/natriuretisch-peptide-geleide-therapie-bij-hoogrisico-hartfalen-jama-guide-it/","published":"2017-08-22"},{"url":"https://hartvaat.nl/2017/07/18/palliatieve-zorg-bij-hartfalen-de-pal-hf-gerandomiseerde-trial/","published":"2017-07-18"},{"url":"https://hartvaat.nl/2017/06/01/primaire-preventie-icd-bij-niet-ischemische-cardiomyopathie-meta-analyse/","published":"2017-06-01"},{"url":"https://hartvaat.nl/2017/05/09/ranolazine-na-incomplete-pci-bij-diabetes-versus-zonder-diabetes-river-pci/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2016/01/05/ranolazine-bij-angina-en-kwaliteit-van-leven-na-pci-met-incomplete-revascularisa/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-gaudet","type":"person","url":"https://hartvaat.nl/mensen/daniel-gaudet/","name":"Daniel Gaudet","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":23,"articles":[{"url":"https://hartvaat.nl/2026/05/24/eas-consensus-wereldwijde-harmonisatie-van-lipidenklinieken/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/25/verve-102-eenmalige-base-editing-schakelt-pcsk9-blijvend-uit-fase-1/","published":"2026-05-25"},{"url":"https://hartvaat.nl/2026/02/01/de-verborgen-nierschade-bij-chylomicronemiesyndromen/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2025/12/22/evinacumab-bij-kinderen-van-5-17-jaar-met-homozygote-familiaire-hypercholesterol/","published":"2025-12-22"},{"url":"https://hartvaat.nl/2025/05/20/plozasiran-en-lipoproteine-deeltjesgrootte-bij-hypertriglyceridemie/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/05/03/solbinsiran-langwerkend-sirna-tegen-angptl3-duurzaamheid-en-effectiviteit/","published":"2025-05-03"},{"url":"https://hartvaat.nl/2025/01/09/plozasiran-bij-persisterende-chylomicronemie-en-pancreatitisrisico-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2024/09/12/zodasiran-sirna-tegen-angptl3-bij-gemengde-hyperlipidemie-nejm/","published":"2024-09-12"},{"url":"https://hartvaat.nl/2024/09/12/plozasiran-sirna-tegen-apoc3-bij-gemengde-hyperlipidemie-nejm/","published":"2024-09-12"},{"url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2024/07/01/plozasiran-sirna-tegen-apoc3-bij-ernstige-hypertriglyceridemie-shasta-2/","published":"2024-07-01"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-hypertriglyceridemie-en-hoog-cv-risico-nejm/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2023/11/01/evinacumab-bij-refractaire-hypercholesterolemie-langetermijn-effectiviteit-en-ve/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2022/11/17/olpasiran-sirna-verlaagt-lipoproteine-a-spectaculair-in-fase-2-trial/","published":"2022-11-17"},{"url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2020/12/10/evinacumab-bij-refractaire-hypercholesterolemie-nejm/","published":"2020-12-10"},{"url":"https://hartvaat.nl/2020/10/21/vupanorsen-angptl3-antisense-en-triglyceriden-ehj/","published":"2020-10-21"},{"url":"https://hartvaat.nl/2020/10/01/evolocumab-bij-pediatrische-heterozygoot-fh-nejm-hauser-rct/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/08/20/evinacumab-bij-homozygoot-familiaire-hypercholesterolemie-nejm/","published":"2020-08-20"},{"url":"https://hartvaat.nl/2020/07/14/alirocumab-bij-homozygoot-fh-odyssey-hofh/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2019/08/08/volanesorsen-en-triglyceriden-bij-familiair-chylomicronemiesyndroom-nejm/","published":"2019-08-08"},{"url":"https://hartvaat.nl/2017/08/29/rosuvastatine-bij-kinderen-met-homozygote-familiaire-hypercholesterolemie/","published":"2017-08-29"}],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/triglyceriden-en-remnantdeeltjes/","title":"Sessie 1: Triglyceriden en remnantdeeltjes"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"erik-stroes","type":"person","url":"https://hartvaat.nl/mensen/erik-stroes/","name":"Erik S.G. Stroes","title":"Amsterdam UMC, Amsterdam","dutch_institution":true,"orcid":"","scholar":"","website":"","article_count":20,"articles":[{"url":"https://hartvaat.nl/2026/05/24/eas-consensus-wereldwijde-harmonisatie-van-lipidenklinieken/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/02/27/macrofaagbelasting-in-carotisplaque-voorspelt-cardiovasculaire-events-na-endarte/","published":"2026-03-02"},{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2026/01/13/enlicitide-orale-pcsk9-remmer-bij-heterozygote-fh-fase-3/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","published":"2025-10-02"},{"url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-familiaire-chylomicronemie-nejm-fase-3/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2023/11/01/evinacumab-bij-refractaire-hypercholesterolemie-langetermijn-effectiviteit-en-ve/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2022/05/03/korte-interfererende-rna-tegen-lp-a-jama-fase-1-dosisstudie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/09/21/pcsk9-remming-en-geoxideerde-fosfolipiden/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2020/12/10/evinacumab-bij-refractaire-hypercholesterolemie-nejm/","published":"2020-12-10"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2020/01/16/lp-a-verlaging-bij-cardiovasculaire-ziekte-nejm/","published":"2020-01-16"},{"url":"https://hartvaat.nl/2019/11/12/bempedoinezuur-toegevoegd-aan-statines-bij-hoog-cv-risico-jama-clear-harmony/","published":"2019-11-12"},{"url":"https://hartvaat.nl/2019/09/01/persisterende-arteriele-wandinflammatie-bij-verhoogd-lp-a-ondanks-lage-ldl/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/08/volanesorsen-en-triglyceriden-bij-familiair-chylomicronemiesyndroom-nejm/","published":"2019-08-08"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2016/04/19/evolocumab-versus-ezetimibe-bij-statine-intolerante-patienten-de-gauss-3-trial/","published":"2016-04-19"}],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/triglyceriden-en-remnantdeeltjes/","title":"Sessie 1: Triglyceriden en remnantdeeltjes"},{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/implementatie-lipidenmanagement/","title":"Sessie 4: Implementatie van lipidenmanagement — praktische uitdagingen"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-a-spertus","type":"person","url":"https://hartvaat.nl/mensen/john-a-spertus/","name":"John A Spertus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":26,"articles":[{"url":"https://hartvaat.nl/2026/01/27/vroege-versus-late-gestageerde-pci-na-subintimale-re-entry-bij-cto/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/09/23/pci-versus-cabg-en-gezondheidsstatus-bij-stabiel-coronairlijden/","published":"2025-09-23"},{"url":"https://hartvaat.nl/2025/09/16/ischemia-anginatrajecten-na-invasieve-versus-conservatieve-strategie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/01/01/kccq-interpretatie-bij-hartfalen-patient-ankering/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2024/05/28/pro-hf-routine-prom-meting-in-hartfalenpolikliniek-verbetert-uitkomsten/","published":"2024-05-28"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/08/01/mondiale-vergelijking-van-heropnamepercentages-bij-hartfalen/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2023/07/18/bioresorbeerbare-coronaire-scaffolds-vijfjaarsuitkomsten-met-verbeterde-techniek/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2023/07/18/sglt2-remmers-verbeteren-kwaliteit-van-leven-gelijk-bij-zwarte-en-witte-hartfale/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/09/06/klinisch-beslisondersteuning-vermindert-acute-nierschade-bij-coronairangiografie/","published":"2022-09-06"},{"url":"https://hartvaat.nl/2022/04/19/externe-validatie-van-de-freedom-score-voor-pci-versus-cabg/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2020/11/24/2020-acc-aha-prestatie-en-kwaliteitsmaten-voor-hartfalen/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/10/31/syntax-score-ii-herontwikkeling-voor-gepersonaliseerde-revascularisatiebeslissin/","published":"2020-10-31"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/23/gezondheidsstatus-na-invasieve-of-conservatieve-zorg-bij-coronairlijden-met-gevo/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/11/26/2019-aha-acc-prestatie-en-kwaliteitsmaten-voor-hoge-bloeddruk/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/10/22/individualisering-van-revascularisatiestrategie-bij-diabetes-met-multivatenlijde/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/05/07/gezondheidsstatus-na-mitraclip-bij-hf-met-secundaire-mr-coapt/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/04/30/leefstijl-hba1c-en-overleving-bij-stabiel-coronairlijden-met-diabetes/","published":"2019-04-30"},{"url":"https://hartvaat.nl/2016/04/26/predictieregel-voor-voordeel-en-schade-van-dapt-na-1-jaar-pci-jama-validatiestud/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kazuomi-kario","type":"person","url":"https://hartvaat.nl/mensen/kazuomi-kario/","name":"Kazuomi Kario","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":23,"articles":[{"url":"https://hartvaat.nl/2026/10/01/esh-convenant-polshorloges-bloeddrukmeters-acceptabele-nauwkeurigheid-maar-klini/","published":"2026-09-02"},{"url":"https://hartvaat.nl/2026/05/11/wisdom-hmod-nachtelijke-pols-bloeddrukmeting-voorspelt-onafhankelijk-linkerventr/","published":"2026-07-09"},{"url":"https://hartvaat.nl/2026/03/04/winterhypertensie-koude-als-cardiovasculaire-risicofactor/","published":"2026-04-05"},{"url":"https://hartvaat.nl/2026/02/10/nieuwe-medicamenteuze-therapieen-voor-hypertensie/","published":"2026-03-14"},{"url":"https://hartvaat.nl/2026/02/11/ffr-geleide-nierslagaderstenting-bij-atherosclerotische-renovasculaire-hypertens/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2024/11/12/rf-renale-denervatie-bij-ongecontroleerde-hypertensie-in-china-gerandomiseerde-t/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2022/07/01/pulsatiele-hemodynamiek-voorspelt-bloeddrukrespons-op-renale-denervatie/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/11/01/bloeddrukvariabiliteit-en-dementie-cognitieve-stoornis-meta-analyse/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/10/21/digitale-therapeutica-bij-essentiele-hypertensie-herb-dh1-pivottrial/","published":"2021-10-21"},{"url":"https://hartvaat.nl/2021/09/30/intensieve-bloeddrukcontrole-bij-oudere-patienten-met-hypertensie-nejm-step/","published":"2021-09-30"},{"url":"https://hartvaat.nl/2021/09/07/hartfrequentie-en-uitkomsten-van-renale-denervatie-bij-ongecontroleerde-hyperten/","published":"2021-09-07"},{"url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2018/10/09/24-uurs-ambulante-bloeddrukreductie-na-renale-denervatie-spyral-htn-off-med/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2018/06/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-6-maandsresultat/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2018/06/01/interarmbloeddrukverschil-en-beroerte-ipd-meta-analyse/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2017/03/01/sacubitril-valsartan-versus-olmesartan-op-centrale-hemodynamiek-bij-ouderen-para/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2017/01/07/verminderd-bloeddrukverlagend-effect-van-renale-denervatie-bij-geisoleerde-systo/","published":"2017-01-07"},{"url":"https://hartvaat.nl/2016/04/01/prognostisch-effect-van-nachtelijke-bloeddrukdaling-bij-hypertensie-de-abc-h-stu/","published":"2016-04-01"}],"videos":[{"url":"https://hartvaat.nl/video/aldosteron-ontregeling-hypertensie-esc/nieuwe-data-in-praktijk-kario/","title":"Wat betekent nieuwe data voor de praktijk? — Kazuomi Kario"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"morten-schou","type":"person","url":"https://hartvaat.nl/mensen/morten-schou/","name":"Morten Schou","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":26,"articles":[{"url":"https://hartvaat.nl/2026/10/01/voorgebruik-van-opioiden-verhoogt-sterfte-en-ziekenhuisopnames-na-tavi-deens-coh/","published":"2026-08-21"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/22/thoracentese-bij-acuut-hartfalen-gerandomiseerde-trial/","published":"2025-04-22"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","published":"2024-08-27"},{"url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2023/04/01/mesenchymale-stamcellen-bij-ischemisch-hartfalen-deense-fase-ii-trial/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/07/01/empagliflozine-en-lv-volumes-en-functie-bij-hfref-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/06/01/metabole-effecten-van-empagliflozine-bij-hf-empire-hf-metabolic-gerandomiseerde-/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/12/08/empagliflozine-en-hemodynamiek-bij-hfref/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ori-ben-yehuda","type":"person","url":"https://hartvaat.nl/mensen/ori-ben-yehuda/","name":"Ori Ben-Yehuda","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":26,"articles":[{"url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/07/18/bioresorbeerbare-coronaire-scaffolds-vijfjaarsuitkomsten-met-verbeterde-techniek/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2021/07/15/ultradunne-versus-conventionele-2e-generatie-des-langetermijn-meta-analyse/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/05/05/gezondheidsstatus-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/04/14/langetermijnuitkomsten-bij-vrouwen-en-mannen-na-pci/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/04/23/hedendaagse-uitkomsten-na-cabg-voor-hoofdstamlijden/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/07/31/bnp-bij-linker-hoofdstamrevascularisatie-excel-analyse/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"},{"url":"https://hartvaat.nl/2017/12/12/implantatiechniek-en-uitkomsten-van-bioresorbeerbare-scaffolds-absorb-analyses/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/10/03/ridaforolimus-versus-zotarolimus-eluting-stents-gerandomiseerde-primaire-resulta/","published":"2017-10-03"},{"url":"https://hartvaat.nl/2017/05/09/ranolazine-na-incomplete-pci-bij-diabetes-versus-zonder-diabetes-river-pci/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2016/11/26/oct-versus-ivus-versus-angiografie-bij-coronaire-stentimplantatie-lancet-ilumien/","published":"2016-11-26"},{"url":"https://hartvaat.nl/2016/04/12/infarctgrootte-en-uitkomsten-na-primaire-pci-patientanalyse-uit-10-trials/","published":"2016-04-12"},{"url":"https://hartvaat.nl/2016/01/09/ranolazine-bij-incomplete-revascularisatie-na-pci-de-river-pci-trial/","published":"2016-01-09"},{"url":"https://hartvaat.nl/2016/01/05/ranolazine-bij-angina-en-kwaliteit-van-leven-na-pci-met-incomplete-revascularisa/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-k-whelton","type":"person","url":"https://hartvaat.nl/mensen/paul-k-whelton/","name":"Paul K Whelton","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":26,"articles":[{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/08/30/bloeddrukverlagende-effectiviteit-van-antihypertensiva-en-combinaties-uitgebreid/","published":"2025-08-30"},{"url":"https://hartvaat.nl/2024/11/01/optimale-antihypertensieve-systolische-bloeddruk-meta-analyse/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2024/08/01/alcohol-en-hypertensierisico-dosis-respons-meta-analyse-van-niet-experimentele-s/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2023/10/01/alcoholconsumptie-en-bloeddruk-dosis-respons-meta-analyse/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2022/09/20/harmonisatie-van-acc-aha-en-esc-esh-bloeddrukrichtlijnen/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/01/01/farmacologische-hypertensiebehandeling-bij-volwassenen-who-richtlijn-samenvattin/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2021/04/27/patientselectie-voor-intensieve-bloeddrukbehandeling-naar-voordeel-en-bijwerking/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/04/20/natriumreductie-en-bloeddruk-dosis-respons-meta-analyse-van-experimentele-studie/","published":"2021-04-20"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/06/01/intensieve-versus-standaard-bloeddruk-naar-tertielen-in-sprint/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/04/01/2017-acc-aha-richtlijn-voor-hoge-bloeddruk-bij-volwassenen-jama-cardiology-overz/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2018/01/09/diastolische-bloeddruk-en-intensieve-bloeddrukcontrole-sprint-analyse/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/07/01/systolische-bloeddrukreductie-en-cv-risico-netwerkmeta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/10/11/natriuminname-en-totale-mortaliteit-over-20-jaar-trials-of-hypertension-preventi/","published":"2016-10-11"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"roland-e-schmieder","type":"person","url":"https://hartvaat.nl/mensen/roland-e-schmieder/","name":"Roland E Schmieder","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":26,"articles":[{"url":"https://hartvaat.nl/2024/11/12/renale-denervatie-bij-hypertensie-uitgebreide-meta-analyse-van-alle-trials/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/06/11/target-bp-i-alcohol-gemedieerde-renale-denervatie-bij-hypertensie/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2023/06/01/angiotensinepathways-onder-empagliflozine-bij-chronisch-hartfalen/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/12/01/finerenon-bloeddrukeffecten-en-cardiorenale-uitkomsten-bij-ckd-en-diabetes/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/07/01/pulsatiele-hemodynamiek-voorspelt-bloeddrukrespons-op-renale-denervatie/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/12/01/empagliflozine-en-vaatfunctie-bij-chronisch-hf/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/07/hartfrequentie-en-uitkomsten-van-renale-denervatie-bij-ongecontroleerde-hyperten/","published":"2021-09-07"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2020/03/01/slagvolumeveranderingen-na-renale-denervatie-cardiale-mri-inzichten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/12/01/centrale-iliacale-av-anastomose-bij-ongecontroleerde-hypertensie-rox-control-htn/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2017/11/21/sacubitril-valsartan-versus-olmesartan-en-cardiovasculaire-remodellering-bij-hyp/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2017/11/01/gemiddelde-bloeddruk-en-visit-to-visit-variabiliteit-als-gecombineerde-voorspell/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/19/empagliflozine-en-vasculaire-functie-en-centrale-hemodynamiek-bij-diabetes-type-/","published":"2017-09-19"},{"url":"https://hartvaat.nl/2017/08/01/nauwkeurigheid-van-manchetbloeddrukmeting-systematische-review-en-meta-analyse/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/06/03/bereikte-bloeddruk-en-cv-uitkomsten-bij-hoogrisicopatienten-ontarget-transcend/","published":"2017-06-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a-john-camm","type":"person","url":"https://hartvaat.nl/mensen/a-john-camm/","name":"A John Camm","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":25,"articles":[{"url":"https://hartvaat.nl/2026/08/25/risicogestuurde-af-screening-met-machine-learning-verhoogt-detectiegraad-find-af/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/05/21/find-af-biomarker-stratificeert-prognose-bij-hfref-met-atriale-cardiomyopathie-z/","published":"2026-06-08"},{"url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/03/28/athena-post-hoc-dronedaron-als-effectieve-vroege-ritmecontrole/","published":"2025-03-28"},{"url":"https://hartvaat.nl/2025/03/28/geinhaleerde-flecainide-voor-cardioversie-van-recent-onset-af-lancet/","published":"2025-03-28"},{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2024/03/26/doac-s-bij-device-gedetecteerd-af-meta-analyse-noah-afnet-6-en-artesia/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2023/05/19/east-afnet-4-vroege-ritmecontrole-bij-af-is-kosteneffectief/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","published":"2022-09-13"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2021/03/08/multi-katheter-cryotherapie-versus-rf-ablatie-bij-langdurig-persisterend-af-gera/","published":"2021-03-08"},{"url":"https://hartvaat.nl/2021/01/27/periprocedurele-antistolling-bij-eliminate-af-ononderbroken-edoxaban-versus-vka/","published":"2021-01-27"},{"url":"https://hartvaat.nl/2020/12/22/digoxine-versus-bisoprolol-voor-frequentiecontrole-bij-af-en-qol-jama-rate-af/","published":"2020-12-22"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2018/08/01/2018-ehra-praktische-gids-doac-s-bij-af-europace-editie/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/04/21/2018-ehra-praktische-gids-voor-doac-gebruik-bij-af/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2017/01/01/percutane-linker-hartoorsluiting-munchen-consensusdocument-over-definities-en-ei/","published":"2017-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anthony-rodgers","type":"person","url":"https://hartvaat.nl/mensen/anthony-rodgers/","name":"Anthony Rodgers","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":25,"articles":[{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2026/01/01/consistentie-van-bloeddrukrespons-op-kaliumverrijkt-zout-ssass-subanalyse/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2025/08/30/bloeddrukverlagende-effectiviteit-van-antihypertensiva-en-combinaties-uitgebreid/","published":"2025-08-30"},{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2024/10/01/lage-dosis-drievoudige-pil-versus-standaardzorg-bij-hypertensie-in-nigeria/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/06/01/lage-dosis-drievoudige-viervoudige-combinatiepil-versus-monotherapie-bij-hyperte/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/04/25/mk-0616-eerste-orale-pcsk9-remmer-in-fase-2b/","published":"2023-04-25"},{"url":"https://hartvaat.nl/2023/03/01/korttermijn-bloeddrukmetingen-voorspellen-langetermijneffect-van-behandeling/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/09/26/zoutvervangers-verminderen-cardiovasculaire-events-systematische-review/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2022/06/01/lage-dosis-drievoudige-combinatietherapie-bij-hypertensie-triumph-secundaire-ana/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2022/05/10/sms-voor-medicatietrouw-en-secundaire-preventie-na-acs-textmeds/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","published":"2021-09-18"},{"url":"https://hartvaat.nl/2020/11/01/lage-dosis-triple-combinatie-en-therapeutische-inertie-bij-hypertensie-jama-card/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2019/06/01/bloeddrukverlaging-naar-uitgangsdruk-en-cv-risico-bij-diabetes-type-2/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/01/01/acute-creatininestijging-bij-start-ace-remmer-en-effecten-van-voortzetting-analy/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2019/01/01/polypil-en-cardiovasculaire-preventie-meta-analyse-van-gerandomiseerde-trials/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/08/14/drievoudige-lage-dosis-antihypertensivacombinatie-versus-standaardzorg-jama-gera/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2017/07/11/positieve-luchtwegdruk-en-cv-events-bij-slaapapneu-jama-meta-analyse/","published":"2017-07-11"},{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"},{"url":"https://hartvaat.nl/2016/11/22/plasma-lipidomiek-verbetert-cardiovasculaire-risicovoorspelling-bij-diabetes-typ/","published":"2016-11-22"},{"url":"https://hartvaat.nl/2016/03/05/bloeddrukverlaging-ter-preventie-van-hart-en-vaatziekten-systematische-review-en/","published":"2016-03-05"},{"url":"https://hartvaat.nl/2016/01/30/intensieve-bloeddrukverlaging-en-cardiovasculaire-en-renale-uitkomsten-systemati/","published":"2016-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-e-newby","type":"person","url":"https://hartvaat.nl/mensen/david-e-newby/","name":"David E Newby","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":25,"articles":[{"url":"https://hartvaat.nl/2026/05/25/verve-102-eenmalige-base-editing-schakelt-pcsk9-blijvend-uit-fase-1/","published":"2026-05-25"},{"url":"https://hartvaat.nl/2025/11/11/risicostratificatie-met-hoog-sensitief-troponine-op-de-seh-veiligheidsanalyse/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/02/03/klinische-risicopredictie-ct-coronairangiografie-en-cv-events-bij-nieuwe-angina/","published":"2025-02-03"},{"url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","published":"2025-01-25"},{"url":"https://hartvaat.nl/2025/01/21/evolved-vroege-interventie-bij-asymptomatische-ernstige-aortastenose-met-myocard/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/11/07/invasieve-strategie-bij-ouderen-met-mi-gerandomiseerde-trial-nejm/","published":"2024-11-07"},{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/08/01/inspannings-ecg-versus-ccta-bij-stabiele-angina-post-hoc-vergelijking/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/05/05/laag-attenuatie-plaque-op-ccta-voorspelt-mi-scot-heart-resultaten/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/01/29/coronaire-plaquekenmerken-en-adverse-uitkomsten-scot-heart/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","published":"2018-09-06"},{"url":"https://hartvaat.nl/2018/09/04/troponine-i-en-cardiovasculair-risico-bij-copd/","published":"2018-09-04"},{"url":"https://hartvaat.nl/2018/09/01/bloeddruk-hartfrequentie-en-mortaliteit-bij-copd-summit-trial/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/04/01/sekseverschillen-in-effectiviteit-van-orale-p2y12-remmers-meta-analyse/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/11/21/hoog-sensitief-troponine-i-en-uitkomsten-bij-verdenking-acs-jama-studie/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2017/10/01/inhalatiecorticosteroid-beta-2-agonist-en-cardiovasculaire-uitkomsten-bij-copd/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/12/27/hoog-sensitief-troponine-statinetherapie-en-risico-op-coronairlijden/","published":"2016-12-27"},{"url":"https://hartvaat.nl/2016/04/30/fluticason-vilanterol-en-overleving-bij-copd-met-verhoogd-cardiovasculair-risico/","published":"2016-04-30"},{"url":"https://hartvaat.nl/2016/04/19/ct-coronairangiografie-voor-het-sturen-van-beleid-bij-coronairlijden/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"emanuele-barbato","type":"person","url":"https://hartvaat.nl/mensen/emanuele-barbato/","name":"Emanuele Barbato","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":25,"articles":[{"url":"https://hartvaat.nl/2026/03/06/debat-preventieve-pci-bij-kwetsbare-plaques-als-standaardbehandeling/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","published":"2025-07-21"},{"url":"https://hartvaat.nl/2025/03/13/minoca-pathologische-bevindingen-bij-invasieve-beoordeling-meta-analyse/","published":"2025-03-13"},{"url":"https://hartvaat.nl/2025/02/18/lage-dosis-sirolimus-bdp-stent-versus-tweede-generatie-des-non-inferioriteit/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2024/09/01/periprocedureel-mi-na-pci-en-langetermijnmortaliteit-meta-analyse/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/12/20/ticagrelor-versus-prasugrel-en-coronaire-microcirculatie-bij-pci/","published":"2023-12-20"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2020/11/07/complete-revascularisatie-vermindert-cv-dood-bij-stemi-met-multivatenlijden-meta/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2019/10/24/genotype-geleide-p2y12-remmerkeuze-bij-primaire-pci-nejm-popular-genetics/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/04/01/ffr-verbetering-na-pci-en-uitkomsten-inclusief-symptoomverlichting/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/09/01/langetermijnimpact-van-cto-rekanalisatie-bij-stemi-patienten/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2018/01/30/kosteneffectiviteit-van-ffr-geleide-pci-bij-stabiele-coronairlijden/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2017/01/01/ontwikkeling-van-linkerventrikelhypertrofie-bij-behandelde-hypertensie-campania-/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/11/29/natuurlijk-beloop-van-coronaire-atherosclerose-met-ffr-prospectieve-studie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/10/11/pci-van-chronische-totale-occlusie-bij-stemi-met-multivatenlijden-explore-trial/","published":"2016-10-11"},{"url":"https://hartvaat.nl/2016/09/13/clopidogrel-versus-ticagrelor-bij-diabetes-na-pci-gerandomiseerde-trial/","published":"2016-09-13"},{"url":"https://hartvaat.nl/2016/07/12/prasugrel-versus-clopidogrel-en-coronaire-microvasculaire-functie-bij-electieve-/","published":"2016-07-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"javier-escaned","type":"person","url":"https://hartvaat.nl/mensen/javier-escaned/","name":"Javier Escaned","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":25,"articles":[{"url":"https://hartvaat.nl/2026/05/26/esc-consensusverklaring-over-microvasculaire-obstructie-en-no-reflow-na-stemi/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/12/29/functionele-en-morfologische-karakterisering-van-coronaire-atherosclerose/","published":"2025-12-29"},{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/01/01/ffr-versus-ifr-bij-coronaire-revascularisatie-vijfjaars-follow-up/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","published":"2024-11-09"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/thin-cap-fibroatheroom-voorspelt-events-bij-diabetes-met-normale-ffr-combine-oct/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/11/07/complete-revascularisatie-vermindert-cv-dood-bij-stemi-met-multivatenlijden-meta/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/01/temporele-veranderingen-in-coronaire-hemodynamiek-bij-niet-culprit-vaten-na-stem/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/01/29/microvasculaire-schade-bij-gerevasculariseerde-stemi-met-ticagrelor-versus-prasu/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/07/07/revascularisatie-versus-optimale-medicamenteuze-therapie-bij-cto-gerandomiseerde/","published":"2018-07-07"},{"url":"https://hartvaat.nl/2018/05/07/esc-eapci-taskforce-rapport-over-bioresorbeerbare-scaffolds-executive-summary/","published":"2018-05-07"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2017/01/15/linker-hartoorsluiting-versus-medicamenteuze-behandeling-bij-af-netwerkmeta-anal/","published":"2017-01-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jean-claude-tardif","type":"person","url":"https://hartvaat.nl/mensen/jean-claude-tardif/","name":"Jean-Claude Tardif","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":25,"articles":[{"url":"https://hartvaat.nl/2026/05/25/verve-102-eenmalige-base-editing-schakelt-pcsk9-blijvend-uit-fase-1/","published":"2026-05-25"},{"url":"https://hartvaat.nl/2026/01/13/enlicitide-orale-pcsk9-remmer-bij-heterozygote-fh-fase-3/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-vasculaire-preventie-meta-analyse-van-lange-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2024/04/23/lp-a-en-cv-risicoreductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2023/04/01/natriumzirconiumcyclosilicaat-bij-hyperkaliemie-en-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","published":"2022-08-02"},{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2021/11/01/af-last-en-qol-na-af-ablatie-cabana-substudie/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/16/lp-a-verlaging-bij-cardiovasculaire-ziekte-nejm/","published":"2020-01-16"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"},{"url":"https://hartvaat.nl/2019/12/01/gunstige-effecten-van-ivabradine-bij-hf-met-lage-ef-en-hartfrequentie-77-bpm/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/01/03/icosapent-ethyl-en-cardiovasculaire-uitkomsten-bij-hypertriglyceridemie-nejm-red/","published":"2019-01-03"},{"url":"https://hartvaat.nl/2018/02/01/lipoproteine-a-en-recidiverende-ischemische-events-na-acs-dal-outcomes-analyse/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/05/09/agressieve-bloeddrukcontrole-en-recidief-van-af-na-ablatie-gerandomiseerde-trial/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/04/20/ldl-reductievariabiliteit-en-antilichaamvorming-bij-bococizumab-nejm/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2016/12/06/dalcetrapib-wijzigt-de-relatie-tussen-hdl-cholesterol-en-crp/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/10/18/canakinumab-en-arteriele-effecten-bij-atherosclerose-met-diabetes-of-glucosetole/","published":"2016-10-18"},{"url":"https://hartvaat.nl/2016/01/26/p-selectine-antagonist-inclacumab-bij-coronaire-bypasschirurgie-select-cabg-tria/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karl-swedberg","type":"person","url":"https://hartvaat.nl/mensen/karl-swedberg/","name":"Karl Swedberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":25,"articles":[{"url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/08/01/candesartan-dosering-bij-mannen-versus-vrouwen-met-chronisch-hartfalen/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2024/06/25/raas-blokkade-bij-hartfalen-voordeel-onafhankelijk-van-etniciteit-jama-meta-anal/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2024/06/18/mra-bij-hartfalen-met-nierfunctiestoornissen-veiligheid-en-effectiviteit/","published":"2024-06-18"},{"url":"https://hartvaat.nl/2023/10/01/ivabradine-bij-hoogrisico-hartfalenpatienten-shift-analyse/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2019/12/01/gunstige-effecten-van-ivabradine-bij-hf-met-lage-ef-en-hartfrequentie-77-bpm/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2019/03/26/bnp-tijdens-sacubitril-valsartan-paradigm-hf/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2019/02/26/sacubitril-valsartan-en-biomarkers-van-extracellulaire-matrixregulatie-bij-hfref/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2019/01/08/hfref-differentiele-impact-op-mannen-en-vrouwen/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/12/01/number-needed-to-treat-met-arni-voor-preventie-van-cv-dood-of-hf-hospitalisatie/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/06/01/sacubitril-valsartan-en-fysieke-en-sociale-activiteitsbeperkingen-bij-hf-paradig/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/11/14/af-type-en-uitkomsten-bij-hfref/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/04/14/systolische-bloeddruk-en-werkzaamheid-van-sacubitril-valsartan-bij-chronisch-hfr/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/03/07/cva-risico-bij-chronisch-hartfalen-met-behouden-ef-zonder-af-charm-analyse/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2017/01/01/verminderd-hyperkaliemierisico-met-mra-door-sacubitril-valsartan-bij-hartfalen/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/12/06/prognostische-implicaties-van-nt-probnp-veranderingen-bij-hartfalen/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/11/29/bmi-en-nauwkeurigheid-van-nt-probnp-en-bnp-voor-diagnose-van-acuut-hartfalen/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/07/19/sacubitril-valsartan-en-30-daagse-heropname-na-hartfalenhospitalisatie/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/06/07/klinische-verslechtering-van-poliklinisch-behandeld-hartfalen-paradigm-hf-analys/","published":"2016-06-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kieran-f-docherty","type":"person","url":"https://hartvaat.nl/mensen/kieran-f-docherty/","name":"Kieran F Docherty","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":25,"articles":[{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2026/01/05/magnesium-en-uitkomsten-bij-hfref-galactic-hf-subanalyse/","published":"2026-01-05"},{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","published":"2022-09-03"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"neil-r-poulter","type":"person","url":"https://hartvaat.nl/mensen/neil-r-poulter/","name":"Neil R Poulter","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":25,"articles":[{"url":"https://hartvaat.nl/2025/07/28/ascot-legacy-atorvastatine-verlaagt-cv-events-over-20-jaar/","published":"2025-07-28"},{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","published":"2025-05-29"},{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2023/03/30/ablatie-versus-antiaritmica-voor-vermindering-van-ziekenhuisbezoeken-bij-af/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/03/01/korttermijn-bloeddrukmetingen-voorspellen-langetermijneffect-van-behandeling/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/11/01/antihypertensieve-combinaties-bij-afrikaanse-patienten-creole-secundaire-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/22/time-avonddosering-antihypertensiva-biedt-geen-voordeel-boven-ochtenddosering/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2020/06/01/2020-ish-mondiale-hypertensie-praktijkrichtlijnen/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/03/17/liraglutide-cv-uitkomsten-bij-diabetes-met-of-zonder-hartfalen-leader/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/06/20/vergelijking-van-duale-therapieen-voor-bloeddrukverlaging-bij-afrikaanse-afrikan/","published":"2019-06-20"},{"url":"https://hartvaat.nl/2019/01/01/acute-creatininestijging-bij-start-ace-remmer-en-effecten-van-voortzetting-analy/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-bij-diabetes-type-2-met-ckd-leader-renale-analyse/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-cv-uitkomsten-met-of-zonder-eerder-mi-leader/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/10/01/ochtend-versus-avonddosering-van-antihypertensiva-gerandomiseerde-crossover-tria/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/09/29/langetermijnmortaliteit-na-bloeddruk-en-lipidenverlaging-bij-hypertensie-ascot-l/","published":"2018-09-29"},{"url":"https://hartvaat.nl/2018/05/15/liraglutide-bij-diabetes-type-2-met-polyvasculaire-ziekte-leader-analyse/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2017/09/28/exenatide-eenmaal-per-week-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-ne/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/08/24/degludec-versus-glargine-bij-diabetes-type-2-nejm-devote-werkzaamheid-en-veiligh/","published":"2017-08-24"},{"url":"https://hartvaat.nl/2017/08/01/bloeddrukvariabiliteit-en-vasculaire-events-bij-diabetes-type-2/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/06/24/bijwerkingen-bij-niet-geblindeerde-versus-geblindeerde-statinetherapie-lancet-as/","published":"2017-06-24"},{"url":"https://hartvaat.nl/2016/11/22/plasma-lipidomiek-verbetert-cardiovasculaire-risicovoorspelling-bij-diabetes-typ/","published":"2016-11-22"},{"url":"https://hartvaat.nl/2016/11/07/ace-remmer-en-groeisnelheid-van-kleine-abdominale-aorta-aneurysmata-gerandomisee/","published":"2016-11-07"},{"url":"https://hartvaat.nl/2016/07/28/liraglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-leader-trial/","published":"2016-07-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-peter-libby","type":"person","url":"https://hartvaat.nl/mensen/dr-peter-libby/","name":"Peter Libby","title":"Brigham and Women's Hospital, Boston, VS","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/07/09/bempedoinezuur-versus-statines-vergelijking-van-cv-voordelen/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2020/02/01/il-1-remming-en-bloeddruk-hypertensie-en-residueel-inflammatoir-risico-cantos/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/03/05/canakinumab-ter-preventie-van-hartfalen-hospitalisatie-cantos-analyse/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2019/02/21/laaggedoseerd-methotrexaat-voor-preventie-van-atherosclerotische-events-nejm-cir/","published":"2019-02-21"},{"url":"https://hartvaat.nl/2017/11/21/bloeddrukeffecten-van-ibuprofen-naproxen-en-celecoxib-bij-artritis-precision-abp/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2017/10/21/canakinumab-en-longkankerincidentie-bij-atherosclerose-lancet-cantos-exploratief/","published":"2017-10-21"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"}],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/welkom-en-introductie/","title":"Welkom en introductie"},{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/keynote-lipiden-pathogenese-plaquemodulatie/","title":"Keynote: Lipiden bij hart- en vaatziekten — van pathogenese tot plaquemodulatie"},{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/lipoproteïne-a/","title":"Sessie 3: Lipoproteïne(a)"},{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/samenvatting-en-afsluiting/","title":"Samenvatting en afsluiting"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-s-sever","type":"person","url":"https://hartvaat.nl/mensen/peter-s-sever/","name":"Peter S Sever","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":25,"articles":[{"url":"https://hartvaat.nl/2026/01/13/effectiviteit-en-veiligheid-van-zeer-laag-bereikt-ldl-na-ischemisch-cva/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2025/07/28/ascot-legacy-atorvastatine-verlaagt-cv-events-over-20-jaar/","published":"2025-07-28"},{"url":"https://hartvaat.nl/2025/05/20/intensieve-ldl-verlaging-met-evolocumab-bij-auto-immuunziekten-rct/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2022/08/30/biomarkers-voorspellen-complexe-coronaire-revascularisatie-in-fourier/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2021/09/21/bijwerkingspatronen-in-crossover-trial-statine-placebo-geen-behandeling-statinwi/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/02/01/evolocumab-bij-metabool-syndroom-na-acs-fourier/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/11/26/n-of-1-trial-van-statine-placebo-of-geen-behandeling-voor-bijwerkingen-nejm-stat/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2020/11/21/ldl-verlaging-bij-ouderen-lancet-meta-analyse-werkzaamheid-en-veiligheid/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/02/25/genetische-risicoscore-voorspelt-voordeel-van-evolocumab-fourier/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2019/07/01/evolocumab-en-totale-cv-events-bij-cardiovasculaire-ziekte-fourier-analyse/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/18/evolocumab-bij-ckd-werkzaamheid-en-veiligheid-in-de-fourier-trial/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2019/02/01/spironolacton-en-collageenmetabolisme-biomarkers-bij-ongecontroleerde-hypertensi/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2019/01/01/interindividuele-variatie-in-ldl-verlaging-met-evolocumab-fourier-analyse/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/10/01/ochtend-versus-avonddosering-van-antihypertensiva-gerandomiseerde-crossover-tria/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/09/29/langetermijnmortaliteit-na-bloeddruk-en-lipidenverlaging-bij-hypertensie-ascot-l/","published":"2018-09-29"},{"url":"https://hartvaat.nl/2018/08/21/klinisch-voordeel-van-evolocumab-naar-ernst-van-coronairlijden-fourier/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/07/10/inflammatie-en-cholesterol-in-de-fourier-trial/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/12/01/evolocumab-bij-hoogrisicopatienten-met-laag-ldl-op-statine-fourier-subanalyse/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2017/08/17/cognitieve-functie-in-de-fourier-trial-met-evolocumab-nejm-ebbinghaus/","published":"2017-08-17"},{"url":"https://hartvaat.nl/2017/06/24/bijwerkingen-bij-niet-geblindeerde-versus-geblindeerde-statinetherapie-lancet-as/","published":"2017-06-24"},{"url":"https://hartvaat.nl/2017/05/04/evolocumab-en-klinische-uitkomsten-bij-cardiovasculaire-ziekte-nejm-fourier/","published":"2017-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-harriette-van-spall","type":"person","url":"https://hartvaat.nl/mensen/prof-harriette-van-spall/","name":"Prof. Harriette Van Spall","title":"Cardioloog, McMaster University, Hamilton, Canada","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":1,"articles":[{"url":"https://hartvaat.nl/2026/03/03/expertopinie-hierarchische-eindpunten-op-basis-van-verslechterend-hartfalen-voor/","published":"2026-03-03"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-switch-swedeheart-lbct/","title":"SWITCH SWEDEHEART: prasugrel versus ticagrelor, het gesprek"},{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-amundsen-lbct/","title":"AMUNDSEN: evolocumab vóór de PCI, het gesprek"},{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-presc1se-mi-lbct/","title":"PRESC1SE-MI: het 0/1-uuralgoritme, het gesprek"},{"url":"https://hartvaat.nl/video/hfa-2026-late-breaking-science/masterclass-globalising-hf-zannad-van-spall/","title":"Masterclass — Hartfalen-evidence wereldwijd inclusiever maken"},{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/champion-af-hartoorocclusie-late-breaker/","title":"CHAMPION-AF: Hartoorocclusie versus orale antistolling — resultaten en implicaties"},{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/alert-onderbehandeling-aortastenose-mitralisinsufficiëntie/","title":"ALERT: Onderbehandeling bij aortastenose en mitralisinsufficiëntie"},{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/pro-tavi-pci-bij-tavi-late-breaker/","title":"PRO-TAVI: Routinematige PCI bij TAVI — nodig of niet?"},{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/dig-rhd-digoxine-reumatische-hartziekte/","title":"Dig-RHD: Digoxine bij reumatische hartziekte"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefan-h-hohnloser","type":"person","url":"https://hartvaat.nl/mensen/stefan-h-hohnloser/","name":"Stefan H Hohnloser","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":25,"articles":[{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/03/28/athena-post-hoc-dronedaron-als-effectieve-vroege-ritmecontrole/","published":"2025-03-28"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","published":"2023-05-21"},{"url":"https://hartvaat.nl/2022/11/22/athena-subanalyse-dronedaron-effectief-ongeacht-leeftijd-en-geslacht-bij-af/","published":"2022-11-22"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/10/09/voorspellers-van-sinusritme-6-weken-na-af-cardioversie-x-vert/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2021/01/27/periprocedurele-antistolling-bij-eliminate-af-ononderbroken-edoxaban-versus-vka/","published":"2021-01-27"},{"url":"https://hartvaat.nl/2020/04/28/apixaban-versus-warfarine-bij-af-met-gevorderde-ckd/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2019/10/01/quadripolaire-versus-bipolaire-lv-leads-bij-crt-klinische-uitkomsten/","published":"2019-10-01"},{"url":"https://hartvaat.nl/2019/09/21/ononderbroken-edoxaban-versus-vka-bij-af-ablatie-eliminate-af/","published":"2019-09-21"},{"url":"https://hartvaat.nl/2019/07/01/hospitalisatieredenen-en-mortaliteitsrisico-bij-af-met-dabigatran-versus-warfari/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/01/heparinedosering-bij-ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-re/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/05/14/dabigatran-duale-therapie-met-ticagrelor-of-clopidogrel-na-pci-bij-af-re-dual-pc/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2018/05/14/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-meta-analyse/","published":"2018-05-14"},{"url":"https://hartvaat.nl/2018/03/13/digoxine-en-mortaliteit-bij-patienten-met-atriumfibrilleren/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","published":"2017-10-19"},{"url":"https://hartvaat.nl/2017/10/01/korte-dabigatran-onderbreking-voor-device-implantatie-re-ly-multicenterervaring/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/04/27/ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-nejm-re-circuit/","published":"2017-04-27"},{"url":"https://hartvaat.nl/2016/12/01/rivaroxaban-versus-vka-bij-periprocedurele-antistolling-rond-af-ablatie/","published":"2016-12-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/09/01/apixaban-5-mg-bij-af-met-hoge-leeftijd-laag-gewicht-of-hoog-creatinine-aristotle/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/07/01/apixaban-versus-warfarine-bij-af-in-relatie-tot-nierfunctie-aristotle-analyse/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"claes-held","type":"person","url":"https://hartvaat.nl/mensen/claes-held/","name":"Claes Held","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":24,"articles":[{"url":"https://hartvaat.nl/2024/11/02/bioadaptor-implantaat-versus-drug-eluting-stent-bij-stabiel-coronairlijden/","published":"2024-11-02"},{"url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","published":"2024-04-30"},{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/18/abyss-betablokkers-na-mi-met-behouden-ef-niet-nodig-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/04/11/heterogeniteit-in-bloeddrukrespons-op-antihypertensiva-jama-cross-over-rct/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2020/01/07/nsaid-s-en-oac-bij-af-aristotle-analyse/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"},{"url":"https://hartvaat.nl/2018/12/01/multipele-biomarkers-en-mortaliteitsrisico-na-acs-jama-cardiology/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/08/01/uitkomsten-bij-af-met-oac-bij-mitralis-of-aortakleplijden/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","published":"2018-02-07"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-bij-stabiel-coronairlijden-stability-inzic/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/04/01/niet-ernstige-bloedingen-met-apixaban-versus-warfarine-bij-af/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2017/03/14/afweging-myocardinfarct-versus-bloedingstype-en-mortaliteit-na-acs-tra-2p-timi-5/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","published":"2016-06-04"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"colin-berry","type":"person","url":"https://hartvaat.nl/mensen/colin-berry/","name":"Colin Berry","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":24,"articles":[{"url":"https://hartvaat.nl/2026/02/03/coronaire-vaatspasmen-bij-overlevenden-van-hartstilstand/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/12/29/functionele-en-morfologische-karakterisering-van-coronaire-atherosclerose/","published":"2025-12-29"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-vasculaire-preventie-meta-analyse-van-lange-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","published":"2025-01-25"},{"url":"https://hartvaat.nl/2024/07/12/nste-acs-na-cabg-meta-analyse-van-behandelstrategieen/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2024/03/12/rapid-nstemi-zeer-vroege-invasieve-strategie-bij-hoger-risico-nstemi/","published":"2024-03-12"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2022/08/30/ripcord-2-routinematige-ffr-meting-versus-conventionele-angiografie/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2021/12/01/post-stenting-ffr-versus-angiografie-voor-pci-optimalisatie-target-ffr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/05/01/pci-versus-medicamenteus-bij-angina-met-ffr-in-de-grijze-zone/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/03/31/laaggedoseerde-alteplase-bij-primaire-pci-naar-ischemietijd/","published":"2020-03-31"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","published":"2018-09-06"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/12/15/infarctgrootte-en-linkerkamerremodellering-na-preventieve-pci/","published":"2016-12-15"},{"url":"https://hartvaat.nl/2016/04/19/ct-coronairangiografie-voor-het-sturen-van-beleid-bij-coronairlijden/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-saibal-kar","type":"person","url":"https://hartvaat.nl/mensen/dr-saibal-kar/","name":"Dr. Saibal Kar","title":"Los Robles Regional Medical Center, VS","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/05/05/expanded-bij-73-verbetert-tricuspidalisinsufficientie-binnen-30-dagen-na-m-teer-/","published":"2026-06-26"},{"url":"https://hartvaat.nl/2026/03/28/champion-af-watchman-flx-non-inferieur-aan-noac-s-en-superieur-in-bloedingsreduc/","published":"2026-03-29"},{"url":"https://hartvaat.nl/2026/03/16/vroege-linkerventrikel-reverse-remodellering-na-mitralisklep-edge-to-edge-repara/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2025/06/10/triluminate-tweejaarsresultaten-transcatheter-tr-repair-duurzaam-effectief/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/05/18/triluminate-transcatheter-tricuspidaliskleprepair-bij-ernstige-tr-nejm/","published":"2023-05-18"},{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","published":"2022-11-15"},{"url":"https://hartvaat.nl/2022/05/01/nierdisfunctie-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2021/04/01/ero-lvedv-ratio-en-respons-op-mitraclip-jama-cardiology/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/05/05/gezondheidsstatus-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/12/17/echo-uitkomsten-na-mitraclip-bij-secundaire-mr-coapt-echocardiografisch/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/05/07/gezondheidsstatus-na-mitraclip-bij-hf-met-secundaire-mr-coapt/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"},{"url":"https://hartvaat.nl/2017/12/19/5-jaarsuitkomsten-na-linker-hartoorsluiting-prevail-en-protect-af/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/01/01/percutane-linker-hartoorsluiting-munchen-consensusdocument-over-definities-en-ei/","published":"2017-01-01"}],"videos":[{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/champion-af-hartoorocclusie-late-breaker/","title":"CHAMPION-AF: Hartoorocclusie versus orale antistolling — resultaten en implicaties"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frank-ruschitzka","type":"person","url":"https://hartvaat.nl/mensen/frank-ruschitzka/","name":"Frank Ruschitzka","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":24,"articles":[{"url":"https://hartvaat.nl/2026/05/05/vericiguat-en-sgc-stimulatoren-bij-hartfalen-werkingsmechanisme-en-plaats-na-vic/","published":"2026-06-26"},{"url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","published":"2023-06-09"},{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","published":"2022-09-29"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2018/06/01/geindividualiseerd-patiromer-doseringsregime-bij-hf-met-ckd-en-hyperkaliemie/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/03/27/crt-bij-hartfalen-met-smal-qrs-complex/","published":"2018-03-27"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/11/21/bloeddrukeffecten-van-ibuprofen-naproxen-en-celecoxib-bij-artritis-precision-abp/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2017/06/14/overschakelen-van-niet-selectieve-nsaid-s-naar-celecoxib-de-scot-trial/","published":"2017-06-14"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/03/07/lv-global-longitudinal-strain-en-prognose-bij-hartfalen-met-smal-qrs-en-crt/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"},{"url":"https://hartvaat.nl/2016/01/01/persisterende-echocardiografische-dyssynchronie-voorspelt-ongunstige-uitkomsten-/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mark-woodward","type":"person","url":"https://hartvaat.nl/mensen/mark-woodward/","name":"Mark Woodward","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":24,"articles":[{"url":"https://hartvaat.nl/2026/04/09/sekseverschillen-in-lipiden-en-lipoproteinen-en-het-cardiovasculaire-risico-uk-b/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/25/bloeddrukverlaging-beschermt-over-het-hele-spectrum-van-chronische-nierschade-la/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2026/03/24/systemische-inflammatie-en-recidief-na-een-af-gerelateerd-herseninfarct/","published":"2026-03-24"},{"url":"https://hartvaat.nl/2025/03/01/frailteit-en-antihypertensieve-behandeling-bij-ouderen-meta-analyse/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2023/11/01/sekseverschillen-in-effect-van-bloeddrukverlaging-ipd-meta-analyse/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/03/01/korttermijn-bloeddrukmetingen-voorspellen-langetermijneffect-van-behandeling/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/12/21/bloeddrukverlaging-en-dementiepreventie-ipd-meta-analyse/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/07/27/langetermijneffect-van-antihypertensiva-op-bloeddruk-meta-analyse-op-individueel/","published":"2022-07-27"},{"url":"https://hartvaat.nl/2021/09/01/albuminurietesting-bij-hypertensie-en-diabetes-ipd-meta-analyse/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/10/01/thuismonitoring-met-technologie-ondersteund-management-bij-chronisch-hf-gerandom/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/06/01/bloeddrukverlaging-naar-uitgangsdruk-en-cv-risico-bij-diabetes-type-2/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-bij-acs-in-resource-beperkte-ziekenhuizen-jama-cardiology-/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2019/01/01/acute-creatininestijging-bij-start-ace-remmer-en-effecten-van-voortzetting-analy/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2017/11/01/tijdsverloop-van-bloeddrukverandering-door-zoutreductie-en-dash-dieet/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/08/01/bloeddrukvariabiliteit-en-vasculaire-events-bij-diabetes-type-2/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"},{"url":"https://hartvaat.nl/2016/11/22/plasma-lipidomiek-verbetert-cardiovasculaire-risicovoorspelling-bij-diabetes-typ/","published":"2016-11-22"},{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","published":"2016-06-16"},{"url":"https://hartvaat.nl/2016/01/30/intensieve-bloeddrukverlaging-en-cardiovasculaire-en-renale-uitkomsten-systemati/","published":"2016-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-w-armstrong","type":"person","url":"https://hartvaat.nl/mensen/paul-w-armstrong/","name":"Paul W Armstrong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":24,"articles":[{"url":"https://hartvaat.nl/2025/12/01/geografische-variatie-in-hfref-patientkenmerken-en-behandeling/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/04/01/vericiguat-voordeel-geprojecteerd-op-paradigm-hf-en-dapa-hf-populaties/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2023/10/03/vericiguat-bij-hfref-is-kosteneffectief-victoria-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2023/08/29/stream-2-halve-dosis-tenecteplase-bij-ouderen-met-stemi/","published":"2023-08-29"},{"url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/11/01/invloed-van-acs-trials-buiten-de-primaire-hypothese-systematische-review/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2019/01/02/preventie-van-cardiogene-shock-na-acuut-mi/","published":"2019-01-02"},{"url":"https://hartvaat.nl/2017/11/01/hypertensiecontrole-bij-diabetes-met-recidiverende-cv-events-tecos-globale-resul/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/26/secundaire-cardiovasculaire-preventie-bij-diabetes-type-2-tecos-internationale-i/","published":"2017-09-26"},{"url":"https://hartvaat.nl/2017/08/01/voorspelling-van-bloedingsrisico-tijdens-dapt-na-acs/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/06/27/hospitalisatie-voor-nieuw-gediagnosticeerd-versus-verslechterend-chronisch-hartf/","published":"2017-06-27"},{"url":"https://hartvaat.nl/2017/03/14/afweging-myocardinfarct-versus-bloedingstype-en-mortaliteit-na-acs-tra-2p-timi-5/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/08/01/eerder-clopidogrelgebruik-en-uitkomsten-bij-conservatief-behandeld-acs/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"},{"url":"https://hartvaat.nl/2016/04/19/trends-in-behandeling-en-uitkomsten-bij-nste-acs-naar-leeftijd/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/04/01/ischemisch-risicogebied-en-reperfusiemethode-bij-stemi-klinische-implicaties/","published":"2016-04-01"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"},{"url":"https://hartvaat.nl/2016/03/01/cyp2c19-metaboliseerdersstatus-en-uitkomsten-bij-acs-prasugrel-versus-clopidogre/","published":"2016-03-01"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"},{"url":"https://hartvaat.nl/2016/01/21/neoplasiedetectie-bij-langdurige-dapt-met-prasugrel-versus-clopidogrel-triton-ti/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-van-der-meer","type":"person","url":"https://hartvaat.nl/mensen/peter-van-der-meer/","name":"Peter van der Meer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":24,"articles":[{"url":"https://hartvaat.nl/2026/05/10/decision-trial-digoxine-staken-bij-hartfalen-leidt-tot-zevenvoudige-stijging-in-/","published":"2026-06-25"},{"url":"https://hartvaat.nl/2026/05/10/decision-onttrekkingssubstudie-stoppen-van-digoxine-na-lange-behandeling-leidt-t/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/05/10/decision-lage-dosis-digoxine-mist-primair-eindpunt-bij-hf-m-ref-maar-suggereert-/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2026/03/03/spierstofwisseling-bij-hfpef-verminderde-oxidatieve-capaciteit-los-van-ijzergebr/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2023/07/20/ni006-antilichaam-voor-afbraak-van-cardiale-transthyretine-amyloid-nejm-fase-1/","published":"2023-07-20"},{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"takeshi-kimura","type":"person","url":"https://hartvaat.nl/mensen/takeshi-kimura/","name":"Takeshi Kimura","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":24,"articles":[{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","published":"2025-09-13"},{"url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/12/01/absorb-scaffold-5-jaarsresultaten-systematische-meta-analyse/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/05/14/dabigatran-duale-therapie-met-ticagrelor-of-clopidogrel-na-pci-bij-af-re-dual-pc/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/05/14/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-meta-analyse/","published":"2018-05-14"},{"url":"https://hartvaat.nl/2018/05/08/hoog-versus-laaggedoseerd-pitavastatine-bij-stabiel-coronairlijden-real-cad/","published":"2018-05-08"},{"url":"https://hartvaat.nl/2018/01/30/absorb-bioresorbeerbare-scaffold-3-jaarsresultaten-ipd-meta-analyse/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2017/12/12/implantatiechniek-en-uitkomsten-van-bioresorbeerbare-scaffolds-absorb-analyses/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","published":"2017-10-19"},{"url":"https://hartvaat.nl/2017/09/01/late-trombotische-events-na-bioresorbeerbare-scaffold-meta-analyse-van-gerandomi/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/08/19/absorb-bioresorbeerbare-scaffold-lancet-2-jaars-systematische-review-en-meta-ana/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2016/02/14/kortdurend-antiaritmica-na-katheterablatie-voor-atriumfibrilleren-east-af-trial/","published":"2016-02-14"},{"url":"https://hartvaat.nl/2016/02/06/bioresorbeerbare-versus-metallic-stents-meta-analyse-van-gerandomiseerde-trials/","published":"2016-02-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vlado-perkovic","type":"person","url":"https://hartvaat.nl/mensen/vlado-perkovic/","name":"Vlado Perkovic","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":24,"articles":[{"url":"https://hartvaat.nl/2026/06/19/vrouwen-met-ckd-krijgen-minder-vaak-ras-remmers-en-sglt2-remmers-dan-mannen/","published":"2026-08-10"},{"url":"https://hartvaat.nl/2026/02/27/sglt2-remmers-bij-ernstig-verminderde-nierfunctie-data-uit-credence/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2026/01/20/voorspelling-van-individuele-corticosteroidrespons-bij-iga-nefropathie-testing-t/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","published":"2025-03-24"},{"url":"https://hartvaat.nl/2024/11/26/glp-1-agonisten-alleen-en-met-sglt2-remmers-cv-renale-en-veiligheidsuitkomsten/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/10/22/flow-semaglutide-vermindert-hartfalen-bij-diabetes-en-ckd/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/07/11/flow-semaglutide-beschermt-nieren-bij-type-2-diabetes-en-ckd-nejm-gerelateerd/","published":"2024-07-11"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-niet-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/04/01/canagliflozine-naar-diureticagebruik-canvas-post-hoc-analyse/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"},{"url":"https://hartvaat.nl/2019/05/28/canagliflozine-en-hf-uitkomsten-bij-behouden-versus-verminderde-ef-canvas/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2019/01/01/acute-creatininestijging-bij-start-ace-remmer-en-effecten-van-voortzetting-analy/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/07/31/canagliflozine-en-hartfalen-bij-diabetes-type-2-canvas-programma/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/01/23/canagliflozine-voor-primaire-en-secundaire-cardiovasculaire-preventie-canvas/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/08/17/canagliflozine-en-cardiovasculaire-en-renale-events-bij-diabetes-type-2-nejm-can/","published":"2017-08-17"},{"url":"https://hartvaat.nl/2017/07/11/positieve-luchtwegdruk-en-cv-events-bij-slaapapneu-jama-meta-analyse/","published":"2017-07-11"},{"url":"https://hartvaat.nl/2016/01/30/intensieve-bloeddrukverlaging-en-cardiovasculaire-en-renale-uitkomsten-systemati/","published":"2016-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antoni-bayes-genis","type":"person","url":"https://hartvaat.nl/mensen/antoni-bayes-genis/","name":"Antoni Bayés-Genís","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":23,"articles":[{"url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2026/03/03/tien-jaar-real-world-sacubitril-valsartan-mortaliteitsreductie-bevestigd-maar-sl/","published":"2026-04-20"},{"url":"https://hartvaat.nl/2025/12/09/aspree-cardiale-stress-en-bloeddrukmanagement-bij-ouderen/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/11/14/nierfunctietrajecten-voor-en-na-hospitalisatie-voor-hfref/","published":"2025-11-14"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/01/colica-colchicine-bij-acuut-gedecompenseerd-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/01/betablokkerstaken-verbetert-inspanningscapaciteit-bij-hfpef/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/07/25/omega-3-biomarkers-en-incident-af-ipd-analyse/","published":"2023-07-25"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/11/23/betablokkerstaken-en-functionele-capaciteit-bij-hfpef/","published":"2021-11-23"},{"url":"https://hartvaat.nl/2019/12/17/uitgebreide-vasodilatatie-versus-standaardzorg-bij-acuut-hf-jama-galactic-hf-pil/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2018/04/14/sildenafil-bij-persisterende-pulmonale-hypertensie-na-klepchirurgie/","published":"2018-04-14"},{"url":"https://hartvaat.nl/2018/01/16/hoog-sensitief-troponine-t-bij-chronisch-hartfalen-individuele-patientdata-meta-/","published":"2018-01-16"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bernard-de-bruyne","type":"person","url":"https://hartvaat.nl/mensen/bernard-de-bruyne/","name":"Bernard De Bruyne","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":23,"articles":[{"url":"https://hartvaat.nl/2026/03/28/coronaire-autoregulatie-samenspel-van-epicardiale-en-microvasculaire-weerstand/","published":"2026-03-28"},{"url":"https://hartvaat.nl/2026/01/13/risicofactoren-en-plaquevolume-op-coronaire-ct-angiografie-lessen-uit-het-advanc/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2025/12/29/functionele-en-morfologische-karakterisering-van-coronaire-atherosclerose/","published":"2025-12-29"},{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2025/06/09/tino-stents-versus-des-bij-acs-ipd-meta-analyse/","published":"2025-06-09"},{"url":"https://hartvaat.nl/2025/06/01/ffr-geleide-pci-versus-cabg-bij-diffuus-coronairlijden/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/01/tino-gecoate-versus-everolimus-eluting-stents-bij-acs-tides-acs-vijfjaarsdata/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2022/08/30/ripcord-2-routinematige-ffr-meting-versus-conventionele-angiografie/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2019/09/24/asymptomatische-patienten-met-abnormale-ffr-medicamenteus-versus-pci/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2019/04/01/ffr-verbetering-na-pci-en-uitkomsten-inclusief-symptoomverlichting/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/10/16/hoge-coronaire-shear-stress-voorspelt-myocardinfarct/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2018/01/30/kosteneffectiviteit-van-ffr-geleide-pci-bij-stabiele-coronairlijden/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2016/11/29/natuurlijk-beloop-van-coronaire-atherosclerose-met-ffr-prospectieve-studie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/07/12/prasugrel-versus-clopidogrel-en-coronaire-microvasculaire-functie-bij-electieve-/","published":"2016-07-12"},{"url":"https://hartvaat.nl/2016/04/12/prognostische-waarde-van-residuele-coronairstenosen-na-functioneel-complete-reva/","published":"2016-04-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jan-h-cornel","type":"person","url":"https://hartvaat.nl/mensen/jan-h-cornel/","name":"Jan H Cornel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":23,"articles":[{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2021/08/31/colchicine-bij-chronisch-coronairlijden-met-versus-zonder-eerder-acs/","published":"2021-08-31"},{"url":"https://hartvaat.nl/2021/07/21/laaggedoseerd-colchicine-bij-coronairlijden-meta-analyse-van-gerandomiseerde-tri/","published":"2021-07-21"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/03/05/canakinumab-ter-preventie-van-hartfalen-hospitalisatie-cantos-analyse/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2017/09/26/secundaire-cardiovasculaire-preventie-bij-diabetes-type-2-tecos-internationale-i/","published":"2017-09-26"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/08/01/voorspelling-van-bloedingsrisico-tijdens-dapt-na-acs/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/09/27/intensieve-glucoseregulatie-bij-hyperglycemisch-acs-langetermijnfollow-up-biomar/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jung-min-ahn","type":"person","url":"https://hartvaat.nl/mensen/jung-min-ahn/","name":"Jung-Min Ahn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":23,"articles":[{"url":"https://hartvaat.nl/2026/03/06/debat-preventieve-pci-bij-kwetsbare-plaques-als-standaardbehandeling/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/12/05/edoxaban-bij-af-en-stabiel-coronairlijden-antitrombotische-monotherapie/","published":"2024-12-05"},{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","published":"2024-05-04"},{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/11/22/ees-versus-cabg-bij-meervatslijden-langetermijn-follow-up-van-rct-s/","published":"2022-11-22"},{"url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","published":"2022-09-08"},{"url":"https://hartvaat.nl/2022/04/19/externe-validatie-van-de-freedom-score-voor-pci-versus-cabg/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2020/10/31/syntax-score-ii-herontwikkeling-voor-gepersonaliseerde-revascularisatiebeslissin/","published":"2020-10-31"},{"url":"https://hartvaat.nl/2020/05/05/des-versus-cabg-bij-linker-hoofdstam-10-jaarsresultaten-excel-extended/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/12/03/klinisch-significante-bloedingen-met-ticagrelor-versus-clopidogrel-bij-koreaanse/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2018/02/13/richtlijngetrouwe-medicamenteuze-therapie-in-contemporaine-revascularisatietrial/","published":"2018-02-13"},{"url":"https://hartvaat.nl/2017/07/01/syntax-scores-en-uitkomsten-bij-diabetes-met-multivatenlijden-gepoolde-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2016/09/06/pci-versus-cabg-bij-onbeschermde-hoofdstamziekte-uitkomsten/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/04/19/statinebehandeling-en-plaquesamenstelling-dubbelblinde-gerandomiseerde-studie/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-b-leon","type":"person","url":"https://hartvaat.nl/mensen/martin-b-leon/","name":"Martin B Leon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":23,"articles":[{"url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/02/18/lage-dosis-sirolimus-bdp-stent-versus-tweede-generatie-des-non-inferioriteit/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2024/07/16/revascularisatiestrategieen-na-mi-systematische-review-en-meta-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/03/05/gelijktijdige-laa-occlusie-en-tavr-bij-af-haalbaarheid/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","published":"2023-11-23"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2022/10/22/symplicity-htn-3-langetermijn-follow-up-renale-denervatie-bij-resistente-hyperte/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/07/15/ultradunne-versus-conventionele-2e-generatie-des-langetermijn-meta-analyse/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/09/07/des-versus-cabg-bij-hoofdstamlijden-mortaliteits-meta-analyse/","published":"2020-09-07"},{"url":"https://hartvaat.nl/2020/04/14/langetermijnuitkomsten-bij-vrouwen-en-mannen-na-pci/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-ballonexpandeerbare-klep-bij-laagrisicopatienten-nejm-partner-3/","published":"2019-05-02"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"},{"url":"https://hartvaat.nl/2017/10/03/ridaforolimus-versus-zotarolimus-eluting-stents-gerandomiseerde-primaire-resulta/","published":"2017-10-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sripal-bangalore","type":"person","url":"https://hartvaat.nl/mensen/sripal-bangalore/","name":"Sripal Bangalore","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":23,"articles":[{"url":"https://hartvaat.nl/2025/09/23/pci-versus-cabg-en-gezondheidsstatus-bij-stabiel-coronairlijden/","published":"2025-09-23"},{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/01/07/optimale-strategie-voor-complete-revascularisatie-bij-stemi-met-meervatslijden-m/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/12/05/intravasculaire-beeldvorming-versus-functionele-versus-angiografische-pci-begele/","published":"2023-12-05"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/01/timing-van-antihypertensiva-meta-analyse-van-rct-s-bevestigt-flexibiliteit/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/01/18/2021-acc-aha-scai-richtlijn-voor-coronaire-revascularisatie-executive-summary/","published":"2022-01-18"},{"url":"https://hartvaat.nl/2021/07/15/ultradunne-versus-conventionele-2e-generatie-des-langetermijn-meta-analyse/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/09/01/routine-revascularisatie-versus-medicamenteus-bij-stabiel-coronairlijden-meta-an/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/23/gezondheidsstatus-na-invasieve-of-conservatieve-zorg-bij-coronairlijden-met-gevo/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2020/01/28/orale-antistolling-bij-af-op-langdurige-hemodialyse/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2018/11/13/ultradunne-versus-dikkere-drug-eluting-stents-systematische-review/","published":"2018-11-13"},{"url":"https://hartvaat.nl/2017/04/06/gewichtsfluctuaties-en-cardiovasculaire-uitkomsten-bij-coronairlijden-nejm/","published":"2017-04-06"},{"url":"https://hartvaat.nl/2016/06/01/pci-bij-insulinebehandelde-versus-niet-insulinebehandelde-diabetes-freedom-trial/","published":"2016-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"valentin-fuster","type":"person","url":"https://hartvaat.nl/mensen/valentin-fuster/","name":"Valentín Fuster","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":23,"articles":[{"url":"https://hartvaat.nl/2026/02/11/reboot-betablokkers-na-mi-sekseverschillen/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","published":"2025-09-13"},{"url":"https://hartvaat.nl/2025/04/10/dapagliflozine-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2025-04-10"},{"url":"https://hartvaat.nl/2022/09/15/polypill-voor-secundaire-cardiovasculaire-preventie-secure-trial-in-nejm/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2022/04/19/externe-validatie-van-de-freedom-score-voor-pci-versus-cabg/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/04/27/groepsmedisch-consult-en-microfinanciering-bij-diabetes-hypertensie-in-kenia/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-bij-niet-diabetische-hfref-emperor-reduced-subanalyse/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/10/31/syntax-score-ii-herontwikkeling-voor-gepersonaliseerde-revascularisatiebeslissin/","published":"2020-10-31"},{"url":"https://hartvaat.nl/2020/02/18/ticagrelor-met-of-zonder-aspirine-na-pci-twilight-plaatjessubstudie/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/10/22/individualisering-van-revascularisatiestrategie-bij-diabetes-met-multivatenlijde/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/15/community-health-workers-verbeteren-koppeling-met-hypertensiezorg-in-kenia/","published":"2019-10-15"},{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","published":"2019-02-19"},{"url":"https://hartvaat.nl/2018/12/11/syntax-score-bij-diabetes-met-coronaire-revascularisatie-freedom/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2018/02/13/richtlijngetrouwe-medicamenteuze-therapie-in-contemporaine-revascularisatietrial/","published":"2018-02-13"},{"url":"https://hartvaat.nl/2017/05/30/polygene-risicoscore-en-relatief-voordeel-van-statinetherapie-primaire-preventie/","published":"2017-05-30"},{"url":"https://hartvaat.nl/2017/01/17/dapt-versus-aspirine-monotherapie-bij-diabetes-met-multivatenlijden-na-cabg-free/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/05/10/timing-van-metoprolol-bij-stemi-effect-op-infarctgrootte-en-ventrikelfunctie/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/02/09/peergroepinterventie-voor-cardiovasculaire-risicofactoren-de-fifty-fifty-trial/","published":"2016-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adnan-kastrati","type":"person","url":"https://hartvaat.nl/mensen/adnan-kastrati/","name":"Adnan Kastrati","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":22,"articles":[{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/04/17/in-stent-restenose-tienjaarsuitkomsten-plain-balloon-vs-dcb-vs-des-isar-desire-3/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2021/11/01/antiplaatjestherapie-bij-mi-zonder-obstructief-coronairlijden-minoca/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2019/01/15/10-jaarsuitkomsten-van-drie-limus-eluting-stents-coating-vergelijking/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/07/bioresorbeerbare-scaffold-versus-ees-bij-stabiel-coronairlijden-prospectieve-tri/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/05/07/esc-eapci-taskforce-rapport-over-bioresorbeerbare-scaffolds-executive-summary/","published":"2018-05-07"},{"url":"https://hartvaat.nl/2018/01/07/2017-esc-richtlijn-voor-stemi-management/","published":"2018-01-07"},{"url":"https://hartvaat.nl/2017/11/07/stentontwerp-en-dapt-duur-effect-op-ischemie-en-bloedingen-netwerkmeta-analyse/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2017/10/01/pci-versus-cabg-bij-linker-hoofdstamstenose-jama-cardiology-systematische-review/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/08/19/optimale-timing-van-invasieve-strategie-bij-nste-acs-lancet-meta-analyse/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2016/02/06/bioresorbeerbare-versus-metallic-stents-meta-analyse-van-gerandomiseerde-trials/","published":"2016-02-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"elliott-m-antman","type":"person","url":"https://hartvaat.nl/mensen/elliott-m-antman/","name":"Elliott M Antman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":22,"articles":[{"url":"https://hartvaat.nl/2026/02/24/systemische-embolieen-bij-af-ipd-mega-meta-analyse-van-71-683-patienten/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2024/09/01/eldercare-af-subanalyse-dosisreductie-edoxaban-bij-80-jarigen-met-af/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2021/03/09/halve-versus-volle-dosis-edoxaban-bij-af-gerandomiseerde-vergelijking/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2020/03/17/non-culprit-mi-na-pci-bij-acs/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/12/17/uitkomsten-van-vrouwen-versus-mannen-na-nste-acs/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/09/01/edoxaban-versus-warfarine-naar-gemiddelde-bloeddruk-bij-af-met-hypertensie/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/16/edoxaban-versus-warfarine-bij-af-met-leverziekte-engage-af-timi-48/","published":"2019-07-16"},{"url":"https://hartvaat.nl/2019/05/14/bmi-en-uitkomsten-bij-af-behandeld-met-edoxaban-of-warfarine-engage-af-timi-48/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/05/14/edoxaban-bij-aziatische-af-patienten-concentraties-en-anti-xa-activiteit/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/02/05/abc-scores-voor-cva-en-bloedingsrisico-bij-af-prestatieverbetering/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2019/02/01/edoxaban-en-implanteerbare-cardiale-devices-engage-af-timi-48/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/10/30/endogene-factor-xa-activiteit-en-edoxaban-farmacodynamische-marker-en-klinische-/","published":"2018-10-30"},{"url":"https://hartvaat.nl/2018/09/25/edoxaban-versus-warfarine-bij-latijns-amerikaanse-af-patienten-engage-af-timi-48/","published":"2018-09-25"},{"url":"https://hartvaat.nl/2017/03/21/kleplijden-en-edoxaban-versus-warfarine-bij-af-engage-af-timi-48/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2017/03/21/nieuwe-risicovoorspellingsscore-bij-af-voor-netto-klinisch-resultaat-engage-af-t/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/09/13/edoxaban-versus-warfarine-bij-af-patienten-met-valrisico-engage-af-timi-48-analy/","published":"2016-09-13"},{"url":"https://hartvaat.nl/2016/08/02/omega-3-vetzuren-en-linkerkamerremodellering-na-acuut-mi-omega-remodel-trial/","published":"2016-08-02"},{"url":"https://hartvaat.nl/2016/07/05/nierfunctie-en-uitkomsten-met-edoxaban-in-de-engage-af-timi-48-trial/","published":"2016-07-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gianluca-campo","type":"person","url":"https://hartvaat.nl/mensen/gianluca-campo/","name":"Gianluca Campo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":22,"articles":[{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2025/11/11/ct-angiografie-of-standaardzorg-na-pci-van-de-linker-hoofdstam/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/09/11/multidomein-revalidatie-bij-ouderen-na-mi-gerandomiseerde-trial-nejm/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","published":"2024-11-09"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2022/10/18/asundexian-factor-xia-remmer-na-acs-fase-2-dosisfindingsstudie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2020/11/07/complete-revascularisatie-vermindert-cv-dood-bij-stemi-met-multivatenlijden-meta/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/11/01/inspanningsinterventie-verbetert-qol-na-mi-bij-ouderen-gerandomiseerde-trial/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/08/04/cangrelor-tirofiban-en-prasugrel-bij-stemi-primaire-resultaten/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2019/10/12/edoxaban-versus-vka-gebaseerd-antitrombotisch-regime-na-stenting-bij-af-lancet-e/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2016/01/23/everolimus-eluting-stent-versus-bare-metal-stent-bij-stemi-5-jaarsresultaten-exa/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giuseppe-m-c-rosano","type":"person","url":"https://hartvaat.nl/mensen/giuseppe-m-c-rosano/","name":"Giuseppe M C Rosano","title":"Cardioloog, San Raffaele, Rome","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/02/01/finerenon-en-lvh-bij-ckd-en-diabetes/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2024/08/01/coronaire-microvasculaire-disfunctie-bij-hfpef-meta-analyse/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2023/10/01/ivabradine-bij-hoogrisico-hartfalenpatienten-shift-analyse/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2023/04/01/intraveneus-ijzer-bij-hartfalen-meta-analyse-op-studieniveau/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2022/06/14/euroheart-datastandaarden-voor-hartfalenregistraties/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/06/20/hartfrequentie-en-ritme-en-het-voordeel-van-betablokkers-bij-hartfalen/","published":"2017-06-20"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-heart-failure-guidelines/","title":"De nieuwe ESC-hartfalenrichtlijn: de kernpunten"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jonathan-p-piccini","type":"person","url":"https://hartvaat.nl/mensen/jonathan-p-piccini/","name":"Jonathan P Piccini","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":22,"articles":[{"url":"https://hartvaat.nl/2026/04/07/zorgpaden-na-nieuw-vastgesteld-atriumfibrilleren-rol-van-de-elektrofysioloog-en-/","published":"2026-07-18"},{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/03/28/athena-post-hoc-dronedaron-als-effectieve-vroege-ritmecontrole/","published":"2025-03-28"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","published":"2022-08-16"},{"url":"https://hartvaat.nl/2022/04/09/asundexian-factor-xia-remmer-versus-apixaban-bij-af-lancet-pacific-af/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/06/01/continue-cardiale-monitoring-versus-standaardzorg-bij-cryptogeen-cva-jama/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-medicamenteus-bij-af-en-kwaliteit-van-leven-jama-cabana-q/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/12/01/ras-etniciteit-en-oac-gebruik-bij-af-orbit-af/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2017/01/01/axafa-afnet-5-apixaban-versus-vka-bij-af-ablatie-studieprotocol/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/12/20/off-label-doac-dosering-en-ongunstige-uitkomsten-orbit-af-ii-register/","published":"2016-12-20"},{"url":"https://hartvaat.nl/2016/08/01/hospitalisaties-bij-atriumfibrilleren-analyse-uit-rocket-af/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/07/05/verslechterende-nierfunctie-en-uitkomsten-met-rivaroxaban-versus-warfarine-rocke/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/07/01/natief-kleplijden-bij-af-patienten-op-warfarine-of-rivaroxaban/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/01/26/polyfarmacie-en-werkzaamheid-van-rivaroxaban-versus-warfarine-bij-atriumfibrille/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lisette-okkels-jensen","type":"person","url":"https://hartvaat.nl/mensen/lisette-okkels-jensen/","name":"Lisette Okkels Jensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":22,"articles":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/11/01/ifr-versus-ffr-en-vijfjaarsmortaliteit-swedeheart-en-define-flair/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/10/20/box-bloeddrukdoelen-bij-comateuze-overlevenden-van-hartstilstand/","published":"2022-10-20"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","published":"2019-10-19"},{"url":"https://hartvaat.nl/2018/12/04/ffr-versus-angiografie-geleide-cabg/","published":"2018-12-04"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"},{"url":"https://hartvaat.nl/2016/02/23/everolimus-versus-sirolimus-eluting-stents-5-jaarsresultaten-sort-out-iv/","published":"2016-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matthew-t-roe","type":"person","url":"https://hartvaat.nl/mensen/matthew-t-roe/","name":"Matthew T Roe","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":22,"articles":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2020/07/14/vergelijking-van-orale-p2y12-remmers-bij-acs-netwerkmeta-analyse-van-52-816-pati/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2020/05/19/pav-en-vte-na-acs-rol-van-lp-a-en-modificatie-door-alirocumab/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"},{"url":"https://hartvaat.nl/2017/08/01/voorspelling-van-bloedingsrisico-tijdens-dapt-na-acs/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2016/08/01/eerder-clopidogrelgebruik-en-uitkomsten-bij-conservatief-behandeld-acs/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"},{"url":"https://hartvaat.nl/2016/03/01/cyp2c19-metaboliseerdersstatus-en-uitkomsten-bij-acs-prasugrel-versus-clopidogre/","published":"2016-03-01"},{"url":"https://hartvaat.nl/2016/01/21/neoplasiedetectie-bij-langdurige-dapt-met-prasugrel-versus-clopidogrel-triton-ti/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michelle-l-o-donoghue","type":"person","url":"https://hartvaat.nl/mensen/michelle-l-o-donoghue/","name":"Michelle L O'Donoghue","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":22,"articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/03/28/lp-a-verhoogt-risico-op-veneuze-trombo-embolie-bij-premenopauzale-vrouwen-en-hor/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2026/01/13/effectiviteit-en-veiligheid-van-zeer-laag-bereikt-ldl-na-ischemisch-cva/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/02/11/langetermijn-evolocumab-bij-ouderen-effectiviteit-en-veiligheid/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/07/25/omega-3-biomarkers-en-incident-af-ipd-analyse/","published":"2023-07-25"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/11/17/olpasiran-sirna-verlaagt-lipoproteine-a-spectaculair-in-fase-2-trial/","published":"2022-11-17"},{"url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","published":"2022-10-11"},{"url":"https://hartvaat.nl/2020/08/11/veiligheid-van-aspirinestaken-met-p2y12-achtergrond-na-pci-meta-analyse/","published":"2020-08-11"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2019/12/17/uitkomsten-van-vrouwen-versus-mannen-na-nste-acs/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/10/15/triglyceridenverlaging-en-cv-risicoreductie-over-therapeutische-klassen-meta-ana/","published":"2019-10-15"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2018/06/01/fgf-23-en-recidiverende-cv-events-na-acs/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/01/19/werkzaamheid-en-veiligheid-van-cangrelor-bij-vrouwen-versus-mannen-tijdens-pci-c/","published":"2016-01-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"orly-vardeny","type":"person","url":"https://hartvaat.nl/mensen/orly-vardeny/","name":"Orly Vardeny","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":22,"articles":[{"url":"https://hartvaat.nl/2026/05/26/state-of-the-art-mra-s-bij-hartfalen-en-nierziekte-over-alle-ejectiefracties/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2026/05/11/finearts-hf-subanalyse-virale-luchtweginfecties-triggeren-hartfalen-verslechteri/","published":"2026-05-12"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/06/01/invested-griepvaccin-immuunrespons-bij-hoog-risico-cv-patienten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2017/01/01/verminderd-hyperkaliemierisico-met-mra-door-sacubitril-valsartan-bij-hartfalen/","published":"2017-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sotirios-tsimikas","type":"person","url":"https://hartvaat.nl/mensen/sotirios-tsimikas/","name":"Sotirios Tsimikas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":22,"articles":[{"url":"https://hartvaat.nl/2026/02/23/analytische-validatie-van-een-directe-lp-a-cholesterolbepaling/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/02/21/aspirine-lipoproteine-a-en-aortaklepstenose-de-mesa-studie/","published":"2026-02-21"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","published":"2025-10-02"},{"url":"https://hartvaat.nl/2025/01/28/lp-a-en-ldl-cholesterol-onafhankelijke-cv-risicopaden/","published":"2025-01-28"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-hypertriglyceridemie-en-hoog-cv-risico-nejm/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-familiaire-chylomicronemie-nejm-fase-3/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2022/03/22/pelacarsen-op-lp-a-cholesterol-en-gecorrigeerd-ldl-cholesterol/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2021/09/21/pcsk9-remming-en-geoxideerde-fosfolipiden/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/10/21/vupanorsen-angptl3-antisense-en-triglyceriden-ehj/","published":"2020-10-21"},{"url":"https://hartvaat.nl/2020/06/21/statinetherapie-verhoogt-lipoproteine-a-spiegels/","published":"2020-06-21"},{"url":"https://hartvaat.nl/2020/02/25/polygene-risicoscore-en-voordeel-van-alirocumab-bij-coronairlijden-odyssey-outco/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2020/01/16/lp-a-verlaging-bij-cardiovasculaire-ziekte-nejm/","published":"2020-01-16"},{"url":"https://hartvaat.nl/2019/09/01/galnac-geconjugeerd-antisense-tegen-apoc3-triglyceriden-en-atherogene-lipoprotei/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/08/volanesorsen-en-triglyceriden-bij-familiair-chylomicronemiesyndroom-nejm/","published":"2019-08-08"},{"url":"https://hartvaat.nl/2018/10/13/lp-a-baseline-en-on-statin-voor-cv-eventvoorspelling-lancet-ipd-meta-analyse/","published":"2018-10-13"},{"url":"https://hartvaat.nl/2017/07/20/angptl3-antisense-oligonucleotiden-cardiovasculaire-en-metabole-effecten-nejm/","published":"2017-07-20"},{"url":"https://hartvaat.nl/2017/01/17/geoxideerde-fosfolipiden-op-apob-100-en-recidiverende-ischemische-events-na-cva/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steffen-desch","type":"person","url":"https://hartvaat.nl/mensen/steffen-desch/","name":"Steffen Desch","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":22,"articles":[{"url":"https://hartvaat.nl/2026/03/03/4-eiwitmodel-voor-cardiogene-shock-prognose-danger-substudie/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2025/12/01/scai-shockklassen-en-prognose-bij-ami-cardiogene-shock-danger-substudie/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/12/16/gp-iib-iiia-remmers-bij-acuut-mi-en-microvasculaire-obstructie-meta-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2023/03/28/culprit-interventie-bij-cardiogene-shock-met-hartstilstand/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2021/01/19/residuele-syntax-score-bij-cardiogene-shock/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/04/21/morfine-met-metoclopramide-en-ticagrelor-plaatjesremming-bij-acuut-mi/","published":"2020-04-21"},{"url":"https://hartvaat.nl/2020/03/01/slagvolumeveranderingen-na-renale-denervatie-cardiale-mri-inzichten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/08/01/renale-denervatie-bij-geisoleerde-systolische-hypertensie-vergelijking-van-kathe/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/01/29/drie-armen-vergelijkende-renale-denervatie-radiosound-htn/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2019/01/22/milde-hypothermie-bij-cardiogene-shock-complicerend-mi/","published":"2019-01-22"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/12/14/mechanische-ondersteuning-bij-cardiogene-shock-systematische-review-en-meta-anal/","published":"2017-12-14"},{"url":"https://hartvaat.nl/2017/08/19/optimale-timing-van-invasieve-strategie-bij-nste-acs-lancet-meta-analyse/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2017/08/01/des-versus-bms-bij-acuut-mi-met-cardiogene-shock/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/04/18/risicostratificatie-bij-cardiogene-shock-na-acuut-myocardinfarct/","published":"2017-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a-michael-lincoff","type":"person","url":"https://hartvaat.nl/mensen/a-michael-lincoff/","name":"A Michael Lincoff","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/08/18/semaglutide-verlaagt-hscrp-en-ontstekingsactiviteit-bij-ascvd-patienten-met-over/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","published":"2024-08-24"},{"url":"https://hartvaat.nl/2024/07/09/bempedoinezuur-versus-statines-vergelijking-van-cv-voordelen/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/03/01/clear-outcomes-bempedoinezuur-vermindert-totale-cv-events-bij-statine-intolerant/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/12/14/select-semaglutide-vermindert-cv-events-bij-obesitas-zonder-diabetes-nejm/","published":"2023-12-14"},{"url":"https://hartvaat.nl/2023/07/13/traverse-testosteronsubstitutie-cardiovasculair-veilig-bij-hypogonadisme/","published":"2023-07-13"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/10/01/crp-op-lp-a-geassocieerd-cv-risico-bij-optimaal-behandelde-hoogrisicopatienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/04/01/initieel-en-serieel-crp-en-cv-events-en-dood-na-acs-jama-cardiology/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2017/11/21/bloeddrukeffecten-van-ibuprofen-naproxen-en-celecoxib-bij-artritis-precision-abp/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"},{"url":"https://hartvaat.nl/2016/01/21/langdurige-duale-antiplaatjestherapie-bij-patienten-met-eerder-myocardinfarct-me/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andreas-goette","type":"person","url":"https://hartvaat.nl/mensen/andreas-goette/","name":"Andreas Goette","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2024/03/26/doac-s-bij-device-gedetecteerd-af-meta-analyse-noah-afnet-6-en-artesia/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","published":"2022-09-13"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2020/12/14/edoxaban-bij-af-met-pci-naar-acute-versus-chronische-coronaire-presentatie-entru/","published":"2020-12-14"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/01/optimaal-antitrombotisch-regime-bij-af-na-pci-jama-cardiology-netwerkmeta-analys/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/12/07/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-veiligheid-en-werk/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2019/11/01/determinanten-van-linkeratriumtrombi-bij-geplande-cardioversie-ensure-af/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/12/edoxaban-versus-vka-gebaseerd-antitrombotisch-regime-na-stenting-bij-af-lancet-e/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2018/12/01/edoxaban-verhoogt-behandeltevredenheid-en-vermindert-zorggebruik-engage-af-timi-/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2017/05/01/data-mining-van-de-antipaf-afnet-2-trial-angiotensine-ii-antagonisten-en-paroxys/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2016/10/22/edoxaban-versus-enoxaparine-warfarine-bij-cardioversie-van-af-ensure-af-trial/","published":"2016-10-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andreas-m-zeiher","type":"person","url":"https://hartvaat.nl/mensen/andreas-m-zeiher/","name":"Andreas M Zeiher","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/02/04/aanhoudende-ldl-verlaging-met-alirocumab-in-odyssey-outcomes/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"},{"url":"https://hartvaat.nl/2016/06/01/herhaalde-intracoronaire-beenmergcelinjectie-bij-hartfalen-resultaten-uit-een-re/","published":"2016-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"basil-s-lewis","type":"person","url":"https://hartvaat.nl/mensen/basil-s-lewis/","name":"Basil S Lewis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/05/01/vroegtijdig-permanent-staken-van-apixaban-of-warfarine-bij-af/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2018/08/21/klinisch-voordeel-van-evolocumab-naar-ernst-van-coronairlijden-fourier/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/08/01/uitkomsten-bij-af-met-oac-bij-mitralis-of-aortakleplijden/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2017/12/01/evolocumab-bij-hoogrisicopatienten-met-laag-ldl-op-statine-fourier-subanalyse/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2016/07/26/atherotrombotische-risicostratificatie-en-vorapaxar-bij-stabiel-ischemisch-hartl/","published":"2016-07-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bryan-williams","type":"person","url":"https://hartvaat.nl/mensen/bryan-williams/","name":"Bryan Williams","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/02/10/nieuwe-medicamenteuze-therapieen-voor-hypertensie/","published":"2026-03-14"},{"url":"https://hartvaat.nl/2026/03/07/baxdrostat-verlaagt-bloeddruk-significant-bij-resistente-hypertensie/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/03/07/bax24-baxdrostat-en-ambulante-bloeddruk-bij-resistente-hypertensie/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2025/10/09/baxdrostat-bij-ongecontroleerde-en-resistente-hypertensie-effectiviteit-en-veili/","published":"2025-10-09"},{"url":"https://hartvaat.nl/2025/06/17/spironolacton-versus-amiloride-bij-resistente-hypertensie-gerandomiseerde-trial/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2022/10/22/time-avonddosering-antihypertensiva-biedt-geen-voordeel-boven-ochtenddosering/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2022/09/20/harmonisatie-van-acc-aha-en-esc-esh-bloeddrukrichtlijnen/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2021/08/01/polsgolfcalibratie-en-implicaties-voor-bloeddrukmeting-meta-analyse/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2020/06/01/2020-ish-mondiale-hypertensie-praktijkrichtlijnen/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2019/10/26/patiromer-voor-spironolactongebruik-bij-resistente-hypertensie-met-ckd-lancet-am/","published":"2019-10-26"},{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/01/bloeddrukverlaging-naar-uitgangsdruk-en-cv-risico-bij-diabetes-type-2/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/01/01/acute-creatininestijging-bij-start-ace-remmer-en-effecten-van-voortzetting-analy/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/09/01/bereikte-diastolische-bloeddruk-en-polsdruk-bij-streef-sbp-en-cv-uitkomsten-bij-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/08/01/nauwkeurigheid-van-manchetbloeddrukmeting-systematische-review-en-meta-analyse/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/08/01/bloeddrukvariabiliteit-en-vasculaire-events-bij-diabetes-type-2/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/06/03/bereikte-bloeddruk-en-cv-uitkomsten-bij-hoogrisicopatienten-ontarget-transcend/","published":"2017-06-03"},{"url":"https://hartvaat.nl/2017/03/01/sacubitril-valsartan-versus-olmesartan-op-centrale-hemodynamiek-bij-ouderen-para/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/11/22/plasma-lipidomiek-verbetert-cardiovasculaire-risicovoorspelling-bij-diabetes-typ/","published":"2016-11-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-p-taggart","type":"person","url":"https://hartvaat.nl/mensen/david-p-taggart/","name":"David P Taggart","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/01/05/leeftijd-en-10-jaarsuitkomsten-na-cabg-art-trial/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/06/postoperatief-af-en-langetermijn-cva-risico-na-geisoleerde-cabg/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/07/14/radiale-arterie-versus-vena-saphena-graft-bij-cabg-jama-langetermijn-meta-analys/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2019/08/13/off-pump-versus-on-pump-cabg-bij-hoofdstamcoronairlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/04/23/hedendaagse-uitkomsten-na-cabg-voor-hoofdstamlijden/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2019/01/31/bilaterale-versus-enkele-mammaria-interna-grafts-na-10-jaar-nejm-art/","published":"2019-01-31"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/07/31/bnp-bij-linker-hoofdstamrevascularisatie-excel-analyse/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2018/02/13/richtlijngetrouwe-medicamenteuze-therapie-in-contemporaine-revascularisatietrial/","published":"2018-02-13"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"},{"url":"https://hartvaat.nl/2017/08/01/radiale-arterie-graft-als-aanvulling-op-mammaria-interna-grafts-bij-cabg/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/03/14/drie-arteriele-grafts-verbeteren-langetermijnoverleving-meta-analyse-van-propens/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/12/29/bilaterale-versus-enkelvoudige-a-mammaria-interna-grafts-nejm-art-trial/","published":"2016-12-29"},{"url":"https://hartvaat.nl/2016/12/15/off-pump-versus-on-pump-cabg-5-jaarsresultaten-nejm-coronary-trial/","published":"2016-12-15"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-clara-saldarriaga","type":"person","url":"https://hartvaat.nl/mensen/dr-clara-saldarriaga/","name":"Dr. Clara Saldarriaga","title":"Hoogleraar Cardiologie, Universidad de Antioquia, Medellín, Colombia","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/05/off-label-dosering-van-sacubitril-valsartan-wijdverspreid-in-de-praktijk/","published":"2026-07-30"},{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2022/04/09/natriumreductie-100-mmol-bij-hartfalen-lancet-sodium-hf/","published":"2022-04-09"}],"videos":[{"url":"https://hartvaat.nl/video/sglt2-initiatie-hartfalen-opname/samenvatting-en-kernpunten/","title":"Samenvatting en kernboodschappen"},{"url":"https://hartvaat.nl/video/sglt2-initiatie-hartfalen-opname/context-en-ziektelast/","title":"Context en ziektelast"},{"url":"https://hartvaat.nl/video/sglt2-initiatie-hartfalen-opname/rationale-voor-de-trial/","title":"Rationale voor de studie"},{"url":"https://hartvaat.nl/video/sglt2-initiatie-hartfalen-opname/trialresultaten/","title":"Trialresultaten"},{"url":"https://hartvaat.nl/video/sglt2-initiatie-hartfalen-opname/klinische-implicaties/","title":"Klinische implicaties"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"duk-woo-park","type":"person","url":"https://hartvaat.nl/mensen/duk-woo-park/","name":"Duk-Woo Park","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/03/06/debat-preventieve-pci-bij-kwetsbare-plaques-als-standaardbehandeling/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/01/01/antistolling-alleen-of-met-plaatjesremming-bij-coronairlijden-meta-analyse/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2026/03/12/off-label-onderdosering-edoxaban-bij-af-en-systemische-embolieen/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/12/05/edoxaban-bij-af-en-stabiel-coronairlijden-antitrombotische-monotherapie/","published":"2024-12-05"},{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","published":"2024-05-04"},{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/11/22/ees-versus-cabg-bij-meervatslijden-langetermijn-follow-up-van-rct-s/","published":"2022-11-22"},{"url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","published":"2022-09-08"},{"url":"https://hartvaat.nl/2022/04/19/externe-validatie-van-de-freedom-score-voor-pci-versus-cabg/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2020/10/31/syntax-score-ii-herontwikkeling-voor-gepersonaliseerde-revascularisatiebeslissin/","published":"2020-10-31"},{"url":"https://hartvaat.nl/2020/05/05/des-versus-cabg-bij-linker-hoofdstam-10-jaarsresultaten-excel-extended/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/12/03/klinisch-significante-bloedingen-met-ticagrelor-versus-clopidogrel-bij-koreaanse/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2016/04/19/statinebehandeling-en-plaquesamenstelling-dubbelblinde-gerandomiseerde-studie/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eileen-o-meara","type":"person","url":"https://hartvaat.nl/mensen/eileen-o-meara/","name":"Eileen O'Meara","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2023/09/14/heart-fid-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-nejm/","published":"2023-09-14"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/03/10/routine-versus-selectieve-cardiale-mri-bij-niet-ischemisch-hf-outsmart-hf/","published":"2020-03-10"},{"url":"https://hartvaat.nl/2019/12/10/echocardiografische-kenmerken-bij-hfpef/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2019/12/01/gunstige-effecten-van-ivabradine-bij-hf-met-lage-ef-en-hartfrequentie-77-bpm/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/02/26/sacubitril-valsartan-en-biomarkers-van-extracellulaire-matrixregulatie-bij-hfref/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/10/01/natriuretische-peptiden-en-cardiovasculaire-prognose-bij-hfpef-topcat/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2016/02/01/invloed-van-ejectiefractie-op-uitkomsten-van-spironolacton-bij-hfpef/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eric-j-velazquez","type":"person","url":"https://hartvaat.nl/mensen/eric-j-velazquez/","name":"Eric J Velazquez","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/02/01/transform-hf-torsemide-versus-furosemide-bij-nieuw-vs-chronisch-hartfalen/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/10/21/prompt-ahf-epd-alerts-verbeteren-hartfalenmedicatie-bij-ontslag/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/11/transform-hf-torsemide-versus-furosemide-geen-verschil-in-symptomen/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/07/04/sacubitril-valsartan-bij-hfmref-hfpef-met-verslechterend-hartfalen/","published":"2023-07-04"},{"url":"https://hartvaat.nl/2023/01/17/transform-hf-torsemide-biedt-geen-overlevingsvoordeel-boven-furosemide/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/06/07/elektronische-alerts-verbeteren-hartfalenbehandeling-in-de-polikliniek/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2021/08/01/gdf-15-en-liraglutide-behandeling-bij-hf-patienten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2020/09/01/arni-naar-hf-voorgeschiedenis-en-raas-antagonistgebruik/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/02/01/arni-initiatie-na-acuut-gedecompenseerd-hf-pioneer-hf-open-label-extensie/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/10/21/cv-biomarkers-bij-acuut-gedecompenseerd-hf-met-sacubitril-valsartan-pioneer-hf/","published":"2019-10-21"},{"url":"https://hartvaat.nl/2019/10/15/community-health-workers-verbeteren-koppeling-met-hypertensiezorg-in-kenia/","published":"2019-10-15"},{"url":"https://hartvaat.nl/2019/05/07/sacubitril-valsartan-of-enalapril-bij-acuut-gedecompenseerd-hf-pioneer-hf-klinis/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/02/07/angiotensine-neprilysineremming-bij-acuut-gedecompenseerd-hf-nejm-pioneer-hf/","published":"2019-02-07"},{"url":"https://hartvaat.nl/2018/12/01/mitraclip-plus-medicamenteus-versus-medicamenteus-alleen-bij-hf-met-mr-meta-anal/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/12/01/liraglutide-en-gewicht-bij-gevorderd-hfref-fight-trial-inzichten/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/02/20/sekseverschillen-bij-ischemisch-hartfalen-na-cabg-stich-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/03/21/plotse-hartdood-bij-ischemisch-hartfalen-na-cabg-stich-resultaten/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/11/01/tienjaarsuitkomsten-na-cabg-naar-leeftijd-bij-hartfalen-met-lv-systolische-disfu/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/21/coronaire-bypasschirurgie-bij-ischemische-cardiomyopathie-nejm-stich-trial/","published":"2016-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"goran-stankovic","type":"person","url":"https://hartvaat.nl/mensen/goran-stankovic/","name":"Goran Stanković","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/03/04/stapsgewijze-provisionale-versus-systematische-dualstent-bij-ware-linker-hoofdst/","published":"2025-03-04"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/10/01/ebc-hoofdstam-stentstudie-provisional-versus-systematisch-dubbel-stenten/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","published":"2019-10-19"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2017/08/19/optimale-timing-van-invasieve-strategie-bij-nste-acs-lancet-meta-analyse/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2017/01/10/trombusaspiratie-bij-stemi-individuele-patientdata-meta-analyse/","published":"2017-01-10"},{"url":"https://hartvaat.nl/2016/06/21/myocardiale-blush-en-microvasculaire-reperfusie-na-handmatige-trombectomie-bij-s/","published":"2016-06-21"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ian-ford","type":"person","url":"https://hartvaat.nl/mensen/ian-ford/","name":"Ian Ford","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","published":"2024-04-21"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/10/01/ivabradine-bij-hoogrisico-hartfalenpatienten-shift-analyse/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"},{"url":"https://hartvaat.nl/2022/10/22/time-avonddosering-antihypertensiva-biedt-geen-voordeel-boven-ochtenddosering/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2022/10/08/all-heart-allopurinol-verbetert-cv-uitkomsten-niet-bij-ischemische-hartziekte/","published":"2022-10-08"},{"url":"https://hartvaat.nl/2020/09/19/trimetazidine-na-pci-lancet-atpci-gerandomiseerde-trial/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2020/03/31/laaggedoseerde-alteplase-bij-primaire-pci-naar-ischemietijd/","published":"2020-03-31"},{"url":"https://hartvaat.nl/2019/12/01/gunstige-effecten-van-ivabradine-bij-hf-met-lage-ef-en-hartfrequentie-77-bpm/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/11/27/metabolome-consequenties-van-pcsk9-remming-versus-statinetherapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2018/03/27/crt-bij-hartfalen-met-smal-qrs-complex/","published":"2018-03-27"},{"url":"https://hartvaat.nl/2017/11/14/ldl-verlaging-voor-primaire-preventie-bij-mannen-met-primaire-ldl-verhoging/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/06/14/overschakelen-van-niet-selectieve-nsaid-s-naar-celecoxib-de-scot-trial/","published":"2017-06-14"},{"url":"https://hartvaat.nl/2017/05/30/polygene-risicoscore-en-relatief-voordeel-van-statinetherapie-primaire-preventie/","published":"2017-05-30"},{"url":"https://hartvaat.nl/2017/03/07/lv-global-longitudinal-strain-en-prognose-bij-hartfalen-met-smal-qrs-en-crt/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2016/12/27/hoog-sensitief-troponine-statinetherapie-en-risico-op-coronairlijden/","published":"2016-12-27"},{"url":"https://hartvaat.nl/2016/01/01/persisterende-echocardiografische-dyssynchronie-voorspelt-ongunstige-uitkomsten-/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"james-p-howard","type":"person","url":"https://hartvaat.nl/mensen/james-p-howard/","name":"James P Howard","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/02/14/tricorder-ai-stethoscoop-voor-triple-cv-ziektedetectie/","published":"2026-02-14"},{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/16/revascularisatiestrategieen-na-mi-systematische-review-en-meta-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/06/11/remote-beoordeling-na-acs-gerandomiseerde-trial/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2023/03/30/upgrade-van-rv-pacemaker-naar-crt-of-geleidingssysteempacing-meta-analyse/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/02/16/catheterablatie-verbetert-cv-uitkomsten-bij-af-en-hartfalen-meta-analyse-van-rct/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/19/coronaire-flowreserve-en-cardiovasculaire-uitkomsten-meta-analyse/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/09/21/bijwerkingspatronen-in-crossover-trial-statine-placebo-geen-behandeling-statinwi/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/07/15/ultradunne-versus-conventionele-2e-generatie-des-langetermijn-meta-analyse/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2020/11/26/n-of-1-trial-van-statine-placebo-of-geen-behandeling-voor-bijwerkingen-nejm-stat/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2020/09/07/des-versus-cabg-bij-hoofdstamlijden-mortaliteits-meta-analyse/","published":"2020-09-07"},{"url":"https://hartvaat.nl/2019/08/01/optimale-laesieset-bij-persisterend-af-ablatie-meta-regressie/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johann-bauersachs","type":"person","url":"https://hartvaat.nl/mensen/johann-bauersachs/","name":"Johann Bauersachs","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/05/10/hf-revert-antisense-mirna-remmer-cdr132l-mist-primair-eindpunt-na-infarct-met-ve/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/03/06/veroudering-en-myocarddisfunctie-het-hart-jong-houden/","published":"2026-03-26"},{"url":"https://hartvaat.nl/2026/02/28/hartfalen-bij-ouderen-van-epidemiologie-tot-behandeling/","published":"2026-03-06"},{"url":"https://hartvaat.nl/2026/02/23/verhoogd-activine-a-bij-peripartum-cardiomyopathie-en-tijdens-lv-herstel/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/25/digitoxine-bij-hfref-gerandomiseerde-trial-nejm/","published":"2025-09-25"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/rv-disfunctie-voorspelt-langetermijnherstel-bij-de-novo-hfref-prolong-ii/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/08/20/tadalafil-bij-gecombineerde-post-en-precapillaire-ph-en-hfpef/","published":"2024-08-20"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2021/01/07/antisense-tegen-microrna-132-bij-hartfalen-fase-1b-resultaten/","published":"2021-01-07"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2019/10/21/digoxine-en-mortaliteit-gerandomiseerd-versus-observationeel-in-de-dig-trial/","published":"2019-10-21"},{"url":"https://hartvaat.nl/2018/09/22/telemedische-interventie-bij-hartfalen-lancet-tim-hf2/","published":"2018-09-22"},{"url":"https://hartvaat.nl/2017/10/14/intracoronaire-beenmergceltransfer-na-mi-de-boost-2-gerandomiseerde-trial/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-r-teerlink","type":"person","url":"https://hartvaat.nl/mensen/john-r-teerlink/","name":"John R Teerlink","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/01/05/magnesium-en-uitkomsten-bij-hfref-galactic-hf-subanalyse/","published":"2026-01-05"},{"url":"https://hartvaat.nl/2024/09/24/2024-acc-beslispad-klinische-beoordeling-en-trajectmanagement-bij-hfpef/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2019/12/01/hepatorenale-disfunctie-identificeert-hoogrisico-acuut-hf-relax-ahf/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2019/04/01/icd-mortaliteit-naar-hartfalenetiologie-propensity-matched-analyse/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/10/01/linkeratriumvolume-en-cv-uitkomsten-bij-systolisch-hf-antitromboticaeffect/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/08/07/trv027-biased-ligand-van-de-angiotensine-ii-receptor-bij-acuut-hartfalen-gerando/","published":"2017-08-07"},{"url":"https://hartvaat.nl/2017/06/27/hospitalisatie-voor-nieuw-gediagnosticeerd-versus-verslechterend-chronisch-hartf/","published":"2017-06-27"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/12/10/omecamtiv-mecarbil-bij-chronisch-hartfalen-lancet-cosmic-hf-fase-2-trial/","published":"2016-12-10"},{"url":"https://hartvaat.nl/2016/03/29/omecamtiv-mecarbil-bij-acuut-hartfalen-de-atomic-ahf-studie/","published":"2016-03-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"keith-g-oldroyd","type":"person","url":"https://hartvaat.nl/mensen/keith-g-oldroyd/","name":"Keith G Oldroyd","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/post-stenting-ffr-versus-angiografie-voor-pci-optimalisatie-target-ffr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/01/pci-versus-medicamenteus-bij-angina-met-ffr-in-de-grijze-zone/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/03/31/laaggedoseerde-alteplase-bij-primaire-pci-naar-ischemietijd/","published":"2020-03-31"},{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","published":"2020-01-18"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2016/12/15/infarctgrootte-en-linkerkamerremodellering-na-preventieve-pci/","published":"2016-12-15"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matthew-j-price","type":"person","url":"https://hartvaat.nl/mensen/matthew-j-price/","name":"Matthew J Price","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/05/05/expanded-bij-73-verbetert-tricuspidalisinsufficientie-binnen-30-dagen-na-m-teer-/","published":"2026-06-26"},{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2025/06/10/triluminate-tweejaarsresultaten-transcatheter-tr-repair-duurzaam-effectief/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/01/splanchnische-zenuwablatie-bij-hfpef-endovasculaire-benadering/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2023/08/02/peri-device-lekkage-bij-laa-occluders-mechanismen-en-voorspellers/","published":"2023-08-02"},{"url":"https://hartvaat.nl/2023/05/18/triluminate-transcatheter-tricuspidaliskleprepair-bij-ernstige-tr-nejm/","published":"2023-05-18"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2018/12/07/laesiecomplexiteit-en-periprocedurele-events-bij-potente-iv-antiplaatjestherapie/","published":"2018-12-07"},{"url":"https://hartvaat.nl/2018/07/31/antitrombotische-therapie-bij-af-met-oac-na-pci-aha-scientific-statement/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2017/12/19/5-jaarsuitkomsten-na-linker-hartoorsluiting-prevail-en-protect-af/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/02/01/cangrelor-versus-gpiib-iiia-remmers-ischemie-en-bloedingsrisico-s-vergeleken/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/01/17/cangrelor-met-en-zonder-gpiib-iiia-remmers-bij-pci/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/11/29/presentatie-buiten-kantoortijden-versus-tijdens-kantoortijden-bij-stemi-champion/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/09/06/consistente-reductie-in-periprocedureel-mi-met-cangrelor-champion-analyses/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/04/07/cangrelor-en-toegangsplaats-effect-op-ischemische-en-bloedingsevents-champion-ph/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/01/19/werkzaamheid-en-veiligheid-van-cangrelor-bij-vrouwen-versus-mannen-tijdens-pci-c/","published":"2016-01-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michiel-rienstra","type":"person","url":"https://hartvaat.nl/mensen/michiel-rienstra/","name":"Michiel Rienstra","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/05/28/atriumfibrilleren-en-hartfalen-versterken-elkaar-en-verhogen-sterfte-aanzienlijk/","published":"2026-07-28"},{"url":"https://hartvaat.nl/2026/05/10/decision-trial-digoxine-staken-bij-hartfalen-leidt-tot-zevenvoudige-stijging-in-/","published":"2026-06-25"},{"url":"https://hartvaat.nl/2026/02/03/aanbesteding-van-cardiale-implanteerbare-devices-in-europa-waarde-of-kosten/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/03/28/geinhaleerde-flecainide-voor-cardioversie-van-recent-onset-af-lancet/","published":"2025-03-28"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2024/08/21/pa-drukmonitoring-bij-chronisch-hartfalen-effecten-over-klinische-subgroepen/","published":"2024-08-21"},{"url":"https://hartvaat.nl/2023/11/10/rate-control-bij-af-calciumantagonisten-versus-betablokkers/","published":"2023-11-10"},{"url":"https://hartvaat.nl/2023/06/24/monitor-hf-pa-drukmonitoring-bij-hartfalen-effectief-in-europa-lancet-rct/","published":"2023-06-24"},{"url":"https://hartvaat.nl/2022/07/15/race-3-langetermijnresultaten-gerichte-behandeling-bij-vroeg-persisterend-af-en-/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2022/05/21/bariatrische-chirurgie-en-cardiovasculaire-ziekte-meta-analyse/","published":"2022-05-21"},{"url":"https://hartvaat.nl/2022/03/02/frequentiecontrolemiddelen-verschillen-in-preventie-van-af-progressie/","published":"2022-03-02"},{"url":"https://hartvaat.nl/2021/12/07/av-junctieablatie-plus-crt-bij-permanent-af-met-smal-qrs-apaf-crt-mortaliteitsan/","published":"2021-12-07"},{"url":"https://hartvaat.nl/2021/09/08/antiaritmica-bij-vroeg-persisterend-af-met-hf-race-3/","published":"2021-09-08"},{"url":"https://hartvaat.nl/2020/07/01/subklinische-atherosclerose-en-incident-af-meta-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2020/05/01/predictiemodellen-voor-af-in-de-community-meta-analyse/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/02/01/verpleegkundig-geleide-versus-standaard-af-zorg/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/04/18/vroege-of-uitgestelde-cardioversie-bij-recent-onset-af-nejm-race-7-acwas/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2019/04/01/upstream-therapie-verbetert-qol-bij-persisterend-af-arrest-af/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/08/21/behandeling-van-onderliggende-aandoeningen-verbetert-sinusritme-na-af-arrest-af/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2017/02/21/genetische-obesitas-en-risico-op-atriumfibrilleren-mendeliaanse-randomisatie/","published":"2017-02-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicholas-l-mills","type":"person","url":"https://hartvaat.nl/mensen/nicholas-l-mills/","name":"Nicholas L Mills","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/04/08/vision-postoperatief-atriumfibrilleren-na-hartchirurgie-verhoogt-sterfte-na-een-/","published":"2026-07-15"},{"url":"https://hartvaat.nl/2025/11/11/risicostratificatie-met-hoog-sensitief-troponine-op-de-seh-veiligheidsanalyse/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","published":"2025-01-25"},{"url":"https://hartvaat.nl/2025/01/21/evolved-vroege-interventie-bij-asymptomatische-ernstige-aortastenose-met-myocard/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2022/11/01/arteriele-stijfheid-en-endotheeldysfunctie-bij-anca-geassocieerde-vasculitis/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/01/13/risicofactoren-voor-type-1-en-type-2-mi/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2021/07/08/grace-2-0-score-bij-type-1-en-type-2-mi/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2020/08/01/inspannings-ecg-versus-ccta-bij-stabiele-angina-post-hoc-vergelijking/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/05/05/laag-attenuatie-plaque-op-ccta-voorspelt-mi-scot-heart-resultaten/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/08/01/endothelinereceptorantagonisme-verbetert-lipidenprofielen-en-verlaagt-pcsk9-bij-/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","published":"2018-09-06"},{"url":"https://hartvaat.nl/2018/09/04/troponine-i-en-cardiovasculair-risico-bij-copd/","published":"2018-09-04"},{"url":"https://hartvaat.nl/2018/04/01/sekseverschillen-in-effectiviteit-van-orale-p2y12-remmers-meta-analyse/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/11/21/hoog-sensitief-troponine-i-en-uitkomsten-bij-verdenking-acs-jama-studie/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2016/12/27/hoog-sensitief-troponine-statinetherapie-en-risico-op-coronairlijden/","published":"2016-12-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"otavio-berwanger","type":"person","url":"https://hartvaat.nl/mensen/otavio-berwanger/","name":"Otávio Berwanger","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2025/08/30/bloeddrukverlagende-effectiviteit-van-antihypertensiva-en-combinaties-uitgebreid/","published":"2025-08-30"},{"url":"https://hartvaat.nl/2024/09/03/augustus-4-weg-vergelijking-antitrombotische-strategieen-bij-af-na-acs-pci/","published":"2024-09-03"},{"url":"https://hartvaat.nl/2024/02/13/bariatrische-chirurgie-en-bloeddruk-na-5-jaar-gerandomiseerde-trial/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/11/01/vip-acs-dubbele-dosis-griepvaccinatie-na-acs-verbetert-uitkomsten-niet/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2020/11/26/rivaroxaban-bij-af-met-bioprothese-mitralisklep-nejm-river/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-en-evidence-based-prescriptie-bij-hoog-cv-risico-jama-card/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2019/03/01/bariatrische-chirurgie-versus-medicamenteus-beleid-op-24-uurs-ambulante-bloeddru/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/11/01/timing-van-atorvastatine-oplaaddosis-voor-pci-bij-acs-jama-cardiology/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/06/09/dabigatran-bij-myocardschade-na-niet-cardiale-chirurgie-lancet-manage-trial/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/04/03/oplaaddosis-atorvastatine-voor-pci-jama-gerandomiseerde-trial/","published":"2018-04-03"},{"url":"https://hartvaat.nl/2018/03/13/bariatrische-chirurgie-bij-obese-patienten-met-hypertensie-gateway-gerandomiseer/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2017/10/14/multifacet-interventie-voor-oac-gebruik-bij-af-lancet-impact-af/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2016/01/07/preoperatief-statinegebruik-en-cardiovasculaire-complicaties-bij-niet-cardiale-c/","published":"2016-01-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philippe-genereux","type":"person","url":"https://hartvaat.nl/mensen/philippe-genereux/","name":"Philippe Généreux","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/04/12/orbitale-atherectomie-versus-ballonangioplastie-voor-des-bij-ernstig-verkalkte-l/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","published":"2023-11-23"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-ballonexpandeerbare-klep-bij-laagrisicopatienten-nejm-partner-3/","published":"2019-05-02"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/12/07/laesiecomplexiteit-en-periprocedurele-events-bij-potente-iv-antiplaatjestherapie/","published":"2018-12-07"},{"url":"https://hartvaat.nl/2018/10/27/absorb-iv-bioresorbeerbare-scaffold-30-daags-en-1-jaarsresultaten/","published":"2018-10-27"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/07/07/orbusneich-combo-stent-japan-usa-harmonee-gerandomiseerde-multicenter-trial/","published":"2018-07-07"},{"url":"https://hartvaat.nl/2017/10/10/dagelijks-ischemie-en-bloedingsrisico-na-primaire-pci-voor-stemi/","published":"2017-10-10"},{"url":"https://hartvaat.nl/2017/10/03/ridaforolimus-versus-zotarolimus-eluting-stents-gerandomiseerde-primaire-resulta/","published":"2017-10-03"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2016/12/20/bloedingen-voor-coronairangiografie-bij-nste-acs/","published":"2016-12-20"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"},{"url":"https://hartvaat.nl/2016/11/26/oct-versus-ivus-versus-angiografie-bij-coronaire-stentimplantatie-lancet-ilumien/","published":"2016-11-26"},{"url":"https://hartvaat.nl/2016/04/07/cangrelor-en-toegangsplaats-effect-op-ischemische-en-bloedingsevents-champion-ph/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/01/09/ranolazine-bij-incomplete-revascularisatie-na-pci-de-river-pci-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-byeong-keuk-kim","type":"person","url":"https://hartvaat.nl/mensen/prof-byeong-keuk-kim/","name":"Prof. Byeong-Keuk Kim","title":"Cardioloog, Severance Hospital, Yonsei University, Seoul","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","published":"2023-04-04"},{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"},{"url":"https://hartvaat.nl/2020/06/16/ticagrelor-monotherapie-versus-dapt-op-bloedingen-en-cv-events-bij-acs-jama-tico/","published":"2020-06-16"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-a-close-hotline/","title":"A-CLOSE: clopidogrel of verlengde DAPT na hoogrisico-PCI"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vera-a-bittner","type":"person","url":"https://hartvaat.nl/mensen/vera-a-bittner/","name":"Vera A Bittner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/05/26/odyssey-outcomes-post-hoc-hscrp-en-il-6-zijn-complementaire-prognostische-marker/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","published":"2021-08-03"},{"url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/05/19/pav-en-vte-na-acs-rol-van-lp-a-en-modificatie-door-alirocumab/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/02/04/aanhoudende-ldl-verlaging-met-alirocumab-in-odyssey-outcomes/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wolfgang-koenig","type":"person","url":"https://hartvaat.nl/mensen/wolfgang-koenig/","name":"Wolfgang Koenig","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":21,"articles":[{"url":"https://hartvaat.nl/2026/03/02/barrieres-bij-implementatie-van-lipidenverlagende-therapie-in-de-praktijk/","published":"2026-03-26"},{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-vasculaire-preventie-meta-analyse-van-lange-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/12/21/orion-11-inclisiran-verlaagt-ldl-effectief-bij-primaire-preventie/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2022/10/14/dal-gene-farmacogenetica-geleide-dalcetrapib-na-acs/","published":"2022-10-14"},{"url":"https://hartvaat.nl/2021/05/01/mcp-1-en-cardiovasculaire-mortaliteit-populatie-gebaseerde-meta-analyse/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-bij-heterozygote-familiaire-hypercholesterolemie-nejm-orion-9/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-fase-3-bij-verhoogd-ldl-nejm-orion-10-en-orion-11/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2020/04/01/biomarkers-bij-hf-met-centrale-slaapapneu-serve-hf/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2018/10/23/evolocumab-en-coronaire-plaquesamenstelling-glagov-beeldvorming/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/09/01/hdl-mimeticum-met-recombinant-apoa-i-milano-en-coronairlijden-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/04/20/ldl-reductievariabiliteit-en-antilichaamvorming-bij-bococizumab-nejm/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","published":"2016-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bernard-zinman","type":"person","url":"https://hartvaat.nl/mensen/bernard-zinman/","name":"Bernard Zinman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":20,"articles":[{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2020/01/07/hypoglykemie-cv-uitkomsten-en-empagliflozine-empa-reg-outcome/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/11/19/empagliflozine-en-lv-massa-bij-diabetes-type-2-met-coronairlijden-empa-heart/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/08/01/empagliflozine-voorkomt-progressie-van-ckd-empa-reg-outcome-renale-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"},{"url":"https://hartvaat.nl/2019/06/04/microvasculaire-ziekte-en-cv-events-bij-diabetes-type-2/","published":"2019-06-04"},{"url":"https://hartvaat.nl/2019/03/12/empagliflozine-vermindert-mortaliteit-en-hf-hospitalisatie-over-het-cv-risicospe/","published":"2019-03-12"},{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-cv-uitkomsten-met-of-zonder-eerder-mi-leader/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/05/15/liraglutide-bij-diabetes-type-2-met-polyvasculaire-ziekte-leader-analyse/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2018/02/01/empagliflozine-en-cv-dood-en-hf-hospitalisatie-over-het-hf-spectrum-empa-reg-out/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2018/01/23/empagliflozine-bij-diabetes-type-2-met-perifeer-vaatlijden-empa-reg-outcome/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2018/01/09/empagliflozine-bij-diabetes-type-2-met-cardiovasculaire-ziekte-en-ckd-empa-reg-o/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/09/28/exenatide-eenmaal-per-week-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-ne/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/08/24/degludec-versus-glargine-bij-diabetes-type-2-nejm-devote-werkzaamheid-en-veiligh/","published":"2017-08-24"},{"url":"https://hartvaat.nl/2016/07/28/empagliflozine-en-progressie-van-nierziekte-bij-diabetes-type-2-nejm-empa-reg-re/","published":"2016-07-28"},{"url":"https://hartvaat.nl/2016/07/28/liraglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-leader-trial/","published":"2016-07-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"burkert-pieske","type":"person","url":"https://hartvaat.nl/mensen/burkert-pieske/","name":"Burkert Pieske","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":20,"articles":[{"url":"https://hartvaat.nl/2025/06/01/trainingseffect-op-diastolische-functie-bij-hfpef/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2023/11/01/beta3-lvh-mirabegron-bij-linkerventrikel-hypertrofie-fase-2b-rct/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2022/12/01/vericiguat-en-nt-probnp-bij-hfref-victoria-subanalyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/10/01/verschillende-trainingsvormen-en-hdl-functie-bij-hfpef-optimex-substudie/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/11/16/sacubitril-valsartan-versus-standaardtherapie-op-nt-probnp-en-inspanningscapacit/","published":"2021-11-16"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/02/09/hiit-matig-continu-of-richtlijnadvies-en-piek-vo2-bij-hfref-jama-smartex-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/06/01/economische-impact-van-hfpef-aldo-dhf-inzichten/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2020/04/14/systolische-bloeddruk-bij-hfpef-behandeld-met-sacubitril-valsartan-paragon-hf/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2019/08/01/strain-encoded-mri-voor-beoordeling-van-myocardiale-deformatie/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/02/01/hoeveelheid-of-intensiteit-van-inspanning-bij-hfpef/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/04/14/vericiguat-bij-verslechterend-chronisch-hfpef-socrates-preserved-resultaten/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-m-reid","type":"person","url":"https://hartvaat.nl/mensen/christopher-m-reid/","name":"Christopher M Reid","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":20,"articles":[{"url":"https://hartvaat.nl/2026/02/23/pathfinder-trial-betere-naleving-van-hartfalenrichtlijnen-in-de-huisartsenprakti/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/06/01/bloeddrukverlaging-bij-centrale-hypertensie-gerandomiseerde-trial/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/11/01/sekseverschillen-in-effect-van-bloeddrukverlaging-ipd-meta-analyse/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","published":"2021-09-18"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/01/langetermijn-bloeddrukvariabiliteit-en-cv-risico-bij-ouderen-in-de-community/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/07/07/statinegebruik-en-invaliditeitsvrije-overleving-bij-gezonde-ouderen/","published":"2020-07-07"},{"url":"https://hartvaat.nl/2019/01/01/polypil-en-cardiovasculaire-preventie-meta-analyse-van-gerandomiseerde-trials/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/08/01/door-to-balloon-tijd-en-uitkomsten-bij-stemi-meta-analyse/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/08/19/vergelijking-van-fibrinolytica-bij-stemi-lancet-netwerkmeta-analyse/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"darrel-p-francis","type":"person","url":"https://hartvaat.nl/mensen/darrel-p-francis/","name":"Darrel P Francis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":20,"articles":[{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/06/11/remote-beoordeling-na-acs-gerandomiseerde-trial/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2023/03/30/upgrade-van-rv-pacemaker-naar-crt-of-geleidingssysteempacing-meta-analyse/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/02/16/catheterablatie-verbetert-cv-uitkomsten-bij-af-en-hartfalen-meta-analyse-van-rct/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/09/21/bijwerkingspatronen-in-crossover-trial-statine-placebo-geen-behandeling-statinwi/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2020/12/14/katheterablatie-versus-thoracoscopische-ablatie-bij-langdurig-persisterend-af-ca/","published":"2020-12-14"},{"url":"https://hartvaat.nl/2020/11/26/n-of-1-trial-van-statine-placebo-of-geen-behandeling-voor-bijwerkingen-nejm-stat/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2020/09/07/des-versus-cabg-bij-hoofdstamlijden-mortaliteits-meta-analyse/","published":"2020-09-07"},{"url":"https://hartvaat.nl/2019/08/01/optimale-laesieset-bij-persisterend-af-ablatie-meta-regressie/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/04/17/sglt2-remmers-glp-1-agonisten-en-dpp-4-remmers-vergelijkende-cardiovasculaire-me/","published":"2018-04-17"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/07/01/crt-werkingsmechanismen-en-mogelijkheden-voor-verdere-verbetering/","published":"2017-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giuseppe-mancia","type":"person","url":"https://hartvaat.nl/mensen/giuseppe-mancia/","name":"Giuseppe Mancia","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":20,"articles":[{"url":"https://hartvaat.nl/2025/08/01/sympathische-overactiviteit-bij-resistente-hypertensie-meta-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/14/hartfrequentieverlagende-middelen-en-uitkomsten-bij-hypertensie-cvd-meta-analyse/","published":"2025-07-14"},{"url":"https://hartvaat.nl/2025/01/01/reproduceerbaarheid-en-behandeleffect-op-kantoor-versus-ambulante-bloeddrukrelat/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/07/01/value-trial-cv-uitkomsten-bij-hypertensie-met-perifeer-vaatlijden/","published":"2024-07-01"},{"url":"https://hartvaat.nl/2024/05/01/bloeddrukstreefwaarden-en-residueel-risico-systematische-review-en-meta-regressi/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/03/01/renale-denervatie-en-sympathische-activiteit-systematische-review/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2023/03/01/korttermijn-bloeddrukmetingen-voorspellen-langetermijneffect-van-behandeling/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/09/20/harmonisatie-van-acc-aha-en-esc-esh-bloeddrukrichtlijnen/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2020/06/01/arb-versus-calciumantagonist-bloeddrukprofiel-en-klinische-effecten-vergelijking/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/01/bloeddrukverlaging-naar-uitgangsdruk-en-cv-risico-bij-diabetes-type-2/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/01/01/acute-creatininestijging-bij-start-ace-remmer-en-effecten-van-voortzetting-analy/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/09/01/bereikte-diastolische-bloeddruk-en-polsdruk-bij-streef-sbp-en-cv-uitkomsten-bij-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/08/01/sympathische-zenuwactivatie-bij-essentiele-hypertensie-meta-analyse/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/11/01/gemiddelde-bloeddruk-en-visit-to-visit-variabiliteit-als-gecombineerde-voorspell/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/08/01/bloeddrukvariabiliteit-en-vasculaire-events-bij-diabetes-type-2/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/06/03/bereikte-bloeddruk-en-cv-uitkomsten-bij-hoogrisicopatienten-ontarget-transcend/","published":"2017-06-03"},{"url":"https://hartvaat.nl/2017/01/07/verminderd-bloeddrukverlagend-effect-van-renale-denervatie-bij-geisoleerde-systo/","published":"2017-01-07"},{"url":"https://hartvaat.nl/2016/12/01/empagliflozine-en-bloeddruk-bij-diabetes-type-2-met-hypertensie-naar-achtergrond/","published":"2016-12-01"},{"url":"https://hartvaat.nl/2016/03/21/cardiovasculaire-uitkomsten-bij-verschillende-bereiktestreefdrukken-in-de-value-/","published":"2016-03-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"isabelle-c-van-gelder","type":"person","url":"https://hartvaat.nl/mensen/isabelle-c-van-gelder/","name":"Isabelle C Van Gelder","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":20,"articles":[{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/11/10/rate-control-bij-af-calciumantagonisten-versus-betablokkers/","published":"2023-11-10"},{"url":"https://hartvaat.nl/2022/07/15/race-3-langetermijnresultaten-gerichte-behandeling-bij-vroeg-persisterend-af-en-/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2022/03/02/frequentiecontrolemiddelen-verschillen-in-preventie-van-af-progressie/","published":"2022-03-02"},{"url":"https://hartvaat.nl/2021/12/07/av-junctieablatie-plus-crt-bij-permanent-af-met-smal-qrs-apaf-crt-mortaliteitsan/","published":"2021-12-07"},{"url":"https://hartvaat.nl/2021/09/08/antiaritmica-bij-vroeg-persisterend-af-met-hf-race-3/","published":"2021-09-08"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/07/01/subklinische-atherosclerose-en-incident-af-meta-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2020/02/01/verpleegkundig-geleide-versus-standaard-af-zorg/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/04/18/vroege-of-uitgestelde-cardioversie-bij-recent-onset-af-nejm-race-7-acwas/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2019/04/01/upstream-therapie-verbetert-qol-bij-persisterend-af-arrest-af/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/08/21/behandeling-van-onderliggende-aandoeningen-verbetert-sinusritme-na-af-arrest-af/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-rossing","type":"person","url":"https://hartvaat.nl/mensen/peter-rossing/","name":"Peter Rossing","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":20,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/05/25/kdigo-overzicht-de-nier-centraal-in-het-cardiovasculair-renaal-metabool-ckm-synd/","published":"2026-05-31"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2026/03/29/confidence-analyse-acute-egfr-daling-bij-empagliflozin-finerenone-is-reversibel-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/03/05/finerenon-effectief-bij-type-1-diabetes-met-chronische-nierziekte/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/02/23/semaglutide-vermindert-infectierisico-bij-diabetes-en-chronische-nierziekte/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/10/07/relatie-tussen-obesitas-en-ckd-conclusies-van-een-kdigo-conferentie/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","published":"2025-03-24"},{"url":"https://hartvaat.nl/2025/02/01/finerenon-en-lvh-bij-ckd-en-diabetes/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/10/22/flow-semaglutide-vermindert-hartfalen-bij-diabetes-en-ckd/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/07/11/flow-semaglutide-beschermt-nieren-bij-type-2-diabetes-en-ckd-nejm-gerelateerd/","published":"2024-07-11"},{"url":"https://hartvaat.nl/2022/12/01/finerenon-bloeddrukeffecten-en-cardiorenale-uitkomsten-bij-ckd-en-diabetes/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/02/10/finerenon-cv-en-renale-uitkomsten-bij-diabetes-met-ckd-fidelity-gepoolde-analyse/","published":"2022-02-10"},{"url":"https://hartvaat.nl/2022/02/08/finerenon-vermindert-incident-hf-bij-ckd-met-diabetes-fidelity/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/12/09/finerenon-bij-nierziekte-met-diabetes-type-2-nejm-figaro-dkd/","published":"2021-12-09"},{"url":"https://hartvaat.nl/2021/07/13/finerenon-vermindert-nieuw-onset-af-bij-ckd-met-diabetes-fidelio-dkd/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/03/31/dapagliflozine-en-mortaliteit-bij-ckd-dapa-ckd-pre-gespecificeerde-analyse/","published":"2021-03-31"},{"url":"https://hartvaat.nl/2021/02/09/finerenon-en-cardiovasculaire-uitkomsten-bij-ckd-met-diabetes-type-2-fidelio-dkd/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/08/dapagliflozine-bij-chronische-nierziekte-nejm-dapa-ckd/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2019/10/01/bardoxolone-en-urine-albumine-creatinine-ratio-bij-diabetes-met-ckd-stadium-4/","published":"2019-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yangsoo-jang","type":"person","url":"https://hartvaat.nl/mensen/yangsoo-jang/","name":"Yangsoo Jang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":20,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","published":"2023-04-04"},{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"},{"url":"https://hartvaat.nl/2020/06/16/ticagrelor-monotherapie-versus-dapt-op-bloedingen-en-cv-events-bij-acs-jama-tico/","published":"2020-06-16"},{"url":"https://hartvaat.nl/2020/05/05/des-versus-cabg-bij-linker-hoofdstam-10-jaarsresultaten-excel-extended/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ziad-hijazi","type":"person","url":"https://hartvaat.nl/mensen/ziad-hijazi/","name":"Ziad Hijazi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":20,"articles":[{"url":"https://hartvaat.nl/2025/11/25/abc-af-risicoscores-voor-gepersonaliseerde-af-behandeling/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2025/07/05/optimale-timing-van-anticoagulatie-na-ischemisch-cva-en-af-collaboratief-project/","published":"2025-07-05"},{"url":"https://hartvaat.nl/2024/12/03/nt-probnp-en-ecg-screening-bij-75-jarigen-voor-af-detectie-rct/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/10/01/neurofilament-light-chain-en-cva-risico-bij-af/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","published":"2023-05-21"},{"url":"https://hartvaat.nl/2022/10/04/timing-vroege-versus-late-noac-start-na-ischemisch-cva-bij-af/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2020/11/01/ace2-niveaus-en-covid-19-risicofactoren-bij-af-patienten/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/04/28/apixaban-versus-warfarine-bij-af-met-gevorderde-ckd/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2020/01/01/stapsgewijze-af-screening-met-nt-probnp-strokestop-ii-resultaten/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","published":"2018-02-07"},{"url":"https://hartvaat.nl/2017/08/01/nt-probnp-bij-systematische-screening-op-atriumfibrilleren/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/11/29/biomarkergebaseerde-cva-risicoscore-bij-atriumfibrilleren-validatie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/09/01/apixaban-5-mg-bij-af-met-hoge-leeftijd-laag-gewicht-of-hoog-creatinine-aristotle/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/07/01/apixaban-versus-warfarine-bij-af-in-relatie-tot-nierfunctie-aristotle-analyse/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","published":"2016-06-04"},{"url":"https://hartvaat.nl/2016/04/01/biomarkers-van-inflammatie-en-cardiovasculair-risico-bij-patienten-met-atriumfib/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eric-vicaut","type":"person","url":"https://hartvaat.nl/mensen/eric-vicaut/","name":"Éric Vicaut","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":20,"articles":[{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/11/20/afbouw-van-antihypertensieve-behandeling-bij-verpleeghuisbewoners-rct/","published":"2025-11-20"},{"url":"https://hartvaat.nl/2025/10/23/aspirine-bij-chronisch-coronairsyndroom-plus-oac-wel-of-niet/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/11/19/afloat-flecainide-voorkomt-af-na-pfo-sluiting-rct/","published":"2024-11-19"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2024/04/16/postprocedurale-anticoagulatie-na-primaire-pci-voor-stemi-multicenter-studie/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2021/01/19/residuele-syntax-score-bij-cardiogene-shock/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"},{"url":"https://hartvaat.nl/2020/08/25/carotisatherosclerose-evolutie-bij-ldl-streefwaarde-70-na-ischemisch-cva-tst-sub/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/01/02/vergelijking-van-twee-ldl-streefwaarden-na-ischemisch-cva-nejm-tst/","published":"2020-01-02"},{"url":"https://hartvaat.nl/2019/03/05/timing-van-prasugrel-start-en-coronairangiografie-bij-nstemi/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2018/11/01/aldosteronblokkade-bij-myocardinfarct-ipd-analyse-van-twee-trials/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/08/19/optimale-timing-van-invasieve-strategie-bij-nste-acs-lancet-meta-analyse/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/04/26/vroege-aldosteronblokkade-bij-acuut-myocardinfarct-de-albatross-trial/","published":"2016-04-26"},{"url":"https://hartvaat.nl/2016/01/21/stoppen-of-doorgaan-met-clopidogrel-12-maanden-na-drug-eluting-stent-optidual-tr/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ajay-j-kirtane","type":"person","url":"https://hartvaat.nl/mensen/ajay-j-kirtane/","name":"Ajay J Kirtane","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2025/08/19/paclitaxel-gecoate-ballon-bij-multilayer-in-stent-restenose-agent-ide-subgroep/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/04/12/orbitale-atherectomie-versus-ballonangioplastie-voor-des-bij-ernstig-verkalkte-l/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/11/12/renale-denervatie-bij-hypertensie-uitgebreide-meta-analyse-van-alle-trials/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2020/09/15/ami-management-tijdens-covid-19-scai-positiedocument/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/09/07/des-versus-cabg-bij-hoofdstamlijden-mortaliteits-meta-analyse/","published":"2020-09-07"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/04/09/sham-gecontroleerde-rct-s-van-renale-denervatie-meta-analyse/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2019/02/19/lv-unloading-tijdens-ecmo-bij-cardiogene-shock/","published":"2019-02-19"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/10/10/dagelijks-ischemie-en-bloedingsrisico-na-primaire-pci-voor-stemi/","published":"2017-10-10"},{"url":"https://hartvaat.nl/2017/06/01/korte-procedureduur-met-bivalirudine-en-risico-op-acute-stenttrombose-bij-stemi/","published":"2017-06-01"},{"url":"https://hartvaat.nl/2016/12/20/bloedingen-voor-coronairangiografie-bij-nste-acs/","published":"2016-12-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"axel-linke","type":"person","url":"https://hartvaat.nl/mensen/axel-linke/","name":"Axel Linke","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2026/03/03/4-eiwitmodel-voor-cardiogene-shock-prognose-danger-substudie/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/trainingseffect-op-diastolische-functie-bij-hfpef/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2024/04/01/inspanningstraining-en-hoog-sensitief-troponine-i-bij-hfref/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/10/01/verschillende-trainingsvormen-en-hdl-functie-bij-hfpef-optimex-substudie/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/06/01/inspanningstraining-en-hs-troponine-t-bij-hfref/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/02/09/hiit-matig-continu-of-richtlijnadvies-en-piek-vo2-bij-hfref-jama-smartex-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2018/09/08/drug-coated-balloons-bij-kleine-coronairarterien-lancet-basket-small-2/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2017/02/28/hoog-intensieve-intervaltraining-bij-hartfalen-met-verminderde-ejectiefractie/","published":"2017-02-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-hassager","type":"person","url":"https://hartvaat.nl/mensen/christian-hassager/","name":"Christian Hassager","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/09/01/af-en-icd-bij-niet-ischemische-hfref-impliciaties-voor-devicetherapie/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/12/05/bloeddruk-en-zuurstofstreefwaarden-en-nierschade-na-hartstilstand/","published":"2023-12-05"},{"url":"https://hartvaat.nl/2022/10/20/box-bloeddrukdoelen-bij-comateuze-overlevenden-van-hartstilstand/","published":"2022-10-20"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-juhl-terkelsen","type":"person","url":"https://hartvaat.nl/mensen/christian-juhl-terkelsen/","name":"Christian Juhl Terkelsen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2026/10/01/voorgebruik-van-opioiden-verhoogt-sterfte-en-ziekenhuisopnames-na-tavi-deens-coh/","published":"2026-08-21"},{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/10/12/aromi-prehospitale-copeptine-versnelt-mi-uitsluiting/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","published":"2019-10-19"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/07/01/remote-ischemische-conditionering-en-vertraging-van-het-zorgsysteem-bij-stemi/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dan-eik-hofsten","type":"person","url":"https://hartvaat.nl/mensen/dan-eik-hofsten/","name":"Dan Eik Høfsten","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2025/09/01/af-en-icd-bij-niet-ischemische-hfref-impliciaties-voor-devicetherapie/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/04/22/thoracentese-bij-acuut-hartfalen-gerandomiseerde-trial/","published":"2025-04-22"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2023/02/23/ct-coronairangiografie-bij-75-jarigen-met-nste-acs/","published":"2023-02-23"},{"url":"https://hartvaat.nl/2022/10/20/box-bloeddrukdoelen-bij-comateuze-overlevenden-van-hartstilstand/","published":"2022-10-20"},{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dragos-vinereanu","type":"person","url":"https://hartvaat.nl/mensen/dragos-vinereanu/","name":"Dragos Vinereanu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/01/07/euroheart-definities-van-klinische-studie-eindpunten-voor-cvd/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2018/08/01/uitkomsten-bij-af-met-oac-bij-mitralis-of-aortakleplijden/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/03/13/digoxine-en-mortaliteit-bij-patienten-met-atriumfibrilleren/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2017/10/14/multifacet-interventie-voor-oac-gebruik-bij-af-lancet-impact-af/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2017/04/01/niet-ernstige-bloedingen-met-apixaban-versus-warfarine-bij-af/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"george-d-dangas","type":"person","url":"https://hartvaat.nl/mensen/george-d-dangas/","name":"George D Dangas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/02/18/ticagrelor-met-of-zonder-aspirine-na-pci-twilight-plaatjessubstudie/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","published":"2019-02-19"},{"url":"https://hartvaat.nl/2017/10/10/dagelijks-ischemie-en-bloedingsrisico-na-primaire-pci-voor-stemi/","published":"2017-10-10"},{"url":"https://hartvaat.nl/2017/06/01/korte-procedureduur-met-bivalirudine-en-risico-op-acute-stenttrombose-bij-stemi/","published":"2017-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hussein-r-al-khalidi","type":"person","url":"https://hartvaat.nl/mensen/hussein-r-al-khalidi/","name":"Hussein R Al-Khalidi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2024/07/16/interventie-voor-evidence-based-zorg-bij-diabetes-en-cv-risico/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/04/18/gecoordineerde-zorg-optimaliseert-cv-preventie-bij-type-2-diabetes-jama-rct/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/12/06/apixaban-bij-af-op-hemodialyse-eerste-gerandomiseerde-trial/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","published":"2022-08-16"},{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2022/03/15/leeftijd-en-uitkomsten-van-katheterablatie-versus-medicatie-bij-af-cabana/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2021/07/13/ablatie-versus-medicatie-bij-af-naar-ras-en-etniciteit/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/06/30/af-recidief-na-ablatie-versus-antiaritmica-in-cabana/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/03/05/inspanningstest-versus-ccta-bij-diabetes-met-verdenking-coronairlijden/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/07/07/orbusneich-combo-stent-japan-usa-harmonee-gerandomiseerde-multicenter-trial/","published":"2018-07-07"},{"url":"https://hartvaat.nl/2017/10/14/multifacet-interventie-voor-oac-gebruik-bij-af-lancet-impact-af/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2017/01/01/axafa-afnet-5-apixaban-versus-vka-bij-af-ablatie-studieprotocol/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/08/16/bio-absorbeerbare-intracoronaire-matrix-ter-preventie-van-ventriculaire-remodell/","published":"2016-08-16"},{"url":"https://hartvaat.nl/2016/04/21/coronaire-bypasschirurgie-bij-ischemische-cardiomyopathie-nejm-stich-trial/","published":"2016-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jesper-hastrup-svendsen","type":"person","url":"https://hartvaat.nl/mensen/jesper-hastrup-svendsen/","name":"Jesper Hastrup Svendsen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2026/01/20/af-screening-naar-genetisch-risico-loop-subanalyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/15/hypokaliemie-en-af-gedetecteerd-door-implanteerbare-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2025/12/15/circadiaanse-patronen-van-af-en-ziekteprogressie-via-implanted-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2025/09/01/af-en-icd-bij-niet-ischemische-hfref-impliciaties-voor-devicetherapie/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2023/06/13/loop-substudie-nt-probnp-verbetert-af-screeningsopbrengst/","published":"2023-06-13"},{"url":"https://hartvaat.nl/2022/09/01/bloeddruk-beinvloedt-opbrengst-van-af-screening-loop-substudie/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/01/icd-bij-niet-ischemisch-systolisch-hf-met-coronaire-atherosclerose-danish/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2020/05/12/ritme-monitoringstrategieen-voor-af-screening-uitgebreide-evaluatie/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2019/12/03/natuurlijk-beloop-van-subklinisch-af-gedetecteerd-door-implanteerbare-looprecord/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/07/01/qt-als-voorspeller-van-af-recidief-na-ablatie-en-amiodaronimpact-amio-cat/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"},{"url":"https://hartvaat.nl/2016/02/01/peri-infarctpacing-ter-preventie-van-linkerkamerremodellering-na-groot-myocardin/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-chalmers","type":"person","url":"https://hartvaat.nl/mensen/john-chalmers/","name":"John Chalmers","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2026/04/25/bloeddrukverlaging-beschermt-over-het-hele-spectrum-van-chronische-nierschade-la/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/11/01/sekseverschillen-in-effect-van-bloeddrukverlaging-ipd-meta-analyse/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2023/03/01/korttermijn-bloeddrukmetingen-voorspellen-langetermijneffect-van-behandeling/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/12/21/bloeddrukverlaging-en-dementiepreventie-ipd-meta-analyse/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2021/11/13/bloeddrukverlaging-en-risico-op-diabetes-type-2-lancet-bplttc-ipd-meta-analyse/","published":"2021-11-13"},{"url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","published":"2021-09-18"},{"url":"https://hartvaat.nl/2019/06/01/bloeddrukverlaging-naar-uitgangsdruk-en-cv-risico-bij-diabetes-type-2/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"},{"url":"https://hartvaat.nl/2019/01/01/acute-creatininestijging-bij-start-ace-remmer-en-effecten-van-voortzetting-analy/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2017/08/01/bloeddrukvariabiliteit-en-vasculaire-events-bij-diabetes-type-2/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"},{"url":"https://hartvaat.nl/2016/11/22/plasma-lipidomiek-verbetert-cardiovasculaire-risicovoorspelling-bij-diabetes-typ/","published":"2016-11-22"},{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","published":"2016-06-16"},{"url":"https://hartvaat.nl/2016/03/05/bloeddrukverlaging-ter-preventie-van-hart-en-vaatziekten-systematische-review-en/","published":"2016-03-05"},{"url":"https://hartvaat.nl/2016/01/30/intensieve-bloeddrukverlaging-en-cardiovasculaire-en-renale-uitkomsten-systemati/","published":"2016-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lorenz-raber","type":"person","url":"https://hartvaat.nl/mensen/lorenz-raber/","name":"Lorenz Räber","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","published":"2026-04-09"},{"url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neoatherosclerose-na-stemi-secundaire-analyse/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/08/01/biodegradeerbare-versus-duurzame-polymeer-ees-langetermijn-neoatherosclerose/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/08/amulet-versus-watchman-flx-driejaarsresultaten-laa-sluiting/","published":"2025-07-08"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","published":"2024-02-06"},{"url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/11/19/evolocumab-voor-vroege-ldl-verlaging-bij-acs-evopacs/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/07/01/lokale-hemodynamische-krachten-en-fenotype-van-coronaire-plaques/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/04/07/statines-en-niet-statine-ldl-verlagers-en-cardiovasculaire-uitkomsten-meta-analy/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"},{"url":"https://hartvaat.nl/2016/12/01/tienjaarsuitkomsten-van-eerste-generatie-drug-eluting-stents-ses-versus-pes/","published":"2016-12-01"},{"url":"https://hartvaat.nl/2016/01/14/bioresorbeerbare-versus-metallic-everolimus-eluting-stent-bij-stemi-gerandomisee/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mandeep-r-mehra","type":"person","url":"https://hartvaat.nl/mensen/mandeep-r-mehra/","name":"Mandeep R Mehra","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2026/02/23/aspirinestop-bij-lvad-met-vka-veiligheidsanalyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/03/01/aspirine-en-hemocompatibiliteit-na-lvad-bij-atherosclerotisch-vaatlijden/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2024/08/06/doac-bij-heartmate-3-lvad-eerste-gerandomiseerde-trial/","published":"2024-08-06"},{"url":"https://hartvaat.nl/2024/02/13/implanteerbare-hemodynamische-monitoren-verbeteren-overleving-bij-hfref/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2022/09/27/momentum-3-vijfjaarsresultaten-heartmate-3-versus-axiale-lvad/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/07/14/guide-hf-en-de-impact-van-covid-19-op-hartfalenuitkomsten/","published":"2022-07-14"},{"url":"https://hartvaat.nl/2021/09/11/hemodynamisch-geleid-hf-management-lancet-guide-hf/","published":"2021-09-11"},{"url":"https://hartvaat.nl/2020/04/01/lvad-gebruik-als-bridge-to-transplant-versus-destination-therapy-momentum-3/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2019/11/21/rivaroxaban-en-cva-tia-bij-hf-met-coronairlijden-en-sinusritme-commander-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/06/01/rivaroxaban-en-trombo-embolische-events-bij-hf-met-coronairlijden-en-sinusritme-/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2019/01/08/cva-analyse-in-momentum-3-langetermijncohort/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/10/30/zorggebruik-en-kosten-in-momentum-3-langetermijnstudie/","published":"2018-10-30"},{"url":"https://hartvaat.nl/2018/10/04/rivaroxaban-bij-hartfalen-met-sinusritme-en-coronairlijden-nejm-commander-hf/","published":"2018-10-04"},{"url":"https://hartvaat.nl/2018/06/01/maatschappelijk-werker-palliatieve-zorg-bij-hoogrisico-hf-swap-hf-pilot/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/05/23/hemocompatibiliteitsuitkomsten-van-heartmate-3-na-6-maanden-momentum-3/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","published":"2017-02-02"},{"url":"https://hartvaat.nl/2017/01/01/richtlijnen-voor-listing-van-harttransplantatiekandidaten-10-jaarsupdate/","published":"2017-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marianna-adamo","type":"person","url":"https://hartvaat.nl/mensen/marianna-adamo/","name":"Marianna Adamo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2026/05/06/transseptale-punctie-bij-linkshartinterventies-nieuwe-esc-consensus-over-technie/","published":"2026-07-29"},{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/05/26/esc-consensus-vrouwenhartcentra-whc-als-nieuw-zorgmodel-in-europa/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/28/gestandaardiseerd-stappenplan-voor-tricuspidalisinsufficientie-van-verwijzing-to/","published":"2026-04-19"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/02/03/geslachtsverschillen-bij-patienten-met-gevorderd-hartfalen/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/01/hartfalen-tijdens-de-covid-19-pandemie-klinische-en-organisatorische-dilemma-s/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2019/12/01/hoogtepunten-in-hartfalen-2019/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2018/12/01/mitraclip-plus-medicamenteus-versus-medicamenteus-alleen-bij-hf-met-mr-meta-anal/","published":"2018-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicholas-a-marston","type":"person","url":"https://hartvaat.nl/mensen/nicholas-a-marston/","name":"Nicholas A Marston","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","published":"2025-10-02"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-hypertriglyceridemie-en-hoog-cv-risico-nejm/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/04/01/lp-a-en-hscrp-als-cv-risicofactoren-primaire-en-secundaire-preventie/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2022/12/01/serieel-hoog-sensitief-troponine-t-voorspelt-cv-events-na-acs-odyssey-analyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/05/03/vupanorsen-en-non-hdl-cholesterol-bij-statinebehandelde-patienten-translate-timi/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2020/11/21/ldl-verlaging-bij-ouderen-lancet-meta-analyse-werkzaamheid-en-veiligheid/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/11/01/klinische-toepassing-van-hs-troponine-in-het-ascvd-raamwerk-jama-cardiology/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/02/25/genetische-risicoscore-voorspelt-voordeel-van-evolocumab-fourier/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2019/10/15/triglyceridenverlaging-en-cv-risicoreductie-over-therapeutische-klassen-meta-ana/","published":"2019-10-15"}],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/triglyceriden-en-remnantdeeltjes/","title":"Sessie 1: Triglyceriden en remnantdeeltjes"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-gabor-kiss","type":"person","url":"https://hartvaat.nl/mensen/robert-gabor-kiss/","name":"Róbert Gábor Kiss","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"suzanne-oparil","type":"person","url":"https://hartvaat.nl/mensen/suzanne-oparil/","name":"Suzanne Oparil","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2022/10/22/symplicity-htn-3-langetermijn-follow-up-renale-denervatie-bij-resistente-hyperte/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/05/12/behandeling-van-milde-chronische-hypertensie-in-de-zwangerschap-nejm-chap/","published":"2022-05-12"},{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2021/04/01/intensieve-versus-standaard-bloeddruk-op-cva-subtypes-sprint/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/03/01/orthostatische-hypotensie-cv-uitkomsten-en-adverse-events-sprint-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2018/06/01/intensieve-versus-standaard-bloeddruk-naar-tertielen-in-sprint/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/02/01/nauwkeurigheid-van-bloeddrukmeters-in-de-zwangerschap-systematische-review/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/08/24/intensieve-bloeddrukbehandeling-en-patientgerapporteerde-uitkomsten-nejm-sprint-/","published":"2017-08-24"},{"url":"https://hartvaat.nl/2017/02/01/bereikte-bloeddruk-en-cardiovasculaire-uitkomsten-bij-oudere-patienten-met-geiso/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2016/11/01/intensieve-bloeddrukbehandeling-120-80-mmhg-bij-cardiovasculair-risico-protagoni/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/07/01/medicatie-non-adherentie-en-visit-to-visit-bloeddrukvariabiliteit-target-bp-stud/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"},{"url":"https://hartvaat.nl/2016/03/01/voorschrijfpatronen-van-thiazidediuretica-in-de-sprint-trial/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"william-f-mcintyre","type":"person","url":"https://hartvaat.nl/mensen/william-f-mcintyre/","name":"William F McIntyre","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2026/04/08/vision-postoperatief-atriumfibrilleren-na-hartchirurgie-verhoogt-sterfte-na-een-/","published":"2026-07-15"},{"url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/11/26/artesia-subanalyse-cva-risico-naar-frequentie-en-duur-van-subclinisch-af/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/01/af-ablatie-bij-hfref-versus-hfpef-meta-analyse/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/03/26/doac-s-bij-device-gedetecteerd-af-meta-analyse-noah-afnet-6-en-artesia/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/03/07/mra-s-verminderen-af-risico-meta-analyse-van-klinische-trials/","published":"2024-03-07"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/11/04/colchicine-vermindert-perioperatief-af-na-thoraxchirurgie-lancet-rct/","published":"2023-11-04"},{"url":"https://hartvaat.nl/2023/02/16/technieken-om-cardioversiesucces-bij-af-te-verbeteren-meta-analyse/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2022/10/13/voorbehandeling-met-antiaritmica-voor-cardioversie-bij-af-netwerk-meta-analyse/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2021/08/06/orale-antiaritmica-voor-cardioversie-van-recent-onset-af-netwerkmeta-analyse/","published":"2021-08-06"},{"url":"https://hartvaat.nl/2021/06/15/prevalentie-van-linkeratriumtrombus-bij-geanticoaguleerde-af-patienten/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2021/05/01/screening-op-af-bij-ouderen-jama-cardiology-gerandomiseerde-trial/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2019/08/01/vernakalant-voor-cardioversie-van-recent-onset-af-meta-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/01/amiodaron-voor-en-na-electrische-cardioversie-van-af-meta-analyse/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/05/08/vasopressine-plus-catecholamines-en-af-bij-distributieve-shock-jama-meta-analyse/","published":"2018-05-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ziad-a-ali","type":"person","url":"https://hartvaat.nl/mensen/ziad-a-ali/","name":"Ziad A Ali","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":19,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2025/12/29/functionele-en-morfologische-karakterisering-van-coronaire-atherosclerose/","published":"2025-12-29"},{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2025/07/15/oct-gebaseerde-post-pci-fysiologiebeoordeling-voorspelt-klinische-uitkomsten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/04/12/orbitale-atherectomie-versus-ballonangioplastie-voor-des-bij-ernstig-verkalkte-l/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/03/02/intravasculaire-beeldvorming-bij-des-implantatie-lancet-netwerk-meta-analyse/","published":"2024-03-02"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2020/09/07/des-versus-cabg-bij-hoofdstamlijden-mortaliteits-meta-analyse/","published":"2020-09-07"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/12/01/absorb-scaffold-5-jaarsresultaten-systematische-meta-analyse/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2018/01/30/absorb-bioresorbeerbare-scaffold-3-jaarsresultaten-ipd-meta-analyse/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2017/08/19/absorb-bioresorbeerbare-scaffold-lancet-2-jaars-systematische-review-en-meta-ana/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2016/11/26/oct-versus-ivus-versus-angiografie-bij-coronaire-stentimplantatie-lancet-ilumien/","published":"2016-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alvaro-a-avezum","type":"person","url":"https://hartvaat.nl/mensen/alvaro-a-avezum/","name":"Alvaro A Avezum","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2022/09/15/invictus-rivaroxaban-versus-warfarine-bij-reumatische-hartziekte-en-af/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/07/08/cv-uitkomsten-bij-diabetes-met-vastgesteld-of-hoog-risico-coronairlijden-dulaglu/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","published":"2021-06-03"},{"url":"https://hartvaat.nl/2021/01/01/rivaroxaban-plus-aspirine-bij-symptomatisch-pav-compass-subanalyse/","published":"2021-01-01"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2019/08/13/rivaroxaban-met-of-zonder-aspirine-bij-hf-met-coronair-of-perifeer-vaatlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2018/08/01/uitkomsten-bij-af-met-oac-bij-mitralis-of-aortakleplijden/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2016/12/15/off-pump-versus-on-pump-cabg-5-jaarsresultaten-nejm-coronary-trial/","published":"2016-12-15"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"axel-brandes","type":"person","url":"https://hartvaat.nl/mensen/axel-brandes/","name":"Axel Brandes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/01/20/af-screening-naar-genetisch-risico-loop-subanalyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/15/hypokaliemie-en-af-gedetecteerd-door-implanteerbare-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2025/12/15/circadiaanse-patronen-van-af-en-ziekteprogressie-via-implanted-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2023/06/13/loop-substudie-nt-probnp-verbetert-af-screeningsopbrengst/","published":"2023-06-13"},{"url":"https://hartvaat.nl/2022/09/01/bloeddruk-beinvloedt-opbrengst-van-af-screening-loop-substudie/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/07/01/subklinische-atherosclerose-en-incident-af-meta-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2020/05/12/ritme-monitoringstrategieen-voor-af-screening-uitgebreide-evaluatie/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2019/12/03/natuurlijk-beloop-van-subklinisch-af-gedetecteerd-door-implanteerbare-looprecord/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-m-wojdyla","type":"person","url":"https://hartvaat.nl/mensen/daniel-m-wojdyla/","name":"Daniel M Wojdyla","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/04/01/prevent-risicoscore-presteert-robuust-in-de-dagelijkse-ehr-praktijk/","published":"2026-07-15"},{"url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/03/25/antitrombotische-therapie-bij-af-na-acs-pci-augustus-gecombineerde-inzichten/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2024/09/03/augustus-4-weg-vergelijking-antitrombotische-strategieen-bij-af-na-acs-pci/","published":"2024-09-03"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/02/01/transform-hf-torsemide-versus-furosemide-bij-nieuw-vs-chronisch-hartfalen/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2022/02/08/antitrombotische-therapie-bij-af-na-acs-of-pci-jacc-overzicht/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/05/01/vroegtijdig-permanent-staken-van-apixaban-of-warfarine-bij-af/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2020/04/28/apixaban-versus-warfarine-bij-af-met-gevorderde-ckd/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2020/03/17/klinische-en-farmacologische-effecten-van-apixaban-dosisaanpassing-aristotle/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2020/01/07/nsaid-s-en-oac-bij-af-aristotle-analyse/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2018/03/13/digoxine-en-mortaliteit-bij-patienten-met-atriumfibrilleren/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2017/04/01/niet-ernstige-bloedingen-met-apixaban-versus-warfarine-bij-af/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-r-holmes","type":"person","url":"https://hartvaat.nl/mensen/david-r-holmes/","name":"David R Holmes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/10/22/implanteerbare-monitor-voor-snellere-behandeling-bij-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/04/23/implanteerbaar-cardiaal-alertsysteem-voor-vroege-herkenning-van-stemi/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2018/07/31/antitrombotische-therapie-bij-af-met-oac-na-pci-aha-scientific-statement/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/05/19/des-versus-bms-in-veneuze-bypass-grafts-lancet-dubbelblinde-trial/","published":"2018-05-19"},{"url":"https://hartvaat.nl/2017/12/19/5-jaarsuitkomsten-na-linker-hartoorsluiting-prevail-en-protect-af/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/01/01/percutane-linker-hartoorsluiting-munchen-consensusdocument-over-definities-en-ei/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/05/03/diabetes-en-preventie-van-laat-myocardinfarct-na-stenting-dapt-studie/","published":"2016-05-03"},{"url":"https://hartvaat.nl/2016/01/05/doodsoorzaken-na-pci-versus-cabg-bij-complex-coronairlijden-5-jaarsfollow-up-van/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-ambarish-pandey","type":"person","url":"https://hartvaat.nl/mensen/dr-ambarish-pandey/","name":"Dr. Ambarish Pandey","title":"Cardioloog, UT Southwestern Medical Center, Dallas, VS","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/06/26/finerenone-verlaagt-hart-en-vaatrisico-via-vroege-daling-van-uacr-en-systolische/","published":"2026-08-06"},{"url":"https://hartvaat.nl/2025/01/01/ai-voorspelt-hartfalen-op-basis-van-12-afleidingen-ecg-in-grote-cohortanalyse/","published":"2026-03-17"},{"url":"https://hartvaat.nl/2025/12/09/aspree-cardiale-stress-en-bloeddrukmanagement-bij-ouderen/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/06/01/humain-hfpef-nieuwe-metabole-accelerator-bij-obesitas-hfpef-rct/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2024/07/16/interventie-voor-evidence-based-zorg-bij-diabetes-en-cv-risico/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2023/02/01/fysieke-revalidatie-bij-fragiele-ouderen-met-acuut-hartfalen/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/07/12/frailteit-beinvloedt-effect-van-inspanningstraining-bij-hartfalen-hf-action-anal/","published":"2022-07-12"},{"url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/10/19/diabetes-met-cardiomyopathie-in-de-community-prevalentie-en-prognose/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2020/12/22/lichaamssamenstelling-en-risico-op-hartfalen-en-mi-prospectieve-analyse/","published":"2020-12-22"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/05/21/vroegtijdig-staken-van-ticagrelor-bij-secundaire-cv-preventie-jacc-review/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2017/11/01/totale-occlusie-van-de-culprit-arterie-bij-nstemi-meta-analyse/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2016/08/01/sedentair-gedrag-en-cardiovasculair-risico-continue-dosis-responsrelatie-in-meta/","published":"2016-08-01"}],"videos":[{"url":"https://hartvaat.nl/video/hfa-2026-late-breaking-science/transform-hf-diureticaresistentie/","title":"TRANSFORM-HF — Inzichten in diureticaresistentie bij hartfalen"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"e-magnus-ohman","type":"person","url":"https://hartvaat.nl/mensen/e-magnus-ohman/","name":"E Magnus Ohman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/10/12/overbrugging-van-antiplaatjestherapie-na-pci-jacc-review/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/07/14/vergelijking-van-orale-p2y12-remmers-bij-acs-netwerkmeta-analyse-van-52-816-pati/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2017/08/01/voorspelling-van-bloedingsrisico-tijdens-dapt-na-acs/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/05/09/ranolazine-na-incomplete-pci-bij-diabetes-versus-zonder-diabetes-river-pci/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2016/08/01/eerder-clopidogrelgebruik-en-uitkomsten-bij-conservatief-behandeld-acs/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/04/12/infarctgrootte-en-uitkomsten-na-primaire-pci-patientanalyse-uit-10-trials/","published":"2016-04-12"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"},{"url":"https://hartvaat.nl/2016/03/01/cyp2c19-metaboliseerdersstatus-en-uitkomsten-bij-acs-prasugrel-versus-clopidogre/","published":"2016-03-01"},{"url":"https://hartvaat.nl/2016/01/21/neoplasiedetectie-bij-langdurige-dapt-met-prasugrel-versus-clopidogrel-triton-ti/","published":"2016-01-21"},{"url":"https://hartvaat.nl/2016/01/09/ranolazine-bij-incomplete-revascularisatie-na-pci-de-river-pci-trial/","published":"2016-01-09"},{"url":"https://hartvaat.nl/2016/01/05/ranolazine-bij-angina-en-kwaliteit-van-leven-na-pci-met-incomplete-revascularisa/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"erica-l-goodrich","type":"person","url":"https://hartvaat.nl/mensen/erica-l-goodrich/","name":"Erica L Goodrich","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","published":"2025-10-02"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-hypertriglyceridemie-en-hoog-cv-risico-nejm/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2022/09/01/dapagliflozine-effectief-ongeacht-cv-achtergrondmedicatie-declare-subanalyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/11/01/klinische-toepassing-van-hs-troponine-in-het-ascvd-raamwerk-jama-cardiology/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"},{"url":"https://hartvaat.nl/2016/09/20/cva-preventie-met-ticagrelor-na-myocardinfarct-pegasus-timi-54-inzichten/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hans-eiskjaer","type":"person","url":"https://hartvaat.nl/mensen/hans-eiskjaer/","name":"Hans Eiskjær","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/09/01/af-en-icd-bij-niet-ischemische-hfref-impliciaties-voor-devicetherapie/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2022/04/01/icd-bij-niet-ischemisch-systolisch-hf-met-coronaire-atherosclerose-danish/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/04/30/ketonlichaam-3-hydroxybutyraat-bij-chronisch-hartfalen-cardiovasculaire-effecten/","published":"2019-04-30"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-d-puskas","type":"person","url":"https://hartvaat.nl/mensen/john-d-puskas/","name":"John D Puskas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2021/12/04/posterieure-pericardiotomie-ter-preventie-van-af-na-hartchirurgie-lancet-palacs/","published":"2021-12-04"},{"url":"https://hartvaat.nl/2020/07/14/radiale-arterie-versus-vena-saphena-graft-bij-cabg-jama-langetermijn-meta-analys/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/08/13/off-pump-versus-on-pump-cabg-bij-hoofdstamcoronairlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2019/04/23/hedendaagse-uitkomsten-na-cabg-voor-hoofdstamlijden/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2019/01/31/bilaterale-versus-enkele-mammaria-interna-grafts-na-10-jaar-nejm-art/","published":"2019-01-31"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"},{"url":"https://hartvaat.nl/2017/03/14/drie-arteriele-grafts-verbeteren-langetermijnoverleving-meta-analyse-van-propens/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jonathan-m-kalman","type":"person","url":"https://hartvaat.nl/mensen/jonathan-m-kalman/","name":"Jonathan M Kalman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2025/12/01/arrest-af-agressieve-risicofactorreductie-en-ablatie-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/07/14/vroege-versus-late-af-ablatie-impact-op-aritmierecidief/","published":"2023-07-14"},{"url":"https://hartvaat.nl/2023/02/16/hoog-vermogen-korte-duur-versus-laag-vermogen-langere-duur-posteriore-ablatie-bi/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2021/07/18/procedurevolume-en-complicaties-bij-af-ablatie-meta-analyse/","published":"2021-07-18"},{"url":"https://hartvaat.nl/2020/01/02/alcoholonthouding-bij-drinkers-met-af-nejm-gerandomiseerde-trial/","published":"2020-01-02"},{"url":"https://hartvaat.nl/2018/11/01/uitkomsten-van-ablatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/07/01/rotorablatie-bij-atriumfibrilleren-systematische-review/","published":"2018-07-01"},{"url":"https://hartvaat.nl/2018/04/21/subklinisch-device-gedetecteerd-af-en-cva-risico-meta-analyse/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/10/17/katheterablatie-versus-frequentiecontrole-bij-af-met-systolische-disfunctie-came/","published":"2017-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jose-luis-lopez-sendon","type":"person","url":"https://hartvaat.nl/mensen/jose-luis-lopez-sendon/","name":"Jose Luis Lopez-Sendon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-vasculaire-preventie-meta-analyse-van-lange-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/12/01/vericiguat-en-nt-probnp-bij-hfref-victoria-subanalyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2016/08/16/bio-absorbeerbare-intracoronaire-matrix-ter-preventie-van-ventriculaire-remodell/","published":"2016-08-16"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/02/02/reductie-in-totale-cardiovasculaire-events-met-ezetimibe-simvastatine-na-acs-imp/","published":"2016-02-02"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jurrien-m-ten-berg","type":"person","url":"https://hartvaat.nl/mensen/jurrien-m-ten-berg/","name":"Jurriën M Ten Berg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2025/12/21/tavi-plus-ffr-geleide-pci-gecombineerde-benadering-onderzocht/","published":"2025-12-21"},{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2022/08/09/ticagrelor-dapt-en-veneuze-graftfalen-na-cabg-systematische-review/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","published":"2022-03-07"},{"url":"https://hartvaat.nl/2020/11/10/ticagrelor-plus-aspirine-en-safeneuze-graft-patency-na-cabg/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2020/05/01/optimaal-antitrombotisch-regime-bij-af-na-pci-jama-cardiology-netwerkmeta-analys/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/10/24/genotype-geleide-p2y12-remmerkeuze-bij-primaire-pci-nejm-popular-genetics/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/08/01/antitrombotische-strategieen-bij-af-na-pci-jama-cardiology-veiligheids-en-werkza/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/05/14/dabigatran-duale-therapie-met-ticagrelor-of-clopidogrel-na-pci-bij-af-re-dual-pc/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/03/05/timing-van-prasugrel-start-en-coronairangiografie-bij-nstemi/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2018/05/14/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-meta-analyse/","published":"2018-05-14"},{"url":"https://hartvaat.nl/2018/03/13/doac-s-bij-af-met-ckd-systematische-review-werkzaamheid-en-veiligheid/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","published":"2017-10-19"},{"url":"https://hartvaat.nl/2017/10/01/langetermijnmortaliteit-en-prehospitale-tirofibanbehandeling-bij-stemi/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/07/01/1-jaarsmortaliteit-bivalirudine-versus-heparine-in-de-ambulance-bij-stemi-matrix/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/01/03/traditionele-cv-risicofactoren-en-veneuze-trombo-embolie-individuele-patientdata/","published":"2017-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lene-holmvang","type":"person","url":"https://hartvaat.nl/mensen/lene-holmvang/","name":"Lene Holmvang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/02/23/ct-coronairangiografie-bij-75-jarigen-met-nste-acs/","published":"2023-02-23"},{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"manel-sabate","type":"person","url":"https://hartvaat.nl/mensen/manel-sabate/","name":"Manel Sabaté","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/11/25/amphilimus-versus-zotarolimus-eluting-stent-bij-diabetes-en-coronairlijden/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2023/04/08/biovasc-directe-versus-gestageerde-complete-revascularisatie-bij-acs-met-meervat/","published":"2023-04-08"},{"url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/03/31/amphilimus-versus-zotarolimus-stents-bij-diabetes-sugar-gerandomiseerde-trial/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/12/03/magnesium-resorbeerbare-scaffold-versus-metallic-stent-bij-stemi-biosolve-iii/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"},{"url":"https://hartvaat.nl/2016/01/23/everolimus-eluting-stent-versus-bare-metal-stent-bij-stemi-5-jaarsresultaten-exa/","published":"2016-01-23"},{"url":"https://hartvaat.nl/2016/01/14/bioresorbeerbare-versus-metallic-everolimus-eluting-stent-bij-stemi-gerandomisee/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marco-alings","type":"person","url":"https://hartvaat.nl/mensen/marco-alings/","name":"Marco Alings","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/05/10/decision-trial-digoxine-staken-bij-hartfalen-leidt-tot-zevenvoudige-stijging-in-/","published":"2026-06-25"},{"url":"https://hartvaat.nl/2026/05/10/decision-onttrekkingssubstudie-stoppen-van-digoxine-na-lange-behandeling-leidt-t/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/11/26/artesia-subanalyse-cva-risico-naar-frequentie-en-duur-van-subclinisch-af/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/03/26/doac-s-bij-device-gedetecteerd-af-meta-analyse-noah-afnet-6-en-artesia/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2022/07/15/race-3-langetermijnresultaten-gerichte-behandeling-bij-vroeg-persisterend-af-en-/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2021/09/08/antiaritmica-bij-vroeg-persisterend-af-met-hf-race-3/","published":"2021-09-08"},{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","published":"2021-06-03"},{"url":"https://hartvaat.nl/2019/12/07/individueel-levenslang-voordeel-en-bloedingsrisico-van-rivaroxaban-plus-aspirine/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2019/04/18/vroege-of-uitgestelde-cardioversie-bij-recent-onset-af-nejm-race-7-acwas/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2019/04/01/upstream-therapie-verbetert-qol-bij-persisterend-af-arrest-af/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/08/21/behandeling-van-onderliggende-aandoeningen-verbetert-sinusritme-na-af-arrest-af/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-d-ezekowitz","type":"person","url":"https://hartvaat.nl/mensen/michael-d-ezekowitz/","name":"Michael D Ezekowitz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/10/09/voorspellers-van-sinusritme-6-weken-na-af-cardioversie-x-vert/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2020/11/01/ace2-niveaus-en-covid-19-risicofactoren-bij-af-patienten/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2019/11/01/determinanten-van-linkeratriumtrombi-bij-geplande-cardioversie-ensure-af/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/07/09/2019-aha-acc-hrs-gerichte-update-van-de-af-richtlijn/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/07/01/hospitalisatieredenen-en-mortaliteitsrisico-bij-af-met-dabigatran-versus-warfari/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/12/01/edoxaban-verhoogt-behandeltevredenheid-en-vermindert-zorggebruik-engage-af-timi-/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-versus-heparine-vka-bij-cardioversie-voor-af-emanate-trial/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/07/17/oac-plus-nsaid-bij-af-risico-op-ernstige-bloedingen/","published":"2018-07-17"},{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","published":"2018-02-07"},{"url":"https://hartvaat.nl/2018/02/01/dabigatran-versus-warfarine-bij-af-met-linkerventrikelhypertrofie-re-ly/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/10/01/korte-dabigatran-onderbreking-voor-device-implantatie-re-ly-multicenterervaring/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/07/01/dabigatran-naar-leeftijd-bij-atriumfibrilleren-re-ly-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/11/29/biomarkergebaseerde-cva-risicoscore-bij-atriumfibrilleren-validatie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/10/22/edoxaban-versus-enoxaparine-warfarine-bij-cardioversie-van-af-ensure-af-trial/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/08/23/dabigatran-versus-warfarine-bij-af-met-kleplijden-re-ly-analyse/","published":"2016-08-23"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnevaluatie-van-dabigatran-150-versus-110-mg-bij-niet-valvulair-af/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","published":"2016-06-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-e-farkouh","type":"person","url":"https://hartvaat.nl/mensen/michael-e-farkouh/","name":"Michael E Farkouh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2024/09/10/tact-2-chelatietherapie-na-mi-bij-diabetes-negatieve-trial/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2024/06/01/invested-griepvaccin-immuunrespons-bij-hoog-risico-cv-patienten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/01/05/nejm-interventie-voor-snelle-ambulante-follow-up-na-acuut-hartfalen/","published":"2023-01-05"},{"url":"https://hartvaat.nl/2022/04/19/externe-validatie-van-de-freedom-score-voor-pci-versus-cabg/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/03/16/plaatjesreactiviteit-bij-acs-in-afwachting-van-chirurgische-revascularisatie/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/31/syntax-score-ii-herontwikkeling-voor-gepersonaliseerde-revascularisatiebeslissin/","published":"2020-10-31"},{"url":"https://hartvaat.nl/2020/08/25/genotype-geleide-p2y12-selectie-versus-clopidogrel-na-pci-jama-tailor-pci/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/11/19/empagliflozine-en-lv-massa-bij-diabetes-type-2-met-coronairlijden-empa-heart/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/11/01/interventies-voor-statinevoorschrijving-bij-primaire-cv-preventie-meta-analyse/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/22/individualisering-van-revascularisatiestrategie-bij-diabetes-met-multivatenlijde/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","published":"2019-02-19"},{"url":"https://hartvaat.nl/2018/12/11/syntax-score-bij-diabetes-met-coronaire-revascularisatie-freedom/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2018/02/13/richtlijngetrouwe-medicamenteuze-therapie-in-contemporaine-revascularisatietrial/","published":"2018-02-13"},{"url":"https://hartvaat.nl/2017/12/19/chirurgische-versus-percutane-revascularisatie-bij-diabetes-met-acs/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/01/17/dapt-versus-aspirine-monotherapie-bij-diabetes-met-multivatenlijden-na-cabg-free/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-maeng","type":"person","url":"https://hartvaat.nl/mensen/michael-maeng/","name":"Michael Mæng","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/03/15/5-jaars-ifr-versus-ffr-geleide-pci-define-flair-ifr-swedeheart/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2020/02/14/danami-2-16-jaarsfollow-up-primaire-pci-versus-fibrinolyse/","published":"2020-02-14"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","published":"2019-10-19"},{"url":"https://hartvaat.nl/2019/01/07/bioresorbeerbare-scaffold-versus-ees-bij-stabiel-coronairlijden-prospectieve-tri/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","published":"2017-10-19"},{"url":"https://hartvaat.nl/2017/05/11/instantaneous-wave-free-ratio-versus-ffr-voor-pci-indicatie-nejm-ifr-swedeheart/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"},{"url":"https://hartvaat.nl/2016/02/23/everolimus-versus-sirolimus-eluting-stents-5-jaarsresultaten-sort-out-iv/","published":"2016-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"salvatore-brugaletta","type":"person","url":"https://hartvaat.nl/mensen/salvatore-brugaletta/","name":"Salvatore Brugaletta","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-laagrisico-acuut-mi/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2025/11/25/amphilimus-versus-zotarolimus-eluting-stent-bij-diabetes-en-coronairlijden/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2023/04/08/biovasc-directe-versus-gestageerde-complete-revascularisatie-bij-acs-met-meervat/","published":"2023-04-08"},{"url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/03/31/amphilimus-versus-zotarolimus-stents-bij-diabetes-sugar-gerandomiseerde-trial/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2019/12/03/magnesium-resorbeerbare-scaffold-versus-metallic-stent-bij-stemi-biosolve-iii/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/08/07/adenosine-en-ticagrelorspiegels-bij-patienten-met-en-zonder-ticagrelor-dyspneu/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2018/03/20/effecten-van-ticagrelor-prasugrel-of-clopidogrel-op-endotheelfunctie/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2016/01/23/everolimus-eluting-stent-versus-bare-metal-stent-bij-stemi-5-jaarsresultaten-exa/","published":"2016-01-23"},{"url":"https://hartvaat.nl/2016/01/14/bioresorbeerbare-versus-metallic-everolimus-eluting-stent-bij-stemi-gerandomisee/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sergio-leonardi","type":"person","url":"https://hartvaat.nl/mensen/sergio-leonardi/","name":"Sergio Leonardi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/12/09/gepersonaliseerde-versus-standaard-dapt-duur-na-pci-gerandomiseerde-trial/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/02/02/dalend-hemoglobine-en-prognose-bij-acs-hospitalisatie/","published":"2021-02-02"},{"url":"https://hartvaat.nl/2020/08/04/cangrelor-tirofiban-en-prasugrel-bij-stemi-primaire-resultaten/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/04/14/aki-en-bloedingen-en-mortaliteit-na-radiale-versus-femorale-toegang-bij-acs/","published":"2019-04-14"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/effecten-van-ticagrelor-prasugrel-of-clopidogrel-op-endotheelfunctie/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2018/03/13/digoxine-en-mortaliteit-bij-patienten-met-atriumfibrilleren/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2016/09/06/consistente-reductie-in-periprocedureel-mi-met-cangrelor-champion-analyses/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"usman-baber","type":"person","url":"https://hartvaat.nl/mensen/usman-baber/","name":"Usman Baber","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2026/02/24/yellow-iii-intracoronaire-beeldvorming-en-genexpressie-na-maximale-lipideverlagi/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/02/18/ticagrelor-met-of-zonder-aspirine-na-pci-twilight-plaatjessubstudie/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2017/05/30/polygene-risicoscore-en-relatief-voordeel-van-statinetherapie-primaire-preventie/","published":"2017-05-30"},{"url":"https://hartvaat.nl/2016/09/06/duur-van-dapt-systematische-review-voor-de-acc-aha-gerichte-update-2016/","published":"2016-09-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"w-schuyler-jones","type":"person","url":"https://hartvaat.nl/mensen/w-schuyler-jones/","name":"W Schuyler Jones","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":18,"articles":[{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/03/25/antitrombotische-therapie-bij-af-na-acs-pci-augustus-gecombineerde-inzichten/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/09/01/aspirinedosering-voor-secundaire-preventie-bij-mannen-versus-vrouwen/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2023/12/12/voyager-pad-rivaroxaban-plus-aspirine-na-endovasculaire-revascularisatie-voor-pa/","published":"2023-12-12"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2022/10/18/asundexian-factor-xia-remmer-na-acs-fase-2-dosisfindingsstudie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/04/09/asundexian-factor-xia-remmer-versus-apixaban-bij-af-lancet-pacific-af/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/10/12/overbrugging-van-antiplaatjestherapie-na-pci-jacc-review/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/01/01/mi-bij-pav-patienten-incidentie-en-uitkomsten-euclid/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/12/25/cv-en-ledemaat-uitkomsten-bij-diabetes-met-pav-euclid/","published":"2018-12-25"},{"url":"https://hartvaat.nl/2018/10/02/cv-uitkomsten-na-endovasculaire-versus-chirurgische-revascularisatie-onderste-le/","published":"2018-10-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"assen-r-goudev","type":"person","url":"https://hartvaat.nl/mensen/assen-r-goudev/","name":"Assen R Goudev","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","published":"2024-08-24"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2021/10/01/uitgebreide-vasodilatatie-en-qol-bij-acuut-hf-substudie/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2019/12/17/uitgebreide-vasodilatatie-versus-standaardzorg-bij-acuut-hf-jama-galactic-hf-pil/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2016/12/10/omecamtiv-mecarbil-bij-chronisch-hartfalen-lancet-cosmic-hf-fase-2-trial/","published":"2016-12-10"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"clyde-w-yancy","type":"person","url":"https://hartvaat.nl/mensen/clyde-w-yancy/","name":"Clyde W Yancy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/05/19/sglt2-remmers-bij-oudere-patienten-opgenomen-voor-hfref-24-sterfte-en-16-heropna/","published":"2026-06-15"},{"url":"https://hartvaat.nl/2024/04/16/2024-acc-expert-consensus-behandeling-van-hfref-beslispad-geactualiseerd/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2023/05/09/2023-acc-expert-consensus-management-van-hfpef/","published":"2023-05-09"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2021/02/16/2021-acc-hf-behandeloptimalisatie-update-antwoorden-op-10-cruciale-vragen/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/11/24/2020-acc-aha-prestatie-en-kwaliteitsmaten-voor-hartfalen/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/03/17/2020-acc-hfsa-ishlt-verklaring-voor-gevorderd-hf-en-transplantatiespecialisten/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/07/09/2019-aha-acc-hrs-gerichte-update-van-de-af-richtlijn/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2016/12/06/comorbiditeiten-bij-hartfalen-hypertensie-obesitas-diabetes-hyperlipidemie-en-me/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/05/01/intracoronaire-adenylylcyclase-6-gentherapie-bij-hartfalen-gerandomiseerde-trial/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daichi-shimbo","type":"person","url":"https://hartvaat.nl/mensen/daichi-shimbo/","name":"Daichi Shimbo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/10/01/esh-convenant-polshorloges-bloeddrukmeters-acceptabele-nauwkeurigheid-maar-klini/","published":"2026-09-02"},{"url":"https://hartvaat.nl/2026/05/12/nhlbi-workshop-bloeddrukmeting-verfijnen-door-de-hele-levensloop-heen-knelpunten/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2025/01/01/ultra-lage-dosis-combinatiepil-als-startbehandeling-voor-hypertensie/","published":"2026-03-02"},{"url":"https://hartvaat.nl/2026/01/22/verschil-tussen-klinische-en-ambulante-bloeddruk-en-valrisico-bij-ouderen/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/28/prevent-vergelijkingen-voor-intensieve-versus-standaard-bloeddrukcontrole/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/08/01/hele-genoomsequencing-onthult-nieuwe-bloeddruk-loci/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/07/27/heeft-deze-volwassene-hypertensie-jama-rational-clinical-examination/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2020/10/01/intensieve-versus-standaard-bloeddrukbehandeling-op-white-coat-effect-en-gemaske/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2018/02/01/nauwkeurigheid-van-bloeddrukmeters-in-de-zwangerschap-systematische-review/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/02/09/generaliseerbaarheid-van-sprint-resultaten-naar-de-algemene-bevolking/","published":"2016-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-erlinge","type":"person","url":"https://hartvaat.nl/mensen/david-erlinge/","name":"David Erlinge","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2025/12/11/ticagrelor-plus-aspirine-versus-aspirine-na-cabg-voor-acs-gerandomiseerde-trial/","published":"2025-12-11"},{"url":"https://hartvaat.nl/2025/12/01/dapagliflozine-na-mi-naar-ef-cardiometabole-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/10/07/help-mi-helicobacter-pylori-screening-na-acuut-mi-cluster-rct/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/01/07/euroheart-definities-van-klinische-studie-eindpunten-voor-cvd/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/11/02/bioadaptor-implantaat-versus-drug-eluting-stent-bij-stabiel-coronairlijden/","published":"2024-11-02"},{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2024/04/18/abyss-betablokkers-na-mi-met-behouden-ef-niet-nodig-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/08/01/sekseverschillen-in-effectiviteit-van-hartfalenmedicatie-meta-analyse/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2022/03/15/5-jaars-ifr-versus-ffr-geleide-pci-define-flair-ifr-swedeheart/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2018/12/11/langetermijneffecten-van-zuurstof-op-sterfte-of-hf-hospitalisatie-na-verdenking-/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/08/01/zuurstoftherapie-bij-stemi-overzichtsartikel/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/09/28/zuurstoftherapie-bij-vermoedelijk-acuut-myocardinfarct-nejm-deto2x-ami/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/05/11/instantaneous-wave-free-ratio-versus-ffr-voor-pci-indicatie-nejm-ifr-swedeheart/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-simone-biscaglia","type":"person","url":"https://hartvaat.nl/mensen/dr-simone-biscaglia/","name":"Dr. Simone Biscaglia","title":"Cardioloog, University Hospital of Ferrara","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2025/12/09/gepersonaliseerde-versus-standaard-dapt-duur-na-pci-gerandomiseerde-trial/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/11/11/ct-angiografie-of-standaardzorg-na-pci-van-de-linker-hoofdstam/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/09/11/multidomein-revalidatie-bij-ouderen-na-mi-gerandomiseerde-trial-nejm/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","published":"2024-11-09"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2020/11/07/complete-revascularisatie-vermindert-cv-dood-bij-stemi-met-multivatenlijden-meta/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/11/01/inspanningsinterventie-verbetert-qol-na-mi-bij-ouderen-gerandomiseerde-trial/","published":"2020-11-01"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-air-stemi-hotline/","title":"AIR-STEMI: angiografisch afgeleide FFR bij STEMI"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eldrin-f-lewis","type":"person","url":"https://hartvaat.nl/mensen/eldrin-f-lewis/","name":"Eldrin F Lewis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2024/10/01/plotse-dood-na-mi-inzichten-uit-valiant-en-paradise-mi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/10/tact-2-chelatietherapie-na-mi-bij-diabetes-negatieve-trial/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2020/06/01/variatie-in-uitkomsten-tussen-complexe-hfpef-fenotypen/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2018/10/01/natriuretische-peptiden-en-cardiovasculaire-prognose-bij-hfpef-topcat/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/06/01/sacubitril-valsartan-en-fysieke-en-sociale-activiteitsbeperkingen-bij-hf-paradig/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/09/12/lichamelijke-activiteit-en-prognose-bij-hfpef-topcat-analyse/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2016/07/05/advance-care-planning-video-bij-gevorderd-hartfalen-gerandomiseerde-trial/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/02/01/invloed-van-ejectiefractie-op-uitkomsten-van-spironolacton-bij-hfpef/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"erin-a-bohula","type":"person","url":"https://hartvaat.nl/mensen/erin-a-bohula/","name":"Erin A Bohula","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/01/13/effectiviteit-en-veiligheid-van-zeer-laag-bereikt-ldl-na-ischemisch-cva/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2019/09/01/simvastatine-ezetimibe-versus-simvastatine-na-acs-bij-75-plussers-jama-cardiolog/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2018/07/10/inflammatie-en-cholesterol-in-de-fourier-trial/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/04/10/ezetimibe-bij-diabetes-versus-zonder-diabetes-improve-it-subanalyse/","published":"2018-04-10"},{"url":"https://hartvaat.nl/2017/12/19/cva-preventie-met-ezetimibe-bij-acs-improve-it-analyse/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2016/12/21/ezetimibe-bij-post-cabg-patienten-met-acs-improve-it-subanalyse/","published":"2016-12-21"},{"url":"https://hartvaat.nl/2016/07/26/atherotrombotische-risicostratificatie-en-vorapaxar-bij-stabiel-ischemisch-hartl/","published":"2016-07-26"},{"url":"https://hartvaat.nl/2016/07/05/nierfunctie-en-uitkomsten-met-edoxaban-in-de-engage-af-timi-48-trial/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/02/02/reductie-in-totale-cardiovasculaire-events-met-ezetimibe-simvastatine-na-acs-imp/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"finn-gustafsson","type":"person","url":"https://hartvaat.nl/mensen/finn-gustafsson/","name":"Finn Gustafsson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/02/23/aspirinestop-bij-lvad-met-vka-veiligheidsanalyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/04/22/thoracentese-bij-acuut-hartfalen-gerandomiseerde-trial/","published":"2025-04-22"},{"url":"https://hartvaat.nl/2025/03/01/aspirine-en-hemocompatibiliteit-na-lvad-bij-atherosclerotisch-vaatlijden/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2022/12/01/hartfalen-tijdens-de-covid-19-pandemie-klinische-en-organisatorische-dilemma-s/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/07/01/empagliflozine-en-lv-volumes-en-functie-bij-hfref-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/06/01/metabole-effecten-van-empagliflozine-bij-hf-empire-hf-metabolic-gerandomiseerde-/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/12/08/empagliflozine-en-hemodynamiek-bij-hfref/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2019/11/26/interatriale-shunt-en-pulmonale-vaatfunctie-bij-hfpef/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/02/01/herhaalde-levosimendan-infusies-bij-gevorderd-chronisch-hf-in-de-kwetsbare-postd/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/08/01/kenmerken-en-prognose-van-hfmref-versus-hfref-en-hfpef-langetermijn/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"george-a-wells","type":"person","url":"https://hartvaat.nl/mensen/george-a-wells/","name":"George A Wells","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/02/20/vanish2-catheterablatie-versus-antiaritmica-bij-ventriculaire-tachycardie-nejm/","published":"2025-02-20"},{"url":"https://hartvaat.nl/2024/01/18/raft-langetermijn-crt-d-bij-hartfalen-nejm-14-jaarsresultaten/","published":"2024-01-18"},{"url":"https://hartvaat.nl/2023/05/01/aware-uitgebreide-ablatie-vermindert-af-recidief-niet-boven-standaard-pvi/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2022/02/01/sekse-en-gender-in-crt-studies-systematische-review/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2021/08/05/milrinone-versus-dobutamine-bij-cardiogene-shock-nejm-doremi/","published":"2021-08-05"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"},{"url":"https://hartvaat.nl/2020/03/10/routine-versus-selectieve-cardiale-mri-bij-niet-ischemisch-hf-outsmart-hf/","published":"2020-03-10"},{"url":"https://hartvaat.nl/2020/02/01/elektrische-versus-farmacologische-cardioversie-bij-acuut-af-op-de-seh-lancet-ra/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2020/02/01/femorale-versus-radiale-toegang-bij-stemi-jama-cardiology-safari-stemi/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2018/11/21/voortzetten-versus-onderbreken-doac-bij-device-chirurgie-bruise-control-2/","published":"2018-11-21"},{"url":"https://hartvaat.nl/2018/01/09/risico-s-van-overinterpretatie-van-interimdata-lessen-uit-de-total-trial/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/05/09/agressieve-bloeddrukcontrole-en-recidief-van-af-na-ablatie-gerandomiseerde-trial/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2016/07/14/ablatie-versus-escalatie-van-antiaritmica-bij-ventriculaire-tachycardie-nejm-van/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hein-heidbuchel","type":"person","url":"https://hartvaat.nl/mensen/hein-heidbuchel/","name":"Hein Heidbüchel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/02/03/kortste-af-cycluslengte-in-de-longvenen-identificeert-pvi-responders/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/02/05/smartphone-ppg-voor-af-detectie-en-management-verbeterde-screening/","published":"2025-02-05"},{"url":"https://hartvaat.nl/2024/12/26/gerichte-patienteneducatie-vermindert-ongeplande-cv-events-bij-af/","published":"2024-12-26"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2021/01/27/periprocedurele-antistolling-bij-eliminate-af-ononderbroken-edoxaban-versus-vka/","published":"2021-01-27"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/01/01/weglaten-van-aspirine-bij-gecombineerde-antitrombotische-therapie-voor-af-acs-he/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/01/determinanten-van-linkeratriumtrombi-bij-geplande-cardioversie-ensure-af/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/09/21/ononderbroken-edoxaban-versus-vka-bij-af-ablatie-eliminate-af/","published":"2019-09-21"},{"url":"https://hartvaat.nl/2018/08/01/2018-ehra-praktische-gids-doac-s-bij-af-europace-editie/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/04/21/2018-ehra-praktische-gids-voor-doac-gebruik-bij-af/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2018/04/21/telemonitoring-verbetert-doac-therapietrouw-bij-af/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/07/2016-esc-richtlijn-voor-atriumfibrilleren-in-samenwerking-met-eacts/","published":"2016-10-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"heribert-schunkert","type":"person","url":"https://hartvaat.nl/mensen/heribert-schunkert/","name":"Heribert Schunkert","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/02/23/immunoadsorptie-bij-gedilateerde-cardiomyopathie-de-iaso-dcm-trial/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/02/05/de-erfelijke-basis-van-coronairlijden-nejm-overzicht/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2026/02/03/kenmerken-van-asymptomatische-patienten-met-hartfalen-en-verminderde-ejectiefrac/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/04/17/in-stent-restenose-tienjaarsuitkomsten-plain-balloon-vs-dcb-vs-des-isar-desire-3/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2019/01/15/10-jaarsuitkomsten-van-drie-limus-eluting-stents-coating-vergelijking/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/07/bioresorbeerbare-scaffold-versus-ees-bij-stabiel-coronairlijden-prospectieve-tri/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/02/01/katheterablatie-bij-af-met-hartfalen-nejm-castle-af/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/10/01/pci-versus-cabg-bij-linker-hoofdstamstenose-jama-cardiology-systematische-review/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/06/28/escitalopram-bij-hartfalen-en-depressie-de-mood-hf-trial/","published":"2016-06-28"},{"url":"https://hartvaat.nl/2016/02/06/bioresorbeerbare-versus-metallic-stents-meta-analyse-van-gerandomiseerde-trials/","published":"2016-02-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hyo-soo-kim","type":"person","url":"https://hartvaat.nl/mensen/hyo-soo-kim/","name":"Hyo-Soo Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","published":"2025-11-08"},{"url":"https://hartvaat.nl/2025/05/01/aspirine-versus-clopidogrel-na-coronaire-stenting-naar-bloedingsrisico-en-comple/","published":"2025-05-01"},{"url":"https://hartvaat.nl/2023/10/17/antiplaatjesmonotherapie-na-pci-clopidogrel-versus-aspirine-naar-risicoprofiel/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/05/02/korte-versus-standaard-dapt-na-pci-met-moderne-des-meta-analyse/","published":"2023-05-02"},{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2023/01/10/host-exam-extended-clopidogrel-superieur-aan-aspirine-als-monotherapie-na-pci/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2021/06/26/aspirine-versus-clopidogrel-voor-chronische-monotherapie-na-pci-lancet-host-exam/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2021/03/16/duurzame-versus-biodegradeerbare-polymer-des-bij-acs-meta-analyse/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/10/10/prasugrel-gebaseerde-dapt-de-escalatie-na-pci-bij-acs-lancet-host-reduce-polytec/","published":"2020-10-10"},{"url":"https://hartvaat.nl/2020/05/05/des-versus-cabg-bij-linker-hoofdstam-10-jaarsresultaten-excel-extended/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jacob-a-udell","type":"person","url":"https://hartvaat.nl/mensen/jacob-a-udell/","name":"Jacob A Udell","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/06/01/invested-griepvaccin-immuunrespons-bij-hoog-risico-cv-patienten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2023/01/05/nejm-interventie-voor-snelle-ambulante-follow-up-na-acuut-hartfalen/","published":"2023-01-05"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/02/01/geschiktheid-voor-sglt2-remmers-bij-diabetespatienten-opgenomen-met-hartfalen/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/11/01/interventies-voor-statinevoorschrijving-bij-primaire-cv-preventie-meta-analyse/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2018/06/01/fgf-23-en-recidiverende-cv-events-na-acs/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/02/01/cv-uitkomsten-naar-albumin-en-nierziekte-bij-diabetes-type-2-met-hoog-cv-risico/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/09/05/cardiovasculair-risico-na-fertiliteitstherapie-systematische-review-en-meta-anal/","published":"2017-09-05"},{"url":"https://hartvaat.nl/2016/01/21/langdurige-duale-antiplaatjestherapie-bij-patienten-met-eerder-myocardinfarct-me/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeong-gun-park","type":"person","url":"https://hartvaat.nl/mensen/jeong-gun-park/","name":"Jeong-Gun Park","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/01/13/effectiviteit-en-veiligheid-van-zeer-laag-bereikt-ldl-na-ischemisch-cva/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/12/01/serieel-hoog-sensitief-troponine-t-voorspelt-cv-events-na-acs-odyssey-analyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/05/03/vupanorsen-en-non-hdl-cholesterol-bij-statinebehandelde-patienten-translate-timi/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/10/12/baseline-ldl-en-klinische-uitkomsten-van-ezetimibe-plus-statine-improve-it/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/03/09/halve-versus-volle-dosis-edoxaban-bij-af-gerandomiseerde-vergelijking/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2019/06/18/evolocumab-bij-ckd-werkzaamheid-en-veiligheid-in-de-fourier-trial/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2018/07/10/inflammatie-en-cholesterol-in-de-fourier-trial/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/04/10/ezetimibe-bij-diabetes-versus-zonder-diabetes-improve-it-subanalyse/","published":"2018-04-10"},{"url":"https://hartvaat.nl/2017/12/19/cva-preventie-met-ezetimibe-bij-acs-improve-it-analyse/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2017/05/01/langetermijnveiligheid-van-zeer-lage-ldl-cholesterolniveaus-improve-it-analyse/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/12/21/ezetimibe-bij-post-cabg-patienten-met-acs-improve-it-subanalyse/","published":"2016-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johanne-silvain","type":"person","url":"https://hartvaat.nl/mensen/johanne-silvain/","name":"Johanne Silvain","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/11/19/afloat-flecainide-voorkomt-af-na-pfo-sluiting-rct/","published":"2024-11-19"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2023/09/26/biodegradeerbare-versus-duurzame-polymeer-stents-bij-hoog-bloedingsrisico/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"},{"url":"https://hartvaat.nl/2019/03/05/timing-van-prasugrel-start-en-coronairangiografie-bij-nstemi/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/09/27/oct-geleide-pci-optimalisatie-bij-nste-acs-gerandomiseerde-trial/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/04/26/vroege-aldosteronblokkade-bij-acuut-myocardinfarct-de-albatross-trial/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johannes-f-e-mann","type":"person","url":"https://hartvaat.nl/mensen/johannes-f-e-mann/","name":"Johannes F E Mann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/03/29/confidence-analyse-acute-egfr-daling-bij-empagliflozin-finerenone-is-reversibel-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/02/23/semaglutide-vermindert-infectierisico-bij-diabetes-en-chronische-nierziekte/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","published":"2025-05-29"},{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","published":"2025-03-24"},{"url":"https://hartvaat.nl/2024/10/22/flow-semaglutide-vermindert-hartfalen-bij-diabetes-en-ckd/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/07/11/flow-semaglutide-beschermt-nieren-bij-type-2-diabetes-en-ckd-nejm-gerelateerd/","published":"2024-07-11"},{"url":"https://hartvaat.nl/2023/02/01/aspirine-en-cardiovasculaire-uitkomsten-bij-chronische-nierziekte/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/03/01/kdigo-2021-bloeddruk-bij-ckd-executive-summary/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2020/10/08/dapagliflozine-bij-chronische-nierziekte-nejm-dapa-ckd/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-bij-diabetes-type-2-met-ckd-leader-renale-analyse/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/09/01/bereikte-diastolische-bloeddruk-en-polsdruk-bij-streef-sbp-en-cv-uitkomsten-bij-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/05/15/liraglutide-bij-diabetes-type-2-met-polyvasculaire-ziekte-leader-analyse/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2017/06/03/bereikte-bloeddruk-en-cv-uitkomsten-bij-hoogrisicopatienten-ontarget-transcend/","published":"2017-06-03"},{"url":"https://hartvaat.nl/2016/07/28/liraglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-leader-trial/","published":"2016-07-28"},{"url":"https://hartvaat.nl/2016/06/01/langetermijneffecten-van-atorvastatine-bij-diabetes-type-2-op-hemodialyse-4d-tri/","published":"2016-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karen-sliwa","type":"person","url":"https://hartvaat.nl/mensen/karen-sliwa/","name":"Karen Sliwa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2022/11/01/antihypertensieve-combinaties-bij-afrikaanse-patienten-creole-secundaire-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/20/vergelijking-van-duale-therapieen-voor-bloeddrukverlaging-bij-afrikaanse-afrikan/","published":"2019-06-20"},{"url":"https://hartvaat.nl/2018/09/01/bereikte-diastolische-bloeddruk-en-polsdruk-bij-streef-sbp-en-cv-uitkomsten-bij-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/06/03/bereikte-bloeddruk-en-cv-uitkomsten-bij-hoogrisicopatienten-ontarget-transcend/","published":"2017-06-03"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lluis-mont","type":"person","url":"https://hartvaat.nl/mensen/lluis-mont/","name":"Lluís Mont","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/06/02/autonoom-remodelling-vormt-onafhankelijk-domein-binnen-atriale-cardiomyopathie/","published":"2026-08-11"},{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2021/12/07/av-junctieablatie-plus-crt-bij-permanent-af-met-smal-qrs-apaf-crt-mortaliteitsan/","published":"2021-12-07"},{"url":"https://hartvaat.nl/2021/01/27/periprocedurele-antistolling-bij-eliminate-af-ononderbroken-edoxaban-versus-vka/","published":"2021-01-27"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/10/01/optimale-interlaesieafstand-bij-ablatie-index-geleide-af-ablatie-gerandomiseerde/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/09/21/ononderbroken-edoxaban-versus-vka-bij-af-ablatie-eliminate-af/","published":"2019-09-21"},{"url":"https://hartvaat.nl/2019/05/01/thoracoscopische-versus-katheterablatie-bij-af-langetermijn-fast-trial/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2019/04/01/pr-interval-en-pacingmodus-en-af-incidentie-bij-tweekamer-pacemaker/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/12/01/av-junctieablatie-plus-crt-bij-permanent-af-gerandomiseerde-trial/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2017/01/01/axafa-afnet-5-apixaban-versus-vka-bij-af-ablatie-studieprotocol/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/02/01/rechterkamerseptumpacing-versus-apexpacing-bij-crt-defibrillator-gerandomiseerde/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matthew-j-shun-shin","type":"person","url":"https://hartvaat.nl/mensen/matthew-j-shun-shin/","name":"Matthew J Shun-Shin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2023/03/30/upgrade-van-rv-pacemaker-naar-crt-of-geleidingssysteempacing-meta-analyse/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/02/16/catheterablatie-verbetert-cv-uitkomsten-bij-af-en-hartfalen-meta-analyse-van-rct/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/19/coronaire-flowreserve-en-cardiovasculaire-uitkomsten-meta-analyse/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/09/21/bijwerkingspatronen-in-crossover-trial-statine-placebo-geen-behandeling-statinwi/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2020/11/26/n-of-1-trial-van-statine-placebo-of-geen-behandeling-voor-bijwerkingen-nejm-stat/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2019/08/01/optimale-laesieset-bij-persisterend-af-ablatie-meta-regressie/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/04/17/sglt2-remmers-glp-1-agonisten-en-dpp-4-remmers-vergelijkende-cardiovasculaire-me/","published":"2018-04-17"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"myeong-ki-hong","type":"person","url":"https://hartvaat.nl/mensen/myeong-ki-hong/","name":"Myeong-Ki Hong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","published":"2023-04-04"},{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"},{"url":"https://hartvaat.nl/2020/06/16/ticagrelor-monotherapie-versus-dapt-op-bloedingen-en-cv-events-bij-acs-jama-tico/","published":"2020-06-16"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-muntner","type":"person","url":"https://hartvaat.nl/mensen/paul-muntner/","name":"Paul Muntner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/04/09/sekseverschillen-in-lipiden-en-lipoproteinen-en-het-cardiovasculaire-risico-uk-b/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/05/12/nhlbi-workshop-bloeddrukmeting-verfijnen-door-de-hele-levensloop-heen-knelpunten/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/03/02/barrieres-bij-implementatie-van-lipidenverlagende-therapie-in-de-praktijk/","published":"2026-03-26"},{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2021/03/01/kdigo-2021-bloeddruk-bij-ckd-executive-summary/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2020/10/01/intensieve-versus-standaard-bloeddrukbehandeling-op-white-coat-effect-en-gemaske/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/26/2019-aha-acc-prestatie-en-kwaliteitsmaten-voor-hoge-bloeddruk/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/06/01/bloeddrukverlaging-naar-uitgangsdruk-en-cv-risico-bij-diabetes-type-2/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/02/01/nauwkeurigheid-van-bloeddrukmeters-in-de-zwangerschap-systematische-review/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/08/01/bloeddrukvariabiliteit-en-vasculaire-events-bij-diabetes-type-2/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/07/01/medicatie-non-adherentie-en-visit-to-visit-bloeddrukvariabiliteit-target-bp-stud/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/02/09/generaliseerbaarheid-van-sprint-resultaten-naar-de-algemene-bevolking/","published":"2016-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philip-e-aylward","type":"person","url":"https://hartvaat.nl/mensen/philip-e-aylward/","name":"Philip E Aylward","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-bij-stabiel-coronairlijden-stability-inzic/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/03/14/afweging-myocardinfarct-versus-bloedingstype-en-mortaliteit-na-acs-tra-2p-timi-5/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/07/26/atherotrombotische-risicostratificatie-en-vorapaxar-bij-stabiel-ischemisch-hartl/","published":"2016-07-26"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/05/21/af-type-en-risico-op-trombo-embolie-mortaliteit-en-bloedingen-systematische-revi/","published":"2016-05-21"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philipp-lurz","type":"person","url":"https://hartvaat.nl/mensen/philipp-lurz/","name":"Philipp Lurz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2025/09/25/digitoxine-bij-hfref-gerandomiseerde-trial-nejm/","published":"2025-09-25"},{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2019/08/01/renale-denervatie-bij-geisoleerde-systolische-hypertensie-vergelijking-van-kathe/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/01/29/drie-armen-vergelijkende-renale-denervatie-radiosound-htn/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2019/01/22/milde-hypothermie-bij-cardiogene-shock-complicerend-mi/","published":"2019-01-22"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2018/02/03/sirolimus-eluting-bioabsorbeerbare-stent-versus-everolimus-eluting-stent-na-mi-l/","published":"2018-02-03"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pieter-c-smits","type":"person","url":"https://hartvaat.nl/mensen/pieter-c-smits/","name":"Pieter C Smits","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-laagrisico-acuut-mi/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2024/11/02/bioadaptor-implantaat-versus-drug-eluting-stent-bij-stabiel-coronairlijden/","published":"2024-11-02"},{"url":"https://hartvaat.nl/2024/01/01/verkorte-dapt-bij-hoog-bloedingsrisico-geen-sekseverschillen/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2020/12/15/prehospitaal-gemalen-prasugrel-bij-stemi-gerandomiseerde-trial/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/08/01/complete-versus-culprit-only-revascularisatie-bij-stemi-jama-cardiology-meta-ana/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/04/14/langetermijnuitkomsten-bij-vrouwen-en-mannen-na-pci/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2017/10/03/ridaforolimus-versus-zotarolimus-eluting-stents-gerandomiseerde-primaire-resulta/","published":"2017-10-03"},{"url":"https://hartvaat.nl/2017/03/30/ffr-geleide-multivaten-pci-bij-myocardinfarct-nejm-compare-acute/","published":"2017-03-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pim-a-l-tonino","type":"person","url":"https://hartvaat.nl/mensen/pim-a-l-tonino/","name":"Pim A L Tonino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/06/09/tino-stents-versus-des-bij-acs-ipd-meta-analyse/","published":"2025-06-09"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/01/tino-gecoate-versus-everolimus-eluting-stents-bij-acs-tides-acs-vijfjaarsdata/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2019/04/01/ffr-verbetering-na-pci-en-uitkomsten-inclusief-symptoomverlichting/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2018/01/30/kosteneffectiviteit-van-ffr-geleide-pci-bij-stabiele-coronairlijden/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2016/11/29/natuurlijk-beloop-van-coronaire-atherosclerose-met-ffr-prospectieve-studie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/04/12/prognostische-waarde-van-residuele-coronairstenosen-na-functioneel-complete-reva/","published":"2016-04-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-rolf-wachter","type":"person","url":"https://hartvaat.nl/mensen/prof-rolf-wachter/","name":"Prof. Rolf Wachter","title":"Cardioloog, Universitätsklinikum Leipzig","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/02/23/immunoadsorptie-bij-gedilateerde-cardiomyopathie-de-iaso-dcm-trial/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/02/03/kenmerken-van-asymptomatische-patienten-met-hartfalen-en-verminderde-ejectiefrac/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/03/15/doac-s-versus-geen-anticoagulatie-na-intracraniele-bloeding-bij-af-meta-analyse/","published":"2025-03-15"},{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2024/08/20/tadalafil-bij-gecombineerde-post-en-precapillaire-ph-en-hfpef/","published":"2024-08-20"},{"url":"https://hartvaat.nl/2023/11/01/beta3-lvh-mirabegron-bij-linkerventrikel-hypertrofie-fase-2b-rct/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/02/01/diabetes-en-sacubitril-valsartan-titratie-bij-hartfalen-na-opname/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/12/01/baseline-parameters-en-1-jaars-qol-bij-hf-na-crt-d-esc-hf/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/11/30/voorspellers-van-af-ontwikkeling-bij-embolic-stroke-of-undetermined-source-re-sp/","published":"2021-11-30"},{"url":"https://hartvaat.nl/2021/11/16/sacubitril-valsartan-versus-standaardtherapie-op-nt-probnp-en-inspanningscapacit/","published":"2021-11-16"},{"url":"https://hartvaat.nl/2021/05/01/screening-op-af-bij-ouderen-jama-cardiology-gerandomiseerde-trial/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2020/06/01/economische-impact-van-hfpef-aldo-dhf-inzichten/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2018/02/01/hoeveelheid-of-intensiteit-van-inspanning-bij-hfpef/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/06/28/escitalopram-bij-hartfalen-en-depressie-de-mood-hf-trial/","published":"2016-06-28"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-pvi-sham-af-hotline/","title":"PVI-SHAM-AF: ablatie versus schijnprocedure"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"raymond-r-townsend","type":"person","url":"https://hartvaat.nl/mensen/raymond-r-townsend/","name":"Raymond R Townsend","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/05/12/nhlbi-workshop-bloeddrukmeting-verfijnen-door-de-hele-levensloop-heen-knelpunten/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2025/03/01/kaliumnitraat-bij-hfpef-gerandomiseerde-trial/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2022/10/22/symplicity-htn-3-langetermijn-follow-up-renale-denervatie-bij-resistente-hyperte/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2022/07/01/pulsatiele-hemodynamiek-voorspelt-bloeddrukrespons-op-renale-denervatie/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/09/07/hartfrequentie-en-uitkomsten-van-renale-denervatie-bij-ongecontroleerde-hyperten/","published":"2021-09-07"},{"url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2020/03/01/orthostatische-hypotensie-cv-uitkomsten-en-adverse-events-sprint-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/03/01/ambulante-hartfrequentiereductie-na-renale-denervatie-bij-hypertensie-zonder-med/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/10/09/24-uurs-ambulante-bloeddrukreductie-na-renale-denervatie-spyral-htn-off-med/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2018/06/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-6-maandsresultat/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/11/01/therapieresistente-hypertensie-na-sprint-evaluatie-en-management/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"raul-moreno","type":"person","url":"https://hartvaat.nl/mensen/raul-moreno/","name":"Raúl Moreno","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2023/04/08/biovasc-directe-versus-gestageerde-complete-revascularisatie-bij-acs-met-meervat/","published":"2023-04-08"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"samir-r-kapadia","type":"person","url":"https://hartvaat.nl/mensen/samir-r-kapadia/","name":"Samir R Kapadia","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/09/01/anemie-verergert-mortaliteit-en-hartfalenheropnames-na-tavr-bij-patienten-boven-/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/06/10/triluminate-tweejaarsresultaten-transcatheter-tr-repair-duurzaam-effectief/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/03/05/gelijktijdige-laa-occlusie-en-tavr-bij-af-haalbaarheid/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","published":"2023-11-23"},{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","published":"2022-11-15"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/13/dapt-na-pci-met-des-netwerkmeta-analyse-van-duur-en-intensiteit/","published":"2020-10-13"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-ballonexpandeerbare-klep-bij-laagrisicopatienten-nejm-partner-3/","published":"2019-05-02"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sigrun-halvorsen","type":"person","url":"https://hartvaat.nl/mensen/sigrun-halvorsen/","name":"Sigrun Halvorsen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/05/25/betami-danblock-is-representatief-betablokker-effect-ook-geldig-in-echte-noorse-/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2026/05/26/esc-consensus-vrouwenhartcentra-whc-als-nieuw-zorgmodel-in-europa/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","published":"2025-09-13"},{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/12/21/culprit-shock-integratie-in-2017-esc-stemi-richtlijn-richtlijncommissie-standpun/","published":"2018-12-21"},{"url":"https://hartvaat.nl/2018/01/07/2017-esc-richtlijn-voor-stemi-management/","published":"2018-01-07"},{"url":"https://hartvaat.nl/2017/09/26/secundaire-cardiovasculaire-preventie-bij-diabetes-type-2-tecos-internationale-i/","published":"2017-09-26"},{"url":"https://hartvaat.nl/2016/09/01/apixaban-5-mg-bij-af-met-hoge-leeftijd-laag-gewicht-of-hoog-creatinine-aristotle/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"},{"url":"https://hartvaat.nl/2016/04/01/ischemisch-risicogebied-en-reperfusiemethode-bij-stemi-klinische-implicaties/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"terje-r-pedersen","type":"person","url":"https://hartvaat.nl/mensen/terje-r-pedersen/","name":"Terje R Pedersen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2021/02/01/evolocumab-bij-metabool-syndroom-na-acs-fourier/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/02/25/genetische-risicoscore-voorspelt-voordeel-van-evolocumab-fourier/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2019/07/01/evolocumab-en-totale-cv-events-bij-cardiovasculaire-ziekte-fourier-analyse/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/18/evolocumab-bij-ckd-werkzaamheid-en-veiligheid-in-de-fourier-trial/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2019/01/01/interindividuele-variatie-in-ldl-verlaging-met-evolocumab-fourier-analyse/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/10/13/lp-a-baseline-en-on-statin-voor-cv-eventvoorspelling-lancet-ipd-meta-analyse/","published":"2018-10-13"},{"url":"https://hartvaat.nl/2018/08/21/klinisch-voordeel-van-evolocumab-naar-ernst-van-coronairlijden-fourier/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/07/10/inflammatie-en-cholesterol-in-de-fourier-trial/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/12/01/evolocumab-bij-hoogrisicopatienten-met-laag-ldl-op-statine-fourier-subanalyse/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2017/08/17/cognitieve-functie-in-de-fourier-trial-met-evolocumab-nejm-ebbinghaus/","published":"2017-08-17"},{"url":"https://hartvaat.nl/2017/05/04/evolocumab-en-klinische-uitkomsten-bij-cardiovasculaire-ziekte-nejm-fourier/","published":"2017-05-04"},{"url":"https://hartvaat.nl/2016/10/14/2016-esc-eas-richtlijn-voor-het-management-van-dyslipidemieen/","published":"2016-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"uwe-zeymer","type":"person","url":"https://hartvaat.nl/mensen/uwe-zeymer/","name":"Uwe Zeymer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/03/03/4-eiwitmodel-voor-cardiogene-shock-prognose-danger-substudie/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2025/12/01/scai-shockklassen-en-prognose-bij-ami-cardiogene-shock-danger-substudie/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2023/03/28/culprit-interventie-bij-cardiogene-shock-met-hartstilstand/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2021/01/19/residuele-syntax-score-bij-cardiogene-shock/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","published":"2017-10-19"},{"url":"https://hartvaat.nl/2017/08/01/des-versus-bms-bij-acuut-mi-met-cardiogene-shock/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/07/01/1-jaarsmortaliteit-bivalirudine-versus-heparine-in-de-ambulance-bij-stemi-matrix/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/04/18/risicostratificatie-bij-cardiogene-shock-na-acuut-myocardinfarct/","published":"2017-04-18"},{"url":"https://hartvaat.nl/2016/08/16/bio-absorbeerbare-intracoronaire-matrix-ter-preventie-van-ventriculaire-remodell/","published":"2016-08-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"victor-c-shi","type":"person","url":"https://hartvaat.nl/mensen/victor-c-shi/","name":"Victor C Shi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/11/16/sacubitril-valsartan-versus-standaardtherapie-op-nt-probnp-en-inspanningscapacit/","published":"2021-11-16"},{"url":"https://hartvaat.nl/2021/02/01/polsdruk-prognose-en-sacubitril-valsartan-bij-hfpef-paragon-hf/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/09/29/arni-en-renale-uitkomsten-bij-hfpef-paragon-hf/","published":"2020-09-29"},{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/04/14/systolische-bloeddruk-bij-hfpef-behandeld-met-sacubitril-valsartan-paragon-hf/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/28/eerdere-hf-hospitalisatie-en-sacubitril-valsartan-versus-valsartan-bij-hfpef-par/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/03/26/bnp-tijdens-sacubitril-valsartan-paradigm-hf/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2019/02/26/sacubitril-valsartan-en-biomarkers-van-extracellulaire-matrixregulatie-bij-hfref/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/06/01/sacubitril-valsartan-en-fysieke-en-sociale-activiteitsbeperkingen-bij-hf-paradig/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/04/14/systolische-bloeddruk-en-werkzaamheid-van-sacubitril-valsartan-bij-chronisch-hfr/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/01/01/verminderd-hyperkaliemierisico-met-mra-door-sacubitril-valsartan-bij-hartfalen/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/12/06/prognostische-implicaties-van-nt-probnp-veranderingen-bij-hartfalen/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/11/29/bmi-en-nauwkeurigheid-van-nt-probnp-en-bnp-voor-diagnose-van-acuut-hartfalen/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/07/19/sacubitril-valsartan-en-30-daagse-heropname-na-hartfalenhospitalisatie/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/06/07/klinische-verslechtering-van-poliklinisch-behandeld-hartfalen-paradigm-hf-analys/","published":"2016-06-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wilfried-mullens","type":"person","url":"https://hartvaat.nl/mensen/wilfried-mullens/","name":"Wilfried Mullens","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":17,"articles":[{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2026/05/05/off-label-dosering-van-sacubitril-valsartan-wijdverspreid-in-de-praktijk/","published":"2026-07-30"},{"url":"https://hartvaat.nl/2026/05/09/praise-mr-sacubitril-valsartan-verbetert-inspanningshemodynamiek-bij-hfpef-met-a/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2026/03/25/inspanningsecho-identificeert-hcm-patienten-die-baat-hebben-bij-mavacamten/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/09/30/adaptresponse-adaptieve-versus-conventionele-crt-bij-hartfalen-lancet/","published":"2023-09-30"},{"url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","published":"2023-06-09"},{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/12/01/hartfalen-tijdens-de-covid-19-pandemie-klinische-en-organisatorische-dilemma-s/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","published":"2022-09-29"},{"url":"https://hartvaat.nl/2021/12/21/iv-ijzercarboxymaltose-en-cardiale-reverse-remodellering-na-crt-iron-crt/","published":"2021-12-21"},{"url":"https://hartvaat.nl/2020/10/01/sekseverschillen-in-kenmerken-en-qol-bij-crt-patienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/03/31/staken-van-neurohumorale-blokkade-na-crt/","published":"2020-03-31"},{"url":"https://hartvaat.nl/2018/06/01/implementatie-van-sacubitril-valsartan-in-de-klinische-praktijk-inzichten/","published":"2018-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexandre-mebazaa","type":"person","url":"https://hartvaat.nl/mensen/alexandre-mebazaa/","name":"Alexandre Mebazaa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/03/03/tien-jaar-real-world-sacubitril-valsartan-mortaliteitsreductie-bevestigd-maar-sl/","published":"2026-04-20"},{"url":"https://hartvaat.nl/2026/03/16/natrium-hf-subanalyse-natriuretische-peptiden-lopen-achter-op-de-klinische-ontst/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","published":"2023-06-09"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","published":"2022-09-29"},{"url":"https://hartvaat.nl/2020/11/17/seh-zorgbundel-en-30-daags-ontslag-en-overleving-bij-oudere-hf-patienten-jama/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2018/07/10/epinefrine-versus-norepinefrine-bij-cardiogene-shock-na-acuut-mi/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-j-s-coats","type":"person","url":"https://hartvaat.nl/mensen/andrew-j-s-coats/","name":"Andrew J S Coats","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/02/01/finerenon-en-lvh-bij-ckd-en-diabetes/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/06/14/euroheart-datastandaarden-voor-hartfalenregistraties/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/04/01/robuustheid-van-sglt2-remmer-hf-trials-evaluatie/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2021/10/16/betablokker-respons-bij-hf-met-sinusritme-en-af-machine-learning-clusteranalyse/","published":"2021-10-16"},{"url":"https://hartvaat.nl/2020/12/01/sglt2-remmers-bij-hartfalen-systematische-review-en-meta-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/12/01/ijzercarboxymaltose-bij-ijzerdeficient-hartfalen-meta-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2019/04/02/inspanningsrevalidatie-bij-hf-ipd-meta-analyse-van-inspanningscapaciteit-en-qol/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/06/20/hartfrequentie-en-ritme-en-het-voordeel-van-betablokkers-bij-hartfalen/","published":"2017-06-20"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anthony-h-gershlick","type":"person","url":"https://hartvaat.nl/mensen/anthony-h-gershlick/","name":"Anthony H Gershlick","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2024/03/12/rapid-nstemi-zeer-vroege-invasieve-strategie-bij-hoger-risico-nstemi/","published":"2024-03-12"},{"url":"https://hartvaat.nl/2022/10/13/revived-bcis2-pci-verbetert-overleving-niet-bij-ischemische-lv-disfunctie/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2020/08/01/complete-versus-culprit-only-revascularisatie-bij-stemi-jama-cardiology-meta-ana/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2019/12/24/langetermijnfollow-up-van-complete-versus-laesie-only-revascularisatie-bij-stemi/","published":"2019-12-24"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/07/07/revascularisatie-versus-optimale-medicamenteuze-therapie-bij-cto-gerandomiseerde/","published":"2018-07-07"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"},{"url":"https://hartvaat.nl/2016/06/21/strategieen-om-microvasculaire-obstructie-te-verminderen-bij-primaire-pci-relief/","published":"2016-06-21"},{"url":"https://hartvaat.nl/2016/06/07/ischemie-en-infarct-bij-stemi-met-multivatenlijden-cvlprit-nucleaire-substudie/","published":"2016-06-07"},{"url":"https://hartvaat.nl/2016/04/26/predictieregel-voor-voordeel-en-schade-van-dapt-na-1-jaar-pci-jama-validatiestud/","published":"2016-04-26"},{"url":"https://hartvaat.nl/2016/04/01/ischemisch-risicogebied-en-reperfusiemethode-bij-stemi-klinische-implicaties/","published":"2016-04-01"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bon-kwon-koo","type":"person","url":"https://hartvaat.nl/mensen/bon-kwon-koo/","name":"Bon-Kwon Koo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/05/01/aspirine-versus-clopidogrel-na-coronaire-stenting-naar-bloedingsrisico-en-comple/","published":"2025-05-01"},{"url":"https://hartvaat.nl/2025/04/26/angiografie-afgeleide-ffr-versus-ivus-bij-pci-gerandomiseerde-trial/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/10/17/antiplaatjesmonotherapie-na-pci-clopidogrel-versus-aspirine-naar-risicoprofiel/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/05/02/korte-versus-standaard-dapt-na-pci-met-moderne-des-meta-analyse/","published":"2023-05-02"},{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2023/01/10/host-exam-extended-clopidogrel-superieur-aan-aspirine-als-monotherapie-na-pci/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2021/06/26/aspirine-versus-clopidogrel-voor-chronische-monotherapie-na-pci-lancet-host-exam/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2021/03/16/duurzame-versus-biodegradeerbare-polymer-des-bij-acs-meta-analyse/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/10/10/prasugrel-gebaseerde-dapt-de-escalatie-na-pci-bij-acs-lancet-host-reduce-polytec/","published":"2020-10-10"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-j-maron","type":"person","url":"https://hartvaat.nl/mensen/david-j-maron/","name":"David J Maron","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2025/09/23/pci-versus-cabg-en-gezondheidsstatus-bij-stabiel-coronairlijden/","published":"2025-09-23"},{"url":"https://hartvaat.nl/2025/09/16/ischemia-anginatrajecten-na-invasieve-versus-conservatieve-strategie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/02/28/incidenteel-coronair-calcium-op-ct-thorax-ai-gestuurde-screening-verbetert-stati/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/09/01/routine-revascularisatie-versus-medicamenteus-bij-stabiel-coronairlijden-meta-an/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/23/gezondheidsstatus-na-invasieve-of-conservatieve-zorg-bij-coronairlijden-met-gevo/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/04/30/leefstijl-hba1c-en-overleving-bij-stabiel-coronairlijden-met-diabetes/","published":"2019-04-30"},{"url":"https://hartvaat.nl/2017/02/07/acc-aats-aha-2016-criteria-voor-gepaste-coronaire-revascularisatie-bij-acs-en-st/","published":"2017-02-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-j-whellan","type":"person","url":"https://hartvaat.nl/mensen/david-j-whellan/","name":"David J Whellan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2023/02/01/fysieke-revalidatie-bij-fragiele-ouderen-met-acuut-hartfalen/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"},{"url":"https://hartvaat.nl/2022/07/12/frailteit-beinvloedt-effect-van-inspanningstraining-bij-hartfalen-hf-action-anal/","published":"2022-07-12"},{"url":"https://hartvaat.nl/2022/02/01/economische-uitkomsten-van-revalidatie-bij-ouderen-met-acuut-hf-rehab-hf/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2021/07/15/fysieke-revalidatie-bij-oudere-gehospitaliseerde-hf-patienten-nejm-rehab-hf/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/04/02/inspanningsrevalidatie-bij-hf-ipd-meta-analyse-van-inspanningscapaciteit-en-qol/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/11/27/economische-en-qol-uitkomsten-van-nt-probnp-geleide-hf-therapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","published":"2018-11-06"},{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/08/22/natriuretisch-peptide-geleide-therapie-bij-hoogrisico-hartfalen-jama-guide-it/","published":"2017-08-22"},{"url":"https://hartvaat.nl/2017/05/16/oraal-ijzer-bij-hfref-met-ijzerdeficientie-jama-ironout-hf/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2017/04/04/inspanningstraining-bij-chronisch-hartfalen-met-atriumfibrilleren/","published":"2017-04-04"},{"url":"https://hartvaat.nl/2017/03/28/adaptieve-servoventilatie-bij-hartfalen-de-cat-hf-trial/","published":"2017-03-28"},{"url":"https://hartvaat.nl/2016/08/02/liraglutide-en-klinische-stabiliteit-bij-gevorderd-hartfalen-met-verminderde-ef-/","published":"2016-08-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dean-j-kereiakes","type":"person","url":"https://hartvaat.nl/mensen/dean-j-kereiakes/","name":"Dean J Kereiakes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2023/07/18/bioresorbeerbare-coronaire-scaffolds-vijfjaarsuitkomsten-met-verbeterde-techniek/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2019/12/01/absorb-scaffold-5-jaarsresultaten-systematische-meta-analyse/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2018/10/27/absorb-iv-bioresorbeerbare-scaffold-30-daags-en-1-jaarsresultaten/","published":"2018-10-27"},{"url":"https://hartvaat.nl/2018/01/30/absorb-bioresorbeerbare-scaffold-3-jaarsresultaten-ipd-meta-analyse/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2017/12/12/implantatiechniek-en-uitkomsten-van-bioresorbeerbare-scaffolds-absorb-analyses/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/12/12/3-jaarsresultaten-van-bioresorbeerbare-scaffolds-absorb-iii-trial/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/10/31/laesiecomplexiteit-en-uitkomsten-van-verlengde-dapt-na-pci/","published":"2017-10-31"},{"url":"https://hartvaat.nl/2017/08/19/absorb-bioresorbeerbare-scaffold-lancet-2-jaars-systematische-review-en-meta-ana/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2017/05/02/mi-risico-na-stoppen-van-thienopyridine-dapt-studie/","published":"2017-05-02"},{"url":"https://hartvaat.nl/2016/10/04/impact-van-optimale-medicamenteuze-therapie-in-de-dapt-studie/","published":"2016-10-04"},{"url":"https://hartvaat.nl/2016/05/31/dapt-score-validatie-bij-patienten-met-en-zonder-eerder-myocardinfarct/","published":"2016-05-31"},{"url":"https://hartvaat.nl/2016/05/03/diabetes-en-preventie-van-laat-myocardinfarct-na-stenting-dapt-studie/","published":"2016-05-03"},{"url":"https://hartvaat.nl/2016/04/26/predictieregel-voor-voordeel-en-schade-van-dapt-na-1-jaar-pci-jama-validatiestud/","published":"2016-04-26"},{"url":"https://hartvaat.nl/2016/01/21/doodsoorzaken-bij-langdurige-dapt-na-coronaire-stents/","published":"2016-01-21"},{"url":"https://hartvaat.nl/2016/01/21/langdurige-duale-antiplaatjestherapie-bij-patienten-met-eerder-myocardinfarct-me/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dipak-kotecha","type":"person","url":"https://hartvaat.nl/mensen/dipak-kotecha/","name":"Dipak Kotecha","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/05/21/find-af-biomarker-stratificeert-prognose-bij-hfref-met-atriale-cardiomyopathie-z/","published":"2026-06-08"},{"url":"https://hartvaat.nl/2025/03/26/rate-af-kosteneffectiviteit-van-digoxine-versus-betablokkers-bij-permanent-af/","published":"2025-03-26"},{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2022/09/26/smartphone-detectie-van-af-via-fotoplethysmografie-meta-analyse/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2021/10/16/betablokker-respons-bij-hf-met-sinusritme-en-af-machine-learning-clusteranalyse/","published":"2021-10-16"},{"url":"https://hartvaat.nl/2021/07/01/transformatie-van-klinisch-onderzoek-door-patientbetrokkenheid-rate-af/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/12/22/digoxine-versus-bisoprolol-voor-frequentiecontrole-bij-af-en-qol-jama-rate-af/","published":"2020-12-22"},{"url":"https://hartvaat.nl/2020/05/01/predictie-van-af-recidief-na-ablatie-systematische-review-van-prognostische-mode/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2019/05/01/thoracoscopische-versus-katheterablatie-bij-af-langetermijn-fast-trial/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2018/10/16/doac-s-halveren-trombo-embolische-events-na-af-cardioversie-versus-warfarine/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/09/01/validiteit-en-reproduceerbaarheid-van-echocardiografie-bij-af-systematische-revi/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/06/20/hartfrequentie-en-ritme-en-het-voordeel-van-betablokkers-bij-hartfalen/","published":"2017-06-20"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/07/2016-esc-richtlijn-voor-atriumfibrilleren-in-samenwerking-met-eacts/","published":"2016-10-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"guillaume-cayla","type":"person","url":"https://hartvaat.nl/mensen/guillaume-cayla/","name":"Guillaume Cayla","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2025/01/01/antistolling-alleen-of-met-plaatjesremming-bij-coronairlijden-meta-analyse/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-laagrisico-acuut-mi/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2025/10/23/aspirine-bij-chronisch-coronairsyndroom-plus-oac-wel-of-niet/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/11/19/afloat-flecainide-voorkomt-af-na-pfo-sluiting-rct/","published":"2024-11-19"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2023/09/26/biodegradeerbare-versus-duurzame-polymeer-stents-bij-hoog-bloedingsrisico/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2021/11/09/ffr-voor-behandeling-van-multivatencoronairlijden-jacc/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"},{"url":"https://hartvaat.nl/2018/02/03/sirolimus-eluting-bioabsorbeerbare-stent-versus-everolimus-eluting-stent-na-mi-l/","published":"2018-02-03"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/04/26/vroege-aldosteronblokkade-bij-acuut-myocardinfarct-de-albatross-trial/","published":"2016-04-26"},{"url":"https://hartvaat.nl/2016/01/21/stoppen-of-doorgaan-met-clopidogrel-12-maanden-na-drug-eluting-stent-optidual-tr/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"itamar-raz","type":"person","url":"https://hartvaat.nl/mensen/itamar-raz/","name":"Itamar Raz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/04/01/lp-a-en-hscrp-als-cv-risicofactoren-primaire-en-secundaire-preventie/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2022/09/01/dapagliflozine-effectief-ongeacht-cv-achtergrondmedicatie-declare-subanalyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-bij-diabetes-type-2-met-ckd-leader-renale-analyse/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/02/01/cv-uitkomsten-naar-albumin-en-nierziekte-bij-diabetes-type-2-met-hoog-cv-risico/","published":"2018-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jackson-t-wright","type":"person","url":"https://hartvaat.nl/mensen/jackson-t-wright/","name":"Jackson T Wright","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2020/03/01/orthostatische-hypotensie-cv-uitkomsten-en-adverse-events-sprint-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/01/01/intensieve-versus-standaard-bloeddrukcontrole-op-ambulante-bloeddruk-sprint-resu/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/08/01/apol1-nierrisicovarianten-en-cerebrale-wittestoflaesies/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"},{"url":"https://hartvaat.nl/2016/03/01/voorschrijfpatronen-van-thiazidediuretica-in-de-sprint-trial/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jindrich-spinar","type":"person","url":"https://hartvaat.nl/mensen/jindrich-spinar/","name":"Jindřich Špinar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/04/10/ezetimibe-bij-diabetes-versus-zonder-diabetes-improve-it-subanalyse/","published":"2018-04-10"},{"url":"https://hartvaat.nl/2016/12/10/omecamtiv-mecarbil-bij-chronisch-hartfalen-lancet-cosmic-hf-fase-2-trial/","published":"2016-12-10"},{"url":"https://hartvaat.nl/2016/10/22/edoxaban-versus-enoxaparine-warfarine-bij-cardioversie-van-af-ensure-af-trial/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/09/20/cva-preventie-met-ticagrelor-na-myocardinfarct-pegasus-timi-54-inzichten/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-b-buse","type":"person","url":"https://hartvaat.nl/mensen/john-b-buse/","name":"John B Buse","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","published":"2025-05-29"},{"url":"https://hartvaat.nl/2022/09/22/grade-vergelijking-glucoseverlagende-middelen-op-microvasculaire-en-cv-uitkomste/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2020/04/28/open-label-drop-in-van-glucoseverlagende-medicatie-en-exscel-uitkomsten/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2020/03/17/liraglutide-cv-uitkomsten-bij-diabetes-met-of-zonder-hartfalen-leader/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/12/01/eerste-en-recidiverende-cv-events-met-liraglutide-bij-diabetes-type-2-leader/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-cv-uitkomsten-met-of-zonder-eerder-mi-leader/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/05/15/liraglutide-bij-diabetes-type-2-met-polyvasculaire-ziekte-leader-analyse/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2017/11/01/hypertensiecontrole-bij-diabetes-met-recidiverende-cv-events-tecos-globale-resul/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/28/exenatide-eenmaal-per-week-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-ne/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/08/24/degludec-versus-glargine-bij-diabetes-type-2-nejm-devote-werkzaamheid-en-veiligh/","published":"2017-08-24"},{"url":"https://hartvaat.nl/2017/04/01/fenofibraat-en-langetermijn-cardiovasculair-risico-bij-statinebehandelde-diabete/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/07/28/liraglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-leader-trial/","published":"2016-07-28"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"},{"url":"https://hartvaat.nl/2016/03/08/naltrexon-bupropion-en-cardiovasculaire-events-bij-obesitas-gerandomiseerde-tria/","published":"2016-03-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joseph-f-sabik","type":"person","url":"https://hartvaat.nl/mensen/joseph-f-sabik/","name":"Joseph F Sabik","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/08/13/off-pump-versus-on-pump-cabg-bij-hoofdstamcoronairlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/07/31/bnp-bij-linker-hoofdstamrevascularisatie-excel-analyse/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"julio-nunez","type":"person","url":"https://hartvaat.nl/mensen/julio-nunez/","name":"Julio Núñez","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/06/26/machine-learning-voorspelt-diureticumrespons-bij-acuut-hartfalen-drc-ahf/","published":"2026-08-06"},{"url":"https://hartvaat.nl/2026/04/20/raas-blokkade-in-de-levenscyclus-van-de-nier-actuele-behandelstandaard/","published":"2026-05-02"},{"url":"https://hartvaat.nl/2026/03/03/expertopinie-hierarchische-eindpunten-op-basis-van-verslechterend-hartfalen-voor/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/02/03/bio-impedantie-voor-vochtstatusbepaling-en-prognose-bij-chronisch-hartfalen/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/07/28/routine-invasieve-strategie-en-herinfarctrisico-bij-fragiele-ouderen-met-nste-ac/","published":"2025-07-28"},{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/01/colica-colchicine-bij-acuut-gedecompenseerd-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2024/04/01/betablokkerstaken-verbetert-inspanningscapaciteit-bij-hfpef/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/04/01/iv-ferricarboxymaltose-verbetert-linkeratriale-strain-bij-hartfalen-myocardial-i/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2021/11/23/betablokkerstaken-en-functionele-capaciteit-bij-hfpef/","published":"2021-11-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"junbo-ge","type":"person","url":"https://hartvaat.nl/mensen/junbo-ge/","name":"Junbo Ge","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/04/10/vroege-evolocumab-na-hartinfarct-verlaagt-mace-bij-uitgestelde-randstenosen/","published":"2026-05-25"},{"url":"https://hartvaat.nl/2025/06/09/remote-ischemische-preconditionering-en-nierschade-na-coronairangiografie/","published":"2025-06-09"},{"url":"https://hartvaat.nl/2025/01/30/summit-tirzepatide-bij-hfpef-met-obesitas-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/02/01/maggic-score-voor-mortaliteitsvoorspelling-bij-klepziekte/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/01/17/option-indobufen-als-aspirine-alternatief-in-dapt-na-pci/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/05/25/hydratie-ter-preventie-van-nierschade-na-primaire-pci-gerandomiseerde-trial/","published":"2022-05-25"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2017/04/01/optimale-systolische-bloeddruk-voor-primaire-cva-preventie-bij-hypertensie-csppt/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/07/01/polsgolfsnelheid-en-bloeddrukcontrole-als-onafhankelijke-voorspellers-van-cva-bi/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"laura-mauri","type":"person","url":"https://hartvaat.nl/mensen/laura-mauri/","name":"Laura Mauri","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2018/10/01/transcatheter-interatriale-shunt-bij-hfpef-1-jaarsresultaten/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/07/31/antitrombotische-therapie-bij-af-met-oac-na-pci-aha-scientific-statement/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2018/01/23/transcatheter-interatriale-shunt-bij-hfpef-reduce-lap-hf-i/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/10/31/laesiecomplexiteit-en-uitkomsten-van-verlengde-dapt-na-pci/","published":"2017-10-31"},{"url":"https://hartvaat.nl/2017/10/21/ultradunne-bioresorbeerbare-versus-dunne-duurzame-polymer-stents-lancet-bioscien/","published":"2017-10-21"},{"url":"https://hartvaat.nl/2017/05/02/mi-risico-na-stoppen-van-thienopyridine-dapt-studie/","published":"2017-05-02"},{"url":"https://hartvaat.nl/2016/10/04/impact-van-optimale-medicamenteuze-therapie-in-de-dapt-studie/","published":"2016-10-04"},{"url":"https://hartvaat.nl/2016/09/20/cva-preventie-met-ticagrelor-na-myocardinfarct-pegasus-timi-54-inzichten/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/05/31/dapt-score-validatie-bij-patienten-met-en-zonder-eerder-myocardinfarct/","published":"2016-05-31"},{"url":"https://hartvaat.nl/2016/05/03/diabetes-en-preventie-van-laat-myocardinfarct-na-stenting-dapt-studie/","published":"2016-05-03"},{"url":"https://hartvaat.nl/2016/04/26/predictieregel-voor-voordeel-en-schade-van-dapt-na-1-jaar-pci-jama-validatiestud/","published":"2016-04-26"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"},{"url":"https://hartvaat.nl/2016/01/21/doodsoorzaken-bij-langdurige-dapt-na-coronaire-stents/","published":"2016-01-21"},{"url":"https://hartvaat.nl/2016/01/21/langdurige-duale-antiplaatjestherapie-bij-patienten-met-eerder-myocardinfarct-me/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"m-cecilia-bahit","type":"person","url":"https://hartvaat.nl/mensen/m-cecilia-bahit/","name":"M Cecilia Bahit","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/08/25/extracraniale-bloedingen-komen-bij-26-van-af-patienten-op-antistolling-voor-comb/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/01/06/sacubitril-valsartan-versus-enalapril-bij-chagas-hartfalen/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/11/30/voorspellers-van-af-ontwikkeling-bij-embolic-stroke-of-undetermined-source-re-sp/","published":"2021-11-30"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2017/10/14/multifacet-interventie-voor-oac-gebruik-bij-af-lancet-impact-af/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2017/04/01/niet-ernstige-bloedingen-met-apixaban-versus-warfarine-bij-af/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mark-a-hlatky","type":"person","url":"https://hartvaat.nl/mensen/mark-a-hlatky/","name":"Mark A Hlatky","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/01/01/vitamine-d-voorkomt-statine-gerelateerde-spierklachten-niet/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2018/10/09/hypoglykemie-en-troponine-elevatie-bij-diabetes-met-coronairlijden/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2018/01/30/kosteneffectiviteit-van-ffr-geleide-pci-bij-stabiele-coronairlijden/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2016/03/29/drug-eluting-versus-bare-metal-stents-bij-pci-patienten-met-eindstadium-nierziek/","published":"2016-03-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"muhammad-shahzeb-khan","type":"person","url":"https://hartvaat.nl/mensen/muhammad-shahzeb-khan/","name":"Muhammad Shahzeb Khan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/03/03/c-mic-ii-hartfunctie-inspanningscapaciteit-en-kwaliteit-van-leven-zijn-verwante-/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2025/01/01/hartfalenpreventie-bewijsgeneratie-trialontwerp-en-regulatoire-trajecten/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2023/12/21/iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-ipd-meta-analyse/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2022/04/06/nierfunctiebeoordeling-en-eindpuntbepaling-in-klinische-trials-ehj/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2022/04/01/robuustheid-van-sglt2-remmer-hf-trials-evaluatie/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2021/10/19/diabetes-met-cardiomyopathie-in-de-community-prevalentie-en-prognose/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2020/12/01/sglt2-remmers-bij-hartfalen-systematische-review-en-meta-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/12/01/ijzercarboxymaltose-bij-ijzerdeficient-hartfalen-meta-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/13/dapt-na-pci-met-des-netwerkmeta-analyse-van-duur-en-intensiteit/","published":"2020-10-13"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2019/09/01/icd-en-overleving-bij-gevorderd-hf-met-continue-flow-lvad/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2017/11/01/raas-blokkade-bij-hfpef-systematische-review-en-meta-analyse/","published":"2017-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nick-curzen","type":"person","url":"https://hartvaat.nl/mensen/nick-curzen/","name":"Nick Curzen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/03/12/rapid-nstemi-zeer-vroege-invasieve-strategie-bij-hoger-risico-nstemi/","published":"2024-03-12"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2022/09/01/timing-van-invasieve-strategie-bij-nste-acs-meta-analyse-van-rct-s/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/08/30/ripcord-2-routinematige-ffr-meting-versus-conventionele-angiografie/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/05/25/jbs-richtlijn-management-van-hartstilstand-in-het-cathlab/","published":"2022-05-25"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2019/12/24/langetermijnfollow-up-van-complete-versus-laesie-only-revascularisatie-bij-stemi/","published":"2019-12-24"},{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2016/11/29/natuurlijk-beloop-van-coronaire-atherosclerose-met-ffr-prospectieve-studie/","published":"2016-11-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nico-h-j-pijls","type":"person","url":"https://hartvaat.nl/mensen/nico-h-j-pijls/","name":"Nico H J Pijls","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/03/28/coronaire-autoregulatie-samenspel-van-epicardiale-en-microvasculaire-weerstand/","published":"2026-03-28"},{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2025/06/09/tino-stents-versus-des-bij-acs-ipd-meta-analyse/","published":"2025-06-09"},{"url":"https://hartvaat.nl/2025/06/01/ffr-geleide-pci-versus-cabg-bij-diffuus-coronairlijden/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/01/tino-gecoate-versus-everolimus-eluting-stents-bij-acs-tides-acs-vijfjaarsdata/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2019/09/24/asymptomatische-patienten-met-abnormale-ffr-medicamenteus-versus-pci/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2019/04/01/ffr-verbetering-na-pci-en-uitkomsten-inclusief-symptoomverlichting/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2018/01/30/kosteneffectiviteit-van-ffr-geleide-pci-bij-stabiele-coronairlijden/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2016/11/29/natuurlijk-beloop-van-coronaire-atherosclerose-met-ffr-prospectieve-studie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/04/12/prognostische-waarde-van-residuele-coronairstenosen-na-functioneel-complete-reva/","published":"2016-04-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"norman-mangner","type":"person","url":"https://hartvaat.nl/mensen/norman-mangner/","name":"Norman Mangner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/03/25/palliatieve-zorg-in-de-cardiologie-een-state-of-the-art-overzicht/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/03/03/4-eiwitmodel-voor-cardiogene-shock-prognose-danger-substudie/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/02/19/delirium-in-de-cardiovasculaire-geneeskunde/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2020/11/07/drug-coated-balloons-versus-des-bij-kleine-coronairarterien-lancet-basket-small-/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2019/01/22/milde-hypothermie-bij-cardiogene-shock-complicerend-mi/","published":"2019-01-22"},{"url":"https://hartvaat.nl/2018/09/08/drug-coated-balloons-bij-kleine-coronairarterien-lancet-basket-small-2/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2017/02/28/hoog-intensieve-intervaltraining-bij-hartfalen-met-verminderde-ejectiefractie/","published":"2017-02-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"patrick-rossignol","type":"person","url":"https://hartvaat.nl/mensen/patrick-rossignol/","name":"Patrick Rossignol","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/02/01/aprocitentan-bij-ckd-en-resistente-hypertensie/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/11/20/afbouw-van-antihypertensieve-behandeling-bij-verpleeghuisbewoners-rct/","published":"2025-11-20"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/02/01/matige-hypothermie-versus-normothermie-bij-cardiogene-shock-met-va-ecmo-jama-hyp/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2021/12/01/longechogeleide-behandeling-bij-hemodialysepatienten-met-hoog-cv-risico-gerandom/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2020/04/01/biomarkers-bij-hf-met-centrale-slaapapneu-serve-hf/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2019/10/26/patiromer-voor-spironolactongebruik-bij-resistente-hypertensie-met-ckd-lancet-am/","published":"2019-10-26"},{"url":"https://hartvaat.nl/2019/02/01/spironolacton-en-collageenmetabolisme-biomarkers-bij-ongecontroleerde-hypertensi/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/07/10/epinefrine-versus-norepinefrine-bij-cardiogene-shock-na-acuut-mi/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/06/01/geindividualiseerd-patiromer-doseringsregime-bij-hf-met-ckd-en-hyperkaliemie/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/02/20/cva-risico-bij-verminderde-ef-na-mi-zonder-af/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/03/01/24-uurs-bloeddrukmonitoring-bij-renale-denervatie-denerhtn-studie/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-a-heidenreich","type":"person","url":"https://hartvaat.nl/mensen/paul-a-heidenreich/","name":"Paul A Heidenreich","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2024/09/17/2024-acc-aha-kwaliteitsmaatstaven-voor-hartfalen-geactualiseerd/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2024/05/28/pro-hf-routine-prom-meting-in-hartfalenpolikliniek-verbetert-uitkomsten/","published":"2024-05-28"},{"url":"https://hartvaat.nl/2023/01/11/metamfetamine-geassocieerd-hartfalen-systematische-review/","published":"2023-01-11"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/04/27/2021-acc-aha-kerngegevenselementen-voor-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/01/26/2020-acc-aha-kwaliteitsmaten-voor-af-geactualiseerd/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/11/24/2020-acc-aha-prestatie-en-kwaliteitsmaten-voor-hartfalen/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/02/01/geschiktheid-voor-sglt2-remmers-bij-diabetespatienten-opgenomen-met-hartfalen/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/11/26/2019-aha-acc-prestatie-en-kwaliteitsmaten-voor-hoge-bloeddruk/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/07/09/2019-aha-acc-hrs-gerichte-update-van-de-af-richtlijn/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"petr-kala","type":"person","url":"https://hartvaat.nl/mensen/petr-kala/","name":"Petr Kala","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2025/11/11/ffr-geleide-complete-versus-culprit-only-revascularisatie-bij-nstemi/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2022/01/04/4-jaars-laa-sluiting-versus-niet-warfarine-oac-bij-af/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"},{"url":"https://hartvaat.nl/2020/06/30/laa-sluiting-versus-doac-bij-hoogrisico-af-vergelijkende-analyse/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2018/01/30/prasugrel-versus-ticagrelor-bij-primaire-pci-voor-mi-1-jaarsuitkomsten/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2016/11/22/prasugrel-versus-ticagrelor-bij-acuut-mi-met-primaire-pci-multicenter-trial/","published":"2016-11-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"raffaele-de-caterina","type":"person","url":"https://hartvaat.nl/mensen/raffaele-de-caterina/","name":"Raffaele De Caterina","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2026/03/06/debat-preventieve-pci-bij-kwetsbare-plaques-als-standaardbehandeling/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2020/05/09/p2y12-monotherapie-of-aspirine-voor-secundaire-preventie-lancet-meta-analyse/","published":"2020-05-09"},{"url":"https://hartvaat.nl/2020/03/17/klinische-en-farmacologische-effecten-van-apixaban-dosisaanpassing-aristotle/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2020/01/07/nsaid-s-en-oac-bij-af-aristotle-analyse/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/11/01/determinanten-van-linkeratriumtrombi-bij-geplande-cardioversie-ensure-af/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/10/16/doac-s-halveren-trombo-embolische-events-na-af-cardioversie-versus-warfarine/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/08/14/adma-en-sdma-voorspellen-uitkomsten-bij-af-aristotle-substudie/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/06/14/langetermijnuitkomsten-bij-angina-zonder-obstructief-coronairlijden-systematisch/","published":"2018-06-14"},{"url":"https://hartvaat.nl/2018/03/13/digoxine-en-mortaliteit-bij-patienten-met-atriumfibrilleren/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2017/03/28/edoxaban-bij-af-met-bioprothese-hartkleppen-trombo-emboliepreventie/","published":"2017-03-28"},{"url":"https://hartvaat.nl/2017/03/21/kleplijden-en-edoxaban-versus-warfarine-bij-af-engage-af-timi-48/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2017/03/21/doac-s-bij-af-met-kleplijden-jacc-review/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"richard-e-pratley","type":"person","url":"https://hartvaat.nl/mensen/richard-e-pratley/","name":"Richard E Pratley","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/03/05/finerenon-effectief-bij-type-1-diabetes-met-chronische-nierziekte/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/02/23/semaglutide-vermindert-infectierisico-bij-diabetes-en-chronische-nierziekte/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","published":"2025-03-24"},{"url":"https://hartvaat.nl/2024/11/26/glp-1-agonisten-alleen-en-met-sglt2-remmers-cv-renale-en-veiligheidsuitkomsten/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/10/22/flow-semaglutide-vermindert-hartfalen-bij-diabetes-en-ckd/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/07/11/flow-semaglutide-beschermt-nieren-bij-type-2-diabetes-en-ckd-nejm-gerelateerd/","published":"2024-07-11"},{"url":"https://hartvaat.nl/2023/03/28/amplitude-o-dosisrespons-van-efpeglenatide-op-cv-uitkomsten-bij-diabetes/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2021/09/02/efpeglenatide-en-cv-en-renale-uitkomsten-bij-diabetes-type-2-nejm-amplitude-o/","published":"2021-09-02"},{"url":"https://hartvaat.nl/2021/02/01/sglt2-remmers-en-cv-renale-uitkomsten-bij-diabetes-type-2-jama-cardiology-meta-a/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/12/08/ertugliflozine-en-hf-events-bij-diabetes-met-atherosclerotische-cvd-vertis-cv/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/10/08/ertugliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-vertis-cv/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/03/17/liraglutide-cv-uitkomsten-bij-diabetes-met-of-zonder-hartfalen-leader/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-cv-uitkomsten-met-of-zonder-eerder-mi-leader/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/05/15/liraglutide-bij-diabetes-type-2-met-polyvasculaire-ziekte-leader-analyse/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2017/08/24/degludec-versus-glargine-bij-diabetes-type-2-nejm-devote-werkzaamheid-en-veiligh/","published":"2017-08-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-s-rosenson","type":"person","url":"https://hartvaat.nl/mensen/robert-s-rosenson/","name":"Robert S Rosenson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/03/02/barrieres-bij-implementatie-van-lipidenverlagende-therapie-in-de-praktijk/","published":"2026-03-26"},{"url":"https://hartvaat.nl/2025/05/20/plozasiran-en-lipoproteine-deeltjesgrootte-bij-hypertriglyceridemie/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/05/03/solbinsiran-langwerkend-sirna-tegen-angptl3-duurzaamheid-en-effectiviteit/","published":"2025-05-03"},{"url":"https://hartvaat.nl/2025/01/09/plozasiran-bij-persisterende-chylomicronemie-en-pancreatitisrisico-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2024/09/12/zodasiran-sirna-tegen-angptl3-bij-gemengde-hyperlipidemie-nejm/","published":"2024-09-12"},{"url":"https://hartvaat.nl/2024/09/12/plozasiran-sirna-tegen-apoc3-bij-gemengde-hyperlipidemie-nejm/","published":"2024-09-12"},{"url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2024/07/01/plozasiran-sirna-tegen-apoc3-bij-ernstige-hypertriglyceridemie-shasta-2/","published":"2024-07-01"},{"url":"https://hartvaat.nl/2023/11/01/evinacumab-bij-refractaire-hypercholesterolemie-langetermijn-effectiviteit-en-ve/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2022/11/17/olpasiran-sirna-verlaagt-lipoproteine-a-spectaculair-in-fase-2-trial/","published":"2022-11-17"},{"url":"https://hartvaat.nl/2020/12/10/evinacumab-bij-refractaire-hypercholesterolemie-nejm/","published":"2020-12-10"},{"url":"https://hartvaat.nl/2020/08/20/evinacumab-bij-homozygoot-familiaire-hypercholesterolemie-nejm/","published":"2020-08-20"},{"url":"https://hartvaat.nl/2020/07/14/alirocumab-bij-homozygoot-fh-odyssey-hofh/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2020/05/26/evolocumab-bij-hiv-met-dyslipidemie-beijerinck-gerandomiseerde-studie/","published":"2020-05-26"},{"url":"https://hartvaat.nl/2017/09/26/sams-ci-score-toegepast-op-gerandomiseerde-trial-over-statine-myopathie/","published":"2017-09-26"},{"url":"https://hartvaat.nl/2016/04/19/evolocumab-versus-ezetimibe-bij-statine-intolerante-patienten-de-gauss-3-trial/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sunil-v-rao","type":"person","url":"https://hartvaat.nl/mensen/sunil-v-rao/","name":"Sunil V Rao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/asundexian-factor-xia-remmer-na-acs-fase-2-dosisfindingsstudie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/01/18/2021-acc-aha-scai-richtlijn-voor-coronaire-revascularisatie-executive-summary/","published":"2022-01-18"},{"url":"https://hartvaat.nl/2021/10/12/overbrugging-van-antiplaatjestherapie-na-pci-jacc-review/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/02/16/2021-acc-consensus-same-day-ontslag-na-pci/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2020/09/15/ami-management-tijdens-covid-19-scai-positiedocument/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2018/05/19/des-versus-bms-in-veneuze-bypass-grafts-lancet-dubbelblinde-trial/","published":"2018-05-19"},{"url":"https://hartvaat.nl/2016/08/16/bio-absorbeerbare-intracoronaire-matrix-ter-preventie-van-ventriculaire-remodell/","published":"2016-08-16"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tim-friede","type":"person","url":"https://hartvaat.nl/mensen/tim-friede/","name":"Tim Friede","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/05/05/reduce-mfa-dzhk25-trial-naar-antifibrotische-therapie-tegen-myocardfibrose-na-ta/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/02/03/kenmerken-van-asymptomatische-patienten-met-hartfalen-en-verminderde-ejectiefrac/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/05/iv-ferricarboxymaltose-en-inspanningscapaciteit-bij-hfpef-met-ijzerdeficientie/","published":"2024-10-05"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2023/12/21/iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-ipd-meta-analyse/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/04/01/robuustheid-van-sglt2-remmer-hf-trials-evaluatie/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/12/01/sglt2-remmers-bij-hartfalen-systematische-review-en-meta-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vijay-k-chopra","type":"person","url":"https://hartvaat.nl/mensen/vijay-k-chopra/","name":"Vijay K Chopra","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vivek-y-reddy","type":"person","url":"https://hartvaat.nl/mensen/vivek-y-reddy/","name":"Vivek Y Reddy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/10/15/lage-voorspelde-adherentie-verhoogt-stroke-risico-bij-af-patienten-die-starten-m/","published":"2026-08-08"},{"url":"https://hartvaat.nl/2026/02/03/upgrade-van-draadloze-pacemaker-van-enkelvoudig-naar-tweekamersysteem/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/04/03/laa-sluiting-na-af-ablatie-gerandomiseerde-trial-nejm/","published":"2025-04-03"},{"url":"https://hartvaat.nl/2024/12/01/splanchnische-zenuwablatie-bij-hfpef-endovasculaire-benadering/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/07/02/pfa-versus-thermale-ablatie-bij-paroxysmaal-af-aritmielastanalyse/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/02/01/pulmonaalvenenstenose-na-pfa-versus-thermale-ablatie-vergelijking/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/11/02/advent-pulsed-field-ablatie-non-inferieur-aan-thermale-ablatie-bij-af-nejm/","published":"2023-11-02"},{"url":"https://hartvaat.nl/2023/02/08/redo-firm-firm-geleide-ablatie-verbetert-uitkomst-niet-bij-recidief-af/","published":"2023-02-08"},{"url":"https://hartvaat.nl/2022/01/04/4-jaars-laa-sluiting-versus-niet-warfarine-oac-bij-af/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2021/06/01/katheterablatie-of-antiaritmica-als-eerstelijnstherapie-bij-af-jama-cardiology-m/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/12/08/laa-sluiting-versus-oac-bij-af-meta-analyse-van-gerandomiseerde-trials/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/11/17/transcatheter-bariatrische-embolotherapie-voor-gewichtsreductie-bij-obesitas/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2020/06/30/laa-sluiting-versus-doac-bij-hoogrisico-af-vergelijkende-analyse/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2017/12/19/5-jaarsuitkomsten-na-linker-hartoorsluiting-prevail-en-protect-af/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/10/01/terminatie-van-persisterend-af-tijdens-pvi-inzichten-uit-magic-af/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/05/21/stapsgewijze-ablatie-gestuurd-door-laaggedoseerd-ibutilide-bij-chronisch-af-magi/","published":"2016-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"william-f-fearon","type":"person","url":"https://hartvaat.nl/mensen/william-f-fearon/","name":"William F Fearon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":16,"articles":[{"url":"https://hartvaat.nl/2026/01/06/caviar-alirocumab-bij-cardiale-allograft-vasculopathie-na-harttransplantatie/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/06/01/ffr-geleide-pci-versus-cabg-bij-diffuus-coronairlijden/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2025/04/26/angiografie-afgeleide-ffr-versus-ivus-bij-pci-gerandomiseerde-trial/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2019/09/24/asymptomatische-patienten-met-abnormale-ffr-medicamenteus-versus-pci/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2019/04/01/ffr-verbetering-na-pci-en-uitkomsten-inclusief-symptoomverlichting/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/10/16/hoge-coronaire-shear-stress-voorspelt-myocardinfarct/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2018/01/30/kosteneffectiviteit-van-ffr-geleide-pci-bij-stabiele-coronairlijden/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2016/11/29/natuurlijk-beloop-van-coronaire-atherosclerose-met-ffr-prospectieve-studie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/04/12/prognostische-waarde-van-residuele-coronairstenosen-na-functioneel-complete-reva/","published":"2016-04-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adrian-p-banning","type":"person","url":"https://hartvaat.nl/mensen/adrian-p-banning/","name":"Adrian P Banning","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2025/03/04/stapsgewijze-provisionale-versus-systematische-dualstent-bij-ware-linker-hoofdst/","published":"2025-03-04"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2024/03/12/rapid-nstemi-zeer-vroege-invasieve-strategie-bij-hoger-risico-nstemi/","published":"2024-03-12"},{"url":"https://hartvaat.nl/2022/09/01/timing-van-invasieve-strategie-bij-nste-acs-meta-analyse-van-rct-s/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/10/01/ebc-hoofdstam-stentstudie-provisional-versus-systematisch-dubbel-stenten/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/04/23/hedendaagse-uitkomsten-na-cabg-voor-hoofdstamlijden/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/07/31/bnp-bij-linker-hoofdstamrevascularisatie-excel-analyse/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alasdair-d-henderson","type":"person","url":"https://hartvaat.nl/mensen/alasdair-d-henderson/","name":"Alasdair D Henderson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/01/05/magnesium-en-uitkomsten-bij-hfref-galactic-hf-subanalyse/","published":"2026-01-05"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","published":"2024-09-21"},{"url":"https://hartvaat.nl/2024/06/18/mra-bij-hartfalen-met-nierfunctiestoornissen-veiligheid-en-effectiviteit/","published":"2024-06-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alberico-l-catapano","type":"person","url":"https://hartvaat.nl/mensen/alberico-l-catapano/","name":"Alberico L Catapano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/05/18/global-hicc-register-950-hofh-patienten-uit-45-landen-slechts-4-haalt-ldl-doelen/","published":"2026-06-17"},{"url":"https://hartvaat.nl/2026/05/22/orale-pcsk9-remmers-meta-analyse-bevestigt-krachtige-ldl-daling/","published":"2026-06-07"},{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/04/24/santorini-uk-ldl-doel-onbereikt-bij-meerderheid-van-hoogrisicopatienten-na-1-jaa/","published":"2026-05-08"},{"url":"https://hartvaat.nl/2026/04/22/angptl3-remmers-verlagen-breed-lipidenspectrum-vooral-remnant-en-triglyceriden/","published":"2026-05-05"},{"url":"https://hartvaat.nl/2026/02/05/orale-pcsk9-remmer-enlicitide-verlaagt-ldl-met-57-placebogecontroleerde-trial/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2026/01/13/enlicitide-orale-pcsk9-remmer-bij-heterozygote-fh-fase-3/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2023/04/25/mk-0616-eerste-orale-pcsk9-remmer-in-fase-2b/","published":"2023-04-25"},{"url":"https://hartvaat.nl/2019/03/14/bempedoinezuur-voor-ldl-verlaging-nejm-veiligheid-en-werkzaamheid/","published":"2019-03-14"},{"url":"https://hartvaat.nl/2018/07/14/ldl-verlaging-en-cv-events-met-pcsk9-remmers-meta-analyse-van-gerandomiseerde-tr/","published":"2018-07-14"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2017/11/14/ldl-verlaging-voor-primaire-preventie-bij-mannen-met-primaire-ldl-verhoging/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2016/10/14/2016-esc-eas-richtlijn-voor-het-management-van-dyslipidemieen/","published":"2016-10-14"},{"url":"https://hartvaat.nl/2016/08/01/2016-europese-richtlijnen-voor-cardiovasculaire-preventie-in-de-klinische-prakti/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrea-natale","type":"person","url":"https://hartvaat.nl/mensen/andrea-natale/","name":"Andrea Natale","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/04/07/zorgpaden-na-nieuw-vastgesteld-atriumfibrilleren-rol-van-de-elektrofysioloog-en-/","published":"2026-07-18"},{"url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","published":"2026-05-27"},{"url":"https://hartvaat.nl/2025/09/01/sedatie-versus-narcose-bij-af-catheterablatie-meta-analyse/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/03/pfa-versus-cryoballon-voor-af-ablatie-multielectrode-vergelijking/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/02/01/pulmonaalvenenstenose-na-pfa-versus-thermale-ablatie-vergelijking/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/11/02/advent-pulsed-field-ablatie-non-inferieur-aan-thermale-ablatie-bij-af-nejm/","published":"2023-11-02"},{"url":"https://hartvaat.nl/2021/02/05/laa-isolatie-tijdens-af-ablatie-geactualiseerde-meta-analyse/","published":"2021-02-05"},{"url":"https://hartvaat.nl/2020/10/27/af-ablatie-met-vena-van-marshall-ethanol-versus-ablatie-alleen-jama-venus/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2018/10/01/ononderbroken-doac-versus-vka-bij-af-ablatie-meta-analyse/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/08/01/linker-hartoorisolatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2016/12/01/rivaroxaban-versus-vka-bij-periprocedurele-antistolling-rond-af-ablatie/","published":"2016-12-01"},{"url":"https://hartvaat.nl/2016/11/01/linker-hartoorisolatie-bij-langdurig-persisterend-af-de-belief-trial/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/26/ablatie-versus-amiodaron-bij-persisterend-af-met-hartfalen-en-icd-gerandomiseerd/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"benjamin-m-scirica","type":"person","url":"https://hartvaat.nl/mensen/benjamin-m-scirica/","name":"Benjamin M Scirica","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/07/01/bestaande-cv-data-benutten-voor-hypertensiedetectie-en-behandeling-vital-trial/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","published":"2024-08-24"},{"url":"https://hartvaat.nl/2024/06/04/drive-remote-management-verbetert-richtlijnmedicatie-bij-hartfalen/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/04/01/lp-a-en-hscrp-als-cv-risicofactoren-primaire-en-secundaire-preventie/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/03/17/non-culprit-mi-na-pci-bij-acs/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/03/12/empagliflozine-vermindert-mortaliteit-en-hf-hospitalisatie-over-het-cv-risicospe/","published":"2019-03-12"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2018/02/01/cv-uitkomsten-naar-albumin-en-nierziekte-bij-diabetes-type-2-met-hoog-cv-risico/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/07/26/atherotrombotische-risicostratificatie-en-vorapaxar-bij-stabiel-ischemisch-hartl/","published":"2016-07-26"},{"url":"https://hartvaat.nl/2016/07/19/serieel-cardiaal-troponine-met-hoog-sensitieve-assay-bij-stabiel-ischemisch-hart/","published":"2016-07-19"},{"url":"https://hartvaat.nl/2016/03/08/acute-ledischemie-en-vorapaxar-bij-perifeer-arterieel-vaatlijden-tra-2p-timi-50-/","published":"2016-03-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carsten-skurk","type":"person","url":"https://hartvaat.nl/mensen/carsten-skurk/","name":"Carsten Skurk","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/02/19/delirium-in-de-cardiovasculaire-geneeskunde/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/04/03/laa-sluiting-na-af-ablatie-gerandomiseerde-trial-nejm/","published":"2025-04-03"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dan-atar","type":"person","url":"https://hartvaat.nl/mensen/dan-atar/","name":"Dan Atar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/05/25/betami-danblock-is-representatief-betablokker-effect-ook-geldig-in-echte-noorse-/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2026/01/13/effectiviteit-en-veiligheid-van-zeer-laag-bereikt-ldl-na-ischemisch-cva/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","published":"2025-09-13"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/02/11/langetermijn-evolocumab-bij-ouderen-effectiviteit-en-veiligheid/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","published":"2022-10-11"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/07/de-tien-geboden-van-de-2016-esc-af-richtlijn/","published":"2016-10-07"},{"url":"https://hartvaat.nl/2016/10/07/2016-esc-richtlijn-voor-atriumfibrilleren-in-samenwerking-met-eacts/","published":"2016-10-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-c-wheeler","type":"person","url":"https://hartvaat.nl/mensen/david-c-wheeler/","name":"David C Wheeler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/02/23/ijzertekort-bij-chronische-nierziekte-en-hartfalen-expertperspectieven/","published":"2026-03-04"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2023/11/25/zenith-ckd-zibotentan-plus-dapagliflozine-bij-ckd-lancet/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-niet-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/03/31/dapagliflozine-en-mortaliteit-bij-ckd-dapa-ckd-pre-gespecificeerde-analyse/","published":"2021-03-31"},{"url":"https://hartvaat.nl/2020/10/08/dapagliflozine-bij-chronische-nierziekte-nejm-dapa-ckd/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"},{"url":"https://hartvaat.nl/2018/10/09/sacubitril-valsartan-versus-irbesartan-bij-chronische-nierziekte/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2017/02/01/reverse-causality-in-de-associatie-bloeddruk-cardiovasculair-risico-bij-ckd/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-hildick-smith","type":"person","url":"https://hartvaat.nl/mensen/david-hildick-smith/","name":"David Hildick-Smith","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/04/16/pandora-register-supra-versus-intra-annulaire-kleppen-bij-tavr-in-tavr/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/03/04/stapsgewijze-provisionale-versus-systematische-dualstent-bij-ware-linker-hoofdst/","published":"2025-03-04"},{"url":"https://hartvaat.nl/2024/06/14/invasief-versus-conservatief-bij-ouderen-met-nste-acs-ipd-meta-analyse/","published":"2024-06-14"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/30/ripcord-2-routinematige-ffr-meting-versus-conventionele-angiografie/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/10/01/ebc-hoofdstam-stentstudie-provisional-versus-systematisch-dubbel-stenten/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","published":"2020-01-18"},{"url":"https://hartvaat.nl/2018/07/07/revascularisatie-versus-optimale-medicamenteuze-therapie-bij-cto-gerandomiseerde/","published":"2018-07-07"},{"url":"https://hartvaat.nl/2017/11/07/stentontwerp-en-dapt-duur-effect-op-ischemie-en-bloedingen-netwerkmeta-analyse/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2017/09/14/pfo-sluiting-of-antiplaatjestherapie-bij-cryptogeen-cva-nejm-close/","published":"2017-09-14"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-david-berg","type":"person","url":"https://hartvaat.nl/mensen/dr-david-berg/","name":"Dr. David Berg","title":"Cardioloog, Brigham and Women's Hospital; Harvard Medical School, Boston, VS","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":0,"articles":[],"videos":[{"url":"https://hartvaat.nl/video/sglt2-initiatie-hartfalen-opname/samenvatting-en-kernpunten/","title":"Samenvatting en kernboodschappen"},{"url":"https://hartvaat.nl/video/sglt2-initiatie-hartfalen-opname/context-en-ziektelast/","title":"Context en ziektelast"},{"url":"https://hartvaat.nl/video/sglt2-initiatie-hartfalen-opname/rationale-voor-de-trial/","title":"Rationale voor de studie"},{"url":"https://hartvaat.nl/video/sglt2-initiatie-hartfalen-opname/trialresultaten/","title":"Trialresultaten"},{"url":"https://hartvaat.nl/video/sglt2-initiatie-hartfalen-opname/klinische-implicaties/","title":"Klinische implicaties"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"enrico-frigoli","type":"person","url":"https://hartvaat.nl/mensen/enrico-frigoli/","name":"Enrico Frigoli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2024/01/01/verkorte-dapt-bij-hoog-bloedingsrisico-geen-sekseverschillen/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/02/02/dalend-hemoglobine-en-prognose-bij-acs-hospitalisatie/","published":"2021-02-02"},{"url":"https://hartvaat.nl/2019/04/14/aki-en-bloedingen-en-mortaliteit-na-radiale-versus-femorale-toegang-bij-acs/","published":"2019-04-14"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/05/23/stralingsblootstelling-en-vasculaire-toegang-bij-acs-rad-matrix-trial/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gennaro-sardella","type":"person","url":"https://hartvaat.nl/mensen/gennaro-sardella/","name":"Gennaro Sardella","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/04/01/sacubitril-valsartan-na-acuut-mi-meta-analyse-van-in-hospital-initiatie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/08/08/prasugrel-of-ticagrelor-bij-stemi-met-diabetes/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/05/23/stralingsblootstelling-en-vasculaire-toegang-bij-acs-rad-matrix-trial/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hiddo-j-l-heerspink","type":"person","url":"https://hartvaat.nl/mensen/hiddo-j-l-heerspink/","name":"Hiddo J L Heerspink","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/04/24/nkf-consensus-standaardiseer-urine-afname-om-albuminurie-betrouwbaar-te-meten/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/29/confidence-analyse-acute-egfr-daling-bij-empagliflozin-finerenone-is-reversibel-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/03/05/finerenon-effectief-bij-type-1-diabetes-met-chronische-nierziekte/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/02/01/dapagliflozine-bij-cv-risico-met-zonder-diabetes-cardiorenale-effecten/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2024/11/26/glp-1-agonisten-alleen-en-met-sglt2-remmers-cv-renale-en-veiligheidsuitkomsten/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2023/11/25/zenith-ckd-zibotentan-plus-dapagliflozine-bij-ckd-lancet/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2021/03/31/dapagliflozine-en-mortaliteit-bij-ckd-dapa-ckd-pre-gespecificeerde-analyse/","published":"2021-03-31"},{"url":"https://hartvaat.nl/2020/10/08/dapagliflozine-bij-chronische-nierziekte-nejm-dapa-ckd/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/10/01/bardoxolone-en-urine-albumine-creatinine-ratio-bij-diabetes-met-ckd-stadium-4/","published":"2019-10-01"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ileana-l-pina","type":"person","url":"https://hartvaat.nl/mensen/ileana-l-pina/","name":"Ileana L Piña","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/dosisrespons-van-sacubitril-valsartan-bij-hfref/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2018/11/27/economische-en-qol-uitkomsten-van-nt-probnp-geleide-hf-therapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2018/02/20/sekseverschillen-bij-ischemisch-hartfalen-na-cabg-stich-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/08/22/natriuretisch-peptide-geleide-therapie-bij-hoogrisico-hartfalen-jama-guide-it/","published":"2017-08-22"},{"url":"https://hartvaat.nl/2017/04/04/inspanningstraining-bij-chronisch-hartfalen-met-atriumfibrilleren/","published":"2017-04-04"},{"url":"https://hartvaat.nl/2016/02/23/inspanningstestvariabelen-als-mortaliteitsvoorspellers-bij-chronisch-systolisch-/","published":"2016-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ingo-eitel","type":"person","url":"https://hartvaat.nl/mensen/ingo-eitel/","name":"Ingo Eitel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2025/10/07/laa-occlusie-bij-terminale-nierziekte-ipd-meta-analyse/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2024/12/16/gp-iib-iiia-remmers-bij-acuut-mi-en-microvasculaire-obstructie-meta-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2020/04/21/morfine-met-metoclopramide-en-ticagrelor-plaatjesremming-bij-acuut-mi/","published":"2020-04-21"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/01/22/milde-hypothermie-bij-cardiogene-shock-complicerend-mi/","published":"2019-01-22"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/14/mechanische-ondersteuning-bij-cardiogene-shock-systematische-review-en-meta-anal/","published":"2017-12-14"},{"url":"https://hartvaat.nl/2017/08/01/des-versus-bms-bij-acuut-mi-met-cardiogene-shock/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/04/18/risicostratificatie-bij-cardiogene-shock-na-acuut-myocardinfarct/","published":"2017-04-18"},{"url":"https://hartvaat.nl/2016/08/16/intracoronair-abciximab-bij-diabetespatienten-met-primaire-pci-1-jaarsresultaten/","published":"2016-08-16"},{"url":"https://hartvaat.nl/2016/04/12/infarctgrootte-en-uitkomsten-na-primaire-pci-patientanalyse-uit-10-trials/","published":"2016-04-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"irene-m-lang","type":"person","url":"https://hartvaat.nl/mensen/irene-m-lang/","name":"Irene M Lang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/05/25/longembolie-epidemiologie-stijgende-last-bij-vergrijzing-preventiestrategieen-bl/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","published":"2026-04-09"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2022/09/21/riociguat-bij-pulmonale-hypertensie-en-hfpef-haemodynamic-trial/","published":"2022-09-21"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/08/01/seksegerelateerde-uitkomsten-bij-hoog-bloedingsrisico-na-pci-leaders-free/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2019/04/01/prehospitale-hypothermie-bij-stemi-gerandomiseerde-trial/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/02/20/sekseverschillen-bij-ischemisch-hartfalen-na-cabg-stich-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2018/02/20/morbiditeit-bij-pulmonaal-arteriele-hypertensie-als-prognostische-marker-voor-mo/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"},{"url":"https://hartvaat.nl/2017/03/21/plotse-hartdood-bij-ischemisch-hartfalen-na-cabg-stich-resultaten/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/01/01/2015-esc-ers-richtlijn-voor-diagnostiek-en-behandeling-van-pulmonale-hypertensie/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jan-belohlavek","type":"person","url":"https://hartvaat.nl/mensen/jan-belohlavek/","name":"Jan Bělohlávek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/01/16/watchful-leefstijl-wandelinterventie-bij-hfref/","published":"2024-01-16"},{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/02/07/ecmo-cs-ecmo-bij-cardiogene-shock-verbetert-overleving-niet/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2023/02/01/diabetes-en-sacubitril-valsartan-titratie-bij-hartfalen-na-opname/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2020/10/01/accelerometrie-bij-cv-patienten-systematische-review-met-praktische-aanbevelinge/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-l-sapp","type":"person","url":"https://hartvaat.nl/mensen/john-l-sapp/","name":"John L Sapp","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/01/01/haptoglobinefenotype-en-cv-risico-accord-bloeddruk-rct/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2025/02/20/vanish2-catheterablatie-versus-antiaritmica-bij-ventriculaire-tachycardie-nejm/","published":"2025-02-20"},{"url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","published":"2024-02-16"},{"url":"https://hartvaat.nl/2024/01/18/raft-langetermijn-crt-d-bij-hartfalen-nejm-14-jaarsresultaten/","published":"2024-01-18"},{"url":"https://hartvaat.nl/2023/05/01/aware-uitgebreide-ablatie-vermindert-af-recidief-niet-boven-standaard-pvi/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2022/07/15/vt-ablatie-versus-antiaritmica-bij-myocardinfarct-locatie-maakt-uit/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2021/11/01/af-last-en-qol-na-af-ablatie-cabana-substudie/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"},{"url":"https://hartvaat.nl/2020/02/11/haptoglobinefenotype-wijzigt-het-effect-van-intensieve-glycemische-controle-op-c/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2019/11/26/cryoballon-versus-rf-ablatie-bij-af-beoordeeld-met-continue-monitoring-cryo-firs/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2018/11/21/voortzetten-versus-onderbreken-doac-bij-device-chirurgie-bruise-control-2/","published":"2018-11-21"},{"url":"https://hartvaat.nl/2017/05/09/agressieve-bloeddrukcontrole-en-recidief-van-af-na-ablatie-gerandomiseerde-trial/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2016/07/14/ablatie-versus-escalatie-van-antiaritmica-bij-ventriculaire-tachycardie-nejm-van/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joo-yong-hahn","type":"person","url":"https://hartvaat.nl/mensen/joo-yong-hahn/","name":"Joo-Yong Hahn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","published":"2024-05-04"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jose-francisco-kerr-saraiva","type":"person","url":"https://hartvaat.nl/mensen/jose-francisco-kerr-saraiva/","name":"José Francisco Kerr Saraiva","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/01/06/sacubitril-valsartan-versus-enalapril-bij-chagas-hartfalen/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2020/11/26/rivaroxaban-bij-af-met-bioprothese-mitralisklep-nejm-river/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-en-evidence-based-prescriptie-bij-hoog-cv-risico-jama-card/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kuniaki-takahashi","type":"person","url":"https://hartvaat.nl/mensen/kuniaki-takahashi/","name":"Kuniaki Takahashi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/01/06/caviar-alirocumab-bij-cardiale-allograft-vasculopathie-na-harttransplantatie/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/06/01/ffr-geleide-pci-versus-cabg-bij-diffuus-coronairlijden/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2022/04/19/externe-validatie-van-de-freedom-score-voor-pci-versus-cabg/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/31/syntax-score-ii-herontwikkeling-voor-gepersonaliseerde-revascularisatiebeslissin/","published":"2020-10-31"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicolas-girerd","type":"person","url":"https://hartvaat.nl/mensen/nicolas-girerd/","name":"Nicolas Girerd","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/08/18/tafamidis-bij-attr-cardiomyopathie-kosteffectiviteit-onder-de-maat-in-vier-europ/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/05/23/paradise-cohort-hartfalen-en-copd-samen-verhogen-de-langetermijnmortaliteit-met-/","published":"2026-06-05"},{"url":"https://hartvaat.nl/2026/05/10/hartfalen-en-infarct-verdrievoudigen-het-risico-op-kanker-vooral-hematologisch/","published":"2026-05-11"},{"url":"https://hartvaat.nl/2025/01/01/hartfalenpreventie-bewijsgeneratie-trialontwerp-en-regulatoire-trajecten/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/03/vroeg-starten-met-mra-na-acuut-hartfalen-of-myocardinfarct-meta-analyse/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2026/02/03/semaglutide-versus-tirzepatide-bij-patienten-met-obesitas-en-hfpef/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/11/14/nierfunctietrajecten-voor-en-na-hospitalisatie-voor-hfref/","published":"2025-11-14"},{"url":"https://hartvaat.nl/2025/10/01/ambulante-iv-diurese-bij-chronisch-hf-decongest-inzichten/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2022/02/01/matige-hypothermie-versus-normothermie-bij-cardiogene-shock-met-va-ecmo-jama-hyp/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2019/02/01/spironolacton-en-collageenmetabolisme-biomarkers-bij-ongecontroleerde-hypertensi/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/07/10/epinefrine-versus-norepinefrine-bij-cardiogene-shock-na-acuut-mi/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/02/20/cva-risico-bij-verminderde-ef-na-mi-zonder-af/","published":"2018-02-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"olof-bengtsson","type":"person","url":"https://hartvaat.nl/mensen/olof-bengtsson/","name":"Olof Bengtsson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ovidiu-chioncel","type":"person","url":"https://hartvaat.nl/mensen/ovidiu-chioncel/","name":"Ovidiu Chioncel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/05/25/het-spectrum-van-congestie-bij-hartfalen-pathofysiologie-en-diagnostische-strate/","published":"2026-05-31"},{"url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2026/03/20/evolution-hf-cee-ba-real-world-dapagliflozin-bij-hfref-in-centraal-en-oost-europ/","published":"2026-03-20"},{"url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2022/12/01/hartfalen-tijdens-de-covid-19-pandemie-klinische-en-organisatorische-dilemma-s/","published":"2022-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-nordbeck","type":"person","url":"https://hartvaat.nl/mensen/peter-nordbeck/","name":"Peter Nordbeck","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2021/11/08/closed-loop-stimulatie-en-cardiopulmonale-variabelen-bij-chronisch-hf-met-chrono/","published":"2021-11-08"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-elmir-omerovic","type":"person","url":"https://hartvaat.nl/mensen/prof-elmir-omerovic/","name":"Prof. Elmir Omerovic","title":"Cardioloog, Sahlgrenska Universitetssjukhuset, Göteborg","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2022/03/15/5-jaars-ifr-versus-ffr-geleide-pci-define-flair-ifr-swedeheart/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/04/01/ventriculaire-aritmie-of-overlijden-na-stemi-versus-takotsubo/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/12/11/langetermijneffecten-van-zuurstof-op-sterfte-of-hf-hospitalisatie-na-verdenking-/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/08/01/zuurstoftherapie-bij-stemi-overzichtsartikel/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/09/28/zuurstoftherapie-bij-vermoedelijk-acuut-myocardinfarct-nejm-deto2x-ami/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/05/11/instantaneous-wave-free-ratio-versus-ffr-voor-pci-indicatie-nejm-ifr-swedeheart/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2017/03/30/ffr-geleide-multivaten-pci-bij-myocardinfarct-nejm-compare-acute/","published":"2017-03-30"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-switch-swedeheart-lbct/","title":"SWITCH SWEDEHEART: prasugrel versus ticagrelor, het gesprek"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rajiv-agarwal","type":"person","url":"https://hartvaat.nl/mensen/rajiv-agarwal/","name":"Rajiv Agarwal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/06/26/finerenone-verlaagt-hart-en-vaatrisico-via-vroege-daling-van-uacr-en-systolische/","published":"2026-08-06"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2026/03/29/confidence-analyse-acute-egfr-daling-bij-empagliflozin-finerenone-is-reversibel-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2022/12/01/finerenon-bloeddrukeffecten-en-cardiorenale-uitkomsten-bij-ckd-en-diabetes/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/02/10/finerenon-cv-en-renale-uitkomsten-bij-diabetes-met-ckd-fidelity-gepoolde-analyse/","published":"2022-02-10"},{"url":"https://hartvaat.nl/2022/02/08/finerenon-vermindert-incident-hf-bij-ckd-met-diabetes-fidelity/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/12/30/chlorthalidon-bij-hypertensie-met-gevorderde-ckd-nejm-click/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2021/12/09/finerenon-bij-nierziekte-met-diabetes-type-2-nejm-figaro-dkd/","published":"2021-12-09"},{"url":"https://hartvaat.nl/2021/07/13/finerenon-vermindert-nieuw-onset-af-bij-ckd-met-diabetes-fidelio-dkd/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/02/09/finerenon-en-cardiovasculaire-uitkomsten-bij-ckd-met-diabetes-type-2-fidelio-dkd/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/10/26/patiromer-voor-spironolactongebruik-bij-resistente-hypertensie-met-ckd-lancet-am/","published":"2019-10-26"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rasha-k-al-lamee","type":"person","url":"https://hartvaat.nl/mensen/rasha-k-al-lamee/","name":"Rasha K Al-Lamee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/06/11/remote-beoordeling-na-acs-gerandomiseerde-trial/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/19/coronaire-flowreserve-en-cardiovasculaire-uitkomsten-meta-analyse/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sanjit-s-jolly","type":"person","url":"https://hartvaat.nl/mensen/sanjit-s-jolly/","name":"Sanjit S Jolly","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/01/27/intracoronair-lage-dosis-rtpa-bij-primaire-pci-voor-stemi-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2023/11/04/colchicine-vermindert-perioperatief-af-na-thoraxchirurgie-lancet-rct/","published":"2023-11-04"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/07/21/laaggedoseerd-colchicine-bij-coronairlijden-meta-analyse-van-gerandomiseerde-tri/","published":"2021-07-21"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2018/01/09/risico-s-van-overinterpretatie-van-interimdata-lessen-uit-de-total-trial/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/01/10/trombusaspiratie-bij-stemi-individuele-patientdata-meta-analyse/","published":"2017-01-10"},{"url":"https://hartvaat.nl/2016/06/21/myocardiale-blush-en-microvasculaire-reperfusie-na-handmatige-trombectomie-bij-s/","published":"2016-06-21"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"scot-garg","type":"person","url":"https://hartvaat.nl/mensen/scot-garg/","name":"Scot Garg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/02/24/invloed-van-coronaire-ziekte-patronen-op-klinische-uitkomsten-pullback-pressure-/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2026/02/05/driejaarsuitkomsten-van-linker-hartoorsluiting-met-of-zonder-ablatie-record-stud/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2022/08/30/ripcord-2-routinematige-ffr-meting-versus-conventionele-angiografie/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sung-jin-hong","type":"person","url":"https://hartvaat.nl/mensen/sung-jin-hong/","name":"Sung-Jin Hong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","published":"2023-04-04"},{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"},{"url":"https://hartvaat.nl/2020/06/16/ticagrelor-monotherapie-versus-dapt-op-bloedingen-en-cv-events-bij-acs-jama-tico/","published":"2020-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ulrich-schotten","type":"person","url":"https://hartvaat.nl/mensen/ulrich-schotten/","name":"Ulrich Schotten","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/06/02/smartphone-app-voor-symptoomregistratie-na-ablatie-bij-atriumfibrilleren-isolati/","published":"2026-08-12"},{"url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2021/11/08/preoperatieve-tte-voor-voorspelling-van-postoperatief-af-meta-analyse/","published":"2021-11-08"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2017/01/01/axafa-afnet-5-apixaban-versus-vka-bij-af-ablatie-studieprotocol/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/07/2016-esc-richtlijn-voor-atriumfibrilleren-in-samenwerking-met-eacts/","published":"2016-10-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vijay-kunadian","type":"person","url":"https://hartvaat.nl/mensen/vijay-kunadian/","name":"Vijay Kunadian","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2025/07/28/routine-invasieve-strategie-en-herinfarctrisico-bij-fragiele-ouderen-met-nste-ac/","published":"2025-07-28"},{"url":"https://hartvaat.nl/2025/01/21/evolved-vroege-interventie-bij-asymptomatische-ernstige-aortastenose-met-myocard/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/11/07/invasieve-strategie-bij-ouderen-met-mi-gerandomiseerde-trial-nejm/","published":"2024-11-07"},{"url":"https://hartvaat.nl/2024/07/12/nste-acs-na-cabg-meta-analyse-van-behandelstrategieen/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2024/06/14/invasief-versus-conservatief-bij-ouderen-met-nste-acs-ipd-meta-analyse/","published":"2024-06-14"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2016/06/21/strategieen-om-microvasculaire-obstructie-te-verminderen-bij-primaire-pci-relief/","published":"2016-06-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yan-li","type":"person","url":"https://hartvaat.nl/mensen/yan-li/","name":"Yan Li","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":15,"articles":[{"url":"https://hartvaat.nl/2026/10/01/esh-convenant-polshorloges-bloeddrukmeters-acceptabele-nauwkeurigheid-maar-klini/","published":"2026-09-02"},{"url":"https://hartvaat.nl/2026/04/01/intensieve-bloeddrukcontrole-en-cognitieve-functie-gerandomiseerde-trial/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/01/01/effect-van-baduanjin-op-bloeddruk-bij-hoog-normaal-bloeddruk-gerandomiseerde-tri/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/06/esprit-intensieve-bloeddrukcontrole-bij-fragiele-patienten-post-hoc-analyse/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/10/28/esprit-bescheiden-effecten-van-intensieve-bloeddrukverlaging-op-kwaliteit-van-le/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukcontrole-en-cva-preventie/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/07/20/sbp-120-versus-140-mmhg-bij-hoog-cv-risico-meta-analyse-van-intensieve-behandeli/","published":"2024-07-20"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/11/26/bivalirudine-versus-heparine-bij-primaire-pci-voor-stemi-lancet-trial/","published":"2022-11-26"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2020/11/10/chinese-kruidenformule-voor-gemaskeerde-hypertensie-gerandomiseerde-placebogecon/","published":"2020-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"akiko-maehara","type":"person","url":"https://hartvaat.nl/mensen/akiko-maehara/","name":"Akiko Maehara","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2025/07/15/oct-gebaseerde-post-pci-fysiologiebeoordeling-voorspelt-klinische-uitkomsten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/04/12/orbitale-atherectomie-versus-ballonangioplastie-voor-des-bij-ernstig-verkalkte-l/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2025/02/18/lage-dosis-sirolimus-bdp-stent-versus-tweede-generatie-des-non-inferioriteit/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/03/02/intravasculaire-beeldvorming-bij-des-implantatie-lancet-netwerk-meta-analyse/","published":"2024-03-02"},{"url":"https://hartvaat.nl/2023/12/05/intravasculaire-beeldvorming-versus-functionele-versus-angiografische-pci-begele/","published":"2023-12-05"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2020/04/14/langetermijnuitkomsten-bij-vrouwen-en-mannen-na-pci/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2018/07/07/orbusneich-combo-stent-japan-usa-harmonee-gerandomiseerde-multicenter-trial/","published":"2018-07-07"},{"url":"https://hartvaat.nl/2016/11/26/oct-versus-ivus-versus-angiografie-bij-coronaire-stentimplantatie-lancet-ilumien/","published":"2016-11-26"},{"url":"https://hartvaat.nl/2016/04/12/infarctgrootte-en-uitkomsten-na-primaire-pci-patientanalyse-uit-10-trials/","published":"2016-04-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexander-p-benz","type":"person","url":"https://hartvaat.nl/mensen/alexander-p-benz/","name":"Alexander P Benz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/08/25/extracraniale-bloedingen-komen-bij-26-van-af-patienten-op-antistolling-voor-comb/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/11/26/artesia-subanalyse-cva-risico-naar-frequentie-en-duur-van-subclinisch-af/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/10/01/neurofilament-light-chain-en-cva-risico-bij-af/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/01/af-ablatie-bij-hfref-versus-hfpef-meta-analyse/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/03/26/doac-s-bij-device-gedetecteerd-af-meta-analyse-noah-afnet-6-en-artesia/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/03/07/mra-s-verminderen-af-risico-meta-analyse-van-klinische-trials/","published":"2024-03-07"},{"url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","published":"2023-05-21"},{"url":"https://hartvaat.nl/2023/02/16/technieken-om-cardioversiesucces-bij-af-te-verbeteren-meta-analyse/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/08/06/orale-antiaritmica-voor-cardioversie-van-recent-onset-af-netwerkmeta-analyse/","published":"2021-08-06"},{"url":"https://hartvaat.nl/2021/05/01/screening-op-af-bij-ouderen-jama-cardiology-gerandomiseerde-trial/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2019/10/01/quadripolaire-versus-bipolaire-lv-leads-bij-crt-klinische-uitkomsten/","published":"2019-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrzej-budaj","type":"person","url":"https://hartvaat.nl/mensen/andrzej-budaj/","name":"Andrzej Budaj","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2024/09/03/augustus-4-weg-vergelijking-antitrombotische-strategieen-bij-af-na-acs-pci/","published":"2024-09-03"},{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2022/10/18/asundexian-factor-xia-remmer-na-acs-fase-2-dosisfindingsstudie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2021/11/01/antiplaatjestherapie-bij-mi-zonder-obstructief-coronairlijden-minoca/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2020/07/14/vergelijking-van-orale-p2y12-remmers-bij-acs-netwerkmeta-analyse-van-52-816-pati/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2018/06/01/fgf-23-en-recidiverende-cv-events-na-acs/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anoop-s-v-shah","type":"person","url":"https://hartvaat.nl/mensen/anoop-s-v-shah/","name":"Anoop S V Shah","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","published":"2025-01-25"},{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2021/07/08/grace-2-0-score-bij-type-1-en-type-2-mi/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2020/05/05/laag-attenuatie-plaque-op-ccta-voorspelt-mi-scot-heart-resultaten/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/01/29/coronaire-plaquekenmerken-en-adverse-uitkomsten-scot-heart/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","published":"2018-09-06"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/11/21/hoog-sensitief-troponine-i-en-uitkomsten-bij-verdenking-acs-jama-studie/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2016/12/27/hoog-sensitief-troponine-statinetherapie-en-risico-op-coronairlijden/","published":"2016-12-27"},{"url":"https://hartvaat.nl/2016/04/19/ct-coronairangiografie-voor-het-sturen-van-beleid-bij-coronairlijden/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"biykem-bozkurt","type":"person","url":"https://hartvaat.nl/mensen/biykem-bozkurt/","name":"Biykem Bozkurt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2026/03/03/tien-jaar-real-world-sacubitril-valsartan-mortaliteitsreductie-bevestigd-maar-sl/","published":"2026-04-20"},{"url":"https://hartvaat.nl/2026/03/06/kdigo-consensusconferentie-uitdagingen-bij-gecombineerd-hartfalen-en-nierziekte/","published":"2026-03-15"},{"url":"https://hartvaat.nl/2024/09/24/2024-acc-beslispad-klinische-beoordeling-en-trajectmanagement-bij-hfpef/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2024/09/17/2024-acc-aha-kwaliteitsmaatstaven-voor-hartfalen-geactualiseerd/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/04/27/2021-acc-aha-kerngegevenselementen-voor-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2016/12/06/comorbiditeiten-bij-hartfalen-hypertensie-obesitas-diabetes-hyperlipidemie-en-me/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brian-a-bergmark","type":"person","url":"https://hartvaat.nl/mensen/brian-a-bergmark/","name":"Brian A Bergmark","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","published":"2025-10-02"},{"url":"https://hartvaat.nl/2025/07/15/oct-gebaseerde-post-pci-fysiologiebeoordeling-voorspelt-klinische-uitkomsten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-hypertriglyceridemie-en-hoog-cv-risico-nejm/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/08/30/biomarkers-voorspellen-complexe-coronaire-revascularisatie-in-fourier/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/05/03/vupanorsen-en-non-hdl-cholesterol-bij-statinebehandelde-patienten-translate-timi/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/03/17/non-culprit-mi-na-pci-bij-acs/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/09/01/edoxaban-versus-warfarine-naar-gemiddelde-bloeddruk-bij-af-met-hypertensie/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/06/01/fgf-23-en-recidiverende-cv-events-na-acs/","published":"2018-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carlo-briguori","type":"person","url":"https://hartvaat.nl/mensen/carlo-briguori/","name":"Carlo Briguori","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2024/09/01/periprocedureel-mi-na-pci-en-langetermijnmortaliteit-meta-analyse/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/03/19/nierschade-na-minimale-contrasttoediening-bij-acs/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-torp-pedersen","type":"person","url":"https://hartvaat.nl/mensen/christian-torp-pedersen/","name":"Christian Torp-Pedersen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/03/28/athena-post-hoc-dronedaron-als-effectieve-vroege-ritmecontrole/","published":"2025-03-28"},{"url":"https://hartvaat.nl/2023/02/23/ct-coronairangiografie-bij-75-jarigen-met-nste-acs/","published":"2023-02-23"},{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2017/06/07/dagelijkse-telemonitoring-van-icd-s-gepoolde-analyse-van-drie-gerandomiseerde-tr/","published":"2017-06-07"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"davide-capodanno","type":"person","url":"https://hartvaat.nl/mensen/davide-capodanno/","name":"Davide Capodanno","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/08/18/glp-1-agonisten-verlagen-cardiovasculaire-risicos-bij-diabetes-en-obesitas-overz/","published":"2026-08-25"},{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2026/05/19/salamander-register-95-5-technisch-succes-bij-stand-alone-linker-hartoor-occlusi/","published":"2026-06-10"},{"url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/12/09/gepersonaliseerde-versus-standaard-dapt-duur-na-pci-gerandomiseerde-trial/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","published":"2025-07-21"},{"url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/04/02/ivus-versus-oct-versus-angiografie-voor-pci-begeleiding-meta-analyse/","published":"2024-04-02"},{"url":"https://hartvaat.nl/2023/09/26/biodegradeerbare-versus-duurzame-polymeer-stents-bij-hoog-bloedingsrisico/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","published":"2022-03-07"},{"url":"https://hartvaat.nl/2021/04/17/geleide-versus-standaard-antiplaatjestherapie-na-pci-lancet-meta-analyse/","published":"2021-04-17"},{"url":"https://hartvaat.nl/2021/01/21/korte-dapt-gevolgd-door-p2y12-mono-versus-verlengde-dapt-meta-analyse/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2018/05/07/esc-eapci-taskforce-rapport-over-bioresorbeerbare-scaffolds-executive-summary/","published":"2018-05-07"},{"url":"https://hartvaat.nl/2017/09/01/late-trombotische-events-na-bioresorbeerbare-scaffold-meta-analyse-van-gerandomi/","published":"2017-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dorairaj-prabhakaran","type":"person","url":"https://hartvaat.nl/mensen/dorairaj-prabhakaran/","name":"Dorairaj Prabhakaran","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/09/01/pm2-5-blootstelling-versnelt-daling-van-egfr-bij-volwassenen/","published":"2026-08-24"},{"url":"https://hartvaat.nl/2022/06/01/lage-dosis-drievoudige-combinatietherapie-bij-hypertensie-triumph-secundaire-ana/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2020/11/01/lage-dosis-triple-combinatie-en-therapeutische-inertie-bij-hypertensie-jama-card/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/06/01/2020-ish-mondiale-hypertensie-praktijkrichtlijnen/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/04/07/yoga-gebaseerde-hartrevalidatie-na-acuut-mi-gerandomiseerde-trial/","published":"2020-04-07"},{"url":"https://hartvaat.nl/2019/03/01/ziekenhuisgebaseerde-kwaliteitsinterventies-bij-hartfalen-systematische-review/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/08/14/drievoudige-lage-dosis-antihypertensivacombinatie-versus-standaardzorg-jama-gera/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/02/13/kwaliteitsverbeteringsinterventie-bij-acuut-mi-in-india-jama-acs-quik/","published":"2018-02-13"},{"url":"https://hartvaat.nl/2017/08/01/voorspelling-van-bloedingsrisico-tijdens-dapt-na-acs/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/12/15/off-pump-versus-on-pump-cabg-5-jaarsresultaten-nejm-coronary-trial/","published":"2016-12-15"},{"url":"https://hartvaat.nl/2016/08/01/eerder-clopidogrelgebruik-en-uitkomsten-bij-conservatief-behandeld-acs/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"},{"url":"https://hartvaat.nl/2016/03/01/cyp2c19-metaboliseerdersstatus-en-uitkomsten-bij-acs-prasugrel-versus-clopidogre/","published":"2016-03-01"},{"url":"https://hartvaat.nl/2016/01/21/neoplasiedetectie-bij-langdurige-dapt-met-prasugrel-versus-clopidogrel-triton-ti/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-kevin-damman","type":"person","url":"https://hartvaat.nl/mensen/dr-kevin-damman/","name":"Dr. Kevin Damman","title":"Cardioloog, Universitair Medisch Centrum Groningen","dutch_institution":true,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/10/decision-trial-digoxine-staken-bij-hartfalen-leidt-tot-zevenvoudige-stijging-in-/","published":"2026-06-25"},{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","published":"2023-06-09"},{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","published":"2022-09-29"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-ckd-guidelines/","title":"De ESC-richtlijn hart en nier: wat verandert er in de praktijk?"},{"url":"https://hartvaat.nl/video/hfa-2026-late-breaking-science/decision-digit-hf-dig-meta-digitalis/","title":"Digitalis in hartfalen — DECISION + DIGIT-HF + DIG meta-analyse"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"emilie-p-belley-cote","type":"person","url":"https://hartvaat.nl/mensen/emilie-p-belley-cote/","name":"Emilie P Belley-Côté","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/04/08/vision-postoperatief-atriumfibrilleren-na-hartchirurgie-verhoogt-sterfte-na-een-/","published":"2026-07-15"},{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2024/06/01/af-ablatie-bij-hfref-versus-hfpef-meta-analyse/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/10/24/laaos-iii-laa-occlusie-en-anticoagulatiegebruik/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2023/02/16/technieken-om-cardioversiesucces-bij-af-te-verbeteren-meta-analyse/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2022/10/13/voorbehandeling-met-antiaritmica-voor-cardioversie-bij-af-netwerk-meta-analyse/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2021/08/06/orale-antiaritmica-voor-cardioversie-van-recent-onset-af-netwerkmeta-analyse/","published":"2021-08-06"},{"url":"https://hartvaat.nl/2021/06/15/prevalentie-van-linkeratriumtrombus-bij-geanticoaguleerde-af-patienten/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","published":"2021-06-03"},{"url":"https://hartvaat.nl/2019/06/01/amiodaron-voor-en-na-electrische-cardioversie-van-af-meta-analyse/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/09/27/6-maandsuitkomsten-van-restrictieve-versus-liberale-transfusie-bij-hartchirurgie/","published":"2018-09-27"},{"url":"https://hartvaat.nl/2018/09/01/chirurgische-af-ablatie-systematische-review-en-meta-analyse-van-rct-s/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/05/08/vasopressine-plus-catecholamines-en-af-bij-distributieve-shock-jama-meta-analyse/","published":"2018-05-08"},{"url":"https://hartvaat.nl/2017/11/30/restrictieve-versus-liberale-bloedtransfusie-bij-hartchirurgie-nejm-trics-iii/","published":"2017-11-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"g-kees-hovingh","type":"person","url":"https://hartvaat.nl/mensen/g-kees-hovingh/","name":"G Kees Hovingh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/08/18/semaglutide-verlaagt-hscrp-en-ontstekingsactiviteit-bij-ascvd-patienten-met-over/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/05/18/global-hicc-register-950-hofh-patienten-uit-45-landen-slechts-4-haalt-ldl-doelen/","published":"2026-06-17"},{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","published":"2025-05-29"},{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","published":"2024-08-24"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/12/14/select-semaglutide-vermindert-cv-events-bij-obesitas-zonder-diabetes-nejm/","published":"2023-12-14"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2020/10/01/evolocumab-bij-pediatrische-heterozygoot-fh-nejm-hauser-rct/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/08/20/evinacumab-bij-homozygoot-familiaire-hypercholesterolemie-nejm/","published":"2020-08-20"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2016/05/01/ly3015014-een-nieuw-monoklonaal-pcsk9-antilichaam-gerandomiseerde-fase-2-trial/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giovanni-esposito","type":"person","url":"https://hartvaat.nl/mensen/giovanni-esposito/","name":"Giovanni Esposito","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2025/01/01/antistolling-alleen-of-met-plaatjesremming-bij-coronairlijden-meta-analyse/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2026/02/03/langetermijnwaarde-van-inspanningstesten-bij-hypertrofische-cardiomyopathie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/12/09/gepersonaliseerde-versus-standaard-dapt-duur-na-pci-gerandomiseerde-trial/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2024/03/19/nierschade-na-minimale-contrasttoediening-bij-acs/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2023/04/08/biovasc-directe-versus-gestageerde-complete-revascularisatie-bij-acs-met-meervat/","published":"2023-04-08"},{"url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/02/02/dalend-hemoglobine-en-prognose-bij-acs-hospitalisatie/","published":"2021-02-02"},{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/08/04/cangrelor-tirofiban-en-prasugrel-bij-stemi-primaire-resultaten/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/10/14/tmao-als-cardiovasculaire-risicobiomarker-systematische-review-en-meta-analyse/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2017/01/01/ontwikkeling-van-linkerventrikelhypertrofie-bij-behandelde-hypertensie-campania-/","published":"2017-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jacob-eifer-moller","type":"person","url":"https://hartvaat.nl/mensen/jacob-eifer-moller/","name":"Jacob Eifer Møller","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/12/05/bloeddruk-en-zuurstofstreefwaarden-en-nierschade-na-hartstilstand/","published":"2023-12-05"},{"url":"https://hartvaat.nl/2022/10/20/box-bloeddrukdoelen-bij-comateuze-overlevenden-van-hartstilstand/","published":"2022-10-20"},{"url":"https://hartvaat.nl/2021/10/01/aortaklepcalcificatie-en-cv-risicofactoren-bij-oudere-deense-mannen/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/07/01/empagliflozine-en-lv-volumes-en-functie-bij-hfref-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/06/01/metabole-effecten-van-empagliflozine-bij-hf-empire-hf-metabolic-gerandomiseerde-/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/12/08/empagliflozine-en-hemodynamiek-bij-hfref/","published":"2020-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jacob-thomsen-lonborg","type":"person","url":"https://hartvaat.nl/mensen/jacob-thomsen-lonborg/","name":"Jacob Thomsen Lønborg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","published":"2019-10-19"},{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jan-a-staessen","type":"person","url":"https://hartvaat.nl/mensen/jan-a-staessen/","name":"Jan A Staessen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/10/07/2024-esc-richtlijn-voor-management-van-hypertensie/","published":"2024-10-07"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2023/04/01/lichaamshouding-en-orthostatische-hypotensie-bij-hypertensie-syst-eur-analyse/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2022/12/21/bloeddrukverlaging-en-dementiepreventie-ipd-meta-analyse/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2021/05/05/bloeddrukvariabiliteit-en-uitkomsten-bij-hfpef/","published":"2021-05-05"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2020/08/01/antidiabetica-en-cardiovasculaire-geneeskunde-meta-analyse-en-perspectief/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2018/10/01/prognostische-waarde-van-gemaskeerd-ongecontroleerde-hypertensie/","published":"2018-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jawad-h-butt","type":"person","url":"https://hartvaat.nl/mensen/jawad-h-butt/","name":"Jawad H Butt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/09/01/af-en-icd-bij-niet-ischemische-hfref-impliciaties-voor-devicetherapie/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeff-d-williamson","type":"person","url":"https://hartvaat.nl/mensen/jeff-d-williamson/","name":"Jeff D Williamson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/03/01/frailteit-en-antihypertensieve-behandeling-bij-ouderen-meta-analyse/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2024/08/01/sarcopenie-en-intensieve-bloeddrukbehandeling-sprint-subanalyse/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2024/03/01/thuisbloeddruk-geleide-farmacotherapie-via-telezorg-meta-analyse-van-vs-trials/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/07/01/leeftijdsbias-draagt-bij-aan-therapeutische-inertie-bij-bloeddrukmanagement/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2016/08/01/apol1-nierrisicovarianten-en-cerebrale-wittestoflaesies/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ji-guang-wang","type":"person","url":"https://hartvaat.nl/mensen/ji-guang-wang/","name":"Ji-Guang Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/03/07/baxdrostat-verlaagt-bloeddruk-significant-bij-resistente-hypertensie/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/03/07/bax24-baxdrostat-en-ambulante-bloeddruk-bij-resistente-hypertensie/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/01/aprocitentan-bij-ckd-en-resistente-hypertensie/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/10/09/baxdrostat-bij-ongecontroleerde-en-resistente-hypertensie-effectiviteit-en-veili/","published":"2025-10-09"},{"url":"https://hartvaat.nl/2025/09/01/systolische-bloeddrukamplificatie-ipd-meta-analyse/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2025/04/01/aprocitentan-bij-zwarte-patienten-met-hypertensie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/12/03/precision-aprocitentan-bij-resistente-hypertensie-eerste-endothelineantagonist/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2022/10/01/bloeddruk-in-hogere-versus-lagere-arm-en-cv-uitkomsten-interpress-ipd-meta-analy/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2020/11/10/chinese-kruidenformule-voor-gemaskeerde-hypertensie-gerandomiseerde-placebogecon/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"josef-kautzner","type":"person","url":"https://hartvaat.nl/mensen/josef-kautzner/","name":"Josef Kautzner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","published":"2026-05-27"},{"url":"https://hartvaat.nl/2026/04/13/intracardiale-echocardiografie-in-de-elektrofysiologie-gezamenlijk-ehra-eapci-st/","published":"2026-05-23"},{"url":"https://hartvaat.nl/2025/10/07/cti-blok-na-pfa-versus-rf-cryo-ablatie-gerandomiseerde-vergelijking/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2021/01/27/periprocedurele-antistolling-bij-eliminate-af-ononderbroken-edoxaban-versus-vka/","published":"2021-01-27"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/09/21/ononderbroken-edoxaban-versus-vka-bij-af-ablatie-eliminate-af/","published":"2019-09-21"},{"url":"https://hartvaat.nl/2018/07/01/echogeleide-versus-conventionele-femorale-venepunctie-bij-af-ablatie-gerandomise/","published":"2018-07-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"judith-s-hochman","type":"person","url":"https://hartvaat.nl/mensen/judith-s-hochman/","name":"Judith S Hochman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2025/09/23/pci-versus-cabg-en-gezondheidsstatus-bij-stabiel-coronairlijden/","published":"2025-09-23"},{"url":"https://hartvaat.nl/2025/09/16/ischemia-anginatrajecten-na-invasieve-versus-conservatieve-strategie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/09/01/routine-revascularisatie-versus-medicamenteus-bij-stabiel-coronairlijden-meta-an/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/07/01/thuisluchtzuivering-en-bloeddruk-systematische-review/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/23/gezondheidsstatus-na-invasieve-of-conservatieve-zorg-bij-coronairlijden-met-gevo/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"julio-rosenstock","type":"person","url":"https://hartvaat.nl/mensen/julio-rosenstock/","name":"Julio Rosenstock","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/03/29/confidence-analyse-acute-egfr-daling-bij-empagliflozin-finerenone-is-reversibel-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2025/09/18/orforglipron-bij-vroeg-type-2-diabetes-nejm-fase-3/","published":"2025-09-18"},{"url":"https://hartvaat.nl/2024/07/09/selectieve-aldosereductaseremmer-bij-diabetische-cardiomyopathie-rct/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2023/09/07/orforglipron-dagelijkse-orale-glp-1-agonist-bij-obesitas-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2023/08/12/retatrutide-triple-gip-glp-1-glucagonagonist-bij-type-2-diabetes-lancet-fase-2/","published":"2023-08-12"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2023/04/25/mk-0616-eerste-orale-pcsk9-remmer-in-fase-2b/","published":"2023-04-25"},{"url":"https://hartvaat.nl/2023/03/28/amplitude-o-dosisrespons-van-efpeglenatide-op-cv-uitkomsten-bij-diabetes/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2021/09/02/efpeglenatide-en-cv-en-renale-uitkomsten-bij-diabetes-type-2-nejm-amplitude-o/","published":"2021-09-02"},{"url":"https://hartvaat.nl/2021/07/10/tirzepatide-bij-diabetes-type-2-lancet-surpass-1-fase-3/","published":"2021-07-10"},{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2016/11/10/semaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-sustain-6/","published":"2016-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kavita-sharma","type":"person","url":"https://hartvaat.nl/mensen/kavita-sharma/","name":"Kavita Sharma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/06/01/humain-hfpef-nieuwe-metabole-accelerator-bij-obesitas-hfpef-rct/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/nierfunctie-en-dapagliflozine-effect-op-gezondheidsstatus-define-hf/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","published":"2024-08-27"},{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2023/07/04/sacubitril-valsartan-bij-hfmref-hfpef-met-verslechterend-hartfalen/","published":"2023-07-04"},{"url":"https://hartvaat.nl/2023/04/18/aha-scientific-statement-gestructureerde-inspanningstraining-bij-hfpef/","published":"2023-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"konstantinos-tsioufis","type":"person","url":"https://hartvaat.nl/mensen/konstantinos-tsioufis/","name":"Konstantinos Tsioufis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/06/24/sglt2-remmers-en-bloeddrukdoelen-bij-hypertensief-hfpef-een-overzicht-van-richtl/","published":"2026-08-08"},{"url":"https://hartvaat.nl/2026/02/26/lp-a-geassocieerd-met-microvasculaire-disfunctie-bij-niet-obstructief-coronairli/","published":"2026-03-10"},{"url":"https://hartvaat.nl/2025/07/14/hartfrequentieverlagende-middelen-en-uitkomsten-bij-hypertensie-cvd-meta-analyse/","published":"2025-07-14"},{"url":"https://hartvaat.nl/2024/05/01/bloeddrukstreefwaarden-en-residueel-risico-systematische-review-en-meta-regressi/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/09/07/hartfrequentie-en-uitkomsten-van-renale-denervatie-bij-ongecontroleerde-hyperten/","published":"2021-09-07"},{"url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2018/06/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-6-maandsresultat/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/12/01/centrale-iliacale-av-anastomose-bij-ongecontroleerde-hypertensie-rox-control-htn/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","published":"2017-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lars-h-lund","type":"person","url":"https://hartvaat.nl/mensen/lars-h-lund/","name":"Lars H Lund","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/04/07/confident-hfpef-machine-learning-voorspelt-sterfte-en-opname-beter-dan-bestaande/","published":"2026-07-20"},{"url":"https://hartvaat.nl/2026/03/27/nt-probnp-afkapwaarden-voor-hartfalentrials-optimaliseren-swedehf/","published":"2026-03-27"},{"url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2025/12/01/re-perfuse-relaxinereceptoragonist-en-renale-perfusie-bij-hfref-fase-1b/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2024/08/01/coronaire-microvasculaire-disfunctie-bij-hfpef-meta-analyse/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2024/02/01/acyl-ghreline-verbetert-cardiac-output-met-behoud-van-rv-pa-koppeling-bij-hf/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/06/09/acyl-ghreline-verbetert-hartfunctie-bij-hartfalen/","published":"2023-06-09"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/06/14/euroheart-datastandaarden-voor-hartfalenregistraties/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2018/06/01/hemodynamische-effecten-van-levosimendan-bij-gevorderd-stabiel-chronisch-hartfal/","published":"2018-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matthew-j-budoff","type":"person","url":"https://hartvaat.nl/mensen/matthew-j-budoff/","name":"Matthew J Budoff","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/02/21/aspirine-lipoproteine-a-en-aortaklepstenose-de-mesa-studie/","published":"2026-02-21"},{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2024/08/27/stop-semaglutide-vermindert-epicardiaal-vetweefsel-bij-type-2-diabetes/","published":"2024-08-27"},{"url":"https://hartvaat.nl/2023/06/01/genetische-bijdrage-aan-aortastenose-dyslipidemie-inflammatie-en-verkalking/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/05/31/langetermijneffect-van-metformine-en-leefstijlinterventie-op-cardiovasculaire-ev/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/06/01/geisoleerde-diastolische-hypertensie-cohort-en-meta-analyse-voor-behandeldrempel/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/21/icosapent-ethyl-en-coronaire-atheroscleroseprogressie-bij-verhoogde-triglyceride/","published":"2020-10-21"},{"url":"https://hartvaat.nl/2020/08/25/machine-learning-voor-lv-diastolische-functie-op-ecg/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2017/11/21/coronair-calcium-en-prognostische-waarde-bij-pijn-op-de-borst-promise-studie/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2017/07/04/langetermijn-metformine-en-leefstijl-en-coronair-calcium-diabetes-prevention-pro/","published":"2017-07-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"melanie-j-davies","type":"person","url":"https://hartvaat.nl/mensen/melanie-j-davies/","name":"Melanie J Davies","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2025/08/14/cagrisema-gecombineerd-cagrilintide-en-semaglutide-bij-overgewicht-nejm/","published":"2025-08-14"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/af-en-semaglutide-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","published":"2024-08-27"},{"url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2022/01/01/sglt2-remmers-over-het-cv-ziektespectrum-overzicht/","published":"2022-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michel-azizi","type":"person","url":"https://hartvaat.nl/mensen/michel-azizi/","name":"Michel Azizi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/02/10/nieuwe-medicamenteuze-therapieen-voor-hypertensie/","published":"2026-03-14"},{"url":"https://hartvaat.nl/2026/03/07/baxdrostat-verlaagt-bloeddruk-significant-bij-resistente-hypertensie/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/03/07/bax24-baxdrostat-en-ambulante-bloeddruk-bij-resistente-hypertensie/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2025/10/09/baxdrostat-bij-ongecontroleerde-en-resistente-hypertensie-effectiviteit-en-veili/","published":"2025-10-09"},{"url":"https://hartvaat.nl/2024/11/12/renale-denervatie-bij-hypertensie-uitgebreide-meta-analyse-van-alle-trials/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/09/01/normalisatie-van-arteriele-stijfheid-en-cv-events-sparte-studie/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2020/10/01/sequentiele-nefronblokkade-met-gecombineerde-diuretica-bij-resistente-hypertensi/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/03/01/24-uurs-bloeddrukmonitoring-bij-renale-denervatie-denerhtn-studie/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/09/20/medicatietrouw-en-bloeddrukeffecten-van-renale-denervatie-rsd-pathway-2-analyse/","published":"2016-09-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mikaela-sjostrand","type":"person","url":"https://hartvaat.nl/mensen/mikaela-sjostrand/","name":"Mikaela Sjöstrand","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2018/02/01/cv-uitkomsten-naar-albumin-en-nierziekte-bij-diabetes-type-2-met-hoog-cv-risico/","published":"2018-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"milan-milojevic","type":"person","url":"https://hartvaat.nl/mensen/milan-milojevic/","name":"Milan Milojevic","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/06/13/ml-modellen-voorspellen-sterfte-bij-post-cardiotomisch-shock-op-ecmo-elso-regist/","published":"2026-08-10"},{"url":"https://hartvaat.nl/2025/01/01/vroege-heropnames-na-chirurgische-aortaklepvervanging-beinvloeden-trial-eindpunt/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2018/02/13/richtlijngetrouwe-medicamenteuze-therapie-in-contemporaine-revascularisatietrial/","published":"2018-02-13"},{"url":"https://hartvaat.nl/2016/01/05/doodsoorzaken-na-pci-versus-cabg-bij-complex-coronairlijden-5-jaarsfollow-up-van/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ofri-mosenzon","type":"person","url":"https://hartvaat.nl/mensen/ofri-mosenzon/","name":"Ofri Mosenzon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2022/09/01/dapagliflozine-effectief-ongeacht-cv-achtergrondmedicatie-declare-subanalyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/08/29/orale-semaglutide-en-cv-uitkomsten-bij-diabetes-type-2-nejm-pioneer-6/","published":"2019-08-29"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-bij-diabetes-type-2-met-ckd-leader-renale-analyse/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/02/01/cv-uitkomsten-naar-albumin-en-nierziekte-bij-diabetes-type-2-met-hoog-cv-risico/","published":"2018-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ovidiu-dressler","type":"person","url":"https://hartvaat.nl/mensen/ovidiu-dressler/","name":"Ovidiu Dressler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2019/12/01/absorb-scaffold-5-jaarsresultaten-systematische-meta-analyse/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/08/13/off-pump-versus-on-pump-cabg-bij-hoofdstamcoronairlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/04/23/hedendaagse-uitkomsten-na-cabg-voor-hoofdstamlijden/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2017/12/12/implantatiechniek-en-uitkomsten-van-bioresorbeerbare-scaffolds-absorb-analyses/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"},{"url":"https://hartvaat.nl/2016/01/09/ranolazine-bij-incomplete-revascularisatie-na-pci-de-river-pci-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-clemmensen","type":"person","url":"https://hartvaat.nl/mensen/peter-clemmensen/","name":"Peter Clemmensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-nir-uriel","type":"person","url":"https://hartvaat.nl/mensen/prof-nir-uriel/","name":"Prof. Nir Uriel","title":"Hoogleraar, Director Advanced HF en Harttransplantatie, Columbia University, New York, VS","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/02/23/aspirinestop-bij-lvad-met-vka-veiligheidsanalyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/03/01/aspirine-en-hemocompatibiliteit-na-lvad-bij-atherosclerotisch-vaatlijden/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2024/12/01/splanchnische-zenuwablatie-bij-hfpef-endovasculaire-benadering/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2022/09/27/momentum-3-vijfjaarsresultaten-heartmate-3-versus-axiale-lvad/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2020/04/01/lvad-gebruik-als-bridge-to-transplant-versus-destination-therapy-momentum-3/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2019/01/08/cva-analyse-in-momentum-3-langetermijncohort/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/10/30/zorggebruik-en-kosten-in-momentum-3-langetermijnstudie/","published":"2018-10-30"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/05/23/hemocompatibiliteitsuitkomsten-van-heartmate-3-na-6-maanden-momentum-3/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","published":"2017-02-02"}],"videos":[{"url":"https://hartvaat.nl/video/hfa-2026-late-breaking-science/overleving-gevorderd-hartfalen-ouderen/","title":"Overleving bij gevorderd hartfalen — LVAD versus harttransplantatie bij middelbare en oudere patiënten"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-j-glynn","type":"person","url":"https://hartvaat.nl/mensen/robert-j-glynn/","name":"Robert J Glynn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2023/04/15/inflammatie-en-cholesterol-als-cv-voorspellers-onder-statinetherapie-lancet-anal/","published":"2023-04-15"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","published":"2022-08-02"},{"url":"https://hartvaat.nl/2020/08/14/il-6-crp-en-ldl-als-biomarkers-van-residueel-risico-vergelijking/","published":"2020-08-14"},{"url":"https://hartvaat.nl/2020/02/01/il-1-remming-en-bloeddruk-hypertensie-en-residueel-inflammatoir-risico-cantos/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/03/05/canakinumab-ter-preventie-van-hartfalen-hospitalisatie-cantos-analyse/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2019/02/21/laaggedoseerd-methotrexaat-voor-preventie-van-atherosclerotische-events-nejm-cir/","published":"2019-02-21"},{"url":"https://hartvaat.nl/2017/10/21/canakinumab-en-longkankerincidentie-bij-atherosclerose-lancet-cantos-exploratief/","published":"2017-10-21"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/06/20/cholesteroleffluxcapaciteit-hdl-deeltjesaantal-en-cv-events-jupiter-analyse/","published":"2017-06-20"},{"url":"https://hartvaat.nl/2017/06/01/voedingsstatus-en-langetermijn-multivitaminegebruik-en-cv-risico-phs-ii-analyse/","published":"2017-06-01"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/04/20/ldl-reductievariabiliteit-en-antilichaamvorming-bij-bococizumab-nejm/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2016/05/01/lipoproteinen-insulineresistentie-en-rosuvastatine-bij-incident-type-2-diabetes/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sasko-kedev","type":"person","url":"https://hartvaat.nl/mensen/sasko-kedev/","name":"Sasko Kedev","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/01/10/trombusaspiratie-bij-stemi-individuele-patientdata-meta-analyse/","published":"2017-01-10"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sidney-c-smith","type":"person","url":"https://hartvaat.nl/mensen/sidney-c-smith/","name":"Sidney C Smith","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2022/10/04/2022-acc-expert-consensus-niet-statine-therapieen-voor-ldl-verlaging-bij-ascvd/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2019/11/26/2019-aha-acc-prestatie-en-kwaliteitsmaten-voor-hoge-bloeddruk/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2017/10/03/2017-acc-gerichte-update-niet-statinetherapie-voor-ldl-verlaging/","published":"2017-10-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephan-willems","type":"person","url":"https://hartvaat.nl/mensen/stephan-willems/","name":"Stephan Willems","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2021/10/09/gewichtsverlies-voor-af-ablatie-sort-af-gerandomiseerde-trial/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2021/07/18/cryoballonablatie-versus-antiaritmica-als-eerstelijns-paf-therapie/","published":"2021-07-18"},{"url":"https://hartvaat.nl/2021/03/08/katheterablatie-om-af-progressie-te-vertragen-attest-gerandomiseerde-trial/","published":"2021-03-08"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/09/24/interne-versus-externe-cardioversie-bij-atriale-aritmieen-met-icd/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2019/06/01/heparinedosering-bij-ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-re/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/01/01/energiebron-en-vroeg-af-recidief-cryoballon-versus-radiofrequentie/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/04/27/ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-nejm-re-circuit/","published":"2017-04-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephen-j-greene","type":"person","url":"https://hartvaat.nl/mensen/stephen-j-greene/","name":"Stephen J Greene","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/05/19/sglt2-remmers-bij-oudere-patienten-opgenomen-voor-hfref-24-sterfte-en-16-heropna/","published":"2026-06-15"},{"url":"https://hartvaat.nl/2026/02/03/intraveneus-ijzer-bij-hartfalen-met-ijzertekort-meta-analyse-met-trial-sequentie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2024/02/01/transform-hf-torsemide-versus-furosemide-bij-nieuw-vs-chronisch-hartfalen/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/07/11/transform-hf-torsemide-versus-furosemide-geen-verschil-in-symptomen/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2023/01/17/transform-hf-torsemide-biedt-geen-overlevingsvoordeel-boven-furosemide/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/04/01/robuustheid-van-sglt2-remmer-hf-trials-evaluatie/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2021/12/01/sacubitril-valsartan-uitgebreide-fda-labeling-jama-cardiology-implicaties/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/12/01/sglt2-remmers-bij-hartfalen-systematische-review-en-meta-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/06/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-acs-trials-jama-cardiology/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2018/10/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-hf-trials-jama-cardiology-review/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/03/01/poliklinische-verslechtering-van-hartfalen-als-therapiedoel-jama-cardiology-revi/","published":"2018-03-01"},{"url":"https://hartvaat.nl/2017/11/01/raas-blokkade-bij-hfpef-systematische-review-en-meta-analyse/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/06/27/hospitalisatie-voor-nieuw-gediagnosticeerd-versus-verslechterend-chronisch-hartf/","published":"2017-06-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sren-rasmussen","type":"person","url":"https://hartvaat.nl/mensen/sren-rasmussen/","name":"Søren Rasmussen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/08/18/semaglutide-verlaagt-hscrp-en-ontstekingsactiviteit-bij-ascvd-patienten-met-over/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","published":"2025-03-24"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/af-en-semaglutide-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/flow-semaglutide-vermindert-hartfalen-bij-diabetes-en-ckd/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","published":"2024-08-24"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2019/12/01/eerste-en-recidiverende-cv-events-met-liraglutide-bij-diabetes-type-2-leader/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-cv-uitkomsten-met-of-zonder-eerder-mi-leader/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/05/15/liraglutide-bij-diabetes-type-2-met-polyvasculaire-ziekte-leader-analyse/","published":"2018-05-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tabassome-simon","type":"person","url":"https://hartvaat.nl/mensen/tabassome-simon/","name":"Tabassome Simon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/10/23/aspirine-bij-chronisch-coronairsyndroom-plus-oac-wel-of-niet/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","published":"2024-04-30"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2022/09/15/polypill-voor-secundaire-cardiovasculaire-preventie-secure-trial-in-nejm/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/11/17/seh-zorgbundel-en-30-daags-ontslag-en-overleving-bij-oudere-hf-patienten-jama/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"venu-menon","type":"person","url":"https://hartvaat.nl/mensen/venu-menon/","name":"Venu Menon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/03/11/summit-tirzepatide-en-klinisch-traject-bij-hfpef-met-obesitas-langetermijn/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/02/25/summit-tirzepatide-vermindert-lv-massa-en-paracardiaal-vetweefsel-bij-hfpef/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/01/30/summit-tirzepatide-bij-hfpef-met-obesitas-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2024/03/05/gelijktijdige-laa-occlusie-en-tavr-bij-af-haalbaarheid/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2024/03/01/clear-outcomes-bempedoinezuur-vermindert-totale-cv-events-bij-statine-intolerant/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/10/01/crp-op-lp-a-geassocieerd-cv-risico-bij-optimaal-behandelde-hoogrisicopatienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/04/01/initieel-en-serieel-crp-en-cv-events-en-dood-na-acs-jama-cardiology/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2017/11/21/bloeddrukeffecten-van-ibuprofen-naproxen-en-celecoxib-bij-artritis-precision-abp/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wang","type":"person","url":"https://hartvaat.nl/mensen/wang/","name":"Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":14,"articles":[{"url":"https://hartvaat.nl/2026/04/10/subklinische-atherosclerose-bij-vrouwen-na-pre-eclampsie-systematische-review-en/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/04/10/proteomics-onthult-vier-subgroepen-van-acuut-hfpef-met-eigen-biologische-routes-/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/04/17/verhoogd-crp-voorspelt-hartfalen-bij-kankeroverlevenden-uk-biobank/","published":"2026-07-21"},{"url":"https://hartvaat.nl/2026/05/26/asymptomatische-matige-ernstige-aortaklepinsufficientie-niet-benigne-meta-analys/","published":"2026-07-03"},{"url":"https://hartvaat.nl/2026/04/24/ita-bypass-veilig-bij-patienten-met-eerdere-mediastinale-bestraling-maryland-coh/","published":"2026-05-22"},{"url":"https://hartvaat.nl/2026/04/24/astma-geassocieerd-met-verhoogd-risico-op-degeneratieve-hartklepziekte-uk-bioban/","published":"2026-05-11"},{"url":"https://hartvaat.nl/2026/04/24/cardiovasculaire-ziekte-bij-sikkelcelziekte-ondergediagnosticeerde-drijver-van-m/","published":"2026-05-11"},{"url":"https://hartvaat.nl/2026/03/25/geleidelijk-afbouwen-van-rilonacept-bij-recidiverende-pericarditis-voorkomt-vake/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/02/26/hiv-infectie-hangt-onafhankelijk-samen-met-meer-en-kwetsbaardere-halsslagaderpla/","published":"2026-02-26"},{"url":"https://hartvaat.nl/2026/02/12/ct-coronairangiografie-bij-nstemi-uitstekende-diagnostische-nauwkeurigheid-maar-/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/02/machine-learning-nomogram-voorspelt-vroeg-transplantaatfalen-na-harttransplantat/","published":"2026-02-02"},{"url":"https://hartvaat.nl/2026/01/30/off-label-lage-dosis-bloedplaatjesremmers-bij-coronairlijden-minder-infarcten-en/","published":"2026-01-30"},{"url":"https://hartvaat.nl/2026/01/29/lineaire-ablatie-van-de-voorwand-van-het-linkeratrium-vermindert-af-recidieven-b/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2026/01/09/littekenweefsel-voorspelt-plotse-hartdood-na-een-infarct-grotendeels-buiten-de-e/","published":"2026-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adam-d-devore","type":"person","url":"https://hartvaat.nl/mensen/adam-d-devore/","name":"Adam D DeVore","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2023/10/24/inhalatief-epoprostenol-versus-no-bij-rechterventrikel-falen-na-hartchirurgie/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/08/01/gdf-15-en-liraglutide-behandeling-bij-hf-patienten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2020/09/01/arni-naar-hf-voorgeschiedenis-en-raas-antagonistgebruik/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/02/01/arni-initiatie-na-acuut-gedecompenseerd-hf-pioneer-hf-open-label-extensie/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2020/02/01/geschiktheid-voor-sglt2-remmers-bij-diabetespatienten-opgenomen-met-hartfalen/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/10/21/cv-biomarkers-bij-acuut-gedecompenseerd-hf-met-sacubitril-valsartan-pioneer-hf/","published":"2019-10-21"},{"url":"https://hartvaat.nl/2019/05/07/sacubitril-valsartan-of-enalapril-bij-acuut-gedecompenseerd-hf-pioneer-hf-klinis/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/02/07/angiotensine-neprilysineremming-bij-acuut-gedecompenseerd-hf-nejm-pioneer-hf/","published":"2019-02-07"},{"url":"https://hartvaat.nl/2018/12/01/liraglutide-en-gewicht-bij-gevorderd-hfref-fight-trial-inzichten/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2016/08/01/hospitalisaties-bij-atriumfibrilleren-analyse-uit-rocket-af/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alain-cohen-solal","type":"person","url":"https://hartvaat.nl/mensen/alain-cohen-solal/","name":"Alain Cohen-Solal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/12/01/geografische-variatie-in-hfref-patientkenmerken-en-behandeling/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2022/12/01/vericiguat-en-nt-probnp-bij-hfref-victoria-subanalyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-p-ambrosy","type":"person","url":"https://hartvaat.nl/mensen/andrew-p-ambrosy/","name":"Andrew P Ambrosy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/04/30/kp-chemo-cumulatieve-incidentie-cancer-therapy-related-cardiac-dysfunction-8-4-h/","published":"2026-07-02"},{"url":"https://hartvaat.nl/2026/05/25/het-spectrum-van-congestie-bij-hartfalen-pathofysiologie-en-diagnostische-strate/","published":"2026-05-31"},{"url":"https://hartvaat.nl/2025/06/01/nierfunctie-en-dapagliflozine-effect-op-gezondheidsstatus-define-hf/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2023/07/11/transform-hf-torsemide-versus-furosemide-geen-verschil-in-symptomen/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/04/01/intraveneus-ijzer-bij-hartfalen-meta-analyse-op-studieniveau/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2022/12/01/hartfalen-tijdens-de-covid-19-pandemie-klinische-en-organisatorische-dilemma-s/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/08/01/gdf-15-en-liraglutide-behandeling-bij-hf-patienten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2020/09/01/arni-naar-hf-voorgeschiedenis-en-raas-antagonistgebruik/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/02/01/arni-initiatie-na-acuut-gedecompenseerd-hf-pioneer-hf-open-label-extensie/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/05/07/sacubitril-valsartan-of-enalapril-bij-acuut-gedecompenseerd-hf-pioneer-hf-klinis/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/02/07/angiotensine-neprilysineremming-bij-acuut-gedecompenseerd-hf-nejm-pioneer-hf/","published":"2019-02-07"},{"url":"https://hartvaat.nl/2018/12/01/liraglutide-en-gewicht-bij-gevorderd-hfref-fight-trial-inzichten/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2017/06/27/hospitalisatie-voor-nieuw-gediagnosticeerd-versus-verslechterend-chronisch-hartf/","published":"2017-06-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"atul-verma","type":"person","url":"https://hartvaat.nl/mensen/atul-verma/","name":"Atul Verma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","published":"2026-05-27"},{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/10/31/vrouwen-met-persisterend-af-pvi-alleen-is-onvoldoende/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2023/05/30/complicaties-van-af-ablatie-actueel-overzicht/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"},{"url":"https://hartvaat.nl/2019/11/26/cryoballon-versus-rf-ablatie-bij-af-beoordeeld-met-continue-monitoring-cryo-firs/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/06/01/heparinedosering-bij-ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-re/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/11/21/voortzetten-versus-onderbreken-doac-bij-device-chirurgie-bruise-control-2/","published":"2018-11-21"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/04/27/ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-nejm-re-circuit/","published":"2017-04-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"baris-gencer","type":"person","url":"https://hartvaat.nl/mensen/baris-gencer/","name":"Baris Gencer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/04/17/schildklierdisfunctie-en-hart-en-vaatziekten-ehj-overzicht/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2022/11/17/olpasiran-sirna-verlaagt-lipoproteine-a-spectaculair-in-fase-2-trial/","published":"2022-11-17"},{"url":"https://hartvaat.nl/2022/10/01/sekseverschillen-in-af-risico-vital-rhythm-studie/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/12/21/langdurige-omega-3-suppletie-en-af-risico-meta-analyse-van-cv-trials/","published":"2021-12-21"},{"url":"https://hartvaat.nl/2021/03/16/omega-3-en-vitamine-d-en-incident-af-jama-vital-af/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/11/21/ldl-verlaging-bij-ouderen-lancet-meta-analyse-werkzaamheid-en-veiligheid/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/12/cognitie-na-ldl-verlaging-met-evolocumab-fourier-follow-up/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2019/11/19/evolocumab-voor-vroege-ldl-verlaging-bij-acs-evopacs/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c-david-mazer","type":"person","url":"https://hartvaat.nl/mensen/c-david-mazer/","name":"C David Mazer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/03/09/semaglutide-stimuleert-anti-inflammatoire-stamcelflux-vanuit-beenmerg/","published":"2026-03-09"},{"url":"https://hartvaat.nl/2026/02/19/evolocumab-en-doorgankelijkheid-van-veneuze-bypasses-na-cabg-newton-cabg-cardiol/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","published":"2025-09-20"},{"url":"https://hartvaat.nl/2023/06/01/igfbp7-en-lv-massaregressie-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/diabetesduur-beinvloedt-lv-massaregressie-met-empagliflozine/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2021/12/01/sglt2-remmers-en-cardiale-remodellering-meta-analyse-van-mri-trials/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","published":"2021-06-03"},{"url":"https://hartvaat.nl/2019/11/19/empagliflozine-en-lv-massa-bij-diabetes-type-2-met-coronairlijden-empa-heart/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/04/01/restrictieve-versus-liberale-transfusie-bij-hartchirurgie-meta-analyse/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/09/27/6-maandsuitkomsten-van-restrictieve-versus-liberale-transfusie-bij-hartchirurgie/","published":"2018-09-27"},{"url":"https://hartvaat.nl/2018/01/23/empagliflozine-bij-diabetes-type-2-met-perifeer-vaatlijden-empa-reg-outcome/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/11/30/restrictieve-versus-liberale-bloedtransfusie-bij-hartchirurgie-nejm-trics-iii/","published":"2017-11-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chris-p-gale","type":"person","url":"https://hartvaat.nl/mensen/chris-p-gale/","name":"Chris P Gale","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/08/25/risicogestuurde-af-screening-met-machine-learning-verhoogt-detectiegraad-find-af/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/05/21/find-af-biomarker-stratificeert-prognose-bij-hfref-met-atriale-cardiomyopathie-z/","published":"2026-06-08"},{"url":"https://hartvaat.nl/2026/03/25/meta-analyse-glp-1-agonisten-voorkomen-hartfalen-in-type-2-diabetes-sterkste-eff/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/01/07/euroheart-definities-van-klinische-studie-eindpunten-voor-cvd/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/03/12/rapid-nstemi-zeer-vroege-invasieve-strategie-bij-hoger-risico-nstemi/","published":"2024-03-12"},{"url":"https://hartvaat.nl/2022/09/01/collaterale-schade-van-covid-19-aan-cardiovasculaire-zorg-meta-analyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/09/01/timing-van-invasieve-strategie-bij-nste-acs-meta-analyse-van-rct-s/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/06/14/euroheart-datastandaarden-voor-hartfalenregistraties/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/06/10/voorspelling-van-atriumfibrilleren-in-elektronische-gezondheidsdossiers-systemat/","published":"2022-06-10"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2021/03/01/objectieve-risicobeoordeling-versus-standaardzorg-bij-acs-jama-cardiology/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2021/03/01/langetermijn-overlevingsvoordeel-van-ramipril-bij-mi-met-hf/","published":"2021-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"craig-s-anderson","type":"person","url":"https://hartvaat.nl/mensen/craig-s-anderson/","name":"Craig S Anderson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/03/01/frailteit-en-antihypertensieve-behandeling-bij-ouderen-meta-analyse/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2024/05/30/right-2-ambulancebloeddrukverlaging-bij-hyperacuut-cva-nejm-vervolgresultaten/","published":"2024-05-30"},{"url":"https://hartvaat.nl/2023/09/05/optimal-bp-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-jama/","published":"2023-09-05"},{"url":"https://hartvaat.nl/2023/07/01/interact3-bundeled-care-bij-acute-intracerebrale-bloeding-lancet/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/12/21/bloeddrukverlaging-en-dementiepreventie-ipd-meta-analyse/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/11/05/enchanted2-mt-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-is-schadelij/","published":"2022-11-05"},{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"},{"url":"https://hartvaat.nl/2017/07/11/positieve-luchtwegdruk-en-cv-events-bij-slaapapneu-jama-meta-analyse/","published":"2017-07-11"},{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","published":"2016-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dariusz-dudek","type":"person","url":"https://hartvaat.nl/mensen/dariusz-dudek/","name":"Dariusz Dudek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","published":"2025-07-21"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/11/07/complete-revascularisatie-vermindert-cv-dood-bij-stemi-met-multivatenlijden-meta/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/03/05/timing-van-prasugrel-start-en-coronairangiografie-bij-nstemi/","published":"2019-03-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-h-birnie","type":"person","url":"https://hartvaat.nl/mensen/david-h-birnie/","name":"David H Birnie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/09/30/adaptresponse-adaptieve-versus-conventionele-crt-bij-hartfalen-lancet/","published":"2023-09-30"},{"url":"https://hartvaat.nl/2023/05/01/aware-uitgebreide-ablatie-vermindert-af-recidief-niet-boven-standaard-pvi/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2022/02/01/sekse-en-gender-in-crt-studies-systematische-review/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2020/10/01/sekseverschillen-in-kenmerken-en-qol-bij-crt-patienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/02/01/elektrische-versus-farmacologische-cardioversie-bij-acuut-af-op-de-seh-lancet-ra/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2018/11/21/voortzetten-versus-onderbreken-doac-bij-device-chirurgie-bruise-control-2/","published":"2018-11-21"},{"url":"https://hartvaat.nl/2017/10/01/korte-dabigatran-onderbreking-voor-device-implantatie-re-ly-multicenterervaring/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/05/09/agressieve-bloeddrukcontrole-en-recidief-van-af-na-ablatie-gerandomiseerde-trial/","published":"2017-05-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"denis-xavier","type":"person","url":"https://hartvaat.nl/mensen/denis-xavier/","name":"Denis Xavier","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/08/16/achieve-spironolacton-bij-dialysepatienten-internationale-rct/","published":"2025-08-16"},{"url":"https://hartvaat.nl/2023/02/01/aspirine-en-cardiovasculaire-uitkomsten-bij-chronische-nierziekte/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/05/01/vroegtijdig-permanent-staken-van-apixaban-of-warfarine-bij-af/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/06/09/dabigatran-bij-myocardschade-na-niet-cardiale-chirurgie-lancet-manage-trial/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/10/14/multifacet-interventie-voor-oac-gebruik-bij-af-lancet-impact-af/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dirk-sibbing","type":"person","url":"https://hartvaat.nl/mensen/dirk-sibbing/","name":"Dirk Sibbing","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","published":"2025-07-21"},{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","published":"2022-03-07"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"do-yoon-kang","type":"person","url":"https://hartvaat.nl/mensen/do-yoon-kang/","name":"Do-Yoon Kang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/03/06/debat-preventieve-pci-bij-kwetsbare-plaques-als-standaardbehandeling/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2026/03/12/off-label-onderdosering-edoxaban-bij-af-en-systemische-embolieen/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/12/05/edoxaban-bij-af-en-stabiel-coronairlijden-antitrombotische-monotherapie/","published":"2024-12-05"},{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","published":"2024-05-04"},{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/11/22/ees-versus-cabg-bij-meervatslijden-langetermijn-follow-up-van-rct-s/","published":"2022-11-22"},{"url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","published":"2022-09-08"},{"url":"https://hartvaat.nl/2020/05/05/des-versus-cabg-bij-linker-hoofdstam-10-jaarsresultaten-excel-extended/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/12/03/klinisch-significante-bloedingen-met-ticagrelor-versus-clopidogrel-bij-koreaanse/","published":"2019-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"donald-m-lloyd-jones","type":"person","url":"https://hartvaat.nl/mensen/donald-m-lloyd-jones/","name":"Donald M Lloyd-Jones","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2022/10/04/2022-acc-expert-consensus-niet-statine-therapieen-voor-ldl-verlaging-bij-ascvd/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2018/02/13/kwaliteitsverbeteringsinterventie-bij-acuut-mi-in-india-jama-acs-quik/","published":"2018-02-13"},{"url":"https://hartvaat.nl/2017/10/03/2017-acc-gerichte-update-niet-statinetherapie-voor-ldl-verlaging/","published":"2017-10-03"},{"url":"https://hartvaat.nl/2017/02/01/bereikte-bloeddruk-en-cardiovasculaire-uitkomsten-bij-oudere-patienten-met-geiso/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"edgar-pete-r-miller","type":"person","url":"https://hartvaat.nl/mensen/edgar-pete-r-miller/","name":"Edgar Pete R Miller","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/01/06/gofresh-dash-boodschappen-en-bloeddrukeffect-rct/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2024/07/16/rich-life-gelijkwaardige-hypertensiezorg-voor-achtergestelde-populaties/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2021/11/01/rustduur-voor-bloeddrukmeting-best-rest-trial/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/06/01/dieet-en-natriumreductie-op-cardiale-schade-en-inflammatie-dash-sodium/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/03/01/orthostatische-hypotensie-cv-uitkomsten-en-adverse-events-sprint-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2020/03/01/natriumreductie-en-energie-metabolisme-gewicht-en-dorst-dash-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-systematische-review-circulation/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/01/hypertensiebehandeling-en-orthostatische-hypotensie-relatie-met-cv-ziekte/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/06/01/systematische-review-voor-de-2017-acc-aha-hypertensierichtlijn-hypertension-edit/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/05/15/systematische-review-voor-de-2017-acc-aha-hypertensierichtlijn/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2017/12/12/natriumreductie-en-dash-dieet-naar-uitgangs-bloeddruk/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/11/01/tijdsverloop-van-bloeddrukverandering-door-zoutreductie-en-dash-dieet/","published":"2017-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eric-boersma","type":"person","url":"https://hartvaat.nl/mensen/eric-boersma/","name":"Eric Boersma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/04/28/geen-sekseverschillen-in-werkzaamheid-van-hartfalenmedicatie-meta-analyse-van-13/","published":"2026-05-05"},{"url":"https://hartvaat.nl/2024/08/21/pa-drukmonitoring-bij-chronisch-hartfalen-effecten-over-klinische-subgroepen/","published":"2024-08-21"},{"url":"https://hartvaat.nl/2023/10/01/pa-drukmonitoring-bij-chronisch-hartfalen-meta-analyse-van-drie-rct-s/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/08/14/telemonitoring-bij-hartfalen-meta-analyse-van-alle-strategieen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/24/monitor-hf-pa-drukmonitoring-bij-hartfalen-effectief-in-europa-lancet-rct/","published":"2023-06-24"},{"url":"https://hartvaat.nl/2023/04/08/biovasc-directe-versus-gestageerde-complete-revascularisatie-bij-acs-met-meervat/","published":"2023-04-08"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2019/10/01/telemedicine-en-mortaliteit-bij-acuut-mi-systematische-review-en-meta-analyse/","published":"2019-10-01"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2018/03/01/twee-geavanceerde-en-verlengde-hartrevalidatieprogramma-s-gerandomiseerde-trial/","published":"2018-03-01"},{"url":"https://hartvaat.nl/2016/09/27/intensieve-glucoseregulatie-bij-hyperglycemisch-acs-langetermijnfollow-up-biomar/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/01/05/ct-coronairangiografie-bij-verdenking-acs-in-het-tijdperk-van-hoog-sensitief-tro/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eric-d-peterson","type":"person","url":"https://hartvaat.nl/mensen/eric-d-peterson/","name":"Eric D Peterson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2023/10/24/cts-ami-tongxinluo-bij-acuut-mi-jama-mega-trial/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2020/05/01/zelfgerapporteerde-versus-apotheekgeregistreerde-medicatietrouw-compass-analyse/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/01/01/p2y12-copay-reductie-en-therapietrouw-aan-andere-secundaire-preventiemiddelen/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-bij-acs-in-resource-beperkte-ziekenhuizen-jama-cardiology-/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2019/01/01/medicatie-copay-vouchers-en-p2y12-gebruik-en-cv-events-na-mi-jama/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/12/01/ras-etniciteit-en-oac-gebruik-bij-af-orbit-af/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/12/01/cardiovasculaire-risicocommunicatie-en-patientperceptie-jama-cardiology/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2017/11/01/hypertensiecontrole-bij-diabetes-met-recidiverende-cv-events-tecos-globale-resul/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/26/secundaire-cardiovasculaire-preventie-bij-diabetes-type-2-tecos-internationale-i/","published":"2017-09-26"},{"url":"https://hartvaat.nl/2017/01/24/heropnames-bij-af-patienten-na-stenting-twee-antitromboticastrategieen-vergeleke/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/12/22/preventie-van-bloedingen-bij-af-patienten-die-pci-ondergaan-nejm-pioneer-af-pci/","published":"2016-12-22"},{"url":"https://hartvaat.nl/2016/12/20/off-label-doac-dosering-en-ongunstige-uitkomsten-orbit-af-ii-register/","published":"2016-12-20"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gad-cotter","type":"person","url":"https://hartvaat.nl/mensen/gad-cotter/","name":"Gad Cotter","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/03/16/natrium-hf-subanalyse-natriuretische-peptiden-lopen-achter-op-de-klinische-ontst/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/12/01/gelijktijdige-griep-en-rsv-vaccinatie-bij-hoogrisico-hartfalenpatienten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2019/12/01/hepatorenale-disfunctie-identificeert-hoogrisico-acuut-hf-relax-ahf/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2017/08/07/trv027-biased-ligand-van-de-angiotensine-ii-receptor-bij-acuut-hartfalen-gerando/","published":"2017-08-07"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gaetano-m-de-ferrari","type":"person","url":"https://hartvaat.nl/mensen/gaetano-m-de-ferrari/","name":"Gaetano M De Ferrari","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/04/20/stopstorm-stereotactische-bestraling-reduceert-refractaire-vt-met-80/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2025/11/11/ct-angiografie-of-standaardzorg-na-pci-van-de-linker-hoofdstam/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/04/29/vroege-iabp-bij-hartfalen-gerelateerde-cardiogene-shock-gerandomiseerde-trial/","published":"2025-04-29"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/12/09/ideale-blankingperiode-na-af-ablatie-bewijs-voor-herziening/","published":"2022-12-09"},{"url":"https://hartvaat.nl/2018/08/21/klinisch-voordeel-van-evolocumab-naar-ernst-van-coronairlijden-fourier/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/03/13/digoxine-en-mortaliteit-bij-patienten-met-atriumfibrilleren/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2017/05/01/langetermijnveiligheid-van-zeer-lage-ldl-cholesterolniveaus-improve-it-analyse/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/07/26/atherotrombotische-risicostratificatie-en-vorapaxar-bij-stabiel-ischemisch-hartl/","published":"2016-07-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"glenn-m-chertow","type":"person","url":"https://hartvaat.nl/mensen/glenn-m-chertow/","name":"Glenn M Chertow","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/01/01/dialysaat-kalium-3-0-mmol-l-met-natriumzirconiumcyclosilicaat-bij-dialyse/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2023/04/01/natriumzirconiumcyclosilicaat-bij-hyperkaliemie-en-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2022/12/06/apixaban-bij-af-op-hemodialyse-eerste-gerandomiseerde-trial/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2021/03/31/dapagliflozine-en-mortaliteit-bij-ckd-dapa-ckd-pre-gespecificeerde-analyse/","published":"2021-03-31"},{"url":"https://hartvaat.nl/2020/10/08/dapagliflozine-bij-chronische-nierziekte-nejm-dapa-ckd/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/04/28/apixaban-versus-warfarine-bij-af-met-gevorderde-ckd/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/23/gezondheidsstatus-na-invasieve-of-conservatieve-zorg-bij-coronairlijden-met-gevo/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2019/10/01/bardoxolone-en-urine-albumine-creatinine-ratio-bij-diabetes-met-ckd-stadium-4/","published":"2019-10-01"},{"url":"https://hartvaat.nl/2018/01/09/diastolische-bloeddruk-en-intensieve-bloeddrukcontrole-sprint-analyse/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"},{"url":"https://hartvaat.nl/2016/03/01/voorschrijfpatronen-van-thiazidediuretica-in-de-sprint-trial/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"graham-s-hillis","type":"person","url":"https://hartvaat.nl/mensen/graham-s-hillis/","name":"Graham S Hillis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/04/08/vision-postoperatief-atriumfibrilleren-na-hartchirurgie-verhoogt-sterfte-na-een-/","published":"2026-07-15"},{"url":"https://hartvaat.nl/2026/02/23/pathfinder-trial-betere-naleving-van-hartfalenrichtlijnen-in-de-huisartsenprakti/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/05/02/determinanten-van-medicatietrouw-na-acs-secundaire-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2025/01/21/evolved-vroege-interventie-bij-asymptomatische-ernstige-aortastenose-met-myocard/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2022/05/10/sms-voor-medicatietrouw-en-secundaire-preventie-na-acs-textmeds/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","published":"2021-09-18"},{"url":"https://hartvaat.nl/2021/03/01/objectieve-risicobeoordeling-versus-standaardzorg-bij-acs-jama-cardiology/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2019/01/01/polypil-en-cardiovasculaire-preventie-meta-analyse-van-gerandomiseerde-trials/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/11/22/plasma-lipidomiek-verbetert-cardiovasculaire-risicovoorspelling-bij-diabetes-typ/","published":"2016-11-22"},{"url":"https://hartvaat.nl/2016/01/30/intensieve-bloeddrukverlaging-en-cardiovasculaire-en-renale-uitkomsten-systemati/","published":"2016-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"henning-kelbk","type":"person","url":"https://hartvaat.nl/mensen/henning-kelbk/","name":"Henning Kelbæk","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2023/09/26/biodegradeerbare-versus-duurzame-polymeer-stents-bij-hoog-bloedingsrisico/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2023/02/23/ct-coronairangiografie-bij-75-jarigen-met-nste-acs/","published":"2023-02-23"},{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ibrahim-akin","type":"person","url":"https://hartvaat.nl/mensen/ibrahim-akin/","name":"Ibrahim Akin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/02/03/kenmerken-van-asymptomatische-patienten-met-hartfalen-en-verminderde-ejectiefrac/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/12/01/scai-shockklassen-en-prognose-bij-ami-cardiogene-shock-danger-substudie/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/10/07/laa-occlusie-bij-terminale-nierziekte-ipd-meta-analyse/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2021/01/19/residuele-syntax-score-bij-cardiogene-shock/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jackie-bosch","type":"person","url":"https://hartvaat.nl/mensen/jackie-bosch/","name":"Jackie Bosch","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/08/25/extracraniale-bloedingen-komen-bij-26-van-af-patienten-op-antistolling-voor-comb/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2020/05/19/bloeddrukverlaging-en-dementie-of-cognitieve-stoornis-jama-meta-analyse/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2019/12/07/individueel-levenslang-voordeel-en-bloedingsrisico-van-rivaroxaban-plus-aspirine/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2019/08/13/rivaroxaban-met-of-zonder-aspirine-bij-hf-met-coronair-of-perifeer-vaatlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2018/03/01/omega-3-vetzuursupplementen-en-cv-risico-jama-cardiology-meta-analyse-van-10-tri/","published":"2018-03-01"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"james-a-de-lemos","type":"person","url":"https://hartvaat.nl/mensen/james-a-de-lemos/","name":"James A de Lemos","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2024/09/16/tirzepatide-en-bloeddrukverlaging-surmount-1-gestratificeerde-analyse/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2024/09/01/troponine-nt-probnp-en-cognitieve-uitkomsten-in-sprint/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/10/18/intensieve-bloeddrukverlaging-bij-maligne-linkerventrikel-hypertrofie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/05/01/mcp-1-en-cardiovasculaire-mortaliteit-populatie-gebaseerde-meta-analyse/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2016/08/01/sedentair-gedrag-en-cardiovasculair-risico-continue-dosis-responsrelatie-in-meta/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"james-c-fang","type":"person","url":"https://hartvaat.nl/mensen/james-c-fang/","name":"James C Fang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2024/10/15/aha-scientific-statement-nierdisfunctie-bij-gevorderd-hartfalen/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2018/10/01/natriuretische-peptiden-en-cardiovasculaire-prognose-bij-hfpef-topcat/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/09/12/lichamelijke-activiteit-en-prognose-bij-hfpef-topcat-analyse/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jan-biegus","type":"person","url":"https://hartvaat.nl/mensen/jan-biegus/","name":"Jan Biegus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/06/26/machine-learning-voorspelt-diureticumrespons-bij-acuut-hartfalen-drc-ahf/","published":"2026-08-06"},{"url":"https://hartvaat.nl/2026/05/26/adipokineprofiel-bij-acuut-hartfalen-voorspelt-natriuretische-respons-en-mortali/","published":"2026-05-30"},{"url":"https://hartvaat.nl/2026/05/10/delta-hf-thoracale-duct-lymfedecongestie-via-elym-systeem-haalbaar-bij-acute-har/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/03/03/expertopinie-hierarchische-eindpunten-op-basis-van-verslechterend-hartfalen-voor/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/12/01/gelijktijdige-griep-en-rsv-vaccinatie-bij-hoogrisico-hartfalenpatienten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2019/12/01/hepatorenale-disfunctie-identificeert-hoogrisico-acuut-hf-relax-ahf/","published":"2019-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jan-j-piek","type":"person","url":"https://hartvaat.nl/mensen/jan-j-piek/","name":"Jan J Piek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/01/29/microvasculaire-schade-bij-gerevasculariseerde-stemi-met-ticagrelor-versus-prasu/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/06/15/bioresorbeerbare-scaffolds-versus-metallic-stents-bij-routine-pci-nejm-aida/","published":"2017-06-15"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-circulatoire-ondersteuning-versus-iabp-bij-cardiogene-shoc/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","published":"2016-06-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeehoon-kang","type":"person","url":"https://hartvaat.nl/mensen/jeehoon-kang/","name":"Jeehoon Kang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","published":"2025-11-08"},{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/05/01/aspirine-versus-clopidogrel-na-coronaire-stenting-naar-bloedingsrisico-en-comple/","published":"2025-05-01"},{"url":"https://hartvaat.nl/2023/10/17/antiplaatjesmonotherapie-na-pci-clopidogrel-versus-aspirine-naar-risicoprofiel/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/05/02/korte-versus-standaard-dapt-na-pci-met-moderne-des-meta-analyse/","published":"2023-05-02"},{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2023/01/10/host-exam-extended-clopidogrel-superieur-aan-aspirine-als-monotherapie-na-pci/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2021/06/26/aspirine-versus-clopidogrel-voor-chronische-monotherapie-na-pci-lancet-host-exam/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2021/03/16/duurzame-versus-biodegradeerbare-polymer-des-bij-acs-meta-analyse/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/10/10/prasugrel-gebaseerde-dapt-de-escalatie-na-pci-bij-acs-lancet-host-reduce-polytec/","published":"2020-10-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jennifer-b-green","type":"person","url":"https://hartvaat.nl/mensen/jennifer-b-green/","name":"Jennifer B Green","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/03/29/confidence-analyse-acute-egfr-daling-bij-empagliflozin-finerenone-is-reversibel-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/02/23/van-internationale-richtlijnen-naar-nationale-implementatie-bij-cardio-renaal-me/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2024/07/16/interventie-voor-evidence-based-zorg-bij-diabetes-en-cv-risico/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/03/26/grade-cv-uitkomsten-van-glucoseverlagende-middelen-bij-type-2-diabetes/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2023/08/08/glp-1-agonisten-met-en-zonder-sglt2-remmers-bij-type-2-diabetes-jacc-analyse/","published":"2023-08-08"},{"url":"https://hartvaat.nl/2023/04/18/gecoordineerde-zorg-optimaliseert-cv-preventie-bij-type-2-diabetes-jama-rct/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2022/09/22/grade-vergelijking-glucoseverlagende-middelen-op-microvasculaire-en-cv-uitkomste/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2018/10/27/albiglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-harmony-ou/","published":"2018-10-27"},{"url":"https://hartvaat.nl/2017/11/01/hypertensiecontrole-bij-diabetes-met-recidiverende-cv-events-tecos-globale-resul/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/26/secundaire-cardiovasculaire-preventie-bij-diabetes-type-2-tecos-internationale-i/","published":"2017-09-26"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jing-li","type":"person","url":"https://hartvaat.nl/mensen/jing-li/","name":"Jing Li","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/04/01/intensieve-bloeddrukcontrole-en-cognitieve-functie-gerandomiseerde-trial/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/06/esprit-intensieve-bloeddrukcontrole-bij-fragiele-patienten-post-hoc-analyse/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/10/28/esprit-bescheiden-effecten-van-intensieve-bloeddrukverlaging-op-kwaliteit-van-le/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukverlaging-en-retinale-microvasculatuur/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukcontrole-en-cva-preventie/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2024/07/20/sbp-120-versus-140-mmhg-bij-hoog-cv-risico-meta-analyse-van-intensieve-behandeli/","published":"2024-07-20"},{"url":"https://hartvaat.nl/2024/06/01/opt-birisk-clopidogrel-monotherapie-bij-acs-met-hoog-ischemisch-en-bloedingsrisi/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2022/12/01/klebsiella-pneumoniae-als-mogelijke-oorzaak-van-hypertensie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/08/09/vertraagde-afgifteformulering-van-ivabradine-bij-systolisch-hartfalen/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/07/27/veiligheid-van-pcsk9-remmers-systematische-review-en-meta-analyse/","published":"2022-07-27"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-a-cairns","type":"person","url":"https://hartvaat.nl/mensen/john-a-cairns/","name":"John A Cairns","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/08/01/complete-versus-culprit-only-revascularisatie-bij-stemi-jama-cardiology-meta-ana/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2018/01/09/risico-s-van-overinterpretatie-van-interimdata-lessen-uit-de-total-trial/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/01/10/trombusaspiratie-bij-stemi-individuele-patientdata-meta-analyse/","published":"2017-01-10"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"josep-comin-colet","type":"person","url":"https://hartvaat.nl/mensen/josep-comin-colet/","name":"Josep Comin-Colet","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/04/17/atriumfibrilleren-in-catalonie-prevalentie-gestabiliseerd-incidentie-gedaald-2-v/","published":"2026-07-19"},{"url":"https://hartvaat.nl/2025/11/25/amphilimus-versus-zotarolimus-eluting-stent-bij-diabetes-en-coronairlijden/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/03/31/amphilimus-versus-zotarolimus-stents-bij-diabetes-sugar-gerandomiseerde-trial/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/09/29/arni-en-renale-uitkomsten-bij-hfpef-paragon-hf/","published":"2020-09-29"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jung-sun-kim","type":"person","url":"https://hartvaat.nl/mensen/jung-sun-kim/","name":"Jung-Sun Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/01/01/antistolling-alleen-of-met-plaatjesremming-bij-coronairlijden-meta-analyse/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","published":"2023-04-04"},{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"},{"url":"https://hartvaat.nl/2020/06/16/ticagrelor-monotherapie-versus-dapt-op-bloedingen-en-cv-events-bij-acs-jama-tico/","published":"2020-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kerry-l-lee","type":"person","url":"https://hartvaat.nl/mensen/kerry-l-lee/","name":"Kerry L Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","published":"2022-08-16"},{"url":"https://hartvaat.nl/2022/03/15/leeftijd-en-uitkomsten-van-katheterablatie-versus-medicatie-bij-af-cabana/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2020/07/28/langetermijn-icd-uitkomsten-scd-heft/","published":"2020-07-28"},{"url":"https://hartvaat.nl/2020/06/30/af-recidief-na-ablatie-versus-antiaritmica-in-cabana/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-medicamenteus-bij-af-en-kwaliteit-van-leven-jama-cabana-q/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/03/05/inspanningstest-versus-ccta-bij-diabetes-met-verdenking-coronairlijden/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2018/02/20/sekseverschillen-bij-ischemisch-hartfalen-na-cabg-stich-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/11/21/coronair-calcium-en-prognostische-waarde-bij-pijn-op-de-borst-promise-studie/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2017/06/01/primaire-preventie-icd-bij-niet-ischemische-cardiomyopathie-meta-analyse/","published":"2017-06-01"},{"url":"https://hartvaat.nl/2017/03/21/plotse-hartdood-bij-ischemisch-hartfalen-na-cabg-stich-resultaten/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/11/01/tienjaarsuitkomsten-na-cabg-naar-leeftijd-bij-hartfalen-met-lv-systolische-disfu/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/21/coronaire-bypasschirurgie-bij-ischemische-cardiomyopathie-nejm-stich-trial/","published":"2016-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kyeong-ho-yun","type":"person","url":"https://hartvaat.nl/mensen/kyeong-ho-yun/","name":"Kyeong Ho Yun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/01/01/intravasculaire-beeldvorming-superieur-aan-angiografie-bij-complexe-pci-5-jaarsr/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"},{"url":"https://hartvaat.nl/2020/06/16/ticagrelor-monotherapie-versus-dapt-op-bloedingen-en-cv-events-bij-acs-jama-tico/","published":"2020-06-16"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kyung-woo-park","type":"person","url":"https://hartvaat.nl/mensen/kyung-woo-park/","name":"Kyung Woo Park","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","published":"2025-11-08"},{"url":"https://hartvaat.nl/2025/05/01/aspirine-versus-clopidogrel-na-coronaire-stenting-naar-bloedingsrisico-en-comple/","published":"2025-05-01"},{"url":"https://hartvaat.nl/2023/10/17/antiplaatjesmonotherapie-na-pci-clopidogrel-versus-aspirine-naar-risicoprofiel/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/05/02/korte-versus-standaard-dapt-na-pci-met-moderne-des-meta-analyse/","published":"2023-05-02"},{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2023/01/10/host-exam-extended-clopidogrel-superieur-aan-aspirine-als-monotherapie-na-pci/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2021/06/26/aspirine-versus-clopidogrel-voor-chronische-monotherapie-na-pci-lancet-host-exam/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2021/03/16/duurzame-versus-biodegradeerbare-polymer-des-bij-acs-meta-analyse/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/10/10/prasugrel-gebaseerde-dapt-de-escalatie-na-pci-bij-acs-lancet-host-reduce-polytec/","published":"2020-10-10"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"laurent-billot","type":"person","url":"https://hartvaat.nl/mensen/laurent-billot/","name":"Laurent Billot","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2026/01/20/voorspelling-van-individuele-corticosteroidrespons-bij-iga-nefropathie-testing-t/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2024/05/30/right-2-ambulancebloeddrukverlaging-bij-hyperacuut-cva-nejm-vervolgresultaten/","published":"2024-05-30"},{"url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/07/01/interact3-bundeled-care-bij-acute-intracerebrale-bloeding-lancet/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2022/11/05/enchanted2-mt-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-is-schadelij/","published":"2022-11-05"},{"url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","published":"2021-09-18"},{"url":"https://hartvaat.nl/2020/11/01/lage-dosis-triple-combinatie-en-therapeutische-inertie-bij-hypertensie-jama-card/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-bij-acs-in-resource-beperkte-ziekenhuizen-jama-cardiology-/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"},{"url":"https://hartvaat.nl/2018/08/14/drievoudige-lage-dosis-antihypertensivacombinatie-versus-standaardzorg-jama-gera/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","published":"2016-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lawrence-j-appel","type":"person","url":"https://hartvaat.nl/mensen/lawrence-j-appel/","name":"Lawrence J Appel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2023/07/01/metabolomics-en-bloeddrukrespons-op-dash-dieet/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2021/11/01/rustduur-voor-bloeddrukmeting-best-rest-trial/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/06/01/dieet-en-natriumreductie-op-cardiale-schade-en-inflammatie-dash-sodium/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/03/01/orthostatische-hypotensie-cv-uitkomsten-en-adverse-events-sprint-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2020/03/01/natriumreductie-en-energie-metabolisme-gewicht-en-dorst-dash-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2020/01/21/voedingscholesterol-en-cv-risico-aha-science-advisory/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2018/10/01/hypertensiebehandeling-en-orthostatische-hypotensie-relatie-met-cv-ziekte/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/05/01/natriuminname-en-bloeddruk-varieren-met-energie-inname-dash-secundaire-analyse/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/12/12/natriumreductie-en-dash-dieet-naar-uitgangs-bloeddruk/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/11/01/tijdsverloop-van-bloeddrukverandering-door-zoutreductie-en-dash-dieet/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2016/10/11/natriuminname-en-totale-mortaliteit-over-20-jaar-trials-of-hypertension-preventi/","published":"2016-10-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marc-cohen","type":"person","url":"https://hartvaat.nl/mensen/marc-cohen/","name":"Marc Cohen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2020/11/01/klinische-toepassing-van-hs-troponine-in-het-ascvd-raamwerk-jama-cardiology/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2017/11/14/timing-van-angiografie-bij-hoogrisico-nstemi-acuity-analyse/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/08/01/kosteneffectiviteit-van-langdurig-ticagrelor-na-mi-pegasus-timi-54/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/01/24/heropnames-bij-af-patienten-na-stenting-twee-antitromboticastrategieen-vergeleke/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/12/22/preventie-van-bloedingen-bij-af-patienten-die-pci-ondergaan-nejm-pioneer-af-pci/","published":"2016-12-22"},{"url":"https://hartvaat.nl/2016/09/20/cva-preventie-met-ticagrelor-na-myocardinfarct-pegasus-timi-54-inzichten/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/06/14/reductie-van-ischemische-events-met-ticagrelor-bij-diabetes-na-myocardinfarct-pe/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/04/12/protonpompremmers-verminderen-gastro-intestinale-events-ongeacht-aspirinedosis-b/","published":"2016-04-12"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/03/15/plaatjesremming-met-ticagrelor-60-mg-versus-90-mg-in-de-pegasus-timi-54-trial/","published":"2016-03-15"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-markus-schlaich","type":"person","url":"https://hartvaat.nl/mensen/prof-markus-schlaich/","name":"Markus Schlaich","title":"Nefroloog en hypertensiespecialist, Royal Perth Hospital en University of Western Australia","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":1,"articles":[{"url":"https://hartvaat.nl/2020/06/01/2020-ish-mondiale-hypertensie-praktijkrichtlijnen/","published":"2020-06-01"}],"videos":[{"url":"https://hartvaat.nl/video/aldosteron-ontregeling-hypertensie-esc/kernboodschappen/","title":"Kernboodschappen"},{"url":"https://hartvaat.nl/video/aldosteron-ontregeling-hypertensie-esc/onvervulde-behoeften-hypertensie-aldosteron/","title":"Onvervulde behoeften bij hypertensie en de rol van aldosteron"},{"url":"https://hartvaat.nl/video/aldosteron-ontregeling-hypertensie-esc/bax-htn-resultaten/","title":"Bax-HTN studieresultaten"},{"url":"https://hartvaat.nl/video/aldosteron-ontregeling-hypertensie-esc/bax-htn-implicaties-praktijk/","title":"De Bax-HTN resultaten en implicaties voor de praktijk"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-fahy","type":"person","url":"https://hartvaat.nl/mensen/martin-fahy/","name":"Martin Fahy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2022/10/22/symplicity-htn-3-langetermijn-follow-up-renale-denervatie-bij-resistente-hyperte/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2022/07/01/pulsatiele-hemodynamiek-voorspelt-bloeddrukrespons-op-renale-denervatie/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/09/07/hartfrequentie-en-uitkomsten-van-renale-denervatie-bij-ongecontroleerde-hyperten/","published":"2021-09-07"},{"url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2019/03/01/ambulante-hartfrequentiereductie-na-renale-denervatie-bij-hypertensie-zonder-med/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/10/09/24-uurs-ambulante-bloeddrukreductie-na-renale-denervatie-spyral-htn-off-med/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2018/06/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-6-maandsresultat/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2017/01/07/verminderd-bloeddrukverlagend-effect-van-renale-denervatie-bij-geisoleerde-systo/","published":"2017-01-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicolas-m-van-mieghem","type":"person","url":"https://hartvaat.nl/mensen/nicolas-m-van-mieghem/","name":"Nicolas M Van Mieghem","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/08/18/echocardiografie-overschatte-drukgradienten-na-tav-in-tav-met-ballon-expandable-/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2025/08/14/hartfalen-mondiale-economische-ziektelast/","published":"2025-08-14"},{"url":"https://hartvaat.nl/2025/04/01/socio-economische-ongelijkheid-en-hartfalenuitkomsten-systematische-review/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2024/09/01/eldercare-af-subanalyse-dosisreductie-edoxaban-bij-80-jarigen-met-af/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/04/08/biovasc-directe-versus-gestageerde-complete-revascularisatie-bij-acs-met-meervat/","published":"2023-04-08"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2020/12/15/prehospitaal-gemalen-prasugrel-bij-stemi-gerandomiseerde-trial/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/10/01/natuurlijk-beloop-van-asymptomatische-ernstige-aortastenose-jama-cardiology-meta/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/01/29/microvasculaire-schade-bij-gerevasculariseerde-stemi-met-ticagrelor-versus-prasu/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"p-christian-schulze","type":"person","url":"https://hartvaat.nl/mensen/p-christian-schulze/","name":"P Christian Schulze","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2022/07/26/empag-hf-vroege-empagliflozine-bij-acuut-hartfalen-verbetert-diurese/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2018/09/22/telemedische-interventie-bij-hartfalen-lancet-tim-hf2/","published":"2018-09-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"patrice-desvigne-nickens","type":"person","url":"https://hartvaat.nl/mensen/patrice-desvigne-nickens/","name":"Patrice Desvigne-Nickens","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/05/12/nhlbi-workshop-bloeddrukmeting-verfijnen-door-de-hele-levensloop-heen-knelpunten/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2023/08/24/reprieve-pitavastatine-vermindert-cv-events-bij-hiv-nejm/","published":"2023-08-24"},{"url":"https://hartvaat.nl/2023/07/11/transform-hf-torsemide-versus-furosemide-geen-verschil-in-symptomen/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/04/18/aha-scientific-statement-gestructureerde-inspanningstraining-bij-hfpef/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2023/01/17/transform-hf-torsemide-biedt-geen-overlevingsvoordeel-boven-furosemide/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","published":"2018-11-06"},{"url":"https://hartvaat.nl/2018/02/20/sekseverschillen-bij-ischemisch-hartfalen-na-cabg-stich-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/08/22/natriuretisch-peptide-geleide-therapie-bij-hoogrisico-hartfalen-jama-guide-it/","published":"2017-08-22"},{"url":"https://hartvaat.nl/2017/05/16/oraal-ijzer-bij-hfref-met-ijzerdeficientie-jama-ironout-hf/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/04/21/coronaire-bypasschirurgie-bij-ischemische-cardiomyopathie-nejm-stich-trial/","published":"2016-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-d-o-kane","type":"person","url":"https://hartvaat.nl/mensen/peter-d-o-kane/","name":"Peter D O'Kane","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/23/anatomische-versus-viabiliteitsgerichte-completeness-van-revascularisatie/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2024/03/12/rapid-nstemi-zeer-vroege-invasieve-strategie-bij-hoger-risico-nstemi/","published":"2024-03-12"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2022/10/13/revived-bcis2-pci-verbetert-overleving-niet-bij-ischemische-lv-disfunctie/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2022/08/30/ripcord-2-routinematige-ffr-meting-versus-conventionele-angiografie/","published":"2022-08-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-m-kistler","type":"person","url":"https://hartvaat.nl/mensen/peter-m-kistler/","name":"Peter M Kistler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/07/14/vroege-versus-late-af-ablatie-impact-op-aritmierecidief/","published":"2023-07-14"},{"url":"https://hartvaat.nl/2023/02/16/hoog-vermogen-korte-duur-versus-laag-vermogen-langere-duur-posteriore-ablatie-bi/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2021/07/18/procedurevolume-en-complicaties-bij-af-ablatie-meta-analyse/","published":"2021-07-18"},{"url":"https://hartvaat.nl/2020/01/02/alcoholonthouding-bij-drinkers-met-af-nejm-gerandomiseerde-trial/","published":"2020-01-02"},{"url":"https://hartvaat.nl/2018/07/01/rotorablatie-bij-atriumfibrilleren-systematische-review/","published":"2018-07-01"},{"url":"https://hartvaat.nl/2017/10/17/katheterablatie-versus-frequentiecontrole-bij-af-met-systolische-disfunctie-came/","published":"2017-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-r-sinnaeve","type":"person","url":"https://hartvaat.nl/mensen/peter-r-sinnaeve/","name":"Peter R Sinnaeve","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2023/08/29/stream-2-halve-dosis-tenecteplase-bij-ouderen-met-stemi/","published":"2023-08-29"},{"url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","published":"2021-08-03"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/05/26/subcutaan-selatogrel-remt-plaatjesaggregatie-bij-acuut-mi/","published":"2020-05-26"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2019/01/02/preventie-van-cardiogene-shock-na-acuut-mi/","published":"2019-01-02"},{"url":"https://hartvaat.nl/2018/08/01/inhalatie-stikstofoxide-bij-stemi-nomi-gerandomiseerde-trial/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/08/01/2018-ehra-praktische-gids-doac-s-bij-af-europace-editie/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/04/21/2018-ehra-praktische-gids-voor-doac-gebruik-bij-af/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"remo-h-m-furtado","type":"person","url":"https://hartvaat.nl/mensen/remo-h-m-furtado/","name":"Remo H M Furtado","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/01/06/sacubitril-valsartan-versus-enalapril-bij-chagas-hartfalen/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2022/11/01/vip-acs-dubbele-dosis-griepvaccinatie-na-acs-verbetert-uitkomsten-niet/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/08/30/biomarkers-voorspellen-complexe-coronaire-revascularisatie-in-fourier/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/03/16/plaatjesreactiviteit-bij-acs-in-afwachting-van-chirurgische-revascularisatie/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/01/28/morfine-en-cv-uitkomsten-bij-nste-acs-jacc-analyse/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"richard-a-shlofmitz","type":"person","url":"https://hartvaat.nl/mensen/richard-a-shlofmitz/","name":"Richard A Shlofmitz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2025/08/19/paclitaxel-gecoate-ballon-bij-multilayer-in-stent-restenose-agent-ide-subgroep/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/04/12/orbitale-atherectomie-versus-ballonangioplastie-voor-des-bij-ernstig-verkalkte-l/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2016/11/26/oct-versus-ivus-versus-angiografie-bij-coronaire-stentimplantatie-lancet-ilumien/","published":"2016-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"richard-p-whitlock","type":"person","url":"https://hartvaat.nl/mensen/richard-p-whitlock/","name":"Richard P Whitlock","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/04/08/vision-postoperatief-atriumfibrilleren-na-hartchirurgie-verhoogt-sterfte-na-een-/","published":"2026-07-15"},{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","published":"2025-09-20"},{"url":"https://hartvaat.nl/2023/10/24/laaos-iii-laa-occlusie-en-anticoagulatiegebruik/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2022/10/13/voorbehandeling-met-antiaritmica-voor-cardioversie-bij-af-netwerk-meta-analyse/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2021/08/06/orale-antiaritmica-voor-cardioversie-van-recent-onset-af-netwerkmeta-analyse/","published":"2021-08-06"},{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","published":"2021-06-03"},{"url":"https://hartvaat.nl/2019/08/01/vernakalant-voor-cardioversie-van-recent-onset-af-meta-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/01/amiodaron-voor-en-na-electrische-cardioversie-van-af-meta-analyse/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/09/27/6-maandsuitkomsten-van-restrictieve-versus-liberale-transfusie-bij-hartchirurgie/","published":"2018-09-27"},{"url":"https://hartvaat.nl/2018/09/01/chirurgische-af-ablatie-systematische-review-en-meta-analyse-van-rct-s/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/05/08/vasopressine-plus-catecholamines-en-af-bij-distributieve-shock-jama-meta-analyse/","published":"2018-05-08"},{"url":"https://hartvaat.nl/2017/11/30/restrictieve-versus-liberale-bloedtransfusie-bij-hartchirurgie-nejm-trics-iii/","published":"2017-11-30"},{"url":"https://hartvaat.nl/2016/12/15/off-pump-versus-on-pump-cabg-5-jaarsresultaten-nejm-coronary-trial/","published":"2016-12-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robbert-j-de-winter","type":"person","url":"https://hartvaat.nl/mensen/robbert-j-de-winter/","name":"Robbert J de Winter","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2024/07/12/nste-acs-na-cabg-meta-analyse-van-behandelstrategieen/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/01/bloeddruk-na-stenting-bij-aortacoarctatie-systematische-review-en-meta-analyse/","published":"2019-10-01"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2018/02/03/sirolimus-eluting-bioabsorbeerbare-stent-versus-everolimus-eluting-stent-na-mi-l/","published":"2018-02-03"},{"url":"https://hartvaat.nl/2017/12/05/j-curve-bij-gerandomiseerde-bloeddrukstreefwaarden-sprint-experimentele-analyse/","published":"2017-12-05"},{"url":"https://hartvaat.nl/2017/09/01/late-trombotische-events-na-bioresorbeerbare-scaffold-meta-analyse-van-gerandomi/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/06/15/bioresorbeerbare-scaffolds-versus-metallic-stents-bij-routine-pci-nejm-aida/","published":"2017-06-15"},{"url":"https://hartvaat.nl/2017/04/18/vroeg-invasief-versus-selectieve-strategie-bij-nste-acs-ictus-trial-langetermijn/","published":"2017-04-18"},{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-circulatoire-ondersteuning-versus-iabp-bij-cardiogene-shoc/","published":"2017-01-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"seung-ho-hur","type":"person","url":"https://hartvaat.nl/mensen/seung-ho-hur/","name":"Seung-Ho Hur","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/10/17/antiplaatjesmonotherapie-na-pci-clopidogrel-versus-aspirine-naar-risicoprofiel/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/05/02/korte-versus-standaard-dapt-na-pci-met-moderne-des-meta-analyse/","published":"2023-05-02"},{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2023/01/10/host-exam-extended-clopidogrel-superieur-aan-aspirine-als-monotherapie-na-pci/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","published":"2022-09-08"},{"url":"https://hartvaat.nl/2021/06/26/aspirine-versus-clopidogrel-voor-chronische-monotherapie-na-pci-lancet-host-exam/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2018/04/01/valsartan-en-linkerkamerremodellering-na-mi/","published":"2018-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shelley-zieroth","type":"person","url":"https://hartvaat.nl/mensen/shelley-zieroth/","name":"Shelley Zieroth","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/04/sacubitril-valsartan-bij-hfmref-hfpef-met-verslechterend-hartfalen/","published":"2023-07-04"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2022/04/09/natriumreductie-100-mmol-bij-hartfalen-lancet-sodium-hf/","published":"2022-04-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steen-pehrson","type":"person","url":"https://hartvaat.nl/mensen/steen-pehrson/","name":"Steen Pehrson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/01/af-en-icd-bij-niet-ischemische-hfref-impliciaties-voor-devicetherapie/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2022/04/01/icd-bij-niet-ischemisch-systolisch-hf-met-coronaire-atherosclerose-danish/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/07/01/qt-als-voorspeller-van-af-recidief-na-ablatie-en-amiodaronimpact-amio-cat/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/01/01/supraventriculaire-ectopie-na-af-ablatie-voorspelt-recidief/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephen-p-juraschek","type":"person","url":"https://hartvaat.nl/mensen/stephen-p-juraschek/","name":"Stephen P Juraschek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/05/12/nhlbi-workshop-bloeddrukmeting-verfijnen-door-de-hele-levensloop-heen-knelpunten/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/01/06/gofresh-dash-boodschappen-en-bloeddrukeffect-rct/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/04/01/hypotensieve-episodes-op-24-uurs-abpm-en-cognitieve-functie-sprint-inzichten/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/04/01/lichaamshouding-en-orthostatische-hypotensie-bij-hypertensie-syst-eur-analyse/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2021/06/01/dieet-en-natriumreductie-op-cardiale-schade-en-inflammatie-dash-sodium/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/05/01/langetermijnvoordeel-van-intensieve-bloeddrukcontrole-op-resterende-levensduur-s/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/03/01/orthostatische-hypotensie-cv-uitkomsten-en-adverse-events-sprint-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2020/03/01/natriumreductie-en-energie-metabolisme-gewicht-en-dorst-dash-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/10/01/antihypertensivaklasse-en-vallen-syncope-en-orthostatische-hypotensie-bij-oudere/","published":"2019-10-01"},{"url":"https://hartvaat.nl/2018/10/01/hypertensiebehandeling-en-orthostatische-hypotensie-relatie-met-cv-ziekte/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/12/12/natriumreductie-en-dash-dieet-naar-uitgangs-bloeddruk/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/11/01/tijdsverloop-van-bloeddrukverandering-door-zoutreductie-en-dash-dieet/","published":"2017-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stuart-j-head","type":"person","url":"https://hartvaat.nl/mensen/stuart-j-head/","name":"Stuart J Head","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/31/syntax-score-ii-herontwikkeling-voor-gepersonaliseerde-revascularisatiebeslissin/","published":"2020-10-31"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/10/01/natuurlijk-beloop-van-asymptomatische-ernstige-aortastenose-jama-cardiology-meta/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2016/01/05/doodsoorzaken-na-pci-versus-cabg-bij-complex-coronairlijden-5-jaarsfollow-up-van/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sukhjinder-s-nijjer","type":"person","url":"https://hartvaat.nl/mensen/sukhjinder-s-nijjer/","name":"Sukhjinder S Nijjer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/01/ffr-versus-ifr-bij-coronaire-revascularisatie-vijfjaars-follow-up/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"timothy-d-henry","type":"person","url":"https://hartvaat.nl/mensen/timothy-d-henry/","name":"Timothy D Henry","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2023/03/07/mesenchymale-precursorcellen-bij-hfref-gerandomiseerde-trial/","published":"2023-03-07"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/09/15/ami-management-tijdens-covid-19-scai-positiedocument/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/05/01/zelfgerapporteerde-versus-apotheekgeregistreerde-medicatietrouw-compass-analyse/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/01/01/p2y12-copay-reductie-en-therapietrouw-aan-andere-secundaire-preventiemiddelen/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/01/01/medicatie-copay-vouchers-en-p2y12-gebruik-en-cv-events-na-mi-jama/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/08/16/bio-absorbeerbare-intracoronaire-matrix-ter-preventie-van-ventriculaire-remodell/","published":"2016-08-16"},{"url":"https://hartvaat.nl/2016/06/11/ixmyelocel-t-bij-ischemisch-hartfalen-lancet-dubbelblinde-gerandomiseerde-trial/","published":"2016-06-11"},{"url":"https://hartvaat.nl/2016/05/01/intracoronaire-adenylylcyclase-6-gentherapie-bij-hartfalen-gerandomiseerde-trial/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"valentina-kutyifa","type":"person","url":"https://hartvaat.nl/mensen/valentina-kutyifa/","name":"Valentina Kutyifa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/07/02/upgrade-rv-naar-crt-pacing-bij-hartfalen-met-af-voordelen-bevestigd/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/10/21/upgrade-van-rv-pacing-naar-crt-bij-hartfalen-gerandomiseerde-trial/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2017/11/01/klinische-presentatie-bij-eerste-hartfalenhospitalisatie-voorspelt-geen-heropnam/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/01/budapest-crt-upgrade-study-studieontwerp-voor-crt-upgrade/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/05/16/comorbiditeiten-en-crt-respons-madit-crt-langetermijnfollow-up/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/09/20/volledig-linkszijdig-reverse-remodelling-bij-crt-madit-crt-substudie/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/01/26/relatieve-wanddikte-en-risico-op-ventriculaire-tachyaritmieen-bij-linkerkamerdis/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"w-h-wilson-tang","type":"person","url":"https://hartvaat.nl/mensen/w-h-wilson-tang/","name":"W H Wilson Tang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2024/10/15/aha-scientific-statement-nierdisfunctie-bij-gevorderd-hartfalen/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2024/08/01/sarcopenie-en-intensieve-bloeddrukbehandeling-sprint-subanalyse/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2024/07/09/selectieve-aldosereductaseremmer-bij-diabetische-cardiomyopathie-rct/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2021/10/19/diabetes-met-cardiomyopathie-in-de-community-prevalentie-en-prognose/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/03/01/genoomwijde-analyse-identificeert-nieuwe-mi-gevoeligheidsloci/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2020/03/31/staken-van-neurohumorale-blokkade-na-crt/","published":"2020-03-31"},{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","published":"2018-11-06"},{"url":"https://hartvaat.nl/2018/05/08/nierfunctieverslechtering-bij-acuut-hartfalen-met-agressieve-diurese-geen-tubula/","published":"2018-05-08"},{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/05/16/oraal-ijzer-bij-hfref-met-ijzerdeficientie-jama-ironout-hf/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2017/02/28/myocardiaal-herstel-bij-systolisch-hartfalen-met-auto-antilichamen-tegen-1-adren/","published":"2017-02-28"},{"url":"https://hartvaat.nl/2016/05/17/verminderde-cardiac-index-is-niet-de-primaire-oorzaak-van-nierdisfunctie-bij-har/","published":"2016-05-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"waheed-jamal","type":"person","url":"https://hartvaat.nl/mensen/waheed-jamal/","name":"Waheed Jamal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-en-renale-uitkomsten-bij-hartfalen-nejm-emperor-reduced-renal/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/03/23/mra-en-empagliflozine-interactie-bij-hf-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/03/23/empagliflozine-bij-hfref-met-volume-overbelasting-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/09/19/sglt2-remmers-bij-hfref-meta-analyse-van-emperor-reduced-en-dapa-hf/","published":"2020-09-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"william-e-boden","type":"person","url":"https://hartvaat.nl/mensen/william-e-boden/","name":"William E Boden","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/03/06/debat-preventieve-pci-bij-kwetsbare-plaques-als-standaardbehandeling/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2026/02/23/het-jaar-in-de-cardiovasculaire-geneeskunde-2025-top-10-publicaties-ischemische-/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/09/23/pci-versus-cabg-en-gezondheidsstatus-bij-stabiel-coronairlijden/","published":"2025-09-23"},{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/13/traverse-testosteronsubstitutie-cardiovasculair-veilig-bij-hypogonadisme/","published":"2023-07-13"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/04/30/leefstijl-hba1c-en-overleving-bij-stabiel-coronairlijden-met-diabetes/","published":"2019-04-30"},{"url":"https://hartvaat.nl/2016/08/01/eerder-clopidogrelgebruik-en-uitkomsten-bij-conservatief-behandeld-acs/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wojciech-wojakowski","type":"person","url":"https://hartvaat.nl/mensen/wojciech-wojakowski/","name":"Wojciech Wojakowski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":13,"articles":[{"url":"https://hartvaat.nl/2026/05/19/salamander-register-95-5-technisch-succes-bij-stand-alone-linker-hartoor-occlusi/","published":"2026-06-10"},{"url":"https://hartvaat.nl/2026/02/26/cardiogene-shock-bij-myocardinfarct-resultaten-van-het-shock-pol-register/","published":"2026-03-02"},{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/03/levosimendan-infusies-en-klinisch-beloop-bij-hartfalen-levo-d-resultaten/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/11/11/ct-angiografie-of-standaardzorg-na-pci-van-de-linker-hoofdstam/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2021/12/01/thin-cap-fibroatheroom-voorspelt-events-bij-diabetes-met-normale-ffr-combine-oct/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adam-p-bress","type":"person","url":"https://hartvaat.nl/mensen/adam-p-bress/","name":"Adam P Bress","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/05/12/nhlbi-workshop-bloeddrukmeting-verfijnen-door-de-hele-levensloop-heen-knelpunten/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukcontrole-en-cerebrale-small-vessel-disease-markers/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/28/prevent-vergelijkingen-voor-intensieve-versus-standaard-bloeddrukcontrole/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2023/08/01/combinatietabletten-voor-intensieve-bloeddrukbehandeling-sprint-analyse/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2023/07/01/leeftijdsbias-draagt-bij-aan-therapeutische-inertie-bij-bloeddrukmanagement/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/08/01/hele-genoomsequencing-onthult-nieuwe-bloeddruk-loci/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/04/27/patientselectie-voor-intensieve-bloeddrukbehandeling-naar-voordeel-en-bijwerking/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2016/02/09/generaliseerbaarheid-van-sprint-resultaten-naar-de-algemene-bevolking/","published":"2016-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"agneta-siegbahn","type":"person","url":"https://hartvaat.nl/mensen/agneta-siegbahn/","name":"Agneta Siegbahn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2020/11/01/ace2-niveaus-en-covid-19-risicofactoren-bij-af-patienten/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/03/17/klinische-en-farmacologische-effecten-van-apixaban-dosisaanpassing-aristotle/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/12/01/multipele-biomarkers-en-mortaliteitsrisico-na-acs-jama-cardiology/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/04/01/fibrinestoleigenschappen-en-klinische-uitkomsten-na-acs-plato-substudie/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","published":"2018-02-07"},{"url":"https://hartvaat.nl/2016/11/29/biomarkergebaseerde-cva-risicoscore-bij-atriumfibrilleren-validatie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/07/01/apixaban-versus-warfarine-bij-af-in-relatie-tot-nierfunctie-aristotle-analyse/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","published":"2016-06-04"},{"url":"https://hartvaat.nl/2016/04/21/gdf-15-voorspelt-bloedingen-en-cardiovasculaire-events-bij-acuut-coronair-syndro/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/04/01/biomarkers-van-inflammatie-en-cardiovasculair-risico-bij-patienten-met-atriumfib/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"albertino-damasceno","type":"person","url":"https://hartvaat.nl/mensen/albertino-damasceno/","name":"Albertino Damasceno","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2022/11/01/antihypertensieve-combinaties-bij-afrikaanse-patienten-creole-secundaire-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/09/15/invictus-rivaroxaban-versus-warfarine-bij-reumatische-hartziekte-en-af/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2021/03/09/bloeddrukverlagende-medicatie-naar-hypertensierichtlijn-in-lage-middeninkomensla/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2019/08/24/hypertensiezorg-in-44-lage-en-middeninkomenslanden-lancet/","published":"2019-08-24"},{"url":"https://hartvaat.nl/2019/06/20/vergelijking-van-duale-therapieen-voor-bloeddrukverlaging-bij-afrikaanse-afrikan/","published":"2019-06-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-ana-maria-cebrian-cuenca","type":"person","url":"https://hartvaat.nl/mensen/dr-ana-maria-cebrian-cuenca/","name":"Ana María Cebrián Cuenca","title":"Huisarts, Murcia; Universitair docent, Miguel Hernández Universiteit, Spanje","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":0,"articles":[],"videos":[{"url":"https://hartvaat.nl/video/aldosteron-ontregeling-hypertensie-esc/kernboodschappen/","title":"Kernboodschappen"},{"url":"https://hartvaat.nl/video/aldosteron-ontregeling-hypertensie-esc/onvervulde-behoeften-hypertensie-aldosteron/","title":"Onvervulde behoeften bij hypertensie en de rol van aldosteron"},{"url":"https://hartvaat.nl/video/aldosteron-ontregeling-hypertensie-esc/bax-htn-resultaten/","title":"Bax-HTN studieresultaten"},{"url":"https://hartvaat.nl/video/aldosteron-ontregeling-hypertensie-esc/bax-htn-implicaties-praktijk/","title":"De Bax-HTN resultaten en implicaties voor de praktijk"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andreas-metzner","type":"person","url":"https://hartvaat.nl/mensen/andreas-metzner/","name":"Andreas Metzner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/04/14/ulysses-echogeleide-venapunctie-halveert-toegangscomplicaties-bij-af-ablatie/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/17/ablatiestrategie-bij-af-recidief-na-duurzame-pvi/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2023/05/19/east-afnet-4-vroege-ritmecontrole-bij-af-is-kosteneffectief/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","published":"2022-09-13"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2019/09/24/interne-versus-externe-cardioversie-bij-atriale-aritmieen-met-icd/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2016/10/07/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-af-herinterventierate-e/","published":"2016-10-07"},{"url":"https://hartvaat.nl/2016/06/09/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-atriumfibrilleren-nejm-/","published":"2016-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-s-p-sharp","type":"person","url":"https://hartvaat.nl/mensen/andrew-s-p-sharp/","name":"Andrew S P Sharp","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anna-franzone","type":"person","url":"https://hartvaat.nl/mensen/anna-franzone/","name":"Anna Franzone","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/12/09/gepersonaliseerde-versus-standaard-dapt-duur-na-pci-gerandomiseerde-trial/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/07/08/amulet-versus-watchman-flx-driejaarsresultaten-laa-sluiting/","published":"2025-07-08"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","published":"2024-02-06"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2017/10/14/tmao-als-cardiovasculaire-risicobiomarker-systematische-review-en-meta-analyse/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2016/10/01/langere-versus-korte-dapt-na-pci-met-en-zonder-periprocedureel-mi-jama-cardiolog/","published":"2016-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antonio-colombo","type":"person","url":"https://hartvaat.nl/mensen/antonio-colombo/","name":"Antonio Colombo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2025/05/02/paclitaxel-gecoate-ballonnen-versus-des-bij-kleine-vaten-ipd-meta-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2022/10/01/mitraclip-bij-secundaire-mitralisklepinsufficientie-meta-analyse-ischemisch-vs-n/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2017/11/07/stentontwerp-en-dapt-duur-effect-op-ischemie-en-bloedingen-netwerkmeta-analyse/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2016/01/05/doodsoorzaken-na-pci-versus-cabg-bij-complex-coronairlijden-5-jaarsfollow-up-van/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"arnoud-w-j-van-t-hof","type":"person","url":"https://hartvaat.nl/mensen/arnoud-w-j-van-t-hof/","name":"Arnoud W J van 't Hof","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/11/11/ffr-geleide-complete-versus-culprit-only-revascularisatie-bij-nstemi/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2019/10/24/genotype-geleide-p2y12-remmerkeuze-bij-primaire-pci-nejm-popular-genetics/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/10/01/langetermijnmortaliteit-en-prehospitale-tirofibanbehandeling-bij-stemi/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/08/19/optimale-timing-van-invasieve-strategie-bij-nste-acs-lancet-meta-analyse/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2017/07/01/1-jaarsmortaliteit-bivalirudine-versus-heparine-in-de-ambulance-bij-stemi-matrix/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","published":"2016-06-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bernhard-witzenbichler","type":"person","url":"https://hartvaat.nl/mensen/bernhard-witzenbichler/","name":"Bernhard Witzenbichler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"beth-a-davison","type":"person","url":"https://hartvaat.nl/mensen/beth-a-davison/","name":"Beth A Davison","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/03/16/natrium-hf-subanalyse-natriuretische-peptiden-lopen-achter-op-de-klinische-ontst/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2019/12/01/hepatorenale-disfunctie-identificeert-hoogrisico-acuut-hf-relax-ahf/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2017/08/07/trv027-biased-ligand-van-de-angiotensine-ii-receptor-bij-acuut-hartfalen-gerando/","published":"2017-08-07"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carmelo-a-milano","type":"person","url":"https://hartvaat.nl/mensen/carmelo-a-milano/","name":"Carmelo A Milano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2023/10/24/inhalatief-epoprostenol-versus-no-bij-rechterventrikel-falen-na-hartchirurgie/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2018/10/30/zorggebruik-en-kosten-in-momentum-3-langetermijnstudie/","published":"2018-10-30"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/02/02/intrapericardiale-lvad-bij-gevorderd-hartfalen-nejm/","published":"2017-02-02"},{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","published":"2017-02-02"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/26/langketen-acylcarnitines-bij-hartfalen-prognostische-waarde-en-reversibiliteit-m/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chern-en-chiang","type":"person","url":"https://hartvaat.nl/mensen/chern-en-chiang/","name":"Chern-En Chiang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/05/14/verlaagde-dosis-doac-bij-af-werkzaamheid-en-veiligheid-meta-analyse/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chul-min-ahn","type":"person","url":"https://hartvaat.nl/mensen/chul-min-ahn/","name":"Chul-Min Ahn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","published":"2023-04-04"},{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"},{"url":"https://hartvaat.nl/2020/06/16/ticagrelor-monotherapie-versus-dapt-op-bloedingen-en-cv-events-bij-acs-jama-tico/","published":"2020-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"clemens-von-birgelen","type":"person","url":"https://hartvaat.nl/mensen/clemens-von-birgelen/","name":"Clemens von Birgelen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2021/12/01/thin-cap-fibroatheroom-voorspelt-events-bij-diabetes-met-normale-ffr-combine-oct/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/11/10/ticagrelor-plus-aspirine-en-safeneuze-graft-patency-na-cabg/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2020/04/25/clopidogrel-versus-ticagrelor-of-prasugrel-bij-70-plussers-met-nste-acs-lancet-p/","published":"2020-04-25"},{"url":"https://hartvaat.nl/2020/04/14/langetermijnuitkomsten-bij-vrouwen-en-mannen-na-pci/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/08/01/temporele-veranderingen-in-coronaire-hemodynamiek-bij-niet-culprit-vaten-na-stem/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/07/01/uitkomsten-van-des-in-kleine-coronairen-naar-strutdikte-jama-cardiology-meta-ana/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/01/29/microvasculaire-schade-bij-gerevasculariseerde-stemi-met-ticagrelor-versus-prasu/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/10/06/resolute-onyx-versus-orsiro-stent-lancet-gerandomiseerde-non-inferioriteitstrial/","published":"2018-10-06"},{"url":"https://hartvaat.nl/2017/03/01/5-jaarsuitkomsten-van-zotarolimus-en-everolimus-eluting-stents-trial-en-real-wor/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/11/26/ultradunne-biodegradeerbare-versus-duurzame-polymer-des-lancet-gerandomiseerde-t/","published":"2016-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-w-jones","type":"person","url":"https://hartvaat.nl/mensen/daniel-w-jones/","name":"Daniel W Jones","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2016/01/14/intracoronaire-beenmergcelinfusie-bij-acuut-myocardinfarct-de-regenerate-ami-tri/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-a-mcallister","type":"person","url":"https://hartvaat.nl/mensen/david-a-mcallister/","name":"David A McAllister","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/04/07/kosteneffectiviteit-van-stapsgewijze-lipidenverlaging-na-coronaire-bypasschirurg/","published":"2026-07-18"},{"url":"https://hartvaat.nl/2025/03/25/leeftijds-en-sekseverschillen-in-effectiviteit-van-diabetesbehandeling-netwerk-m/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2021/07/08/grace-2-0-score-bij-type-1-en-type-2-mi/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/04/01/sekseverschillen-in-effectiviteit-van-orale-p2y12-remmers-meta-analyse/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/11/21/hoog-sensitief-troponine-i-en-uitkomsten-bij-verdenking-acs-jama-studie/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2016/12/27/hoog-sensitief-troponine-statinetherapie-en-risico-op-coronairlijden/","published":"2016-12-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-kallend","type":"person","url":"https://hartvaat.nl/mensen/david-kallend/","name":"David Kallend","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2024/09/01/lerodalcibep-bij-ascvd-of-hoog-risico-fase-3-resultaten/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/10/21/lerodalcibep-bij-familiaire-hypercholesterolemie-liberate-hefh-langetermijndata/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2022/12/21/orion-11-inclisiran-verlaagt-ldl-effectief-bij-primaire-preventie/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-bij-heterozygote-familiaire-hypercholesterolemie-nejm-orion-9/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-fase-3-bij-verhoogd-ldl-nejm-orion-10-en-orion-11/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2019/11/01/inclisiran-1-of-2-dosis-en-ldl-cholesterol-orion-1-1-jaarsfollow-up/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2018/09/25/sirna-tegen-pcsk9-en-atherogene-lipoproteinen-orion-1-secundaire-eindpunten/","published":"2018-09-25"},{"url":"https://hartvaat.nl/2018/09/01/hdl-mimeticum-met-recombinant-apoa-i-milano-en-coronairlijden-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/02/01/lipoproteine-a-en-recidiverende-ischemische-events-na-acs-dal-outcomes-analyse/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/04/13/inclisiran-bij-patienten-met-hoog-cv-risico-en-verhoogd-ldl-nejm-orion-1/","published":"2017-04-13"},{"url":"https://hartvaat.nl/2017/01/05/inclisiran-een-langwerkende-rna-interferentie-pcsk9-remmer-nejm/","published":"2017-01-05"},{"url":"https://hartvaat.nl/2016/12/06/dalcetrapib-wijzigt-de-relatie-tussen-hdl-cholesterol-en-crp/","published":"2016-12-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-z-i-cherney","type":"person","url":"https://hartvaat.nl/mensen/david-z-i-cherney/","name":"David Z I Cherney","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/03/05/finerenon-effectief-bij-type-1-diabetes-met-chronische-nierziekte/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/02/01/dapagliflozine-bij-cv-risico-met-zonder-diabetes-cardiorenale-effecten/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","published":"2025-03-24"},{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2022/08/09/renale-en-vasculaire-effecten-van-gecombineerde-sglt2-en-ace-remming/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2021/02/01/sglt2-remmers-en-cv-renale-uitkomsten-bij-diabetes-type-2-jama-cardiology-meta-a/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/12/08/ertugliflozine-en-hf-events-bij-diabetes-met-atherosclerotische-cvd-vertis-cv/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/10/08/ertugliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-vertis-cv/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2019/08/01/empagliflozine-voorkomt-progressie-van-ckd-empa-reg-outcome-renale-analyse/","published":"2019-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"donghoon-choi","type":"person","url":"https://hartvaat.nl/mensen/donghoon-choi/","name":"Donghoon Choi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","published":"2023-04-04"},{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"},{"url":"https://hartvaat.nl/2020/06/16/ticagrelor-monotherapie-versus-dapt-op-bloedingen-en-cv-events-bij-acs-jama-tico/","published":"2020-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"doyeon-hwang","type":"person","url":"https://hartvaat.nl/mensen/doyeon-hwang/","name":"Doyeon Hwang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","published":"2025-11-08"},{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/05/01/aspirine-versus-clopidogrel-na-coronaire-stenting-naar-bloedingsrisico-en-comple/","published":"2025-05-01"},{"url":"https://hartvaat.nl/2023/10/17/antiplaatjesmonotherapie-na-pci-clopidogrel-versus-aspirine-naar-risicoprofiel/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/05/02/korte-versus-standaard-dapt-na-pci-met-moderne-des-meta-analyse/","published":"2023-05-02"},{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2023/01/10/host-exam-extended-clopidogrel-superieur-aan-aspirine-als-monotherapie-na-pci/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2021/03/16/duurzame-versus-biodegradeerbare-polymer-des-bij-acs-meta-analyse/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/10/10/prasugrel-gebaseerde-dapt-de-escalatie-na-pci-bij-acs-lancet-host-reduce-polytec/","published":"2020-10-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"efthymios-n-deliargyris","type":"person","url":"https://hartvaat.nl/mensen/efthymios-n-deliargyris/","name":"Efthymios N Deliargyris","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2018/12/07/laesiecomplexiteit-en-periprocedurele-events-bij-potente-iv-antiplaatjestherapie/","published":"2018-12-07"},{"url":"https://hartvaat.nl/2017/10/10/dagelijks-ischemie-en-bloedingsrisico-na-primaire-pci-voor-stemi/","published":"2017-10-10"},{"url":"https://hartvaat.nl/2017/07/01/1-jaarsmortaliteit-bivalirudine-versus-heparine-in-de-ambulance-bij-stemi-matrix/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/06/01/korte-procedureduur-met-bivalirudine-en-risico-op-acute-stenttrombose-bij-stemi/","published":"2017-06-01"},{"url":"https://hartvaat.nl/2017/02/01/cangrelor-versus-gpiib-iiia-remmers-ischemie-en-bloedingsrisico-s-vergeleken/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/01/17/cangrelor-met-en-zonder-gpiib-iiia-remmers-bij-pci/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/12/20/bloedingen-voor-coronairangiografie-bij-nste-acs/","published":"2016-12-20"},{"url":"https://hartvaat.nl/2016/11/29/presentatie-buiten-kantoortijden-versus-tijdens-kantoortijden-bij-stemi-champion/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/09/06/consistente-reductie-in-periprocedureel-mi-met-cangrelor-champion-analyses/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/04/07/cangrelor-en-toegangsplaats-effect-op-ischemische-en-bloedingsevents-champion-ph/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/01/19/werkzaamheid-en-veiligheid-van-cangrelor-bij-vrouwen-versus-mannen-tijdens-pci-c/","published":"2016-01-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"elaine-m-hylek","type":"person","url":"https://hartvaat.nl/mensen/elaine-m-hylek/","name":"Elaine M Hylek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2020/01/07/nsaid-s-en-oac-bij-af-aristotle-analyse/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/08/14/adma-en-sdma-voorspellen-uitkomsten-bij-af-aristotle-substudie/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","published":"2018-02-07"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/04/01/niet-ernstige-bloedingen-met-apixaban-versus-warfarine-bij-af/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/11/29/biomarkergebaseerde-cva-risicoscore-bij-atriumfibrilleren-validatie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","published":"2016-06-04"},{"url":"https://hartvaat.nl/2016/04/01/biomarkers-van-inflammatie-en-cardiovasculair-risico-bij-patienten-met-atriumfib/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eric-van-belle","type":"person","url":"https://hartvaat.nl/mensen/eric-van-belle/","name":"Eric Van Belle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/05/19/esc-atlas-2025-3-miljoen-cvd-doden-per-jaar-in-europa-middeninkomenlanden-hebben/","published":"2026-06-13"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2025/12/21/tavi-plus-ffr-geleide-pci-gecombineerde-benadering-onderzocht/","published":"2025-12-21"},{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","published":"2024-11-09"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/11/01/aldosteronblokkade-bij-myocardinfarct-ipd-analyse-van-twee-trials/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/09/27/oct-geleide-pci-optimalisatie-bij-nste-acs-gerandomiseerde-trial/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/04/26/vroege-aldosteronblokkade-bij-acuut-myocardinfarct-de-albatross-trial/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eva-m-lonn","type":"person","url":"https://hartvaat.nl/mensen/eva-m-lonn/","name":"Eva M Lonn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2023/02/01/diabetes-en-sacubitril-valsartan-titratie-bij-hartfalen-na-opname/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/09/01/bereikte-diastolische-bloeddruk-en-polsdruk-bij-streef-sbp-en-cv-uitkomsten-bij-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2017/06/03/bereikte-bloeddruk-en-cv-uitkomsten-bij-hoogrisicopatienten-ontarget-transcend/","published":"2017-06-03"},{"url":"https://hartvaat.nl/2017/05/16/statines-voor-primaire-preventie-bij-ouderen-meta-analyse-van-jupiter-en-hope-3/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/11/01/intensieve-bloeddrukbehandeling-120-80-mmhg-antagonist-standpunt/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fozia-z-ahmed","type":"person","url":"https://hartvaat.nl/mensen/fozia-z-ahmed/","name":"Fozia Z Ahmed","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/02/23/ijzertekort-bij-chronische-nierziekte-en-hartfalen-expertperspectieven/","published":"2026-03-04"},{"url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2025/04/01/ambulante-behandeling-van-gedecompenseerd-hartfalen-meta-analyse/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frank-w-rockhold","type":"person","url":"https://hartvaat.nl/mensen/frank-w-rockhold/","name":"Frank W Rockhold","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2023/09/14/heart-fid-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-nejm/","published":"2023-09-14"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/01/01/mi-bij-pav-patienten-incidentie-en-uitkomsten-euclid/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/12/25/cv-en-ledemaat-uitkomsten-bij-diabetes-met-pav-euclid/","published":"2018-12-25"},{"url":"https://hartvaat.nl/2018/10/02/cv-uitkomsten-na-endovasculaire-versus-chirurgische-revascularisatie-onderste-le/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frans-van-de-werf","type":"person","url":"https://hartvaat.nl/mensen/frans-van-de-werf/","name":"Frans Van de Werf","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2023/08/29/stream-2-halve-dosis-tenecteplase-bij-ouderen-met-stemi/","published":"2023-08-29"},{"url":"https://hartvaat.nl/2022/09/15/polypill-voor-secundaire-cardiovasculaire-preventie-secure-trial-in-nejm/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2019/01/02/preventie-van-cardiogene-shock-na-acuut-mi/","published":"2019-01-02"},{"url":"https://hartvaat.nl/2018/08/01/inhalatie-stikstofoxide-bij-stemi-nomi-gerandomiseerde-trial/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/12/19/cva-preventie-met-ezetimibe-bij-acs-improve-it-analyse/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/11/01/hypertensiecontrole-bij-diabetes-met-recidiverende-cv-events-tecos-globale-resul/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/03/14/afweging-myocardinfarct-versus-bloedingstype-en-mortaliteit-na-acs-tra-2p-timi-5/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"},{"url":"https://hartvaat.nl/2016/04/19/trends-in-behandeling-en-uitkomsten-bij-nste-acs-naar-leeftijd/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/04/01/ischemisch-risicogebied-en-reperfusiemethode-bij-stemi-klinische-implicaties/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"franz-josef-neumann","type":"person","url":"https://hartvaat.nl/mensen/franz-josef-neumann/","name":"Franz-Josef Neumann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/12/21/culprit-shock-integratie-in-2017-esc-stemi-richtlijn-richtlijncommissie-standpun/","published":"2018-12-21"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2017/08/19/optimale-timing-van-invasieve-strategie-bij-nste-acs-lancet-meta-analyse/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2017/03/30/ffr-geleide-multivaten-pci-bij-myocardinfarct-nejm-compare-acute/","published":"2017-03-30"},{"url":"https://hartvaat.nl/2016/07/19/immatuur-plaatjesaantal-versus-gevestigde-voorspellers-van-plaatjesreactiviteit-/","published":"2016-07-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francois-mach","type":"person","url":"https://hartvaat.nl/mensen/francois-mach/","name":"François Mach","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2020/10/01/evolocumab-bij-pediatrische-heterozygoot-fh-nejm-hauser-rct/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/12/cognitie-na-ldl-verlaging-met-evolocumab-fourier-follow-up/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2019/11/19/evolocumab-voor-vroege-ldl-verlaging-bij-acs-evopacs/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2018/04/07/statines-en-niet-statine-ldl-verlagers-en-cardiovasculaire-uitkomsten-meta-analy/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2017/08/17/cognitieve-functie-in-de-fourier-trial-met-evolocumab-nejm-ebbinghaus/","published":"2017-08-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frederick-j-raal","type":"person","url":"https://hartvaat.nl/mensen/frederick-j-raal/","name":"Frederick J Raal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/05/18/global-hicc-register-950-hofh-patienten-uit-45-landen-slechts-4-haalt-ldl-doelen/","published":"2026-06-17"},{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/25/eas-consensus-familiaire-hypercholesterolemie-bij-kinderen-en-adolescenten/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2024/01/30/orion-5-inclisiran-bij-homozygote-fh/","published":"2024-01-30"},{"url":"https://hartvaat.nl/2023/10/21/lerodalcibep-bij-familiaire-hypercholesterolemie-liberate-hefh-langetermijndata/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2022/12/21/orion-11-inclisiran-verlaagt-ldl-effectief-bij-primaire-preventie/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2020/08/20/evinacumab-bij-homozygoot-familiaire-hypercholesterolemie-nejm/","published":"2020-08-20"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-bij-heterozygote-familiaire-hypercholesterolemie-nejm-orion-9/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-fase-3-bij-verhoogd-ldl-nejm-orion-10-en-orion-11/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2019/10/29/langetermijn-werkzaamheid-en-veiligheid-van-evolocumab-bij-hypercholesterolemie/","published":"2019-10-29"},{"url":"https://hartvaat.nl/2017/08/29/rosuvastatine-bij-kinderen-met-homozygote-familiaire-hypercholesterolemie/","published":"2017-08-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gregory-ducrocq","type":"person","url":"https://hartvaat.nl/mensen/gregory-ducrocq/","name":"Grégory Ducrocq","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/01/14/tri-fr-transcatheter-edge-to-edge-repair-bij-geisoleerde-ernstige-tr-rct/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"},{"url":"https://hartvaat.nl/2020/01/02/vergelijking-van-twee-ldl-streefwaarden-na-ischemisch-cva-nejm-tst/","published":"2020-01-02"},{"url":"https://hartvaat.nl/2017/11/14/timing-van-angiografie-bij-hoogrisico-nstemi-acuity-analyse/","published":"2017-11-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"harmony-r-reynolds","type":"person","url":"https://hartvaat.nl/mensen/harmony-r-reynolds/","name":"Harmony R Reynolds","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/09/23/pci-versus-cabg-en-gezondheidsstatus-bij-stabiel-coronairlijden/","published":"2025-09-23"},{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/04/11/ambulante-beslisondersteuning-verbetert-mra-voorschrijving-bij-hfref/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/23/gezondheidsstatus-na-invasieve-of-conservatieve-zorg-bij-coronairlijden-met-gevo/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jens-flensted-lassen","type":"person","url":"https://hartvaat.nl/mensen/jens-flensted-lassen/","name":"Jens Flensted Lassen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/03/04/stapsgewijze-provisionale-versus-systematische-dualstent-bij-ware-linker-hoofdst/","published":"2025-03-04"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2021/10/01/ebc-hoofdstam-stentstudie-provisional-versus-systematisch-dubbel-stenten/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","published":"2020-01-18"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","published":"2019-10-19"},{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"},{"url":"https://hartvaat.nl/2016/02/23/everolimus-versus-sirolimus-eluting-stents-5-jaarsresultaten-sort-out-iv/","published":"2016-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jens-jakob-thune","type":"person","url":"https://hartvaat.nl/mensen/jens-jakob-thune/","name":"Jens Jakob Thune","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/01/af-en-icd-bij-niet-ischemische-hfref-impliciaties-voor-devicetherapie/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/04/22/thoracentese-bij-acuut-hartfalen-gerandomiseerde-trial/","published":"2025-04-22"},{"url":"https://hartvaat.nl/2022/10/20/box-bloeddrukdoelen-bij-comateuze-overlevenden-van-hartstilstand/","published":"2022-10-20"},{"url":"https://hartvaat.nl/2022/04/01/icd-bij-niet-ischemisch-systolisch-hf-met-coronaire-atherosclerose-danish/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"},{"url":"https://hartvaat.nl/2016/02/01/regionale-hartdisfunctie-en-prognose-na-myocardinfarct-met-lv-disfunctie-of-hart/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jiang-he","type":"person","url":"https://hartvaat.nl/mensen/jiang-he/","name":"Jiang He","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/02/01/antihypertensieve-behandeling-na-acuut-ischemisch-cva-continueren-of-niet/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/03/27/intensieve-bloeddrukcontrole-bij-type-2-diabetes-nejm/","published":"2025-03-27"},{"url":"https://hartvaat.nl/2024/11/01/optimale-antihypertensieve-systolische-bloeddruk-meta-analyse/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/09/01/nieuwe-metabolieten-geassocieerd-met-bloeddrukrespons-op-dieetinterventies/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/03/18/intensieve-bloeddrukinterventie-door-niet-artsen-in-lage-inkomenslanden-lancet-r/","published":"2023-03-18"},{"url":"https://hartvaat.nl/2022/08/01/hele-genoomsequencing-onthult-nieuwe-bloeddruk-loci/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2022/05/21/dorpsarts-geleide-multifacet-interventie-voor-bloeddrukcontrole-in-ruraal-china-/","published":"2022-05-21"},{"url":"https://hartvaat.nl/2021/05/05/intensieve-bloeddruk-en-aortastijfheid-sprint-heart/","published":"2021-05-05"},{"url":"https://hartvaat.nl/2021/04/01/aerobe-training-bevordert-angiogenese-en-verlaagt-bloeddruk-bij-hypertensie-exca/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2017/09/19/community-health-worker-interventie-voor-bloeddrukcontrole-in-argentina-jama-tri/","published":"2017-09-19"},{"url":"https://hartvaat.nl/2017/08/01/intensieve-bloeddrukverlaging-en-linkerventrikelhypertrofie-sprint-echocardiogra/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/07/01/systolische-bloeddrukreductie-en-cv-risico-netwerkmeta-analyse/","published":"2017-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joseph-m-massaro","type":"person","url":"https://hartvaat.nl/mensen/joseph-m-massaro/","name":"Joseph M Massaro","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2018/10/01/transcatheter-interatriale-shunt-bij-hfpef-1-jaarsresultaten/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/01/23/transcatheter-interatriale-shunt-bij-hfpef-reduce-lap-hf-i/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/10/31/laesiecomplexiteit-en-uitkomsten-van-verlengde-dapt-na-pci/","published":"2017-10-31"},{"url":"https://hartvaat.nl/2017/10/21/ultradunne-bioresorbeerbare-versus-dunne-duurzame-polymer-stents-lancet-bioscien/","published":"2017-10-21"},{"url":"https://hartvaat.nl/2017/05/02/mi-risico-na-stoppen-van-thienopyridine-dapt-studie/","published":"2017-05-02"},{"url":"https://hartvaat.nl/2017/03/21/kortetermijneffecten-van-tolvaptan-bij-acuut-hartfalen-met-volume-overbelasting/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/10/04/impact-van-optimale-medicamenteuze-therapie-in-de-dapt-studie/","published":"2016-10-04"},{"url":"https://hartvaat.nl/2016/05/31/dapt-score-validatie-bij-patienten-met-en-zonder-eerder-myocardinfarct/","published":"2016-05-31"},{"url":"https://hartvaat.nl/2016/05/03/diabetes-en-preventie-van-laat-myocardinfarct-na-stenting-dapt-studie/","published":"2016-05-03"},{"url":"https://hartvaat.nl/2016/04/26/predictieregel-voor-voordeel-en-schade-van-dapt-na-1-jaar-pci-jama-validatiestud/","published":"2016-04-26"},{"url":"https://hartvaat.nl/2016/01/21/doodsoorzaken-bij-langdurige-dapt-na-coronaire-stents/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jozine-m-ter-maaten","type":"person","url":"https://hartvaat.nl/mensen/jozine-m-ter-maaten/","name":"Jozine M Ter Maaten","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/05/25/kdigo-overzicht-de-nier-centraal-in-het-cardiovasculair-renaal-metabool-ckm-synd/","published":"2026-05-31"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/08/01/candesartan-dosering-bij-mannen-versus-vrouwen-met-chronisch-hartfalen/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","published":"2023-06-09"},{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","published":"2022-09-29"},{"url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2016/05/17/verminderde-cardiac-index-is-niet-de-primaire-oorzaak-van-nierdisfunctie-bij-har/","published":"2016-05-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karl-ludwig-laugwitz","type":"person","url":"https://hartvaat.nl/mensen/karl-ludwig-laugwitz/","name":"Karl-Ludwig Laugwitz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/05/05/perifere-zuurstofextractie-bepaalt-belasting-bij-arrhythmogene-cardiomyopathie-f/","published":"2026-07-31"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/04/17/in-stent-restenose-tienjaarsuitkomsten-plain-balloon-vs-dcb-vs-des-isar-desire-3/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2019/01/15/10-jaarsuitkomsten-van-drie-limus-eluting-stents-coating-vergelijking/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/07/bioresorbeerbare-scaffold-versus-ees-bij-stabiel-coronairlijden-prospectieve-tri/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2017/03/01/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-af-geactualiseerde-meta/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kazem-rahimi","type":"person","url":"https://hartvaat.nl/mensen/kazem-rahimi/","name":"Kazem Rahimi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/04/25/bloeddrukverlaging-beschermt-over-het-hele-spectrum-van-chronische-nierschade-la/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2025/08/30/bloeddrukverlagende-effectiviteit-van-antihypertensiva-en-combinaties-uitgebreid/","published":"2025-08-30"},{"url":"https://hartvaat.nl/2025/03/26/rate-af-kosteneffectiviteit-van-digoxine-versus-betablokkers-bij-permanent-af/","published":"2025-03-26"},{"url":"https://hartvaat.nl/2024/10/07/2024-esc-richtlijn-voor-management-van-hypertensie/","published":"2024-10-07"},{"url":"https://hartvaat.nl/2023/11/01/sekseverschillen-in-effect-van-bloeddrukverlaging-ipd-meta-analyse/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2022/07/27/langetermijneffect-van-antihypertensiva-op-bloeddruk-meta-analyse-op-individueel/","published":"2022-07-27"},{"url":"https://hartvaat.nl/2021/11/13/bloeddrukverlaging-en-risico-op-diabetes-type-2-lancet-bplttc-ipd-meta-analyse/","published":"2021-11-13"},{"url":"https://hartvaat.nl/2020/12/22/digoxine-versus-bisoprolol-voor-frequentiecontrole-bij-af-en-qol-jama-rate-af/","published":"2020-12-22"},{"url":"https://hartvaat.nl/2020/10/01/thuismonitoring-met-technologie-ondersteund-management-bij-chronisch-hf-gerandom/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/05/01/inflammatiemarkers-en-risico-op-hypertensie-meta-analyse-van-cohortstudies/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2016/03/05/bloeddrukverlaging-ter-preventie-van-hart-en-vaatziekten-systematische-review-en/","published":"2016-03-05"},{"url":"https://hartvaat.nl/2016/01/30/intensieve-bloeddrukverlaging-en-cardiovasculaire-en-renale-uitkomsten-systemati/","published":"2016-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kevin-r-bainey","type":"person","url":"https://hartvaat.nl/mensen/kevin-r-bainey/","name":"Kevin R Bainey","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/01/27/intracoronair-lage-dosis-rtpa-bij-primaire-pci-voor-stemi-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2023/08/29/stream-2-halve-dosis-tenecteplase-bij-ouderen-met-stemi/","published":"2023-08-29"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/05/01/remote-ischemische-conditionering-bij-stemi-registergebaseerde-gerandomiseerde-t/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/08/01/complete-versus-culprit-only-revascularisatie-bij-stemi-jama-cardiology-meta-ana/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2016/04/01/ischemisch-risicogebied-en-reperfusiemethode-bij-stemi-klinische-implicaties/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"li-li","type":"person","url":"https://hartvaat.nl/mensen/li-li/","name":"Li Li","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/03/29/confidence-analyse-acute-egfr-daling-bij-empagliflozin-finerenone-is-reversibel-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/02/16/fibrilline-1-is-een-nieuw-ligand-van-de-egf-receptor-dat-mesangiumcellen-activee/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2024/06/01/opt-birisk-clopidogrel-monotherapie-bij-acs-met-hoog-ischemisch-en-bloedingsrisi/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"},{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lucas-petri-damiani","type":"person","url":"https://hartvaat.nl/mensen/lucas-petri-damiani/","name":"Lucas Petri Damiani","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/03/17/answer-hf-sacubitril-valsartan-versus-enalapril-bij-chagas-hf-primaire-resultate/","published":"2026-03-17"},{"url":"https://hartvaat.nl/2026/01/06/sacubitril-valsartan-versus-enalapril-bij-chagas-hartfalen/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2024/02/13/bariatrische-chirurgie-en-bloeddruk-na-5-jaar-gerandomiseerde-trial/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2022/11/01/vip-acs-dubbele-dosis-griepvaccinatie-na-acs-verbetert-uitkomsten-niet/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2020/11/26/rivaroxaban-bij-af-met-bioprothese-mitralisklep-nejm-river/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-en-evidence-based-prescriptie-bij-hoog-cv-risico-jama-card/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2019/03/01/bariatrische-chirurgie-versus-medicamenteus-beleid-op-24-uurs-ambulante-bloeddru/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/11/01/timing-van-atorvastatine-oplaaddosis-voor-pci-bij-acs-jama-cardiology/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/04/03/oplaaddosis-atorvastatine-voor-pci-jama-gerandomiseerde-trial/","published":"2018-04-03"},{"url":"https://hartvaat.nl/2018/03/13/bariatrische-chirurgie-bij-obese-patienten-met-hypertensie-gateway-gerandomiseer/","published":"2018-03-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marco-roffi","type":"person","url":"https://hartvaat.nl/mensen/marco-roffi/","name":"Marco Roffi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2023/11/25/biodegradeerbare-versus-duurzame-polymeer-des-bij-stemi-langetermijndata/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2019/10/05/biodegradeerbare-versus-duurzame-polymer-des-bij-stemi-gerandomiseerde-trial/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/12/21/culprit-shock-integratie-in-2017-esc-stemi-richtlijn-richtlijncommissie-standpun/","published":"2018-12-21"},{"url":"https://hartvaat.nl/2018/09/01/ultradunne-biodegradeerbare-versus-dunne-duurzame-stents-lancet-gerandomiseerde-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/01/07/2017-esc-richtlijn-voor-stemi-management/","published":"2018-01-07"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mario-f-gaudino","type":"person","url":"https://hartvaat.nl/mensen/mario-f-gaudino/","name":"Mario F Gaudino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/05/13/aha-scientific-statement-2026-secundaire-preventie-na-coronaire-bypassoperatie-e/","published":"2026-05-15"},{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2022/08/09/ticagrelor-dapt-en-veneuze-graftfalen-na-cabg-systematische-review/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2022/01/18/2021-acc-aha-scai-richtlijn-voor-coronaire-revascularisatie-executive-summary/","published":"2022-01-18"},{"url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/12/04/posterieure-pericardiotomie-ter-preventie-van-af-na-hartchirurgie-lancet-palacs/","published":"2021-12-04"},{"url":"https://hartvaat.nl/2021/01/05/leeftijd-en-10-jaarsuitkomsten-na-cabg-art-trial/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/06/postoperatief-af-en-langetermijn-cva-risico-na-geisoleerde-cabg/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/07/14/radiale-arterie-versus-vena-saphena-graft-bij-cabg-jama-langetermijn-meta-analys/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2019/01/31/bilaterale-versus-enkele-mammaria-interna-grafts-na-10-jaar-nejm-art/","published":"2019-01-31"},{"url":"https://hartvaat.nl/2017/03/14/drie-arteriele-grafts-verbeteren-langetermijnoverleving-meta-analyse-van-propens/","published":"2017-03-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"niels-van-royen","type":"person","url":"https://hartvaat.nl/mensen/niels-van-royen/","name":"Niels van Royen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/11/11/ffr-geleide-complete-versus-culprit-only-revascularisatie-bij-nstemi/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/02/18/lage-dosis-sirolimus-bdp-stent-versus-tweede-generatie-des-non-inferioriteit/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2023/05/14/prehospitale-troponine-voor-uitsluiting-nste-acs-gerandomiseerde-trial/","published":"2023-05-14"},{"url":"https://hartvaat.nl/2020/12/01/coronairangiografie-na-hartstilstand-zonder-st-elevatie-coact-1-jaarsuitkomsten/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/01/temporele-veranderingen-in-coronaire-hemodynamiek-bij-niet-culprit-vaten-na-stem/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/04/11/coronairangiografie-na-hartstilstand-zonder-st-elevatie-nejm-coact/","published":"2019-04-11"},{"url":"https://hartvaat.nl/2019/01/29/microvasculaire-schade-bij-gerevasculariseerde-stemi-met-ticagrelor-versus-prasu/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","published":"2016-06-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nikolaus-marx","type":"person","url":"https://hartvaat.nl/mensen/nikolaus-marx/","name":"Nikolaus Marx","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/04/12/lipidenmanagement-bij-type-2-diabetes-richt-je-op-alle-atherogene-lipoproteinen-/","published":"2026-07-19"},{"url":"https://hartvaat.nl/2026/04/16/pcsk9-remmers-verlagen-events-bij-ascvd-zonder-eerder-infarct-of-beroerte-real-w/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2026/02/23/van-internationale-richtlijnen-naar-nationale-implementatie-bij-cardio-renaal-me/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","published":"2025-05-29"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/08/01/empagliflozine-vermindert-nierletselmarkers-bij-acuut-hartfalen/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","published":"2019-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"p-j-devereaux","type":"person","url":"https://hartvaat.nl/mensen/p-j-devereaux/","name":"P J Devereaux","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/04/08/vision-postoperatief-atriumfibrilleren-na-hartchirurgie-verhoogt-sterfte-na-een-/","published":"2026-07-15"},{"url":"https://hartvaat.nl/2025/08/16/achieve-spironolacton-bij-dialysepatienten-internationale-rct/","published":"2025-08-16"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2023/11/04/colchicine-vermindert-perioperatief-af-na-thoraxchirurgie-lancet-rct/","published":"2023-11-04"},{"url":"https://hartvaat.nl/2023/10/24/laaos-iii-laa-occlusie-en-anticoagulatiegebruik/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2021/08/06/orale-antiaritmica-voor-cardioversie-van-recent-onset-af-netwerkmeta-analyse/","published":"2021-08-06"},{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","published":"2021-06-03"},{"url":"https://hartvaat.nl/2018/06/09/dabigatran-bij-myocardschade-na-niet-cardiale-chirurgie-lancet-manage-trial/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/08/15/overleving-na-geisoleerde-postoperatieve-troponine-elevatie/","published":"2017-08-15"},{"url":"https://hartvaat.nl/2016/12/15/off-pump-versus-on-pump-cabg-5-jaarsresultaten-nejm-coronary-trial/","published":"2016-12-15"},{"url":"https://hartvaat.nl/2016/01/07/preoperatief-statinegebruik-en-cardiovasculaire-complicaties-bij-niet-cardiale-c/","published":"2016-01-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"patricio-lopez-jaramillo","type":"person","url":"https://hartvaat.nl/mensen/patricio-lopez-jaramillo/","name":"Patricio López-Jaramillo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2022/01/01/farmacologische-hypertensiebehandeling-bij-volwassenen-who-richtlijn-samenvattin/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","published":"2021-08-03"},{"url":"https://hartvaat.nl/2021/07/08/cv-uitkomsten-bij-diabetes-met-vastgesteld-of-hoog-risico-coronairlijden-dulaglu/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/10/05/uitgebreide-community-interventie-bij-hypertensie-lancet-hope-4/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"petr-widimsky","type":"person","url":"https://hartvaat.nl/mensen/petr-widimsky/","name":"Petr Widimský","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2022/01/04/4-jaars-laa-sluiting-versus-niet-warfarine-oac-bij-af/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2021/07/01/cv-gevolgen-van-stoppen-met-laaggedoseerd-rivaroxaban-bij-chronisch-vaatlijden/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/09/19/trimetazidine-na-pci-lancet-atpci-gerandomiseerde-trial/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2020/06/30/laa-sluiting-versus-doac-bij-hoogrisico-af-vergelijkende-analyse/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2019/03/05/timing-van-prasugrel-start-en-coronairangiografie-bij-nstemi/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2018/01/30/prasugrel-versus-ticagrelor-bij-primaire-pci-voor-mi-1-jaarsuitkomsten/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2018/01/07/2017-esc-richtlijn-voor-stemi-management/","published":"2018-01-07"},{"url":"https://hartvaat.nl/2016/11/22/prasugrel-versus-ticagrelor-bij-acuut-mi-met-primaire-pci-multicenter-trial/","published":"2016-11-22"},{"url":"https://hartvaat.nl/2016/02/01/spironolacton-versus-renale-denervatie-bij-therapieresistente-hypertensie-prague/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philip-d-adamson","type":"person","url":"https://hartvaat.nl/mensen/philip-d-adamson/","name":"Philip D Adamson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","published":"2025-01-25"},{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/08/01/inspannings-ecg-versus-ccta-bij-stabiele-angina-post-hoc-vergelijking/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/05/05/laag-attenuatie-plaque-op-ccta-voorspelt-mi-scot-heart-resultaten/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/01/29/coronaire-plaquekenmerken-en-adverse-uitkomsten-scot-heart/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","published":"2018-09-06"},{"url":"https://hartvaat.nl/2018/09/04/troponine-i-en-cardiovasculair-risico-bij-copd/","published":"2018-09-04"},{"url":"https://hartvaat.nl/2018/04/01/sekseverschillen-in-effectiviteit-van-orale-p2y12-remmers-meta-analyse/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"qiang-li","type":"person","url":"https://hartvaat.nl/mensen/qiang-li/","name":"Qiang Li","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2025/12/09/nieuw-bifasisch-pfa-systeem-versus-thermale-ablatie-bij-paroxysmaal-af/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2024/05/30/right-2-ambulancebloeddrukverlaging-bij-hyperacuut-cva-nejm-vervolgresultaten/","published":"2024-05-30"},{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/07/01/interact3-bundeled-care-bij-acute-intracerebrale-bloeding-lancet/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2022/11/05/enchanted2-mt-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-is-schadelij/","published":"2022-11-05"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"},{"url":"https://hartvaat.nl/2018/01/23/canagliflozine-voor-primaire-en-secundaire-cardiovasculaire-preventie-canvas/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/12/01/voorkeur-voor-pikant-eten-versterkt-zoutwaarneming-en-vermindert-zoutinname-en-b/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","published":"2016-06-16"},{"url":"https://hartvaat.nl/2016/03/01/taurinesuppletie-verlaagt-bloeddruk-en-verbetert-vaatfunctie-bij-prehypertensie/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ran-kornowski","type":"person","url":"https://hartvaat.nl/mensen/ran-kornowski/","name":"Ran Kornowski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2017/10/03/ridaforolimus-versus-zotarolimus-eluting-stents-gerandomiseerde-primaire-resulta/","published":"2017-10-03"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ricardo-petraco","type":"person","url":"https://hartvaat.nl/mensen/ricardo-petraco/","name":"Ricardo Petraco","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/01/ffr-versus-ifr-bij-coronaire-revascularisatie-vijfjaars-follow-up/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/19/coronaire-flowreserve-en-cardiovasculaire-uitkomsten-meta-analyse/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/01/temporele-veranderingen-in-coronaire-hemodynamiek-bij-niet-culprit-vaten-na-stem/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"richard-j-mcmanus","type":"person","url":"https://hartvaat.nl/mensen/richard-j-mcmanus/","name":"Richard J McManus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/11/01/bloeddrukzelfmanagement-en-vasculaire-remodelling-na-hypertensieve-zwangerschap/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/10/07/2024-esc-richtlijn-voor-management-van-hypertensie/","published":"2024-10-07"},{"url":"https://hartvaat.nl/2024/02/13/pop-ht-bloeddrukzelfmanagement-verbetert-cardiale-remodelling-na-hypertensieve-z/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2023/11/28/pop-ht-zelfmanagement-van-bloeddruk-na-hypertensieve-zwangerschap-jama-rct/","published":"2023-11-28"},{"url":"https://hartvaat.nl/2022/10/01/bloeddruk-in-hogere-versus-lagere-arm-en-cv-uitkomsten-interpress-ipd-meta-analy/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-bloeddrukcontrole-bij-risicozwangerschap-jama-bump-2/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2020/05/26/antihypertensieve-medicatiereductie-versus-standaardzorg-bij-ouderen-jama-optimi/","published":"2020-05-26"},{"url":"https://hartvaat.nl/2019/06/01/kosteneffectiviteit-van-telemonitoring-en-zelfmeting-van-bloeddruk-tasminh4/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/09/01/thuis-versus-praktijkbloeddrukmeting-in-de-zwangerschap/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/08/01/zelfmanagement-van-postnatale-hypertensie-de-snap-ht-trial/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/03/10/zelfgemeten-bloeddruk-met-of-zonder-telemonitoring-voor-medicatietitratie-lancet/","published":"2018-03-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-w-yeh","type":"person","url":"https://hartvaat.nl/mensen/robert-w-yeh/","name":"Robert W Yeh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/08/19/paclitaxel-gecoate-ballon-bij-multilayer-in-stent-restenose-agent-ide-subgroep/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/02/18/lage-dosis-sirolimus-bdp-stent-versus-tweede-generatie-des-non-inferioriteit/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2021/04/27/patientselectie-voor-intensieve-bloeddrukbehandeling-naar-voordeel-en-bijwerking/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2017/10/31/laesiecomplexiteit-en-uitkomsten-van-verlengde-dapt-na-pci/","published":"2017-10-31"},{"url":"https://hartvaat.nl/2017/06/01/korte-procedureduur-met-bivalirudine-en-risico-op-acute-stenttrombose-bij-stemi/","published":"2017-06-01"},{"url":"https://hartvaat.nl/2017/05/02/mi-risico-na-stoppen-van-thienopyridine-dapt-studie/","published":"2017-05-02"},{"url":"https://hartvaat.nl/2016/10/04/impact-van-optimale-medicamenteuze-therapie-in-de-dapt-studie/","published":"2016-10-04"},{"url":"https://hartvaat.nl/2016/05/31/dapt-score-validatie-bij-patienten-met-en-zonder-eerder-myocardinfarct/","published":"2016-05-31"},{"url":"https://hartvaat.nl/2016/05/03/diabetes-en-preventie-van-laat-myocardinfarct-na-stenting-dapt-studie/","published":"2016-05-03"},{"url":"https://hartvaat.nl/2016/04/26/predictieregel-voor-voordeel-en-schade-van-dapt-na-1-jaar-pci-jama-validatiestud/","published":"2016-04-26"},{"url":"https://hartvaat.nl/2016/01/21/doodsoorzaken-bij-langdurige-dapt-na-coronaire-stents/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"runlin-gao","type":"person","url":"https://hartvaat.nl/mensen/runlin-gao/","name":"Runlin Gao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/01/01/sirolimus-eluerende-bioresorbeerbare-stents-versus-everolimus-eluerende-stents-i/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2024/11/12/rf-renale-denervatie-bij-ongecontroleerde-hypertensie-in-china-gerandomiseerde-t/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/02/01/maggic-score-voor-mortaliteitsvoorspelling-bij-klepziekte/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/10/24/cts-ami-tongxinluo-bij-acuut-mi-jama-mega-trial/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2020/05/01/werkplek-multicomponentinterventie-voor-hypertensie-jama-cardiology/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/12/01/absorb-scaffold-5-jaarsresultaten-systematische-meta-analyse/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-bij-acs-in-resource-beperkte-ziekenhuizen-jama-cardiology-/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2018/01/30/absorb-bioresorbeerbare-scaffold-3-jaarsresultaten-ipd-meta-analyse/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2017/12/12/implantatiechniek-en-uitkomsten-van-bioresorbeerbare-scaffolds-absorb-analyses/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/09/01/late-trombotische-events-na-bioresorbeerbare-scaffold-meta-analyse-van-gerandomi/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/08/19/absorb-bioresorbeerbare-scaffold-lancet-2-jaars-systematische-review-en-meta-ana/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2016/05/17/biodegradeerbare-sirolimus-eluting-stents-de-panda-iii-trial/","published":"2016-05-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"samantha-sartori","type":"person","url":"https://hartvaat.nl/mensen/samantha-sartori/","name":"Samantha Sartori","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-bij-niet-diabetische-hfref-emperor-reduced-subanalyse/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/02/18/ticagrelor-met-of-zonder-aspirine-na-pci-twilight-plaatjessubstudie/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2017/05/30/polygene-risicoscore-en-relatief-voordeel-van-statinetherapie-primaire-preventie/","published":"2017-05-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sayan-sen","type":"person","url":"https://hartvaat.nl/mensen/sayan-sen/","name":"Sayan Sen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/01/ffr-versus-ifr-bij-coronaire-revascularisatie-vijfjaars-follow-up/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/19/coronaire-flowreserve-en-cardiovasculaire-uitkomsten-meta-analyse/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"scott-m-wasserman","type":"person","url":"https://hartvaat.nl/mensen/scott-m-wasserman/","name":"Scott M Wasserman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2019/10/29/langetermijn-werkzaamheid-en-veiligheid-van-evolocumab-bij-hypercholesterolemie/","published":"2019-10-29"},{"url":"https://hartvaat.nl/2019/09/01/persisterende-arteriele-wandinflammatie-bij-verhoogd-lp-a-ondanks-lage-ldl/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/06/18/evolocumab-bij-ckd-werkzaamheid-en-veiligheid-in-de-fourier-trial/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2019/01/01/interindividuele-variatie-in-ldl-verlaging-met-evolocumab-fourier-analyse/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/10/23/evolocumab-en-coronaire-plaquesamenstelling-glagov-beeldvorming/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2017/08/17/cognitieve-functie-in-de-fourier-trial-met-evolocumab-nejm-ebbinghaus/","published":"2017-08-17"},{"url":"https://hartvaat.nl/2017/05/04/evolocumab-en-klinische-uitkomsten-bij-cardiovasculaire-ziekte-nejm-fourier/","published":"2017-05-04"},{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/04/19/evolocumab-versus-ezetimibe-bij-statine-intolerante-patienten-de-gauss-3-trial/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/03/29/omecamtiv-mecarbil-bij-acuut-hartfalen-de-atomic-ahf-studie/","published":"2016-03-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"simon-a-m-thom","type":"person","url":"https://hartvaat.nl/mensen/simon-a-m-thom/","name":"Simon A M Thom","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/06/01/lage-dosis-drievoudige-combinatietherapie-bij-hypertensie-triumph-secundaire-ana/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2021/09/21/bijwerkingspatronen-in-crossover-trial-statine-placebo-geen-behandeling-statinwi/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2020/11/26/n-of-1-trial-van-statine-placebo-of-geen-behandeling-voor-bijwerkingen-nejm-stat/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2020/11/01/lage-dosis-triple-combinatie-en-therapeutische-inertie-bij-hypertensie-jama-card/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2019/01/01/polypil-en-cardiovasculaire-preventie-meta-analyse-van-gerandomiseerde-trials/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/01/ochtend-versus-avonddosering-van-antihypertensiva-gerandomiseerde-crossover-tria/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/08/14/drievoudige-lage-dosis-antihypertensivacombinatie-versus-standaardzorg-jama-gera/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefan-p-janssens","type":"person","url":"https://hartvaat.nl/mensen/stefan-p-janssens/","name":"Stefan P Janssens","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/04/01/betrokkenheid-van-huisartsenzorg-bij-multidisciplinair-hf-management-meta-analys/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/08/18/optimale-bloeddruk-bij-shock-na-mi-en-hartstilstand/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2020/08/01/antidiabetica-en-cardiovasculaire-geneeskunde-meta-analyse-en-perspectief/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/01/28/eerdere-hf-hospitalisatie-en-sacubitril-valsartan-versus-valsartan-bij-hfpef-par/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2018/08/01/inhalatie-stikstofoxide-bij-stemi-nomi-gerandomiseerde-trial/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steffen-schneider","type":"person","url":"https://hartvaat.nl/mensen/steffen-schneider/","name":"Steffen Schneider","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2025/12/01/scai-shockklassen-en-prognose-bij-ami-cardiogene-shock-danger-substudie/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2023/03/28/culprit-interventie-bij-cardiogene-shock-met-hartstilstand/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/08/01/des-versus-bms-bij-acuut-mi-met-cardiogene-shock/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/01/01/percutane-linker-hartoorsluiting-munchen-consensusdocument-over-definities-en-ei/","published":"2017-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephen-e-fremes","type":"person","url":"https://hartvaat.nl/mensen/stephen-e-fremes/","name":"Stephen E Fremes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/04/07/kosteneffectiviteit-van-stapsgewijze-lipidenverlaging-na-coronaire-bypasschirurg/","published":"2026-07-18"},{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/08/09/ticagrelor-dapt-en-veneuze-graftfalen-na-cabg-systematische-review/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2022/01/18/2021-acc-aha-scai-richtlijn-voor-coronaire-revascularisatie-executive-summary/","published":"2022-01-18"},{"url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/12/04/posterieure-pericardiotomie-ter-preventie-van-af-na-hartchirurgie-lancet-palacs/","published":"2021-12-04"},{"url":"https://hartvaat.nl/2021/01/05/leeftijd-en-10-jaarsuitkomsten-na-cabg-art-trial/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/07/14/radiale-arterie-versus-vena-saphena-graft-bij-cabg-jama-langetermijn-meta-analys/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2018/09/27/6-maandsuitkomsten-van-restrictieve-versus-liberale-transfusie-bij-hartchirurgie/","published":"2018-09-27"},{"url":"https://hartvaat.nl/2017/11/30/restrictieve-versus-liberale-bloedtransfusie-bij-hartchirurgie-nejm-trics-iii/","published":"2017-11-30"},{"url":"https://hartvaat.nl/2017/05/25/levosimendan-bij-lv-disfunctie-voor-hartchirurgie-nejm-levo-cts/","published":"2017-05-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tienush-rassaf","type":"person","url":"https://hartvaat.nl/mensen/tienush-rassaf/","name":"Tienush Rassaf","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/12/01/scai-shockklassen-en-prognose-bij-ami-cardiogene-shock-danger-substudie/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/10/01/bnp-nt-probnp-stratificeert-prognose-gelijk-met-en-zonder-hartfalen-meta-analyse/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2019/08/01/hartfalen-door-kankerbehandeling-kunnen-we-het-voorkomen/","published":"2019-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tzvetana-katova","type":"person","url":"https://hartvaat.nl/mensen/tzvetana-katova/","name":"Tzvetana Katova","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2018/06/01/sacubitril-valsartan-en-fysieke-en-sociale-activiteitsbeperkingen-bij-hf-paradig/","published":"2018-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"umberto-benedetto","type":"person","url":"https://hartvaat.nl/mensen/umberto-benedetto/","name":"Umberto Benedetto","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/01/05/leeftijd-en-10-jaarsuitkomsten-na-cabg-art-trial/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/06/postoperatief-af-en-langetermijn-cva-risico-na-geisoleerde-cabg/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/07/14/radiale-arterie-versus-vena-saphena-graft-bij-cabg-jama-langetermijn-meta-analys/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/08/13/off-pump-versus-on-pump-cabg-bij-hoofdstamcoronairlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/01/31/bilaterale-versus-enkele-mammaria-interna-grafts-na-10-jaar-nejm-art/","published":"2019-01-31"},{"url":"https://hartvaat.nl/2017/08/01/radiale-arterie-graft-als-aanvulling-op-mammaria-interna-grafts-bij-cabg/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2017/03/14/drie-arteriele-grafts-verbeteren-langetermijnoverleving-meta-analyse-van-propens/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/12/29/bilaterale-versus-enkelvoudige-a-mammaria-interna-grafts-nejm-art-trial/","published":"2016-12-29"},{"url":"https://hartvaat.nl/2016/02/07/impact-van-pcsk9-remmers-op-lipidenniveaus-en-uitkomsten-netwerkmeta-analyse/","published":"2016-02-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"william-wijns","type":"person","url":"https://hartvaat.nl/mensen/william-wijns/","name":"William Wijns","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2018/05/07/esc-eapci-taskforce-rapport-over-bioresorbeerbare-scaffolds-executive-summary/","published":"2018-05-07"},{"url":"https://hartvaat.nl/2018/02/03/sirolimus-eluting-bioabsorbeerbare-stent-versus-everolimus-eluting-stent-na-mi-l/","published":"2018-02-03"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/07/12/prasugrel-versus-clopidogrel-en-coronaire-microvasculaire-functie-bij-electieve-/","published":"2016-07-12"},{"url":"https://hartvaat.nl/2016/04/26/predictieregel-voor-voordeel-en-schade-van-dapt-na-1-jaar-pci-jama-validatiestud/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yaling-han","type":"person","url":"https://hartvaat.nl/mensen/yaling-han/","name":"Yaling Han","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2024/06/01/opt-birisk-clopidogrel-monotherapie-bij-acs-met-hoog-ischemisch-en-bloedingsrisi/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/10/24/cts-ami-tongxinluo-bij-acuut-mi-jama-mega-trial/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/11/26/bivalirudine-versus-heparine-bij-primaire-pci-voor-stemi-lancet-trial/","published":"2022-11-26"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/06/01/sglt2-remmers-bij-hartfalen-geupdatete-meta-analyse-bevestigt-breed-voordeel/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2022/01/18/magnetisch-gecontroleerde-capsule-endoscopie-voor-antiplaatjestherapie-gi-schade/","published":"2022-01-18"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"},{"url":"https://hartvaat.nl/2017/10/17/farmaco-invasieve-strategie-met-halve-dosis-alteplase-versus-primaire-pci-bij-st/","published":"2017-10-17"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yong-huo","type":"person","url":"https://hartvaat.nl/mensen/yong-huo/","name":"Yong Huo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/06/26/inclisiran-als-monotherapie-verlaagt-ldl-c-met-47-5-in-chinese-volwassenen-victo/","published":"2026-08-09"},{"url":"https://hartvaat.nl/2025/01/01/langetermijn-cardiovasculaire-en-niet-cardiovasculaire-mortaliteit-na-acuut-coro/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2022/06/01/interatriale-shuntdevices-bij-hartfalen-systematische-review-en-meta-analyse/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2022/05/25/hydratie-ter-preventie-van-nierschade-na-primaire-pci-gerandomiseerde-trial/","published":"2022-05-25"},{"url":"https://hartvaat.nl/2020/02/01/geschatte-cva-vrije-overleving-van-foliumzuurtherapie-bij-hypertensie-csppt/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-bij-acs-in-resource-beperkte-ziekenhuizen-jama-cardiology-/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2018/05/15/trombocytenaantal-beinvloedt-werkzaamheid-van-foliumzuur-bij-cva-preventie/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2017/10/14/multifacet-interventie-voor-oac-gebruik-bij-af-lancet-impact-af/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2017/08/01/foliumzuurtherapie-en-nieuwe-proteinurie-bij-chinese-hypertensieve-patienten-csp/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/04/01/optimale-systolische-bloeddruk-voor-primaire-cva-preventie-bij-hypertensie-csppt/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/07/01/polsgolfsnelheid-en-bloeddrukcontrole-als-onafhankelijke-voorspellers-van-cva-bi/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"young-guk-ko","type":"person","url":"https://hartvaat.nl/mensen/young-guk-ko/","name":"Young-Guk Ko","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":12,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","published":"2023-04-04"},{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"},{"url":"https://hartvaat.nl/2020/06/16/ticagrelor-monotherapie-versus-dapt-op-bloedingen-en-cv-events-bij-acs-jama-tico/","published":"2020-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"abdul-salam","type":"person","url":"https://hartvaat.nl/mensen/abdul-salam/","name":"Abdul Salam","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/08/30/bloeddrukverlagende-effectiviteit-van-antihypertensiva-en-combinaties-uitgebreid/","published":"2025-08-30"},{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2024/10/01/lage-dosis-drievoudige-pil-versus-standaardzorg-bij-hypertensie-in-nigeria/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2022/07/27/langetermijneffect-van-antihypertensiva-op-bloeddruk-meta-analyse-op-individueel/","published":"2022-07-27"},{"url":"https://hartvaat.nl/2022/06/01/lage-dosis-drievoudige-combinatietherapie-bij-hypertensie-triumph-secundaire-ana/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2020/11/01/lage-dosis-triple-combinatie-en-therapeutische-inertie-bij-hypertensie-jama-card/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2018/08/14/drievoudige-lage-dosis-antihypertensivacombinatie-versus-standaardzorg-jama-gera/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"},{"url":"https://hartvaat.nl/2016/01/30/intensieve-bloeddrukverlaging-en-cardiovasculaire-en-renale-uitkomsten-systemati/","published":"2016-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alaide-chieffo","type":"person","url":"https://hartvaat.nl/mensen/alaide-chieffo/","name":"Alaide Chieffo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2026/05/19/esc-atlas-2025-3-miljoen-cvd-doden-per-jaar-in-europa-middeninkomenlanden-hebben/","published":"2026-06-13"},{"url":"https://hartvaat.nl/2026/05/26/esc-consensus-vrouwenhartcentra-whc-als-nieuw-zorgmodel-in-europa/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","published":"2025-07-21"},{"url":"https://hartvaat.nl/2025/03/04/stapsgewijze-provisionale-versus-systematische-dualstent-bij-ware-linker-hoofdst/","published":"2025-03-04"},{"url":"https://hartvaat.nl/2024/01/01/verkorte-dapt-bij-hoog-bloedingsrisico-geen-sekseverschillen/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2021/10/01/ebc-hoofdstam-stentstudie-provisional-versus-systematisch-dubbel-stenten/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2017/11/07/stentontwerp-en-dapt-duur-effect-op-ischemie-en-bloedingen-netwerkmeta-analyse/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amin-polzin","type":"person","url":"https://hartvaat.nl/mensen/amin-polzin/","name":"Amin Polzin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anders-junker","type":"person","url":"https://hartvaat.nl/mensen/anders-junker/","name":"Anders Junker","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2018/12/04/ffr-versus-angiografie-geleide-cabg/","published":"2018-12-04"},{"url":"https://hartvaat.nl/2016/02/23/everolimus-versus-sirolimus-eluting-stents-5-jaarsresultaten-sort-out-iv/","published":"2016-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"arif-elvan","type":"person","url":"https://hartvaat.nl/mensen/arif-elvan/","name":"Arif Elvan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2022/03/02/frequentiecontrolemiddelen-verschillen-in-preventie-van-af-progressie/","published":"2022-03-02"},{"url":"https://hartvaat.nl/2021/12/07/gold-force-multi-elektrode-rf-versus-irrigated-rf-bij-af-gerandomiseerde-trial/","published":"2021-12-07"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/08/07/geintegreerd-af-management-in-de-huisartsenpraktijk-all-in-clustergerandomiseerd/","published":"2020-08-07"},{"url":"https://hartvaat.nl/2020/02/01/verpleegkundig-geleide-versus-standaard-af-zorg/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2016/10/07/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-af-herinterventierate-e/","published":"2016-10-07"},{"url":"https://hartvaat.nl/2016/06/09/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-atriumfibrilleren-nejm-/","published":"2016-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"avivit-cahn","type":"person","url":"https://hartvaat.nl/mensen/avivit-cahn/","name":"Avivit Cahn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2022/09/01/dapagliflozine-effectief-ongeacht-cv-achtergrondmedicatie-declare-subanalyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bong-ki-lee","type":"person","url":"https://hartvaat.nl/mensen/bong-ki-lee/","name":"Bong-Ki Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","published":"2024-05-04"},{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2022/11/22/ees-versus-cabg-bij-meervatslijden-langetermijn-follow-up-van-rct-s/","published":"2022-11-22"},{"url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","published":"2022-09-08"},{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","published":"2019-04-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brian-k-whisenant","type":"person","url":"https://hartvaat.nl/mensen/brian-k-whisenant/","name":"Brian K Whisenant","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/06/10/triluminate-tweejaarsresultaten-transcatheter-tr-repair-duurzaam-effectief/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2024/06/06/smart-zelf-expanderend-versus-ballonexpandeerbaar-tavr-bij-kleine-annulus-nejm/","published":"2024-06-06"},{"url":"https://hartvaat.nl/2024/03/05/gelijktijdige-laa-occlusie-en-tavr-bij-af-haalbaarheid/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/05/18/triluminate-transcatheter-tricuspidaliskleprepair-bij-ernstige-tr-nejm/","published":"2023-05-18"},{"url":"https://hartvaat.nl/2022/05/01/nierdisfunctie-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2019/12/17/echo-uitkomsten-na-mitraclip-bij-secundaire-mr-coapt-echocardiografisch/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carol-m-mangione","type":"person","url":"https://hartvaat.nl/mensen/carol-m-mangione/","name":"Carol M Mangione","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"},{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","published":"2017-07-11"},{"url":"https://hartvaat.nl/2016/11/15/statines-voor-primaire-cardiovasculaire-preventie-uspstf-aanbeveling/","published":"2016-11-15"},{"url":"https://hartvaat.nl/2016/08/09/lipidescreening-bij-kinderen-en-adolescenten-uspstf-aanbeveling/","published":"2016-08-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chang-wook-nam","type":"person","url":"https://hartvaat.nl/mensen/chang-wook-nam/","name":"Chang-Wook Nam","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2025/04/26/angiografie-afgeleide-ffr-versus-ivus-bij-pci-gerandomiseerde-trial/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","published":"2024-05-04"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2016/04/12/prognostische-waarde-van-residuele-coronairstenosen-na-functioneel-complete-reva/","published":"2016-04-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chao-gao","type":"person","url":"https://hartvaat.nl/mensen/chao-gao/","name":"Chao Gao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/02/05/driejaarsuitkomsten-van-linker-hartoorsluiting-met-of-zonder-ablatie-record-stud/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"charles-a-simonton","type":"person","url":"https://hartvaat.nl/mensen/charles-a-simonton/","name":"Charles A Simonton","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2019/12/01/absorb-scaffold-5-jaarsresultaten-systematische-meta-analyse/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/01/30/absorb-bioresorbeerbare-scaffold-3-jaarsresultaten-ipd-meta-analyse/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"},{"url":"https://hartvaat.nl/2017/12/12/3-jaarsresultaten-van-bioresorbeerbare-scaffolds-absorb-iii-trial/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/08/19/absorb-bioresorbeerbare-scaffold-lancet-2-jaars-systematische-review-en-meta-ana/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-mueller","type":"person","url":"https://hartvaat.nl/mensen/christian-mueller/","name":"Christian Mueller","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2024/12/16/gp-iib-iiia-remmers-bij-acuut-mi-en-microvasculaire-obstructie-meta-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2021/10/01/uitgebreide-vasodilatatie-en-qol-bij-acuut-hf-substudie/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/05/26/subcutaan-selatogrel-remt-plaatjesaggregatie-bij-acuut-mi/","published":"2020-05-26"},{"url":"https://hartvaat.nl/2019/12/17/uitgebreide-vasodilatatie-versus-standaardzorg-bij-acuut-hf-jama-galactic-hf-pil/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/11/19/evolocumab-voor-vroege-ldl-verlaging-bij-acs-evopacs/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2018/09/08/drug-coated-balloons-bij-kleine-coronairarterien-lancet-basket-small-2/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2017/11/21/hoog-sensitief-troponine-i-en-uitkomsten-bij-verdenking-acs-jama-studie/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christoph-bode","type":"person","url":"https://hartvaat.nl/mensen/christoph-bode/","name":"Christoph Bode","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2017/11/14/timing-van-angiografie-bij-hoogrisico-nstemi-acuity-analyse/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2017/01/24/heropnames-bij-af-patienten-na-stenting-twee-antitromboticastrategieen-vergeleke/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/12/22/preventie-van-bloedingen-bij-af-patienten-die-pci-ondergaan-nejm-pioneer-af-pci/","published":"2016-12-22"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/04/21/mtp-131-bij-reperfusieschade-na-stemi-de-embrace-stemi-fase-2a-trial/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-a-rajkumar","type":"person","url":"https://hartvaat.nl/mensen/christopher-a-rajkumar/","name":"Christopher A Rajkumar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/19/coronaire-flowreserve-en-cardiovasculaire-uitkomsten-meta-analyse/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/09/21/bijwerkingspatronen-in-crossover-trial-statine-placebo-geen-behandeling-statinwi/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2020/11/26/n-of-1-trial-van-statine-placebo-of-geen-behandeling-voor-bijwerkingen-nejm-stat/","published":"2020-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"clara-k-chow","type":"person","url":"https://hartvaat.nl/mensen/clara-k-chow/","name":"Clara K Chow","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2025/05/02/determinanten-van-medicatietrouw-na-acs-secundaire-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/06/01/lage-dosis-drievoudige-viervoudige-combinatiepil-versus-monotherapie-bij-hyperte/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/05/10/sms-voor-medicatietrouw-en-secundaire-preventie-na-acs-textmeds/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","published":"2021-09-18"},{"url":"https://hartvaat.nl/2021/03/01/objectieve-risicobeoordeling-versus-standaardzorg-bij-acs-jama-cardiology/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2020/08/01/diagnostische-nauwkeurigheid-van-handheld-ecg-devices-voor-af-community-versus-z/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"},{"url":"https://hartvaat.nl/2016/12/01/lacunes-in-hypertensierichtlijnen-in-lage-en-middeninkomenslanden-systematische-/","published":"2016-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d-scott-lim","type":"person","url":"https://hartvaat.nl/mensen/d-scott-lim/","name":"D Scott Lim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","published":"2022-11-15"},{"url":"https://hartvaat.nl/2021/04/01/ero-lvedv-ratio-en-respons-op-mitraclip-jama-cardiology/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/05/05/gezondheidsstatus-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/12/17/echo-uitkomsten-na-mitraclip-bij-secundaire-mr-coapt-echocardiografisch/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/05/07/gezondheidsstatus-na-mitraclip-bij-hf-met-secundaire-mr-coapt/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-lindholm","type":"person","url":"https://hartvaat.nl/mensen/daniel-lindholm/","name":"Daniel Lindholm","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2018/12/01/multipele-biomarkers-en-mortaliteitsrisico-na-acs-jama-cardiology/","published":"2018-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-a-wood","type":"person","url":"https://hartvaat.nl/mensen/david-a-wood/","name":"David A Wood","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/06/27/tavr-bij-patienten-65-jaar-hogere-sterfte-en-heropnames-dan-chirurgie-maar-onvol/","published":"2026-08-04"},{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2024/06/06/smart-zelf-expanderend-versus-ballonexpandeerbaar-tavr-bij-kleine-annulus-nejm/","published":"2024-06-06"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/08/01/complete-versus-culprit-only-revascularisatie-bij-stemi-jama-cardiology-meta-ana/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2016/10/14/2016-esc-eas-richtlijn-voor-het-management-van-dyslipidemieen/","published":"2016-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"douglas-l-mann","type":"person","url":"https://hartvaat.nl/mensen/douglas-l-mann/","name":"Douglas L Mann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2019/04/01/icd-mortaliteit-naar-hartfalenetiologie-propensity-matched-analyse/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","published":"2018-11-06"},{"url":"https://hartvaat.nl/2018/10/01/linkeratriumvolume-en-cv-uitkomsten-bij-systolisch-hf-antitromboticaeffect/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2016/08/02/liraglutide-en-klinische-stabiliteit-bij-gevorderd-hartfalen-met-verminderde-ef-/","published":"2016-08-02"},{"url":"https://hartvaat.nl/2016/07/12/nervus-vagus-stimulatie-bij-hartfalen-de-inovate-hf-trial/","published":"2016-07-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"douglas-l-packer","type":"person","url":"https://hartvaat.nl/mensen/douglas-l-packer/","name":"Douglas L Packer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/12/01/comorbiditeitsbelasting-en-uitkomsten-van-ablatie-versus-medicatie-bij-af/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","published":"2022-08-16"},{"url":"https://hartvaat.nl/2022/03/15/leeftijd-en-uitkomsten-van-katheterablatie-versus-medicatie-bij-af-cabana/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/07/18/cryoballonablatie-versus-antiaritmica-als-eerstelijns-paf-therapie/","published":"2021-07-18"},{"url":"https://hartvaat.nl/2021/07/13/ablatie-versus-medicatie-bij-af-naar-ras-en-etniciteit/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2020/07/28/langetermijn-icd-uitkomsten-scd-heft/","published":"2020-07-28"},{"url":"https://hartvaat.nl/2020/06/30/af-recidief-na-ablatie-versus-antiaritmica-in-cabana/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-medicamenteus-bij-af-en-kwaliteit-van-leven-jama-cabana-q/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-michiel-voskuil","type":"person","url":"https://hartvaat.nl/mensen/dr-michiel-voskuil/","name":"Dr. Michiel Voskuil","title":"UMC Utrecht, Nederland","dutch_institution":true,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/04/16/pandora-register-supra-versus-intra-annulaire-kleppen-bij-tavr-in-tavr/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2020/12/01/coronairangiografie-na-hartstilstand-zonder-st-elevatie-coact-1-jaarsuitkomsten/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/04/25/clopidogrel-versus-ticagrelor-of-prasugrel-bij-70-plussers-met-nste-acs-lancet-p/","published":"2020-04-25"},{"url":"https://hartvaat.nl/2019/10/01/bloeddruk-na-stenting-bij-aortacoarctatie-systematische-review-en-meta-analyse/","published":"2019-10-01"},{"url":"https://hartvaat.nl/2019/04/11/coronairangiografie-na-hartstilstand-zonder-st-elevatie-nejm-coact/","published":"2019-04-11"},{"url":"https://hartvaat.nl/2019/01/02/permanente-versus-polymeervrije-des-all-comers-gerandomiseerde-trial/","published":"2019-01-02"},{"url":"https://hartvaat.nl/2017/04/01/medicatietrouw-en-het-effect-van-renale-denervatie-de-sympathy-trial/","published":"2017-04-01"}],"videos":[{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/pro-tavi-pci-bij-tavi-late-breaker/","title":"PRO-TAVI: Routinematige PCI bij TAVI — nodig of niet?"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eun-seok-shin","type":"person","url":"https://hartvaat.nl/mensen/eun-seok-shin/","name":"Eun-Seok Shin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/05/01/aspirine-versus-clopidogrel-na-coronaire-stenting-naar-bloedingsrisico-en-comple/","published":"2025-05-01"},{"url":"https://hartvaat.nl/2025/04/26/angiografie-afgeleide-ffr-versus-ivus-bij-pci-gerandomiseerde-trial/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2025/01/07/dcb-voor-zijtak-bij-provisionale-stenting-gerandomiseerde-trial/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2023/10/17/antiplaatjesmonotherapie-na-pci-clopidogrel-versus-aspirine-naar-risicoprofiel/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/01/10/host-exam-extended-clopidogrel-superieur-aan-aspirine-als-monotherapie-na-pci/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/10/09/ongeleide-de-escalatie-van-ticagrelor-naar-clopidogrel-na-mi-met-pci-lancet-talo/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2021/06/26/aspirine-versus-clopidogrel-voor-chronische-monotherapie-na-pci-lancet-host-exam/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fabrizio-d-ascenzo","type":"person","url":"https://hartvaat.nl/mensen/fabrizio-d-ascenzo/","name":"Fabrizio D'Ascenzo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/05/19/salamander-register-95-5-technisch-succes-bij-stand-alone-linker-hartoor-occlusi/","published":"2026-06-10"},{"url":"https://hartvaat.nl/2025/11/11/ct-angiografie-of-standaardzorg-na-pci-van-de-linker-hoofdstam/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/04/01/sacubitril-valsartan-na-acuut-mi-meta-analyse-van-in-hospital-initiatie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/10/01/crt-bij-inotroop-afhankelijk-hartfalen-meta-analyse/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2020/11/07/complete-revascularisatie-vermindert-cv-dood-bij-stemi-met-multivatenlijden-meta/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2019/02/01/geautomatiseerde-praktijkmeting-versus-andere-bloeddrukmeetmethoden/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/08/01/farmacologische-behandeling-van-hypertensie-bij-kinderen-netwerkmeta-analyse/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/11/07/stentontwerp-en-dapt-duur-effect-op-ischemie-en-bloedingen-netwerkmeta-analyse/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2017/05/30/tijdstrends-in-complicaties-van-bioresorbeerbare-versus-metallic-stents/","published":"2017-05-30"},{"url":"https://hartvaat.nl/2017/03/14/drie-arteriele-grafts-verbeteren-langetermijnoverleving-meta-analyse-van-propens/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/12/21/statines-voor-primaire-preventie-bij-hiv-positieve-patienten-systematische-revie/","published":"2016-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fady-i-malik","type":"person","url":"https://hartvaat.nl/mensen/fady-i-malik/","name":"Fady I Malik","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/03/05/aficamten-veilig-en-effectief-bij-langdurige-behandeling-van-obstructieve-hcm/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2026/01/05/magnesium-en-uitkomsten-bij-hfref-galactic-hf-subanalyse/","published":"2026-01-05"},{"url":"https://hartvaat.nl/2025/10/07/nieuwe-inspanningsherstelpatronen-als-maat-voor-cardiale-prestatie/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2016/12/10/omecamtiv-mecarbil-bij-chronisch-hartfalen-lancet-cosmic-hf-fase-2-trial/","published":"2016-12-10"},{"url":"https://hartvaat.nl/2016/03/29/omecamtiv-mecarbil-bij-acuut-hartfalen-de-atomic-ahf-studie/","published":"2016-03-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fausto-j-pinto","type":"person","url":"https://hartvaat.nl/mensen/fausto-j-pinto/","name":"Fausto J Pinto","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-vasculaire-preventie-meta-analyse-van-lange-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2023/11/01/beta3-lvh-mirabegron-bij-linkerventrikel-hypertrofie-fase-2b-rct/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/03/01/griepvaccinatie-bij-hartfalen-meta-analyse-van-observationele-studies/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fernando-alfonso","type":"person","url":"https://hartvaat.nl/mensen/fernando-alfonso/","name":"Fernando Alfonso","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2025/07/28/routine-invasieve-strategie-en-herinfarctrisico-bij-fragiele-ouderen-met-nste-ac/","published":"2025-07-28"},{"url":"https://hartvaat.nl/2025/05/02/paclitaxel-gecoate-ballonnen-versus-des-bij-kleine-vaten-ipd-meta-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2021/12/01/thin-cap-fibroatheroom-voorspelt-events-bij-diabetes-met-normale-ffr-combine-oct/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2019/12/03/magnesium-resorbeerbare-scaffold-versus-metallic-stent-bij-stemi-biosolve-iii/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/01/07/bioresorbeerbare-scaffold-versus-ees-bij-stabiel-coronairlijden-prospectieve-tri/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2016/11/26/oct-versus-ivus-versus-angiografie-bij-coronaire-stentimplantatie-lancet-ilumien/","published":"2016-11-26"},{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","published":"2016-06-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frank-edelmann","type":"person","url":"https://hartvaat.nl/mensen/frank-edelmann/","name":"Frank Edelmann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/02/03/kenmerken-van-asymptomatische-patienten-met-hartfalen-en-verminderde-ejectiefrac/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2023/11/01/beta3-lvh-mirabegron-bij-linkerventrikel-hypertrofie-fase-2b-rct/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2021/12/01/baseline-parameters-en-1-jaars-qol-bij-hf-na-crt-d-esc-hf/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/02/09/hiit-matig-continu-of-richtlijnadvies-en-piek-vo2-bij-hfref-jama-smartex-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/06/01/economische-impact-van-hfpef-aldo-dhf-inzichten/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2018/09/22/telemedische-interventie-bij-hartfalen-lancet-tim-hf2/","published":"2018-09-22"},{"url":"https://hartvaat.nl/2018/02/01/hoeveelheid-of-intensiteit-van-inspanning-bij-hfpef/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/06/28/escitalopram-bij-hartfalen-en-depressie-de-mood-hf-trial/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francois-roubille","type":"person","url":"https://hartvaat.nl/mensen/francois-roubille/","name":"François Roubille","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/08/18/tafamidis-bij-attr-cardiomyopathie-kosteffectiviteit-onder-de-maat-in-vier-europ/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/03/06/laminopathieen-natuurlijk-beloop-en-voorspelmodel-voor-hartfalen/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-vasculaire-preventie-meta-analyse-van-lange-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2021/11/09/ffr-voor-behandeling-van-multivatencoronairlijden-jacc/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/10/01/crp-sst2-en-gdf-15-multimarker-voor-prognostische-stratificatie-bij-stabiel-hf/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/04/01/sst2-voor-hartfalenmanagement-stade-hf-pilotstudie/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"},{"url":"https://hartvaat.nl/2016/04/26/vroege-aldosteronblokkade-bij-acuut-myocardinfarct-de-albatross-trial/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"georg-fuernau","type":"person","url":"https://hartvaat.nl/mensen/georg-fuernau/","name":"Georg Fuernau","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2023/03/28/culprit-interventie-bij-cardiogene-shock-met-hartstilstand/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/04/21/morfine-met-metoclopramide-en-ticagrelor-plaatjesremming-bij-acuut-mi/","published":"2020-04-21"},{"url":"https://hartvaat.nl/2019/01/22/milde-hypothermie-bij-cardiogene-shock-complicerend-mi/","published":"2019-01-22"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/12/14/mechanische-ondersteuning-bij-cardiogene-shock-systematische-review-en-meta-anal/","published":"2017-12-14"},{"url":"https://hartvaat.nl/2017/08/01/des-versus-bms-bij-acuut-mi-met-cardiogene-shock/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/04/18/risicostratificatie-bij-cardiogene-shock-na-acuut-myocardinfarct/","published":"2017-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gerd-hasenfuss","type":"person","url":"https://hartvaat.nl/mensen/gerd-hasenfuss/","name":"Gerd Hasenfuß","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/05/05/reduce-mfa-dzhk25-trial-naar-antifibrotische-therapie-tegen-myocardfibrose-na-ta/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2026/02/03/kenmerken-van-asymptomatische-patienten-met-hartfalen-en-verminderde-ejectiefrac/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/12/01/baseline-parameters-en-1-jaars-qol-bij-hf-na-crt-d-esc-hf/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/06/01/economische-impact-van-hfpef-aldo-dhf-inzichten/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2018/02/01/hoeveelheid-of-intensiteit-van-inspanning-bij-hfpef/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gerry-p-mccann","type":"person","url":"https://hartvaat.nl/mensen/gerry-p-mccann/","name":"Gerry P McCann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2025/01/21/evolved-vroege-interventie-bij-asymptomatische-ernstige-aortastenose-met-myocard/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2024/03/12/rapid-nstemi-zeer-vroege-invasieve-strategie-bij-hoger-risico-nstemi/","published":"2024-03-12"},{"url":"https://hartvaat.nl/2022/09/01/timing-van-invasieve-strategie-bij-nste-acs-meta-analyse-van-rct-s/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/01/01/sglt2-remmers-over-het-cv-ziektespectrum-overzicht/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2020/03/31/laaggedoseerde-alteplase-bij-primaire-pci-naar-ischemietijd/","published":"2020-03-31"},{"url":"https://hartvaat.nl/2019/12/24/langetermijnfollow-up-van-complete-versus-laesie-only-revascularisatie-bij-stemi/","published":"2019-12-24"},{"url":"https://hartvaat.nl/2018/12/01/dagelijkse-remote-ischemische-conditionering-na-acuut-mi-gerandomiseerde-trial/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2016/06/21/strategieen-om-microvasculaire-obstructie-te-verminderen-bij-primaire-pci-relief/","published":"2016-06-21"},{"url":"https://hartvaat.nl/2016/06/07/ischemie-en-infarct-bij-stemi-met-multivatenlijden-cvlprit-nucleaire-substudie/","published":"2016-06-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gianluigi-savarese","type":"person","url":"https://hartvaat.nl/mensen/gianluigi-savarese/","name":"Gianluigi Savarese","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2026/03/03/tien-jaar-real-world-sacubitril-valsartan-mortaliteitsreductie-bevestigd-maar-sl/","published":"2026-04-20"},{"url":"https://hartvaat.nl/2026/03/27/nt-probnp-afkapwaarden-voor-hartfalentrials-optimaliseren-swedehf/","published":"2026-03-27"},{"url":"https://hartvaat.nl/2026/03/17/langetermijneffecten-van-sacubitril-valsartan-bij-hfref-italiaanse-real-world-st/","published":"2026-03-17"},{"url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2026/02/03/vroeg-starten-met-mra-na-acuut-hartfalen-of-myocardinfarct-meta-analyse/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2026/02/03/semaglutide-versus-tirzepatide-bij-patienten-met-obesitas-en-hfpef/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2024/08/01/coronaire-microvasculaire-disfunctie-bij-hfpef-meta-analyse/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2023/04/01/intraveneus-ijzer-bij-hartfalen-meta-analyse-op-studieniveau/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gilles-r-dagenais","type":"person","url":"https://hartvaat.nl/mensen/gilles-r-dagenais/","name":"Gilles R Dagenais","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2023/08/24/vaste-dosiscombinatietherapie-voor-primaire-cv-preventie-ipd-meta-analyse/","published":"2023-08-24"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/07/08/cv-uitkomsten-bij-diabetes-met-vastgesteld-of-hoog-risico-coronairlijden-dulaglu/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/07/01/cv-gevolgen-van-stoppen-met-laaggedoseerd-rivaroxaban-bij-chronisch-vaatlijden/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giuseppe-gargiulo","type":"person","url":"https://hartvaat.nl/mensen/giuseppe-gargiulo/","name":"Giuseppe Gargiulo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/01/01/antistolling-alleen-of-met-plaatjesremming-bij-coronairlijden-meta-analyse/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/02/02/dalend-hemoglobine-en-prognose-bij-acs-hospitalisatie/","published":"2021-02-02"},{"url":"https://hartvaat.nl/2021/01/21/korte-dapt-gevolgd-door-p2y12-mono-versus-verlengde-dapt-meta-analyse/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2020/08/04/cangrelor-tirofiban-en-prasugrel-bij-stemi-primaire-resultaten/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2019/12/07/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-veiligheid-en-werk/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2019/10/12/edoxaban-versus-vka-gebaseerd-antitrombotisch-regime-na-stenting-bij-af-lancet-e/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/10/14/tmao-als-cardiovasculaire-risicobiomarker-systematische-review-en-meta-analyse/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2016/10/01/langere-versus-korte-dapt-na-pci-met-en-zonder-periprocedureel-mi-jama-cardiolog/","published":"2016-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gunter-breithardt","type":"person","url":"https://hartvaat.nl/mensen/gunter-breithardt/","name":"Günter Breithardt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2023/01/24/axadia-afnet-8-apixaban-versus-vka-bij-af-op-hemodialyse/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","published":"2022-09-13"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2016/07/05/verslechterende-nierfunctie-en-uitkomsten-met-rivaroxaban-versus-warfarine-rocke/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/07/01/natief-kleplijden-bij-af-patienten-op-warfarine-of-rivaroxaban/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/01/26/polyfarmacie-en-werkzaamheid-van-rivaroxaban-versus-warfarine-bij-atriumfibrille/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hans-erik-botker","type":"person","url":"https://hartvaat.nl/mensen/hans-erik-botker/","name":"Hans Erik Bøtker","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2020/02/14/danami-2-16-jaarsfollow-up-primaire-pci-versus-fibrinolyse/","published":"2020-02-14"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","published":"2019-10-19"},{"url":"https://hartvaat.nl/2019/04/30/ketonlichaam-3-hydroxybutyraat-bij-chronisch-hartfalen-cardiovasculaire-effecten/","published":"2019-04-30"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/07/01/remote-ischemische-conditionering-en-vertraging-van-het-zorgsysteem-bij-stemi/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hyeon-cheol-gwon","type":"person","url":"https://hartvaat.nl/mensen/hyeon-cheol-gwon/","name":"Hyeon-Cheol Gwon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2020/05/05/des-versus-cabg-bij-linker-hoofdstam-10-jaarsresultaten-excel-extended/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"james-lay-flurrie","type":"person","url":"https://hartvaat.nl/mensen/james-lay-flurrie/","name":"James Lay-Flurrie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jan-steffel","type":"person","url":"https://hartvaat.nl/mensen/jan-steffel/","name":"Jan Steffel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/09/01/eldercare-af-subanalyse-dosisreductie-edoxaban-bij-80-jarigen-met-af/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/03/09/halve-versus-volle-dosis-edoxaban-bij-af-gerandomiseerde-vergelijking/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2019/02/01/edoxaban-en-implanteerbare-cardiale-devices-engage-af-timi-48/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/08/01/2018-ehra-praktische-gids-doac-s-bij-af-europace-editie/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/04/21/2018-ehra-praktische-gids-voor-doac-gebruik-bij-af/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2016/09/13/edoxaban-versus-warfarine-bij-af-patienten-met-valrisico-engage-af-timi-48-analy/","published":"2016-09-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeffrey-m-testani","type":"person","url":"https://hartvaat.nl/mensen/jeffrey-m-testani/","name":"Jeffrey M Testani","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/04/27/nierfunctiestoornis-verergert-pulmonale-vaatziekte-bij-hfpef/","published":"2026-07-16"},{"url":"https://hartvaat.nl/2026/03/23/clorotic-subanalyse-acute-egfr-daling-door-thiaziden-bij-acuut-hf-is-geen-progno/","published":"2026-04-21"},{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2024/09/24/dapagliflozine-verbetert-arteriele-en-veneuze-compliantie-bij-hfpef/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2023/01/17/transform-hf-torsemide-biedt-geen-overlevingsvoordeel-boven-furosemide/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/09/15/empagliflozine-bij-hartfalen-diuretische-en-cardiorenale-effecten/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2018/05/08/nierfunctieverslechtering-bij-acuut-hartfalen-met-agressieve-diurese-geen-tubula/","published":"2018-05-08"},{"url":"https://hartvaat.nl/2016/05/17/verminderde-cardiac-index-is-niet-de-primaire-oorzaak-van-nierdisfunctie-bij-har/","published":"2016-05-17"},{"url":"https://hartvaat.nl/2016/01/26/langketen-acylcarnitines-bij-hartfalen-prognostische-waarde-en-reversibiliteit-m/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeroen-j-bax","type":"person","url":"https://hartvaat.nl/mensen/jeroen-j-bax/","name":"Jeroen J Bax","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/03/28/gestandaardiseerd-stappenplan-voor-tricuspidalisinsufficientie-van-verwijzing-to/","published":"2026-04-19"},{"url":"https://hartvaat.nl/2026/01/13/risicofactoren-en-plaquevolume-op-coronaire-ct-angiografie-lessen-uit-het-advanc/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2022/06/21/mri-geleide-fibroseablatie-versus-conventionele-ablatie-bij-persisterend-af/","published":"2022-06-21"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2018/03/27/crt-bij-hartfalen-met-smal-qrs-complex/","published":"2018-03-27"},{"url":"https://hartvaat.nl/2017/03/07/lv-global-longitudinal-strain-en-prognose-bij-hartfalen-met-smal-qrs-en-crt/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2016/02/01/peri-infarctpacing-ter-preventie-van-linkerkamerremodellering-na-groot-myocardin/","published":"2016-02-01"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"},{"url":"https://hartvaat.nl/2016/01/01/persisterende-echocardiografische-dyssynchronie-voorspelt-ongunstige-uitkomsten-/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jin-ok-jeong","type":"person","url":"https://hartvaat.nl/mensen/jin-ok-jeong/","name":"Jin-Ok Jeong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/03/25/bmi-en-prognose-bij-acuut-hartfalen-verschillen-per-fenotype-en-geslacht/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","published":"2025-11-08"},{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2025/06/17/spironolacton-versus-amiloride-bij-resistente-hypertensie-gerandomiseerde-trial/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","published":"2024-05-04"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jing-chen","type":"person","url":"https://hartvaat.nl/mensen/jing-chen/","name":"Jing Chen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/08/26/glp-1-receptoragonisten-verlagen-nierkankerrisico-na-metabole-bariatrische-chiru/","published":"2026-09-02"},{"url":"https://hartvaat.nl/2026/02/01/antihypertensieve-behandeling-na-acuut-ischemisch-cva-continueren-of-niet/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/10/14/heparine-bij-eerste-medisch-contact-versus-voor-primaire-pci-bij-stemi/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2024/09/01/nieuwe-metabolieten-geassocieerd-met-bloeddrukrespons-op-dieetinterventies/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/05/11/ivus-acs-ivus-geleide-pci-bij-acs-superieur-lancet/","published":"2024-05-11"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2021/05/05/intensieve-bloeddruk-en-aortastijfheid-sprint-heart/","published":"2021-05-05"},{"url":"https://hartvaat.nl/2021/04/01/intensieve-versus-standaard-bloeddruk-op-cva-subtypes-sprint/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2017/09/19/community-health-worker-interventie-voor-bloeddrukcontrole-in-argentina-jama-tri/","published":"2017-09-19"},{"url":"https://hartvaat.nl/2017/07/01/systolische-bloeddrukreductie-en-cv-risico-netwerkmeta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/03/01/taurinesuppletie-verlaagt-bloeddruk-en-verbetert-vaatfunctie-bij-prehypertensie/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joanna-j-wykrzykowska","type":"person","url":"https://hartvaat.nl/mensen/joanna-j-wykrzykowska/","name":"Joanna J Wykrzykowska","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2017/06/15/bioresorbeerbare-scaffolds-versus-metallic-stents-bij-routine-pci-nejm-aida/","published":"2017-06-15"},{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-circulatoire-ondersteuning-versus-iabp-bij-cardiogene-shoc/","published":"2017-01-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-p-greenwood","type":"person","url":"https://hartvaat.nl/mensen/john-p-greenwood/","name":"John P Greenwood","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/01/21/evolved-vroege-interventie-bij-asymptomatische-ernstige-aortastenose-met-myocard/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/03/12/rapid-nstemi-zeer-vroege-invasieve-strategie-bij-hoger-risico-nstemi/","published":"2024-03-12"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2022/10/13/revived-bcis2-pci-verbetert-overleving-niet-bij-ischemische-lv-disfunctie/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2020/07/21/levothyroxine-bij-subklinische-hypothyreoidie-na-acuut-mi-jama/","published":"2020-07-21"},{"url":"https://hartvaat.nl/2020/03/31/laaggedoseerde-alteplase-bij-primaire-pci-naar-ischemietijd/","published":"2020-03-31"},{"url":"https://hartvaat.nl/2019/12/24/langetermijnfollow-up-van-complete-versus-laesie-only-revascularisatie-bij-stemi/","published":"2019-12-24"},{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","published":"2019-10-19"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2016/06/21/strategieen-om-microvasculaire-obstructie-te-verminderen-bij-primaire-pci-relief/","published":"2016-06-21"},{"url":"https://hartvaat.nl/2016/06/07/vitamine-d-bij-chronisch-hartfalen-de-vindicate-studie/","published":"2016-06-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-p-h-wilding","type":"person","url":"https://hartvaat.nl/mensen/john-p-h-wilding/","name":"John P H Wilding","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/08/14/cagrisema-gecombineerd-cagrilintide-en-semaglutide-bij-overgewicht-nejm/","published":"2025-08-14"},{"url":"https://hartvaat.nl/2022/09/01/dapagliflozine-effectief-ongeacht-cv-achtergrondmedicatie-declare-subanalyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joseph-l-witztum","type":"person","url":"https://hartvaat.nl/mensen/joseph-l-witztum/","name":"Joseph L Witztum","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-familiaire-chylomicronemie-nejm-fase-3/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2022/03/22/pelacarsen-op-lp-a-cholesterol-en-gecorrigeerd-ldl-cholesterol/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2020/10/21/vupanorsen-angptl3-antisense-en-triglyceriden-ehj/","published":"2020-10-21"},{"url":"https://hartvaat.nl/2020/06/21/statinetherapie-verhoogt-lipoproteine-a-spiegels/","published":"2020-06-21"},{"url":"https://hartvaat.nl/2020/01/16/lp-a-verlaging-bij-cardiovasculaire-ziekte-nejm/","published":"2020-01-16"},{"url":"https://hartvaat.nl/2019/09/01/galnac-geconjugeerd-antisense-tegen-apoc3-triglyceriden-en-atherogene-lipoprotei/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/08/volanesorsen-en-triglyceriden-bij-familiair-chylomicronemiesyndroom-nejm/","published":"2019-08-08"},{"url":"https://hartvaat.nl/2017/07/20/angptl3-antisense-oligonucleotiden-cardiovasculaire-en-metabole-effecten-nejm/","published":"2017-07-20"},{"url":"https://hartvaat.nl/2017/01/17/geoxideerde-fosfolipiden-op-apob-100-en-recidiverende-ischemische-events-na-cva/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karina-w-davidson","type":"person","url":"https://hartvaat.nl/mensen/karina-w-davidson/","name":"Karina W Davidson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"},{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","published":"2017-07-11"},{"url":"https://hartvaat.nl/2016/11/15/statines-voor-primaire-cardiovasculaire-preventie-uspstf-aanbeveling/","published":"2016-11-15"},{"url":"https://hartvaat.nl/2016/08/09/lipidescreening-bij-kinderen-en-adolescenten-uspstf-aanbeveling/","published":"2016-08-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karl-heinz-kuck","type":"person","url":"https://hartvaat.nl/mensen/karl-heinz-kuck/","name":"Karl-Heinz Kuck","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/05/02/style-af-veneuze-closure-device-versus-figuur-van-acht-hechting-na-af-ablatie/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","published":"2022-09-13"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2021/03/08/katheterablatie-om-af-progressie-te-vertragen-attest-gerandomiseerde-trial/","published":"2021-03-08"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/10/01/lage-arteriele-compliance-en-cv-morbiditeit-bij-aortaklepstenose/","published":"2019-10-01"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2016/10/07/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-af-herinterventierate-e/","published":"2016-10-07"},{"url":"https://hartvaat.nl/2016/06/09/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-atriumfibrilleren-nejm-/","published":"2016-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"laurent-macle","type":"person","url":"https://hartvaat.nl/mensen/laurent-macle/","name":"Laurent Macle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","published":"2024-02-16"},{"url":"https://hartvaat.nl/2023/05/30/complicaties-van-af-ablatie-actueel-overzicht/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2021/11/01/af-last-en-qol-na-af-ablatie-cabana-substudie/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"},{"url":"https://hartvaat.nl/2020/02/01/elektrische-versus-farmacologische-cardioversie-bij-acuut-af-op-de-seh-lancet-ra/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/11/26/cryoballon-versus-rf-ablatie-bij-af-beoordeeld-met-continue-monitoring-cryo-firs/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"luigi-di-biase","type":"person","url":"https://hartvaat.nl/mensen/luigi-di-biase/","name":"Luigi Di Biase","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2021/02/05/laa-isolatie-tijdens-af-ablatie-geactualiseerde-meta-analyse/","published":"2021-02-05"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2018/10/01/ononderbroken-doac-versus-vka-bij-af-ablatie-meta-analyse/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/08/01/linker-hartoorisolatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/01/01/axafa-afnet-5-apixaban-versus-vka-bij-af-ablatie-studieprotocol/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/11/01/linker-hartoorisolatie-bij-langdurig-persisterend-af-de-belief-trial/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/26/ablatie-versus-amiodaron-bij-persisterend-af-met-hartfalen-en-icd-gerandomiseerd/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"luis-m-ruilope","type":"person","url":"https://hartvaat.nl/mensen/luis-m-ruilope/","name":"Luis M Ruilope","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2025/02/01/finerenon-en-lvh-bij-ckd-en-diabetes/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2022/12/01/finerenon-bloeddrukeffecten-en-cardiorenale-uitkomsten-bij-ckd-en-diabetes/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/02/10/finerenon-cv-en-renale-uitkomsten-bij-diabetes-met-ckd-fidelity-gepoolde-analyse/","published":"2022-02-10"},{"url":"https://hartvaat.nl/2022/02/08/finerenon-vermindert-incident-hf-bij-ckd-met-diabetes-fidelity/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/12/09/finerenon-bij-nierziekte-met-diabetes-type-2-nejm-figaro-dkd/","published":"2021-12-09"},{"url":"https://hartvaat.nl/2021/12/01/acute-aerobe-training-en-kortdurende-ambulante-bloeddrukreductie-bij-hypertensie/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/07/13/finerenon-vermindert-nieuw-onset-af-bij-ckd-met-diabetes-fidelio-dkd/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/02/09/finerenon-en-cardiovasculaire-uitkomsten-bij-ckd-met-diabetes-type-2-fidelio-dkd/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2018/10/01/prognostische-waarde-van-gemaskeerd-ongecontroleerde-hypertensie/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lynne-warner-stevenson","type":"person","url":"https://hartvaat.nl/mensen/lynne-warner-stevenson/","name":"Lynne Warner Stevenson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2024/09/24/2024-acc-beslispad-klinische-beoordeling-en-trajectmanagement-bij-hfpef/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2018/06/01/maatschappelijk-werker-palliatieve-zorg-bij-hoogrisico-hf-swap-hf-pilot/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/10/10/pulmonalisdrukgeleide-therapie-bij-hfref/","published":"2017-10-10"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/07/05/advance-care-planning-video-bij-gevorderd-hartfalen-gerandomiseerde-trial/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/01/30/hemodynamische-telemonitoring-bij-chronisch-hartfalen-volledige-champion-resulta/","published":"2016-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marc-r-dweck","type":"person","url":"https://hartvaat.nl/mensen/marc-r-dweck/","name":"Marc R Dweck","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","published":"2025-01-25"},{"url":"https://hartvaat.nl/2025/01/21/evolved-vroege-interventie-bij-asymptomatische-ernstige-aortastenose-met-myocard/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2020/08/01/inspannings-ecg-versus-ccta-bij-stabiele-angina-post-hoc-vergelijking/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/05/05/laag-attenuatie-plaque-op-ccta-voorspelt-mi-scot-heart-resultaten/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/01/29/coronaire-plaquekenmerken-en-adverse-uitkomsten-scot-heart/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","published":"2018-09-06"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"}],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/implementatie-lipidenmanagement/","title":"Sessie 4: Implementatie van lipidenmanagement — praktische uitdagingen"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"markus-p-schlaich","type":"person","url":"https://hartvaat.nl/mensen/markus-p-schlaich/","name":"Markus P Schlaich","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/03/07/baxdrostat-verlaagt-bloeddruk-significant-bij-resistente-hypertensie/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/03/07/bax24-baxdrostat-en-ambulante-bloeddruk-bij-resistente-hypertensie/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2026/02/01/aprocitentan-bij-ckd-en-resistente-hypertensie/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/04/01/aprocitentan-bij-zwarte-patienten-met-hypertensie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2024/06/01/renale-denervatie-langetermijn-bloeddrukeffect-bevestigd-meta-analyse/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2022/12/03/precision-aprocitentan-bij-resistente-hypertensie-eerste-endothelineantagonist/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","published":"2021-09-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-m-givertz","type":"person","url":"https://hartvaat.nl/mensen/michael-m-givertz/","name":"Michael M Givertz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/02/23/aspirinestop-bij-lvad-met-vka-veiligheidsanalyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2019/01/08/cva-analyse-in-momentum-3-langetermijncohort/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","published":"2018-11-06"},{"url":"https://hartvaat.nl/2017/10/10/pulmonalisdrukgeleide-therapie-bij-hfref/","published":"2017-10-10"},{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/05/16/oraal-ijzer-bij-hfref-met-ijzerdeficientie-jama-ironout-hf/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/08/02/liraglutide-en-klinische-stabiliteit-bij-gevorderd-hartfalen-met-verminderde-ef-/","published":"2016-08-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-miller","type":"person","url":"https://hartvaat.nl/mensen/michael-miller/","name":"Michael Miller","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2024/04/23/lp-a-en-cv-risicoreductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/04/01/icosapent-ethyl-na-acs-reduce-it-subanalyse/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","published":"2022-08-02"},{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/08/31/2021-acc-consensus-ascvd-risicoreductie-bij-persistente-hypertriglyceridemie/","published":"2021-08-31"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/01/03/icosapent-ethyl-en-cardiovasculaire-uitkomsten-bij-hypertriglyceridemie-nejm-red/","published":"2019-01-03"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michele-f-mercuri","type":"person","url":"https://hartvaat.nl/mensen/michele-f-mercuri/","name":"Michele F Mercuri","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2023/07/20/ni006-antilichaam-voor-afbraak-van-cardiale-transthyretine-amyloid-nejm-fase-1/","published":"2023-07-20"},{"url":"https://hartvaat.nl/2019/07/16/edoxaban-versus-warfarine-bij-af-met-leverziekte-engage-af-timi-48/","published":"2019-07-16"},{"url":"https://hartvaat.nl/2019/05/14/bmi-en-uitkomsten-bij-af-behandeld-met-edoxaban-of-warfarine-engage-af-timi-48/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/05/14/edoxaban-bij-aziatische-af-patienten-concentraties-en-anti-xa-activiteit/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/02/05/abc-scores-voor-cva-en-bloedingsrisico-bij-af-prestatieverbetering/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2019/02/01/edoxaban-en-implanteerbare-cardiale-devices-engage-af-timi-48/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/10/30/endogene-factor-xa-activiteit-en-edoxaban-farmacodynamische-marker-en-klinische-/","published":"2018-10-30"},{"url":"https://hartvaat.nl/2017/03/28/edoxaban-bij-af-met-bioprothese-hartkleppen-trombo-emboliepreventie/","published":"2017-03-28"},{"url":"https://hartvaat.nl/2017/03/21/kleplijden-en-edoxaban-versus-warfarine-bij-af-engage-af-timi-48/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2017/03/21/nieuwe-risicovoorspellingsscore-bij-af-voor-netto-klinisch-resultaat-engage-af-t/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/10/22/edoxaban-versus-enoxaparine-warfarine-bij-cardioversie-van-af-ensure-af-trial/","published":"2016-10-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mitchell-w-krucoff","type":"person","url":"https://hartvaat.nl/mensen/mitchell-w-krucoff/","name":"Mitchell W Krucoff","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/04/12/orbitale-atherectomie-versus-ballonangioplastie-voor-des-bij-ernstig-verkalkte-l/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/12/15/prehospitaal-gemalen-prasugrel-bij-stemi-gerandomiseerde-trial/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/10/22/implanteerbare-monitor-voor-snellere-behandeling-bij-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/04/23/implanteerbaar-cardiaal-alertsysteem-voor-vroege-herkenning-van-stemi/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2018/07/07/orbusneich-combo-stent-japan-usa-harmonee-gerandomiseerde-multicenter-trial/","published":"2018-07-07"},{"url":"https://hartvaat.nl/2016/08/16/bio-absorbeerbare-intracoronaire-matrix-ter-preventie-van-ventriculaire-remodell/","published":"2016-08-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nelson-wang","type":"person","url":"https://hartvaat.nl/mensen/nelson-wang/","name":"Nelson Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/01/01/consistentie-van-bloeddrukrespons-op-kaliumverrijkt-zout-ssass-subanalyse/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2025/08/30/bloeddrukverlagende-effectiviteit-van-antihypertensiva-en-combinaties-uitgebreid/","published":"2025-08-30"},{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/06/01/lage-dosis-drievoudige-viervoudige-combinatiepil-versus-monotherapie-bij-hyperte/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/03/01/korttermijn-bloeddrukmetingen-voorspellen-langetermijneffect-van-behandeling/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/06/01/lage-dosis-drievoudige-combinatietherapie-bij-hypertensie-triumph-secundaire-ana/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2020/11/01/lage-dosis-triple-combinatie-en-therapeutische-inertie-bij-hypertensie-jama-card/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2019/02/01/tricuspidalisinsufficientie-en-mortaliteit-onafhankelijk-van-ph-en-rechterventri/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/03/01/voorspellers-van-succesvolle-cto-pci-systematische-review-en-meta-analyse/","published":"2018-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicholas-m-pajewski","type":"person","url":"https://hartvaat.nl/mensen/nicholas-m-pajewski/","name":"Nicholas M Pajewski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukcontrole-en-cerebrale-small-vessel-disease-markers/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/09/01/troponine-nt-probnp-en-cognitieve-uitkomsten-in-sprint/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/07/01/leeftijdsbias-draagt-bij-aan-therapeutische-inertie-bij-bloeddrukmanagement/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2021/05/05/intensieve-bloeddruk-en-aortastijfheid-sprint-heart/","published":"2021-05-05"},{"url":"https://hartvaat.nl/2021/04/27/patientselectie-voor-intensieve-bloeddrukbehandeling-naar-voordeel-en-bijwerking/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2017/08/24/intensieve-bloeddrukbehandeling-en-patientgerapporteerde-uitkomsten-nejm-sprint-/","published":"2017-08-24"},{"url":"https://hartvaat.nl/2017/01/01/intensieve-versus-standaard-bloeddrukcontrole-op-ambulante-bloeddruk-sprint-resu/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/08/01/apol1-nierrisicovarianten-en-cerebrale-wittestoflaesies/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ole-de-backer","type":"person","url":"https://hartvaat.nl/mensen/ole-de-backer/","name":"Ole De Backer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/04/16/pandora-register-supra-versus-intra-annulaire-kleppen-bij-tavr-in-tavr/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/02/19/geleidingsstoornissen-na-transkatheter-aortaklepimplantatie/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2024/04/01/notion-10-jaar-tavr-versus-chirurgie-bij-laagrisico-aortastenose/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pedro-g-m-de-barros-e-silva","type":"person","url":"https://hartvaat.nl/mensen/pedro-g-m-de-barros-e-silva/","name":"Pedro G M de Barros E Silva","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/01/06/sacubitril-valsartan-versus-enalapril-bij-chagas-hartfalen/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/02/01/message-hf-geautomatiseerde-sms-na-hartfalenopname-verbetert-uitkomsten-niet/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2021/01/19/stoppen-versus-doorgaan-met-ace-remmers-arb-s-bij-gehospitaliseerde-patienten-ja/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2020/11/26/rivaroxaban-bij-af-met-bioprothese-mitralisklep-nejm-river/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2018/11/01/timing-van-atorvastatine-oplaaddosis-voor-pci-bij-acs-jama-cardiology/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/04/03/oplaaddosis-atorvastatine-voor-pci-jama-gerandomiseerde-trial/","published":"2018-04-03"},{"url":"https://hartvaat.nl/2017/10/14/multifacet-interventie-voor-oac-gebruik-bij-af-lancet-impact-af/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peggy-gao","type":"person","url":"https://hartvaat.nl/mensen/peggy-gao/","name":"Peggy Gao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2023/08/24/vaste-dosiscombinatietherapie-voor-primaire-cv-preventie-ipd-meta-analyse/","published":"2023-08-24"},{"url":"https://hartvaat.nl/2023/02/01/aspirine-en-cardiovasculaire-uitkomsten-bij-chronische-nierziekte/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/11/01/antiplaatjestherapie-bij-mi-zonder-obstructief-coronairlijden-minoca/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2018/01/09/risico-s-van-overinterpretatie-van-interimdata-lessen-uit-de-total-trial/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/01/10/trombusaspiratie-bij-stemi-individuele-patientdata-meta-analyse/","published":"2017-01-10"},{"url":"https://hartvaat.nl/2016/12/15/off-pump-versus-on-pump-cabg-5-jaarsresultaten-nejm-coronary-trial/","published":"2016-12-15"},{"url":"https://hartvaat.nl/2016/06/21/myocardiale-blush-en-microvasculaire-reperfusie-na-handmatige-trombectomie-bij-s/","published":"2016-06-21"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pierluigi-tricoci","type":"person","url":"https://hartvaat.nl/mensen/pierluigi-tricoci/","name":"Pierluigi Tricoci","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"},{"url":"https://hartvaat.nl/2017/08/01/voorspelling-van-bloedingsrisico-tijdens-dapt-na-acs/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/03/14/afweging-myocardinfarct-versus-bloedingstype-en-mortaliteit-na-acs-tra-2p-timi-5/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/04/19/trends-in-behandeling-en-uitkomsten-bij-nste-acs-naar-leeftijd/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prabhakar-viswanathan","type":"person","url":"https://hartvaat.nl/mensen/prabhakar-viswanathan/","name":"Prabhakar Viswanathan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prem-pais","type":"person","url":"https://hartvaat.nl/mensen/prem-pais/","name":"Prem Pais","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2023/08/24/vaste-dosiscombinatietherapie-voor-primaire-cv-preventie-ipd-meta-analyse/","published":"2023-08-24"},{"url":"https://hartvaat.nl/2023/02/01/aspirine-en-cardiovasculaire-uitkomsten-bij-chronische-nierziekte/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/11/01/antiplaatjestherapie-bij-mi-zonder-obstructief-coronairlijden-minoca/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/07/08/cv-uitkomsten-bij-diabetes-met-vastgesteld-of-hoog-risico-coronairlijden-dulaglu/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-marianna-fontana","type":"person","url":"https://hartvaat.nl/mensen/prof-marianna-fontana/","name":"Prof. Marianna Fontana","title":"Hoogleraar cardiologie, National Amyloidosis Centre, University College London, VK","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/08/26/vutrisiran-stabiliseert-rechterventrikel-functie-bij-attr-cardiomyopathie-helios/","published":"2026-09-03"},{"url":"https://hartvaat.nl/2026/06/22/cardiale-amyloidose-komt-frequent-voor-bij-hfpef-aortastenose-en-lvh-meta-analys/","published":"2026-08-10"},{"url":"https://hartvaat.nl/2026/05/27/multimodaal-ai-model-verhoogt-accuratesse-van-echo-diagnose-cardiale-amyloidose/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2025/02/25/ambulante-hf-verslechtering-bij-attr-cm-attr-act-subanalyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/02/25/ambulante-hartfalenverslechtering-bij-attr-cardiomyopathie-attr-act-analyse/","published":"2025-02-25"}],"videos":[{"url":"https://hartvaat.nl/video/hfa-2026-late-breaking-science/attribute-cm-outpatient-worsening-fontana/","title":"ATTRibute-CM — Acoramidis en poliklinische verslechtering van hartfalen"},{"url":"https://hartvaat.nl/video/hfa-2026-late-breaking-science/attribute-cm-peer-to-peer-fontana-lopez/","title":"ATTRibute-CM peer-to-peer — Van trial naar dagelijkse praktijk"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ramon-corbalan","type":"person","url":"https://hartvaat.nl/mensen/ramon-corbalan/","name":"Ramón Corbalán","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/09/25/edoxaban-versus-warfarine-bij-latijns-amerikaanse-af-patienten-engage-af-timi-48/","published":"2018-09-25"},{"url":"https://hartvaat.nl/2018/04/10/ezetimibe-bij-diabetes-versus-zonder-diabetes-improve-it-subanalyse/","published":"2018-04-10"},{"url":"https://hartvaat.nl/2016/08/01/eerder-clopidogrelgebruik-en-uitkomsten-bij-conservatief-behandeld-acs/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/07/26/atherotrombotische-risicostratificatie-en-vorapaxar-bij-stabiel-ischemisch-hartl/","published":"2016-07-26"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-jan-m-van-geuns","type":"person","url":"https://hartvaat.nl/mensen/robert-jan-m-van-geuns/","name":"Robert-Jan M van Geuns","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/01/27/pci-van-natief-coronairvat-versus-veneuze-graft-na-eerdere-cabg-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/05/14/prehospitale-troponine-voor-uitsluiting-nste-acs-gerandomiseerde-trial/","published":"2023-05-14"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"},{"url":"https://hartvaat.nl/2017/07/01/syntax-scores-en-uitkomsten-bij-diabetes-met-multivatenlijden-gepoolde-analyse/","published":"2017-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"salvatore-cassese","type":"person","url":"https://hartvaat.nl/mensen/salvatore-cassese/","name":"Salvatore Cassese","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/12/09/gepersonaliseerde-versus-standaard-dapt-duur-na-pci-gerandomiseerde-trial/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2023/04/17/in-stent-restenose-tienjaarsuitkomsten-plain-balloon-vs-dcb-vs-des-isar-desire-3/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2019/01/15/10-jaarsuitkomsten-van-drie-limus-eluting-stents-coating-vergelijking/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/07/bioresorbeerbare-scaffold-versus-ees-bij-stabiel-coronairlijden-prospectieve-tri/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2017/10/01/pci-versus-cabg-bij-linker-hoofdstamstenose-jama-cardiology-systematische-review/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/02/06/bioresorbeerbare-versus-metallic-stents-meta-analyse-van-gerandomiseerde-trials/","published":"2016-02-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"scott-d-berkowitz","type":"person","url":"https://hartvaat.nl/mensen/scott-d-berkowitz/","name":"Scott D Berkowitz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2023/12/12/voyager-pad-rivaroxaban-plus-aspirine-na-endovasculaire-revascularisatie-voor-pa/","published":"2023-12-12"},{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/07/01/cv-gevolgen-van-stoppen-met-laaggedoseerd-rivaroxaban-bij-chronisch-vaatlijden/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/01/01/rivaroxaban-plus-aspirine-bij-symptomatisch-pav-compass-subanalyse/","published":"2021-01-01"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2019/12/07/individueel-levenslang-voordeel-en-bloedingsrisico-van-rivaroxaban-plus-aspirine/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2016/08/01/hospitalisaties-bij-atriumfibrilleren-analyse-uit-rocket-af/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/07/05/verslechterende-nierfunctie-en-uitkomsten-met-rivaroxaban-versus-warfarine-rocke/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/07/01/natief-kleplijden-bij-af-patienten-op-warfarine-of-rivaroxaban/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/01/26/polyfarmacie-en-werkzaamheid-van-rivaroxaban-versus-warfarine-bij-atriumfibrille/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"seung-jun-lee","type":"person","url":"https://hartvaat.nl/mensen/seung-jun-lee/","name":"Seung-Jun Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","published":"2023-04-04"},{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"seung-woon-rha","type":"person","url":"https://hartvaat.nl/mensen/seung-woon-rha/","name":"Seung-Woon Rha","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/05/21/bij-coronaire-vasospasmen-zonder-significante-stenose-voorspelt-verhoogd-lp-a-ge/","published":"2026-06-08"},{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2023/01/10/host-exam-extended-clopidogrel-superieur-aan-aspirine-als-monotherapie-na-pci/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2022/11/22/ees-versus-cabg-bij-meervatslijden-langetermijn-follow-up-van-rct-s/","published":"2022-11-22"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"},{"url":"https://hartvaat.nl/2021/06/26/aspirine-versus-clopidogrel-voor-chronische-monotherapie-na-pci-lancet-host-exam/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2021/03/16/duurzame-versus-biodegradeerbare-polymer-des-bij-acs-meta-analyse/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/05/05/des-versus-cabg-bij-linker-hoofdstam-10-jaarsresultaten-excel-extended/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","published":"2019-04-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sheldon-e-litwin","type":"person","url":"https://hartvaat.nl/mensen/sheldon-e-litwin/","name":"Sheldon E Litwin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/09/09/summit-tirzepatide-effect-bij-hfpef-met-en-zonder-diabetes/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/06/01/humain-hfpef-nieuwe-metabole-accelerator-bij-obesitas-hfpef-rct/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/03/11/summit-tirzepatide-en-klinisch-traject-bij-hfpef-met-obesitas-langetermijn/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/01/30/summit-tirzepatide-bij-hfpef-met-obesitas-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/12/01/splanchnische-zenuwablatie-bij-hfpef-endovasculaire-benadering/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2019/11/26/interatriale-shunt-en-pulmonale-vaatfunctie-bij-hfpef/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2018/10/01/transcatheter-interatriale-shunt-bij-hfpef-1-jaarsresultaten/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/01/23/transcatheter-interatriale-shunt-bij-hfpef-reduce-lap-hf-i/","published":"2018-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sung-cheol-yun","type":"person","url":"https://hartvaat.nl/mensen/sung-cheol-yun/","name":"Sung-Cheol Yun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2024/12/05/edoxaban-bij-af-en-stabiel-coronairlijden-antitrombotische-monotherapie/","published":"2024-12-05"},{"url":"https://hartvaat.nl/2024/06/11/effort-ertugliflozine-bij-functionele-mitralisinsufficientie-en-hartfalen/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","published":"2024-05-04"},{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/11/22/ees-versus-cabg-bij-meervatslijden-langetermijn-follow-up-van-rct-s/","published":"2022-11-22"},{"url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","published":"2022-09-08"},{"url":"https://hartvaat.nl/2020/05/05/des-versus-cabg-bij-linker-hoofdstam-10-jaarsresultaten-excel-extended/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/12/03/klinisch-significante-bloedingen-met-ticagrelor-versus-clopidogrel-bij-koreaanse/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/03/12/arni-bij-functionele-mitralisklepinsufficientie/","published":"2019-03-12"},{"url":"https://hartvaat.nl/2016/04/19/statinebehandeling-en-plaquesamenstelling-dubbelblinde-gerandomiseerde-studie/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tamar-s-polonsky","type":"person","url":"https://hartvaat.nl/mensen/tamar-s-polonsky/","name":"Tamar S Polonsky","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/09/01/aspirinedosering-voor-secundaire-preventie-bij-mannen-versus-vrouwen/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2020/01/21/voedingscholesterol-en-cv-risico-aha-science-advisory/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/06/25/systematische-review-voor-de-2018-aha-acc-cholesterolrichtlijn-jacc/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/systematische-review-voor-de-2018-aha-acc-cholesterolrichtlijn/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-systematische-review-circulation/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/06/01/systematische-review-voor-de-2017-acc-aha-hypertensierichtlijn-hypertension-edit/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/05/15/systematische-review-voor-de-2017-acc-aha-hypertensierichtlijn/","published":"2018-05-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-a-zelniker","type":"person","url":"https://hartvaat.nl/mensen/thomas-a-zelniker/","name":"Thomas A Zelniker","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/05/05/dapa-hd-eerste-gerandomiseerde-studie-naar-dapagliflozin-bij-hemodialyse-patient/","published":"2026-06-29"},{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2022/08/30/biomarkers-voorspellen-complexe-coronaire-revascularisatie-in-fourier/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"timothy-collier","type":"person","url":"https://hartvaat.nl/mensen/timothy-collier/","name":"Timothy Collier","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2022/09/15/polypill-voor-secundaire-cardiovasculaire-preventie-secure-trial-in-nejm/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/02/01/spironolacton-en-collageenmetabolisme-biomarkers-bij-ongecontroleerde-hypertensi/","published":"2019-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tom-greene","type":"person","url":"https://hartvaat.nl/mensen/tom-greene/","name":"Tom Greene","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2025/10/28/prevent-vergelijkingen-voor-intensieve-versus-standaard-bloeddrukcontrole/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2023/07/01/leeftijdsbias-draagt-bij-aan-therapeutische-inertie-bij-bloeddrukmanagement/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/06/21/mri-geleide-fibroseablatie-versus-conventionele-ablatie-bij-persisterend-af/","published":"2022-06-21"},{"url":"https://hartvaat.nl/2021/04/27/patientselectie-voor-intensieve-bloeddrukbehandeling-naar-voordeel-en-bijwerking/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/10/08/dapagliflozine-bij-chronische-nierziekte-nejm-dapa-ckd/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"},{"url":"https://hartvaat.nl/2018/05/01/natriuminname-en-bloeddruk-varieren-met-energie-inname-dash-secundaire-analyse/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/01/09/diastolische-bloeddruk-en-intensieve-bloeddrukcontrole-sprint-analyse/","published":"2018-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vidal-essebag","type":"person","url":"https://hartvaat.nl/mensen/vidal-essebag/","name":"Vidal Essebag","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/02/20/vanish2-catheterablatie-versus-antiaritmica-bij-ventriculaire-tachycardie-nejm/","published":"2025-02-20"},{"url":"https://hartvaat.nl/2023/09/30/adaptresponse-adaptieve-versus-conventionele-crt-bij-hartfalen-lancet/","published":"2023-09-30"},{"url":"https://hartvaat.nl/2023/05/01/aware-uitgebreide-ablatie-vermindert-af-recidief-niet-boven-standaard-pvi/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2022/07/15/vt-ablatie-versus-antiaritmica-bij-myocardinfarct-locatie-maakt-uit/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"},{"url":"https://hartvaat.nl/2018/11/21/voortzetten-versus-onderbreken-doac-bij-device-chirurgie-bruise-control-2/","published":"2018-11-21"},{"url":"https://hartvaat.nl/2017/10/01/korte-dabigatran-onderbreking-voor-device-implantatie-re-ly-multicenterervaring/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/07/14/ablatie-versus-escalatie-van-antiaritmica-bij-ventriculaire-tachycardie-nejm-van/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xin-du","type":"person","url":"https://hartvaat.nl/mensen/xin-du/","name":"Xin Du","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukverlaging-bij-ongediagnosticeerde-hfpef-met-hoog-risico/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/06/13/frailteit-en-intensieve-bloeddrukcontrole-bij-diabetes/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2024/11/12/recaticimab-als-toevoeging-aan-statines-fase-3-remain-2/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-bij-acs-in-resource-beperkte-ziekenhuizen-jama-cardiology-/","published":"2019-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yong-joon-lee","type":"person","url":"https://hartvaat.nl/mensen/yong-joon-lee/","name":"Yong-Joon Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":11,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","published":"2023-04-04"},{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aaron-crowley","type":"person","url":"https://hartvaat.nl/mensen/aaron-crowley/","name":"Aaron Crowley","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2019/12/01/absorb-scaffold-5-jaarsresultaten-systematische-meta-analyse/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/04/23/hedendaagse-uitkomsten-na-cabg-voor-hoofdstamlijden/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/07/31/bnp-bij-linker-hoofdstamrevascularisatie-excel-analyse/","published":"2018-07-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aleksandr-voskoboinik","type":"person","url":"https://hartvaat.nl/mensen/aleksandr-voskoboinik/","name":"Aleksandr Voskoboinik","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/02/16/hoog-vermogen-korte-duur-versus-laag-vermogen-langere-duur-posteriore-ablatie-bi/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2020/01/02/alcoholonthouding-bij-drinkers-met-af-nejm-gerandomiseerde-trial/","published":"2020-01-02"},{"url":"https://hartvaat.nl/2018/07/01/rotorablatie-bij-atriumfibrilleren-systematische-review/","published":"2018-07-01"},{"url":"https://hartvaat.nl/2017/10/17/katheterablatie-versus-frequentiecontrole-bij-af-met-systolische-disfunctie-came/","published":"2017-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aletta-e-schutte","type":"person","url":"https://hartvaat.nl/mensen/aletta-e-schutte/","name":"Aletta E Schutte","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/10/01/esh-convenant-polshorloges-bloeddrukmeters-acceptabele-nauwkeurigheid-maar-klini/","published":"2026-09-02"},{"url":"https://hartvaat.nl/2025/12/09/aspree-cardiale-stress-en-bloeddrukmanagement-bij-ouderen/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/11/01/magnesiumsuppletie-en-bloeddruk-meta-analyse-van-rct-s/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/08/30/bloeddrukverlagende-effectiviteit-van-antihypertensiva-en-combinaties-uitgebreid/","published":"2025-08-30"},{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2024/10/01/lage-dosis-drievoudige-pil-versus-standaardzorg-bij-hypertensie-in-nigeria/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/06/01/lage-dosis-drievoudige-combinatietherapie-bij-hypertensie-triumph-secundaire-ana/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2020/06/01/2020-ish-mondiale-hypertensie-praktijkrichtlijnen/","published":"2020-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alfred-k-cheung","type":"person","url":"https://hartvaat.nl/mensen/alfred-k-cheung/","name":"Alfred K Cheung","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2021/03/01/kdigo-2021-bloeddruk-bij-ckd-executive-summary/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/01/09/diastolische-bloeddruk-en-intensieve-bloeddrukcontrole-sprint-analyse/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/03/01/voorschrijfpatronen-van-thiazidediuretica-in-de-sprint-trial/","published":"2016-03-01"},{"url":"https://hartvaat.nl/2016/02/01/sprint-resultaten-en-implicaties-voor-de-nefrologie/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anders-himmelmann","type":"person","url":"https://hartvaat.nl/mensen/anders-himmelmann/","name":"Anders Himmelmann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2024/05/16/annexa-i-andexanet-alfa-bij-factor-xa-remmer-geassocieerde-intracerebrale-bloedi/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","published":"2024-04-30"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"},{"url":"https://hartvaat.nl/2018/12/01/multipele-biomarkers-en-mortaliteitsrisico-na-acs-jama-cardiology/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/04/01/fibrinestoleigenschappen-en-klinische-uitkomsten-na-acs-plato-substudie/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2016/04/21/gdf-15-voorspelt-bloedingen-en-cardiovasculaire-events-bij-acuut-coronair-syndro/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/04/01/veiligheid-en-werkzaamheid-van-ticagrelor-versus-clopidogrel-bij-primaire-pci-vo/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrea-santarelli","type":"person","url":"https://hartvaat.nl/mensen/andrea-santarelli/","name":"Andrea Santarelli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/11/11/ct-angiografie-of-standaardzorg-na-pci-van-de-linker-hoofdstam/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/07/complete-revascularisatie-vermindert-cv-dood-bij-stemi-met-multivatenlijden-meta/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2016/02/02/ciclosporine-a-bij-gereperfuseerd-myocardinfarct-de-multicenter-cycle-trial/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-l-clark","type":"person","url":"https://hartvaat.nl/mensen/andrew-l-clark/","name":"Andrew L Clark","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/05/04/congestie-bij-chronisch-hartfalen-echografie-vult-klinisch-onderzoek-aan-en-voor/","published":"2026-07-01"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","published":"2024-04-21"},{"url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2022/10/13/revived-bcis2-pci-verbetert-overleving-niet-bij-ischemische-lv-disfunctie/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2019/12/01/orale-morfine-bij-dyspneu-bij-chronisch-hartfalen-gerandomiseerde-placebogecontr/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2016/04/01/effect-van-extra-zuurstof-op-inspanningsprestatie-bij-chronisch-hartfalen/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andre-zimerman","type":"person","url":"https://hartvaat.nl/mensen/andre-zimerman/","name":"André Zimerman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/08/25/extracraniale-bloedingen-komen-bij-26-van-af-patienten-op-antistolling-voor-comb/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","published":"2025-10-02"},{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2025/05/20/intensieve-ldl-verlaging-met-evolocumab-bij-auto-immuunziekten-rct/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2024/09/01/eldercare-af-subanalyse-dosisreductie-edoxaban-bij-80-jarigen-met-af/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-hypertriglyceridemie-en-hoog-cv-risico-nejm/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/11/01/vip-acs-dubbele-dosis-griepvaccinatie-na-acs-verbetert-uitkomsten-niet/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2019/11/21/diureticastaken-bij-stabiel-mild-hf-zonder-vochtretentie/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antonia-zapf","type":"person","url":"https://hartvaat.nl/mensen/antonia-zapf/","name":"Antonia Zapf","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/12/02/geindividualiseerd-perioperatief-bloeddrukmanagement-bij-grote-buikchirurgie/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2024/03/26/doac-s-bij-device-gedetecteerd-af-meta-analyse-noah-afnet-6-en-artesia/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","published":"2022-09-13"},{"url":"https://hartvaat.nl/2020/06/01/economische-impact-van-hfpef-aldo-dhf-inzichten/","published":"2020-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anushka-patel","type":"person","url":"https://hartvaat.nl/mensen/anushka-patel/","name":"Anushka Patel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2023/06/01/lage-dosis-drievoudige-viervoudige-combinatiepil-versus-monotherapie-bij-hyperte/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/06/01/lage-dosis-drievoudige-combinatietherapie-bij-hypertensie-triumph-secundaire-ana/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","published":"2021-09-18"},{"url":"https://hartvaat.nl/2020/11/01/lage-dosis-triple-combinatie-en-therapeutische-inertie-bij-hypertensie-jama-card/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-bij-acs-in-resource-beperkte-ziekenhuizen-jama-cardiology-/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2019/01/01/polypil-en-cardiovasculaire-preventie-meta-analyse-van-gerandomiseerde-trials/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/08/14/drievoudige-lage-dosis-antihypertensivacombinatie-versus-standaardzorg-jama-gera/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"armando-lira-pineda","type":"person","url":"https://hartvaat.nl/mensen/armando-lira-pineda/","name":"Armando Lira Pineda","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2024/04/23/lp-a-en-cv-risicoreductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/04/01/icosapent-ethyl-na-acs-reduce-it-subanalyse/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2021/02/01/evolocumab-bij-metabool-syndroom-na-acs-fourier/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/02/25/genetische-risicoscore-voorspelt-voordeel-van-evolocumab-fourier/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2019/06/18/evolocumab-bij-ckd-werkzaamheid-en-veiligheid-in-de-fourier-trial/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2018/07/10/inflammatie-en-cholesterol-in-de-fourier-trial/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/12/01/evolocumab-bij-hoogrisicopatienten-met-laag-ldl-op-statine-fourier-subanalyse/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"borja-ibanez","type":"person","url":"https://hartvaat.nl/mensen/borja-ibanez/","name":"Borja Ibáñez","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/02/11/reboot-betablokkers-na-mi-sekseverschillen/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","published":"2025-09-13"},{"url":"https://hartvaat.nl/2025/04/10/dapagliflozine-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2025-04-10"},{"url":"https://hartvaat.nl/2024/12/01/colica-colchicine-bij-acuut-gedecompenseerd-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","published":"2019-10-19"},{"url":"https://hartvaat.nl/2018/12/21/culprit-shock-integratie-in-2017-esc-stemi-richtlijn-richtlijncommissie-standpun/","published":"2018-12-21"},{"url":"https://hartvaat.nl/2018/01/07/2017-esc-richtlijn-voor-stemi-management/","published":"2018-01-07"},{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/05/10/timing-van-metoprolol-bij-stemi-effect-op-infarctgrootte-en-ventrikelfunctie/","published":"2016-05-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brendan-m-everett","type":"person","url":"https://hartvaat.nl/mensen/brendan-m-everett/","name":"Brendan M Everett","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/02/20/biomarkers-voor-atherosclerotische-events-bij-reumatoide-artritis-lp-a-als-voors/","published":"2026-02-20"},{"url":"https://hartvaat.nl/2024/03/26/grade-cv-uitkomsten-van-glucoseverlagende-middelen-bij-type-2-diabetes/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2020/09/01/2020-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2019/03/05/canakinumab-ter-preventie-van-hartfalen-hospitalisatie-cantos-analyse/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2019/02/21/laaggedoseerd-methotrexaat-voor-preventie-van-atherosclerotische-events-nejm-cir/","published":"2019-02-21"},{"url":"https://hartvaat.nl/2018/12/18/2018-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/10/09/hypoglykemie-en-troponine-elevatie-bij-diabetes-met-coronairlijden/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2017/10/21/canakinumab-en-longkankerincidentie-bij-atherosclerose-lancet-cantos-exploratief/","published":"2017-10-21"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"changsheng-ma","type":"person","url":"https://hartvaat.nl/mensen/changsheng-ma/","name":"Changsheng Ma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/09/01/inflammatie-als-risicofactor-krijgt-onvoldoende-ruimte-in-de-ascvd-en-ckd-prakti/","published":"2026-07-26"},{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2024/04/16/postprocedurale-anticoagulatie-na-primaire-pci-voor-stemi-multicenter-studie/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2022/09/15/invictus-rivaroxaban-versus-warfarine-bij-reumatische-hartziekte-en-af/","published":"2022-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-sticherling","type":"person","url":"https://hartvaat.nl/mensen/christian-sticherling/","name":"Christian Sticherling","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/06/02/pulsfield-ablatie-levert-betere-vrijwaring-van-recidief-dan-cryoballoon-bij-paro/","published":"2026-08-12"},{"url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/04/17/pfa-versus-cryoballon-bij-paroxysmaal-af-gerandomiseerde-trial/","published":"2025-04-17"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/11/02/duurzaamheid-van-pvi-bij-af-meta-analyse/","published":"2023-11-02"},{"url":"https://hartvaat.nl/2023/02/14/cryoballon-pvi-als-eerstelijnsbehandeling-voor-typisch-atriumflutter/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2016/10/07/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-af-herinterventierate-e/","published":"2016-10-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-conen","type":"person","url":"https://hartvaat.nl/mensen/david-conen/","name":"David Conen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2024/06/01/af-ablatie-bij-hfref-versus-hfpef-meta-analyse/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/03/07/mra-s-verminderen-af-risico-meta-analyse-van-klinische-trials/","published":"2024-03-07"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/11/04/colchicine-vermindert-perioperatief-af-na-thoraxchirurgie-lancet-rct/","published":"2023-11-04"},{"url":"https://hartvaat.nl/2021/08/06/orale-antiaritmica-voor-cardioversie-van-recent-onset-af-netwerkmeta-analyse/","published":"2021-08-06"},{"url":"https://hartvaat.nl/2019/12/17/uitgebreide-vasodilatatie-versus-standaardzorg-bij-acuut-hf-jama-galactic-hf-pil/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/12/01/linkeratriumdimensie-en-cv-uitkomsten-bij-patienten-met-en-zonder-af-meta-analys/","published":"2019-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"derek-p-chew","type":"person","url":"https://hartvaat.nl/mensen/derek-p-chew/","name":"Derek P Chew","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2025/11/01/pneumokokkenvaccinatie-en-cv-eventpreventie-ipd-meta-analyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2022/05/10/sms-voor-medicatietrouw-en-secundaire-preventie-na-acs-textmeds/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2021/10/01/acute-pleiotrope-effecten-van-dapagliflozine-bij-diabetes-type-2-met-hfref-cross/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/07/13/late-rapid-tnt-uitkomsten-0-1-uur-hs-troponine-t-bij-verdenking-acs/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/03/01/objectieve-risicobeoordeling-versus-standaardzorg-bij-acs-jama-cardiology/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2019/11/05/1-uur-troponine-t-protocol-bij-verdenking-acs-gerandomiseerde-rapid-tnt-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2016/08/16/bio-absorbeerbare-intracoronaire-matrix-ter-preventie-van-ventriculaire-remodell/","published":"2016-08-16"},{"url":"https://hartvaat.nl/2016/05/21/af-type-en-risico-op-trombo-embolie-mortaliteit-en-bloedingen-systematische-revi/","published":"2016-05-21"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"donald-e-cutlip","type":"person","url":"https://hartvaat.nl/mensen/donald-e-cutlip/","name":"Donald E Cutlip","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2017/10/31/laesiecomplexiteit-en-uitkomsten-van-verlengde-dapt-na-pci/","published":"2017-10-31"},{"url":"https://hartvaat.nl/2017/10/21/ultradunne-bioresorbeerbare-versus-dunne-duurzame-polymer-stents-lancet-bioscien/","published":"2017-10-21"},{"url":"https://hartvaat.nl/2017/05/02/mi-risico-na-stoppen-van-thienopyridine-dapt-studie/","published":"2017-05-02"},{"url":"https://hartvaat.nl/2016/10/04/impact-van-optimale-medicamenteuze-therapie-in-de-dapt-studie/","published":"2016-10-04"},{"url":"https://hartvaat.nl/2016/05/31/dapt-score-validatie-bij-patienten-met-en-zonder-eerder-myocardinfarct/","published":"2016-05-31"},{"url":"https://hartvaat.nl/2016/05/03/diabetes-en-preventie-van-laat-myocardinfarct-na-stenting-dapt-studie/","published":"2016-05-03"},{"url":"https://hartvaat.nl/2016/04/26/predictieregel-voor-voordeel-en-schade-van-dapt-na-1-jaar-pci-jama-validatiestud/","published":"2016-04-26"},{"url":"https://hartvaat.nl/2016/01/21/doodsoorzaken-bij-langdurige-dapt-na-coronaire-stents/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-anuradha-lala","type":"person","url":"https://hartvaat.nl/mensen/dr-anuradha-lala/","name":"Dr. Anuradha Lala","title":"Icahn School of Medicine at Mount Sinai, New York, VS","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/01/01/hartfalenpreventie-bewijsgeneratie-trialontwerp-en-regulatoire-trajecten/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-bij-niet-diabetische-hfref-emperor-reduced-subanalyse/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/03/17/2020-acc-hfsa-ishlt-verklaring-voor-gevorderd-hf-en-transplantatiespecialisten/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2018/12/01/liraglutide-en-gewicht-bij-gevorderd-hfref-fight-trial-inzichten/","published":"2018-12-01"}],"videos":[{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/highlights-stemi-dtu-gofresh-hi-peitho/","title":"Highlights: STEMI-DTU, GoFreshRx en HI-PEITHO samengevat"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eliot-a-brinton","type":"person","url":"https://hartvaat.nl/mensen/eliot-a-brinton/","name":"Eliot A Brinton","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2024/04/23/lp-a-en-cv-risicoreductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/04/01/icosapent-ethyl-na-acs-reduce-it-subanalyse/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","published":"2022-08-02"},{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/01/03/icosapent-ethyl-en-cardiovasculaire-uitkomsten-bij-hypertriglyceridemie-nejm-red/","published":"2019-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"federico-m-asch","type":"person","url":"https://hartvaat.nl/mensen/federico-m-asch/","name":"Federico M Asch","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/05/05/expanded-bij-73-verbetert-tricuspidalisinsufficientie-binnen-30-dagen-na-m-teer-/","published":"2026-06-26"},{"url":"https://hartvaat.nl/2026/05/27/multimodaal-ai-model-verhoogt-accuratesse-van-echo-diagnose-cardiale-amyloidose/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2026/03/16/vroege-linkerventrikel-reverse-remodellering-na-mitralisklep-edge-to-edge-repara/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2025/04/03/laa-sluiting-na-af-ablatie-gerandomiseerde-trial-nejm/","published":"2025-04-03"},{"url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","published":"2022-11-15"},{"url":"https://hartvaat.nl/2021/04/01/ero-lvedv-ratio-en-respons-op-mitraclip-jama-cardiology/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/12/17/echo-uitkomsten-na-mitraclip-bij-secundaire-mr-coapt-echocardiografisch/","published":"2019-12-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"filippo-crea","type":"person","url":"https://hartvaat.nl/mensen/filippo-crea/","name":"Filippo Crea","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/03/05/cardio-oncologie-een-snel-veranderend-vakgebied/","published":"2026-04-02"},{"url":"https://hartvaat.nl/2026/02/23/ehj-editoriaal-hartfalen-en-cardiomyopathieen/","published":"2026-04-01"},{"url":"https://hartvaat.nl/2025/11/18/cv-effecten-en-verdraagbaarheid-van-glp-1-agonisten-meta-analyse/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2024/08/01/coronaire-microvasculaire-disfunctie-bij-hfpef-meta-analyse/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2022/07/21/permanente-pacemaker-na-tavi-langetermijneffect-op-klinische-uitkomsten/","published":"2022-07-21"},{"url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","published":"2022-03-07"},{"url":"https://hartvaat.nl/2021/12/04/posterieure-pericardiotomie-ter-preventie-van-af-na-hartchirurgie-lancet-palacs/","published":"2021-12-04"},{"url":"https://hartvaat.nl/2020/04/01/intracraniele-bloedingen-versus-stenttrombose-met-doac-antiplaatjes-versus-tripl/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2018/01/07/2017-esc-richtlijn-voor-stemi-management/","published":"2018-01-07"},{"url":"https://hartvaat.nl/2017/05/30/tijdstrends-in-complicaties-van-bioresorbeerbare-versus-metallic-stents/","published":"2017-05-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frants-pedersen","type":"person","url":"https://hartvaat.nl/mensen/frants-pedersen/","name":"Frants Pedersen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2022/04/01/icd-bij-niet-ischemisch-systolisch-hf-met-coronaire-atherosclerose-danish/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gbenga-ogedegbe","type":"person","url":"https://hartvaat.nl/mensen/gbenga-ogedegbe/","name":"Gbenga Ogedegbe","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2024/07/02/thuisbloeddruktelemonitoring-en-nurse-case-management-na-cva-jama-rct/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"},{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"geoffrey-lee","type":"person","url":"https://hartvaat.nl/mensen/geoffrey-lee/","name":"Geoffrey Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/07/14/vroege-versus-late-af-ablatie-impact-op-aritmierecidief/","published":"2023-07-14"},{"url":"https://hartvaat.nl/2023/02/16/hoog-vermogen-korte-duur-versus-laag-vermogen-langere-duur-posteriore-ablatie-bi/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2018/07/01/rotorablatie-bij-atriumfibrilleren-systematische-review/","published":"2018-07-01"},{"url":"https://hartvaat.nl/2017/10/17/katheterablatie-versus-frequentiecontrole-bij-af-met-systolische-disfunctie-came/","published":"2017-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gerard-c-m-linssen","type":"person","url":"https://hartvaat.nl/mensen/gerard-c-m-linssen/","name":"Gerard C M Linssen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/08/21/pa-drukmonitoring-bij-chronisch-hartfalen-effecten-over-klinische-subgroepen/","published":"2024-08-21"},{"url":"https://hartvaat.nl/2023/06/24/monitor-hf-pa-drukmonitoring-bij-hartfalen-effectief-in-europa-lancet-rct/","published":"2023-06-24"},{"url":"https://hartvaat.nl/2019/07/01/uitkomsten-van-des-in-kleine-coronairen-naar-strutdikte-jama-cardiology-meta-ana/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/10/06/resolute-onyx-versus-orsiro-stent-lancet-gerandomiseerde-non-inferioriteitstrial/","published":"2018-10-06"},{"url":"https://hartvaat.nl/2017/03/01/5-jaarsuitkomsten-van-zotarolimus-en-everolimus-eluting-stents-trial-en-real-wor/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/11/26/ultradunne-biodegradeerbare-versus-duurzame-polymer-des-lancet-gerandomiseerde-t/","published":"2016-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gilles-lemesle","type":"person","url":"https://hartvaat.nl/mensen/gilles-lemesle/","name":"Gilles Lemesle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/06/27/oac-monotherapie-is-superieur-aan-combinatie-met-antiplatelets-bij-stabiele-ccs-/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2025/01/01/antistolling-alleen-of-met-plaatjesremming-bij-coronairlijden-meta-analyse/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-laagrisico-acuut-mi/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2025/10/23/aspirine-bij-chronisch-coronairsyndroom-plus-oac-wel-of-niet/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","published":"2021-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gregory-d-lewis","type":"person","url":"https://hartvaat.nl/mensen/gregory-d-lewis/","name":"Gregory D Lewis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/10/07/nieuwe-inspanningsherstelpatronen-als-maat-voor-cardiale-prestatie/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/06/01/humain-hfpef-nieuwe-metabole-accelerator-bij-obesitas-hfpef-rct/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/10/01/amethyst-verinurad-plus-allopurinol-bij-hfpef-negatieve-trial/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/07/09/selectieve-aldosereductaseremmer-bij-diabetische-cardiomyopathie-rct/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2023/09/14/heart-fid-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-nejm/","published":"2023-09-14"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"},{"url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2020/10/20/praliciguat-en-piek-vo2-bij-hfpef-jama-capacity-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","published":"2018-11-06"},{"url":"https://hartvaat.nl/2017/05/16/oraal-ijzer-bij-hfref-met-ijzerdeficientie-jama-ironout-hf/","published":"2017-05-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"han-mo-yang","type":"person","url":"https://hartvaat.nl/mensen/han-mo-yang/","name":"Han-Mo Yang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","published":"2025-11-08"},{"url":"https://hartvaat.nl/2025/05/01/aspirine-versus-clopidogrel-na-coronaire-stenting-naar-bloedingsrisico-en-comple/","published":"2025-05-01"},{"url":"https://hartvaat.nl/2023/10/17/antiplaatjesmonotherapie-na-pci-clopidogrel-versus-aspirine-naar-risicoprofiel/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/05/02/korte-versus-standaard-dapt-na-pci-met-moderne-des-meta-analyse/","published":"2023-05-02"},{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2023/01/10/host-exam-extended-clopidogrel-superieur-aan-aspirine-als-monotherapie-na-pci/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2021/06/26/aspirine-versus-clopidogrel-voor-chronische-monotherapie-na-pci-lancet-host-exam/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2021/03/16/duurzame-versus-biodegradeerbare-polymer-des-bij-acs-meta-analyse/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/10/10/prasugrel-gebaseerde-dapt-de-escalatie-na-pci-bij-acs-lancet-host-reduce-polytec/","published":"2020-10-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"harlan-m-krumholz","type":"person","url":"https://hartvaat.nl/mensen/harlan-m-krumholz/","name":"Harlan M. Krumholz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/01/01/wat-betekent-verbetering-bij-hypertrofische-cardiomyopathie/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2025/01/01/van-overleving-naar-rentmeesterschap-hypergespecialiseerde-cardiovasculaire-zorg/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/01/01/langdurige-blootstelling-aan-bosbranden-pm2-5-en-cardiovasculaire-ziekenhuisopna/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/01/01/wanneer-zorg-autonoom-wordt-ai-en-de-toekomst-van-de-cardiovasculaire-geneeskund/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/01/01/cardiovasculaire-gezondheid-van-vrouwen-van-inclusie-naar-onderzoeksontwerp/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2024/09/16/tirzepatide-en-bloeddrukverlaging-surmount-1-gestratificeerde-analyse/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2019/11/16/vergelijking-van-eerstelijns-antihypertensiva-lancet-systematische-multinational/","published":"2019-11-16"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2017/07/01/heterogeniteit-in-vroege-respons-op-antihypertensiva-allhat/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"iain-b-squire","type":"person","url":"https://hartvaat.nl/mensen/iain-b-squire/","name":"Iain B Squire","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2025/04/01/ambulante-behandeling-van-gedecompenseerd-hartfalen-meta-analyse/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","published":"2024-04-21"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"},{"url":"https://hartvaat.nl/2022/01/01/sglt2-remmers-over-het-cv-ziektespectrum-overzicht/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"islam-y-elgendy","type":"person","url":"https://hartvaat.nl/mensen/islam-y-elgendy/","name":"Islam Y Elgendy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/05/05/mavacamten-in-de-praktijk-zwarte-patienten-krijgen-55-minder-vaak-toegang-atrium/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2025/08/01/lipideparameters-en-prognose-bij-hartfalen-meta-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2022/10/25/2022-acc-aha-datadefinities-voor-pijn-op-de-borst-en-acuut-myocardinfarct/","published":"2022-10-25"},{"url":"https://hartvaat.nl/2022/10/13/ffr-geleide-versus-angiografie-geleide-revascularisatie-meta-analyse-van-rct-s/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2017/09/01/provisional-versus-twee-stentstrategie-bij-bifurcatielaesies-meta-analyse/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2016/11/01/langetermijnmortaliteit-bij-hypertensie-met-coronairlijden-invest-us-cohort/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/08/02/impact-van-coronaire-laesielengte-op-uitkomsten-bij-ivus-geleide-pci/","published":"2016-08-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"james-c-spratt","type":"person","url":"https://hartvaat.nl/mensen/james-c-spratt/","name":"James C Spratt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/01/27/pci-van-natief-coronairvat-versus-veneuze-graft-na-eerdere-cabg-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2024/07/23/anatomische-versus-viabiliteitsgerichte-completeness-van-revascularisatie/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2022/10/13/revived-bcis2-pci-verbetert-overleving-niet-bij-ischemische-lv-disfunctie/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2018/07/07/revascularisatie-versus-optimale-medicamenteuze-therapie-bij-cto-gerandomiseerde/","published":"2018-07-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jamie-p-dwyer","type":"person","url":"https://hartvaat.nl/mensen/jamie-p-dwyer/","name":"Jamie P Dwyer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/03/07/baxdrostat-verlaagt-bloeddruk-significant-bij-resistente-hypertensie/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/03/07/bax24-baxdrostat-en-ambulante-bloeddruk-bij-resistente-hypertensie/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2025/10/09/baxdrostat-bij-ongecontroleerde-en-resistente-hypertensie-effectiviteit-en-veili/","published":"2025-10-09"},{"url":"https://hartvaat.nl/2022/07/27/langetermijneffect-van-antihypertensiva-op-bloeddruk-meta-analyse-op-individueel/","published":"2022-07-27"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/06/01/intensieve-versus-standaard-bloeddruk-naar-tertielen-in-sprint/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/01/01/intensieve-versus-standaard-bloeddrukcontrole-op-ambulante-bloeddruk-sprint-resu/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/03/01/voorschrijfpatronen-van-thiazidediuretica-in-de-sprint-trial/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jayne-prats","type":"person","url":"https://hartvaat.nl/mensen/jayne-prats/","name":"Jayne Prats","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","published":"2024-04-30"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2018/12/07/laesiecomplexiteit-en-periprocedurele-events-bij-potente-iv-antiplaatjestherapie/","published":"2018-12-07"},{"url":"https://hartvaat.nl/2017/10/10/dagelijks-ischemie-en-bloedingsrisico-na-primaire-pci-voor-stemi/","published":"2017-10-10"},{"url":"https://hartvaat.nl/2017/02/01/cangrelor-versus-gpiib-iiia-remmers-ischemie-en-bloedingsrisico-s-vergeleken/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/01/17/cangrelor-met-en-zonder-gpiib-iiia-remmers-bij-pci/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/11/29/presentatie-buiten-kantoortijden-versus-tijdens-kantoortijden-bij-stemi-champion/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/09/06/consistente-reductie-in-periprocedureel-mi-met-cangrelor-champion-analyses/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/04/07/cangrelor-en-toegangsplaats-effect-op-ischemische-en-bloedingsevents-champion-ph/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/01/19/werkzaamheid-en-veiligheid-van-cangrelor-bij-vrouwen-versus-mannen-tijdens-pci-c/","published":"2016-01-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jean-francois-tanguay","type":"person","url":"https://hartvaat.nl/mensen/jean-francois-tanguay/","name":"Jean-François Tanguay","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/02/18/lage-dosis-sirolimus-bdp-stent-versus-tweede-generatie-des-non-inferioriteit/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2021/11/01/antiplaatjestherapie-bij-mi-zonder-obstructief-coronairlijden-minoca/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2020/08/25/genotype-geleide-p2y12-selectie-versus-clopidogrel-na-pci-jama-tailor-pci/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/03/05/timing-van-prasugrel-start-en-coronairangiografie-bij-nstemi/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","published":"2019-02-19"},{"url":"https://hartvaat.nl/2018/07/31/antitrombotische-therapie-bij-af-met-oac-na-pci-aha-scientific-statement/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2016/08/16/bio-absorbeerbare-intracoronaire-matrix-ter-preventie-van-ventriculaire-remodell/","published":"2016-08-16"},{"url":"https://hartvaat.nl/2016/05/03/diabetes-en-preventie-van-laat-myocardinfarct-na-stenting-dapt-studie/","published":"2016-05-03"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jennifer-a-white","type":"person","url":"https://hartvaat.nl/mensen/jennifer-a-white/","name":"Jennifer A White","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2020/01/28/morfine-en-cv-uitkomsten-bij-nste-acs-jacc-analyse/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2019/09/01/simvastatine-ezetimibe-versus-simvastatine-na-acs-bij-75-plussers-jama-cardiolog/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/04/10/ezetimibe-bij-diabetes-versus-zonder-diabetes-improve-it-subanalyse/","published":"2018-04-10"},{"url":"https://hartvaat.nl/2017/12/19/cva-preventie-met-ezetimibe-bij-acs-improve-it-analyse/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2017/05/01/langetermijnveiligheid-van-zeer-lage-ldl-cholesterolniveaus-improve-it-analyse/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/12/21/ezetimibe-bij-post-cabg-patienten-met-acs-improve-it-subanalyse/","published":"2016-12-21"},{"url":"https://hartvaat.nl/2016/08/16/bio-absorbeerbare-intracoronaire-matrix-ter-preventie-van-ventriculaire-remodell/","published":"2016-08-16"},{"url":"https://hartvaat.nl/2016/02/02/reductie-in-totale-cardiovasculaire-events-met-ezetimibe-simvastatine-na-acs-imp/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-r-davies","type":"person","url":"https://hartvaat.nl/mensen/john-r-davies/","name":"John R Davies","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jonathan-l-halperin","type":"person","url":"https://hartvaat.nl/mensen/jonathan-l-halperin/","name":"Jonathan L Halperin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2023/03/14/real-time-remote-monitoring-voorspelt-maligne-ventriculaire-aritmieen/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2022/03/02/kenmerken-van-patienten-met-atriale-high-rate-episodes-bij-icd-crt/","published":"2022-03-02"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-versus-heparine-vka-bij-cardioversie-voor-af-emanate-trial/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2017/03/28/edoxaban-bij-af-met-bioprothese-hartkleppen-trombo-emboliepreventie/","published":"2017-03-28"},{"url":"https://hartvaat.nl/2017/01/24/heropnames-bij-af-patienten-na-stenting-twee-antitromboticastrategieen-vergeleke/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/12/22/preventie-van-bloedingen-bij-af-patienten-die-pci-ondergaan-nejm-pioneer-af-pci/","published":"2016-12-22"},{"url":"https://hartvaat.nl/2016/08/01/hospitalisaties-bij-atriumfibrilleren-analyse-uit-rocket-af/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/07/01/natief-kleplijden-bij-af-patienten-op-warfarine-of-rivaroxaban/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/01/26/polyfarmacie-en-werkzaamheid-van-rivaroxaban-versus-warfarine-bij-atriumfibrille/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jong-young-lee","type":"person","url":"https://hartvaat.nl/mensen/jong-young-lee/","name":"Jong-Young Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/01/01/intravasculaire-beeldvorming-superieur-aan-angiografie-bij-complexe-pci-5-jaarsr/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/05/01/angiografie-versus-ivus-voor-des-implantatie-gerandomiseerde-trial/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","published":"2023-04-04"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","published":"2019-04-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joon-hyung-doh","type":"person","url":"https://hartvaat.nl/mensen/joon-hyung-doh/","name":"Joon-Hyung Doh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joost-daemen","type":"person","url":"https://hartvaat.nl/mensen/joost-daemen/","name":"Joost Daemen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/08/18/echocardiografie-overschatte-drukgradienten-na-tav-in-tav-met-ballon-expandable-/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jung-kyu-han","type":"person","url":"https://hartvaat.nl/mensen/jung-kyu-han/","name":"Jung-Kyu Han","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","published":"2025-11-08"},{"url":"https://hartvaat.nl/2025/05/01/aspirine-versus-clopidogrel-na-coronaire-stenting-naar-bloedingsrisico-en-comple/","published":"2025-05-01"},{"url":"https://hartvaat.nl/2023/10/17/antiplaatjesmonotherapie-na-pci-clopidogrel-versus-aspirine-naar-risicoprofiel/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/05/02/korte-versus-standaard-dapt-na-pci-met-moderne-des-meta-analyse/","published":"2023-05-02"},{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2023/01/10/host-exam-extended-clopidogrel-superieur-aan-aspirine-als-monotherapie-na-pci/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2021/06/26/aspirine-versus-clopidogrel-voor-chronische-monotherapie-na-pci-lancet-host-exam/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2021/03/16/duurzame-versus-biodegradeerbare-polymer-des-bij-acs-meta-analyse/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/10/10/prasugrel-gebaseerde-dapt-de-escalatie-na-pci-bij-acs-lancet-host-reduce-polytec/","published":"2020-10-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"justin-e-davies","type":"person","url":"https://hartvaat.nl/mensen/justin-e-davies/","name":"Justin E Davies","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/01/01/ffr-versus-ifr-bij-coronaire-revascularisatie-vijfjaars-follow-up/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/01/temporele-veranderingen-in-coronaire-hemodynamiek-bij-niet-culprit-vaten-na-stem/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2017/08/01/nauwkeurigheid-van-manchetbloeddrukmeting-systematische-review-en-meta-analyse/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"katherine-r-tuttle","type":"person","url":"https://hartvaat.nl/mensen/katherine-r-tuttle/","name":"Katherine R Tuttle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/10/01/il-6-remmers-als-nieuwe-aanpak-bij-chronische-nierziekte-en-hart-en-vaatziekten/","published":"2026-09-04"},{"url":"https://hartvaat.nl/2026/02/10/nieuwe-medicamenteuze-therapieen-voor-hypertensie/","published":"2026-03-14"},{"url":"https://hartvaat.nl/2026/03/05/finerenon-effectief-bij-type-1-diabetes-met-chronische-nierziekte/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/02/23/semaglutide-vermindert-infectierisico-bij-diabetes-en-chronische-nierziekte/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/01/14/glp-1-receptoragonisten-en-de-volgende-generatie-incretinegebaseerde-middelen/","published":"2026-01-14"},{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","published":"2025-03-24"},{"url":"https://hartvaat.nl/2024/11/26/glp-1-agonisten-alleen-en-met-sglt2-remmers-cv-renale-en-veiligheidsuitkomsten/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/10/22/flow-semaglutide-vermindert-hartfalen-bij-diabetes-en-ckd/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/07/11/flow-semaglutide-beschermt-nieren-bij-type-2-diabetes-en-ckd-nejm-gerelateerd/","published":"2024-07-11"},{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kathy-wolski","type":"person","url":"https://hartvaat.nl/mensen/kathy-wolski/","name":"Kathy Wolski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/05/08/lorundrostat-bij-ongecontroleerde-hypertensie-fase-3-nejm/","published":"2025-05-08"},{"url":"https://hartvaat.nl/2024/03/05/gelijktijdige-laa-occlusie-en-tavr-bij-af-haalbaarheid/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/07/13/traverse-testosteronsubstitutie-cardiovasculair-veilig-bij-hypogonadisme/","published":"2023-07-13"},{"url":"https://hartvaat.nl/2022/05/03/korte-interfererende-rna-tegen-lp-a-jama-fase-1-dosisstudie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/10/01/crp-op-lp-a-geassocieerd-cv-risico-bij-optimaal-behandelde-hoogrisicopatienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2018/10/23/evolocumab-en-coronaire-plaquesamenstelling-glagov-beeldvorming/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/09/01/hdl-mimeticum-met-recombinant-apoa-i-milano-en-coronairlijden-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/02/16/bariatrische-chirurgie-versus-intensieve-medicamenteuze-therapie-bij-diabetes-5-/","published":"2017-02-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"katrina-e-donahue","type":"person","url":"https://hartvaat.nl/mensen/katrina-e-donahue/","name":"Katrina E Donahue","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"},{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/07/27/heeft-deze-volwassene-hypertensie-jama-rational-clinical-examination/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"keith-c-ferdinand","type":"person","url":"https://hartvaat.nl/mensen/keith-c-ferdinand/","name":"Keith C Ferdinand","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/05/12/nhlbi-workshop-bloeddrukmeting-verfijnen-door-de-hele-levensloop-heen-knelpunten/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/01/aprocitentan-bij-zwarte-patienten-met-hypertensie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2019/04/30/empagliflozine-antihyperglycemische-en-bloeddrukeffecten-bij-zwarte-diabetespati/","published":"2019-04-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ken-okumura","type":"person","url":"https://hartvaat.nl/mensen/ken-okumura/","name":"Ken Okumura","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/05/19/eldercare-af-post-hoc-edoxaban-spiegel-en-pt-13s-voorspellen-bloedingsrisico-bij/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2022/06/01/edoxaban-15-mg-bij-zeer-oude-patienten-met-atriumfibrilleren-eldercare-subanalys/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2022/03/01/edoxaban-15-mg-naar-nierfunctie-bij-zeer-oude-af-eldercare-subanalyse/","published":"2022-03-01"},{"url":"https://hartvaat.nl/2020/10/29/laaggedoseerd-edoxaban-bij-zeer-oude-af-patienten-nejm-eldercare-af/","published":"2020-10-29"},{"url":"https://hartvaat.nl/2019/06/01/heparinedosering-bij-ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-re/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/04/27/ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-nejm-re-circuit/","published":"2017-04-27"},{"url":"https://hartvaat.nl/2016/12/27/hotballoon-pulmonaalvene-ablatie-bij-paroxysmaal-af-japanse-multicenter-trial/","published":"2016-12-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kenji-ando","type":"person","url":"https://hartvaat.nl/mensen/kenji-ando/","name":"Kenji Ando","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neoatherosclerose-na-stemi-secundaire-analyse/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/08/01/biodegradeerbare-versus-duurzame-polymeer-ees-langetermijn-neoatherosclerose/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kenneth-dickstein","type":"person","url":"https://hartvaat.nl/mensen/kenneth-dickstein/","name":"Kenneth Dickstein","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2019/01/08/hfref-differentiele-impact-op-mannen-en-vrouwen/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/03/27/crt-bij-hartfalen-met-smal-qrs-complex/","published":"2018-03-27"},{"url":"https://hartvaat.nl/2018/02/20/cva-risico-bij-verminderde-ef-na-mi-zonder-af/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/11/14/af-type-en-uitkomsten-bij-hfref/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/10/14/intracoronaire-beenmergceltransfer-na-mi-de-boost-2-gerandomiseerde-trial/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/03/07/lv-global-longitudinal-strain-en-prognose-bij-hartfalen-met-smal-qrs-en-crt/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2016/04/21/aliskiren-enalapril-of-de-combinatie-bij-hartfalen-nejm-atmosphere-trial/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/03/29/omecamtiv-mecarbil-bij-acuut-hartfalen-de-atomic-ahf-studie/","published":"2016-03-29"},{"url":"https://hartvaat.nl/2016/01/01/persisterende-echocardiografische-dyssynchronie-voorspelt-ongunstige-uitkomsten-/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"krzysztof-narkiewicz","type":"person","url":"https://hartvaat.nl/mensen/krzysztof-narkiewicz/","name":"Krzysztof Narkiewicz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/01/aprocitentan-bij-ckd-en-resistente-hypertensie/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/04/01/aprocitentan-bij-zwarte-patienten-met-hypertensie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/12/03/precision-aprocitentan-bij-resistente-hypertensie-eerste-endothelineantagonist/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2021/09/01/normalisatie-van-arteriele-stijfheid-en-cv-events-sparte-studie/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2018/08/01/renale-denervatie-bij-resistente-hypertensie-met-obstructieve-slaapapneu-proof-o/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lale-tokgozoglu","type":"person","url":"https://hartvaat.nl/mensen/lale-tokgozoglu/","name":"Lale Tokgözoğlu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/16/pcsk9-remmers-verlagen-events-bij-ascvd-zonder-eerder-infarct-of-beroerte-real-w/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2026/05/24/eas-consensus-wereldwijde-harmonisatie-van-lipidenklinieken/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2016/10/14/2016-esc-eas-richtlijn-voor-het-management-van-dyslipidemieen/","published":"2016-10-14"}],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/ldl-cholesterol/","title":"Sessie 2: LDL-cholesterol"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lars-eckardt","type":"person","url":"https://hartvaat.nl/mensen/lars-eckardt/","name":"Lars Eckardt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2020/12/14/edoxaban-bij-af-met-pci-naar-acute-versus-chronische-coronaire-presentatie-entru/","published":"2020-12-14"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/12/07/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-veiligheid-en-werk/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2019/10/12/edoxaban-versus-vka-gebaseerd-antitrombotisch-regime-na-stenting-bij-af-lancet-e/","published":"2019-10-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lars-videbk","type":"person","url":"https://hartvaat.nl/mensen/lars-videbk/","name":"Lars Videbæk","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/01/af-en-icd-bij-niet-ischemische-hfref-impliciaties-voor-devicetherapie/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/07/01/empagliflozine-en-lv-volumes-en-functie-bij-hfref-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2020/12/08/empagliflozine-en-hemodynamiek-bij-hfref/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"laurence-d-sterns","type":"person","url":"https://hartvaat.nl/mensen/laurence-d-sterns/","name":"Laurence D Sterns","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2024/01/18/raft-langetermijn-crt-d-bij-hartfalen-nejm-14-jaarsresultaten/","published":"2024-01-18"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/05/01/aware-uitgebreide-ablatie-vermindert-af-recidief-niet-boven-standaard-pvi/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2022/07/15/vt-ablatie-versus-antiaritmica-bij-myocardinfarct-locatie-maakt-uit/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2019/08/01/optimale-laesieset-bij-persisterend-af-ablatie-meta-regressie/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2016/07/14/ablatie-versus-escalatie-van-antiaritmica-bij-ventriculaire-tachycardie-nejm-van/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lena-rivard","type":"person","url":"https://hartvaat.nl/mensen/lena-rivard/","name":"Lena Rivard","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/02/20/vanish2-catheterablatie-versus-antiaritmica-bij-ventriculaire-tachycardie-nejm/","published":"2025-02-20"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/03/26/doac-s-bij-device-gedetecteerd-af-meta-analyse-noah-afnet-6-en-artesia/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2022/07/15/vt-ablatie-versus-antiaritmica-bij-myocardinfarct-locatie-maakt-uit/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2017/05/09/agressieve-bloeddrukcontrole-en-recidief-van-af-na-ablatie-gerandomiseerde-trial/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2016/07/14/ablatie-versus-escalatie-van-antiaritmica-bij-ventriculaire-tachycardie-nejm-van/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"leslie-cho","type":"person","url":"https://hartvaat.nl/mensen/leslie-cho/","name":"Leslie Cho","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/07/09/bempedoinezuur-versus-statines-vergelijking-van-cv-voordelen/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/03/01/clear-outcomes-bempedoinezuur-vermindert-totale-cv-events-bij-statine-intolerant/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2022/05/03/korte-interfererende-rna-tegen-lp-a-jama-fase-1-dosisstudie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2020/10/01/crp-op-lp-a-geassocieerd-cv-risico-bij-optimaal-behandelde-hoogrisicopatienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2018/10/23/evolocumab-en-coronaire-plaquesamenstelling-glagov-beeldvorming/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","published":"2016-12-13"}],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/lipoproteïne-a/","title":"Sessie 3: Lipoproteïne(a)"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"magnus-petersson","type":"person","url":"https://hartvaat.nl/mensen/magnus-petersson/","name":"Magnus Petersson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marat-fudim","type":"person","url":"https://hartvaat.nl/mensen/marat-fudim/","name":"Marat Fudim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/08/18/c-mic-apparaat-vermindert-hartfalen-ernst-onafhankelijk-van-gdmt-aanpassingen-c-/","published":"2026-08-25"},{"url":"https://hartvaat.nl/2026/04/07/confident-hfpef-machine-learning-voorspelt-sterfte-en-opname-beter-dan-bestaande/","published":"2026-07-20"},{"url":"https://hartvaat.nl/2026/03/03/c-mic-ii-hartfunctie-inspanningscapaciteit-en-kwaliteit-van-leven-zijn-verwante-/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/02/03/intraveneus-ijzer-bij-hartfalen-met-ijzertekort-meta-analyse-met-trial-sequentie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/12/01/gelijktijdige-griep-en-rsv-vaccinatie-bij-hoogrisico-hartfalenpatienten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/02/01/iv-ijzer-bij-hartfalen-en-ijzerdeficientie-geactualiseerde-meta-analyse-van-rct-/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/12/01/splanchnische-zenuwablatie-bij-hfpef-endovasculaire-benadering/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2023/04/01/intraveneus-ijzer-bij-hartfalen-meta-analyse-op-studieniveau/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2021/10/26/vroege-impedantie-geleide-interventie-verbetert-langetermijn-hf-uitkomsten/","published":"2021-10-26"},{"url":"https://hartvaat.nl/2021/08/01/gdf-15-en-liraglutide-behandeling-bij-hf-patienten/","published":"2021-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"margaret-m-redfield","type":"person","url":"https://hartvaat.nl/mensen/margaret-m-redfield/","name":"Margaret M Redfield","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2020/10/20/praliciguat-en-piek-vo2-bij-hfpef-jama-capacity-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","published":"2018-11-06"},{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/05/16/oraal-ijzer-bij-hfref-met-ijzerdeficientie-jama-ironout-hf/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/08/02/liraglutide-en-klinische-stabiliteit-bij-gevorderd-hartfalen-met-verminderde-ef-/","published":"2016-08-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-halle","type":"person","url":"https://hartvaat.nl/mensen/martin-halle/","name":"Martin Halle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/05/05/perifere-zuurstofextractie-bepaalt-belasting-bij-arrhythmogene-cardiomyopathie-f/","published":"2026-07-31"},{"url":"https://hartvaat.nl/2025/06/01/trainingseffect-op-diastolische-functie-bij-hfpef/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/04/01/inspanningstraining-en-hoog-sensitief-troponine-i-bij-hfref/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/04/18/aha-scientific-statement-gestructureerde-inspanningstraining-bij-hfpef/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/10/01/verschillende-trainingsvormen-en-hdl-functie-bij-hfpef-optimex-substudie/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/06/01/inspanningstraining-en-hs-troponine-t-bij-hfref/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/02/09/hiit-matig-continu-of-richtlijnadvies-en-piek-vo2-bij-hfref-jama-smartex-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2018/02/01/hoeveelheid-of-intensiteit-van-inspanning-bij-hfpef/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/02/28/hoog-intensieve-intervaltraining-bij-hartfalen-met-verminderde-ejectiefractie/","published":"2017-02-28"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"masaharu-akao","type":"person","url":"https://hartvaat.nl/mensen/masaharu-akao/","name":"Masaharu Akao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/05/19/eldercare-af-post-hoc-edoxaban-spiegel-en-pt-13s-voorspellen-bloedingsrisico-bij/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2022/08/01/rivaroxaban-monotherapie-versus-combinatie-met-plaatjesremmers-bij-af-en-coronai/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2022/06/01/edoxaban-15-mg-bij-zeer-oude-patienten-met-atriumfibrilleren-eldercare-subanalys/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2022/03/01/edoxaban-15-mg-naar-nierfunctie-bij-zeer-oude-af-eldercare-subanalyse/","published":"2022-03-01"},{"url":"https://hartvaat.nl/2021/11/01/aspirine-versus-p2y12-remmer-met-antistolling-bij-af/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2020/10/29/laaggedoseerd-edoxaban-bij-zeer-oude-af-patienten-nejm-eldercare-af/","published":"2020-10-29"},{"url":"https://hartvaat.nl/2019/09/19/antitrombotische-therapie-bij-af-met-stabiel-coronairlijden-nejm-afire/","published":"2019-09-19"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-hanna","type":"person","url":"https://hartvaat.nl/mensen/michael-hanna/","name":"Michael Hanna","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2021/05/01/vroegtijdig-permanent-staken-van-apixaban-of-warfarine-bij-af/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/08/14/adma-en-sdma-voorspellen-uitkomsten-bij-af-aristotle-substudie/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/08/01/uitkomsten-bij-af-met-oac-bij-mitralis-of-aortakleplijden/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/03/13/digoxine-en-mortaliteit-bij-patienten-met-atriumfibrilleren/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2017/04/01/niet-ernstige-bloedingen-met-apixaban-versus-warfarine-bij-af/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/09/01/apixaban-5-mg-bij-af-met-hoge-leeftijd-laag-gewicht-of-hoog-creatinine-aristotle/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/07/01/apixaban-versus-warfarine-bij-af-in-relatie-tot-nierfunctie-aristotle-analyse/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/04/01/biomarkers-van-inflammatie-en-cardiovasculair-risico-bij-patienten-met-atriumfib/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-j-barry","type":"person","url":"https://hartvaat.nl/mensen/michael-j-barry/","name":"Michael J Barry","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"},{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","published":"2017-07-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-r-gold","type":"person","url":"https://hartvaat.nl/mensen/michael-r-gold/","name":"Michael R Gold","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/11/26/artesia-subanalyse-cva-risico-naar-frequentie-en-duur-van-subclinisch-af/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/10/01/draadloos-ultrasound-gebaseerd-crt-systeem-bij-hartfalen/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/09/30/adaptresponse-adaptieve-versus-conventionele-crt-bij-hartfalen-lancet/","published":"2023-09-30"},{"url":"https://hartvaat.nl/2022/09/27/linkerbundeltakpacing-versus-biventriculaire-pacing-voor-crt-gerandomiseerde-tri/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2020/10/01/sekseverschillen-in-kenmerken-en-qol-bij-crt-patienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/08/20/2018-acc-aha-hrs-richtlijn-voor-bradycardie-en-geleidingsstoornissen/","published":"2019-08-20"},{"url":"https://hartvaat.nl/2016/07/12/nervus-vagus-stimulatie-bij-hartfalen-de-inovate-hf-trial/","published":"2016-07-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mitja-lainscak","type":"person","url":"https://hartvaat.nl/mensen/mitja-lainscak/","name":"Mitja Lainscak","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/05/11/ehj-editorial-cleland-wereldwijde-hartfalenprevalentie-overschrijdt-600-miljoen-/","published":"2026-05-12"},{"url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/02/01/transveneuze-frenische-zenuwstimulatie-bij-centraal-slaapapneu-en-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/05/iv-ferricarboxymaltose-en-inspanningscapaciteit-bij-hfpef-met-ijzerdeficientie/","published":"2024-10-05"},{"url":"https://hartvaat.nl/2019/03/05/canakinumab-ter-preventie-van-hartfalen-hospitalisatie-cantos-analyse/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2018/08/01/langetermijn-patiromer-bij-hyperkaliemie-met-mild-hf-en-diabetische-nefropathie/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/06/01/geindividualiseerd-patiromer-doseringsregime-bij-hf-met-ckd-en-hyperkaliemie/","published":"2018-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mona-fiuzat","type":"person","url":"https://hartvaat.nl/mensen/mona-fiuzat/","name":"Mona Fiuzat","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2018/11/27/economische-en-qol-uitkomsten-van-nt-probnp-geleide-hf-therapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2018/10/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-hf-trials-jama-cardiology-review/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/08/22/natriuretisch-peptide-geleide-therapie-bij-hoogrisico-hartfalen-jama-guide-it/","published":"2017-08-22"},{"url":"https://hartvaat.nl/2017/07/18/palliatieve-zorg-bij-hartfalen-de-pal-hf-gerandomiseerde-trial/","published":"2017-07-18"},{"url":"https://hartvaat.nl/2017/04/04/inspanningstraining-bij-chronisch-hartfalen-met-atriumfibrilleren/","published":"2017-04-04"},{"url":"https://hartvaat.nl/2017/03/28/adaptieve-servoventilatie-bij-hartfalen-de-cat-hf-trial/","published":"2017-03-28"},{"url":"https://hartvaat.nl/2017/03/21/werkzaamheid-en-veiligheid-van-tolvaptan-bij-gehospitaliseerd-acuut-hartfalen/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/01/26/langketen-acylcarnitines-bij-hartfalen-prognostische-waarde-en-reversibiliteit-m/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicolas-danchin","type":"person","url":"https://hartvaat.nl/mensen/nicolas-danchin/","name":"Nicolas Danchin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/10/23/aspirine-bij-chronisch-coronairsyndroom-plus-oac-wel-of-niet/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/09/01/normalisatie-van-arteriele-stijfheid-en-cv-events-sparte-studie/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/09/19/trimetazidine-na-pci-lancet-atpci-gerandomiseerde-trial/","published":"2020-09-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ole-frobert","type":"person","url":"https://hartvaat.nl/mensen/ole-frobert/","name":"Ole Fröbert","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/10/07/help-mi-helicobacter-pylori-screening-na-acuut-mi-cluster-rct/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/06/13/griepvaccinatie-en-cardiovasculaire-bescherming-inflammatie-heroverwogen-bij-isc/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2024/11/02/bioadaptor-implantaat-versus-drug-eluting-stent-bij-stabiel-coronairlijden/","published":"2024-11-02"},{"url":"https://hartvaat.nl/2022/03/15/5-jaars-ifr-versus-ffr-geleide-pci-define-flair-ifr-swedeheart/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","published":"2020-01-18"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/05/11/instantaneous-wave-free-ratio-versus-ffr-voor-pci-indicatie-nejm-ifr-swedeheart/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paolo-calabro","type":"person","url":"https://hartvaat.nl/mensen/paolo-calabro/","name":"Paolo Calabrò","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/12/09/gepersonaliseerde-versus-standaard-dapt-duur-na-pci-gerandomiseerde-trial/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2021/02/02/dalend-hemoglobine-en-prognose-bij-acs-hospitalisatie/","published":"2021-02-02"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/05/23/stralingsblootstelling-en-vasculaire-toegang-bij-acs-rad-matrix-trial/","published":"2017-05-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"patrick-t-ellinor","type":"person","url":"https://hartvaat.nl/mensen/patrick-t-ellinor/","name":"Patrick T Ellinor","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/02/10/stressor-geassocieerd-af-incidentie-risicofactoren-en-uitkomsten/","published":"2026-02-10"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2022/03/29/af-screening-bij-ouderen-in-de-huisartsenpraktijk-vital-af-gerandomiseerde-trial/","published":"2022-03-29"},{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/02/25/genetische-risicoscore-voorspelt-voordeel-van-evolocumab-fourier/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2019/07/09/2019-aha-acc-hrs-gerichte-update-van-de-af-richtlijn/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/02/01/genetische-schildklierfunctievoorspellers-en-af-jama-cardiology-mendeliaanse-ran/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/02/21/genetische-obesitas-en-risico-op-atriumfibrilleren-mendeliaanse-randomisatie/","published":"2017-02-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-a-grayburn","type":"person","url":"https://hartvaat.nl/mensen/paul-a-grayburn/","name":"Paul A Grayburn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","published":"2022-11-15"},{"url":"https://hartvaat.nl/2021/04/01/ero-lvedv-ratio-en-respons-op-mitraclip-jama-cardiology/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2019/12/17/echo-uitkomsten-na-mitraclip-bij-secundaire-mr-coapt-echocardiografisch/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philipp-sommer","type":"person","url":"https://hartvaat.nl/mensen/philipp-sommer/","name":"Philipp Sommer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/05/06/transseptale-punctie-bij-linkshartinterventies-nieuwe-esc-consensus-over-technie/","published":"2026-07-29"},{"url":"https://hartvaat.nl/2026/02/03/varipure-studie-pulsed-field-ablatie-in-de-dagelijkse-af-praktijk/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/02/03/aanbesteding-van-cardiale-implanteerbare-devices-in-europa-waarde-of-kosten/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2024/12/17/ablatiestrategie-bij-af-recidief-na-duurzame-pvi/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/05/02/style-af-veneuze-closure-device-versus-figuur-van-acht-hechting-na-af-ablatie/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2023/10/12/castle-htx-af-ablatie-bij-eindstadium-hartfalen-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/02/08/redo-firm-firm-geleide-ablatie-verbetert-uitkomst-niet-bij-recidief-af/","published":"2023-02-08"},{"url":"https://hartvaat.nl/2021/05/21/firm-ablatie-versus-pvi-bij-paroxysmaal-af-gerandomiseerde-resultaten/","published":"2021-05-21"},{"url":"https://hartvaat.nl/2020/10/01/slokdarmsonde-bij-rf-ablatie-voor-af-opera-prospectieve-gerandomiseerde-trial/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2018/11/01/individueel-aangepaste-versus-gestandaardiseerde-substraatmodificatie-bij-rf-abl/","published":"2018-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pierre-amarenco","type":"person","url":"https://hartvaat.nl/mensen/pierre-amarenco/","name":"Pierre Amarenco","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2024/05/16/annexa-i-andexanet-alfa-bij-factor-xa-remmer-geassocieerde-intracerebrale-bloedi/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2020/08/25/carotisatherosclerose-evolutie-bij-ldl-streefwaarde-70-na-ischemisch-cva-tst-sub/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/05/05/atorvastatine-vermindert-eerste-en-volgende-vasculaire-events-sparcl/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/01/02/vergelijking-van-twee-ldl-streefwaarden-na-ischemisch-cva-nejm-tst/","published":"2020-01-02"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/04/20/ldl-reductievariabiliteit-en-antilichaamvorming-bij-bococizumab-nejm/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2016/11/08/residueel-vasculair-risico-bij-secundaire-preventie-verdeling-van-10-jaarsrisico/","published":"2016-11-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pieter-martens","type":"person","url":"https://hartvaat.nl/mensen/pieter-martens/","name":"Pieter Martens","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/05/09/praise-mr-sacubitril-valsartan-verbetert-inspanningshemodynamiek-bij-hfpef-met-a/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/03/25/inspanningsecho-identificeert-hcm-patienten-die-baat-hebben-bij-mavacamten/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2024/10/15/aha-scientific-statement-nierdisfunctie-bij-gevorderd-hartfalen/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","published":"2023-06-09"},{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","published":"2022-09-29"},{"url":"https://hartvaat.nl/2021/12/21/iv-ijzercarboxymaltose-en-cardiale-reverse-remodellering-na-crt-iron-crt/","published":"2021-12-21"},{"url":"https://hartvaat.nl/2020/03/31/staken-van-neurohumorale-blokkade-na-crt/","published":"2020-03-31"},{"url":"https://hartvaat.nl/2018/06/01/implementatie-van-sacubitril-valsartan-in-de-klinische-praktijk-inzichten/","published":"2018-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pim-van-der-harst","type":"person","url":"https://hartvaat.nl/mensen/pim-van-der-harst/","name":"Pim van der Harst","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/05/05/cmr-laci-21-identificeert-hoogrisicopatienten-met-hfref-onafhankelijk-van-lvef-e/","published":"2026-06-30"},{"url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/10/05/ketonlichamen-en-functionele-uitkomsten-na-stemi/","published":"2021-10-05"},{"url":"https://hartvaat.nl/2020/12/01/coronairangiografie-na-hartstilstand-zonder-st-elevatie-coact-1-jaarsuitkomsten/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/11/10/ticagrelor-plus-aspirine-en-safeneuze-graft-patency-na-cabg/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2020/07/01/nieuwe-dna-methyleringsloci-voor-bloeddruk-erfelijkheid-en-genexpressie/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2019/10/24/genotype-geleide-p2y12-remmerkeuze-bij-primaire-pci-nejm-popular-genetics/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/04/11/coronairangiografie-na-hartstilstand-zonder-st-elevatie-nejm-coact/","published":"2019-04-11"},{"url":"https://hartvaat.nl/2018/10/01/transcatheter-interatriale-shunt-bij-hfpef-1-jaarsresultaten/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/01/23/transcatheter-interatriale-shunt-bij-hfpef-reduce-lap-hf-i/","published":"2018-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"piroze-m-davierwala","type":"person","url":"https://hartvaat.nl/mensen/piroze-m-davierwala/","name":"Piroze M Davierwala","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","published":"2019-10-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pradeep-natarajan","type":"person","url":"https://hartvaat.nl/mensen/pradeep-natarajan/","name":"Pradeep Natarajan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/03/28/lp-a-verhoogt-risico-op-veneuze-trombo-embolie-bij-premenopauzale-vrouwen-en-hor/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2026/03/26/acc-verklaring-2026-gen-editing-als-therapie-bij-hart-en-vaatziekten/","published":"2026-03-26"},{"url":"https://hartvaat.nl/2026/03/04/genetisch-bevestigde-familiaire-hypercholesterolemie-in-de-vs-prevalentie-en-ond/","published":"2026-03-22"},{"url":"https://hartvaat.nl/2025/01/01/polygeen-risico-gestuurde-detectie-en-behandeling-van-subklinische-coronaire-ath/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/22/genetische-voorspelling-van-lp-a-spiegels-in-diverse-populaties/","published":"2026-02-22"},{"url":"https://hartvaat.nl/2026/02/05/de-erfelijke-basis-van-coronairlijden-nejm-overzicht/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2025/12/24/genomische-ontdekking-bij-nefrotisch-syndroom-mefv-varianten-als-risicofactor-vo/","published":"2025-12-24"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/04/01/lp-a-en-hscrp-als-cv-risicofactoren-primaire-en-secundaire-preventie/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2017/05/30/polygene-risicoscore-en-relatief-voordeel-van-statinetherapie-primaire-preventie/","published":"2017-05-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-jorg-hausleiter","type":"person","url":"https://hartvaat.nl/mensen/prof-jorg-hausleiter/","name":"Prof. Jörg Hausleiter","title":"Cardioloog, LMU Klinikum, München","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2019/05/14/ecls-bij-cardiogene-shock-na-acuut-mi/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-tric-i-hf-hotline/","title":"TRIC-I-HF: tricuspidalisklepherstel bij hartfalen, de uitkomsten"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rasmus-paulin-beske","type":"person","url":"https://hartvaat.nl/mensen/rasmus-paulin-beske/","name":"Rasmus Paulin Beske","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2023/12/05/bloeddruk-en-zuurstofstreefwaarden-en-nierschade-na-hartstilstand/","published":"2023-12-05"},{"url":"https://hartvaat.nl/2022/10/20/box-bloeddrukdoelen-bij-comateuze-overlevenden-van-hartstilstand/","published":"2022-10-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ratika-parkash","type":"person","url":"https://hartvaat.nl/mensen/ratika-parkash/","name":"Ratika Parkash","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/02/20/vanish2-catheterablatie-versus-antiaritmica-bij-ventriculaire-tachycardie-nejm/","published":"2025-02-20"},{"url":"https://hartvaat.nl/2024/06/01/af-ablatie-bij-hfref-versus-hfpef-meta-analyse/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/01/18/raft-langetermijn-crt-d-bij-hartfalen-nejm-14-jaarsresultaten/","published":"2024-01-18"},{"url":"https://hartvaat.nl/2023/05/01/aware-uitgebreide-ablatie-vermindert-af-recidief-niet-boven-standaard-pvi/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2022/07/15/vt-ablatie-versus-antiaritmica-bij-myocardinfarct-locatie-maakt-uit/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2017/10/01/korte-dabigatran-onderbreking-voor-device-implantatie-re-ly-multicenterervaring/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/05/09/agressieve-bloeddrukcontrole-en-recidief-van-af-na-ablatie-gerandomiseerde-trial/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2016/07/14/ablatie-versus-escalatie-van-antiaritmica-bij-ventriculaire-tachycardie-nejm-van/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rebecca-t-hahn","type":"person","url":"https://hartvaat.nl/mensen/rebecca-t-hahn/","name":"Rebecca T Hahn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/06/10/triluminate-tweejaarsresultaten-transcatheter-tr-repair-duurzaam-effectief/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","published":"2023-11-23"},{"url":"https://hartvaat.nl/2023/05/18/triluminate-transcatheter-tricuspidaliskleprepair-bij-ernstige-tr-nejm/","published":"2023-05-18"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-ballonexpandeerbare-klep-bij-laagrisicopatienten-nejm-partner-3/","published":"2019-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rishi-puri","type":"person","url":"https://hartvaat.nl/mensen/rishi-puri/","name":"Rishi Puri","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/09/01/anemie-verergert-mortaliteit-en-hartfalenheropnames-na-tavr-bij-patienten-boven-/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/01/12/lipide-inhoud-in-verkalkte-plaques-kenmerken-en-respons-op-lage-ldl-c/","published":"2026-01-12"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/01/crp-op-lp-a-geassocieerd-cv-risico-bij-optimaal-behandelde-hoogrisicopatienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2019/04/01/initieel-en-serieel-crp-en-cv-events-en-dood-na-acs-jama-cardiology/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/10/23/evolocumab-en-coronaire-plaquesamenstelling-glagov-beeldvorming/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/09/01/hdl-mimeticum-met-recombinant-apoa-i-milano-en-coronairlijden-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","published":"2016-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-a-byrne","type":"person","url":"https://hartvaat.nl/mensen/robert-a-byrne/","name":"Robert A Byrne","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2021/01/21/korte-dapt-gevolgd-door-p2y12-mono-versus-verlengde-dapt-meta-analyse/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2019/01/15/10-jaarsuitkomsten-van-drie-limus-eluting-stents-coating-vergelijking/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/07/bioresorbeerbare-scaffold-versus-ees-bij-stabiel-coronairlijden-prospectieve-tri/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/05/07/esc-eapci-taskforce-rapport-over-bioresorbeerbare-scaffolds-executive-summary/","published":"2018-05-07"},{"url":"https://hartvaat.nl/2017/10/01/pci-versus-cabg-bij-linker-hoofdstamstenose-jama-cardiology-systematische-review/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"},{"url":"https://hartvaat.nl/2017/01/01/percutane-linker-hartoorsluiting-munchen-consensusdocument-over-definities-en-ei/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/02/06/bioresorbeerbare-versus-metallic-stents-meta-analyse-van-gerandomiseerde-trials/","published":"2016-02-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-c-welsh","type":"person","url":"https://hartvaat.nl/mensen/robert-c-welsh/","name":"Robert C Welsh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/01/27/intracoronair-lage-dosis-rtpa-bij-primaire-pci-voor-stemi-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2023/08/29/stream-2-halve-dosis-tenecteplase-bij-ouderen-met-stemi/","published":"2023-08-29"},{"url":"https://hartvaat.nl/2022/05/01/remote-ischemische-conditionering-bij-stemi-registergebaseerde-gerandomiseerde-t/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2020/08/25/genotype-geleide-p2y12-selectie-versus-clopidogrel-na-pci-jama-tailor-pci/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sakis-themistoclakis","type":"person","url":"https://hartvaat.nl/mensen/sakis-themistoclakis/","name":"Sakis Themistoclakis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/03/17/athena-register-pulsed-field-ablatie-voor-atriumfibrilleren-ook-effectief-bij-ha/","published":"2026-04-20"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/11/01/determinanten-van-linkeratriumtrombi-bij-geplande-cardioversie-ensure-af/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2016/11/01/linker-hartoorisolatie-bij-langdurig-persisterend-af-de-belief-trial/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/26/ablatie-versus-amiodaron-bij-persisterend-af-met-hartfalen-en-icd-gerandomiseerd/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"samia-mora","type":"person","url":"https://hartvaat.nl/mensen/samia-mora/","name":"Samia Mora","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2023/01/01/vitamine-d-voorkomt-statine-gerelateerde-spierklachten-niet/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2021/03/16/omega-3-en-vitamine-d-en-incident-af-jama-vital-af/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/03/03/vitamine-d-en-omega-3-en-hartfalen-hospitalisatie-vital-heart-failure/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2018/10/13/lp-a-baseline-en-on-statin-voor-cv-eventvoorspelling-lancet-ipd-meta-analyse/","published":"2018-10-13"},{"url":"https://hartvaat.nl/2017/06/20/cholesteroleffluxcapaciteit-hdl-deeltjesaantal-en-cv-events-jupiter-analyse/","published":"2017-06-20"},{"url":"https://hartvaat.nl/2016/05/01/lipoproteinen-insulineresistentie-en-rosuvastatine-bij-incident-type-2-diabetes/","published":"2016-05-01"},{"url":"https://hartvaat.nl/2016/05/01/procentuele-ldl-verlaging-bij-hoogintensieve-statinetherapie-implicaties-voor-ri/","published":"2016-05-01"}],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/lipoproteïne-a/","title":"Sessie 3: Lipoproteïne(a)"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"samin-k-sharma","type":"person","url":"https://hartvaat.nl/mensen/samin-k-sharma/","name":"Samin K Sharma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/02/24/yellow-iii-intracoronaire-beeldvorming-en-genexpressie-na-maximale-lipideverlagi/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/02/18/ticagrelor-met-of-zonder-aspirine-na-pci-twilight-plaatjessubstudie/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","published":"2019-02-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"seth-j-baum","type":"person","url":"https://hartvaat.nl/mensen/seth-j-baum/","name":"Seth J Baum","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/09/09/summit-tirzepatide-effect-bij-hfpef-met-en-zonder-diabetes/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/03/11/summit-tirzepatide-en-klinisch-traject-bij-hfpef-met-obesitas-langetermijn/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/01/30/summit-tirzepatide-bij-hfpef-met-obesitas-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2023/11/01/evinacumab-bij-refractaire-hypercholesterolemie-langetermijn-effectiviteit-en-ve/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2022/11/17/olpasiran-sirna-verlaagt-lipoproteine-a-spectaculair-in-fase-2-trial/","published":"2022-11-17"},{"url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2020/12/10/evinacumab-bij-refractaire-hypercholesterolemie-nejm/","published":"2020-12-10"},{"url":"https://hartvaat.nl/2020/10/21/vupanorsen-angptl3-antisense-en-triglyceriden-ehj/","published":"2020-10-21"},{"url":"https://hartvaat.nl/2020/01/16/lp-a-verlaging-bij-cardiovasculaire-ziekte-nejm/","published":"2020-01-16"},{"url":"https://hartvaat.nl/2019/11/12/bempedoinezuur-toegevoegd-aan-statines-bij-hoog-cv-risico-jama-clear-harmony/","published":"2019-11-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shinya-goto","type":"person","url":"https://hartvaat.nl/mensen/shinya-goto/","name":"Shinya Goto","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2017/04/01/niet-ernstige-bloedingen-met-apixaban-versus-warfarine-bij-af/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/09/20/cva-preventie-met-ticagrelor-na-myocardinfarct-pegasus-timi-54-inzichten/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"siddharth-m-patel","type":"person","url":"https://hartvaat.nl/mensen/siddharth-m-patel/","name":"Siddharth M Patel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2022/12/01/serieel-hoog-sensitief-troponine-t-voorspelt-cv-events-na-acs-odyssey-analyse/","published":"2022-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steffen-massberg","type":"person","url":"https://hartvaat.nl/mensen/steffen-massberg/","name":"Steffen Massberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/10/01/cardiale-amyloidose-komt-bij-9-van-tavi-patienten-voor-ongeacht-stromingspatroon/","published":"2026-08-27"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/05/14/ecls-bij-cardiogene-shock-na-acuut-mi/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2017/07/14/voorspelling-van-plotse-versus-niet-plotse-hartdood-na-mi-met-verminderde-lvef/","published":"2017-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephen-g-ellis","type":"person","url":"https://hartvaat.nl/mensen/stephen-g-ellis/","name":"Stephen G Ellis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2023/07/18/bioresorbeerbare-coronaire-scaffolds-vijfjaarsuitkomsten-met-verbeterde-techniek/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2019/12/01/absorb-scaffold-5-jaarsresultaten-systematische-meta-analyse/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2018/10/27/absorb-iv-bioresorbeerbare-scaffold-30-daags-en-1-jaarsresultaten/","published":"2018-10-27"},{"url":"https://hartvaat.nl/2018/05/14/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-meta-analyse/","published":"2018-05-14"},{"url":"https://hartvaat.nl/2018/01/30/absorb-bioresorbeerbare-scaffold-3-jaarsresultaten-ipd-meta-analyse/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2017/12/12/implantatiechniek-en-uitkomsten-van-bioresorbeerbare-scaffolds-absorb-analyses/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/12/12/3-jaarsresultaten-van-bioresorbeerbare-scaffolds-absorb-iii-trial/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","published":"2017-10-19"},{"url":"https://hartvaat.nl/2017/08/19/absorb-bioresorbeerbare-scaffold-lancet-2-jaars-systematische-review-en-meta-ana/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stuart-kupfer","type":"person","url":"https://hartvaat.nl/mensen/stuart-kupfer/","name":"Stuart Kupfer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/03/05/aficamten-veilig-en-effectief-bij-langdurige-behandeling-van-obstructieve-hcm/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2026/01/05/magnesium-en-uitkomsten-bij-hfref-galactic-hf-subanalyse/","published":"2026-01-05"},{"url":"https://hartvaat.nl/2025/10/07/nieuwe-inspanningsherstelpatronen-als-maat-voor-cardiale-prestatie/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2017/05/16/serieel-hoog-sensitief-troponine-i-en-cv-uitkomsten-bij-diabetes-type-2-examine/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/09/01/ace-remmers-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-met-dpp-4-remmers/","published":"2016-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tariq-ahmad","type":"person","url":"https://hartvaat.nl/mensen/tariq-ahmad/","name":"Tariq Ahmad","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2024/09/24/2024-acc-beslispad-klinische-beoordeling-en-trajectmanagement-bij-hfpef/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2023/10/21/prompt-ahf-epd-alerts-verbeteren-hartfalenmedicatie-bij-ontslag/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2022/06/07/elektronische-alerts-verbeteren-hartfalenbehandeling-in-de-polikliniek/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2021/08/01/klinische-fenotypen-zijn-effectiever-dan-ef-categorieen-voor-hf-uitkomsten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2020/09/15/empagliflozine-bij-hartfalen-diuretische-en-cardiorenale-effecten/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2018/05/08/nierfunctieverslechtering-bij-acuut-hartfalen-met-agressieve-diurese-geen-tubula/","published":"2018-05-08"},{"url":"https://hartvaat.nl/2016/05/17/verminderde-cardiac-index-is-niet-de-primaire-oorzaak-van-nierdisfunctie-bij-har/","published":"2016-05-17"},{"url":"https://hartvaat.nl/2016/01/26/langketen-acylcarnitines-bij-hartfalen-prognostische-waarde-en-reversibiliteit-m/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"terry-a-jacobson","type":"person","url":"https://hartvaat.nl/mensen/terry-a-jacobson/","name":"Terry A Jacobson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2024/04/23/lp-a-en-cv-risicoreductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/04/01/icosapent-ethyl-na-acs-reduce-it-subanalyse/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","published":"2022-08-02"},{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/01/03/icosapent-ethyl-en-cardiovasculaire-uitkomsten-bij-hypertriglyceridemie-nejm-red/","published":"2019-01-03"},{"url":"https://hartvaat.nl/2017/09/26/sams-ci-score-toegepast-op-gerandomiseerde-trial-over-statine-myopathie/","published":"2017-09-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-f-luscher","type":"person","url":"https://hartvaat.nl/mensen/thomas-f-luscher/","name":"Thomas F Lüscher","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/05/19/esc-atlas-2025-3-miljoen-cvd-doden-per-jaar-in-europa-middeninkomenlanden-hebben/","published":"2026-06-13"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2022/09/01/collaterale-schade-van-covid-19-aan-cardiovasculaire-zorg-meta-analyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/11/01/ct-coronairangiografie-voor-heart-team-besluitvorming-bij-multivatenlijden/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/07/14/ldl-verlaging-en-cv-events-met-pcsk9-remmers-meta-analyse-van-gerandomiseerde-tr/","published":"2018-07-14"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2017/11/21/bloeddrukeffecten-van-ibuprofen-naproxen-en-celecoxib-bij-artritis-precision-abp/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2016/12/01/tienjaarsuitkomsten-van-eerste-generatie-drug-eluting-stents-ses-versus-pes/","published":"2016-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"upendra-kaul","type":"person","url":"https://hartvaat.nl/mensen/upendra-kaul/","name":"Upendra Kaul","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2016/06/01/pci-bij-insulinebehandelde-versus-niet-insulinebehandelde-diabetes-freedom-trial/","published":"2016-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vinod-h-thourani","type":"person","url":"https://hartvaat.nl/mensen/vinod-h-thourani/","name":"Vinod H Thourani","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/06/10/triluminate-tweejaarsresultaten-transcatheter-tr-repair-duurzaam-effectief/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","published":"2023-11-23"},{"url":"https://hartvaat.nl/2023/05/18/triluminate-transcatheter-tricuspidaliskleprepair-bij-ernstige-tr-nejm/","published":"2023-05-18"},{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2021/02/09/2020-acc-consensus-anticoagulatie-en-antiplaatjestherapie-bij-af-of-vte/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-ballonexpandeerbare-klep-bij-laagrisicopatienten-nejm-partner-3/","published":"2019-05-02"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"william-e-kraus","type":"person","url":"https://hartvaat.nl/mensen/william-e-kraus/","name":"William E Kraus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2023/01/10/dagelijkse-stappen-en-cardiovasculaire-ziekte-geharmoniseerde-meta-analyse/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2022/07/12/frailteit-beinvloedt-effect-van-inspanningstraining-bij-hartfalen-hf-action-anal/","published":"2022-07-12"},{"url":"https://hartvaat.nl/2021/10/12/leefstijlmodificatie-bij-resistente-hypertensie-triumph-gerandomiseerde-trial/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/03/01/genoomwijde-analyse-identificeert-nieuwe-mi-gevoeligheidsloci/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2017/07/20/genetische-en-farmacologische-inactivatie-van-angptl3-en-cardiovasculaire-ziekte/","published":"2017-07-20"},{"url":"https://hartvaat.nl/2017/04/04/inspanningstraining-bij-chronisch-hartfalen-met-atriumfibrilleren/","published":"2017-04-04"},{"url":"https://hartvaat.nl/2016/04/05/hartrevalidatie-versterkt-met-stressmanagementtraining-gerandomiseerde-trial/","published":"2016-04-05"},{"url":"https://hartvaat.nl/2016/02/23/inspanningstestvariabelen-als-mortaliteitsvoorspellers-bij-chronisch-systolisch-/","published":"2016-02-23"},{"url":"https://hartvaat.nl/2016/01/26/langketen-acylcarnitines-bij-hartfalen-prognostische-waarde-en-reversibiliteit-m/","published":"2016-01-26"},{"url":"https://hartvaat.nl/2016/01/05/calorierestrictie-of-aerobe-training-bij-obese-ouderen-met-hfpef-effect-op-vo2-p/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xavier-rossello","type":"person","url":"https://hartvaat.nl/mensen/xavier-rossello/","name":"Xavier Rossello","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/02/11/reboot-betablokkers-na-mi-sekseverschillen/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","published":"2025-09-13"},{"url":"https://hartvaat.nl/2025/04/10/dapagliflozine-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2025-04-10"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2022/03/31/amphilimus-versus-zotarolimus-stents-bij-diabetes-sugar-gerandomiseerde-trial/","published":"2022-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yogesh-n-v-reddy","type":"person","url":"https://hartvaat.nl/mensen/yogesh-n-v-reddy/","name":"Yogesh N V Reddy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2026/04/27/nierfunctiestoornis-verergert-pulmonale-vaatziekte-bij-hfpef/","published":"2026-07-16"},{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2024/09/24/dapagliflozine-verbetert-arteriele-en-veneuze-compliantie-bij-hfpef/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2024/09/01/dapagliflozine-en-rv-pulmonale-interactie-bij-hfpef/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/09/05/cameo-dapa-cardiale-en-metabole-effecten-van-dapagliflozine-bij-hfpef/","published":"2023-09-05"},{"url":"https://hartvaat.nl/2019/11/26/interatriale-shunt-en-pulmonale-vaatfunctie-bij-hfpef/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2017/07/11/arteriele-verstijving-bij-inspanning-bij-hfpef/","published":"2017-07-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"young-bin-song","type":"person","url":"https://hartvaat.nl/mensen/young-bin-song/","name":"Young Bin Song","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/01/01/intravasculaire-beeldvorming-superieur-aan-angiografie-bij-complexe-pci-5-jaarsr/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yuliya-lokhnygina","type":"person","url":"https://hartvaat.nl/mensen/yuliya-lokhnygina/","name":"Yuliya Lokhnygina","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2020/04/28/open-label-drop-in-van-glucoseverlagende-medicatie-en-exscel-uitkomsten/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2019/09/01/simvastatine-ezetimibe-versus-simvastatine-na-acs-bij-75-plussers-jama-cardiolog/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2017/11/01/hypertensiecontrole-bij-diabetes-met-recidiverende-cv-events-tecos-globale-resul/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/28/exenatide-eenmaal-per-week-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-ne/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/09/26/secundaire-cardiovasculaire-preventie-bij-diabetes-type-2-tecos-internationale-i/","published":"2017-09-26"},{"url":"https://hartvaat.nl/2017/03/14/afweging-myocardinfarct-versus-bloedingstype-en-mortaliteit-na-acs-tra-2p-timi-5/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/07/05/verslechterende-nierfunctie-en-uitkomsten-met-rivaroxaban-versus-warfarine-rocke/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/07/01/natief-kleplijden-bij-af-patienten-op-warfarine-of-rivaroxaban/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"},{"url":"https://hartvaat.nl/2016/02/02/reductie-in-totale-cardiovasculaire-events-met-ezetimibe-simvastatine-na-acs-imp/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yves-rosenberg","type":"person","url":"https://hartvaat.nl/mensen/yves-rosenberg/","name":"Yves Rosenberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":10,"articles":[{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/10/tact-2-chelatietherapie-na-mi-bij-diabetes-negatieve-trial/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2020/08/25/genotype-geleide-p2y12-selectie-versus-clopidogrel-na-pci-jama-tailor-pci/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/06/30/af-recidief-na-ablatie-versus-antiaritmica-in-cabana/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-medicamenteus-bij-af-en-kwaliteit-van-leven-jama-cabana-q/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/02/21/laaggedoseerd-methotrexaat-voor-preventie-van-atherosclerotische-events-nejm-cir/","published":"2019-02-21"},{"url":"https://hartvaat.nl/2017/04/01/fenofibraat-en-langetermijn-cardiovasculair-risico-bij-statinebehandelde-diabete/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adam-j-nelson","type":"person","url":"https://hartvaat.nl/mensen/adam-j-nelson/","name":"Adam J Nelson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/05/uk-biobank-na-ischemisch-cva-of-tia-is-het-risico-op-hartfalen-groter-dan-dat-op/","published":"2026-06-29"},{"url":"https://hartvaat.nl/2026/05/25/obicetrapib-verlaagt-naast-ldl-en-apob-ook-lipoproteine-a/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2025/10/07/obicetrapib-en-mace-bij-hoogrisicopatienten-gepoolde-analyse/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2024/07/16/interventie-voor-evidence-based-zorg-bij-diabetes-en-cv-risico/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/03/01/clear-outcomes-bempedoinezuur-vermindert-totale-cv-events-bij-statine-intolerant/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/04/18/gecoordineerde-zorg-optimaliseert-cv-preventie-bij-type-2-diabetes-jama-rct/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2021/07/13/late-rapid-tnt-uitkomsten-0-1-uur-hs-troponine-t-bij-verdenking-acs/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2019/11/05/1-uur-troponine-t-protocol-bij-verdenking-acs-gerandomiseerde-rapid-tnt-trial/","published":"2019-11-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adel-aminian","type":"person","url":"https://hartvaat.nl/mensen/adel-aminian/","name":"Adel Aminian","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/07/08/amulet-versus-watchman-flx-driejaarsresultaten-laa-sluiting/","published":"2025-07-08"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","published":"2024-02-06"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2018/10/06/resolute-onyx-versus-orsiro-stent-lancet-gerandomiseerde-non-inferioriteitstrial/","published":"2018-10-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"albert-wiegman","type":"person","url":"https://hartvaat.nl/mensen/albert-wiegman/","name":"Albert Wiegman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/18/global-hicc-register-950-hofh-patienten-uit-45-landen-slechts-4-haalt-ldl-doelen/","published":"2026-06-17"},{"url":"https://hartvaat.nl/2026/05/25/eas-consensus-familiaire-hypercholesterolemie-bij-kinderen-en-adolescenten/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/03/24/cascadescreening-op-verhoogd-lp-a-via-kinderen-opbrengst-in-de-praktijk-amsterda/","published":"2026-03-24"},{"url":"https://hartvaat.nl/2026/02/03/statine-intolerantie-bij-kinderen-met-familiaire-hypercholesterolemie-15-jaar-kl/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/12/22/evinacumab-bij-kinderen-van-5-17-jaar-met-homozygote-familiaire-hypercholesterol/","published":"2025-12-22"},{"url":"https://hartvaat.nl/2025/06/24/inclisiran-bij-adolescenten-met-homozygote-fh-effectiviteit-en-veiligheid/","published":"2025-06-24"},{"url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2020/10/01/evolocumab-bij-pediatrische-heterozygoot-fh-nejm-hauser-rct/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2017/08/29/rosuvastatine-bij-kinderen-met-homozygote-familiaire-hypercholesterolemie/","published":"2017-08-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andreas-schafer","type":"person","url":"https://hartvaat.nl/mensen/andreas-schafer/","name":"Andreas Schäfer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/03/25/palliatieve-zorg-in-de-cardiologie-een-state-of-the-art-overzicht/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/02/19/delirium-in-de-cardiovasculaire-geneeskunde/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-m-tonkin","type":"person","url":"https://hartvaat.nl/mensen/andrew-m-tonkin/","name":"Andrew M Tonkin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2025/12/09/aspree-cardiale-stress-en-bloeddrukmanagement-bij-ouderen/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/11/01/pneumokokkenvaccinatie-en-cv-eventpreventie-ipd-meta-analyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/01/28/lp-a-en-ldl-cholesterol-onafhankelijke-cv-risicopaden/","published":"2025-01-28"},{"url":"https://hartvaat.nl/2020/12/01/langetermijn-bloeddrukvariabiliteit-en-cv-risico-bij-ouderen-in-de-community/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/07/07/statinegebruik-en-invaliditeitsvrije-overleving-bij-gezonde-ouderen/","published":"2020-07-07"},{"url":"https://hartvaat.nl/2019/01/01/polypil-en-cardiovasculaire-preventie-meta-analyse-van-gerandomiseerde-trials/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/10/13/lp-a-baseline-en-on-statin-voor-cv-eventvoorspelling-lancet-ipd-meta-analyse/","published":"2018-10-13"},{"url":"https://hartvaat.nl/2016/11/22/plasma-lipidomiek-verbetert-cardiovasculaire-risicovoorspelling-bij-diabetes-typ/","published":"2016-11-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anita-deswal","type":"person","url":"https://hartvaat.nl/mensen/anita-deswal/","name":"Anita Deswal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/05/vroege-harttoxiciteit-na-doxorubicine-bij-jongvolwassenen-met-sarcoom/","published":"2026-07-29"},{"url":"https://hartvaat.nl/2026/05/27/multimodaal-ai-model-verhoogt-accuratesse-van-echo-diagnose-cardiale-amyloidose/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2023/05/09/2023-acc-expert-consensus-management-van-hfpef/","published":"2023-05-09"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2016/12/06/comorbiditeiten-bij-hartfalen-hypertensie-obesitas-diabetes-hyperlipidemie-en-me/","published":"2016-12-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anthony-j-dalby","type":"person","url":"https://hartvaat.nl/mensen/anthony-j-dalby/","name":"Anthony J Dalby","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2017/12/19/cva-preventie-met-ezetimibe-bij-acs-improve-it-analyse/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2016/09/20/cva-preventie-met-ticagrelor-na-myocardinfarct-pegasus-timi-54-inzichten/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/08/01/eerder-clopidogrelgebruik-en-uitkomsten-bij-conservatief-behandeld-acs/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ashkan-eftekhari","type":"person","url":"https://hartvaat.nl/mensen/ashkan-eftekhari/","name":"Ashkan Eftekhari","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/10/01/voorgebruik-van-opioiden-verhoogt-sterfte-en-ziekenhuisopnames-na-tavi-deens-coh/","published":"2026-08-21"},{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","published":"2024-11-09"},{"url":"https://hartvaat.nl/2023/11/01/ifr-versus-ffr-en-vijfjaarsmortaliteit-swedeheart-en-define-flair/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"atul-anand","type":"person","url":"https://hartvaat.nl/mensen/atul-anand/","name":"Atul Anand","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/11/11/risicostratificatie-met-hoog-sensitief-troponine-op-de-seh-veiligheidsanalyse/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2021/07/08/grace-2-0-score-bij-type-1-en-type-2-mi/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/08/01/endothelinereceptorantagonisme-verbetert-lipidenprofielen-en-verlaagt-pcsk9-bij-/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/04/01/sekseverschillen-in-effectiviteit-van-orale-p2y12-remmers-meta-analyse/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2017/11/21/hoog-sensitief-troponine-i-en-uitkomsten-bij-verdenking-acs-jama-studie/","published":"2017-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"barry-r-davis","type":"person","url":"https://hartvaat.nl/mensen/barry-r-davis/","name":"Barry R Davis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/04/25/bloeddrukverlaging-beschermt-over-het-hele-spectrum-van-chronische-nierschade-la/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2023/11/01/sekseverschillen-in-effect-van-bloeddrukverlaging-ipd-meta-analyse/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/07/27/langetermijneffect-van-antihypertensiva-op-bloeddruk-meta-analyse-op-individueel/","published":"2022-07-27"},{"url":"https://hartvaat.nl/2021/11/13/bloeddrukverlaging-en-risico-op-diabetes-type-2-lancet-bplttc-ipd-meta-analyse/","published":"2021-11-13"},{"url":"https://hartvaat.nl/2019/10/01/antihypertensivaklasse-en-vallen-syncope-en-orthostatische-hypotensie-bij-oudere/","published":"2019-10-01"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2017/07/01/heterogeniteit-in-vroege-respons-op-antihypertensiva-allhat/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/07/01/medicatie-non-adherentie-en-visit-to-visit-bloeddrukvariabiliteit-target-bp-stud/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bernard-j-gersh","type":"person","url":"https://hartvaat.nl/mensen/bernard-j-gersh/","name":"Bernard J Gersh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2020/01/07/nsaid-s-en-oac-bij-af-aristotle-analyse/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/08/01/uitkomsten-bij-af-met-oac-bij-mitralis-of-aortakleplijden/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/07/31/bnp-bij-linker-hoofdstamrevascularisatie-excel-analyse/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2017/02/14/doac-s-bij-af-met-kleplijden-excl-significante-mitralisstenose-meta-analyse/","published":"2017-02-14"},{"url":"https://hartvaat.nl/2016/12/20/off-label-doac-dosering-en-ongunstige-uitkomsten-orbit-af-ii-register/","published":"2016-12-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"boyoung-joung","type":"person","url":"https://hartvaat.nl/mensen/boyoung-joung/","name":"Boyoung Joung","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/10/14/alone-af-langetermijn-anticoagulatieonthouding-na-af-ablatie-rct/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2024/12/03/ct-gestuurde-atriale-wanddiktemapping-bij-cryoballon-pvi/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2019/05/14/wanneer-doac-stoppen-voor-af-ablatie-multicenter-analyse/","published":"2019-05-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brendon-l-neuen","type":"person","url":"https://hartvaat.nl/mensen/brendon-l-neuen/","name":"Brendon L Neuen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/02/27/sglt2-remmers-bij-ernstig-verminderde-nierfunctie-data-uit-credence/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2025/01/01/timing-van-cardiovasculaire-en-renale-voordelen-van-finerenon-bij-hartfalen-en-c/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/24/risicovoorspellingsmodellen-voor-ouderen-met-chronische-nierziekte/","published":"2025-12-24"},{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2024/11/26/glp-1-agonisten-alleen-en-met-sglt2-remmers-cv-renale-en-veiligheidsuitkomsten/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/06/04/sacubitril-valsartan-bij-hartfalen-over-het-nierfunctiespectrum/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2021/04/01/canagliflozine-naar-diureticagebruik-canvas-post-hoc-analyse/","published":"2021-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bruno-r-da-costa","type":"person","url":"https://hartvaat.nl/mensen/bruno-r-da-costa/","name":"Bruno R da Costa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/06/09/tino-stents-versus-des-bij-acs-ipd-meta-analyse/","published":"2025-06-09"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/07/01/tino-gecoate-versus-everolimus-eluting-stents-bij-acs-tides-acs-vijfjaarsdata/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2020/10/01/natuurlijk-beloop-van-asymptomatische-ernstige-aortastenose-jama-cardiology-meta/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/09/24/asymptomatische-patienten-met-abnormale-ffr-medicamenteus-versus-pci/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2019/04/01/restrictieve-versus-liberale-transfusie-bij-hartchirurgie-meta-analyse/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2017/11/28/schildklierfunctie-en-risico-op-af-subclinische-hypothyreoidie/","published":"2017-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brge-g-nordestgaard","type":"person","url":"https://hartvaat.nl/mensen/brge-g-nordestgaard/","name":"Børge G Nordestgaard","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/03/02/barrieres-bij-implementatie-van-lipidenverlagende-therapie-in-de-praktijk/","published":"2026-03-26"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2020/05/26/wereldwijde-prevalentie-van-familiaire-hypercholesterolemie-meta-analyse-van-11-/","published":"2020-05-26"},{"url":"https://hartvaat.nl/2020/01/16/lp-a-verlaging-bij-cardiovasculaire-ziekte-nejm/","published":"2020-01-16"},{"url":"https://hartvaat.nl/2019/09/17/ldl-cholesterol-en-micro-versus-macrovasculaire-ziekte-mendeliaanse-randomisatie/","published":"2019-09-17"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2017/07/20/genetische-en-farmacologische-inactivatie-van-angptl3-en-cardiovasculaire-ziekte/","published":"2017-07-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carlos-collet","type":"person","url":"https://hartvaat.nl/mensen/carlos-collet/","name":"Carlos Collet","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/26/esc-consensusverklaring-over-microvasculaire-obstructie-en-no-reflow-na-stemi/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2025/12/29/functionele-en-morfologische-karakterisering-van-coronaire-atherosclerose/","published":"2025-12-29"},{"url":"https://hartvaat.nl/2025/06/09/tino-stents-versus-des-bij-acs-ipd-meta-analyse/","published":"2025-06-09"},{"url":"https://hartvaat.nl/2023/07/01/tino-gecoate-versus-everolimus-eluting-stents-bij-acs-tides-acs-vijfjaarsdata/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/09/24/asymptomatische-patienten-met-abnormale-ffr-medicamenteus-versus-pci/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2018/11/01/ct-coronairangiografie-voor-heart-team-besluitvorming-bij-multivatenlijden/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/09/01/late-trombotische-events-na-bioresorbeerbare-scaffold-meta-analyse-van-gerandomi/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2016/09/06/pci-versus-cabg-bij-onbeschermde-hoofdstamziekte-uitkomsten/","published":"2016-09-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chetan-b-patel","type":"person","url":"https://hartvaat.nl/mensen/chetan-b-patel/","name":"Chetan B Patel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2023/10/24/inhalatief-epoprostenol-versus-no-bij-rechterventrikel-falen-na-hartchirurgie/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/07/18/palliatieve-zorg-bij-hartfalen-de-pal-hf-gerandomiseerde-trial/","published":"2017-07-18"},{"url":"https://hartvaat.nl/2017/05/23/hemocompatibiliteitsuitkomsten-van-heartmate-3-na-6-maanden-momentum-3/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/03/21/werkzaamheid-en-veiligheid-van-tolvaptan-bij-gehospitaliseerd-acuut-hartfalen/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","published":"2017-02-02"},{"url":"https://hartvaat.nl/2016/01/26/langketen-acylcarnitines-bij-hartfalen-prognostische-waarde-en-reversibiliteit-m/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-e-singer","type":"person","url":"https://hartvaat.nl/mensen/daniel-e-singer/","name":"Daniel E Singer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/02/10/stressor-geassocieerd-af-incidentie-risicofactoren-en-uitkomsten/","published":"2026-02-10"},{"url":"https://hartvaat.nl/2024/11/19/screening-op-niet-gediagnosticeerd-af-voor-cva-preventie-gerandomiseerde-trial/","published":"2024-11-19"},{"url":"https://hartvaat.nl/2022/03/29/af-screening-bij-ouderen-in-de-huisartsenpraktijk-vital-af-gerandomiseerde-trial/","published":"2022-03-29"},{"url":"https://hartvaat.nl/2018/12/01/ras-etniciteit-en-oac-gebruik-bij-af-orbit-af/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2016/12/20/off-label-doac-dosering-en-ongunstige-uitkomsten-orbit-af-ii-register/","published":"2016-12-20"},{"url":"https://hartvaat.nl/2016/08/01/hospitalisaties-bij-atriumfibrilleren-analyse-uit-rocket-af/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/07/05/verslechterende-nierfunctie-en-uitkomsten-met-rivaroxaban-versus-warfarine-rocke/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/07/01/natief-kleplijden-bij-af-patienten-op-warfarine-of-rivaroxaban/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/01/26/polyfarmacie-en-werkzaamheid-van-rivaroxaban-versus-warfarine-bij-atriumfibrille/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-j-f-m-thuijs","type":"person","url":"https://hartvaat.nl/mensen/daniel-j-f-m-thuijs/","name":"Daniel J F M Thuijs","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","published":"2019-10-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-m-kaye","type":"person","url":"https://hartvaat.nl/mensen/david-m-kaye/","name":"David M Kaye","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2020/01/02/alcoholonthouding-bij-drinkers-met-af-nejm-gerandomiseerde-trial/","published":"2020-01-02"},{"url":"https://hartvaat.nl/2020/01/01/obesitas-opzettelijk-gewichtsverlies-en-hartfalen-meta-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/26/interatriale-shunt-en-pulmonale-vaatfunctie-bij-hfpef/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2018/10/01/transcatheter-interatriale-shunt-bij-hfpef-1-jaarsresultaten/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/01/23/transcatheter-interatriale-shunt-bij-hfpef-reduce-lap-hf-i/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/10/17/katheterablatie-versus-frequentiecontrole-bij-af-met-systolische-disfunctie-came/","published":"2017-10-17"},{"url":"https://hartvaat.nl/2016/03/01/effect-van-aanvullende-zuurstoftoediening-op-myocardschade-bij-stemi/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-m-reboussin","type":"person","url":"https://hartvaat.nl/mensen/david-m-reboussin/","name":"David M Reboussin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukcontrole-en-cerebrale-small-vessel-disease-markers/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-systematische-review-circulation/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/06/01/systematische-review-voor-de-2017-acc-aha-hypertensierichtlijn-hypertension-edit/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/05/15/systematische-review-voor-de-2017-acc-aha-hypertensierichtlijn/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","published":"2017-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"davide-cao","type":"person","url":"https://hartvaat.nl/mensen/davide-cao/","name":"Davide Cao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2022/10/01/mitraclip-bij-secundaire-mitralisklepinsufficientie-meta-analyse-ischemisch-vs-n/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/05/09/p2y12-monotherapie-of-aspirine-voor-secundaire-preventie-lancet-meta-analyse/","published":"2020-05-09"},{"url":"https://hartvaat.nl/2018/03/01/doac-plus-antiplaatjestherapie-voor-secundaire-preventie-na-acs-meta-analyse/","published":"2018-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"diana-a-gorog","type":"person","url":"https://hartvaat.nl/mensen/diana-a-gorog/","name":"Diana A Gorog","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/08/21/allegra-kunstklep-toont-veelbelovende-techniek-en-veiligheidsresultaten-bij-valv/","published":"2026-08-30"},{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2026/02/23/het-jaar-in-de-cardiovasculaire-geneeskunde-2025-top-10-publicaties-ischemische-/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","published":"2025-07-21"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2023/01/24/pcsk9-remming-bij-covid-19-anti-inflammatoir-potentieel-onderzocht/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2022/04/09/asundexian-factor-xia-remmer-versus-apixaban-bij-af-lancet-pacific-af/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","published":"2019-10-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dirk-von-lewinski","type":"person","url":"https://hartvaat.nl/mensen/dirk-von-lewinski/","name":"Dirk von Lewinski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2022/11/01/emmy-empagliflozine-na-acuut-myocardinfarct-verbetert-nt-probnp-en-remodelling/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eloi-marijon","type":"person","url":"https://hartvaat.nl/mensen/eloi-marijon/","name":"Eloi Marijon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/03/06/laminopathieen-natuurlijk-beloop-en-voorspelmodel-voor-hartfalen/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/04/03/laa-sluiting-na-af-ablatie-gerandomiseerde-trial-nejm/","published":"2025-04-03"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/11/19/afloat-flecainide-voorkomt-af-na-pfo-sluiting-rct/","published":"2024-11-19"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/03/uitgebreide-versus-standaard-remote-monitoring-bij-crt-en-hartfalen/","published":"2024-10-03"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2020/06/01/trends-in-plotse-hartdood-bij-hf-met-crt-systematische-review/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2018/03/01/doodsoorzaken-bij-crt-met-en-zonder-defibrillator-meta-analyse/","published":"2018-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"elsayed-z-soliman","type":"person","url":"https://hartvaat.nl/mensen/elsayed-z-soliman/","name":"Elsayed Z Soliman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/04/20/biomarkers-voorspellen-coronairlijden-bij-atriumfibrilleren-regards/","published":"2026-07-16"},{"url":"https://hartvaat.nl/2024/09/01/troponine-nt-probnp-en-cognitieve-uitkomsten-in-sprint/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/06/01/intensieve-bloeddrukcontrole-en-geleidingsziekten-sprint-post-hoc-analyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/10/18/intensieve-bloeddrukverlaging-bij-maligne-linkerventrikel-hypertrofie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/06/01/intensieve-bloeddrukverlaging-en-risico-op-af-sprint-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2017/08/01/intensieve-bloeddrukverlaging-en-linkerventrikelhypertrofie-sprint-echocardiogra/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/02/21/genetische-obesitas-en-risico-op-atriumfibrilleren-mendeliaanse-randomisatie/","published":"2017-02-21"},{"url":"https://hartvaat.nl/2016/08/01/vitamine-d-en-incidentie-van-atriumfibrilleren-de-aric-studie/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"emma-svennberg","type":"person","url":"https://hartvaat.nl/mensen/emma-svennberg/","name":"Emma Svennberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/08/25/risicogestuurde-af-screening-met-machine-learning-verhoogt-detectiegraad-find-af/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2024/12/03/nt-probnp-en-ecg-screening-bij-75-jarigen-voor-af-detectie-rct/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/01/14/strokestop-af-screening-is-kosteneffectief-bij-75-76-jarigen/","published":"2023-01-14"},{"url":"https://hartvaat.nl/2021/10/23/systematische-af-screening-en-klinische-uitkomsten-lancet-strokestop/","published":"2021-10-23"},{"url":"https://hartvaat.nl/2020/01/01/stapsgewijze-af-screening-met-nt-probnp-strokestop-ii-resultaten/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2017/08/01/nt-probnp-bij-systematische-screening-op-atriumfibrilleren/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/02/01/stapsgewijze-massascreening-op-af-met-nt-probnp-strokestop-ii-studieontwerp/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"etienne-puymirat","type":"person","url":"https://hartvaat.nl/mensen/etienne-puymirat/","name":"Etienne Puymirat","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/10/23/aspirine-bij-chronisch-coronairsyndroom-plus-oac-wel-of-niet/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","published":"2021-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eva-prescott","type":"person","url":"https://hartvaat.nl/mensen/eva-prescott/","name":"Eva Prescott","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/25/betami-danblock-is-representatief-betablokker-effect-ook-geldig-in-echte-noorse-/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2024/04/01/inspanningstraining-en-hoog-sensitief-troponine-i-bij-hfref/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2021/06/01/inspanningstraining-en-hs-troponine-t-bij-hfref/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2018/01/07/2017-esc-richtlijn-voor-stemi-management/","published":"2018-01-07"},{"url":"https://hartvaat.nl/2017/02/28/hoog-intensieve-intervaltraining-bij-hartfalen-met-verminderde-ejectiefractie/","published":"2017-02-28"},{"url":"https://hartvaat.nl/2017/01/03/traditionele-cv-risicofactoren-en-veneuze-trombo-embolie-individuele-patientdata/","published":"2017-01-03"},{"url":"https://hartvaat.nl/2016/08/01/2016-europese-richtlijnen-voor-cardiovasculaire-preventie-in-de-klinische-prakti/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"florentina-a-simader","type":"person","url":"https://hartvaat.nl/mensen/florentina-a-simader/","name":"Florentina A Simader","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2023/03/30/upgrade-van-rv-pacemaker-naar-crt-of-geleidingssysteempacing-meta-analyse/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/02/16/catheterablatie-verbetert-cv-uitkomsten-bij-af-en-hartfalen-meta-analyse-van-rct/","published":"2023-02-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"folkert-w-asselbergs","type":"person","url":"https://hartvaat.nl/mensen/folkert-w-asselbergs/","name":"Folkert W Asselbergs","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/02/24/kwaliteitscriteria-voor-ai-implementatie-in-de-cardiologie-bijgewerkt/","published":"2026-04-01"},{"url":"https://hartvaat.nl/2024/08/21/pa-drukmonitoring-bij-chronisch-hartfalen-effecten-over-klinische-subgroepen/","published":"2024-08-21"},{"url":"https://hartvaat.nl/2023/06/24/monitor-hf-pa-drukmonitoring-bij-hartfalen-effectief-in-europa-lancet-rct/","published":"2023-06-24"},{"url":"https://hartvaat.nl/2022/10/01/bloedbiomerkers-voor-prognose-bij-hypertrofische-cardiomyopathie-meta-analyse/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2022/09/26/smartphone-detectie-van-af-via-fotoplethysmografie-meta-analyse/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2021/03/01/genoomwijde-analyse-identificeert-nieuwe-mi-gevoeligheidsloci/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2019/10/24/genotype-geleide-p2y12-remmerkeuze-bij-primaire-pci-nejm-popular-genetics/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2018/01/01/genetische-associatie-van-lipiden-en-lipide-doelwitten-met-abdominaal-aorta-aneu/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francesco-bedogni","type":"person","url":"https://hartvaat.nl/mensen/francesco-bedogni/","name":"Francesco Bedogni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/04/16/pandora-register-supra-versus-intra-annulaire-kleppen-bij-tavr-in-tavr/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/02/03/linkerbundeltakpacing-versus-rechterventrikel-pacing-na-tavi/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","published":"2024-02-06"},{"url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2017/05/30/tijdstrends-in-complicaties-van-bioresorbeerbare-versus-metallic-stents/","published":"2017-05-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frank-e-harrell","type":"person","url":"https://hartvaat.nl/mensen/frank-e-harrell/","name":"Frank E Harrell","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2024/04/09/dapagliflozine-bij-acuut-hartfalen-effectiviteit-en-veiligheid/","published":"2024-04-09"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"george-c-m-siontis","type":"person","url":"https://hartvaat.nl/mensen/george-c-m-siontis/","name":"George C M Siontis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neoatherosclerose-na-stemi-secundaire-analyse/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/08/01/biodegradeerbare-versus-duurzame-polymeer-ees-langetermijn-neoatherosclerose/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2021/10/01/paroxetine-grk2-remming-versus-placebo-bij-anterieur-mi-jama-cardiology/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2018/09/01/ultradunne-biodegradeerbare-versus-dunne-duurzame-stents-lancet-gerandomiseerde-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/04/07/statines-en-niet-statine-ldl-verlagers-en-cardiovasculaire-uitkomsten-meta-analy/","published":"2018-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gerald-f-watts","type":"person","url":"https://hartvaat.nl/mensen/gerald-f-watts/","name":"Gerald F Watts","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/25/eas-consensus-familiaire-hypercholesterolemie-bij-kinderen-en-adolescenten/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/04/01/risicofactoren-voor-cardiovasculaire-events-bij-heterozygote-familiaire-hypercho/","published":"2026-05-06"},{"url":"https://hartvaat.nl/2025/01/09/plozasiran-bij-persisterende-chylomicronemie-en-pancreatitisrisico-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2024/09/12/zodasiran-sirna-tegen-angptl3-bij-gemengde-hyperlipidemie-nejm/","published":"2024-09-12"},{"url":"https://hartvaat.nl/2024/07/01/plozasiran-sirna-tegen-apoc3-bij-ernstige-hypertriglyceridemie-shasta-2/","published":"2024-07-01"},{"url":"https://hartvaat.nl/2022/05/03/korte-interfererende-rna-tegen-lp-a-jama-fase-1-dosisstudie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2020/06/02/prevalentie-van-fh-bij-atherosclerotische-cv-ziekte-meta-analyse/","published":"2020-06-02"},{"url":"https://hartvaat.nl/2017/11/14/ldl-verlaging-voor-primaire-preventie-bij-mannen-met-primaire-ldl-verhoging/","published":"2017-11-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gianfranco-parati","type":"person","url":"https://hartvaat.nl/mensen/gianfranco-parati/","name":"Gianfranco Parati","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/10/01/esh-convenant-polshorloges-bloeddrukmeters-acceptabele-nauwkeurigheid-maar-klini/","published":"2026-09-02"},{"url":"https://hartvaat.nl/2026/05/01/cardioselectieve-betablokkers-veilig-en-nuttig-bij-copd-systematische-review/","published":"2026-08-01"},{"url":"https://hartvaat.nl/2025/12/09/aspree-cardiale-stress-en-bloeddrukmanagement-bij-ouderen/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2022/10/01/inspanningshemodynamiek-bij-hfpef-systematische-review-en-meta-analyse/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/12/07/av-junctieablatie-plus-crt-bij-permanent-af-met-smal-qrs-apaf-crt-mortaliteitsan/","published":"2021-12-07"},{"url":"https://hartvaat.nl/2021/02/01/therapietrouw-aan-single-pill-versus-vrije-combinatietherapie-bij-hypertensie-me/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/06/01/arb-versus-calciumantagonist-bloeddrukprofiel-en-klinische-effecten-vergelijking/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/04/01/optimale-systolische-bloeddruk-voor-primaire-cva-preventie-bij-hypertensie-csppt/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gianni-casella","type":"person","url":"https://hartvaat.nl/mensen/gianni-casella/","name":"Gianni Casella","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/01/01/rivaroxaban-discontinueringspercentages-bij-niet-valvulair-af-in-de-italiaanse-p/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/09/11/multidomein-revalidatie-bij-ouderen-na-mi-gerandomiseerde-trial-nejm/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","published":"2024-11-09"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2020/11/07/complete-revascularisatie-vermindert-cv-dood-bij-stemi-met-multivatenlijden-meta/","published":"2020-11-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giuseppe-biondi-zoccai","type":"person","url":"https://hartvaat.nl/mensen/giuseppe-biondi-zoccai/","name":"Giuseppe Biondi-Zoccai","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2022/09/01/collaterale-schade-van-covid-19-aan-cardiovasculaire-zorg-meta-analyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","published":"2022-03-07"},{"url":"https://hartvaat.nl/2020/07/14/radiale-arterie-versus-vena-saphena-graft-bij-cabg-jama-langetermijn-meta-analys/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2016/12/21/statines-voor-primaire-preventie-bij-hiv-positieve-patienten-systematische-revie/","published":"2016-12-21"},{"url":"https://hartvaat.nl/2016/02/07/impact-van-pcsk9-remmers-op-lipidenniveaus-en-uitkomsten-netwerkmeta-analyse/","published":"2016-02-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"graham-d-cole","type":"person","url":"https://hartvaat.nl/mensen/graham-d-cole/","name":"Graham D Cole","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"guy-amit","type":"person","url":"https://hartvaat.nl/mensen/guy-amit/","name":"Guy Amit","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/02/20/vanish2-catheterablatie-versus-antiaritmica-bij-ventriculaire-tachycardie-nejm/","published":"2025-02-20"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2022/10/13/voorbehandeling-met-antiaritmica-voor-cardioversie-bij-af-netwerk-meta-analyse/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2021/06/15/prevalentie-van-linkeratriumtrombus-bij-geanticoaguleerde-af-patienten/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"},{"url":"https://hartvaat.nl/2019/06/01/amiodaron-voor-en-na-electrische-cardioversie-van-af-meta-analyse/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2017/07/01/werkzaamheid-van-katheterablatie-bij-niet-paroxysmaal-atriumfibrilleren-jama-car/","published":"2017-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hariharan-sugumar","type":"person","url":"https://hartvaat.nl/mensen/hariharan-sugumar/","name":"Hariharan Sugumar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/02/16/hoog-vermogen-korte-duur-versus-laag-vermogen-langere-duur-posteriore-ablatie-bi/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2020/01/02/alcoholonthouding-bij-drinkers-met-af-nejm-gerandomiseerde-trial/","published":"2020-01-02"},{"url":"https://hartvaat.nl/2017/10/17/katheterablatie-versus-frequentiecontrole-bij-af-met-systolische-disfunctie-came/","published":"2017-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"henrik-schmidt","type":"person","url":"https://hartvaat.nl/mensen/henrik-schmidt/","name":"Henrik Schmidt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/12/05/bloeddruk-en-zuurstofstreefwaarden-en-nierschade-na-hartstilstand/","published":"2023-12-05"},{"url":"https://hartvaat.nl/2022/10/20/box-bloeddrukdoelen-bij-comateuze-overlevenden-van-hartstilstand/","published":"2022-10-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hironori-hara","type":"person","url":"https://hartvaat.nl/mensen/hironori-hara/","name":"Hironori Hara","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"huei-wang","type":"person","url":"https://hartvaat.nl/mensen/huei-wang/","name":"Huei Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/01/13/effectiviteit-en-veiligheid-van-zeer-laag-bereikt-ldl-na-ischemisch-cva/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2025/05/20/intensieve-ldl-verlaging-met-evolocumab-bij-auto-immuunziekten-rct/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2022/11/17/olpasiran-sirna-verlaagt-lipoproteine-a-spectaculair-in-fase-2-trial/","published":"2022-11-17"},{"url":"https://hartvaat.nl/2020/05/12/cognitie-na-ldl-verlaging-met-evolocumab-fourier-follow-up/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/02/25/genetische-risicoscore-voorspelt-voordeel-van-evolocumab-fourier/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2018/07/10/inflammatie-en-cholesterol-in-de-fourier-trial/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2017/08/17/cognitieve-functie-in-de-fourier-trial-met-evolocumab-nejm-ebbinghaus/","published":"2017-08-17"},{"url":"https://hartvaat.nl/2017/05/04/evolocumab-en-klinische-uitkomsten-bij-cardiovasculaire-ziekte-nejm-fourier/","published":"2017-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hwee-teoh","type":"person","url":"https://hartvaat.nl/mensen/hwee-teoh/","name":"Hwee Teoh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/03/09/semaglutide-stimuleert-anti-inflammatoire-stamcelflux-vanuit-beenmerg/","published":"2026-03-09"},{"url":"https://hartvaat.nl/2026/02/19/evolocumab-en-doorgankelijkheid-van-veneuze-bypasses-na-cabg-newton-cabg-cardiol/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","published":"2025-09-20"},{"url":"https://hartvaat.nl/2023/06/01/igfbp7-en-lv-massaregressie-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/nlr-en-cardiale-remodelling-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/diabetesduur-beinvloedt-lv-massaregressie-met-empagliflozine/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2019/11/19/empagliflozine-en-lv-massa-bij-diabetes-type-2-met-coronairlijden-empa-heart/","published":"2019-11-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ildiko-lingvay","type":"person","url":"https://hartvaat.nl/mensen/ildiko-lingvay/","name":"Ildiko Lingvay","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/08/18/semaglutide-verlaagt-hscrp-en-ontstekingsactiviteit-bij-ascvd-patienten-met-over/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","published":"2024-08-24"},{"url":"https://hartvaat.nl/2024/07/16/interventie-voor-evidence-based-zorg-bij-diabetes-en-cv-risico/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2023/12/14/select-semaglutide-vermindert-cv-events-bij-obesitas-zonder-diabetes-nejm/","published":"2023-12-14"},{"url":"https://hartvaat.nl/2023/07/18/sglt2-remmers-verbeteren-kwaliteit-van-leven-gelijk-bij-zwarte-en-witte-hartfale/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2023/04/18/gecoordineerde-zorg-optimaliseert-cv-preventie-bij-type-2-diabetes-jama-rct/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2019/08/29/orale-semaglutide-en-cv-uitkomsten-bij-diabetes-type-2-nejm-pioneer-6/","published":"2019-08-29"},{"url":"https://hartvaat.nl/2016/11/10/semaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-sustain-6/","published":"2016-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ingrid-a-m-gause-nilsson","type":"person","url":"https://hartvaat.nl/mensen/ingrid-a-m-gause-nilsson/","name":"Ingrid A M Gause-Nilsson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2022/09/01/dapagliflozine-effectief-ongeacht-cv-achtergrondmedicatie-declare-subanalyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ioanna-kosmidou","type":"person","url":"https://hartvaat.nl/mensen/ioanna-kosmidou/","name":"Ioanna Kosmidou","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/09/07/des-versus-cabg-bij-hoofdstamlijden-mortaliteits-meta-analyse/","published":"2020-09-07"},{"url":"https://hartvaat.nl/2020/04/14/langetermijnuitkomsten-bij-vrouwen-en-mannen-na-pci/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"james-e-udelson","type":"person","url":"https://hartvaat.nl/mensen/james-e-udelson/","name":"James E Udelson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2020/10/20/praliciguat-en-piek-vo2-bij-hfpef-jama-capacity-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2019/01/15/lv-unloading-voor-reperfusie-bij-anterieure-stemi-dtu-stemi-pilot/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2017/03/21/kortetermijneffecten-van-tolvaptan-bij-acuut-hartfalen-met-volume-overbelasting/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/04/12/infarctgrootte-en-uitkomsten-na-primaire-pci-patientanalyse-uit-10-trials/","published":"2016-04-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"janine-poss","type":"person","url":"https://hartvaat.nl/mensen/janine-poss/","name":"Janine Pöss","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/03/03/4-eiwitmodel-voor-cardiogene-shock-prognose-danger-substudie/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2025/12/01/scai-shockklassen-en-prognose-bij-ami-cardiogene-shock-danger-substudie/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2020/04/21/morfine-met-metoclopramide-en-ticagrelor-plaatjesremming-bij-acuut-mi/","published":"2020-04-21"},{"url":"https://hartvaat.nl/2017/12/14/mechanische-ondersteuning-bij-cardiogene-shock-systematische-review-en-meta-anal/","published":"2017-12-14"},{"url":"https://hartvaat.nl/2017/04/18/risicostratificatie-bij-cardiogene-shock-na-acuut-myocardinfarct/","published":"2017-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jason-g-andrade","type":"person","url":"https://hartvaat.nl/mensen/jason-g-andrade/","name":"Jason G Andrade","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","published":"2026-05-27"},{"url":"https://hartvaat.nl/2026/03/07/lancet-seminar-atriumfibrilleren-in-2026/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","published":"2024-02-16"},{"url":"https://hartvaat.nl/2023/05/30/complicaties-van-af-ablatie-actueel-overzicht/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2021/12/01/hartfalen-en-atriumflutter-systematische-review/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/11/01/af-last-en-qol-na-af-ablatie-cabana-substudie/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"},{"url":"https://hartvaat.nl/2019/11/26/cryoballon-versus-rf-ablatie-bij-af-beoordeeld-met-continue-monitoring-cryo-firs/","published":"2019-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jasper-j-brugts","type":"person","url":"https://hartvaat.nl/mensen/jasper-j-brugts/","name":"Jasper J Brugts","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/04/28/geen-sekseverschillen-in-werkzaamheid-van-hartfalenmedicatie-meta-analyse-van-13/","published":"2026-05-05"},{"url":"https://hartvaat.nl/2025/08/14/hartfalen-mondiale-economische-ziektelast/","published":"2025-08-14"},{"url":"https://hartvaat.nl/2025/04/01/socio-economische-ongelijkheid-en-hartfalenuitkomsten-systematische-review/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/08/21/pa-drukmonitoring-bij-chronisch-hartfalen-effecten-over-klinische-subgroepen/","published":"2024-08-21"},{"url":"https://hartvaat.nl/2023/10/01/pa-drukmonitoring-bij-chronisch-hartfalen-meta-analyse-van-drie-rct-s/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/08/14/telemonitoring-bij-hartfalen-meta-analyse-van-alle-strategieen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/24/monitor-hf-pa-drukmonitoring-bij-hartfalen-effectief-in-europa-lancet-rct/","published":"2023-06-24"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeffrey-s-berger","type":"person","url":"https://hartvaat.nl/mensen/jeffrey-s-berger/","name":"Jeffrey S Berger","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/07/01/timing-van-antihypertensiva-meta-analyse-van-rct-s-bevestigt-flexibiliteit/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/01/01/mi-bij-pav-patienten-incidentie-en-uitkomsten-euclid/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/12/25/cv-en-ledemaat-uitkomsten-bij-diabetes-met-pav-euclid/","published":"2018-12-25"},{"url":"https://hartvaat.nl/2018/10/02/cv-uitkomsten-na-endovasculaire-versus-chirurgische-revascularisatie-onderste-le/","published":"2018-10-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jian-an-wang","type":"person","url":"https://hartvaat.nl/mensen/jian-an-wang/","name":"Jian'an Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/25/explorer-cn-week-78-langetermijneffect-en-veiligheid-van-mavacamten-bij-chinese-/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/05/20/angptl3-antilichaam-bij-suboptimaal-gecontroleerde-hyperlipidemie-fase-2/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/04/26/angiografie-afgeleide-ffr-versus-ivus-bij-pci-gerandomiseerde-trial/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/08/09/vertraagde-afgifteformulering-van-ivabradine-bij-systolisch-hartfalen/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2016/05/17/biodegradeerbare-sirolimus-eluting-stents-de-panda-iii-trial/","published":"2016-05-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jianjian-gong","type":"person","url":"https://hartvaat.nl/mensen/jianjian-gong/","name":"Jianjian Gong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/08/01/nt-probnp-veranderingen-en-klinische-uitkomsten-bij-pediatrisch-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2017/04/14/systolische-bloeddruk-en-werkzaamheid-van-sacubitril-valsartan-bij-chronisch-hfr/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2016/12/06/prognostische-implicaties-van-nt-probnp-veranderingen-bij-hartfalen/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/06/07/klinische-verslechtering-van-poliklinisch-behandeld-hartfalen-paradigm-hf-analys/","published":"2016-06-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jianzeng-dong","type":"person","url":"https://hartvaat.nl/mensen/jianzeng-dong/","name":"Jianzeng Dong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukverlaging-bij-ongediagnosticeerde-hfpef-met-hoog-risico/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/06/13/frailteit-en-intensieve-bloeddrukcontrole-bij-diabetes/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","published":"2022-10-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joann-e-manson","type":"person","url":"https://hartvaat.nl/mensen/joann-e-manson/","name":"JoAnn E Manson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/10/01/langetermijneffect-van-cacao-extract-op-incident-hypertensie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2023/01/01/vitamine-d-voorkomt-statine-gerelateerde-spierklachten-niet/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/10/01/sekseverschillen-in-af-risico-vital-rhythm-studie/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/12/21/langdurige-omega-3-suppletie-en-af-risico-meta-analyse-van-cv-trials/","published":"2021-12-21"},{"url":"https://hartvaat.nl/2021/03/16/omega-3-en-vitamine-d-en-incident-af-jama-vital-af/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/11/10/vitamine-d-omega-3-of-krachttraining-en-klinische-uitkomsten-bij-ouderen-jama-do/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2020/03/03/vitamine-d-en-omega-3-en-hartfalen-hospitalisatie-vital-heart-failure/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2017/06/01/voedingsstatus-en-langetermijn-multivitaminegebruik-en-cv-risico-phs-ii-analyse/","published":"2017-06-01"},{"url":"https://hartvaat.nl/2017/01/03/traditionele-cv-risicofactoren-en-veneuze-trombo-embolie-individuele-patientdata/","published":"2017-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-b-wong","type":"person","url":"https://hartvaat.nl/mensen/john-b-wong/","name":"John B Wong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"},{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jonathan-d-newman","type":"person","url":"https://hartvaat.nl/mensen/jonathan-d-newman/","name":"Jonathan D Newman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2024/09/10/tact-2-chelatietherapie-na-mi-bij-diabetes-negatieve-trial/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2023/07/01/timing-van-antihypertensiva-meta-analyse-van-rct-s-bevestigt-flexibiliteit/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2020/07/01/thuisluchtzuivering-en-bloeddruk-systematische-review/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2020/05/12/management-van-stabiel-coronairlijden-bij-diabetes-type-2-aha-scientific-stateme/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joo-myung-lee","type":"person","url":"https://hartvaat.nl/mensen/joo-myung-lee/","name":"Joo Myung Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/01/01/intravasculaire-beeldvorming-superieur-aan-angiografie-bij-complexe-pci-5-jaarsr/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"josep-rodes-cabau","type":"person","url":"https://hartvaat.nl/mensen/josep-rodes-cabau/","name":"Josep Rodés-Cabau","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/02/19/geleidingsstoornissen-na-transkatheter-aortaklepimplantatie/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/12/23/korte-anticoagulatie-versus-dapt-na-laa-occlusie-devicetrombosepreventie/","published":"2025-12-23"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/01/lage-dosis-doac-versus-dapt-na-laa-occlusie-gerandomiseerde-trial/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joseph-c-cleveland","type":"person","url":"https://hartvaat.nl/mensen/joseph-c-cleveland/","name":"Joseph C Cleveland","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2022/09/27/momentum-3-vijfjaarsresultaten-heartmate-3-versus-axiale-lvad/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2020/04/01/lvad-gebruik-als-bridge-to-transplant-versus-destination-therapy-momentum-3/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2019/07/09/2019-aha-acc-hrs-gerichte-update-van-de-af-richtlijn/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2019/01/08/cva-analyse-in-momentum-3-langetermijncohort/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/10/30/zorggebruik-en-kosten-in-momentum-3-langetermijnstudie/","published":"2018-10-30"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/05/23/hemocompatibiliteitsuitkomsten-van-heartmate-3-na-6-maanden-momentum-3/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","published":"2017-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"josephine-harrington","type":"person","url":"https://hartvaat.nl/mensen/josephine-harrington/","name":"Josephine Harrington","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/11/18/2025-acc-scientific-statement-obesitasmanagement-bij-hartfalen/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2023/09/14/heart-fid-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-nejm/","published":"2023-09-14"},{"url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","published":"2023-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jose-p-s-henriques","type":"person","url":"https://hartvaat.nl/mensen/jose-p-s-henriques/","name":"José P S Henriques","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/01/27/pci-van-natief-coronairvat-versus-veneuze-graft-na-eerdere-cabg-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2019/04/11/coronairangiografie-na-hartstilstand-zonder-st-elevatie-nejm-coact/","published":"2019-04-11"},{"url":"https://hartvaat.nl/2018/09/01/langetermijnimpact-van-cto-rekanalisatie-bij-stemi-patienten/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/12/14/mechanische-ondersteuning-bij-cardiogene-shock-systematische-review-en-meta-anal/","published":"2017-12-14"},{"url":"https://hartvaat.nl/2017/06/15/bioresorbeerbare-scaffolds-versus-metallic-stents-bij-routine-pci-nejm-aida/","published":"2017-06-15"},{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-ondersteuning-versus-iabp-bij-cardiogene-shock-meta-analys/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-circulatoire-ondersteuning-versus-iabp-bij-cardiogene-shoc/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/10/11/pci-van-chronische-totale-occlusie-bij-stemi-met-multivatenlijden-explore-trial/","published":"2016-10-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jyothis-t-george","type":"person","url":"https://hartvaat.nl/mensen/jyothis-t-george/","name":"Jyothis T George","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2020/01/07/hypoglykemie-cv-uitkomsten-en-empagliflozine-empa-reg-outcome/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/06/04/microvasculaire-ziekte-en-cv-events-bij-diabetes-type-2/","published":"2019-06-04"},{"url":"https://hartvaat.nl/2019/04/30/empagliflozine-antihyperglycemische-en-bloeddrukeffecten-bij-zwarte-diabetespati/","published":"2019-04-30"},{"url":"https://hartvaat.nl/2019/03/12/empagliflozine-vermindert-mortaliteit-en-hf-hospitalisatie-over-het-cv-risicospe/","published":"2019-03-12"},{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/02/01/empagliflozine-en-cv-dood-en-hf-hospitalisatie-over-het-hf-spectrum-empa-reg-out/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2018/01/23/empagliflozine-bij-diabetes-type-2-met-perifeer-vaatlijden-empa-reg-outcome/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2018/01/09/empagliflozine-bij-diabetes-type-2-met-cardiovasculaire-ziekte-en-ckd-empa-reg-o/","published":"2018-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kim-k-birtcher","type":"person","url":"https://hartvaat.nl/mensen/kim-k-birtcher/","name":"Kim K Birtcher","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2022/10/04/2022-acc-expert-consensus-niet-statine-therapieen-voor-ldl-verlaging-bij-ascvd/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2021/08/31/2021-acc-consensus-ascvd-risicoreductie-bij-persistente-hypertriglyceridemie/","published":"2021-08-31"},{"url":"https://hartvaat.nl/2020/09/01/2020-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2018/12/18/2018-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2017/10/03/2017-acc-gerichte-update-niet-statinetherapie-voor-ldl-verlaging/","published":"2017-10-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kirkwood-f-adams","type":"person","url":"https://hartvaat.nl/mensen/kirkwood-f-adams/","name":"Kirkwood F Adams","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2024/04/09/dapagliflozine-bij-acuut-hartfalen-effectiviteit-en-veiligheid/","published":"2024-04-09"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2018/11/27/economische-en-qol-uitkomsten-van-nt-probnp-geleide-hf-therapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2017/08/22/natriuretisch-peptide-geleide-therapie-bij-hoogrisico-hartfalen-jama-guide-it/","published":"2017-08-22"},{"url":"https://hartvaat.nl/2017/03/21/werkzaamheid-en-veiligheid-van-tolvaptan-bij-gehospitaliseerd-acuut-hartfalen/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/12/10/omecamtiv-mecarbil-bij-chronisch-hartfalen-lancet-cosmic-hf-fase-2-trial/","published":"2016-12-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"koon-k-teo","type":"person","url":"https://hartvaat.nl/mensen/koon-k-teo/","name":"Koon K Teo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/04/25/bloeddrukverlaging-beschermt-over-het-hele-spectrum-van-chronische-nierschade-la/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2023/11/01/sekseverschillen-in-effect-van-bloeddrukverlaging-ipd-meta-analyse/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2021/11/13/bloeddrukverlaging-en-risico-op-diabetes-type-2-lancet-bplttc-ipd-meta-analyse/","published":"2021-11-13"},{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/04/30/leefstijl-hba1c-en-overleving-bij-stabiel-coronairlijden-met-diabetes/","published":"2019-04-30"},{"url":"https://hartvaat.nl/2018/09/01/bereikte-diastolische-bloeddruk-en-polsdruk-bij-streef-sbp-en-cv-uitkomsten-bij-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/11/01/gemiddelde-bloeddruk-en-visit-to-visit-variabiliteit-als-gecombineerde-voorspell/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/06/03/bereikte-bloeddruk-en-cv-uitkomsten-bij-hoogrisicopatienten-ontarget-transcend/","published":"2017-06-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kreton-mavromatis","type":"person","url":"https://hartvaat.nl/mensen/kreton-mavromatis/","name":"Kreton Mavromatis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2018/05/19/des-versus-bms-in-veneuze-bypass-grafts-lancet-dubbelblinde-trial/","published":"2018-05-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"leslie-l-davis","type":"person","url":"https://hartvaat.nl/mensen/leslie-l-davis/","name":"Leslie L Davis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/24/2024-acc-beslispad-klinische-beoordeling-en-trajectmanagement-bij-hfpef/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2024/04/16/2024-acc-expert-consensus-behandeling-van-hfref-beslispad-geactualiseerd/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2023/05/09/2023-acc-expert-consensus-management-van-hfpef/","published":"2023-05-09"},{"url":"https://hartvaat.nl/2021/02/16/2021-acc-hf-behandeloptimalisatie-update-antwoorden-op-10-cruciale-vragen/","published":"2021-02-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lucas-lauder","type":"person","url":"https://hartvaat.nl/mensen/lucas-lauder/","name":"Lucas Lauder","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/03/07/aldosteronsynthaseremming-bij-resistente-hypertensie-beloften-en-onzekerheden/","published":"2026-03-20"},{"url":"https://hartvaat.nl/2026/02/27/bloeddruk-time-in-target-range-voorspelt-sterfte-bij-hypertensie/","published":"2026-03-06"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2024/11/12/renale-denervatie-bij-hypertensie-uitgebreide-meta-analyse-van-alle-trials/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/12/rf-renale-denervatie-bij-ongecontroleerde-hypertensie-in-china-gerandomiseerde-t/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/10/07/2024-esc-richtlijn-voor-management-van-hypertensie/","published":"2024-10-07"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2023/08/01/atrial-flow-regulator-en-overleving-bij-hartfalen-voorspelde-impact/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","published":"2021-06-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lucy-c-chappell","type":"person","url":"https://hartvaat.nl/mensen/lucy-c-chappell/","name":"Lucy C Chappell","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/10/01/nitraatsuppletie-haalbaar-en-veilig-bij-zwangeren-met-ckd-orchard-beet/","published":"2026-09-04"},{"url":"https://hartvaat.nl/2025/11/01/bloeddrukzelfmanagement-en-vasculaire-remodelling-na-hypertensieve-zwangerschap/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/02/13/pop-ht-bloeddrukzelfmanagement-verbetert-cardiale-remodelling-na-hypertensieve-z/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2023/11/28/pop-ht-zelfmanagement-van-bloeddruk-na-hypertensieve-zwangerschap-jama-rct/","published":"2023-11-28"},{"url":"https://hartvaat.nl/2023/07/29/cradle-4-geplande-bevalling-versus-afwachten-bij-laat-preterm-pre-eclampsie-in-l/","published":"2023-07-29"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-bloeddrukcontrole-bij-risicozwangerschap-jama-bump-2/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2019/05/04/plgf-voor-beoordeling-van-pre-eclampsie-lancet-parrot-stepped-wedge-trial/","published":"2019-05-04"},{"url":"https://hartvaat.nl/2017/11/01/labetalol-versus-nifedipine-bij-chronische-hypertensie-in-de-zwangerschap-gerand/","published":"2017-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maciej-banach","type":"person","url":"https://hartvaat.nl/mensen/maciej-banach/","name":"Maciej Banach","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/02/03/vochtbeperking-versus-liberale-inname-bij-hartfalen-meta-analyse-van-rct-s/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","published":"2025-10-02"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2022/09/07/prevalentie-van-statine-intolerantie-meta-analyse-nuanceert-het-probleem/","published":"2022-09-07"},{"url":"https://hartvaat.nl/2021/04/01/telereh-hf-etiologie-subanalyse-van-telerevalidatie-bij-hartfalen/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/03/01/hybride-telerevalidatie-bij-hartfalen-jama-cardiology-tele-hf-trial/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2018/12/01/edoxaban-verhoogt-behandeltevredenheid-en-vermindert-zorggebruik-engage-af-timi-/","published":"2018-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"manish-saxena","type":"person","url":"https://hartvaat.nl/mensen/manish-saxena/","name":"Manish Saxena","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/08/05/lorundrostat-bij-ongecontroleerde-en-therapieresistente-hypertensie-fase-3-resul/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/07/01/kardia-2-zilebesiran-als-toevoeging-bij-ongecontroleerde-hypertensie-rct/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2024/06/11/target-bp-i-alcohol-gemedieerde-renale-denervatie-bij-hypertensie/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/12/01/centrale-iliacale-av-anastomose-bij-ongecontroleerde-hypertensie-rox-control-htn/","published":"2017-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mark-h-drazner","type":"person","url":"https://hartvaat.nl/mensen/mark-h-drazner/","name":"Mark H Drazner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/04/17/glp-1-receptoragonisten-geassocieerd-met-lagere-mortaliteit-bij-hfref/","published":"2026-05-26"},{"url":"https://hartvaat.nl/2024/09/24/2024-acc-beslispad-klinische-beoordeling-en-trajectmanagement-bij-hfpef/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2020/03/17/2020-acc-hfsa-ishlt-verklaring-voor-gevorderd-hf-en-transplantatiespecialisten/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martine-gilard","type":"person","url":"https://hartvaat.nl/mensen/martine-gilard/","name":"Martine Gilard","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/01/01/antistolling-alleen-of-met-plaatjesremming-bij-coronairlijden-meta-analyse/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/10/23/aspirine-bij-chronisch-coronairsyndroom-plus-oac-wel-of-niet/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2018/12/13/percutaan-herstel-of-medicamenteuze-therapie-bij-secundaire-mr-nejm-mitra-fr/","published":"2018-12-13"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"masafumi-ono","type":"person","url":"https://hartvaat.nl/mensen/masafumi-ono/","name":"Masafumi Ono","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matteo-tebaldi","type":"person","url":"https://hartvaat.nl/mensen/matteo-tebaldi/","name":"Matteo Tebaldi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/11/11/ct-angiografie-of-standaardzorg-na-pci-van-de-linker-hoofdstam/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2020/11/07/complete-revascularisatie-vermindert-cv-dood-bij-stemi-met-multivatenlijden-meta/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/08/04/cangrelor-tirofiban-en-prasugrel-bij-stemi-primaire-resultaten/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2017/05/23/stralingsblootstelling-en-vasculaire-toegang-bij-acs-rad-matrix-trial/","published":"2017-05-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matthew-r-weir","type":"person","url":"https://hartvaat.nl/mensen/matthew-r-weir/","name":"Matthew R Weir","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/03/29/confidence-analyse-acute-egfr-daling-bij-empagliflozin-finerenone-is-reversibel-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2025/08/05/lorundrostat-bij-ongecontroleerde-en-therapieresistente-hypertensie-fase-3-resul/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/05/08/lorundrostat-bij-ongecontroleerde-hypertensie-fase-3-nejm/","published":"2025-05-08"},{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/04/06/nierfunctiebeoordeling-en-eindpuntbepaling-in-klinische-trials-ehj/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2019/08/01/empagliflozine-voorkomt-progressie-van-ckd-empa-reg-outcome-renale-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/08/01/langetermijn-patiromer-bij-hyperkaliemie-met-mild-hf-en-diabetische-nefropathie/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2016/09/01/patiromer-verlaagt-aldosteron-bij-ckd-patienten-met-hyperkaliemie-op-raas-remmer/","published":"2016-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mattia-branca","type":"person","url":"https://hartvaat.nl/mensen/mattia-branca/","name":"Mattia Branca","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/07/05/optimale-timing-van-anticoagulatie-na-ischemisch-cva-en-af-collaboratief-project/","published":"2025-07-05"},{"url":"https://hartvaat.nl/2024/07/02/vroege-versus-late-doac-na-cva-met-hemorrhagische-transformatie-bij-af/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/06/29/elan-vroege-versus-late-anticoagulatie-na-cva-bij-af-nejm/","published":"2023-06-29"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-a-blazing","type":"person","url":"https://hartvaat.nl/mensen/michael-a-blazing/","name":"Michael A Blazing","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/12/01/serieel-hoog-sensitief-troponine-t-voorspelt-cv-events-na-acs-odyssey-analyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/10/12/baseline-ldl-en-klinische-uitkomsten-van-ezetimibe-plus-statine-improve-it/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2019/09/01/simvastatine-ezetimibe-versus-simvastatine-na-acs-bij-75-plussers-jama-cardiolog/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/04/10/ezetimibe-bij-diabetes-versus-zonder-diabetes-improve-it-subanalyse/","published":"2018-04-10"},{"url":"https://hartvaat.nl/2017/12/19/cva-preventie-met-ezetimibe-bij-acs-improve-it-analyse/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/05/01/langetermijnveiligheid-van-zeer-lage-ldl-cholesterolniveaus-improve-it-analyse/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/12/21/ezetimibe-bij-post-cabg-patienten-met-acs-improve-it-subanalyse/","published":"2016-12-21"},{"url":"https://hartvaat.nl/2016/02/02/reductie-in-totale-cardiovasculaire-events-met-ezetimibe-simvastatine-na-acs-imp/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-j-foley","type":"person","url":"https://hartvaat.nl/mensen/michael-j-foley/","name":"Michael J Foley","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/19/coronaire-flowreserve-en-cardiovasculaire-uitkomsten-meta-analyse/","published":"2022-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-joner","type":"person","url":"https://hartvaat.nl/mensen/michael-joner/","name":"Michael Joner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2023/04/17/in-stent-restenose-tienjaarsuitkomsten-plain-balloon-vs-dcb-vs-des-isar-desire-3/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/01/15/10-jaarsuitkomsten-van-drie-limus-eluting-stents-coating-vergelijking/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/07/bioresorbeerbare-scaffold-versus-ees-bij-stabiel-coronairlijden-prospectieve-tri/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/05/07/esc-eapci-taskforce-rapport-over-bioresorbeerbare-scaffolds-executive-summary/","published":"2018-05-07"},{"url":"https://hartvaat.nl/2017/10/01/pci-versus-cabg-bij-linker-hoofdstamstenose-jama-cardiology-systematische-review/","published":"2017-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michel-komajda","type":"person","url":"https://hartvaat.nl/mensen/michel-komajda/","name":"Michel Komajda","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2023/10/01/ivabradine-bij-hoogrisico-hartfalenpatienten-shift-analyse/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2019/12/01/gunstige-effecten-van-ivabradine-bij-hf-met-lage-ef-en-hartfrequentie-77-bpm/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2017/03/07/cva-risico-bij-chronisch-hartfalen-met-behouden-ef-zonder-af-charm-analyse/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2017/02/21/diabetesstatus-en-cardiovasculaire-uitkomsten-bij-hfpef-klinische-en-echocardiog/","published":"2017-02-21"},{"url":"https://hartvaat.nl/2016/01/21/stoppen-of-doorgaan-met-clopidogrel-12-maanden-na-drug-eluting-stent-optidual-tr/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michelle-c-williams","type":"person","url":"https://hartvaat.nl/mensen/michelle-c-williams/","name":"Michelle C Williams","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/02/03/klinische-risicopredictie-ct-coronairangiografie-en-cv-events-bij-nieuwe-angina/","published":"2025-02-03"},{"url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","published":"2025-01-25"},{"url":"https://hartvaat.nl/2020/08/01/inspannings-ecg-versus-ccta-bij-stabiele-angina-post-hoc-vergelijking/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/05/05/laag-attenuatie-plaque-op-ccta-voorspelt-mi-scot-heart-resultaten/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/01/29/coronaire-plaquekenmerken-en-adverse-uitkomsten-scot-heart/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","published":"2018-09-06"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/04/19/ct-coronairangiografie-voor-het-sturen-van-beleid-bij-coronairlijden/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"morgan-e-grams","type":"person","url":"https://hartvaat.nl/mensen/morgan-e-grams/","name":"Morgan E. Grams","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/25/kdigo-overzicht-de-nier-centraal-in-het-cardiovasculair-renaal-metabool-ckm-synd/","published":"2026-05-31"},{"url":"https://hartvaat.nl/2026/03/03/kdigo-versnelt-richtlijnontwikkeling-voor-nierziekten/","published":"2026-03-27"},{"url":"https://hartvaat.nl/2026/03/06/kdigo-consensusconferentie-uitdagingen-bij-gecombineerd-hartfalen-en-nierziekte/","published":"2026-03-15"},{"url":"https://hartvaat.nl/2026/02/18/groene-dialyse-duurzame-zorg-groei-en-innovatie-kdigo-conferentie/","published":"2026-02-18"},{"url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2025/10/07/relatie-tussen-obesitas-en-ckd-conclusies-van-een-kdigo-conferentie/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2021/09/01/albuminurietesting-bij-hypertensie-en-diabetes-ipd-meta-analyse/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2016/02/04/risicoprojectie-voor-nierfalen-bij-levende-nierdonorkandidaten/","published":"2016-02-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nancy-r-cook","type":"person","url":"https://hartvaat.nl/mensen/nancy-r-cook/","name":"Nancy R Cook","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2024/12/05/inflammatie-cholesterol-lp-a-en-30-jaars-cv-uitkomsten-bij-vrouwen/","published":"2024-12-05"},{"url":"https://hartvaat.nl/2023/01/01/vitamine-d-voorkomt-statine-gerelateerde-spierklachten-niet/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/10/01/sekseverschillen-in-af-risico-vital-rhythm-studie/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/12/21/langdurige-omega-3-suppletie-en-af-risico-meta-analyse-van-cv-trials/","published":"2021-12-21"},{"url":"https://hartvaat.nl/2021/03/16/omega-3-en-vitamine-d-en-incident-af-jama-vital-af/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/05/05/triglyceriderijk-lipoproteinecholesterol-small-dense-ldl-en-cv-events/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/03/03/vitamine-d-en-omega-3-en-hartfalen-hospitalisatie-vital-heart-failure/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2016/10/11/natriuminname-en-totale-mortaliteit-over-20-jaar-trials-of-hypertension-preventi/","published":"2016-10-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"narimon-honarpour","type":"person","url":"https://hartvaat.nl/mensen/narimon-honarpour/","name":"Narimon Honarpour","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/05/20/intensieve-ldl-verlaging-met-evolocumab-bij-auto-immuunziekten-rct/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2021/02/01/evolocumab-bij-metabool-syndroom-na-acs-fourier/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2019/07/01/evolocumab-en-totale-cv-events-bij-cardiovasculaire-ziekte-fourier-analyse/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/08/21/klinisch-voordeel-van-evolocumab-naar-ernst-van-coronairlijden-fourier/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/07/10/inflammatie-en-cholesterol-in-de-fourier-trial/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2017/08/17/cognitieve-functie-in-de-fourier-trial-met-evolocumab-nejm-ebbinghaus/","published":"2017-08-17"},{"url":"https://hartvaat.nl/2017/05/04/evolocumab-en-klinische-uitkomsten-bij-cardiovasculaire-ziekte-nejm-fourier/","published":"2017-05-04"},{"url":"https://hartvaat.nl/2016/12/10/omecamtiv-mecarbil-bij-chronisch-hartfalen-lancet-cosmic-hf-fase-2-trial/","published":"2016-12-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"niels-e-bruun","type":"person","url":"https://hartvaat.nl/mensen/niels-e-bruun/","name":"Niels E Bruun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/11/20/kaliumverhoging-bij-hoogrisicopatienten-voor-ventriculaire-aritmieen-rct/","published":"2025-11-20"},{"url":"https://hartvaat.nl/2025/09/01/af-en-icd-bij-niet-ischemische-hfref-impliciaties-voor-devicetherapie/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"oskar-angeras","type":"person","url":"https://hartvaat.nl/mensen/oskar-angeras/","name":"Oskar Angerås","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/10/07/help-mi-helicobacter-pylori-screening-na-acuut-mi-cluster-rct/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2018/08/01/zuurstoftherapie-bij-stemi-overzichtsartikel/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/03/30/ffr-geleide-multivaten-pci-bij-myocardinfarct-nejm-compare-acute/","published":"2017-03-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"patrick-m-moriarty","type":"person","url":"https://hartvaat.nl/mensen/patrick-m-moriarty/","name":"Patrick M Moriarty","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/19/lipoproteine-aferese-blijft-relevant-in-het-tijdperk-van-pcsk9-remmers-en-sirna/","published":"2026-06-12"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2020/01/16/lp-a-verlaging-bij-cardiovasculaire-ziekte-nejm/","published":"2020-01-16"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2016/12/21/alirocumab-bij-heterozygoot-fh-met-lipoproteine-aferese-odyssey-escape/","published":"2016-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"patrick-t-o-gara","type":"person","url":"https://hartvaat.nl/mensen/patrick-t-o-gara/","name":"Patrick T O'Gara","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-a-gurbel","type":"person","url":"https://hartvaat.nl/mensen/paul-a-gurbel/","name":"Paul A Gurbel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2023/01/24/pcsk9-remming-bij-covid-19-anti-inflammatoir-potentieel-onderzocht/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/03/16/plaatjesreactiviteit-bij-acs-in-afwachting-van-chirurgische-revascularisatie/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/07/14/vergelijking-van-orale-p2y12-remmers-bij-acs-netwerkmeta-analyse-van-52-816-pati/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2020/02/18/ticagrelor-met-of-zonder-aspirine-na-pci-twilight-plaatjessubstudie/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2018/04/17/uitgangs-ldl-en-mortaliteitsreductie-na-ldl-verlaging-jama-meta-analyse/","published":"2018-04-17"},{"url":"https://hartvaat.nl/2016/03/01/cyp2c19-metaboliseerdersstatus-en-uitkomsten-bij-acs-prasugrel-versus-clopidogre/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-e-carson","type":"person","url":"https://hartvaat.nl/mensen/peter-e-carson/","name":"Peter E Carson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2017/03/21/plotse-hartdood-bij-ischemisch-hartfalen-na-cabg-stich-resultaten/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2017/03/07/cva-risico-bij-chronisch-hartfalen-met-behouden-ef-zonder-af-charm-analyse/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2017/02/21/diabetesstatus-en-cardiovasculaire-uitkomsten-bij-hfpef-klinische-en-echocardiog/","published":"2017-02-21"},{"url":"https://hartvaat.nl/2016/11/01/tienjaarsuitkomsten-na-cabg-naar-leeftijd-bij-hartfalen-met-lv-systolische-disfu/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-held","type":"person","url":"https://hartvaat.nl/mensen/peter-held/","name":"Peter Held","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2019/01/01/mi-bij-pav-patienten-incidentie-en-uitkomsten-euclid/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/12/25/cv-en-ledemaat-uitkomsten-bij-diabetes-met-pav-euclid/","published":"2018-12-25"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2016/09/20/cva-preventie-met-ticagrelor-na-myocardinfarct-pegasus-timi-54-inzichten/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/06/14/reductie-van-ischemische-events-met-ticagrelor-bij-diabetes-na-myocardinfarct-pe/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"petr-jarolim","type":"person","url":"https://hartvaat.nl/mensen/petr-jarolim/","name":"Petr Jarolim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/12/01/serieel-hoog-sensitief-troponine-t-voorspelt-cv-events-na-acs-odyssey-analyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2020/11/01/klinische-toepassing-van-hs-troponine-in-het-ascvd-raamwerk-jama-cardiology/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2019/02/05/abc-scores-voor-cva-en-bloedingsrisico-bij-af-prestatieverbetering/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/06/01/fgf-23-en-recidiverende-cv-events-na-acs/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/08/08/canagliflozine-en-cardiovasculaire-biomarkers-bij-oudere-diabetespatienten/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/05/16/serieel-hoog-sensitief-troponine-i-en-cv-uitkomsten-bij-diabetes-type-2-examine/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/07/19/serieel-cardiaal-troponine-met-hoog-sensitieve-assay-bij-stabiel-ischemisch-hart/","published":"2016-07-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pierpaolo-pellicori","type":"person","url":"https://hartvaat.nl/mensen/pierpaolo-pellicori/","name":"Pierpaolo Pellicori","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/04/congestie-bij-chronisch-hartfalen-echografie-vult-klinisch-onderzoek-aan-en-voor/","published":"2026-07-01"},{"url":"https://hartvaat.nl/2026/05/11/ehj-editorial-cleland-wereldwijde-hartfalenprevalentie-overschrijdt-600-miljoen-/","published":"2026-05-12"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","published":"2024-04-21"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2016/04/01/effect-van-extra-zuurstof-op-inspanningsprestatie-bij-chronisch-hartfalen/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-nicole-karam","type":"person","url":"https://hartvaat.nl/mensen/prof-nicole-karam/","name":"Prof. Nicole Karam","title":"Cardioloog, Hôpital Européen Georges-Pompidou, Parijs","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2025/01/14/tri-fr-transcatheter-edge-to-edge-repair-bij-geisoleerde-ernstige-tr-rct/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2018/12/13/percutaan-herstel-of-medicamenteuze-therapie-bij-secundaire-mr-nejm-mitra-fr/","published":"2018-12-13"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-karam-highlights/","title":"Kleplijden op ESC 2026: de praktijkveranderende data"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"r-scott-wright","type":"person","url":"https://hartvaat.nl/mensen/r-scott-wright/","name":"R Scott Wright","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/07/22/victorion-initiate-inclisiran-monotherapie-bij-patienten-zonder-ascvd/","published":"2025-07-22"},{"url":"https://hartvaat.nl/2022/12/21/orion-11-inclisiran-verlaagt-ldl-effectief-bij-primaire-preventie/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-bij-heterozygote-familiaire-hypercholesterolemie-nejm-orion-9/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-fase-3-bij-verhoogd-ldl-nejm-orion-10-en-orion-11/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2019/11/01/inclisiran-1-of-2-dosis-en-ldl-cholesterol-orion-1-1-jaarsfollow-up/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2018/09/25/sirna-tegen-pcsk9-en-atherogene-lipoproteinen-orion-1-secundaire-eindpunten/","published":"2018-09-25"},{"url":"https://hartvaat.nl/2018/09/01/hdl-mimeticum-met-recombinant-apoa-i-milano-en-coronairlijden-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/04/13/inclisiran-bij-patienten-met-hoog-cv-risico-en-verhoogd-ldl-nejm-orion-1/","published":"2017-04-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"raffaele-piccolo","type":"person","url":"https://hartvaat.nl/mensen/raffaele-piccolo/","name":"Raffaele Piccolo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/01/01/antistolling-alleen-of-met-plaatjesremming-bij-coronairlijden-meta-analyse/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2025/12/09/gepersonaliseerde-versus-standaard-dapt-duur-na-pci-gerandomiseerde-trial/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2020/08/04/cangrelor-tirofiban-en-prasugrel-bij-stemi-primaire-resultaten/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2018/09/01/ultradunne-biodegradeerbare-versus-dunne-duurzame-stents-lancet-gerandomiseerde-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/04/07/statines-en-niet-statine-ldl-verlagers-en-cardiovasculaire-uitkomsten-meta-analy/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2016/10/01/langere-versus-korte-dapt-na-pci-met-en-zonder-periprocedureel-mi-jama-cardiolog/","published":"2016-10-01"},{"url":"https://hartvaat.nl/2016/08/16/intracoronair-abciximab-bij-diabetespatienten-met-primaire-pci-1-jaarsresultaten/","published":"2016-08-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rajeev-k-pathak","type":"person","url":"https://hartvaat.nl/mensen/rajeev-k-pathak/","name":"Rajeev K Pathak","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/12/01/arrest-af-agressieve-risicofactorreductie-en-ablatie-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2022/12/01/langetermijnmortaliteit-bij-hfmref-systematische-review-en-meta-analyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2018/11/01/uitkomsten-van-ablatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","published":"2018-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"renate-b-schnabel","type":"person","url":"https://hartvaat.nl/mensen/renate-b-schnabel/","name":"Renate B Schnabel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2020/05/01/predictiemodellen-voor-af-in-de-community-meta-analyse/","published":"2020-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-d-brook","type":"person","url":"https://hartvaat.nl/mensen/robert-d-brook/","name":"Robert D Brook","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/12/nhlbi-workshop-bloeddrukmeting-verfijnen-door-de-hele-levensloop-heen-knelpunten/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/05/19/mobiele-screeningseenheid-in-detroit-70-van-inwoners-in-achtergestelde-wijken-he/","published":"2026-06-11"},{"url":"https://hartvaat.nl/2021/09/01/ace-remmer-plus-calciumantagonist-bij-zwarte-hypertensieve-patienten/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2021/03/03/verminderde-verkeersgerelateerde-luchtvervuiling-en-bloeddruk-gerandomiseerde-cr/","published":"2021-03-03"},{"url":"https://hartvaat.nl/2018/11/01/therapieresistente-hypertensie-aha-scientific-statement-over-detectie-evaluatie-/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/09/04/troponine-i-en-cardiovasculair-risico-bij-copd/","published":"2018-09-04"},{"url":"https://hartvaat.nl/2018/09/01/bloeddruk-hartfrequentie-en-mortaliteit-bij-copd-summit-trial/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/10/01/inhalatiecorticosteroid-beta-2-agonist-en-cardiovasculaire-uitkomsten-bij-copd/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/04/30/fluticason-vilanterol-en-overleving-bij-copd-met-verhoogd-cardiovasculair-risico/","published":"2016-04-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rodrigo-modolo","type":"person","url":"https://hartvaat.nl/mensen/rodrigo-modolo/","name":"Rodrigo Modolo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2021/06/01/serumkalium-en-prognose-bij-symptomatisch-hf/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/04/23/hedendaagse-uitkomsten-na-cabg-voor-hoofdstamlijden/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"roger-s-blumenthal","type":"person","url":"https://hartvaat.nl/mensen/roger-s-blumenthal/","name":"Roger S Blumenthal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/22/il-6-sterker-met-hart-en-vaatziekte-geassocieerd-dan-ldl-lp-a-en-crp/","published":"2026-05-22"},{"url":"https://hartvaat.nl/2026/03/16/the-lancet-commentaar-vroege-atheroma-preventie-als-kosteneffectieve-route-naar-/","published":"2026-04-28"},{"url":"https://hartvaat.nl/2026/02/21/aspirine-lipoproteine-a-en-aortaklepstenose-de-mesa-studie/","published":"2026-02-21"},{"url":"https://hartvaat.nl/2021/06/01/geisoleerde-diastolische-hypertensie-cohort-en-meta-analyse-voor-behandeldrempel/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2018/01/16/intraveneus-fentanyl-en-ticagrelorabsorptie-bij-pci/","published":"2018-01-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sean-m-o-brien","type":"person","url":"https://hartvaat.nl/mensen/sean-m-o-brien/","name":"Sean M O'Brien","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/09/23/pci-versus-cabg-en-gezondheidsstatus-bij-stabiel-coronairlijden/","published":"2025-09-23"},{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/23/gezondheidsstatus-na-invasieve-of-conservatieve-zorg-bij-coronairlijden-met-gevo/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sebastian-zimmer","type":"person","url":"https://hartvaat.nl/mensen/sebastian-zimmer/","name":"Sebastian Zimmer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/03/25/palliatieve-zorg-in-de-cardiologie-een-state-of-the-art-overzicht/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/02/19/delirium-in-de-cardiovasculaire-geneeskunde/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shao-liang-chen","type":"person","url":"https://hartvaat.nl/mensen/shao-liang-chen/","name":"Shao-Liang Chen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2025/01/07/dcb-voor-zijtak-bij-provisionale-stenting-gerandomiseerde-trial/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/12/01/korte-dapt-na-des-bij-acs-ipd-meta-analyse-bevestigt-veiligheid/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/11/ivus-acs-ivus-geleide-pci-bij-acs-superieur-lancet/","published":"2024-05-11"},{"url":"https://hartvaat.nl/2024/05/11/ticagrelor-monotherapie-versus-dapt-na-1-maand-bij-acs-lancet-rct/","published":"2024-05-11"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2018/12/18/ivus-versus-angiografie-geleide-des-implantatie-de-ultimate-trial/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"soon-jun-hong","type":"person","url":"https://hartvaat.nl/mensen/soon-jun-hong/","name":"Soon Jun Hong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/04/01/lage-dosis-tel-aml-chtd-combinatietablet-versus-standaard-tel-fase-iii/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/05/01/angiografie-versus-ivus-voor-des-implantatie-gerandomiseerde-trial/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"},{"url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","published":"2022-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefan-stork","type":"person","url":"https://hartvaat.nl/mensen/stefan-stork/","name":"Stefan Störk","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2026/02/03/kenmerken-van-asymptomatische-patienten-met-hartfalen-en-verminderde-ejectiefrac/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/09/25/digitoxine-bij-hfref-gerandomiseerde-trial-nejm/","published":"2025-09-25"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2019/04/01/spironolacton-en-lv-massa-bij-hemodialysepatienten-gerandomiseerde-trial/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2019/02/01/herhaalde-levosimendan-infusies-bij-gevorderd-chronisch-hf-in-de-kwetsbare-postd/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/09/22/telemedische-interventie-bij-hartfalen-lancet-tim-hf2/","published":"2018-09-22"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2016/06/28/escitalopram-bij-hartfalen-en-depressie-de-mood-hf-trial/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephan-b-felix","type":"person","url":"https://hartvaat.nl/mensen/stephan-b-felix/","name":"Stephan B Felix","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/02/23/immunoadsorptie-bij-gedilateerde-cardiomyopathie-de-iaso-dcm-trial/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2018/12/01/ularitide-en-andere-vasoactieve-stoffen-bij-acuut-hf-systematische-review/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2017/10/14/intracoronaire-beenmergceltransfer-na-mi-de-boost-2-gerandomiseerde-trial/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephen-b-heitner","type":"person","url":"https://hartvaat.nl/mensen/stephen-b-heitner/","name":"Stephen B Heitner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/03/05/aficamten-veilig-en-effectief-bij-langdurige-behandeling-van-obstructieve-hcm/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2026/01/05/magnesium-en-uitkomsten-bij-hfref-galactic-hf-subanalyse/","published":"2026-01-05"},{"url":"https://hartvaat.nl/2025/10/07/nieuwe-inspanningsherstelpatronen-als-maat-voor-cardiale-prestatie/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2019/07/23/ag10-transthyretinestabilisator-bij-symptomatische-attr-cardiomyopathie/","published":"2019-07-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephen-c-bain","type":"person","url":"https://hartvaat.nl/mensen/stephen-c-bain/","name":"Stephen C Bain","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/12/20/orforglipron-bij-obesitas-nejm-definitieve-fase-3-resultaten/","published":"2025-12-20"},{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","published":"2025-05-29"},{"url":"https://hartvaat.nl/2020/03/17/liraglutide-cv-uitkomsten-bij-diabetes-met-of-zonder-hartfalen-leader/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/12/01/eerste-en-recidiverende-cv-events-met-liraglutide-bij-diabetes-type-2-leader/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/08/29/orale-semaglutide-en-cv-uitkomsten-bij-diabetes-type-2-nejm-pioneer-6/","published":"2019-08-29"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-cv-uitkomsten-met-of-zonder-eerder-mi-leader/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/05/15/liraglutide-bij-diabetes-type-2-met-polyvasculaire-ziekte-leader-analyse/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2016/11/10/semaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-sustain-6/","published":"2016-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steven-e-kahn","type":"person","url":"https://hartvaat.nl/mensen/steven-e-kahn/","name":"Steven E Kahn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/08/18/semaglutide-verlaagt-hscrp-en-ontstekingsactiviteit-bij-ascvd-patienten-met-over/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","published":"2024-08-24"},{"url":"https://hartvaat.nl/2023/12/14/select-semaglutide-vermindert-cv-events-bij-obesitas-zonder-diabetes-nejm/","published":"2023-12-14"},{"url":"https://hartvaat.nl/2022/09/22/grade-vergelijking-glucoseverlagende-middelen-op-microvasculaire-en-cv-uitkomste/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2021/11/13/tirzepatide-versus-insuline-glargine-bij-diabetes-type-2-met-hoog-cv-risico-lanc/","published":"2021-11-13"},{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","published":"2019-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stylianos-tzeis","type":"person","url":"https://hartvaat.nl/mensen/stylianos-tzeis/","name":"Stylianos Tzeis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/05/06/transseptale-punctie-bij-linkshartinterventies-nieuwe-esc-consensus-over-technie/","published":"2026-07-29"},{"url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","published":"2026-05-27"},{"url":"https://hartvaat.nl/2026/04/13/intracardiale-echocardiografie-in-de-elektrofysiologie-gezamenlijk-ehra-eapci-st/","published":"2026-05-23"},{"url":"https://hartvaat.nl/2026/05/06/circulerend-mir-10b-5p-voorspelt-af-recidief-na-ablatie/","published":"2026-05-06"},{"url":"https://hartvaat.nl/2026/03/30/linear-trial-lattice-tip-katheter-verslaat-standaard-irrigatie-bij-cti-ablatie-v/","published":"2026-04-19"},{"url":"https://hartvaat.nl/2026/02/03/ice-bij-af-ablatie-veiligheid-en-effectiviteit-meta-analyse/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/03/af-ablatie-timing-naar-af-duur-impact-op-aritmierecidief/","published":"2025-06-03"},{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/02/08/voorspellers-van-af-recidief-na-ablatie-en-cardioversie-umbrella-review/","published":"2023-02-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"svend-eggert-jensen","type":"person","url":"https://hartvaat.nl/mensen/svend-eggert-jensen/","name":"Svend Eggert Jensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","published":"2025-09-13"},{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2018/12/04/ffr-versus-angiografie-geleide-cabg/","published":"2018-12-04"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-kellerth","type":"person","url":"https://hartvaat.nl/mensen/thomas-kellerth/","name":"Thomas Kellerth","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2024/11/02/bioadaptor-implantaat-versus-drug-eluting-stent-bij-stabiel-coronairlijden/","published":"2024-11-02"},{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/18/abyss-betablokkers-na-mi-met-behouden-ef-niet-nodig-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","published":"2020-01-18"},{"url":"https://hartvaat.nl/2018/12/11/langetermijneffecten-van-zuurstof-op-sterfte-of-hf-hospitalisatie-na-verdenking-/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/08/01/zuurstoftherapie-bij-stemi-overzichtsartikel/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/09/28/zuurstoftherapie-bij-vermoedelijk-acuut-myocardinfarct-nejm-deto2x-ami/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-munzel","type":"person","url":"https://hartvaat.nl/mensen/thomas-munzel/","name":"Thomas Münzel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/02/26/cardiologen-onderschatten-omgevingsrisicofactoren/","published":"2026-04-09"},{"url":"https://hartvaat.nl/2026/01/20/milieustressoren-en-cardiovasculaire-gezondheid-gezamenlijk-statement-esc-acc-ah/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2021/10/01/uitgebreide-vasodilatatie-en-qol-bij-acuut-hf-substudie/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/09/01/clopidogrel-versus-prasugrel-versus-ticagrelor-op-endotheelfunctie-en-inflammati/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2019/12/17/uitgebreide-vasodilatatie-versus-standaardzorg-bij-acuut-hf-jama-galactic-hf-pil/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2016/03/01/bioresorbeerbare-scaffold-trombose-multicenteranalyse-van-klinische-presentatie-/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tobias-geisler","type":"person","url":"https://hartvaat.nl/mensen/tobias-geisler/","name":"Tobias Geisler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ton-oude-ophuis","type":"person","url":"https://hartvaat.nl/mensen/ton-oude-ophuis/","name":"Ton Oude Ophuis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/02/03/sirolimus-eluting-bioabsorbeerbare-stent-versus-everolimus-eluting-stent-na-mi-l/","published":"2018-02-03"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/09/20/cva-preventie-met-ticagrelor-na-myocardinfarct-pegasus-timi-54-inzichten/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vojtech-melenovsky","type":"person","url":"https://hartvaat.nl/mensen/vojtech-melenovsky/","name":"Vojtěch Melenovský","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/04/27/nierfunctiestoornis-verergert-pulmonale-vaatziekte-bij-hfpef/","published":"2026-07-16"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/08/06/doac-bij-heartmate-3-lvad-eerste-gerandomiseerde-trial/","published":"2024-08-06"},{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2017/07/11/arteriele-verstijving-bij-inspanning-bij-hfpef/","published":"2017-07-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"walter-p-abhayaratna","type":"person","url":"https://hartvaat.nl/mensen/walter-p-abhayaratna/","name":"Walter P Abhayaratna","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2025/12/01/arrest-af-agressieve-risicofactorreductie-en-ablatie-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/11/01/pneumokokkenvaccinatie-en-cv-eventpreventie-ipd-meta-analyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/06/01/bloeddrukverlaging-bij-centrale-hypertensie-gerandomiseerde-trial/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2022/12/01/langetermijnmortaliteit-bij-hfmref-systematische-review-en-meta-analyse/","published":"2022-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wolfram-doehner","type":"person","url":"https://hartvaat.nl/mensen/wolfram-doehner/","name":"Wolfram Doehner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":9,"articles":[{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2024/10/05/iv-ferricarboxymaltose-en-inspanningscapaciteit-bij-hfpef-met-ijzerdeficientie/","published":"2024-10-05"},{"url":"https://hartvaat.nl/2022/09/15/polypill-voor-secundaire-cardiovasculaire-preventie-secure-trial-in-nejm/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/12/01/ijzercarboxymaltose-bij-ijzerdeficient-hartfalen-meta-analyse/","published":"2020-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"abhinav-sharma","type":"person","url":"https://hartvaat.nl/mensen/abhinav-sharma/","name":"Abhinav Sharma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/02/22/kosteneffectiviteit-van-sglt2-remmers-en-glp-1-agonisten-bij-hoog-cardiovasculai/","published":"2026-02-22"},{"url":"https://hartvaat.nl/2025/08/05/sglt2-remmer-met-en-zonder-mra-bij-hartfalen-gecombineerde-analyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2021/08/01/gdf-15-en-liraglutide-behandeling-bij-hf-patienten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2020/02/01/geschiktheid-voor-sglt2-remmers-bij-diabetespatienten-opgenomen-met-hartfalen/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/03/05/inspanningstest-versus-ccta-bij-diabetes-met-verdenking-coronairlijden/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2018/12/01/liraglutide-en-gewicht-bij-gevorderd-hfref-fight-trial-inzichten/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/02/20/cva-risico-bij-verminderde-ef-na-mi-zonder-af/","published":"2018-02-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adrian-quan","type":"person","url":"https://hartvaat.nl/mensen/adrian-quan/","name":"Adrian Quan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/03/09/semaglutide-stimuleert-anti-inflammatoire-stamcelflux-vanuit-beenmerg/","published":"2026-03-09"},{"url":"https://hartvaat.nl/2026/02/19/evolocumab-en-doorgankelijkheid-van-veneuze-bypasses-na-cabg-newton-cabg-cardiol/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","published":"2025-09-20"},{"url":"https://hartvaat.nl/2023/06/01/igfbp7-en-lv-massaregressie-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/nlr-en-cardiale-remodelling-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/diabetesduur-beinvloedt-lv-massaregressie-met-empagliflozine/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2019/11/19/empagliflozine-en-lv-massa-bij-diabetes-type-2-met-coronairlijden-empa-heart/","published":"2019-11-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alberto-aimo","type":"person","url":"https://hartvaat.nl/mensen/alberto-aimo/","name":"Alberto Aimo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/06/22/cardiale-amyloidose-komt-frequent-voor-bij-hfpef-aortastenose-en-lvh-meta-analys/","published":"2026-08-10"},{"url":"https://hartvaat.nl/2026/05/05/sterftecijfers-in-controle-armen-van-hartfalen-rcts-dalen-niet-ondanks-betere-ac/","published":"2026-07-30"},{"url":"https://hartvaat.nl/2026/03/17/langetermijneffecten-van-sacubitril-valsartan-bij-hfref-italiaanse-real-world-st/","published":"2026-03-17"},{"url":"https://hartvaat.nl/2025/01/01/atriale-mechanische-contractie-voorspelt-cerebrovasculair-risico-bij-transthyret/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/01/01/serum-transthyretine-voor-en-na-tafamidisstart-als-uitkomstvoorspeller-bij-attr-/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2024/12/01/colica-colchicine-bij-acuut-gedecompenseerd-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2018/05/01/crt-voordeel-bij-concordant-versus-discordant-linksbundeltakblok-esc-hf-pilot/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/01/16/hoog-sensitief-troponine-t-bij-chronisch-hartfalen-individuele-patientdata-meta-/","published":"2018-01-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alex-h-krist","type":"person","url":"https://hartvaat.nl/mensen/alex-h-krist/","name":"Alex H Krist","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","published":"2017-07-11"},{"url":"https://hartvaat.nl/2016/11/15/statines-voor-primaire-cardiovasculaire-preventie-uspstf-aanbeveling/","published":"2016-11-15"},{"url":"https://hartvaat.nl/2016/08/09/lipidescreening-bij-kinderen-en-adolescenten-uspstf-aanbeveling/","published":"2016-08-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexander-jobs","type":"person","url":"https://hartvaat.nl/mensen/alexander-jobs/","name":"Alexander Jobs","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2019/09/24/interne-versus-externe-cardioversie-bij-atriale-aritmieen-met-icd/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2019/01/22/milde-hypothermie-bij-cardiogene-shock-complicerend-mi/","published":"2019-01-22"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/14/mechanische-ondersteuning-bij-cardiogene-shock-systematische-review-en-meta-anal/","published":"2017-12-14"},{"url":"https://hartvaat.nl/2017/08/19/optimale-timing-van-invasieve-strategie-bij-nste-acs-lancet-meta-analyse/","published":"2017-08-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexandre-b-cavalcanti","type":"person","url":"https://hartvaat.nl/mensen/alexandre-b-cavalcanti/","name":"Alexandre B Cavalcanti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/02/13/bariatrische-chirurgie-en-bloeddruk-na-5-jaar-gerandomiseerde-trial/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2024/02/01/message-hf-geautomatiseerde-sms-na-hartfalenopname-verbetert-uitkomsten-niet/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2021/12/01/sms-strategie-bij-patienten-na-recente-hf-opname-studieontwerp/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/11/26/rivaroxaban-bij-af-met-bioprothese-mitralisklep-nejm-river/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2019/03/01/bariatrische-chirurgie-versus-medicamenteus-beleid-op-24-uurs-ambulante-bloeddru/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/04/03/oplaaddosis-atorvastatine-voor-pci-jama-gerandomiseerde-trial/","published":"2018-04-03"},{"url":"https://hartvaat.nl/2018/03/13/bariatrische-chirurgie-bij-obese-patienten-met-hypertensie-gateway-gerandomiseer/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2016/01/07/preoperatief-statinegebruik-en-cardiovasculaire-complicaties-bij-niet-cardiale-c/","published":"2016-01-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amit-v-khera","type":"person","url":"https://hartvaat.nl/mensen/amit-v-khera/","name":"Amit V Khera","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/04/10/genprobcad-gecombineerde-monogene-en-polygene-risicobepaling-voor-coronairlijden/","published":"2026-07-15"},{"url":"https://hartvaat.nl/2026/05/25/verve-102-eenmalige-base-editing-schakelt-pcsk9-blijvend-uit-fase-1/","published":"2026-05-25"},{"url":"https://hartvaat.nl/2026/01/29/nla-consensusupdate-familiaire-hypercholesterolemie-screening-diagnostiek-en-beh/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2019/06/25/systematische-review-voor-de-2018-aha-acc-cholesterolrichtlijn-jacc/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/systematische-review-voor-de-2018-aha-acc-cholesterolrichtlijn/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2017/06/20/cholesteroleffluxcapaciteit-hdl-deeltjesaantal-en-cv-events-jupiter-analyse/","published":"2017-06-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andreas-rillig","type":"person","url":"https://hartvaat.nl/mensen/andreas-rillig/","name":"Andreas Rillig","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/04/14/ulysses-echogeleide-venapunctie-halveert-toegangscomplicaties-bij-af-ablatie/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2025/10/31/pfa-versus-thermale-ablatie-periprocedurale-en-middellangetermijneffecten/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/17/ablatiestrategie-bij-af-recidief-na-duurzame-pvi/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2023/05/19/east-afnet-4-vroege-ritmecontrole-bij-af-is-kosteneffectief/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","published":"2022-09-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrejs-erglis","type":"person","url":"https://hartvaat.nl/mensen/andrejs-erglis/","name":"Andrejs Erglis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","published":"2020-01-18"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/07/07/revascularisatie-versus-optimale-medicamenteuze-therapie-bij-cto-gerandomiseerde/","published":"2018-07-07"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-r-chapman","type":"person","url":"https://hartvaat.nl/mensen/andrew-r-chapman/","name":"Andrew R Chapman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/11/11/risicostratificatie-met-hoog-sensitief-troponine-op-de-seh-veiligheidsanalyse/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/01/13/risicofactoren-voor-type-1-en-type-2-mi/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2021/07/08/grace-2-0-score-bij-type-1-en-type-2-mi/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2017/11/21/hoog-sensitief-troponine-i-en-uitkomsten-bij-verdenking-acs-jama-studie/","published":"2017-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andres-iniguez","type":"person","url":"https://hartvaat.nl/mensen/andres-iniguez/","name":"Andrés Iñiguez","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2019/12/03/magnesium-resorbeerbare-scaffold-versus-metallic-stent-bij-stemi-biosolve-iii/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/01/23/everolimus-eluting-stent-versus-bare-metal-stent-bij-stemi-5-jaarsresultaten-exa/","published":"2016-01-23"},{"url":"https://hartvaat.nl/2016/01/14/bioresorbeerbare-versus-metallic-everolimus-eluting-stent-bij-stemi-gerandomisee/","published":"2016-01-14"},{"url":"https://hartvaat.nl/2016/01/09/ranolazine-bij-incomplete-revascularisatie-na-pci-de-river-pci-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ann-marie-navar","type":"person","url":"https://hartvaat.nl/mensen/ann-marie-navar/","name":"Ann Marie Navar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/19/victorion-inception-vroege-inclisiran-na-acuut-coronair-syndroom-verviervoudigt-/","published":"2026-06-12"},{"url":"https://hartvaat.nl/2026/02/05/orale-pcsk9-remmer-enlicitide-verlaagt-ldl-met-57-placebogecontroleerde-trial/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2026/01/13/enlicitide-orale-pcsk9-remmer-bij-heterozygote-fh-fase-3/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2025/01/21/muvalaplin-orale-lp-a-verlaging-nejm-gerandomiseerde-trial/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2018/12/01/cardiovasculaire-risicocommunicatie-en-patientperceptie-jama-cardiology/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2017/11/01/hypertensiecontrole-bij-diabetes-met-recidiverende-cv-events-tecos-globale-resul/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/26/secundaire-cardiovasculaire-preventie-bij-diabetes-type-2-tecos-internationale-i/","published":"2017-09-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anne-freund","type":"person","url":"https://hartvaat.nl/mensen/anne-freund/","name":"Anne Freund","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/01/01/coact-trial-langetermijnlessen-over-coronairangiografie-na-reanimatie/","published":"2026-03-17"},{"url":"https://hartvaat.nl/2026/03/03/4-eiwitmodel-voor-cardiogene-shock-prognose-danger-substudie/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2025/12/01/scai-shockklassen-en-prognose-bij-ami-cardiogene-shock-danger-substudie/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anthony-p-carnicelli","type":"person","url":"https://hartvaat.nl/mensen/anthony-p-carnicelli/","name":"Anthony P Carnicelli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/02/24/systemische-embolieen-bij-af-ipd-mega-meta-analyse-van-71-683-patienten/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","published":"2023-05-21"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/05/01/vroegtijdig-permanent-staken-van-apixaban-of-warfarine-bij-af/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2017/03/28/edoxaban-bij-af-met-bioprothese-hartkleppen-trombo-emboliepreventie/","published":"2017-03-28"},{"url":"https://hartvaat.nl/2017/03/21/kleplijden-en-edoxaban-versus-warfarine-bij-af-engage-af-timi-48/","published":"2017-03-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"arend-mosterd","type":"person","url":"https://hartvaat.nl/mensen/arend-mosterd/","name":"Arend Mosterd","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/10/decision-trial-digoxine-staken-bij-hartfalen-leidt-tot-zevenvoudige-stijging-in-/","published":"2026-06-25"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2024/08/21/pa-drukmonitoring-bij-chronisch-hartfalen-effecten-over-klinische-subgroepen/","published":"2024-08-21"},{"url":"https://hartvaat.nl/2023/06/24/monitor-hf-pa-drukmonitoring-bij-hartfalen-effectief-in-europa-lancet-rct/","published":"2023-06-24"},{"url":"https://hartvaat.nl/2021/08/31/colchicine-bij-chronisch-coronairlijden-met-versus-zonder-eerder-acs/","published":"2021-08-31"},{"url":"https://hartvaat.nl/2021/07/21/laaggedoseerd-colchicine-bij-coronairlijden-meta-analyse-van-gerandomiseerde-tri/","published":"2021-07-21"},{"url":"https://hartvaat.nl/2019/10/24/genotype-geleide-p2y12-remmerkeuze-bij-primaire-pci-nejm-popular-genetics/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bernard-r-chaitman","type":"person","url":"https://hartvaat.nl/mensen/bernard-r-chaitman/","name":"Bernard R Chaitman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/23/gezondheidsstatus-na-invasieve-of-conservatieve-zorg-bij-coronairlijden-met-gevo/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carina-blomstrom-lundqvist","type":"person","url":"https://hartvaat.nl/mensen/carina-blomstrom-lundqvist/","name":"Carina Blomström-Lundqvist","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/10/07/vroege-substraatablatie-versus-antiaritmica-bij-vt-gerandomiseerde-trial/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2023/01/11/inadequate-noac-dosering-bij-af-uitkomsten-en-oorzaken-meta-analyse/","published":"2023-01-11"},{"url":"https://hartvaat.nl/2019/03/19/katheterablatie-versus-antiaritmica-en-kwaliteit-van-leven-bij-af-jama-captaf/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2018/11/01/kwaliteit-van-leven-na-mitralisklepchirurgie-met-en-zonder-epicardiale-cryoablat/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/10/01/enkele-versus-dubbele-cryoballon-applicatie-bij-af-effectiviteit-en-veiligheid/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/01/01/percutane-linker-hartoorsluiting-munchen-consensusdocument-over-definities-en-ei/","published":"2017-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carlos-a-morillo","type":"person","url":"https://hartvaat.nl/mensen/carlos-a-morillo/","name":"Carlos A Morillo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/01/06/sacubitril-valsartan-versus-enalapril-bij-chagas-hartfalen/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2023/05/01/aware-uitgebreide-ablatie-vermindert-af-recidief-niet-boven-standaard-pvi/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"},{"url":"https://hartvaat.nl/2021/01/27/periprocedurele-antistolling-bij-eliminate-af-ononderbroken-edoxaban-versus-vka/","published":"2021-01-27"},{"url":"https://hartvaat.nl/2020/10/27/af-ablatie-met-vena-van-marshall-ethanol-versus-ablatie-alleen-jama-venus/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2019/09/21/ononderbroken-edoxaban-versus-vka-bij-af-ablatie-eliminate-af/","published":"2019-09-21"},{"url":"https://hartvaat.nl/2017/07/01/werkzaamheid-van-katheterablatie-bij-niet-paroxysmaal-atriumfibrilleren-jama-car/","published":"2017-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chan-joon-kim","type":"person","url":"https://hartvaat.nl/mensen/chan-joon-kim/","name":"Chan Joon Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/01/01/intravasculaire-beeldvorming-superieur-aan-angiografie-bij-complexe-pci-5-jaarsr/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2025/09/06/directe-versus-gestageerde-complete-revascularisatie-tijdens-index-opname-bij-st/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/01/talos-ami-dapt-de-escalatie-veilig-bij-mi-met-hoog-ischemisch-risico/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2021/10/09/ongeleide-de-escalatie-van-ticagrelor-naar-clopidogrel-na-mi-met-pci-lancet-talo/","published":"2021-10-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chao-jiang","type":"person","url":"https://hartvaat.nl/mensen/chao-jiang/","name":"Chao Jiang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukverlaging-bij-ongediagnosticeerde-hfpef-met-hoog-risico/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/06/13/frailteit-en-intensieve-bloeddrukcontrole-bij-diabetes/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","published":"2022-10-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chim-c-lang","type":"person","url":"https://hartvaat.nl/mensen/chim-c-lang/","name":"Chim C Lang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/01/21/evolved-vroege-interventie-bij-asymptomatische-ernstige-aortastenose-met-myocard/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","published":"2024-08-24"},{"url":"https://hartvaat.nl/2022/10/22/time-avonddosering-antihypertensiva-biedt-geen-voordeel-boven-ochtenddosering/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2020/11/03/sglt2-remming-plus-lisdiuretica-bij-diabetes-type-2-met-ckd-renale-en-cv-effecte/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/09/21/dapagliflozine-op-lv-hypertrofie-bij-diabetes-type-2-dapa-lvh-gerandomiseerde-tr/","published":"2020-09-21"},{"url":"https://hartvaat.nl/2019/11/01/metformine-en-linkerventrikelhypertrofie-bij-coronairlijden-zonder-diabetes-gera/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/02/12/genetisch-risico-op-coronairlijden-en-ontwikkeling-van-hfref-versus-hfpef/","published":"2019-02-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-jung","type":"person","url":"https://hartvaat.nl/mensen/christian-jung/","name":"Christian Jung","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/03/25/palliatieve-zorg-in-de-cardiologie-een-state-of-the-art-overzicht/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/02/19/delirium-in-de-cardiovasculaire-geneeskunde/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/12/01/scai-shockklassen-en-prognose-bij-ami-cardiogene-shock-danger-substudie/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2019/01/22/milde-hypothermie-bij-cardiogene-shock-complicerend-mi/","published":"2019-01-22"},{"url":"https://hartvaat.nl/2017/08/01/des-versus-bms-bij-acuut-mi-met-cardiogene-shock/","published":"2017-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christophe-leclercq","type":"person","url":"https://hartvaat.nl/mensen/christophe-leclercq/","name":"Christophe Leclercq","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/06/03/multipoint-pacing-vermindert-hf-hospitalisaties-en-sterfte-bij-crt-non-responder/","published":"2025-06-03"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/03/uitgebreide-versus-standaard-remote-monitoring-bij-crt-en-hartfalen/","published":"2024-10-03"},{"url":"https://hartvaat.nl/2023/10/05/more-crt-mpp-multipoint-pacing-bij-crt-non-responders/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2023/09/30/adaptresponse-adaptieve-versus-conventionele-crt-bij-hartfalen-lancet/","published":"2023-09-30"},{"url":"https://hartvaat.nl/2020/10/01/sekseverschillen-in-kenmerken-en-qol-bij-crt-patienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/09/14/crt-non-responder-naar-responder-conversie-more-crt-mpp/","published":"2019-09-14"},{"url":"https://hartvaat.nl/2016/02/01/rechterkamerseptumpacing-versus-apexpacing-bij-crt-defibrillator-gerandomiseerde/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-edwards","type":"person","url":"https://hartvaat.nl/mensen/christopher-edwards/","name":"Christopher Edwards","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/03/16/natrium-hf-subanalyse-natriuretische-peptiden-lopen-achter-op-de-klinische-ontst/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-m-kramer","type":"person","url":"https://hartvaat.nl/mensen/christopher-m-kramer/","name":"Christopher M Kramer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/09/09/summit-tirzepatide-effect-bij-hfpef-met-en-zonder-diabetes/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/07/29/summit-bmi-centrale-adipositas-en-gewichtsverlies-beinvloeden-tirzepatide-effect/","published":"2025-07-29"},{"url":"https://hartvaat.nl/2025/05/13/summit-tirzepatide-en-ckd-interactie-bij-hfpef-met-obesitas/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/03/11/summit-tirzepatide-en-klinisch-traject-bij-hfpef-met-obesitas-langetermijn/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/02/25/summit-tirzepatide-vermindert-lv-massa-en-paracardiaal-vetweefsel-bij-hfpef/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/01/30/summit-tirzepatide-bij-hfpef-met-obesitas-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","published":"2023-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ciaran-j-mcmullan","type":"person","url":"https://hartvaat.nl/mensen/ciaran-j-mcmullan/","name":"Ciaran J McMullan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/01/geografische-variatie-in-hfref-patientkenmerken-en-behandeling/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/04/01/vericiguat-voordeel-geprojecteerd-op-paradigm-hf-en-dapa-hf-populaties/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2017/05/01/melatoninesecretie-en-myocardinfarctrisico-geneste-case-controlstudie/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2017/02/01/urinezuurverlagende-middelen-en-endotheelfunctie-gerandomiseerde-trial/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"claudio-tondo","type":"person","url":"https://hartvaat.nl/mensen/claudio-tondo/","name":"Claudio Tondo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/06/02/catheterablatie-bij-atriumfibrilleren-in-cardiale-amyloidose-levert-42-ritmievri/","published":"2026-08-11"},{"url":"https://hartvaat.nl/2026/03/17/athena-register-pulsed-field-ablatie-voor-atriumfibrilleren-ook-effectief-bij-ha/","published":"2026-04-20"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2016/11/01/linker-hartoorisolatie-bij-langdurig-persisterend-af-de-belief-trial/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/07/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-af-herinterventierate-e/","published":"2016-10-07"},{"url":"https://hartvaat.nl/2016/06/09/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-atriumfibrilleren-nejm-/","published":"2016-06-09"},{"url":"https://hartvaat.nl/2016/04/26/ablatie-versus-amiodaron-bij-persisterend-af-met-hartfalen-en-icd-gerandomiseerd/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cordula-zeller","type":"person","url":"https://hartvaat.nl/mensen/cordula-zeller/","name":"Cordula Zeller","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/09/26/geblindeerde-stopstudie-voordelen-empagliflozine-verdwijnen-na-staken-bij-hf/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-en-renale-uitkomsten-bij-hartfalen-nejm-emperor-reduced-renal/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2016/12/01/empagliflozine-en-bloeddruk-bij-diabetes-type-2-met-hypertensie-naar-achtergrond/","published":"2016-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-burkhoff","type":"person","url":"https://hartvaat.nl/mensen/daniel-burkhoff/","name":"Daniel Burkhoff","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2024/12/01/splanchnische-zenuwablatie-bij-hfpef-endovasculaire-benadering/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/09/24/dapagliflozine-verbetert-arteriele-en-veneuze-compliantie-bij-hfpef/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2019/11/26/interatriale-shunt-en-pulmonale-vaatfunctie-bij-hfpef/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2018/10/01/transcatheter-interatriale-shunt-bij-hfpef-1-jaarsresultaten/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/01/23/transcatheter-interatriale-shunt-bij-hfpef-reduce-lap-hf-i/","published":"2018-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-j-goldstein","type":"person","url":"https://hartvaat.nl/mensen/daniel-j-goldstein/","name":"Daniel J Goldstein","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2022/09/27/momentum-3-vijfjaarsresultaten-heartmate-3-versus-axiale-lvad/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2020/04/01/lvad-gebruik-als-bridge-to-transplant-versus-destination-therapy-momentum-3/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2019/01/08/cva-analyse-in-momentum-3-langetermijncohort/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/10/30/zorggebruik-en-kosten-in-momentum-3-langetermijnstudie/","published":"2018-10-30"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/05/23/hemocompatibiliteitsuitkomsten-van-heartmate-3-na-6-maanden-momentum-3/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","published":"2017-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-scherr","type":"person","url":"https://hartvaat.nl/mensen/daniel-scherr/","name":"Daniel Scherr","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/06/02/catheterablatie-bij-atriumfibrilleren-in-cardiale-amyloidose-levert-42-ritmievri/","published":"2026-08-11"},{"url":"https://hartvaat.nl/2026/05/19/esc-atlas-2025-3-miljoen-cvd-doden-per-jaar-in-europa-middeninkomenlanden-hebben/","published":"2026-06-13"},{"url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","published":"2026-05-27"},{"url":"https://hartvaat.nl/2026/04/20/stopstorm-stereotactische-bestraling-reduceert-refractaire-vt-met-80/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2026/02/03/varipure-studie-pulsed-field-ablatie-in-de-dagelijkse-af-praktijk/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniele-giacoppo","type":"person","url":"https://hartvaat.nl/mensen/daniele-giacoppo/","name":"Daniele Giacoppo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/08/18/glp-1-agonisten-verlagen-cardiovasculaire-risicos-bij-diabetes-en-obesitas-overz/","published":"2026-08-25"},{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2025/05/02/paclitaxel-gecoate-ballonnen-versus-des-bij-kleine-vaten-ipd-meta-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2024/04/02/ivus-versus-oct-versus-angiografie-voor-pci-begeleiding-meta-analyse/","published":"2024-04-02"},{"url":"https://hartvaat.nl/2023/04/17/in-stent-restenose-tienjaarsuitkomsten-plain-balloon-vs-dcb-vs-des-isar-desire-3/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/01/21/korte-dapt-gevolgd-door-p2y12-mono-versus-verlengde-dapt-meta-analyse/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2017/10/01/pci-versus-cabg-bij-linker-hoofdstamstenose-jama-cardiology-systematische-review/","published":"2017-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-chieng","type":"person","url":"https://hartvaat.nl/mensen/david-chieng/","name":"David Chieng","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/07/14/vroege-versus-late-af-ablatie-impact-op-aritmierecidief/","published":"2023-07-14"},{"url":"https://hartvaat.nl/2023/02/16/hoog-vermogen-korte-duur-versus-laag-vermogen-langere-duur-posteriore-ablatie-bi/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-j-moliterno","type":"person","url":"https://hartvaat.nl/mensen/david-j-moliterno/","name":"David J Moliterno","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2018/07/31/antitrombotische-therapie-bij-af-met-oac-na-pci-aha-scientific-statement/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2017/03/14/afweging-myocardinfarct-versus-bloedingstype-en-mortaliteit-na-acs-tra-2p-timi-5/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-l-demets","type":"person","url":"https://hartvaat.nl/mensen/david-l-demets/","name":"David L DeMets","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"deok-kyu-cho","type":"person","url":"https://hartvaat.nl/mensen/deok-kyu-cho/","name":"Deok-Kyu Cho","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2020/06/16/ticagrelor-monotherapie-versus-dapt-op-bloedingen-en-cv-events-bij-acs-jama-tico/","published":"2020-06-16"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dhanunjaya-lakkireddy","type":"person","url":"https://hartvaat.nl/mensen/dhanunjaya-lakkireddy/","name":"Dhanunjaya Lakkireddy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/11/emerge-laa-amulet-occluder-in-12-180-patienten-96-succes-1-jaars-beroerte-1-6-re/","published":"2026-06-25"},{"url":"https://hartvaat.nl/2025/03/25/amulet-ide-vijfjaarsresultaten-laa-occlusie-met-amulet/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2023/08/02/peri-device-lekkage-bij-laa-occluders-mechanismen-en-voorspellers/","published":"2023-08-02"},{"url":"https://hartvaat.nl/2021/02/05/laa-isolatie-tijdens-af-ablatie-geactualiseerde-meta-analyse/","published":"2021-02-05"},{"url":"https://hartvaat.nl/2018/01/01/linkeratriumvolume-voorspelt-af-recidief-na-radiofrequentieablatie-meta-analyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/01/01/percutane-linker-hartoorsluiting-munchen-consensusdocument-over-definities-en-ei/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/11/01/linker-hartoorisolatie-bij-langdurig-persisterend-af-de-belief-trial/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/26/ablatie-versus-amiodaron-bij-persisterend-af-met-hartfalen-en-icd-gerandomiseerd/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dion-stub","type":"person","url":"https://hartvaat.nl/mensen/dion-stub/","name":"Dion Stub","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2021/11/09/colchicine-na-acs-2-jaars-cops-follow-up/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2021/10/14/lignocaine-versus-opioiden-op-antiplaatjeseffect-van-ticagrelor-local-trial/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2020/11/24/vroege-coronairangiografie-versus-uitstel-na-hartstilstand-zonder-st-elevatie-pi/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/17/colchicine-bij-acs-australische-cops-gerandomiseerde-trial/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2020/03/01/ambulancedienst-vertragingen-bij-stemi-meta-analyse/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2020/01/02/alcoholonthouding-bij-drinkers-met-af-nejm-gerandomiseerde-trial/","published":"2020-01-02"},{"url":"https://hartvaat.nl/2018/10/01/zuurstof-bij-verdenking-acuut-mi-meta-analyse-van-gerandomiseerde-trials/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2016/03/01/effect-van-aanvullende-zuurstoftoediening-op-myocardschade-bij-stemi/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"domenico-d-amario","type":"person","url":"https://hartvaat.nl/mensen/domenico-d-amario/","name":"Domenico D'Amario","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2026/03/24/myocardiale-brug-praktische-gids-voor-diagnose-en-behandeling-in-het-ccta-tijdpe/","published":"2026-04-21"},{"url":"https://hartvaat.nl/2026/02/03/vroeg-starten-met-mra-na-acuut-hartfalen-of-myocardinfarct-meta-analyse/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/11/18/cv-effecten-en-verdraagbaarheid-van-glp-1-agonisten-meta-analyse/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/07/09/coronaire-plaquefenotypeveranderingen-bij-lipidenverlagende-therapie-en-cardiova/","published":"2025-07-09"},{"url":"https://hartvaat.nl/2024/08/01/coronaire-microvasculaire-disfunctie-bij-hfpef-meta-analyse/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2022/07/21/permanente-pacemaker-na-tavi-langetermijneffect-op-klinische-uitkomsten/","published":"2022-07-21"},{"url":"https://hartvaat.nl/2021/04/17/geleide-versus-standaard-antiplaatjestherapie-na-pci-lancet-meta-analyse/","published":"2021-04-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-guillaume-baudry","type":"person","url":"https://hartvaat.nl/mensen/dr-guillaume-baudry/","name":"Dr. Guillaume Baudry","title":"Cardioloog, CHRU Nancy, Frankrijk","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/08/18/tafamidis-bij-attr-cardiomyopathie-kosteffectiviteit-onder-de-maat-in-vier-europ/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/05/09/uf-care-trial-ultrafiltratie-bij-type-2-cardiorenaal-syndroom-geen-significante-/","published":"2026-06-25"},{"url":"https://hartvaat.nl/2026/05/23/paradise-cohort-hartfalen-en-copd-samen-verhogen-de-langetermijnmortaliteit-met-/","published":"2026-06-05"},{"url":"https://hartvaat.nl/2026/05/10/paradise-gelijktijdig-acuut-hartfalen-plus-luchtweginfectie-verhoogt-sterfte-tij/","published":"2026-05-11"},{"url":"https://hartvaat.nl/2026/02/03/semaglutide-versus-tirzepatide-bij-patienten-met-obesitas-en-hfpef/","published":"2026-02-03"}],"videos":[{"url":"https://hartvaat.nl/video/hfa-2026-late-breaking-science/uf-care-ultrafiltratie-cardiorenaal/","title":"UF-CARE — Ultrafiltratie bij type-2 cardiorenaal syndroom"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"edimar-alcides-bocchi","type":"person","url":"https://hartvaat.nl/mensen/edimar-alcides-bocchi/","name":"Edimar Alcides Bocchi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/03/17/answer-hf-sacubitril-valsartan-versus-enalapril-bij-chagas-hf-primaire-resultate/","published":"2026-03-17"},{"url":"https://hartvaat.nl/2026/01/06/sacubitril-valsartan-versus-enalapril-bij-chagas-hartfalen/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2018/06/01/ivabradine-bij-hartfalen-door-chagas-ziekte-shift-post-hoc-analyse/","published":"2018-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"edward-p-gerstenfeld","type":"person","url":"https://hartvaat.nl/mensen/edward-p-gerstenfeld/","name":"Edward P Gerstenfeld","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/01/27/decaf-cafeinehoudende-koffie-en-af-gerandomiseerde-trial/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2024/07/02/pfa-versus-thermale-ablatie-bij-paroxysmaal-af-aritmielastanalyse/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/02/01/pulmonaalvenenstenose-na-pfa-versus-thermale-ablatie-vergelijking/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/11/02/advent-pulsed-field-ablatie-non-inferieur-aan-thermale-ablatie-bij-af-nejm/","published":"2023-11-02"},{"url":"https://hartvaat.nl/2019/06/01/heparinedosering-bij-ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-re/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/04/27/ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-nejm-re-circuit/","published":"2017-04-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"edwin-j-r-van-beek","type":"person","url":"https://hartvaat.nl/mensen/edwin-j-r-van-beek/","name":"Edwin J R van Beek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","published":"2025-01-25"},{"url":"https://hartvaat.nl/2020/08/01/inspannings-ecg-versus-ccta-bij-stabiele-angina-post-hoc-vergelijking/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/05/05/laag-attenuatie-plaque-op-ccta-voorspelt-mi-scot-heart-resultaten/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/01/29/coronaire-plaquekenmerken-en-adverse-uitkomsten-scot-heart/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","published":"2018-09-06"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/04/19/ct-coronairangiografie-voor-het-sturen-van-beleid-bij-coronairlijden/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"emile-ferrari","type":"person","url":"https://hartvaat.nl/mensen/emile-ferrari/","name":"Emile Ferrari","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2017/03/01/24-uurs-bloeddrukmonitoring-bij-renale-denervatie-denerhtn-studie/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/09/20/medicatietrouw-en-bloeddrukeffecten-van-renale-denervatie-rsd-pathway-2-analyse/","published":"2016-09-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"farzin-beygui","type":"person","url":"https://hartvaat.nl/mensen/farzin-beygui/","name":"Farzin Beygui","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-laagrisico-acuut-mi/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/11/19/afloat-flecainide-voorkomt-af-na-pfo-sluiting-rct/","published":"2024-11-19"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"},{"url":"https://hartvaat.nl/2018/11/01/aldosteronblokkade-bij-myocardinfarct-ipd-analyse-van-twee-trials/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/04/26/vroege-aldosteronblokkade-bij-acuut-myocardinfarct-de-albatross-trial/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ferdinando-varbella","type":"person","url":"https://hartvaat.nl/mensen/ferdinando-varbella/","name":"Ferdinando Varbella","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/11/11/ct-angiografie-of-standaardzorg-na-pci-van-de-linker-hoofdstam/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"finnian-r-mc-causland","type":"person","url":"https://hartvaat.nl/mensen/finnian-r-mc-causland/","name":"Finnian R Mc Causland","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/12/matige-koffiedrinken-waarschijnlijk-veilig-en-mogelijk-gunstig-bij-chronische-ni/","published":"2026-07-29"},{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/06/04/sacubitril-valsartan-bij-hartfalen-over-het-nierfunctiespectrum/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2020/09/29/arni-en-renale-uitkomsten-bij-hfpef-paragon-hf/","published":"2020-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francesco-franchi","type":"person","url":"https://hartvaat.nl/mensen/francesco-franchi/","name":"Francesco Franchi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","published":"2022-03-07"},{"url":"https://hartvaat.nl/2021/04/17/geleide-versus-standaard-antiplaatjestherapie-na-pci-lancet-meta-analyse/","published":"2021-04-17"},{"url":"https://hartvaat.nl/2020/10/13/laaggedoseerd-ticagrelor-versus-standaard-clopidogrel-bij-diabetes-farmacodynami/","published":"2020-10-13"},{"url":"https://hartvaat.nl/2019/04/02/cangrelor-en-gemalen-ticagrelor-bij-stemi-met-primaire-pci/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2016/09/13/prasugrel-versus-ticagrelor-bij-diabetes-type-2-met-coronairlijden-optimus-4-stu/","published":"2016-09-13"},{"url":"https://hartvaat.nl/2016/05/03/gemalen-prasugrel-bij-stemi-met-primaire-pci-de-crush-studie/","published":"2016-05-03"},{"url":"https://hartvaat.nl/2016/03/15/plaatjesremming-met-ticagrelor-60-mg-versus-90-mg-in-de-pegasus-timi-54-trial/","published":"2016-03-15"},{"url":"https://hartvaat.nl/2016/02/16/ticagrelor-versus-clopidogrel-bij-troponine-negatieve-laagrisico-acs-met-ad-hoc-/","published":"2016-02-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frank-l-j-visseren","type":"person","url":"https://hartvaat.nl/mensen/frank-l-j-visseren/","name":"Frank L J Visseren","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2022/10/01/smartphone-app-thuisbloeddrukmeting-versus-kantoor-en-ambulante-meting/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/01/01/plasmatrogconcentraties-van-antihypertensiva-voor-therapietrouwbeoordeling-meta-/","published":"2021-01-01"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2019/12/07/individueel-levenslang-voordeel-en-bloedingsrisico-van-rivaroxaban-plus-aspirine/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2018/10/01/geschat-individueel-levensvoordeel-van-pcsk9-remming-bij-statinebehandelde-cad-p/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/04/13/inclisiran-bij-patienten-met-hoog-cv-risico-en-verhoogd-ldl-nejm-orion-1/","published":"2017-04-13"},{"url":"https://hartvaat.nl/2016/11/08/residueel-vasculair-risico-bij-secundaire-preventie-verdeling-van-10-jaarsrisico/","published":"2016-11-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frans-h-rutten","type":"person","url":"https://hartvaat.nl/mensen/frans-h-rutten/","name":"Frans H Rutten","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/05/nederlandse-huisartsenpost-1-op-20-contacten-voor-benauwdheid-betreft-hartfalen-/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2025/12/01/economische-ziektelast-van-hartfalen-in-europa-systematische-review/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/01/23/switchen-van-vka-naar-noac-bij-fragiele-ouderen-met-af-veilig/","published":"2024-01-23"},{"url":"https://hartvaat.nl/2021/10/01/apothekerzorg-bij-poliklinisch-hf-meta-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2020/08/07/geintegreerd-af-management-in-de-huisartsenpraktijk-all-in-clustergerandomiseerd/","published":"2020-08-07"},{"url":"https://hartvaat.nl/2018/08/01/opportunistische-hf-screening-met-natriuretische-peptiden-bij-af-ipd-meta-analys/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francois-schiele","type":"person","url":"https://hartvaat.nl/mensen/francois-schiele/","name":"François Schiele","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/09/15/polypill-voor-secundaire-cardiovasculaire-preventie-secure-trial-in-nejm/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2020/12/14/edoxaban-bij-af-met-pci-naar-acute-versus-chronische-coronaire-presentatie-entru/","published":"2020-12-14"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2016/09/27/oct-geleide-pci-optimalisatie-bij-nste-acs-gerandomiseerde-trial/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/08/01/eerder-clopidogrelgebruik-en-uitkomsten-bij-conservatief-behandeld-acs/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gary-s-mintz","type":"person","url":"https://hartvaat.nl/mensen/gary-s-mintz/","name":"Gary S Mintz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/05/11/ivus-acs-ivus-geleide-pci-bij-acs-superieur-lancet/","published":"2024-05-11"},{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","published":"2024-05-04"},{"url":"https://hartvaat.nl/2023/12/05/intravasculaire-beeldvorming-versus-functionele-versus-angiografische-pci-begele/","published":"2023-12-05"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"},{"url":"https://hartvaat.nl/2016/11/26/oct-versus-ivus-versus-angiografie-bij-coronaire-stentimplantatie-lancet-ilumien/","published":"2016-11-26"},{"url":"https://hartvaat.nl/2016/04/19/statinebehandeling-en-plaquesamenstelling-dubbelblinde-gerandomiseerde-studie/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giles-roditi","type":"person","url":"https://hartvaat.nl/mensen/giles-roditi/","name":"Giles Roditi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","published":"2025-01-25"},{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/05/05/laag-attenuatie-plaque-op-ccta-voorspelt-mi-scot-heart-resultaten/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/01/29/coronaire-plaquekenmerken-en-adverse-uitkomsten-scot-heart/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","published":"2018-09-06"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/04/19/ct-coronairangiografie-voor-het-sturen-van-beleid-bij-coronairlijden/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giora-weisz","type":"person","url":"https://hartvaat.nl/mensen/giora-weisz/","name":"Giora Weisz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2017/05/09/ranolazine-na-incomplete-pci-bij-diabetes-versus-zonder-diabetes-river-pci/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2016/01/09/ranolazine-bij-incomplete-revascularisatie-na-pci-de-river-pci-trial/","published":"2016-01-09"},{"url":"https://hartvaat.nl/2016/01/05/ranolazine-bij-angina-en-kwaliteit-van-leven-na-pci-met-incomplete-revascularisa/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giulio-g-stefanini","type":"person","url":"https://hartvaat.nl/mensen/giulio-g-stefanini/","name":"Giulio G Stefanini","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/12/09/gepersonaliseerde-versus-standaard-dapt-duur-na-pci-gerandomiseerde-trial/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2022/10/01/mitraclip-bij-secundaire-mitralisklepinsufficientie-meta-analyse-ischemisch-vs-n/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2020/05/09/p2y12-monotherapie-of-aspirine-voor-secundaire-preventie-lancet-meta-analyse/","published":"2020-05-09"},{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","published":"2019-02-19"},{"url":"https://hartvaat.nl/2018/05/07/esc-eapci-taskforce-rapport-over-bioresorbeerbare-scaffolds-executive-summary/","published":"2018-05-07"},{"url":"https://hartvaat.nl/2018/03/01/doac-plus-antiplaatjestherapie-voor-secundaire-preventie-na-acs-meta-analyse/","published":"2018-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giuseppe-tarantini","type":"person","url":"https://hartvaat.nl/mensen/giuseppe-tarantini/","name":"Giuseppe Tarantini","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-laagrisico-acuut-mi/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2021/01/21/korte-dapt-gevolgd-door-p2y12-mono-versus-verlengde-dapt-meta-analyse/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gregory-m-marcus","type":"person","url":"https://hartvaat.nl/mensen/gregory-m-marcus/","name":"Gregory M Marcus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/01/27/decaf-cafeinehoudende-koffie-en-af-gerandomiseerde-trial/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2024/10/21/dieet-en-af-risico-systematische-review/","published":"2024-10-21"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2023/06/01/intensieve-bloeddrukcontrole-en-geleidingsziekten-sprint-post-hoc-analyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/02/01/geindividualiseerde-triggerstudies-bij-paroxysmaal-af-jama-i-stop-afib/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2016/04/01/orale-antistolling-bij-atriumfibrilleren-over-het-spectrum-van-beroerterisico-ga/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hakim-moulay-dehbi","type":"person","url":"https://hartvaat.nl/mensen/hakim-moulay-dehbi/","name":"Hakim-Moulay Dehbi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/07/05/optimale-timing-van-anticoagulatie-na-ischemisch-cva-en-af-collaboratief-project/","published":"2025-07-05"},{"url":"https://hartvaat.nl/2025/01/01/ffr-versus-ifr-bij-coronaire-revascularisatie-vijfjaars-follow-up/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"haran-burri","type":"person","url":"https://hartvaat.nl/mensen/haran-burri/","name":"Haran Burri","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/03/28/gestandaardiseerd-stappenplan-voor-tricuspidalisinsufficientie-van-verwijzing-to/","published":"2026-04-19"},{"url":"https://hartvaat.nl/2026/02/03/intracardiale-elektrogrammen-bij-perforatie-tijdens-linkerbundeltakpacing/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2026/02/03/aanbesteding-van-cardiale-implanteerbare-devices-in-europa-waarde-of-kosten/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/03/multipoint-pacing-vermindert-hf-hospitalisaties-en-sterfte-bij-crt-non-responder/","published":"2025-06-03"},{"url":"https://hartvaat.nl/2023/10/05/more-crt-mpp-multipoint-pacing-bij-crt-non-responders/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2023/05/19/geleidingssysteempacing-in-europa-inzichten-uit-klinische-praktijk/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2019/09/14/crt-non-responder-naar-responder-conversie-more-crt-mpp/","published":"2019-09-14"},{"url":"https://hartvaat.nl/2018/05/01/risicostratificatie-met-geintegreerde-devicediagnostiek-bij-hartfalen/","published":"2018-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"helen-m-colhoun","type":"person","url":"https://hartvaat.nl/mensen/helen-m-colhoun/","name":"Helen M Colhoun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/08/18/semaglutide-verlaagt-hscrp-en-ontstekingsactiviteit-bij-ascvd-patienten-met-over/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/03/05/finerenon-effectief-bij-type-1-diabetes-met-chronische-nierziekte/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","published":"2024-08-24"},{"url":"https://hartvaat.nl/2023/12/14/select-semaglutide-vermindert-cv-events-bij-obesitas-zonder-diabetes-nejm/","published":"2023-12-14"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2018/10/13/lp-a-baseline-en-on-statin-voor-cv-eventvoorspelling-lancet-ipd-meta-analyse/","published":"2018-10-13"},{"url":"https://hartvaat.nl/2017/12/21/lilrb5-variant-geassocieerd-met-statine-intolerantie-en-myalgie/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2016/10/14/geen-effect-van-pcsk9-remmer-alirocumab-op-diabetes-incidentie-odyssey-analyse/","published":"2016-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"henry-krum","type":"person","url":"https://hartvaat.nl/mensen/henry-krum/","name":"Henry Krum","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2018/03/27/crt-bij-hartfalen-met-smal-qrs-complex/","published":"2018-03-27"},{"url":"https://hartvaat.nl/2017/11/21/bloeddrukeffecten-van-ibuprofen-naproxen-en-celecoxib-bij-artritis-precision-abp/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"},{"url":"https://hartvaat.nl/2017/03/07/lv-global-longitudinal-strain-en-prognose-bij-hartfalen-met-smal-qrs-en-crt/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2016/07/14/finerenon-versus-eplerenon-bij-hartfalen-met-diabetes-en-verslechterende-nierfun/","published":"2016-07-14"},{"url":"https://hartvaat.nl/2016/04/21/aliskiren-enalapril-of-de-combinatie-bij-hartfalen-nejm-atmosphere-trial/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/01/01/persisterende-echocardiografische-dyssynchronie-voorspelt-ongunstige-uitkomsten-/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"henry-n-ginsberg","type":"person","url":"https://hartvaat.nl/mensen/henry-n-ginsberg/","name":"Henry N Ginsberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-familiaire-chylomicronemie-nejm-fase-3/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2020/04/28/apabetalone-en-cv-events-bij-acs-met-diabetes-type-2-jama-betonmace/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2020/02/25/polygene-risicoscore-en-voordeel-van-alirocumab-bij-coronairlijden-odyssey-outco/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2020/02/11/haptoglobinefenotype-wijzigt-het-effect-van-intensieve-glycemische-controle-op-c/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2017/04/01/fenofibraat-en-langetermijn-cardiovasculair-risico-bij-statinebehandelde-diabete/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/12/13/alirocumab-en-reductie-in-atherogene-lipiden-en-cardiovasculaire-events-10-odyss/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/10/14/geen-effect-van-pcsk9-remmer-alirocumab-op-diabetes-incidentie-odyssey-analyse/","published":"2016-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hirotoshi-watanabe","type":"person","url":"https://hartvaat.nl/mensen/hirotoshi-watanabe/","name":"Hirotoshi Watanabe","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hisao-ogawa","type":"person","url":"https://hartvaat.nl/mensen/hisao-ogawa/","name":"Hisao Ogawa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2022/08/01/rivaroxaban-monotherapie-versus-combinatie-met-plaatjesremmers-bij-af-en-coronai/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/11/01/aspirine-versus-p2y12-remmer-met-antistolling-bij-af/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2019/09/19/antitrombotische-therapie-bij-af-met-stabiel-coronairlijden-nejm-afire/","published":"2019-09-19"},{"url":"https://hartvaat.nl/2019/06/07/febuxostat-voor-cerebraal-en-cardiorenovasculaire-eventpreventie-freed/","published":"2019-06-07"},{"url":"https://hartvaat.nl/2018/05/08/hoog-versus-laaggedoseerd-pitavastatine-bij-stabiel-coronairlijden-real-cad/","published":"2018-05-08"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/02/14/laaggedoseerde-aspirine-voor-primaire-cardiovasculaire-preventie-bij-diabetes-ty/","published":"2017-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hugh-calkins","type":"person","url":"https://hartvaat.nl/mensen/hugh-calkins/","name":"Hugh Calkins","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/07/02/pfa-versus-thermale-ablatie-bij-paroxysmaal-af-aritmielastanalyse/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/02/amaze-pvi-met-of-zonder-laa-ligatie-bij-af-jama-rct/","published":"2024-04-02"},{"url":"https://hartvaat.nl/2022/06/21/mri-geleide-fibroseablatie-versus-conventionele-ablatie-bij-persisterend-af/","published":"2022-06-21"},{"url":"https://hartvaat.nl/2019/07/09/2019-aha-acc-hrs-gerichte-update-van-de-af-richtlijn/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/06/01/heparinedosering-bij-ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-re/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/04/27/ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-nejm-re-circuit/","published":"2017-04-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hector-bueno","type":"person","url":"https://hartvaat.nl/mensen/hector-bueno/","name":"Héctor Bueno","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/07/28/routine-invasieve-strategie-en-herinfarctrisico-bij-fragiele-ouderen-met-nste-ac/","published":"2025-07-28"},{"url":"https://hartvaat.nl/2022/09/15/polypill-voor-secundaire-cardiovasculaire-preventie-secure-trial-in-nejm/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2018/12/21/culprit-shock-integratie-in-2017-esc-stemi-richtlijn-richtlijncommissie-standpun/","published":"2018-12-21"},{"url":"https://hartvaat.nl/2018/01/07/2017-esc-richtlijn-voor-stemi-management/","published":"2018-01-07"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ian-j-kulac","type":"person","url":"https://hartvaat.nl/mensen/ian-j-kulac/","name":"Ian J Kulac","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/10/07/nieuwe-inspanningsherstelpatronen-als-maat-voor-cardiale-prestatie/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ioanna-gouni-berthold","type":"person","url":"https://hartvaat.nl/mensen/ioanna-gouni-berthold/","name":"Ioanna Gouni-Berthold","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/01/16/lp-a-verlaging-bij-cardiovasculaire-ziekte-nejm/","published":"2020-01-16"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2017/08/01/vitamine-d-en-mortaliteit-bij-hartfalen-de-evita-3-jaars-gerandomiseerde-trial/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/04/19/evolocumab-versus-ezetimibe-bij-statine-intolerante-patienten-de-gauss-3-trial/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jacek-kubica","type":"person","url":"https://hartvaat.nl/mensen/jacek-kubica/","name":"Jacek Kubica","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/19/salamander-register-95-5-technisch-succes-bij-stand-alone-linker-hartoor-occlusi/","published":"2026-06-10"},{"url":"https://hartvaat.nl/2026/02/03/levosimendan-infusies-en-klinisch-beloop-bij-hartfalen-levo-d-resultaten/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2023/01/24/pcsk9-remming-bij-covid-19-anti-inflammatoir-potentieel-onderzocht/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/07/14/vergelijking-van-orale-p2y12-remmers-bij-acs-netwerkmeta-analyse-van-52-816-pati/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2018/04/17/uitgangs-ldl-en-mortaliteitsreductie-na-ldl-verlaging-jama-meta-analyse/","published":"2018-04-17"},{"url":"https://hartvaat.nl/2016/01/14/morfine-vertraagt-en-vermindert-de-werking-van-ticagrelor-bij-myocardinfarct-de-/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jan-basile","type":"person","url":"https://hartvaat.nl/mensen/jan-basile/","name":"Jan Basile","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2020/02/01/bloeddrukcontrole-en-diabetes-incidentie-sprint-resultaten/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jang-whan-bae","type":"person","url":"https://hartvaat.nl/mensen/jang-whan-bae/","name":"Jang-Whan Bae","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/05/01/aspirine-versus-clopidogrel-na-coronaire-stenting-naar-bloedingsrisico-en-comple/","published":"2025-05-01"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/01/10/host-exam-extended-clopidogrel-superieur-aan-aspirine-als-monotherapie-na-pci/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2021/06/26/aspirine-versus-clopidogrel-voor-chronische-monotherapie-na-pci-lancet-host-exam/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2020/10/10/prasugrel-gebaseerde-dapt-de-escalatie-na-pci-bij-acs-lancet-host-reduce-polytec/","published":"2020-10-10"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jean-g-macfadyen","type":"person","url":"https://hartvaat.nl/mensen/jean-g-macfadyen/","name":"Jean G MacFadyen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/04/15/inflammatie-en-cholesterol-als-cv-voorspellers-onder-statinetherapie-lancet-anal/","published":"2023-04-15"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","published":"2022-08-02"},{"url":"https://hartvaat.nl/2020/08/14/il-6-crp-en-ldl-als-biomarkers-van-residueel-risico-vergelijking/","published":"2020-08-14"},{"url":"https://hartvaat.nl/2020/02/01/il-1-remming-en-bloeddruk-hypertensie-en-residueel-inflammatoir-risico-cantos/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/02/21/laaggedoseerd-methotrexaat-voor-preventie-van-atherosclerotische-events-nejm-cir/","published":"2019-02-21"},{"url":"https://hartvaat.nl/2017/10/21/canakinumab-en-longkankerincidentie-bij-atherosclerose-lancet-cantos-exploratief/","published":"2017-10-21"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jean-francois-roux","type":"person","url":"https://hartvaat.nl/mensen/jean-francois-roux/","name":"Jean-Francois Roux","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/02/20/vanish2-catheterablatie-versus-antiaritmica-bij-ventriculaire-tachycardie-nejm/","published":"2025-02-20"},{"url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","published":"2024-02-16"},{"url":"https://hartvaat.nl/2023/05/01/aware-uitgebreide-ablatie-vermindert-af-recidief-niet-boven-standaard-pvi/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"},{"url":"https://hartvaat.nl/2017/05/09/agressieve-bloeddrukcontrole-en-recidief-van-af-na-ablatie-gerandomiseerde-trial/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2016/07/14/ablatie-versus-escalatie-van-antiaritmica-bij-ventriculaire-tachycardie-nejm-van/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeffrey-t-bates","type":"person","url":"https://hartvaat.nl/mensen/jeffrey-t-bates/","name":"Jeffrey T Bates","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/05/05/intensieve-bloeddruk-en-aortastijfheid-sprint-heart/","published":"2021-05-05"},{"url":"https://hartvaat.nl/2021/04/01/intensieve-versus-standaard-bloeddruk-op-cva-subtypes-sprint/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/06/01/intensieve-bloeddrukverlaging-en-risico-op-af-sprint-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2017/08/01/intensieve-bloeddrukverlaging-en-linkerventrikelhypertrofie-sprint-echocardiogra/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/01/01/intensieve-versus-standaard-bloeddrukcontrole-op-ambulante-bloeddruk-sprint-resu/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/08/01/apol1-nierrisicovarianten-en-cerebrale-wittestoflaesies/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jens-haarbo","type":"person","url":"https://hartvaat.nl/mensen/jens-haarbo/","name":"Jens Haarbo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/10/21/minimalisatie-van-atriale-pacing-bij-sinusknoopziekte-vermindert-af/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2022/04/01/icd-bij-niet-ischemisch-systolisch-hf-met-coronaire-atherosclerose-danish/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jerome-l-fleg","type":"person","url":"https://hartvaat.nl/mensen/jerome-l-fleg/","name":"Jerome L Fleg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/04/18/aha-scientific-statement-gestructureerde-inspanningstraining-bij-hfpef/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/23/gezondheidsstatus-na-invasieve-of-conservatieve-zorg-bij-coronairlijden-met-gevo/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2017/04/01/fenofibraat-en-langetermijn-cardiovasculair-risico-bij-statinebehandelde-diabete/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/10/01/orthostatische-hypotensie-in-de-accord-bloeddruk-trial-prevalentie-en-klinische-/","published":"2016-10-01"},{"url":"https://hartvaat.nl/2016/02/23/inspanningstestvariabelen-als-mortaliteitsvoorspellers-bij-chronisch-systolisch-/","published":"2016-02-23"},{"url":"https://hartvaat.nl/2016/02/01/invloed-van-ejectiefractie-op-uitkomsten-van-spironolacton-bij-hfpef/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joakim-alfredsson","type":"person","url":"https://hartvaat.nl/mensen/joakim-alfredsson/","name":"Joakim Alfredsson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/12/11/ticagrelor-plus-aspirine-versus-aspirine-na-cabg-voor-acs-gerandomiseerde-trial/","published":"2025-12-11"},{"url":"https://hartvaat.nl/2025/10/07/help-mi-helicobacter-pylori-screening-na-acuut-mi-cluster-rct/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/01/07/euroheart-definities-van-klinische-studie-eindpunten-voor-cvd/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/04/18/abyss-betablokkers-na-mi-met-behouden-ef-niet-nodig-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2018/12/11/langetermijneffecten-van-zuurstof-op-sterfte-of-hf-hospitalisatie-na-verdenking-/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/08/01/zuurstoftherapie-bij-stemi-overzichtsartikel/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/09/28/zuurstoftherapie-bij-vermoedelijk-acuut-myocardinfarct-nejm-deto2x-ami/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/08/01/voorspelling-van-bloedingsrisico-tijdens-dapt-na-acs/","published":"2017-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jochen-wohrle","type":"person","url":"https://hartvaat.nl/mensen/jochen-wohrle/","name":"Jochen Wöhrle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/07/drug-coated-balloons-versus-des-bij-kleine-coronairarterien-lancet-basket-small-/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2018/09/08/drug-coated-balloons-bij-kleine-coronairarterien-lancet-basket-small-2/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/02/03/sirolimus-eluting-bioabsorbeerbare-stent-versus-everolimus-eluting-stent-na-mi-l/","published":"2018-02-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johan-sundstrom","type":"person","url":"https://hartvaat.nl/mensen/johan-sundstrom/","name":"Johan Sundström","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/01/01/consistentie-van-bloeddrukrespons-op-kaliumverrijkt-zout-ssass-subanalyse/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2024/04/18/abyss-betablokkers-na-mi-met-behouden-ef-niet-nodig-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/04/11/heterogeniteit-in-bloeddrukrespons-op-antihypertensiva-jama-cross-over-rct/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2023/03/10/mondiale-prevalentie-uitkomsten-en-kosten-van-hartfalen-careme-studie/","published":"2023-03-10"},{"url":"https://hartvaat.nl/2022/07/27/langetermijneffect-van-antihypertensiva-op-bloeddruk-meta-analyse-op-individueel/","published":"2022-07-27"},{"url":"https://hartvaat.nl/2022/04/19/therapeutische-doelen-voor-hf-via-proteomics-en-mendeliaanse-randomisatie/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/11/13/bloeddrukverlaging-en-risico-op-diabetes-type-2-lancet-bplttc-ipd-meta-analyse/","published":"2021-11-13"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-e-deanfield","type":"person","url":"https://hartvaat.nl/mensen/john-e-deanfield/","name":"John E Deanfield","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/08/18/semaglutide-verlaagt-hscrp-en-ontstekingsactiviteit-bij-ascvd-patienten-met-over/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2025/12/01/dapagliflozine-na-mi-naar-ef-cardiometabole-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","published":"2025-05-29"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","published":"2024-08-24"},{"url":"https://hartvaat.nl/2023/12/14/select-semaglutide-vermindert-cv-events-bij-obesitas-zonder-diabetes-nejm/","published":"2023-12-14"},{"url":"https://hartvaat.nl/2022/09/01/collaterale-schade-van-covid-19-aan-cardiovasculaire-zorg-meta-analyse/","published":"2022-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-m-flack","type":"person","url":"https://hartvaat.nl/mensen/john-m-flack/","name":"John M Flack","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/03/07/baxdrostat-verlaagt-bloeddruk-significant-bij-resistente-hypertensie/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/03/07/bax24-baxdrostat-en-ambulante-bloeddruk-bij-resistente-hypertensie/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2026/02/01/aprocitentan-bij-ckd-en-resistente-hypertensie/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/10/09/baxdrostat-bij-ongecontroleerde-en-resistente-hypertensie-effectiviteit-en-veili/","published":"2025-10-09"},{"url":"https://hartvaat.nl/2025/05/08/lorundrostat-bij-ongecontroleerde-hypertensie-fase-3-nejm/","published":"2025-05-08"},{"url":"https://hartvaat.nl/2025/04/01/aprocitentan-bij-zwarte-patienten-met-hypertensie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2022/12/03/precision-aprocitentan-bij-resistente-hypertensie-eerste-endothelineantagonist/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2018/11/01/therapieresistente-hypertensie-aha-scientific-statement-over-detectie-evaluatie-/","published":"2018-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jonathan-g-howlett","type":"person","url":"https://hartvaat.nl/mensen/jonathan-g-howlett/","name":"Jonathan G Howlett","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2022/04/09/natriumreductie-100-mmol-bij-hartfalen-lancet-sodium-hf/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joris-r-de-groot","type":"person","url":"https://hartvaat.nl/mensen/joris-r-de-groot/","name":"Joris R de Groot","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/10/15/lage-voorspelde-adherentie-verhoogt-stroke-risico-bij-af-patienten-die-starten-m/","published":"2026-08-08"},{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2023/01/11/inadequate-noac-dosering-bij-af-uitkomsten-en-oorzaken-meta-analyse/","published":"2023-01-11"},{"url":"https://hartvaat.nl/2019/11/01/determinanten-van-linkeratriumtrombi-bij-geplande-cardioversie-ensure-af/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2018/09/01/last-van-atriale-high-rate-episodes-en-cva-risico-systematische-review/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2016/10/22/edoxaban-versus-enoxaparine-warfarine-bij-cardioversie-van-af-ensure-af-trial/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/09/13/ganglionplexusablatie-bij-gevorderd-atriumfibrilleren-de-afact-studie/","published":"2016-09-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"josep-brugada","type":"person","url":"https://hartvaat.nl/mensen/josep-brugada/","name":"Josep Brugada","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2018/03/27/crt-bij-hartfalen-met-smal-qrs-complex/","published":"2018-03-27"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/03/07/lv-global-longitudinal-strain-en-prognose-bij-hartfalen-met-smal-qrs-en-crt/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2017/03/07/contractiliteitssensor-geleide-crt-optimalisatie-respond-crt-trial/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2016/10/07/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-af-herinterventierate-e/","published":"2016-10-07"},{"url":"https://hartvaat.nl/2016/06/09/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-atriumfibrilleren-nejm-/","published":"2016-06-09"},{"url":"https://hartvaat.nl/2016/01/01/persisterende-echocardiografische-dyssynchronie-voorspelt-ongunstige-uitkomsten-/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joseph-b-morton","type":"person","url":"https://hartvaat.nl/mensen/joseph-b-morton/","name":"Joseph B Morton","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/07/14/vroege-versus-late-af-ablatie-impact-op-aritmierecidief/","published":"2023-07-14"},{"url":"https://hartvaat.nl/2023/02/16/hoog-vermogen-korte-duur-versus-laag-vermogen-langere-duur-posteriore-ablatie-bi/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jose-l-zamorano","type":"person","url":"https://hartvaat.nl/mensen/jose-l-zamorano/","name":"José L Zamorano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/14/2016-esc-eas-richtlijn-voor-het-management-van-dyslipidemieen/","published":"2016-10-14"},{"url":"https://hartvaat.nl/2016/09/13/edoxaban-versus-warfarine-bij-af-patienten-met-valrisico-engage-af-timi-48-analy/","published":"2016-09-13"},{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","published":"2016-06-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jose-ramon-gonzalez-juanatey","type":"person","url":"https://hartvaat.nl/mensen/jose-ramon-gonzalez-juanatey/","name":"José Ramón González-Juanatey","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/18/naar-precisiecardiologie-na-het-hartinfarct-opkomende-biomarkers-voor-risicostra/","published":"2026-06-18"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2024/12/01/colica-colchicine-bij-acuut-gedecompenseerd-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2018/04/14/sildenafil-bij-persisterende-pulmonale-hypertensie-na-klepchirurgie/","published":"2018-04-14"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jozef-bartunek","type":"person","url":"https://hartvaat.nl/mensen/jozef-bartunek/","name":"Jozef Bartunek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2023/12/20/ticagrelor-versus-prasugrel-en-coronaire-microcirculatie-bij-pci/","published":"2023-12-20"},{"url":"https://hartvaat.nl/2023/08/01/atrial-flow-regulator-en-overleving-bij-hartfalen-voorspelde-impact/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2018/10/01/transcatheter-interatriale-shunt-bij-hfpef-1-jaarsresultaten/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/07/12/prasugrel-versus-clopidogrel-en-coronaire-microvasculaire-functie-bij-electieve-/","published":"2016-07-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"juan-sanchis","type":"person","url":"https://hartvaat.nl/mensen/juan-sanchis/","name":"Juan Sanchis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/02/03/bio-impedantie-voor-vochtstatusbepaling-en-prognose-bij-chronisch-hartfalen/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/07/28/routine-invasieve-strategie-en-herinfarctrisico-bij-fragiele-ouderen-met-nste-ac/","published":"2025-07-28"},{"url":"https://hartvaat.nl/2024/07/12/nste-acs-na-cabg-meta-analyse-van-behandelstrategieen/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2024/06/14/invasief-versus-conservatief-bij-ouderen-met-nste-acs-ipd-meta-analyse/","published":"2024-06-14"},{"url":"https://hartvaat.nl/2024/04/01/betablokkerstaken-verbetert-inspanningscapaciteit-bij-hfpef/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/04/01/iv-ferricarboxymaltose-verbetert-linkeratriale-strain-bij-hartfalen-myocardial-i/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2021/11/23/betablokkerstaken-en-functionele-capaciteit-bij-hfpef/","published":"2021-11-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jun-cai","type":"person","url":"https://hartvaat.nl/mensen/jun-cai/","name":"Jun Cai","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/10/28/step-6-jaarsresultaten-intensieve-bloeddrukcontrole-bij-ouderen-langetermijn/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/08/01/voordeel-en-risico-van-intensieve-bloeddrukcontrole-naar-cv-risico/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/09/01/hypertensieduur-en-effect-van-intensieve-bloeddrukbehandeling/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/12/01/step-trial-diastolische-bloeddruk-beinvloedt-effect-van-intensieve-behandeling/","published":"2023-12-01"},{"url":"https://hartvaat.nl/2023/09/01/step-substudie-intensieve-bloeddrukverlaging-verbetert-lvh-bij-ouderen/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/12/01/klebsiella-pneumoniae-als-mogelijke-oorzaak-van-hypertensie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/09/30/intensieve-bloeddrukcontrole-bij-oudere-patienten-met-hypertensie-nejm-step/","published":"2021-09-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karen-p-alexander","type":"person","url":"https://hartvaat.nl/mensen/karen-p-alexander/","name":"Karen P Alexander","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2017/05/09/ranolazine-na-incomplete-pci-bij-diabetes-versus-zonder-diabetes-river-pci/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2016/04/19/trends-in-behandeling-en-uitkomsten-bij-nste-acs-naar-leeftijd/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/01/09/ranolazine-bij-incomplete-revascularisatie-na-pci-de-river-pci-trial/","published":"2016-01-09"},{"url":"https://hartvaat.nl/2016/01/05/ranolazine-bij-angina-en-kwaliteit-van-leven-na-pci-met-incomplete-revascularisa/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karl-wegscheider","type":"person","url":"https://hartvaat.nl/mensen/karl-wegscheider/","name":"Karl Wegscheider","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2023/05/19/east-afnet-4-vroege-ritmecontrole-bij-af-is-kosteneffectief/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","published":"2022-09-13"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/04/01/biomarkers-bij-hf-met-centrale-slaapapneu-serve-hf/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2018/09/22/telemedische-interventie-bij-hartfalen-lancet-tim-hf2/","published":"2018-09-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karsten-t-veien","type":"person","url":"https://hartvaat.nl/mensen/karsten-t-veien/","name":"Karsten T Veien","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2018/12/04/ffr-versus-angiografie-geleide-cabg/","published":"2018-12-04"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kenneth-a-ellenbogen","type":"person","url":"https://hartvaat.nl/mensen/kenneth-a-ellenbogen/","name":"Kenneth A Ellenbogen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/09/01/la-low-voltage-prevalentie-en-voorspellers-bij-paroxysmaal-versus-niet-paroxysma/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2023/11/02/advent-pulsed-field-ablatie-non-inferieur-aan-thermale-ablatie-bij-af-nejm/","published":"2023-11-02"},{"url":"https://hartvaat.nl/2022/09/27/linkerbundeltakpacing-versus-biventriculaire-pacing-voor-crt-gerandomiseerde-tri/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2020/10/27/af-ablatie-met-vena-van-marshall-ethanol-versus-ablatie-alleen-jama-venus/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2019/08/20/2018-acc-aha-hrs-richtlijn-voor-bradycardie-en-geleidingsstoornissen/","published":"2019-08-20"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2016/05/17/institutionele-en-operateurvereisten-voor-linker-hartoorocclusie-scai-acc-hrs-st/","published":"2016-05-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ketil-jorgen-haugan","type":"person","url":"https://hartvaat.nl/mensen/ketil-jorgen-haugan/","name":"Ketil Jørgen Haugan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/01/20/af-screening-naar-genetisch-risico-loop-subanalyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/15/hypokaliemie-en-af-gedetecteerd-door-implanteerbare-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2025/12/15/circadiaanse-patronen-van-af-en-ziekteprogressie-via-implanted-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2025/11/20/kaliumverhoging-bij-hoogrisicopatienten-voor-ventriculaire-aritmieen-rct/","published":"2025-11-20"},{"url":"https://hartvaat.nl/2023/06/13/loop-substudie-nt-probnp-verbetert-af-screeningsopbrengst/","published":"2023-06-13"},{"url":"https://hartvaat.nl/2022/09/01/bloeddruk-beinvloedt-opbrengst-van-af-screening-loop-substudie/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2020/05/12/ritme-monitoringstrategieen-voor-af-screening-uitgebreide-evaluatie/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2019/12/03/natuurlijk-beloop-van-subklinisch-af-gedetecteerd-door-implanteerbare-looprecord/","published":"2019-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"koji-takagi","type":"person","url":"https://hartvaat.nl/mensen/koji-takagi/","name":"Koji Takagi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/03/16/natrium-hf-subanalyse-natriuretische-peptiden-lopen-achter-op-de-klinische-ontst/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"leanne-dyal","type":"person","url":"https://hartvaat.nl/mensen/leanne-dyal/","name":"Leanne Dyal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/09/02/efpeglenatide-en-cv-en-renale-uitkomsten-bij-diabetes-type-2-nejm-amplitude-o/","published":"2021-09-02"},{"url":"https://hartvaat.nl/2021/07/08/cv-uitkomsten-bij-diabetes-met-vastgesteld-of-hoog-risico-coronairlijden-dulaglu/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2021/07/01/cv-gevolgen-van-stoppen-met-laaggedoseerd-rivaroxaban-bij-chronisch-vaatlijden/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/01/01/rivaroxaban-plus-aspirine-bij-symptomatisch-pav-compass-subanalyse/","published":"2021-01-01"},{"url":"https://hartvaat.nl/2019/12/07/individueel-levenslang-voordeel-en-bloedingsrisico-van-rivaroxaban-plus-aspirine/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"leonardo-calo","type":"person","url":"https://hartvaat.nl/mensen/leonardo-calo/","name":"Leonardo Calò","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/05/cmr-laci-21-identificeert-hoogrisicopatienten-met-hfref-onafhankelijk-van-lvef-e/","published":"2026-06-30"},{"url":"https://hartvaat.nl/2025/06/03/multipoint-pacing-vermindert-hf-hospitalisaties-en-sterfte-bij-crt-non-responder/","published":"2025-06-03"},{"url":"https://hartvaat.nl/2023/10/05/more-crt-mpp-multipoint-pacing-bij-crt-non-responders/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/06/21/timing-van-vt-ablatie-bij-icd-patienten-partita-trial/","published":"2022-06-21"},{"url":"https://hartvaat.nl/2022/02/02/thuismonitoring-temporele-trends-en-baseline-risico-voor-hf-voorspelling-bij-icd/","published":"2022-02-02"},{"url":"https://hartvaat.nl/2021/12/07/av-junctieablatie-plus-crt-bij-permanent-af-met-smal-qrs-apaf-crt-mortaliteitsan/","published":"2021-12-07"},{"url":"https://hartvaat.nl/2019/09/14/crt-non-responder-naar-responder-conversie-more-crt-mpp/","published":"2019-09-14"},{"url":"https://hartvaat.nl/2018/12/01/av-junctieablatie-plus-crt-bij-permanent-af-gerandomiseerde-trial/","published":"2018-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"li-shen","type":"person","url":"https://hartvaat.nl/mensen/li-shen/","name":"Li Shen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/06/25/raas-blokkade-bij-hartfalen-voordeel-onafhankelijk-van-etniciteit-jama-meta-anal/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2024/06/18/mra-bij-hartfalen-met-nierfunctiestoornissen-veiligheid-en-effectiviteit/","published":"2024-06-18"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2019/01/08/hfref-differentiele-impact-op-mannen-en-vrouwen/","published":"2019-01-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lixia-jiao","type":"person","url":"https://hartvaat.nl/mensen/lixia-jiao/","name":"Lixia Jiao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/04/01/icosapent-ethyl-na-acs-reduce-it-subanalyse/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","published":"2022-08-02"},{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/01/03/icosapent-ethyl-en-cardiovasculaire-uitkomsten-bij-hypertriglyceridemie-nejm-red/","published":"2019-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"malte-kelm","type":"person","url":"https://hartvaat.nl/mensen/malte-kelm/","name":"Malte Kelm","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/03/25/palliatieve-zorg-in-de-cardiologie-een-state-of-the-art-overzicht/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/02/19/delirium-in-de-cardiovasculaire-geneeskunde/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/02/01/nnt-van-nieuwe-antidiabetica-voor-cv-uitkomsten-meta-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mamas-a-mamas","type":"person","url":"https://hartvaat.nl/mensen/mamas-a-mamas/","name":"Mamas A Mamas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/22/brede-inzet-van-oraal-semaglutide-in-de-vs-zou-jaarlijks-tot-60-000-cardiovascul/","published":"2026-06-05"},{"url":"https://hartvaat.nl/2026/05/26/esc-consensus-vrouwenhartcentra-whc-als-nieuw-zorgmodel-in-europa/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2023/05/19/slokdarmkoeling-voorkomt-oesofagale-schade-bij-af-ablatie-meta-analyse/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2023/03/28/culprit-interventie-bij-cardiogene-shock-met-hartstilstand/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2022/08/30/ripcord-2-routinematige-ffr-meting-versus-conventionele-angiografie/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2021/08/01/klinische-fenotypen-zijn-effectiever-dan-ef-categorieen-voor-hf-uitkomsten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2021/01/27/mobiele-gezondheidstoepassingen-voor-af-detectie-systematische-review/","published":"2021-01-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"margaret-f-prescott","type":"person","url":"https://hartvaat.nl/mensen/margaret-f-prescott/","name":"Margaret F Prescott","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/08/01/nt-probnp-veranderingen-en-klinische-uitkomsten-bij-pediatrisch-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2022/10/18/dosisrespons-van-sacubitril-valsartan-bij-hfref/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2019/10/21/cv-biomarkers-bij-acuut-gedecompenseerd-hf-met-sacubitril-valsartan-pioneer-hf/","published":"2019-10-21"},{"url":"https://hartvaat.nl/2019/02/26/sacubitril-valsartan-en-biomarkers-van-extracellulaire-matrixregulatie-bij-hfref/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2017/01/01/sacubitril-valsartan-en-natriurese-diurese-en-bloeddruk-bij-zoutgevoelige-hypert/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/12/06/prognostische-implicaties-van-nt-probnp-veranderingen-bij-hartfalen/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/11/29/bmi-en-nauwkeurigheid-van-nt-probnp-en-bnp-voor-diagnose-van-acuut-hartfalen/","published":"2016-11-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martha-kubik","type":"person","url":"https://hartvaat.nl/mensen/martha-kubik/","name":"Martha Kubik","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"},{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mary-n-walsh","type":"person","url":"https://hartvaat.nl/mensen/mary-n-walsh/","name":"Mary N Walsh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2024/10/01/draadloos-ultrasound-gebaseerd-crt-systeem-bij-hartfalen/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/04/16/2024-acc-expert-consensus-behandeling-van-hfref-beslispad-geactualiseerd/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2021/02/16/2021-acc-hf-behandeloptimalisatie-update-antwoorden-op-10-cruciale-vragen/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","published":"2017-02-02"},{"url":"https://hartvaat.nl/2016/02/23/inspanningstestvariabelen-als-mortaliteitsvoorspellers-bij-chronisch-systolisch-/","published":"2016-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mathew-s-maurer","type":"person","url":"https://hartvaat.nl/mensen/mathew-s-maurer/","name":"Mathew S Maurer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/27/multimodaal-ai-model-verhoogt-accuratesse-van-echo-diagnose-cardiale-amyloidose/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2026/02/10/2025-acc-attr-cm-evaluatie-en-management-beknopte-klinische-richtlijn/","published":"2026-02-10"},{"url":"https://hartvaat.nl/2025/05/27/vutrisiran-bij-attr-cm-impact-van-hartfalenernst-op-effectiviteit/","published":"2025-05-27"},{"url":"https://hartvaat.nl/2025/02/25/ambulante-hf-verslechtering-bij-attr-cm-attr-act-subanalyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/02/25/ambulante-hartfalenverslechtering-bij-attr-cardiomyopathie-attr-act-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2024/01/01/tafamidis-en-cardiale-functie-bij-attr-cm-post-hoc-attr-act-analyse/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2019/07/23/ag10-transthyretinestabilisator-bij-symptomatische-attr-cardiomyopathie/","published":"2019-07-23"},{"url":"https://hartvaat.nl/2018/09/13/tafamidis-bij-transthyretine-amyloid-cardiomyopathie-nejm-attr-act/","published":"2018-09-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matteo-pagnesi","type":"person","url":"https://hartvaat.nl/mensen/matteo-pagnesi/","name":"Matteo Pagnesi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/06/26/machine-learning-voorspelt-diureticumrespons-bij-acuut-hartfalen-drc-ahf/","published":"2026-08-06"},{"url":"https://hartvaat.nl/2026/02/03/geslachtsverschillen-bij-patienten-met-gevorderd-hartfalen/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matthias-dupont","type":"person","url":"https://hartvaat.nl/mensen/matthias-dupont/","name":"Matthias Dupont","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","published":"2023-06-09"},{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","published":"2022-09-29"},{"url":"https://hartvaat.nl/2021/12/21/iv-ijzercarboxymaltose-en-cardiale-reverse-remodellering-na-crt-iron-crt/","published":"2021-12-21"},{"url":"https://hartvaat.nl/2020/08/18/optimale-bloeddruk-bij-shock-na-mi-en-hartstilstand/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2020/03/31/staken-van-neurohumorale-blokkade-na-crt/","published":"2020-03-31"},{"url":"https://hartvaat.nl/2018/06/01/implementatie-van-sacubitril-valsartan-in-de-klinische-praktijk-inzichten/","published":"2018-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matyas-keltai","type":"person","url":"https://hartvaat.nl/mensen/matyas-keltai/","name":"Matyas Keltai","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2016/07/01/apixaban-versus-warfarine-bij-af-in-relatie-tot-nierfunctie-aristotle-analyse/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"meg-j-jardine","type":"person","url":"https://hartvaat.nl/mensen/meg-j-jardine/","name":"Meg J Jardine","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/03/06/kdigo-consensusconferentie-uitdagingen-bij-gecombineerd-hartfalen-en-nierziekte/","published":"2026-03-15"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/24/risicovoorspellingsmodellen-voor-ouderen-met-chronische-nierziekte/","published":"2025-12-24"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2021/04/01/canagliflozine-naar-diureticagebruik-canvas-post-hoc-analyse/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"meike-brinker","type":"person","url":"https://hartvaat.nl/mensen/meike-brinker/","name":"Meike Brinker","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2026/03/05/finerenon-effectief-bij-type-1-diabetes-met-chronische-nierziekte/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/01/finerenon-en-lvh-bij-ckd-en-diabetes/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-a-nauck","type":"person","url":"https://hartvaat.nl/mensen/michael-a-nauck/","name":"Michael A Nauck","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/01/14/glp-1-receptoragonisten-en-de-volgende-generatie-incretinegebaseerde-middelen/","published":"2026-01-14"},{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2020/03/17/liraglutide-cv-uitkomsten-bij-diabetes-met-of-zonder-hartfalen-leader/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/12/01/eerste-en-recidiverende-cv-events-met-liraglutide-bij-diabetes-type-2-leader/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-cv-uitkomsten-met-of-zonder-eerder-mi-leader/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/11/17/ly3298176-duale-gip-glp-1-agonist-bij-diabetes-type-2-lancet-tirzepatide-fase-2/","published":"2018-11-17"},{"url":"https://hartvaat.nl/2018/05/15/liraglutide-bij-diabetes-type-2-met-polyvasculaire-ziekte-leader-analyse/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2016/07/28/liraglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-leader-trial/","published":"2016-07-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-d-hill","type":"person","url":"https://hartvaat.nl/mensen/michael-d-hill/","name":"Michael D Hill","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/06/17/bedmed-timing-van-antihypertensieve-medicatie-en-cv-events-jama-definitieve-tria/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2024/07/13/convince-langetermijn-colchicine-voor-preventie-van-recidief-niet-cardioembolisc/","published":"2024-07-13"},{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2021/06/01/implanteerbare-versus-verlengde-externe-ecg-monitoring-voor-af-na-ischemisch-cva/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2018/10/09/sacubitril-valsartan-versus-irbesartan-bij-chronische-nierziekte/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2016/05/05/perioperatief-rosuvastatine-bij-hartchirurgie-nejm-trial/","published":"2016-05-05"},{"url":"https://hartvaat.nl/2016/03/17/langetermijnresultaten-van-stenting-versus-endarteriectomie-bij-carotisstenose/","published":"2016-03-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-silverstein","type":"person","url":"https://hartvaat.nl/mensen/michael-silverstein/","name":"Michael Silverstein","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","published":"2017-07-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-v-rocco","type":"person","url":"https://hartvaat.nl/mensen/michael-v-rocco/","name":"Michael V Rocco","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2021/05/05/intensieve-bloeddruk-en-aortastijfheid-sprint-heart/","published":"2021-05-05"},{"url":"https://hartvaat.nl/2020/12/01/intensieve-bloeddrukcontrole-en-alle-hospitalisaties-sprint/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2016/08/01/apol1-nierrisicovarianten-en-cerebrale-wittestoflaesies/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/02/01/sprint-resultaten-en-implicaties-voor-de-nefrologie/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michal-tendera","type":"person","url":"https://hartvaat.nl/mensen/michal-tendera/","name":"Michal Tendera","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2020/09/19/trimetazidine-na-pci-lancet-atpci-gerandomiseerde-trial/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2018/09/22/aspirine-voor-primaire-preventie-bij-matig-cv-risico-lancet-arrive/","published":"2018-09-22"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/04/21/mtp-131-bij-reperfusieschade-na-stemi-de-embrace-stemi-fase-2a-trial/","published":"2016-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michele-robertson","type":"person","url":"https://hartvaat.nl/mensen/michele-robertson/","name":"Michele Robertson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","published":"2024-04-21"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"},{"url":"https://hartvaat.nl/2018/03/27/crt-bij-hartfalen-met-smal-qrs-complex/","published":"2018-03-27"},{"url":"https://hartvaat.nl/2017/11/14/ldl-verlaging-voor-primaire-preventie-bij-mannen-met-primaire-ldl-verhoging/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/03/07/lv-global-longitudinal-strain-en-prognose-bij-hartfalen-met-smal-qrs-en-crt/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2016/01/01/persisterende-echocardiografische-dyssynchronie-voorspelt-ongunstige-uitkomsten-/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michelle-m-kittleson","type":"person","url":"https://hartvaat.nl/mensen/michelle-m-kittleson/","name":"Michelle M Kittleson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/02/10/2025-acc-attr-cm-evaluatie-en-management-beknopte-klinische-richtlijn/","published":"2026-02-10"},{"url":"https://hartvaat.nl/2025/11/18/2025-acc-scientific-statement-obesitasmanagement-bij-hartfalen/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2024/09/17/2024-acc-aha-kwaliteitsmaatstaven-voor-hartfalen-geactualiseerd/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2023/05/09/2023-acc-expert-consensus-management-van-hfpef/","published":"2023-05-09"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/01/26/2020-acc-aha-kwaliteitsmaten-voor-af-geactualiseerd/","published":"2021-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mikhail-sumin","type":"person","url":"https://hartvaat.nl/mensen/mikhail-sumin/","name":"Mikhail Sumin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/05/13/empagliflozine-erytropoese-en-ijzermobilisatie-bij-hartfalen/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2024/11/12/sglt2-remming-en-proteomische-handtekeningen-bij-hartfalen-bevestiging/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2022/12/21/empagliflozine-en-het-circulerend-proteoom-bij-hartfalen-emperor-mechanismen/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"myung-ho-jeong","type":"person","url":"https://hartvaat.nl/mensen/myung-ho-jeong/","name":"Myung Ho Jeong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/09/06/directe-versus-gestageerde-complete-revascularisatie-tijdens-index-opname-bij-st/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2023/11/14/early-unload-vroege-lv-ontlading-bij-va-ecmo-gerandomiseerde-trial/","published":"2023-11-14"},{"url":"https://hartvaat.nl/2021/10/09/ongeleide-de-escalatie-van-ticagrelor-naar-clopidogrel-na-mi-met-pci-lancet-talo/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2020/08/25/genotype-geleide-p2y12-selectie-versus-clopidogrel-na-pci-jama-tailor-pci/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2018/07/24/escitalopram-versus-placebo-bij-depressie-na-acs-en-langetermijn-cardiale-uitkom/","published":"2018-07-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"neil-j-weissman","type":"person","url":"https://hartvaat.nl/mensen/neil-j-weissman/","name":"Neil J Weissman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/01/01/tafamidis-en-cardiale-functie-bij-attr-cm-post-hoc-attr-act-analyse/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2021/04/01/ero-lvedv-ratio-en-respons-op-mitraclip-jama-cardiology/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2019/12/17/echo-uitkomsten-na-mitraclip-bij-secundaire-mr-coapt-echocardiografisch/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"niels-r-holm","type":"person","url":"https://hartvaat.nl/mensen/niels-r-holm/","name":"Niels R Holm","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/03/02/intravasculaire-beeldvorming-bij-des-implantatie-lancet-netwerk-meta-analyse/","published":"2024-03-02"},{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","published":"2020-01-18"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nisha-bansal","type":"person","url":"https://hartvaat.nl/mensen/nisha-bansal/","name":"Nisha Bansal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/25/kdigo-overzicht-de-nier-centraal-in-het-cardiovasculair-renaal-metabool-ckm-synd/","published":"2026-05-31"},{"url":"https://hartvaat.nl/2026/03/06/kdigo-consensusconferentie-uitdagingen-bij-gecombineerd-hartfalen-en-nierziekte/","published":"2026-03-15"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2024/10/15/aha-scientific-statement-nierdisfunctie-bij-gevorderd-hartfalen/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2022/12/06/apixaban-bij-af-op-hemodialyse-eerste-gerandomiseerde-trial/","published":"2022-12-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ollie-ostlund","type":"person","url":"https://hartvaat.nl/mensen/ollie-ostlund/","name":"Ollie Östlund","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/10/07/help-mi-helicobacter-pylori-screening-na-acuut-mi-cluster-rct/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2024/04/18/abyss-betablokkers-na-mi-met-behouden-ef-niet-nodig-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/04/11/heterogeniteit-in-bloeddrukrespons-op-antihypertensiva-jama-cross-over-rct/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2018/12/11/langetermijneffecten-van-zuurstof-op-sterfte-of-hf-hospitalisatie-na-verdenking-/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/08/01/zuurstoftherapie-bij-stemi-overzichtsartikel/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/09/28/zuurstoftherapie-bij-vermoedelijk-acuut-myocardinfarct-nejm-deto2x-ami/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","published":"2017-09-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"panos-vardas","type":"person","url":"https://hartvaat.nl/mensen/panos-vardas/","name":"Panos Vardas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/03/30/linear-trial-lattice-tip-katheter-verslaat-standaard-irrigatie-bij-cti-ablatie-v/","published":"2026-04-19"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2023/05/19/east-afnet-4-vroege-ritmecontrole-bij-af-is-kosteneffectief/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","published":"2022-09-13"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-novak","type":"person","url":"https://hartvaat.nl/mensen/paul-novak/","name":"Paul Novak","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","published":"2024-02-16"},{"url":"https://hartvaat.nl/2023/05/01/aware-uitgebreide-ablatie-vermindert-af-recidief-niet-boven-standaard-pvi/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2021/11/01/af-last-en-qol-na-af-ablatie-cabana-substudie/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"},{"url":"https://hartvaat.nl/2019/11/26/cryoballon-versus-rf-ablatie-bij-af-beoordeeld-met-continue-monitoring-cryo-firs/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2017/05/09/agressieve-bloeddrukcontrole-en-recidief-van-af-na-ablatie-gerandomiseerde-trial/","published":"2017-05-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-j-kelly","type":"person","url":"https://hartvaat.nl/mensen/peter-j-kelly/","name":"Peter J Kelly","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/03/24/systemische-inflammatie-en-recidief-na-een-af-gerelateerd-herseninfarct/","published":"2026-03-24"},{"url":"https://hartvaat.nl/2026/02/19/secundaire-preventie-na-ischemisch-cva-overzicht-uit-het-nejm/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/01/13/effectiviteit-en-veiligheid-van-zeer-laag-bereikt-ldl-na-ischemisch-cva/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2024/07/13/convince-langetermijn-colchicine-voor-preventie-van-recidief-niet-cardioembolisc/","published":"2024-07-13"},{"url":"https://hartvaat.nl/2024/07/02/vroege-versus-late-doac-na-cva-met-hemorrhagische-transformatie-bij-af/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/06/29/elan-vroege-versus-late-anticoagulatie-na-cva-bij-af-nejm/","published":"2023-06-29"},{"url":"https://hartvaat.nl/2021/07/21/laaggedoseerd-colchicine-bij-coronairlijden-meta-analyse-van-gerandomiseerde-tri/","published":"2021-07-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-kolkhof","type":"person","url":"https://hartvaat.nl/mensen/peter-kolkhof/","name":"Peter Kolkhof","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2022/02/10/finerenon-cv-en-renale-uitkomsten-bij-diabetes-met-ckd-fidelity-gepoolde-analyse/","published":"2022-02-10"},{"url":"https://hartvaat.nl/2022/02/08/finerenon-vermindert-incident-hf-bij-ckd-met-diabetes-fidelity/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/12/09/finerenon-bij-nierziekte-met-diabetes-type-2-nejm-figaro-dkd/","published":"2021-12-09"},{"url":"https://hartvaat.nl/2021/07/13/finerenon-vermindert-nieuw-onset-af-bij-ckd-met-diabetes-fidelio-dkd/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/02/09/finerenon-en-cardiovasculaire-uitkomsten-bij-ckd-met-diabetes-type-2-fidelio-dkd/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2016/07/14/finerenon-versus-eplerenon-bij-hartfalen-met-diabetes-en-verslechterende-nierfun/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-s-pang","type":"person","url":"https://hartvaat.nl/mensen/peter-s-pang/","name":"Peter S Pang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"},{"url":"https://hartvaat.nl/2021/02/01/zelfzorginterventie-en-90-daags-uitkomsten-bij-acuut-hf-na-seh-ontslag-jama-card/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2017/08/07/trv027-biased-ligand-van-de-angiotensine-ii-receptor-bij-acuut-hartfalen-gerando/","published":"2017-08-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"petr-jansky","type":"person","url":"https://hartvaat.nl/mensen/petr-jansky/","name":"Petr Jansky","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/07/08/cv-uitkomsten-bij-diabetes-met-vastgesteld-of-hoog-risico-coronairlijden-dulaglu/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2018/08/14/adma-en-sdma-voorspellen-uitkomsten-bij-af-aristotle-substudie/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/08/01/uitkomsten-bij-af-met-oac-bij-mitralis-of-aortakleplijden/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"raj-r-makkar","type":"person","url":"https://hartvaat.nl/mensen/raj-r-makkar/","name":"Raj R Makkar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/06/10/triluminate-tweejaarsresultaten-transcatheter-tr-repair-duurzaam-effectief/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","published":"2023-11-23"},{"url":"https://hartvaat.nl/2023/05/18/triluminate-transcatheter-tricuspidaliskleprepair-bij-ernstige-tr-nejm/","published":"2023-05-18"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-ballonexpandeerbare-klep-bij-laagrisicopatienten-nejm-partner-3/","published":"2019-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rajiv-mahajan","type":"person","url":"https://hartvaat.nl/mensen/rajiv-mahajan/","name":"Rajiv Mahajan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2022/09/01/af-voorspelt-cognitieve-achteruitgang-meta-analyse-van-2-8-miljoen-personen/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/11/01/bloeddrukvariabiliteit-en-dementie-cognitieve-stoornis-meta-analyse/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2020/01/01/obesitas-opzettelijk-gewichtsverlies-en-hartfalen-meta-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/09/24/interne-versus-externe-cardioversie-bij-atriale-aritmieen-met-icd/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2018/11/01/uitkomsten-van-ablatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/04/21/subklinisch-device-gedetecteerd-af-en-cva-risico-meta-analyse/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2017/12/01/geintegreerde-zorg-bij-atriumfibrilleren-systematische-review-en-meta-analyse/","published":"2017-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ralph-t-doyle","type":"person","url":"https://hartvaat.nl/mensen/ralph-t-doyle/","name":"Ralph T Doyle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/04/23/lp-a-en-cv-risicoreductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/04/01/icosapent-ethyl-na-acs-reduce-it-subanalyse/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/01/03/icosapent-ethyl-en-cardiovasculaire-uitkomsten-bij-hypertriglyceridemie-nejm-red/","published":"2019-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"randall-c-starling","type":"person","url":"https://hartvaat.nl/mensen/randall-c-starling/","name":"Randall C Starling","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/04/sacubitril-valsartan-bij-hfmref-hfpef-met-verslechterend-hartfalen/","published":"2023-07-04"},{"url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2017/06/27/hospitalisatie-voor-nieuw-gediagnosticeerd-versus-verslechterend-chronisch-hartf/","published":"2017-06-27"},{"url":"https://hartvaat.nl/2017/02/28/myocardiaal-herstel-bij-systolisch-hartfalen-met-auto-antilichamen-tegen-1-adren/","published":"2017-02-28"},{"url":"https://hartvaat.nl/2016/07/12/nervus-vagus-stimulatie-bij-hartfalen-de-inovate-hf-trial/","published":"2016-07-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"riccardo-cappato","type":"person","url":"https://hartvaat.nl/mensen/riccardo-cappato/","name":"Riccardo Cappato","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2021/10/09/voorspellers-van-sinusritme-6-weken-na-af-cardioversie-x-vert/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2021/01/27/periprocedurele-antistolling-bij-eliminate-af-ononderbroken-edoxaban-versus-vka/","published":"2021-01-27"},{"url":"https://hartvaat.nl/2019/09/21/ononderbroken-edoxaban-versus-vka-bij-af-ablatie-eliminate-af/","published":"2019-09-21"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/01/01/percutane-linker-hartoorsluiting-munchen-consensusdocument-over-definities-en-ei/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/12/01/rivaroxaban-versus-vka-bij-periprocedurele-antistolling-rond-af-ablatie/","published":"2016-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rita-pavasini","type":"person","url":"https://hartvaat.nl/mensen/rita-pavasini/","name":"Rita Pavasini","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/09/11/multidomein-revalidatie-bij-ouderen-na-mi-gerandomiseerde-trial-nejm/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2020/11/07/complete-revascularisatie-vermindert-cv-dood-bij-stemi-met-multivatenlijden-meta/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/11/01/inspanningsinterventie-verbetert-qol-na-mi-bij-ouderen-gerandomiseerde-trial/","published":"2020-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-g-tieleman","type":"person","url":"https://hartvaat.nl/mensen/robert-g-tieleman/","name":"Robert G Tieleman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/11/10/rate-control-bij-af-calciumantagonisten-versus-betablokkers/","published":"2023-11-10"},{"url":"https://hartvaat.nl/2022/07/15/race-3-langetermijnresultaten-gerichte-behandeling-bij-vroeg-persisterend-af-en-/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2022/03/02/frequentiecontrolemiddelen-verschillen-in-preventie-van-af-progressie/","published":"2022-03-02"},{"url":"https://hartvaat.nl/2021/09/08/antiaritmica-bij-vroeg-persisterend-af-met-hf-race-3/","published":"2021-09-08"},{"url":"https://hartvaat.nl/2020/02/01/verpleegkundig-geleide-versus-standaard-af-zorg/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/12/01/geintegreerde-gespecialiseerde-af-poliklinieken-verlagen-totale-mortaliteit-post/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/04/01/upstream-therapie-verbetert-qol-bij-persisterend-af-arrest-af/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/08/21/behandeling-van-onderliggende-aandoeningen-verbetert-sinusritme-na-af-arrest-af/","published":"2018-08-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-s-mckelvie","type":"person","url":"https://hartvaat.nl/mensen/robert-s-mckelvie/","name":"Robert S McKelvie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/01/05/nejm-interventie-voor-snelle-ambulante-follow-up-na-acuut-hartfalen/","published":"2023-01-05"},{"url":"https://hartvaat.nl/2022/04/09/natriumreductie-100-mmol-bij-hartfalen-lancet-sodium-hf/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2017/03/07/cva-risico-bij-chronisch-hartfalen-met-behouden-ef-zonder-af-charm-analyse/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2017/02/21/diabetesstatus-en-cardiovasculaire-uitkomsten-bij-hfpef-klinische-en-echocardiog/","published":"2017-02-21"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rodica-pop-busui","type":"person","url":"https://hartvaat.nl/mensen/rodica-pop-busui/","name":"Rodica Pop-Busui","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/09/01/cardiorenale-bescherming-door-sglt2-remmers-glp-1-agonisten-en-mra-s-bij-type-1-/","published":"2026-08-07"},{"url":"https://hartvaat.nl/2026/09/01/cardiorenale-risicos-bij-type-1-diabetes-een-overzicht-van-de-huidige-stand-van-/","published":"2026-08-07"},{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","published":"2025-05-29"},{"url":"https://hartvaat.nl/2024/07/16/interventie-voor-evidence-based-zorg-bij-diabetes-en-cv-risico/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2023/04/18/gecoordineerde-zorg-optimaliseert-cv-preventie-bij-type-2-diabetes-jama-rct/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/09/22/grade-vergelijking-glucoseverlagende-middelen-op-microvasculaire-en-cv-uitkomste/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2016/10/01/orthostatische-hypotensie-in-de-accord-bloeddruk-trial-prevalentie-en-klinische-/","published":"2016-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rodrigo-estevez-loureiro","type":"person","url":"https://hartvaat.nl/mensen/rodrigo-estevez-loureiro/","name":"Rodrigo Estévez-Loureiro","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/05/05/expanded-bij-73-verbetert-tricuspidalisinsufficientie-binnen-30-dagen-na-m-teer-/","published":"2026-06-26"},{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/03/16/vroege-linkerventrikel-reverse-remodellering-na-mitralisklep-edge-to-edge-repara/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2025/12/23/korte-anticoagulatie-versus-dapt-na-laa-occlusie-devicetrombosepreventie/","published":"2025-12-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ron-t-gansevoort","type":"person","url":"https://hartvaat.nl/mensen/ron-t-gansevoort/","name":"Ron T Gansevoort","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/29/lichaamsrondheidsindex-bri-voorspelt-sterfte-bij-nierpatienten-beter-dan-bmi/","published":"2026-07-27"},{"url":"https://hartvaat.nl/2026/04/24/nkf-consensus-standaardiseer-urine-afname-om-albuminurie-betrouwbaar-te-meten/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2021/09/01/albuminurietesting-bij-hypertensie-en-diabetes-ipd-meta-analyse/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/09/22/sekse-specifieke-cv-risicofactoren-en-biomarkers-bij-incident-hartfalen/","published":"2020-09-22"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2017/01/03/traditionele-cv-risicofactoren-en-veneuze-trombo-embolie-individuele-patientdata/","published":"2017-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rory-collins","type":"person","url":"https://hartvaat.nl/mensen/rory-collins/","name":"Rory Collins","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2019/07/01/kosteneffectiviteit-van-statines-en-ezetimibe-bij-chronische-nierziekte/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/10/18/omega-3-vetzuursupplementen-bij-diabetes-nejm-ascend-omega-3/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2018/10/18/aspirine-voor-primaire-preventie-bij-diabetes-nejm-ascend/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2018/03/01/omega-3-vetzuursupplementen-en-cv-risico-jama-cardiology-meta-analyse-van-10-tri/","published":"2018-03-01"},{"url":"https://hartvaat.nl/2018/02/01/differentiele-effecten-van-pcsk9-varianten-op-coronairlijden-versus-ischemisch-c/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/09/28/anacetrapib-bij-atherosclerotisch-vaatlijden-nejm-hps3-timi55-reveal/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/06/24/bijwerkingen-bij-niet-geblindeerde-versus-geblindeerde-statinetherapie-lancet-as/","published":"2017-06-24"},{"url":"https://hartvaat.nl/2016/05/05/perioperatief-rosuvastatine-bij-hartchirurgie-nejm-trial/","published":"2016-05-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rury-r-holman","type":"person","url":"https://hartvaat.nl/mensen/rury-r-holman/","name":"Rury R Holman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/05/30/empagliflozine-en-cardiale-energiestofwisseling-bij-hartfalen-empa-vision/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2022/11/01/emmy-empagliflozine-na-acuut-myocardinfarct-verbetert-nt-probnp-en-remodelling/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2020/04/28/open-label-drop-in-van-glucoseverlagende-medicatie-en-exscel-uitkomsten/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2017/11/01/hypertensiecontrole-bij-diabetes-met-recidiverende-cv-events-tecos-globale-resul/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/28/exenatide-eenmaal-per-week-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-ne/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/09/26/secundaire-cardiovasculaire-preventie-bij-diabetes-type-2-tecos-internationale-i/","published":"2017-09-26"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rutao-wang","type":"person","url":"https://hartvaat.nl/mensen/rutao-wang/","name":"Rutao Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ruth-webster","type":"person","url":"https://hartvaat.nl/mensen/ruth-webster/","name":"Ruth Webster","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/06/01/lage-dosis-drievoudige-viervoudige-combinatiepil-versus-monotherapie-bij-hyperte/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/06/01/lage-dosis-drievoudige-combinatietherapie-bij-hypertensie-triumph-secundaire-ana/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","published":"2021-09-18"},{"url":"https://hartvaat.nl/2020/11/01/lage-dosis-triple-combinatie-en-therapeutische-inertie-bij-hypertensie-jama-card/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2019/01/01/polypil-en-cardiovasculaire-preventie-meta-analyse-van-gerandomiseerde-trials/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/08/14/drievoudige-lage-dosis-antihypertensivacombinatie-versus-standaardzorg-jama-gera/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"salim-s-virani","type":"person","url":"https://hartvaat.nl/mensen/salim-s-virani/","name":"Salim S Virani","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/02/24/lipide-aferese-verlaagt-lp-a-met-60-75-systematische-review-en-meta-analyse/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2023/05/02/gepersonaliseerde-beslisondersteuning-verhoogt-statinegebruik-bij-ascvd/","published":"2023-05-02"},{"url":"https://hartvaat.nl/2021/08/31/2021-acc-consensus-ascvd-risicoreductie-bij-persistente-hypertriglyceridemie/","published":"2021-08-31"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2018/12/01/cardiovasculaire-risicocommunicatie-en-patientperceptie-jama-cardiology/","published":"2018-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sana-m-al-khatib","type":"person","url":"https://hartvaat.nl/mensen/sana-m-al-khatib/","name":"Sana M Al-Khatib","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2021/05/01/vroegtijdig-permanent-staken-van-apixaban-of-warfarine-bij-af/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2020/01/07/nsaid-s-en-oac-bij-af-aristotle-analyse/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/03/13/digoxine-en-mortaliteit-bij-patienten-met-atriumfibrilleren/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2017/06/01/primaire-preventie-icd-bij-niet-ischemische-cardiomyopathie-meta-analyse/","published":"2017-06-01"},{"url":"https://hartvaat.nl/2017/05/16/comorbiditeiten-en-crt-respons-madit-crt-langetermijnfollow-up/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2017/03/21/plotse-hartdood-bij-ischemisch-hartfalen-na-cabg-stich-resultaten/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/09/01/apixaban-5-mg-bij-af-met-hoge-leeftijd-laag-gewicht-of-hoog-creatinine-aristotle/","published":"2016-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sandeep-prabhu","type":"person","url":"https://hartvaat.nl/mensen/sandeep-prabhu/","name":"Sandeep Prabhu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/02/16/hoog-vermogen-korte-duur-versus-laag-vermogen-langere-duur-posteriore-ablatie-bi/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2020/01/02/alcoholonthouding-bij-drinkers-met-af-nejm-gerandomiseerde-trial/","published":"2020-01-02"},{"url":"https://hartvaat.nl/2017/10/17/katheterablatie-versus-frequentiecontrole-bij-af-met-systolische-disfunctie-came/","published":"2017-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sandra-j-taler","type":"person","url":"https://hartvaat.nl/mensen/sandra-j-taler/","name":"Sandra J Taler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2018/11/01/therapieresistente-hypertensie-aha-scientific-statement-over-detectie-evaluatie-/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","published":"2018-10-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"satoru-suwa","type":"person","url":"https://hartvaat.nl/mensen/satoru-suwa/","name":"Satoru Suwa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/08/premier-in-hospital-start-van-sacubitril-valsartan-bij-acuut-hartfalen/","published":"2024-11-08"},{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2022/12/01/daprodustat-bij-anemie-en-hartfalen-met-ckd-gerandomiseerde-studie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sebastian-ewen","type":"person","url":"https://hartvaat.nl/mensen/sebastian-ewen/","name":"Sebastian Ewen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/09/07/hartfrequentie-en-uitkomsten-van-renale-denervatie-bij-ongecontroleerde-hyperten/","published":"2021-09-07"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2020/03/10/overleving-na-revascularisatie-met-paclitaxel-gecoate-ballonnen/","published":"2020-03-10"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2017/01/07/verminderd-bloeddrukverlagend-effect-van-renale-denervatie-bij-geisoleerde-systo/","published":"2017-01-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sebastian-kufner","type":"person","url":"https://hartvaat.nl/mensen/sebastian-kufner/","name":"Sebastian Kufner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/04/17/in-stent-restenose-tienjaarsuitkomsten-plain-balloon-vs-dcb-vs-des-isar-desire-3/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2019/01/15/10-jaarsuitkomsten-van-drie-limus-eluting-stents-coating-vergelijking/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2016/02/06/bioresorbeerbare-versus-metallic-stents-meta-analyse-van-gerandomiseerde-trials/","published":"2016-02-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"serge-korjian","type":"person","url":"https://hartvaat.nl/mensen/serge-korjian/","name":"Serge Korjian","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2017/01/24/heropnames-bij-af-patienten-na-stenting-twee-antitromboticastrategieen-vergeleke/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/12/22/preventie-van-bloedingen-bij-af-patienten-die-pci-ondergaan-nejm-pioneer-af-pci/","published":"2016-12-22"},{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/04/21/mtp-131-bij-reperfusieschade-na-stemi-de-embrace-stemi-fase-2a-trial/","published":"2016-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shih-ann-chen","type":"person","url":"https://hartvaat.nl/mensen/shih-ann-chen/","name":"Shih-Ann Chen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2019/05/14/edoxaban-bij-aziatische-af-patienten-concentraties-en-anti-xa-activiteit/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shun-fu-lee","type":"person","url":"https://hartvaat.nl/mensen/shun-fu-lee/","name":"Shun Fu Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/08/16/achieve-spironolacton-bij-dialysepatienten-internationale-rct/","published":"2025-08-16"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/11/26/artesia-subanalyse-cva-risico-naar-frequentie-en-duur-van-subclinisch-af/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2021/08/01/klinische-fenotypen-zijn-effectiever-dan-ef-categorieen-voor-hf-uitkomsten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2019/02/26/patientgerichte-transitional-care-bij-hf-hospitalisatie-jama-pact-hf/","published":"2019-02-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steffen-helqvist","type":"person","url":"https://hartvaat.nl/mensen/steffen-helqvist/","name":"Steffen Helqvist","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/04/01/mesenchymale-stamcellen-bij-ischemisch-hartfalen-deense-fase-ii-trial/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steven-b-ketchum","type":"person","url":"https://hartvaat.nl/mensen/steven-b-ketchum/","name":"Steven B Ketchum","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/04/23/lp-a-en-cv-risicoreductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2024/04/01/icosapent-ethyl-na-acs-reduce-it-subanalyse/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/01/03/icosapent-ethyl-en-cardiovasculaire-uitkomsten-bij-hypertriglyceridemie-nejm-red/","published":"2019-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steven-o-marx","type":"person","url":"https://hartvaat.nl/mensen/steven-o-marx/","name":"Steven O Marx","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/07/18/bioresorbeerbare-coronaire-scaffolds-vijfjaarsuitkomsten-met-verbeterde-techniek/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"},{"url":"https://hartvaat.nl/2018/10/27/absorb-iv-bioresorbeerbare-scaffold-30-daags-en-1-jaarsresultaten/","published":"2018-10-27"},{"url":"https://hartvaat.nl/2017/12/12/3-jaarsresultaten-van-bioresorbeerbare-scaffolds-absorb-iii-trial/","published":"2017-12-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"takeshi-morimoto","type":"person","url":"https://hartvaat.nl/mensen/takeshi-morimoto/","name":"Takeshi Morimoto","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2017/02/14/laaggedoseerde-aspirine-voor-primaire-cardiovasculaire-preventie-bij-diabetes-ty/","published":"2017-02-14"},{"url":"https://hartvaat.nl/2016/02/14/kortdurend-antiaritmica-na-katheterablatie-voor-atriumfibrilleren-east-af-trial/","published":"2016-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tara-i-chang","type":"person","url":"https://hartvaat.nl/mensen/tara-i-chang/","name":"Tara I Chang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2021/03/01/kdigo-2021-bloeddruk-bij-ckd-executive-summary/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2020/06/01/intensieve-bloeddrukverlaging-en-risico-op-af-sprint-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2020/05/01/bloeddruk-en-volumemanagement-bij-dialyse-kdigo-controverseconferentie/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/07/01/medicatie-non-adherentie-en-visit-to-visit-bloeddrukvariabiliteit-target-bp-stud/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/03/29/drug-eluting-versus-bare-metal-stents-bij-pci-patienten-met-eindstadium-nierziek/","published":"2016-03-29"},{"url":"https://hartvaat.nl/2016/03/01/voorschrijfpatronen-van-thiazidediuretica-in-de-sprint-trial/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tej-sheth","type":"person","url":"https://hartvaat.nl/mensen/tej-sheth/","name":"Tej Sheth","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/01/27/intracoronair-lage-dosis-rtpa-bij-primaire-pci-voor-stemi-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2016/06/21/myocardiale-blush-en-microvasculaire-reperfusie-na-handmatige-trombectomie-bij-s/","published":"2016-06-21"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"theresa-mcdonagh","type":"person","url":"https://hartvaat.nl/mensen/theresa-mcdonagh/","name":"Theresa McDonagh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2026/02/19/competenties-na-certificering-en-cardiovasculaire-zorgverlening/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2022/06/14/euroheart-datastandaarden-voor-hartfalenregistraties/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2019/05/21/ijzerisomaltosides-en-skeletspierdenergie-bij-chronisch-hf-met-ijzerdeficientie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2018/03/01/medicamenteuze-behandeling-en-uitkomsten-bij-hfpef-systematische-review-en-meta-/","published":"2018-03-01"},{"url":"https://hartvaat.nl/2016/01/01/2015-esc-ers-richtlijn-voor-diagnostiek-en-behandeling-van-pulmonale-hypertensie/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thilo-noack","type":"person","url":"https://hartvaat.nl/mensen/thilo-noack/","name":"Thilo Noack","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","published":"2019-10-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-pilgrim","type":"person","url":"https://hartvaat.nl/mensen/thomas-pilgrim/","name":"Thomas Pilgrim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/02/19/geleidingsstoornissen-na-transkatheter-aortaklepimplantatie/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2023/11/25/biodegradeerbare-versus-duurzame-polymeer-des-bij-stemi-langetermijndata/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2021/10/01/paroxetine-grk2-remming-versus-placebo-bij-anterieur-mi-jama-cardiology/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2019/10/05/biodegradeerbare-versus-duurzame-polymer-des-bij-stemi-gerandomiseerde-trial/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2018/09/01/ultradunne-biodegradeerbare-versus-dunne-duurzame-stents-lancet-gerandomiseerde-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2016/12/01/tienjaarsuitkomsten-van-eerste-generatie-drug-eluting-stents-ses-versus-pes/","published":"2016-12-01"},{"url":"https://hartvaat.nl/2016/01/14/bioresorbeerbare-versus-metallic-everolimus-eluting-stent-bij-stemi-gerandomisee/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-r-keeble","type":"person","url":"https://hartvaat.nl/mensen/thomas-r-keeble/","name":"Thomas R Keeble","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2022/05/25/jbs-richtlijn-management-van-hartstilstand-in-het-cathlab/","published":"2022-05-25"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tommaso-gori","type":"person","url":"https://hartvaat.nl/mensen/tommaso-gori/","name":"Tommaso Gori","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/07/15/oct-gebaseerde-post-pci-fysiologiebeoordeling-voorspelt-klinische-uitkomsten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2023/07/18/bioresorbeerbare-coronaire-scaffolds-vijfjaarsuitkomsten-met-verbeterde-techniek/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/09/01/clopidogrel-versus-prasugrel-versus-ticagrelor-op-endotheelfunctie-en-inflammati/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2019/12/17/uitgebreide-vasodilatatie-versus-standaardzorg-bij-acuut-hf-jama-galactic-hf-pil/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2018/10/27/absorb-iv-bioresorbeerbare-scaffold-30-daags-en-1-jaarsresultaten/","published":"2018-10-27"},{"url":"https://hartvaat.nl/2016/03/01/bioresorbeerbare-scaffold-trombose-multicenteranalyse-van-klinische-presentatie-/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"urs-fischer","type":"person","url":"https://hartvaat.nl/mensen/urs-fischer/","name":"Urs Fischer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2025/07/08/amulet-versus-watchman-flx-driejaarsresultaten-laa-sluiting/","published":"2025-07-08"},{"url":"https://hartvaat.nl/2025/07/05/optimale-timing-van-anticoagulatie-na-ischemisch-cva-en-af-collaboratief-project/","published":"2025-07-05"},{"url":"https://hartvaat.nl/2024/07/13/convince-langetermijn-colchicine-voor-preventie-van-recidief-niet-cardioembolisc/","published":"2024-07-13"},{"url":"https://hartvaat.nl/2024/07/02/vroege-versus-late-doac-na-cva-met-hemorrhagische-transformatie-bij-af/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","published":"2024-02-06"},{"url":"https://hartvaat.nl/2023/06/29/elan-vroege-versus-late-anticoagulatie-na-cva-bij-af-nejm/","published":"2023-06-29"},{"url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","published":"2022-03-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"valeria-paradies","type":"person","url":"https://hartvaat.nl/mensen/valeria-paradies/","name":"Valeria Paradies","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-laagrisico-acuut-mi/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","published":"2025-07-21"},{"url":"https://hartvaat.nl/2024/07/09/cangrelor-en-infarctgrootte-bij-stemi-gerandomiseerde-trial/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2020/12/15/prehospitaal-gemalen-prasugrel-bij-stemi-gerandomiseerde-trial/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2018/06/19/cardioprotectieve-therapieen-en-area-at-risk-bij-gereperfuseerd-stemi-cmr-analys/","published":"2018-06-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vincenzo-guiducci","type":"person","url":"https://hartvaat.nl/mensen/vincenzo-guiducci/","name":"Vincenzo Guiducci","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/11/11/ct-angiografie-of-standaardzorg-na-pci-van-de-linker-hoofdstam/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","published":"2024-11-09"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/07/complete-revascularisatie-vermindert-cv-dood-bij-stemi-met-multivatenlijden-meta/","published":"2020-11-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"w-morris-brown","type":"person","url":"https://hartvaat.nl/mensen/w-morris-brown/","name":"W Morris Brown","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/08/13/off-pump-versus-on-pump-cabg-bij-hoofdstamcoronairlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/07/31/bnp-bij-linker-hoofdstamrevascularisatie-excel-analyse/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wolfgang-rottbauer","type":"person","url":"https://hartvaat.nl/mensen/wolfgang-rottbauer/","name":"Wolfgang Rottbauer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/05/05/expanded-bij-73-verbetert-tricuspidalisinsufficientie-binnen-30-dagen-na-m-teer-/","published":"2026-06-26"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/16/vroege-linkerventrikel-reverse-remodellering-na-mitralisklep-edge-to-edge-repara/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"woong-chol-kang","type":"person","url":"https://hartvaat.nl/mensen/woong-chol-kang/","name":"Woong Chol Kang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","published":"2023-04-04"},{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2022/11/22/ees-versus-cabg-bij-meervatslijden-langetermijn-follow-up-van-rct-s/","published":"2022-11-22"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xu-liu","type":"person","url":"https://hartvaat.nl/mensen/xu-liu/","name":"Xu Liu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/02/11/ffr-geleide-nierslagaderstenting-bij-atherosclerotische-renovasculaire-hypertens/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/01/ice-versus-tee-bij-af-ablatie-gerandomiseerde-trial/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/10/31/pfa-versus-thermale-ablatie-periprocedurale-en-middellangetermijneffecten/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2025/10/31/herhaalde-in-situ-ablatie-versus-uitgebreide-ablatie-bij-recidief-persisterend-a/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2025/08/12/catheterablatie-versus-rate-control-bij-persisterend-af-en-ouder-hartfalen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2023/05/19/drie-substraatstrategieen-voor-persisterend-af-vergeleken-multicenter-rct/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2021/05/21/extrapulmonale-vein-driver-mapping-bij-persisterend-af-bij-obese-patienten/","published":"2021-05-21"},{"url":"https://hartvaat.nl/2021/05/21/katheterablatie-versus-medicatie-bij-persisterend-en-langdurig-persisterend-af-l/","published":"2021-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yan-zhang","type":"person","url":"https://hartvaat.nl/mensen/yan-zhang/","name":"Yan Zhang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/12/31/annexine-a1-verergert-activatie-van-eilandjessterrecellen-via-triglyceridenafbra/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/11/ffr-geleide-nierslagaderstenting-bij-atherosclerotische-renovasculaire-hypertens/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/01/01/gedeeltelijke-cardiale-denervatie-voorkomt-af-na-cabg-rct/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2022/06/01/interatriale-shuntdevices-bij-hartfalen-systematische-review-en-meta-analyse/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2021/04/01/sarcopenie-bij-hartfalen-systematische-review-en-meta-analyse/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2018/05/15/trombocytenaantal-beinvloedt-werkzaamheid-van-foliumzuur-bij-cva-preventie/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2017/04/01/optimale-systolische-bloeddruk-voor-primaire-cva-preventie-bij-hypertensie-csppt/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/07/01/polsgolfsnelheid-en-bloeddrukcontrole-als-onafhankelijke-voorspellers-van-cva-bi/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yangfeng-wu","type":"person","url":"https://hartvaat.nl/mensen/yangfeng-wu/","name":"Yangfeng Wu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/01/01/consistentie-van-bloeddrukrespons-op-kaliumverrijkt-zout-ssass-subanalyse/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/20/zoutvervanger-voorkomt-hypertensie-bij-normotensieve-volwassenen/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2022/09/26/zoutvervangers-verminderen-cardiovasculaire-events-systematische-review/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2022/07/26/chinees-hartgezond-dieet-verlaagt-bloeddruk-effectief-gerandomiseerde-trial/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/05/17/kosteneffectiviteit-van-zoutsubstitutie-ssass-analyse/","published":"2022-05-17"},{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","published":"2021-09-16"},{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-bij-acs-in-resource-beperkte-ziekenhuizen-jama-cardiology-/","published":"2019-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yi-li","type":"person","url":"https://hartvaat.nl/mensen/yi-li/","name":"Yi Li","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/07/14/depressietrajecten-bij-hfpef-impact-op-uitkomsten/","published":"2025-07-14"},{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2024/06/01/opt-birisk-clopidogrel-monotherapie-bij-acs-met-hoog-ischemisch-en-bloedingsrisi/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/11/26/bivalirudine-versus-heparine-bij-primaire-pci-voor-stemi-lancet-trial/","published":"2022-11-26"},{"url":"https://hartvaat.nl/2022/06/01/sglt2-remmers-bij-hartfalen-geupdatete-meta-analyse-bevestigt-breed-voordeel/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2022/01/18/magnetisch-gecontroleerde-capsule-endoscopie-voor-antiplaatjestherapie-gi-schade/","published":"2022-01-18"},{"url":"https://hartvaat.nl/2016/05/17/biodegradeerbare-sirolimus-eluting-stents-de-panda-iii-trial/","published":"2016-05-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"young-joon-hong","type":"person","url":"https://hartvaat.nl/mensen/young-joon-hong/","name":"Young Joon Hong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/09/06/directe-versus-gestageerde-complete-revascularisatie-tijdens-index-opname-bij-st/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/11/14/early-unload-vroege-lv-ontlading-bij-va-ecmo-gerandomiseerde-trial/","published":"2023-11-14"},{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2018/07/24/escitalopram-versus-placebo-bij-depressie-na-acs-en-langetermijn-cardiale-uitkom/","published":"2018-07-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yousif-ahmad","type":"person","url":"https://hartvaat.nl/mensen/yousif-ahmad/","name":"Yousif Ahmad","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/07/16/revascularisatiestrategieen-na-mi-systematische-review-en-meta-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/03/02/intravasculaire-beeldvorming-bij-des-implantatie-lancet-netwerk-meta-analyse/","published":"2024-03-02"},{"url":"https://hartvaat.nl/2023/02/16/catheterablatie-verbetert-cv-uitkomsten-bij-af-en-hartfalen-meta-analyse-van-rct/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2022/04/19/coronaire-flowreserve-en-cardiovasculaire-uitkomsten-meta-analyse/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/07/15/ultradunne-versus-conventionele-2e-generatie-des-langetermijn-meta-analyse/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2020/09/07/des-versus-cabg-bij-hoofdstamlijden-mortaliteits-meta-analyse/","published":"2020-09-07"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yundai-chen","type":"person","url":"https://hartvaat.nl/mensen/yundai-chen/","name":"Yundai Chen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2020/04/07/mobiele-gezondheidstechnologie-voor-af-zorg/","published":"2020-04-07"},{"url":"https://hartvaat.nl/2017/04/01/optimale-systolische-bloeddruk-voor-primaire-cva-preventie-bij-hypertensie-csppt/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/07/01/polsgolfsnelheid-en-bloeddrukcontrole-als-onafhankelijke-voorspellers-van-cva-bi/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yvonne-commodore-mensah","type":"person","url":"https://hartvaat.nl/mensen/yvonne-commodore-mensah/","name":"Yvonne Commodore-Mensah","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2026/05/12/nhlbi-workshop-bloeddrukmeting-verfijnen-door-de-hele-levensloop-heen-knelpunten/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2024/08/01/sociale-determinanten-en-hypertensie-uitkomsten-systematische-review/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2019/11/26/2019-aha-acc-prestatie-en-kwaliteitsmaten-voor-hoge-bloeddruk/","published":"2019-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zsolt-piroth","type":"person","url":"https://hartvaat.nl/mensen/zsolt-piroth/","name":"Zsolt Piroth","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":8,"articles":[{"url":"https://hartvaat.nl/2025/11/11/ffr-geleide-complete-versus-culprit-only-revascularisatie-bij-nstemi/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2017/03/30/ffr-geleide-multivaten-pci-bij-myocardinfarct-nejm-compare-acute/","published":"2017-03-30"},{"url":"https://hartvaat.nl/2016/11/29/natuurlijk-beloop-van-coronaire-atherosclerose-met-ffr-prospectieve-studie/","published":"2016-11-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"abdourahmane-diallo","type":"person","url":"https://hartvaat.nl/mensen/abdourahmane-diallo/","name":"Abdourahmane Diallo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/11/20/afbouw-van-antihypertensieve-behandeling-bij-verpleeghuisbewoners-rct/","published":"2025-11-20"},{"url":"https://hartvaat.nl/2025/10/23/aspirine-bij-chronisch-coronairsyndroom-plus-oac-wel-of-niet/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/11/19/afloat-flecainide-voorkomt-af-na-pfo-sluiting-rct/","published":"2024-11-19"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2016/01/21/stoppen-of-doorgaan-met-clopidogrel-12-maanden-na-drug-eluting-stent-optidual-tr/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adam-witkowski","type":"person","url":"https://hartvaat.nl/mensen/adam-witkowski/","name":"Adam Witkowski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2020/07/01/phactr1-en-fibromusculaire-dysplasie-arcadia-pol-meta-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2018/08/01/renale-denervatie-bij-resistente-hypertensie-met-obstructieve-slaapapneu-proof-o/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/12/01/centrale-iliacale-av-anastomose-bij-ongecontroleerde-hypertensie-rox-control-htn/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2016/01/05/ranolazine-bij-angina-en-kwaliteit-van-leven-na-pci-met-incomplete-revascularisa/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"addison-a-taylor","type":"person","url":"https://hartvaat.nl/mensen/addison-a-taylor/","name":"Addison A Taylor","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/12/29/chloortalidon-versus-hydrochloorthiazide-geen-verschil-in-cv-events/","published":"2022-12-29"},{"url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/05/05/intensieve-bloeddruk-en-aortastijfheid-sprint-heart/","published":"2021-05-05"},{"url":"https://hartvaat.nl/2020/03/01/orthostatische-hypotensie-cv-uitkomsten-en-adverse-events-sprint-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2017/01/01/intensieve-versus-standaard-bloeddrukcontrole-op-ambulante-bloeddruk-sprint-resu/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/03/01/voorschrijfpatronen-van-thiazidediuretica-in-de-sprint-trial/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adeera-levin","type":"person","url":"https://hartvaat.nl/mensen/adeera-levin/","name":"Adeera Levin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/06/19/vrouwen-met-ckd-krijgen-minder-vaak-ras-remmers-en-sglt2-remmers-dan-mannen/","published":"2026-08-10"},{"url":"https://hartvaat.nl/2026/05/25/kdigo-overzicht-de-nier-centraal-in-het-cardiovasculair-renaal-metabool-ckm-synd/","published":"2026-05-31"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alex-j-mclellan","type":"person","url":"https://hartvaat.nl/mensen/alex-j-mclellan/","name":"Alex J McLellan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/07/14/vroege-versus-late-af-ablatie-impact-op-aritmierecidief/","published":"2023-07-14"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexandre-abizaid","type":"person","url":"https://hartvaat.nl/mensen/alexandre-abizaid/","name":"Alexandre Abizaid","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/19/kanker-en-coronaire-atherosclerotische-plaquebelasting-inzichten-uit-de-bravado-/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2017/12/12/implantatiechniek-en-uitkomsten-van-bioresorbeerbare-scaffolds-absorb-analyses/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alfredo-e-rodriguez","type":"person","url":"https://hartvaat.nl/mensen/alfredo-e-rodriguez/","name":"Alfredo E Rodriguez","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2016/08/01/cabg-versus-pci-en-risico-op-myocardinfarct-en-revascularisatie-bij-ckd-patiente/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amir-a-mahabadi","type":"person","url":"https://hartvaat.nl/mensen/amir-a-mahabadi/","name":"Amir A Mahabadi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/02/23/immunoadsorptie-bij-gedilateerde-cardiomyopathie-de-iaso-dcm-trial/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/10/01/bnp-nt-probnp-stratificeert-prognose-gelijk-met-en-zonder-hartfalen-meta-analyse/","published":"2022-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andreas-baumbach","type":"person","url":"https://hartvaat.nl/mensen/andreas-baumbach/","name":"Andreas Baumbach","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/16/pandora-register-supra-versus-intra-annulaire-kleppen-bij-tavr-in-tavr/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","published":"2026-04-09"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2019/07/01/lokale-hemodynamische-krachten-en-fenotype-van-coronaire-plaques/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/05/07/esc-eapci-taskforce-rapport-over-bioresorbeerbare-scaffolds-executive-summary/","published":"2018-05-07"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"angele-moryusef","type":"person","url":"https://hartvaat.nl/mensen/angele-moryusef/","name":"Angèle Moryusef","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anthony-mathur","type":"person","url":"https://hartvaat.nl/mensen/anthony-mathur/","name":"Anthony Mathur","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","published":"2026-04-09"},{"url":"https://hartvaat.nl/2024/07/12/nste-acs-na-cabg-meta-analyse-van-behandelstrategieen/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2024/05/13/nitrate-cin-nitraat-beschermt-tegen-contrastnefropathie-na-acs/","published":"2024-05-13"},{"url":"https://hartvaat.nl/2022/04/01/5-jaarsfollow-up-van-intracoronaire-celtherapie-na-mi-regenerate-ami/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2017/04/01/intracoronair-nitriet-onderdrukt-de-inflammatoire-respons-na-primaire-pci/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/01/14/intracoronaire-beenmergcelinfusie-bij-acuut-myocardinfarct-de-regenerate-ami-tri/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anthony-s-l-tang","type":"person","url":"https://hartvaat.nl/mensen/anthony-s-l-tang/","name":"Anthony S L Tang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/02/20/vanish2-catheterablatie-versus-antiaritmica-bij-ventriculaire-tachycardie-nejm/","published":"2025-02-20"},{"url":"https://hartvaat.nl/2024/06/01/af-ablatie-bij-hfref-versus-hfpef-meta-analyse/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/01/18/raft-langetermijn-crt-d-bij-hartfalen-nejm-14-jaarsresultaten/","published":"2024-01-18"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2019/11/26/cryoballon-versus-rf-ablatie-bij-af-beoordeeld-met-continue-monitoring-cryo-firs/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2017/05/09/agressieve-bloeddrukcontrole-en-recidief-van-af-na-ablatie-gerandomiseerde-trial/","published":"2017-05-09"},{"url":"https://hartvaat.nl/2016/07/14/ablatie-versus-escalatie-van-antiaritmica-bij-ventriculaire-tachycardie-nejm-van/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"arman-qamar","type":"person","url":"https://hartvaat.nl/mensen/arman-qamar/","name":"Arman Qamar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/10/genprobcad-gecombineerde-monogene-en-polygene-risicobepaling-voor-coronairlijden/","published":"2026-07-15"},{"url":"https://hartvaat.nl/2022/12/01/serieel-hoog-sensitief-troponine-t-voorspelt-cv-events-na-acs-odyssey-analyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2019/07/16/edoxaban-versus-warfarine-bij-af-met-leverziekte-engage-af-timi-48/","published":"2019-07-16"},{"url":"https://hartvaat.nl/2019/05/21/vroegtijdig-staken-van-ticagrelor-bij-secundaire-cv-preventie-jacc-review/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2019/01/01/interindividuele-variatie-in-ldl-verlaging-met-evolocumab-fourier-analyse/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","published":"2018-09-20"},{"url":"https://hartvaat.nl/2018/05/14/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-meta-analyse/","published":"2018-05-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"arno-w-hoes","type":"person","url":"https://hartvaat.nl/mensen/arno-w-hoes/","name":"Arno W Hoes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/01/23/switchen-van-vka-naar-noac-bij-fragiele-ouderen-met-af-veilig/","published":"2024-01-23"},{"url":"https://hartvaat.nl/2021/06/01/diagnostiek-van-hartfalen-in-de-huisartsenpraktijk-ipd-meta-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/08/07/geintegreerd-af-management-in-de-huisartsenpraktijk-all-in-clustergerandomiseerd/","published":"2020-08-07"},{"url":"https://hartvaat.nl/2018/08/01/opportunistische-hf-screening-met-natriuretische-peptiden-bij-af-ipd-meta-analys/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2016/10/14/2016-esc-eas-richtlijn-voor-het-management-van-dyslipidemieen/","published":"2016-10-14"},{"url":"https://hartvaat.nl/2016/08/01/2016-europese-richtlijnen-voor-cardiovasculaire-preventie-in-de-klinische-prakti/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/03/22/zelfmanagementinterventies-bij-hartfalen-individuele-patientdata-meta-analyse/","published":"2016-03-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"barbara-casadei","type":"person","url":"https://hartvaat.nl/mensen/barbara-casadei/","name":"Barbara Casadei","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/10/21/amalfi-remote-screening-voor-asymptomatisch-af-gerandomiseerde-trial/","published":"2025-10-21"},{"url":"https://hartvaat.nl/2025/01/07/euroheart-definities-van-klinische-studie-eindpunten-voor-cvd/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2023/11/01/beta3-lvh-mirabegron-bij-linkerventrikel-hypertrofie-fase-2b-rct/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2022/06/14/euroheart-datastandaarden-voor-hartfalenregistraties/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/07/2016-esc-richtlijn-voor-atriumfibrilleren-in-samenwerking-met-eacts/","published":"2016-10-07"},{"url":"https://hartvaat.nl/2016/05/05/perioperatief-rosuvastatine-bij-hartchirurgie-nejm-trial/","published":"2016-05-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"behnood-bikdeli","type":"person","url":"https://hartvaat.nl/mensen/behnood-bikdeli/","name":"Behnood Bikdeli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2026/05/25/longembolie-epidemiologie-stijgende-last-bij-vergrijzing-preventiestrategieen-bl/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2026/03/28/lp-a-verhoogt-risico-op-veneuze-trombo-embolie-bij-premenopauzale-vrouwen-en-hor/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","published":"2022-03-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"benoit-lattuca","type":"person","url":"https://hartvaat.nl/mensen/benoit-lattuca/","name":"Benoit Lattuca","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/07/01/calcified-oct-versus-angiografie-bij-pci-van-verkalkte-laesies/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"},{"url":"https://hartvaat.nl/2019/03/05/timing-van-prasugrel-start-en-coronairangiografie-bij-nstemi/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bernard-chevalier","type":"person","url":"https://hartvaat.nl/mensen/bernard-chevalier/","name":"Bernard Chevalier","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2019/12/01/absorb-scaffold-5-jaarsresultaten-systematische-meta-analyse/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2018/01/30/absorb-bioresorbeerbare-scaffold-3-jaarsresultaten-ipd-meta-analyse/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2017/12/12/implantatiechniek-en-uitkomsten-van-bioresorbeerbare-scaffolds-absorb-analyses/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bjrn-bendz","type":"person","url":"https://hartvaat.nl/mensen/bjrn-bendz/","name":"Bjørn Bendz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2024/06/14/invasief-versus-conservatief-bij-ouderen-met-nste-acs-ipd-meta-analyse/","published":"2024-06-14"},{"url":"https://hartvaat.nl/2021/04/20/il-6-receptorremming-bij-acuut-stemi-gerandomiseerde-trial/","published":"2021-04-20"},{"url":"https://hartvaat.nl/2017/10/01/il-6-remming-en-coronaire-microvasculaire-en-endotheelfunctie-bij-myocardinfarct/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/09/29/drug-eluting-of-bare-metal-stents-bij-coronairlijden-nejm-norstent-trial/","published":"2016-09-29"},{"url":"https://hartvaat.nl/2016/08/07/il-6-receptorantagonist-tocilizumab-bij-nstemi-effect-op-inflammatie-en-troponin/","published":"2016-08-07"},{"url":"https://hartvaat.nl/2016/03/12/invasieve-versus-conservatieve-strategie-bij-80-plussers-met-nstemi-gerandomisee/","published":"2016-03-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cara-east","type":"person","url":"https://hartvaat.nl/mensen/cara-east/","name":"Cara East","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2018/06/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-6-maandsresultat/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2016/06/11/ixmyelocel-t-bij-ischemisch-hartfalen-lancet-dubbelblinde-gerandomiseerde-trial/","published":"2016-06-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carl-e-orringer","type":"person","url":"https://hartvaat.nl/mensen/carl-e-orringer/","name":"Carl E Orringer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/10/04/2022-acc-expert-consensus-niet-statine-therapieen-voor-ldl-verlaging-bij-ascvd/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2021/08/31/2021-acc-consensus-ascvd-risicoreductie-bij-persistente-hypertriglyceridemie/","published":"2021-08-31"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2017/10/03/2017-acc-gerichte-update-niet-statinetherapie-voor-ldl-verlaging/","published":"2017-10-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carl-j-pepine","type":"person","url":"https://hartvaat.nl/mensen/carl-j-pepine/","name":"Carl J Pepine","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/25/bloeddrukverlaging-beschermt-over-het-hele-spectrum-van-chronische-nierschade-la/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2026/03/06/debat-preventieve-pci-bij-kwetsbare-plaques-als-standaardbehandeling/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/11/01/sekseverschillen-in-effect-van-bloeddrukverlaging-ipd-meta-analyse/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2021/11/13/bloeddrukverlaging-en-risico-op-diabetes-type-2-lancet-bplttc-ipd-meta-analyse/","published":"2021-11-13"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2016/11/01/langetermijnmortaliteit-bij-hypertensie-met-coronairlijden-invest-us-cohort/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cecilia-linde","type":"person","url":"https://hartvaat.nl/mensen/cecilia-linde/","name":"Cecilia Linde","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/09/prefers-stockholm-nieuw-ontstaan-hfpef-heeft-slechtere-langetermijnuitkomsten-da/","published":"2026-07-19"},{"url":"https://hartvaat.nl/2026/02/19/competenties-na-certificering-en-cardiovasculaire-zorgverlening/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chen","type":"person","url":"https://hartvaat.nl/mensen/chen/","name":"Chen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/03/machine-learningmodel-voorspelt-periprocedurele-complicaties-bij-tavi-voor-bicus/","published":"2026-07-25"},{"url":"https://hartvaat.nl/2026/03/03/voorspelmodellen-voor-hartfalen-bij-patienten-met-instabiele-angina-pectoris/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/02/26/hiv-infectie-hangt-onafhankelijk-samen-met-meer-en-kwetsbaardere-halsslagaderpla/","published":"2026-02-26"},{"url":"https://hartvaat.nl/2026/02/23/luchtvervuiling-en-multimorbiditeit-verhogen-het-risico-op-atriumfibrilleren/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/02/02/machine-learning-nomogram-voorspelt-vroeg-transplantaatfalen-na-harttransplantat/","published":"2026-02-02"},{"url":"https://hartvaat.nl/2026/01/29/lineaire-ablatie-van-de-voorwand-van-het-linkeratrium-vermindert-af-recidieven-b/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2026/01/09/littekenweefsel-voorspelt-plotse-hartdood-na-een-infarct-grotendeels-buiten-de-e/","published":"2026-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cheol-whan-lee","type":"person","url":"https://hartvaat.nl/mensen/cheol-whan-lee/","name":"Cheol Whan Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/01/lage-dosis-tel-aml-chtd-combinatietablet-versus-standaard-tel-fase-iii/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/05/01/angiografie-versus-ivus-voor-des-implantatie-gerandomiseerde-trial/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2017/07/01/syntax-scores-en-uitkomsten-bij-diabetes-met-multivatenlijden-gepoolde-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/04/19/statinebehandeling-en-plaquesamenstelling-dubbelblinde-gerandomiseerde-studie/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/01/21/langdurige-duale-antiplaatjestherapie-bij-patienten-met-eerder-myocardinfarct-me/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chien-wen-tseng","type":"person","url":"https://hartvaat.nl/mensen/chien-wen-tseng/","name":"Chien-Wen Tseng","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"},{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","published":"2017-07-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christine-m-albert","type":"person","url":"https://hartvaat.nl/mensen/christine-m-albert/","name":"Christine M Albert","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/10/21/dieet-en-af-risico-systematische-review/","published":"2024-10-21"},{"url":"https://hartvaat.nl/2023/07/25/omega-3-biomarkers-en-incident-af-ipd-analyse/","published":"2023-07-25"},{"url":"https://hartvaat.nl/2022/10/01/sekseverschillen-in-af-risico-vital-rhythm-studie/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/12/21/langdurige-omega-3-suppletie-en-af-risico-meta-analyse-van-cv-trials/","published":"2021-12-21"},{"url":"https://hartvaat.nl/2021/03/16/omega-3-en-vitamine-d-en-incident-af-jama-vital-af/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/03/03/vitamine-d-en-omega-3-en-hartfalen-hospitalisatie-vital-heart-failure/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2017/02/21/genetische-obesitas-en-risico-op-atriumfibrilleren-mendeliaanse-randomisatie/","published":"2017-02-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christoph-kaiser","type":"person","url":"https://hartvaat.nl/mensen/christoph-kaiser/","name":"Christoph Kaiser","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2023/11/25/biodegradeerbare-versus-duurzame-polymeer-des-bij-stemi-langetermijndata/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2020/11/07/drug-coated-balloons-versus-des-bij-kleine-coronairarterien-lancet-basket-small-/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2019/10/05/biodegradeerbare-versus-duurzame-polymer-des-bij-stemi-gerandomiseerde-trial/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2018/09/08/drug-coated-balloons-bij-kleine-coronairarterien-lancet-basket-small-2/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/09/01/ultradunne-biodegradeerbare-versus-dunne-duurzame-stents-lancet-gerandomiseerde-/","published":"2018-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-t-salerno","type":"person","url":"https://hartvaat.nl/mensen/christopher-t-salerno/","name":"Christopher T Salerno","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/09/27/momentum-3-vijfjaarsresultaten-heartmate-3-versus-axiale-lvad/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2019/01/08/cva-analyse-in-momentum-3-langetermijncohort/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/10/30/zorggebruik-en-kosten-in-momentum-3-langetermijnstudie/","published":"2018-10-30"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/05/23/hemocompatibiliteitsuitkomsten-van-heartmate-3-na-6-maanden-momentum-3/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","published":"2017-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"claus-graff","type":"person","url":"https://hartvaat.nl/mensen/claus-graff/","name":"Claus Graff","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/01/20/af-screening-naar-genetisch-risico-loop-subanalyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/15/hypokaliemie-en-af-gedetecteerd-door-implanteerbare-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2025/12/15/circadiaanse-patronen-van-af-en-ziekteprogressie-via-implanted-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2023/06/13/loop-substudie-nt-probnp-verbetert-af-screeningsopbrengst/","published":"2023-06-13"},{"url":"https://hartvaat.nl/2022/09/01/bloeddruk-beinvloedt-opbrengst-van-af-screening-loop-substudie/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2020/05/12/ritme-monitoringstrategieen-voor-af-screening-uitgebreide-evaluatie/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2019/12/03/natuurlijk-beloop-van-subklinisch-af-gedetecteerd-door-implanteerbare-looprecord/","published":"2019-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cora-e-lewis","type":"person","url":"https://hartvaat.nl/mensen/cora-e-lewis/","name":"Cora E Lewis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2020/06/01/intensieve-bloeddrukverlaging-en-risico-op-af-sprint-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/08/01/intensieve-bloeddrukverlaging-en-linkerventrikelhypertrofie-sprint-echocardiogra/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/11/01/intensieve-bloeddrukbehandeling-120-80-mmhg-bij-cardiovasculair-risico-protagoni/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"corinne-hanotin","type":"person","url":"https://hartvaat.nl/mensen/corinne-hanotin/","name":"Corinne Hanotin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniela-tomasoni","type":"person","url":"https://hartvaat.nl/mensen/daniela-tomasoni/","name":"Daniela Tomasoni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/03/geslachtsverschillen-bij-patienten-met-gevorderd-hartfalen/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2021/10/01/sacubitril-valsartan-in-real-life-europese-hfref-meta-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2019/12/01/hoogtepunten-in-hartfalen-2019/","published":"2019-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"danielle-m-brennan","type":"person","url":"https://hartvaat.nl/mensen/danielle-m-brennan/","name":"Danielle M Brennan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/05/17/tandem-obicetrapib-plus-ezetimibe-voor-ldl-verlaging-lancet-fase-3/","published":"2025-05-17"},{"url":"https://hartvaat.nl/2024/03/01/clear-outcomes-bempedoinezuur-vermindert-totale-cv-events-bij-statine-intolerant/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2023/01/03/rosuvastatine-versus-voedingssupplementen-voor-lipidenmanagement/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2018/10/23/evolocumab-en-coronaire-plaquesamenstelling-glagov-beeldvorming/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/04/19/evolocumab-versus-ezetimibe-bij-statine-intolerante-patienten-de-gauss-3-trial/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-fitchett","type":"person","url":"https://hartvaat.nl/mensen/david-fitchett/","name":"David Fitchett","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2020/01/07/hypoglykemie-cv-uitkomsten-en-empagliflozine-empa-reg-outcome/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/06/04/microvasculaire-ziekte-en-cv-events-bij-diabetes-type-2/","published":"2019-06-04"},{"url":"https://hartvaat.nl/2019/03/12/empagliflozine-vermindert-mortaliteit-en-hf-hospitalisatie-over-het-cv-risicospe/","published":"2019-03-12"},{"url":"https://hartvaat.nl/2018/02/01/empagliflozine-en-cv-dood-en-hf-hospitalisatie-over-het-hf-spectrum-empa-reg-out/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2018/01/23/empagliflozine-bij-diabetes-type-2-met-perifeer-vaatlijden-empa-reg-outcome/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2018/01/09/empagliflozine-bij-diabetes-type-2-met-cardiovasculaire-ziekte-en-ckd-empa-reg-o/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2016/07/28/empagliflozine-en-progressie-van-nierziekte-bij-diabetes-type-2-nejm-empa-reg-re/","published":"2016-07-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-m-charytan","type":"person","url":"https://hartvaat.nl/mensen/david-m-charytan/","name":"David M Charytan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","published":"2025-03-24"},{"url":"https://hartvaat.nl/2025/01/01/dialysaat-kalium-3-0-mmol-l-met-natriumzirconiumcyclosilicaat-bij-dialyse/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/06/18/evolocumab-bij-ckd-werkzaamheid-en-veiligheid-in-de-fourier-trial/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"},{"url":"https://hartvaat.nl/2016/08/01/cabg-versus-pci-en-risico-op-myocardinfarct-en-revascularisatie-bij-ckd-patiente/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-m-leistner","type":"person","url":"https://hartvaat.nl/mensen/david-m-leistner/","name":"David M Leistner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/02/10/propionaat-vermindert-atherosclerose-via-immuunregulatie-van-intestinaal-cholest/","published":"2022-02-10"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-m-thompson","type":"person","url":"https://hartvaat.nl/mensen/david-m-thompson/","name":"David M Thompson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/09/21/bijwerkingspatronen-in-crossover-trial-statine-placebo-geen-behandeling-statinwi/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2020/11/26/n-of-1-trial-van-statine-placebo-of-geen-behandeling-voor-bijwerkingen-nejm-stat/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/01/ochtend-versus-avonddosering-van-antihypertensiva-gerandomiseerde-crossover-tria/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/06/24/bijwerkingen-bij-niet-geblindeerde-versus-geblindeerde-statinetherapie-lancet-as/","published":"2017-06-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-sim","type":"person","url":"https://hartvaat.nl/mensen/david-sim/","name":"David Sim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"derk-w-krieger","type":"person","url":"https://hartvaat.nl/mensen/derk-w-krieger/","name":"Derk W Krieger","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/01/20/af-screening-naar-genetisch-risico-loop-subanalyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/15/hypokaliemie-en-af-gedetecteerd-door-implanteerbare-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2025/12/15/circadiaanse-patronen-van-af-en-ziekteprogressie-via-implanted-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2023/06/13/loop-substudie-nt-probnp-verbetert-af-screeningsopbrengst/","published":"2023-06-13"},{"url":"https://hartvaat.nl/2022/09/01/bloeddruk-beinvloedt-opbrengst-van-af-screening-loop-substudie/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2020/05/12/ritme-monitoringstrategieen-voor-af-screening-uitgebreide-evaluatie/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2019/12/03/natuurlijk-beloop-van-subklinisch-af-gedetecteerd-door-implanteerbare-looprecord/","published":"2019-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dick-de-zeeuw","type":"person","url":"https://hartvaat.nl/mensen/dick-de-zeeuw/","name":"Dick de Zeeuw","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"},{"url":"https://hartvaat.nl/2019/05/28/canagliflozine-en-hf-uitkomsten-bij-behouden-versus-verminderde-ef-canvas/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2018/07/31/canagliflozine-en-hartfalen-bij-diabetes-type-2-canvas-programma/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/01/23/canagliflozine-voor-primaire-en-secundaire-cardiovasculaire-preventie-canvas/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/08/17/canagliflozine-en-cardiovasculaire-en-renale-events-bij-diabetes-type-2-nejm-can/","published":"2017-08-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"diego-ardissino","type":"person","url":"https://hartvaat.nl/mensen/diego-ardissino/","name":"Diego Ardissino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2018/05/01/farmacogenomisch-gestuurd-antiplaatjestherapie-bij-acs-pharmclo-trial/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-bij-stabiel-coronairlijden-stability-inzic/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/04/01/veiligheid-en-werkzaamheid-van-ticagrelor-versus-clopidogrel-bij-primaire-pci-vo/","published":"2016-04-01"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dietmar-trenk","type":"person","url":"https://hartvaat.nl/mensen/dietmar-trenk/","name":"Dietmar Trenk","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2016/07/19/immatuur-plaatjesaantal-versus-gevestigde-voorspellers-van-plaatjesreactiviteit-/","published":"2016-07-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dirk-j-blom","type":"person","url":"https://hartvaat.nl/mensen/dirk-j-blom/","name":"Dirk J Blom","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/18/global-hicc-register-950-hofh-patienten-uit-45-landen-slechts-4-haalt-ldl-doelen/","published":"2026-06-17"},{"url":"https://hartvaat.nl/2026/02/05/orale-pcsk9-remmer-enlicitide-verlaagt-ldl-met-57-placebogecontroleerde-trial/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2023/10/21/lerodalcibep-bij-familiaire-hypercholesterolemie-liberate-hefh-langetermijndata/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2020/07/14/alirocumab-bij-homozygoot-fh-odyssey-hofh/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2019/08/08/volanesorsen-en-triglyceriden-bij-familiair-chylomicronemiesyndroom-nejm/","published":"2019-08-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dominik-linz","type":"person","url":"https://hartvaat.nl/mensen/dominik-linz/","name":"Dominik Linz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/06/02/smartphone-app-voor-symptoomregistratie-na-ablatie-bij-atriumfibrilleren-isolati/","published":"2026-08-12"},{"url":"https://hartvaat.nl/2025/12/01/arrest-af-agressieve-risicofactorreductie-en-ablatie-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/10/31/pfa-versus-thermale-ablatie-periprocedurale-en-middellangetermijneffecten/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2024/10/21/dieet-en-af-risico-systematische-review/","published":"2024-10-21"},{"url":"https://hartvaat.nl/2023/12/01/adaptieve-servoventilatie-en-hypoxemische-belasting-bij-hartfalen/","published":"2023-12-01"},{"url":"https://hartvaat.nl/2022/09/01/af-voorspelt-cognitieve-achteruitgang-meta-analyse-van-2-8-miljoen-personen/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2020/01/01/obesitas-opzettelijk-gewichtsverlies-en-hartfalen-meta-analyse/","published":"2020-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"donald-e-casey","type":"person","url":"https://hartvaat.nl/mensen/donald-e-casey/","name":"Donald E Casey","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2019/11/26/2019-aha-acc-prestatie-en-kwaliteitsmaten-voor-hoge-bloeddruk/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-ahmad-masri","type":"person","url":"https://hartvaat.nl/mensen/dr-ahmad-masri/","name":"Dr. Ahmad Masri","title":"Cardioloog, Oregon Health & Science University, Portland","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/05/aficamten-veilig-en-effectief-bij-langdurige-behandeling-van-obstructieve-hcm/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/01/01/aficamten-bij-obstructieve-hcm-multidomeinanalyse-van-maple-hcm/","published":"2026-03-14"},{"url":"https://hartvaat.nl/2025/01/01/aficamten-versus-metoprolol-betere-levenskwaliteit-bij-obstructieve-hcm/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","published":"2023-01-03"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-acacia-hcm-lbct/","title":"ACACIA-HCM: aficamten bij niet-obstructieve HCM"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"emelia-j-benjamin","type":"person","url":"https://hartvaat.nl/mensen/emelia-j-benjamin/","name":"Emelia J Benjamin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/11/18/2025-acc-scientific-statement-obesitasmanagement-bij-hartfalen/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2021/05/01/mcp-1-en-cardiovasculaire-mortaliteit-populatie-gebaseerde-meta-analyse/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2020/09/22/sekse-specifieke-cv-risicofactoren-en-biomarkers-bij-incident-hartfalen/","published":"2020-09-22"},{"url":"https://hartvaat.nl/2017/02/21/genetische-obesitas-en-risico-op-atriumfibrilleren-mendeliaanse-randomisatie/","published":"2017-02-21"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"emeline-m-van-craenenbroeck","type":"person","url":"https://hartvaat.nl/mensen/emeline-m-van-craenenbroeck/","name":"Emeline M Van Craenenbroeck","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/23/lp-a-en-ai-ccta-onthullen-onzichtbaar-restrisico-voorbij-de-calciumscore/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/06/01/trainingseffect-op-diastolische-functie-bij-hfpef/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/04/01/inspanningstraining-en-hoog-sensitief-troponine-i-bij-hfref/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2022/10/01/verschillende-trainingsvormen-en-hdl-functie-bij-hfpef-optimex-substudie/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/06/01/inspanningstraining-en-hs-troponine-t-bij-hfref/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/02/09/hiit-matig-continu-of-richtlijnadvies-en-piek-vo2-bij-hfref-jama-smartex-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2017/02/28/hoog-intensieve-intervaltraining-bij-hartfalen-met-verminderde-ejectiefractie/","published":"2017-02-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"enrico-cerrato","type":"person","url":"https://hartvaat.nl/mensen/enrico-cerrato/","name":"Enrico Cerrato","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/11/11/ct-angiografie-of-standaardzorg-na-pci-van-de-linker-hoofdstam/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2017/05/23/stralingsblootstelling-en-vasculaire-toegang-bij-acs-rad-matrix-trial/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2016/12/21/statines-voor-primaire-preventie-bij-hiv-positieve-patienten-systematische-revie/","published":"2016-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"erik-jrgensen","type":"person","url":"https://hartvaat.nl/mensen/erik-jrgensen/","name":"Erik Jørgensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2023/04/01/mesenchymale-stamcellen-bij-ischemisch-hartfalen-deense-fase-ii-trial/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"esa-m-davis","type":"person","url":"https://hartvaat.nl/mensen/esa-m-davis/","name":"Esa M Davis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"},{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"etienne-gayat","type":"person","url":"https://hartvaat.nl/mensen/etienne-gayat/","name":"Etienne Gayat","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/09/08/gepersonaliseerde-bloeddrukregeling-tijdens-thrombectomie-verbetert-functionele-/","published":"2026-08-19"},{"url":"https://hartvaat.nl/2025/09/01/preoperatief-cv-risico-en-raas-remmergebruik-postoperatieve-uitkomsten/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eva-c-jensen","type":"person","url":"https://hartvaat.nl/mensen/eva-c-jensen/","name":"Eva C Jensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f-d-richard-hobbs","type":"person","url":"https://hartvaat.nl/mensen/f-d-richard-hobbs/","name":"F D Richard Hobbs","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2023/06/01/natriuretisch-peptide-screening-voor-lv-disfunctie-diagnostische-nauwkeurigheid/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2021/06/01/diagnostiek-van-hartfalen-in-de-huisartsenpraktijk-ipd-meta-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/05/26/antihypertensieve-medicatiereductie-versus-standaardzorg-bij-ouderen-jama-optimi/","published":"2020-05-26"},{"url":"https://hartvaat.nl/2019/06/01/kosteneffectiviteit-van-telemonitoring-en-zelfmeting-van-bloeddruk-tasminh4/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/03/10/zelfgemeten-bloeddruk-met-of-zonder-telemonitoring-voor-medicatietitratie-lancet/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2017/06/14/overschakelen-van-niet-selectieve-nsaid-s-naar-celecoxib-de-scot-trial/","published":"2017-06-14"},{"url":"https://hartvaat.nl/2016/08/01/2016-europese-richtlijnen-voor-cardiovasculaire-preventie-in-de-klinische-prakti/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fabiana-rollini","type":"person","url":"https://hartvaat.nl/mensen/fabiana-rollini/","name":"Fabiana Rollini","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","published":"2022-03-07"},{"url":"https://hartvaat.nl/2021/04/17/geleide-versus-standaard-antiplaatjestherapie-na-pci-lancet-meta-analyse/","published":"2021-04-17"},{"url":"https://hartvaat.nl/2020/10/13/laaggedoseerd-ticagrelor-versus-standaard-clopidogrel-bij-diabetes-farmacodynami/","published":"2020-10-13"},{"url":"https://hartvaat.nl/2019/04/02/cangrelor-en-gemalen-ticagrelor-bij-stemi-met-primaire-pci/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2016/09/13/prasugrel-versus-ticagrelor-bij-diabetes-type-2-met-coronairlijden-optimus-4-stu/","published":"2016-09-13"},{"url":"https://hartvaat.nl/2016/05/03/gemalen-prasugrel-bij-stemi-met-primaire-pci-de-crush-studie/","published":"2016-05-03"},{"url":"https://hartvaat.nl/2016/03/15/plaatjesremming-met-ticagrelor-60-mg-versus-90-mg-in-de-pegasus-timi-54-trial/","published":"2016-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"faisal-sharif","type":"person","url":"https://hartvaat.nl/mensen/faisal-sharif/","name":"Faisal Sharif","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"felicita-andreotti","type":"person","url":"https://hartvaat.nl/mensen/felicita-andreotti/","name":"Felicita Andreotti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2023/01/24/pcsk9-remming-bij-covid-19-anti-inflammatoir-potentieel-onderzocht/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/04/01/intracraniele-bloedingen-versus-stenttrombose-met-doac-antiplaatjes-versus-tripl/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2018/04/17/uitgangs-ldl-en-mortaliteitsreductie-na-ldl-verlaging-jama-meta-analyse/","published":"2018-04-17"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fiona-e-strachan","type":"person","url":"https://hartvaat.nl/mensen/fiona-e-strachan/","name":"Fiona E Strachan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2021/07/08/grace-2-0-score-bij-type-1-en-type-2-mi/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2017/11/21/hoog-sensitief-troponine-i-en-uitkomsten-bij-verdenking-acs-jama-studie/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2016/12/27/hoog-sensitief-troponine-statinetherapie-en-risico-op-coronairlijden/","published":"2016-12-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fiyyaz-ahmed-jushuf","type":"person","url":"https://hartvaat.nl/mensen/fiyyaz-ahmed-jushuf/","name":"Fiyyaz Ahmed-Jushuf","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francesco-burzotta","type":"person","url":"https://hartvaat.nl/mensen/francesco-burzotta/","name":"Francesco Burzotta","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2026/02/24/colchicine-bij-chronische-inflammatoire-cardiomyopathie-de-cmp-mythic-trial/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2025/03/04/stapsgewijze-provisionale-versus-systematische-dualstent-bij-ware-linker-hoofdst/","published":"2025-03-04"},{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2022/07/21/permanente-pacemaker-na-tavi-langetermijneffect-op-klinische-uitkomsten/","published":"2022-07-21"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/10/01/ebc-hoofdstam-stentstudie-provisional-versus-systematisch-dubbel-stenten/","published":"2021-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francesco-maisano","type":"person","url":"https://hartvaat.nl/mensen/francesco-maisano/","name":"Francesco Maisano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/05/05/expanded-bij-73-verbetert-tricuspidalisinsufficientie-binnen-30-dagen-na-m-teer-/","published":"2026-06-26"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/28/gestandaardiseerd-stappenplan-voor-tricuspidalisinsufficientie-van-verwijzing-to/","published":"2026-04-19"},{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/03/16/vroege-linkerventrikel-reverse-remodellering-na-mitralisklep-edge-to-edge-repara/","published":"2026-03-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francis-d-pagani","type":"person","url":"https://hartvaat.nl/mensen/francis-d-pagani/","name":"Francis D Pagani","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/23/aspirinestop-bij-lvad-met-vka-veiligheidsanalyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/03/01/aspirine-en-hemocompatibiliteit-na-lvad-bij-atherosclerotisch-vaatlijden/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2018/10/30/zorggebruik-en-kosten-in-momentum-3-langetermijnstudie/","published":"2018-10-30"},{"url":"https://hartvaat.nl/2017/02/02/intrapericardiale-lvad-bij-gevorderd-hartfalen-nejm/","published":"2017-02-02"},{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","published":"2017-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frank-m-sacks","type":"person","url":"https://hartvaat.nl/mensen/frank-m-sacks/","name":"Frank M Sacks","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2021/06/01/dieet-en-natriumreductie-op-cardiale-schade-en-inflammatie-dash-sodium/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2019/12/01/genetische-gevoeligheid-eiwitinname-en-bloeddrukverandering-pounds-lost/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2018/03/27/hdl-subspecies-met-apoliproteine-c-iii-en-coronairlijden-vier-cohorten/","published":"2018-03-27"},{"url":"https://hartvaat.nl/2017/11/01/tijdsverloop-van-bloeddrukverandering-door-zoutreductie-en-dash-dieet/","published":"2017-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frederik-m-zimmermann","type":"person","url":"https://hartvaat.nl/mensen/frederik-m-zimmermann/","name":"Frederik M Zimmermann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/01/06/caviar-alirocumab-bij-cardiale-allograft-vasculopathie-na-harttransplantatie/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/06/01/ffr-geleide-pci-versus-cabg-bij-diffuus-coronairlijden/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"friedrich-w-mohr","type":"person","url":"https://hartvaat.nl/mensen/friedrich-w-mohr/","name":"Friedrich W Mohr","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2016/01/05/doodsoorzaken-na-pci-versus-cabg-bij-complex-coronairlijden-5-jaarsfollow-up-van/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"g-b-john-mancini","type":"person","url":"https://hartvaat.nl/mensen/g-b-john-mancini/","name":"G B John Mancini","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/19/evolocumab-en-doorgankelijkheid-van-veneuze-bypasses-na-cabg-newton-cabg-cardiol/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","published":"2025-09-20"},{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/04/30/leefstijl-hba1c-en-overleving-bij-stabiel-coronairlijden-met-diabetes/","published":"2019-04-30"},{"url":"https://hartvaat.nl/2017/12/19/chirurgische-versus-percutane-revascularisatie-bij-diabetes-met-acs/","published":"2017-12-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"garen-manvelian","type":"person","url":"https://hartvaat.nl/mensen/garen-manvelian/","name":"Garen Manvelian","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","published":"2021-08-03"},{"url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/02/25/polygene-risicoscore-en-voordeel-van-alirocumab-bij-coronairlijden-odyssey-outco/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2017/09/26/sams-ci-score-toegepast-op-gerandomiseerde-trial-over-statine-myopathie/","published":"2017-09-26"},{"url":"https://hartvaat.nl/2016/12/21/alirocumab-bij-heterozygoot-fh-met-lipoproteine-aferese-odyssey-escape/","published":"2016-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gemma-a-figtree","type":"person","url":"https://hartvaat.nl/mensen/gemma-a-figtree/","name":"Gemma A Figtree","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2021/04/01/canagliflozine-naar-diureticagebruik-canvas-post-hoc-analyse/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2019/05/28/canagliflozine-en-hf-uitkomsten-bij-behouden-versus-verminderde-ef-canvas/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2018/07/31/canagliflozine-en-hartfalen-bij-diabetes-type-2-canvas-programma/","published":"2018-07-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gennaro-giustino","type":"person","url":"https://hartvaat.nl/mensen/gennaro-giustino/","name":"Gennaro Giustino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","published":"2022-11-15"},{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2017/10/10/dagelijks-ischemie-en-bloedingsrisico-na-primaire-pci-voor-stemi/","published":"2017-10-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gian-luca-di-tanna","type":"person","url":"https://hartvaat.nl/mensen/gian-luca-di-tanna/","name":"Gian Luca Di Tanna","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2022/09/26/zoutvervangers-verminderen-cardiovasculaire-events-systematische-review/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2022/06/01/lage-dosis-drievoudige-combinatietherapie-bij-hypertensie-triumph-secundaire-ana/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2022/05/17/kosteneffectiviteit-van-zoutsubstitutie-ssass-analyse/","published":"2022-05-17"},{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","published":"2021-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gianluca-pontone","type":"person","url":"https://hartvaat.nl/mensen/gianluca-pontone/","name":"Gianluca Pontone","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/05/cmr-laci-21-identificeert-hoogrisicopatienten-met-hfref-onafhankelijk-van-lvef-e/","published":"2026-06-30"},{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/02/24/colchicine-bij-chronische-inflammatoire-cardiomyopathie-de-cmp-mythic-trial/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2026/01/13/risicofactoren-en-plaquevolume-op-coronaire-ct-angiografie-lessen-uit-het-advanc/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2018/11/01/ct-coronairangiografie-voor-heart-team-besluitvorming-bij-multivatenlijden/","published":"2018-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giulia-magnani","type":"person","url":"https://hartvaat.nl/mensen/giulia-magnani/","name":"Giulia Magnani","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2016/10/01/langere-versus-korte-dapt-na-pci-met-en-zonder-periprocedureel-mi-jama-cardiolog/","published":"2016-10-01"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","published":"2016-04-07"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giuseppe-ando","type":"person","url":"https://hartvaat.nl/mensen/giuseppe-ando/","name":"Giuseppe Andò","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/01/01/verkorte-dapt-bij-hoog-bloedingsrisico-geen-sekseverschillen/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2021/02/02/dalend-hemoglobine-en-prognose-bij-acs-hospitalisatie/","published":"2021-02-02"},{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"h-asita-de-silva","type":"person","url":"https://hartvaat.nl/mensen/h-asita-de-silva/","name":"H Asita de Silva","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2022/06/01/lage-dosis-drievoudige-combinatietherapie-bij-hypertensie-triumph-secundaire-ana/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2020/02/20/community-interventie-voor-hypertensie-in-ruraal-zuid-azie-nejm/","published":"2020-02-20"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2018/08/14/drievoudige-lage-dosis-antihypertensivacombinatie-versus-standaardzorg-jama-gera/","published":"2018-08-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"handrean-soran","type":"person","url":"https://hartvaat.nl/mensen/handrean-soran/","name":"Handrean Soran","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/25/verve-102-eenmalige-base-editing-schakelt-pcsk9-blijvend-uit-fase-1/","published":"2026-05-25"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-familiaire-chylomicronemie-nejm-fase-3/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2019/08/08/volanesorsen-en-triglyceriden-bij-familiair-chylomicronemiesyndroom-nejm/","published":"2019-08-08"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/02/14/cholesterolniveaus-en-de-rol-bij-het-identificeren-van-statinenontvangers/","published":"2017-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hans-christoph-diener","type":"person","url":"https://hartvaat.nl/mensen/hans-christoph-diener/","name":"Hans-Christoph Diener","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2021/11/30/voorspellers-van-af-ontwikkeling-bij-embolic-stroke-of-undetermined-source-re-sp/","published":"2021-11-30"},{"url":"https://hartvaat.nl/2021/01/27/periprocedurele-antistolling-bij-eliminate-af-ononderbroken-edoxaban-versus-vka/","published":"2021-01-27"},{"url":"https://hartvaat.nl/2019/09/21/ononderbroken-edoxaban-versus-vka-bij-af-ablatie-eliminate-af/","published":"2019-09-21"},{"url":"https://hartvaat.nl/2017/01/01/percutane-linker-hartoorsluiting-munchen-consensusdocument-over-definities-en-ei/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/07/2016-esc-richtlijn-voor-atriumfibrilleren-in-samenwerking-met-eacts/","published":"2016-10-07"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnevaluatie-van-dabigatran-150-versus-110-mg-bij-niet-valvulair-af/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hans-henrik-tilsted","type":"person","url":"https://hartvaat.nl/mensen/hans-henrik-tilsted/","name":"Hans-Henrik Tilsted","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hans-peter-brunner-la-rocca","type":"person","url":"https://hartvaat.nl/mensen/hans-peter-brunner-la-rocca/","name":"Hans-Peter Brunner-La Rocca","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/08/21/pa-drukmonitoring-bij-chronisch-hartfalen-effecten-over-klinische-subgroepen/","published":"2024-08-21"},{"url":"https://hartvaat.nl/2023/06/24/monitor-hf-pa-drukmonitoring-bij-hartfalen-effectief-in-europa-lancet-rct/","published":"2023-06-24"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2019/11/19/beeldvorming-geleide-versus-routinezorg-bij-nstemi-jacc/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2018/01/16/hoog-sensitief-troponine-t-bij-chronisch-hartfalen-individuele-patientdata-meta-/","published":"2018-01-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"harriette-g-c-van-spall","type":"person","url":"https://hartvaat.nl/mensen/harriette-g-c-van-spall/","name":"Harriette G C Van Spall","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/26/state-of-the-art-mra-s-bij-hartfalen-en-nierziekte-over-alle-ejectiefracties/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2026/02/23/nierbescherming-na-harttransplantatie-risicoreductie-en-therapeutische-mogelijkh/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2024/09/17/2024-acc-aha-kwaliteitsmaatstaven-voor-hartfalen-geactualiseerd/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2022/09/01/collaterale-schade-van-covid-19-aan-cardiovasculaire-zorg-meta-analyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/08/01/klinische-fenotypen-zijn-effectiever-dan-ef-categorieen-voor-hf-uitkomsten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2021/01/27/mobiele-gezondheidstoepassingen-voor-af-detectie-systematische-review/","published":"2021-01-27"},{"url":"https://hartvaat.nl/2019/02/26/patientgerichte-transitional-care-bij-hf-hospitalisatie-jama-pact-hf/","published":"2019-02-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hertzel-c-gerstein","type":"person","url":"https://hartvaat.nl/mensen/hertzel-c-gerstein/","name":"Hertzel C Gerstein","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/11/26/glp-1-agonisten-alleen-en-met-sglt2-remmers-cv-renale-en-veiligheidsuitkomsten/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2023/03/28/amplitude-o-dosisrespons-van-efpeglenatide-op-cv-uitkomsten-bij-diabetes/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2021/09/02/efpeglenatide-en-cv-en-renale-uitkomsten-bij-diabetes-type-2-nejm-amplitude-o/","published":"2021-09-02"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2018/03/01/omega-3-vetzuursupplementen-en-cv-risico-jama-cardiology-meta-analyse-van-10-tri/","published":"2018-03-01"},{"url":"https://hartvaat.nl/2017/04/01/fenofibraat-en-langetermijn-cardiovasculair-risico-bij-statinebehandelde-diabete/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hideyuki-kawashima","type":"person","url":"https://hartvaat.nl/mensen/hideyuki-kawashima/","name":"Hideyuki Kawashima","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","published":"2020-08-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hillary-mulder","type":"person","url":"https://hartvaat.nl/mensen/hillary-mulder/","name":"Hillary Mulder","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2020/01/07/nsaid-s-en-oac-bij-af-aristotle-analyse/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/01/01/mi-bij-pav-patienten-incidentie-en-uitkomsten-euclid/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/10/02/cv-uitkomsten-na-endovasculaire-versus-chirurgische-revascularisatie-onderste-le/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2018/08/01/uitkomsten-bij-af-met-oac-bij-mitralis-of-aortakleplijden/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hiroshi-ito","type":"person","url":"https://hartvaat.nl/mensen/hiroshi-ito/","name":"Hiroshi Ito","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2022/02/01/luseogliflozine-en-geschat-plasmavolume-bij-hfpef/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2018/05/08/hoog-versus-laaggedoseerd-pitavastatine-bij-stabiel-coronairlijden-real-cad/","published":"2018-05-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hiroyuki-tsutsui","type":"person","url":"https://hartvaat.nl/mensen/hiroyuki-tsutsui/","name":"Hiroyuki Tsutsui","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/01/30/edoxaban-versus-warfarine-bij-chronische-trombo-embolische-pulmonale-hypertensie/","published":"2024-01-30"},{"url":"https://hartvaat.nl/2022/08/01/thuisrevalidatie-met-ict-voor-fragiele-hartfalenpatienten/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"italo-porto","type":"person","url":"https://hartvaat.nl/mensen/italo-porto/","name":"Italo Porto","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/25/pah-met-renaal-diabetische-overlap-komt-vaak-voor-en-geeft-tweemaal-zo-hoog-mort/","published":"2026-06-01"},{"url":"https://hartvaat.nl/2026/05/26/esc-consensusverklaring-over-microvasculaire-obstructie-en-no-reflow-na-stemi/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/01/01/rivaroxaban-discontinueringspercentages-bij-niet-valvulair-af-in-de-italiaanse-p/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2021/10/01/sacubitril-valsartan-in-real-life-europese-hfref-meta-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/04/17/geleide-versus-standaard-antiplaatjestherapie-na-pci-lancet-meta-analyse/","published":"2021-04-17"},{"url":"https://hartvaat.nl/2020/04/01/intracraniele-bloedingen-versus-stenttrombose-met-doac-antiplaatjes-versus-tripl/","published":"2020-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"j-dawn-abbott","type":"person","url":"https://hartvaat.nl/mensen/j-dawn-abbott/","name":"J Dawn Abbott","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/08/19/paclitaxel-gecoate-ballon-bij-multilayer-in-stent-restenose-agent-ide-subgroep/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2020/08/25/genotype-geleide-p2y12-selectie-versus-clopidogrel-na-pci-jama-tailor-pci/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2018/09/18/hartfalen-na-cva-tia-bij-insulineresistente-patienten-behandeld-met-pioglitazon/","published":"2018-09-18"},{"url":"https://hartvaat.nl/2017/09/01/provisional-versus-twee-stentstrategie-bij-bifurcatielaesies-meta-analyse/","published":"2017-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"j-a","type":"person","url":"https://hartvaat.nl/mensen/j-a/","name":"J. A.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/03/warrior-trial-intensieve-medicamenteuze-behandeling-verbetert-de-uitkomsten-niet/","published":"2026-07-24"},{"url":"https://hartvaat.nl/2026/04/10/zuinig-machine-learningmodel-voorspelt-1-jaarssterfte-en-zinloosheid-na-tavi/","published":"2026-07-23"},{"url":"https://hartvaat.nl/2026/04/10/proteomics-onthult-vier-subgroepen-van-acuut-hfpef-met-eigen-biologische-routes-/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/04/10/tweelingzwangerschap-bij-vrouwen-met-een-hartaandoening-geeft-een-hoog-risico-op/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/05/26/asymptomatische-matige-ernstige-aortaklepinsufficientie-niet-benigne-meta-analys/","published":"2026-07-03"},{"url":"https://hartvaat.nl/2026/02/10/welke-hartfalenpatienten-ontwikkelen-ernstige-mitralisinsufficientie-voorspellen/","published":"2026-02-10"},{"url":"https://hartvaat.nl/2026/01/23/etnische-verschillen-in-aortadiameters-indiase-versus-nederlandse-patienten-amst/","published":"2026-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"j-w","type":"person","url":"https://hartvaat.nl/mensen/j-w/","name":"J. W.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/10/tweelingzwangerschap-bij-vrouwen-met-een-hartaandoening-geeft-een-hoog-risico-op/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/04/24/sekseverschillen-bij-infectieuze-endocarditis-vrouwen-vaker-conservatief-behande/","published":"2026-07-20"},{"url":"https://hartvaat.nl/2026/04/29/geisoleerde-secundaire-tricuspidalisinsufficientie-na-linkszijdige-klepchirurgie/","published":"2026-07-12"},{"url":"https://hartvaat.nl/2026/04/29/erasmus-mc-linkeratrium-strain-voorspelt-aritmieen-na-chirurgische-correctie-van/","published":"2026-07-11"},{"url":"https://hartvaat.nl/2026/05/21/million-women-study-ernstige-obesitas-verviervoudigt-risico-op-af-en-hartfalen-s/","published":"2026-07-05"},{"url":"https://hartvaat.nl/2026/04/24/crt-bij-volwassenen-met-systemische-rechterventrikel-gemengde-uitkomsten-in-inte/","published":"2026-05-09"},{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-myocardinfarct-winratio-analyse-uit-de-cle/","published":"2026-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jacob-m-mishell","type":"person","url":"https://hartvaat.nl/mensen/jacob-m-mishell/","name":"Jacob M Mishell","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/05/01/nierdisfunctie-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2019/12/17/echo-uitkomsten-na-mitraclip-bij-secundaire-mr-coapt-echocardiografisch/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/05/07/gezondheidsstatus-na-mitraclip-bij-hf-met-secundaire-mr-coapt/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"james-stevermer","type":"person","url":"https://hartvaat.nl/mensen/james-stevermer/","name":"James Stevermer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"},{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"james-w-choi","type":"person","url":"https://hartvaat.nl/mensen/james-w-choi/","name":"James W Choi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/02/18/lage-dosis-sirolimus-bdp-stent-versus-tweede-generatie-des-non-inferioriteit/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2023/07/18/bioresorbeerbare-coronaire-scaffolds-vijfjaarsuitkomsten-met-verbeterde-techniek/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2018/10/27/absorb-iv-bioresorbeerbare-scaffold-30-daags-en-1-jaarsresultaten/","published":"2018-10-27"},{"url":"https://hartvaat.nl/2018/06/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-6-maandsresultat/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jamie-layland","type":"person","url":"https://hartvaat.nl/mensen/jamie-layland/","name":"Jamie Layland","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2024/07/10/intracoronaire-trombolyse-bij-stemi-meta-analyse/","published":"2024-07-10"},{"url":"https://hartvaat.nl/2021/11/09/colchicine-na-acs-2-jaars-cops-follow-up/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2021/07/21/laaggedoseerd-colchicine-bij-coronairlijden-meta-analyse-van-gerandomiseerde-tri/","published":"2021-07-21"},{"url":"https://hartvaat.nl/2020/11/17/colchicine-bij-acs-australische-cops-gerandomiseerde-trial/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2017/10/17/katheterablatie-versus-frequentiecontrole-bij-af-met-systolische-disfunctie-came/","published":"2017-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jay-m-edelberg","type":"person","url":"https://hartvaat.nl/mensen/jay-m-edelberg/","name":"Jay M Edelberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jean-champagne","type":"person","url":"https://hartvaat.nl/mensen/jean-champagne/","name":"Jean Champagne","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/12/23/korte-anticoagulatie-versus-dapt-na-laa-occlusie-devicetrombosepreventie/","published":"2025-12-23"},{"url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","published":"2024-02-16"},{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2021/11/01/af-last-en-qol-na-af-ablatie-cabana-substudie/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"},{"url":"https://hartvaat.nl/2019/11/26/cryoballon-versus-rf-ablatie-bij-af-beoordeeld-met-continue-monitoring-cryo-firs/","published":"2019-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jean-philippe-collet","type":"person","url":"https://hartvaat.nl/mensen/jean-philippe-collet/","name":"Jean-Philippe Collet","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"},{"url":"https://hartvaat.nl/2019/03/05/timing-van-prasugrel-start-en-coronairangiografie-bij-nstemi/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/04/26/vroege-aldosteronblokkade-bij-acuut-myocardinfarct-de-albatross-trial/","published":"2016-04-26"},{"url":"https://hartvaat.nl/2016/01/21/langdurige-duale-antiplaatjestherapie-bij-patienten-met-eerder-myocardinfarct-me/","published":"2016-01-21"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeanne-e-poole","type":"person","url":"https://hartvaat.nl/mensen/jeanne-e-poole/","name":"Jeanne E Poole","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","published":"2022-08-16"},{"url":"https://hartvaat.nl/2022/03/15/leeftijd-en-uitkomsten-van-katheterablatie-versus-medicatie-bij-af-cabana/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/07/13/ablatie-versus-medicatie-bij-af-naar-ras-en-etniciteit/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2020/07/28/langetermijn-icd-uitkomsten-scd-heft/","published":"2020-07-28"},{"url":"https://hartvaat.nl/2020/06/30/af-recidief-na-ablatie-versus-antiaritmica-in-cabana/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-medicamenteus-bij-af-en-kwaliteit-van-leven-jama-cabana-q/","published":"2019-04-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeffrey-l-probstfield","type":"person","url":"https://hartvaat.nl/mensen/jeffrey-l-probstfield/","name":"Jeffrey L Probstfield","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2021/07/08/cv-uitkomsten-bij-diabetes-met-vastgesteld-of-hoog-risico-coronairlijden-dulaglu/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2021/07/01/cv-gevolgen-van-stoppen-met-laaggedoseerd-rivaroxaban-bij-chronisch-vaatlijden/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2019/08/13/rivaroxaban-met-of-zonder-aspirine-bij-hf-met-coronair-of-perifeer-vaatlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2017/04/01/fenofibraat-en-langetermijn-cardiovasculair-risico-bij-statinebehandelde-diabete/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jens-aaroe","type":"person","url":"https://hartvaat.nl/mensen/jens-aaroe/","name":"Jens Aarøe","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","published":"2019-10-19"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jia-wang","type":"person","url":"https://hartvaat.nl/mensen/jia-wang/","name":"Jia Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/06/15/prevalentie-van-linkeratriumtrombus-bij-geanticoaguleerde-af-patienten/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2017/10/01/korte-dabigatran-onderbreking-voor-device-implantatie-re-ly-multicenterervaring/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/07/01/dabigatran-naar-leeftijd-bij-atriumfibrilleren-re-ly-analyse/","published":"2017-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jiamin-liu","type":"person","url":"https://hartvaat.nl/mensen/jiamin-liu/","name":"Jiamin Liu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/01/intensieve-bloeddrukcontrole-en-cognitieve-functie-gerandomiseerde-trial/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/01/01/effect-van-baduanjin-op-bloeddruk-bij-hoog-normaal-bloeddruk-gerandomiseerde-tri/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/06/esprit-intensieve-bloeddrukcontrole-bij-fragiele-patienten-post-hoc-analyse/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/10/28/esprit-bescheiden-effecten-van-intensieve-bloeddrukverlaging-op-kwaliteit-van-le/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukcontrole-en-cva-preventie/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2024/07/20/sbp-120-versus-140-mmhg-bij-hoog-cv-risico-meta-analyse-van-intensieve-behandeli/","published":"2024-07-20"},{"url":"https://hartvaat.nl/2024/04/16/postprocedurale-anticoagulatie-na-primaire-pci-voor-stemi-multicenter-studie/","published":"2024-04-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jianhua-wu","type":"person","url":"https://hartvaat.nl/mensen/jianhua-wu/","name":"Jianhua Wu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/08/25/risicogestuurde-af-screening-met-machine-learning-verhoogt-detectiegraad-find-af/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/05/21/find-af-biomarker-stratificeert-prognose-bij-hfref-met-atriale-cardiomyopathie-z/","published":"2026-06-08"},{"url":"https://hartvaat.nl/2026/03/25/meta-analyse-glp-1-agonisten-voorkomen-hartfalen-in-type-2-diabetes-sterkste-eff/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2023/10/24/cts-ami-tongxinluo-bij-acuut-mi-jama-mega-trial/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2022/09/01/collaterale-schade-van-covid-19-aan-cardiovasculaire-zorg-meta-analyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/06/10/voorspelling-van-atriumfibrilleren-in-elektronische-gezondheidsdossiers-systemat/","published":"2022-06-10"},{"url":"https://hartvaat.nl/2021/03/01/langetermijn-overlevingsvoordeel-van-ramipril-bij-mi-met-hf/","published":"2021-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jiguang-wang","type":"person","url":"https://hartvaat.nl/mensen/jiguang-wang/","name":"Jiguang Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/10/01/esh-convenant-polshorloges-bloeddrukmeters-acceptabele-nauwkeurigheid-maar-klini/","published":"2026-09-02"},{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2026/02/01/innovatieve-wereldwijde-modellen-voor-ckd-zorg-casestudies-en-strategieen/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2021/02/01/therapietrouw-aan-single-pill-versus-vrije-combinatietherapie-bij-hypertensie-me/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2017/08/01/nauwkeurigheid-van-manchetbloeddrukmeting-systematische-review-en-meta-analyse/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/04/01/optimale-systolische-bloeddruk-voor-primaire-cva-preventie-bij-hypertensie-csppt/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","published":"2016-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jiri-jarkovsky","type":"person","url":"https://hartvaat.nl/mensen/jiri-jarkovsky/","name":"Jiri Jarkovsky","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/07/08/catheterablatie-versus-leefstijlmodificatie-plus-antiaritmica-bij-af-gerandomise/","published":"2025-07-08"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/02/07/ecmo-cs-ecmo-bij-cardiogene-shock-verbetert-overleving-niet/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2022/01/04/4-jaars-laa-sluiting-versus-niet-warfarine-oac-bij-af/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2020/06/30/laa-sluiting-versus-doac-bij-hoogrisico-af-vergelijkende-analyse/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2018/01/30/prasugrel-versus-ticagrelor-bij-primaire-pci-voor-mi-1-jaarsuitkomsten/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2016/11/22/prasugrel-versus-ticagrelor-bij-acuut-mi-met-primaire-pci-multicenter-trial/","published":"2016-11-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joachim-h-ix","type":"person","url":"https://hartvaat.nl/mensen/joachim-h-ix/","name":"Joachim H Ix","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/08/20/aangetaste-tubulaire-secretiecapaciteit-verhoogt-cardiovasculaire-sterfte-hunt-s/","published":"2026-08-28"},{"url":"https://hartvaat.nl/2026/03/13/tubulaire-nierschade-hangt-samen-met-natriumretentie-en-diureticarespons-bij-acu/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2024/09/01/troponine-nt-probnp-en-cognitieve-uitkomsten-in-sprint/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2022/10/18/intensieve-bloeddrukverlaging-bij-maligne-linkerventrikel-hypertrofie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2021/03/01/kdigo-2021-bloeddruk-bij-ckd-executive-summary/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johan-engdahl","type":"person","url":"https://hartvaat.nl/mensen/johan-engdahl/","name":"Johan Engdahl","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/09/01/systematische-af-screening-met-gedetailleerde-fenotypering-en-risicopredictie/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/03/nt-probnp-en-ecg-screening-bij-75-jarigen-voor-af-detectie-rct/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2023/01/14/strokestop-af-screening-is-kosteneffectief-bij-75-76-jarigen/","published":"2023-01-14"},{"url":"https://hartvaat.nl/2021/10/23/systematische-af-screening-en-klinische-uitkomsten-lancet-strokestop/","published":"2021-10-23"},{"url":"https://hartvaat.nl/2020/01/01/stapsgewijze-af-screening-met-nt-probnp-strokestop-ii-resultaten/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2017/08/01/nt-probnp-bij-systematische-screening-op-atriumfibrilleren/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/02/01/stapsgewijze-massascreening-op-af-met-nt-probnp-strokestop-ii-studieontwerp/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-gregson","type":"person","url":"https://hartvaat.nl/mensen/john-gregson/","name":"John Gregson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2023/10/01/pa-drukmonitoring-bij-chronisch-hartfalen-meta-analyse-van-drie-rct-s/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/01/05/staken-van-hf-medicatie-bij-herstelde-dilaterende-cardiomyopathie-lancet-tred-hf/","published":"2019-01-05"},{"url":"https://hartvaat.nl/2018/02/20/cva-risico-bij-verminderde-ef-na-mi-zonder-af/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-j-atherton","type":"person","url":"https://hartvaat.nl/mensen/john-j-atherton/","name":"John J Atherton","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/23/pathfinder-trial-betere-naleving-van-hartfalenrichtlijnen-in-de-huisartsenprakti/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/05/02/determinanten-van-medicatietrouw-na-acs-secundaire-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2022/05/10/sms-voor-medicatietrouw-en-secundaire-preventie-na-acs-textmeds/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2022/04/09/natriumreductie-100-mmol-bij-hartfalen-lancet-sodium-hf/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/10/01/sglt2-remmers-en-hf-hospitalisatie-en-hartfunctie-systematische-review/","published":"2021-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-m-lachin","type":"person","url":"https://hartvaat.nl/mensen/john-m-lachin/","name":"John M Lachin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/09/22/grade-vergelijking-glucoseverlagende-middelen-op-microvasculaire-en-cv-uitkomste/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2018/02/01/empagliflozine-en-cv-dood-en-hf-hospitalisatie-over-het-hf-spectrum-empa-reg-out/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2018/01/09/empagliflozine-bij-diabetes-type-2-met-cardiovasculaire-ziekte-en-ckd-empa-reg-o/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/11/01/hypertensiecontrole-bij-diabetes-met-recidiverende-cv-events-tecos-globale-resul/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/04/20/frequentie-van-evidence-based-retinopathiescreening-bij-diabetes-type-1-nejm/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2016/07/28/empagliflozine-en-progressie-van-nierziekte-bij-diabetes-type-2-nejm-empa-reg-re/","published":"2016-07-28"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-w-epling","type":"person","url":"https://hartvaat.nl/mensen/john-w-epling/","name":"John W Epling","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","published":"2017-07-11"},{"url":"https://hartvaat.nl/2016/11/15/statines-voor-primaire-cardiovasculaire-preventie-uspstf-aanbeveling/","published":"2016-11-15"},{"url":"https://hartvaat.nl/2016/08/09/lipidescreening-bij-kinderen-en-adolescenten-uspstf-aanbeveling/","published":"2016-08-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-w-mcevoy","type":"person","url":"https://hartvaat.nl/mensen/john-w-mcevoy/","name":"John W McEvoy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/10/07/semaglutide-en-bloeddruk-ipd-meta-analyse/","published":"2024-10-07"},{"url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/01/geisoleerde-diastolische-hypertensie-cohort-en-meta-analyse-voor-behandeldrempel/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/06/01/bloeddrukverlaging-naar-uitgangsdruk-en-cv-risico-bij-diabetes-type-2/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/01/16/intraveneus-fentanyl-en-ticagrelorabsorptie-bij-pci/","published":"2018-01-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"josep-redon","type":"person","url":"https://hartvaat.nl/mensen/josep-redon/","name":"Josep Redon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/09/01/bereikte-diastolische-bloeddruk-en-polsdruk-bij-streef-sbp-en-cv-uitkomsten-bij-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/11/01/gemiddelde-bloeddruk-en-visit-to-visit-variabiliteit-als-gecombineerde-voorspell/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/06/03/bereikte-bloeddruk-en-cv-uitkomsten-bij-hoogrisicopatienten-ontarget-transcend/","published":"2017-06-03"},{"url":"https://hartvaat.nl/2016/08/01/2016-europese-richtlijnen-voor-cardiovasculaire-preventie-in-de-klinische-prakti/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joseph-j-saseen","type":"person","url":"https://hartvaat.nl/mensen/joseph-j-saseen/","name":"Joseph J Saseen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/01/29/nla-consensusupdate-familiaire-hypercholesterolemie-screening-diagnostiek-en-beh/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2024/06/25/vasculair-zorgteam-versus-educatie-bij-perifeer-arterieel-vaatlijden/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2016/11/22/management-van-klinisch-significante-geneesmiddelinteracties-met-statines-aha-aa/","published":"2016-11-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"juan-f-iglesias","type":"person","url":"https://hartvaat.nl/mensen/juan-f-iglesias/","name":"Juan F Iglesias","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2023/11/25/biodegradeerbare-versus-duurzame-polymeer-des-bij-stemi-langetermijndata/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2020/12/22/fentanyl-versus-morfine-op-ticagrelor-plaatjesremming-bij-stemi/","published":"2020-12-22"},{"url":"https://hartvaat.nl/2019/11/19/evolocumab-voor-vroege-ldl-verlaging-bij-acs-evopacs/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/10/05/biodegradeerbare-versus-duurzame-polymer-des-bij-stemi-gerandomiseerde-trial/","published":"2019-10-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"julie-e-buring","type":"person","url":"https://hartvaat.nl/mensen/julie-e-buring/","name":"Julie E Buring","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/12/05/inflammatie-cholesterol-lp-a-en-30-jaars-cv-uitkomsten-bij-vrouwen/","published":"2024-12-05"},{"url":"https://hartvaat.nl/2023/01/01/vitamine-d-voorkomt-statine-gerelateerde-spierklachten-niet/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2021/03/16/omega-3-en-vitamine-d-en-incident-af-jama-vital-af/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/05/05/triglyceriderijk-lipoproteinecholesterol-small-dense-ldl-en-cv-events/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/03/03/vitamine-d-en-omega-3-en-hartfalen-hospitalisatie-vital-heart-failure/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2017/06/01/voedingsstatus-en-langetermijn-multivitaminegebruik-en-cv-risico-phs-ii-analyse/","published":"2017-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jun-pu","type":"person","url":"https://hartvaat.nl/mensen/jun-pu/","name":"Jun Pu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/26/ai-clustering-identificeert-functionele-risicofenotypen-bij-hartfalen/","published":"2026-04-06"},{"url":"https://hartvaat.nl/2026/02/12/gdmt-na-functioneel-complete-revascularisatie-prognostische-impact/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/04/26/angiografie-afgeleide-ffr-versus-ivus-bij-pci-gerandomiseerde-trial/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/12/06/gemodificeerde-transseptale-punctie-bij-laa-occlusie-rct/","published":"2023-12-06"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2017/10/17/farmaco-invasieve-strategie-met-halve-dosis-alteplase-versus-primaire-pci-bij-st/","published":"2017-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jun-zhu","type":"person","url":"https://hartvaat.nl/mensen/jun-zhu/","name":"Jun Zhu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/04/01/intraprocedurele-eindpunten-voor-duurzame-pvi-gerandomiseerde-trial-van-vier-tec/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karina-v-bunting","type":"person","url":"https://hartvaat.nl/mensen/karina-v-bunting/","name":"Karina V Bunting","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/03/26/rate-af-kosteneffectiviteit-van-digoxine-versus-betablokkers-bij-permanent-af/","published":"2025-03-26"},{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2022/09/26/smartphone-detectie-van-af-via-fotoplethysmografie-meta-analyse/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2021/10/16/betablokker-respons-bij-hf-met-sinusritme-en-af-machine-learning-clusteranalyse/","published":"2021-10-16"},{"url":"https://hartvaat.nl/2021/07/01/transformatie-van-klinisch-onderzoek-door-patientbetrokkenheid-rate-af/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/12/22/digoxine-versus-bisoprolol-voor-frequentiecontrole-bij-af-en-qol-jama-rate-af/","published":"2020-12-22"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karl-georg-haeusler","type":"person","url":"https://hartvaat.nl/mensen/karl-georg-haeusler/","name":"Karl Georg Haeusler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2023/01/24/axadia-afnet-8-apixaban-versus-vka-bij-af-op-hemodialyse/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/08/01/2018-ehra-praktische-gids-doac-s-bij-af-europace-editie/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/04/21/2018-ehra-praktische-gids-voor-doac-gebruik-bij-af/","published":"2018-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karol-e-watson","type":"person","url":"https://hartvaat.nl/mensen/karol-e-watson/","name":"Karol E Watson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/03/02/barrieres-bij-implementatie-van-lipidenverlagende-therapie-in-de-praktijk/","published":"2026-03-26"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2023/01/03/rosuvastatine-versus-voedingssupplementen-voor-lipidenmanagement/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/05/31/langetermijneffect-van-metformine-en-leefstijlinterventie-op-cardiovasculaire-ev/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2017/07/04/langetermijn-metformine-en-leefstijl-en-coronair-calcium-diabetes-prevention-pro/","published":"2017-07-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"katherine-l-tucker","type":"person","url":"https://hartvaat.nl/mensen/katherine-l-tucker/","name":"Katherine L Tucker","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/11/01/bloeddrukzelfmanagement-en-vasculaire-remodelling-na-hypertensieve-zwangerschap/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/02/13/pop-ht-bloeddrukzelfmanagement-verbetert-cardiale-remodelling-na-hypertensieve-z/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2023/11/28/pop-ht-zelfmanagement-van-bloeddruk-na-hypertensieve-zwangerschap-jama-rct/","published":"2023-11-28"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-bloeddrukcontrole-bij-risicozwangerschap-jama-bump-2/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2018/09/01/thuis-versus-praktijkbloeddrukmeting-in-de-zwangerschap/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/08/01/zelfmanagement-van-postnatale-hypertensie-de-snap-ht-trial/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"katsumi-miyauchi","type":"person","url":"https://hartvaat.nl/mensen/katsumi-miyauchi/","name":"Katsumi Miyauchi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/08/06/racing-subanalyse-matige-statine-plus-ezetimibe-voor-secundaire-preventie/","published":"2024-08-06"},{"url":"https://hartvaat.nl/2022/12/01/daprodustat-bij-anemie-en-hartfalen-met-ckd-gerandomiseerde-studie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/08/01/rivaroxaban-monotherapie-versus-combinatie-met-plaatjesremmers-bij-af-en-coronai/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/11/01/aspirine-versus-p2y12-remmer-met-antistolling-bij-af/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2019/09/19/antitrombotische-therapie-bij-af-met-stabiel-coronairlijden-nejm-afire/","published":"2019-09-19"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/05/08/hoog-versus-laaggedoseerd-pitavastatine-bij-stabiel-coronairlijden-real-cad/","published":"2018-05-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kazuo-kimura","type":"person","url":"https://hartvaat.nl/mensen/kazuo-kimura/","name":"Kazuo Kimura","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/08/06/racing-subanalyse-matige-statine-plus-ezetimibe-voor-secundaire-preventie/","published":"2024-08-06"},{"url":"https://hartvaat.nl/2022/08/01/rivaroxaban-monotherapie-versus-combinatie-met-plaatjesremmers-bij-af-en-coronai/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/11/01/aspirine-versus-p2y12-remmer-met-antistolling-bij-af/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2019/09/19/antitrombotische-therapie-bij-af-met-stabiel-coronairlijden-nejm-afire/","published":"2019-09-19"},{"url":"https://hartvaat.nl/2019/06/07/febuxostat-voor-cerebraal-en-cardiorenovasculaire-eventpreventie-freed/","published":"2019-06-07"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/05/08/hoog-versus-laaggedoseerd-pitavastatine-bij-stabiel-coronairlijden-real-cad/","published":"2018-05-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kenneth-j-mukamal","type":"person","url":"https://hartvaat.nl/mensen/kenneth-j-mukamal/","name":"Kenneth J Mukamal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/01/06/gofresh-dash-boodschappen-en-bloeddrukeffect-rct/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/04/01/lichaamshouding-en-orthostatische-hypotensie-bij-hypertensie-syst-eur-analyse/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2021/06/01/dieet-en-natriumreductie-op-cardiale-schade-en-inflammatie-dash-sodium/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2019/10/01/antihypertensivaklasse-en-vallen-syncope-en-orthostatische-hypotensie-bij-oudere/","published":"2019-10-01"},{"url":"https://hartvaat.nl/2018/10/01/hypertensiebehandeling-en-orthostatische-hypotensie-relatie-met-cv-ziekte/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/03/27/hdl-subspecies-met-apoliproteine-c-iii-en-coronairlijden-vier-cohorten/","published":"2018-03-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"khalid-yusoff","type":"person","url":"https://hartvaat.nl/mensen/khalid-yusoff/","name":"Khalid Yusoff","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2019/10/05/uitgebreide-community-interventie-bij-hypertensie-lancet-hope-4/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kim-a-connelly","type":"person","url":"https://hartvaat.nl/mensen/kim-a-connelly/","name":"Kim A Connelly","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2023/06/01/igfbp7-en-lv-massaregressie-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/nlr-en-cardiale-remodelling-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/diabetesduur-beinvloedt-lv-massaregressie-met-empagliflozine/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2020/03/10/routine-versus-selectieve-cardiale-mri-bij-niet-ischemisch-hf-outsmart-hf/","published":"2020-03-10"},{"url":"https://hartvaat.nl/2019/11/19/empagliflozine-en-lv-massa-bij-diabetes-type-2-met-coronairlijden-empa-heart/","published":"2019-11-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kiyoshi-hibi","type":"person","url":"https://hartvaat.nl/mensen/kiyoshi-hibi/","name":"Kiyoshi Hibi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2018/05/08/hoog-versus-laaggedoseerd-pitavastatine-bij-stabiel-coronairlijden-real-cad/","published":"2018-05-08"},{"url":"https://hartvaat.nl/2017/11/07/optische-frequentiedomeinbeeldvorming-versus-ivus-bij-pci-opinion-trial/","published":"2017-11-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kuan-ken-lee","type":"person","url":"https://hartvaat.nl/mensen/kuan-ken-lee/","name":"Kuan Ken Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/11/11/risicostratificatie-met-hoog-sensitief-troponine-op-de-seh-veiligheidsanalyse/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/04/01/sekseverschillen-in-effectiviteit-van-orale-p2y12-remmers-meta-analyse/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2017/11/21/hoog-sensitief-troponine-i-en-uitkomsten-bij-verdenking-acs-jama-studie/","published":"2017-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"larry-a-allen","type":"person","url":"https://hartvaat.nl/mensen/larry-a-allen/","name":"Larry A Allen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/04/16/2024-acc-expert-consensus-behandeling-van-hfref-beslispad-geactualiseerd/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2021/02/16/2021-acc-hf-behandeloptimalisatie-update-antwoorden-op-10-cruciale-vragen/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2018/12/01/ras-etniciteit-en-oac-gebruik-bij-af-orbit-af/","published":"2018-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lars-gullestad","type":"person","url":"https://hartvaat.nl/mensen/lars-gullestad/","name":"Lars Gullestad","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2021/04/20/il-6-receptorremming-bij-acuut-stemi-gerandomiseerde-trial/","published":"2021-04-20"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2018/12/01/pro-gastrin-releasing-peptide-en-uitkomsten-bij-hf-met-anemie-red-hf/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2017/10/01/il-6-remming-en-coronaire-microvasculaire-en-endotheelfunctie-bij-myocardinfarct/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/08/07/il-6-receptorantagonist-tocilizumab-bij-nstemi-effect-op-inflammatie-en-troponin/","published":"2016-08-07"},{"url":"https://hartvaat.nl/2016/03/12/invasieve-versus-conservatieve-strategie-bij-80-plussers-met-nstemi-gerandomisee/","published":"2016-03-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lars-jakobsen","type":"person","url":"https://hartvaat.nl/mensen/lars-jakobsen/","name":"Lars Jakobsen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2022/03/15/5-jaars-ifr-versus-ffr-geleide-pci-define-flair-ifr-swedeheart/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2017/05/11/instantaneous-wave-free-ratio-versus-ffr-voor-pci-indicatie-nejm-ifr-swedeheart/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lars-lind","type":"person","url":"https://hartvaat.nl/mensen/lars-lind/","name":"Lars Lind","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/03/03/plasma-eiwitprofielen-onthullen-gedeelde-en-fenotype-specifieke-routes-bij-hartf/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2023/07/25/omega-3-biomarkers-en-incident-af-ipd-analyse/","published":"2023-07-25"},{"url":"https://hartvaat.nl/2023/04/11/heterogeniteit-in-bloeddrukrespons-op-antihypertensiva-jama-cross-over-rct/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2022/04/19/therapeutische-doelen-voor-hf-via-proteomics-en-mendeliaanse-randomisatie/","published":"2022-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"laurence-s-sperling","type":"person","url":"https://hartvaat.nl/mensen/laurence-s-sperling/","name":"Laurence S Sperling","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/21/aspirine-lipoproteine-a-en-aortaklepstenose-de-mesa-studie/","published":"2026-02-21"},{"url":"https://hartvaat.nl/2020/09/01/2020-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2018/12/18/2018-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2018-12-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"leopoldo-s-piegas","type":"person","url":"https://hartvaat.nl/mensen/leopoldo-s-piegas/","name":"Leopoldo S Piegas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2016/12/15/off-pump-versus-on-pump-cabg-5-jaarsresultaten-nejm-coronary-trial/","published":"2016-12-15"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"liang-han-ling","type":"person","url":"https://hartvaat.nl/mensen/liang-han-ling/","name":"Liang-Han Ling","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/02/16/hoog-vermogen-korte-duur-versus-laag-vermogen-langere-duur-posteriore-ablatie-bi/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2017/10/17/katheterablatie-versus-frequentiecontrole-bij-af-met-systolische-disfunctie-came/","published":"2017-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lilin-she","type":"person","url":"https://hartvaat.nl/mensen/lilin-she/","name":"Lilin She","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2023/09/14/heart-fid-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-nejm/","published":"2023-09-14"},{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2018/02/20/sekseverschillen-bij-ischemisch-hartfalen-na-cabg-stich-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/03/21/plotse-hartdood-bij-ischemisch-hartfalen-na-cabg-stich-resultaten/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/11/01/tienjaarsuitkomsten-na-cabg-naar-leeftijd-bij-hartfalen-met-lv-systolische-disfu/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/21/coronaire-bypasschirurgie-bij-ischemische-cardiomyopathie-nejm-stich-trial/","published":"2016-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lori-pbert","type":"person","url":"https://hartvaat.nl/mensen/lori-pbert/","name":"Lori Pbert","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"},{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"louise-segan","type":"person","url":"https://hartvaat.nl/mensen/louise-segan/","name":"Louise Segan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/02/16/hoog-vermogen-korte-duur-versus-laag-vermogen-langere-duur-posteriore-ablatie-bi/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"laszlo-geller","type":"person","url":"https://hartvaat.nl/mensen/laszlo-geller/","name":"László Gellér","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/21/eplerenon-halveert-recidief-ventriculaire-tachycardie-versus-spironolacton-bij-h/","published":"2026-06-08"},{"url":"https://hartvaat.nl/2024/07/02/upgrade-rv-naar-crt-pacing-bij-hartfalen-met-af-voordelen-bevestigd/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/10/21/upgrade-van-rv-pacing-naar-crt-bij-hartfalen-gerandomiseerde-trial/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2023/05/19/geleidingssysteempacing-in-europa-inzichten-uit-klinische-praktijk/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2021/03/08/katheterablatie-om-af-progressie-te-vertragen-attest-gerandomiseerde-trial/","published":"2021-03-08"},{"url":"https://hartvaat.nl/2017/11/01/klinische-presentatie-bij-eerste-hartfalenhospitalisatie-voorspelt-geen-heropnam/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/01/budapest-crt-upgrade-study-studieontwerp-voor-crt-upgrade/","published":"2017-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"m-a","type":"person","url":"https://hartvaat.nl/mensen/m-a/","name":"M. A.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/03/warrior-trial-intensieve-medicamenteuze-behandeling-verbetert-de-uitkomsten-niet/","published":"2026-07-24"},{"url":"https://hartvaat.nl/2026/04/22/een-op-de-tien-volwassenen-met-een-aangeboren-hartafwijking-heeft-een-syndroom-e/","published":"2026-07-21"},{"url":"https://hartvaat.nl/2026/04/29/geleidingssysteem-pacing-slaat-rechterventrikel-pacing-bij-av-blok-70-hartfalen-/","published":"2026-07-12"},{"url":"https://hartvaat.nl/2026/04/24/verminderde-nierfunctie-verhoogt-hartfalenrisico-bij-ouderen-aspree-cohort/","published":"2026-05-08"},{"url":"https://hartvaat.nl/2026/03/25/waarom-de-sterfte-na-een-hartinfarct-daalde-15-jaar-nationale-data-uit-engeland-/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/03/10/machine-learning-voorspelt-30-daagse-sterfte-na-een-dotterbehandeling-australisc/","published":"2026-03-10"},{"url":"https://hartvaat.nl/2026/02/23/objectief-gemeten-lichaamsbeweging-en-levenskwaliteit-bij-hypertrofische-cardiom/","published":"2026-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mahesh-j-patel","type":"person","url":"https://hartvaat.nl/mensen/mahesh-j-patel/","name":"Mahesh J Patel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/10/23/sotatercept-bij-pah-binnen-het-eerste-jaar-na-diagnose-stellar-subanalyse/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","published":"2020-05-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marco-proietti","type":"person","url":"https://hartvaat.nl/mensen/marco-proietti/","name":"Marco Proietti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2022/10/13/cerebrale-microbloedingen-en-risico-bij-af-systematische-review/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2022/09/15/polypill-voor-secundaire-cardiovasculaire-preventie-secure-trial-in-nejm/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2021/09/14/copd-bij-af-prevalentie-management-en-impact-meta-analyse/","published":"2021-09-14"},{"url":"https://hartvaat.nl/2020/01/01/weglaten-van-aspirine-bij-gecombineerde-antitrombotische-therapie-voor-af-acs-he/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2018/06/01/preventie-van-atriumfibrilleren-beoordeling-van-huidig-bewijs/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/11/01/bloeddrukvariabiliteit-en-uitkomsten-bij-af-affirm-studie/","published":"2017-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"margaret-mcentegart","type":"person","url":"https://hartvaat.nl/mensen/margaret-mcentegart/","name":"Margaret McEntegart","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/07/23/anatomische-versus-viabiliteitsgerichte-completeness-van-revascularisatie/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2022/10/13/revived-bcis2-pci-verbetert-overleving-niet-bij-ischemische-lv-disfunctie/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2021/12/01/post-stenting-ffr-versus-angiografie-voor-pci-optimalisatie-target-ffr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/05/01/pci-versus-medicamenteus-bij-angina-met-ffr-in-de-grijze-zone/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/03/31/laaggedoseerde-alteplase-bij-primaire-pci-naar-ischemietijd/","published":"2020-03-31"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2016/12/15/infarctgrootte-en-linkerkamerremodellering-na-preventieve-pci/","published":"2016-12-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maria-novosadova","type":"person","url":"https://hartvaat.nl/mensen/maria-novosadova/","name":"Maria Novosadova","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mark-a-supiano","type":"person","url":"https://hartvaat.nl/mensen/mark-a-supiano/","name":"Mark A Supiano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/06/01/bloeddrukcontrole-en-arteriele-stijfheidsmechanismen-in-sprint/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2023/07/01/leeftijdsbias-draagt-bij-aan-therapeutische-inertie-bij-bloeddrukmanagement/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2021/05/05/intensieve-bloeddruk-en-aortastijfheid-sprint-heart/","published":"2021-05-05"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2017/08/24/intensieve-bloeddrukbehandeling-en-patientgerapporteerde-uitkomsten-nejm-sprint-/","published":"2017-08-24"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mark-r-nelson","type":"person","url":"https://hartvaat.nl/mensen/mark-r-nelson/","name":"Mark R Nelson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/12/09/aspree-cardiale-stress-en-bloeddrukmanagement-bij-ouderen/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","published":"2021-09-18"},{"url":"https://hartvaat.nl/2020/12/01/langetermijn-bloeddrukvariabiliteit-en-cv-risico-bij-ouderen-in-de-community/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/07/07/statinegebruik-en-invaliditeitsvrije-overleving-bij-gezonde-ouderen/","published":"2020-07-07"},{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matthew-a-cavender","type":"person","url":"https://hartvaat.nl/mensen/matthew-a-cavender/","name":"Matthew A Cavender","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","published":"2025-05-29"},{"url":"https://hartvaat.nl/2024/07/16/interventie-voor-evidence-based-zorg-bij-diabetes-en-cv-risico/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2023/04/18/gecoordineerde-zorg-optimaliseert-cv-preventie-bij-type-2-diabetes-jama-rct/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2017/07/18/sglt2-remmers-en-lager-risico-op-hartfalen-en-sterfte-versus-andere-glucoseverla/","published":"2017-07-18"},{"url":"https://hartvaat.nl/2017/05/16/serieel-hoog-sensitief-troponine-i-en-cv-uitkomsten-bij-diabetes-type-2-examine/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/09/06/consistente-reductie-in-periprocedureel-mi-met-cangrelor-champion-analyses/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mehmet-b-yilmaz","type":"person","url":"https://hartvaat.nl/mensen/mehmet-b-yilmaz/","name":"Mehmet B Yilmaz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/11/25/frequente-pvc-s-en-risico-op-af-hf-cva-en-sterfte/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"melissa-e-middeldorp","type":"person","url":"https://hartvaat.nl/mensen/melissa-e-middeldorp/","name":"Melissa E Middeldorp","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/03/07/lancet-seminar-atriumfibrilleren-in-2026/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2025/12/01/arrest-af-agressieve-risicofactorreductie-en-ablatie-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/10/21/dieet-en-af-risico-systematische-review/","published":"2024-10-21"},{"url":"https://hartvaat.nl/2021/10/09/klinische-risicofactoren-voor-cva-bij-anticoagulantie-naieve-af-meta-analyse/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2018/04/21/subklinisch-device-gedetecteerd-af-en-cva-risico-meta-analyse/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2017/12/01/geintegreerde-zorg-bij-atriumfibrilleren-systematische-review-en-meta-analyse/","published":"2017-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-cabana","type":"person","url":"https://hartvaat.nl/mensen/michael-cabana/","name":"Michael Cabana","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"},{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-d-shapiro","type":"person","url":"https://hartvaat.nl/mensen/michael-d-shapiro/","name":"Michael D Shapiro","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/16/lp-a-en-hscrp-voorspellen-ascvd-bij-mensen-zonder-klassieke-risicofactoren/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/05/15/aspirine-voor-primaire-preventie-bij-verhoogd-lp-a-of-lpa-varianten-levert-geen-/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2026/05/22/il-6-sterker-met-hart-en-vaatziekte-geassocieerd-dan-ldl-lp-a-en-crp/","published":"2026-05-22"},{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/08/01/sarcopenie-en-intensieve-bloeddrukbehandeling-sprint-subanalyse/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2020/01/16/lp-a-verlaging-bij-cardiovasculaire-ziekte-nejm/","published":"2020-01-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-j-blaha","type":"person","url":"https://hartvaat.nl/mensen/michael-j-blaha/","name":"Michael J Blaha","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/22/il-6-sterker-met-hart-en-vaatziekte-geassocieerd-dan-ldl-lp-a-en-crp/","published":"2026-05-22"},{"url":"https://hartvaat.nl/2026/02/21/aspirine-lipoproteine-a-en-aortaklepstenose-de-mesa-studie/","published":"2026-02-21"},{"url":"https://hartvaat.nl/2021/06/01/geisoleerde-diastolische-hypertensie-cohort-en-meta-analyse-voor-behandeldrempel/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/09/22/sekse-specifieke-cv-risicofactoren-en-biomarkers-bij-incident-hartfalen/","published":"2020-09-22"},{"url":"https://hartvaat.nl/2020/07/28/evolocumab-op-atherogene-lipoproteinen-in-de-peri-infarctperiode-gerandomiseerde/","published":"2020-07-28"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-k-parides","type":"person","url":"https://hartvaat.nl/mensen/michael-k-parides/","name":"Michael K Parides","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2017/10/01/terminatie-van-persisterend-af-tijdens-pvi-inzichten-uit-magic-af/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/05/21/stapsgewijze-ablatie-gestuurd-door-laaggedoseerd-ibutilide-bij-chronisch-af-magi/","published":"2016-05-21"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michaela-mattheus","type":"person","url":"https://hartvaat.nl/mensen/michaela-mattheus/","name":"Michaela Mattheus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2020/01/07/hypoglykemie-cv-uitkomsten-en-empagliflozine-empa-reg-outcome/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2018/01/09/empagliflozine-bij-diabetes-type-2-met-cardiovasculaire-ziekte-en-ckd-empa-reg-o/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2016/07/28/empagliflozine-en-progressie-van-nierziekte-bij-diabetes-type-2-nejm-empa-reg-re/","published":"2016-07-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michel-jadoul","type":"person","url":"https://hartvaat.nl/mensen/michel-jadoul/","name":"Michel Jadoul","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/25/kdigo-overzicht-de-nier-centraal-in-het-cardiovasculair-renaal-metabool-ckm-synd/","published":"2026-05-31"},{"url":"https://hartvaat.nl/2026/03/03/kdigo-versnelt-richtlijnontwikkeling-voor-nierziekten/","published":"2026-03-27"},{"url":"https://hartvaat.nl/2026/03/06/kdigo-consensusconferentie-uitdagingen-bij-gecombineerd-hartfalen-en-nierziekte/","published":"2026-03-15"},{"url":"https://hartvaat.nl/2026/02/24/effecten-van-micro-en-nanoplastics-op-de-nieren/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2026/02/18/groene-dialyse-duurzame-zorg-groei-en-innovatie-kdigo-conferentie/","published":"2026-02-18"},{"url":"https://hartvaat.nl/2025/10/07/relatie-tussen-obesitas-en-ckd-conclusies-van-een-kdigo-conferentie/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2020/05/01/bloeddruk-en-volumemanagement-bij-dialyse-kdigo-controverseconferentie/","published":"2020-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michela-casella","type":"person","url":"https://hartvaat.nl/mensen/michela-casella/","name":"Michela Casella","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/06/02/catheterablatie-bij-atriumfibrilleren-in-cardiale-amyloidose-levert-42-ritmievri/","published":"2026-08-11"},{"url":"https://hartvaat.nl/2026/04/13/intracardiale-echocardiografie-in-de-elektrofysiologie-gezamenlijk-ehra-eapci-st/","published":"2026-05-23"},{"url":"https://hartvaat.nl/2026/03/17/athena-register-pulsed-field-ablatie-voor-atriumfibrilleren-ook-effectief-bij-ha/","published":"2026-04-20"},{"url":"https://hartvaat.nl/2026/02/26/fluoroscopieminimalisatie-bij-svt-ablatie-door-vrouwelijke-elektrofysiologen/","published":"2026-04-06"},{"url":"https://hartvaat.nl/2026/02/24/colchicine-bij-chronische-inflammatoire-cardiomyopathie-de-cmp-mythic-trial/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2016/11/01/linker-hartoorisolatie-bij-langdurig-persisterend-af-de-belief-trial/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/26/ablatie-versus-amiodaron-bij-persisterend-af-met-hartfalen-en-icd-gerandomiseerd/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michele-emdin","type":"person","url":"https://hartvaat.nl/mensen/michele-emdin/","name":"Michele Emdin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/06/22/cardiale-amyloidose-komt-frequent-voor-bij-hfpef-aortastenose-en-lvh-meta-analys/","published":"2026-08-10"},{"url":"https://hartvaat.nl/2026/05/05/sterftecijfers-in-controle-armen-van-hartfalen-rcts-dalen-niet-ondanks-betere-ac/","published":"2026-07-30"},{"url":"https://hartvaat.nl/2026/05/19/lipoproteine-aferese-blijft-relevant-in-het-tijdperk-van-pcsk9-remmers-en-sirna/","published":"2026-06-12"},{"url":"https://hartvaat.nl/2026/03/17/langetermijneffecten-van-sacubitril-valsartan-bij-hfref-italiaanse-real-world-st/","published":"2026-03-17"},{"url":"https://hartvaat.nl/2018/05/01/crt-voordeel-bij-concordant-versus-discordant-linksbundeltakblok-esc-hf-pilot/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/01/16/hoog-sensitief-troponine-t-bij-chronisch-hartfalen-individuele-patientdata-meta-/","published":"2018-01-16"},{"url":"https://hartvaat.nl/2017/09/12/centrale-apneus-gedurende-24-uur-en-prognose-bij-hartfalen/","published":"2017-09-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"natalie-a-bello","type":"person","url":"https://hartvaat.nl/mensen/natalie-a-bello/","name":"Natalie A Bello","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2018/02/01/nauwkeurigheid-van-bloeddrukmeters-in-de-zwangerschap-systematische-review/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/01/01/intensieve-versus-standaard-bloeddrukcontrole-op-ambulante-bloeddruk-sprint-resu/","published":"2017-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicholas-collins","type":"person","url":"https://hartvaat.nl/mensen/nicholas-collins/","name":"Nicholas Collins","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/05/02/determinanten-van-medicatietrouw-na-acs-secundaire-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2024/12/16/scoff-nuchter-versus-niet-nuchter-voor-hartkatheterisatie-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2022/07/01/behandeling-van-acuut-coronair-syndroom-in-ruraal-australie-moracs-trial/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/05/10/sms-voor-medicatietrouw-en-secundaire-preventie-na-acs-textmeds/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2021/11/09/colchicine-na-acs-2-jaars-cops-follow-up/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2021/07/01/camkii-delta-remming-en-ventriculaire-remodellering-na-mi-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/11/17/colchicine-bij-acs-australische-cops-gerandomiseerde-trial/","published":"2020-11-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicholas-j-lembo","type":"person","url":"https://hartvaat.nl/mensen/nicholas-j-lembo/","name":"Nicholas J Lembo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/07/31/bnp-bij-linker-hoofdstamrevascularisatie-excel-analyse/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicolas-meneveau","type":"person","url":"https://hartvaat.nl/mensen/nicolas-meneveau/","name":"Nicolas Meneveau","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/07/08/amulet-versus-watchman-flx-driejaarsresultaten-laa-sluiting/","published":"2025-07-08"},{"url":"https://hartvaat.nl/2025/07/01/calcified-oct-versus-angiografie-bij-pci-van-verkalkte-laesies/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","published":"2024-02-06"},{"url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2017/09/14/pfo-sluiting-of-antistolling-versus-antiplaatjestherapie-na-cva-nejm-reduce/","published":"2017-09-14"},{"url":"https://hartvaat.nl/2016/09/27/oct-geleide-pci-optimalisatie-bij-nste-acs-gerandomiseerde-trial/","published":"2016-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nils-witt","type":"person","url":"https://hartvaat.nl/mensen/nils-witt/","name":"Nils Witt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2018/08/01/zuurstoftherapie-bij-stemi-overzichtsartikel/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2017/09/28/zuurstoftherapie-bij-vermoedelijk-acuut-myocardinfarct-nejm-deto2x-ami/","published":"2017-09-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"odd-erik-johansen","type":"person","url":"https://hartvaat.nl/mensen/odd-erik-johansen/","name":"Odd Erik Johansen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2020/01/07/hypoglykemie-cv-uitkomsten-en-empagliflozine-empa-reg-outcome/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2019/03/12/empagliflozine-vermindert-mortaliteit-en-hf-hospitalisatie-over-het-cv-risicospe/","published":"2019-03-12"},{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/02/01/empagliflozine-en-cv-dood-en-hf-hospitalisatie-over-het-hf-spectrum-empa-reg-out/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/12/01/empagliflozine-en-bloeddruk-bij-diabetes-type-2-met-hypertensie-naar-achtergrond/","published":"2016-12-01"},{"url":"https://hartvaat.nl/2016/07/28/empagliflozine-en-progressie-van-nierziekte-bij-diabetes-type-2-nejm-empa-reg-re/","published":"2016-07-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pamela-s-douglas","type":"person","url":"https://hartvaat.nl/mensen/pamela-s-douglas/","name":"Pamela S Douglas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/02/03/klinische-risicopredictie-ct-coronairangiografie-en-cv-events-bij-nieuwe-angina/","published":"2025-02-03"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/08/24/reprieve-pitavastatine-vermindert-cv-events-bij-hiv-nejm/","published":"2023-08-24"},{"url":"https://hartvaat.nl/2020/06/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-acs-trials-jama-cardiology/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2019/03/05/inspanningstest-versus-ccta-bij-diabetes-met-verdenking-coronairlijden/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2017/11/21/coronair-calcium-en-prognostische-waarde-bij-pijn-op-de-borst-promise-studie/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2016/08/16/bio-absorbeerbare-intracoronaire-matrix-ter-preventie-van-ventriculaire-remodell/","published":"2016-08-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paolo-sganzerla","type":"person","url":"https://hartvaat.nl/mensen/paolo-sganzerla/","name":"Paolo Sganzerla","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/06/05/verlaagde-dosis-prasugrel-versus-standaard-clopidogrel-bij-oudere-acs-patienten/","published":"2018-06-05"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2016/02/02/ciclosporine-a-bij-gereperfuseerd-myocardinfarct-de-multicenter-cycle-trial/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pascal-motreff","type":"person","url":"https://hartvaat.nl/mensen/pascal-motreff/","name":"Pascal Motreff","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-laagrisico-acuut-mi/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2021/11/09/ffr-voor-behandeling-van-multivatencoronairlijden-jacc/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/09/27/oct-geleide-pci-optimalisatie-bij-nste-acs-gerandomiseerde-trial/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/04/26/vroege-aldosteronblokkade-bij-acuut-myocardinfarct-de-albatross-trial/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-leeson","type":"person","url":"https://hartvaat.nl/mensen/paul-leeson/","name":"Paul Leeson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/11/01/bloeddrukzelfmanagement-en-vasculaire-remodelling-na-hypertensieve-zwangerschap/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/02/13/pop-ht-bloeddrukzelfmanagement-verbetert-cardiale-remodelling-na-hypertensieve-z/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2023/11/28/pop-ht-zelfmanagement-van-bloeddruk-na-hypertensieve-zwangerschap-jama-rct/","published":"2023-11-28"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-bloeddrukcontrole-bij-risicozwangerschap-jama-bump-2/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2018/08/01/zelfmanagement-van-postnatale-hypertensie-de-snap-ht-trial/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2016/07/01/bewegingsadvies-als-behandeling-van-prehypertensie-en-hypertensie-bij-jongvolwas/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-welsh","type":"person","url":"https://hartvaat.nl/mensen/paul-welsh/","name":"Paul Welsh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/03/31/laaggedoseerde-alteplase-bij-primaire-pci-naar-ischemietijd/","published":"2020-03-31"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/11/27/metabolome-consequenties-van-pcsk9-remming-versus-statinetherapie/","published":"2018-11-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pavel-osmancik","type":"person","url":"https://hartvaat.nl/mensen/pavel-osmancik/","name":"Pavel Osmančík","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/26/pfa-sham-pulsed-field-ablatie-verslaat-sham-procedure-overtuigend-bij-atriumfibr/","published":"2026-07-02"},{"url":"https://hartvaat.nl/2025/07/22/cooperative-pfa-driearmige-gerandomiseerde-trial-van-pfa-versus-rf-versus-cryo/","published":"2025-07-22"},{"url":"https://hartvaat.nl/2025/07/08/catheterablatie-versus-leefstijlmodificatie-plus-antiaritmica-bij-af-gerandomise/","published":"2025-07-08"},{"url":"https://hartvaat.nl/2024/02/01/sequentiele-hybride-ablatie-versus-chirurgische-cryomaze-bij-af-met-structurele-/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2022/01/04/4-jaars-laa-sluiting-versus-niet-warfarine-oac-bij-af/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2020/12/08/laa-sluiting-versus-oac-bij-af-meta-analyse-van-gerandomiseerde-trials/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/06/30/laa-sluiting-versus-doac-bij-hoogrisico-af-vergelijkende-analyse/","published":"2020-06-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"per-johanson","type":"person","url":"https://hartvaat.nl/mensen/per-johanson/","name":"Per Johanson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2020/11/01/klinische-toepassing-van-hs-troponine-in-het-ascvd-raamwerk-jama-cardiology/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"perry-m-elliott","type":"person","url":"https://hartvaat.nl/mensen/perry-m-elliott/","name":"Perry M Elliott","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/03/06/laminopathieen-natuurlijk-beloop-en-voorspelmodel-voor-hartfalen/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2026/03/05/aficamten-veilig-en-effectief-bij-langdurige-behandeling-van-obstructieve-hcm/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2024/01/01/tafamidis-en-cardiale-functie-bij-attr-cm-post-hoc-attr-act-analyse/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2019/10/01/beeldvorming-bij-cardiale-amyloidose-diagnostische-prestatie-meta-analyse/","published":"2019-10-01"},{"url":"https://hartvaat.nl/2019/03/01/trimetazidine-bij-niet-obstructieve-hcm-jama-cardiology-gerandomiseerde-trial/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/09/13/tafamidis-bij-transthyretine-amyloid-cardiomyopathie-nejm-attr-act/","published":"2018-09-13"},{"url":"https://hartvaat.nl/2016/10/01/katheterablatie-bij-af-met-hypertrofische-cardiomyopathie-systematische-review-e/","published":"2016-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"petar-m-seferovic","type":"person","url":"https://hartvaat.nl/mensen/petar-m-seferovic/","name":"Petar M Seferovic","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2026/02/23/immunoadsorptie-bij-gedilateerde-cardiomyopathie-de-iaso-dcm-trial/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/12/01/economische-ziektelast-van-hartfalen-in-europa-systematische-review/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/06/14/euroheart-datastandaarden-voor-hartfalenregistraties/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-l-j-wijngaard","type":"person","url":"https://hartvaat.nl/mensen/peter-l-j-wijngaard/","name":"Peter L J Wijngaard","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2020/04/16/inclisiran-bij-heterozygote-familiaire-hypercholesterolemie-nejm-orion-9/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-fase-3-bij-verhoogd-ldl-nejm-orion-10-en-orion-11/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2019/11/01/inclisiran-1-of-2-dosis-en-ldl-cholesterol-orion-1-1-jaarsfollow-up/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2018/09/25/sirna-tegen-pcsk9-en-atherogene-lipoproteinen-orion-1-secundaire-eindpunten/","published":"2018-09-25"},{"url":"https://hartvaat.nl/2018/09/01/hdl-mimeticum-met-recombinant-apoa-i-milano-en-coronairlijden-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/04/13/inclisiran-bij-patienten-met-hoog-cv-risico-en-verhoogd-ldl-nejm-orion-1/","published":"2017-04-13"},{"url":"https://hartvaat.nl/2017/01/05/inclisiran-een-langwerkende-rna-interferentie-pcsk9-remmer-nejm/","published":"2017-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-verhamme","type":"person","url":"https://hartvaat.nl/mensen/peter-verhamme/","name":"Peter Verhamme","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2024/05/16/annexa-i-andexanet-alfa-bij-factor-xa-remmer-geassocieerde-intracerebrale-bloedi/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2021/01/01/rivaroxaban-plus-aspirine-bij-symptomatisch-pav-compass-subanalyse/","published":"2021-01-01"},{"url":"https://hartvaat.nl/2018/08/01/2018-ehra-praktische-gids-doac-s-bij-af-europace-editie/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/04/21/2018-ehra-praktische-gids-voor-doac-gebruik-bij-af/","published":"2018-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ply-chichareon","type":"person","url":"https://hartvaat.nl/mensen/ply-chichareon/","name":"Ply Chichareon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/04/23/hedendaagse-uitkomsten-na-cabg-voor-hoofdstamlijden/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"poornima-sood","type":"person","url":"https://hartvaat.nl/mensen/poornima-sood/","name":"Poornima Sood","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/07/14/guide-hf-en-de-impact-van-covid-19-op-hartfalenuitkomsten/","published":"2022-07-14"},{"url":"https://hartvaat.nl/2021/09/11/hemodynamisch-geleid-hf-management-lancet-guide-hf/","published":"2021-09-11"},{"url":"https://hartvaat.nl/2020/04/01/lvad-gebruik-als-bridge-to-transplant-versus-destination-therapy-momentum-3/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2018/10/30/zorggebruik-en-kosten-in-momentum-3-langetermijnstudie/","published":"2018-10-30"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/05/23/hemocompatibiliteitsuitkomsten-van-heartmate-3-na-6-maanden-momentum-3/","published":"2017-05-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-mathew-s-maurer","type":"person","url":"https://hartvaat.nl/mensen/prof-mathew-s-maurer/","name":"Prof. Mathew S. Maurer","title":"Hoogleraar cardiologie, Columbia University Irving Medical Center, New York, VS","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":1,"articles":[{"url":"https://hartvaat.nl/2025/01/01/stijging-van-serum-transthyretine-na-tafamidis-voorspelt-betere-overleving-bij-a/","published":"2026-03-01"}],"videos":[{"url":"https://hartvaat.nl/video/hfa-2026-late-breaking-science/cardio-ttransform-deep-dive-maurer/","title":"CARDIO-TTRansform — Studieopzet en baseline-karakteristieken"},{"url":"https://hartvaat.nl/video/hfa-2026-late-breaking-science/cardio-ttransform-peer-to-peer-maurer-davis/","title":"CARDIO-TTRansform peer-to-peer — Silencer- versus stabilisator-therapie"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rajesh-k-kharbanda","type":"person","url":"https://hartvaat.nl/mensen/rajesh-k-kharbanda/","name":"Rajesh K Kharbanda","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","published":"2019-10-19"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"raul-d-santos","type":"person","url":"https://hartvaat.nl/mensen/raul-d-santos/","name":"Raul D Santos","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/25/eas-consensus-familiaire-hypercholesterolemie-bij-kinderen-en-adolescenten/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2020/10/01/evolocumab-bij-pediatrische-heterozygoot-fh-nejm-hauser-rct/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"},{"url":"https://hartvaat.nl/2017/04/20/ldl-reductievariabiliteit-en-antilichaamvorming-bij-bococizumab-nejm/","published":"2017-04-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ravinay-bhindi","type":"person","url":"https://hartvaat.nl/mensen/ravinay-bhindi/","name":"Ravinay Bhindi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2022/05/10/sms-voor-medicatietrouw-en-secundaire-preventie-na-acs-textmeds/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2021/11/09/colchicine-na-acs-2-jaars-cops-follow-up/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2020/11/17/colchicine-bij-acs-australische-cops-gerandomiseerde-trial/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"raymond-tukkie","type":"person","url":"https://hartvaat.nl/mensen/raymond-tukkie/","name":"Raymond Tukkie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/08/21/pa-drukmonitoring-bij-chronisch-hartfalen-effecten-over-klinische-subgroepen/","published":"2024-08-21"},{"url":"https://hartvaat.nl/2022/07/15/race-3-langetermijnresultaten-gerichte-behandeling-bij-vroeg-persisterend-af-en-/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2022/03/02/frequentiecontrolemiddelen-verschillen-in-preventie-van-af-progressie/","published":"2022-03-02"},{"url":"https://hartvaat.nl/2020/02/01/verpleegkundig-geleide-versus-standaard-af-zorg/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/04/01/pr-interval-en-pacingmodus-en-af-incidentie-bij-tweekamer-pacemaker/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2019/04/01/upstream-therapie-verbetert-qol-bij-persisterend-af-arrest-af/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/08/21/behandeling-van-onderliggende-aandoeningen-verbetert-sinusritme-na-af-arrest-af/","published":"2018-08-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"renato-h-n-santos","type":"person","url":"https://hartvaat.nl/mensen/renato-h-n-santos/","name":"Renato H N Santos","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/02/01/message-hf-geautomatiseerde-sms-na-hartfalenopname-verbetert-uitkomsten-niet/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2020/11/26/rivaroxaban-bij-af-met-bioprothese-mitralisklep-nejm-river/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/03/01/bariatrische-chirurgie-versus-medicamenteus-beleid-op-24-uurs-ambulante-bloeddru/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/11/01/timing-van-atorvastatine-oplaaddosis-voor-pci-bij-acs-jama-cardiology/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/04/03/oplaaddosis-atorvastatine-voor-pci-jama-gerandomiseerde-trial/","published":"2018-04-03"},{"url":"https://hartvaat.nl/2018/03/13/bariatrische-chirurgie-bij-obese-patienten-met-hypertensie-gateway-gerandomiseer/","published":"2018-03-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"richard-haynes","type":"person","url":"https://hartvaat.nl/mensen/richard-haynes/","name":"Richard Haynes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2019/07/01/kosteneffectiviteit-van-statines-en-ezetimibe-bij-chronische-nierziekte/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/10/18/omega-3-vetzuursupplementen-bij-diabetes-nejm-ascend-omega-3/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2018/10/18/aspirine-voor-primaire-preventie-bij-diabetes-nejm-ascend/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2018/10/09/sacubitril-valsartan-versus-irbesartan-bij-chronische-nierziekte/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2017/02/01/reverse-causality-in-de-associatie-bloeddruk-cardiovasculair-risico-bij-ckd/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-d-toto","type":"person","url":"https://hartvaat.nl/mensen/robert-d-toto/","name":"Robert D Toto","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/08/10/urine-albumine-en-natrium-hebben-prognostische-waarde-bij-hartfalen-experimentel/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2024/04/04/pragmatische-trial-van-hospitalisatieratio-bij-ckd-nejm/","published":"2024-04-04"},{"url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/03/31/dapagliflozine-en-mortaliteit-bij-ckd-dapa-ckd-pre-gespecificeerde-analyse/","published":"2021-03-31"},{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2016/08/01/apol1-nierrisicovarianten-en-cerebrale-wittestoflaesies/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"roland-richard-tilz","type":"person","url":"https://hartvaat.nl/mensen/roland-richard-tilz/","name":"Roland Richard Tilz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/20/stopstorm-stereotactische-bestraling-reduceert-refractaire-vt-met-80/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2024/12/17/ablatiestrategie-bij-af-recidief-na-duurzame-pvi/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/05/02/style-af-veneuze-closure-device-versus-figuur-van-acht-hechting-na-af-ablatie/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2022/07/15/geindividualiseerde-versus-standaard-cryoballonablatie-bij-paroxysmaal-af/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2021/10/09/gewichtsverlies-voor-af-ablatie-sort-af-gerandomiseerde-trial/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2021/05/21/firm-ablatie-versus-pvi-bij-paroxysmaal-af-gerandomiseerde-resultaten/","published":"2021-05-21"},{"url":"https://hartvaat.nl/2019/09/24/interne-versus-externe-cardioversie-bij-atriale-aritmieen-met-icd/","published":"2019-09-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ron-blankstein","type":"person","url":"https://hartvaat.nl/mensen/ron-blankstein/","name":"Ron Blankstein","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2025/07/01/bestaande-cv-data-benutten-voor-hypertensiedetectie-en-behandeling-vital-trial/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2016/08/02/omega-3-vetzuren-en-linkerkamerremodellering-na-acuut-mi-omega-remodel-trial/","published":"2016-08-02"}],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/implementatie-lipidenmanagement/","title":"Sessie 4: Implementatie van lipidenmanagement — praktische uitdagingen"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ronald-aronson","type":"person","url":"https://hartvaat.nl/mensen/ronald-aronson/","name":"Ronald Aronson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/03/25/antitrombotische-therapie-bij-af-na-acs-pci-augustus-gecombineerde-inzichten/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2024/09/03/augustus-4-weg-vergelijking-antitrombotische-strategieen-bij-af-na-acs-pci/","published":"2024-09-03"},{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2022/02/08/antitrombotische-therapie-bij-af-na-acs-of-pci-jacc-overzicht/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"samer-mansour","type":"person","url":"https://hartvaat.nl/mensen/samer-mansour/","name":"Samer Mansour","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sandeep-brar","type":"person","url":"https://hartvaat.nl/mensen/sandeep-brar/","name":"Sandeep Brar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2022/10/22/symplicity-htn-3-langetermijn-follow-up-renale-denervatie-bij-resistente-hyperte/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2018/06/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-6-maandsresultat/","published":"2018-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sang-ho-jo","type":"person","url":"https://hartvaat.nl/mensen/sang-ho-jo/","name":"Sang-Ho Jo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/01/lage-dosis-tel-aml-chtd-combinatietablet-versus-standaard-tel-fase-iii/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","published":"2025-11-08"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/10/17/antiplaatjesmonotherapie-na-pci-clopidogrel-versus-aspirine-naar-risicoprofiel/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","published":"2022-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"scott-s-emerson","type":"person","url":"https://hartvaat.nl/mensen/scott-s-emerson/","name":"Scott S Emerson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/08/18/semaglutide-verlaagt-hscrp-en-ontstekingsactiviteit-bij-ascvd-patienten-met-over/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","published":"2025-05-29"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","published":"2024-08-24"},{"url":"https://hartvaat.nl/2023/12/14/select-semaglutide-vermindert-cv-events-bij-obesitas-zonder-diabetes-nejm/","published":"2023-12-14"},{"url":"https://hartvaat.nl/2017/08/24/degludec-versus-glargine-bij-diabetes-type-2-nejm-devote-werkzaamheid-en-veiligh/","published":"2017-08-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"serge-boveda","type":"person","url":"https://hartvaat.nl/mensen/serge-boveda/","name":"Serge Boveda","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/03/aanbesteding-van-cardiale-implanteerbare-devices-in-europa-waarde-of-kosten/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/10/31/pfa-versus-thermale-ablatie-periprocedurale-en-middellangetermijneffecten/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2024/12/03/pfa-versus-cryoballon-voor-af-ablatie-multielectrode-vergelijking/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2022/01/04/enkele-freeze-cryoballonablatie-bij-af-ehra-systematische-review/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2020/06/01/trends-in-plotse-hartdood-bij-hf-met-crt-systematische-review/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2018/03/01/doodsoorzaken-bij-crt-met-en-zonder-defibrillator-meta-analyse/","published":"2018-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shahar-lavi","type":"person","url":"https://hartvaat.nl/mensen/shahar-lavi/","name":"Shahar Lavi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shmuel-chen","type":"person","url":"https://hartvaat.nl/mensen/shmuel-chen/","name":"Shmuel Chen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/07/31/bnp-bij-linker-hoofdstamrevascularisatie-excel-analyse/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sonia-s-anand","type":"person","url":"https://hartvaat.nl/mensen/sonia-s-anand/","name":"Sonia S Anand","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2023/12/12/voyager-pad-rivaroxaban-plus-aspirine-na-endovasculaire-revascularisatie-voor-pa/","published":"2023-12-12"},{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/01/01/rivaroxaban-plus-aspirine-bij-symptomatisch-pav-compass-subanalyse/","published":"2021-01-01"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2016/08/01/digitale-gezondheidsinterventie-voor-cardiovasculaire-risicoverlaging-gerandomis/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefan-stortecky","type":"person","url":"https://hartvaat.nl/mensen/stefan-stortecky/","name":"Stefan Stortecky","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neoatherosclerose-na-stemi-secundaire-analyse/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/08/01/biodegradeerbare-versus-duurzame-polymeer-ees-langetermijn-neoatherosclerose/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2021/10/01/paroxetine-grk2-remming-versus-placebo-bij-anterieur-mi-jama-cardiology/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2019/10/05/biodegradeerbare-versus-duurzame-polymer-des-bij-stemi-gerandomiseerde-trial/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2016/12/01/tienjaarsuitkomsten-van-eerste-generatie-drug-eluting-stents-ses-versus-pes/","published":"2016-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefanie-schupke","type":"person","url":"https://hartvaat.nl/mensen/stefanie-schupke/","name":"Stefanie Schüpke","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefano-corda","type":"person","url":"https://hartvaat.nl/mensen/stefano-corda/","name":"Stefano Corda","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/05/05/vericiguat-en-sgc-stimulatoren-bij-hartfalen-werkingsmechanisme-en-plaats-na-vic/","published":"2026-06-26"},{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/12/01/geografische-variatie-in-hfref-patientkenmerken-en-behandeling/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/04/01/vericiguat-voordeel-geprojecteerd-op-paradigm-hf-en-dapa-hf-populaties/","published":"2025-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefano-del-prato","type":"person","url":"https://hartvaat.nl/mensen/stefano-del-prato/","name":"Stefano Del Prato","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2024/07/09/selectieve-aldosereductaseremmer-bij-diabetische-cardiomyopathie-rct/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2023/08/08/glp-1-agonisten-met-en-zonder-sglt2-remmers-bij-type-2-diabetes-jacc-analyse/","published":"2023-08-08"},{"url":"https://hartvaat.nl/2023/03/28/amplitude-o-dosisrespons-van-efpeglenatide-op-cv-uitkomsten-bij-diabetes/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2021/11/13/tirzepatide-versus-insuline-glargine-bij-diabetes-type-2-met-hoog-cv-risico-lanc/","published":"2021-11-13"},{"url":"https://hartvaat.nl/2021/09/02/efpeglenatide-en-cv-en-renale-uitkomsten-bij-diabetes-type-2-nejm-amplitude-o/","published":"2021-09-02"},{"url":"https://hartvaat.nl/2018/10/27/albiglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-harmony-ou/","published":"2018-10-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephan-baldus","type":"person","url":"https://hartvaat.nl/mensen/stephan-baldus/","name":"Stephan Baldus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/03/25/palliatieve-zorg-in-de-cardiologie-een-state-of-the-art-overzicht/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/08/20/tadalafil-bij-gecombineerde-post-en-precapillaire-ph-en-hfpef/","published":"2024-08-20"},{"url":"https://hartvaat.nl/2023/03/21/coronairangiografie-na-hartstilstand-zonder-stemi-netwerk-meta-analyse/","published":"2023-03-21"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/09/24/interne-versus-externe-cardioversie-bij-atriale-aritmieen-met-icd/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2017/04/01/oscillerende-whole-body-vibratie-verbetert-inspanningscapaciteit-bij-pah/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephan-von-haehling","type":"person","url":"https://hartvaat.nl/mensen/stephan-von-haehling/","name":"Stephan von Haehling","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/02/01/finerenon-en-lvh-bij-ckd-en-diabetes/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/10/05/iv-ferricarboxymaltose-en-inspanningscapaciteit-bij-hfpef-met-ijzerdeficientie/","published":"2024-10-05"},{"url":"https://hartvaat.nl/2022/07/26/empag-hf-vroege-empagliflozine-bij-acuut-hartfalen-verbetert-diurese/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/12/01/ijzercarboxymaltose-bij-ijzerdeficient-hartfalen-meta-analyse/","published":"2020-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steven-a-lubitz","type":"person","url":"https://hartvaat.nl/mensen/steven-a-lubitz/","name":"Steven A Lubitz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/10/stressor-geassocieerd-af-incidentie-risicofactoren-en-uitkomsten/","published":"2026-02-10"},{"url":"https://hartvaat.nl/2024/11/19/screening-op-niet-gediagnosticeerd-af-voor-cva-preventie-gerandomiseerde-trial/","published":"2024-11-19"},{"url":"https://hartvaat.nl/2022/03/29/af-screening-bij-ouderen-in-de-huisartsenpraktijk-vital-af-gerandomiseerde-trial/","published":"2022-03-29"},{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/02/25/genetische-risicoscore-voorspelt-voordeel-van-evolocumab-fourier/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2017/02/21/genetische-obesitas-en-risico-op-atriumfibrilleren-mendeliaanse-randomisatie/","published":"2017-02-21"},{"url":"https://hartvaat.nl/2016/04/01/orale-antistolling-bij-atriumfibrilleren-over-het-spectrum-van-beroerterisico-ga/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steven-e-mcnulty","type":"person","url":"https://hartvaat.nl/mensen/steven-e-mcnulty/","name":"Steven E McNulty","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/08/01/gdf-15-en-liraglutide-behandeling-bij-hf-patienten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2018/12/01/liraglutide-en-gewicht-bij-gevorderd-hfref-fight-trial-inzichten/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/05/16/oraal-ijzer-bij-hfref-met-ijzerdeficientie-jama-ironout-hf/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/08/02/liraglutide-en-klinische-stabiliteit-bij-gevorderd-hartfalen-met-verminderde-ef-/","published":"2016-08-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steven-p-marso","type":"person","url":"https://hartvaat.nl/mensen/steven-p-marso/","name":"Steven P Marso","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2020/03/17/liraglutide-cv-uitkomsten-bij-diabetes-met-of-zonder-hartfalen-leader/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-cv-uitkomsten-met-of-zonder-eerder-mi-leader/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2018/05/15/liraglutide-bij-diabetes-type-2-met-polyvasculaire-ziekte-leader-analyse/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2017/09/28/exenatide-eenmaal-per-week-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-ne/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/08/24/degludec-versus-glargine-bij-diabetes-type-2-nejm-devote-werkzaamheid-en-veiligh/","published":"2017-08-24"},{"url":"https://hartvaat.nl/2016/11/10/semaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-sustain-6/","published":"2016-11-10"},{"url":"https://hartvaat.nl/2016/07/28/liraglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-leader-trial/","published":"2016-07-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"suzanne-de-waha-thiele","type":"person","url":"https://hartvaat.nl/mensen/suzanne-de-waha-thiele/","name":"Suzanne de Waha-Thiele","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2023/03/28/culprit-interventie-bij-cardiogene-shock-met-hartstilstand/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/04/21/morfine-met-metoclopramide-en-ticagrelor-plaatjesremming-bij-acuut-mi/","published":"2020-04-21"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/01/22/milde-hypothermie-bij-cardiogene-shock-complicerend-mi/","published":"2019-01-22"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sylvain-losdat","type":"person","url":"https://hartvaat.nl/mensen/sylvain-losdat/","name":"Sylvain Losdat","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","published":"2026-04-09"},{"url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neoatherosclerose-na-stemi-secundaire-analyse/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/08/01/biodegradeerbare-versus-duurzame-polymeer-ees-langetermijn-neoatherosclerose/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2023/11/25/biodegradeerbare-versus-duurzame-polymeer-des-bij-stemi-langetermijndata/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2019/10/05/biodegradeerbare-versus-duurzame-polymer-des-bij-stemi-gerandomiseerde-trial/","published":"2019-10-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sren-hjberg","type":"person","url":"https://hartvaat.nl/mensen/sren-hjberg/","name":"Søren Højberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/01/20/af-screening-naar-genetisch-risico-loop-subanalyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/12/15/hypokaliemie-en-af-gedetecteerd-door-implanteerbare-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2025/12/15/circadiaanse-patronen-van-af-en-ziekteprogressie-via-implanted-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2023/06/13/loop-substudie-nt-probnp-verbetert-af-screeningsopbrengst/","published":"2023-06-13"},{"url":"https://hartvaat.nl/2022/09/01/bloeddruk-beinvloedt-opbrengst-van-af-screening-loop-substudie/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2020/05/12/ritme-monitoringstrategieen-voor-af-screening-uitgebreide-evaluatie/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2019/12/03/natuurlijk-beloop-van-subklinisch-af-gedetecteerd-door-implanteerbare-looprecord/","published":"2019-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sren-zoga-diederichsen","type":"person","url":"https://hartvaat.nl/mensen/sren-zoga-diederichsen/","name":"Søren Zöga Diederichsen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/12/15/hypokaliemie-en-af-gedetecteerd-door-implanteerbare-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2025/12/15/circadiaanse-patronen-van-af-en-ziekteprogressie-via-implanted-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2023/06/13/loop-substudie-nt-probnp-verbetert-af-screeningsopbrengst/","published":"2023-06-13"},{"url":"https://hartvaat.nl/2022/09/01/bloeddruk-beinvloedt-opbrengst-van-af-screening-loop-substudie/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2020/05/12/ritme-monitoringstrategieen-voor-af-screening-uitgebreide-evaluatie/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2019/12/03/natuurlijk-beloop-van-subklinisch-af-gedetecteerd-door-implanteerbare-looprecord/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/07/01/qt-als-voorspeller-van-af-recidief-na-ablatie-en-amiodaronimpact-amio-cat/","published":"2019-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-cuisset","type":"person","url":"https://hartvaat.nl/mensen/thomas-cuisset/","name":"Thomas Cuisset","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-laagrisico-acuut-mi/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2021/08/24/de-escalatie-van-dapt-bij-acs-jacc-review/","published":"2021-08-24"},{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/11/14/timing-van-angiografie-bij-hoogrisico-nstemi-acuity-analyse/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/11/01/switchen-van-dapt-na-acs-de-topic-trial/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-h-marwick","type":"person","url":"https://hartvaat.nl/mensen/thomas-h-marwick/","name":"Thomas H Marwick","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2024/09/16/langetermijn-hartfalenrisico-bij-volwassen-kankeroverlevenden-meta-analyse/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2024/07/09/selectieve-aldosereductaseremmer-bij-diabetische-cardiomyopathie-rct/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/06/01/bloeddrukverlaging-bij-centrale-hypertensie-gerandomiseerde-trial/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2022/04/09/natriumreductie-100-mmol-bij-hartfalen-lancet-sodium-hf/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/10/01/niet-invasieve-technieken-en-biomarkers-voor-poliklinisch-vochtmanagement-bij-hf/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/04/01/lv-longitudinale-systolische-functieparameters-als-voorspellers-bij-hfpef/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2016/10/25/aldosteronantagonisme-en-inspanningstolerantie-bij-hfpef/","published":"2016-10-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thompson-g-robinson","type":"person","url":"https://hartvaat.nl/mensen/thompson-g-robinson/","name":"Thompson G Robinson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2024/05/30/right-2-ambulancebloeddrukverlaging-bij-hyperacuut-cva-nejm-vervolgresultaten/","published":"2024-05-30"},{"url":"https://hartvaat.nl/2024/05/16/annexa-i-andexanet-alfa-bij-factor-xa-remmer-geassocieerde-intracerebrale-bloedi/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2022/11/05/enchanted2-mt-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-is-schadelij/","published":"2022-11-05"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"},{"url":"https://hartvaat.nl/2017/05/01/voortzetten-of-tijdelijk-stoppen-van-antihypertensiva-bij-acuut-cva-ipd-meta-ana/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","published":"2016-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thorsten-lewalter","type":"person","url":"https://hartvaat.nl/mensen/thorsten-lewalter/","name":"Thorsten Lewalter","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2020/12/14/edoxaban-bij-af-met-pci-naar-acute-versus-chronische-coronaire-presentatie-entru/","published":"2020-12-14"},{"url":"https://hartvaat.nl/2019/12/07/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-veiligheid-en-werk/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2019/10/12/edoxaban-versus-vka-gebaseerd-antitrombotisch-regime-na-stenting-bij-af-lancet-e/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/06/07/dagelijkse-telemonitoring-van-icd-s-gepoolde-analyse-van-drie-gerandomiseerde-tr/","published":"2017-06-07"},{"url":"https://hartvaat.nl/2017/01/01/percutane-linker-hartoorsluiting-munchen-consensusdocument-over-definities-en-ei/","published":"2017-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"toru-kondo","type":"person","url":"https://hartvaat.nl/mensen/toru-kondo/","name":"Toru Kondo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2019/10/01/neuromusculaire-elektrische-stimulatie-bij-acuut-hartfalen-haalbaarheid/","published":"2019-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ulrich-p-jorde","type":"person","url":"https://hartvaat.nl/mensen/ulrich-p-jorde/","name":"Ulrich P Jorde","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/23/aspirinestop-bij-lvad-met-vka-veiligheidsanalyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/06/10/triluminate-tweejaarsresultaten-transcatheter-tr-repair-duurzaam-effectief/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/03/01/aspirine-en-hemocompatibiliteit-na-lvad-bij-atherosclerotisch-vaatlijden/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2023/05/18/triluminate-transcatheter-tricuspidaliskleprepair-bij-ernstige-tr-nejm/","published":"2023-05-18"},{"url":"https://hartvaat.nl/2019/01/08/cva-analyse-in-momentum-3-langetermijncohort/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","published":"2017-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vasileios-panoulas","type":"person","url":"https://hartvaat.nl/mensen/vasileios-panoulas/","name":"Vasileios Panoulas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"veronica-j-alexander","type":"person","url":"https://hartvaat.nl/mensen/veronica-j-alexander/","name":"Veronica J Alexander","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","published":"2025-10-02"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-hypertriglyceridemie-en-hoog-cv-risico-nejm/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-familiaire-chylomicronemie-nejm-fase-3/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2019/09/01/galnac-geconjugeerd-antisense-tegen-apoc3-triglyceriden-en-atherogene-lipoprotei/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/08/volanesorsen-en-triglyceriden-bij-familiair-chylomicronemiesyndroom-nejm/","published":"2019-08-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"viveka-frykman","type":"person","url":"https://hartvaat.nl/mensen/viveka-frykman/","name":"Viveka Frykman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/11/25/abc-af-risicoscores-voor-gepersonaliseerde-af-behandeling/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2024/12/03/nt-probnp-en-ecg-screening-bij-75-jarigen-voor-af-detectie-rct/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2023/01/14/strokestop-af-screening-is-kosteneffectief-bij-75-76-jarigen/","published":"2023-01-14"},{"url":"https://hartvaat.nl/2021/10/23/systematische-af-screening-en-klinische-uitkomsten-lancet-strokestop/","published":"2021-10-23"},{"url":"https://hartvaat.nl/2020/01/01/stapsgewijze-af-screening-met-nt-probnp-strokestop-ii-resultaten/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2017/08/01/nt-probnp-bij-systematische-screening-op-atriumfibrilleren/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/02/01/stapsgewijze-massascreening-op-af-met-nt-probnp-strokestop-ii-studieontwerp/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"walter-t-ambrosius","type":"person","url":"https://hartvaat.nl/mensen/walter-t-ambrosius/","name":"Walter T Ambrosius","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2021/04/01/intensieve-versus-standaard-bloeddruk-op-cva-subtypes-sprint/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/06/01/intensieve-bloeddrukverlaging-en-risico-op-af-sprint-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2018/06/01/intensieve-versus-standaard-bloeddruk-naar-tertielen-in-sprint/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/08/01/intensieve-bloeddrukverlaging-en-linkerventrikelhypertrofie-sprint-echocardiogra/","published":"2017-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"weon-kim","type":"person","url":"https://hartvaat.nl/mensen/weon-kim/","name":"Weon Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/01/lage-dosis-tel-aml-chtd-combinatietablet-versus-standaard-tel-fase-iii/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/09/06/directe-versus-gestageerde-complete-revascularisatie-tijdens-index-opname-bij-st/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2023/05/02/korte-versus-standaard-dapt-na-pci-met-moderne-des-meta-analyse/","published":"2023-05-02"},{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","published":"2022-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"william-b-white","type":"person","url":"https://hartvaat.nl/mensen/william-b-white/","name":"William B White","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/12/01/hoog-versus-laag-natrium-oxybaat-en-bloeddruk-bij-narcolepsie/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2019/11/12/intensieve-versus-standaard-ambulante-bloeddrukcontrole-en-cerebrovasculaire-uit/","published":"2019-11-12"},{"url":"https://hartvaat.nl/2019/10/26/patiromer-voor-spironolactongebruik-bij-resistente-hypertensie-met-ckd-lancet-am/","published":"2019-10-26"},{"url":"https://hartvaat.nl/2019/04/09/sham-gecontroleerde-rct-s-van-renale-denervatie-meta-analyse/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/11/01/therapieresistente-hypertensie-aha-scientific-statement-over-detectie-evaluatie-/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/05/16/serieel-hoog-sensitief-troponine-i-en-cv-uitkomsten-bij-diabetes-type-2-examine/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/09/01/ace-remmers-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-met-dpp-4-remmers/","published":"2016-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"william-g-herrington","type":"person","url":"https://hartvaat.nl/mensen/william-g-herrington/","name":"William G Herrington","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2019/07/01/kosteneffectiviteit-van-statines-en-ezetimibe-bij-chronische-nierziekte/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/10/09/sacubitril-valsartan-versus-irbesartan-bij-chronische-nierziekte/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2017/02/01/reverse-causality-in-de-associatie-bloeddruk-cardiovasculair-risico-bij-ckd/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"y-joseph-woo","type":"person","url":"https://hartvaat.nl/mensen/y-joseph-woo/","name":"Y Joseph Woo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2020/03/24/screening-en-profylactisch-amiodaron-vermindert-postoperatief-af/","published":"2020-03-24"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yang-wang","type":"person","url":"https://hartvaat.nl/mensen/yang-wang/","name":"Yang Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/04/01/intensieve-bloeddrukcontrole-en-cognitieve-functie-gerandomiseerde-trial/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/03/01/lichaamsbeweging-beinvloedt-de-relatie-tussen-crp-triglyceriden-en-coronaire-ath/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/01/01/gedeeltelijke-cardiale-denervatie-voorkomt-af-na-cabg-rct/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2022/07/27/veiligheid-van-pcsk9-remmers-systematische-review-en-meta-analyse/","published":"2022-07-27"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2020/02/01/geschatte-cva-vrije-overleving-van-foliumzuurtherapie-bij-hypertensie-csppt/","published":"2020-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yu-ling-yu","type":"person","url":"https://hartvaat.nl/mensen/yu-ling-yu/","name":"Yu-Ling Yu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":7,"articles":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2023/04/01/lichaamshouding-en-orthostatische-hypotensie-bij-hypertensie-syst-eur-analyse/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adel-r-rizkala","type":"person","url":"https://hartvaat.nl/mensen/adel-r-rizkala/","name":"Adel R Rizkala","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2017/04/14/systolische-bloeddruk-en-werkzaamheid-van-sacubitril-valsartan-bij-chronisch-hfr/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2016/06/07/klinische-verslechtering-van-poliklinisch-behandeld-hartfalen-paradigm-hf-analys/","published":"2016-06-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adrian-d-elliott","type":"person","url":"https://hartvaat.nl/mensen/adrian-d-elliott/","name":"Adrian D Elliott","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2025/12/01/arrest-af-agressieve-risicofactorreductie-en-ablatie-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2022/09/01/af-voorspelt-cognitieve-achteruitgang-meta-analyse-van-2-8-miljoen-personen/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2018/11/01/uitkomsten-van-ablatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/04/21/subklinisch-device-gedetecteerd-af-en-cva-risico-meta-analyse/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2017/12/01/geintegreerde-zorg-bij-atriumfibrilleren-systematische-review-en-meta-analyse/","published":"2017-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alan-j-moskowitz","type":"person","url":"https://hartvaat.nl/mensen/alan-j-moskowitz/","name":"Alan J Moskowitz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alasdair-gray","type":"person","url":"https://hartvaat.nl/mensen/alasdair-gray/","name":"Alasdair Gray","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/11/risicostratificatie-met-hoog-sensitief-troponine-op-de-seh-veiligheidsanalyse/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2017/11/21/hoog-sensitief-troponine-i-en-uitkomsten-bij-verdenking-acs-jama-studie/","published":"2017-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alastair-m-gray","type":"person","url":"https://hartvaat.nl/mensen/alastair-m-gray/","name":"Alastair M Gray","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/01/05/leeftijd-en-10-jaarsuitkomsten-na-cabg-art-trial/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/06/postoperatief-af-en-langetermijn-cva-risico-na-geisoleerde-cabg/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2019/07/01/kosteneffectiviteit-van-statines-en-ezetimibe-bij-chronische-nierziekte/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/01/31/bilaterale-versus-enkele-mammaria-interna-grafts-na-10-jaar-nejm-art/","published":"2019-01-31"},{"url":"https://hartvaat.nl/2017/08/01/radiale-arterie-graft-als-aanvulling-op-mammaria-interna-grafts-bij-cabg/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/12/29/bilaterale-versus-enkelvoudige-a-mammaria-interna-grafts-nejm-art-trial/","published":"2016-12-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alberto-menozzi","type":"person","url":"https://hartvaat.nl/mensen/alberto-menozzi/","name":"Alberto Menozzi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2017/02/01/cangrelor-versus-gpiib-iiia-remmers-ischemie-en-bloedingsrisico-s-vergeleken/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2017/01/17/cangrelor-met-en-zonder-gpiib-iiia-remmers-bij-pci/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alberto-ortiz","type":"person","url":"https://hartvaat.nl/mensen/alberto-ortiz/","name":"Alberto Ortiz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/31/era-s-abcde-raamwerk-voor-preventie-van-nierziekten/","published":"2026-03-31"},{"url":"https://hartvaat.nl/2026/02/25/de-mondiale-ziektelast-van-chronische-nierziekte-elke-20-seconden-een-sterfgeval/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2026/02/09/communicatie-tussen-nier-en-hart-via-extracellulaire-vesikels/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2026/01/24/oproep-tot-actie-europese-trials-nodig-tegen-tsunami-van-nierfalen/","published":"2026-01-24"},{"url":"https://hartvaat.nl/2026/01/15/populatiegebaseerde-egfr-verdelingen-voor-vroege-identificatie-van-chronische-ni/","published":"2026-01-15"},{"url":"https://hartvaat.nl/2026/01/02/albuminurie-en-cardiovasculair-risico-gemiste-kans-in-de-2025-esc-eas-dyslipidem/","published":"2026-01-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexander-c-fanaroff","type":"person","url":"https://hartvaat.nl/mensen/alexander-c-fanaroff/","name":"Alexander C Fanaroff","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/05/01/apothekerverwijzingen-voor-statine-start-twee-cluster-rct-s/","published":"2025-05-01"},{"url":"https://hartvaat.nl/2024/09/03/augustus-4-weg-vergelijking-antitrombotische-strategieen-bij-af-na-acs-pci/","published":"2024-09-03"},{"url":"https://hartvaat.nl/2022/02/08/antitrombotische-therapie-bij-af-na-acs-of-pci-jacc-overzicht/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2020/05/01/zelfgerapporteerde-versus-apotheekgeregistreerde-medicatietrouw-compass-analyse/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/01/01/p2y12-copay-reductie-en-therapietrouw-aan-andere-secundaire-preventiemiddelen/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2017/05/09/ranolazine-na-incomplete-pci-bij-diabetes-versus-zonder-diabetes-river-pci/","published":"2017-05-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexander-romanov","type":"person","url":"https://hartvaat.nl/mensen/alexander-romanov/","name":"Alexander Romanov","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/02/22/temporaire-ruggenmergstimulatie-ter-preventie-van-postoperatief-af/","published":"2022-02-22"},{"url":"https://hartvaat.nl/2021/03/08/katheterablatie-om-af-progressie-te-vertragen-attest-gerandomiseerde-trial/","published":"2021-03-08"},{"url":"https://hartvaat.nl/2020/08/25/pulmonale-arterie-denervatie-bij-residuele-ph-na-endarterectomie/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2017/03/21/plotse-hartdood-bij-ischemisch-hartfalen-na-cabg-stich-resultaten/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2016/11/01/tienjaarsuitkomsten-na-cabg-naar-leeftijd-bij-hartfalen-met-lv-systolische-disfu/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexandra-n-nowbar","type":"person","url":"https://hartvaat.nl/mensen/alexandra-n-nowbar/","name":"Alexandra N Nowbar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/19/coronaire-flowreserve-en-cardiovasculaire-uitkomsten-meta-analyse/","published":"2022-04-19"},{"url":"https://hartvaat.nl/2021/09/21/bijwerkingspatronen-in-crossover-trial-statine-placebo-geen-behandeling-statinwi/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2020/11/26/n-of-1-trial-van-statine-placebo-of-geen-behandeling-voor-bijwerkingen-nejm-stat/","published":"2020-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amanda-hunter","type":"person","url":"https://hartvaat.nl/mensen/amanda-hunter/","name":"Amanda Hunter","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2020/05/05/laag-attenuatie-plaque-op-ccta-voorspelt-mi-scot-heart-resultaten/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/01/29/coronaire-plaquekenmerken-en-adverse-uitkomsten-scot-heart/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","published":"2018-09-06"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/04/19/ct-coronairangiografie-voor-het-sturen-van-beleid-bij-coronairlijden/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amer-joseph","type":"person","url":"https://hartvaat.nl/mensen/amer-joseph/","name":"Amer Joseph","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/12/01/finerenon-bloeddrukeffecten-en-cardiorenale-uitkomsten-bij-ckd-en-diabetes/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/02/10/finerenon-cv-en-renale-uitkomsten-bij-diabetes-met-ckd-fidelity-gepoolde-analyse/","published":"2022-02-10"},{"url":"https://hartvaat.nl/2022/02/08/finerenon-vermindert-incident-hf-bij-ckd-met-diabetes-fidelity/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/12/09/finerenon-bij-nierziekte-met-diabetes-type-2-nejm-figaro-dkd/","published":"2021-12-09"},{"url":"https://hartvaat.nl/2021/07/13/finerenon-vermindert-nieuw-onset-af-bij-ckd-met-diabetes-fidelio-dkd/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/02/09/finerenon-en-cardiovasculaire-uitkomsten-bij-ckd-met-diabetes-type-2-fidelio-dkd/","published":"2021-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andre-lamy","type":"person","url":"https://hartvaat.nl/mensen/andre-lamy/","name":"Andre Lamy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/08/vision-postoperatief-atriumfibrilleren-na-hartchirurgie-verhoogt-sterfte-na-een-/","published":"2026-07-15"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","published":"2021-06-03"},{"url":"https://hartvaat.nl/2018/02/13/richtlijngetrouwe-medicamenteuze-therapie-in-contemporaine-revascularisatietrial/","published":"2018-02-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrea-m-russo","type":"person","url":"https://hartvaat.nl/mensen/andrea-m-russo/","name":"Andrea M Russo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/07/zorgpaden-na-nieuw-vastgesteld-atriumfibrilleren-rol-van-de-elektrofysioloog-en-/","published":"2026-07-18"},{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2022/03/15/leeftijd-en-uitkomsten-van-katheterablatie-versus-medicatie-bij-af-cabana/","published":"2022-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrea-scalise","type":"person","url":"https://hartvaat.nl/mensen/andrea-scalise/","name":"Andrea Scalise","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrei-carvalho-sposito","type":"person","url":"https://hartvaat.nl/mensen/andrei-carvalho-sposito/","name":"Andrei Carvalho Sposito","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/08/14/dapagliflozin-verlaagt-serum-klotho-bij-dialysepatienten-zonder-effect-op-botbio/","published":"2026-08-22"},{"url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2023/04/01/aspirine-in-primaire-preventie-en-hartfalenrisico-meta-analyse/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2021/06/01/serumkalium-en-prognose-bij-symptomatisch-hf/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2018/04/03/oplaaddosis-atorvastatine-voor-pci-jama-gerandomiseerde-trial/","published":"2018-04-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-e-moran","type":"person","url":"https://hartvaat.nl/mensen/andrew-e-moran/","name":"Andrew E Moran","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/10/28/prevent-vergelijkingen-voor-intensieve-versus-standaard-bloeddrukcontrole/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2023/06/01/team-based-care-bij-hypertensie-meta-analyse-bevestigt-effectiviteit-en-kostenef/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/01/01/farmacologische-hypertensiebehandeling-bij-volwassenen-who-richtlijn-samenvattin/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/04/27/patientselectie-voor-intensieve-bloeddrukbehandeling-naar-voordeel-en-bijwerking/","published":"2021-04-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-t-yan","type":"person","url":"https://hartvaat.nl/mensen/andrew-t-yan/","name":"Andrew T Yan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/06/01/igfbp7-en-lv-massaregressie-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/nlr-en-cardiale-remodelling-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/diabetesduur-beinvloedt-lv-massaregressie-met-empagliflozine/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2021/03/01/objectieve-risicobeoordeling-versus-standaardzorg-bij-acs-jama-cardiology/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2019/11/19/empagliflozine-en-lv-massa-bij-diabetes-type-2-met-coronairlijden-empa-heart/","published":"2019-11-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrzej-wiecek","type":"person","url":"https://hartvaat.nl/mensen/andrzej-wiecek/","name":"Andrzej Więcek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/08/21/scd-bij-ckd-en-dialyse-heterogene-aritmieen-en-mechanisme-gestuurde-preventie/","published":"2026-08-29"},{"url":"https://hartvaat.nl/2026/02/09/communicatie-tussen-nier-en-hart-via-extracellulaire-vesikels/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-niet-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/12/01/longechogeleide-behandeling-bij-hemodialysepatienten-met-hoog-cv-risico-gerandom/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2017/02/01/reverse-causality-in-de-associatie-bloeddruk-cardiovasculair-risico-bij-ckd/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andre-d-avila","type":"person","url":"https://hartvaat.nl/mensen/andre-d-avila/","name":"André d'Avila","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/09/01/sedatie-versus-narcose-bij-af-catheterablatie-meta-analyse/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/07/02/pfa-versus-thermale-ablatie-bij-paroxysmaal-af-aritmielastanalyse/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/10/01/terminatie-van-persisterend-af-tijdens-pvi-inzichten-uit-magic-af/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/05/21/stapsgewijze-ablatie-gestuurd-door-laaggedoseerd-ibutilide-bij-chronisch-af-magi/","published":"2016-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ankeet-s-bhatt","type":"person","url":"https://hartvaat.nl/mensen/ankeet-s-bhatt/","name":"Ankeet S Bhatt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/30/kp-chemo-cumulatieve-incidentie-cancer-therapy-related-cardiac-dysfunction-8-4-h/","published":"2026-07-02"},{"url":"https://hartvaat.nl/2025/01/01/nudge-flu-subanalyse-griepvaccinatie-nudges-bij-mi-langetermijn/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2024/05/27/nudge-flu-elektronische-nudges-verhogen-griepvaccinatie-na-mi/","published":"2024-05-27"},{"url":"https://hartvaat.nl/2021/12/01/sacubitril-valsartan-uitgebreide-fda-labeling-jama-cardiology-implicaties/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","published":"2021-04-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anne-s-hellkamp","type":"person","url":"https://hartvaat.nl/mensen/anne-s-hellkamp/","name":"Anne S Hellkamp","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2020/07/28/langetermijn-icd-uitkomsten-scd-heft/","published":"2020-07-28"},{"url":"https://hartvaat.nl/2016/08/01/hospitalisaties-bij-atriumfibrilleren-analyse-uit-rocket-af/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/07/05/verslechterende-nierfunctie-en-uitkomsten-met-rivaroxaban-versus-warfarine-rocke/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/07/01/natief-kleplijden-bij-af-patienten-op-warfarine-of-rivaroxaban/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/01/26/langketen-acylcarnitines-bij-hartfalen-prognostische-waarde-en-reversibiliteit-m/","published":"2016-01-26"},{"url":"https://hartvaat.nl/2016/01/26/polyfarmacie-en-werkzaamheid-van-rivaroxaban-versus-warfarine-bij-atriumfibrille/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"annetine-c-gelijns","type":"person","url":"https://hartvaat.nl/mensen/annetine-c-gelijns/","name":"Annetine C Gelijns","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antoine-kimmoun","type":"person","url":"https://hartvaat.nl/mensen/antoine-kimmoun/","name":"Antoine Kimmoun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/02/01/matige-hypothermie-versus-normothermie-bij-cardiogene-shock-met-va-ecmo-jama-hyp/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2018/07/10/epinefrine-versus-norepinefrine-bij-cardiogene-shock-na-acuut-mi/","published":"2018-07-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antonino-di-franco","type":"person","url":"https://hartvaat.nl/mensen/antonino-di-franco/","name":"Antonino Di Franco","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/12/04/posterieure-pericardiotomie-ter-preventie-van-af-na-hartchirurgie-lancet-palacs/","published":"2021-12-04"},{"url":"https://hartvaat.nl/2021/01/05/leeftijd-en-10-jaarsuitkomsten-na-cabg-art-trial/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/07/14/radiale-arterie-versus-vena-saphena-graft-bij-cabg-jama-langetermijn-meta-analys/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2017/03/14/drie-arteriele-grafts-verbeteren-langetermijnoverleving-meta-analyse-van-propens/","published":"2017-03-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antonio-popolo-rubbio","type":"person","url":"https://hartvaat.nl/mensen/antonio-popolo-rubbio/","name":"Antonio Popolo Rubbio","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/16/pandora-register-supra-versus-intra-annulaire-kleppen-bij-tavr-in-tavr/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2022/10/01/mitraclip-bij-secundaire-mitralisklepinsufficientie-meta-analyse-ischemisch-vs-n/","published":"2022-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"arian-sultan","type":"person","url":"https://hartvaat.nl/mensen/arian-sultan/","name":"Arian Sultan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/14/ulysses-echogeleide-venapunctie-halveert-toegangscomplicaties-bij-af-ablatie/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","published":"2026-05-27"},{"url":"https://hartvaat.nl/2025/05/07/hoog-vermogen-korte-duur-rf-ablatie-versus-cryoballon-bij-paroxysmaal-af-rct/","published":"2025-05-07"},{"url":"https://hartvaat.nl/2024/12/17/ablatiestrategie-bij-af-recidief-na-duurzame-pvi/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2021/10/09/gewichtsverlies-voor-af-ablatie-sort-af-gerandomiseerde-trial/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2019/09/24/interne-versus-externe-cardioversie-bij-atriale-aritmieen-met-icd/","published":"2019-09-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aris-moschovitis","type":"person","url":"https://hartvaat.nl/mensen/aris-moschovitis/","name":"Aris Moschovitis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2019/07/01/lokale-hemodynamische-krachten-en-fenotype-van-coronaire-plaques/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2016/12/01/tienjaarsuitkomsten-van-eerste-generatie-drug-eluting-stents-ses-versus-pes/","published":"2016-12-01"},{"url":"https://hartvaat.nl/2016/10/01/langere-versus-korte-dapt-na-pci-met-en-zonder-periprocedureel-mi-jama-cardiolog/","published":"2016-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"arthur-j-moss","type":"person","url":"https://hartvaat.nl/mensen/arthur-j-moss/","name":"Arthur J Moss","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2018/05/01/crt-voordeel-bij-concordant-versus-discordant-linksbundeltakblok-esc-hf-pilot/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/11/01/klinische-presentatie-bij-eerste-hartfalenhospitalisatie-voorspelt-geen-heropnam/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/01/budapest-crt-upgrade-study-studieontwerp-voor-crt-upgrade/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/05/16/comorbiditeiten-en-crt-respons-madit-crt-langetermijnfollow-up/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/09/20/volledig-linkszijdig-reverse-remodelling-bij-crt-madit-crt-substudie/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/01/26/relatieve-wanddikte-en-risico-op-ventriculaire-tachyaritmieen-bij-linkerkamerdis/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"axel-haupt","type":"person","url":"https://hartvaat.nl/mensen/axel-haupt/","name":"Axel Haupt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/05/03/solbinsiran-langwerkend-sirna-tegen-angptl3-duurzaamheid-en-effectiviteit/","published":"2025-05-03"},{"url":"https://hartvaat.nl/2025/01/21/muvalaplin-orale-lp-a-verlaging-nejm-gerandomiseerde-trial/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2023/09/07/orforglipron-dagelijkse-orale-glp-1-agonist-bij-obesitas-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2023/08/12/retatrutide-triple-gip-glp-1-glucagonagonist-bij-type-2-diabetes-lancet-fase-2/","published":"2023-08-12"},{"url":"https://hartvaat.nl/2022/11/26/triple-gip-glp-1-glucagonreceptoragonist-bij-type-2-diabetes-fase-1b/","published":"2022-11-26"},{"url":"https://hartvaat.nl/2018/11/17/ly3298176-duale-gip-glp-1-agonist-bij-diabetes-type-2-lancet-tirzepatide-fase-2/","published":"2018-11-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"barry-greenberg","type":"person","url":"https://hartvaat.nl/mensen/barry-greenberg/","name":"Barry Greenberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/03/07/mesenchymale-precursorcellen-bij-hfref-gerandomiseerde-trial/","published":"2023-03-07"},{"url":"https://hartvaat.nl/2019/12/01/hepatorenale-disfunctie-identificeert-hoogrisico-acuut-hf-relax-ahf/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/11/21/rivaroxaban-en-cva-tia-bij-hf-met-coronairlijden-en-sinusritme-commander-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/06/01/rivaroxaban-en-trombo-embolische-events-bij-hf-met-coronairlijden-en-sinusritme-/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/10/04/rivaroxaban-bij-hartfalen-met-sinusritme-en-coronairlijden-nejm-commander-hf/","published":"2018-10-04"},{"url":"https://hartvaat.nl/2016/03/19/serca2a-gentherapie-bij-hartfalen-de-cupid-2-trial/","published":"2016-03-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bent-raungaard","type":"person","url":"https://hartvaat.nl/mensen/bent-raungaard/","name":"Bent Raungaard","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bernard-thibault","type":"person","url":"https://hartvaat.nl/mensen/bernard-thibault/","name":"Bernard Thibault","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/06/03/multipoint-pacing-vermindert-hf-hospitalisaties-en-sterfte-bij-crt-non-responder/","published":"2025-06-03"},{"url":"https://hartvaat.nl/2024/01/18/raft-langetermijn-crt-d-bij-hartfalen-nejm-14-jaarsresultaten/","published":"2024-01-18"},{"url":"https://hartvaat.nl/2023/10/05/more-crt-mpp-multipoint-pacing-bij-crt-non-responders/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2019/09/14/crt-non-responder-naar-responder-conversie-more-crt-mpp/","published":"2019-09-14"},{"url":"https://hartvaat.nl/2017/04/01/aanvullende-elektroden-op-de-quartet-lv-lead-bieden-meer-crt-programmeringsmogel/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/07/14/ablatie-versus-escalatie-van-antiaritmica-bij-ventriculaire-tachycardie-nejm-van/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bertil-lindahl","type":"person","url":"https://hartvaat.nl/mensen/bertil-lindahl/","name":"Bertil Lindahl","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/04/18/abyss-betablokkers-na-mi-met-behouden-ef-niet-nodig-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2019/01/12/visualisatie-van-asymptomatische-atherosclerose-voor-cv-preventie-lancet-vipviza/","published":"2019-01-12"},{"url":"https://hartvaat.nl/2018/12/11/langetermijneffecten-van-zuurstof-op-sterfte-of-hf-hospitalisatie-na-verdenking-/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/08/01/zuurstoftherapie-bij-stemi-overzichtsartikel/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/09/28/zuurstoftherapie-bij-vermoedelijk-acuut-myocardinfarct-nejm-deto2x-ami/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2016/10/15/vroeg-invasief-versus-conservatief-bij-nste-acs-15-jaarsfollow-up-frisc-ii/","published":"2016-10-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bin-wang","type":"person","url":"https://hartvaat.nl/mensen/bin-wang/","name":"Bin Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/26/intensieve-bloeddrukbehandeling-en-cognitieve-functie-een-gerandomiseerde-klinis/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/04/01/intensieve-bloeddrukcontrole-en-cognitieve-functie-gerandomiseerde-trial/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukverlaging-en-retinale-microvasculatuur/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/01/07/dcb-voor-zijtak-bij-provisionale-stenting-gerandomiseerde-trial/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/06/01/opt-birisk-clopidogrel-monotherapie-bij-acs-met-hoog-ischemisch-en-bloedingsrisi/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2016/03/01/taurinesuppletie-verlaagt-bloeddruk-en-verbetert-vaatfunctie-bij-prehypertensie/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"binita-shah","type":"person","url":"https://hartvaat.nl/mensen/binita-shah/","name":"Binita Shah","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","published":"2019-02-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bo-yu","type":"person","url":"https://hartvaat.nl/mensen/bo-yu/","name":"Bo Yu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/12/gdmt-na-functioneel-complete-revascularisatie-prognostische-impact/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2024/10/21/shensong-yangxin-voorkomt-af-recidief-na-ablatie-bij-persisterend-af/","published":"2024-10-21"},{"url":"https://hartvaat.nl/2024/09/24/colchicine-en-coronaire-plaquestabiliteit-na-acs-oct-studie/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2021/05/21/katheterablatie-versus-medicatie-bij-persisterend-en-langdurig-persisterend-af-l/","published":"2021-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"boris-schmidt","type":"person","url":"https://hartvaat.nl/mensen/boris-schmidt/","name":"Boris Schmidt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/14/ulysses-echogeleide-venapunctie-halveert-toegangscomplicaties-bij-af-ablatie/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2025/10/31/pfa-versus-thermale-ablatie-periprocedurale-en-middellangetermijneffecten/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2025/04/03/laa-sluiting-na-af-ablatie-gerandomiseerde-trial-nejm/","published":"2025-04-03"},{"url":"https://hartvaat.nl/2025/03/25/amulet-ide-vijfjaarsresultaten-laa-occlusie-met-amulet/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2024/12/17/ablatiestrategie-bij-af-recidief-na-duurzame-pvi/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2018/08/01/linker-hartoorisolatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bruce-m-psaty","type":"person","url":"https://hartvaat.nl/mensen/bruce-m-psaty/","name":"Bruce M Psaty","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/07/25/omega-3-biomarkers-en-incident-af-ipd-analyse/","published":"2023-07-25"},{"url":"https://hartvaat.nl/2022/08/01/hele-genoomsequencing-onthult-nieuwe-bloeddruk-loci/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/06/01/geisoleerde-diastolische-hypertensie-cohort-en-meta-analyse-voor-behandeldrempel/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/09/22/sekse-specifieke-cv-risicofactoren-en-biomarkers-bij-incident-hartfalen/","published":"2020-09-22"},{"url":"https://hartvaat.nl/2019/08/20/dna-methylering-in-leukocyten-voorspelt-mi-en-coronairlijden/","published":"2019-08-20"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bruno-r-nascimento","type":"person","url":"https://hartvaat.nl/mensen/bruno-r-nascimento/","name":"Bruno R Nascimento","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2024/12/01/korte-dapt-na-des-bij-acs-ipd-meta-analyse-bevestigt-veiligheid/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2023/10/31/antitrombotische-therapie-na-laa-occlusie-netwerk-meta-analyse/","published":"2023-10-31"},{"url":"https://hartvaat.nl/2022/11/01/vip-acs-dubbele-dosis-griepvaccinatie-na-acs-verbetert-uitkomsten-niet/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2019/01/01/implementatie-van-mi-zorgsystemen-in-lage-en-middeninkomenslanden/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/04/03/oplaaddosis-atorvastatine-voor-pci-jama-gerandomiseerde-trial/","published":"2018-04-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"caihua-sang","type":"person","url":"https://hartvaat.nl/mensen/caihua-sang/","name":"Caihua Sang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","published":"2022-10-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"camilla-hage","type":"person","url":"https://hartvaat.nl/mensen/camilla-hage/","name":"Camilla Hage","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/06/27/frailte-versnelt-hartfalenprogressie-en-vermindert-therapietolerantie/","published":"2026-08-04"},{"url":"https://hartvaat.nl/2026/04/09/prefers-stockholm-nieuw-ontstaan-hfpef-heeft-slechtere-langetermijnuitkomsten-da/","published":"2026-07-19"},{"url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2024/02/01/acyl-ghreline-verbetert-cardiac-output-met-behoud-van-rv-pa-koppeling-bij-hf/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/06/09/acyl-ghreline-verbetert-hartfunctie-bij-hartfalen/","published":"2023-06-09"},{"url":"https://hartvaat.nl/2018/06/01/hemodynamische-effecten-van-levosimendan-bij-gevorderd-stabiel-chronisch-hartfal/","published":"2018-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carl-e-schotborgh","type":"person","url":"https://hartvaat.nl/mensen/carl-e-schotborgh/","name":"Carl E Schotborgh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2023/04/08/biovasc-directe-versus-gestageerde-complete-revascularisatie-bij-acs-met-meervat/","published":"2023-04-08"},{"url":"https://hartvaat.nl/2019/07/01/uitkomsten-van-des-in-kleine-coronairen-naar-strutdikte-jama-cardiology-meta-ana/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/10/06/resolute-onyx-versus-orsiro-stent-lancet-gerandomiseerde-non-inferioriteitstrial/","published":"2018-10-06"},{"url":"https://hartvaat.nl/2017/03/30/ffr-geleide-multivaten-pci-bij-myocardinfarct-nejm-compare-acute/","published":"2017-03-30"},{"url":"https://hartvaat.nl/2016/11/26/ultradunne-biodegradeerbare-versus-duurzame-polymer-des-lancet-gerandomiseerde-t/","published":"2016-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carmen-a-peralta","type":"person","url":"https://hartvaat.nl/mensen/carmen-a-peralta/","name":"Carmen A Peralta","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2016/02/09/intensieve-versus-standaard-bloeddrukcontrole-en-nierfunctie-na-lacunair-herseni/","published":"2016-02-09"},{"url":"https://hartvaat.nl/2016/01/01/bereikte-bloeddruk-en-uitkomsten-in-de-sps3-trial-bij-lacunaire-herseninfarcten/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chenxi-jiang","type":"person","url":"https://hartvaat.nl/mensen/chenxi-jiang/","name":"Chenxi Jiang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","published":"2022-10-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chenyang-jiang","type":"person","url":"https://hartvaat.nl/mensen/chenyang-jiang/","name":"Chenyang Jiang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/05/driejaarsuitkomsten-van-linker-hartoorsluiting-met-of-zonder-ablatie-record-stud/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/12/09/nieuw-bifasisch-pfa-systeem-versus-thermale-ablatie-bij-paroxysmaal-af/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2024/10/21/shensong-yangxin-voorkomt-af-recidief-na-ablatie-bij-persisterend-af/","published":"2024-10-21"},{"url":"https://hartvaat.nl/2020/04/01/intraprocedurele-eindpunten-voor-duurzame-pvi-gerandomiseerde-trial-van-vier-tec/","published":"2020-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chinthanie-ramasundarahettige","type":"person","url":"https://hartvaat.nl/mensen/chinthanie-ramasundarahettige/","name":"Chinthanie Ramasundarahettige","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/24/laaos-iii-laa-occlusie-en-anticoagulatiegebruik/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2023/03/28/amplitude-o-dosisrespons-van-efpeglenatide-op-cv-uitkomsten-bij-diabetes/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2022/09/15/invictus-rivaroxaban-versus-warfarine-bij-reumatische-hartziekte-en-af/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2021/09/02/efpeglenatide-en-cv-en-renale-uitkomsten-bij-diabetes-type-2-nejm-amplitude-o/","published":"2021-09-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-besler","type":"person","url":"https://hartvaat.nl/mensen/christian-besler/","name":"Christian Besler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2020/03/01/slagvolumeveranderingen-na-renale-denervatie-cardiale-mri-inzichten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/08/01/renale-denervatie-bij-geisoleerde-systolische-hypertensie-vergelijking-van-kathe/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/01/29/drie-armen-vergelijkende-renale-denervatie-radiosound-htn/","published":"2019-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-ott","type":"person","url":"https://hartvaat.nl/mensen/christian-ott/","name":"Christian Ott","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/06/01/angiotensinepathways-onder-empagliflozine-bij-chronisch-hartfalen/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2021/12/01/empagliflozine-en-vaatfunctie-bij-chronisch-hf/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2017/12/01/centrale-iliacale-av-anastomose-bij-ongecontroleerde-hypertensie-rox-control-htn/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2017/11/21/sacubitril-valsartan-versus-olmesartan-en-cardiovasculaire-remodellering-bij-hyp/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2017/09/19/empagliflozine-en-vasculaire-functie-en-centrale-hemodynamiek-bij-diabetes-type-/","published":"2017-09-19"},{"url":"https://hartvaat.nl/2017/08/01/nauwkeurigheid-van-manchetbloeddrukmeting-systematische-review-en-meta-analyse/","published":"2017-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christiane-e-angermann","type":"person","url":"https://hartvaat.nl/mensen/christiane-e-angermann/","name":"Christiane E Angermann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/04/22/anemie-beinvloedt-ijzerhomeostase-en-empagliflozine-respons-bij-hf/","published":"2025-04-22"},{"url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2020/04/01/biomarkers-bij-hf-met-centrale-slaapapneu-serve-hf/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2018/09/22/telemedische-interventie-bij-hartfalen-lancet-tim-hf2/","published":"2018-09-22"},{"url":"https://hartvaat.nl/2016/06/28/escitalopram-bij-hartfalen-en-depressie-de-mood-hf-trial/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christoph-liebetrau","type":"person","url":"https://hartvaat.nl/mensen/christoph-liebetrau/","name":"Christoph Liebetrau","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-c-nessel","type":"person","url":"https://hartvaat.nl/mensen/christopher-c-nessel/","name":"Christopher C Nessel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2019/06/01/rivaroxaban-en-trombo-embolische-events-bij-hf-met-coronairlijden-en-sinusritme-/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/10/04/rivaroxaban-bij-hartfalen-met-sinusritme-en-coronairlijden-nejm-commander-hf/","published":"2018-10-04"},{"url":"https://hartvaat.nl/2016/08/01/hospitalisaties-bij-atriumfibrilleren-analyse-uit-rocket-af/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/07/05/verslechterende-nierfunctie-en-uitkomsten-met-rivaroxaban-versus-warfarine-rocke/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/07/01/natief-kleplijden-bij-af-patienten-op-warfarine-of-rivaroxaban/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/01/26/polyfarmacie-en-werkzaamheid-van-rivaroxaban-versus-warfarine-bij-atriumfibrille/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-e-kurtz","type":"person","url":"https://hartvaat.nl/mensen/christopher-e-kurtz/","name":"Christopher E Kurtz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2020/10/01/evolocumab-bij-pediatrische-heterozygoot-fh-nejm-hauser-rct/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/12/cognitie-na-ldl-verlaging-met-evolocumab-fourier-follow-up/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2019/07/01/evolocumab-en-totale-cv-events-bij-cardiovasculaire-ziekte-fourier-analyse/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/01/01/interindividuele-variatie-in-ldl-verlaging-met-evolocumab-fourier-analyse/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/08/21/klinisch-voordeel-van-evolocumab-naar-ernst-van-coronairlijden-fourier/","published":"2018-08-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chyke-a-doubeni","type":"person","url":"https://hartvaat.nl/mensen/chyke-a-doubeni/","name":"Chyke A Doubeni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","published":"2017-07-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"colin-baigent","type":"person","url":"https://hartvaat.nl/mensen/colin-baigent/","name":"Colin Baigent","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2019/07/01/kosteneffectiviteit-van-statines-en-ezetimibe-bij-chronische-nierziekte/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/10/18/omega-3-vetzuursupplementen-bij-diabetes-nejm-ascend-omega-3/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2018/10/18/aspirine-voor-primaire-preventie-bij-diabetes-nejm-ascend/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2018/10/09/sacubitril-valsartan-versus-irbesartan-bij-chronische-nierziekte/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2017/02/01/reverse-causality-in-de-associatie-bloeddruk-cardiovasculair-risico-bij-ckd/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"craig-granowitz","type":"person","url":"https://hartvaat.nl/mensen/craig-granowitz/","name":"Craig Granowitz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/01/03/icosapent-ethyl-en-cardiovasculaire-uitkomsten-bij-hypertriglyceridemie-nejm-red/","published":"2019-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cyril-camaro","type":"person","url":"https://hartvaat.nl/mensen/cyril-camaro/","name":"Cyril Camaro","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/02/therapietrouw-aan-lipidenverlagende-medicatie-na-pci-in-nederland/","published":"2026-03-28"},{"url":"https://hartvaat.nl/2025/11/11/ffr-geleide-complete-versus-culprit-only-revascularisatie-bij-nstemi/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2023/05/14/prehospitale-troponine-voor-uitsluiting-nste-acs-gerandomiseerde-trial/","published":"2023-05-14"},{"url":"https://hartvaat.nl/2021/12/01/thin-cap-fibroatheroom-voorspelt-events-bij-diabetes-met-normale-ffr-combine-oct/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/12/01/coronairangiografie-na-hartstilstand-zonder-st-elevatie-coact-1-jaarsuitkomsten/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/04/11/coronairangiografie-na-hartstilstand-zonder-st-elevatie-nejm-coact/","published":"2019-04-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dan-wichterle","type":"person","url":"https://hartvaat.nl/mensen/dan-wichterle/","name":"Dan Wichterle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/06/transseptale-punctie-bij-linkshartinterventies-nieuwe-esc-consensus-over-technie/","published":"2026-07-29"},{"url":"https://hartvaat.nl/2025/10/07/cti-blok-na-pfa-versus-rf-cryo-ablatie-gerandomiseerde-vergelijking/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2024/02/01/sequentiele-hybride-ablatie-versus-chirurgische-cryomaze-bij-af-met-structurele-/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2023/08/02/gerichte-lv-leadplaatsing-bij-crt-meta-analyse-van-beeldvorming-en-elektrisch-ge/","published":"2023-08-02"},{"url":"https://hartvaat.nl/2018/07/01/echogeleide-versus-conventionele-femorale-venepunctie-bij-af-ablatie-gerandomise/","published":"2018-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-a-jones","type":"person","url":"https://hartvaat.nl/mensen/daniel-a-jones/","name":"Daniel A Jones","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/12/01/dapagliflozine-na-mi-naar-ef-cardiometabole-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/07/12/nste-acs-na-cabg-meta-analyse-van-behandelstrategieen/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2024/05/13/nitrate-cin-nitraat-beschermt-tegen-contrastnefropathie-na-acs/","published":"2024-05-13"},{"url":"https://hartvaat.nl/2022/04/01/5-jaarsfollow-up-van-intracoronaire-celtherapie-na-mi-regenerate-ami/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2017/04/01/intracoronair-nitriet-onderdrukt-de-inflammatoire-respons-na-primaire-pci/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-i-sessler","type":"person","url":"https://hartvaat.nl/mensen/daniel-i-sessler/","name":"Daniel I Sessler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/12/02/geindividualiseerd-perioperatief-bloeddrukmanagement-bij-grote-buikchirurgie/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2025/09/23/intensief-versus-conventioneel-intraoperatief-bloeddrukmanagement-en-cv-events-n/","published":"2025-09-23"},{"url":"https://hartvaat.nl/2023/11/04/colchicine-vermindert-perioperatief-af-na-thoraxchirurgie-lancet-rct/","published":"2023-11-04"},{"url":"https://hartvaat.nl/2020/07/18/dexmedetomidine-voor-af-en-delier-na-hartchirurgie-lancet-decade/","published":"2020-07-18"},{"url":"https://hartvaat.nl/2018/06/09/dabigatran-bij-myocardschade-na-niet-cardiale-chirurgie-lancet-manage-trial/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/08/15/overleving-na-geisoleerde-postoperatieve-troponine-elevatie/","published":"2017-08-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-d-berg","type":"person","url":"https://hartvaat.nl/mensen/david-d-berg/","name":"David D Berg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2019/02/05/abc-scores-voor-cva-en-bloedingsrisico-bij-af-prestatieverbetering/","published":"2019-02-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dennis-h-lau","type":"person","url":"https://hartvaat.nl/mensen/dennis-h-lau/","name":"Dennis H Lau","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/12/01/arrest-af-agressieve-risicofactorreductie-en-ablatie-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2022/09/01/af-voorspelt-cognitieve-achteruitgang-meta-analyse-van-2-8-miljoen-personen/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/10/09/klinische-risicofactoren-voor-cva-bij-anticoagulantie-naieve-af-meta-analyse/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2018/11/01/uitkomsten-van-ablatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/04/21/subklinisch-device-gedetecteerd-af-en-cva-risico-meta-analyse/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2017/12/01/geintegreerde-zorg-bij-atriumfibrilleren-systematische-review-en-meta-analyse/","published":"2017-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"derek-j-hausenloy","type":"person","url":"https://hartvaat.nl/mensen/derek-j-hausenloy/","name":"Derek J Hausenloy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/07/09/cangrelor-en-infarctgrootte-bij-stemi-gerandomiseerde-trial/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2023/06/01/remote-ischemische-conditionering-bij-milde-hypertensie-zonder-medicatie-rct/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2021/07/01/remote-post-ontslag-behandeling-na-mi-door-paramedici-versus-standaardzorg-jama-/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","published":"2019-10-19"},{"url":"https://hartvaat.nl/2018/06/19/cardioprotectieve-therapieen-en-area-at-risk-bij-gereperfuseerd-stemi-cmr-analys/","published":"2018-06-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"deyong-long","type":"person","url":"https://hartvaat.nl/mensen/deyong-long/","name":"Deyong Long","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","published":"2022-10-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"didier-carrie","type":"person","url":"https://hartvaat.nl/mensen/didier-carrie/","name":"Didier Carrié","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/12/13/percutaan-herstel-of-medicamenteuze-therapie-bij-secundaire-mr-nejm-mitra-fr/","published":"2018-12-13"},{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/01/21/stoppen-of-doorgaan-met-clopidogrel-12-maanden-na-drug-eluting-stent-optidual-tr/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"diederick-e-grobbee","type":"person","url":"https://hartvaat.nl/mensen/diederick-e-grobbee/","name":"Diederick E Grobbee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2019/01/01/polypil-en-cardiovasculaire-preventie-meta-analyse-van-gerandomiseerde-trials/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2017/06/14/overschakelen-van-niet-selectieve-nsaid-s-naar-celecoxib-de-scot-trial/","published":"2017-06-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"domingo-a-pascual-figal","type":"person","url":"https://hartvaat.nl/mensen/domingo-a-pascual-figal/","name":"Domingo A Pascual-Figal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2024/12/01/colica-colchicine-bij-acuut-gedecompenseerd-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2023/02/01/diabetes-en-sacubitril-valsartan-titratie-bij-hartfalen-na-opname/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-purvi-parwani","type":"person","url":"https://hartvaat.nl/mensen/dr-purvi-parwani/","name":"Dr. Purvi Parwani","title":"Cardioloog, Loma Linda University, VS","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":0,"articles":[],"videos":[{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/between-sessions-champion-af-hi-peitho-stemi-dtu/","title":"Tussen de sessies: CHAMPION-AF, HI-PEITHO en STEMI-DTU samengevat"},{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/between-sessions-vesalius-kardinal-chip-bcis3/","title":"Tussen de sessies: VESALIUS-CV, KARDINAL, CHIP-BCIS3 en meer"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-sara-saberi","type":"person","url":"https://hartvaat.nl/mensen/dr-sara-saberi/","name":"Dr. Sara Saberi","title":"Expert erfelijke hart- en vaatziekten","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/01/01/aficamten-en-de-toekomst-van-obstructieve-hcm-behandeling/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/03/05/aficamten-veilig-en-effectief-bij-langdurige-behandeling-van-obstructieve-hcm/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","published":"2023-01-03"}],"videos":[{"url":"https://hartvaat.nl/video/cardiomyopathie-diagnose-hcm-saberi/diagnostiek-hypertrofische-cardiomyopathie/","title":"Diagnostiek van hypertrofische cardiomyopathie"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"emilia-bagiella","type":"person","url":"https://hartvaat.nl/mensen/emilia-bagiella/","name":"Emilia Bagiella","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2021/01/05/leeftijd-en-10-jaarsuitkomsten-na-cabg-art-trial/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eri-t-kato","type":"person","url":"https://hartvaat.nl/mensen/eri-t-kato/","name":"Eri T Kato","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","published":"2019-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eric-bruckert","type":"person","url":"https://hartvaat.nl/mensen/eric-bruckert/","name":"Eric Bruckert","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/06/24/inclisiran-bij-adolescenten-met-homozygote-fh-effectiviteit-en-veiligheid/","published":"2025-06-24"},{"url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2020/08/25/carotisatherosclerose-evolutie-bij-ldl-streefwaarde-70-na-ischemisch-cva-tst-sub/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/01/02/vergelijking-van-twee-ldl-streefwaarden-na-ischemisch-cva-nejm-tst/","published":"2020-01-02"},{"url":"https://hartvaat.nl/2019/08/08/volanesorsen-en-triglyceriden-bij-familiair-chylomicronemiesyndroom-nejm/","published":"2019-08-08"},{"url":"https://hartvaat.nl/2016/04/19/evolocumab-versus-ezetimibe-bij-statine-intolerante-patienten-de-gauss-3-trial/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"erwan-donal","type":"person","url":"https://hartvaat.nl/mensen/erwan-donal/","name":"Erwan Donal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/22/m-teer-werkt-over-het-volledige-lvef-spectrum-vergroot-linkeratrium-volume-voors/","published":"2026-06-06"},{"url":"https://hartvaat.nl/2026/03/28/gestandaardiseerd-stappenplan-voor-tricuspidalisinsufficientie-van-verwijzing-to/","published":"2026-04-19"},{"url":"https://hartvaat.nl/2026/02/03/effect-van-mavacamten-op-risicoscores-voor-plotse-hartdood-bij-hypertrofische-ca/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/01/14/tri-fr-transcatheter-edge-to-edge-repair-bij-geisoleerde-ernstige-tr-rct/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2023/07/20/ni006-antilichaam-voor-afbraak-van-cardiale-transthyretine-amyloid-nejm-fase-1/","published":"2023-07-20"},{"url":"https://hartvaat.nl/2018/12/13/percutaan-herstel-of-medicamenteuze-therapie-bij-secundaire-mr-nejm-mitra-fr/","published":"2018-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"estella-kanevsky","type":"person","url":"https://hartvaat.nl/mensen/estella-kanevsky/","name":"Estella Kanevsky","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","published":"2018-11-24"},{"url":"https://hartvaat.nl/2018/02/01/cv-uitkomsten-naar-albumin-en-nierziekte-bij-diabetes-type-2-met-hoog-cv-risico/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2017/08/17/cognitieve-functie-in-de-fourier-trial-met-evolocumab-nejm-ebbinghaus/","published":"2017-08-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eva-goncalvesova","type":"person","url":"https://hartvaat.nl/mensen/eva-goncalvesova/","name":"Eva Goncalvesova","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eva-kleine","type":"person","url":"https://hartvaat.nl/mensen/eva-kleine/","name":"Eva Kleine","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/11/30/voorspellers-van-af-ontwikkeling-bij-embolic-stroke-of-undetermined-source-re-sp/","published":"2021-11-30"},{"url":"https://hartvaat.nl/2019/06/01/heparinedosering-bij-ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-re/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/05/14/dabigatran-duale-therapie-met-ticagrelor-of-clopidogrel-na-pci-bij-af-re-dual-pc/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2018/03/13/doac-s-bij-af-met-ckd-systematische-review-werkzaamheid-en-veiligheid/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2018/02/01/dabigatran-versus-warfarine-bij-af-met-linkerventrikelhypertrofie-re-ly/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","published":"2017-10-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eva-korup","type":"person","url":"https://hartvaat.nl/mensen/eva-korup/","name":"Eva Korup","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"evgeny-pokushalov","type":"person","url":"https://hartvaat.nl/mensen/evgeny-pokushalov/","name":"Evgeny Pokushalov","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2020/08/25/pulmonale-arterie-denervatie-bij-residuele-ph-na-endarterectomie/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/12/01/av-junctieablatie-plus-crt-bij-permanent-af-gerandomiseerde-trial/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/02/01/katheterablatie-bij-af-met-hartfalen-nejm-castle-af/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ewa-a-jankowska","type":"person","url":"https://hartvaat.nl/mensen/ewa-a-jankowska/","name":"Ewa A Jankowska","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/12/21/iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-ipd-meta-analyse/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/04/01/lv-longitudinale-systolische-functieparameters-als-voorspellers-bij-hfpef/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ewa-karwatowska-prokopczuk","type":"person","url":"https://hartvaat.nl/mensen/ewa-karwatowska-prokopczuk/","name":"Ewa Karwatowska-Prokopczuk","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-hypertriglyceridemie-en-hoog-cv-risico-nejm/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-familiaire-chylomicronemie-nejm-fase-3/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2022/03/22/pelacarsen-op-lp-a-cholesterol-en-gecorrigeerd-ldl-cholesterol/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2020/10/21/vupanorsen-angptl3-antisense-en-triglyceriden-ehj/","published":"2020-10-21"},{"url":"https://hartvaat.nl/2020/01/16/lp-a-verlaging-bij-cardiovasculaire-ziekte-nejm/","published":"2020-01-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fan-fan-hou","type":"person","url":"https://hartvaat.nl/mensen/fan-fan-hou/","name":"Fan Fan Hou","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/27/smoothened-signalering-bevordert-nierfibrose-via-autofagieremming/","published":"2026-04-10"},{"url":"https://hartvaat.nl/2021/03/31/dapagliflozine-en-mortaliteit-bij-ckd-dapa-ckd-pre-gespecificeerde-analyse/","published":"2021-03-31"},{"url":"https://hartvaat.nl/2021/03/01/kdigo-2021-bloeddruk-bij-ckd-executive-summary/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2018/05/15/trombocytenaantal-beinvloedt-werkzaamheid-van-foliumzuur-bij-cva-preventie/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2017/08/01/foliumzuurtherapie-en-nieuwe-proteinurie-bij-chinese-hypertensieve-patienten-csp/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/07/01/polsgolfsnelheid-en-bloeddrukcontrole-als-onafhankelijke-voorspellers-van-cva-bi/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fang-fei-wei","type":"person","url":"https://hartvaat.nl/mensen/fang-fei-wei/","name":"Fang-Fei Wei","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/06/01/hypertensie-wijzigt-de-relatie-tussen-lp-a-en-mortaliteit-bij-acuut-gedecompense/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2021/05/05/bloeddrukvariabiliteit-en-uitkomsten-bij-hfpef/","published":"2021-05-05"},{"url":"https://hartvaat.nl/2020/11/10/chinese-kruidenformule-voor-gemaskeerde-hypertensie-gerandomiseerde-placebogecon/","published":"2020-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"faris-al-khalili","type":"person","url":"https://hartvaat.nl/mensen/faris-al-khalili/","name":"Faris Al-Khalili","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/12/03/nt-probnp-en-ecg-screening-bij-75-jarigen-voor-af-detectie-rct/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2023/01/14/strokestop-af-screening-is-kosteneffectief-bij-75-76-jarigen/","published":"2023-01-14"},{"url":"https://hartvaat.nl/2021/10/23/systematische-af-screening-en-klinische-uitkomsten-lancet-strokestop/","published":"2021-10-23"},{"url":"https://hartvaat.nl/2020/01/01/stapsgewijze-af-screening-met-nt-probnp-strokestop-ii-resultaten/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2017/08/01/nt-probnp-bij-systematische-screening-op-atriumfibrilleren/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/02/01/stapsgewijze-massascreening-op-af-met-nt-probnp-strokestop-ii-studieontwerp/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"federico-de-marco","type":"person","url":"https://hartvaat.nl/mensen/federico-de-marco/","name":"Federico De Marco","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2025/07/08/amulet-versus-watchman-flx-driejaarsresultaten-laa-sluiting/","published":"2025-07-08"},{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","published":"2024-02-06"},{"url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2017/05/30/tijdstrends-in-complicaties-van-bioresorbeerbare-versus-metallic-stents/","published":"2017-05-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"felice-gragnano","type":"person","url":"https://hartvaat.nl/mensen/felice-gragnano/","name":"Felice Gragnano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2021/02/02/dalend-hemoglobine-en-prognose-bij-acs-hospitalisatie/","published":"2021-02-02"},{"url":"https://hartvaat.nl/2020/08/04/cangrelor-tirofiban-en-prasugrel-bij-stemi-primaire-resultaten/","published":"2020-08-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"florence-leclercq","type":"person","url":"https://hartvaat.nl/mensen/florence-leclercq/","name":"Florence Leclercq","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2020/10/01/crp-sst2-en-gdf-15-multimarker-voor-prognostische-stratificatie-bij-stabiel-hf/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/04/01/sst2-voor-hartfalenmanagement-stade-hf-pilotstudie/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2018/12/13/percutaan-herstel-of-medicamenteuze-therapie-bij-secundaire-mr-nejm-mitra-fr/","published":"2018-12-13"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/01/21/stoppen-of-doorgaan-met-clopidogrel-12-maanden-na-drug-eluting-stent-optidual-tr/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"florian-kronenberg","type":"person","url":"https://hartvaat.nl/mensen/florian-kronenberg/","name":"Florian Kronenberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/01/11/zeventien-jaar-voor-verandering-doorbreken-de-2025-esc-eas-dyslipidemierichtlijn/","published":"2026-01-11"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2018/10/13/lp-a-baseline-en-on-statin-voor-cv-eventvoorspelling-lancet-ipd-meta-analyse/","published":"2018-10-13"}],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/lipoproteïne-a/","title":"Sessie 3: Lipoproteïne(a)"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francesco-costa","type":"person","url":"https://hartvaat.nl/mensen/francesco-costa/","name":"Francesco Costa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2025/12/09/gepersonaliseerde-versus-standaard-dapt-duur-na-pci-gerandomiseerde-trial/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","published":"2025-07-21"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2017/03/14/afweging-myocardinfarct-versus-bloedingstype-en-mortaliteit-na-acs-tra-2p-timi-5/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/01/21/langdurige-duale-antiplaatjestherapie-bij-patienten-met-eerder-myocardinfarct-me/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francesco-nordio","type":"person","url":"https://hartvaat.nl/mensen/francesco-nordio/","name":"Francesco Nordio","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2020/02/25/genetische-risicoscore-voorspelt-voordeel-van-evolocumab-fourier/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2019/07/16/edoxaban-versus-warfarine-bij-af-met-leverziekte-engage-af-timi-48/","published":"2019-07-16"},{"url":"https://hartvaat.nl/2019/02/05/abc-scores-voor-cva-en-bloedingsrisico-bij-af-prestatieverbetering/","published":"2019-02-05"},{"url":"https://hartvaat.nl/2017/03/28/edoxaban-bij-af-met-bioprothese-hartkleppen-trombo-emboliepreventie/","published":"2017-03-28"},{"url":"https://hartvaat.nl/2017/03/21/kleplijden-en-edoxaban-versus-warfarine-bij-af-engage-af-timi-48/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2017/03/21/nieuwe-risicovoorspellingsscore-bij-af-voor-netto-klinisch-resultaat-engage-af-t/","published":"2017-03-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"franck-boccara","type":"person","url":"https://hartvaat.nl/mensen/franck-boccara/","name":"Franck Boccara","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/06/laminopathieen-natuurlijk-beloop-en-voorspelmodel-voor-hartfalen/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2026/02/01/therapeutische-innovaties-in-de-secundaire-preventie-van-cardiovasculair-risico/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"},{"url":"https://hartvaat.nl/2020/05/26/evolocumab-bij-hiv-met-dyslipidemie-beijerinck-gerandomiseerde-studie/","published":"2020-05-26"},{"url":"https://hartvaat.nl/2016/01/21/stoppen-of-doorgaan-met-clopidogrel-12-maanden-na-drug-eluting-stent-optidual-tr/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"franco-fabbiocchi","type":"person","url":"https://hartvaat.nl/mensen/franco-fabbiocchi/","name":"Franco Fabbiocchi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2017/04/01/polymeervrije-biolimus-stent-bij-hoog-bloedingsrisico-met-acs-leaders-free-subst/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/11/26/oct-versus-ivus-versus-angiografie-bij-coronaire-stentimplantatie-lancet-ilumien/","published":"2016-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frederick-a-masoudi","type":"person","url":"https://hartvaat.nl/mensen/frederick-a-masoudi/","name":"Frederick A Masoudi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/04/16/2024-acc-expert-consensus-behandeling-van-hfref-beslispad-geactualiseerd/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2021/02/16/2021-acc-hf-behandeloptimalisatie-update-antwoorden-op-10-cruciale-vragen/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frederic-anselme","type":"person","url":"https://hartvaat.nl/mensen/frederic-anselme/","name":"Frédéric Anselme","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/06/laminopathieen-natuurlijk-beloop-en-voorspelmodel-voor-hartfalen/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/07/08/amulet-versus-watchman-flx-driejaarsresultaten-laa-sluiting/","published":"2025-07-08"},{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","published":"2024-02-06"},{"url":"https://hartvaat.nl/2023/05/19/geleidingssysteempacing-in-europa-inzichten-uit-klinische-praktijk/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/07/18/cryoballonablatie-versus-antiaritmica-als-eerstelijns-paf-therapie/","published":"2021-07-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gerald-s-bloomfield","type":"person","url":"https://hartvaat.nl/mensen/gerald-s-bloomfield/","name":"Gerald S Bloomfield","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/08/24/reprieve-pitavastatine-vermindert-cv-events-bij-hiv-nejm/","published":"2023-08-24"},{"url":"https://hartvaat.nl/2023/02/01/cv-risicomodellen-bij-hiv-patienten-systematische-review/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/04/27/groepsmedisch-consult-en-microfinanciering-bij-diabetes-hypertensie-in-kenia/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2019/10/15/community-health-workers-verbeteren-koppeling-met-hypertensiezorg-in-kenia/","published":"2019-10-15"},{"url":"https://hartvaat.nl/2018/07/01/hypertensie-bij-hiv-nieuwe-pathofysiologische-mechanismen/","published":"2018-07-01"},{"url":"https://hartvaat.nl/2016/12/01/lacunes-in-hypertensierichtlijnen-in-lage-en-middeninkomenslanden-systematische-/","published":"2016-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gert-richardt","type":"person","url":"https://hartvaat.nl/mensen/gert-richardt/","name":"Gert Richardt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2017/03/30/ffr-geleide-multivaten-pci-bij-myocardinfarct-nejm-compare-acute/","published":"2017-03-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giulio-guagliumi","type":"person","url":"https://hartvaat.nl/mensen/giulio-guagliumi/","name":"Giulio Guagliumi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2025/07/15/oct-gebaseerde-post-pci-fysiologiebeoordeling-voorspelt-klinische-uitkomsten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2016/11/26/oct-versus-ivus-versus-angiografie-bij-coronaire-stentimplantatie-lancet-ilumien/","published":"2016-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gorav-ailawadi","type":"person","url":"https://hartvaat.nl/mensen/gorav-ailawadi/","name":"Gorav Ailawadi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/05/01/nierdisfunctie-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gregory-f-michaud","type":"person","url":"https://hartvaat.nl/mensen/gregory-f-michaud/","name":"Gregory F Michaud","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2018/10/01/ononderbroken-doac-versus-vka-bij-af-ablatie-meta-analyse/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/08/01/linker-hartoorisolatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/10/01/terminatie-van-persisterend-af-tijdens-pvi-inzichten-uit-magic-af/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/05/21/stapsgewijze-ablatie-gestuurd-door-laaggedoseerd-ibutilide-bij-chronisch-af-magi/","published":"2016-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"guido-grassi","type":"person","url":"https://hartvaat.nl/mensen/guido-grassi/","name":"Guido Grassi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/08/01/sympathische-overactiviteit-bij-resistente-hypertensie-meta-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/01/01/reproduceerbaarheid-en-behandeleffect-op-kantoor-versus-ambulante-bloeddrukrelat/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2023/03/01/renale-denervatie-en-sympathische-activiteit-systematische-review/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2018/08/01/sympathische-zenuwactivatie-bij-essentiele-hypertensie-meta-analyse/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/07/01/sport-versus-beroepsmatige-lichamelijke-activiteit-en-cardiovasculair-risico/","published":"2018-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"haibo-zhang","type":"person","url":"https://hartvaat.nl/mensen/haibo-zhang/","name":"Haibo Zhang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/01/intensieve-bloeddrukcontrole-en-cognitieve-functie-gerandomiseerde-trial/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/01/01/effect-van-baduanjin-op-bloeddruk-bij-hoog-normaal-bloeddruk-gerandomiseerde-tri/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/06/esprit-intensieve-bloeddrukcontrole-bij-fragiele-patienten-post-hoc-analyse/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/10/28/esprit-bescheiden-effecten-van-intensieve-bloeddrukverlaging-op-kwaliteit-van-le/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukcontrole-en-cva-preventie/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2024/07/20/sbp-120-versus-140-mmhg-bij-hoog-cv-risico-meta-analyse-van-intensieve-behandeli/","published":"2024-07-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hardi-mundl","type":"person","url":"https://hartvaat.nl/mensen/hardi-mundl/","name":"Hardi Mundl","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2022/10/18/asundexian-factor-xia-remmer-na-acs-fase-2-dosisfindingsstudie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/04/09/asundexian-factor-xia-remmer-versus-apixaban-bij-af-lancet-pacific-af/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"helge-mollmann","type":"person","url":"https://hartvaat.nl/mensen/helge-mollmann/","name":"Helge Möllmann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/06/06/smart-zelf-expanderend-versus-ballonexpandeerbaar-tavr-bij-kleine-annulus-nejm/","published":"2024-06-06"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hisatomi-arima","type":"person","url":"https://hartvaat.nl/mensen/hisatomi-arima/","name":"Hisatomi Arima","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2024/05/30/right-2-ambulancebloeddrukverlaging-bij-hyperacuut-cva-nejm-vervolgresultaten/","published":"2024-05-30"},{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","published":"2016-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hyo-suk-ahn","type":"person","url":"https://hartvaat.nl/mensen/hyo-suk-ahn/","name":"Hyo-Suk Ahn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/25/bmi-en-prognose-bij-acuut-hartfalen-verschillen-per-fenotype-en-geslacht/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/04/01/lage-dosis-tel-aml-chtd-combinatietablet-versus-standaard-tel-fase-iii/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","published":"2025-11-08"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/10/17/antiplaatjesmonotherapie-na-pci-clopidogrel-versus-aspirine-naar-risicoprofiel/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hyun-jae-kang","type":"person","url":"https://hartvaat.nl/mensen/hyun-jae-kang/","name":"Hyun-Jae Kang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/05/02/korte-versus-standaard-dapt-na-pci-met-moderne-des-meta-analyse/","published":"2023-05-02"},{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2021/03/16/duurzame-versus-biodegradeerbare-polymer-des-bij-acs-meta-analyse/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/10/10/prasugrel-gebaseerde-dapt-de-escalatie-na-pci-bij-acs-lancet-host-reduce-polytec/","published":"2020-10-10"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"havard-dalen","type":"person","url":"https://hartvaat.nl/mensen/havard-dalen/","name":"Håvard Dalen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/04/01/inspanningstraining-en-hoog-sensitief-troponine-i-bij-hfref/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/08/01/telerevalidatie-haalbaar-voor-hartfalenpatienten-zonder-toegang-tot-poliklinisch/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2022/08/01/cardiorenaal-syndroom-en-fitheid-bij-hartfalen-telerevalidatie-trial/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2022/06/01/vijf-jaar-inspanningstraining-verbetert-cardiovasculair-risicoprofiel-bij-oudere/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2021/06/01/inspanningstraining-en-hs-troponine-t-bij-hfref/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2017/02/28/hoog-intensieve-intervaltraining-bij-hartfalen-met-verminderde-ejectiefractie/","published":"2017-02-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"iginio-colaiori","type":"person","url":"https://hartvaat.nl/mensen/iginio-colaiori/","name":"Iginio Colaiori","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/12/20/ticagrelor-versus-prasugrel-en-coronaire-microcirculatie-bij-pci/","published":"2023-12-20"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2016/09/13/clopidogrel-versus-ticagrelor-bij-diabetes-na-pci-gerandomiseerde-trial/","published":"2016-09-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"imre-ungi","type":"person","url":"https://hartvaat.nl/mensen/imre-ungi/","name":"Imre Ungi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"j-michael-gaziano","type":"person","url":"https://hartvaat.nl/mensen/j-michael-gaziano/","name":"J Michael Gaziano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/03/03/vitamine-d-en-omega-3-en-hartfalen-hospitalisatie-vital-heart-failure/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2019/01/10/endoscopische-versus-open-veneoogst-bij-cabg-nejm-regroup/","published":"2019-01-10"},{"url":"https://hartvaat.nl/2018/09/22/aspirine-voor-primaire-preventie-bij-matig-cv-risico-lancet-arrive/","published":"2018-09-22"},{"url":"https://hartvaat.nl/2018/04/10/geen-verband-tussen-hartfalen-en-kankerincidentie/","published":"2018-04-10"},{"url":"https://hartvaat.nl/2017/06/01/voedingsstatus-en-langetermijn-multivitaminegebruik-en-cv-risico-phs-ii-analyse/","published":"2017-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jagmeet-p-singh","type":"person","url":"https://hartvaat.nl/mensen/jagmeet-p-singh/","name":"Jagmeet P Singh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/10/01/draadloos-ultrasound-gebaseerd-crt-systeem-bij-hartfalen/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2021/08/06/ventriculaire-aritmie-bij-crt-responders-en-super-responders-meta-analyse/","published":"2021-08-06"},{"url":"https://hartvaat.nl/2018/03/27/crt-bij-hartfalen-met-smal-qrs-complex/","published":"2018-03-27"},{"url":"https://hartvaat.nl/2017/03/07/lv-global-longitudinal-strain-en-prognose-bij-hartfalen-met-smal-qrs-en-crt/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2017/03/07/contractiliteitssensor-geleide-crt-optimalisatie-respond-crt-trial/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2016/01/01/persisterende-echocardiografische-dyssynchronie-voorspelt-ongunstige-uitkomsten-/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"janet-m-schnee","type":"person","url":"https://hartvaat.nl/mensen/janet-m-schnee/","name":"Janet M Schnee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/09/28/nt-probnp-prognose-en-empagliflozine-effect-bij-emperor-reduced/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jarett-d-berry","type":"person","url":"https://hartvaat.nl/mensen/jarett-d-berry/","name":"Jarett D Berry","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/09/01/troponine-nt-probnp-en-cognitieve-uitkomsten-in-sprint/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2022/10/18/intensieve-bloeddrukverlaging-bij-maligne-linkerventrikel-hypertrofie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/12/22/lichaamssamenstelling-en-risico-op-hartfalen-en-mi-prospectieve-analyse/","published":"2020-12-22"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2016/08/01/sedentair-gedrag-en-cardiovasculair-risico-continue-dosis-responsrelatie-in-meta/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jasper-tromp","type":"person","url":"https://hartvaat.nl/mensen/jasper-tromp/","name":"Jasper Tromp","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/28/atriumfibrilleren-en-hartfalen-versterken-elkaar-en-verhogen-sterfte-aanzienlijk/","published":"2026-07-28"},{"url":"https://hartvaat.nl/2026/03/05/ai-echocardiografie-door-niet-specialisten-kosteneffectiviteitsanalyse-uit-singa/","published":"2026-04-08"},{"url":"https://hartvaat.nl/2025/12/16/farmacologische-behandeling-van-hfref-geactualiseerde-systematische-review/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","published":"2019-08-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jean-guillaume-dillinger","type":"person","url":"https://hartvaat.nl/mensen/jean-guillaume-dillinger/","name":"Jean-Guillaume Dillinger","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/22/lge-granulariteit-op-cmr-voorspelt-sterfte-bij-eindstadium-hypertrofische-cardio/","published":"2026-06-06"},{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeanine-e-roeters-van-lennep","type":"person","url":"https://hartvaat.nl/mensen/jeanine-e-roeters-van-lennep/","name":"Jeanine E Roeters van Lennep","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/18/global-hicc-register-950-hofh-patienten-uit-45-landen-slechts-4-haalt-ldl-doelen/","published":"2026-06-17"},{"url":"https://hartvaat.nl/2026/05/25/eas-consensus-familiaire-hypercholesterolemie-bij-kinderen-en-adolescenten/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/04/19/fh-vrouwen-verliezen-mediaan-2-9-jaar-lipidenverlagende-behandeling-rond-elke-ki/","published":"2026-05-05"},{"url":"https://hartvaat.nl/2026/04/28/geen-sekseverschillen-in-werkzaamheid-van-hartfalenmedicatie-meta-analyse-van-13/","published":"2026-05-05"},{"url":"https://hartvaat.nl/2026/01/16/statinegebruik-in-de-zwangerschap-en-congenitale-afwijkingen-noors-cohort/","published":"2026-01-16"},{"url":"https://hartvaat.nl/2025/11/26/lipideveranderingen-bij-vrouwen-met-fh-tijdens-de-menopauzale-transitie/","published":"2025-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeffrey-a-cutler","type":"person","url":"https://hartvaat.nl/mensen/jeffrey-a-cutler/","name":"Jeffrey A Cutler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2016/10/01/orthostatische-hypotensie-in-de-accord-bloeddruk-trial-prevalentie-en-klinische-/","published":"2016-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeffrey-i-weitz","type":"person","url":"https://hartvaat.nl/mensen/jeffrey-i-weitz/","name":"Jeffrey I Weitz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"},{"url":"https://hartvaat.nl/2018/10/30/endogene-factor-xa-activiteit-en-edoxaban-farmacodynamische-marker-en-klinische-/","published":"2018-10-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeffrey-s-borer","type":"person","url":"https://hartvaat.nl/mensen/jeffrey-s-borer/","name":"Jeffrey S Borer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/10/01/ivabradine-bij-hoogrisico-hartfalenpatienten-shift-analyse/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2019/12/01/gunstige-effecten-van-ivabradine-bij-hf-met-lage-ef-en-hartfrequentie-77-bpm/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2018/03/27/crt-bij-hartfalen-met-smal-qrs-complex/","published":"2018-03-27"},{"url":"https://hartvaat.nl/2017/11/21/bloeddrukeffecten-van-ibuprofen-naproxen-en-celecoxib-bij-artritis-precision-abp/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2017/03/07/lv-global-longitudinal-strain-en-prognose-bij-hartfalen-met-smal-qrs-en-crt/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2016/01/01/persisterende-echocardiografische-dyssynchronie-voorspelt-ongunstige-uitkomsten-/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeffrey-whittle","type":"person","url":"https://hartvaat.nl/mensen/jeffrey-whittle/","name":"Jeffrey Whittle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/09/01/aspirinedosering-voor-secundaire-preventie-bij-mannen-versus-vrouwen/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2018/01/09/diastolische-bloeddruk-en-intensieve-bloeddrukcontrole-sprint-analyse/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jenifer-m-brown","type":"person","url":"https://hartvaat.nl/mensen/jenifer-m-brown/","name":"Jenifer M Brown","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/10/nieuwe-medicamenteuze-therapieen-voor-hypertensie/","published":"2026-03-14"},{"url":"https://hartvaat.nl/2026/03/07/baxdrostat-verlaagt-bloeddruk-significant-bij-resistente-hypertensie/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/03/07/bax24-baxdrostat-en-ambulante-bloeddruk-bij-resistente-hypertensie/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2025/10/09/baxdrostat-bij-ongecontroleerde-en-resistente-hypertensie-effectiviteit-en-veili/","published":"2025-10-09"},{"url":"https://hartvaat.nl/2020/09/01/2020-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2018/12/18/2018-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2018-12-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jennifer-s-lees","type":"person","url":"https://hartvaat.nl/mensen/jennifer-s-lees/","name":"Jennifer S Lees","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/06/30/kfre-aangepast-voor-multimorbiditeit-verbetert-schatting-nierfalenrisico/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2026/03/31/era-s-abcde-raamwerk-voor-preventie-van-nierziekten/","published":"2026-03-31"},{"url":"https://hartvaat.nl/2026/02/25/de-mondiale-ziektelast-van-chronische-nierziekte-elke-20-seconden-een-sterfgeval/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2026/01/24/oproep-tot-actie-europese-trials-nodig-tegen-tsunami-van-nierfalen/","published":"2026-01-24"},{"url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jens-erik-nielsen-kudsk","type":"person","url":"https://hartvaat.nl/mensen/jens-erik-nielsen-kudsk/","name":"Jens Erik Nielsen-Kudsk","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/06/02/doac-gebruik-na-ablatie-voor-atriumfibrilleren-aanhouderij-daalt-na-drie-jaar/","published":"2026-08-11"},{"url":"https://hartvaat.nl/2026/04/13/intracardiale-echocardiografie-in-de-elektrofysiologie-gezamenlijk-ehra-eapci-st/","published":"2026-05-23"},{"url":"https://hartvaat.nl/2026/03/28/champion-af-watchman-flx-non-inferieur-aan-noac-s-en-superieur-in-bloedingsreduc/","published":"2026-03-29"},{"url":"https://hartvaat.nl/2025/04/03/laa-sluiting-na-af-ablatie-gerandomiseerde-trial-nejm/","published":"2025-04-03"},{"url":"https://hartvaat.nl/2025/03/25/amulet-ide-vijfjaarsresultaten-laa-occlusie-met-amulet/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2023/08/02/peri-device-lekkage-bij-laa-occluders-mechanismen-en-voorspellers/","published":"2023-08-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jens-ulrik-staehr-jensen","type":"person","url":"https://hartvaat.nl/mensen/jens-ulrik-staehr-jensen/","name":"Jens Ulrik Stæhr Jensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/10/28/rsv-vaccin-vermindert-cv-hospitalisaties-bij-ouderen/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/01/01/nudge-flu-subanalyse-griepvaccinatie-nudges-bij-mi-langetermijn/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/05/27/nudge-flu-elektronische-nudges-verhogen-griepvaccinatie-na-mi/","published":"2024-05-27"},{"url":"https://hartvaat.nl/2022/03/15/5-jaars-ifr-versus-ffr-geleide-pci-define-flair-ifr-swedeheart/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/05/11/instantaneous-wave-free-ratio-versus-ffr-voor-pci-indicatie-nejm-ifr-swedeheart/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeong-hoon-yang","type":"person","url":"https://hartvaat.nl/mensen/jeong-hoon-yang/","name":"Jeong Hoon Yang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeroen-dauw","type":"person","url":"https://hartvaat.nl/mensen/jeroen-dauw/","name":"Jeroen Dauw","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","published":"2023-06-09"},{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","published":"2022-09-29"},{"url":"https://hartvaat.nl/2021/12/21/iv-ijzercarboxymaltose-en-cardiale-reverse-remodellering-na-crt-iron-crt/","published":"2021-12-21"},{"url":"https://hartvaat.nl/2020/03/31/staken-van-neurohumorale-blokkade-na-crt/","published":"2020-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeroen-m-l-hendriks","type":"person","url":"https://hartvaat.nl/mensen/jeroen-m-l-hendriks/","name":"Jeroen M L Hendriks","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2020/01/01/obesitas-opzettelijk-gewichtsverlies-en-hartfalen-meta-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/12/01/geintegreerde-gespecialiseerde-af-poliklinieken-verlagen-totale-mortaliteit-post/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2018/04/21/subklinisch-device-gedetecteerd-af-en-cva-risico-meta-analyse/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2017/12/01/geintegreerde-zorg-bij-atriumfibrilleren-systematische-review-en-meta-analyse/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/07/2016-esc-richtlijn-voor-atriumfibrilleren-in-samenwerking-met-eacts/","published":"2016-10-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jerome-i-rotter","type":"person","url":"https://hartvaat.nl/mensen/jerome-i-rotter/","name":"Jerome I Rotter","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/06/01/genetische-bijdrage-aan-aortastenose-dyslipidemie-inflammatie-en-verkalking/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/08/01/hele-genoomsequencing-onthult-nieuwe-bloeddruk-loci/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2019/08/20/dna-methylering-in-leukocyten-voorspelt-mi-en-coronairlijden/","published":"2019-08-20"},{"url":"https://hartvaat.nl/2018/10/23/lpa-varianten-en-residueel-cv-risico-bij-statinebehandelde-patienten/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/06/01/gwas-van-pr-interval-bij-hispanic-latino-s-nieuw-locus-bij-id2/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/07/20/genetische-en-farmacologische-inactivatie-van-angptl3-en-cardiovasculaire-ziekte/","published":"2017-07-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jesper-kjaergaard","type":"person","url":"https://hartvaat.nl/mensen/jesper-kjaergaard/","name":"Jesper Kjærgaard","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/12/05/bloeddruk-en-zuurstofstreefwaarden-en-nierschade-na-hartstilstand/","published":"2023-12-05"},{"url":"https://hartvaat.nl/2022/10/20/box-bloeddrukdoelen-bij-comateuze-overlevenden-van-hartstilstand/","published":"2022-10-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jessica-tyrwhitt","type":"person","url":"https://hartvaat.nl/mensen/jessica-tyrwhitt/","name":"Jessica Tyrwhitt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/08/16/achieve-spironolacton-bij-dialysepatienten-internationale-rct/","published":"2025-08-16"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2023/02/01/aspirine-en-cardiovasculaire-uitkomsten-bij-chronische-nierziekte/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","published":"2021-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jie-yu","type":"person","url":"https://hartvaat.nl/mensen/jie-yu/","name":"Jie Yu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2022/09/26/zoutvervangers-verminderen-cardiovasculaire-events-systematische-review/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2022/05/17/kosteneffectiviteit-van-zoutsubstitutie-ssass-analyse/","published":"2022-05-17"},{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","published":"2021-09-16"},{"url":"https://hartvaat.nl/2021/04/01/canagliflozine-naar-diureticagebruik-canvas-post-hoc-analyse/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2017/07/11/positieve-luchtwegdruk-en-cv-events-bij-slaapapneu-jama-meta-analyse/","published":"2017-07-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jing-kan","type":"person","url":"https://hartvaat.nl/mensen/jing-kan/","name":"Jing Kan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/01/07/dcb-voor-zijtak-bij-provisionale-stenting-gerandomiseerde-trial/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/05/11/ivus-acs-ivus-geleide-pci-bij-acs-superieur-lancet/","published":"2024-05-11"},{"url":"https://hartvaat.nl/2024/05/11/ticagrelor-monotherapie-versus-dapt-na-1-maand-bij-acs-lancet-rct/","published":"2024-05-11"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2018/12/18/ivus-versus-angiografie-geleide-des-implantatie-de-ultimate-trial/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jing-wang","type":"person","url":"https://hartvaat.nl/mensen/jing-wang/","name":"Jing Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/06/vereenvoudigde-linkervoorhoofdaanhangsel-occlusie-onder-fluoroscopie-met-watchma/","published":"2026-07-29"},{"url":"https://hartvaat.nl/2026/02/21/pelacarsen-vermindert-de-behoefte-aan-lipoproteine-a-aferese-lp-a-frontiers-aphe/","published":"2026-02-21"},{"url":"https://hartvaat.nl/2026/02/12/aanhoudende-monocytactivatie-door-geoxideerd-ldl-en-vrij-cholesterol/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/03/27/intensieve-bloeddrukcontrole-bij-type-2-diabetes-nejm/","published":"2025-03-27"},{"url":"https://hartvaat.nl/2021/06/01/sglt2-remmers-versus-arni-bij-hfref-meta-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2019/09/01/metformine-en-aorta-aneurysma-systematische-review-en-meta-analyse/","published":"2019-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joachim-weil","type":"person","url":"https://hartvaat.nl/mensen/joachim-weil/","name":"Joachim Weil","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2021/09/07/hartfrequentie-en-uitkomsten-van-renale-denervatie-bij-ongecontroleerde-hyperten/","published":"2021-09-07"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2019/03/01/ambulante-hartfrequentiereductie-na-renale-denervatie-bij-hypertensie-zonder-med/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/10/09/24-uurs-ambulante-bloeddrukreductie-na-renale-denervatie-spyral-htn-off-med/","published":"2018-10-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johannes-brachmann","type":"person","url":"https://hartvaat.nl/mensen/johannes-brachmann/","name":"Johannes Brachmann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/06/21/mri-geleide-fibroseablatie-versus-conventionele-ablatie-bij-persisterend-af/","published":"2022-06-21"},{"url":"https://hartvaat.nl/2019/09/24/interne-versus-externe-cardioversie-bij-atriale-aritmieen-met-icd/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2018/02/01/katheterablatie-bij-af-met-hartfalen-nejm-castle-af/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/03/07/contractiliteitssensor-geleide-crt-optimalisatie-respond-crt-trial/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2017/01/01/percutane-linker-hartoorsluiting-munchen-consensusdocument-over-definities-en-ei/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/11/01/vochtstatustelemonitoring-bij-hartfalen-gerandomiseerde-trial/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-d-varigos","type":"person","url":"https://hartvaat.nl/mensen/john-d-varigos/","name":"John D Varigos","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-k-french","type":"person","url":"https://hartvaat.nl/mensen/john-k-french/","name":"John K French","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/08/29/stream-2-halve-dosis-tenecteplase-bij-ouderen-met-stemi/","published":"2023-08-29"},{"url":"https://hartvaat.nl/2022/07/01/behandeling-van-acuut-coronair-syndroom-in-ruraal-australie-moracs-trial/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2021/07/13/late-rapid-tnt-uitkomsten-0-1-uur-hs-troponine-t-bij-verdenking-acs/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2019/11/05/1-uur-troponine-t-protocol-bij-verdenking-acs-gerandomiseerde-rapid-tnt-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","published":"2019-02-19"},{"url":"https://hartvaat.nl/2018/12/11/syntax-score-bij-diabetes-met-coronaire-revascularisatie-freedom/","published":"2018-12-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jonathan-mant","type":"person","url":"https://hartvaat.nl/mensen/jonathan-mant/","name":"Jonathan Mant","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/07/lancet-seminar-atriumfibrilleren-in-2026/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2025/12/01/economische-ziektelast-van-hartfalen-in-europa-systematische-review/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2020/05/26/antihypertensieve-medicatiereductie-versus-standaardzorg-bij-ouderen-jama-optimi/","published":"2020-05-26"},{"url":"https://hartvaat.nl/2019/06/01/kosteneffectiviteit-van-telemonitoring-en-zelfmeting-van-bloeddruk-tasminh4/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/03/10/zelfgemeten-bloeddruk-met-of-zonder-telemonitoring-voor-medicatietitratie-lancet/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2016/01/30/intensieve-bloeddrukverlaging-en-cardiovasculaire-en-renale-uitkomsten-systemati/","published":"2016-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jong-hwa-ahn","type":"person","url":"https://hartvaat.nl/mensen/jong-hwa-ahn/","name":"Jong-Hwa Ahn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/01/lage-dosis-tel-aml-chtd-combinatietablet-versus-standaard-tel-fase-iii/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","published":"2025-11-08"},{"url":"https://hartvaat.nl/2025/09/06/directe-versus-gestageerde-complete-revascularisatie-tijdens-index-opname-bij-st/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jordana-b-cohen","type":"person","url":"https://hartvaat.nl/mensen/jordana-b-cohen/","name":"Jordana B Cohen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/12/nhlbi-workshop-bloeddrukmeting-verfijnen-door-de-hele-levensloop-heen-knelpunten/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/28/prevent-vergelijkingen-voor-intensieve-versus-standaard-bloeddrukcontrole/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/03/01/kaliumnitraat-bij-hfpef-gerandomiseerde-trial/","published":"2025-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jorge-plutzky","type":"person","url":"https://hartvaat.nl/mensen/jorge-plutzky/","name":"Jorge Plutzky","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/08/18/semaglutide-verlaagt-hscrp-en-ontstekingsactiviteit-bij-ascvd-patienten-met-over/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","published":"2024-08-24"},{"url":"https://hartvaat.nl/2024/06/04/drive-remote-management-verbetert-richtlijnmedicatie-bij-hartfalen/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2023/12/14/select-semaglutide-vermindert-cv-events-bij-obesitas-zonder-diabetes-nejm/","published":"2023-12-14"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jose-luis-merino","type":"person","url":"https://hartvaat.nl/mensen/jose-luis-merino/","name":"Jose Luis Merino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/03/aanbesteding-van-cardiale-implanteerbare-devices-in-europa-waarde-of-kosten/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/03/28/geinhaleerde-flecainide-voor-cardioversie-van-recent-onset-af-lancet/","published":"2025-03-28"},{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2019/11/01/determinanten-van-linkeratriumtrombi-bij-geplande-cardioversie-ensure-af/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2016/10/22/edoxaban-versus-enoxaparine-warfarine-bij-cardioversie-van-af-ensure-af-trial/","published":"2016-10-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"juha-hartikainen","type":"person","url":"https://hartvaat.nl/mensen/juha-hartikainen/","name":"Juha Hartikainen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/08/25/risicogestuurde-af-screening-met-machine-learning-verhoogt-detectiegraad-find-af/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/05/19/finacaf-n-229-565-hartfalen-verhoogt-cva-risico-bij-af-vooral-bij-jongere-patien/","published":"2026-06-17"},{"url":"https://hartvaat.nl/2025/10/07/vroege-substraatablatie-versus-antiaritmica-bij-vt-gerandomiseerde-trial/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2018/01/01/supraventriculaire-ectopie-na-af-ablatie-voorspelt-recidief/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/03/01/katheterablatie-als-eerstelijnsbehandeling-bij-paroxysmaal-af-5-jaarsresultaten/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"julia-vogler","type":"person","url":"https://hartvaat.nl/mensen/julia-vogler/","name":"Julia Vogler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/14/ulysses-echogeleide-venapunctie-halveert-toegangscomplicaties-bij-af-ablatie/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2024/12/17/ablatiestrategie-bij-af-recidief-na-duurzame-pvi/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/05/02/style-af-veneuze-closure-device-versus-figuur-van-acht-hechting-na-af-ablatie/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2022/07/15/geindividualiseerde-versus-standaard-cryoballonablatie-bij-paroxysmaal-af/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2021/10/09/gewichtsverlies-voor-af-ablatie-sort-af-gerandomiseerde-trial/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2021/05/21/firm-ablatie-versus-pvi-bij-paroxysmaal-af-gerandomiseerde-resultaten/","published":"2021-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kari-saunamaki","type":"person","url":"https://hartvaat.nl/mensen/kari-saunamaki/","name":"Kari Saunamäki","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karl-fengler","type":"person","url":"https://hartvaat.nl/mensen/karl-fengler/","name":"Karl Fengler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2020/03/01/slagvolumeveranderingen-na-renale-denervatie-cardiale-mri-inzichten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/08/01/renale-denervatie-bij-geisoleerde-systolische-hypertensie-vergelijking-van-kathe/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/01/29/drie-armen-vergelijkende-renale-denervatie-radiosound-htn/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2019/01/22/milde-hypothermie-bij-cardiogene-shock-complicerend-mi/","published":"2019-01-22"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karl-patrik-kresoja","type":"person","url":"https://hartvaat.nl/mensen/karl-patrik-kresoja/","name":"Karl-Patrik Kresoja","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/28/gestandaardiseerd-stappenplan-voor-tricuspidalisinsufficientie-van-verwijzing-to/","published":"2026-04-19"},{"url":"https://hartvaat.nl/2020/03/01/slagvolumeveranderingen-na-renale-denervatie-cardiale-mri-inzichten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/08/01/renale-denervatie-bij-geisoleerde-systolische-hypertensie-vergelijking-van-kathe/","published":"2019-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"katharina-mayer","type":"person","url":"https://hartvaat.nl/mensen/katharina-mayer/","name":"Katharina Mayer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2019/01/15/10-jaarsuitkomsten-van-drie-limus-eluting-stents-coating-vergelijking/","published":"2019-01-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"katie-harris","type":"person","url":"https://hartvaat.nl/mensen/katie-harris/","name":"Katie Harris","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/09/sekseverschillen-in-lipiden-en-lipoproteinen-en-het-cardiovasculaire-risico-uk-b/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/03/24/systemische-inflammatie-en-recidief-na-een-af-gerelateerd-herseninfarct/","published":"2026-03-24"},{"url":"https://hartvaat.nl/2025/11/01/magnesiumsuppletie-en-bloeddruk-meta-analyse-van-rct-s/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/03/01/frailteit-en-antihypertensieve-behandeling-bij-ouderen-meta-analyse/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2023/03/01/korttermijn-bloeddrukmetingen-voorspellen-langetermijneffect-van-behandeling/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/12/21/bloeddrukverlaging-en-dementiepreventie-ipd-meta-analyse/","published":"2022-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"katrin-borof","type":"person","url":"https://hartvaat.nl/mensen/katrin-borof/","name":"Katrin Borof","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","published":"2022-09-13"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-kausik-ray","type":"person","url":"https://hartvaat.nl/mensen/prof-kausik-ray/","name":"Kausik Ray","title":"Imperial College London, VK","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":0,"articles":[],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/ldl-cholesterol/","title":"Sessie 2: LDL-cholesterol"},{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/implementatie-lipidenmanagement/","title":"Sessie 4: Implementatie van lipidenmanagement — praktische uitdagingen"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kelley-r-h-branch","type":"person","url":"https://hartvaat.nl/mensen/kelley-r-h-branch/","name":"Kelley R H Branch","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/03/28/amplitude-o-dosisrespons-van-efpeglenatide-op-cv-uitkomsten-bij-diabetes/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2021/09/02/efpeglenatide-en-cv-en-renale-uitkomsten-bij-diabetes-type-2-nejm-amplitude-o/","published":"2021-09-02"},{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kenneth-b-margulies","type":"person","url":"https://hartvaat.nl/mensen/kenneth-b-margulies/","name":"Kenneth B Margulies","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/03/01/kaliumnitraat-bij-hfpef-gerandomiseerde-trial/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2018/12/01/liraglutide-en-gewicht-bij-gevorderd-hfref-fight-trial-inzichten/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","published":"2018-11-06"},{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2016/08/02/liraglutide-en-klinische-stabiliteit-bij-gevorderd-hartfalen-met-verminderde-ef-/","published":"2016-08-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"khaja-m-chinnakondepalli","type":"person","url":"https://hartvaat.nl/mensen/khaja-m-chinnakondepalli/","name":"Khaja M Chinnakondepalli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","published":"2024-08-27"},{"url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2019/05/07/gezondheidsstatus-na-mitraclip-bij-hf-met-secundaire-mr-coapt/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ki-hong-choi","type":"person","url":"https://hartvaat.nl/mensen/ki-hong-choi/","name":"Ki Hong Choi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kirsten-b-holven","type":"person","url":"https://hartvaat.nl/mensen/kirsten-b-holven/","name":"Kirsten B. Holven","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/25/eas-consensus-familiaire-hypercholesterolemie-bij-kinderen-en-adolescenten/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/04/19/fh-vrouwen-verliezen-mediaan-2-9-jaar-lipidenverlagende-behandeling-rond-elke-ki/","published":"2026-05-05"},{"url":"https://hartvaat.nl/2026/02/19/enkelvoudige-onverzadigde-vetzuren-in-vetweefsel-en-het-risico-op-perifeer-vaatl/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/01/16/statinegebruik-in-de-zwangerschap-en-congenitale-afwijkingen-noors-cohort/","published":"2026-01-16"},{"url":"https://hartvaat.nl/2025/11/26/lipideveranderingen-bij-vrouwen-met-fh-tijdens-de-menopauzale-transitie/","published":"2025-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"konstantinos-c-koskinas","type":"person","url":"https://hartvaat.nl/mensen/konstantinos-c-koskinas/","name":"Konstantinos C Koskinas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","published":"2026-04-09"},{"url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neoatherosclerose-na-stemi-secundaire-analyse/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2019/11/19/evolocumab-voor-vroege-ldl-verlaging-bij-acs-evopacs/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2018/04/07/statines-en-niet-statine-ldl-verlagers-en-cardiovasculaire-uitkomsten-meta-analy/","published":"2018-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kristi-h-monahan","type":"person","url":"https://hartvaat.nl/mensen/kristi-h-monahan/","name":"Kristi H Monahan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","published":"2022-08-16"},{"url":"https://hartvaat.nl/2022/03/15/leeftijd-en-uitkomsten-van-katheterablatie-versus-medicatie-bij-af-cabana/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/07/13/ablatie-versus-medicatie-bij-af-naar-ras-en-etniciteit/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2020/06/30/af-recidief-na-ablatie-versus-antiaritmica-in-cabana/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-medicamenteus-bij-af-en-kwaliteit-van-leven-jama-cabana-q/","published":"2019-04-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kristian-wachtell","type":"person","url":"https://hartvaat.nl/mensen/kristian-wachtell/","name":"Kristian Wachtell","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/11/01/sekseverschillen-in-effect-van-bloeddrukverlaging-ipd-meta-analyse/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2021/05/05/veroorzaken-betablokkers-depressie-systematische-review-en-meta-analyse/","published":"2021-05-05"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kunihiro-matsushita","type":"person","url":"https://hartvaat.nl/mensen/kunihiro-matsushita/","name":"Kunihiro Matsushita","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/27/albuminurie-geassocieerd-met-verhoogd-risico-op-abdominaal-aorta-aneurysma/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2021/11/01/rustduur-voor-bloeddrukmeting-best-rest-trial/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/09/01/albuminurietesting-bij-hypertensie-en-diabetes-ipd-meta-analyse/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2017/01/03/traditionele-cv-risicofactoren-en-veneuze-trombo-embolie-individuele-patientdata/","published":"2017-01-03"},{"url":"https://hartvaat.nl/2016/02/04/risicoprojectie-voor-nierfalen-bij-levende-nierdonorkandidaten/","published":"2016-02-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lama-ghazi","type":"person","url":"https://hartvaat.nl/mensen/lama-ghazi/","name":"Lama Ghazi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/10/21/prompt-ahf-epd-alerts-verbeteren-hartfalenmedicatie-bij-ontslag/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2023/03/28/secundaire-hypertensie-bij-kinderen-jama-klinische-diagnostiek/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2022/06/07/elektronische-alerts-verbeteren-hartfalenbehandeling-in-de-polikliniek/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2020/10/01/intensieve-versus-standaard-bloeddrukbehandeling-op-white-coat-effect-en-gemaske/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/06/01/intensieve-bloeddrukverlaging-en-risico-op-af-sprint-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2017/08/01/intensieve-bloeddrukverlaging-en-linkerventrikelhypertrofie-sprint-echocardiogra/","published":"2017-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"larissa-fabritz","type":"person","url":"https://hartvaat.nl/mensen/larissa-fabritz/","name":"Larissa Fabritz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2020/05/01/predictie-van-af-recidief-na-ablatie-systematische-review-van-prognostische-mode/","published":"2020-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lars-s-maier","type":"person","url":"https://hartvaat.nl/mensen/lars-s-maier/","name":"Lars S Maier","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/23/residuele-linker-atriale-v-golf-voorspelt-de-uitkomst-van-mitralisklep-edge-to-e/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2025/12/01/economische-ziektelast-van-hartfalen-in-europa-systematische-review/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/25/digitoxine-bij-hfref-gerandomiseerde-trial-nejm/","published":"2025-09-25"},{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"laura-a-magee","type":"person","url":"https://hartvaat.nl/mensen/laura-a-magee/","name":"Laura A Magee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/03/01/orale-antihypertensiva-bij-niet-ernstige-zwangerschapshypertensie-netwerkmeta-an/","published":"2022-03-01"},{"url":"https://hartvaat.nl/2019/09/21/orale-antihypertensiva-bij-ernstige-hypertensie-in-de-zwangerschap-lancet-vergel/","published":"2019-09-21"},{"url":"https://hartvaat.nl/2018/06/01/amenorroe-duur-bij-start-antihypertensiva-in-de-zwangerschap-chips-secundaire-an/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/12/01/placental-growth-factor-als-prognostisch-instrument-bij-hypertensieve-zwangersch/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2016/11/01/chips-trial-is-ernstige-hypertensie-in-de-zwangerschap-meer-dan-alleen-verhoogde/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/01/kostenimplicaties-van-minder-strikte-versus-strikte-bloeddrukcontrole-bij-zwange/","published":"2016-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lawton-s-cooper","type":"person","url":"https://hartvaat.nl/mensen/lawton-s-cooper/","name":"Lawton S Cooper","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/06/01/invested-griepvaccin-immuunrespons-bij-hoog-risico-cv-patienten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2018/11/27/economische-en-qol-uitkomsten-van-nt-probnp-geleide-hf-therapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2017/08/22/natriuretisch-peptide-geleide-therapie-bij-hoogrisico-hartfalen-jama-guide-it/","published":"2017-08-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"leif-friberg","type":"person","url":"https://hartvaat.nl/mensen/leif-friberg/","name":"Leif Friberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/12/03/nt-probnp-en-ecg-screening-bij-75-jarigen-voor-af-detectie-rct/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2023/01/14/strokestop-af-screening-is-kosteneffectief-bij-75-76-jarigen/","published":"2023-01-14"},{"url":"https://hartvaat.nl/2021/10/23/systematische-af-screening-en-klinische-uitkomsten-lancet-strokestop/","published":"2021-10-23"},{"url":"https://hartvaat.nl/2020/01/01/stapsgewijze-af-screening-met-nt-probnp-strokestop-ii-resultaten/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2017/08/01/nt-probnp-bij-systematische-screening-op-atriumfibrilleren/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/02/01/stapsgewijze-massascreening-op-af-met-nt-probnp-strokestop-ii-studieontwerp/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lene-klvgaard","type":"person","url":"https://hartvaat.nl/mensen/lene-klvgaard/","name":"Lene Kløvgaard","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lia-evi-bang","type":"person","url":"https://hartvaat.nl/mensen/lia-evi-bang/","name":"Lia Evi Bang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/03/coronaire-vaatspasmen-bij-overlevenden-van-hartstilstand/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lianglong-chen","type":"person","url":"https://hartvaat.nl/mensen/lianglong-chen/","name":"Lianglong Chen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/05/11/ticagrelor-monotherapie-versus-dapt-na-1-maand-bij-acs-lancet-rct/","published":"2024-05-11"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"},{"url":"https://hartvaat.nl/2017/10/17/farmaco-invasieve-strategie-met-halve-dosis-alteplase-versus-primaire-pci-bij-st/","published":"2017-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ling-tao","type":"person","url":"https://hartvaat.nl/mensen/ling-tao/","name":"Ling Tao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/05/driejaarsuitkomsten-van-linker-hartoorsluiting-met-of-zonder-ablatie-record-stud/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2022/01/18/magnetisch-gecontroleerde-capsule-endoscopie-voor-antiplaatjestherapie-gi-schade/","published":"2022-01-18"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lionel-tarassenko","type":"person","url":"https://hartvaat.nl/mensen/lionel-tarassenko/","name":"Lionel Tarassenko","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-bloeddrukcontrole-bij-risicozwangerschap-jama-bump-2/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2020/10/01/thuismonitoring-met-technologie-ondersteund-management-bij-chronisch-hf-gerandom/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2018/08/01/zelfmanagement-van-postnatale-hypertensie-de-snap-ht-trial/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/03/10/zelfgemeten-bloeddruk-met-of-zonder-telemonitoring-voor-medicatietitratie-lancet/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2016/02/09/sms-berichten-ter-ondersteuning-van-therapietrouw-bij-hoge-bloeddruk-de-star-tri/","published":"2016-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"liu-he","type":"person","url":"https://hartvaat.nl/mensen/liu-he/","name":"Liu He","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2024/11/12/recaticimab-als-toevoeging-aan-statines-fase-3-remain-2/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","published":"2022-10-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"luc-janssens","type":"person","url":"https://hartvaat.nl/mensen/luc-janssens/","name":"Luc Janssens","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/02/18/lage-dosis-sirolimus-bdp-stent-versus-tweede-generatie-des-non-inferioriteit/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/01/02/preventie-van-cardiogene-shock-na-acuut-mi/","published":"2019-01-02"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lucy-mackillop","type":"person","url":"https://hartvaat.nl/mensen/lucy-mackillop/","name":"Lucy Mackillop","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/01/bloeddrukzelfmanagement-en-vasculaire-remodelling-na-hypertensieve-zwangerschap/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/02/13/pop-ht-bloeddrukzelfmanagement-verbetert-cardiale-remodelling-na-hypertensieve-z/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2023/11/28/pop-ht-zelfmanagement-van-bloeddruk-na-hypertensieve-zwangerschap-jama-rct/","published":"2023-11-28"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-bloeddrukcontrole-bij-risicozwangerschap-jama-bump-2/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2018/09/01/thuis-versus-praktijkbloeddrukmeting-in-de-zwangerschap/","published":"2018-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"luis-nombela-franco","type":"person","url":"https://hartvaat.nl/mensen/luis-nombela-franco/","name":"Luis Nombela-Franco","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/12/23/korte-anticoagulatie-versus-dapt-na-laa-occlusie-devicetrombosepreventie/","published":"2025-12-23"},{"url":"https://hartvaat.nl/2025/12/21/tavi-plus-ffr-geleide-pci-gecombineerde-benadering-onderzocht/","published":"2025-12-21"},{"url":"https://hartvaat.nl/2025/04/10/dapagliflozine-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2025-04-10"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2017/01/15/linker-hartoorsluiting-versus-medicamenteuze-behandeling-bij-af-netwerkmeta-anal/","published":"2017-01-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"luis-ortega-paz","type":"person","url":"https://hartvaat.nl/mensen/luis-ortega-paz/","name":"Luis Ortega-Paz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/18/cv-effecten-en-verdraagbaarheid-van-glp-1-agonisten-meta-analyse/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2019/12/03/magnesium-resorbeerbare-scaffold-versus-metallic-stent-bij-stemi-biosolve-iii/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2018/08/07/adenosine-en-ticagrelorspiegels-bij-patienten-met-en-zonder-ticagrelor-dyspneu/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2018/03/20/effecten-van-ticagrelor-prasugrel-of-clopidogrel-op-endotheelfunctie/","published":"2018-03-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lutgarde-thijs","type":"person","url":"https://hartvaat.nl/mensen/lutgarde-thijs/","name":"Lutgarde Thijs","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/12/21/bloeddrukverlaging-en-dementiepreventie-ipd-meta-analyse/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2021/05/05/bloeddrukvariabiliteit-en-uitkomsten-bij-hfpef/","published":"2021-05-05"},{"url":"https://hartvaat.nl/2020/08/01/antidiabetica-en-cardiovasculaire-geneeskunde-meta-analyse-en-perspectief/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2018/10/01/prognostische-waarde-van-gemaskeerd-ongecontroleerde-hypertensie/","published":"2018-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mahboob-rahman","type":"person","url":"https://hartvaat.nl/mensen/mahboob-rahman/","name":"Mahboob Rahman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/01/09/diastolische-bloeddruk-en-intensieve-bloeddrukcontrole-sprint-analyse/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/01/01/intensieve-versus-standaard-bloeddrukcontrole-op-ambulante-bloeddruk-sprint-resu/","published":"2017-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mandeep-s-sidhu","type":"person","url":"https://hartvaat.nl/mensen/mandeep-s-sidhu/","name":"Mandeep S Sidhu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/23/gezondheidsstatus-na-invasieve-of-conservatieve-zorg-bij-coronairlijden-met-gevo/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","published":"2019-02-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marc-w-deyell","type":"person","url":"https://hartvaat.nl/mensen/marc-w-deyell/","name":"Marc W Deyell","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","published":"2024-02-16"},{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2021/11/01/af-last-en-qol-na-af-ablatie-cabana-substudie/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"},{"url":"https://hartvaat.nl/2019/11/26/cryoballon-versus-rf-ablatie-bij-af-beoordeeld-met-continue-monitoring-cryo-firs/","published":"2019-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maria-borentain","type":"person","url":"https://hartvaat.nl/mensen/maria-borentain/","name":"Maria Borentain","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maria-dorobantu","type":"person","url":"https://hartvaat.nl/mensen/maria-dorobantu/","name":"Maria Dorobantu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2021/03/09/bloeddrukverlagende-medicatie-naar-hypertensierichtlijn-in-lage-middeninkomensla/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2019/08/24/hypertensiezorg-in-44-lage-en-middeninkomenslanden-lancet/","published":"2019-08-24"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maria-rosa-costanzo","type":"person","url":"https://hartvaat.nl/mensen/maria-rosa-costanzo/","name":"Maria Rosa Costanzo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/05/off-label-dosering-van-sacubitril-valsartan-wijdverspreid-in-de-praktijk/","published":"2026-07-30"},{"url":"https://hartvaat.nl/2025/02/01/transveneuze-frenische-zenuwstimulatie-bij-centraal-slaapapneu-en-hartfalen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/02/13/implanteerbare-hemodynamische-monitoren-verbeteren-overleving-bij-hfref/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2022/07/14/guide-hf-en-de-impact-van-covid-19-op-hartfalenuitkomsten/","published":"2022-07-14"},{"url":"https://hartvaat.nl/2021/09/11/hemodynamisch-geleid-hf-management-lancet-guide-hf/","published":"2021-09-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mariell-jessup","type":"person","url":"https://hartvaat.nl/mensen/mariell-jessup/","name":"Mariell Jessup","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2018/10/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-hf-trials-jama-cardiology-review/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2016/12/06/comorbiditeiten-bij-hartfalen-hypertensie-obesitas-diabetes-hyperlipidemie-en-me/","published":"2016-12-06"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marius-m-hoeper","type":"person","url":"https://hartvaat.nl/mensen/marius-m-hoeper/","name":"Marius M Hoeper","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/10/23/sotatercept-bij-pah-binnen-het-eerste-jaar-na-diagnose-stellar-subanalyse/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2024/08/20/tadalafil-bij-gecombineerde-post-en-precapillaire-ph-en-hfpef/","published":"2024-08-20"},{"url":"https://hartvaat.nl/2024/06/18/sildenafil-dosisvergelijking-bij-pulmonale-arteriele-hypertensie/","published":"2024-06-18"},{"url":"https://hartvaat.nl/2023/04/20/stellar-sotatercept-bij-pulmonale-arteriele-hypertensie-nejm-fase-3/","published":"2023-04-20"},{"url":"https://hartvaat.nl/2018/02/20/morbiditeit-bij-pulmonaal-arteriele-hypertensie-als-prognostische-marker-voor-mo/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/04/01/hemodynamische-effecten-van-riociguat-bij-inoperabel-cteph/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marius-placzek","type":"person","url":"https://hartvaat.nl/mensen/marius-placzek/","name":"Marius Placzek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/05/reduce-mfa-dzhk25-trial-naar-antifibrotische-therapie-tegen-myocardfibrose-na-ta/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/02/03/kenmerken-van-asymptomatische-patienten-met-hartfalen-en-verminderde-ejectiefrac/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marko-noc","type":"person","url":"https://hartvaat.nl/mensen/marko-noc/","name":"Marko Noc","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2023/03/28/culprit-interventie-bij-cardiogene-shock-met-hartstilstand/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2020/11/24/vroege-coronairangiografie-versus-uitstel-na-hartstilstand-zonder-st-elevatie-pi/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2016/12/20/ticagrelor-versus-clopidogrel-bij-comateuze-overlevenden-van-reanimatie-met-pci/","published":"2016-12-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"markus-f-scheerer","type":"person","url":"https://hartvaat.nl/mensen/markus-f-scheerer/","name":"Markus F Scheerer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/05/finerenon-effectief-bij-type-1-diabetes-met-chronische-nierziekte/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martina-rothenbuhler","type":"person","url":"https://hartvaat.nl/mensen/martina-rothenbuhler/","name":"Martina Rothenbühler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2019/04/14/aki-en-bloedingen-en-mortaliteit-na-radiale-versus-femorale-toegang-bij-acs/","published":"2019-04-14"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2017/05/23/stralingsblootstelling-en-vasculaire-toegang-bij-acs-rad-matrix-trial/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marwah-abdalla","type":"person","url":"https://hartvaat.nl/mensen/marwah-abdalla/","name":"Marwah Abdalla","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/12/nhlbi-workshop-bloeddrukmeting-verfijnen-door-de-hele-levensloop-heen-knelpunten/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maryam-kavousi","type":"person","url":"https://hartvaat.nl/mensen/maryam-kavousi/","name":"Maryam Kavousi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/19/esc-atlas-2025-3-miljoen-cvd-doden-per-jaar-in-europa-middeninkomenlanden-hebben/","published":"2026-06-13"},{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2023/07/25/omega-3-biomarkers-en-incident-af-ipd-analyse/","published":"2023-07-25"},{"url":"https://hartvaat.nl/2023/02/08/stolling-en-atriumfibrilleren-systematische-review-en-meta-analyse/","published":"2023-02-08"},{"url":"https://hartvaat.nl/2021/05/01/mcp-1-en-cardiovasculaire-mortaliteit-populatie-gebaseerde-meta-analyse/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"masafumi-kitakaze","type":"person","url":"https://hartvaat.nl/mensen/masafumi-kitakaze/","name":"Masafumi Kitakaze","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2020/08/01/canagliflozine-bij-diabetes-type-2-met-chronisch-hf-candle-gerandomiseerde-trial/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"masahiro-murakami","type":"person","url":"https://hartvaat.nl/mensen/masahiro-murakami/","name":"Masahiro Murakami","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/09/09/summit-tirzepatide-effect-bij-hfpef-met-en-zonder-diabetes/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/07/29/summit-bmi-centrale-adipositas-en-gewichtsverlies-beinvloeden-tirzepatide-effect/","published":"2025-07-29"},{"url":"https://hartvaat.nl/2025/05/13/summit-tirzepatide-en-ckd-interactie-bij-hfpef-met-obesitas/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/03/11/summit-tirzepatide-en-klinisch-traject-bij-hfpef-met-obesitas-langetermijn/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/02/25/summit-tirzepatide-vermindert-lv-massa-en-paracardiaal-vetweefsel-bij-hfpef/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/01/30/summit-tirzepatide-bij-hfpef-met-obesitas-nejm/","published":"2025-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"massimo-grimaldi","type":"person","url":"https://hartvaat.nl/mensen/massimo-grimaldi/","name":"Massimo Grimaldi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/03/rechterhart-hemodynamiek-voor-risicostratificatie-bij-pulmonale-arteriele-hypert/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/09/21/ononderbroken-edoxaban-versus-vka-bij-af-ablatie-eliminate-af/","published":"2019-09-21"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2017/04/27/ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-nejm-re-circuit/","published":"2017-04-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matthias-bossard","type":"person","url":"https://hartvaat.nl/mensen/matthias-bossard/","name":"Matthias Bossard","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2021/11/01/antiplaatjestherapie-bij-mi-zonder-obstructief-coronairlijden-minoca/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2019/12/17/uitgebreide-vasodilatatie-versus-standaardzorg-bij-acuut-hf-jama-galactic-hf-pil/","published":"2019-12-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mattia-galli","type":"person","url":"https://hartvaat.nl/mensen/mattia-galli/","name":"Mattia Galli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2025/11/18/cv-effecten-en-verdraagbaarheid-van-glp-1-agonisten-meta-analyse/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2024/08/01/coronaire-microvasculaire-disfunctie-bij-hfpef-meta-analyse/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","published":"2022-03-07"},{"url":"https://hartvaat.nl/2021/04/17/geleide-versus-standaard-antiplaatjestherapie-na-pci-lancet-meta-analyse/","published":"2021-04-17"},{"url":"https://hartvaat.nl/2020/04/01/intracraniele-bloedingen-versus-stenttrombose-met-doac-antiplaatjes-versus-tripl/","published":"2020-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maurizio-ferrario","type":"person","url":"https://hartvaat.nl/mensen/maurizio-ferrario/","name":"Maurizio Ferrario","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/06/05/verlaagde-dosis-prasugrel-versus-standaard-clopidogrel-bij-oudere-acs-patienten/","published":"2018-06-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"melchior-seyfarth","type":"person","url":"https://hartvaat.nl/mensen/melchior-seyfarth/","name":"Melchior Seyfarth","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2017/12/14/mechanische-ondersteuning-bij-cardiogene-shock-systematische-review-en-meta-anal/","published":"2017-12-14"},{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-ondersteuning-versus-iabp-bij-cardiogene-shock-meta-analys/","published":"2017-01-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"melvin-d-lobo","type":"person","url":"https://hartvaat.nl/mensen/melvin-d-lobo/","name":"Melvin D Lobo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/12/01/centrale-iliacale-av-anastomose-bij-ongecontroleerde-hypertensie-rox-control-htn/","published":"2017-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-cheung","type":"person","url":"https://hartvaat.nl/mensen/michael-cheung/","name":"Michael Cheung","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/25/kdigo-overzicht-de-nier-centraal-in-het-cardiovasculair-renaal-metabool-ckm-synd/","published":"2026-05-31"},{"url":"https://hartvaat.nl/2026/03/06/kdigo-consensusconferentie-uitdagingen-bij-gecombineerd-hartfalen-en-nierziekte/","published":"2026-03-15"},{"url":"https://hartvaat.nl/2026/02/18/groene-dialyse-duurzame-zorg-groei-en-innovatie-kdigo-conferentie/","published":"2026-02-18"},{"url":"https://hartvaat.nl/2025/10/07/relatie-tussen-obesitas-en-ckd-conclusies-van-een-kdigo-conferentie/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2021/03/01/kdigo-2021-bloeddruk-bij-ckd-executive-summary/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2020/05/01/bloeddruk-en-volumemanagement-bij-dialyse-kdigo-controverseconferentie/","published":"2020-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-e-nassif","type":"person","url":"https://hartvaat.nl/mensen/michael-e-nassif/","name":"Michael E Nassif","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/05/aficamten-veilig-en-effectief-bij-langdurige-behandeling-van-obstructieve-hcm/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/01/01/aficamten-bij-obstructieve-hcm-multidomeinanalyse-van-maple-hcm/","published":"2026-03-14"},{"url":"https://hartvaat.nl/2025/01/01/aficamten-versus-metoprolol-betere-levenskwaliteit-bij-obstructieve-hcm/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2021/04/27/empagliflozine-en-pulmonalisdruk-bij-hf-embrace-hf/","published":"2021-04-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-g-shlipak","type":"person","url":"https://hartvaat.nl/mensen/michael-g-shlipak/","name":"Michael G Shlipak","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/08/20/aangetaste-tubulaire-secretiecapaciteit-verhoogt-cardiovasculaire-sterfte-hunt-s/","published":"2026-08-28"},{"url":"https://hartvaat.nl/2026/03/13/tubulaire-nierschade-hangt-samen-met-natriumretentie-en-diureticarespons-bij-acu/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2024/09/01/troponine-nt-probnp-en-cognitieve-uitkomsten-in-sprint/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2022/10/18/intensieve-bloeddrukverlaging-bij-maligne-linkerventrikel-hypertrofie/","published":"2022-10-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-j-reardon","type":"person","url":"https://hartvaat.nl/mensen/michael-j-reardon/","name":"Michael J Reardon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2020/10/01/natuurlijk-beloop-van-asymptomatische-ernstige-aortastenose-jama-cardiology-meta/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-zelfexpanderende-klep-bij-laagrisicopatienten-nejm-evolut-low-risk/","published":"2019-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-kuhne","type":"person","url":"https://hartvaat.nl/mensen/michael-kuhne/","name":"Michael Kühne","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/06/02/pulsfield-ablatie-levert-betere-vrijwaring-van-recidief-dan-cryoballoon-bij-paro/","published":"2026-08-12"},{"url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","published":"2026-05-27"},{"url":"https://hartvaat.nl/2026/03/30/leadless-atriaal-pacen-geeft-minder-complicaties-dan-transveneus-1-jaars-medicar/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2025/04/17/pfa-versus-cryoballon-bij-paroxysmaal-af-gerandomiseerde-trial/","published":"2025-04-17"},{"url":"https://hartvaat.nl/2023/11/02/duurzaamheid-van-pvi-bij-af-meta-analyse/","published":"2023-11-02"},{"url":"https://hartvaat.nl/2016/10/07/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-af-herinterventierate-e/","published":"2016-10-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-t-lu","type":"person","url":"https://hartvaat.nl/mensen/michael-t-lu/","name":"Michael T Lu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/28/epic-hiv-trial-pcsk9-remming-ter-cardiovasculaire-preventie-bij-hiv-patienten/","published":"2026-04-06"},{"url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","published":"2025-10-02"},{"url":"https://hartvaat.nl/2023/08/24/reprieve-pitavastatine-vermindert-cv-events-bij-hiv-nejm/","published":"2023-08-24"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2019/03/05/inspanningstest-versus-ccta-bij-diabetes-met-verdenking-coronairlijden/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2017/11/21/coronair-calcium-en-prognostische-waarde-bij-pijn-op-de-borst-promise-studie/","published":"2017-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mikael-dellborg","type":"person","url":"https://hartvaat.nl/mensen/mikael-dellborg/","name":"Mikael Dellborg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/02/02/reductie-in-totale-cardiovasculaire-events-met-ezetimibe-simvastatine-na-acs-imp/","published":"2016-02-02"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"milad-nazarzadeh","type":"person","url":"https://hartvaat.nl/mensen/milad-nazarzadeh/","name":"Milad Nazarzadeh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/25/bloeddrukverlaging-beschermt-over-het-hele-spectrum-van-chronische-nierschade-la/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2023/11/01/sekseverschillen-in-effect-van-bloeddrukverlaging-ipd-meta-analyse/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2022/07/27/langetermijneffect-van-antihypertensiva-op-bloeddruk-meta-analyse-op-individueel/","published":"2022-07-27"},{"url":"https://hartvaat.nl/2021/11/13/bloeddrukverlaging-en-risico-op-diabetes-type-2-lancet-bplttc-ipd-meta-analyse/","published":"2021-11-13"},{"url":"https://hartvaat.nl/2020/10/01/thuismonitoring-met-technologie-ondersteund-management-bij-chronisch-hf-gerandom/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/05/01/inflammatiemarkers-en-risico-op-hypertensie-meta-analyse-van-cohortstudies/","published":"2019-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"min-chul-kim","type":"person","url":"https://hartvaat.nl/mensen/min-chul-kim/","name":"Min Chul Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/09/06/directe-versus-gestageerde-complete-revascularisatie-tijdens-index-opname-bij-st/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2023/11/14/early-unload-vroege-lv-ontlading-bij-va-ecmo-gerandomiseerde-trial/","published":"2023-11-14"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2021/10/09/ongeleide-de-escalatie-van-ticagrelor-naar-clopidogrel-na-mi-met-pci-lancet-talo/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2018/07/24/escitalopram-versus-placebo-bij-depressie-na-acs-en-langetermijn-cardiale-uitkom/","published":"2018-07-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mina-k-chung","type":"person","url":"https://hartvaat.nl/mensen/mina-k-chung/","name":"Mina K Chung","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mirvat-alasnag","type":"person","url":"https://hartvaat.nl/mensen/mirvat-alasnag/","name":"Mirvat Alasnag","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2026/05/26/esc-consensus-vrouwenhartcentra-whc-als-nieuw-zorgmodel-in-europa/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","published":"2025-07-21"},{"url":"https://hartvaat.nl/2024/01/01/verkorte-dapt-bij-hoog-bloedingsrisico-geen-sekseverschillen/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mitsuaki-matsumura","type":"person","url":"https://hartvaat.nl/mensen/mitsuaki-matsumura/","name":"Mitsuaki Matsumura","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2016/11/26/oct-versus-ivus-versus-angiografie-bij-coronaire-stentimplantatie-lancet-ilumien/","published":"2016-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"modele-o-ogunniyi","type":"person","url":"https://hartvaat.nl/mensen/modele-o-ogunniyi/","name":"Modele O Ogunniyi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2024/10/15/aha-scientific-statement-nierdisfunctie-bij-gevorderd-hartfalen/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"monica-m-colvin","type":"person","url":"https://hartvaat.nl/mensen/monica-m-colvin/","name":"Monica M Colvin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"moussa-mansour","type":"person","url":"https://hartvaat.nl/mensen/moussa-mansour/","name":"Moussa Mansour","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/07/02/pfa-versus-thermale-ablatie-bij-paroxysmaal-af-aritmielastanalyse/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/02/01/pulmonaalvenenstenose-na-pfa-versus-thermale-ablatie-vergelijking/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/11/02/advent-pulsed-field-ablatie-non-inferieur-aan-thermale-ablatie-bij-af-nejm/","published":"2023-11-02"},{"url":"https://hartvaat.nl/2022/06/21/mri-geleide-fibroseablatie-versus-conventionele-ablatie-bij-persisterend-af/","published":"2022-06-21"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mu-qin","type":"person","url":"https://hartvaat.nl/mensen/mu-qin/","name":"Mu Qin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/12/01/ice-versus-tee-bij-af-ablatie-gerandomiseerde-trial/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/10/31/pfa-versus-thermale-ablatie-periprocedurale-en-middellangetermijneffecten/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2025/10/31/herhaalde-in-situ-ablatie-versus-uitgebreide-ablatie-bij-recidief-persisterend-a/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2025/08/12/catheterablatie-versus-rate-control-bij-persisterend-af-en-ouder-hartfalen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2023/05/19/drie-substraatstrategieen-voor-persisterend-af-vergeleken-multicenter-rct/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2021/05/21/extrapulmonale-vein-driver-mapping-bij-persisterend-af-bij-obese-patienten/","published":"2021-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mukul-sharma","type":"person","url":"https://hartvaat.nl/mensen/mukul-sharma/","name":"Mukul Sharma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2024/05/16/annexa-i-andexanet-alfa-bij-factor-xa-remmer-geassocieerde-intracerebrale-bloedi/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2023/10/24/laaos-iii-laa-occlusie-en-anticoagulatiegebruik/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","published":"2021-06-03"},{"url":"https://hartvaat.nl/2018/06/09/dabigatran-bij-myocardschade-na-niet-cardiale-chirurgie-lancet-manage-trial/","published":"2018-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"neil-j-stone","type":"person","url":"https://hartvaat.nl/mensen/neil-j-stone/","name":"Neil J Stone","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/01/01/vitamine-d-voorkomt-statine-gerelateerde-spierklachten-niet/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2021/08/31/2021-acc-consensus-ascvd-risicoreductie-bij-persistente-hypertriglyceridemie/","published":"2021-08-31"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicholas-a-boon","type":"person","url":"https://hartvaat.nl/mensen/nicholas-a-boon/","name":"Nicholas A Boon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","published":"2025-01-25"},{"url":"https://hartvaat.nl/2025/01/21/evolved-vroege-interventie-bij-asymptomatische-ernstige-aortastenose-met-myocard/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","published":"2018-09-06"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/04/19/ct-coronairangiografie-voor-het-sturen-van-beleid-bij-coronairlijden/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicolas-delarche","type":"person","url":"https://hartvaat.nl/mensen/nicolas-delarche/","name":"Nicolas Delarche","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/04/26/vroege-aldosteronblokkade-bij-acuut-myocardinfarct-de-albatross-trial/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nikolaos-dagres","type":"person","url":"https://hartvaat.nl/mensen/nikolaos-dagres/","name":"Nikolaos Dagres","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/10/12/castle-htx-af-ablatie-bij-eindstadium-hartfalen-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/02/16/p-golfduur-voorspelt-af-recidief-na-catheterablatie-meta-analyse/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2020/01/01/weglaten-van-aspirine-bij-gecombineerde-antitrombotische-therapie-voor-af-acs-he/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2018/11/01/individueel-aangepaste-versus-gestandaardiseerde-substraatmodificatie-bij-rf-abl/","published":"2018-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"norihiro-kogame","type":"person","url":"https://hartvaat.nl/mensen/norihiro-kogame/","name":"Norihiro Kogame","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/04/23/hedendaagse-uitkomsten-na-cabg-voor-hoofdstamlijden/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"oleg-averkov","type":"person","url":"https://hartvaat.nl/mensen/oleg-averkov/","name":"Oleg Averkov","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"olivier-barthelemy","type":"person","url":"https://hartvaat.nl/mensen/olivier-barthelemy/","name":"Olivier Barthélémy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/11/09/ffr-voor-behandeling-van-multivatencoronairlijden-jacc/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2021/01/19/residuele-syntax-score-bij-cardiogene-shock/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"olivier-f-bertrand","type":"person","url":"https://hartvaat.nl/mensen/olivier-f-bertrand/","name":"Olivier F Bertrand","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/02/18/lage-dosis-sirolimus-bdp-stent-versus-tweede-generatie-des-non-inferioriteit/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pablo-garcia-pavia","type":"person","url":"https://hartvaat.nl/mensen/pablo-garcia-pavia/","name":"Pablo Garcia-Pavia","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/01/01/aficamten-bij-obstructieve-hcm-multidomeinanalyse-van-maple-hcm/","published":"2026-03-14"},{"url":"https://hartvaat.nl/2025/01/01/aficamten-versus-metoprolol-betere-levenskwaliteit-bij-obstructieve-hcm/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2025/05/27/vutrisiran-bij-attr-cm-impact-van-hartfalenernst-op-effectiviteit/","published":"2025-05-27"},{"url":"https://hartvaat.nl/2024/01/01/tafamidis-en-cardiale-functie-bij-attr-cm-post-hoc-attr-act-analyse/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2023/07/20/ni006-antilichaam-voor-afbraak-van-cardiale-transthyretine-amyloid-nejm-fase-1/","published":"2023-07-20"},{"url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","published":"2023-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pamela-b-morris","type":"person","url":"https://hartvaat.nl/mensen/pamela-b-morris/","name":"Pamela B Morris","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/10/04/2022-acc-expert-consensus-niet-statine-therapieen-voor-ldl-verlaging-bij-ascvd/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2021/08/31/2021-acc-consensus-ascvd-risicoreductie-bij-persistente-hypertriglyceridemie/","published":"2021-08-31"},{"url":"https://hartvaat.nl/2020/09/01/2020-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2018/12/18/2018-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2017/10/03/2017-acc-gerichte-update-niet-statinetherapie-voor-ldl-verlaging/","published":"2017-10-03"},{"url":"https://hartvaat.nl/2016/11/22/management-van-klinisch-significante-geneesmiddelinteracties-met-statines-aha-aa/","published":"2016-11-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pantelis-a-sarafidis","type":"person","url":"https://hartvaat.nl/mensen/pantelis-a-sarafidis/","name":"Pantelis A Sarafidis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/27/consensus-breid-het-cardio-renaal-metabool-syndroom-uit-met-de-lever-cklms-in-de/","published":"2026-07-18"},{"url":"https://hartvaat.nl/2026/01/27/aldosteronsynthase-remmers-bij-ongecontroleerde-en-resistente-hypertensie-bij-ck/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2022/12/01/finerenon-bloeddrukeffecten-en-cardiorenale-uitkomsten-bij-ckd-en-diabetes/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/12/01/longechogeleide-behandeling-bij-hemodialysepatienten-met-hoog-cv-risico-gerandom/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/05/01/bloeddruk-en-volumemanagement-bij-dialyse-kdigo-controverseconferentie/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/06/01/longechogeleide-drooggewichtreductie-en-ambulante-bloeddruk-bij-hemodialyse/","published":"2019-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"patrick-b-mark","type":"person","url":"https://hartvaat.nl/mensen/patrick-b-mark/","name":"Patrick B Mark","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/06/30/kfre-aangepast-voor-multimorbiditeit-verbetert-schatting-nierfalenrisico/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2026/05/29/cardiovasculaire-ziekte-blijft-leidend-na-niertransplantatie-overzicht-van-uitda/","published":"2026-07-28"},{"url":"https://hartvaat.nl/2026/02/25/de-mondiale-ziektelast-van-chronische-nierziekte-elke-20-seconden-een-sterfgeval/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2026/02/09/communicatie-tussen-nier-en-hart-via-extracellulaire-vesikels/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/08/16/achieve-spironolacton-bij-dialysepatienten-internationale-rct/","published":"2025-08-16"},{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","published":"2021-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"patrick-goldstein","type":"person","url":"https://hartvaat.nl/mensen/patrick-goldstein/","name":"Patrick Goldstein","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/08/29/stream-2-halve-dosis-tenecteplase-bij-ouderen-met-stemi/","published":"2023-08-29"},{"url":"https://hartvaat.nl/2019/03/05/timing-van-prasugrel-start-en-coronairangiografie-bij-nstemi/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2016/04/26/vroege-aldosteronblokkade-bij-acuut-myocardinfarct-de-albatross-trial/","published":"2016-04-26"},{"url":"https://hartvaat.nl/2016/04/01/ischemisch-risicogebied-en-reperfusiemethode-bij-stemi-klinische-implicaties/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-elliott","type":"person","url":"https://hartvaat.nl/mensen/paul-elliott/","name":"Paul Elliott","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/07/30/visinname-en-visgerelateerde-metabolieten-geassocieerd-met-lagere-triglyceriden-/","published":"2026-08-16"},{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2022/09/26/zoutvervangers-verminderen-cardiovasculaire-events-systematische-review/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2022/05/17/kosteneffectiviteit-van-zoutsubstitutie-ssass-analyse/","published":"2022-05-17"},{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","published":"2021-09-16"},{"url":"https://hartvaat.nl/2021/02/01/urinezuur-bloeddruk-en-cv-ziekte-mendeliaanse-randomisatie-en-meta-analyse/","published":"2021-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-j-l-ong","type":"person","url":"https://hartvaat.nl/mensen/paul-j-l-ong/","name":"Paul J L Ong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2017/04/01/polymeervrije-biolimus-stent-bij-hoog-bloedingsrisico-met-acs-leaders-free-subst/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2017/03/30/ffr-geleide-multivaten-pci-bij-myocardinfarct-nejm-compare-acute/","published":"2017-03-30"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-r-kalra","type":"person","url":"https://hartvaat.nl/mensen/paul-r-kalra/","name":"Paul R Kalra","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/23/ijzertekort-bij-chronische-nierziekte-en-hartfalen-expertperspectieven/","published":"2026-03-04"},{"url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","published":"2024-04-21"},{"url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pedro-a-lemos","type":"person","url":"https://hartvaat.nl/mensen/pedro-a-lemos/","name":"Pedro A Lemos","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2022/11/01/vip-acs-dubbele-dosis-griepvaccinatie-na-acs-verbetert-uitkomsten-niet/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2017/07/01/syntax-scores-en-uitkomsten-bij-diabetes-met-multivatenlijden-gepoolde-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/05/31/diagnostische-ultrageluidspulsen-verbeteren-microvasculaire-flow-bij-stemi-met-m/","published":"2016-05-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-k-smith","type":"person","url":"https://hartvaat.nl/mensen/peter-k-smith/","name":"Peter K Smith","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2017/02/07/acc-aats-aha-2016-criteria-voor-gepaste-coronaire-revascularisatie-bij-acs-en-st/","published":"2017-02-07"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-leong-sit","type":"person","url":"https://hartvaat.nl/mensen/peter-leong-sit/","name":"Peter Leong-Sit","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","published":"2024-02-16"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2021/11/01/af-last-en-qol-na-af-ablatie-cabana-substudie/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2019/11/26/cryoballon-versus-rf-ablatie-bij-af-beoordeeld-met-continue-monitoring-cryo-firs/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2016/07/14/ablatie-versus-escalatie-van-antiaritmica-bij-ventriculaire-tachycardie-nejm-van/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-von-dadelszen","type":"person","url":"https://hartvaat.nl/mensen/peter-von-dadelszen/","name":"Peter von Dadelszen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/03/01/orale-antihypertensiva-bij-niet-ernstige-zwangerschapshypertensie-netwerkmeta-an/","published":"2022-03-01"},{"url":"https://hartvaat.nl/2019/09/21/orale-antihypertensiva-bij-ernstige-hypertensie-in-de-zwangerschap-lancet-vergel/","published":"2019-09-21"},{"url":"https://hartvaat.nl/2018/06/01/amenorroe-duur-bij-start-antihypertensiva-in-de-zwangerschap-chips-secundaire-an/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/12/01/placental-growth-factor-als-prognostisch-instrument-bij-hypertensieve-zwangersch/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2016/11/01/chips-trial-is-ernstige-hypertensie-in-de-zwangerschap-meer-dan-alleen-verhoogde/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/01/kostenimplicaties-van-minder-strikte-versus-strikte-bloeddrukcontrole-bij-zwange/","published":"2016-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"petr-neuzil","type":"person","url":"https://hartvaat.nl/mensen/petr-neuzil/","name":"Petr Neuzil","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/03/upgrade-van-draadloze-pacemaker-van-enkelvoudig-naar-tweekamersysteem/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2022/01/04/4-jaars-laa-sluiting-versus-niet-warfarine-oac-bij-af/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2020/12/08/laa-sluiting-versus-oac-bij-af-meta-analyse-van-gerandomiseerde-trials/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/06/30/laa-sluiting-versus-doac-bij-hoogrisico-af-vergelijkende-analyse/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2017/12/19/5-jaarsuitkomsten-na-linker-hartoorsluiting-prevail-en-protect-af/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2016/04/26/ablatie-versus-amiodaron-bij-persisterend-af-met-hartfalen-en-icd-gerandomiseerd/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"petra-nijst","type":"person","url":"https://hartvaat.nl/mensen/petra-nijst/","name":"Petra Nijst","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","published":"2023-06-09"},{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","published":"2022-09-29"},{"url":"https://hartvaat.nl/2021/12/21/iv-ijzercarboxymaltose-en-cardiale-reverse-remodellering-na-crt-iron-crt/","published":"2021-12-21"},{"url":"https://hartvaat.nl/2020/03/31/staken-van-neurohumorale-blokkade-na-crt/","published":"2020-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philip-a-kalra","type":"person","url":"https://hartvaat.nl/mensen/philip-a-kalra/","name":"Philip A Kalra","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/23/ijzertekort-bij-chronische-nierziekte-en-hartfalen-expertperspectieven/","published":"2026-03-04"},{"url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","published":"2024-04-21"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"},{"url":"https://hartvaat.nl/2018/10/09/sacubitril-valsartan-versus-irbesartan-bij-chronische-nierziekte/","published":"2018-10-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philip-joseph","type":"person","url":"https://hartvaat.nl/mensen/philip-joseph/","name":"Philip Joseph","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2026/05/13/wereldwijde-hf-registry-fev1-is-een-onafhankelijke-prognostische-factor-pleidooi/","published":"2026-05-15"},{"url":"https://hartvaat.nl/2023/08/24/vaste-dosiscombinatietherapie-voor-primaire-cv-preventie-ipd-meta-analyse/","published":"2023-08-24"},{"url":"https://hartvaat.nl/2023/02/01/aspirine-en-cardiovasculaire-uitkomsten-bij-chronische-nierziekte/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","published":"2021-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philippe-gosse","type":"person","url":"https://hartvaat.nl/mensen/philippe-gosse/","name":"Philippe Gosse","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/09/01/normalisatie-van-arteriele-stijfheid-en-cv-events-sparte-studie/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2017/03/01/24-uurs-bloeddrukmonitoring-bij-renale-denervatie-denerhtn-studie/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/09/20/medicatietrouw-en-bloeddrukeffecten-van-renale-denervatie-rsd-pathway-2-analyse/","published":"2016-09-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pierre-voisine","type":"person","url":"https://hartvaat.nl/mensen/pierre-voisine/","name":"Pierre Voisine","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/01/01/mitralisklepherstel-bij-degeneratief-mr-met-matige-tricuspidalisinsufficientie-2/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2021/12/04/posterieure-pericardiotomie-ter-preventie-van-af-na-hartchirurgie-lancet-palacs/","published":"2021-12-04"},{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","published":"2021-06-03"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pooja-dewan","type":"person","url":"https://hartvaat.nl/mensen/pooja-dewan/","name":"Pooja Dewan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/08/01/candesartan-dosering-bij-mannen-versus-vrouwen-met-chronisch-hartfalen/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2019/01/08/hfref-differentiele-impact-op-mannen-en-vrouwen/","published":"2019-01-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"poulabi-banerjee","type":"person","url":"https://hartvaat.nl/mensen/poulabi-banerjee/","name":"Poulabi Banerjee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2020/08/20/evinacumab-bij-homozygoot-familiaire-hypercholesterolemie-nejm/","published":"2020-08-20"},{"url":"https://hartvaat.nl/2020/07/14/alirocumab-bij-homozygoot-fh-odyssey-hofh/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2020/02/25/polygene-risicoscore-en-voordeel-van-alirocumab-bij-coronairlijden-odyssey-outco/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2019/08/06/angptl3-remming-met-monoklonaal-antilichaam-verlaagt-triglyceriden/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2017/07/20/genetische-en-farmacologische-inactivatie-van-angptl3-en-cardiovasculaire-ziekte/","published":"2017-07-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-deepak-l-bhatt","type":"person","url":"https://hartvaat.nl/mensen/prof-deepak-l-bhatt/","name":"Prof. Deepak L. Bhatt","title":"Directeur, Mount Sinai Fuster Heart Hospital, New York, VS","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":0,"articles":[],"videos":[{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/expert-momentum-hypercortisolisme-hypertensie-bhatt/","title":"Expertinterview: MOMENTUM — hypercortisolisme bij resistente hypertensie"},{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/highlights-surpass-cvot-hi-peitho-surviv/","title":"Highlights: SURPASS-CVOT, HI-PEITHO en SURVIV samengevat"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-henning-bundgaard","type":"person","url":"https://hartvaat.nl/mensen/prof-henning-bundgaard/","name":"Prof. Henning Bundgaard","title":"Cardioloog, Rigshospitalet, Kopenhagen","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/11/20/kaliumverhoging-bij-hoogrisicopatienten-voor-ventriculaire-aritmieen-rct/","published":"2025-11-20"},{"url":"https://hartvaat.nl/2023/06/01/genetische-bijdrage-aan-aortastenose-dyslipidemie-inflammatie-en-verkalking/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/03/21/genetische-varianten-geassocieerd-met-syncope-neurale-en-autonome-processen/","published":"2023-03-21"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-poet-ii-lbct/","title":"POET-II: kortere antibioticaduur bij endocarditis"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-sophia-zoungas","type":"person","url":"https://hartvaat.nl/mensen/prof-sophia-zoungas/","name":"Prof. Sophia Zoungas","title":"Hoogleraar, School of Public Health, Monash University, Melbourne","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2019/01/01/acute-creatininestijging-bij-start-ace-remmer-en-effecten-van-voortzetting-analy/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2016/11/22/plasma-lipidomiek-verbetert-cardiovasculaire-risicovoorspelling-bij-diabetes-typ/","published":"2016-11-22"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-staree-hotline/","title":"STAREE: statines voor gezonde 70-plussers"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ramesh-nadarajah","type":"person","url":"https://hartvaat.nl/mensen/ramesh-nadarajah/","name":"Ramesh Nadarajah","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/08/25/risicogestuurde-af-screening-met-machine-learning-verhoogt-detectiegraad-find-af/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/05/21/find-af-biomarker-stratificeert-prognose-bij-hfref-met-atriale-cardiomyopathie-z/","published":"2026-06-08"},{"url":"https://hartvaat.nl/2026/03/25/meta-analyse-glp-1-agonisten-voorkomen-hartfalen-in-type-2-diabetes-sterkste-eff/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/01/07/euroheart-definities-van-klinische-studie-eindpunten-voor-cvd/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2022/09/01/collaterale-schade-van-covid-19-aan-cardiovasculaire-zorg-meta-analyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/06/10/voorspelling-van-atriumfibrilleren-in-elektronische-gezondheidsdossiers-systemat/","published":"2022-06-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ransi-somaratne","type":"person","url":"https://hartvaat.nl/mensen/ransi-somaratne/","name":"Ransi Somaratne","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2018/10/23/evolocumab-en-coronaire-plaquesamenstelling-glagov-beeldvorming/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/12/01/evolocumab-bij-hoogrisicopatienten-met-laag-ldl-op-statine-fourier-subanalyse/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/04/19/evolocumab-versus-ezetimibe-bij-statine-intolerante-patienten-de-gauss-3-trial/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rebecca-a-juliano","type":"person","url":"https://hartvaat.nl/mensen/rebecca-a-juliano/","name":"Rebecca A Juliano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/01/03/icosapent-ethyl-en-cardiovasculaire-uitkomsten-bij-hypertriglyceridemie-nejm-red/","published":"2019-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"renicus-s-hermanides","type":"person","url":"https://hartvaat.nl/mensen/renicus-s-hermanides/","name":"Renicus S Hermanides","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/12/21/tavi-plus-ffr-geleide-pci-gecombineerde-benadering-onderzocht/","published":"2025-12-21"},{"url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2022/10/18/asundexian-factor-xia-remmer-na-acs-fase-2-dosisfindingsstudie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2021/12/01/thin-cap-fibroatheroom-voorspelt-events-bij-diabetes-met-normale-ffr-combine-oct/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2019/10/24/genotype-geleide-p2y12-remmerkeuze-bij-primaire-pci-nejm-popular-genetics/","published":"2019-10-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ribo-tang","type":"person","url":"https://hartvaat.nl/mensen/ribo-tang/","name":"Ribo Tang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","published":"2022-10-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ricardo-correa-rotter","type":"person","url":"https://hartvaat.nl/mensen/ricardo-correa-rotter/","name":"Ricardo Correa-Rotter","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/20/raas-blokkade-in-de-levenscyclus-van-de-nier-actuele-behandelstandaard/","published":"2026-05-02"},{"url":"https://hartvaat.nl/2026/03/29/confidence-analyse-acute-egfr-daling-bij-empagliflozin-finerenone-is-reversibel-/","published":"2026-04-17"},{"url":"https://hartvaat.nl/2026/03/01/niergezonheid-voor-iedereen-zorg-voor-mensen-bescherming-van-de-planeet/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","published":"2025-03-24"},{"url":"https://hartvaat.nl/2021/03/31/dapagliflozine-en-mortaliteit-bij-ckd-dapa-ckd-pre-gespecificeerde-analyse/","published":"2021-03-31"},{"url":"https://hartvaat.nl/2020/10/08/dapagliflozine-bij-chronische-nierziekte-nejm-dapa-ckd/","published":"2020-10-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"richard-c-becker","type":"person","url":"https://hartvaat.nl/mensen/richard-c-becker/","name":"Richard C Becker","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2016/08/01/hospitalisaties-bij-atriumfibrilleren-analyse-uit-rocket-af/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/07/05/verslechterende-nierfunctie-en-uitkomsten-met-rivaroxaban-versus-warfarine-rocke/","published":"2016-07-05"},{"url":"https://hartvaat.nl/2016/07/01/natief-kleplijden-bij-af-patienten-op-warfarine-of-rivaroxaban/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/04/21/gdf-15-voorspelt-bloedingen-en-cardiovasculaire-events-bij-acuut-coronair-syndro/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/01/26/polyfarmacie-en-werkzaamheid-van-rivaroxaban-versus-warfarine-bij-atriumfibrille/","published":"2016-01-26"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"richard-j-schilling","type":"person","url":"https://hartvaat.nl/mensen/richard-j-schilling/","name":"Richard J Schilling","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2020/11/01/ablatie-index-geleide-af-ablatie-geactualiseerde-meta-analyse/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2019/06/01/heparinedosering-bij-ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-re/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/04/27/ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-nejm-re-circuit/","published":"2017-04-27"},{"url":"https://hartvaat.nl/2016/03/01/intrathoracale-impedantiemonitoring-bij-chronisch-hartfalen-de-limit-chf-studie/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-a-hegele","type":"person","url":"https://hartvaat.nl/mensen/robert-a-hegele/","name":"Robert A Hegele","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/01/29/nla-consensusupdate-familiaire-hypercholesterolemie-screening-diagnostiek-en-beh/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2025/06/24/inclisiran-bij-adolescenten-met-homozygote-fh-effectiviteit-en-veiligheid/","published":"2025-06-24"},{"url":"https://hartvaat.nl/2025/05/20/plozasiran-en-lipoproteine-deeltjesgrootte-bij-hypertriglyceridemie/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/01/09/plozasiran-bij-persisterende-chylomicronemie-en-pancreatitisrisico-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2024/09/12/zodasiran-sirna-tegen-angptl3-bij-gemengde-hyperlipidemie-nejm/","published":"2024-09-12"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-familiaire-chylomicronemie-nejm-fase-3/","published":"2024-05-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-gil","type":"person","url":"https://hartvaat.nl/mensen/robert-gil/","name":"Robert Gil","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/03/05/nationaal-cardiologisch-netwerk-als-nieuwe-zorgstandaard-in-polen/","published":"2026-04-12"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"roberto-latini","type":"person","url":"https://hartvaat.nl/mensen/roberto-latini/","name":"Roberto Latini","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/11/reboot-betablokkers-na-mi-sekseverschillen/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","published":"2025-09-13"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2018/01/16/hoog-sensitief-troponine-t-bij-chronisch-hartfalen-individuele-patientdata-meta-/","published":"2018-01-16"},{"url":"https://hartvaat.nl/2016/02/02/ciclosporine-a-bij-gereperfuseerd-myocardinfarct-de-multicenter-cycle-trial/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robin-hofmann","type":"person","url":"https://hartvaat.nl/mensen/robin-hofmann/","name":"Robin Hofmann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/10/07/help-mi-helicobacter-pylori-screening-na-acuut-mi-cluster-rct/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2024/04/18/abyss-betablokkers-na-mi-met-behouden-ef-niet-nodig-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2018/12/11/langetermijneffecten-van-zuurstof-op-sterfte-of-hf-hospitalisatie-na-verdenking-/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/10/01/zuurstof-bij-verdenking-acuut-mi-meta-analyse-van-gerandomiseerde-trials/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/08/01/zuurstoftherapie-bij-stemi-overzichtsartikel/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/09/28/zuurstoftherapie-bij-vermoedelijk-acuut-myocardinfarct-nejm-deto2x-ami/","published":"2017-09-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robin-lemmens","type":"person","url":"https://hartvaat.nl/mensen/robin-lemmens/","name":"Robin Lemmens","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/07/05/optimale-timing-van-anticoagulatie-na-ischemisch-cva-en-af-collaboratief-project/","published":"2025-07-05"},{"url":"https://hartvaat.nl/2024/07/13/convince-langetermijn-colchicine-voor-preventie-van-recidief-niet-cardioembolisc/","published":"2024-07-13"},{"url":"https://hartvaat.nl/2024/07/02/vroege-versus-late-doac-na-cva-met-hemorrhagische-transformatie-bij-af/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/05/16/annexa-i-andexanet-alfa-bij-factor-xa-remmer-geassocieerde-intracerebrale-bloedi/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2023/06/29/elan-vroege-versus-late-anticoagulatie-na-cva-bij-af-nejm/","published":"2023-06-29"},{"url":"https://hartvaat.nl/2020/08/18/optimale-bloeddruk-bij-shock-na-mi-en-hartstilstand/","published":"2020-08-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rod-s-taylor","type":"person","url":"https://hartvaat.nl/mensen/rod-s-taylor/","name":"Rod S Taylor","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/24/cochrane-review-interventies-om-deelname-aan-hartrevalidatie-te-bevorderen/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2025/12/01/hartrevalidatie-en-kwaliteit-van-leven-bij-hfpef-meta-analyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2023/02/07/inspanningsgerichte-hartrevalidatie-bij-coronairlijden-geactualiseerde-meta-anal/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2022/10/01/bloeddruk-in-hogere-versus-lagere-arm-en-cv-uitkomsten-interpress-ipd-meta-analy/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2019/04/02/inspanningsrevalidatie-bij-hf-ipd-meta-analyse-van-inspanningscapaciteit-en-qol/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/09/01/hartrevalidatie-en-lichamelijke-activiteit-systematische-review-en-meta-analyse/","published":"2018-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ronald-b-goldberg","type":"person","url":"https://hartvaat.nl/mensen/ronald-b-goldberg/","name":"Ronald B Goldberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/05/31/langetermijneffect-van-metformine-en-leefstijlinterventie-op-cardiovasculaire-ev/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2017/07/04/langetermijn-metformine-en-leefstijl-en-coronair-calcium-diabetes-prevention-pro/","published":"2017-07-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rui-providencia","type":"person","url":"https://hartvaat.nl/mensen/rui-providencia/","name":"Rui Providência","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/10/01/crt-bij-inotroop-afhankelijk-hartfalen-meta-analyse/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2022/01/04/enkele-freeze-cryoballonablatie-bij-af-ehra-systematische-review/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2020/11/01/ablatie-index-geleide-af-ablatie-geactualiseerde-meta-analyse/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/06/01/trends-in-plotse-hartdood-bij-hf-met-crt-systematische-review/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2018/03/01/doodsoorzaken-bij-crt-met-en-zonder-defibrillator-meta-analyse/","published":"2018-03-01"},{"url":"https://hartvaat.nl/2016/10/01/katheterablatie-bij-af-met-hypertrofische-cardiomyopathie-systematische-review-e/","published":"2016-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rune-wiseth","type":"person","url":"https://hartvaat.nl/mensen/rune-wiseth/","name":"Rune Wiseth","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2021/04/20/il-6-receptorremming-bij-acuut-stemi-gerandomiseerde-trial/","published":"2021-04-20"},{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2017/10/01/il-6-remming-en-coronaire-microvasculaire-en-endotheelfunctie-bij-myocardinfarct/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/09/29/drug-eluting-of-bare-metal-stents-bij-coronairlijden-nejm-norstent-trial/","published":"2016-09-29"},{"url":"https://hartvaat.nl/2016/08/07/il-6-receptorantagonist-tocilizumab-bij-nstemi-effect-op-inflammatie-en-troponin/","published":"2016-08-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sadiya-s-khan","type":"person","url":"https://hartvaat.nl/mensen/sadiya-s-khan/","name":"Sadiya S Khan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2021/04/01/canagliflozine-naar-diureticagebruik-canvas-post-hoc-analyse/","published":"2021-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sanghamitra-mohanty","type":"person","url":"https://hartvaat.nl/mensen/sanghamitra-mohanty/","name":"Sanghamitra Mohanty","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/09/01/sedatie-versus-narcose-bij-af-catheterablatie-meta-analyse/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/03/pfa-versus-cryoballon-voor-af-ablatie-multielectrode-vergelijking/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2021/02/05/laa-isolatie-tijdens-af-ablatie-geactualiseerde-meta-analyse/","published":"2021-02-05"},{"url":"https://hartvaat.nl/2018/08/01/linker-hartoorisolatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2016/11/01/linker-hartoorisolatie-bij-langdurig-persisterend-af-de-belief-trial/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/26/ablatie-versus-amiodaron-bij-persisterend-af-met-hartfalen-en-icd-gerandomiseerd/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"saqib-chowdhary","type":"person","url":"https://hartvaat.nl/mensen/saqib-chowdhary/","name":"Saqib Chowdhary","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2016/06/21/myocardiale-blush-en-microvasculaire-reperfusie-na-handmatige-trombectomie-bij-s/","published":"2016-06-21"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"scott-mcnitt","type":"person","url":"https://hartvaat.nl/mensen/scott-mcnitt/","name":"Scott McNitt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2018/05/01/crt-voordeel-bij-concordant-versus-discordant-linksbundeltakblok-esc-hf-pilot/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/11/01/klinische-presentatie-bij-eerste-hartfalenhospitalisatie-voorspelt-geen-heropnam/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/07/14/voorspelling-van-plotse-versus-niet-plotse-hartdood-na-mi-met-verminderde-lvef/","published":"2017-07-14"},{"url":"https://hartvaat.nl/2017/05/16/comorbiditeiten-en-crt-respons-madit-crt-langetermijnfollow-up/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/09/20/volledig-linkszijdig-reverse-remodelling-bij-crt-madit-crt-substudie/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/01/26/relatieve-wanddikte-en-risico-op-ventriculaire-tachyaritmieen-bij-linkerkamerdis/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sean-d-pokorney","type":"person","url":"https://hartvaat.nl/mensen/sean-d-pokorney/","name":"Sean D Pokorney","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/07/zorgpaden-na-nieuw-vastgesteld-atriumfibrilleren-rol-van-de-elektrofysioloog-en-/","published":"2026-07-18"},{"url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/06/apixaban-bij-af-op-hemodialyse-eerste-gerandomiseerde-trial/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2020/04/28/apixaban-versus-warfarine-bij-af-met-gevorderde-ckd/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2017/10/14/multifacet-interventie-voor-oac-gebruik-bij-af-lancet-impact-af/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2017/03/21/plotse-hartdood-bij-ischemisch-hartfalen-na-cabg-stich-resultaten/","published":"2017-03-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sean-p-collins","type":"person","url":"https://hartvaat.nl/mensen/sean-p-collins/","name":"Sean P Collins","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/04/09/dapagliflozine-bij-acuut-hartfalen-effectiviteit-en-veiligheid/","published":"2024-04-09"},{"url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/12/01/hartfalen-tijdens-de-covid-19-pandemie-klinische-en-organisatorische-dilemma-s/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2021/02/01/zelfzorginterventie-en-90-daags-uitkomsten-bij-acuut-hf-na-seh-ontslag-jama-card/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2017/08/07/trv027-biased-ligand-van-de-angiotensine-ii-receptor-bij-acuut-hartfalen-gerando/","published":"2017-08-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shayna-chotai","type":"person","url":"https://hartvaat.nl/mensen/shayna-chotai/","name":"Shayna Chotai","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shazia-ali","type":"person","url":"https://hartvaat.nl/mensen/shazia-ali/","name":"Shazia Ali","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/12/22/evinacumab-bij-kinderen-van-5-17-jaar-met-homozygote-familiaire-hypercholesterol/","published":"2025-12-22"},{"url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2023/11/01/evinacumab-bij-refractaire-hypercholesterolemie-langetermijn-effectiviteit-en-ve/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2020/12/10/evinacumab-bij-refractaire-hypercholesterolemie-nejm/","published":"2020-12-10"},{"url":"https://hartvaat.nl/2020/08/20/evinacumab-bij-homozygoot-familiaire-hypercholesterolemie-nejm/","published":"2020-08-20"},{"url":"https://hartvaat.nl/2020/07/14/alirocumab-bij-homozygoot-fh-odyssey-hofh/","published":"2020-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shrikant-i-bangdiwala","type":"person","url":"https://hartvaat.nl/mensen/shrikant-i-bangdiwala/","name":"Shrikant I Bangdiwala","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/01/01/rivaroxaban-plus-aspirine-bij-symptomatisch-pav-compass-subanalyse/","published":"2021-01-01"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2019/10/05/uitgebreide-community-interventie-bij-hypertensie-lancet-hope-4/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2018/06/09/dabigatran-bij-myocardschade-na-niet-cardiale-chirurgie-lancet-manage-trial/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"siddique-a-abbasi","type":"person","url":"https://hartvaat.nl/mensen/siddique-a-abbasi/","name":"Siddique A Abbasi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","published":"2022-10-11"},{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2016/08/02/omega-3-vetzuren-en-linkerkamerremodellering-na-acuut-mi-omega-remodel-trial/","published":"2016-08-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sjoerd-h-hofma","type":"person","url":"https://hartvaat.nl/mensen/sjoerd-h-hofma/","name":"Sjoerd H Hofma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2020/04/25/clopidogrel-versus-ticagrelor-of-prasugrel-bij-70-plussers-met-nste-acs-lancet-p/","published":"2020-04-25"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2018/02/03/sirolimus-eluting-bioabsorbeerbare-stent-versus-everolimus-eluting-stent-na-mi-l/","published":"2018-02-03"},{"url":"https://hartvaat.nl/2017/06/15/bioresorbeerbare-scaffolds-versus-metallic-stents-bij-routine-pci-nejm-aida/","published":"2017-06-15"},{"url":"https://hartvaat.nl/2016/01/14/bioresorbeerbare-versus-metallic-everolimus-eluting-stent-bij-stemi-gerandomisee/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"songnan-li","type":"person","url":"https://hartvaat.nl/mensen/songnan-li/","name":"Songnan Li","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/12/09/nieuw-bifasisch-pfa-systeem-versus-thermale-ablatie-bij-paroxysmaal-af/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","published":"2023-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephan-rosenkranz","type":"person","url":"https://hartvaat.nl/mensen/stephan-rosenkranz/","name":"Stephan Rosenkranz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/05/12/cadence-sotatercept-verlaagt-pulmonale-vaatweerstand-bij-gecombineerde-pre-postc/","published":"2026-05-12"},{"url":"https://hartvaat.nl/2024/08/20/tadalafil-bij-gecombineerde-post-en-precapillaire-ph-en-hfpef/","published":"2024-08-20"},{"url":"https://hartvaat.nl/2023/04/20/stellar-sotatercept-bij-pulmonale-arteriele-hypertensie-nejm-fase-3/","published":"2023-04-20"},{"url":"https://hartvaat.nl/2017/04/01/oscillerende-whole-body-vibratie-verbetert-inspanningscapaciteit-bij-pah/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/01/01/inspanningstraining-verbetert-zuurstofopname-en-hemodynamiek-bij-ernstige-pulmon/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephen-gerry","type":"person","url":"https://hartvaat.nl/mensen/stephen-gerry/","name":"Stephen Gerry","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2021/01/05/leeftijd-en-10-jaarsuitkomsten-na-cabg-art-trial/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/06/postoperatief-af-en-langetermijn-cva-risico-na-geisoleerde-cabg/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2019/01/31/bilaterale-versus-enkele-mammaria-interna-grafts-na-10-jaar-nejm-art/","published":"2019-01-31"},{"url":"https://hartvaat.nl/2017/08/01/radiale-arterie-graft-als-aanvulling-op-mammaria-interna-grafts-bij-cabg/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/12/29/bilaterale-versus-enkelvoudige-a-mammaria-interna-grafts-nejm-art-trial/","published":"2016-12-29"},{"url":"https://hartvaat.nl/2016/07/01/bewegingsadvies-als-behandeling-van-prehypertensie-en-hypertensie-bij-jongvolwas/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephane-cook","type":"person","url":"https://hartvaat.nl/mensen/stephane-cook/","name":"Stéphane Cook","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/06/27/tavr-bij-patienten-65-jaar-hogere-sterfte-en-heropnames-dan-chirurgie-maar-onvol/","published":"2026-08-04"},{"url":"https://hartvaat.nl/2023/11/25/biodegradeerbare-versus-duurzame-polymeer-des-bij-stemi-langetermijndata/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2019/11/19/evolocumab-voor-vroege-ldl-verlaging-bij-acs-evopacs/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2018/09/01/ultradunne-biodegradeerbare-versus-dunne-duurzame-stents-lancet-gerandomiseerde-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/09/01/late-trombotische-events-na-bioresorbeerbare-scaffold-meta-analyse-van-gerandomi/","published":"2017-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"suneel-talwar","type":"person","url":"https://hartvaat.nl/mensen/suneel-talwar/","name":"Suneel Talwar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sung-gyun-ahn","type":"person","url":"https://hartvaat.nl/mensen/sung-gyun-ahn/","name":"Sung Gyun Ahn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2022/11/22/ees-versus-cabg-bij-meervatslijden-langetermijn-follow-up-van-rct-s/","published":"2022-11-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"susanna-price","type":"person","url":"https://hartvaat.nl/mensen/susanna-price/","name":"Susanna Price","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/05/13/hypothese-falen-van-het-raas-verklaart-inappropriate-vasodilatatie-bij-cardiogen/","published":"2026-06-21"},{"url":"https://hartvaat.nl/2026/05/19/esc-atlas-2025-3-miljoen-cvd-doden-per-jaar-in-europa-middeninkomenlanden-hebben/","published":"2026-06-13"},{"url":"https://hartvaat.nl/2026/05/26/esc-consensus-vrouwenhartcentra-whc-als-nieuw-zorgmodel-in-europa/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2026/02/19/competenties-na-certificering-en-cardiovasculaire-zorgverlening/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"suzanne-v-arnold","type":"person","url":"https://hartvaat.nl/mensen/suzanne-v-arnold/","name":"Suzanne V Arnold","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/09/16/ischemia-anginatrajecten-na-invasieve-versus-conservatieve-strategie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/01/01/kccq-interpretatie-bij-hartfalen-patient-ankering/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2020/05/12/management-van-stabiel-coronairlijden-bij-diabetes-type-2-aha-scientific-stateme/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/05/05/gezondheidsstatus-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/10/22/individualisering-van-revascularisatiestrategie-bij-diabetes-met-multivatenlijde/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/05/07/gezondheidsstatus-na-mitraclip-bij-hf-met-secundaire-mr-coapt/","published":"2019-05-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sven-schnaidt","type":"person","url":"https://hartvaat.nl/mensen/sven-schnaidt/","name":"Sven Schnaidt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","published":"2019-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"taek-kyu-park","type":"person","url":"https://hartvaat.nl/mensen/taek-kyu-park/","name":"Taek Kyu Park","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"takashi-akasaka","type":"person","url":"https://hartvaat.nl/mensen/takashi-akasaka/","name":"Takashi Akasaka","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2017/11/07/optische-frequentiedomeinbeeldvorming-versus-ivus-bij-pci-opinion-trial/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2016/11/26/oct-versus-ivus-versus-angiografie-bij-coronaire-stentimplantatie-lancet-ilumien/","published":"2016-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"taoufik-ouarrak","type":"person","url":"https://hartvaat.nl/mensen/taoufik-ouarrak/","name":"Taoufik Ouarrak","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/12/01/scai-shockklassen-en-prognose-bij-ami-cardiogene-shock-danger-substudie/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2023/03/28/culprit-interventie-bij-cardiogene-shock-met-hartstilstand/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2017/04/18/risicostratificatie-bij-cardiogene-shock-na-acuut-myocardinfarct/","published":"2017-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thibault-lhermusier","type":"person","url":"https://hartvaat.nl/mensen/thibault-lhermusier/","name":"Thibault Lhermusier","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-laagrisico-acuut-mi/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2023/09/26/biodegradeerbare-versus-duurzame-polymeer-stents-bij-hoog-bloedingsrisico/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"},{"url":"https://hartvaat.nl/2016/02/07/impact-van-pcsk9-remmers-op-lipidenniveaus-en-uitkomsten-netwerkmeta-analyse/","published":"2016-02-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-hovasse","type":"person","url":"https://hartvaat.nl/mensen/thomas-hovasse/","name":"Thomas Hovasse","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/22/lge-granulariteit-op-cmr-voorspelt-sterfte-bij-eindstadium-hypertrofische-cardio/","published":"2026-06-06"},{"url":"https://hartvaat.nl/2025/03/04/stapsgewijze-provisionale-versus-systematische-dualstent-bij-ware-linker-hoofdst/","published":"2025-03-04"},{"url":"https://hartvaat.nl/2021/10/01/ebc-hoofdstam-stentstudie-provisional-versus-systematisch-dubbel-stenten/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2018/07/07/revascularisatie-versus-optimale-medicamenteuze-therapie-bij-cto-gerandomiseerde/","published":"2018-07-07"},{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-j-povsic","type":"person","url":"https://hartvaat.nl/mensen/thomas-j-povsic/","name":"Thomas J Povsic","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tom-de-potter","type":"person","url":"https://hartvaat.nl/mensen/tom-de-potter/","name":"Tom De Potter","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/06/02/catheterablatie-bij-atriumfibrilleren-in-cardiale-amyloidose-levert-42-ritmievri/","published":"2026-08-11"},{"url":"https://hartvaat.nl/2026/02/03/varipure-studie-pulsed-field-ablatie-in-de-dagelijkse-af-praktijk/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2025/10/31/vrouwen-met-persisterend-af-pvi-alleen-is-onvoldoende/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/04/21/pvi-met-versus-zonder-antiaritmica-bij-recidiverend-af-powder-af/","published":"2018-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tor-biering-srensen","type":"person","url":"https://hartvaat.nl/mensen/tor-biering-srensen/","name":"Tor Biering-Sørensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/10/28/rsv-vaccin-vermindert-cv-hospitalisaties-bij-ouderen/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/01/01/nudge-flu-subanalyse-griepvaccinatie-nudges-bij-mi-langetermijn/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/05/27/nudge-flu-elektronische-nudges-verhogen-griepvaccinatie-na-mi/","published":"2024-05-27"},{"url":"https://hartvaat.nl/2023/06/01/intensieve-bloeddrukcontrole-en-geleidingsziekten-sprint-post-hoc-analyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tracy-y-wang","type":"person","url":"https://hartvaat.nl/mensen/tracy-y-wang/","name":"Tracy Y Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/01/03/rosuvastatine-versus-voedingssupplementen-voor-lipidenmanagement/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2021/10/12/overbrugging-van-antiplaatjestherapie-na-pci-jacc-review/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2020/05/01/zelfgerapporteerde-versus-apotheekgeregistreerde-medicatietrouw-compass-analyse/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/01/01/p2y12-copay-reductie-en-therapietrouw-aan-andere-secundaire-preventiemiddelen/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/01/01/medicatie-copay-vouchers-en-p2y12-gebruik-en-cv-events-na-mi-jama/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/12/01/cardiovasculaire-risicocommunicatie-en-patientperceptie-jama-cardiology/","published":"2018-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tristram-d-bahnson","type":"person","url":"https://hartvaat.nl/mensen/tristram-d-bahnson/","name":"Tristram D Bahnson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","published":"2022-08-16"},{"url":"https://hartvaat.nl/2022/03/15/leeftijd-en-uitkomsten-van-katheterablatie-versus-medicatie-bij-af-cabana/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/07/13/ablatie-versus-medicatie-bij-af-naar-ras-en-etniciteit/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2020/06/30/af-recidief-na-ablatie-versus-antiaritmica-in-cabana/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-medicamenteus-bij-af-en-kwaliteit-van-leven-jama-cabana-q/","published":"2019-04-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tushar-kotecha","type":"person","url":"https://hartvaat.nl/mensen/tushar-kotecha/","name":"Tushar Kotecha","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ugo-limbruno","type":"person","url":"https://hartvaat.nl/mensen/ugo-limbruno/","name":"Ugo Limbruno","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2016/02/02/ciclosporine-a-bij-gereperfuseerd-myocardinfarct-de-multicenter-cycle-trial/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ulrica-wilderang","type":"person","url":"https://hartvaat.nl/mensen/ulrica-wilderang/","name":"Ulrica Wilderäng","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/10/09/baxdrostat-bij-ongecontroleerde-en-resistente-hypertensie-effectiviteit-en-veili/","published":"2025-10-09"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ulrich-laufs","type":"person","url":"https://hartvaat.nl/mensen/ulrich-laufs/","name":"Ulrich Laufs","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/24/eas-consensus-wereldwijde-harmonisatie-van-lipidenklinieken/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/02/26/niet-statine-therapie-welk-middel-voor-welke-patient/","published":"2026-03-09"},{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2021/10/01/apothekerzorg-bij-poliklinisch-hf-meta-analyse/","published":"2021-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ulrika-andersson","type":"person","url":"https://hartvaat.nl/mensen/ulrika-andersson/","name":"Ulrika Andersson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/08/14/adma-en-sdma-voorspellen-uitkomsten-bij-af-aristotle-substudie/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2016/09/01/apixaban-5-mg-bij-af-met-hoge-leeftijd-laag-gewicht-of-hoog-creatinine-aristotle/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/07/01/apixaban-versus-warfarine-bij-af-in-relatie-tot-nierfunctie-aristotle-analyse/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/04/01/biomarkers-van-inflammatie-en-cardiovasculair-risico-bij-patienten-met-atriumfib/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"valeria-caso","type":"person","url":"https://hartvaat.nl/mensen/valeria-caso/","name":"Valeria Caso","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/03/15/doac-s-versus-geen-anticoagulatie-na-intracraniele-bloeding-bij-af-meta-analyse/","published":"2025-03-15"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/01/11/inadequate-noac-dosering-bij-af-uitkomsten-en-oorzaken-meta-analyse/","published":"2023-01-11"},{"url":"https://hartvaat.nl/2022/04/09/asundexian-factor-xia-remmer-versus-apixaban-bij-af-lancet-pacific-af/","published":"2022-04-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vijay-nambi","type":"person","url":"https://hartvaat.nl/mensen/vijay-nambi/","name":"Vijay Nambi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/12/23/top-liberaal-versus-restrictief-transfusiebeleid-bij-hoogrisico-hartchirurgie/","published":"2025-12-23"},{"url":"https://hartvaat.nl/2024/09/01/troponine-nt-probnp-en-cognitieve-uitkomsten-in-sprint/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/10/18/intensieve-bloeddrukverlaging-bij-maligne-linkerventrikel-hypertrofie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vladimir-dzavik","type":"person","url":"https://hartvaat.nl/mensen/vladimir-dzavik/","name":"Vladimír Džavík","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2018/01/09/risico-s-van-overinterpretatie-van-interimdata-lessen-uit-de-total-trial/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/01/10/trombusaspiratie-bij-stemi-individuele-patientdata-meta-analyse/","published":"2017-01-10"},{"url":"https://hartvaat.nl/2016/06/21/myocardiale-blush-en-microvasculaire-reperfusie-na-handmatige-trombectomie-bij-s/","published":"2016-06-21"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wanpen-vongpatanasin","type":"person","url":"https://hartvaat.nl/mensen/wanpen-vongpatanasin/","name":"Wanpen Vongpatanasin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2023/12/01/kaliummagnesiumcitraat-versus-kaliumchloride-bij-thiazide-bijwerkingen/","published":"2023-12-01"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2018/10/01/prognostische-waarde-van-gemaskeerd-ongecontroleerde-hypertensie/","published":"2018-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"warren-j-cantor","type":"person","url":"https://hartvaat.nl/mensen/warren-j-cantor/","name":"Warren J Cantor","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wayne-shaw","type":"person","url":"https://hartvaat.nl/mensen/wayne-shaw/","name":"Wayne Shaw","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2022/02/08/stress-cardiale-biomarkers-en-cv-renale-uitkomsten-bij-canagliflozine/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2020/11/03/canagliflozine-en-nt-probnp-implicaties-voor-cv-risicoreductie/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2019/05/28/canagliflozine-en-hf-uitkomsten-bij-behouden-versus-verminderde-ef-canvas/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2018/07/31/canagliflozine-en-hartfalen-bij-diabetes-type-2-canvas-programma/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/01/23/canagliflozine-voor-primaire-en-secundaire-cardiovasculaire-preventie-canvas/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/08/17/canagliflozine-en-cardiovasculaire-en-renale-events-bij-diabetes-type-2-nejm-can/","published":"2017-08-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wei-li","type":"person","url":"https://hartvaat.nl/mensen/wei-li/","name":"Wei Li","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/06/vereenvoudigde-linkervoorhoofdaanhangsel-occlusie-onder-fluoroscopie-met-watchma/","published":"2026-07-29"},{"url":"https://hartvaat.nl/2025/12/15/m7g-methyltransferase-mettl1-bevordert-acuut-nierletsel-via-mitochondriale-disfu/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2025/12/09/nieuw-bifasisch-pfa-systeem-versus-thermale-ablatie-bij-paroxysmaal-af/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2025/09/01/pvi-met-of-zonder-empirische-svc-isolatie-bij-af-ablatie/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/11/12/rf-renale-denervatie-bij-ongecontroleerde-hypertensie-in-china-gerandomiseerde-t/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2018/12/04/echocardiografische-screening-op-ph-bij-aangeboren-hartafwijkingen-jacc-review/","published":"2018-12-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"whady-a-hueb","type":"person","url":"https://hartvaat.nl/mensen/whady-a-hueb/","name":"Whady A Hueb","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","published":"2019-02-19"},{"url":"https://hartvaat.nl/2018/12/11/syntax-score-bij-diabetes-met-coronaire-revascularisatie-freedom/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2016/08/01/cabg-versus-pci-en-risico-op-myocardinfarct-en-revascularisatie-bij-ckd-patiente/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wojciech-zareba","type":"person","url":"https://hartvaat.nl/mensen/wojciech-zareba/","name":"Wojciech Zareba","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2020/03/01/hybride-telerevalidatie-bij-hartfalen-jama-cardiology-tele-hf-trial/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2018/05/01/crt-voordeel-bij-concordant-versus-discordant-linksbundeltakblok-esc-hf-pilot/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/07/14/voorspelling-van-plotse-versus-niet-plotse-hartdood-na-mi-met-verminderde-lvef/","published":"2017-07-14"},{"url":"https://hartvaat.nl/2017/05/16/comorbiditeiten-en-crt-respons-madit-crt-langetermijnfollow-up/","published":"2017-05-16"},{"url":"https://hartvaat.nl/2016/09/20/volledig-linkszijdig-reverse-remodelling-bij-crt-madit-crt-substudie/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/01/26/relatieve-wanddikte-en-risico-op-ventriculaire-tachyaritmieen-bij-linkerkamerdis/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xia-wang","type":"person","url":"https://hartvaat.nl/mensen/xia-wang/","name":"Xia Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2023/07/01/interact3-bundeled-care-bij-acute-intracerebrale-bloeding-lancet/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/02/01/multifactoriele-optimalisatie-van-chronisch-hartfalen-gerandomiseerde-studie/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/11/05/enchanted2-mt-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-is-schadelij/","published":"2022-11-05"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"},{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","published":"2016-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xianhui-qin","type":"person","url":"https://hartvaat.nl/mensen/xianhui-qin/","name":"Xianhui Qin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/12/23/plasma-proteomische-biomarkers-voor-risico-en-therapeutische-doelen-bij-abdomina/","published":"2025-12-23"},{"url":"https://hartvaat.nl/2020/02/01/geschatte-cva-vrije-overleving-van-foliumzuurtherapie-bij-hypertensie-csppt/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2018/05/15/trombocytenaantal-beinvloedt-werkzaamheid-van-foliumzuur-bij-cva-preventie/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2017/08/01/foliumzuurtherapie-en-nieuwe-proteinurie-bij-chinese-hypertensieve-patienten-csp/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/04/01/optimale-systolische-bloeddruk-voor-primaire-cva-preventie-bij-hypertensie-csppt/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/07/01/polsgolfsnelheid-en-bloeddrukcontrole-als-onafhankelijke-voorspellers-van-cva-bi/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xiaoying-chen","type":"person","url":"https://hartvaat.nl/mensen/xiaoying-chen/","name":"Xiaoying Chen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/03/01/frailteit-en-antihypertensieve-behandeling-bij-ouderen-meta-analyse/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2024/05/30/right-2-ambulancebloeddrukverlaging-bij-hyperacuut-cva-nejm-vervolgresultaten/","published":"2024-05-30"},{"url":"https://hartvaat.nl/2023/07/01/interact3-bundeled-care-bij-acute-intracerebrale-bloeding-lancet/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2022/11/05/enchanted2-mt-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-is-schadelij/","published":"2022-11-05"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"},{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","published":"2016-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xueyuan-guo","type":"person","url":"https://hartvaat.nl/mensen/xueyuan-guo/","name":"Xueyuan Guo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","published":"2022-10-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yang","type":"person","url":"https://hartvaat.nl/mensen/yang/","name":"Yang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/03/machine-learningmodel-voorspelt-periprocedurele-complicaties-bij-tavi-voor-bicus/","published":"2026-07-25"},{"url":"https://hartvaat.nl/2026/04/17/verhoogd-crp-voorspelt-hartfalen-bij-kankeroverlevenden-uk-biobank/","published":"2026-07-21"},{"url":"https://hartvaat.nl/2026/03/25/vrouwen-krijgen-een-type-a-aortadissectie-bij-een-kleinere-aortadiameter-door-hu/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/02/26/hiv-infectie-hangt-onafhankelijk-samen-met-meer-en-kwetsbaardere-halsslagaderpla/","published":"2026-02-26"},{"url":"https://hartvaat.nl/2026/02/20/geintegreerd-machine-learningmodel-voorspelt-cardiovasculair-risico-beter-dan-de/","published":"2026-02-20"},{"url":"https://hartvaat.nl/2026/01/09/littekenweefsel-voorspelt-plotse-hartdood-na-een-infarct-grotendeels-buiten-de-e/","published":"2026-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yang-ou","type":"person","url":"https://hartvaat.nl/mensen/yang-ou/","name":"Yang Ou","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/09/09/summit-tirzepatide-effect-bij-hfpef-met-en-zonder-diabetes/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2025/07/29/summit-bmi-centrale-adipositas-en-gewichtsverlies-beinvloeden-tirzepatide-effect/","published":"2025-07-29"},{"url":"https://hartvaat.nl/2025/05/13/summit-tirzepatide-en-ckd-interactie-bij-hfpef-met-obesitas/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/03/11/summit-tirzepatide-en-klinisch-traject-bij-hfpef-met-obesitas-langetermijn/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/02/25/summit-tirzepatide-vermindert-lv-massa-en-paracardiaal-vetweefsel-bij-hfpef/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/01/30/summit-tirzepatide-bij-hfpef-met-obesitas-nejm/","published":"2025-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ying-sun","type":"person","url":"https://hartvaat.nl/mensen/ying-sun/","name":"Ying Sun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/01/intensieve-bloeddrukcontrole-en-cognitieve-functie-gerandomiseerde-trial/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/01/01/effect-van-baduanjin-op-bloeddruk-bij-hoog-normaal-bloeddruk-gerandomiseerde-tri/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/06/esprit-intensieve-bloeddrukcontrole-bij-fragiele-patienten-post-hoc-analyse/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/10/28/esprit-bescheiden-effecten-van-intensieve-bloeddrukverlaging-op-kwaliteit-van-le/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukverlaging-en-retinale-microvasculatuur/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukcontrole-en-cva-preventie/","published":"2025-10-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ying-wang","type":"person","url":"https://hartvaat.nl/mensen/ying-wang/","name":"Ying Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/08/15/3d-ct-fluoroscopie-fusie-maakt-laac-efficienter-minder-contrast-minder-straling-/","published":"2026-07-01"},{"url":"https://hartvaat.nl/2025/12/01/ice-versus-tee-bij-af-ablatie-gerandomiseerde-trial/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/11/12/recaticimab-als-toevoeging-aan-statines-fase-3-remain-2/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/12/recaticimab-monotherapie-bij-niet-familiaire-hypercholesterolemie-fase-3-remain-/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2023/06/01/remote-ischemische-conditionering-bij-milde-hypertensie-zonder-medicatie-rct/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/05/19/drie-substraatstrategieen-voor-persisterend-af-vergeleken-multicenter-rct/","published":"2023-05-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yohei-sotomi","type":"person","url":"https://hartvaat.nl/mensen/yohei-sotomi/","name":"Yohei Sotomi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/09/01/nierfunctie-en-effectiviteit-van-lva-ablatie-na-pvi-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2017/09/01/late-trombotische-events-na-bioresorbeerbare-scaffold-meta-analyse-van-gerandomi/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"},{"url":"https://hartvaat.nl/2017/07/01/syntax-scores-en-uitkomsten-bij-diabetes-met-multivatenlijden-gepoolde-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/09/06/pci-versus-cabg-bij-onbeschermde-hoofdstamziekte-uitkomsten/","published":"2016-09-06"},{"url":"https://hartvaat.nl/2016/01/14/bioresorbeerbare-versus-metallic-everolimus-eluting-stent-bij-stemi-gerandomisee/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yongjun-wang","type":"person","url":"https://hartvaat.nl/mensen/yongjun-wang/","name":"Yongjun Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/05/tenecteplase-versus-standaardbehandeling-bij-basilaris-occlusie-in-the-lancet/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2026/02/01/antihypertensieve-behandeling-na-acuut-ischemisch-cva-continueren-of-niet/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2026/01/01/insulineresistentie-en-bloeddrukcontrole-op-cognitieve-uitkomsten/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2022/11/05/enchanted2-mt-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-is-schadelij/","published":"2022-11-05"},{"url":"https://hartvaat.nl/2016/09/15/intensieve-bloeddrukverlaging-bij-acute-hersenbloeding-nejm-atach-2-trial/","published":"2016-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"young-hak-kim","type":"person","url":"https://hartvaat.nl/mensen/young-hak-kim/","name":"Young-Hak Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2024/05/01/angiografie-versus-ivus-voor-des-implantatie-gerandomiseerde-trial/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2020/05/05/des-versus-cabg-bij-linker-hoofdstam-10-jaarsresultaten-excel-extended/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2016/04/19/statinebehandeling-en-plaquesamenstelling-dubbelblinde-gerandomiseerde-studie/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"young-hoon-kim","type":"person","url":"https://hartvaat.nl/mensen/young-hoon-kim/","name":"Young-Hoon Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2019/05/14/wanneer-doac-stoppen-voor-af-ablatie-multicenter-analyse/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/04/01/lineaire-versus-focale-cfae-ablatie-bij-niet-paroxysmaal-af/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/10/01/terminatie-van-persisterend-af-tijdens-pvi-inzichten-uit-magic-af/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/05/21/stapsgewijze-ablatie-gestuurd-door-laaggedoseerd-ibutilide-bij-chronisch-af-magi/","published":"2016-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"young-hyo-lim","type":"person","url":"https://hartvaat.nl/mensen/young-hyo-lim/","name":"Young-Hyo Lim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","published":"2025-11-08"},{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2020/10/10/prasugrel-gebaseerde-dapt-de-escalatie-na-pci-bij-acs-lancet-host-reduce-polytec/","published":"2020-10-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yu-zhang","type":"person","url":"https://hartvaat.nl/mensen/yu-zhang/","name":"Yu Zhang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2025/12/01/ice-versus-tee-bij-af-ablatie-gerandomiseerde-trial/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/10/31/herhaalde-in-situ-ablatie-versus-uitgebreide-ablatie-bij-recidief-persisterend-a/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2025/08/12/catheterablatie-versus-rate-control-bij-persisterend-af-en-ouder-hartfalen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2023/05/19/drie-substraatstrategieen-voor-persisterend-af-vergeleken-multicenter-rct/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2022/08/09/vertraagde-afgifteformulering-van-ivabradine-bij-systolisch-hartfalen/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2021/05/21/extrapulmonale-vein-driver-mapping-bij-persisterend-af-bij-obese-patienten/","published":"2021-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yun-hyeong-cho","type":"person","url":"https://hartvaat.nl/mensen/yun-hyeong-cho/","name":"Yun-Hyeong Cho","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"},{"url":"https://hartvaat.nl/2020/06/16/ticagrelor-monotherapie-versus-dapt-op-bloedingen-en-cv-events-bij-acs-jama-tico/","published":"2020-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zachary-i-whinnett","type":"person","url":"https://hartvaat.nl/mensen/zachary-i-whinnett/","name":"Zachary I Whinnett","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2023/05/19/geleidingssysteempacing-in-europa-inzichten-uit-klinische-praktijk/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2023/03/30/ablatie-versus-antiaritmica-voor-vermindering-van-ziekenhuisbezoeken-bij-af/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/03/30/upgrade-van-rv-pacemaker-naar-crt-of-geleidingssysteempacing-meta-analyse/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/02/16/catheterablatie-verbetert-cv-uitkomsten-bij-af-en-hartfalen-meta-analyse-van-rct/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2022/05/03/triventriculaire-pacing-bij-hf-strive-hf-gerandomiseerde-trial/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2017/07/01/crt-werkingsmechanismen-en-mogelijkheden-voor-verdere-verbetering/","published":"2017-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zhang","type":"person","url":"https://hartvaat.nl/mensen/zhang/","name":"Zhang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/04/03/machine-learningmodel-voorspelt-periprocedurele-complicaties-bij-tavi-voor-bicus/","published":"2026-07-25"},{"url":"https://hartvaat.nl/2026/03/03/voorspelmodellen-voor-hartfalen-bij-patienten-met-instabiele-angina-pectoris/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/02/26/hiv-infectie-hangt-onafhankelijk-samen-met-meer-en-kwetsbaardere-halsslagaderpla/","published":"2026-02-26"},{"url":"https://hartvaat.nl/2026/02/23/luchtvervuiling-en-multimorbiditeit-verhogen-het-risico-op-atriumfibrilleren/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/02/20/kosteneffectiviteit-van-mavacamten-bij-obstructieve-hcm-gezondheidswinst-maar-ee/","published":"2026-02-20"},{"url":"https://hartvaat.nl/2026/01/29/lineaire-ablatie-van-de-voorwand-van-het-linkeratrium-vermindert-af-recidieven-b/","published":"2026-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zhen-wang","type":"person","url":"https://hartvaat.nl/mensen/zhen-wang/","name":"Zhen Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/08/20/ouderlijke-obesitas-verhoogt-cardiorenale-risico-s-bij-nakomelingen-review/","published":"2026-08-28"},{"url":"https://hartvaat.nl/2026/01/08/atriale-strain-overtreft-ventriculaire-strain-bij-detectie-van-hypertensieve-hfp/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2024/11/12/recaticimab-monotherapie-bij-niet-familiaire-hypercholesterolemie-fase-3-remain-/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/06/01/remote-ischemische-conditionering-bij-milde-hypertensie-zonder-medicatie-rct/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2021/06/01/roken-en-hartfalen-mendeliaanse-randomisatie-en-mediatie-analyse/","published":"2021-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zhou","type":"person","url":"https://hartvaat.nl/mensen/zhou/","name":"Zhou","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":6,"articles":[{"url":"https://hartvaat.nl/2026/05/26/recidief-linkerventrikel-trombus-12-recidief-actieve-eerdere-maligniteit-verzesv/","published":"2026-07-03"},{"url":"https://hartvaat.nl/2026/04/24/ita-bypass-veilig-bij-patienten-met-eerdere-mediastinale-bestraling-maryland-coh/","published":"2026-05-22"},{"url":"https://hartvaat.nl/2026/04/24/verminderde-nierfunctie-verhoogt-hartfalenrisico-bij-ouderen-aspree-cohort/","published":"2026-05-08"},{"url":"https://hartvaat.nl/2026/03/31/gespecialiseerde-hartklepklinieken-leiden-tot-betere-richtlijnconforme-zorg/","published":"2026-03-31"},{"url":"https://hartvaat.nl/2026/03/03/voorspelmodellen-voor-hartfalen-bij-patienten-met-instabiele-angina-pectoris/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/01/09/littekenweefsel-voorspelt-plotse-hartdood-na-een-infarct-grotendeels-buiten-de-e/","published":"2026-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a-marc-gillinov","type":"person","url":"https://hartvaat.nl/mensen/a-marc-gillinov/","name":"A Marc Gillinov","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aaron-b-caughey","type":"person","url":"https://hartvaat.nl/mensen/aaron-b-caughey/","name":"Aaron B Caughey","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adam-d-timmis","type":"person","url":"https://hartvaat.nl/mensen/adam-d-timmis/","name":"Adam D Timmis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","published":"2025-01-25"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","published":"2018-09-06"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/04/19/ct-coronairangiografie-voor-het-sturen-van-beleid-bij-coronairlijden/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adrian-wlodarczak","type":"person","url":"https://hartvaat.nl/mensen/adrian-wlodarczak/","name":"Adrian Wlodarczak","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/03/04/stapsgewijze-provisionale-versus-systematische-dualstent-bij-ware-linker-hoofdst/","published":"2025-03-04"},{"url":"https://hartvaat.nl/2023/09/26/biodegradeerbare-versus-duurzame-polymeer-stents-bij-hoog-bloedingsrisico/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2021/10/01/ebc-hoofdstam-stentstudie-provisional-versus-systematisch-dubbel-stenten/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2017/03/30/ffr-geleide-multivaten-pci-bij-myocardinfarct-nejm-compare-acute/","published":"2017-03-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ahmed-m-al-kaisey","type":"person","url":"https://hartvaat.nl/mensen/ahmed-m-al-kaisey/","name":"Ahmed M Al-Kaisey","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/07/14/vroege-versus-late-af-ablatie-impact-op-aritmierecidief/","published":"2023-07-14"},{"url":"https://hartvaat.nl/2023/02/16/hoog-vermogen-korte-duur-versus-laag-vermogen-langere-duur-posteriore-ablatie-bi/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ahran-d-arnold","type":"person","url":"https://hartvaat.nl/mensen/ahran-d-arnold/","name":"Ahran D Arnold","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/03/30/upgrade-van-rv-pacemaker-naar-crt-of-geleidingssysteempacing-meta-analyse/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/02/16/catheterablatie-verbetert-cv-uitkomsten-bij-af-en-hartfalen-meta-analyse-van-rct/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2021/09/21/bijwerkingspatronen-in-crossover-trial-statine-placebo-geen-behandeling-statinwi/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2020/11/26/n-of-1-trial-van-statine-placebo-of-geen-behandeling-voor-bijwerkingen-nejm-stat/","published":"2020-11-26"},{"url":"https://hartvaat.nl/2020/09/07/des-versus-cabg-bij-hoofdstamlijden-mortaliteits-meta-analyse/","published":"2020-09-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"akinobu-itoh","type":"person","url":"https://hartvaat.nl/mensen/akinobu-itoh/","name":"Akinobu Itoh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/04/01/lvad-gebruik-als-bridge-to-transplant-versus-destination-therapy-momentum-3/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2018/10/30/zorggebruik-en-kosten-in-momentum-3-langetermijnstudie/","published":"2018-10-30"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","published":"2017-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alex-mcconnachie","type":"person","url":"https://hartvaat.nl/mensen/alex-mcconnachie/","name":"Alex McConnachie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2022/10/22/time-avonddosering-antihypertensiva-biedt-geen-voordeel-boven-ochtenddosering/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/03/31/laaggedoseerde-alteplase-bij-primaire-pci-naar-ischemietijd/","published":"2020-03-31"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexander-hapfelmeier","type":"person","url":"https://hartvaat.nl/mensen/alexander-hapfelmeier/","name":"Alexander Hapfelmeier","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexander-hirsch","type":"person","url":"https://hartvaat.nl/mensen/alexander-hirsch/","name":"Alexander Hirsch","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/08/18/echocardiografie-overschatte-drukgradienten-na-tav-in-tav-met-ballon-expandable-/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/05/22/epicardiaal-vetweefsel-voorspelt-aritmieen-en-hartfalen-events-bij-genotype-posi/","published":"2026-06-06"},{"url":"https://hartvaat.nl/2018/09/01/langetermijnimpact-van-cto-rekanalisatie-bij-stemi-patienten/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/04/18/vroeg-invasief-versus-selectieve-strategie-bij-nste-acs-ictus-trial-langetermijn/","published":"2017-04-18"},{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-circulatoire-ondersteuning-versus-iabp-bij-cardiogene-shoc/","published":"2017-01-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexander-t-sandhu","type":"person","url":"https://hartvaat.nl/mensen/alexander-t-sandhu/","name":"Alexander T Sandhu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/05/28/pro-hf-routine-prom-meting-in-hartfalenpolikliniek-verbetert-uitkomsten/","published":"2024-05-28"},{"url":"https://hartvaat.nl/2023/02/28/incidenteel-coronair-calcium-op-ct-thorax-ai-gestuurde-screening-verbetert-stati/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexandre-persu","type":"person","url":"https://hartvaat.nl/mensen/alexandre-persu/","name":"Alexandre Persu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/06/11/target-bp-i-alcohol-gemedieerde-renale-denervatie-bij-hypertensie/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2023/11/01/beta3-lvh-mirabegron-bij-linkerventrikel-hypertrofie-fase-2b-rct/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2020/07/01/phactr1-en-fibromusculaire-dysplasie-arcadia-pol-meta-analyse/","published":"2020-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alf-inge-larsen","type":"person","url":"https://hartvaat.nl/mensen/alf-inge-larsen/","name":"Alf Inge Larsen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/25/betami-danblock-is-representatief-betablokker-effect-ook-geldig-in-echte-noorse-/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2024/04/01/inspanningstraining-en-hoog-sensitief-troponine-i-bij-hfref/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2021/06/01/inspanningstraining-en-hs-troponine-t-bij-hfref/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2017/10/14/intracoronaire-beenmergceltransfer-na-mi-de-boost-2-gerandomiseerde-trial/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"allan-d-struthers","type":"person","url":"https://hartvaat.nl/mensen/allan-d-struthers/","name":"Allan D Struthers","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/10/22/time-avonddosering-antihypertensiva-biedt-geen-voordeel-boven-ochtenddosering/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2022/10/08/all-heart-allopurinol-verbetert-cv-uitkomsten-niet-bij-ischemische-hartziekte/","published":"2022-10-08"},{"url":"https://hartvaat.nl/2020/11/03/sglt2-remming-plus-lisdiuretica-bij-diabetes-type-2-met-ckd-renale-en-cv-effecte/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/09/21/dapagliflozine-op-lv-hypertrofie-bij-diabetes-type-2-dapa-lvh-gerandomiseerde-tr/","published":"2020-09-21"},{"url":"https://hartvaat.nl/2019/11/01/metformine-en-linkerventrikelhypertrofie-bij-coronairlijden-zonder-diabetes-gera/","published":"2019-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alun-d-hughes","type":"person","url":"https://hartvaat.nl/mensen/alun-d-hughes/","name":"Alun D Hughes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/09/01/systolische-bloeddrukamplificatie-ipd-meta-analyse/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2020/04/07/yoga-gebaseerde-hartrevalidatie-na-acuut-mi-gerandomiseerde-trial/","published":"2020-04-07"},{"url":"https://hartvaat.nl/2019/10/01/arteriele-golfvormclusters-en-langetermijn-klinisch-nut/","published":"2019-10-01"},{"url":"https://hartvaat.nl/2017/08/01/nauwkeurigheid-van-manchetbloeddrukmeting-systematische-review-en-meta-analyse/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/07/01/crt-werkingsmechanismen-en-mogelijkheden-voor-verdere-verbetering/","published":"2017-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amy-v-ferry","type":"person","url":"https://hartvaat.nl/mensen/amy-v-ferry/","name":"Amy V Ferry","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/11/11/risicostratificatie-met-hoog-sensitief-troponine-op-de-seh-veiligheidsanalyse/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amy-w-talbot","type":"person","url":"https://hartvaat.nl/mensen/amy-w-talbot/","name":"Amy W Talbot","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anastasia-lesogor","type":"person","url":"https://hartvaat.nl/mensen/anastasia-lesogor/","name":"Anastasia Lesogor","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/07/22/victorion-initiate-inclisiran-monotherapie-bij-patienten-zonder-ascvd/","published":"2025-07-22"},{"url":"https://hartvaat.nl/2025/06/24/inclisiran-bij-adolescenten-met-homozygote-fh-effectiviteit-en-veiligheid/","published":"2025-06-24"},{"url":"https://hartvaat.nl/2025/01/28/lp-a-en-ldl-cholesterol-onafhankelijke-cv-risicopaden/","published":"2025-01-28"},{"url":"https://hartvaat.nl/2024/01/30/orion-5-inclisiran-bij-homozygote-fh/","published":"2024-01-30"},{"url":"https://hartvaat.nl/2018/10/13/lp-a-baseline-en-on-statin-voor-cv-eventvoorspelling-lancet-ipd-meta-analyse/","published":"2018-10-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrea-lage","type":"person","url":"https://hartvaat.nl/mensen/andrea-lage/","name":"Andrea Lage","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2022/02/08/finerenon-vermindert-incident-hf-bij-ckd-met-diabetes-fidelity/","published":"2022-02-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrea-saglietto","type":"person","url":"https://hartvaat.nl/mensen/andrea-saglietto/","name":"Andrea Saglietto","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/01/lawt-geleide-pvi-bij-persisterend-af-gepersonaliseerde-benadering/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/08/01/linkeratriale-strain-en-prognose-bij-acuut-en-chronisch-hartfalen-meta-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/03/30/qdot-by-lawt-gepersonaliseerde-pvi-gestuurd-door-linkeratriale-wanddikte/","published":"2024-03-30"},{"url":"https://hartvaat.nl/2022/12/09/ideale-blankingperiode-na-af-ablatie-bewijs-voor-herziening/","published":"2022-12-09"},{"url":"https://hartvaat.nl/2020/11/07/complete-revascularisatie-vermindert-cv-dood-bij-stemi-met-multivatenlijden-meta/","published":"2020-11-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrea-sarkozy","type":"person","url":"https://hartvaat.nl/mensen/andrea-sarkozy/","name":"Andrea Sarkozy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","published":"2026-05-27"},{"url":"https://hartvaat.nl/2026/02/03/kortste-af-cycluslengte-in-de-longvenen-identificeert-pvi-responders/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2024/12/03/pfa-versus-cryoballon-voor-af-ablatie-multielectrode-vergelijking/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2018/04/21/pvi-met-versus-zonder-antiaritmica-bij-recidiverend-af-powder-af/","published":"2018-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andreas-ruck","type":"person","url":"https://hartvaat.nl/mensen/andreas-ruck/","name":"Andreas Rück","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","published":"2024-04-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrzej-bochenek","type":"person","url":"https://hartvaat.nl/mensen/andrzej-bochenek/","name":"Andrzej Bochenek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2019/01/31/bilaterale-versus-enkele-mammaria-interna-grafts-na-10-jaar-nejm-art/","published":"2019-01-31"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anna-m-thgersen","type":"person","url":"https://hartvaat.nl/mensen/anna-m-thgersen/","name":"Anna M Thøgersen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anna-sannino","type":"person","url":"https://hartvaat.nl/mensen/anna-sannino/","name":"Anna Sannino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2017/10/14/tmao-als-cardiovasculaire-risicobiomarker-systematische-review-en-meta-analyse/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"annapoorna-s-kini","type":"person","url":"https://hartvaat.nl/mensen/annapoorna-s-kini/","name":"Annapoorna S Kini","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/24/yellow-iii-intracoronaire-beeldvorming-en-genexpressie-na-maximale-lipideverlagi/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2020/02/18/ticagrelor-met-of-zonder-aspirine-na-pci-twilight-plaatjessubstudie/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2017/12/12/3-jaarsresultaten-van-bioresorbeerbare-scaffolds-absorb-iii-trial/","published":"2017-12-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anne-c-goldberg","type":"person","url":"https://hartvaat.nl/mensen/anne-c-goldberg/","name":"Anne C Goldberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2026/01/29/nla-consensusupdate-familiaire-hypercholesterolemie-screening-diagnostiek-en-beh/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2025/05/17/tandem-obicetrapib-plus-ezetimibe-voor-ldl-verlaging-lancet-fase-3/","published":"2025-05-17"},{"url":"https://hartvaat.nl/2019/11/12/bempedoinezuur-toegevoegd-aan-statines-bij-hoog-cv-risico-jama-clear-harmony/","published":"2019-11-12"},{"url":"https://hartvaat.nl/2018/12/01/cardiovasculaire-risicocommunicatie-en-patientperceptie-jama-cardiology/","published":"2018-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"annica-ravn-fischer","type":"person","url":"https://hartvaat.nl/mensen/annica-ravn-fischer/","name":"Annica Ravn-Fischer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/01/dapagliflozine-na-mi-naar-ef-cardiometabole-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/11/25/abc-af-risicoscores-voor-gepersonaliseerde-af-behandeling/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2024/04/18/abyss-betablokkers-na-mi-met-behouden-ef-niet-nodig-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2018/12/11/langetermijneffecten-van-zuurstof-op-sterfte-of-hf-hospitalisatie-na-verdenking-/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2017/09/28/zuurstoftherapie-bij-vermoedelijk-acuut-myocardinfarct-nejm-deto2x-ami/","published":"2017-09-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antonio-dans","type":"person","url":"https://hartvaat.nl/mensen/antonio-dans/","name":"Antonio Dans","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antonio-fernandez-ortiz","type":"person","url":"https://hartvaat.nl/mensen/antonio-fernandez-ortiz/","name":"Antonio Fernández-Ortiz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2022/03/31/amphilimus-versus-zotarolimus-stents-bij-diabetes-sugar-gerandomiseerde-trial/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2017/01/15/linker-hartoorsluiting-versus-medicamenteuze-behandeling-bij-af-netwerkmeta-anal/","published":"2017-01-15"},{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/05/10/timing-van-metoprolol-bij-stemi-effect-op-infarctgrootte-en-ventrikelfunctie/","published":"2016-05-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antony-walton","type":"person","url":"https://hartvaat.nl/mensen/antony-walton/","name":"Antony Walton","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/06/01/renale-denervatie-langetermijn-bloeddrukeffect-bevestigd-meta-analyse/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-zelfexpanderende-klep-bij-laagrisicopatienten-nejm-evolut-low-risk/","published":"2019-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"atsushi-hirayama","type":"person","url":"https://hartvaat.nl/mensen/atsushi-hirayama/","name":"Atsushi Hirayama","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/08/06/racing-subanalyse-matige-statine-plus-ezetimibe-voor-secundaire-preventie/","published":"2024-08-06"},{"url":"https://hartvaat.nl/2022/08/01/rivaroxaban-monotherapie-versus-combinatie-met-plaatjesremmers-bij-af-en-coronai/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/11/01/aspirine-versus-p2y12-remmer-met-antistolling-bij-af/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2019/09/19/antitrombotische-therapie-bij-af-met-stabiel-coronairlijden-nejm-afire/","published":"2019-09-19"},{"url":"https://hartvaat.nl/2018/05/08/hoog-versus-laaggedoseerd-pitavastatine-bij-stabiel-coronairlijden-real-cad/","published":"2018-05-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"augustin-coisne","type":"person","url":"https://hartvaat.nl/mensen/augustin-coisne/","name":"Augustin Coisne","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/28/gestandaardiseerd-stappenplan-voor-tricuspidalisinsufficientie-van-verwijzing-to/","published":"2026-04-19"},{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2025/01/14/tri-fr-transcatheter-edge-to-edge-repair-bij-geisoleerde-ernstige-tr-rct/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","published":"2023-07-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"azfar-zaman","type":"person","url":"https://hartvaat.nl/mensen/azfar-zaman/","name":"Azfar Zaman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/08/21/allegra-kunstklep-toont-veelbelovende-techniek-en-veiligheidsresultaten-bij-valv/","published":"2026-08-30"},{"url":"https://hartvaat.nl/2020/07/21/levothyroxine-bij-subklinische-hypothyreoidie-na-acuut-mi-jama/","published":"2020-07-21"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bastiaan-geelhoed","type":"person","url":"https://hartvaat.nl/mensen/bastiaan-geelhoed/","name":"Bastiaan Geelhoed","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/07/15/race-3-langetermijnresultaten-gerichte-behandeling-bij-vroeg-persisterend-af-en-/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2021/09/08/antiaritmica-bij-vroeg-persisterend-af-met-hf-race-3/","published":"2021-09-08"},{"url":"https://hartvaat.nl/2019/04/01/upstream-therapie-verbetert-qol-bij-persisterend-af-arrest-af/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/08/21/behandeling-van-onderliggende-aandoeningen-verbetert-sinusritme-na-af-arrest-af/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2017/02/21/genetische-obesitas-en-risico-op-atriumfibrilleren-mendeliaanse-randomisatie/","published":"2017-02-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"belinda-lees","type":"person","url":"https://hartvaat.nl/mensen/belinda-lees/","name":"Belinda Lees","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/01/05/leeftijd-en-10-jaarsuitkomsten-na-cabg-art-trial/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/10/06/postoperatief-af-en-langetermijn-cva-risico-na-geisoleerde-cabg/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2019/01/31/bilaterale-versus-enkele-mammaria-interna-grafts-na-10-jaar-nejm-art/","published":"2019-01-31"},{"url":"https://hartvaat.nl/2017/08/01/radiale-arterie-graft-als-aanvulling-op-mammaria-interna-grafts-bij-cabg/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/12/29/bilaterale-versus-enkelvoudige-a-mammaria-interna-grafts-nejm-art-trial/","published":"2016-12-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"benedikt-schrage","type":"person","url":"https://hartvaat.nl/mensen/benedikt-schrage/","name":"Benedikt Schrage","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/25/palliatieve-zorg-in-de-cardiologie-een-state-of-the-art-overzicht/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/02/19/delirium-in-de-cardiovasculaire-geneeskunde/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"benjamin-hibbert","type":"person","url":"https://hartvaat.nl/mensen/benjamin-hibbert/","name":"Benjamin Hibbert","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/05/apture-shunt-verlaagt-hartfalen-heropnames-bij-patienten-met-hfpef-hfmref-alt-fl/","published":"2026-07-30"},{"url":"https://hartvaat.nl/2025/12/23/korte-anticoagulatie-versus-dapt-na-laa-occlusie-devicetrombosepreventie/","published":"2025-12-23"},{"url":"https://hartvaat.nl/2021/08/05/milrinone-versus-dobutamine-bij-cardiogene-shock-nejm-doremi/","published":"2021-08-05"},{"url":"https://hartvaat.nl/2020/02/01/femorale-versus-radiale-toegang-bij-stemi-jama-cardiology-safari-stemi/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/02/19/lv-unloading-tijdens-ecmo-bij-cardiogene-shock/","published":"2019-02-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bernardo-cortese","type":"person","url":"https://hartvaat.nl/mensen/bernardo-cortese/","name":"Bernardo Cortese","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/19/salamander-register-95-5-technisch-succes-bij-stand-alone-linker-hartoor-occlusi/","published":"2026-06-10"},{"url":"https://hartvaat.nl/2025/05/02/paclitaxel-gecoate-ballonnen-versus-des-bij-kleine-vaten-ipd-meta-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/05/23/stralingsblootstelling-en-vasculaire-toegang-bij-acs-rad-matrix-trial/","published":"2017-05-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bernhard-ludvik","type":"person","url":"https://hartvaat.nl/mensen/bernhard-ludvik/","name":"Bernhard Ludvik","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/05/dapa-hd-eerste-gerandomiseerde-studie-naar-dapagliflozin-bij-hemodialyse-patient/","published":"2026-06-29"},{"url":"https://hartvaat.nl/2026/03/05/semaglutide-bij-perifeer-arterieel-vaatlijden-en-diabetes-stride-trial/","published":"2026-03-20"},{"url":"https://hartvaat.nl/2025/11/18/sekseverschillen-in-semaglutide-effect-bij-pad-stride-subanalyse/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/05/03/semaglutide-en-loopafstand-bij-perifeer-vaatlijden-en-diabetes/","published":"2025-05-03"},{"url":"https://hartvaat.nl/2021/08/14/tirzepatide-versus-insuline-degludec-bij-diabetes-type-2-lancet-surpass-3/","published":"2021-08-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bharathi-upadhya","type":"person","url":"https://hartvaat.nl/mensen/bharathi-upadhya/","name":"Bharathi Upadhya","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/06/23/lifestyle-modificatie-en-metabole-therapieen-bij-cardiometabole-hfpef-overzicht/","published":"2026-08-09"},{"url":"https://hartvaat.nl/2025/06/01/bloeddrukcontrole-en-arteriele-stijfheidsmechanismen-in-sprint/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2023/02/01/fysieke-revalidatie-bij-fragiele-ouderen-met-acuut-hartfalen/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/07/15/fysieke-revalidatie-bij-oudere-gehospitaliseerde-hf-patienten-nejm-rehab-hf/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2021/05/05/intensieve-bloeddruk-en-aortastijfheid-sprint-heart/","published":"2021-05-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"birgit-vogel","type":"person","url":"https://hartvaat.nl/mensen/birgit-vogel/","name":"Birgit Vogel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/02/18/ticagrelor-met-of-zonder-aspirine-na-pci-twilight-plaatjessubstudie/","published":"2020-02-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brandi-meeks","type":"person","url":"https://hartvaat.nl/mensen/brandi-meeks/","name":"Brandi Meeks","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2017/01/10/trombusaspiratie-bij-stemi-individuele-patientdata-meta-analyse/","published":"2017-01-10"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brian-a-ference","type":"person","url":"https://hartvaat.nl/mensen/brian-a-ference/","name":"Brian A Ference","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2019/10/15/triglyceridenverlaging-en-cv-risicoreductie-over-therapeutische-klassen-meta-ana/","published":"2019-10-15"},{"url":"https://hartvaat.nl/2018/07/14/ldl-verlaging-en-cv-events-met-pcsk9-remmers-meta-analyse-van-gerandomiseerde-tr/","published":"2018-07-14"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2016/09/27/ldl-c-verlaging-en-cardiovasculaire-risicoreductie-jama-systematische-review-en-/","published":"2016-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brian-rayner","type":"person","url":"https://hartvaat.nl/mensen/brian-rayner/","name":"Brian Rayner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/23/semaglutide-vermindert-infectierisico-bij-diabetes-en-chronische-nierziekte/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2022/11/01/antihypertensieve-combinaties-bij-afrikaanse-patienten-creole-secundaire-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/01/01/farmacologische-hypertensiebehandeling-bij-volwassenen-who-richtlijn-samenvattin/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2019/06/20/vergelijking-van-duale-therapieen-voor-bloeddrukverlaging-bij-afrikaanse-afrikan/","published":"2019-06-20"},{"url":"https://hartvaat.nl/2016/02/09/sms-berichten-ter-ondersteuning-van-therapietrouw-bij-hoge-bloeddruk-de-star-tri/","published":"2016-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bruce-hug","type":"person","url":"https://hartvaat.nl/mensen/bruce-hug/","name":"Bruce Hug","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bruno-garcia-del-blanco","type":"person","url":"https://hartvaat.nl/mensen/bruno-garcia-del-blanco/","name":"Bruno García Del Blanco","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/11/25/amphilimus-versus-zotarolimus-eluting-stent-bij-diabetes-en-coronairlijden/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2025/04/10/dapagliflozine-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2025-04-10"},{"url":"https://hartvaat.nl/2024/06/06/smart-zelf-expanderend-versus-ballonexpandeerbaar-tavr-bij-kleine-annulus-nejm/","published":"2024-06-06"},{"url":"https://hartvaat.nl/2022/03/31/amphilimus-versus-zotarolimus-stents-bij-diabetes-sugar-gerandomiseerde-trial/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2019/12/03/magnesium-resorbeerbare-scaffold-versus-metallic-stent-bij-stemi-biosolve-iii/","published":"2019-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carl-schultz","type":"person","url":"https://hartvaat.nl/mensen/carl-schultz/","name":"Carl Schultz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2021/07/01/camkii-delta-remming-en-ventriculaire-remodellering-na-mi-jama-cardiology/","published":"2021-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carlo-pappone","type":"person","url":"https://hartvaat.nl/mensen/carlo-pappone/","name":"Carlo Pappone","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/06/02/catheterablatie-bij-atriumfibrilleren-in-cardiale-amyloidose-levert-42-ritmievri/","published":"2026-08-11"},{"url":"https://hartvaat.nl/2026/02/03/linkerbundeltakpacing-versus-rechterventrikel-pacing-na-tavi/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/02/03/varipure-studie-pulsed-field-ablatie-in-de-dagelijkse-af-praktijk/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/02/03/semaglutide-als-aanvulling-op-katheterablatie-bij-obesitas-gerelateerd-atriumfib/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2017/04/01/aanvullende-elektroden-op-de-quartet-lv-lead-bieden-meer-crt-programmeringsmogel/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carlos-roberto-jaen","type":"person","url":"https://hartvaat.nl/mensen/carlos-roberto-jaen/","name":"Carlos Roberto Jaén","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carmine-g-de-pasquale","type":"person","url":"https://hartvaat.nl/mensen/carmine-g-de-pasquale/","name":"Carmine G De Pasquale","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2023/09/14/heart-fid-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-nejm/","published":"2023-09-14"},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2021/10/01/acute-pleiotrope-effecten-van-dapagliflozine-bij-diabetes-type-2-met-hfref-cross/","published":"2021-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carmine-zoccali","type":"person","url":"https://hartvaat.nl/mensen/carmine-zoccali/","name":"Carmine Zoccali","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/08/21/scd-bij-ckd-en-dialyse-heterogene-aritmieen-en-mechanisme-gestuurde-preventie/","published":"2026-08-29"},{"url":"https://hartvaat.nl/2026/02/09/communicatie-tussen-nier-en-hart-via-extracellulaire-vesikels/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2021/12/01/longechogeleide-behandeling-bij-hemodialysepatienten-met-hoog-cv-risico-gerandom/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2019/06/01/longechogeleide-drooggewichtreductie-en-ambulante-bloeddruk-bij-hemodialyse/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/08/01/sympathische-zenuwactivatie-bij-essentiele-hypertensie-meta-analyse/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carol-i-duffy","type":"person","url":"https://hartvaat.nl/mensen/carol-i-duffy/","name":"Carol I Duffy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/09/01/arni-naar-hf-voorgeschiedenis-en-raas-antagonistgebruik/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/02/01/arni-initiatie-na-acuut-gedecompenseerd-hf-pioneer-hf-open-label-extensie/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/10/21/cv-biomarkers-bij-acuut-gedecompenseerd-hf-met-sacubitril-valsartan-pioneer-hf/","published":"2019-10-21"},{"url":"https://hartvaat.nl/2019/05/07/sacubitril-valsartan-of-enalapril-bij-acuut-gedecompenseerd-hf-pioneer-hf-klinis/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/02/07/angiotensine-neprilysineremming-bij-acuut-gedecompenseerd-hf-nejm-pioneer-hf/","published":"2019-02-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"catherine-g-derington","type":"person","url":"https://hartvaat.nl/mensen/catherine-g-derington/","name":"Catherine G Derington","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/10/28/prevent-vergelijkingen-voor-intensieve-versus-standaard-bloeddrukcontrole/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2023/08/01/combinatietabletten-voor-intensieve-bloeddrukbehandeling-sprint-analyse/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2023/07/01/leeftijdsbias-draagt-bij-aan-therapeutische-inertie-bij-bloeddrukmanagement/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2021/04/27/patientselectie-voor-intensieve-bloeddrukbehandeling-naar-voordeel-en-bijwerking/","published":"2021-04-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chandan-m-devireddy","type":"person","url":"https://hartvaat.nl/mensen/chandan-m-devireddy/","name":"Chandan M Devireddy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"changdong-guan","type":"person","url":"https://hartvaat.nl/mensen/changdong-guan/","name":"Changdong Guan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/01/sirolimus-eluerende-bioresorbeerbare-stents-versus-everolimus-eluerende-stents-i/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/12/gdmt-na-functioneel-complete-revascularisatie-prognostische-impact/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2016/05/17/biodegradeerbare-sirolimus-eluting-stents-de-panda-iii-trial/","published":"2016-05-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"charalambos-antoniades","type":"person","url":"https://hartvaat.nl/mensen/charalambos-antoniades/","name":"Charalambos Antoniades","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":2,"articles":[{"url":"https://hartvaat.nl/2026/05/26/esc-consensusverklaring-over-microvasculaire-obstructie-en-no-reflow-na-stemi/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2023/05/30/empagliflozine-en-cardiale-energiestofwisseling-bij-hartfalen-empa-vision/","published":"2023-05-30"}],"videos":[{"url":"https://hartvaat.nl/video/nieuwe-horizonten-dyslipidemie-2026/implementatie-lipidenmanagement/","title":"Sessie 4: Implementatie van lipidenmanagement — praktische uitdagingen"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chen-liu","type":"person","url":"https://hartvaat.nl/mensen/chen-liu/","name":"Chen Liu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/06/01/hypertensie-wijzigt-de-relatie-tussen-lp-a-en-mortaliteit-bij-acuut-gedecompense/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/07/14/depressietrajecten-bij-hfpef-impact-op-uitkomsten/","published":"2025-07-14"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/06/01/s2i2n0-3-score-voorspelt-mortaliteit-bij-hfref-guide-it-subanalyse/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2021/05/05/bloeddrukvariabiliteit-en-uitkomsten-bij-hfpef/","published":"2021-05-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chiadi-e-ndumele","type":"person","url":"https://hartvaat.nl/mensen/chiadi-e-ndumele/","name":"Chiadi E Ndumele","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christiaan-j-vrints","type":"person","url":"https://hartvaat.nl/mensen/christiaan-j-vrints/","name":"Christiaan J Vrints","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/02/03/klinische-risicopredictie-ct-coronairangiografie-en-cv-events-bij-nieuwe-angina/","published":"2025-02-03"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-spaulding","type":"person","url":"https://hartvaat.nl/mensen/christian-spaulding/","name":"Christian Spaulding","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/01/coact-trial-langetermijnlessen-over-coronairangiografie-na-reanimatie/","published":"2026-03-17"},{"url":"https://hartvaat.nl/2024/01/01/verkorte-dapt-bij-hoog-bloedingsrisico-geen-sekseverschillen/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2020/08/01/seksegerelateerde-uitkomsten-bij-hoog-bloedingsrisico-na-pci-leaders-free/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","published":"2018-01-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christianne-l-roumie","type":"person","url":"https://hartvaat.nl/mensen/christianne-l-roumie/","name":"Christianne L Roumie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2020/03/01/orthostatische-hypotensie-cv-uitkomsten-en-adverse-events-sprint-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2020/02/01/bloeddrukcontrole-en-diabetes-incidentie-sprint-resultaten/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"},{"url":"https://hartvaat.nl/2016/03/01/voorschrijfpatronen-van-thiazidediuretica-in-de-sprint-trial/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-a-rinaldi","type":"person","url":"https://hartvaat.nl/mensen/christopher-a-rinaldi/","name":"Christopher A Rinaldi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/10/01/draadloos-ultrasound-gebaseerd-crt-systeem-bij-hartfalen/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2023/10/05/more-crt-mpp-multipoint-pacing-bij-crt-non-responders/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/05/03/triventriculaire-pacing-bij-hf-strive-hf-gerandomiseerde-trial/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2019/09/14/crt-non-responder-naar-responder-conversie-more-crt-mpp/","published":"2019-09-14"},{"url":"https://hartvaat.nl/2017/04/01/aanvullende-elektroden-op-de-quartet-lv-lead-bieden-meer-crt-programmeringsmogel/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-m-cook","type":"person","url":"https://hartvaat.nl/mensen/christopher-m-cook/","name":"Christopher M Cook","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/09/07/des-versus-cabg-bij-hoofdstamlijden-mortaliteits-meta-analyse/","published":"2020-09-07"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/01/temporele-veranderingen-in-coronaire-hemodynamiek-bij-niet-culprit-vaten-na-stem/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-r-ellis","type":"person","url":"https://hartvaat.nl/mensen/christopher-r-ellis/","name":"Christopher R Ellis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/11/emerge-laa-amulet-occluder-in-12-180-patienten-96-succes-1-jaars-beroerte-1-6-re/","published":"2026-06-25"},{"url":"https://hartvaat.nl/2025/03/25/amulet-ide-vijfjaarsresultaten-laa-occlusie-met-amulet/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2024/04/02/amaze-pvi-met-of-zonder-laa-ligatie-bij-af-jama-rct/","published":"2024-04-02"},{"url":"https://hartvaat.nl/2023/11/02/advent-pulsed-field-ablatie-non-inferieur-aan-thermale-ablatie-bij-af-nejm/","published":"2023-11-02"},{"url":"https://hartvaat.nl/2023/08/02/peri-device-lekkage-bij-laa-occluders-mechanismen-en-voorspellers/","published":"2023-08-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"clara-ines-saldarriaga","type":"person","url":"https://hartvaat.nl/mensen/clara-ines-saldarriaga/","name":"Clara Inés Saldarriaga","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cynthia-m-westerhout","type":"person","url":"https://hartvaat.nl/mensen/cynthia-m-westerhout/","name":"Cynthia M Westerhout","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/01/geografische-variatie-in-hfref-patientkenmerken-en-behandeling/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2023/08/29/stream-2-halve-dosis-tenecteplase-bij-ouderen-met-stemi/","published":"2023-08-29"},{"url":"https://hartvaat.nl/2020/11/01/invloed-van-acs-trials-buiten-de-primaire-hypothese-systematische-review/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2016/04/01/ischemisch-risicogebied-en-reperfusiemethode-bij-stemi-klinische-implicaties/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"candida-fonseca","type":"person","url":"https://hartvaat.nl/mensen/candida-fonseca/","name":"Cândida Fonseca","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-j-rader","type":"person","url":"https://hartvaat.nl/mensen/daniel-j-rader/","name":"Daniel J Rader","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/06/01/genetische-bijdrage-aan-aortastenose-dyslipidemie-inflammatie-en-verkalking/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2017/07/20/genetische-en-farmacologische-inactivatie-van-angptl3-en-cardiovasculaire-ziekte/","published":"2017-07-20"},{"url":"https://hartvaat.nl/2017/06/20/cholesteroleffluxcapaciteit-hdl-deeltjesaantal-en-cv-events-jupiter-analyse/","published":"2017-06-20"},{"url":"https://hartvaat.nl/2017/05/30/polygene-risicoscore-en-relatief-voordeel-van-statinetherapie-primaire-preventie/","published":"2017-05-30"},{"url":"https://hartvaat.nl/2016/05/01/ly3015014-een-nieuw-monoklonaal-pcsk9-antilichaam-gerandomiseerde-fase-2-trial/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-l-jacoby","type":"person","url":"https://hartvaat.nl/mensen/daniel-l-jacoby/","name":"Daniel L Jacoby","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/05/aficamten-veilig-en-effectief-bij-langdurige-behandeling-van-obstructieve-hcm/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/10/07/nieuwe-inspanningsherstelpatronen-als-maat-voor-cardiale-prestatie/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2020/09/15/empagliflozine-bij-hartfalen-diuretische-en-cardiorenale-effecten/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2019/07/23/ag10-transthyretinestabilisator-bij-symptomatische-attr-cardiomyopathie/","published":"2019-07-23"},{"url":"https://hartvaat.nl/2018/09/18/hartfalen-na-cva-tia-bij-insulineresistente-patienten-behandeld-met-pioglitazon/","published":"2018-09-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-steven","type":"person","url":"https://hartvaat.nl/mensen/daniel-steven/","name":"Daniel Steven","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2025/05/07/hoog-vermogen-korte-duur-rf-ablatie-versus-cryoballon-bij-paroxysmaal-af-rct/","published":"2025-05-07"},{"url":"https://hartvaat.nl/2024/12/17/ablatiestrategie-bij-af-recidief-na-duurzame-pvi/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2021/10/09/gewichtsverlies-voor-af-ablatie-sort-af-gerandomiseerde-trial/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2019/09/24/interne-versus-externe-cardioversie-bij-atriale-aritmieen-met-icd/","published":"2019-09-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-weilenmann","type":"person","url":"https://hartvaat.nl/mensen/daniel-weilenmann/","name":"Daniel Weilenmann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/11/25/biodegradeerbare-versus-duurzame-polymeer-des-bij-stemi-langetermijndata/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2020/11/07/drug-coated-balloons-versus-des-bij-kleine-coronairarterien-lancet-basket-small-/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2019/10/05/biodegradeerbare-versus-duurzame-polymer-des-bij-stemi-gerandomiseerde-trial/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2018/09/08/drug-coated-balloons-bij-kleine-coronairarterien-lancet-basket-small-2/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/09/01/ultradunne-biodegradeerbare-versus-dunne-duurzame-stents-lancet-gerandomiseerde-/","published":"2018-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-aguilar","type":"person","url":"https://hartvaat.nl/mensen/david-aguilar/","name":"David Aguilar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/09/17/2024-acc-aha-kwaliteitsmaatstaven-voor-hartfalen-geactualiseerd/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2016/12/06/comorbiditeiten-bij-hartfalen-hypertensie-obesitas-diabetes-hyperlipidemie-en-me/","published":"2016-12-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-d-waters","type":"person","url":"https://hartvaat.nl/mensen/david-d-waters/","name":"David D Waters","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/10/14/dal-gene-farmacogenetica-geleide-dalcetrapib-na-acs/","published":"2022-10-14"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"},{"url":"https://hartvaat.nl/2017/04/06/gewichtsfluctuaties-en-cardiovasculaire-uitkomsten-bij-coronairlijden-nejm/","published":"2017-04-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-j-wilber","type":"person","url":"https://hartvaat.nl/mensen/david-j-wilber/","name":"David J Wilber","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/04/02/amaze-pvi-met-of-zonder-laa-ligatie-bij-af-jama-rct/","published":"2024-04-02"},{"url":"https://hartvaat.nl/2023/02/08/redo-firm-firm-geleide-ablatie-verbetert-uitkomst-niet-bij-recidief-af/","published":"2023-02-08"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-preiss","type":"person","url":"https://hartvaat.nl/mensen/david-preiss/","name":"David Preiss","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2017/02/21/diabetesstatus-en-cardiovasculaire-uitkomsten-bij-hfpef-klinische-en-echocardiog/","published":"2017-02-21"},{"url":"https://hartvaat.nl/2016/04/19/evolocumab-versus-ezetimibe-bij-statine-intolerante-patienten-de-gauss-3-trial/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/02/01/nicotinezuurtherapie-en-het-risico-op-diabetes-meta-analyse-van-gerandomiseerde-/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"davor-milicic","type":"person","url":"https://hartvaat.nl/mensen/davor-milicic/","name":"Davor Milicic","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/26/esc-consensusverklaring-over-microvasculaire-obstructie-en-no-reflow-na-stemi/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2020/01/28/eerdere-hf-hospitalisatie-en-sacubitril-valsartan-versus-valsartan-bij-hfpef-par/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"de-wei-an","type":"person","url":"https://hartvaat.nl/mensen/de-wei-an/","name":"De-Wei An","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"debbie-l-cohen","type":"person","url":"https://hartvaat.nl/mensen/debbie-l-cohen/","name":"Debbie L Cohen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2025/05/08/lorundrostat-bij-ongecontroleerde-hypertensie-fase-3-nejm/","published":"2025-05-08"},{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"denis-angoulvant","type":"person","url":"https://hartvaat.nl/mensen/denis-angoulvant/","name":"Denis Angoulvant","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/10/23/aspirine-bij-chronisch-coronairsyndroom-plus-oac-wel-of-niet/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2021/11/09/ffr-voor-behandeling-van-multivatencoronairlijden-jacc/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dennis-wolf","type":"person","url":"https://hartvaat.nl/mensen/dennis-wolf/","name":"Dennis Wolf","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"derek-v-exner","type":"person","url":"https://hartvaat.nl/mensen/derek-v-exner/","name":"Derek V Exner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/03/upgrade-van-draadloze-pacemaker-van-enkelvoudig-naar-tweekamersysteem/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2024/01/18/raft-langetermijn-crt-d-bij-hartfalen-nejm-14-jaarsresultaten/","published":"2024-01-18"},{"url":"https://hartvaat.nl/2023/05/16/afschaffen-eigen-bijdrage-medicatie-vermindert-cardiovasculair-risico-bij-oudere/","published":"2023-05-16"},{"url":"https://hartvaat.nl/2023/05/16/zelfmanagement-via-reclameprincipes-bij-ouderen-met-hoog-cv-risico/","published":"2023-05-16"},{"url":"https://hartvaat.nl/2021/06/01/implanteerbare-versus-verlengde-externe-ecg-monitoring-voor-af-na-ischemisch-cva/","published":"2021-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dhiraj-gupta","type":"person","url":"https://hartvaat.nl/mensen/dhiraj-gupta/","name":"Dhiraj Gupta","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/06/transseptale-punctie-bij-linkshartinterventies-nieuwe-esc-consensus-over-technie/","published":"2026-07-29"},{"url":"https://hartvaat.nl/2023/02/14/cryoballon-pvi-als-eerstelijnsbehandeling-voor-typisch-atriumflutter/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2021/10/01/katheterablatie-als-eerstelijns-paf-therapie-meta-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/12/14/katheterablatie-versus-thoracoscopische-ablatie-bij-langdurig-persisterend-af-ca/","published":"2020-12-14"},{"url":"https://hartvaat.nl/2017/05/01/ablatie-index-als-marker-voor-ablatielaesiekwaliteit-voorspelling-van-pv-reconne/","published":"2017-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"diana-aguiar-de-sousa","type":"person","url":"https://hartvaat.nl/mensen/diana-aguiar-de-sousa/","name":"Diana Aguiar de Sousa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"},{"url":"https://hartvaat.nl/2024/07/02/vroege-versus-late-doac-na-cva-met-hemorrhagische-transformatie-bij-af/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/06/29/elan-vroege-versus-late-anticoagulatie-na-cva-bij-af-nejm/","published":"2023-06-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"didier-tchetche","type":"person","url":"https://hartvaat.nl/mensen/didier-tchetche/","name":"Didier Tchétché","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/16/pandora-register-supra-versus-intra-annulaire-kleppen-bij-tavr-in-tavr/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2024/06/06/smart-zelf-expanderend-versus-ballonexpandeerbaar-tavr-bij-kleine-annulus-nejm/","published":"2024-06-06"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-zelfexpanderende-klep-bij-laagrisicopatienten-nejm-evolut-low-risk/","published":"2019-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dike-b-ojji","type":"person","url":"https://hartvaat.nl/mensen/dike-b-ojji/","name":"Dike B Ojji","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2024/10/01/lage-dosis-drievoudige-pil-versus-standaardzorg-bij-hypertensie-in-nigeria/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2022/11/01/antihypertensieve-combinaties-bij-afrikaanse-patienten-creole-secundaire-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2019/06/20/vergelijking-van-duale-therapieen-voor-bloeddrukverlaging-bij-afrikaanse-afrikan/","published":"2019-06-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dimitri-karmpaliotis","type":"person","url":"https://hartvaat.nl/mensen/dimitri-karmpaliotis/","name":"Dimitri Karmpaliotis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","published":"2020-10-06"},{"url":"https://hartvaat.nl/2020/09/07/des-versus-cabg-bij-hoofdstamlijden-mortaliteits-meta-analyse/","published":"2020-09-07"},{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dimitrios-farmakis","type":"person","url":"https://hartvaat.nl/mensen/dimitrios-farmakis/","name":"Dimitrios Farmakis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2024/05/01/bloeddrukstreefwaarden-en-residueel-risico-systematische-review-en-meta-regressi/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2022/12/01/hartfalen-tijdens-de-covid-19-pandemie-klinische-en-organisatorische-dilemma-s/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","published":"2022-08-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"divaka-perera","type":"person","url":"https://hartvaat.nl/mensen/divaka-perera/","name":"Divaka Perera","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/28/coronaire-autoregulatie-samenspel-van-epicardiale-en-microvasculaire-weerstand/","published":"2026-03-28"},{"url":"https://hartvaat.nl/2025/12/29/functionele-en-morfologische-karakterisering-van-coronaire-atherosclerose/","published":"2025-12-29"},{"url":"https://hartvaat.nl/2024/07/23/anatomische-versus-viabiliteitsgerichte-completeness-van-revascularisatie/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2022/11/24/protecct-ct-bij-verdenking-acs-met-intermediaire-troponinewaarden/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2022/10/13/revived-bcis2-pci-verbetert-overleving-niet-bij-ischemische-lv-disfunctie/","published":"2022-10-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"douglas-g-altman","type":"person","url":"https://hartvaat.nl/mensen/douglas-g-altman/","name":"Douglas G Altman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2019/01/31/bilaterale-versus-enkele-mammaria-interna-grafts-na-10-jaar-nejm-art/","published":"2019-01-31"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/08/01/radiale-arterie-graft-als-aanvulling-op-mammaria-interna-grafts-bij-cabg/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/06/20/hartfrequentie-en-ritme-en-het-voordeel-van-betablokkers-bij-hartfalen/","published":"2017-06-20"},{"url":"https://hartvaat.nl/2016/12/29/bilaterale-versus-enkelvoudige-a-mammaria-interna-grafts-nejm-art-trial/","published":"2016-12-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"douglas-horstmanshof","type":"person","url":"https://hartvaat.nl/mensen/douglas-horstmanshof/","name":"Douglas Horstmanshof","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/09/27/momentum-3-vijfjaarsresultaten-heartmate-3-versus-axiale-lvad/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2021/09/11/hemodynamisch-geleid-hf-management-lancet-guide-hf/","published":"2021-09-11"},{"url":"https://hartvaat.nl/2020/04/01/lvad-gebruik-als-bridge-to-transplant-versus-destination-therapy-momentum-3/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","published":"2017-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-ashkan-shoamanesh","type":"person","url":"https://hartvaat.nl/mensen/dr-ashkan-shoamanesh/","name":"Dr. Ashkan Shoamanesh","title":"Neuroloog, McMaster University, Hamilton, Canada","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":2,"articles":[{"url":"https://hartvaat.nl/2024/05/16/annexa-i-andexanet-alfa-bij-factor-xa-remmer-geassocieerde-intracerebrale-bloedi/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","published":"2023-05-21"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-enrich-af-hotline/","title":"ENRICH-AF: edoxaban na intracraniële bloeding"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-david-zizek","type":"person","url":"https://hartvaat.nl/mensen/dr-david-zizek/","name":"Dr. David Žižek","title":"Cardioloog-elektrofysioloog, UMC Ljubljana, Slovenië","dutch_institution":true,"orcid":"","scholar":"","website":"","article_count":2,"articles":[{"url":"https://hartvaat.nl/2025/09/01/csp-sync-geleidingssysteempacing-versus-biventriculaire-pacing-voor-crt-rct/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/05/02/preventieve-substraatablatie-vermindert-icd-interventies-bij-ischemische-cmp/","published":"2024-05-02"}],"videos":[{"url":"https://hartvaat.nl/video/hfa-2026-late-breaking-science/conduct-af-conductiesysteem-pacing/","title":"CONDUCT-AF — Conductiesysteem-pacing versus biventriculaire pacing na AV-knoopablatie"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-jasper-boeddinghaus","type":"person","url":"https://hartvaat.nl/mensen/dr-jasper-boeddinghaus/","name":"Dr. Jasper Boeddinghaus","title":"Cardioloog, Universitätsspital Basel en Universitätsklinikum Bonn","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":2,"articles":[{"url":"https://hartvaat.nl/2025/01/01/esc-0-1-uur-versus-0-2-of-0-3-uur-hoog-sensitief-troponine-algoritmen-bij-verden/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2019/12/17/uitgebreide-vasodilatatie-versus-standaardzorg-bij-acuut-hf-jama-galactic-hf-pil/","published":"2019-12-17"}],"videos":[{"url":"https://hartvaat.nl/video/esc26-uitslagen-besproken/esc26-presc1se-mi-lbct/","title":"PRESC1SE-MI: het 0/1-uuralgoritme, het gesprek"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-wayne-batchelor","type":"person","url":"https://hartvaat.nl/mensen/dr-wayne-batchelor/","name":"Dr. Wayne Batchelor","title":"Inova Heart and Vascular Institute, VS","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":2,"articles":[{"url":"https://hartvaat.nl/2025/08/19/paclitaxel-gecoate-ballon-bij-multilayer-in-stent-restenose-agent-ide-subgroep/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/06/10/triluminate-tweejaarsresultaten-transcatheter-tr-repair-duurzaam-effectief/","published":"2025-06-10"}],"videos":[{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/alert-onderbehandeling-aortastenose-mitralisinsufficiëntie/","title":"ALERT: Onderbehandeling bij aortastenose en mitralisinsufficiëntie"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"duolao-wang","type":"person","url":"https://hartvaat.nl/mensen/duolao-wang/","name":"Duolao Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/14/inte-africa-2-community-based-versus-facilitair-beheer-hiv-dm-htn/","published":"2026-03-14"},{"url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/10/07/inte-africa-geintegreerd-management-van-hiv-diabetes-en-hypertensie-lancet/","published":"2023-10-07"},{"url":"https://hartvaat.nl/2019/12/24/langetermijnfollow-up-van-complete-versus-laesie-only-revascularisatie-bij-stemi/","published":"2019-12-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"edoardo-casiglia","type":"person","url":"https://hartvaat.nl/mensen/edoardo-casiglia/","name":"Edoardo Casiglia","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"egon-pfarr","type":"person","url":"https://hartvaat.nl/mensen/egon-pfarr/","name":"Egon Pfarr","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2020/09/19/sglt2-remmers-bij-hfref-meta-analyse-van-emperor-reduced-en-dapa-hf/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2019/03/12/empagliflozine-vermindert-mortaliteit-en-hf-hospitalisatie-over-het-cv-risicospe/","published":"2019-03-12"},{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","published":"2019-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eik-vettorazzi","type":"person","url":"https://hartvaat.nl/mensen/eik-vettorazzi/","name":"Eik Vettorazzi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/02/geindividualiseerd-perioperatief-bloeddrukmanagement-bij-grote-buikchirurgie/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","published":"2022-09-13"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2018/09/22/telemedische-interventie-bij-hartfalen-lancet-tim-hf2/","published":"2018-09-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ekkehard-grunig","type":"person","url":"https://hartvaat.nl/mensen/ekkehard-grunig/","name":"Ekkehard Grünig","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/04/20/stellar-sotatercept-bij-pulmonale-arteriele-hypertensie-nejm-fase-3/","published":"2023-04-20"},{"url":"https://hartvaat.nl/2022/09/21/riociguat-bij-pulmonale-hypertensie-en-hfpef-haemodynamic-trial/","published":"2022-09-21"},{"url":"https://hartvaat.nl/2021/06/14/gestandaardiseerde-inspanningstraining-bij-pah-en-cteph-haalbaarheid-en-veilighe/","published":"2021-06-14"},{"url":"https://hartvaat.nl/2017/04/01/hemodynamische-effecten-van-riociguat-bij-inoperabel-cteph/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/01/01/inspanningstraining-verbetert-zuurstofopname-en-hemodynamiek-bij-ernstige-pulmon/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eliana-vieira-santucci","type":"person","url":"https://hartvaat.nl/mensen/eliana-vieira-santucci/","name":"Eliana Vieira Santucci","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/02/13/bariatrische-chirurgie-en-bloeddruk-na-5-jaar-gerandomiseerde-trial/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2019/03/01/bariatrische-chirurgie-versus-medicamenteus-beleid-op-24-uurs-ambulante-bloeddru/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/11/01/timing-van-atorvastatine-oplaaddosis-voor-pci-bij-acs-jama-cardiology/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/04/03/oplaaddosis-atorvastatine-voor-pci-jama-gerandomiseerde-trial/","published":"2018-04-03"},{"url":"https://hartvaat.nl/2018/03/13/bariatrische-chirurgie-bij-obese-patienten-met-hypertensie-gateway-gerandomiseer/","published":"2018-03-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eliano-p-navarese","type":"person","url":"https://hartvaat.nl/mensen/eliano-p-navarese/","name":"Eliano P Navarese","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/01/24/pcsk9-remming-bij-covid-19-anti-inflammatoir-potentieel-onderzocht/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2021/12/07/minimaal-onderbroken-versus-continue-doac-bij-af-ablatie-meta-analyse/","published":"2021-12-07"},{"url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/07/14/vergelijking-van-orale-p2y12-remmers-bij-acs-netwerkmeta-analyse-van-52-816-pati/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2018/04/17/uitgangs-ldl-en-mortaliteitsreductie-na-ldl-verlaging-jama-meta-analyse/","published":"2018-04-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ellen-g-moquete","type":"person","url":"https://hartvaat.nl/mensen/ellen-g-moquete/","name":"Ellen G Moquete","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"elvin-kedhi","type":"person","url":"https://hartvaat.nl/mensen/elvin-kedhi/","name":"Elvin Kedhi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/21/tavi-plus-ffr-geleide-pci-gecombineerde-benadering-onderzocht/","published":"2025-12-21"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2021/12/01/thin-cap-fibroatheroom-voorspelt-events-bij-diabetes-met-normale-ffr-combine-oct/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","published":"2016-06-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"emilio-ros","type":"person","url":"https://hartvaat.nl/mensen/emilio-ros/","name":"Emilio Ros","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/07/urinair-wijnzuur-als-biomarker-voor-wijnconsumptie-en-cv-risico-predimed/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2020/12/08/remnant-cholesterol-versus-ldl-en-incident-cv-ziekte/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/02/11/disfunctioneel-hdl-en-incidentie-van-acs-bij-hoog-cardiovasculair-risico/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2019/05/01/walnotendieet-en-24-uurs-ambulante-bloeddruk-bij-ouderen/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2017/02/14/mediterraan-dieet-verbetert-hdl-functie-bij-hoog-cardiovasculair-risico-gerandom/","published":"2017-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"emily-r-atkins","type":"person","url":"https://hartvaat.nl/mensen/emily-r-atkins/","name":"Emily R Atkins","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/06/01/lage-dosis-drievoudige-viervoudige-combinatiepil-versus-monotherapie-bij-hyperte/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","published":"2021-09-18"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"},{"url":"https://hartvaat.nl/2016/01/30/intensieve-bloeddrukverlaging-en-cardiovasculaire-en-renale-uitkomsten-systemati/","published":"2016-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"enrique-santas","type":"person","url":"https://hartvaat.nl/mensen/enrique-santas/","name":"Enrique Santas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/03/expertopinie-hierarchische-eindpunten-op-basis-van-verslechterend-hartfalen-voor/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/02/03/bio-impedantie-voor-vochtstatusbepaling-en-prognose-bij-chronisch-hartfalen/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2024/04/01/betablokkerstaken-verbetert-inspanningscapaciteit-bij-hfpef/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/04/01/iv-ferricarboxymaltose-verbetert-linkeratriale-strain-bij-hartfalen-myocardial-i/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2021/11/23/betablokkerstaken-en-functionele-capaciteit-bij-hfpef/","published":"2021-11-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eric-b-rimm","type":"person","url":"https://hartvaat.nl/mensen/eric-b-rimm/","name":"Eric B Rimm","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/01/haptoglobinefenotype-en-cv-risico-accord-bloeddruk-rct/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2023/07/25/omega-3-biomarkers-en-incident-af-ipd-analyse/","published":"2023-07-25"},{"url":"https://hartvaat.nl/2020/02/11/haptoglobinefenotype-wijzigt-het-effect-van-intensieve-glycemische-controle-op-c/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2018/03/27/hdl-subspecies-met-apoliproteine-c-iii-en-coronairlijden-vier-cohorten/","published":"2018-03-27"},{"url":"https://hartvaat.nl/2017/05/01/melatoninesecretie-en-myocardinfarctrisico-geneste-case-controlstudie/","published":"2017-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eric-boerwinkle","type":"person","url":"https://hartvaat.nl/mensen/eric-boerwinkle/","name":"Eric Boerwinkle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/24/yellow-iii-intracoronaire-beeldvorming-en-genexpressie-na-maximale-lipideverlagi/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2022/08/01/hele-genoomsequencing-onthult-nieuwe-bloeddruk-loci/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2019/08/20/dna-methylering-in-leukocyten-voorspelt-mi-en-coronairlijden/","published":"2019-08-20"},{"url":"https://hartvaat.nl/2017/01/01/genoomwijde-meta-analyse-van-bloeddrukrespons-op-hydrochloorthiazide/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/03/01/farmacogenomische-meta-analyse-van-bloeddrukrespons-op-betablokkers-bij-afro-ame/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eric-s-leifer","type":"person","url":"https://hartvaat.nl/mensen/eric-s-leifer/","name":"Eric S Leifer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/04/18/aha-scientific-statement-gestructureerde-inspanningstraining-bij-hfpef/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2017/08/22/natriuretisch-peptide-geleide-therapie-bij-hoogrisico-hartfalen-jama-guide-it/","published":"2017-08-22"},{"url":"https://hartvaat.nl/2016/02/23/inspanningstestvariabelen-als-mortaliteitsvoorspellers-bij-chronisch-systolisch-/","published":"2016-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"erion-xhepa","type":"person","url":"https://hartvaat.nl/mensen/erion-xhepa/","name":"Erion Xhepa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/04/17/in-stent-restenose-tienjaarsuitkomsten-plain-balloon-vs-dcb-vs-des-isar-desire-3/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"erlend-eriksen","type":"person","url":"https://hartvaat.nl/mensen/erlend-eriksen/","name":"Erlend Eriksen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2018/09/01/langetermijnimpact-van-cto-rekanalisatie-bij-stemi-patienten/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-ondersteuning-versus-iabp-bij-cardiogene-shock-meta-analys/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-circulatoire-ondersteuning-versus-iabp-bij-cardiogene-shoc/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"},{"url":"https://hartvaat.nl/2016/10/11/pci-van-chronische-totale-occlusie-bij-stemi-met-multivatenlijden-explore-trial/","published":"2016-10-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ernest-spitzer","type":"person","url":"https://hartvaat.nl/mensen/ernest-spitzer/","name":"Ernest Spitzer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","published":"2026-04-09"},{"url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2016/12/01/tienjaarsuitkomsten-van-eerste-generatie-drug-eluting-stents-ses-versus-pes/","published":"2016-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eugene-s-chung","type":"person","url":"https://hartvaat.nl/mensen/eugene-s-chung/","name":"Eugene S Chung","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/23/aspirinestop-bij-lvad-met-vka-veiligheidsanalyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2023/09/30/adaptresponse-adaptieve-versus-conventionele-crt-bij-hartfalen-lancet/","published":"2023-09-30"},{"url":"https://hartvaat.nl/2016/05/10/biventriculaire-versus-rechterkamerpacing-klinische-verbetering-in-de-block-hf-s/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/02/01/peri-infarctpacing-ter-preventie-van-linkerkamerremodellering-na-groot-myocardin/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eva-a-mistry","type":"person","url":"https://hartvaat.nl/mensen/eva-a-mistry/","name":"Eva A Mistry","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2023/09/05/best-ii-bloeddrukmanagement-na-trombectomie-bij-cva-jama/","published":"2023-09-05"},{"url":"https://hartvaat.nl/2020/03/01/bloeddruk-en-uitkomsten-bij-acute-beroerte-trombectomie/","published":"2020-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"evelyne-meekers","type":"person","url":"https://hartvaat.nl/mensen/evelyne-meekers/","name":"Evelyne Meekers","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/09/praise-mr-sacubitril-valsartan-verbetert-inspanningshemodynamiek-bij-hfpef-met-a/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","published":"2023-06-09"},{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","published":"2022-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eugene-p-mcfadden","type":"person","url":"https://hartvaat.nl/mensen/eugene-p-mcfadden/","name":"Eùgene P McFadden","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"f-perry-wilson","type":"person","url":"https://hartvaat.nl/mensen/f-perry-wilson/","name":"F Perry Wilson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/03/28/secundaire-hypertensie-bij-kinderen-jama-klinische-diagnostiek/","published":"2023-03-28"},{"url":"https://hartvaat.nl/2022/06/07/elektronische-alerts-verbeteren-hartfalenbehandeling-in-de-polikliniek/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2020/09/15/empagliflozine-bij-hartfalen-diuretische-en-cardiorenale-effecten/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2018/05/08/nierfunctieverslechtering-bij-acuut-hartfalen-met-agressieve-diurese-geen-tubula/","published":"2018-05-08"},{"url":"https://hartvaat.nl/2016/05/17/verminderde-cardiac-index-is-niet-de-primaire-oorzaak-van-nierdisfunctie-bij-har/","published":"2016-05-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fabien-praz","type":"person","url":"https://hartvaat.nl/mensen/fabien-praz/","name":"Fabien Praz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/28/gestandaardiseerd-stappenplan-voor-tricuspidalisinsufficientie-van-verwijzing-to/","published":"2026-04-19"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fabio-mangiacapra","type":"person","url":"https://hartvaat.nl/mensen/fabio-mangiacapra/","name":"Fabio Mangiacapra","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2024/09/01/periprocedureel-mi-na-pci-en-langetermijnmortaliteit-meta-analyse/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/12/20/ticagrelor-versus-prasugrel-en-coronaire-microcirculatie-bij-pci/","published":"2023-12-20"},{"url":"https://hartvaat.nl/2016/09/13/clopidogrel-versus-ticagrelor-bij-diabetes-na-pci-gerandomiseerde-trial/","published":"2016-09-13"},{"url":"https://hartvaat.nl/2016/07/12/prasugrel-versus-clopidogrel-en-coronaire-microvasculaire-functie-bij-electieve-/","published":"2016-07-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"feifan-ouyang","type":"person","url":"https://hartvaat.nl/mensen/feifan-ouyang/","name":"Feifan Ouyang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/09/nieuw-bifasisch-pfa-systeem-versus-thermale-ablatie-bij-paroxysmaal-af/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2024/10/21/shensong-yangxin-voorkomt-af-recidief-na-ablatie-bij-persisterend-af/","published":"2024-10-21"},{"url":"https://hartvaat.nl/2021/03/08/katheterablatie-om-af-progressie-te-vertragen-attest-gerandomiseerde-trial/","published":"2021-03-08"},{"url":"https://hartvaat.nl/2016/10/07/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-af-herinterventierate-e/","published":"2016-10-07"},{"url":"https://hartvaat.nl/2016/06/09/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-atriumfibrilleren-nejm-/","published":"2016-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fiorenzo-gaita","type":"person","url":"https://hartvaat.nl/mensen/fiorenzo-gaita/","name":"Fiorenzo Gaita","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/12/09/ideale-blankingperiode-na-af-ablatie-bewijs-voor-herziening/","published":"2022-12-09"},{"url":"https://hartvaat.nl/2017/11/07/stentontwerp-en-dapt-duur-effect-op-ischemie-en-bloedingen-netwerkmeta-analyse/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2017/03/14/drie-arteriele-grafts-verbeteren-langetermijnoverleving-meta-analyse-van-propens/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/12/21/statines-voor-primaire-preventie-bij-hiv-positieve-patienten-systematische-revie/","published":"2016-12-21"},{"url":"https://hartvaat.nl/2016/05/01/katheterablatie-van-af-bij-chronisch-hartfalen-state-of-the-art-en-toekomstpersp/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"flaviana-amarante","type":"person","url":"https://hartvaat.nl/mensen/flaviana-amarante/","name":"Flaviana Amarante","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"florian-rader","type":"person","url":"https://hartvaat.nl/mensen/florian-rader/","name":"Florian Rader","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2019/01/02/duurzaamheid-van-bloeddrukeffect-van-kapper-interventie/","published":"2019-01-02"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francesco-fioretti","type":"person","url":"https://hartvaat.nl/mensen/francesco-fioretti/","name":"Francesco Fioretti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/05/apture-shunt-verlaagt-hartfalen-heropnames-bij-patienten-met-hfpef-hfmref-alt-fl/","published":"2026-07-30"},{"url":"https://hartvaat.nl/2026/04/21/jacc-beschouwing-placebo-in-trials-met-incretine-therapie-bij-hartfalen-wetensch/","published":"2026-07-18"},{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/12/01/hfpef-fenotypen-in-device-en-chirurgische-trials-karakterisatie/","published":"2025-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francisco-leyva","type":"person","url":"https://hartvaat.nl/mensen/francisco-leyva/","name":"Francisco Leyva","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/03/aanbesteding-van-cardiale-implanteerbare-devices-in-europa-waarde-of-kosten/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/08/03/dagontslag-versus-overnachting-na-af-ablatie-uitgebreide-meta-analyse/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2020/06/01/trends-in-plotse-hartdood-bij-hf-met-crt-systematische-review/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2017/07/01/crt-werkingsmechanismen-en-mogelijkheden-voor-verdere-verbetering/","published":"2017-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francois-philippon","type":"person","url":"https://hartvaat.nl/mensen/francois-philippon/","name":"François Philippon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/19/geleidingsstoornissen-na-transkatheter-aortaklepimplantatie/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2023/09/30/adaptresponse-adaptieve-versus-conventionele-crt-bij-hartfalen-lancet/","published":"2023-09-30"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2018/11/21/voortzetten-versus-onderbreken-doac-bij-device-chirurgie-bruise-control-2/","published":"2018-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frederic-kontny","type":"person","url":"https://hartvaat.nl/mensen/frederic-kontny/","name":"Frederic Kontny","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2016/10/15/vroeg-invasief-versus-conservatief-bij-nste-acs-15-jaarsfollow-up-frisc-ii/","published":"2016-10-15"},{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"frederik-h-verbrugge","type":"person","url":"https://hartvaat.nl/mensen/frederik-h-verbrugge/","name":"Frederik H Verbrugge","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/09/praise-mr-sacubitril-valsartan-verbetert-inspanningshemodynamiek-bij-hfpef-met-a/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","published":"2023-06-09"},{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","published":"2023-01-17"},{"url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","published":"2022-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"g-andre-ng","type":"person","url":"https://hartvaat.nl/mensen/g-andre-ng/","name":"G André Ng","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/07/01/geleidingssysteempacing-versus-biventriculaire-pacing-bij-av-blok-vergelijkende-/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2017/12/01/centrale-iliacale-av-anastomose-bij-ongecontroleerde-hypertensie-rox-control-htn/","published":"2017-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"george-ntaios","type":"person","url":"https://hartvaat.nl/mensen/george-ntaios/","name":"George Ntaios","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/03/15/doac-s-versus-geen-anticoagulatie-na-intracraniele-bloeding-bij-af-meta-analyse/","published":"2025-03-15"},{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","published":"2025-03-05"},{"url":"https://hartvaat.nl/2024/07/02/vroege-versus-late-doac-na-cva-met-hemorrhagische-transformatie-bij-af/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/06/29/elan-vroege-versus-late-anticoagulatie-na-cva-bij-af-nejm/","published":"2023-06-29"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"george-s-stergiou","type":"person","url":"https://hartvaat.nl/mensen/george-s-stergiou/","name":"George S Stergiou","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/10/01/esh-convenant-polshorloges-bloeddrukmeters-acceptabele-nauwkeurigheid-maar-klini/","published":"2026-09-02"},{"url":"https://hartvaat.nl/2024/07/01/af-screening-tijdens-bloeddrukmeting-diagnostische-nauwkeurigheid/","published":"2024-07-01"},{"url":"https://hartvaat.nl/2020/06/01/2020-ish-mondiale-hypertensie-praktijkrichtlijnen/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/01/01/centrale-versus-perifere-bloeddruk-en-doelorgaanschade-systematische-review-en-m/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gerald-chi","type":"person","url":"https://hartvaat.nl/mensen/gerald-chi/","name":"Gerald Chi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2017/01/24/heropnames-bij-af-patienten-na-stenting-twee-antitromboticastrategieen-vergeleke/","published":"2017-01-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gilles-chatellier","type":"person","url":"https://hartvaat.nl/mensen/gilles-chatellier/","name":"Gilles Chatellier","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/09/01/normalisatie-van-arteriele-stijfheid-en-cv-events-sparte-studie/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2017/09/14/pfo-sluiting-of-antistolling-versus-antiplaatjestherapie-na-cva-nejm-reduce/","published":"2017-09-14"},{"url":"https://hartvaat.nl/2017/03/01/24-uurs-bloeddrukmonitoring-bij-renale-denervatie-denerhtn-studie/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/09/20/medicatietrouw-en-bloeddrukeffecten-van-renale-denervatie-rsd-pathway-2-analyse/","published":"2016-09-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gilles-rioufol","type":"person","url":"https://hartvaat.nl/mensen/gilles-rioufol/","name":"Gilles Rioufol","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2021/11/09/ffr-voor-behandeling-van-multivatencoronairlijden-jacc/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2019/09/24/asymptomatische-patienten-met-abnormale-ffr-medicamenteus-versus-pci/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2016/11/29/natuurlijk-beloop-van-coronaire-atherosclerose-met-ffr-prospectieve-studie/","published":"2016-11-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gintaras-kalinauskas","type":"person","url":"https://hartvaat.nl/mensen/gintaras-kalinauskas/","name":"Gintaras Kalinauskas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","published":"2020-01-18"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giorgio-e-m-melloni","type":"person","url":"https://hartvaat.nl/mensen/giorgio-e-m-melloni/","name":"Giorgio E M Melloni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/24/systemische-embolieen-bij-af-ipd-mega-meta-analyse-van-71-683-patienten/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/04/01/lp-a-en-hscrp-als-cv-risicofactoren-primaire-en-secundaire-preventie/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","published":"2020-05-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giulia-masiero","type":"person","url":"https://hartvaat.nl/mensen/giulia-masiero/","name":"Giulia Masiero","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","published":"2025-07-21"},{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","published":"2020-11-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giulia-renda","type":"person","url":"https://hartvaat.nl/mensen/giulia-renda/","name":"Giulia Renda","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/10/01/sglt2-remmers-geassocieerd-met-lagere-sterfte-bij-attr-cardiomyopathie-meta-anal/","published":"2026-08-21"},{"url":"https://hartvaat.nl/2018/10/16/doac-s-halveren-trombo-embolische-events-na-af-cardioversie-versus-warfarine/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2017/03/28/edoxaban-bij-af-met-bioprothese-hartkleppen-trombo-emboliepreventie/","published":"2017-03-28"},{"url":"https://hartvaat.nl/2017/03/21/kleplijden-en-edoxaban-versus-warfarine-bij-af-engage-af-timi-48/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2017/03/21/doac-s-bij-af-met-kleplijden-jacc-review/","published":"2017-03-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gjin-ndrepepa","type":"person","url":"https://hartvaat.nl/mensen/gjin-ndrepepa/","name":"Gjin Ndrepepa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2016/02/06/bioresorbeerbare-versus-metallic-stents-meta-analyse-van-gerandomiseerde-trials/","published":"2016-02-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gladys-n-janssens","type":"person","url":"https://hartvaat.nl/mensen/gladys-n-janssens/","name":"Gladys N Janssens","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/12/01/coronairangiografie-na-hartstilstand-zonder-st-elevatie-coact-1-jaarsuitkomsten/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/08/01/temporele-veranderingen-in-coronaire-hemodynamiek-bij-niet-culprit-vaten-na-stem/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/04/11/coronairangiografie-na-hartstilstand-zonder-st-elevatie-nejm-coact/","published":"2019-04-11"},{"url":"https://hartvaat.nl/2019/01/29/microvasculaire-schade-bij-gerevasculariseerde-stemi-met-ticagrelor-versus-prasu/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/03/20/effecten-van-ticagrelor-prasugrel-of-clopidogrel-op-endotheelfunctie/","published":"2018-03-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"govinda-j-weerakkody","type":"person","url":"https://hartvaat.nl/mensen/govinda-j-weerakkody/","name":"Govinda J Weerakkody","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","published":"2025-12-18"},{"url":"https://hartvaat.nl/2025/03/11/summit-tirzepatide-en-klinisch-traject-bij-hfpef-met-obesitas-langetermijn/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/01/30/summit-tirzepatide-bij-hfpef-met-obesitas-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2021/11/13/tirzepatide-versus-insuline-glargine-bij-diabetes-type-2-met-hoog-cv-risico-lanc/","published":"2021-11-13"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gregory-w-evans","type":"person","url":"https://hartvaat.nl/mensen/gregory-w-evans/","name":"Gregory W Evans","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2020/03/01/orthostatische-hypotensie-cv-uitkomsten-en-adverse-events-sprint-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2016/10/01/orthostatische-hypotensie-in-de-accord-bloeddruk-trial-prevalentie-en-klinische-/","published":"2016-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gregoire-range","type":"person","url":"https://hartvaat.nl/mensen/gregoire-range/","name":"Grégoire Range","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","published":"2021-07-22"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gunnar-engstrom","type":"person","url":"https://hartvaat.nl/mensen/gunnar-engstrom/","name":"Gunnar Engström","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/20/darmmicrobiota-en-geschatte-glomerulaire-filtratiesnelheid-in-twee-zweedse-cohor/","published":"2026-02-20"},{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/10/01/bloeddruk-in-hogere-versus-lagere-arm-en-cv-uitkomsten-interpress-ipd-meta-analy/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/05/01/mcp-1-en-cardiovasculaire-mortaliteit-populatie-gebaseerde-meta-analyse/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"guosheng-fu","type":"person","url":"https://hartvaat.nl/mensen/guosheng-fu/","name":"Guosheng Fu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/01/sirolimus-eluerende-bioresorbeerbare-stents-versus-everolimus-eluerende-stents-i/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/12/gdmt-na-functioneel-complete-revascularisatie-prognostische-impact/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2020/04/01/intraprocedurele-eindpunten-voor-duurzame-pvi-gerandomiseerde-trial-van-vier-tec/","published":"2020-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"habib-samady","type":"person","url":"https://hartvaat.nl/mensen/habib-samady/","name":"Habib Samady","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/10/16/hoge-coronaire-shear-stress-voorspelt-myocardinfarct/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"},{"url":"https://hartvaat.nl/2016/11/26/oct-versus-ivus-versus-angiografie-bij-coronaire-stentimplantatie-lancet-ilumien/","published":"2016-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hadiza-saidu","type":"person","url":"https://hartvaat.nl/mensen/hadiza-saidu/","name":"Hadiza Saidu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hans-peter-stoll","type":"person","url":"https://hartvaat.nl/mensen/hans-peter-stoll/","name":"Hans-Peter Stoll","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/08/01/seksegerelateerde-uitkomsten-bij-hoog-bloedingsrisico-na-pci-leaders-free/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","published":"2019-11-26"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hany-eteiba","type":"person","url":"https://hartvaat.nl/mensen/hany-eteiba/","name":"Hany Eteiba","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/12/01/post-stenting-ffr-versus-angiografie-voor-pci-optimalisatie-target-ffr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/05/01/pci-versus-medicamenteus-bij-angina-met-ffr-in-de-grijze-zone/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/03/31/laaggedoseerde-alteplase-bij-primaire-pci-naar-ischemietijd/","published":"2020-03-31"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2016/12/15/infarctgrootte-en-linkerkamerremodellering-na-preventieve-pci/","published":"2016-12-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"harald-sourij","type":"person","url":"https://hartvaat.nl/mensen/harald-sourij/","name":"Harald Sourij","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/06/metabool-cardiovasculair-risico-nieuwe-mechanismen-en-therapiekansen/","published":"2026-03-26"},{"url":"https://hartvaat.nl/2026/03/05/semaglutide-bij-perifeer-arterieel-vaatlijden-en-diabetes-stride-trial/","published":"2026-03-20"},{"url":"https://hartvaat.nl/2025/11/18/sekseverschillen-in-semaglutide-effect-bij-pad-stride-subanalyse/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/05/03/semaglutide-en-loopafstand-bij-perifeer-vaatlijden-en-diabetes/","published":"2025-05-03"},{"url":"https://hartvaat.nl/2022/11/01/emmy-empagliflozine-na-acuut-myocardinfarct-verbetert-nt-probnp-en-remodelling/","published":"2022-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"heather-m-johnson","type":"person","url":"https://hartvaat.nl/mensen/heather-m-johnson/","name":"Heather M Johnson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"helen-routledge","type":"person","url":"https://hartvaat.nl/mensen/helen-routledge/","name":"Helen Routledge","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/01/01/verkorte-dapt-bij-hoog-bloedingsrisico-geen-sekseverschillen/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"helina-kassahun","type":"person","url":"https://hartvaat.nl/mensen/helina-kassahun/","name":"Helina Kassahun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/25/mendeliaanse-randomisatie-lp-a-verhoogt-coronarialijden-onafhankelijk-van-ldl-c-/","published":"2026-04-20"},{"url":"https://hartvaat.nl/2022/11/17/olpasiran-sirna-verlaagt-lipoproteine-a-spectaculair-in-fase-2-trial/","published":"2022-11-17"},{"url":"https://hartvaat.nl/2019/09/01/persisterende-arteriele-wandinflammatie-bij-verhoogd-lp-a-ondanks-lage-ldl/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/10/23/evolocumab-en-coronaire-plaquesamenstelling-glagov-beeldvorming/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","published":"2016-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"henrik-steen-hansen","type":"person","url":"https://hartvaat.nl/mensen/henrik-steen-hansen/","name":"Henrik Steen Hansen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2020/02/14/danami-2-16-jaarsfollow-up-primaire-pci-versus-fibrinolyse/","published":"2020-02-14"},{"url":"https://hartvaat.nl/2016/02/23/everolimus-versus-sirolimus-eluting-stents-5-jaarsresultaten-sort-out-iv/","published":"2016-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"henry-seligman","type":"person","url":"https://hartvaat.nl/mensen/henry-seligman/","name":"Henry Seligman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/06/11/remote-beoordeling-na-acs-gerandomiseerde-trial/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/04/19/coronaire-flowreserve-en-cardiovasculaire-uitkomsten-meta-analyse/","published":"2022-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hesong-zeng","type":"person","url":"https://hartvaat.nl/mensen/hesong-zeng/","name":"Hesong Zeng","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/06/01/opt-birisk-clopidogrel-monotherapie-bij-acs-met-hoog-ischemisch-en-bloedingsrisi/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/05/11/ticagrelor-monotherapie-versus-dapt-na-1-maand-bij-acs-lancet-rct/","published":"2024-05-11"},{"url":"https://hartvaat.nl/2022/05/25/hydratie-ter-preventie-van-nierschade-na-primaire-pci-gerandomiseerde-trial/","published":"2022-05-25"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hitoshi-matsuo","type":"person","url":"https://hartvaat.nl/mensen/hitoshi-matsuo/","name":"Hitoshi Matsuo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/13/risicofactoren-en-plaquevolume-op-coronaire-ct-angiografie-lessen-uit-het-advanc/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2025/12/29/functionele-en-morfologische-karakterisering-van-coronaire-atherosclerose/","published":"2025-12-29"},{"url":"https://hartvaat.nl/2022/02/01/ccta-afgeleide-ffr-prognostische-waarde-meta-analyse/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hong-zhang","type":"person","url":"https://hartvaat.nl/mensen/hong-zhang/","name":"Hong Zhang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/20/voorspelling-van-individuele-corticosteroidrespons-bij-iga-nefropathie-testing-t/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2026/01/20/multi-omics-onthult-pathogene-rol-van-iga-7-cellen-bij-iga-nefropathie/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"howard-c-herrmann","type":"person","url":"https://hartvaat.nl/mensen/howard-c-herrmann/","name":"Howard C Herrmann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2024/06/06/smart-zelf-expanderend-versus-ballonexpandeerbaar-tavr-bij-kleine-annulus-nejm/","published":"2024-06-06"},{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","published":"2023-11-23"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2018/10/01/transcatheter-interatriale-shunt-bij-hfpef-1-jaarsresultaten/","published":"2018-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hugo-a-katus","type":"person","url":"https://hartvaat.nl/mensen/hugo-a-katus/","name":"Hugo A Katus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2019/08/01/strain-encoded-mri-voor-beoordeling-van-myocardiale-deformatie/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2017/10/14/intracoronaire-beenmergceltransfer-na-mi-de-boost-2-gerandomiseerde-trial/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2016/04/21/gdf-15-voorspelt-bloedingen-en-cardiovasculaire-events-bij-acuut-coronair-syndro/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/04/01/veiligheid-en-werkzaamheid-van-ticagrelor-versus-clopidogrel-bij-primaire-pci-vo/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"i-min-lee","type":"person","url":"https://hartvaat.nl/mensen/i-min-lee/","name":"I-Min Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/12/05/inflammatie-cholesterol-lp-a-en-30-jaars-cv-uitkomsten-bij-vrouwen/","published":"2024-12-05"},{"url":"https://hartvaat.nl/2023/01/10/dagelijkse-stappen-en-cardiovasculaire-ziekte-geharmoniseerde-meta-analyse/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2023/01/01/vitamine-d-voorkomt-statine-gerelateerde-spierklachten-niet/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/10/01/sekseverschillen-in-af-risico-vital-rhythm-studie/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2020/03/03/vitamine-d-en-omega-3-en-hartfalen-hospitalisatie-vital-heart-failure/","published":"2020-03-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"iain-c-macdougall","type":"person","url":"https://hartvaat.nl/mensen/iain-c-macdougall/","name":"Iain C Macdougall","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-niet-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-dialysepatienten-nejm/","published":"2021-12-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ilan-goldenberg","type":"person","url":"https://hartvaat.nl/mensen/ilan-goldenberg/","name":"Ilan Goldenberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/10/21/upgrade-van-rv-pacing-naar-crt-bij-hartfalen-gerandomiseerde-trial/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2022/05/03/radiale-strain-geleide-leadplaatsing-voor-crt-bij-ischemisch-hf/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2017/09/01/budapest-crt-upgrade-study-studieontwerp-voor-crt-upgrade/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2016/09/20/volledig-linkszijdig-reverse-remodelling-bij-crt-madit-crt-substudie/","published":"2016-09-20"},{"url":"https://hartvaat.nl/2016/01/26/relatieve-wanddikte-en-risico-op-ventriculaire-tachyaritmieen-bij-linkerkamerdis/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ingebjrg-seljeflot","type":"person","url":"https://hartvaat.nl/mensen/ingebjrg-seljeflot/","name":"Ingebjørg Seljeflot","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2021/04/20/il-6-receptorremming-bij-acuut-stemi-gerandomiseerde-trial/","published":"2021-04-20"},{"url":"https://hartvaat.nl/2021/02/09/omega-3-vetzuren-bij-oudere-mi-patienten-omemi-gerandomiseerde-trial/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2018/07/10/il-8-en-infarctgrootte-en-klinische-uitkomsten-bij-stemi/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2018/06/01/complementactivatie-bij-acuut-hartfalen-na-mi-correlatie-met-ernst/","published":"2018-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"isabell-bernlochner","type":"person","url":"https://hartvaat.nl/mensen/isabell-bernlochner/","name":"Isabell Bernlochner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ivo-petrov","type":"person","url":"https://hartvaat.nl/mensen/ivo-petrov/","name":"Ivo Petrov","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"j-antonio-g-lopez","type":"person","url":"https://hartvaat.nl/mensen/j-antonio-g-lopez/","name":"J Antonio G López","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/25/mendeliaanse-randomisatie-lp-a-verhoogt-coronarialijden-onafhankelijk-van-ldl-c-/","published":"2026-04-20"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/11/17/olpasiran-sirna-verlaagt-lipoproteine-a-spectaculair-in-fase-2-trial/","published":"2022-11-17"},{"url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","published":"2022-10-11"},{"url":"https://hartvaat.nl/2020/05/26/evolocumab-bij-hiv-met-dyslipidemie-beijerinck-gerandomiseerde-studie/","published":"2020-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"j-jaime-miranda","type":"person","url":"https://hartvaat.nl/mensen/j-jaime-miranda/","name":"J Jaime Miranda","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/09/26/zoutvervangers-verminderen-cardiovasculaire-events-systematische-review/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2021/05/11/digitale-interventie-voor-depressie-bij-hypertensie-diabetes-in-brazilie-en-peru/","published":"2021-05-11"},{"url":"https://hartvaat.nl/2019/06/01/zoutsubstituten-met-laag-natrium-en-bloeddruk-cva-en-mortaliteit-meta-analyse/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2016/12/01/lacunes-in-hypertensierichtlijnen-in-lage-en-middeninkomenslanden-systematische-/","published":"2016-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jacob-joseph","type":"person","url":"https://hartvaat.nl/mensen/jacob-joseph/","name":"Jacob Joseph","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/06/01/invested-griepvaccin-immuunrespons-bij-hoog-risico-cv-patienten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2021/08/06/ventriculaire-aritmie-bij-crt-responders-en-super-responders-meta-analyse/","published":"2021-08-06"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/03/03/vitamine-d-en-omega-3-en-hartfalen-hospitalisatie-vital-heart-failure/","published":"2020-03-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jae-young-cho","type":"person","url":"https://hartvaat.nl/mensen/jae-young-cho/","name":"Jae Young Cho","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/01/intravasculaire-beeldvorming-superieur-aan-angiografie-bij-complexe-pci-5-jaarsr/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2020/06/16/ticagrelor-monotherapie-versus-dapt-op-bloedingen-en-cv-events-bij-acs-jama-tico/","published":"2020-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jaemin-shim","type":"person","url":"https://hartvaat.nl/mensen/jaemin-shim/","name":"Jaemin Shim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/10/14/alone-af-langetermijn-anticoagulatieonthouding-na-af-ablatie-rct/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2022/10/13/gecombineerde-epicardiale-en-endocardiale-redo-ablatie-bij-persisterend-af/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2019/05/14/wanneer-doac-stoppen-voor-af-ablatie-multicenter-analyse/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2019/04/01/lineaire-versus-focale-cfae-ablatie-bij-niet-paroxysmaal-af/","published":"2019-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"james-hodgkinson","type":"person","url":"https://hartvaat.nl/mensen/james-hodgkinson/","name":"James Hodgkinson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-bloeddrukcontrole-bij-risicozwangerschap-jama-bump-2/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2019/06/01/kosteneffectiviteit-van-telemonitoring-en-zelfmeting-van-bloeddruk-tasminh4/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/09/01/thuis-versus-praktijkbloeddrukmeting-in-de-zwangerschap/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/03/10/zelfgemeten-bloeddruk-met-of-zonder-telemonitoring-voor-medicatietitratie-lancet/","published":"2018-03-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jan-ravkilde","type":"person","url":"https://hartvaat.nl/mensen/jan-ravkilde/","name":"Jan Ravkilde","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","published":"2019-10-19"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"},{"url":"https://hartvaat.nl/2016/02/23/everolimus-versus-sirolimus-eluting-stents-5-jaarsresultaten-sort-out-iv/","published":"2016-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jan-henk-e-dambrink","type":"person","url":"https://hartvaat.nl/mensen/jan-henk-e-dambrink/","name":"Jan-Henk E Dambrink","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/21/tavi-plus-ffr-geleide-pci-gecombineerde-benadering-onderzocht/","published":"2025-12-21"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","published":"2016-06-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jana-buccola","type":"person","url":"https://hartvaat.nl/mensen/jana-buccola/","name":"Jana Buccola","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2025/07/15/oct-gebaseerde-post-pci-fysiologiebeoordeling-voorspelt-klinische-uitkomsten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"janet-wittes","type":"person","url":"https://hartvaat.nl/mensen/janet-wittes/","name":"Janet Wittes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/10/09/baxdrostat-bij-ongecontroleerde-en-resistente-hypertensie-effectiviteit-en-veili/","published":"2025-10-09"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"},{"url":"https://hartvaat.nl/2019/10/21/digoxine-en-mortaliteit-gerandomiseerd-versus-observationeel-in-de-dig-trial/","published":"2019-10-21"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jang-ho-bae","type":"person","url":"https://hartvaat.nl/mensen/jang-ho-bae/","name":"Jang-Ho Bae","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/01/lage-dosis-tel-aml-chtd-combinatietablet-versus-standaard-tel-fase-iii/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2020/08/25/genotype-geleide-p2y12-selectie-versus-clopidogrel-na-pci-jama-tailor-pci/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jaydeep-sarma","type":"person","url":"https://hartvaat.nl/mensen/jaydeep-sarma/","name":"Jaydeep Sarma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/25/jbs-richtlijn-management-van-hartstilstand-in-het-cathlab/","published":"2022-05-25"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jean-noel-trochu","type":"person","url":"https://hartvaat.nl/mensen/jean-noel-trochu/","name":"Jean-Noël Trochu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/06/laminopathieen-natuurlijk-beloop-en-voorspelmodel-voor-hartfalen/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/01/14/tri-fr-transcatheter-edge-to-edge-repair-bij-geisoleerde-ernstige-tr-rct/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2023/11/01/beta3-lvh-mirabegron-bij-linkerventrikel-hypertrofie-fase-2b-rct/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2018/12/13/percutaan-herstel-of-medicamenteuze-therapie-bij-secundaire-mr-nejm-mitra-fr/","published":"2018-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeff-whittle","type":"person","url":"https://hartvaat.nl/mensen/jeff-whittle/","name":"Jeff Whittle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2020/03/01/orthostatische-hypotensie-cv-uitkomsten-en-adverse-events-sprint-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2017/08/24/intensieve-bloeddrukbehandeling-en-patientgerapporteerde-uitkomsten-nejm-sprint-/","published":"2017-08-24"},{"url":"https://hartvaat.nl/2016/07/01/medicatie-non-adherentie-en-visit-to-visit-bloeddrukvariabiliteit-target-bp-stud/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jennifer-a-rymer","type":"person","url":"https://hartvaat.nl/mensen/jennifer-a-rymer/","name":"Jennifer A Rymer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/12/12/voyager-pad-rivaroxaban-plus-aspirine-na-endovasculaire-revascularisatie-voor-pa/","published":"2023-12-12"},{"url":"https://hartvaat.nl/2022/12/06/apixaban-bij-af-op-hemodialyse-eerste-gerandomiseerde-trial/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2021/10/12/overbrugging-van-antiplaatjestherapie-na-pci-jacc-review/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/02/16/2021-acc-consensus-same-day-ontslag-na-pci/","published":"2021-02-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jennifer-hellawell","type":"person","url":"https://hartvaat.nl/mensen/jennifer-hellawell/","name":"Jennifer Hellawell","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/05/20/plozasiran-en-lipoproteine-deeltjesgrootte-bij-hypertriglyceridemie/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/01/09/plozasiran-bij-persisterende-chylomicronemie-en-pancreatitisrisico-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2024/09/12/zodasiran-sirna-tegen-angptl3-bij-gemengde-hyperlipidemie-nejm/","published":"2024-09-12"},{"url":"https://hartvaat.nl/2024/09/12/plozasiran-sirna-tegen-apoc3-bij-gemengde-hyperlipidemie-nejm/","published":"2024-09-12"},{"url":"https://hartvaat.nl/2024/07/01/plozasiran-sirna-tegen-apoc3-bij-ernstige-hypertriglyceridemie-shasta-2/","published":"2024-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jerzy-k-wranicz","type":"person","url":"https://hartvaat.nl/mensen/jerzy-k-wranicz/","name":"Jerzy K Wranicz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2024/07/02/upgrade-rv-naar-crt-pacing-bij-hartfalen-met-af-voordelen-bevestigd/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/10/21/upgrade-van-rv-pacing-naar-crt-bij-hartfalen-gerandomiseerde-trial/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2018/09/27/draagbare-cardioverter-defibrillator-na-myocardinfarct-nejm-vest/","published":"2018-09-27"},{"url":"https://hartvaat.nl/2017/09/01/budapest-crt-upgrade-study-studieontwerp-voor-crt-upgrade/","published":"2017-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jesper-moller-jensen","type":"person","url":"https://hartvaat.nl/mensen/jesper-moller-jensen/","name":"Jesper Møller Jensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/05/03/multimodaliteitsbeeldvorming-geleide-lv-leadplaatsing-bij-crt-langetermijn/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/07/01/empagliflozine-en-lv-volumes-en-functie-bij-hfref-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/06/01/metabole-effecten-van-empagliflozine-bij-hf-empire-hf-metabolic-gerandomiseerde-/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/12/08/empagliflozine-en-hemodynamiek-bij-hfref/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2019/09/01/elektrisch-versus-beeldvorming-geleide-lv-leadplaatsing-bij-crt-gerandomiseerde-/","published":"2019-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jesse-dawson","type":"person","url":"https://hartvaat.nl/mensen/jesse-dawson/","name":"Jesse Dawson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/07/05/optimale-timing-van-anticoagulatie-na-ischemisch-cva-en-af-collaboratief-project/","published":"2025-07-05"},{"url":"https://hartvaat.nl/2024/07/02/vroege-versus-late-doac-na-cva-met-hemorrhagische-transformatie-bij-af/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/06/29/elan-vroege-versus-late-anticoagulatie-na-cva-bij-af-nejm/","published":"2023-06-29"},{"url":"https://hartvaat.nl/2021/02/01/urinezuur-bloeddruk-en-cv-ziekte-mendeliaanse-randomisatie-en-meta-analyse/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jian-zhang","type":"person","url":"https://hartvaat.nl/mensen/jian-zhang/","name":"Jian Zhang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","published":"2020-06-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jianping-guo","type":"person","url":"https://hartvaat.nl/mensen/jianping-guo/","name":"Jianping Guo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2020/05/12/cognitie-na-ldl-verlaging-met-evolocumab-fourier-follow-up/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2020/01/28/morfine-en-cv-uitkomsten-bij-nste-acs-jacc-analyse/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2019/12/17/uitkomsten-van-vrouwen-versus-mannen-na-nste-acs/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2018/06/01/fgf-23-en-recidiverende-cv-events-na-acs/","published":"2018-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jianping-li","type":"person","url":"https://hartvaat.nl/mensen/jianping-li/","name":"Jianping Li","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/01/luchtvervuiling-verhoogt-sterfte-door-hypertensie-case-crossover-studie-bij-2-1-/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/11/ffr-geleide-nierslagaderstenting-bij-atherosclerotische-renovasculaire-hypertens/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2018/05/15/trombocytenaantal-beinvloedt-werkzaamheid-van-foliumzuur-bij-cva-preventie/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2017/04/01/optimale-systolische-bloeddruk-voor-primaire-cva-preventie-bij-hypertensie-csppt/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/07/01/polsgolfsnelheid-en-bloeddrukcontrole-als-onafhankelijke-voorspellers-van-cva-bi/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jing-yu","type":"person","url":"https://hartvaat.nl/mensen/jing-yu/","name":"Jing Yu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/01/non-hdl-hdl-ratio-als-voorspeller-van-cardiovasculaire-ziekte-bij-ckm-syndroom/","published":"2026-04-07"},{"url":"https://hartvaat.nl/2025/10/28/step-6-jaarsresultaten-intensieve-bloeddrukcontrole-bij-ouderen-langetermijn/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2024/11/12/rf-renale-denervatie-bij-ongecontroleerde-hypertensie-in-china-gerandomiseerde-t/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2023/09/01/step-substudie-intensieve-bloeddrukverlaging-verbetert-lvh-bij-ouderen/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/01/01/farmacologische-hypertensiebehandeling-bij-volwassenen-who-richtlijn-samenvattin/","published":"2022-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jocelyn-carter","type":"person","url":"https://hartvaat.nl/mensen/jocelyn-carter/","name":"Jocelyn Carter","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johan-bennett","type":"person","url":"https://hartvaat.nl/mensen/johan-bennett/","name":"Johan Bennett","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/27/pci-van-natief-coronairvat-versus-veneuze-graft-na-eerdere-cabg-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2023/04/08/biovasc-directe-versus-gestageerde-complete-revascularisatie-bij-acs-met-meervat/","published":"2023-04-08"},{"url":"https://hartvaat.nl/2018/08/01/inhalatie-stikstofoxide-bij-stemi-nomi-gerandomiseerde-trial/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/10/21/ultradunne-bioresorbeerbare-versus-dunne-duurzame-polymer-stents-lancet-bioscien/","published":"2017-10-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johan-lindback","type":"person","url":"https://hartvaat.nl/mensen/johan-lindback/","name":"Johan Lindbäck","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/10/01/neurofilament-light-chain-en-cva-risico-bij-af/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2020/11/01/ace2-niveaus-en-covid-19-risicofactoren-bij-af-patienten/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","published":"2018-02-07"},{"url":"https://hartvaat.nl/2016/11/29/biomarkergebaseerde-cva-risicoscore-bij-atriumfibrilleren-validatie/","published":"2016-11-29"},{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","published":"2016-06-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johan-vijgen","type":"person","url":"https://hartvaat.nl/mensen/johan-vijgen/","name":"Johan Vijgen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/12/26/gerichte-patienteneducatie-vermindert-ongeplande-cv-events-bij-af/","published":"2024-12-26"},{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2018/04/21/telemonitoring-verbetert-doac-therapietrouw-bij-af/","published":"2018-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johan-arnlov","type":"person","url":"https://hartvaat.nl/mensen/johan-arnlov/","name":"Johan Ärnlöv","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/20/darmmicrobiota-en-geschatte-glomerulaire-filtratiesnelheid-in-twee-zweedse-cohor/","published":"2026-02-20"},{"url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2023/07/25/omega-3-biomarkers-en-incident-af-ipd-analyse/","published":"2023-07-25"},{"url":"https://hartvaat.nl/2022/04/19/therapeutische-doelen-voor-hf-via-proteomics-en-mendeliaanse-randomisatie/","published":"2022-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johannes-c-kelder","type":"person","url":"https://hartvaat.nl/mensen/johannes-c-kelder/","name":"Johannes C Kelder","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/06/01/diagnostiek-van-hartfalen-in-de-huisartsenpraktijk-ipd-meta-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/11/10/ticagrelor-plus-aspirine-en-safeneuze-graft-patency-na-cabg/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2020/04/25/clopidogrel-versus-ticagrelor-of-prasugrel-bij-70-plussers-met-nste-acs-lancet-p/","published":"2020-04-25"},{"url":"https://hartvaat.nl/2019/10/24/genotype-geleide-p2y12-remmerkeuze-bij-primaire-pci-nejm-popular-genetics/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2019/05/01/thoracoscopische-versus-katheterablatie-bij-af-langetermijn-fast-trial/","published":"2019-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-amerena","type":"person","url":"https://hartvaat.nl/mensen/john-amerena/","name":"John Amerena","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2021/11/09/colchicine-na-acs-2-jaars-cops-follow-up/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2020/11/17/colchicine-bij-acs-australische-cops-gerandomiseerde-trial/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-camm","type":"person","url":"https://hartvaat.nl/mensen/john-camm/","name":"John Camm","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/03/26/rate-af-kosteneffectiviteit-van-digoxine-versus-betablokkers-bij-permanent-af/","published":"2025-03-26"},{"url":"https://hartvaat.nl/2019/09/21/ononderbroken-edoxaban-versus-vka-bij-af-ablatie-eliminate-af/","published":"2019-09-21"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-forbes","type":"person","url":"https://hartvaat.nl/mensen/john-forbes/","name":"John Forbes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/07/13/convince-langetermijn-colchicine-voor-preventie-van-recidief-niet-cardioembolisc/","published":"2024-07-13"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","published":"2018-09-06"},{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/04/19/ct-coronairangiografie-voor-het-sturen-van-beleid-bij-coronairlijden/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-m-ruiz","type":"person","url":"https://hartvaat.nl/mensen/john-m-ruiz/","name":"John M Ruiz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jonas-dominik-haner","type":"person","url":"https://hartvaat.nl/mensen/jonas-dominik-haner/","name":"Jonas Dominik Häner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","published":"2026-04-09"},{"url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neoatherosclerose-na-stemi-secundaire-analyse/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/08/01/biodegradeerbare-versus-duurzame-polymeer-ees-langetermijn-neoatherosclerose/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2019/11/19/evolocumab-voor-vroege-ldl-verlaging-bij-acs-evopacs/","published":"2019-11-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jonathan-w-cunningham","type":"person","url":"https://hartvaat.nl/mensen/jonathan-w-cunningham/","name":"Jonathan W Cunningham","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2020/07/11/levenslang-voordeel-van-uitgebreide-hfref-farmacotherapie-lancet-schatting/","published":"2020-07-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jonathon-leipsic","type":"person","url":"https://hartvaat.nl/mensen/jonathon-leipsic/","name":"Jonathon Leipsic","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2022/02/01/ccta-afgeleide-ffr-prognostische-waarde-meta-analyse/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-ballonexpandeerbare-klep-bij-laagrisicopatienten-nejm-partner-3/","published":"2019-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jorge-a-wong","type":"person","url":"https://hartvaat.nl/mensen/jorge-a-wong/","name":"Jorge A Wong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/06/01/af-ablatie-bij-hfref-versus-hfpef-meta-analyse/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/03/07/mra-s-verminderen-af-risico-meta-analyse-van-klinische-trials/","published":"2024-03-07"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2021/06/15/prevalentie-van-linkeratriumtrombus-bij-geanticoaguleerde-af-patienten/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2021/05/01/screening-op-af-bij-ouderen-jama-cardiology-gerandomiseerde-trial/","published":"2021-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joseph-b-selvanayagam","type":"person","url":"https://hartvaat.nl/mensen/joseph-b-selvanayagam/","name":"Joseph B Selvanayagam","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/10/01/acute-pleiotrope-effecten-van-dapagliflozine-bij-diabetes-type-2-met-hfref-cross/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/07/01/camkii-delta-remming-en-ventriculaire-remodellering-na-mi-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2016/05/21/af-type-en-risico-op-trombo-embolie-mortaliteit-en-bloedingen-systematische-revi/","published":"2016-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joseph-yeboah","type":"person","url":"https://hartvaat.nl/mensen/joseph-yeboah/","name":"Joseph Yeboah","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/08/01/sarcopenie-en-intensieve-bloeddrukbehandeling-sprint-subanalyse/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joshua-hawson","type":"person","url":"https://hartvaat.nl/mensen/joshua-hawson/","name":"Joshua Hawson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/07/14/vroege-versus-late-af-ablatie-impact-op-aritmierecidief/","published":"2023-07-14"},{"url":"https://hartvaat.nl/2023/02/16/hoog-vermogen-korte-duur-versus-laag-vermogen-langere-duur-posteriore-ablatie-bi/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ju-han-kim","type":"person","url":"https://hartvaat.nl/mensen/ju-han-kim/","name":"Ju Han Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/09/06/directe-versus-gestageerde-complete-revascularisatie-tijdens-index-opname-bij-st/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/06/17/spironolacton-versus-amiloride-bij-resistente-hypertensie-gerandomiseerde-trial/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2023/11/14/early-unload-vroege-lv-ontlading-bij-va-ecmo-gerandomiseerde-trial/","published":"2023-11-14"},{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2018/07/24/escitalopram-versus-placebo-bij-depressie-na-acs-en-langetermijn-cardiale-uitkom/","published":"2018-07-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"juan-j-carrero","type":"person","url":"https://hartvaat.nl/mensen/juan-j-carrero/","name":"Juan J Carrero","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/27/albuminurie-geassocieerd-met-verhoogd-risico-op-abdominaal-aorta-aneurysma/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/01/15/populatiegebaseerde-egfr-verdelingen-voor-vroege-identificatie-van-chronische-ni/","published":"2026-01-15"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2022/11/22/cva-risicoscores-bij-af-vergeleken-cha2ds2-vasc-blijft-de-beste/","published":"2022-11-22"},{"url":"https://hartvaat.nl/2021/09/01/albuminurietesting-bij-hypertensie-en-diabetes-ipd-meta-analyse/","published":"2021-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"judy-w-hung","type":"person","url":"https://hartvaat.nl/mensen/judy-w-hung/","name":"Judy W Hung","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/01/mitralisklepherstel-bij-degeneratief-mr-met-matige-tricuspidalisinsufficientie-2/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"julia-grapsa","type":"person","url":"https://hartvaat.nl/mensen/julia-grapsa/","name":"Julia Grapsa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/05/26/esc-consensus-vrouwenhartcentra-whc-als-nieuw-zorgmodel-in-europa/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/28/gestandaardiseerd-stappenplan-voor-tricuspidalisinsufficientie-van-verwijzing-to/","published":"2026-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"julia-w-erath","type":"person","url":"https://hartvaat.nl/mensen/julia-w-erath/","name":"Julia W Erath","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2019/10/01/quadripolaire-versus-bipolaire-lv-leads-bij-crt-klinische-uitkomsten/","published":"2019-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jung-ho-heo","type":"person","url":"https://hartvaat.nl/mensen/jung-ho-heo/","name":"Jung Ho Heo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jorg-lauermann","type":"person","url":"https://hartvaat.nl/mensen/jorg-lauermann/","name":"Jörg Lauermann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/10/07/help-mi-helicobacter-pylori-screening-na-acuut-mi-cluster-rct/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2018/08/01/zuurstoftherapie-bij-stemi-overzichtsartikel/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/09/28/zuurstoftherapie-bij-vermoedelijk-acuut-myocardinfarct-nejm-deto2x-ami/","published":"2017-09-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kai-xu","type":"person","url":"https://hartvaat.nl/mensen/kai-xu/","name":"Kai Xu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/08/12/catheterablatie-versus-rate-control-bij-persisterend-af-en-ouder-hartfalen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2024/04/01/halp-score-hemoglobine-albumine-lymfocyten-trombocyten-en-mortaliteit-bij-hartfa/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/05/19/drie-substraatstrategieen-voor-persisterend-af-vergeleken-multicenter-rct/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2021/05/21/extrapulmonale-vein-driver-mapping-bij-persisterend-af-bij-obese-patienten/","published":"2021-05-21"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kamlesh-khunti","type":"person","url":"https://hartvaat.nl/mensen/kamlesh-khunti/","name":"Kamlesh Khunti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2017/07/18/sglt2-remmers-en-lager-risico-op-hartfalen-en-sterfte-versus-andere-glucoseverla/","published":"2017-07-18"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kare-tang","type":"person","url":"https://hartvaat.nl/mensen/kare-tang/","name":"Kare Tang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karen-c-johnson","type":"person","url":"https://hartvaat.nl/mensen/karen-c-johnson/","name":"Karen C Johnson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2020/12/22/lichaamssamenstelling-en-risico-op-hartfalen-en-mi-prospectieve-analyse/","published":"2020-12-22"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karen-j-collins","type":"person","url":"https://hartvaat.nl/mensen/karen-j-collins/","name":"Karen J Collins","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","published":"2018-10-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"katalin-keltai","type":"person","url":"https://hartvaat.nl/mensen/katalin-keltai/","name":"Katalin Keltai","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"katharina-mueller","type":"person","url":"https://hartvaat.nl/mensen/katharina-mueller/","name":"Katharina Mueller","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2017/04/14/vericiguat-bij-verslechterend-chronisch-hfpef-socrates-preserved-resultaten/","published":"2017-04-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kaycee-m-sink","type":"person","url":"https://hartvaat.nl/mensen/kaycee-m-sink/","name":"Kaycee M Sink","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2016/08/01/apol1-nierrisicovarianten-en-cerebrale-wittestoflaesies/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kazuya-kawai","type":"person","url":"https://hartvaat.nl/mensen/kazuya-kawai/","name":"Kazuya Kawai","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kenneth-egstrup","type":"person","url":"https://hartvaat.nl/mensen/kenneth-egstrup/","name":"Kenneth Egstrup","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2021/10/01/aortaklepcalcificatie-en-cv-risicofactoren-bij-oudere-deense-mannen/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","published":"2016-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kenneth-j-winters","type":"person","url":"https://hartvaat.nl/mensen/kenneth-j-winters/","name":"Kenneth J Winters","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2017/08/01/voorspelling-van-bloedingsrisico-tijdens-dapt-na-acs/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/08/01/eerder-clopidogrelgebruik-en-uitkomsten-bij-conservatief-behandeld-acs/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"},{"url":"https://hartvaat.nl/2016/03/01/cyp2c19-metaboliseerdersstatus-en-uitkomsten-bij-acs-prasugrel-versus-clopidogre/","published":"2016-03-01"},{"url":"https://hartvaat.nl/2016/01/21/neoplasiedetectie-bij-langdurige-dapt-met-prasugrel-versus-clopidogrel-triton-ti/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kenneth-mangion","type":"person","url":"https://hartvaat.nl/mensen/kenneth-mangion/","name":"Kenneth Mangion","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/25/klassieke-lv-gls-overtreft-nieuwe-atriale-cmr-parameters-bij-voorspelling-van-lv/","published":"2026-05-31"},{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2020/05/01/pci-versus-medicamenteus-bij-angina-met-ffr-in-de-grijze-zone/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2016/12/15/infarctgrootte-en-linkerkamerremodellering-na-preventieve-pci/","published":"2016-12-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kevin-duarte","type":"person","url":"https://hartvaat.nl/mensen/kevin-duarte/","name":"Kevin Duarte","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/23/paradise-cohort-hartfalen-en-copd-samen-verhogen-de-langetermijnmortaliteit-met-/","published":"2026-06-05"},{"url":"https://hartvaat.nl/2026/02/03/semaglutide-versus-tirzepatide-bij-patienten-met-obesitas-en-hfpef/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/11/14/nierfunctietrajecten-voor-en-na-hospitalisatie-voor-hfref/","published":"2025-11-14"},{"url":"https://hartvaat.nl/2022/02/01/matige-hypothermie-versus-normothermie-bij-cardiogene-shock-met-va-ecmo-jama-hyp/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2018/07/10/epinefrine-versus-norepinefrine-bij-cardiogene-shock-na-acuut-mi/","published":"2018-07-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kevin-e-thorpe","type":"person","url":"https://hartvaat.nl/mensen/kevin-e-thorpe/","name":"Kevin E Thorpe","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","published":"2025-09-20"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2017/11/30/restrictieve-versus-liberale-bloedtransfusie-bij-hartchirurgie-nejm-trics-iii/","published":"2017-11-30"},{"url":"https://hartvaat.nl/2017/10/01/terminatie-van-persisterend-af-tijdens-pvi-inzichten-uit-magic-af/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/05/21/stapsgewijze-ablatie-gestuurd-door-laaggedoseerd-ibutilide-bij-chronisch-af-magi/","published":"2016-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kevin-j-um","type":"person","url":"https://hartvaat.nl/mensen/kevin-j-um/","name":"Kevin J Um","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/02/16/technieken-om-cardioversiesucces-bij-af-te-verbeteren-meta-analyse/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2022/10/13/voorbehandeling-met-antiaritmica-voor-cardioversie-bij-af-netwerk-meta-analyse/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2021/08/06/orale-antiaritmica-voor-cardioversie-van-recent-onset-af-netwerkmeta-analyse/","published":"2021-08-06"},{"url":"https://hartvaat.nl/2019/06/01/amiodaron-voor-en-na-electrische-cardioversie-van-af-meta-analyse/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/05/08/vasopressine-plus-catecholamines-en-af-bij-distributieve-shock-jama-meta-analyse/","published":"2018-05-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kevin-mccague","type":"person","url":"https://hartvaat.nl/mensen/kevin-mccague/","name":"Kevin McCague","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/09/01/arni-naar-hf-voorgeschiedenis-en-raas-antagonistgebruik/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/02/01/arni-initiatie-na-acuut-gedecompenseerd-hf-pioneer-hf-open-label-extensie/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/10/21/cv-biomarkers-bij-acuut-gedecompenseerd-hf-met-sacubitril-valsartan-pioneer-hf/","published":"2019-10-21"},{"url":"https://hartvaat.nl/2019/05/07/sacubitril-valsartan-of-enalapril-bij-acuut-gedecompenseerd-hf-pioneer-hf-klinis/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/02/07/angiotensine-neprilysineremming-bij-acuut-gedecompenseerd-hf-nejm-pioneer-hf/","published":"2019-02-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"khadijah-breathett","type":"person","url":"https://hartvaat.nl/mensen/khadijah-breathett/","name":"Khadijah Breathett","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/23/nierbescherming-na-harttransplantatie-risicoreductie-en-therapeutische-mogelijkh/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2024/09/17/2024-acc-aha-kwaliteitsmaatstaven-voor-hartfalen-geactualiseerd/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2024/04/16/2024-acc-expert-consensus-behandeling-van-hfref-beslispad-geactualiseerd/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2021/02/16/2021-acc-hf-behandeloptimalisatie-update-antwoorden-op-10-cruciale-vragen/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2020/11/24/2020-acc-aha-prestatie-en-kwaliteitsmaten-voor-hartfalen/","published":"2020-11-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kintur-sanghvi","type":"person","url":"https://hartvaat.nl/mensen/kintur-sanghvi/","name":"Kintur Sanghvi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kirk-u-knowlton","type":"person","url":"https://hartvaat.nl/mensen/kirk-u-knowlton/","name":"Kirk U Knowlton","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/19/victorion-inception-vroege-inclisiran-na-acuut-coronair-syndroom-verviervoudigt-/","published":"2026-06-12"},{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/21/genetische-varianten-geassocieerd-met-syncope-neurale-en-autonome-processen/","published":"2023-03-21"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kiyuk-chang","type":"person","url":"https://hartvaat.nl/mensen/kiyuk-chang/","name":"Kiyuk Chang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/02/01/talos-ami-dapt-de-escalatie-veilig-bij-mi-met-hoog-ischemisch-risico/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2021/10/09/ongeleide-de-escalatie-van-ticagrelor-naar-clopidogrel-na-mi-met-pci-lancet-talo/","published":"2021-10-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"klaus-f-kofoed","type":"person","url":"https://hartvaat.nl/mensen/klaus-f-kofoed/","name":"Klaus F Kofoed","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/02/23/ct-coronairangiografie-bij-75-jarigen-met-nste-acs/","published":"2023-02-23"},{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kris-bogaerts","type":"person","url":"https://hartvaat.nl/mensen/kris-bogaerts/","name":"Kris Bogaerts","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2023/08/29/stream-2-halve-dosis-tenecteplase-bij-ouderen-met-stemi/","published":"2023-08-29"},{"url":"https://hartvaat.nl/2019/01/02/preventie-van-cardiogene-shock-na-acuut-mi/","published":"2019-01-02"},{"url":"https://hartvaat.nl/2018/07/07/revascularisatie-versus-optimale-medicamenteuze-therapie-bij-cto-gerandomiseerde/","published":"2018-07-07"},{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","published":"2018-01-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kunihiko-matsui","type":"person","url":"https://hartvaat.nl/mensen/kunihiko-matsui/","name":"Kunihiko Matsui","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/08/01/rivaroxaban-monotherapie-versus-combinatie-met-plaatjesremmers-bij-af-en-coronai/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/11/01/aspirine-versus-p2y12-remmer-met-antistolling-bij-af/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2019/09/19/antitrombotische-therapie-bij-af-met-stabiel-coronairlijden-nejm-afire/","published":"2019-09-19"},{"url":"https://hartvaat.nl/2019/06/07/febuxostat-voor-cerebraal-en-cardiorenovasculaire-eventpreventie-freed/","published":"2019-06-07"},{"url":"https://hartvaat.nl/2017/08/01/ldl-cholesterol-streefwaarden-met-pitavastatine-ezetimibe-bij-acs-met-dyslipidem/","published":"2017-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"l-kristin-newby","type":"person","url":"https://hartvaat.nl/mensen/l-kristin-newby/","name":"L Kristin Newby","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2020/01/28/morfine-en-cv-uitkomsten-bij-nste-acs-jacc-analyse/","published":"2020-01-28"},{"url":"https://hartvaat.nl/2019/12/17/uitkomsten-van-vrouwen-versus-mannen-na-nste-acs/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2016/04/19/trends-in-behandeling-en-uitkomsten-bij-nste-acs-naar-leeftijd/","published":"2016-04-19"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lars-nepper-christensen","type":"person","url":"https://hartvaat.nl/mensen/lars-nepper-christensen/","name":"Lars Nepper-Christensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lars-ryden","type":"person","url":"https://hartvaat.nl/mensen/lars-ryden/","name":"Lars Rydén","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/23/van-internationale-richtlijnen-naar-nationale-implementatie-bij-cardio-renaal-me/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2021/07/08/cv-uitkomsten-bij-diabetes-met-vastgesteld-of-hoog-risico-coronairlijden-dulaglu/","published":"2021-07-08"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lars-sndergaard","type":"person","url":"https://hartvaat.nl/mensen/lars-sndergaard/","name":"Lars Søndergaard","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2024/04/01/notion-10-jaar-tavr-versus-chirurgie-bij-laagrisico-aortastenose/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2017/09/14/pfo-sluiting-of-antiplaatjestherapie-bij-cryptogeen-cva-nejm-close/","published":"2017-09-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lawrence-j-fine","type":"person","url":"https://hartvaat.nl/mensen/lawrence-j-fine/","name":"Lawrence J Fine","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2020/06/01/intensieve-bloeddrukverlaging-en-risico-op-af-sprint-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/08/01/intensieve-bloeddrukverlaging-en-linkerventrikelhypertrofie-sprint-echocardiogra/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/01/01/intensieve-versus-standaard-bloeddrukcontrole-op-ambulante-bloeddruk-sprint-resu/","published":"2017-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lehana-thabane","type":"person","url":"https://hartvaat.nl/mensen/lehana-thabane/","name":"Lehana Thabane","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/11/01/gemaskeerde-hypertensie-bij-kinderen-prevalentie-en-cv-risico-meta-analyse/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/06/01/eindorgaanschade-bij-kinderen-met-primaire-hypertensie-meta-analyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2019/10/05/uitgebreide-community-interventie-bij-hypertensie-lancet-hope-4/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2019/02/26/patientgerichte-transitional-care-bij-hf-hospitalisatie-jama-pact-hf/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2016/12/01/lacunes-in-hypertensierichtlijnen-in-lage-en-middeninkomenslanden-systematische-/","published":"2016-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lei-song","type":"person","url":"https://hartvaat.nl/mensen/lei-song/","name":"Lei Song","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/01/eheart-trial-real-time-hartteam-verbetert-besluitvorming-bij-complexe-coronaire-/","published":"2026-03-17"},{"url":"https://hartvaat.nl/2025/01/01/sirolimus-eluerende-bioresorbeerbare-stents-versus-everolimus-eluerende-stents-i/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/12/gdmt-na-functioneel-complete-revascularisatie-prognostische-impact/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"leif-thuesen","type":"person","url":"https://hartvaat.nl/mensen/leif-thuesen/","name":"Leif Thuesen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2020/02/14/danami-2-16-jaarsfollow-up-primaire-pci-versus-fibrinolyse/","published":"2020-02-14"},{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","published":"2020-01-18"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lien-desteghe","type":"person","url":"https://hartvaat.nl/mensen/lien-desteghe/","name":"Lien Desteghe","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/02/05/smartphone-ppg-voor-af-detectie-en-management-verbeterde-screening/","published":"2025-02-05"},{"url":"https://hartvaat.nl/2024/12/26/gerichte-patienteneducatie-vermindert-ongeplande-cv-events-bij-af/","published":"2024-12-26"},{"url":"https://hartvaat.nl/2018/08/01/2018-ehra-praktische-gids-doac-s-bij-af-europace-editie/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/04/21/2018-ehra-praktische-gids-voor-doac-gebruik-bij-af/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2018/04/21/telemonitoring-verbetert-doac-therapietrouw-bij-af/","published":"2018-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"liffert-vogt","type":"person","url":"https://hartvaat.nl/mensen/liffert-vogt/","name":"Liffert Vogt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/29/cardiovasculaire-ziekte-blijft-leidend-na-niertransplantatie-overzicht-van-uitda/","published":"2026-07-28"},{"url":"https://hartvaat.nl/2026/02/09/communicatie-tussen-nier-en-hart-via-extracellulaire-vesikels/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2026/01/01/renale-histologie-bij-maligne-hypertensie-systematische-review/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2025/08/05/lorundrostat-bij-ongecontroleerde-en-therapieresistente-hypertensie-fase-3-resul/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2018/12/01/creatininestijging-tijdens-bloeddrukbehandeling-en-uitkomsten-bij-diabetes-type-/","published":"2018-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lili-song","type":"person","url":"https://hartvaat.nl/mensen/lili-song/","name":"Lili Song","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2024/05/30/right-2-ambulancebloeddrukverlaging-bij-hyperacuut-cva-nejm-vervolgresultaten/","published":"2024-05-30"},{"url":"https://hartvaat.nl/2023/07/01/interact3-bundeled-care-bij-acute-intracerebrale-bloeding-lancet/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2022/11/05/enchanted2-mt-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-is-schadelij/","published":"2022-11-05"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"linda-davidson-ray","type":"person","url":"https://hartvaat.nl/mensen/linda-davidson-ray/","name":"Linda Davidson-Ray","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/10/03/vericiguat-bij-hfref-is-kosteneffectief-victoria-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","published":"2022-08-16"},{"url":"https://hartvaat.nl/2020/07/28/langetermijn-icd-uitkomsten-scd-heft/","published":"2020-07-28"},{"url":"https://hartvaat.nl/2018/11/27/economische-en-qol-uitkomsten-van-nt-probnp-geleide-hf-therapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2016/01/05/ranolazine-bij-angina-en-kwaliteit-van-leven-na-pci-met-incomplete-revascularisa/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"liping-huang","type":"person","url":"https://hartvaat.nl/mensen/liping-huang/","name":"Liping Huang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/01/consistentie-van-bloeddrukrespons-op-kaliumverrijkt-zout-ssass-subanalyse/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2022/09/26/zoutvervangers-verminderen-cardiovasculaire-events-systematische-review/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2022/05/17/kosteneffectiviteit-van-zoutsubstitutie-ssass-analyse/","published":"2022-05-17"},{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","published":"2021-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lisa-a-kaltenbach","type":"person","url":"https://hartvaat.nl/mensen/lisa-a-kaltenbach/","name":"Lisa A Kaltenbach","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/04/18/gecoordineerde-zorg-optimaliseert-cv-preventie-bij-type-2-diabetes-jama-rct/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2020/05/01/zelfgerapporteerde-versus-apotheekgeregistreerde-medicatietrouw-compass-analyse/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/01/01/p2y12-copay-reductie-en-therapietrouw-aan-andere-secundaire-preventiemiddelen/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/01/01/medicatie-copay-vouchers-en-p2y12-gebruik-en-cv-events-na-mi-jama/","published":"2019-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lothar-roessig","type":"person","url":"https://hartvaat.nl/mensen/lothar-roessig/","name":"Lothar Roessig","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/12/01/vericiguat-en-nt-probnp-bij-hfref-victoria-subanalyse/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","published":"2020-10-20"},{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2017/04/14/vericiguat-bij-verslechterend-chronisch-hfpef-socrates-preserved-resultaten/","published":"2017-04-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"louis-st-l-o-dea","type":"person","url":"https://hartvaat.nl/mensen/louis-st-l-o-dea/","name":"Louis St L O'Dea","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2020/10/21/vupanorsen-angptl3-antisense-en-triglyceriden-ehj/","published":"2020-10-21"},{"url":"https://hartvaat.nl/2020/01/16/lp-a-verlaging-bij-cardiovasculaire-ziekte-nejm/","published":"2020-01-16"},{"url":"https://hartvaat.nl/2019/09/01/galnac-geconjugeerd-antisense-tegen-apoc3-triglyceriden-en-atherogene-lipoprotei/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/08/volanesorsen-en-triglyceriden-bij-familiair-chylomicronemiesyndroom-nejm/","published":"2019-08-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"louise-bowman","type":"person","url":"https://hartvaat.nl/mensen/louise-bowman/","name":"Louise Bowman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/10/21/amalfi-remote-screening-voor-asymptomatisch-af-gerandomiseerde-trial/","published":"2025-10-21"},{"url":"https://hartvaat.nl/2018/10/18/omega-3-vetzuursupplementen-bij-diabetes-nejm-ascend-omega-3/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2018/10/18/aspirine-voor-primaire-preventie-bij-diabetes-nejm-ascend/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2018/10/09/sacubitril-valsartan-versus-irbesartan-bij-chronische-nierziekte/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2017/09/28/anacetrapib-bij-atherosclerotisch-vaatlijden-nejm-hps3-timi55-reveal/","published":"2017-09-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"luca-monzo","type":"person","url":"https://hartvaat.nl/mensen/luca-monzo/","name":"Luca Monzo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/08/18/tafamidis-bij-attr-cardiomyopathie-kosteffectiviteit-onder-de-maat-in-vier-europ/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/05/23/paradise-cohort-hartfalen-en-copd-samen-verhogen-de-langetermijnmortaliteit-met-/","published":"2026-06-05"},{"url":"https://hartvaat.nl/2026/05/10/paradise-gelijktijdig-acuut-hartfalen-plus-luchtweginfectie-verhoogt-sterfte-tij/","published":"2026-05-11"},{"url":"https://hartvaat.nl/2026/05/09/telesat-prior-hf-telemonitoring-na-hartfalenopname-verbonden-met-46-lagere-morta/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/02/03/semaglutide-versus-tirzepatide-bij-patienten-met-obesitas-en-hfpef/","published":"2026-02-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"luca-testa","type":"person","url":"https://hartvaat.nl/mensen/luca-testa/","name":"Luca Testa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/16/pandora-register-supra-versus-intra-annulaire-kleppen-bij-tavr-in-tavr/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/02/03/linkerbundeltakpacing-versus-rechterventrikel-pacing-na-tavi/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2024/01/01/verkorte-dapt-bij-hoog-bloedingsrisico-geen-sekseverschillen/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2017/05/30/tijdstrends-in-complicaties-van-bioresorbeerbare-versus-metallic-stents/","published":"2017-05-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"luigi-tavazzi","type":"person","url":"https://hartvaat.nl/mensen/luigi-tavazzi/","name":"Luigi Tavazzi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/10/01/ivabradine-bij-hoogrisico-hartfalenpatienten-shift-analyse/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2023/06/01/betablokkers-bij-systolisch-hartfalen-en-pacemakerritme-mortaliteitseffect/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2019/12/01/gunstige-effecten-van-ivabradine-bij-hf-met-lage-ef-en-hartfrequentie-77-bpm/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2018/03/01/omega-3-vetzuursupplementen-en-cv-risico-jama-cardiology-meta-analyse-van-10-tri/","published":"2018-03-01"},{"url":"https://hartvaat.nl/2018/01/16/hoog-sensitief-troponine-t-bij-chronisch-hartfalen-individuele-patientdata-meta-/","published":"2018-01-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lukas-hunziker","type":"person","url":"https://hartvaat.nl/mensen/lukas-hunziker/","name":"Lukas Hunziker","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/03/10/mondiale-prevalentie-uitkomsten-en-kosten-van-hartfalen-careme-studie/","published":"2023-03-10"},{"url":"https://hartvaat.nl/2021/10/01/paroxetine-grk2-remming-versus-placebo-bij-anterieur-mi-jama-cardiology/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/08/04/cangrelor-tirofiban-en-prasugrel-bij-stemi-primaire-resultaten/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/09/01/ultradunne-biodegradeerbare-versus-dunne-duurzame-stents-lancet-gerandomiseerde-/","published":"2018-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lukasz-koltowski","type":"person","url":"https://hartvaat.nl/mensen/lukasz-koltowski/","name":"Lukasz Koltowski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","published":"2024-11-09"},{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ly-mee-yu","type":"person","url":"https://hartvaat.nl/mensen/ly-mee-yu/","name":"Ly-Mee Yu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-bloeddrukcontrole-bij-risicozwangerschap-jama-bump-2/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2020/05/26/antihypertensieve-medicatiereductie-versus-standaardzorg-bij-ouderen-jama-optimi/","published":"2020-05-26"},{"url":"https://hartvaat.nl/2018/03/10/zelfgemeten-bloeddruk-met-of-zonder-telemonitoring-voor-medicatietitratie-lancet/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2016/02/09/sms-berichten-ter-ondersteuning-van-therapietrouw-bij-hoge-bloeddruk-de-star-tri/","published":"2016-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maarten-a-h-van-leeuwen","type":"person","url":"https://hartvaat.nl/mensen/maarten-a-h-van-leeuwen/","name":"Maarten A H van Leeuwen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2019/08/01/temporele-veranderingen-in-coronaire-hemodynamiek-bij-niet-culprit-vaten-na-stem/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/01/29/microvasculaire-schade-bij-gerevasculariseerde-stemi-met-ticagrelor-versus-prasu/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/03/20/effecten-van-ticagrelor-prasugrel-of-clopidogrel-op-endotheelfunctie/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","published":"2016-06-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maciej-lesiak","type":"person","url":"https://hartvaat.nl/mensen/maciej-lesiak/","name":"Maciej Lesiak","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mads-brix-kronborg","type":"person","url":"https://hartvaat.nl/mensen/mads-brix-kronborg/","name":"Mads Brix Kronborg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/06/02/doac-gebruik-na-ablatie-voor-atriumfibrilleren-aanhouderij-daalt-na-drie-jaar/","published":"2026-08-11"},{"url":"https://hartvaat.nl/2023/10/21/minimalisatie-van-atriale-pacing-bij-sinusknoopziekte-vermindert-af/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2023/08/02/gerichte-lv-leadplaatsing-bij-crt-meta-analyse-van-beeldvorming-en-elektrisch-ge/","published":"2023-08-02"},{"url":"https://hartvaat.nl/2022/05/03/multimodaliteitsbeeldvorming-geleide-lv-leadplaatsing-bij-crt-langetermijn/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2019/09/01/elektrisch-versus-beeldvorming-geleide-lv-leadplaatsing-bij-crt-gerandomiseerde-/","published":"2019-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mahesh-v-madhavan","type":"person","url":"https://hartvaat.nl/mensen/mahesh-v-madhavan/","name":"Mahesh V Madhavan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/07/16/revascularisatiestrategieen-na-mi-systematische-review-en-meta-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2021/07/15/ultradunne-versus-conventionele-2e-generatie-des-langetermijn-meta-analyse/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2020/04/14/langetermijnuitkomsten-bij-vrouwen-en-mannen-na-pci/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mahir-karakas","type":"person","url":"https://hartvaat.nl/mensen/mahir-karakas/","name":"Mahir Karakas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/05/iv-ferricarboxymaltose-en-inspanningscapaciteit-bij-hfpef-met-ijzerdeficientie/","published":"2024-10-05"},{"url":"https://hartvaat.nl/2017/04/13/inclisiran-bij-patienten-met-hoog-cv-risico-en-verhoogd-ldl-nejm-orion-1/","published":"2017-04-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"manisha-desai","type":"person","url":"https://hartvaat.nl/mensen/manisha-desai/","name":"Manisha Desai","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2016/08/01/cabg-versus-pci-en-risico-op-myocardinfarct-en-revascularisatie-bij-ckd-patiente/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marc-ditmarsch","type":"person","url":"https://hartvaat.nl/mensen/marc-ditmarsch/","name":"Marc Ditmarsch","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/14/mendeliaanse-randomisatie-hmgcr-remming-verhoogt-diabetesrisico-andere-lipidendo/","published":"2026-06-20"},{"url":"https://hartvaat.nl/2026/05/25/obicetrapib-verlaagt-naast-ldl-en-apob-ook-lipoproteine-a/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2025/10/07/obicetrapib-en-mace-bij-hoogrisicopatienten-gepoolde-analyse/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2025/05/17/tandem-obicetrapib-plus-ezetimibe-voor-ldl-verlaging-lancet-fase-3/","published":"2025-05-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marc-ruel","type":"person","url":"https://hartvaat.nl/mensen/marc-ruel/","name":"Marc Ruel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/13/aha-scientific-statement-2026-secundaire-preventie-na-coronaire-bypassoperatie-e/","published":"2026-05-15"},{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2022/08/09/ticagrelor-dapt-en-veneuze-graftfalen-na-cabg-systematische-review/","published":"2022-08-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marcello-arca","type":"person","url":"https://hartvaat.nl/mensen/marcello-arca/","name":"Marcello Arca","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/02/25/behandeling-van-familiaire-hypercholesterolemie-bij-kinderen-3-jaar-lipigen-regi/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2026/02/01/de-verborgen-nierschade-bij-chylomicronemiesyndromen/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-familiaire-chylomicronemie-nejm-fase-3/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2019/08/08/volanesorsen-en-triglyceriden-bij-familiair-chylomicronemiesyndroom-nejm/","published":"2019-08-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marcello-tonelli","type":"person","url":"https://hartvaat.nl/mensen/marcello-tonelli/","name":"Marcello Tonelli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2023/05/16/afschaffen-eigen-bijdrage-medicatie-vermindert-cardiovasculair-risico-bij-oudere/","published":"2023-05-16"},{"url":"https://hartvaat.nl/2023/05/16/zelfmanagement-via-reclameprincipes-bij-ouderen-met-hoog-cv-risico/","published":"2023-05-16"},{"url":"https://hartvaat.nl/2021/03/01/kdigo-2021-bloeddruk-bij-ckd-executive-summary/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2016/07/19/glucoseverlagende-medicatie-en-cardiovasculaire-events-bij-diabetes-type-2-jama-/","published":"2016-07-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marco-zuin","type":"person","url":"https://hartvaat.nl/mensen/marco-zuin/","name":"Marco Zuin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/05/25/longembolie-epidemiologie-stijgende-last-bij-vergrijzing-preventiestrategieen-bl/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2026/02/25/alcoholgebruik-en-het-ontstaan-van-atriumfibrilleren-dosis-risico-en-dogma-herov/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2025/08/04/lbbap-versus-rv-pacing-tweejaarsresultaten-bij-pacemakergeindiceerde-patienten/","published":"2025-08-04"},{"url":"https://hartvaat.nl/2024/08/03/device-algoritmen-voor-rv-pacingminimalisatie-meta-analyse-van-uitkomsten/","published":"2024-08-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maria-a-pabon","type":"person","url":"https://hartvaat.nl/mensen/maria-a-pabon/","name":"Maria A Pabon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2026/03/28/lp-a-verhoogt-risico-op-veneuze-trombo-embolie-bij-premenopauzale-vrouwen-en-hor/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","published":"2024-05-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maria-mori-brooks","type":"person","url":"https://hartvaat.nl/mensen/maria-mori-brooks/","name":"Maria Mori Brooks","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2018/10/09/hypoglykemie-en-troponine-elevatie-bij-diabetes-met-coronairlijden/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2016/08/01/cabg-versus-pci-en-risico-op-myocardinfarct-en-revascularisatie-bij-ckd-patiente/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marian-branny","type":"person","url":"https://hartvaat.nl/mensen/marian-branny/","name":"Marian Branny","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/01/04/4-jaars-laa-sluiting-versus-niet-warfarine-oac-bij-af/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2020/06/30/laa-sluiting-versus-doac-bij-hoogrisico-af-vergelijkende-analyse/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2018/01/30/prasugrel-versus-ticagrelor-bij-primaire-pci-voor-mi-1-jaarsuitkomsten/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2016/11/22/prasugrel-versus-ticagrelor-bij-acuut-mi-met-primaire-pci-multicenter-trial/","published":"2016-11-22"},{"url":"https://hartvaat.nl/2016/02/01/spironolacton-versus-renale-denervatie-bij-therapieresistente-hypertensie-prague/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marianela-barros","type":"person","url":"https://hartvaat.nl/mensen/marianela-barros/","name":"Marianela Barros","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marie-t-baccara-dinet","type":"person","url":"https://hartvaat.nl/mensen/marie-t-baccara-dinet/","name":"Marie T Baccara-Dinet","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/07/14/alirocumab-bij-homozygoot-fh-odyssey-hofh/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2017/09/26/sams-ci-score-toegepast-op-gerandomiseerde-trial-over-statine-myopathie/","published":"2017-09-26"},{"url":"https://hartvaat.nl/2016/10/14/geen-effect-van-pcsk9-remmer-alirocumab-op-diabetes-incidentie-odyssey-analyse/","published":"2016-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marija-zdravkovic","type":"person","url":"https://hartvaat.nl/mensen/marija-zdravkovic/","name":"Marija Zdravkovic","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/08/18/c-mic-apparaat-vermindert-hartfalen-ernst-onafhankelijk-van-gdmt-aanpassingen-c-/","published":"2026-08-25"},{"url":"https://hartvaat.nl/2026/05/26/esc-consensusverklaring-over-microvasculaire-obstructie-en-no-reflow-na-stemi/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2026/03/03/c-mic-ii-hartfunctie-inspanningscapaciteit-en-kwaliteit-van-leven-zijn-verwante-/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2025/09/25/digitoxine-bij-hfref-gerandomiseerde-trial-nejm/","published":"2025-09-25"},{"url":"https://hartvaat.nl/2021/04/01/cardio-microstroomdevice-bij-chronisch-hf-eerste-klinische-studie/","published":"2021-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mariko-harada-shiba","type":"person","url":"https://hartvaat.nl/mensen/mariko-harada-shiba/","name":"Mariko Harada-Shiba","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/19/lipoproteine-aferese-blijft-relevant-in-het-tijdperk-van-pcsk9-remmers-en-sirna/","published":"2026-06-12"},{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/24/eas-consensus-wereldwijde-harmonisatie-van-lipidenklinieken/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2020/07/14/alirocumab-bij-homozygoot-fh-odyssey-hofh/","published":"2020-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marissa-a-miller","type":"person","url":"https://hartvaat.nl/mensen/marissa-a-miller/","name":"Marissa A Miller","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mariusz-tomaniak","type":"person","url":"https://hartvaat.nl/mensen/mariusz-tomaniak/","name":"Mariusz Tomaniak","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/24/invloed-van-coronaire-ziekte-patronen-op-klinische-uitkomsten-pullback-pressure-/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mark-d-huffman","type":"person","url":"https://hartvaat.nl/mensen/mark-d-huffman/","name":"Mark D Huffman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/10/01/lage-dosis-drievoudige-pil-versus-standaardzorg-bij-hypertensie-in-nigeria/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2022/09/26/zoutvervangers-verminderen-cardiovasculaire-events-systematische-review/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2021/04/01/canagliflozine-naar-diureticagebruik-canvas-post-hoc-analyse/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2019/03/01/ziekenhuisgebaseerde-kwaliteitsinterventies-bij-hartfalen-systematische-review/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/02/13/kwaliteitsverbeteringsinterventie-bij-acuut-mi-in-india-jama-acs-quik/","published":"2018-02-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mark-s-link","type":"person","url":"https://hartvaat.nl/mensen/mark-s-link/","name":"Mark S Link","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mark-w-parsons","type":"person","url":"https://hartvaat.nl/mensen/mark-w-parsons/","name":"Mark W Parsons","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/05/tenecteplase-versus-standaardbehandeling-bij-basilaris-occlusie-in-the-lancet/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2022/11/05/enchanted2-mt-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-is-schadelij/","published":"2022-11-05"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"},{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","published":"2016-06-16"},{"url":"https://hartvaat.nl/2016/04/07/pioglitazon-na-ischemisch-cva-of-tia-gerandomiseerde-nejm-trial/","published":"2016-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-j-landray","type":"person","url":"https://hartvaat.nl/mensen/martin-j-landray/","name":"Martin J Landray","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2019/07/01/kosteneffectiviteit-van-statines-en-ezetimibe-bij-chronische-nierziekte/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/10/09/sacubitril-valsartan-versus-irbesartan-bij-chronische-nierziekte/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2017/09/28/anacetrapib-bij-atherosclerotisch-vaatlijden-nejm-hps3-timi55-reveal/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/02/01/reverse-causality-in-de-associatie-bloeddruk-cardiovasculair-risico-bij-ckd/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-j-swaans","type":"person","url":"https://hartvaat.nl/mensen/martin-j-swaans/","name":"Martin J Swaans","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2021/12/07/gold-force-multi-elektrode-rf-versus-irrigated-rf-bij-af-gerandomiseerde-trial/","published":"2021-12-07"},{"url":"https://hartvaat.nl/2020/11/10/ticagrelor-plus-aspirine-en-safeneuze-graft-patency-na-cabg/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2018/12/01/mitraclip-plus-medicamenteus-versus-medicamenteus-alleen-bij-hf-met-mr-meta-anal/","published":"2018-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"masahiro-natsuaki","type":"person","url":"https://hartvaat.nl/mensen/masahiro-natsuaki/","name":"Masahiro Natsuaki","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"massar-omar","type":"person","url":"https://hartvaat.nl/mensen/massar-omar/","name":"Massar Omar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/09/01/dapagliflozine-en-rv-pulmonale-interactie-bij-hfpef/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/09/05/cameo-dapa-cardiale-en-metabole-effecten-van-dapagliflozine-bij-hfpef/","published":"2023-09-05"},{"url":"https://hartvaat.nl/2021/07/01/empagliflozine-en-lv-volumes-en-functie-bij-hfref-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/06/01/metabole-effecten-van-empagliflozine-bij-hf-empire-hf-metabolic-gerandomiseerde-/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/12/08/empagliflozine-en-hemodynamiek-bij-hfref/","published":"2020-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"massimo-f-piepoli","type":"person","url":"https://hartvaat.nl/mensen/massimo-f-piepoli/","name":"Massimo F Piepoli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2019/04/02/inspanningsrevalidatie-bij-hf-ipd-meta-analyse-van-inspanningscapaciteit-en-qol/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2016/08/01/2016-europese-richtlijnen-voor-cardiovasculaire-preventie-in-de-klinische-prakti/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matias-nordaby","type":"person","url":"https://hartvaat.nl/mensen/matias-nordaby/","name":"Matias Nordaby","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2019/06/01/heparinedosering-bij-ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-re/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/05/14/dabigatran-duale-therapie-met-ticagrelor-of-clopidogrel-na-pci-bij-af-re-dual-pc/","published":"2019-05-14"},{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","published":"2017-10-19"},{"url":"https://hartvaat.nl/2017/04/27/ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-nejm-re-circuit/","published":"2017-04-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matteo-bertini","type":"person","url":"https://hartvaat.nl/mensen/matteo-bertini/","name":"Matteo Bertini","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/06/02/catheterablatie-bij-atriumfibrilleren-in-cardiale-amyloidose-levert-42-ritmievri/","published":"2026-08-11"},{"url":"https://hartvaat.nl/2026/03/17/athena-register-pulsed-field-ablatie-voor-atriumfibrilleren-ook-effectief-bij-ha/","published":"2026-04-20"},{"url":"https://hartvaat.nl/2026/02/25/alcoholgebruik-en-het-ontstaan-van-atriumfibrilleren-dosis-risico-en-dogma-herov/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2025/08/04/lbbap-versus-rv-pacing-tweejaarsresultaten-bij-pacemakergeindiceerde-patienten/","published":"2025-08-04"},{"url":"https://hartvaat.nl/2024/08/03/device-algoritmen-voor-rv-pacingminimalisatie-meta-analyse-van-uitkomsten/","published":"2024-08-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matthew-ginks","type":"person","url":"https://hartvaat.nl/mensen/matthew-ginks/","name":"Matthew Ginks","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2018/01/01/endocardiale-linkerkamer-pacing-voor-crt-systematische-review-en-meta-analyse/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matthew-m-y-lee","type":"person","url":"https://hartvaat.nl/mensen/matthew-m-y-lee/","name":"Matthew M Y Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/10/07/nieuwe-inspanningsherstelpatronen-als-maat-voor-cardiale-prestatie/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2024/06/25/raas-blokkade-bij-hartfalen-voordeel-onafhankelijk-van-etniciteit-jama-meta-anal/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/05/15/implanteerbare-hemodynamische-monitoring-bij-hartfalen-meta-analyse-over-ef-spec/","published":"2023-05-15"},{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","published":"2021-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mattias-duytschaever","type":"person","url":"https://hartvaat.nl/mensen/mattias-duytschaever/","name":"Mattias Duytschaever","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/03/varipure-studie-pulsed-field-ablatie-in-de-dagelijkse-af-praktijk/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2019/08/01/eenvoudige-techniek-voor-pvi-van-linker-longvenen-gerandomiseerde-studie/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/04/21/pvi-met-versus-zonder-antiaritmica-bij-recidiverend-af-powder-af/","published":"2018-04-21"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mauricio-g-cohen","type":"person","url":"https://hartvaat.nl/mensen/mauricio-g-cohen/","name":"Mauricio G Cohen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2022/10/25/2022-acc-aha-datadefinities-voor-pijn-op-de-borst-en-acuut-myocardinfarct/","published":"2022-10-25"},{"url":"https://hartvaat.nl/2022/01/18/2021-acc-aha-scai-richtlijn-voor-coronaire-revascularisatie-executive-summary/","published":"2022-01-18"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maurizio-menichelli","type":"person","url":"https://hartvaat.nl/mensen/maurizio-menichelli/","name":"Maurizio Menichelli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/07/02/closed-loop-stimulatie-vermindert-ahre-s-versus-conventionele-rate-adaptieve-pac/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mauro-biffi","type":"person","url":"https://hartvaat.nl/mensen/mauro-biffi/","name":"Mauro Biffi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/30/leadless-atriaal-pacen-geeft-minder-complicaties-dan-transveneus-1-jaars-medicar/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2026/03/30/crt-zonder-atriale-lead-tweeledig-crt-dx-systeem-non-inferieur-aan-klassieke-dri/","published":"2026-04-25"},{"url":"https://hartvaat.nl/2025/08/04/lbbap-versus-rv-pacing-tweejaarsresultaten-bij-pacemakergeindiceerde-patienten/","published":"2025-08-04"},{"url":"https://hartvaat.nl/2024/10/01/draadloos-ultrasound-gebaseerd-crt-systeem-bij-hartfalen/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2019/04/01/pr-interval-en-pacingmodus-en-af-incidentie-bij-tweekamer-pacemaker/","published":"2019-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mauro-chiarito","type":"person","url":"https://hartvaat.nl/mensen/mauro-chiarito/","name":"Mauro Chiarito","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/03/geslachtsverschillen-bij-patienten-met-gevorderd-hartfalen/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2022/10/01/mitraclip-bij-secundaire-mitralisklepinsufficientie-meta-analyse-ischemisch-vs-n/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2020/05/09/p2y12-monotherapie-of-aspirine-voor-secundaire-preventie-lancet-meta-analyse/","published":"2020-05-09"},{"url":"https://hartvaat.nl/2018/03/01/doac-plus-antiplaatjestherapie-voor-secundaire-preventie-na-acs-meta-analyse/","published":"2018-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maximilian-von-eynatten","type":"person","url":"https://hartvaat.nl/mensen/maximilian-von-eynatten/","name":"Maximilian von Eynatten","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2019/08/01/empagliflozine-voorkomt-progressie-van-ckd-empa-reg-outcome-renale-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","published":"2019-01-15"},{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/01/09/empagliflozine-bij-diabetes-type-2-met-cardiovasculaire-ziekte-en-ckd-empa-reg-o/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2016/07/28/empagliflozine-en-progressie-van-nierziekte-bij-diabetes-type-2-nejm-empa-reg-re/","published":"2016-07-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"magorzata-lelonek","type":"person","url":"https://hartvaat.nl/mensen/magorzata-lelonek/","name":"Małgorzata Lelonek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","published":"2019-10-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-argenziano","type":"person","url":"https://hartvaat.nl/mensen/michael-argenziano/","name":"Michael Argenziano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2017/05/25/levosimendan-bij-lv-disfunctie-voor-hartchirurgie-nejm-levo-cts/","published":"2017-05-25"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-fu","type":"person","url":"https://hartvaat.nl/mensen/michael-fu/","name":"Michael Fu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-g-palazzolo","type":"person","url":"https://hartvaat.nl/mensen/michael-g-palazzolo/","name":"Michael G Palazzolo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/24/systemische-embolieen-bij-af-ipd-mega-meta-analyse-van-71-683-patienten/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2024/09/01/eldercare-af-subanalyse-dosisreductie-edoxaban-bij-80-jarigen-met-af/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","published":"2024-03-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-glikson","type":"person","url":"https://hartvaat.nl/mensen/michael-glikson/","name":"Michael Glikson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2023/08/02/gerichte-lv-leadplaatsing-bij-crt-meta-analyse-van-beeldvorming-en-elektrisch-ge/","published":"2023-08-02"},{"url":"https://hartvaat.nl/2023/05/19/geleidingssysteempacing-in-europa-inzichten-uit-klinische-praktijk/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2023/03/30/upgrade-van-rv-pacemaker-naar-crt-of-geleidingssysteempacing-meta-analyse/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2022/05/03/radiale-strain-geleide-leadplaatsing-voor-crt-bij-ischemisch-hf/","published":"2022-05-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-h-davidson","type":"person","url":"https://hartvaat.nl/mensen/michael-h-davidson/","name":"Michael H Davidson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/25/obicetrapib-verlaagt-naast-ldl-en-apob-ook-lipoproteine-a/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2025/10/07/obicetrapib-en-mace-bij-hoogrisicopatienten-gepoolde-analyse/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2016/12/13/alirocumab-en-reductie-in-atherogene-lipiden-en-cardiovasculaire-events-10-odyss/","published":"2016-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-j-bloch","type":"person","url":"https://hartvaat.nl/mensen/michael-j-bloch/","name":"Michael J Bloch","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-j-pencina","type":"person","url":"https://hartvaat.nl/mensen/michael-j-pencina/","name":"Michael J Pencina","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/01/prevent-risicoscore-presteert-robuust-in-de-dagelijkse-ehr-praktijk/","published":"2026-07-15"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2021/04/01/telereh-hf-etiologie-subanalyse-van-telerevalidatie-bij-hartfalen/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/03/01/hybride-telerevalidatie-bij-hartfalen-jama-cardiology-tele-hf-trial/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-j-rinaldi","type":"person","url":"https://hartvaat.nl/mensen/michael-j-rinaldi/","name":"Michael J Rinaldi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"},{"url":"https://hartvaat.nl/2016/04/26/predictieregel-voor-voordeel-en-schade-van-dapt-na-1-jaar-pci-jama-validatiestud/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-wong","type":"person","url":"https://hartvaat.nl/mensen/michael-wong/","name":"Michael Wong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/02/16/technieken-om-cardioversiesucces-bij-af-te-verbeteren-meta-analyse/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2020/01/02/alcoholonthouding-bij-drinkers-met-af-nejm-gerandomiseerde-trial/","published":"2020-01-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michiel-l-bots","type":"person","url":"https://hartvaat.nl/mensen/michiel-l-bots/","name":"Michiel L Bots","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/10/01/smartphone-app-thuisbloeddrukmeting-versus-kantoor-en-ambulante-meting/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/01/01/plasmatrogconcentraties-van-antihypertensiva-voor-therapietrouwbeoordeling-meta-/","published":"2021-01-01"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2019/01/01/polypil-en-cardiovasculaire-preventie-meta-analyse-van-gerandomiseerde-trials/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2017/04/01/medicatietrouw-en-het-effect-van-renale-denervatie-de-sympathy-trial/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mihai-gheorghiade","type":"person","url":"https://hartvaat.nl/mensen/mihai-gheorghiade/","name":"Mihai Gheorghiade","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2018/10/04/rivaroxaban-bij-hartfalen-met-sinusritme-en-coronairlijden-nejm-commander-hf/","published":"2018-10-04"},{"url":"https://hartvaat.nl/2017/11/01/raas-blokkade-bij-hfpef-systematische-review-en-meta-analyse/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/04/14/vericiguat-bij-verslechterend-chronisch-hfpef-socrates-preserved-resultaten/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/02/07/doodsoorzaken-bij-hartfalen-met-behouden-ejectiefractie/","published":"2017-02-07"},{"url":"https://hartvaat.nl/2016/07/14/finerenon-versus-eplerenon-bij-hartfalen-met-diabetes-en-verslechterende-nierfun/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mika-laine","type":"person","url":"https://hartvaat.nl/mensen/mika-laine/","name":"Mika Laine","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/08/01/baroreflexactivatietherapie-bij-resistente-hypertensie-sham-gecontroleerde-pilot/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2020/03/10/routine-versus-selectieve-cardiale-mri-bij-niet-ischemisch-hf-outsmart-hf/","published":"2020-03-10"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mingming-yang","type":"person","url":"https://hartvaat.nl/mensen/mingming-yang/","name":"Mingming Yang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/05/magnesium-en-uitkomsten-bij-hfref-galactic-hf-subanalyse/","published":"2026-01-05"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/06/18/mra-bij-hartfalen-met-nierfunctiestoornissen-veiligheid-en-effectiviteit/","published":"2024-06-18"},{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","published":"2023-06-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mirjam-kessler","type":"person","url":"https://hartvaat.nl/mensen/mirjam-kessler/","name":"Mirjam Kessler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mohamed-abdel-wahab","type":"person","url":"https://hartvaat.nl/mensen/mohamed-abdel-wahab/","name":"Mohamed Abdel-Wahab","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/06/06/smart-zelf-expanderend-versus-ballonexpandeerbaar-tavr-bij-kleine-annulus-nejm/","published":"2024-06-06"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2017/03/30/ffr-geleide-multivaten-pci-bij-myocardinfarct-nejm-compare-acute/","published":"2017-03-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"monika-diek","type":"person","url":"https://hartvaat.nl/mensen/monika-diek/","name":"Monika Diek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/10/05/iv-ferricarboxymaltose-en-inspanningscapaciteit-bij-hfpef-met-ijzerdeficientie/","published":"2024-10-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"muhammad-shariq-usman","type":"person","url":"https://hartvaat.nl/mensen/muhammad-shariq-usman/","name":"Muhammad Shariq Usman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/09/26/geblindeerde-stopstudie-voordelen-empagliflozine-verdwijnen-na-staken-bij-hf/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","published":"2023-06-27"},{"url":"https://hartvaat.nl/2022/04/01/robuustheid-van-sglt2-remmer-hf-trials-evaluatie/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2020/12/01/sglt2-remmers-bij-hartfalen-systematische-review-en-meta-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/12/01/ijzercarboxymaltose-bij-ijzerdeficient-hartfalen-meta-analyse/","published":"2020-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marten-rosenqvist","type":"person","url":"https://hartvaat.nl/mensen/marten-rosenqvist/","name":"Mårten Rosenqvist","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/12/03/nt-probnp-en-ecg-screening-bij-75-jarigen-voor-af-detectie-rct/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2023/01/14/strokestop-af-screening-is-kosteneffectief-bij-75-76-jarigen/","published":"2023-01-14"},{"url":"https://hartvaat.nl/2021/10/23/systematische-af-screening-en-klinische-uitkomsten-lancet-strokestop/","published":"2021-10-23"},{"url":"https://hartvaat.nl/2020/01/01/stapsgewijze-af-screening-met-nt-probnp-strokestop-ii-resultaten/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2017/02/01/stapsgewijze-massascreening-op-af-met-nt-probnp-strokestop-ii-studieontwerp/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nassir-f-marrouche","type":"person","url":"https://hartvaat.nl/mensen/nassir-f-marrouche/","name":"Nassir F Marrouche","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/05/02/decaaf-ii-af-last-en-symptoomreductie-na-ablatie/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2023/10/12/castle-htx-af-ablatie-bij-eindstadium-hartfalen-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/08/02/decaaf-ii-fibroselocatie-beinvloedt-af-recidief-na-ablatie/","published":"2023-08-02"},{"url":"https://hartvaat.nl/2022/06/21/mri-geleide-fibroseablatie-versus-conventionele-ablatie-bij-persisterend-af/","published":"2022-06-21"},{"url":"https://hartvaat.nl/2018/02/01/katheterablatie-bij-af-met-hartfalen-nejm-castle-af/","published":"2018-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"natalia-pinilla-echeverri","type":"person","url":"https://hartvaat.nl/mensen/natalia-pinilla-echeverri/","name":"Natalia Pinilla-Echeverri","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/27/intracoronair-lage-dosis-rtpa-bij-primaire-pci-voor-stemi-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/07/15/oct-gebaseerde-post-pci-fysiologiebeoordeling-voorspelt-klinische-uitkomsten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"natalie-staplin","type":"person","url":"https://hartvaat.nl/mensen/natalie-staplin/","name":"Natalie Staplin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2018/10/09/sacubitril-valsartan-versus-irbesartan-bij-chronische-nierziekte/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2017/02/01/reverse-causality-in-de-associatie-bloeddruk-cardiovasculair-risico-bij-ckd/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"neal-o-jeffries","type":"person","url":"https://hartvaat.nl/mensen/neal-o-jeffries/","name":"Neal O Jeffries","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"neha-j-pagidipati","type":"person","url":"https://hartvaat.nl/mensen/neha-j-pagidipati/","name":"Neha J Pagidipati","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/07/16/interventie-voor-evidence-based-zorg-bij-diabetes-en-cv-risico/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2023/04/18/gecoordineerde-zorg-optimaliseert-cv-preventie-bij-type-2-diabetes-jama-rct/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2019/03/05/inspanningstest-versus-ccta-bij-diabetes-met-verdenking-coronairlijden/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2017/09/28/exenatide-eenmaal-per-week-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-ne/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/09/26/secundaire-cardiovasculaire-preventie-bij-diabetes-type-2-tecos-internationale-i/","published":"2017-09-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"neil-o-leary","type":"person","url":"https://hartvaat.nl/mensen/neil-o-leary/","name":"Neil O'Leary","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","published":"2022-10-28"},{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","published":"2021-06-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nian-liu","type":"person","url":"https://hartvaat.nl/mensen/nian-liu/","name":"Nian Liu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","published":"2023-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicolas-amabile","type":"person","url":"https://hartvaat.nl/mensen/nicolas-amabile/","name":"Nicolas Amabile","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/06/transseptale-punctie-bij-linkshartinterventies-nieuwe-esc-consensus-over-technie/","published":"2026-07-29"},{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2025/07/01/calcified-oct-versus-angiografie-bij-pci-van-verkalkte-laesies/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2016/09/27/oct-geleide-pci-optimalisatie-bij-nste-acs-gerandomiseerde-trial/","published":"2016-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicolas-noiseux","type":"person","url":"https://hartvaat.nl/mensen/nicolas-noiseux/","name":"Nicolas Noiseux","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/08/13/off-pump-versus-on-pump-cabg-bij-hoofdstamcoronairlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2016/12/15/off-pump-versus-on-pump-cabg-5-jaarsresultaten-nejm-coronary-trial/","published":"2016-12-15"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicoletta-de-cesare","type":"person","url":"https://hartvaat.nl/mensen/nicoletta-de-cesare/","name":"Nicoletta de Cesare","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2016/02/02/ciclosporine-a-bij-gereperfuseerd-myocardinfarct-de-multicenter-cycle-trial/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nieves-gonzalo","type":"person","url":"https://hartvaat.nl/mensen/nieves-gonzalo/","name":"Nieves Gonzalo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2025/11/25/amphilimus-versus-zotarolimus-eluting-stent-bij-diabetes-en-coronairlijden/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2025/07/15/oct-gebaseerde-post-pci-fysiologiebeoordeling-voorspelt-klinische-uitkomsten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2017/01/15/linker-hartoorsluiting-versus-medicamenteuze-behandeling-bij-af-netwerkmeta-anal/","published":"2017-01-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"niklas-dyrby-johansen","type":"person","url":"https://hartvaat.nl/mensen/niklas-dyrby-johansen/","name":"Niklas Dyrby Johansen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/01/hoge-dosis-griepvaccinatie-bij-atherosclerotisch-vaatlijden-flunity-hd-analyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/11/10/hoog-gedoseerd-griepvaccin-vermindert-cardiovasculaire-events-bij-ouderen/","published":"2025-11-10"},{"url":"https://hartvaat.nl/2025/10/28/rsv-vaccin-vermindert-cv-hospitalisaties-bij-ouderen/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/01/01/nudge-flu-subanalyse-griepvaccinatie-nudges-bij-mi-langetermijn/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/05/27/nudge-flu-elektronische-nudges-verhogen-griepvaccinatie-na-mi/","published":"2024-05-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nikola-kozhuharov","type":"person","url":"https://hartvaat.nl/mensen/nikola-kozhuharov/","name":"Nikola Kozhuharov","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/06/02/pulsfield-ablatie-levert-betere-vrijwaring-van-recidief-dan-cryoballoon-bij-paro/","published":"2026-08-12"},{"url":"https://hartvaat.nl/2026/02/03/aanbesteding-van-cardiale-implanteerbare-devices-in-europa-waarde-of-kosten/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/04/17/pfa-versus-cryoballon-bij-paroxysmaal-af-gerandomiseerde-trial/","published":"2025-04-17"},{"url":"https://hartvaat.nl/2021/10/01/uitgebreide-vasodilatatie-en-qol-bij-acuut-hf-substudie/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2019/12/17/uitgebreide-vasodilatatie-versus-standaardzorg-bij-acuut-hf-jama-galactic-hf-pil/","published":"2019-12-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nikos-werner","type":"person","url":"https://hartvaat.nl/mensen/nikos-werner/","name":"Nikos Werner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","published":"2025-02-18"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nilesh-j-samani","type":"person","url":"https://hartvaat.nl/mensen/nilesh-j-samani/","name":"Nilesh J Samani","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/09/01/metformin-verlaagt-risico-op-buikaorta-aneurysma-mr-en-cohortanalyse/","published":"2026-08-20"},{"url":"https://hartvaat.nl/2026/02/05/de-erfelijke-basis-van-coronairlijden-nejm-overzicht/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2018/12/01/dagelijkse-remote-ischemische-conditionering-na-acuut-mi-gerandomiseerde-trial/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/01/01/genetische-associatie-van-lipiden-en-lipide-doelwitten-met-abdominaal-aorta-aneu/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nobuhisa-hagiwara","type":"person","url":"https://hartvaat.nl/mensen/nobuhisa-hagiwara/","name":"Nobuhisa Hagiwara","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/08/01/rivaroxaban-monotherapie-versus-combinatie-met-plaatjesremmers-bij-af-en-coronai/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/11/01/aspirine-versus-p2y12-remmer-met-antistolling-bij-af/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2019/09/19/antitrombotische-therapie-bij-af-met-stabiel-coronairlijden-nejm-afire/","published":"2019-09-19"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2017/08/01/ldl-cholesterol-streefwaarden-met-pitavastatine-ezetimibe-bij-acs-met-dyslipidem/","published":"2017-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"norbert-frey","type":"person","url":"https://hartvaat.nl/mensen/norbert-frey/","name":"Norbert Frey","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/19/tirzepatide-bij-hfpef-obesitas-niet-kosteneffectief-en-niet-betaalbaar-tegen-hui/","published":"2026-06-15"},{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/02/03/neuromusculaire-elektrostimulatie-bij-ernstig-hartfalen-functionele-verbetering/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2016/08/16/bio-absorbeerbare-intracoronaire-matrix-ter-preventie-van-ventriculaire-remodell/","published":"2016-08-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pablo-salinas","type":"person","url":"https://hartvaat.nl/mensen/pablo-salinas/","name":"Pablo Salinas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/23/korte-anticoagulatie-versus-dapt-na-laa-occlusie-devicetrombosepreventie/","published":"2025-12-23"},{"url":"https://hartvaat.nl/2025/11/25/amphilimus-versus-zotarolimus-eluting-stent-bij-diabetes-en-coronairlijden/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2022/03/31/amphilimus-versus-zotarolimus-stents-bij-diabetes-sugar-gerandomiseerde-trial/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2019/12/03/magnesium-resorbeerbare-scaffold-versus-metallic-stent-bij-stemi-biosolve-iii/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2017/01/15/linker-hartoorsluiting-versus-medicamenteuze-behandeling-bij-af-netwerkmeta-anal/","published":"2017-01-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"panagiotis-theofilis","type":"person","url":"https://hartvaat.nl/mensen/panagiotis-theofilis/","name":"Panagiotis Theofilis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/08/15/injecteerbare-lipidendalers-bij-gevorderde-chronische-nierziekte-en-dialyse-narr/","published":"2026-08-24"},{"url":"https://hartvaat.nl/2026/05/06/circulerend-mir-10b-5p-voorspelt-af-recidief-na-ablatie/","published":"2026-05-06"},{"url":"https://hartvaat.nl/2026/02/03/ice-bij-af-ablatie-veiligheid-en-effectiviteit-meta-analyse/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/03/af-ablatie-timing-naar-af-duur-impact-op-aritmierecidief/","published":"2025-06-03"},{"url":"https://hartvaat.nl/2025/04/01/symptomatisch-versus-asymptomatisch-af-en-klinische-uitkomsten-meta-analyse/","published":"2025-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pankaj-puar","type":"person","url":"https://hartvaat.nl/mensen/pankaj-puar/","name":"Pankaj Puar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/06/01/igfbp7-en-lv-massaregressie-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/nlr-en-cardiale-remodelling-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/diabetesduur-beinvloedt-lv-massaregressie-met-empagliflozine/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2021/12/01/sglt2-remmers-en-cardiale-remodellering-meta-analyse-van-mri-trials/","published":"2021-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paolo-canova","type":"person","url":"https://hartvaat.nl/mensen/paolo-canova/","name":"Paolo Canova","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","published":"2020-11-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"patricia-o-guimaraes","type":"person","url":"https://hartvaat.nl/mensen/patricia-o-guimaraes/","name":"Patricia O Guimarães","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/17/answer-hf-sacubitril-valsartan-versus-enalapril-bij-chagas-hf-primaire-resultate/","published":"2026-03-17"},{"url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2024/12/01/korte-dapt-na-des-bij-acs-ipd-meta-analyse-bevestigt-veiligheid/","published":"2024-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"patrick-badertscher","type":"person","url":"https://hartvaat.nl/mensen/patrick-badertscher/","name":"Patrick Badertscher","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/06/02/pulsfield-ablatie-levert-betere-vrijwaring-van-recidief-dan-cryoballoon-bij-paro/","published":"2026-08-12"},{"url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","published":"2026-05-27"},{"url":"https://hartvaat.nl/2025/04/17/pfa-versus-cryoballon-bij-paroxysmaal-af-gerandomiseerde-trial/","published":"2025-04-17"},{"url":"https://hartvaat.nl/2023/11/02/duurzaamheid-van-pvi-bij-af-meta-analyse/","published":"2023-11-02"},{"url":"https://hartvaat.nl/2017/11/21/hoog-sensitief-troponine-i-en-uitkomsten-bij-verdenking-acs-jama-studie/","published":"2017-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"patrick-schloemer","type":"person","url":"https://hartvaat.nl/mensen/patrick-schloemer/","name":"Patrick Schloemer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/05/finerenon-effectief-bij-type-1-diabetes-met-chronische-nierziekte/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2021/12/09/finerenon-bij-nierziekte-met-diabetes-type-2-nejm-figaro-dkd/","published":"2021-12-09"},{"url":"https://hartvaat.nl/2021/02/09/finerenon-en-cardiovasculaire-uitkomsten-bij-ckd-met-diabetes-type-2-fidelio-dkd/","published":"2021-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-guedeney","type":"person","url":"https://hartvaat.nl/mensen/paul-guedeney/","name":"Paul Guedeney","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/11/19/afloat-flecainide-voorkomt-af-na-pfo-sluiting-rct/","published":"2024-11-19"},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2021/01/19/residuele-syntax-score-bij-cardiogene-shock/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-khairy","type":"person","url":"https://hartvaat.nl/mensen/paul-khairy/","name":"Paul Khairy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","published":"2024-02-16"},{"url":"https://hartvaat.nl/2023/05/30/complicaties-van-af-ablatie-actueel-overzicht/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2022/07/15/vt-ablatie-versus-antiaritmica-bij-myocardinfarct-locatie-maakt-uit/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2021/11/01/af-last-en-qol-na-af-ablatie-cabana-substudie/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2019/11/26/cryoballon-versus-rf-ablatie-bij-af-beoordeeld-met-continue-monitoring-cryo-firs/","published":"2019-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-w-x-foley","type":"person","url":"https://hartvaat.nl/mensen/paul-w-x-foley/","name":"Paul W X Foley","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","published":"2024-04-21"},{"url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/05/19/geleidingssysteempacing-in-europa-inzichten-uit-klinische-praktijk/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pavel-cervinka","type":"person","url":"https://hartvaat.nl/mensen/pavel-cervinka/","name":"Pavel Cervinka","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/21/tavi-plus-ffr-geleide-pci-gecombineerde-benadering-onderzocht/","published":"2025-12-21"},{"url":"https://hartvaat.nl/2022/01/04/4-jaars-laa-sluiting-versus-niet-warfarine-oac-bij-af/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2020/06/30/laa-sluiting-versus-doac-bij-hoogrisico-af-vergelijkende-analyse/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2018/01/30/prasugrel-versus-ticagrelor-bij-primaire-pci-voor-mi-1-jaarsuitkomsten/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2016/11/22/prasugrel-versus-ticagrelor-bij-acuut-mi-met-primaire-pci-multicenter-trial/","published":"2016-11-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peep-laanmets","type":"person","url":"https://hartvaat.nl/mensen/peep-laanmets/","name":"Peep Laanmets","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2018/09/01/langetermijnimpact-van-cto-rekanalisatie-bij-stemi-patienten/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2016/10/11/pci-van-chronische-totale-occlusie-bij-stemi-met-multivatenlijden-explore-trial/","published":"2016-10-11"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-haworth","type":"person","url":"https://hartvaat.nl/mensen/peter-haworth/","name":"Peter Haworth","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-m-van-de-ven","type":"person","url":"https://hartvaat.nl/mensen/peter-m-van-de-ven/","name":"Peter M van de Ven","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/01/23/switchen-van-vka-naar-noac-bij-fragiele-ouderen-met-af-veilig/","published":"2024-01-23"},{"url":"https://hartvaat.nl/2020/12/01/coronairangiografie-na-hartstilstand-zonder-st-elevatie-coact-1-jaarsuitkomsten/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/08/01/temporele-veranderingen-in-coronaire-hemodynamiek-bij-niet-culprit-vaten-na-stem/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/04/11/coronairangiografie-na-hartstilstand-zonder-st-elevatie-nejm-coact/","published":"2019-04-11"},{"url":"https://hartvaat.nl/2019/01/29/microvasculaire-schade-bij-gerevasculariseerde-stemi-met-ticagrelor-versus-prasu/","published":"2019-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-w-f-wilson","type":"person","url":"https://hartvaat.nl/mensen/peter-w-f-wilson/","name":"Peter W F Wilson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/25/glp-1-agonisten-en-gezonde-leefstijl-samen-sterker-tegen-hart-en-vaatziekten/","published":"2026-03-08"},{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2019/06/25/systematische-review-voor-de-2018-aha-acc-cholesterolrichtlijn-jacc/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/systematische-review-voor-de-2018-aha-acc-cholesterolrichtlijn/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2018/12/01/cardiovasculaire-risicocommunicatie-en-patientperceptie-jama-cardiology/","published":"2018-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"petr-ostadal","type":"person","url":"https://hartvaat.nl/mensen/petr-ostadal/","name":"Petr Ostadal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2023/02/07/ecmo-cs-ecmo-bij-cardiogene-shock-verbetert-overleving-niet/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"petr-peichl","type":"person","url":"https://hartvaat.nl/mensen/petr-peichl/","name":"Petr Peichl","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/13/intracardiale-echocardiografie-in-de-elektrofysiologie-gezamenlijk-ehra-eapci-st/","published":"2026-05-23"},{"url":"https://hartvaat.nl/2025/10/07/cti-blok-na-pfa-versus-rf-cryo-ablatie-gerandomiseerde-vergelijking/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2022/01/04/4-jaars-laa-sluiting-versus-niet-warfarine-oac-bij-af/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2020/06/30/laa-sluiting-versus-doac-bij-hoogrisico-af-vergelijkende-analyse/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2018/07/01/echogeleide-versus-conventionele-femorale-venepunctie-bij-af-ablatie-gerandomise/","published":"2018-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philip-g-jones","type":"person","url":"https://hartvaat.nl/mensen/philip-g-jones/","name":"Philip G Jones","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/27/vroege-versus-late-gestageerde-pci-na-subintimale-re-entry-bij-cto/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/09/23/pci-versus-cabg-en-gezondheidsstatus-bij-stabiel-coronairlijden/","published":"2025-09-23"},{"url":"https://hartvaat.nl/2025/09/16/ischemia-anginatrajecten-na-invasieve-versus-conservatieve-strategie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/01/01/kccq-interpretatie-bij-hartfalen-patient-ankering/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2020/04/23/gezondheidsstatus-na-invasieve-of-conservatieve-zorg-bij-coronairlijden-met-gevo/","published":"2020-04-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philip-roberts-thomson","type":"person","url":"https://hartvaat.nl/mensen/philip-roberts-thomson/","name":"Philip Roberts-Thomson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/09/01/systolische-bloeddrukamplificatie-ipd-meta-analyse/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/06/01/bloeddrukverlaging-bij-centrale-hypertensie-gerandomiseerde-trial/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2021/11/09/colchicine-na-acs-2-jaars-cops-follow-up/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2020/11/17/colchicine-bij-acs-australische-cops-gerandomiseerde-trial/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2017/08/01/nauwkeurigheid-van-manchetbloeddrukmeting-systematische-review-en-meta-analyse/","published":"2017-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philipp-lauten","type":"person","url":"https://hartvaat.nl/mensen/philipp-lauten/","name":"Philipp Lauten","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philippe-garot","type":"person","url":"https://hartvaat.nl/mensen/philippe-garot/","name":"Philippe Garot","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/22/lge-granulariteit-op-cmr-voorspelt-sterfte-bij-eindstadium-hypertrofische-cardio/","published":"2026-06-06"},{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2023/10/31/antitrombotische-therapie-na-laa-occlusie-netwerk-meta-analyse/","published":"2023-10-31"},{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philippe-l-l-allier","type":"person","url":"https://hartvaat.nl/mensen/philippe-l-l-allier/","name":"Philippe L L'Allier","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/10/14/dal-gene-farmacogenetica-geleide-dalcetrapib-na-acs/","published":"2022-10-14"},{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"},{"url":"https://hartvaat.nl/2016/10/18/canakinumab-en-arteriele-effecten-bij-atherosclerose-met-diabetes-of-glucosetole/","published":"2016-10-18"},{"url":"https://hartvaat.nl/2016/01/26/p-selectine-antagonist-inclacumab-bij-coronaire-bypasschirurgie-select-cabg-tria/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philippe-mabo","type":"person","url":"https://hartvaat.nl/mensen/philippe-mabo/","name":"Philippe Mabo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","published":"2024-12-07"},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2022/02/02/remote-monitoring-en-klinische-uitkomsten-bij-europese-hf-met-icd-langetermijn/","published":"2022-02-02"},{"url":"https://hartvaat.nl/2019/09/01/remote-monitoring-en-patientgerapporteerde-uitkomsten-bij-europese-hf-patienten-/","published":"2019-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philippe-pibarot","type":"person","url":"https://hartvaat.nl/mensen/philippe-pibarot/","name":"Philippe Pibarot","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","published":"2023-11-23"},{"url":"https://hartvaat.nl/2020/10/01/natuurlijk-beloop-van-asymptomatische-ernstige-aortastenose-jama-cardiology-meta/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-ballonexpandeerbare-klep-bij-laagrisicopatienten-nejm-partner-3/","published":"2019-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pil-hyung-lee","type":"person","url":"https://hartvaat.nl/mensen/pil-hyung-lee/","name":"Pil Hyung Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/05/01/angiografie-versus-ivus-voor-des-implantatie-gerandomiseerde-trial/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2020/05/05/des-versus-cabg-bij-linker-hoofdstam-10-jaarsresultaten-excel-extended/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/12/03/klinisch-significante-bloedingen-met-ticagrelor-versus-clopidogrel-bij-koreaanse/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2016/04/19/statinebehandeling-en-plaquesamenstelling-dubbelblinde-gerandomiseerde-studie/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pilar-jimenez-quevedo","type":"person","url":"https://hartvaat.nl/mensen/pilar-jimenez-quevedo/","name":"Pilar Jiménez-Quevedo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/11/25/amphilimus-versus-zotarolimus-eluting-stent-bij-diabetes-en-coronairlijden/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2017/01/15/linker-hartoorsluiting-versus-medicamenteuze-behandeling-bij-af-netwerkmeta-anal/","published":"2017-01-15"},{"url":"https://hartvaat.nl/2016/01/23/everolimus-eluting-stent-versus-bare-metal-stent-bij-stemi-5-jaarsresultaten-exa/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pranas-serpytis","type":"person","url":"https://hartvaat.nl/mensen/pranas-serpytis/","name":"Pranas Serpytis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2016/12/10/omecamtiv-mecarbil-bij-chronisch-hartfalen-lancet-cosmic-hf-fase-2-trial/","published":"2016-12-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prateeti-khazanie","type":"person","url":"https://hartvaat.nl/mensen/prateeti-khazanie/","name":"Prateeti Khazanie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/23/nierbescherming-na-harttransplantatie-risicoreductie-en-therapeutische-mogelijkh/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2024/09/17/2024-acc-aha-kwaliteitsmaatstaven-voor-hartfalen-geactualiseerd/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prof-ganesan-karthikeyan","type":"person","url":"https://hartvaat.nl/mensen/prof-ganesan-karthikeyan/","name":"Prof. Ganesan Karthikeyan","title":"Centre for Chronic Disease Control, India","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":2,"articles":[{"url":"https://hartvaat.nl/2026/05/10/dig-rhd-digoxine-verlaagt-sterfte-en-hartfalen-bij-symptomatische-reumatische-ha/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2022/09/15/invictus-rivaroxaban-versus-warfarine-bij-reumatische-hartziekte-en-af/","published":"2022-09-15"}],"videos":[{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/dig-rhd-digoxine-reumatische-hartziekte/","title":"Dig-RHD: Digoxine bij reumatische hartziekte"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pal-aukrust","type":"person","url":"https://hartvaat.nl/mensen/pal-aukrust/","name":"Pål Aukrust","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/04/20/il-6-receptorremming-bij-acuut-stemi-gerandomiseerde-trial/","published":"2021-04-20"},{"url":"https://hartvaat.nl/2018/12/01/pro-gastrin-releasing-peptide-en-uitkomsten-bij-hf-met-anemie-red-hf/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/06/01/complementactivatie-bij-acuut-hartfalen-na-mi-correlatie-met-ernst/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/10/01/il-6-remming-en-coronaire-microvasculaire-en-endotheelfunctie-bij-myocardinfarct/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/08/07/il-6-receptorantagonist-tocilizumab-bij-nstemi-effect-op-inflammatie-en-troponin/","published":"2016-08-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"qiang-zhao","type":"person","url":"https://hartvaat.nl/mensen/qiang-zhao/","name":"Qiang Zhao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/08/09/ticagrelor-dapt-en-veneuze-graftfalen-na-cabg-systematische-review/","published":"2022-08-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"qing-zhang","type":"person","url":"https://hartvaat.nl/mensen/qing-zhang/","name":"Qing Zhang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/25/explorer-cn-week-78-langetermijneffect-en-veiligheid-van-mavacamten-bij-chinese-/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/01/31/wereldwijde-ziektelast-van-chronische-nierziekte-bij-kinderen-en-adolescenten/","published":"2026-01-31"},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukverlaging-en-retinale-microvasculatuur/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2019/02/01/sms-na-ontslag-verbetert-kortetermijnuitkomsten-en-zelfzorg-bij-chronisch-hf/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2016/04/01/katheterablatie-bij-atriumfibrilleren-met-hypertrofische-cardiomyopathie-meta-an/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"raban-v-jeger","type":"person","url":"https://hartvaat.nl/mensen/raban-v-jeger/","name":"Raban V Jeger","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/05/02/paclitaxel-gecoate-ballonnen-versus-des-bij-kleine-vaten-ipd-meta-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2020/11/07/drug-coated-balloons-versus-des-bij-kleine-coronairarterien-lancet-basket-small-/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/03/10/overleving-na-revascularisatie-met-paclitaxel-gecoate-ballonnen/","published":"2020-03-10"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2018/09/08/drug-coated-balloons-bij-kleine-coronairarterien-lancet-basket-small-2/","published":"2018-09-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rainer-hambrecht","type":"person","url":"https://hartvaat.nl/mensen/rainer-hambrecht/","name":"Rainer Hambrecht","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/09/25/digitoxine-bij-hfref-gerandomiseerde-trial-nejm/","published":"2025-09-25"},{"url":"https://hartvaat.nl/2024/12/16/gp-iib-iiia-remmers-bij-acuut-mi-en-microvasculaire-obstructie-meta-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"},{"url":"https://hartvaat.nl/2017/03/30/ffr-geleide-multivaten-pci-bij-myocardinfarct-nejm-compare-acute/","published":"2017-03-30"},{"url":"https://hartvaat.nl/2017/02/28/hoog-intensieve-intervaltraining-bij-hartfalen-met-verminderde-ejectiefractie/","published":"2017-02-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"raj-verma","type":"person","url":"https://hartvaat.nl/mensen/raj-verma/","name":"Raj Verma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/06/01/igfbp7-en-lv-massaregressie-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/nlr-en-cardiale-remodelling-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/diabetesduur-beinvloedt-lv-massaregressie-met-empagliflozine/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"},{"url":"https://hartvaat.nl/2021/12/01/sglt2-remmers-en-cardiale-remodellering-meta-analyse-van-mri-trials/","published":"2021-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rajibul-mian","type":"person","url":"https://hartvaat.nl/mensen/rajibul-mian/","name":"Rajibul Mian","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/01/27/intracoronair-lage-dosis-rtpa-bij-primaire-pci-voor-stemi-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ralf-e-harskamp","type":"person","url":"https://hartvaat.nl/mensen/ralf-e-harskamp/","name":"Ralf E Harskamp","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/02/08/antitrombotische-therapie-bij-af-na-acs-of-pci-jacc-overzicht/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2020/05/01/optimaal-antitrombotisch-regime-bij-af-na-pci-jama-cardiology-netwerkmeta-analys/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/05/01/predictiemodellen-voor-af-in-de-community-meta-analyse/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/08/01/antitrombotische-strategieen-bij-af-na-pci-jama-cardiology-veiligheids-en-werkza/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/05/01/frequente-premature-atriale-contracties-en-af-hersenischemie-en-mortaliteit-meta/","published":"2019-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"reinhold-kreutz","type":"person","url":"https://hartvaat.nl/mensen/reinhold-kreutz/","name":"Reinhold Kreutz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/27/consensus-breid-het-cardio-renaal-metabool-syndroom-uit-met-de-lever-cklms-in-de/","published":"2026-07-18"},{"url":"https://hartvaat.nl/2025/08/01/ctrh-als-biomarker-voor-medicijneffectiviteit-real-world-bewijs/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2022/09/20/harmonisatie-van-acc-aha-en-esc-esh-bloeddrukrichtlijnen/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2022/08/01/ramipril-bij-hypertensieve-kinderen-op-hemodialyse-search-trial/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/05/05/veroorzaken-betablokkers-depressie-systematische-review-en-meta-analyse/","published":"2021-05-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"reza-jabbari","type":"person","url":"https://hartvaat.nl/mensen/reza-jabbari/","name":"Reza Jabbari","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/07/31/uit-het-hospitaal-hartstilstand-komt-12-keer-vaker-voor-bij-niet-ischemische-car/","published":"2026-08-16"},{"url":"https://hartvaat.nl/2026/02/03/coronaire-vaatspasmen-bij-overlevenden-van-hartstilstand/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","published":"2024-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ricardo-rocha","type":"person","url":"https://hartvaat.nl/mensen/ricardo-rocha/","name":"Ricardo Rocha","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/09/01/arni-naar-hf-voorgeschiedenis-en-raas-antagonistgebruik/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2020/02/01/arni-initiatie-na-acuut-gedecompenseerd-hf-pioneer-hf-open-label-extensie/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/10/21/cv-biomarkers-bij-acuut-gedecompenseerd-hf-met-sacubitril-valsartan-pioneer-hf/","published":"2019-10-21"},{"url":"https://hartvaat.nl/2019/05/07/sacubitril-valsartan-of-enalapril-bij-acuut-gedecompenseerd-hf-pioneer-hf-klinis/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/02/07/angiotensine-neprilysineremming-bij-acuut-gedecompenseerd-hf-nejm-pioneer-hf/","published":"2019-02-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"richard-rokyta","type":"person","url":"https://hartvaat.nl/mensen/richard-rokyta/","name":"Richard Rokyta","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2023/02/07/ecmo-cs-ecmo-bij-cardiogene-shock-verbetert-overleving-niet/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2018/01/30/prasugrel-versus-ticagrelor-bij-primaire-pci-voor-mi-1-jaarsuitkomsten/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2016/11/22/prasugrel-versus-ticagrelor-bij-acuut-mi-met-primaire-pci-multicenter-trial/","published":"2016-11-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"richard-s-geary","type":"person","url":"https://hartvaat.nl/mensen/richard-s-geary/","name":"Richard S Geary","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2020/10/21/vupanorsen-angptl3-antisense-en-triglyceriden-ehj/","published":"2020-10-21"},{"url":"https://hartvaat.nl/2019/09/01/galnac-geconjugeerd-antisense-tegen-apoc3-triglyceriden-en-atherogene-lipoprotei/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/08/08/volanesorsen-en-triglyceriden-bij-familiair-chylomicronemiesyndroom-nejm/","published":"2019-08-08"},{"url":"https://hartvaat.nl/2017/07/20/angptl3-antisense-oligonucleotiden-cardiovasculaire-en-metabole-effecten-nejm/","published":"2017-07-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-d-anderson","type":"person","url":"https://hartvaat.nl/mensen/robert-d-anderson/","name":"Robert D Anderson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/07/14/vroege-versus-late-af-ablatie-impact-op-aritmierecidief/","published":"2023-07-14"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2016/06/11/ixmyelocel-t-bij-ischemisch-hartfalen-lancet-dubbelblinde-gerandomiseerde-trial/","published":"2016-06-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-m-carey","type":"person","url":"https://hartvaat.nl/mensen/robert-m-carey/","name":"Robert M Carey","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/09/20/harmonisatie-van-acc-aha-en-esc-esh-bloeddrukrichtlijnen/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2018/11/01/therapieresistente-hypertensie-aha-scientific-statement-over-detectie-evaluatie-/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/04/01/2017-acc-aha-richtlijn-voor-hoge-bloeddruk-bij-volwassenen-jama-cardiology-overz/","published":"2018-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"roberto-diletti","type":"person","url":"https://hartvaat.nl/mensen/roberto-diletti/","name":"Roberto Diletti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/04/08/biovasc-directe-versus-gestageerde-complete-revascularisatie-bij-acs-met-meervat/","published":"2023-04-08"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2020/12/15/prehospitaal-gemalen-prasugrel-bij-stemi-gerandomiseerde-trial/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/01/29/microvasculaire-schade-bij-gerevasculariseerde-stemi-met-ticagrelor-versus-prasu/","published":"2019-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robin-nijveldt","type":"person","url":"https://hartvaat.nl/mensen/robin-nijveldt/","name":"Robin Nijveldt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2019/08/01/temporele-veranderingen-in-coronaire-hemodynamiek-bij-niet-culprit-vaten-na-stem/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/01/29/microvasculaire-schade-bij-gerevasculariseerde-stemi-met-ticagrelor-versus-prasu/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2016/10/11/pci-van-chronische-totale-occlusie-bij-stemi-met-multivatenlijden-explore-trial/","published":"2016-10-11"},{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","published":"2016-06-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rodney-h-stables","type":"person","url":"https://hartvaat.nl/mensen/rodney-h-stables/","name":"Rodney H Stables","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/08/30/ripcord-2-routinematige-ffr-meting-versus-conventionele-angiografie/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rodney-p-horton","type":"person","url":"https://hartvaat.nl/mensen/rodney-p-horton/","name":"Rodney P Horton","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/03/25/amulet-ide-vijfjaarsresultaten-laa-occlusie-met-amulet/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2024/04/02/amaze-pvi-met-of-zonder-laa-ligatie-bij-af-jama-rct/","published":"2024-04-02"},{"url":"https://hartvaat.nl/2017/12/19/5-jaarsuitkomsten-na-linker-hartoorsluiting-prevail-en-protect-af/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2016/11/01/linker-hartoorisolatie-bij-langdurig-persisterend-af-de-belief-trial/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/26/ablatie-versus-amiodaron-bij-persisterend-af-met-hartfalen-en-icd-gerandomiseerd/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ron-j-g-peters","type":"person","url":"https://hartvaat.nl/mensen/ron-j-g-peters/","name":"Ron J G Peters","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2018/12/01/creatininestijging-tijdens-bloeddrukbehandeling-en-uitkomsten-bij-diabetes-type-/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2016/11/08/residueel-vasculair-risico-bij-secundaire-preventie-verdeling-van-10-jaarsrisico/","published":"2016-11-08"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ross-t-campbell","type":"person","url":"https://hartvaat.nl/mensen/ross-t-campbell/","name":"Ross T Campbell","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2018/10/01/associatie-is-geen-causaliteit-behandeleffecten-bij-hartfalen-en-observationele-/","published":"2018-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ross-t-tsuyuki","type":"person","url":"https://hartvaat.nl/mensen/ross-t-tsuyuki/","name":"Ross T Tsuyuki","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/05/16/afschaffen-eigen-bijdrage-medicatie-vermindert-cardiovasculair-risico-bij-oudere/","published":"2023-05-16"},{"url":"https://hartvaat.nl/2023/05/16/zelfmanagement-via-reclameprincipes-bij-ouderen-met-hoog-cv-risico/","published":"2023-05-16"},{"url":"https://hartvaat.nl/2021/10/01/apothekerzorg-bij-poliklinisch-hf-meta-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2016/06/21/apothekerinterventies-en-cardiovasculair-risico-de-multicenter-rxeach-trial/","published":"2016-06-21"},{"url":"https://hartvaat.nl/2016/03/22/zelfmanagementinterventies-bij-hartfalen-individuele-patientdata-meta-analyse/","published":"2016-03-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ruth-peters","type":"person","url":"https://hartvaat.nl/mensen/ruth-peters/","name":"Ruth Peters","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/03/01/frailteit-en-antihypertensieve-behandeling-bij-ouderen-meta-analyse/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/12/21/bloeddrukverlaging-en-dementiepreventie-ipd-meta-analyse/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2021/11/01/bloeddrukvariabiliteit-en-dementie-cognitieve-stoornis-meta-analyse/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2018/09/01/orthostatische-hypotensie-verhoogt-risico-op-cognitieve-stoornissen/","published":"2018-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"samer-al-said","type":"person","url":"https://hartvaat.nl/mensen/samer-al-said/","name":"Samer Al Said","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/24/systemische-embolieen-bij-af-ipd-mega-meta-analyse-van-71-683-patienten/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2026/01/30/systemische-embolische-events-bij-boezemfibrilleren-een-meta-analyse-op-patientn/","published":"2026-01-30"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/02/11/langetermijn-evolocumab-bij-ouderen-effectiviteit-en-veiligheid/","published":"2025-02-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sandrine-stepien","type":"person","url":"https://hartvaat.nl/mensen/sandrine-stepien/","name":"Sandrine Stepien","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/05/10/sms-voor-medicatietrouw-en-secundaire-preventie-na-acs-textmeds/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","published":"2021-09-16"},{"url":"https://hartvaat.nl/2020/11/01/lage-dosis-triple-combinatie-en-therapeutische-inertie-bij-hypertensie-jama-card/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2019/01/01/polypil-en-cardiovasculaire-preventie-meta-analyse-van-gerandomiseerde-trials/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/08/14/drievoudige-lage-dosis-antihypertensivacombinatie-versus-standaardzorg-jama-gera/","published":"2018-08-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sang-min-kim","type":"person","url":"https://hartvaat.nl/mensen/sang-min-kim/","name":"Sang Min Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/01/intravasculaire-beeldvorming-superieur-aan-angiografie-bij-complexe-pci-5-jaarsr/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sang-hyup-lee","type":"person","url":"https://hartvaat.nl/mensen/sang-hyup-lee/","name":"Sang-Hyup Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","published":"2023-04-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sanobar-parkar","type":"person","url":"https://hartvaat.nl/mensen/sanobar-parkar/","name":"Sanobar Parkar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"},{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","published":"2025-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"satoshi-yasuda","type":"person","url":"https://hartvaat.nl/mensen/satoshi-yasuda/","name":"Satoshi Yasuda","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2024/01/30/edoxaban-versus-warfarine-bij-chronische-trombo-embolische-pulmonale-hypertensie/","published":"2024-01-30"},{"url":"https://hartvaat.nl/2022/08/01/rivaroxaban-monotherapie-versus-combinatie-met-plaatjesremmers-bij-af-en-coronai/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/11/01/aspirine-versus-p2y12-remmer-met-antistolling-bij-af/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2019/09/19/antitrombotische-therapie-bij-af-met-stabiel-coronairlijden-nejm-afire/","published":"2019-09-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"saurabh-kumar","type":"person","url":"https://hartvaat.nl/mensen/saurabh-kumar/","name":"Saurabh Kumar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/06/laminopathieen-natuurlijk-beloop-en-voorspelmodel-voor-hartfalen/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2021/07/18/procedurevolume-en-complicaties-bij-af-ablatie-meta-analyse/","published":"2021-07-18"},{"url":"https://hartvaat.nl/2019/02/01/contact-force-sensing-en-veiligheid-werkzaamheid-van-af-ablatie-geactualiseerde-/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/10/01/ononderbroken-doac-versus-vka-bij-af-ablatie-meta-analyse/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/08/01/linker-hartoorisolatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"scott-l-hummel","type":"person","url":"https://hartvaat.nl/mensen/scott-l-hummel/","name":"Scott L Hummel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/12/01/splanchnische-zenuwablatie-bij-hfpef-endovasculaire-benadering/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2018/10/01/transcatheter-interatriale-shunt-bij-hfpef-1-jaarsresultaten/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/01/23/transcatheter-interatriale-shunt-bij-hfpef-reduce-lap-hf-i/","published":"2018-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"scott-m-grundy","type":"person","url":"https://hartvaat.nl/mensen/scott-m-grundy/","name":"Scott M Grundy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2016/09/27/ldl-c-verlaging-en-cardiovasculaire-risicoreductie-jama-systematische-review-en-/","published":"2016-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"seokhun-yang","type":"person","url":"https://hartvaat.nl/mensen/seokhun-yang/","name":"Seokhun Yang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/04/26/angiografie-afgeleide-ffr-versus-ivus-bij-pci-gerandomiseerde-trial/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/10/17/antiplaatjesmonotherapie-na-pci-clopidogrel-versus-aspirine-naar-risicoprofiel/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/05/02/korte-versus-standaard-dapt-na-pci-met-moderne-des-meta-analyse/","published":"2023-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sergey-tereshchenko","type":"person","url":"https://hartvaat.nl/mensen/sergey-tereshchenko/","name":"Sergey Tereshchenko","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sergio-raposeiras-roubin","type":"person","url":"https://hartvaat.nl/mensen/sergio-raposeiras-roubin/","name":"Sergio Raposeiras-Roubín","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/11/reboot-betablokkers-na-mi-sekseverschillen/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2026/01/20/es-bempedacs-triple-versus-duale-lipidenbehandeling-na-acs/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","published":"2025-09-13"},{"url":"https://hartvaat.nl/2025/04/10/dapagliflozine-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2025-04-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"seung-hyuk-choi","type":"person","url":"https://hartvaat.nl/mensen/seung-hyuk-choi/","name":"Seung-Hyuk Choi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shachi-patel","type":"person","url":"https://hartvaat.nl/mensen/shachi-patel/","name":"Shachi Patel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/06/01/nierfunctie-en-dapagliflozine-effect-op-gezondheidsstatus-define-hf/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","published":"2025-03-18"},{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","published":"2024-08-27"},{"url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-07-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shangyu-wen","type":"person","url":"https://hartvaat.nl/mensen/shangyu-wen/","name":"Shangyu Wen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/01/07/dcb-voor-zijtak-bij-provisionale-stenting-gerandomiseerde-trial/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shingo-matsumoto","type":"person","url":"https://hartvaat.nl/mensen/shingo-matsumoto/","name":"Shingo Matsumoto","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/06/18/mra-bij-hartfalen-met-nierfunctiestoornissen-veiligheid-en-effectiviteit/","published":"2024-06-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shuting-xia","type":"person","url":"https://hartvaat.nl/mensen/shuting-xia/","name":"Shuting Xia","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-familiaire-chylomicronemie-nejm-fase-3/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2022/03/22/pelacarsen-op-lp-a-cholesterol-en-gecorrigeerd-ldl-cholesterol/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2020/01/16/lp-a-verlaging-bij-cardiovasculaire-ziekte-nejm/","published":"2020-01-16"},{"url":"https://hartvaat.nl/2019/09/01/galnac-geconjugeerd-antisense-tegen-apoc3-triglyceriden-en-atherogene-lipoprotei/","published":"2019-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sidney-a-cohen","type":"person","url":"https://hartvaat.nl/mensen/sidney-a-cohen/","name":"Sidney A Cohen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","published":"2021-06-15"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2018/10/09/24-uurs-ambulante-bloeddrukreductie-na-renale-denervatie-spyral-htn-off-med/","published":"2018-10-09"},{"url":"https://hartvaat.nl/2018/06/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-6-maandsresultat/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sigrid-sandner","type":"person","url":"https://hartvaat.nl/mensen/sigrid-sandner/","name":"Sigrid Sandner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/13/aha-scientific-statement-2026-secundaire-preventie-na-coronaire-bypassoperatie-e/","published":"2026-05-15"},{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2022/08/09/ticagrelor-dapt-en-veneuze-graftfalen-na-cabg-systematische-review/","published":"2022-08-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stacey-l-schott","type":"person","url":"https://hartvaat.nl/mensen/stacey-l-schott/","name":"Stacey L Schott","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steen-husted","type":"person","url":"https://hartvaat.nl/mensen/steen-husted/","name":"Steen Husted","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","published":"2017-05-06"},{"url":"https://hartvaat.nl/2016/12/22/preventie-van-bloedingen-bij-af-patienten-die-pci-ondergaan-nejm-pioneer-af-pci/","published":"2016-12-22"},{"url":"https://hartvaat.nl/2016/10/15/vroeg-invasief-versus-conservatief-bij-nste-acs-15-jaarsfollow-up-frisc-ii/","published":"2016-10-15"},{"url":"https://hartvaat.nl/2016/04/21/gdf-15-voorspelt-bloedingen-en-cardiovasculaire-events-bij-acuut-coronair-syndro/","published":"2016-04-21"},{"url":"https://hartvaat.nl/2016/04/01/veiligheid-en-werkzaamheid-van-ticagrelor-versus-clopidogrel-bij-primaire-pci-vo/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steen-z-abildstrm","type":"person","url":"https://hartvaat.nl/mensen/steen-z-abildstrm/","name":"Steen Z Abildstrøm","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefan-agewall","type":"person","url":"https://hartvaat.nl/mensen/stefan-agewall/","name":"Stefan Agewall","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2018/01/07/2017-esc-richtlijn-voor-stemi-management/","published":"2018-01-07"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/08/01/2016-europese-richtlijnen-voor-cardiovasculaire-preventie-in-de-klinische-prakti/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefan-toggweiler","type":"person","url":"https://hartvaat.nl/mensen/stefan-toggweiler/","name":"Stefan Toggweiler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/05/21/1-op-10-patienten-heroptname-binnen-30-dagen-na-tavi-sterfterisico-na-1-jaar-ver/","published":"2026-06-09"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephane-fournier","type":"person","url":"https://hartvaat.nl/mensen/stephane-fournier/","name":"Stephane Fournier","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2019/09/24/asymptomatische-patienten-met-abnormale-ffr-medicamenteus-versus-pci/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2019/04/01/ffr-verbetering-na-pci-en-uitkomsten-inclusief-symptoomverlichting/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2018/10/16/hoge-coronaire-shear-stress-voorspelt-myocardinfarct/","published":"2018-10-16"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephanie-brunner","type":"person","url":"https://hartvaat.nl/mensen/stephanie-brunner/","name":"Stephanie Brunner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/05/21/1-op-10-patienten-heroptname-binnen-30-dagen-na-tavi-sterfterisico-na-1-jaar-ver/","published":"2026-06-09"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephen-quinn","type":"person","url":"https://hartvaat.nl/mensen/stephen-quinn/","name":"Stephen Quinn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/11/09/colchicine-na-acs-2-jaars-cops-follow-up/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2021/07/13/late-rapid-tnt-uitkomsten-0-1-uur-hs-troponine-t-bij-verdenking-acs/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/03/01/objectieve-risicobeoordeling-versus-standaardzorg-bij-acs-jama-cardiology/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2020/11/17/colchicine-bij-acs-australische-cops-gerandomiseerde-trial/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2019/11/05/1-uur-troponine-t-protocol-bij-verdenking-acs-gerandomiseerde-rapid-tnt-trial/","published":"2019-11-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steve-e-humphries","type":"person","url":"https://hartvaat.nl/mensen/steve-e-humphries/","name":"Steve E Humphries","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/08/01/verhoogde-lp-a-komt-vaker-voor-bij-kinderen-met-familiaire-hypercholesterolemie-/","published":"2026-08-02"},{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/25/eas-consensus-familiaire-hypercholesterolemie-bij-kinderen-en-adolescenten/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/05/25/verve-102-eenmalige-base-editing-schakelt-pcsk9-blijvend-uit-fase-1/","published":"2026-05-25"},{"url":"https://hartvaat.nl/2018/01/01/genetische-associatie-van-lipiden-en-lipide-doelwitten-met-abdominaal-aorta-aneu/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steven-j-keteyian","type":"person","url":"https://hartvaat.nl/mensen/steven-j-keteyian/","name":"Steven J Keteyian","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/10/01/heart-camp-connect-beweegadherentie-bij-hfpef-patienten/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2023/04/18/aha-scientific-statement-gestructureerde-inspanningstraining-bij-hfpef/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2019/04/02/inspanningsrevalidatie-bij-hf-ipd-meta-analyse-van-inspanningscapaciteit-en-qol/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2017/04/04/inspanningstraining-bij-chronisch-hartfalen-met-atriumfibrilleren/","published":"2017-04-04"},{"url":"https://hartvaat.nl/2016/02/23/inspanningstestvariabelen-als-mortaliteitsvoorspellers-bij-chronisch-systolisch-/","published":"2016-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steven-m-hollenberg","type":"person","url":"https://hartvaat.nl/mensen/steven-m-hollenberg/","name":"Steven M Hollenberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/09/24/2024-acc-beslispad-klinische-beoordeling-en-trajectmanagement-bij-hfpef/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stuart-watkins","type":"person","url":"https://hartvaat.nl/mensen/stuart-watkins/","name":"Stuart Watkins","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2022/08/30/ripcord-2-routinematige-ffr-meting-versus-conventionele-angiografie/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2021/12/01/post-stenting-ffr-versus-angiografie-voor-pci-optimalisatie-target-ffr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/05/01/pci-versus-medicamenteus-bij-angina-met-ffr-in-de-grijze-zone/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"subhash-banerjee","type":"person","url":"https://hartvaat.nl/mensen/subhash-banerjee/","name":"Subhash Banerjee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/08/21/lipidparadox-bij-kanker-ldl-c-dekt-de-lading-niet-voor-cardiovasculair-risico/","published":"2026-08-30"},{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2021/10/12/overbrugging-van-antiplaatjestherapie-na-pci-jacc-review/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2018/05/19/des-versus-bms-in-veneuze-bypass-grafts-lancet-dubbelblinde-trial/","published":"2018-05-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"svend-aakhus","type":"person","url":"https://hartvaat.nl/mensen/svend-aakhus/","name":"Svend Aakhus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/04/20/il-6-receptorremming-bij-acuut-stemi-gerandomiseerde-trial/","published":"2021-04-20"},{"url":"https://hartvaat.nl/2017/10/01/il-6-remming-en-coronaire-microvasculaire-en-endotheelfunctie-bij-myocardinfarct/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/08/01/nauwkeurigheid-van-manchetbloeddrukmeting-systematische-review-en-meta-analyse/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/08/07/il-6-receptorantagonist-tocilizumab-bij-nstemi-effect-op-inflammatie-en-troponin/","published":"2016-08-07"},{"url":"https://hartvaat.nl/2016/03/12/invasieve-versus-conservatieve-strategie-bij-80-plussers-met-nstemi-gerandomisee/","published":"2016-03-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sverre-e-kjeldsen","type":"person","url":"https://hartvaat.nl/mensen/sverre-e-kjeldsen/","name":"Sverre E Kjeldsen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/25/bloeddrukverlaging-beschermt-over-het-hele-spectrum-van-chronische-nierschade-la/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2024/07/01/value-trial-cv-uitkomsten-bij-hypertensie-met-perifeer-vaatlijden/","published":"2024-07-01"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2020/06/01/arb-versus-calciumantagonist-bloeddrukprofiel-en-klinische-effecten-vergelijking/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2016/03/21/cardiovasculaire-uitkomsten-bij-verschillende-bereiktestreefdrukken-in-de-value-/","published":"2016-03-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"takayoshi-ohkubo","type":"person","url":"https://hartvaat.nl/mensen/takayoshi-ohkubo/","name":"Takayoshi Ohkubo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/10/01/esh-convenant-polshorloges-bloeddrukmeters-acceptabele-nauwkeurigheid-maar-klini/","published":"2026-09-02"},{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2019/01/01/levenslangrisico-op-cva-en-coronairlijden-naar-bloeddrukniveau-epoch-japan/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/06/01/interarmbloeddrukverschil-en-beroerte-ipd-meta-analyse/","published":"2018-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tatsuhiko-otsuka","type":"person","url":"https://hartvaat.nl/mensen/tatsuhiko-otsuka/","name":"Tatsuhiko Otsuka","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","published":"2026-04-09"},{"url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neoatherosclerose-na-stemi-secundaire-analyse/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/08/01/biodegradeerbare-versus-duurzame-polymeer-ees-langetermijn-neoatherosclerose/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-idorn","type":"person","url":"https://hartvaat.nl/mensen/thomas-idorn/","name":"Thomas Idorn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","published":"2025-03-24"},{"url":"https://hartvaat.nl/2024/10/22/flow-semaglutide-vermindert-hartfalen-bij-diabetes-en-ckd/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/07/11/flow-semaglutide-beschermt-nieren-bij-type-2-diabetes-en-ckd-nejm-gerelateerd/","published":"2024-07-11"},{"url":"https://hartvaat.nl/2019/12/01/eerste-en-recidiverende-cv-events-met-liraglutide-bij-diabetes-type-2-leader/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2018/12/18/liraglutide-bij-diabetes-type-2-met-ckd-leader-renale-analyse/","published":"2018-12-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-viethen","type":"person","url":"https://hartvaat.nl/mensen/thomas-viethen/","name":"Thomas Viethen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2022/04/09/asundexian-factor-xia-remmer-versus-apixaban-bij-af-lancet-pacific-af/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2019/06/04/neladenoson-bialanaat-en-inspanningscapaciteit-bij-hfpef-jama-panache/","published":"2019-06-04"},{"url":"https://hartvaat.nl/2017/04/01/oscillerende-whole-body-vibratie-verbetert-inspanningscapaciteit-bij-pah/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thor-ueland","type":"person","url":"https://hartvaat.nl/mensen/thor-ueland/","name":"Thor Ueland","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/04/20/il-6-receptorremming-bij-acuut-stemi-gerandomiseerde-trial/","published":"2021-04-20"},{"url":"https://hartvaat.nl/2018/12/01/pro-gastrin-releasing-peptide-en-uitkomsten-bij-hf-met-anemie-red-hf/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/01/16/hoog-sensitief-troponine-t-bij-chronisch-hartfalen-individuele-patientdata-meta-/","published":"2018-01-16"},{"url":"https://hartvaat.nl/2017/10/01/il-6-remming-en-coronaire-microvasculaire-en-endotheelfunctie-bij-myocardinfarct/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/08/07/il-6-receptorantagonist-tocilizumab-bij-nstemi-effect-op-inflammatie-en-troponin/","published":"2016-08-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tim-s-nawrot","type":"person","url":"https://hartvaat.nl/mensen/tim-s-nawrot/","name":"Tim S Nawrot","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tim-usherwood","type":"person","url":"https://hartvaat.nl/mensen/tim-usherwood/","name":"Tim Usherwood","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","published":"2021-09-18"},{"url":"https://hartvaat.nl/2019/01/01/polypil-en-cardiovasculaire-preventie-meta-analyse-van-gerandomiseerde-trials/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","published":"2017-03-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tiziano-moccetti","type":"person","url":"https://hartvaat.nl/mensen/tiziano-moccetti/","name":"Tiziano Moccetti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2021/11/01/antiplaatjestherapie-bij-mi-zonder-obstructief-coronairlijden-minoca/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2020/05/26/subcutaan-selatogrel-remt-plaatjesaggregatie-bij-acuut-mi/","published":"2020-05-26"},{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tobias-graf","type":"person","url":"https://hartvaat.nl/mensen/tobias-graf/","name":"Tobias Graf","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2020/04/21/morfine-met-metoclopramide-en-ticagrelor-plaatjesremming-bij-acuut-mi/","published":"2020-04-21"},{"url":"https://hartvaat.nl/2016/06/28/escitalopram-bij-hartfalen-en-depressie-de-mood-hf-trial/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tomas-jernberg","type":"person","url":"https://hartvaat.nl/mensen/tomas-jernberg/","name":"Tomas Jernberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/10/07/help-mi-helicobacter-pylori-screening-na-acuut-mi-cluster-rct/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2024/04/18/abyss-betablokkers-na-mi-met-behouden-ef-niet-nodig-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2018/12/11/langetermijneffecten-van-zuurstof-op-sterfte-of-hf-hospitalisatie-na-verdenking-/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/08/01/zuurstoftherapie-bij-stemi-overzichtsartikel/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/09/28/zuurstoftherapie-bij-vermoedelijk-acuut-myocardinfarct-nejm-deto2x-ami/","published":"2017-09-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tomasz-j-guzik","type":"person","url":"https://hartvaat.nl/mensen/tomasz-j-guzik/","name":"Tomasz J Guzik","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/24/parodontale-behandeling-remt-progressie-van-atherosclerose/","published":"2026-04-01"},{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2020/02/01/il-1-remming-en-bloeddruk-hypertensie-en-residueel-inflammatoir-risico-cantos/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/11/01/causaal-verband-periodontitis-en-hypertensie-mendeliaanse-randomisatie-en-rct/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"torsten-doenst","type":"person","url":"https://hartvaat.nl/mensen/torsten-doenst/","name":"Torsten Doenst","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2018/11/01/ct-coronairangiografie-voor-heart-team-besluitvorming-bij-multivatenlijden/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2016/11/01/tienjaarsuitkomsten-na-cabg-naar-leeftijd-bij-hartfalen-met-lv-systolische-disfu/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/21/coronaire-bypasschirurgie-bij-ischemische-cardiomyopathie-nejm-stich-trial/","published":"2016-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"toshiaki-ohkuma","type":"person","url":"https://hartvaat.nl/mensen/toshiaki-ohkuma/","name":"Toshiaki Ohkuma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/10/01/thuismonitoring-met-technologie-ondersteund-management-bij-chronisch-hf-gerandom/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/06/01/bloeddrukverlaging-naar-uitgangsdruk-en-cv-risico-bij-diabetes-type-2/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/01/01/acute-creatininestijging-bij-start-ace-remmer-en-effecten-van-voortzetting-analy/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/06/01/interarmbloeddrukverschil-en-beroerte-ipd-meta-analyse/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/08/01/bloeddrukvariabiliteit-en-vasculaire-events-bij-diabetes-type-2/","published":"2017-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"toshiki-kuno","type":"person","url":"https://hartvaat.nl/mensen/toshiki-kuno/","name":"Toshiki Kuno","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/08/14/vereenvoudigd-crt-systeem-zonder-atriale-pacing-niet-slechter-dan-conventioneel-/","published":"2026-08-21"},{"url":"https://hartvaat.nl/2025/01/07/optimale-strategie-voor-complete-revascularisatie-bij-stemi-met-meervatslijden-m/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2023/12/05/intravasculaire-beeldvorming-versus-functionele-versus-angiografische-pci-begele/","published":"2023-12-05"},{"url":"https://hartvaat.nl/2021/08/24/de-escalatie-van-dapt-bij-acs-jacc-review/","published":"2021-08-24"},{"url":"https://hartvaat.nl/2020/01/28/orale-antistolling-bij-af-op-langdurige-hemodialyse/","published":"2020-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"toyoaki-murohara","type":"person","url":"https://hartvaat.nl/mensen/toyoaki-murohara/","name":"Toyoaki Murohara","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/08/06/racing-subanalyse-matige-statine-plus-ezetimibe-voor-secundaire-preventie/","published":"2024-08-06"},{"url":"https://hartvaat.nl/2024/01/30/edoxaban-versus-warfarine-bij-chronische-trombo-embolische-pulmonale-hypertensie/","published":"2024-01-30"},{"url":"https://hartvaat.nl/2020/08/01/canagliflozine-bij-diabetes-type-2-met-chronisch-hf-candle-gerandomiseerde-trial/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2019/10/01/neuromusculaire-elektrische-stimulatie-bij-acuut-hartfalen-haalbaarheid/","published":"2019-10-01"},{"url":"https://hartvaat.nl/2019/04/01/periprocedurele-antistolling-en-silent-stroke-na-af-ablatie/","published":"2019-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tumaini-rucker-coker","type":"person","url":"https://hartvaat.nl/mensen/tumaini-rucker-coker/","name":"Tumaini Rucker Coker","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tze-fan-chao","type":"person","url":"https://hartvaat.nl/mensen/tze-fan-chao/","name":"Tze-Fan Chao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/03/lichamelijke-activiteit-en-risico-op-complicaties-bij-atriumfibrilleren/","published":"2026-03-06"},{"url":"https://hartvaat.nl/2026/02/19/cardiovasculair-renaal-metabool-samenspel-bij-patienten-met-atriumfibrilleren/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2023/10/05/rivaroxaban-dosering-bij-af-on-label-versus-off-label-in-azie-en-niet-azie/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2019/05/14/edoxaban-bij-aziatische-af-patienten-concentraties-en-anti-xa-activiteit/","published":"2019-05-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"udo-hoffmann","type":"person","url":"https://hartvaat.nl/mensen/udo-hoffmann/","name":"Udo Hoffmann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/08/24/reprieve-pitavastatine-vermindert-cv-events-bij-hiv-nejm/","published":"2023-08-24"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2019/03/05/inspanningstest-versus-ccta-bij-diabetes-met-verdenking-coronairlijden/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2017/11/21/coronair-calcium-en-prognostische-waarde-bij-pijn-op-de-borst-promise-studie/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2016/08/02/omega-3-vetzuren-en-linkerkamerremodellering-na-acuut-mi-omega-remodel-trial/","published":"2016-08-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ulrik-m-mogensen","type":"person","url":"https://hartvaat.nl/mensen/ulrik-m-mogensen/","name":"Ulrik M Mogensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/01/08/hfref-differentiele-impact-op-mannen-en-vrouwen/","published":"2019-01-08"},{"url":"https://hartvaat.nl/2017/11/14/af-type-en-uitkomsten-bij-hfref/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/02/21/diabetesstatus-en-cardiovasculaire-uitkomsten-bij-hfpef-klinische-en-echocardiog/","published":"2017-02-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"umjeet-jolly","type":"person","url":"https://hartvaat.nl/mensen/umjeet-jolly/","name":"Umjeet Jolly","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/02/20/vanish2-catheterablatie-versus-antiaritmica-bij-ventriculaire-tachycardie-nejm/","published":"2025-02-20"},{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ung-kim","type":"person","url":"https://hartvaat.nl/mensen/ung-kim/","name":"Ung Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/05/01/aspirine-versus-clopidogrel-na-coronaire-stenting-naar-bloedingsrisico-en-comple/","published":"2025-05-01"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","published":"2022-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vanessa-debruin","type":"person","url":"https://hartvaat.nl/mensen/vanessa-debruin/","name":"Vanessa DeBruin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2022/10/22/symplicity-htn-3-langetermijn-follow-up-renale-denervatie-bij-resistente-hyperte/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2022/07/01/pulsatiele-hemodynamiek-voorspelt-bloeddrukrespons-op-renale-denervatie/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vanja-vlajnic","type":"person","url":"https://hartvaat.nl/mensen/vanja-vlajnic/","name":"Vanja Vlajnic","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","published":"2020-10-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"victoria-y-ding","type":"person","url":"https://hartvaat.nl/mensen/victoria-y-ding/","name":"Victoria Y Ding","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/06/01/ffr-geleide-pci-versus-cabg-bij-diffuus-coronairlijden/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vivekanand-jha","type":"person","url":"https://hartvaat.nl/mensen/vivekanand-jha/","name":"Vivekanand Jha","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/18/groene-dialyse-duurzame-zorg-groei-en-innovatie-kdigo-conferentie/","published":"2026-02-18"},{"url":"https://hartvaat.nl/2025/08/16/achieve-spironolacton-bij-dialysepatienten-internationale-rct/","published":"2025-08-16"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-niet-dialysepatienten-nejm/","published":"2021-12-16"},{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-dialysepatienten-nejm/","published":"2021-12-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"volker-rudolph","type":"person","url":"https://hartvaat.nl/mensen/volker-rudolph/","name":"Volker Rudolph","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/10/12/castle-htx-af-ablatie-bij-eindstadium-hartfalen-nejm/","published":"2023-10-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wendy-c-taddei-peters","type":"person","url":"https://hartvaat.nl/mensen/wendy-c-taddei-peters/","name":"Wendy C Taddei-Peters","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wilbert-s-aronow","type":"person","url":"https://hartvaat.nl/mensen/wilbert-s-aronow/","name":"Wilbert S Aronow","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2020/03/01/gewicht-en-werkzaamheid-veiligheid-van-doac-s-bij-niet-valvulair-af-meta-analyse/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/09/01/oac-bij-af-met-kleplijden-en-bioprothese-overzicht/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2017/07/01/bioresorbeerbare-scaffold-versus-des-2-jaars-meta-analyse/","published":"2017-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wilhelm-ridderstrale","type":"person","url":"https://hartvaat.nl/mensen/wilhelm-ridderstrale/","name":"Wilhelm Ridderstråle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/01/dapagliflozine-na-mi-naar-ef-cardiometabole-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","published":"2024-04-30"},{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"willem-j-m-dewilde","type":"person","url":"https://hartvaat.nl/mensen/willem-j-m-dewilde/","name":"Willem J M Dewilde","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2019/10/24/genotype-geleide-p2y12-remmerkeuze-bij-primaire-pci-nejm-popular-genetics/","published":"2019-10-24"},{"url":"https://hartvaat.nl/2018/03/13/doac-s-bij-af-met-ckd-systematische-review-werkzaamheid-en-veiligheid/","published":"2018-03-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"william-d-toff","type":"person","url":"https://hartvaat.nl/mensen/william-d-toff/","name":"William D Toff","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/14/katheterablatie-versus-thoracoscopische-ablatie-bij-langdurig-persisterend-af-ca/","published":"2020-12-14"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"william-j-sasiela","type":"person","url":"https://hartvaat.nl/mensen/william-j-sasiela/","name":"William J Sasiela","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/07/09/bempedoinezuur-versus-statines-vergelijking-van-cv-voordelen/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2019/08/06/angptl3-remming-met-monoklonaal-antilichaam-verlaagt-triglyceriden/","published":"2019-08-06"},{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","published":"2018-11-29"},{"url":"https://hartvaat.nl/2017/07/20/genetische-en-farmacologische-inactivatie-van-angptl3-en-cardiovasculaire-ziekte/","published":"2017-07-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"william-s-weintraub","type":"person","url":"https://hartvaat.nl/mensen/william-s-weintraub/","name":"William S Weintraub","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/29/nla-consensusupdate-familiaire-hypercholesterolemie-screening-diagnostiek-en-beh/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2021/04/27/patientselectie-voor-intensieve-bloeddrukbehandeling-naar-voordeel-en-bijwerking/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2021/04/27/2021-acc-aha-kerngegevenselementen-voor-hartfalen/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2019/04/30/leefstijl-hba1c-en-overleving-bij-stabiel-coronairlijden-met-diabetes/","published":"2019-04-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wolfgang-c-winkelmayer","type":"person","url":"https://hartvaat.nl/mensen/wolfgang-c-winkelmayer/","name":"Wolfgang C Winkelmayer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/01/dialysaat-kalium-3-0-mmol-l-met-natriumzirconiumcyclosilicaat-bij-dialyse/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2022/12/06/apixaban-bij-af-op-hemodialyse-eerste-gerandomiseerde-trial/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2020/05/01/bloeddruk-en-volumemanagement-bij-dialyse-kdigo-controverseconferentie/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2016/08/01/cabg-versus-pci-en-risico-op-myocardinfarct-en-revascularisatie-bij-ckd-patiente/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/03/29/drug-eluting-versus-bare-metal-stents-bij-pci-patienten-met-eindstadium-nierziek/","published":"2016-03-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"won-jang-kim","type":"person","url":"https://hartvaat.nl/mensen/won-jang-kim/","name":"Won-Jang Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","published":"2024-05-04"},{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","published":"2022-09-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yanqing-wu","type":"person","url":"https://hartvaat.nl/mensen/yanqing-wu/","name":"Yanqing Wu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2026/01/01/sophocarpine-beschermt-tegen-pulmonale-hypertensie-in-preklinische-modellen/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2024/11/12/recaticimab-monotherapie-bij-niet-familiaire-hypercholesterolemie-fase-3-remain-/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2022/11/26/bivalirudine-versus-heparine-bij-primaire-pci-voor-stemi-lancet-trial/","published":"2022-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yasushi-ueki","type":"person","url":"https://hartvaat.nl/mensen/yasushi-ueki/","name":"Yasushi Ueki","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","published":"2026-04-09"},{"url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neoatherosclerose-na-stemi-secundaire-analyse/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/08/01/biodegradeerbare-versus-duurzame-polymeer-ees-langetermijn-neoatherosclerose/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yi-liu","type":"person","url":"https://hartvaat.nl/mensen/yi-liu/","name":"Yi Liu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/01/01/varenicline-vermindert-ventriculaire-ectopie-na-myocardinfarct/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2026/01/01/effect-van-finerenon-op-de-nierfunctie-bij-diabetische-nefropathie-type-2/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/07/01/interact3-bundeled-care-bij-acute-intracerebrale-bloeding-lancet/","published":"2023-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yingxian-sun","type":"person","url":"https://hartvaat.nl/mensen/yingxian-sun/","name":"Yingxian Sun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2024/09/01/multifactorieel-intensief-bloeddrukmodel-bij-ouderen-en-jongeren/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/03/18/intensieve-bloeddrukinterventie-door-niet-artsen-in-lage-inkomenslanden-lancet-r/","published":"2023-03-18"},{"url":"https://hartvaat.nl/2022/10/01/financiele-prikkels-verbeteren-hypertensiecontrole-chinese-rct/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2022/05/21/dorpsarts-geleide-multifacet-interventie-voor-bloeddrukcontrole-in-ruraal-china-/","published":"2022-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yingying-sang","type":"person","url":"https://hartvaat.nl/mensen/yingying-sang/","name":"Yingying Sang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2021/09/01/albuminurietesting-bij-hypertensie-en-diabetes-ipd-meta-analyse/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2017/01/03/traditionele-cv-risicofactoren-en-veneuze-trombo-embolie-individuele-patientdata/","published":"2017-01-03"},{"url":"https://hartvaat.nl/2016/02/04/risicoprojectie-voor-nierfalen-bij-levende-nierdonorkandidaten/","published":"2016-02-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yiwei-lai","type":"person","url":"https://hartvaat.nl/mensen/yiwei-lai/","name":"Yiwei Lai","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","published":"2022-10-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yoshifumi-naka","type":"person","url":"https://hartvaat.nl/mensen/yoshifumi-naka/","name":"Yoshifumi Naka","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2022/09/27/momentum-3-vijfjaarsresultaten-heartmate-3-versus-axiale-lvad/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2020/04/01/lvad-gebruik-als-bridge-to-transplant-versus-destination-therapy-momentum-3/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","published":"2017-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yoshihiro-morino","type":"person","url":"https://hartvaat.nl/mensen/yoshihiro-morino/","name":"Yoshihiro Morino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2017/11/07/optische-frequentiedomeinbeeldvorming-versus-ivus-bij-pci-opinion-trial/","published":"2017-11-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"youngkeun-ahn","type":"person","url":"https://hartvaat.nl/mensen/youngkeun-ahn/","name":"Youngkeun Ahn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/09/06/directe-versus-gestageerde-complete-revascularisatie-tijdens-index-opname-bij-st/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2023/11/14/early-unload-vroege-lv-ontlading-bij-va-ecmo-gerandomiseerde-trial/","published":"2023-11-14"},{"url":"https://hartvaat.nl/2021/10/09/ongeleide-de-escalatie-van-ticagrelor-naar-clopidogrel-na-mi-met-pci-lancet-talo/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2018/07/24/escitalopram-versus-placebo-bij-depressie-na-acs-en-langetermijn-cardiale-uitkom/","published":"2018-07-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yuhei-kobayashi","type":"person","url":"https://hartvaat.nl/mensen/yuhei-kobayashi/","name":"Yuhei Kobayashi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2019/09/24/asymptomatische-patienten-met-abnormale-ffr-medicamenteus-versus-pci/","published":"2019-09-24"},{"url":"https://hartvaat.nl/2016/04/12/prognostische-waarde-van-residuele-coronairstenosen-na-functioneel-complete-reva/","published":"2016-04-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yuichiro-yano","type":"person","url":"https://hartvaat.nl/mensen/yuichiro-yano/","name":"Yuichiro Yano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/02/01/reactie-op-kanttekeningen-bij-statistiek-van-orale-microbioomdiversiteit-en-mort/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2022/11/01/checkpoint-remmers-verhogen-korttermijnrisico-op-hypertensie-niet-meta-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/11/01/bloeddrukvariabiliteit-en-dementie-cognitieve-stoornis-meta-analyse/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2021/07/27/heeft-deze-volwassene-hypertensie-jama-rational-clinical-examination/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2017/02/01/bereikte-bloeddruk-en-cardiovasculaire-uitkomsten-bij-oudere-patienten-met-geiso/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yukio-ozaki","type":"person","url":"https://hartvaat.nl/mensen/yukio-ozaki/","name":"Yukio Ozaki","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/08/06/racing-subanalyse-matige-statine-plus-ezetimibe-voor-secundaire-preventie/","published":"2024-08-06"},{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","published":"2022-09-27"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","published":"2021-10-28"},{"url":"https://hartvaat.nl/2018/05/08/hoog-versus-laaggedoseerd-pitavastatine-bij-stabiel-coronairlijden-real-cad/","published":"2018-05-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zbigniew-kalarus","type":"person","url":"https://hartvaat.nl/mensen/zbigniew-kalarus/","name":"Zbigniew Kalarus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/05/19/salamander-register-95-5-technisch-succes-bij-stand-alone-linker-hartoor-occlusi/","published":"2026-06-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2021/04/01/telereh-hf-etiologie-subanalyse-van-telerevalidatie-bij-hartfalen/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/05/01/remote-monitoring-vermindert-hospitalisaties-bij-icd-patienten-result-studie/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/03/01/hybride-telerevalidatie-bij-hartfalen-jama-cardiology-tele-hf-trial/","published":"2020-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zhao","type":"person","url":"https://hartvaat.nl/mensen/zhao/","name":"Zhao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/04/10/proteomics-onthult-vier-subgroepen-van-acuut-hfpef-met-eigen-biologische-routes-/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/04/17/verhoogd-crp-voorspelt-hartfalen-bij-kankeroverlevenden-uk-biobank/","published":"2026-07-21"},{"url":"https://hartvaat.nl/2026/04/24/astma-geassocieerd-met-verhoogd-risico-op-degeneratieve-hartklepziekte-uk-bioban/","published":"2026-05-11"},{"url":"https://hartvaat.nl/2026/02/26/hiv-infectie-hangt-onafhankelijk-samen-met-meer-en-kwetsbaardere-halsslagaderpla/","published":"2026-02-26"},{"url":"https://hartvaat.nl/2026/01/09/littekenweefsel-voorspelt-plotse-hartdood-na-een-infarct-grotendeels-buiten-de-e/","published":"2026-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zhifang-wang","type":"person","url":"https://hartvaat.nl/mensen/zhifang-wang/","name":"Zhifang Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/11/12/recaticimab-als-toevoeging-aan-statines-fase-3-remain-2/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/12/rf-renale-denervatie-bij-ongecontroleerde-hypertensie-in-china-gerandomiseerde-t/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/06/01/opt-birisk-clopidogrel-monotherapie-bij-acs-met-hoog-ischemisch-en-bloedingsrisi/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2024/04/16/postprocedurale-anticoagulatie-na-primaire-pci-voor-stemi-multicenter-studie/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2023/10/24/cts-ami-tongxinluo-bij-acuut-mi-jama-mega-trial/","published":"2023-10-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zi-michael-miao","type":"person","url":"https://hartvaat.nl/mensen/zi-michael-miao/","name":"Zi Michael Miao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","published":"2022-06-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zixuan-zhang","type":"person","url":"https://hartvaat.nl/mensen/zixuan-zhang/","name":"Zixuan Zhang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2026/12/01/cardiometabole-index-en-sarcopenie-voorspellen-sterfte-bij-chronische-nierziekte/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2022/05/01/nierdisfunctie-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2020/05/05/gezondheidsstatus-en-uitkomsten-bij-hf-met-mr-coapt/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yvind-ellingsen","type":"person","url":"https://hartvaat.nl/mensen/yvind-ellingsen/","name":"Øyvind Ellingsen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":5,"articles":[{"url":"https://hartvaat.nl/2024/04/01/inspanningstraining-en-hoog-sensitief-troponine-i-bij-hfref/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/08/01/telerevalidatie-haalbaar-voor-hartfalenpatienten-zonder-toegang-tot-poliklinisch/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2022/08/01/cardiorenaal-syndroom-en-fitheid-bij-hartfalen-telerevalidatie-trial/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/06/01/inspanningstraining-en-hs-troponine-t-bij-hfref/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2017/02/28/hoog-intensieve-intervaltraining-bij-hartfalen-met-verminderde-ejectiefractie/","published":"2017-02-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a-j","type":"person","url":"https://hartvaat.nl/mensen/a-j/","name":"A. J.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/17/niet-invasieve-endotypering-met-stress-mri-verbetert-de-behandeling-van-angina-z/","published":"2026-07-21"},{"url":"https://hartvaat.nl/2026/05/04/angina-toevoegen-aan-de-h2fpef-score-verbetert-hfpef-diagnose-bij-vrouwen-geen-w/","published":"2026-07-10"},{"url":"https://hartvaat.nl/2026/03/31/titine-cardiomyopathie-meestal-dcm-of-linksdominante-acm-met-blijvend-ritmestoor/","published":"2026-03-31"},{"url":"https://hartvaat.nl/2026/02/12/ct-coronairangiografie-bij-nstemi-uitstekende-diagnostische-nauwkeurigheid-maar-/","published":"2026-02-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adam-p-silverstein","type":"person","url":"https://hartvaat.nl/mensen/adam-p-silverstein/","name":"Adam P Silverstein","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/03/15/leeftijd-en-uitkomsten-van-katheterablatie-versus-medicatie-bij-af-cabana/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/07/13/ablatie-versus-medicatie-bij-af-naar-ras-en-etniciteit/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2020/06/30/af-recidief-na-ablatie-versus-antiaritmica-in-cabana/","published":"2020-06-30"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adam-torbicki","type":"person","url":"https://hartvaat.nl/mensen/adam-torbicki/","name":"Adam Torbicki","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/02/20/morbiditeit-bij-pulmonaal-arteriele-hypertensie-als-prognostische-marker-voor-mo/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/04/14/macitentan-en-hemodynamiek-bij-pah-seraphin-hemodynamische-substudie/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/04/01/hemodynamische-effecten-van-riociguat-bij-inoperabel-cteph/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/01/01/2015-esc-ers-richtlijn-voor-diagnostiek-en-behandeling-van-pulmonale-hypertensie/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adrian-coles","type":"person","url":"https://hartvaat.nl/mensen/adrian-coles/","name":"Adrian Coles","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","published":"2019-09-03"},{"url":"https://hartvaat.nl/2019/03/05/inspanningstest-versus-ccta-bij-diabetes-met-verdenking-coronairlijden/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2017/11/21/coronair-calcium-en-prognostische-waarde-bij-pijn-op-de-borst-promise-studie/","published":"2017-11-21"},{"url":"https://hartvaat.nl/2017/06/27/hospitalisatie-voor-nieuw-gediagnosticeerd-versus-verslechterend-chronisch-hartf/","published":"2017-06-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"afshin-salsali","type":"person","url":"https://hartvaat.nl/mensen/afshin-salsali/","name":"Afshin Salsali","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2019/04/30/empagliflozine-antihyperglycemische-en-bloeddrukeffecten-bij-zwarte-diabetespati/","published":"2019-04-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aiwen-xing","type":"person","url":"https://hartvaat.nl/mensen/aiwen-xing/","name":"Aiwen Xing","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alan-c-yeung","type":"person","url":"https://hartvaat.nl/mensen/alan-c-yeung/","name":"Alan C Yeung","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alan-maisel","type":"person","url":"https://hartvaat.nl/mensen/alan-maisel/","name":"Alan Maisel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/02/13/implanteerbare-hemodynamische-monitoren-verbeteren-overleving-bij-hfref/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2022/07/14/guide-hf-en-de-impact-van-covid-19-op-hartfalenuitkomsten/","published":"2022-07-14"},{"url":"https://hartvaat.nl/2021/09/11/hemodynamisch-geleid-hf-management-lancet-guide-hf/","published":"2021-09-11"},{"url":"https://hartvaat.nl/2016/05/01/intracoronaire-adenylylcyclase-6-gentherapie-bij-hartfalen-gerandomiseerde-trial/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alan-reid","type":"person","url":"https://hartvaat.nl/mensen/alan-reid/","name":"Alan Reid","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"albert-ariza-sole","type":"person","url":"https://hartvaat.nl/mensen/albert-ariza-sole/","name":"Albert Ariza-Solé","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/20/es-bempedacs-triple-versus-duale-lipidenbehandeling-na-acs/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/07/28/routine-invasieve-strategie-en-herinfarctrisico-bij-fragiele-ouderen-met-nste-ac/","published":"2025-07-28"},{"url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","published":"2021-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"albert-h-m-van-straten","type":"person","url":"https://hartvaat.nl/mensen/albert-h-m-van-straten/","name":"Albert H M van Straten","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2020/11/10/ticagrelor-plus-aspirine-en-safeneuze-graft-patency-na-cabg/","published":"2020-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alberto-dominguez-rodriguez","type":"person","url":"https://hartvaat.nl/mensen/alberto-dominguez-rodriguez/","name":"Alberto Dominguez-Rodriguez","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/11/reboot-betablokkers-na-mi-sekseverschillen/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","published":"2025-09-13"},{"url":"https://hartvaat.nl/2016/08/16/intracoronair-abciximab-bij-diabetespatienten-met-primaire-pci-1-jaarsresultaten/","published":"2016-08-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alberto-j-lorenzatti","type":"person","url":"https://hartvaat.nl/mensen/alberto-j-lorenzatti/","name":"Alberto J Lorenzatti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","published":"2026-01-08"},{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alberto-palazzuoli","type":"person","url":"https://hartvaat.nl/mensen/alberto-palazzuoli/","name":"Alberto Palazzuoli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/25/het-spectrum-van-congestie-bij-hartfalen-pathofysiologie-en-diagnostische-strate/","published":"2026-05-31"},{"url":"https://hartvaat.nl/2026/03/17/langetermijneffecten-van-sacubitril-valsartan-bij-hfref-italiaanse-real-world-st/","published":"2026-03-17"},{"url":"https://hartvaat.nl/2022/12/01/hartfalen-tijdens-de-covid-19-pandemie-klinische-en-organisatorische-dilemma-s/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2017/11/01/iv-lisdiuretica-bij-acuut-hartfalen-diur-ahf-studieontwerp/","published":"2017-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aleksander-zurakowski","type":"person","url":"https://hartvaat.nl/mensen/aleksander-zurakowski/","name":"Aleksander Zurakowski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2016/01/09/ranolazine-bij-incomplete-revascularisatie-na-pci-de-river-pci-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alessandro-sciahbasi","type":"person","url":"https://hartvaat.nl/mensen/alessandro-sciahbasi/","name":"Alessandro Sciahbasi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/01/01/verkorte-dapt-bij-hoog-bloedingsrisico-geen-sekseverschillen/","published":"2024-01-01"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/08/19/optimale-timing-van-invasieve-strategie-bij-nste-acs-lancet-meta-analyse/","published":"2017-08-19"},{"url":"https://hartvaat.nl/2017/05/23/stralingsblootstelling-en-vasculaire-toegang-bij-acs-rad-matrix-trial/","published":"2017-05-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alessandro-sionis","type":"person","url":"https://hartvaat.nl/mensen/alessandro-sionis/","name":"Alessandro Sionis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2025/07/28/routine-invasieve-strategie-en-herinfarctrisico-bij-fragiele-ouderen-met-nste-ac/","published":"2025-07-28"},{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2019/12/17/uitgebreide-vasodilatatie-versus-standaardzorg-bij-acuut-hf-jama-galactic-hf-pil/","published":"2019-12-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alessia-urbinati","type":"person","url":"https://hartvaat.nl/mensen/alessia-urbinati/","name":"Alessia Urbinati","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alex-r-kemper","type":"person","url":"https://hartvaat.nl/mensen/alex-r-kemper/","name":"Alex R Kemper","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","published":"2017-07-11"},{"url":"https://hartvaat.nl/2016/11/15/statines-voor-primaire-cardiovasculaire-preventie-uspstf-aanbeveling/","published":"2016-11-15"},{"url":"https://hartvaat.nl/2016/08/09/lipidescreening-bij-kinderen-en-adolescenten-uspstf-aanbeveling/","published":"2016-08-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexandra-popma","type":"person","url":"https://hartvaat.nl/mensen/alexandra-popma/","name":"Alexandra Popma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/25/1-op-5-oudere-patienten-heeft-hartfalen-opname-binnen-jaar-na-tavr-1-jaarsmortal/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2025/04/12/orbitale-atherectomie-versus-ballonangioplastie-voor-des-bij-ernstig-verkalkte-l/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/02/18/lage-dosis-sirolimus-bdp-stent-versus-tweede-generatie-des-non-inferioriteit/","published":"2025-02-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexandros-briasoulis","type":"person","url":"https://hartvaat.nl/mensen/alexandros-briasoulis/","name":"Alexandros Briasoulis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/07/optimale-strategie-voor-complete-revascularisatie-bij-stemi-met-meervatslijden-m/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2022/11/01/checkpoint-remmers-verhogen-korttermijnrisico-op-hypertensie-niet-meta-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/08/24/de-escalatie-van-dapt-bij-acs-jacc-review/","published":"2021-08-24"},{"url":"https://hartvaat.nl/2020/01/28/orale-antistolling-bij-af-op-langdurige-hemodialyse/","published":"2020-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alison-l-bailey","type":"person","url":"https://hartvaat.nl/mensen/alison-l-bailey/","name":"Alison L Bailey","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alison-seed","type":"person","url":"https://hartvaat.nl/mensen/alison-seed/","name":"Alison Seed","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","published":"2024-04-21"},{"url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"},{"url":"https://hartvaat.nl/2017/08/07/remote-management-van-hartfalen-met-implanteerbare-devices-overzicht/","published":"2017-08-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alp-aytekin","type":"person","url":"https://hartvaat.nl/mensen/alp-aytekin/","name":"Alp Aytekin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alvin-chandra","type":"person","url":"https://hartvaat.nl/mensen/alvin-chandra/","name":"Alvin Chandra","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2018/06/01/sacubitril-valsartan-en-fysieke-en-sociale-activiteitsbeperkingen-bij-hf-paradig/","published":"2018-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amanda-adler","type":"person","url":"https://hartvaat.nl/mensen/amanda-adler/","name":"Amanda Adler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/03/25/leeftijds-en-sekseverschillen-in-effectiviteit-van-diabetesbehandeling-netwerk-m/","published":"2025-03-25"},{"url":"https://hartvaat.nl/2023/05/30/empagliflozine-en-cardiale-energiestofwisseling-bij-hartfalen-empa-vision/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2018/10/18/omega-3-vetzuursupplementen-bij-diabetes-nejm-ascend-omega-3/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2018/10/18/aspirine-voor-primaire-preventie-bij-diabetes-nejm-ascend/","published":"2018-10-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amanda-r-vest","type":"person","url":"https://hartvaat.nl/mensen/amanda-r-vest/","name":"Amanda R Vest","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/18/2025-acc-scientific-statement-obesitasmanagement-bij-hartfalen/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amar-krishnaswamy","type":"person","url":"https://hartvaat.nl/mensen/amar-krishnaswamy/","name":"Amar Krishnaswamy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/09/01/anemie-verergert-mortaliteit-en-hartfalenheropnames-na-tavr-bij-patienten-boven-/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2025/08/19/paclitaxel-gecoate-ballon-bij-multilayer-in-stent-restenose-agent-ide-subgroep/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2024/03/05/gelijktijdige-laa-occlusie-en-tavr-bij-af-haalbaarheid/","published":"2024-03-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amerjeet-s-banning","type":"person","url":"https://hartvaat.nl/mensen/amerjeet-s-banning/","name":"Amerjeet S Banning","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","published":"2023-10-14"},{"url":"https://hartvaat.nl/2019/12/24/langetermijnfollow-up-van-complete-versus-laesie-only-revascularisatie-bij-stemi/","published":"2019-12-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amitava-banerjee","type":"person","url":"https://hartvaat.nl/mensen/amitava-banerjee/","name":"Amitava Banerjee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2024/10/01/crt-bij-inotroop-afhankelijk-hartfalen-meta-analyse/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2023/03/10/mondiale-prevalentie-uitkomsten-en-kosten-van-hartfalen-careme-studie/","published":"2023-03-10"},{"url":"https://hartvaat.nl/2022/09/26/smartphone-detectie-van-af-via-fotoplethysmografie-meta-analyse/","published":"2022-09-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anders-g-olsson","type":"person","url":"https://hartvaat.nl/mensen/anders-g-olsson/","name":"Anders G Olsson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/06/18/evolocumab-bij-ckd-werkzaamheid-en-veiligheid-in-de-fourier-trial/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2018/10/13/lp-a-baseline-en-on-statin-voor-cv-eventvoorspelling-lancet-ipd-meta-analyse/","published":"2018-10-13"},{"url":"https://hartvaat.nl/2018/02/01/lipoproteine-a-en-recidiverende-ischemische-events-na-acs-dal-outcomes-analyse/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2016/12/06/dalcetrapib-wijzigt-de-relatie-tussen-hdl-cholesterol-en-crp/","published":"2016-12-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anders-gaarsdal-holst","type":"person","url":"https://hartvaat.nl/mensen/anders-gaarsdal-holst/","name":"Anders Gaarsdal Holst","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/05/12/ritme-monitoringstrategieen-voor-af-screening-uitgebreide-evaluatie/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2019/12/03/natuurlijk-beloop-van-subklinisch-af-gedetecteerd-door-implanteerbare-looprecord/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2017/01/03/traditionele-cv-risicofactoren-en-veneuze-trombo-embolie-individuele-patientdata/","published":"2017-01-03"},{"url":"https://hartvaat.nl/2016/11/10/semaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-sustain-6/","published":"2016-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrea-erriquez","type":"person","url":"https://hartvaat.nl/mensen/andrea-erriquez/","name":"Andrea Erriquez","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrea-picchi","type":"person","url":"https://hartvaat.nl/mensen/andrea-picchi/","name":"Andrea Picchi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-m-demchuk","type":"person","url":"https://hartvaat.nl/mensen/andrew-m-demchuk/","name":"Andrew M Demchuk","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/05/16/annexa-i-andexanet-alfa-bij-factor-xa-remmer-geassocieerde-intracerebrale-bloedi/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2021/06/01/implanteerbare-versus-verlengde-externe-ecg-monitoring-voor-af-na-ischemisch-cva/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"},{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","published":"2016-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-m-tershakovec","type":"person","url":"https://hartvaat.nl/mensen/andrew-m-tershakovec/","name":"Andrew M Tershakovec","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/10/12/baseline-ldl-en-klinische-uitkomsten-van-ezetimibe-plus-statine-improve-it/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2017/12/19/cva-preventie-met-ezetimibe-bij-acs-improve-it-analyse/","published":"2017-12-19"},{"url":"https://hartvaat.nl/2017/05/01/langetermijnveiligheid-van-zeer-lage-ldl-cholesterolniveaus-improve-it-analyse/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/02/02/reductie-in-totale-cardiovasculaire-events-met-ezetimibe-simvastatine-na-acs-imp/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrzej-januszewicz","type":"person","url":"https://hartvaat.nl/mensen/andrzej-januszewicz/","name":"Andrzej Januszewicz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/27/consensus-breid-het-cardio-renaal-metabool-syndroom-uit-met-de-lever-cklms-in-de/","published":"2026-07-18"},{"url":"https://hartvaat.nl/2020/07/01/phactr1-en-fibromusculaire-dysplasie-arcadia-pol-meta-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2018/08/01/renale-denervatie-bij-resistente-hypertensie-met-obstructieve-slaapapneu-proof-o/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/12/01/centrale-iliacale-av-anastomose-bij-ongecontroleerde-hypertensie-rox-control-htn/","published":"2017-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"angel-cequier","type":"person","url":"https://hartvaat.nl/mensen/angel-cequier/","name":"Angel Cequier","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/12/03/magnesium-resorbeerbare-scaffold-versus-metallic-stent-bij-stemi-biosolve-iii/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2016/01/23/everolimus-eluting-stent-versus-bare-metal-stent-bij-stemi-5-jaarsresultaten-exa/","published":"2016-01-23"},{"url":"https://hartvaat.nl/2016/01/14/bioresorbeerbare-versus-metallic-everolimus-eluting-stent-bij-stemi-gerandomisee/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anna-sonia-petronio","type":"person","url":"https://hartvaat.nl/mensen/anna-sonia-petronio/","name":"Anna Sonia Petronio","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/06/06/smart-zelf-expanderend-versus-ballonexpandeerbaar-tavr-bij-kleine-annulus-nejm/","published":"2024-06-06"},{"url":"https://hartvaat.nl/2022/10/01/mitraclip-bij-secundaire-mitralisklepinsufficientie-meta-analyse-ischemisch-vs-n/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2019/04/14/aki-en-bloedingen-en-mortaliteit-na-radiale-versus-femorale-toegang-bij-acs/","published":"2019-04-14"},{"url":"https://hartvaat.nl/2018/12/01/mitraclip-plus-medicamenteus-versus-medicamenteus-alleen-bij-hf-met-mr-meta-anal/","published":"2018-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"annamaria-kosztin","type":"person","url":"https://hartvaat.nl/mensen/annamaria-kosztin/","name":"Annamária Kosztin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/07/02/upgrade-rv-naar-crt-pacing-bij-hartfalen-met-af-voordelen-bevestigd/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/10/21/upgrade-van-rv-pacing-naar-crt-bij-hartfalen-gerandomiseerde-trial/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2017/11/01/klinische-presentatie-bij-eerste-hartfalenhospitalisatie-voorspelt-geen-heropnam/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/09/01/budapest-crt-upgrade-study-studieontwerp-voor-crt-upgrade/","published":"2017-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anne-b-curtis","type":"person","url":"https://hartvaat.nl/mensen/anne-b-curtis/","name":"Anne B Curtis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/11/22/athena-subanalyse-dronedaron-effectief-ongeacht-leeftijd-en-geslacht-bij-af/","published":"2022-11-22"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2016/05/10/biventriculaire-versus-rechterkamerpacing-klinische-verbetering-in-de-block-hf-s/","published":"2016-05-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anne-h-hobbelt","type":"person","url":"https://hartvaat.nl/mensen/anne-h-hobbelt/","name":"Anne H Hobbelt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/07/15/race-3-langetermijnresultaten-gerichte-behandeling-bij-vroeg-persisterend-af-en-/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2021/09/08/antiaritmica-bij-vroeg-persisterend-af-met-hf-race-3/","published":"2021-09-08"},{"url":"https://hartvaat.nl/2019/04/01/upstream-therapie-verbetert-qol-bij-persisterend-af-arrest-af/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/08/21/behandeling-van-onderliggende-aandoeningen-verbetert-sinusritme-na-af-arrest-af/","published":"2018-08-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anne-marie-valente","type":"person","url":"https://hartvaat.nl/mensen/anne-marie-valente/","name":"Anne Marie Valente","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/01/aangeboren-hartafwijkingen-bij-volwassenen-nieuwe-richtlijnen-kennishiaten-en-ka/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/01/01/wat-is-veranderd-sinds-de-eerste-richtlijn-voor-volwassenen-met-aangeboren-harta/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","published":"2024-01-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anne-pernille-ofstad","type":"person","url":"https://hartvaat.nl/mensen/anne-pernille-ofstad/","name":"Anne Pernille Ofstad","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2020/09/19/sglt2-remmers-bij-hfref-meta-analyse-van-emperor-reduced-en-dapa-hf/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2019/06/04/microvasculaire-ziekte-en-cv-events-bij-diabetes-type-2/","published":"2019-06-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anthony-a-bavry","type":"person","url":"https://hartvaat.nl/mensen/anthony-a-bavry/","name":"Anthony A Bavry","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/05/19/des-versus-bms-in-veneuze-bypass-grafts-lancet-dubbelblinde-trial/","published":"2018-05-19"},{"url":"https://hartvaat.nl/2016/11/01/langetermijnmortaliteit-bij-hypertensie-met-coronairlijden-invest-us-cohort/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/08/02/impact-van-coronaire-laesielengte-op-uitkomsten-bij-ivus-geleide-pci/","published":"2016-08-02"},{"url":"https://hartvaat.nl/2016/05/17/institutionele-en-operateurvereisten-voor-linker-hartoorocclusie-scai-acc-hrs-st/","published":"2016-05-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antone-j-tatooles","type":"person","url":"https://hartvaat.nl/mensen/antone-j-tatooles/","name":"Antone J Tatooles","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/05/23/hemocompatibiliteitsuitkomsten-van-heartmate-3-na-6-maanden-momentum-3/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/02/02/intrapericardiale-lvad-bij-gevorderd-hartfalen-nejm/","published":"2017-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antonio-dello-russo","type":"person","url":"https://hartvaat.nl/mensen/antonio-dello-russo/","name":"Antonio Dello Russo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","published":"2026-05-27"},{"url":"https://hartvaat.nl/2026/03/17/athena-register-pulsed-field-ablatie-voor-atriumfibrilleren-ook-effectief-bij-ha/","published":"2026-04-20"},{"url":"https://hartvaat.nl/2016/11/01/linker-hartoorisolatie-bij-langdurig-persisterend-af-de-belief-trial/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/26/ablatie-versus-amiodaron-bij-persisterend-af-met-hartfalen-en-icd-gerandomiseerd/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antonio-serra","type":"person","url":"https://hartvaat.nl/mensen/antonio-serra/","name":"Antonio Serra","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2019/12/03/magnesium-resorbeerbare-scaffold-versus-metallic-stent-bij-stemi-biosolve-iii/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"},{"url":"https://hartvaat.nl/2016/01/23/everolimus-eluting-stent-versus-bare-metal-stent-bij-stemi-5-jaarsresultaten-exa/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ariel-roguin","type":"person","url":"https://hartvaat.nl/mensen/ariel-roguin/","name":"Ariel Roguin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2021/10/26/vroege-impedantie-geleide-interventie-verbetert-langetermijn-hf-uitkomsten/","published":"2021-10-26"},{"url":"https://hartvaat.nl/2018/10/06/resolute-onyx-versus-orsiro-stent-lancet-gerandomiseerde-non-inferioriteitstrial/","published":"2018-10-06"},{"url":"https://hartvaat.nl/2017/10/21/ultradunne-bioresorbeerbare-versus-dunne-duurzame-polymer-stents-lancet-bioscien/","published":"2017-10-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"arne-johannessen","type":"person","url":"https://hartvaat.nl/mensen/arne-johannessen/","name":"Arne Johannessen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/10/07/vroege-substraatablatie-versus-antiaritmica-bij-vt-gerandomiseerde-trial/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2019/07/01/qt-als-voorspeller-van-af-recidief-na-ablatie-en-amiodaronimpact-amio-cat/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/01/01/supraventriculaire-ectopie-na-af-ablatie-voorspelt-recidief/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/03/01/katheterablatie-als-eerstelijnsbehandeling-bij-paroxysmaal-af-5-jaarsresultaten/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"asma-khalil","type":"person","url":"https://hartvaat.nl/mensen/asma-khalil/","name":"Asma Khalil","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/03/01/orale-antihypertensiva-bij-niet-ernstige-zwangerschapshypertensie-netwerkmeta-an/","published":"2022-03-01"},{"url":"https://hartvaat.nl/2020/07/01/white-coat-hypertensie-in-de-zwangerschap-maternale-en-perinatale-uitkomsten/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2018/09/01/thuis-versus-praktijkbloeddrukmeting-in-de-zwangerschap/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/11/01/labetalol-versus-nifedipine-bij-chronische-hypertensie-in-de-zwangerschap-gerand/","published":"2017-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"attila-kovacs","type":"person","url":"https://hartvaat.nl/mensen/attila-kovacs/","name":"Attila Kovács","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/07/02/upgrade-rv-naar-crt-pacing-bij-hartfalen-met-af-voordelen-bevestigd/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/10/21/upgrade-van-rv-pacing-naar-crt-bij-hartfalen-gerandomiseerde-trial/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2017/09/01/budapest-crt-upgrade-study-studieontwerp-voor-crt-upgrade/","published":"2017-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bahira-shahim","type":"person","url":"https://hartvaat.nl/mensen/bahira-shahim/","name":"Bahira Shahim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","published":"2024-03-19"},{"url":"https://hartvaat.nl/2021/07/15/ultradunne-versus-conventionele-2e-generatie-des-langetermijn-meta-analyse/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","published":"2020-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"barbara-e-stahli","type":"person","url":"https://hartvaat.nl/mensen/barbara-e-stahli/","name":"Barbara E Stähli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","published":"2024-11-09"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2016/01/26/p-selectine-antagonist-inclacumab-bij-coronaire-bypasschirurgie-select-cabg-tria/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bart-maesen","type":"person","url":"https://hartvaat.nl/mensen/bart-maesen/","name":"Bart Maesen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/11/thoracoscopische-af-ablatie-met-bipolaire-clamp-5-jaars-ritmevrijheid-52-met-ant/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2024/10/03/geisoleerde-versus-hybride-thoracoscopische-ablatie-bij-af-korte-en-langetermijn/","published":"2024-10-03"},{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2021/11/08/preoperatieve-tte-voor-voorspelling-van-postoperatief-af-meta-analyse/","published":"2021-11-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bartolome-r-celli","type":"person","url":"https://hartvaat.nl/mensen/bartolome-r-celli/","name":"Bartolome R Celli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/09/04/troponine-i-en-cardiovasculair-risico-bij-copd/","published":"2018-09-04"},{"url":"https://hartvaat.nl/2018/09/01/bloeddruk-hartfrequentie-en-mortaliteit-bij-copd-summit-trial/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/10/01/inhalatiecorticosteroid-beta-2-agonist-en-cardiovasculaire-uitkomsten-bij-copd/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/04/30/fluticason-vilanterol-en-overleving-bij-copd-met-verhoogd-cardiovasculair-risico/","published":"2016-04-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"basky-thilaganathan","type":"person","url":"https://hartvaat.nl/mensen/basky-thilaganathan/","name":"Basky Thilaganathan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/01/bloeddrukzelfmanagement-en-vasculaire-remodelling-na-hypertensieve-zwangerschap/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/02/13/pop-ht-bloeddrukzelfmanagement-verbetert-cardiale-remodelling-na-hypertensieve-z/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2023/11/28/pop-ht-zelfmanagement-van-bloeddruk-na-hypertensieve-zwangerschap-jama-rct/","published":"2023-11-28"},{"url":"https://hartvaat.nl/2020/07/01/white-coat-hypertensie-in-de-zwangerschap-maternale-en-perinatale-uitkomsten/","published":"2020-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ben-hurdus","type":"person","url":"https://hartvaat.nl/mensen/ben-hurdus/","name":"Ben Hurdus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/08/25/risicogestuurde-af-screening-met-machine-learning-verhoogt-detectiegraad-find-af/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/03/25/meta-analyse-glp-1-agonisten-voorkomen-hartfalen-in-type-2-diabetes-sterkste-eff/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2022/09/01/collaterale-schade-van-covid-19-aan-cardiovasculaire-zorg-meta-analyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/06/10/voorspelling-van-atriumfibrilleren-in-elektronische-gezondheidsdossiers-systemat/","published":"2022-06-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"benjamin-d-levine","type":"person","url":"https://hartvaat.nl/mensen/benjamin-d-levine/","name":"Benjamin D Levine","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/12/19/synchronisatie-van-voetstap-en-hartfase-bij-crt-patienten/","published":"2023-12-19"},{"url":"https://hartvaat.nl/2023/01/31/hfpef-inspanningsbeperking-niet-alleen-door-hemodynamiek/","published":"2023-01-31"},{"url":"https://hartvaat.nl/2021/09/21/1-jaar-inspanningstraining-keert-lv-stijfheid-om-bij-stadium-b-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2018/04/10/sedentaire-veroudering-omkeren-op-middelbare-leeftijd-gerandomiseerde-trial-voor/","published":"2018-04-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"benno-j-w-m-rensing","type":"person","url":"https://hartvaat.nl/mensen/benno-j-w-m-rensing/","name":"Benno J W M Rensing","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2020/11/10/ticagrelor-plus-aspirine-en-safeneuze-graft-patency-na-cabg/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2017/12/01/centrale-iliacale-av-anastomose-bij-ongecontroleerde-hypertensie-rox-control-htn/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2016/01/05/ct-coronairangiografie-bij-verdenking-acs-in-het-tijdperk-van-hoog-sensitief-tro/","published":"2016-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bernard-cosyns","type":"person","url":"https://hartvaat.nl/mensen/bernard-cosyns/","name":"Bernard Cosyns","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/05/26/esc-consensus-vrouwenhartcentra-whc-als-nieuw-zorgmodel-in-europa/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2025/01/14/tri-fr-transcatheter-edge-to-edge-repair-bij-geisoleerde-ernstige-tr-rct/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2016/08/01/2016-europese-richtlijnen-voor-cardiovasculaire-preventie-in-de-klinische-prakti/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"binyan-wang","type":"person","url":"https://hartvaat.nl/mensen/binyan-wang/","name":"Binyan Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/02/01/geschatte-cva-vrije-overleving-van-foliumzuurtherapie-bij-hypertensie-csppt/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2018/05/15/trombocytenaantal-beinvloedt-werkzaamheid-van-foliumzuur-bij-cva-preventie/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2017/08/01/foliumzuurtherapie-en-nieuwe-proteinurie-bij-chinese-hypertensieve-patienten-csp/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/07/01/polsgolfsnelheid-en-bloeddrukcontrole-als-onafhankelijke-voorspellers-van-cva-bi/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bjarne-linde-norgaard","type":"person","url":"https://hartvaat.nl/mensen/bjarne-linde-norgaard/","name":"Bjarne Linde Nørgaard","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/05/03/multimodaliteitsbeeldvorming-geleide-lv-leadplaatsing-bij-crt-langetermijn/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/02/01/ccta-afgeleide-ffr-prognostische-waarde-meta-analyse/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/09/01/elektrisch-versus-beeldvorming-geleide-lv-leadplaatsing-bij-crt-gerandomiseerde-/","published":"2019-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bo-lagerqvist","type":"person","url":"https://hartvaat.nl/mensen/bo-lagerqvist/","name":"Bo Lagerqvist","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/08/01/zuurstoftherapie-bij-stemi-overzichtsartikel/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/01/10/trombusaspiratie-bij-stemi-individuele-patientdata-meta-analyse/","published":"2017-01-10"},{"url":"https://hartvaat.nl/2016/10/15/vroeg-invasief-versus-conservatief-bij-nste-acs-15-jaarsfollow-up-frisc-ii/","published":"2016-10-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bo-xu","type":"person","url":"https://hartvaat.nl/mensen/bo-xu/","name":"Bo Xu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2016/05/17/biodegradeerbare-sirolimus-eluting-stents-de-panda-iii-trial/","published":"2016-05-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"boback-ziaeian","type":"person","url":"https://hartvaat.nl/mensen/boback-ziaeian/","name":"Boback Ziaeian","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/19/sglt2-remmers-bij-oudere-patienten-opgenomen-voor-hfref-24-sterfte-en-16-heropna/","published":"2026-06-15"},{"url":"https://hartvaat.nl/2024/09/17/2024-acc-aha-kwaliteitsmaatstaven-voor-hartfalen-geactualiseerd/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2020/11/24/2020-acc-aha-prestatie-en-kwaliteitsmaten-voor-hartfalen/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2019/11/26/2019-aha-acc-prestatie-en-kwaliteitsmaten-voor-hoge-bloeddruk/","published":"2019-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bogdan-alexandru-popescu","type":"person","url":"https://hartvaat.nl/mensen/bogdan-alexandru-popescu/","name":"Bogdan Alexandru Popescu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/07/euroheart-definities-van-klinische-studie-eindpunten-voor-cvd/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2017/09/01/validiteit-en-reproduceerbaarheid-van-echocardiografie-bij-af-systematische-revi/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/07/2016-esc-richtlijn-voor-atriumfibrilleren-in-samenwerking-met-eacts/","published":"2016-10-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bonnie-ky","type":"person","url":"https://hartvaat.nl/mensen/bonnie-ky/","name":"Bonnie Ky","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/20/ecog-acrin-eaq191-intensieve-bloeddrukcontrole-tijdens-vegfr-tki-therapie-haalba/","published":"2026-07-07"},{"url":"https://hartvaat.nl/2026/05/26/car-t-therapie-bij-ouderen-5-8-mace-en-sterk-verhoogde-mortaliteit-cardio-oncolo/","published":"2026-05-30"},{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/08/08/stop-ca-atorvastatine-beschermt-tegen-antracycline-cardiotoxiciteit/","published":"2023-08-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brent-egan","type":"person","url":"https://hartvaat.nl/mensen/brent-egan/","name":"Brent Egan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2025/08/30/bloeddrukverlagende-effectiviteit-van-antihypertensiva-en-combinaties-uitgebreid/","published":"2025-08-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brian-g-katona","type":"person","url":"https://hartvaat.nl/mensen/brian-g-katona/","name":"Brian G Katona","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2019/01/01/mi-bij-pav-patienten-incidentie-en-uitkomsten-euclid/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/12/25/cv-en-ledemaat-uitkomsten-bij-diabetes-met-pav-euclid/","published":"2018-12-25"},{"url":"https://hartvaat.nl/2018/10/02/cv-uitkomsten-na-endovasculaire-versus-chirurgische-revascularisatie-onderste-le/","published":"2018-10-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bridget-anne-kirwan","type":"person","url":"https://hartvaat.nl/mensen/bridget-anne-kirwan/","name":"Bridget-Anne Kirwan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"},{"url":"https://hartvaat.nl/2018/09/22/telemedische-interventie-bij-hartfalen-lancet-tim-hf2/","published":"2018-09-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bronwyn-a-kingwell","type":"person","url":"https://hartvaat.nl/mensen/bronwyn-a-kingwell/","name":"Bronwyn A Kingwell","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2019/04/01/ochtendbeweging-met-of-zonder-zitonderbrekingen-en-bloeddruk-bij-ouderen/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2016/11/22/plasma-lipidomiek-verbetert-cardiovasculaire-risicovoorspelling-bij-diabetes-typ/","published":"2016-11-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bruno-pereira","type":"person","url":"https://hartvaat.nl/mensen/bruno-pereira/","name":"Bruno Pereira","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2021/12/01/thin-cap-fibroatheroom-voorspelt-events-bij-diabetes-met-normale-ffr-combine-oct/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2019/01/02/permanente-versus-polymeervrije-des-all-comers-gerandomiseerde-trial/","published":"2019-01-02"},{"url":"https://hartvaat.nl/2017/10/10/geindividualiseerd-versus-standaard-bloeddrukbeleid-bij-hoog-risico-chirurgiepat/","published":"2017-10-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bruno-scheller","type":"person","url":"https://hartvaat.nl/mensen/bruno-scheller/","name":"Bruno Scheller","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/05/02/paclitaxel-gecoate-ballonnen-versus-des-bij-kleine-vaten-ipd-meta-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2020/11/07/drug-coated-balloons-versus-des-bij-kleine-coronairarterien-lancet-basket-small-/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/03/10/overleving-na-revascularisatie-met-paclitaxel-gecoate-ballonnen/","published":"2020-03-10"},{"url":"https://hartvaat.nl/2018/09/08/drug-coated-balloons-bij-kleine-coronairarterien-lancet-basket-small-2/","published":"2018-09-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bulent-gorenek","type":"person","url":"https://hartvaat.nl/mensen/bulent-gorenek/","name":"Bulent Gorenek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bum-kee-hong","type":"person","url":"https://hartvaat.nl/mensen/bum-kee-hong/","name":"Bum-Kee Hong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","published":"2023-04-04"},{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","published":"2022-07-30"},{"url":"https://hartvaat.nl/2020/06/16/ticagrelor-monotherapie-versus-dapt-op-bloedingen-en-cv-events-bij-acs-jama-tico/","published":"2020-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c-jan-willem-borleffs","type":"person","url":"https://hartvaat.nl/mensen/c-jan-willem-borleffs/","name":"C Jan Willem Borleffs","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/08/21/pa-drukmonitoring-bij-chronisch-hartfalen-effecten-over-klinische-subgroepen/","published":"2024-08-21"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/24/monitor-hf-pa-drukmonitoring-bij-hartfalen-effectief-in-europa-lancet-rct/","published":"2023-06-24"},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c-seth-landefeld","type":"person","url":"https://hartvaat.nl/mensen/c-seth-landefeld/","name":"C Seth Landefeld","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","published":"2017-07-11"},{"url":"https://hartvaat.nl/2016/11/15/statines-voor-primaire-cardiovasculaire-preventie-uspstf-aanbeveling/","published":"2016-11-15"},{"url":"https://hartvaat.nl/2016/08/09/lipidescreening-bij-kinderen-en-adolescenten-uspstf-aanbeveling/","published":"2016-08-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c-j","type":"person","url":"https://hartvaat.nl/mensen/c-j/","name":"C. J.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/03/warrior-trial-intensieve-medicamenteuze-behandeling-verbetert-de-uitkomsten-niet/","published":"2026-07-24"},{"url":"https://hartvaat.nl/2026/05/20/scapis-cohort-diastolische-dysfunctie-even-vaak-bij-prediabetes-als-diabetes-ple/","published":"2026-07-07"},{"url":"https://hartvaat.nl/2026/05/26/recidief-linkerventrikel-trombus-12-recidief-actieve-eerdere-maligniteit-verzesv/","published":"2026-07-03"},{"url":"https://hartvaat.nl/2026/01/06/machine-learning-algoritme-mi3-helpt-een-infarct-uitsluiten-bij-een-onduidelijke/","published":"2026-01-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carine-j-m-doggen","type":"person","url":"https://hartvaat.nl/mensen/carine-j-m-doggen/","name":"Carine J M Doggen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/07/01/uitkomsten-van-des-in-kleine-coronairen-naar-strutdikte-jama-cardiology-meta-ana/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/10/06/resolute-onyx-versus-orsiro-stent-lancet-gerandomiseerde-non-inferioriteitstrial/","published":"2018-10-06"},{"url":"https://hartvaat.nl/2017/03/01/5-jaarsuitkomsten-van-zotarolimus-en-everolimus-eluting-stents-trial-en-real-wor/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/11/26/ultradunne-biodegradeerbare-versus-duurzame-polymer-des-lancet-gerandomiseerde-t/","published":"2016-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carlo-de-asmundis","type":"person","url":"https://hartvaat.nl/mensen/carlo-de-asmundis/","name":"Carlo de Asmundis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/03/pfa-versus-cryoballon-voor-af-ablatie-multielectrode-vergelijking/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2022/01/04/enkele-freeze-cryoballonablatie-bij-af-ehra-systematische-review/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2021/12/07/minimaal-onderbroken-versus-continue-doac-bij-af-ablatie-meta-analyse/","published":"2021-12-07"},{"url":"https://hartvaat.nl/2021/07/18/cryoballonablatie-versus-antiaritmica-als-eerstelijns-paf-therapie/","published":"2021-07-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carol-pollock","type":"person","url":"https://hartvaat.nl/mensen/carol-pollock/","name":"Carol Pollock","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/27/sglt2-remmers-bij-ernstig-verminderde-nierfunctie-data-uit-credence/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","published":"2019-08-27"},{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","published":"2019-06-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carsten-tschope","type":"person","url":"https://hartvaat.nl/mensen/carsten-tschope/","name":"Carsten Tschöpe","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2026/02/23/immunoadsorptie-bij-gedilateerde-cardiomyopathie-de-iaso-dcm-trial/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2018/02/01/hoeveelheid-of-intensiteit-van-inspanning-bij-hfpef/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/10/14/intracoronaire-beenmergceltransfer-na-mi-de-boost-2-gerandomiseerde-trial/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"catherine-p-benziger","type":"person","url":"https://hartvaat.nl/mensen/catherine-p-benziger/","name":"Catherine P Benziger","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/09/01/aspirinedosering-voor-secundaire-preventie-bij-mannen-versus-vrouwen/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"catriona-keerie","type":"person","url":"https://hartvaat.nl/mensen/catriona-keerie/","name":"Catriona Keerie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cecilia-ronnback","type":"person","url":"https://hartvaat.nl/mensen/cecilia-ronnback/","name":"Cecilia Rönnbäck","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/10/22/af-en-semaglutide-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","published":"2024-08-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"celso-amodeo","type":"person","url":"https://hartvaat.nl/mensen/celso-amodeo/","name":"Celso Amodeo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-en-evidence-based-prescriptie-bij-hoog-cv-risico-jama-card/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2019/03/01/bariatrische-chirurgie-versus-medicamenteus-beleid-op-24-uurs-ambulante-bloeddru/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/04/01/spironolacton-versus-clonidine-als-vierde-middel-bij-resistente-hypertensie-reho/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2018/03/13/bariatrische-chirurgie-bij-obese-patienten-met-hypertensie-gateway-gerandomiseer/","published":"2018-03-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"charlotta-e-a-ljungman","type":"person","url":"https://hartvaat.nl/mensen/charlotta-e-a-ljungman/","name":"Charlotta E A Ljungman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"charlotte-eitel","type":"person","url":"https://hartvaat.nl/mensen/charlotte-eitel/","name":"Charlotte Eitel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/05/02/style-af-veneuze-closure-device-versus-figuur-van-acht-hechting-na-af-ablatie/","published":"2024-05-02"},{"url":"https://hartvaat.nl/2022/07/15/geindividualiseerde-versus-standaard-cryoballonablatie-bij-paroxysmaal-af/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2021/05/21/firm-ablatie-versus-pvi-bij-paroxysmaal-af-gerandomiseerde-resultaten/","published":"2021-05-21"},{"url":"https://hartvaat.nl/2018/11/01/individueel-aangepaste-versus-gestandaardiseerde-substraatmodificatie-bij-rf-abl/","published":"2018-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chen-chen","type":"person","url":"https://hartvaat.nl/mensen/chen-chen/","name":"Chen Chen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/05/nucleair-ago2-verergert-hfpef-via-myocardiale-ketogenese/","published":"2026-04-03"},{"url":"https://hartvaat.nl/2024/05/30/right-2-ambulancebloeddrukverlaging-bij-hyperacuut-cva-nejm-vervolgresultaten/","published":"2024-05-30"},{"url":"https://hartvaat.nl/2023/07/01/interact3-bundeled-care-bij-acute-intracerebrale-bloeding-lancet/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2019/02/01/sms-na-ontslag-verbetert-kortetermijnuitkomsten-en-zelfzorg-bij-chronisch-hf/","published":"2019-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cheol-hyun-lee","type":"person","url":"https://hartvaat.nl/mensen/cheol-hyun-lee/","name":"Cheol Hyun Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","published":"2022-09-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chintan-trivedi","type":"person","url":"https://hartvaat.nl/mensen/chintan-trivedi/","name":"Chintan Trivedi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/02/05/laa-isolatie-tijdens-af-ablatie-geactualiseerde-meta-analyse/","published":"2021-02-05"},{"url":"https://hartvaat.nl/2018/08/01/linker-hartoorisolatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2016/11/01/linker-hartoorisolatie-bij-langdurig-persisterend-af-de-belief-trial/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/26/ablatie-versus-amiodaron-bij-persisterend-af-met-hartfalen-en-icd-gerandomiseerd/","published":"2016-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-butter","type":"person","url":"https://hartvaat.nl/mensen/christian-butter/","name":"Christian Butter","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/10/01/draadloos-ultrasound-gebaseerd-crt-systeem-bij-hartfalen/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2021/11/08/closed-loop-stimulatie-en-cardiopulmonale-variabelen-bij-chronisch-hf-met-chrono/","published":"2021-11-08"},{"url":"https://hartvaat.nl/2018/09/22/telemedische-interventie-bij-hartfalen-lancet-tim-hf2/","published":"2018-09-22"},{"url":"https://hartvaat.nl/2016/11/01/vochtstatustelemonitoring-bij-hartfalen-gerandomiseerde-trial/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-hagl","type":"person","url":"https://hartvaat.nl/mensen/christian-hagl/","name":"Christian Hagl","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/25/palliatieve-zorg-in-de-cardiologie-een-state-of-the-art-overzicht/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/02/19/delirium-in-de-cardiovasculaire-geneeskunde/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2019/05/14/ecls-bij-cardiogene-shock-na-acuut-mi/","published":"2019-05-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-meyer","type":"person","url":"https://hartvaat.nl/mensen/christian-meyer/","name":"Christian Meyer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/10/31/pfa-versus-thermale-ablatie-periprocedurale-en-middellangetermijneffecten/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2021/10/09/gewichtsverlies-voor-af-ablatie-sort-af-gerandomiseerde-trial/","published":"2021-10-09"},{"url":"https://hartvaat.nl/2021/07/18/cryoballonablatie-versus-antiaritmica-als-eerstelijns-paf-therapie/","published":"2021-07-18"},{"url":"https://hartvaat.nl/2018/01/01/energiebron-en-vroeg-af-recidief-cryoballon-versus-radiofrequentie/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-sohns","type":"person","url":"https://hartvaat.nl/mensen/christian-sohns/","name":"Christian Sohns","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/03/varipure-studie-pulsed-field-ablatie-in-de-dagelijkse-af-praktijk/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2024/12/17/ablatiestrategie-bij-af-recidief-na-duurzame-pvi/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2023/10/12/castle-htx-af-ablatie-bij-eindstadium-hartfalen-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2022/06/21/mri-geleide-fibroseablatie-versus-conventionele-ablatie-bij-persisterend-af/","published":"2022-06-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-valina","type":"person","url":"https://hartvaat.nl/mensen/christian-valina/","name":"Christian Valina","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","published":"2020-11-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christina-nowack","type":"person","url":"https://hartvaat.nl/mensen/christina-nowack/","name":"Christina Nowack","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/12/01/finerenon-bloeddrukeffecten-en-cardiorenale-uitkomsten-bij-ckd-en-diabetes/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2022/02/10/finerenon-cv-en-renale-uitkomsten-bij-diabetes-met-ckd-fidelity-gepoolde-analyse/","published":"2022-02-10"},{"url":"https://hartvaat.nl/2021/12/09/finerenon-bij-nierziekte-met-diabetes-type-2-nejm-figaro-dkd/","published":"2021-12-09"},{"url":"https://hartvaat.nl/2016/07/14/finerenon-versus-eplerenon-bij-hartfalen-met-diabetes-en-verslechterende-nierfun/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christoph-grani","type":"person","url":"https://hartvaat.nl/mensen/christoph-grani/","name":"Christoph Gräni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/07/08/amulet-versus-watchman-flx-driejaarsresultaten-laa-sluiting/","published":"2025-07-08"},{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","published":"2024-02-06"},{"url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2021/10/01/paroxetine-grk2-remming-versus-placebo-bij-anterieur-mi-jama-cardiology/","published":"2021-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christophe-piot","type":"person","url":"https://hartvaat.nl/mensen/christophe-piot/","name":"Christophe Piot","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-laagrisico-acuut-mi/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2021/11/09/ffr-voor-behandeling-van-multivatencoronairlijden-jacc/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2018/12/13/percutaan-herstel-of-medicamenteuze-therapie-bij-secundaire-mr-nejm-mitra-fr/","published":"2018-12-13"},{"url":"https://hartvaat.nl/2017/09/14/pfo-sluiting-of-antistolling-versus-antiplaatjestherapie-na-cva-nejm-reduce/","published":"2017-09-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-j-weir","type":"person","url":"https://hartvaat.nl/mensen/christopher-j-weir/","name":"Christopher J Weir","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-s-lee","type":"person","url":"https://hartvaat.nl/mensen/christopher-s-lee/","name":"Christopher S Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/06/27/frailte-versnelt-hartfalenprogressie-en-vermindert-therapietolerantie/","published":"2026-08-04"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christos-iliadis","type":"person","url":"https://hartvaat.nl/mensen/christos-iliadis/","name":"Christos Iliadis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2023/08/01/atrial-flow-regulator-en-overleving-bij-hartfalen-voorspelde-impact/","published":"2023-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"claire-bouleti","type":"person","url":"https://hartvaat.nl/mensen/claire-bouleti/","name":"Claire Bouleti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/10/23/aspirine-bij-chronisch-coronairsyndroom-plus-oac-wel-of-niet/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"clare-arnott","type":"person","url":"https://hartvaat.nl/mensen/clare-arnott/","name":"Clare Arnott","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/27/sglt2-remmers-verminderen-epicardiaal-vetweefsel-meta-analyse-van-11-studies/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2026/02/27/sglt2-remmers-bij-ernstig-verminderde-nierfunctie-data-uit-credence/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2021/04/01/canagliflozine-naar-diureticagebruik-canvas-post-hoc-analyse/","published":"2021-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"clare-j-taylor","type":"person","url":"https://hartvaat.nl/mensen/clare-j-taylor/","name":"Clare J Taylor","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/06/01/natriuretisch-peptide-screening-voor-lv-disfunctie-diagnostische-nauwkeurigheid/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2021/06/01/diagnostiek-van-hartfalen-in-de-huisartsenpraktijk-ipd-meta-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2019/12/01/gewichtsverandering-en-risico-op-af-systematische-review-en-meta-analyse/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"clinton-b-wright","type":"person","url":"https://hartvaat.nl/mensen/clinton-b-wright/","name":"Clinton B Wright","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukcontrole-en-cerebrale-small-vessel-disease-markers/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2021/04/01/intensieve-versus-standaard-bloeddruk-op-cva-subtypes-sprint/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"courtney-crim","type":"person","url":"https://hartvaat.nl/mensen/courtney-crim/","name":"Courtney Crim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/09/04/troponine-i-en-cardiovasculair-risico-bij-copd/","published":"2018-09-04"},{"url":"https://hartvaat.nl/2018/09/01/bloeddruk-hartfrequentie-en-mortaliteit-bij-copd-summit-trial/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/10/01/inhalatiecorticosteroid-beta-2-agonist-en-cardiovasculaire-uitkomsten-bij-copd/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/04/30/fluticason-vilanterol-en-overleving-bij-copd-met-verhoogd-cardiovasculair-risico/","published":"2016-04-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"craig-beam","type":"person","url":"https://hartvaat.nl/mensen/craig-beam/","name":"Craig Beam","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d-wyn-davies","type":"person","url":"https://hartvaat.nl/mensen/d-wyn-davies/","name":"D Wyn Davies","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/03/30/ablatie-versus-antiaritmica-voor-vermindering-van-ziekenhuisbezoeken-bij-af/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dabit-arzamendi","type":"person","url":"https://hartvaat.nl/mensen/dabit-arzamendi/","name":"Dabit Arzamendi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2025/12/23/korte-anticoagulatie-versus-dapt-na-laa-occlusie-devicetrombosepreventie/","published":"2025-12-23"},{"url":"https://hartvaat.nl/2025/04/10/dapagliflozine-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2025-04-10"},{"url":"https://hartvaat.nl/2024/10/01/lage-dosis-doac-versus-dapt-na-laa-occlusie-gerandomiseerde-trial/","published":"2024-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dahlia-garza","type":"person","url":"https://hartvaat.nl/mensen/dahlia-garza/","name":"Dahlia Garza","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/10/26/patiromer-voor-spironolactongebruik-bij-resistente-hypertensie-met-ckd-lancet-am/","published":"2019-10-26"},{"url":"https://hartvaat.nl/2018/08/01/langetermijn-patiromer-bij-hyperkaliemie-met-mild-hf-en-diabetische-nefropathie/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/06/01/geindividualiseerd-patiromer-doseringsregime-bij-hf-met-ckd-en-hyperkaliemie/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2016/09/01/patiromer-verlaagt-aldosteron-bij-ckd-patienten-met-hyperkaliemie-op-raas-remmer/","published":"2016-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"damien-bonnet","type":"person","url":"https://hartvaat.nl/mensen/damien-bonnet/","name":"Damien Bonnet","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/06/laminopathieen-natuurlijk-beloop-en-voorspelmodel-voor-hartfalen/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/08/01/nt-probnp-veranderingen-en-klinische-uitkomsten-bij-pediatrisch-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/11/26/panorama-hf-sacubitril-valsartan-bij-pediatrisch-hartfalen-nejm/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2017/09/05/ivabradine-bij-kinderen-met-dilaterende-cardiomyopathie-en-symptomatisch-hartfal/","published":"2017-09-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"damras-tresukosol","type":"person","url":"https://hartvaat.nl/mensen/damras-tresukosol/","name":"Damras Tresukosol","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2022/11/22/ees-versus-cabg-bij-meervatslijden-langetermijn-follow-up-van-rct-s/","published":"2022-11-22"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dan-ioanes","type":"person","url":"https://hartvaat.nl/mensen/dan-ioanes/","name":"Dan Ioanes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2018/09/01/langetermijnimpact-van-cto-rekanalisatie-bij-stemi-patienten/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2016/10/11/pci-van-chronische-totale-occlusie-bij-stemi-met-multivatenlijden-explore-trial/","published":"2016-10-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-cotton","type":"person","url":"https://hartvaat.nl/mensen/daniel-cotton/","name":"Daniel Cotton","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","published":"2021-11-14"},{"url":"https://hartvaat.nl/2021/03/23/empagliflozine-bij-hfref-met-volume-overbelasting-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-e-forman","type":"person","url":"https://hartvaat.nl/mensen/daniel-e-forman/","name":"Daniel E Forman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-e-weiner","type":"person","url":"https://hartvaat.nl/mensen/daniel-e-weiner/","name":"Daniel E Weiner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/05/01/bloeddruk-en-volumemanagement-bij-dialyse-kdigo-controverseconferentie/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2017/08/24/intensieve-bloeddrukbehandeling-en-patientgerapporteerde-uitkomsten-nejm-sprint-/","published":"2017-08-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-isaza","type":"person","url":"https://hartvaat.nl/mensen/daniel-isaza/","name":"Daniel Isaza","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","published":"2018-02-06"},{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","published":"2017-09-12"},{"url":"https://hartvaat.nl/2016/02/02/reductie-in-totale-cardiovasculaire-events-met-ezetimibe-simvastatine-na-acs-imp/","published":"2016-02-02"},{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-levy","type":"person","url":"https://hartvaat.nl/mensen/daniel-levy/","name":"Daniel Levy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/08/01/mondiale-vergelijking-van-heropnamepercentages-bij-hartfalen/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2022/08/01/hele-genoomsequencing-onthult-nieuwe-bloeddruk-loci/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2020/09/22/sekse-specifieke-cv-risicofactoren-en-biomarkers-bij-incident-hartfalen/","published":"2020-09-22"},{"url":"https://hartvaat.nl/2019/08/20/dna-methylering-in-leukocyten-voorspelt-mi-en-coronairlijden/","published":"2019-08-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-modin","type":"person","url":"https://hartvaat.nl/mensen/daniel-modin/","name":"Daniel Modin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/01/hoge-dosis-griepvaccinatie-bij-atherosclerotisch-vaatlijden-flunity-hd-analyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/10/28/rsv-vaccin-vermindert-cv-hospitalisaties-bij-ouderen/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/01/01/nudge-flu-subanalyse-griepvaccinatie-nudges-bij-mi-langetermijn/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/05/27/nudge-flu-elektronische-nudges-verhogen-griepvaccinatie-na-mi/","published":"2024-05-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-munoz","type":"person","url":"https://hartvaat.nl/mensen/daniel-munoz/","name":"Daniel Muñoz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2019/09/19/polypil-voor-cv-preventie-bij-onderbehandelde-populatie-nejm/","published":"2019-09-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-s-berman","type":"person","url":"https://hartvaat.nl/mensen/daniel-s-berman/","name":"Daniel S Berman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2020/05/05/laag-attenuatie-plaque-op-ccta-voorspelt-mi-scot-heart-resultaten/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2019/04/30/leefstijl-hba1c-en-overleving-bij-stabiel-coronairlijden-met-diabetes/","published":"2019-04-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-t-lackland","type":"person","url":"https://hartvaat.nl/mensen/daniel-t-lackland/","name":"Daniel T Lackland","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/11/01/therapieresistente-hypertensie-aha-scientific-statement-over-detectie-evaluatie-/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-systematische-review-circulation/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/06/01/systematische-review-voor-de-2017-acc-aha-hypertensierichtlijn-hypertension-edit/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/05/15/systematische-review-voor-de-2017-acc-aha-hypertensierichtlijn/","published":"2018-05-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniela-trabattoni","type":"person","url":"https://hartvaat.nl/mensen/daniela-trabattoni/","name":"Daniela Trabattoni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/26/esc-consensus-vrouwenhartcentra-whc-als-nieuw-zorgmodel-in-europa/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","published":"2025-07-21"},{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/07/14/vergelijking-van-orale-p2y12-remmers-bij-acs-netwerkmeta-analyse-van-52-816-pati/","published":"2020-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"danielle-duffy","type":"person","url":"https://hartvaat.nl/mensen/danielle-duffy/","name":"Danielle Duffy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","published":"2024-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"darren-mylotte","type":"person","url":"https://hartvaat.nl/mensen/darren-mylotte/","name":"Darren Mylotte","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","published":"2020-03-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"darwin-r-labarthe","type":"person","url":"https://hartvaat.nl/mensen/darwin-r-labarthe/","name":"Darwin R Labarthe","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2022/09/26/zoutvervangers-verminderen-cardiovasculaire-events-systematische-review/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2022/05/17/kosteneffectiviteit-van-zoutsubstitutie-ssass-analyse/","published":"2022-05-17"},{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","published":"2021-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-austin","type":"person","url":"https://hartvaat.nl/mensen/david-austin/","name":"David Austin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/12/01/dapagliflozine-na-mi-naar-ef-cardiometabole-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/11/07/invasieve-strategie-bij-ouderen-met-mi-gerandomiseerde-trial-nejm/","published":"2024-11-07"},{"url":"https://hartvaat.nl/2020/07/21/levothyroxine-bij-subklinische-hypothyreoidie-na-acuut-mi-jama/","published":"2020-07-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-b-delurgio","type":"person","url":"https://hartvaat.nl/mensen/david-b-delurgio/","name":"David B DeLurgio","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/28/champion-af-watchman-flx-non-inferieur-aan-noac-s-en-superieur-in-bloedingsreduc/","published":"2026-03-29"},{"url":"https://hartvaat.nl/2025/04/03/laa-sluiting-na-af-ablatie-gerandomiseerde-trial-nejm/","published":"2025-04-03"},{"url":"https://hartvaat.nl/2023/11/02/advent-pulsed-field-ablatie-non-inferieur-aan-thermale-ablatie-bij-af-nejm/","published":"2023-11-02"},{"url":"https://hartvaat.nl/2020/10/27/af-ablatie-met-vena-van-marshall-ethanol-versus-ablatie-alleen-jama-venus/","published":"2020-10-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-brieger","type":"person","url":"https://hartvaat.nl/mensen/david-brieger/","name":"David Brieger","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/05/02/determinanten-van-medicatietrouw-na-acs-secundaire-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2022/05/10/sms-voor-medicatietrouw-en-secundaire-preventie-na-acs-textmeds/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2021/03/01/objectieve-risicobeoordeling-versus-standaardzorg-bij-acs-jama-cardiology/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-chelmow","type":"person","url":"https://hartvaat.nl/mensen/david-chelmow/","name":"David Chelmow","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","published":"2022-04-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-d-mcmanus","type":"person","url":"https://hartvaat.nl/mensen/david-d-mcmanus/","name":"David D McManus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/10/stressor-geassocieerd-af-incidentie-risicofactoren-en-uitkomsten/","published":"2026-02-10"},{"url":"https://hartvaat.nl/2024/11/19/screening-op-niet-gediagnosticeerd-af-voor-cva-preventie-gerandomiseerde-trial/","published":"2024-11-19"},{"url":"https://hartvaat.nl/2022/03/29/af-screening-bij-ouderen-in-de-huisartsenpraktijk-vital-af-gerandomiseerde-trial/","published":"2022-03-29"},{"url":"https://hartvaat.nl/2021/01/26/2020-acc-aha-kwaliteitsmaten-voor-af-geactualiseerd/","published":"2021-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-e-lanfear","type":"person","url":"https://hartvaat.nl/mensen/david-e-lanfear/","name":"David E Lanfear","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/07/18/sglt2-remmers-verbeteren-kwaliteit-van-leven-gelijk-bij-zwarte-en-witte-hartfale/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-j-webb","type":"person","url":"https://hartvaat.nl/mensen/david-j-webb/","name":"David J Webb","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/07/20/zilebesiran-rna-interferentietherapie-voor-hypertensie-nejm/","published":"2023-07-20"},{"url":"https://hartvaat.nl/2022/11/01/arteriele-stijfheid-en-endotheeldysfunctie-bij-anca-geassocieerde-vasculitis/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/10/22/time-avonddosering-antihypertensiva-biedt-geen-voordeel-boven-ochtenddosering/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2019/08/01/endothelinereceptorantagonisme-verbetert-lipidenprofielen-en-verlaagt-pcsk9-bij-/","published":"2019-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-m-nathan","type":"person","url":"https://hartvaat.nl/mensen/david-m-nathan/","name":"David M Nathan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/10/tact-2-chelatietherapie-na-mi-bij-diabetes-negatieve-trial/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2022/09/22/grade-vergelijking-glucoseverlagende-middelen-op-microvasculaire-en-cv-uitkomste/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2022/05/31/langetermijneffect-van-metformine-en-leefstijlinterventie-op-cardiovasculaire-ev/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2017/04/20/frequentie-van-evidence-based-retinopathiescreening-bij-diabetes-type-1-nejm/","published":"2017-04-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-messika-zeitoun","type":"person","url":"https://hartvaat.nl/mensen/david-messika-zeitoun/","name":"David Messika-Zeitoun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/28/gestandaardiseerd-stappenplan-voor-tricuspidalisinsufficientie-van-verwijzing-to/","published":"2026-04-19"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2023/06/01/genetische-bijdrage-aan-aortastenose-dyslipidemie-inflammatie-en-verkalking/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2018/12/13/percutaan-herstel-of-medicamenteuze-therapie-bij-secundaire-mr-nejm-mitra-fr/","published":"2018-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-p-lee","type":"person","url":"https://hartvaat.nl/mensen/david-p-lee/","name":"David P Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"},{"url":"https://hartvaat.nl/2016/05/03/diabetes-en-preventie-van-laat-myocardinfarct-na-stenting-dapt-studie/","published":"2016-05-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-r-matthews","type":"person","url":"https://hartvaat.nl/mensen/david-r-matthews/","name":"David R Matthews","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/05/28/canagliflozine-en-hf-uitkomsten-bij-behouden-versus-verminderde-ef-canvas/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2018/07/31/canagliflozine-en-hartfalen-bij-diabetes-type-2-canvas-programma/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/01/23/canagliflozine-voor-primaire-en-secundaire-cardiovasculaire-preventie-canvas/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/08/17/canagliflozine-en-cardiovasculaire-en-renale-events-bij-diabetes-type-2-nejm-can/","published":"2017-08-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"davide-stolfo","type":"person","url":"https://hartvaat.nl/mensen/davide-stolfo/","name":"Davide Stolfo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/25/pah-met-renaal-diabetische-overlap-komt-vaak-voor-en-geeft-tweemaal-zo-hoog-mort/","published":"2026-06-01"},{"url":"https://hartvaat.nl/2026/02/03/rechterhart-hemodynamiek-voor-risicostratificatie-bij-pulmonale-arteriele-hypert/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2026/02/03/geslachtsverschillen-bij-patienten-met-gevorderd-hartfalen/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2024/08/01/coronaire-microvasculaire-disfunctie-bij-hfpef-meta-analyse/","published":"2024-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"davis-gates","type":"person","url":"https://hartvaat.nl/mensen/davis-gates/","name":"Davis Gates","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dean-a-fergusson","type":"person","url":"https://hartvaat.nl/mensen/dean-a-fergusson/","name":"Dean A Fergusson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2018/09/27/6-maandsuitkomsten-van-restrictieve-versus-liberale-transfusie-bij-hartchirurgie/","published":"2018-09-27"},{"url":"https://hartvaat.nl/2017/11/30/restrictieve-versus-liberale-bloedtransfusie-bij-hartchirurgie-nejm-trics-iii/","published":"2017-11-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"debabrata-mukherjee","type":"person","url":"https://hartvaat.nl/mensen/debabrata-mukherjee/","name":"Debabrata Mukherjee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"debbie-a-lawlor","type":"person","url":"https://hartvaat.nl/mensen/debbie-a-lawlor/","name":"Debbie A Lawlor","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/08/01/hypertensieve-zwangerschapsaandoeningen-en-dna-methylering-bij-pasgeborenen/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/05/07/zwangerschapsgewichtstoename-en-maternale-en-neonatale-uitkomsten-jama-meta-anal/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2018/11/27/metabolome-consequenties-van-pcsk9-remming-versus-statinetherapie/","published":"2018-11-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"deirdre-a-lane","type":"person","url":"https://hartvaat.nl/mensen/deirdre-a-lane/","name":"Deirdre A Lane","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/07/lancet-seminar-atriumfibrilleren-in-2026/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2025/03/15/doac-s-versus-geen-anticoagulatie-na-intracraniele-bloeding-bij-af-meta-analyse/","published":"2025-03-15"},{"url":"https://hartvaat.nl/2020/04/07/mobiele-gezondheidstechnologie-voor-af-zorg/","published":"2020-04-07"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"denise-mason","type":"person","url":"https://hartvaat.nl/mensen/denise-mason/","name":"Denise Mason","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/05/17/tandem-obicetrapib-plus-ezetimibe-voor-ldl-verlaging-lancet-fase-3/","published":"2025-05-17"},{"url":"https://hartvaat.nl/2024/07/09/bempedoinezuur-versus-statines-vergelijking-van-cv-voordelen/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"derek-s-chew","type":"person","url":"https://hartvaat.nl/mensen/derek-s-chew/","name":"Derek S Chew","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/10/03/vericiguat-bij-hfref-is-kosteneffectief-victoria-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","published":"2022-08-16"},{"url":"https://hartvaat.nl/2022/02/01/economische-uitkomsten-van-revalidatie-bij-ouderen-met-acuut-hf-rehab-hf/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2021/06/01/implanteerbare-versus-verlengde-externe-ecg-monitoring-voor-af-na-ischemisch-cva/","published":"2021-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"derick-m-todd","type":"person","url":"https://hartvaat.nl/mensen/derick-m-todd/","name":"Derick M Todd","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/03/30/ablatie-versus-antiaritmica-voor-vermindering-van-ziekenhuisbezoeken-bij-af/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"},{"url":"https://hartvaat.nl/2017/05/01/ablatie-index-als-marker-voor-ablatielaesiekwaliteit-voorspelling-van-pv-reconne/","published":"2017-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dexter-canoy","type":"person","url":"https://hartvaat.nl/mensen/dexter-canoy/","name":"Dexter Canoy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/25/bloeddrukverlaging-beschermt-over-het-hele-spectrum-van-chronische-nierschade-la/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2023/11/01/sekseverschillen-in-effect-van-bloeddrukverlaging-ipd-meta-analyse/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2022/07/27/langetermijneffect-van-antihypertensiva-op-bloeddruk-meta-analyse-op-individueel/","published":"2022-07-27"},{"url":"https://hartvaat.nl/2021/11/13/bloeddrukverlaging-en-risico-op-diabetes-type-2-lancet-bplttc-ipd-meta-analyse/","published":"2021-11-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dong","type":"person","url":"https://hartvaat.nl/mensen/dong/","name":"Dong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/21/chirurgie-voor-aortaklependocarditis-blijft-hoogrisico-spoed-en-inotropie-sterks/","published":"2026-07-20"},{"url":"https://hartvaat.nl/2026/04/24/cardiovasculaire-ziekte-bij-sikkelcelziekte-ondergediagnosticeerde-drijver-van-m/","published":"2026-05-11"},{"url":"https://hartvaat.nl/2026/02/02/machine-learning-nomogram-voorspelt-vroeg-transplantaatfalen-na-harttransplantat/","published":"2026-02-02"},{"url":"https://hartvaat.nl/2026/01/09/littekenweefsel-voorspelt-plotse-hartdood-na-een-infarct-grotendeels-buiten-de-e/","published":"2026-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dong-ju-choi","type":"person","url":"https://hartvaat.nl/mensen/dong-ju-choi/","name":"Dong-Ju Choi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/05/harttransplantatie-bij-hoogste-urgentie-meer-vroege-infecties-en-sterfte-mede-do/","published":"2026-07-30"},{"url":"https://hartvaat.nl/2026/03/25/bmi-en-prognose-bij-acuut-hartfalen-verschillen-per-fenotype-en-geslacht/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","published":"2021-10-14"},{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","published":"2020-10-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dongfeng-gu","type":"person","url":"https://hartvaat.nl/mensen/dongfeng-gu/","name":"Dongfeng Gu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/13/nt-probnp-en-af-risico-systematische-review-en-meta-analyse/","published":"2025-01-13"},{"url":"https://hartvaat.nl/2022/08/01/hele-genoomsequencing-onthult-nieuwe-bloeddruk-loci/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2019/09/01/interactieve-mobiele-gezondheidsinterventie-en-bloeddrukmanagement/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2017/04/01/optimale-systolische-bloeddruk-voor-primaire-cva-preventie-bij-hypertensie-csppt/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"donogh-maguire","type":"person","url":"https://hartvaat.nl/mensen/donogh-maguire/","name":"Donogh Maguire","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"doron-zahger","type":"person","url":"https://hartvaat.nl/mensen/doron-zahger/","name":"Doron Zahger","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/08/25/risicogestuurde-af-screening-met-machine-learning-verhoogt-detectiegraad-find-af/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"douglas-kling","type":"person","url":"https://hartvaat.nl/mensen/douglas-kling/","name":"Douglas Kling","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/25/obicetrapib-verlaagt-naast-ldl-en-apob-ook-lipoproteine-a/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2025/10/07/obicetrapib-en-mace-bij-hoogrisicopatienten-gepoolde-analyse/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"},{"url":"https://hartvaat.nl/2025/05/17/tandem-obicetrapib-plus-ezetimibe-voor-ldl-verlaging-lancet-fase-3/","published":"2025-05-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dr-ross-t-campbell","type":"person","url":"https://hartvaat.nl/mensen/dr-ross-t-campbell/","name":"Dr. Ross T. Campbell","title":"Senior Lecturer / Cardioloog, University of Glasgow","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":1,"articles":[{"url":"https://hartvaat.nl/2026/05/09/subcut-hf-ii-subcutane-furosemide-thuis-verlaagt-opnameduur-met-5-5-dagen-na-har/","published":"2026-05-11"}],"videos":[{"url":"https://hartvaat.nl/video/hfa-2026-late-breaking-science/subcut-hf-ii/","title":"SUBCUT HF II — Subcutane furosemide thuis verlaagt opnameduur met 5,5 dagen"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dragana-kosevic","type":"person","url":"https://hartvaat.nl/mensen/dragana-kosevic/","name":"Dragana Kosevic","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/03/c-mic-ii-hartfunctie-inspanningscapaciteit-en-kwaliteit-van-leven-zijn-verwante-/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2025/09/25/digitoxine-bij-hfref-gerandomiseerde-trial-nejm/","published":"2025-09-25"},{"url":"https://hartvaat.nl/2021/04/01/cardio-microstroomdevice-bij-chronisch-hf-eerste-klinische-studie/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2018/02/20/sekseverschillen-bij-ischemisch-hartfalen-na-cabg-stich-trial/","published":"2018-02-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-aradi","type":"person","url":"https://hartvaat.nl/mensen/daniel-aradi/","name":"Dániel Aradi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"edouard-benit","type":"person","url":"https://hartvaat.nl/mensen/edouard-benit/","name":"Edouard Benit","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2018/10/06/resolute-onyx-versus-orsiro-stent-lancet-gerandomiseerde-non-inferioriteitstrial/","published":"2018-10-06"},{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","published":"2018-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eduardo-perna","type":"person","url":"https://hartvaat.nl/mensen/eduardo-perna/","name":"Eduardo Perna","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","published":"2023-09-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"elena-arbelo","type":"person","url":"https://hartvaat.nl/mensen/elena-arbelo/","name":"Elena Arbelo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/06/02/catheterablatie-bij-atriumfibrilleren-in-cardiale-amyloidose-levert-42-ritmievri/","published":"2026-08-11"},{"url":"https://hartvaat.nl/2026/04/09/cardiale-screening-van-jonge-sporters-eerste-eapc-aepc-consensus-voor-kinderen/","published":"2026-07-15"},{"url":"https://hartvaat.nl/2026/03/07/lancet-seminar-atriumfibrilleren-in-2026/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/02/03/aanbesteding-van-cardiale-implanteerbare-devices-in-europa-waarde-of-kosten/","published":"2026-02-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"elizabeth-a-magnuson","type":"person","url":"https://hartvaat.nl/mensen/elizabeth-a-magnuson/","name":"Elizabeth A Magnuson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/05/07/gezondheidsstatus-na-mitraclip-bij-hf-met-secundaire-mr-coapt/","published":"2019-05-07"},{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","published":"2017-12-26"},{"url":"https://hartvaat.nl/2017/08/01/kosteneffectiviteit-van-langdurig-ticagrelor-na-mi-pegasus-timi-54/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/04/25/kwaliteit-van-leven-na-chirurgie-of-des-bij-drienvaten-of-hoofdstamlijden/","published":"2017-04-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"elizabeth-a-thomson","type":"person","url":"https://hartvaat.nl/mensen/elizabeth-a-thomson/","name":"Elizabeth A Thomson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","published":"2024-04-21"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"elke-schueler","type":"person","url":"https://hartvaat.nl/mensen/elke-schueler/","name":"Elke Schueler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/05/13/empagliflozine-erytropoese-en-ijzermobilisatie-bij-hartfalen/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2022/11/01/empagliflozine-vermindert-albuminurie-bij-hartfalen-emperor-pooled-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/03/23/mra-en-empagliflozine-interactie-bij-hf-emperor-reduced/","published":"2021-03-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"else-charlotte-sandset","type":"person","url":"https://hartvaat.nl/mensen/else-charlotte-sandset/","name":"Else Charlotte Sandset","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/10/07/2024-esc-richtlijn-voor-management-van-hypertensie/","published":"2024-10-07"},{"url":"https://hartvaat.nl/2024/05/30/right-2-ambulancebloeddrukverlaging-bij-hyperacuut-cva-nejm-vervolgresultaten/","published":"2024-05-30"},{"url":"https://hartvaat.nl/2024/05/16/annexa-i-andexanet-alfa-bij-factor-xa-remmer-geassocieerde-intracerebrale-bloedi/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2020/03/01/bloeddruk-en-uitkomsten-bij-acute-beroerte-trombectomie/","published":"2020-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"emil-hagstrom","type":"person","url":"https://hartvaat.nl/mensen/emil-hagstrom/","name":"Emil Hagström","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/04/11/heterogeniteit-in-bloeddrukrespons-op-antihypertensiva-jama-cross-over-rct/","published":"2023-04-11"},{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2020/02/25/polygene-risicoscore-en-voordeel-van-alirocumab-bij-coronairlijden-odyssey-outco/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2016/04/21/gdf-15-voorspelt-bloedingen-en-cardiovasculaire-events-bij-acuut-coronair-syndro/","published":"2016-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"emily-sammons","type":"person","url":"https://hartvaat.nl/mensen/emily-sammons/","name":"Emily Sammons","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2018/10/18/omega-3-vetzuursupplementen-bij-diabetes-nejm-ascend-omega-3/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2018/10/18/aspirine-voor-primaire-preventie-bij-diabetes-nejm-ascend/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2017/09/28/anacetrapib-bij-atherosclerotisch-vaatlijden-nejm-hps3-timi55-reveal/","published":"2017-09-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"enrico-fabris","type":"person","url":"https://hartvaat.nl/mensen/enrico-fabris/","name":"Enrico Fabris","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2021/12/01/thin-cap-fibroatheroom-voorspelt-events-bij-diabetes-met-normale-ffr-combine-oct/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2017/10/01/langetermijnmortaliteit-en-prehospitale-tirofibanbehandeling-bij-stemi/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2017/07/01/1-jaarsmortaliteit-bivalirudine-versus-heparine-in-de-ambulance-bij-stemi-matrix/","published":"2017-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eric-a-rose","type":"person","url":"https://hartvaat.nl/mensen/eric-a-rose/","name":"Eric A Rose","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"erick-schampaert","type":"person","url":"https://hartvaat.nl/mensen/erick-schampaert/","name":"Erick Schampaert","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"erik-lipsic","type":"person","url":"https://hartvaat.nl/mensen/erik-lipsic/","name":"Erik Lipsic","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/12/21/tavi-plus-ffr-geleide-pci-gecombineerde-benadering-onderzocht/","published":"2025-12-21"},{"url":"https://hartvaat.nl/2021/10/05/ketonlichamen-en-functionele-uitkomsten-na-stemi/","published":"2021-10-05"},{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","published":"2016-06-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"erin-d-michos","type":"person","url":"https://hartvaat.nl/mensen/erin-d-michos/","name":"Erin D Michos","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/05/17/tandem-obicetrapib-plus-ezetimibe-voor-ldl-verlaging-lancet-fase-3/","published":"2025-05-17"},{"url":"https://hartvaat.nl/2023/01/03/rosuvastatine-versus-voedingssupplementen-voor-lipidenmanagement/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2020/10/13/dapt-na-pci-met-des-netwerkmeta-analyse-van-duur-en-intensiteit/","published":"2020-10-13"},{"url":"https://hartvaat.nl/2016/08/01/vitamine-d-en-incidentie-van-atriumfibrilleren-de-aric-studie/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eue-keun-choi","type":"person","url":"https://hartvaat.nl/mensen/eue-keun-choi/","name":"Eue-Keun Choi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/12/off-label-onderdosering-edoxaban-bij-af-en-systemische-embolieen/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/02/27/van-vitamine-k-antagonist-naar-doac-bij-kwetsbare-ouderen-met-af/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2025/10/14/alone-af-langetermijn-anticoagulatieonthouding-na-af-ablatie-rct/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2024/12/05/edoxaban-bij-af-en-stabiel-coronairlijden-antitrombotische-monotherapie/","published":"2024-12-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eun-ho-choo","type":"person","url":"https://hartvaat.nl/mensen/eun-ho-choo/","name":"Eun Ho Choo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/06/directe-versus-gestageerde-complete-revascularisatie-tijdens-index-opname-bij-st/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2024/02/01/talos-ami-dapt-de-escalatie-veilig-bij-mi-met-hoog-ischemisch-risico/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eunju-hurh","type":"person","url":"https://hartvaat.nl/mensen/eunju-hurh/","name":"Eunju Hurh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","published":"2022-04-06"},{"url":"https://hartvaat.nl/2020/10/21/vupanorsen-angptl3-antisense-en-triglyceriden-ehj/","published":"2020-10-21"},{"url":"https://hartvaat.nl/2019/09/01/galnac-geconjugeerd-antisense-tegen-apoc3-triglyceriden-en-atherogene-lipoprotei/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2017/07/20/angptl3-antisense-oligonucleotiden-cardiovasculaire-en-metabole-effecten-nejm/","published":"2017-07-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"eva-gerdts","type":"person","url":"https://hartvaat.nl/mensen/eva-gerdts/","name":"Eva Gerdts","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/10/07/2024-esc-richtlijn-voor-management-van-hypertensie/","published":"2024-10-07"},{"url":"https://hartvaat.nl/2023/11/01/sekseverschillen-in-effect-van-bloeddrukverlaging-ipd-meta-analyse/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2019/10/01/lage-arteriele-compliance-en-cv-morbiditeit-bij-aortaklepstenose/","published":"2019-10-01"},{"url":"https://hartvaat.nl/2017/09/01/slagvolume-en-cardiovasculair-risico-bij-progressie-van-aortaklepstenose/","published":"2017-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"evgeny-kretov","type":"person","url":"https://hartvaat.nl/mensen/evgeny-kretov/","name":"Evgeny Kretov","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/03/04/stapsgewijze-provisionale-versus-systematische-dualstent-bij-ware-linker-hoofdst/","published":"2025-03-04"},{"url":"https://hartvaat.nl/2021/10/01/ebc-hoofdstam-stentstudie-provisional-versus-systematisch-dubbel-stenten/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2020/08/25/pulmonale-arterie-denervatie-bij-residuele-ph-na-endarterectomie/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/01/07/bioresorbeerbare-scaffold-versus-ees-bij-stabiel-coronairlijden-prospectieve-tri/","published":"2019-01-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fang-chen","type":"person","url":"https://hartvaat.nl/mensen/fang-chen/","name":"Fang Chen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/10/28/step-6-jaarsresultaten-intensieve-bloeddrukcontrole-bij-ouderen-langetermijn/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2018/10/18/omega-3-vetzuursupplementen-bij-diabetes-nejm-ascend-omega-3/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2018/10/18/aspirine-voor-primaire-preventie-bij-diabetes-nejm-ascend/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2017/09/28/anacetrapib-bij-atherosclerotisch-vaatlijden-nejm-hps3-timi55-reveal/","published":"2017-09-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fangfang-fan","type":"person","url":"https://hartvaat.nl/mensen/fangfang-fan/","name":"Fangfang Fan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/11/ffr-geleide-nierslagaderstenting-bij-atherosclerotische-renovasculaire-hypertens/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2022/06/01/interatriale-shuntdevices-bij-hartfalen-systematische-review-en-meta-analyse/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2017/04/01/optimale-systolische-bloeddruk-voor-primaire-cva-preventie-bij-hypertensie-csppt/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/07/01/polsgolfsnelheid-en-bloeddrukcontrole-als-onafhankelijke-voorspellers-van-cva-bi/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"federica-galimberti","type":"person","url":"https://hartvaat.nl/mensen/federica-galimberti/","name":"Federica Galimberti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/22/orale-pcsk9-remmers-meta-analyse-bevestigt-krachtige-ldl-daling/","published":"2026-06-07"},{"url":"https://hartvaat.nl/2026/05/24/eas-consensus-wereldwijde-harmonisatie-van-lipidenklinieken/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/04/22/angptl3-remmers-verlagen-breed-lipidenspectrum-vooral-remnant-en-triglyceriden/","published":"2026-05-05"},{"url":"https://hartvaat.nl/2026/02/25/behandeling-van-familiaire-hypercholesterolemie-bij-kinderen-3-jaar-lipigen-regi/","published":"2026-02-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fei-ye","type":"person","url":"https://hartvaat.nl/mensen/fei-ye/","name":"Fei Ye","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/07/dcb-voor-zijtak-bij-provisionale-stenting-gerandomiseerde-trial/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2018/12/18/ivus-versus-angiografie-geleide-des-implantatie-de-ultimate-trial/","published":"2018-12-18"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"felix-bohm","type":"person","url":"https://hartvaat.nl/mensen/felix-bohm/","name":"Felix Böhm","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","published":"2025-12-13"},{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","published":"2024-11-05"},{"url":"https://hartvaat.nl/2024/11/02/bioadaptor-implantaat-versus-drug-eluting-stent-bij-stabiel-coronairlijden/","published":"2024-11-02"},{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","published":"2024-04-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"feng-j-he","type":"person","url":"https://hartvaat.nl/mensen/feng-j-he/","name":"Feng J He","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/11/01/bloeddrukverlagende-medicatie-en-natriumbeperking-gecombineerd-effect/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2020/07/01/natriumreductie-verhoogt-korte-keten-vetzuren-bij-onbehandelde-hypertensie/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2019/07/01/natriumreductie-metaboloom-en-cv-risico-bij-onbehandelde-zwarte-hypertensie/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2016/06/01/matige-zoutreductie-verlaagt-bloeddruk-en-albuminurie-bij-gestoorde-glucosetoler/","published":"2016-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"feng-xie","type":"person","url":"https://hartvaat.nl/mensen/feng-xie/","name":"Feng Xie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/01/sophocarpine-beschermt-tegen-pulmonale-hypertensie-in-preklinische-modellen/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2020/02/01/geschatte-cva-vrije-overleving-van-foliumzuurtherapie-bij-hypertensie-csppt/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/02/26/patientgerichte-transitional-care-bij-hf-hospitalisatie-jama-pact-hf/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2016/05/31/diagnostische-ultrageluidspulsen-verbeteren-microvasculaire-flow-bij-stemi-met-m/","published":"2016-05-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ferenc-horkay","type":"person","url":"https://hartvaat.nl/mensen/ferenc-horkay/","name":"Ferenc Horkay","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/08/13/off-pump-versus-on-pump-cabg-bij-hoofdstamcoronairlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"filip-casselman","type":"person","url":"https://hartvaat.nl/mensen/filip-casselman/","name":"Filip Casselman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"filippo-ottani","type":"person","url":"https://hartvaat.nl/mensen/filippo-ottani/","name":"Filippo Ottani","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","published":"2025-09-13"},{"url":"https://hartvaat.nl/2018/06/05/verlaagde-dosis-prasugrel-versus-standaard-clopidogrel-bij-oudere-acs-patienten/","published":"2018-06-05"},{"url":"https://hartvaat.nl/2016/02/02/ciclosporine-a-bij-gereperfuseerd-myocardinfarct-de-multicenter-cycle-trial/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"filippo-russo","type":"person","url":"https://hartvaat.nl/mensen/filippo-russo/","name":"Filippo Russo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"finlay-a-mcalister","type":"person","url":"https://hartvaat.nl/mensen/finlay-a-mcalister/","name":"Finlay A McAlister","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/06/17/bedmed-timing-van-antihypertensieve-medicatie-en-cv-events-jama-definitieve-tria/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2022/04/09/natriumreductie-100-mmol-bij-hartfalen-lancet-sodium-hf/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2019/08/01/hoog-versus-laag-zuurstof-bij-acuut-hartfalen-hilo-hf-pilot/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/05/01/verlaging-van-diastolische-druk-bij-patienten-met-en-zonder-cardiovasculaire-zie/","published":"2018-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"florian-m-m-baeres","type":"person","url":"https://hartvaat.nl/mensen/florian-m-m-baeres/","name":"Florian M M Baeres","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","published":"2025-03-24"},{"url":"https://hartvaat.nl/2024/10/22/flow-semaglutide-vermindert-hartfalen-bij-diabetes-en-ckd/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/07/11/flow-semaglutide-beschermt-nieren-bij-type-2-diabetes-en-ckd-nejm-gerelateerd/","published":"2024-07-11"},{"url":"https://hartvaat.nl/2020/03/17/liraglutide-cv-uitkomsten-bij-diabetes-met-of-zonder-hartfalen-leader/","published":"2020-03-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"florim-cuculi","type":"person","url":"https://hartvaat.nl/mensen/florim-cuculi/","name":"Florim Cuculi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/21/1-op-10-patienten-heroptname-binnen-30-dagen-na-tavi-sterfterisico-na-1-jaar-ver/","published":"2026-06-09"},{"url":"https://hartvaat.nl/2023/11/25/biodegradeerbare-versus-duurzame-polymeer-des-bij-stemi-langetermijndata/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2018/09/01/ultradunne-biodegradeerbare-versus-dunne-duurzame-stents-lancet-gerandomiseerde-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2016/03/01/bioresorbeerbare-scaffold-trombose-multicenteranalyse-van-klinische-presentatie-/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fosca-quarti-trevano","type":"person","url":"https://hartvaat.nl/mensen/fosca-quarti-trevano/","name":"Fosca Quarti-Trevano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/01/sympathische-overactiviteit-bij-resistente-hypertensie-meta-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/01/01/reproduceerbaarheid-en-behandeleffect-op-kantoor-versus-ambulante-bloeddrukrelat/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2023/03/01/renale-denervatie-en-sympathische-activiteit-systematische-review/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2018/08/01/sympathische-zenuwactivatie-bij-essentiele-hypertensie-meta-analyse/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francesca-mallamaci","type":"person","url":"https://hartvaat.nl/mensen/francesca-mallamaci/","name":"Francesca Mallamaci","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/08/21/scd-bij-ckd-en-dialyse-heterogene-aritmieen-en-mechanisme-gestuurde-preventie/","published":"2026-08-29"},{"url":"https://hartvaat.nl/2026/02/09/communicatie-tussen-nier-en-hart-via-extracellulaire-vesikels/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2021/12/01/longechogeleide-behandeling-bij-hemodialysepatienten-met-hoog-cv-risico-gerandom/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2018/08/01/sympathische-zenuwactivatie-bij-essentiele-hypertensie-meta-analyse/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francesco-cosentino","type":"person","url":"https://hartvaat.nl/mensen/francesco-cosentino/","name":"Francesco Cosentino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/23/van-internationale-richtlijnen-naar-nationale-implementatie-bij-cardio-renaal-me/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2021/02/01/sglt2-remmers-en-cv-renale-uitkomsten-bij-diabetes-type-2-jama-cardiology-meta-a/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/12/08/ertugliflozine-en-hf-events-bij-diabetes-met-atherosclerotische-cvd-vertis-cv/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/10/08/ertugliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-vertis-cv/","published":"2020-10-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"francesco-prati","type":"person","url":"https://hartvaat.nl/mensen/francesco-prati/","name":"Francesco Prati","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"franz-h-messerli","type":"person","url":"https://hartvaat.nl/mensen/franz-h-messerli/","name":"Franz H Messerli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/07/01/timing-van-antihypertensiva-meta-analyse-van-rct-s-bevestigt-flexibiliteit/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2017/04/06/gewichtsfluctuaties-en-cardiovasculaire-uitkomsten-bij-coronairlijden-nejm/","published":"2017-04-06"},{"url":"https://hartvaat.nl/2016/06/01/selectieve-hartfrequentieverlaging-met-ivabradine-verhoogt-centrale-bloeddruk-bi/","published":"2016-06-01"},{"url":"https://hartvaat.nl/2016/02/02/vergelijking-chlorthalidon-en-hydrochloorthiazide-op-24-uurs-ambulante-bloeddruk/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fraser-j-graham","type":"person","url":"https://hartvaat.nl/mensen/fraser-j-graham/","name":"Fraser J Graham","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/23/ijzertekort-bij-chronische-nierziekte-en-hartfalen-expertperspectieven/","published":"2026-03-04"},{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","published":"2024-10-29"},{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","published":"2024-04-21"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fred-m-kusumoto","type":"person","url":"https://hartvaat.nl/mensen/fred-m-kusumoto/","name":"Fred M Kusumoto","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2019/08/20/2018-acc-aha-hrs-richtlijn-voor-bradycardie-en-geleidingsstoornissen/","published":"2019-08-20"},{"url":"https://hartvaat.nl/2016/05/17/institutionele-en-operateurvereisten-voor-linker-hartoorocclusie-scai-acc-hrs-st/","published":"2016-05-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fred-s-apple","type":"person","url":"https://hartvaat.nl/mensen/fred-s-apple/","name":"Fred S Apple","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"},{"url":"https://hartvaat.nl/2017/11/21/hoog-sensitief-troponine-i-en-uitkomsten-bij-verdenking-acs-jama-studie/","published":"2017-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fredrik-calais","type":"person","url":"https://hartvaat.nl/mensen/fredrik-calais/","name":"Fredrik Calais","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2022/03/15/5-jaars-ifr-versus-ffr-geleide-pci-define-flair-ifr-swedeheart/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2017/05/11/instantaneous-wave-free-ratio-versus-ffr-voor-pci-indicatie-nejm-ifr-swedeheart/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"freek-w-a-verheugt","type":"person","url":"https://hartvaat.nl/mensen/freek-w-a-verheugt/","name":"Freek W A Verheugt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/05/01/optimaal-antitrombotisch-regime-bij-af-na-pci-jama-cardiology-netwerkmeta-analys/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/08/01/antitrombotische-strategieen-bij-af-na-pci-jama-cardiology-veiligheids-en-werkza/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2018/11/01/aldosteronblokkade-bij-myocardinfarct-ipd-analyse-van-twee-trials/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/01/24/heropnames-bij-af-patienten-na-stenting-twee-antitromboticastrategieen-vergeleke/","published":"2017-01-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"friedrich-koehler","type":"person","url":"https://hartvaat.nl/mensen/friedrich-koehler/","name":"Friedrich Koehler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2018/09/22/telemedische-interventie-bij-hartfalen-lancet-tim-hf2/","published":"2018-09-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"friedrich-wilhelm-mohr","type":"person","url":"https://hartvaat.nl/mensen/friedrich-wilhelm-mohr/","name":"Friedrich-Wilhelm Mohr","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","published":"2021-07-13"},{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","published":"2019-10-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"fabio-s-silveira","type":"person","url":"https://hartvaat.nl/mensen/fabio-s-silveira/","name":"Fábio S Silveira","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2024/02/01/message-hf-geautomatiseerde-sms-na-hartfalenopname-verbetert-uitkomsten-niet/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2021/12/01/sms-strategie-bij-patienten-na-recente-hf-opname-studieontwerp/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/11/26/rivaroxaban-bij-af-met-bioprothese-mitralisklep-nejm-river/","published":"2020-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gabor-g-toth","type":"person","url":"https://hartvaat.nl/mensen/gabor-g-toth/","name":"Gabor G Toth","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/09/26/biodegradeerbare-versus-duurzame-polymeer-stents-bij-hoog-bloedingsrisico/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2019/04/01/ffr-verbetering-na-pci-en-uitkomsten-inclusief-symptoomverlichting/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2016/11/29/natuurlijk-beloop-van-coronaire-atherosclerose-met-ffr-prospectieve-studie/","published":"2016-11-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gabor-z-duray","type":"person","url":"https://hartvaat.nl/mensen/gabor-z-duray/","name":"Gabor Z Duray","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/07/02/upgrade-rv-naar-crt-pacing-bij-hartfalen-met-af-voordelen-bevestigd/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/10/21/upgrade-van-rv-pacing-naar-crt-bij-hartfalen-gerandomiseerde-trial/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2017/09/01/budapest-crt-upgrade-study-studieontwerp-voor-crt-upgrade/","published":"2017-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"geert-jan-geersing","type":"person","url":"https://hartvaat.nl/mensen/geert-jan-geersing/","name":"Geert-Jan Geersing","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/05/nederlandse-huisartsenpost-1-op-20-contacten-voor-benauwdheid-betreft-hartfalen-/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2024/01/23/switchen-van-vka-naar-noac-bij-fragiele-ouderen-met-af-veilig/","published":"2024-01-23"},{"url":"https://hartvaat.nl/2020/08/07/geintegreerd-af-management-in-de-huisartsenpraktijk-all-in-clustergerandomiseerd/","published":"2020-08-07"},{"url":"https://hartvaat.nl/2018/08/01/opportunistische-hf-screening-met-natriuretische-peptiden-bij-af-ipd-meta-analys/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gema-minana","type":"person","url":"https://hartvaat.nl/mensen/gema-minana/","name":"Gema Miñana","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/03/expertopinie-hierarchische-eindpunten-op-basis-van-verslechterend-hartfalen-voor/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/02/03/bio-impedantie-voor-vochtstatusbepaling-en-prognose-bij-chronisch-hartfalen/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2024/04/01/iv-ferricarboxymaltose-verbetert-linkeratriale-strain-bij-hartfalen-myocardial-i/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2021/11/23/betablokkerstaken-en-functionele-capaciteit-bij-hfpef/","published":"2021-11-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"geoffrey-wong","type":"person","url":"https://hartvaat.nl/mensen/geoffrey-wong/","name":"Geoffrey Wong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2020/01/02/alcoholonthouding-bij-drinkers-met-af-nejm-gerandomiseerde-trial/","published":"2020-01-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"george-d-yancopoulos","type":"person","url":"https://hartvaat.nl/mensen/george-d-yancopoulos/","name":"George D Yancopoulos","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/03/23/photon-aflibercept-8-mg-bij-diabetisch-macula-oedeem-verlengd-doseerinterval/","published":"2024-03-23"},{"url":"https://hartvaat.nl/2020/08/20/evinacumab-bij-homozygoot-familiaire-hypercholesterolemie-nejm/","published":"2020-08-20"},{"url":"https://hartvaat.nl/2020/02/25/polygene-risicoscore-en-voordeel-van-alirocumab-bij-coronairlijden-odyssey-outco/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2017/07/20/genetische-en-farmacologische-inactivatie-van-angptl3-en-cardiovasculaire-ziekte/","published":"2017-07-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"george-giannakoulas","type":"person","url":"https://hartvaat.nl/mensen/george-giannakoulas/","name":"George Giannakoulas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2025/04/01/symptomatisch-versus-asymptomatisch-af-en-klinische-uitkomsten-meta-analyse/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/01/14/residuele-lekkage-na-laa-occlusie-en-uitkomsten-meta-analyse/","published":"2024-01-14"},{"url":"https://hartvaat.nl/2023/11/10/transcatheter-asd-sluiting-bij-ouderen-systematische-review-en-meta-analyse/","published":"2023-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"georgios-tsivgoulis","type":"person","url":"https://hartvaat.nl/mensen/georgios-tsivgoulis/","name":"Georgios Tsivgoulis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/05/tenecteplase-bij-basilarisocclusie-tot-24-uur-veelbelovende-lancet-data/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2024/05/16/annexa-i-andexanet-alfa-bij-factor-xa-remmer-geassocieerde-intracerebrale-bloedi/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2020/03/01/bloeddruk-en-uitkomsten-bij-acute-beroerte-trombectomie/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2017/01/01/bloeddrukverlaging-en-secundaire-cva-preventie-meta-regressieanalyse/","published":"2017-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gheorghe-doros","type":"person","url":"https://hartvaat.nl/mensen/gheorghe-doros/","name":"Gheorghe Doros","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/10/01/atriumfibrilleren-bij-wild-type-transthyretine-cardiale-amyloidose-review/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/05/14/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-meta-analyse/","published":"2018-05-14"},{"url":"https://hartvaat.nl/2017/10/21/ultradunne-bioresorbeerbare-versus-dunne-duurzame-polymer-stents-lancet-bioscien/","published":"2017-10-21"},{"url":"https://hartvaat.nl/2016/04/12/protonpompremmers-verminderen-gastro-intestinale-events-ongeacht-aspirinedosis-b/","published":"2016-04-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giacomo-ruotolo","type":"person","url":"https://hartvaat.nl/mensen/giacomo-ruotolo/","name":"Giacomo Ruotolo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/05/20/solbinsiran-angptl3-remming-van-preklinisch-tot-eerste-humane-studies/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/05/03/solbinsiran-langwerkend-sirna-tegen-angptl3-duurzaamheid-en-effectiviteit/","published":"2025-05-03"},{"url":"https://hartvaat.nl/2020/10/01/crp-op-lp-a-geassocieerd-cv-risico-bij-optimaal-behandelde-hoogrisicopatienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giedrius-davidavicius","type":"person","url":"https://hartvaat.nl/mensen/giedrius-davidavicius/","name":"Giedrius Davidavičius","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gilbert-gosselin","type":"person","url":"https://hartvaat.nl/mensen/gilbert-gosselin/","name":"Gilbert Gosselin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","published":"2021-02-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gilbert-habib","type":"person","url":"https://hartvaat.nl/mensen/gilbert-habib/","name":"Gilbert Habib","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/06/laminopathieen-natuurlijk-beloop-en-voorspelmodel-voor-hartfalen/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2026/02/03/effect-van-mavacamten-op-risicoscores-voor-plotse-hartdood-bij-hypertrofische-ca/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/01/14/tri-fr-transcatheter-edge-to-edge-repair-bij-geisoleerde-ernstige-tr-rct/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2016/02/01/rechterkamerseptumpacing-versus-apexpacing-bij-crt-defibrillator-gerandomiseerde/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gillian-a-j-jessurun","type":"person","url":"https://hartvaat.nl/mensen/gillian-a-j-jessurun/","name":"Gillian A J Jessurun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/12/01/coronairangiografie-na-hartstilstand-zonder-st-elevatie-coact-1-jaarsuitkomsten/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/04/11/coronairangiografie-na-hartstilstand-zonder-st-elevatie-nejm-coact/","published":"2019-04-11"},{"url":"https://hartvaat.nl/2018/10/06/resolute-onyx-versus-orsiro-stent-lancet-gerandomiseerde-non-inferioriteitstrial/","published":"2018-10-06"},{"url":"https://hartvaat.nl/2018/02/03/sirolimus-eluting-bioabsorbeerbare-stent-versus-everolimus-eluting-stent-na-mi-l/","published":"2018-02-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giorgio-sacchetta","type":"person","url":"https://hartvaat.nl/mensen/giorgio-sacchetta/","name":"Giorgio Sacchetta","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giovanni-pedrazzini","type":"person","url":"https://hartvaat.nl/mensen/giovanni-pedrazzini/","name":"Giovanni Pedrazzini","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2019/11/19/evolocumab-voor-vroege-ldl-verlaging-bij-acs-evopacs/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","published":"2019-06-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giulio-francesco-romiti","type":"person","url":"https://hartvaat.nl/mensen/giulio-francesco-romiti/","name":"Giulio Francesco Romiti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/19/cardiovasculair-renaal-metabool-samenspel-bij-patienten-met-atriumfibrilleren/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2022/10/13/cerebrale-microbloedingen-en-risico-bij-af-systematische-review/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2021/09/14/copd-bij-af-prevalentie-management-en-impact-meta-analyse/","published":"2021-09-14"},{"url":"https://hartvaat.nl/2017/11/01/bloeddrukvariabiliteit-en-uitkomsten-bij-af-affirm-studie/","published":"2017-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giuseppe-de-luca","type":"person","url":"https://hartvaat.nl/mensen/giuseppe-de-luca/","name":"Giuseppe De Luca","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/21/tavi-plus-ffr-geleide-pci-gecombineerde-benadering-onderzocht/","published":"2025-12-21"},{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","published":"2023-03-14"},{"url":"https://hartvaat.nl/2021/12/01/thin-cap-fibroatheroom-voorspelt-events-bij-diabetes-met-normale-ffr-combine-oct/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2018/06/05/verlaagde-dosis-prasugrel-versus-standaard-clopidogrel-bij-oudere-acs-patienten/","published":"2018-06-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giuseppe-di-pasquale","type":"person","url":"https://hartvaat.nl/mensen/giuseppe-di-pasquale/","name":"Giuseppe Di Pasquale","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/11/01/antiplaatjestherapie-bij-mi-zonder-obstructief-coronairlijden-minoca/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2020/11/07/complete-revascularisatie-vermindert-cv-dood-bij-stemi-met-multivatenlijden-meta/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","published":"2019-10-10"},{"url":"https://hartvaat.nl/2018/02/01/dabigatran-versus-warfarine-bij-af-met-linkerventrikelhypertrofie-re-ly/","published":"2018-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giuseppe-ferrante","type":"person","url":"https://hartvaat.nl/mensen/giuseppe-ferrante/","name":"Giuseppe Ferrante","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/05/09/p2y12-monotherapie-of-aspirine-voor-secundaire-preventie-lancet-meta-analyse/","published":"2020-05-09"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/01/doac-plus-antiplaatjestherapie-voor-secundaire-preventie-na-acs-meta-analyse/","published":"2018-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giuseppe-patti","type":"person","url":"https://hartvaat.nl/mensen/giuseppe-patti/","name":"Giuseppe Patti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/24/myocardiale-brug-praktische-gids-voor-diagnose-en-behandeling-in-het-ccta-tijdpe/","published":"2026-04-21"},{"url":"https://hartvaat.nl/2026/02/03/vroeg-starten-met-mra-na-acuut-hartfalen-of-myocardinfarct-meta-analyse/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/07/09/coronaire-plaquefenotypeveranderingen-bij-lipidenverlagende-therapie-en-cardiova/","published":"2025-07-09"},{"url":"https://hartvaat.nl/2024/08/01/coronaire-microvasculaire-disfunctie-bij-hfpef-meta-analyse/","published":"2024-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"giuseppe-vadala","type":"person","url":"https://hartvaat.nl/mensen/giuseppe-vadala/","name":"Giuseppe Vadalà","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/26/esc-consensusverklaring-over-microvasculaire-obstructie-en-no-reflow-na-stemi/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gonzalo-pizarro","type":"person","url":"https://hartvaat.nl/mensen/gonzalo-pizarro/","name":"Gonzalo Pizarro","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/11/reboot-betablokkers-na-mi-sekseverschillen/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","published":"2016-06-14"},{"url":"https://hartvaat.nl/2016/05/10/timing-van-metoprolol-bij-stemi-effect-op-infarctgrootte-en-ventrikelfunctie/","published":"2016-05-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gordon-r-reeves","type":"person","url":"https://hartvaat.nl/mensen/gordon-r-reeves/","name":"Gordon R Reeves","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/02/01/fysieke-revalidatie-bij-fragiele-ouderen-met-acuut-hartfalen/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/07/12/frailteit-beinvloedt-effect-van-inspanningstraining-bij-hartfalen-hf-action-anal/","published":"2022-07-12"},{"url":"https://hartvaat.nl/2022/02/01/economische-uitkomsten-van-revalidatie-bij-ouderen-met-acuut-hf-rehab-hf/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2021/07/15/fysieke-revalidatie-bij-oudere-gehospitaliseerde-hf-patienten-nejm-rehab-hf/","published":"2021-07-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"greg-fulcher","type":"person","url":"https://hartvaat.nl/mensen/greg-fulcher/","name":"Greg Fulcher","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/05/28/canagliflozine-en-hf-uitkomsten-bij-behouden-versus-verminderde-ef-canvas/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2018/07/31/canagliflozine-en-hartfalen-bij-diabetes-type-2-canvas-programma/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/01/23/canagliflozine-voor-primaire-en-secundaire-cardiovasculaire-preventie-canvas/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/08/17/canagliflozine-en-cardiovasculaire-en-renale-events-bij-diabetes-type-2-nejm-can/","published":"2017-08-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gregor-fahrni","type":"person","url":"https://hartvaat.nl/mensen/gregor-fahrni/","name":"Gregor Fahrni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/05/02/paclitaxel-gecoate-ballonnen-versus-des-bij-kleine-vaten-ipd-meta-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2024/12/16/gp-iib-iiia-remmers-bij-acuut-mi-en-microvasculaire-obstructie-meta-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2020/05/26/subcutaan-selatogrel-remt-plaatjesaggregatie-bij-acuut-mi/","published":"2020-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gregor-leibundgut","type":"person","url":"https://hartvaat.nl/mensen/gregor-leibundgut/","name":"Gregor Leibundgut","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2020/11/07/drug-coated-balloons-versus-des-bij-kleine-coronairarterien-lancet-basket-small-/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2018/09/08/drug-coated-balloons-bij-kleine-coronairarterien-lancet-basket-small-2/","published":"2018-09-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gregory-a-ewald","type":"person","url":"https://hartvaat.nl/mensen/gregory-a-ewald/","name":"Gregory A Ewald","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/05/23/hemocompatibiliteitsuitkomsten-van-heartmate-3-na-6-maanden-momentum-3/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","published":"2017-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"greta-carrara","type":"person","url":"https://hartvaat.nl/mensen/greta-carrara/","name":"Greta Carrara","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/09/gepersonaliseerde-versus-standaard-dapt-duur-na-pci-gerandomiseerde-trial/","published":"2025-12-09"},{"url":"https://hartvaat.nl/2021/02/02/dalend-hemoglobine-en-prognose-bij-acs-hospitalisatie/","published":"2021-02-02"},{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","published":"2019-02-26"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"grzegorz-smolka","type":"person","url":"https://hartvaat.nl/mensen/grzegorz-smolka/","name":"Grzegorz Smolka","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/19/salamander-register-95-5-technisch-succes-bij-stand-alone-linker-hartoor-occlusi/","published":"2026-06-10"},{"url":"https://hartvaat.nl/2026/02/26/cardiogene-shock-bij-myocardinfarct-resultaten-van-het-shock-pol-register/","published":"2026-03-02"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"guang-ning","type":"person","url":"https://hartvaat.nl/mensen/guang-ning/","name":"Guang Ning","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/03/27/intensieve-bloeddrukcontrole-bij-type-2-diabetes-nejm/","published":"2025-03-27"},{"url":"https://hartvaat.nl/2023/08/01/bloeddrukstreefwaarden-bij-type-2-diabetes-netwerk-meta-analyse/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2023/01/01/opleiding-intelligentie-en-cognitie-onafhankelijke-verbanden-met-hypertensie/","published":"2023-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"guido-tavazzi","type":"person","url":"https://hartvaat.nl/mensen/guido-tavazzi/","name":"Guido Tavazzi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/25/palliatieve-zorg-in-de-cardiologie-een-state-of-the-art-overzicht/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/02/19/delirium-in-de-cardiovasculaire-geneeskunde/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/04/29/vroege-iabp-bij-hartfalen-gerelateerde-cardiogene-shock-gerandomiseerde-trial/","published":"2025-04-29"},{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","published":"2020-05-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"guillaume-bonnet","type":"person","url":"https://hartvaat.nl/mensen/guillaume-bonnet/","name":"Guillaume Bonnet","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/21/tavi-plus-ffr-geleide-pci-gecombineerde-benadering-onderzocht/","published":"2025-12-21"},{"url":"https://hartvaat.nl/2025/01/14/tri-fr-transcatheter-edge-to-edge-repair-bij-geisoleerde-ernstige-tr-rct/","published":"2025-01-14"},{"url":"https://hartvaat.nl/2018/12/13/percutaan-herstel-of-medicamenteuze-therapie-bij-secundaire-mr-nejm-mitra-fr/","published":"2018-12-13"},{"url":"https://hartvaat.nl/2017/11/01/switchen-van-dapt-na-acs-de-topic-trial/","published":"2017-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gunnar-gislason","type":"person","url":"https://hartvaat.nl/mensen/gunnar-gislason/","name":"Gunnar Gislason","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/07/31/uit-het-hospitaal-hartstilstand-komt-12-keer-vaker-voor-bij-niet-ischemische-car/","published":"2026-08-16"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"guozhe-sun","type":"person","url":"https://hartvaat.nl/mensen/guozhe-sun/","name":"Guozhe Sun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2024/09/01/multifactorieel-intensief-bloeddrukmodel-bij-ouderen-en-jongeren/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/03/18/intensieve-bloeddrukinterventie-door-niet-artsen-in-lage-inkomenslanden-lancet-r/","published":"2023-03-18"},{"url":"https://hartvaat.nl/2022/05/21/dorpsarts-geleide-multifacet-interventie-voor-bloeddrukcontrole-in-ruraal-china-/","published":"2022-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gustavs-latkovskis","type":"person","url":"https://hartvaat.nl/mensen/gustavs-latkovskis/","name":"Gustavs Latkovskis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/08/18/semaglutide-verlaagt-hscrp-en-ontstekingsactiviteit-bij-ascvd-patienten-met-over/","published":"2026-08-26"},{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/24/eas-consensus-wereldwijde-harmonisatie-van-lipidenklinieken/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gerald-simonneau","type":"person","url":"https://hartvaat.nl/mensen/gerald-simonneau/","name":"Gérald Simonneau","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/02/20/morbiditeit-bij-pulmonaal-arteriele-hypertensie-als-prognostische-marker-voor-mo/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/04/14/macitentan-en-hemodynamiek-bij-pah-seraphin-hemodynamische-substudie/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/04/01/hemodynamische-effecten-van-riociguat-bij-inoperabel-cteph/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/01/01/2015-esc-ers-richtlijn-voor-diagnostiek-en-behandeling-van-pulmonale-hypertensie/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"gerard-helft","type":"person","url":"https://hartvaat.nl/mensen/gerard-helft/","name":"Gérard Helft","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/11/07/stentontwerp-en-dapt-duur-effect-op-ischemie-en-bloedingen-netwerkmeta-analyse/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2016/01/21/stoppen-of-doorgaan-met-clopidogrel-12-maanden-na-drug-eluting-stent-optidual-tr/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"geraud-souteyrand","type":"person","url":"https://hartvaat.nl/mensen/geraud-souteyrand/","name":"Géraud Souteyrand","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/07/01/calcified-oct-versus-angiografie-bij-pci-van-verkalkte-laesies/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"},{"url":"https://hartvaat.nl/2016/09/27/oct-geleide-pci-optimalisatie-bij-nste-acs-gerandomiseerde-trial/","published":"2016-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"habib-gamra","type":"person","url":"https://hartvaat.nl/mensen/habib-gamra/","name":"Habib Gamra","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/02/01/aspirine-en-cardiovasculaire-uitkomsten-bij-chronische-nierziekte/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"haiying-chen","type":"person","url":"https://hartvaat.nl/mensen/haiying-chen/","name":"Haiying Chen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/02/01/fysieke-revalidatie-bij-fragiele-ouderen-met-acuut-hartfalen/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/02/01/economische-uitkomsten-van-revalidatie-bij-ouderen-met-acuut-hf-rehab-hf/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/07/15/fysieke-revalidatie-bij-oudere-gehospitaliseerde-hf-patienten-nejm-rehab-hf/","published":"2021-07-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hans-j-woerle","type":"person","url":"https://hartvaat.nl/mensen/hans-j-woerle/","name":"Hans J Woerle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/02/01/empagliflozine-en-cv-dood-en-hf-hospitalisatie-over-het-hf-spectrum-empa-reg-out/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2018/01/09/empagliflozine-bij-diabetes-type-2-met-cardiovasculaire-ziekte-en-ckd-empa-reg-o/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2016/12/01/empagliflozine-en-bloeddruk-bij-diabetes-type-2-met-hypertensie-naar-achtergrond/","published":"2016-12-01"},{"url":"https://hartvaat.nl/2016/07/28/empagliflozine-en-progressie-van-nierziekte-bij-diabetes-type-2-nejm-empa-reg-re/","published":"2016-07-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hans-josef-feistritzer","type":"person","url":"https://hartvaat.nl/mensen/hans-josef-feistritzer/","name":"Hans-Josef Feistritzer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/03/4-eiwitmodel-voor-cardiogene-shock-prognose-danger-substudie/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2025/12/01/scai-shockklassen-en-prognose-bij-ami-cardiogene-shock-danger-substudie/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hao-zhou","type":"person","url":"https://hartvaat.nl/mensen/hao-zhou/","name":"Hao Zhou","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/05/20/angptl3-antilichaam-bij-suboptimaal-gecontroleerde-hyperlipidemie-fase-2/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/04/26/angiografie-afgeleide-ffr-versus-ivus-bij-pci-gerandomiseerde-trial/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","published":"2022-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"harpreet-s-bhatia","type":"person","url":"https://hartvaat.nl/mensen/harpreet-s-bhatia/","name":"Harpreet S Bhatia","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/22/il-6-sterker-met-hart-en-vaatziekte-geassocieerd-dan-ldl-lp-a-en-crp/","published":"2026-05-22"},{"url":"https://hartvaat.nl/2026/02/21/aspirine-lipoproteine-a-en-aortaklepstenose-de-mesa-studie/","published":"2026-02-21"},{"url":"https://hartvaat.nl/2025/01/28/lp-a-en-ldl-cholesterol-onafhankelijke-cv-risicopaden/","published":"2025-01-28"},{"url":"https://hartvaat.nl/2021/09/21/pcsk9-remming-en-geoxideerde-fosfolipiden/","published":"2021-09-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"he-huang","type":"person","url":"https://hartvaat.nl/mensen/he-huang/","name":"He Huang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2024/10/21/shensong-yangxin-voorkomt-af-recidief-na-ablatie-bij-persisterend-af/","published":"2024-10-21"},{"url":"https://hartvaat.nl/2022/11/22/ees-versus-cabg-bij-meervatslijden-langetermijn-follow-up-van-rct-s/","published":"2022-11-22"},{"url":"https://hartvaat.nl/2021/05/21/katheterablatie-versus-medicatie-bij-persisterend-en-langdurig-persisterend-af-l/","published":"2021-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hee-tae-yu","type":"person","url":"https://hartvaat.nl/mensen/hee-tae-yu/","name":"Hee Tae Yu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/10/14/alone-af-langetermijn-anticoagulatieonthouding-na-af-ablatie-rct/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2024/12/03/ct-gestuurde-atriale-wanddiktemapping-bij-cryoballon-pvi/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2019/05/14/wanneer-doac-stoppen-voor-af-ablatie-multicenter-analyse/","published":"2019-05-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"helen-reeve-stoffer","type":"person","url":"https://hartvaat.nl/mensen/helen-reeve-stoffer/","name":"Helen Reeve-Stoffer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"helmut-purerfellner","type":"person","url":"https://hartvaat.nl/mensen/helmut-purerfellner/","name":"Helmut Pürerfellner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","published":"2026-05-27"},{"url":"https://hartvaat.nl/2026/02/03/aanbesteding-van-cardiale-implanteerbare-devices-in-europa-waarde-of-kosten/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/10/31/pfa-versus-thermale-ablatie-periprocedurale-en-middellangetermijneffecten/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2024/08/03/dagontslag-versus-overnachting-na-af-ablatie-uitgebreide-meta-analyse/","published":"2024-08-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"helmut-schumacher","type":"person","url":"https://hartvaat.nl/mensen/helmut-schumacher/","name":"Helmut Schumacher","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/09/01/bereikte-diastolische-bloeddruk-en-polsdruk-bij-streef-sbp-en-cv-uitkomsten-bij-/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/11/01/gemiddelde-bloeddruk-en-visit-to-visit-variabiliteit-als-gecombineerde-voorspell/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/06/03/bereikte-bloeddruk-en-cv-uitkomsten-bij-hoogrisicopatienten-ontarget-transcend/","published":"2017-06-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"henri-lu","type":"person","url":"https://hartvaat.nl/mensen/henri-lu/","name":"Henri Lu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/11/finearts-hf-subanalyse-virale-luchtweginfecties-triggeren-hartfalen-verslechteri/","published":"2026-05-12"},{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","published":"2024-05-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"henrik-kjaerulf-jensen","type":"person","url":"https://hartvaat.nl/mensen/henrik-kjaerulf-jensen/","name":"Henrik Kjærulf Jensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/05/03/multimodaliteitsbeeldvorming-geleide-lv-leadplaatsing-bij-crt-langetermijn/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2019/09/01/elektrisch-versus-beeldvorming-geleide-lv-leadplaatsing-bij-crt-gerandomiseerde-/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"henrik-renlund","type":"person","url":"https://hartvaat.nl/mensen/henrik-renlund/","name":"Henrik Renlund","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/25/abc-af-risicoscores-voor-gepersonaliseerde-af-behandeling/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2024/11/02/bioadaptor-implantaat-versus-drug-eluting-stent-bij-stabiel-coronairlijden/","published":"2024-11-02"},{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2017/01/10/trombusaspiratie-bij-stemi-individuele-patientdata-meta-analyse/","published":"2017-01-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"henrik-wiggers","type":"person","url":"https://hartvaat.nl/mensen/henrik-wiggers/","name":"Henrik Wiggers","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/03/metformine-remt-proliferatie-van-fibro-adipogene-stamcellen-uit-falende-harten/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2024/11/12/ketonester-bij-type-2-diabetes-en-hartfalen-cross-over-trial/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/05/07/orale-ketonester-bij-hfref-gerandomiseerde-trial/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2019/04/30/ketonlichaam-3-hydroxybutyraat-bij-chronisch-hartfalen-cardiovasculaire-effecten/","published":"2019-04-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hiroki-shiomi","type":"person","url":"https://hartvaat.nl/mensen/hiroki-shiomi/","name":"Hiroki Shiomi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","published":"2024-05-04"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hiroshi-suzuki","type":"person","url":"https://hartvaat.nl/mensen/hiroshi-suzuki/","name":"Hiroshi Suzuki","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/08/premier-in-hospital-start-van-sacubitril-valsartan-bij-acuut-hartfalen/","published":"2024-11-08"},{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hisato-takagi","type":"person","url":"https://hartvaat.nl/mensen/hisato-takagi/","name":"Hisato Takagi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/07/optimale-strategie-voor-complete-revascularisatie-bij-stemi-met-meervatslijden-m/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2023/12/05/intravasculaire-beeldvorming-versus-functionele-versus-angiografische-pci-begele/","published":"2023-12-05"},{"url":"https://hartvaat.nl/2021/08/24/de-escalatie-van-dapt-bij-acs-jacc-review/","published":"2021-08-24"},{"url":"https://hartvaat.nl/2020/01/28/orale-antistolling-bij-af-op-langdurige-hemodialyse/","published":"2020-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hong-jiang","type":"person","url":"https://hartvaat.nl/mensen/hong-jiang/","name":"Hong Jiang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/10/14/heparine-bij-eerste-medisch-contact-versus-voor-primaire-pci-bij-stemi/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2021/05/21/katheterablatie-versus-medicatie-bij-persisterend-en-langdurig-persisterend-af-l/","published":"2021-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hong-nie","type":"person","url":"https://hartvaat.nl/mensen/hong-nie/","name":"Hong Nie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2021/04/01/ero-lvedv-ratio-en-respons-op-mitraclip-jama-cardiology/","published":"2021-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"horst-sievert","type":"person","url":"https://hartvaat.nl/mensen/horst-sievert/","name":"Horst Sievert","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2023/08/01/atrial-flow-regulator-en-overleving-bij-hartfalen-voorspelde-impact/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2017/01/01/percutane-linker-hartoorsluiting-munchen-consensusdocument-over-definities-en-ei/","published":"2017-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hossein-ardeschir-ghofrani","type":"person","url":"https://hartvaat.nl/mensen/hossein-ardeschir-ghofrani/","name":"Hossein-Ardeschir Ghofrani","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/08/20/tadalafil-bij-gecombineerde-post-en-precapillaire-ph-en-hfpef/","published":"2024-08-20"},{"url":"https://hartvaat.nl/2018/02/20/morbiditeit-bij-pulmonaal-arteriele-hypertensie-als-prognostische-marker-voor-mo/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/04/14/macitentan-en-hemodynamiek-bij-pah-seraphin-hemodynamische-substudie/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/04/01/hemodynamische-effecten-van-riociguat-bij-inoperabel-cteph/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"howard-a-cooper","type":"person","url":"https://hartvaat.nl/mensen/howard-a-cooper/","name":"Howard A Cooper","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2020/03/01/gewicht-en-werkzaamheid-veiligheid-van-doac-s-bij-niet-valvulair-af-meta-analyse/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/09/01/oac-bij-af-met-kleplijden-en-bioprothese-overzicht/","published":"2019-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hoyun-kim","type":"person","url":"https://hartvaat.nl/mensen/hoyun-kim/","name":"Hoyun Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","published":"2023-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hui-nam-pak","type":"person","url":"https://hartvaat.nl/mensen/hui-nam-pak/","name":"Hui-Nam Pak","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/10/14/alone-af-langetermijn-anticoagulatieonthouding-na-af-ablatie-rct/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2024/12/03/ct-gestuurde-atriale-wanddiktemapping-bij-cryoballon-pvi/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2019/05/14/wanneer-doac-stoppen-voor-af-ablatie-multicenter-analyse/","published":"2019-05-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hwanhee-hong","type":"person","url":"https://hartvaat.nl/mensen/hwanhee-hong/","name":"Hwanhee Hong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2020/05/01/optimaal-antitrombotisch-regime-bij-af-na-pci-jama-cardiology-netwerkmeta-analys/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/08/01/antitrombotische-strategieen-bij-af-na-pci-jama-cardiology-veiligheids-en-werkza/","published":"2019-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hyejung-jung","type":"person","url":"https://hartvaat.nl/mensen/hyejung-jung/","name":"Hyejung Jung","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"hyuck-jun-yoon","type":"person","url":"https://hartvaat.nl/mensen/hyuck-jun-yoon/","name":"Hyuck-Jun Yoon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","published":"2025-11-08"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2019/12/03/klinisch-significante-bloedingen-met-ticagrelor-versus-clopidogrel-bij-koreaanse/","published":"2019-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"helio-penna-guimaraes","type":"person","url":"https://hartvaat.nl/mensen/helio-penna-guimaraes/","name":"Hélio Penna Guimarães","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-en-evidence-based-prescriptie-bij-hoog-cv-risico-jama-card/","published":"2019-05-01"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/04/03/oplaaddosis-atorvastatine-voor-pci-jama-gerandomiseerde-trial/","published":"2018-04-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"iacopo-olivotto","type":"person","url":"https://hartvaat.nl/mensen/iacopo-olivotto/","name":"Iacopo Olivotto","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/05/aficamten-veilig-en-effectief-bij-langdurige-behandeling-van-obstructieve-hcm/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/01/01/maple-hcm-is-aficamten-een-keerpunt-bij-obstructieve-hcm/","published":"2026-03-18"},{"url":"https://hartvaat.nl/2025/12/01/economische-ziektelast-van-hartfalen-in-europa-systematische-review/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","published":"2023-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"iain-findlay","type":"person","url":"https://hartvaat.nl/mensen/iain-findlay/","name":"Iain Findlay","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ian-graham","type":"person","url":"https://hartvaat.nl/mensen/ian-graham/","name":"Ian Graham","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","published":"2018-04-07"},{"url":"https://hartvaat.nl/2016/10/14/2016-esc-eas-richtlijn-voor-het-management-van-dyslipidemieen/","published":"2016-10-14"},{"url":"https://hartvaat.nl/2016/08/01/2016-europese-richtlijnen-voor-cardiovasculaire-preventie-in-de-klinische-prakti/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ida-gustafsson","type":"person","url":"https://hartvaat.nl/mensen/ida-gustafsson/","name":"Ida Gustafsson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2023/04/01/mesenchymale-stamcellen-bij-ischemisch-hartfalen-deense-fase-ii-trial/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2021/06/01/metabole-effecten-van-empagliflozine-bij-hf-empire-hf-metabolic-gerandomiseerde-/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2018/01/16/hoog-sensitief-troponine-t-bij-chronisch-hartfalen-individuele-patientdata-meta-/","published":"2018-01-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"iftikhar-j-kullo","type":"person","url":"https://hartvaat.nl/mensen/iftikhar-j-kullo/","name":"Iftikhar J Kullo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/29/nla-consensusupdate-familiaire-hypercholesterolemie-screening-diagnostiek-en-beh/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2018/10/23/lpa-varianten-en-residueel-cv-risico-bij-statinebehandelde-patienten/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2016/06/01/familiaire-belasting-en-statine-initiatie-bij-intermediair-cardiovasculair-risic/","published":"2016-06-01"},{"url":"https://hartvaat.nl/2016/03/22/genetische-risicoscore-en-ldl-cholesterolbehandeling-bij-coronairlijden/","published":"2016-03-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ify-r-mordi","type":"person","url":"https://hartvaat.nl/mensen/ify-r-mordi/","name":"Ify R Mordi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","published":"2022-01-01"},{"url":"https://hartvaat.nl/2020/11/03/sglt2-remming-plus-lisdiuretica-bij-diabetes-type-2-met-ckd-renale-en-cv-effecte/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2019/11/01/metformine-en-linkerventrikelhypertrofie-bij-coronairlijden-zonder-diabetes-gera/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/02/12/genetisch-risico-op-coronairlijden-en-ontwikkeling-van-hfref-versus-hfpef/","published":"2019-02-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ignacio-amat-santos","type":"person","url":"https://hartvaat.nl/mensen/ignacio-amat-santos/","name":"Ignacio Amat Santos","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","published":"2024-11-09"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ignacio-cruz-gonzalez","type":"person","url":"https://hartvaat.nl/mensen/ignacio-cruz-gonzalez/","name":"Ignacio Cruz-González","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2025/12/23/korte-anticoagulatie-versus-dapt-na-laa-occlusie-devicetrombosepreventie/","published":"2025-12-23"},{"url":"https://hartvaat.nl/2025/04/10/dapagliflozine-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2025-04-10"},{"url":"https://hartvaat.nl/2024/10/01/lage-dosis-doac-versus-dapt-na-laa-occlusie-gerandomiseerde-trial/","published":"2024-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ilya-m-nasrallah","type":"person","url":"https://hartvaat.nl/mensen/ilya-m-nasrallah/","name":"Ilya M Nasrallah","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukcontrole-en-cerebrale-small-vessel-disease-markers/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"imad-sheiban","type":"person","url":"https://hartvaat.nl/mensen/imad-sheiban/","name":"Imad Sheiban","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/07/dcb-voor-zijtak-bij-provisionale-stenting-gerandomiseerde-trial/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/05/11/ivus-acs-ivus-geleide-pci-bij-acs-superieur-lancet/","published":"2024-05-11"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ingrid-hopper","type":"person","url":"https://hartvaat.nl/mensen/ingrid-hopper/","name":"Ingrid Hopper","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/01/pneumokokkenvaccinatie-en-cv-eventpreventie-ipd-meta-analyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"iqbal-s-malik","type":"person","url":"https://hartvaat.nl/mensen/iqbal-s-malik/","name":"Iqbal S Malik","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"irina-barash","type":"person","url":"https://hartvaat.nl/mensen/irina-barash/","name":"Irina Barash","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","published":"2025-09-27"},{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","published":"2025-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"itaru-hisauchi","type":"person","url":"https://hartvaat.nl/mensen/itaru-hisauchi/","name":"Itaru Hisauchi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/11/08/premier-in-hospital-start-van-sacubitril-valsartan-bij-acuut-hartfalen/","published":"2024-11-08"},{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2020/08/01/canagliflozine-bij-diabetes-type-2-met-chronisch-hf-candle-gerandomiseerde-trial/","published":"2020-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"itsuro-morishima","type":"person","url":"https://hartvaat.nl/mensen/itsuro-morishima/","name":"Itsuro Morishima","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2016/02/14/kortdurend-antiaritmica-na-katheterablatie-voor-atriumfibrilleren-east-af-trial/","published":"2016-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ivo-m-van-dongen","type":"person","url":"https://hartvaat.nl/mensen/ivo-m-van-dongen/","name":"Ivo M van Dongen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/09/01/langetermijnimpact-van-cto-rekanalisatie-bij-stemi-patienten/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/06/15/bioresorbeerbare-scaffolds-versus-metallic-stents-bij-routine-pci-nejm-aida/","published":"2017-06-15"},{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-circulatoire-ondersteuning-versus-iabp-bij-cardiogene-shoc/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/10/11/pci-van-chronische-totale-occlusie-bij-stemi-met-multivatenlijden-explore-trial/","published":"2016-10-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"j-c","type":"person","url":"https://hartvaat.nl/mensen/j-c/","name":"J. C.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/29/geleidingssysteem-pacing-slaat-rechterventrikel-pacing-bij-av-blok-70-hartfalen-/","published":"2026-07-12"},{"url":"https://hartvaat.nl/2026/02/23/invasieve-coronaire-functietest-bij-anoca-verandert-de-behandeling-bij-driekwart/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-myocardinfarct-winratio-analyse-uit-de-cle/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/01/29/obesitasparadox-bij-het-takotsubosyndroom-ondergewicht-geeft-de-hoogste-sterfte-/","published":"2026-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"j-j","type":"person","url":"https://hartvaat.nl/mensen/j-j/","name":"J. J.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/29/geisoleerde-secundaire-tricuspidalisinsufficientie-na-linkszijdige-klepchirurgie/","published":"2026-07-12"},{"url":"https://hartvaat.nl/2026/05/26/asymptomatische-matige-ernstige-aortaklepinsufficientie-niet-benigne-meta-analys/","published":"2026-07-03"},{"url":"https://hartvaat.nl/2026/04/24/grote-ziekenhuisvariatie-in-mcs-gebruik-bij-myocardinfarct-met-cardiogene-shock/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/01/09/hartfalendiagnostiek-na-corona-bijna-niemand-kreeg-de-echo-binnen-de-aanbevolen-/","published":"2026-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jacob-tfelt-hansen","type":"person","url":"https://hartvaat.nl/mensen/jacob-tfelt-hansen/","name":"Jacob Tfelt-Hansen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/07/31/uit-het-hospitaal-hartstilstand-komt-12-keer-vaker-voor-bij-niet-ischemische-car/","published":"2026-08-16"},{"url":"https://hartvaat.nl/2026/02/03/coronaire-vaatspasmen-bij-overlevenden-van-hartstilstand/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jacopo-francesco-imberti","type":"person","url":"https://hartvaat.nl/mensen/jacopo-francesco-imberti/","name":"Jacopo Francesco Imberti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/04/lbbap-versus-rv-pacing-tweejaarsresultaten-bij-pacemakergeindiceerde-patienten/","published":"2025-08-04"},{"url":"https://hartvaat.nl/2024/08/03/device-algoritmen-voor-rv-pacingminimalisatie-meta-analyse-van-uitkomsten/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2024/08/03/dagontslag-versus-overnachting-na-af-ablatie-uitgebreide-meta-analyse/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2021/10/01/katheterablatie-als-eerstelijns-paf-therapie-meta-analyse/","published":"2021-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jacqueline-e-tamis-holland","type":"person","url":"https://hartvaat.nl/mensen/jacqueline-e-tamis-holland/","name":"Jacqueline E Tamis-Holland","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2022/01/18/2021-acc-aha-scai-richtlijn-voor-coronaire-revascularisatie-executive-summary/","published":"2022-01-18"},{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","published":"2016-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jacques-genest","type":"person","url":"https://hartvaat.nl/mensen/jacques-genest/","name":"Jacques Genest","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/14/sekseverschillen-in-fh-behandeling-meta-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2022/09/07/aortastenose-bij-homozygote-familiaire-hypercholesterolemie-paradigmaverschuivin/","published":"2022-09-07"},{"url":"https://hartvaat.nl/2020/06/02/prevalentie-van-fh-bij-atherosclerotische-cv-ziekte-meta-analyse/","published":"2020-06-02"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jae-woong-choi","type":"person","url":"https://hartvaat.nl/mensen/jae-woong-choi/","name":"Jae Woong Choi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","published":"2022-09-08"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jae-sun-uhm","type":"person","url":"https://hartvaat.nl/mensen/jae-sun-uhm/","name":"Jae-Sun Uhm","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/10/14/alone-af-langetermijn-anticoagulatieonthouding-na-af-ablatie-rct/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2024/12/03/ct-gestuurde-atriale-wanddiktemapping-bij-cryoballon-pvi/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2019/05/14/wanneer-doac-stoppen-voor-af-ablatie-multicenter-analyse/","published":"2019-05-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jagat-narula","type":"person","url":"https://hartvaat.nl/mensen/jagat-narula/","name":"Jagat Narula","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/24/yellow-iii-intracoronaire-beeldvorming-en-genexpressie-na-maximale-lipideverlagi/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2025/09/02/coronaire-flow-capaciteits-geleide-revascularisatie-versus-standaardzorg-rct/","published":"2025-09-02"},{"url":"https://hartvaat.nl/2020/08/25/machine-learning-voor-lv-diastolische-functie-op-ecg/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jaimini-cegla","type":"person","url":"https://hartvaat.nl/mensen/jaimini-cegla/","name":"Jaimini Cegla","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/19/ehj-review-dyslipidemie-bij-kankerpatienten-verhoogd-ascvd-risico-beperkte-data-/","published":"2026-06-14"},{"url":"https://hartvaat.nl/2026/05/25/verve-102-eenmalige-base-editing-schakelt-pcsk9-blijvend-uit-fase-1/","published":"2026-05-25"},{"url":"https://hartvaat.nl/2021/09/21/bijwerkingspatronen-in-crossover-trial-statine-placebo-geen-behandeling-statinwi/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2020/11/26/n-of-1-trial-van-statine-placebo-of-geen-behandeling-voor-bijwerkingen-nejm-stat/","published":"2020-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"james-a-blumenthal","type":"person","url":"https://hartvaat.nl/mensen/james-a-blumenthal/","name":"James A Blumenthal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/12/01/acute-aerobe-training-en-kortdurende-ambulante-bloeddrukreductie-bij-hypertensie/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/10/12/leefstijlmodificatie-bij-resistente-hypertensie-triumph-gerandomiseerde-trial/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2016/04/05/hartrevalidatie-versterkt-met-stressmanagementtraining-gerandomiseerde-trial/","published":"2016-04-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"james-k-min","type":"person","url":"https://hartvaat.nl/mensen/james-k-min/","name":"James K Min","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"},{"url":"https://hartvaat.nl/2018/10/16/hoge-coronaire-shear-stress-voorspelt-myocardinfarct/","published":"2018-10-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"james-l-velianou","type":"person","url":"https://hartvaat.nl/mensen/james-l-velianou/","name":"James L Velianou","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/27/intracoronair-lage-dosis-rtpa-bij-primaire-pci-voor-stemi-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","published":"2018-10-02"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"james-s-gammie","type":"person","url":"https://hartvaat.nl/mensen/james-s-gammie/","name":"James S Gammie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jan-f-gummert","type":"person","url":"https://hartvaat.nl/mensen/jan-f-gummert/","name":"Jan F Gummert","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/10/12/castle-htx-af-ablatie-bij-eindstadium-hartfalen-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/07/01/statinoplaaddosis-voor-cabg-gerandomiseerde-trial/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2017/08/01/vitamine-d-en-mortaliteit-bij-hartfalen-de-evita-3-jaars-gerandomiseerde-trial/","published":"2017-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jan-filipovsky","type":"person","url":"https://hartvaat.nl/mensen/jan-filipovsky/","name":"Jan Filipovský","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jang-hyun-cho","type":"person","url":"https://hartvaat.nl/mensen/jang-hyun-cho/","name":"Jang Hyun Cho","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/06/directe-versus-gestageerde-complete-revascularisatie-tijdens-index-opname-bij-st/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"janice-pogue","type":"person","url":"https://hartvaat.nl/mensen/janice-pogue/","name":"Janice Pogue","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2016/07/01/langetermijnevaluatie-van-dabigatran-150-versus-110-mg-bij-niet-valvulair-af/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jaroslaw-drozdz","type":"person","url":"https://hartvaat.nl/mensen/jaroslaw-drozdz/","name":"Jaroslaw Drozdz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","published":"2022-09-22"},{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","published":"2020-10-27"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jaros-aw-drozdz","type":"person","url":"https://hartvaat.nl/mensen/jaros-aw-drozdz/","name":"Jarosław Drożdż","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jason-n-dungu","type":"person","url":"https://hartvaat.nl/mensen/jason-n-dungu/","name":"Jason N Dungu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/21/evolved-vroege-interventie-bij-asymptomatische-ernstige-aortastenose-met-myocard/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2019/01/05/staken-van-hf-medicatie-bij-herstelde-dilaterende-cardiomyopathie-lancet-tred-hf/","published":"2019-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jawdat-abdulla","type":"person","url":"https://hartvaat.nl/mensen/jawdat-abdulla/","name":"Jawdat Abdulla","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/02/01/ccta-afgeleide-ffr-prognostische-waarde-meta-analyse/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/08/01/kenmerken-en-prognose-van-hfmref-versus-hfref-en-hfpef-langetermijn/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jean-louis-georges","type":"person","url":"https://hartvaat.nl/mensen/jean-louis-georges/","name":"Jean-Louis Georges","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","published":"2026-02-11"},{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2016/01/21/stoppen-of-doorgaan-met-clopidogrel-12-maanden-na-drug-eluting-stent-optidual-tr/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeffrey-b-washam","type":"person","url":"https://hartvaat.nl/mensen/jeffrey-b-washam/","name":"Jeffrey B Washam","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/12/06/apixaban-bij-af-op-hemodialyse-eerste-gerandomiseerde-trial/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2021/10/12/overbrugging-van-antiplaatjestherapie-na-pci-jacc-review/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2020/01/07/nsaid-s-en-oac-bij-af-aristotle-analyse/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2016/01/26/polyfarmacie-en-werkzaamheid-van-rivaroxaban-versus-warfarine-bij-atriumfibrille/","published":"2016-01-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeffrey-e-olgin","type":"person","url":"https://hartvaat.nl/mensen/jeffrey-e-olgin/","name":"Jeffrey E Olgin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/27/decaf-cafeinehoudende-koffie-en-af-gerandomiseerde-trial/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2022/02/01/geindividualiseerde-triggerstudies-bij-paroxysmaal-af-jama-i-stop-afib/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2018/09/27/draagbare-cardioverter-defibrillator-na-myocardinfarct-nejm-vest/","published":"2018-09-27"},{"url":"https://hartvaat.nl/2016/03/15/voorspelling-van-persisterende-lv-disfunctie-na-myocardinfarct-de-predicts-studi/","published":"2016-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeffrey-l-carson","type":"person","url":"https://hartvaat.nl/mensen/jeffrey-l-carson/","name":"Jeffrey L Carson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/23/top-liberaal-versus-restrictief-transfusiebeleid-bij-hoogrisico-hartchirurgie/","published":"2025-12-23"},{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeffrey-s-riesmeyer","type":"person","url":"https://hartvaat.nl/mensen/jeffrey-s-riesmeyer/","name":"Jeffrey S Riesmeyer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/11/13/tirzepatide-versus-insuline-glargine-bij-diabetes-type-2-met-hoog-cv-risico-lanc/","published":"2021-11-13"},{"url":"https://hartvaat.nl/2020/10/01/crp-op-lp-a-geassocieerd-cv-risico-bij-optimaal-behandelde-hoogrisicopatienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jelena-celutkiene","type":"person","url":"https://hartvaat.nl/mensen/jelena-celutkiene/","name":"Jelena Celutkiene","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","published":"2023-06-06"},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","published":"2022-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jennifer-g-robinson","type":"person","url":"https://hartvaat.nl/mensen/jennifer-g-robinson/","name":"Jennifer G Robinson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/12/01/cardiovasculaire-risicocommunicatie-en-patientperceptie-jama-cardiology/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2018/04/17/uitgangs-ldl-en-mortaliteitsreductie-na-ldl-verlaging-jama-meta-analyse/","published":"2018-04-17"},{"url":"https://hartvaat.nl/2017/08/17/cognitieve-functie-in-de-fourier-trial-met-evolocumab-nejm-ebbinghaus/","published":"2017-08-17"},{"url":"https://hartvaat.nl/2016/10/14/geen-effect-van-pcsk9-remmer-alirocumab-op-diabetes-incidentie-odyssey-analyse/","published":"2016-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jennifer-k-sun","type":"person","url":"https://hartvaat.nl/mensen/jennifer-k-sun/","name":"Jennifer K Sun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/08/25/aflibercept-versus-bevacizumab-eerst-bij-diabetisch-macula-oedeem/","published":"2022-08-25"},{"url":"https://hartvaat.nl/2022/02/19/faricimab-bij-diabetisch-maculaoedeem-met-verlengde-dosering-lancet/","published":"2022-02-19"},{"url":"https://hartvaat.nl/2020/12/15/aflibercept-versus-vitrectomie-bij-diabetische-glasvochtbloeding-jama-drcr-net-p/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2019/05/21/aflibercept-versus-fotocoagulatie-versus-observatie-bij-diabetisch-maculaoedeem-/","published":"2019-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jennifer-s-herrick","type":"person","url":"https://hartvaat.nl/mensen/jennifer-s-herrick/","name":"Jennifer S Herrick","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/08/01/combinatietabletten-voor-intensieve-bloeddrukbehandeling-sprint-analyse/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2023/07/01/leeftijdsbias-draagt-bij-aan-therapeutische-inertie-bij-bloeddrukmanagement/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2021/04/27/patientselectie-voor-intensieve-bloeddrukbehandeling-naar-voordeel-en-bijwerking/","published":"2021-04-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jennifer-von-stein","type":"person","url":"https://hartvaat.nl/mensen/jennifer-von-stein/","name":"Jennifer von Stein","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/05/25/1-op-5-oudere-patienten-heeft-hartfalen-opname-binnen-jaar-na-tavr-1-jaarsmortal/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jens-kastrup","type":"person","url":"https://hartvaat.nl/mensen/jens-kastrup/","name":"Jens Kastrup","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/01/science-ii-mesenchymale-stamcellen-bij-niet-ischemisch-hartfalen-negatieve-trial/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2023/04/01/mesenchymale-stamcellen-bij-ischemisch-hartfalen-deense-fase-ii-trial/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2022/04/01/5-jaarsfollow-up-van-intracoronaire-celtherapie-na-mi-regenerate-ami/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2016/01/14/intracoronaire-beenmergcelinfusie-bij-acuut-myocardinfarct-de-regenerate-ami-tri/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jens-wiebe","type":"person","url":"https://hartvaat.nl/mensen/jens-wiebe/","name":"Jens Wiebe","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/04/17/in-stent-restenose-tienjaarsuitkomsten-plain-balloon-vs-dcb-vs-des-isar-desire-3/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2019/01/07/bioresorbeerbare-scaffold-versus-ees-bij-stabiel-coronairlijden-prospectieve-tri/","published":"2019-01-07"},{"url":"https://hartvaat.nl/2017/10/01/pci-versus-cabg-bij-linker-hoofdstamstenose-jama-cardiology-systematische-review/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/02/06/bioresorbeerbare-versus-metallic-stents-meta-analyse-van-gerandomiseerde-trials/","published":"2016-02-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jeremy-william","type":"person","url":"https://hartvaat.nl/mensen/jeremy-william/","name":"Jeremy William","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jian-liu","type":"person","url":"https://hartvaat.nl/mensen/jian-liu/","name":"Jian Liu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/23/intensief-versus-conventioneel-intraoperatief-bloeddrukmanagement-en-cv-events-n/","published":"2025-09-23"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2019/10/01/sekseverschillen-bij-katheterablatie-van-af-meta-analyse/","published":"2019-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jiang","type":"person","url":"https://hartvaat.nl/mensen/jiang/","name":"Jiang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/03/voorspelmodellen-voor-hartfalen-bij-patienten-met-instabiele-angina-pectoris/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/02/26/ai-clustering-onthult-drie-functionele-risicoprofielen-bij-hartfalen/","published":"2026-02-26"},{"url":"https://hartvaat.nl/2026/02/20/kosteneffectiviteit-van-mavacamten-bij-obstructieve-hcm-gezondheidswinst-maar-ee/","published":"2026-02-20"},{"url":"https://hartvaat.nl/2026/02/20/geintegreerd-machine-learningmodel-voorspelt-cardiovasculair-risico-beter-dan-de/","published":"2026-02-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jiangling-liu","type":"person","url":"https://hartvaat.nl/mensen/jiangling-liu/","name":"Jiangling Liu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/01/intensieve-bloeddrukcontrole-en-cognitieve-functie-gerandomiseerde-trial/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/06/esprit-intensieve-bloeddrukcontrole-bij-fragiele-patienten-post-hoc-analyse/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/10/28/esprit-bescheiden-effecten-van-intensieve-bloeddrukverlaging-op-kwaliteit-van-le/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukverlaging-en-retinale-microvasculatuur/","published":"2025-10-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jim-hansen","type":"person","url":"https://hartvaat.nl/mensen/jim-hansen/","name":"Jim Hansen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/07/01/qt-als-voorspeller-van-af-recidief-na-ablatie-en-amiodaronimpact-amio-cat/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jin-bae-lee","type":"person","url":"https://hartvaat.nl/mensen/jin-bae-lee/","name":"Jin Bae Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jin-sin-koh","type":"person","url":"https://hartvaat.nl/mensen/jin-sin-koh/","name":"Jin-Sin Koh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","published":"2025-11-08"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jinho-lee","type":"person","url":"https://hartvaat.nl/mensen/jinho-lee/","name":"Jinho Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","published":"2023-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jiyan-chen","type":"person","url":"https://hartvaat.nl/mensen/jiyan-chen/","name":"Jiyan Chen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/01/sirolimus-eluerende-bioresorbeerbare-stents-versus-everolimus-eluerende-stents-i/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/27/verhoogd-lp-a-en-diabetes-verergeren-samen-de-prognose-bij-coronairlijden/","published":"2026-02-27"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/25/hydratie-ter-preventie-van-nierschade-na-primaire-pci-gerandomiseerde-trial/","published":"2022-05-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joban-sehmi","type":"person","url":"https://hartvaat.nl/mensen/joban-sehmi/","name":"Joban Sehmi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joel-singer","type":"person","url":"https://hartvaat.nl/mensen/joel-singer/","name":"Joel Singer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/03/01/orale-antihypertensiva-bij-niet-ernstige-zwangerschapshypertensie-netwerkmeta-an/","published":"2022-03-01"},{"url":"https://hartvaat.nl/2018/06/01/amenorroe-duur-bij-start-antihypertensiva-in-de-zwangerschap-chips-secundaire-an/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2016/11/01/chips-trial-is-ernstige-hypertensie-in-de-zwangerschap-meer-dan-alleen-verhoogde/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/01/kostenimplicaties-van-minder-strikte-versus-strikte-bloeddrukcontrole-bij-zwange/","published":"2016-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joerg-koglin","type":"person","url":"https://hartvaat.nl/mensen/joerg-koglin/","name":"Joerg Koglin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/10/23/sotatercept-bij-pah-binnen-het-eerste-jaar-na-diagnose-stellar-subanalyse/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2023/04/20/stellar-sotatercept-bij-pulmonale-arteriele-hypertensie-nejm-fase-3/","published":"2023-04-20"},{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","published":"2020-05-14"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johannes-holzmeister","type":"person","url":"https://hartvaat.nl/mensen/johannes-holzmeister/","name":"Johannes Holzmeister","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/03/27/crt-bij-hartfalen-met-smal-qrs-complex/","published":"2018-03-27"},{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2017/03/07/lv-global-longitudinal-strain-en-prognose-bij-hartfalen-met-smal-qrs-en-crt/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2016/01/01/persisterende-echocardiografische-dyssynchronie-voorspelt-ongunstige-uitkomsten-/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johannes-petutschnigg","type":"person","url":"https://hartvaat.nl/mensen/johannes-petutschnigg/","name":"Johannes Petutschnigg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"},{"url":"https://hartvaat.nl/2020/06/01/economische-impact-van-hfpef-aldo-dhf-inzichten/","published":"2020-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johannes-sperzel","type":"person","url":"https://hartvaat.nl/mensen/johannes-sperzel/","name":"Johannes Sperzel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/06/03/multipoint-pacing-vermindert-hf-hospitalisaties-en-sterfte-bij-crt-non-responder/","published":"2025-06-03"},{"url":"https://hartvaat.nl/2023/10/05/more-crt-mpp-multipoint-pacing-bij-crt-non-responders/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2019/09/14/crt-non-responder-naar-responder-conversie-more-crt-mpp/","published":"2019-09-14"},{"url":"https://hartvaat.nl/2017/04/01/aanvullende-elektroden-op-de-quartet-lv-lead-bieden-meer-crt-programmeringsmogel/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-henderson","type":"person","url":"https://hartvaat.nl/mensen/john-henderson/","name":"John Henderson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/03/01/aspirine-en-hemocompatibiliteit-na-lvad-bij-atherosclerotisch-vaatlijden/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2024/02/13/implanteerbare-hemodynamische-monitoren-verbeteren-overleving-bij-hfref/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2022/07/14/guide-hf-en-de-impact-van-covid-19-op-hartfalenuitkomsten/","published":"2022-07-14"},{"url":"https://hartvaat.nl/2021/09/11/hemodynamisch-geleid-hf-management-lancet-guide-hf/","published":"2021-09-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-kjekshus","type":"person","url":"https://hartvaat.nl/mensen/john-kjekshus/","name":"John Kjekshus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/06/20/hartfrequentie-en-ritme-en-het-voordeel-van-betablokkers-bij-hartfalen/","published":"2017-06-20"},{"url":"https://hartvaat.nl/2017/02/28/hoog-intensieve-intervaltraining-bij-hartfalen-met-verminderde-ejectiefractie/","published":"2017-02-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"john-w-ostrominski","type":"person","url":"https://hartvaat.nl/mensen/john-w-ostrominski/","name":"John W Ostrominski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","published":"2026-04-18"},{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","published":"2025-04-07"},{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"johnson","type":"person","url":"https://hartvaat.nl/mensen/johnson/","name":"Johnson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/10/tweelingzwangerschap-bij-vrouwen-met-een-hartaandoening-geeft-een-hoog-risico-op/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/04/30/etnische-verschillen-in-sterfte-na-acuut-coronair-syndroom-hogere-mortaliteit-bi/","published":"2026-07-11"},{"url":"https://hartvaat.nl/2026/02/20/virtuele-afdeling-met-thuismonitoring-is-veilig-voor-patienten-die-wachten-op-sp/","published":"2026-02-20"},{"url":"https://hartvaat.nl/2026/01/23/multidisciplinair-cardiogene-shockteam-verbetert-de-1-jaarsoverleving-bij-infarc/","published":"2026-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jonathan-emberson","type":"person","url":"https://hartvaat.nl/mensen/jonathan-emberson/","name":"Jonathan Emberson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/07/01/kosteneffectiviteit-van-statines-en-ezetimibe-bij-chronische-nierziekte/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2017/02/01/reverse-causality-in-de-associatie-bloeddruk-cardiovasculair-risico-bij-ckd/","published":"2017-02-01"},{"url":"https://hartvaat.nl/2016/05/05/perioperatief-rosuvastatine-bij-hartchirurgie-nejm-trial/","published":"2016-05-05"},{"url":"https://hartvaat.nl/2016/03/05/bloeddrukverlaging-ter-preventie-van-hart-en-vaatziekten-systematische-review-en/","published":"2016-03-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jonathan-h-ward","type":"person","url":"https://hartvaat.nl/mensen/jonathan-h-ward/","name":"Jonathan H Ward","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2023/07/04/sacubitril-valsartan-bij-hfmref-hfpef-met-verslechterend-hartfalen/","published":"2023-07-04"},{"url":"https://hartvaat.nl/2022/10/18/dosisrespons-van-sacubitril-valsartan-bij-hfref/","published":"2022-10-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jonathan-m-hill","type":"person","url":"https://hartvaat.nl/mensen/jonathan-m-hill/","name":"Jonathan M Hill","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joni-k-snyder","type":"person","url":"https://hartvaat.nl/mensen/joni-k-snyder/","name":"Joni K Snyder","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jordi-salas-salvado","type":"person","url":"https://hartvaat.nl/mensen/jordi-salas-salvado/","name":"Jordi Salas-Salvadó","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/07/urinair-wijnzuur-als-biomarker-voor-wijnconsumptie-en-cv-risico-predimed/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2020/12/08/remnant-cholesterol-versus-ldl-en-incident-cv-ziekte/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/02/11/disfunctioneel-hdl-en-incidentie-van-acs-bij-hoog-cardiovasculair-risico/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2017/02/14/mediterraan-dieet-verbetert-hdl-functie-bij-hoog-cardiovasculair-risico-gerandom/","published":"2017-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jose-h-flores-arredondo","type":"person","url":"https://hartvaat.nl/mensen/jose-h-flores-arredondo/","name":"Jose H Flores-Arredondo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/02/11/langetermijn-evolocumab-bij-ouderen-effectiviteit-en-veiligheid/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","published":"2022-10-11"},{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","published":"2021-07-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"josef-coresh","type":"person","url":"https://hartvaat.nl/mensen/josef-coresh/","name":"Josef Coresh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2021/09/01/albuminurietesting-bij-hypertensie-en-diabetes-ipd-meta-analyse/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2016/02/04/risicoprojectie-voor-nierfalen-bij-levende-nierdonorkandidaten/","published":"2016-02-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joseph-e-marine","type":"person","url":"https://hartvaat.nl/mensen/joseph-e-marine/","name":"Joseph E Marine","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/02/09/2020-acc-consensus-anticoagulatie-en-antiplaatjestherapie-bij-af-of-vte/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2021/01/26/2020-acc-aha-kwaliteitsmaten-voor-af-geactualiseerd/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/03/17/2020-acc-hfsa-ishlt-verklaring-voor-gevorderd-hf-en-transplantatiespecialisten/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/08/20/2018-acc-aha-hrs-richtlijn-voor-bradycardie-en-geleidingsstoornissen/","published":"2019-08-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joseph-faiella-tommasino","type":"person","url":"https://hartvaat.nl/mensen/joseph-faiella-tommasino/","name":"Joseph Faiella-Tommasino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jose-boggia","type":"person","url":"https://hartvaat.nl/mensen/jose-boggia/","name":"José Boggia","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jose-tunon","type":"person","url":"https://hartvaat.nl/mensen/jose-tunon/","name":"José Tuñón","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/16/pcsk9-remmers-verlagen-events-bij-ascvd-zonder-eerder-infarct-of-beroerte-real-w/","published":"2026-07-13"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2023/08/01/bio-impedantieanalyse-bij-overgewicht-en-acuut-hartfalen-pilotstudie/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"joyce-peper","type":"person","url":"https://hartvaat.nl/mensen/joyce-peper/","name":"Joyce Peper","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2022/08/09/ticagrelor-dapt-en-veneuze-graftfalen-na-cabg-systematische-review/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2020/11/10/ticagrelor-plus-aspirine-en-safeneuze-graft-patency-na-cabg/","published":"2020-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"julian-d-gillmore","type":"person","url":"https://hartvaat.nl/mensen/julian-d-gillmore/","name":"Julian D Gillmore","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/08/26/vutrisiran-stabiliseert-rechterventrikel-functie-bij-attr-cardiomyopathie-helios/","published":"2026-09-03"},{"url":"https://hartvaat.nl/2025/05/27/vutrisiran-bij-attr-cm-impact-van-hartfalenernst-op-effectiviteit/","published":"2025-05-27"},{"url":"https://hartvaat.nl/2025/02/25/ambulante-hf-verslechtering-bij-attr-cm-attr-act-subanalyse/","published":"2025-02-25"},{"url":"https://hartvaat.nl/2025/02/25/ambulante-hartfalenverslechtering-bij-attr-cardiomyopathie-attr-act-analyse/","published":"2025-02-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"julian-k-r-chun","type":"person","url":"https://hartvaat.nl/mensen/julian-k-r-chun/","name":"Julian K R Chun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/03/ice-bij-af-ablatie-veiligheid-en-effectiviteit-meta-analyse/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2026/02/03/atriumfibrilleren-bij-kankerpatienten-de-esc-richtlijn-2025-in-de-praktijk/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/10/31/pfa-versus-thermale-ablatie-periprocedurale-en-middellangetermijneffecten/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2018/08/01/linker-hartoorisolatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"julie-a-anderson","type":"person","url":"https://hartvaat.nl/mensen/julie-a-anderson/","name":"Julie A Anderson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/09/04/troponine-i-en-cardiovasculair-risico-bij-copd/","published":"2018-09-04"},{"url":"https://hartvaat.nl/2018/09/01/bloeddruk-hartfrequentie-en-mortaliteit-bij-copd-summit-trial/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/10/01/inhalatiecorticosteroid-beta-2-agonist-en-cardiovasculaire-uitkomsten-bij-copd/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/04/30/fluticason-vilanterol-en-overleving-bij-copd-met-verhoogd-cardiovasculair-risico/","published":"2016-04-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"julinda-mehilli","type":"person","url":"https://hartvaat.nl/mensen/julinda-mehilli/","name":"Julinda Mehilli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"julio-a-panza","type":"person","url":"https://hartvaat.nl/mensen/julio-a-panza/","name":"Julio A Panza","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/03/01/gewicht-en-werkzaamheid-veiligheid-van-doac-s-bij-niet-valvulair-af-meta-analyse/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2019/09/01/oac-bij-af-met-kleplijden-en-bioprothese-overzicht/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2016/11/01/tienjaarsuitkomsten-na-cabg-naar-leeftijd-bij-hartfalen-met-lv-systolische-disfu/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/04/21/coronaire-bypasschirurgie-bij-ischemische-cardiomyopathie-nejm-stich-trial/","published":"2016-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jun-won-lee","type":"person","url":"https://hartvaat.nl/mensen/jun-won-lee/","name":"Jun-Won Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jung-hee-lee","type":"person","url":"https://hartvaat.nl/mensen/jung-hee-lee/","name":"Jung-Hee Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/09/06/directe-versus-gestageerde-complete-revascularisatie-tijdens-index-opname-bij-st/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","published":"2022-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jurgen-a-h-r-claassen","type":"person","url":"https://hartvaat.nl/mensen/jurgen-a-h-r-claassen/","name":"Jurgen A H R Claassen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/05/01/antihypertensieve-behandeling-en-cerebrale-bloedflow-meta-analyse/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2021/11/01/bloeddrukvariabiliteit-en-dementie-cognitieve-stoornis-meta-analyse/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2019/11/01/bloeddrukvariabiliteit-en-progressie-van-klinische-alzheimer/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/08/01/nilvadipine-en-cerebrale-bloedflow-bij-alzheimer-gerandomiseerde-trial/","published":"2019-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"justin-g-l-m-luermans","type":"person","url":"https://hartvaat.nl/mensen/justin-g-l-m-luermans/","name":"Justin G L M Luermans","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/11/thoracoscopische-af-ablatie-met-bipolaire-clamp-5-jaars-ritmevrijheid-52-met-ant/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2022/03/02/frequentiecontrolemiddelen-verschillen-in-preventie-van-af-progressie/","published":"2022-03-02"},{"url":"https://hartvaat.nl/2020/02/01/verpleegkundig-geleide-versus-standaard-af-zorg/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/04/18/vroege-of-uitgestelde-cardioversie-bij-recent-onset-af-nejm-race-7-acwas/","published":"2019-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jorg-taubel","type":"person","url":"https://hartvaat.nl/mensen/jorg-taubel/","name":"Jörg Täubel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/25/verve-102-eenmalige-base-editing-schakelt-pcsk9-blijvend-uit-fase-1/","published":"2026-05-25"},{"url":"https://hartvaat.nl/2023/07/20/zilebesiran-rna-interferentietherapie-voor-hypertensie-nejm/","published":"2023-07-20"},{"url":"https://hartvaat.nl/2021/01/07/antisense-tegen-microrna-132-bij-hartfalen-fase-1b-resultaten/","published":"2021-01-07"},{"url":"https://hartvaat.nl/2017/01/05/inclisiran-een-langwerkende-rna-interferentie-pcsk9-remmer-nejm/","published":"2017-01-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"jrgen-vestbo","type":"person","url":"https://hartvaat.nl/mensen/jrgen-vestbo/","name":"Jørgen Vestbo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/09/04/troponine-i-en-cardiovasculair-risico-bij-copd/","published":"2018-09-04"},{"url":"https://hartvaat.nl/2018/09/01/bloeddruk-hartfrequentie-en-mortaliteit-bij-copd-summit-trial/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/10/01/inhalatiecorticosteroid-beta-2-agonist-en-cardiovasculaire-uitkomsten-bij-copd/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/04/30/fluticason-vilanterol-en-overleving-bij-copd-met-verhoogd-cardiovasculair-risico/","published":"2016-04-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"k-r-julian-chun","type":"person","url":"https://hartvaat.nl/mensen/k-r-julian-chun/","name":"K R Julian Chun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/14/ulysses-echogeleide-venapunctie-halveert-toegangscomplicaties-bij-af-ablatie/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2024/12/17/ablatiestrategie-bij-af-recidief-na-duurzame-pvi/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2016/10/07/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-af-herinterventierate-e/","published":"2016-10-07"},{"url":"https://hartvaat.nl/2016/06/09/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-atriumfibrilleren-nejm-/","published":"2016-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kalina-kawecka-jaszcz","type":"person","url":"https://hartvaat.nl/mensen/kalina-kawecka-jaszcz/","name":"Kalina Kawecka-Jaszcz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kamal-gupta","type":"person","url":"https://hartvaat.nl/mensen/kamal-gupta/","name":"Kamal Gupta","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/09/01/aspirinedosering-voor-secundaire-preventie-bij-mannen-versus-vrouwen/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karel-g-m-moons","type":"person","url":"https://hartvaat.nl/mensen/karel-g-m-moons/","name":"Karel G M Moons","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/08/07/geintegreerd-af-management-in-de-huisartsenpraktijk-all-in-clustergerandomiseerd/","published":"2020-08-07"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2018/08/01/opportunistische-hf-screening-met-natriuretische-peptiden-bij-af-ipd-meta-analys/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/02/21/fibrinogeenconcentraat-bij-intraoperatief-bloedverlies-tijdens-hoog-risico-hartc/","published":"2017-02-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karen-l-furie","type":"person","url":"https://hartvaat.nl/mensen/karen-l-furie/","name":"Karen L Furie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/19/secundaire-preventie-na-ischemisch-cva-overzicht-uit-het-nejm/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2019/07/09/2019-aha-acc-hrs-gerichte-update-van-de-af-richtlijn/","published":"2019-07-09"},{"url":"https://hartvaat.nl/2018/09/18/hartfalen-na-cva-tia-bij-insulineresistente-patienten-behandeld-met-pioglitazon/","published":"2018-09-18"},{"url":"https://hartvaat.nl/2016/04/07/pioglitazon-na-ischemisch-cva-of-tia-gerandomiseerde-nejm-trial/","published":"2016-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karen-l-o-sullivan","type":"person","url":"https://hartvaat.nl/mensen/karen-l-o-sullivan/","name":"Karen L O'Sullivan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karin-h-humphries","type":"person","url":"https://hartvaat.nl/mensen/karin-h-humphries/","name":"Karin H Humphries","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/10/22/individualisering-van-revascularisatiestrategie-bij-diabetes-met-multivatenlijde/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/06/14/langetermijnuitkomsten-bij-angina-zonder-obstructief-coronairlijden-systematisch/","published":"2018-06-14"},{"url":"https://hartvaat.nl/2018/05/01/verlaging-van-diastolische-druk-bij-patienten-met-en-zonder-cardiovasculaire-zie/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/12/19/chirurgische-versus-percutane-revascularisatie-bij-diabetes-met-acs/","published":"2017-12-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karl-wallendszus","type":"person","url":"https://hartvaat.nl/mensen/karl-wallendszus/","name":"Karl Wallendszus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2018/10/18/omega-3-vetzuursupplementen-bij-diabetes-nejm-ascend-omega-3/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2018/10/18/aspirine-voor-primaire-preventie-bij-diabetes-nejm-ascend/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2017/09/28/anacetrapib-bij-atherosclerotisch-vaatlijden-nejm-hps3-timi55-reveal/","published":"2017-09-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"karoline-liisberg","type":"person","url":"https://hartvaat.nl/mensen/karoline-liisberg/","name":"Karoline Liisberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kasper-kyhl","type":"person","url":"https://hartvaat.nl/mensen/kasper-kyhl/","name":"Kasper Kyhl","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"katarzyna-stolarz-skrzypek","type":"person","url":"https://hartvaat.nl/mensen/katarzyna-stolarz-skrzypek/","name":"Katarzyna Stolarz-Skrzypek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"katia-audisio","type":"person","url":"https://hartvaat.nl/mensen/katia-audisio/","name":"Katia Audisio","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2022/08/09/ticagrelor-dapt-en-veneuze-graftfalen-na-cabg-systematische-review/","published":"2022-08-09"},{"url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/12/04/posterieure-pericardiotomie-ter-preventie-van-af-na-hartchirurgie-lancet-palacs/","published":"2021-12-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"katja-rohwedder","type":"person","url":"https://hartvaat.nl/mensen/katja-rohwedder/","name":"Katja Rohwedder","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","published":"2025-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"katja-zeppenfeld","type":"person","url":"https://hartvaat.nl/mensen/katja-zeppenfeld/","name":"Katja Zeppenfeld","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/20/stopstorm-stereotactische-bestraling-reduceert-refractaire-vt-met-80/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2026/03/06/laminopathieen-natuurlijk-beloop-en-voorspelmodel-voor-hartfalen/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2017/04/01/beperkte-chirurgische-linkeratriumablatie-bij-af-effectief-maar-vermindert-la-fu/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kazuma-oyama","type":"person","url":"https://hartvaat.nl/mensen/kazuma-oyama/","name":"Kazuma Oyama","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/09/01/dapagliflozine-effectief-ongeacht-cv-achtergrondmedicatie-declare-subanalyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2022/08/30/biomarkers-voorspellen-complexe-coronaire-revascularisatie-in-fourier/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","published":"2022-08-14"},{"url":"https://hartvaat.nl/2021/10/12/baseline-ldl-en-klinische-uitkomsten-van-ezetimibe-plus-statine-improve-it/","published":"2021-10-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kazushige-kadota","type":"person","url":"https://hartvaat.nl/mensen/kazushige-kadota/","name":"Kazushige Kadota","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kei-asayama","type":"person","url":"https://hartvaat.nl/mensen/kei-asayama/","name":"Kei Asayama","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/10/01/esh-convenant-polshorloges-bloeddrukmeters-acceptabele-nauwkeurigheid-maar-klini/","published":"2026-09-02"},{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2019/01/01/levenslangrisico-op-cva-en-coronairlijden-naar-bloeddrukniveau-epoch-japan/","published":"2019-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kengo-kusano","type":"person","url":"https://hartvaat.nl/mensen/kengo-kusano/","name":"Kengo Kusano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/07/crrf-peaf-cryoballon-versus-rf-ablatie-bij-persisterend-af/","published":"2025-11-07"},{"url":"https://hartvaat.nl/2023/09/30/adaptresponse-adaptieve-versus-conventionele-crt-bij-hartfalen-lancet/","published":"2023-09-30"},{"url":"https://hartvaat.nl/2020/10/01/sekseverschillen-in-kenmerken-en-qol-bij-crt-patienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2016/12/27/hotballoon-pulmonaalvene-ablatie-bij-paroxysmaal-af-japanse-multicenter-trial/","published":"2016-12-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kengo-tanabe","type":"person","url":"https://hartvaat.nl/mensen/kengo-tanabe/","name":"Kengo Tanabe","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/11/08/premier-in-hospital-start-van-sacubitril-valsartan-bij-acuut-hartfalen/","published":"2024-11-08"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kent-r-bailey","type":"person","url":"https://hartvaat.nl/mensen/kent-r-bailey/","name":"Kent R Bailey","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2017/01/01/genoomwijde-meta-analyse-van-bloeddrukrespons-op-hydrochloorthiazide/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/06/01/familiaire-belasting-en-statine-initiatie-bij-intermediair-cardiovasculair-risic/","published":"2016-06-01"},{"url":"https://hartvaat.nl/2016/03/22/genetische-risicoscore-en-ldl-cholesterolbehandeling-bij-coronairlijden/","published":"2016-03-22"},{"url":"https://hartvaat.nl/2016/03/01/farmacogenomische-meta-analyse-van-bloeddrukrespons-op-betablokkers-bij-afro-ame/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kershaw-v-patel","type":"person","url":"https://hartvaat.nl/mensen/kershaw-v-patel/","name":"Kershaw V Patel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2021/10/19/diabetes-met-cardiomyopathie-in-de-community-prevalentie-en-prognose/","published":"2021-10-19"},{"url":"https://hartvaat.nl/2020/12/22/lichaamssamenstelling-en-risico-op-hartfalen-en-mi-prospectieve-analyse/","published":"2020-12-22"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kevin-l-thomas","type":"person","url":"https://hartvaat.nl/mensen/kevin-l-thomas/","name":"Kevin L Thomas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2022/12/06/apixaban-bij-af-op-hemodialyse-eerste-gerandomiseerde-trial/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2021/07/13/ablatie-versus-medicatie-bij-af-naar-ras-en-etniciteit/","published":"2021-07-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ki-dong-yoo","type":"person","url":"https://hartvaat.nl/mensen/ki-dong-yoo/","name":"Ki-Dong Yoo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/12/off-label-onderdosering-edoxaban-bij-af-en-systemische-embolieen/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2024/12/05/edoxaban-bij-af-en-stabiel-coronairlijden-antitrombotische-monotherapie/","published":"2024-12-05"},{"url":"https://hartvaat.nl/2024/02/01/talos-ami-dapt-de-escalatie-veilig-bij-mi-met-hoog-ischemisch-risico/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2021/10/09/ongeleide-de-escalatie-van-ticagrelor-naar-clopidogrel-na-mi-met-pci-lancet-talo/","published":"2021-10-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kim-fox","type":"person","url":"https://hartvaat.nl/mensen/kim-fox/","name":"Kim Fox","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","published":"2021-05-18"},{"url":"https://hartvaat.nl/2020/09/19/trimetazidine-na-pci-lancet-atpci-gerandomiseerde-trial/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","published":"2019-10-03"},{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","published":"2019-09-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kim-houlind","type":"person","url":"https://hartvaat.nl/mensen/kim-houlind/","name":"Kim Houlind","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/05/semaglutide-bij-perifeer-arterieel-vaatlijden-en-diabetes-stride-trial/","published":"2026-03-20"},{"url":"https://hartvaat.nl/2025/11/18/sekseverschillen-in-semaglutide-effect-bij-pad-stride-subanalyse/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/05/03/semaglutide-en-loopafstand-bij-perifeer-vaatlijden-en-diabetes/","published":"2025-05-03"},{"url":"https://hartvaat.nl/2023/05/27/best-cli-veneuze-bypass-versus-endovasculair-bij-chronische-kritieke-ischemie/","published":"2023-05-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kim-rajappan","type":"person","url":"https://hartvaat.nl/mensen/kim-rajappan/","name":"Kim Rajappan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","published":"2023-09-28"},{"url":"https://hartvaat.nl/2023/02/14/cryoballon-pvi-als-eerstelijnsbehandeling-voor-typisch-atriumflutter/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/10/13/dagopname-na-af-ablatie-even-veilig-als-overnachting-meta-analyse/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2018/01/01/endocardiale-linkerkamer-pacing-voor-crt-systematische-review-en-meta-analyse/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kirstine-brown-frandsen","type":"person","url":"https://hartvaat.nl/mensen/kirstine-brown-frandsen/","name":"Kirstine Brown-Frandsen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","published":"2025-05-29"},{"url":"https://hartvaat.nl/2023/12/14/select-semaglutide-vermindert-cv-events-bij-obesitas-zonder-diabetes-nejm/","published":"2023-12-14"},{"url":"https://hartvaat.nl/2017/08/24/degludec-versus-glargine-bij-diabetes-type-2-nejm-devote-werkzaamheid-en-veiligh/","published":"2017-08-24"},{"url":"https://hartvaat.nl/2016/07/28/liraglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-leader-trial/","published":"2016-07-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"klaus-k-witte","type":"person","url":"https://hartvaat.nl/mensen/klaus-k-witte/","name":"Klaus K Witte","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/02/01/diabetes-en-sacubitril-valsartan-titratie-bij-hartfalen-na-opname/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2020/05/26/gepersonaliseerde-rate-response-programmering-verbetert-inspanningstolerantie-bi/","published":"2020-05-26"},{"url":"https://hartvaat.nl/2017/08/07/remote-management-van-hartfalen-met-implanteerbare-devices-overzicht/","published":"2017-08-07"},{"url":"https://hartvaat.nl/2016/06/07/vitamine-d-bij-chronisch-hartfalen-de-vindicate-studie/","published":"2016-06-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ko-yamamoto","type":"person","url":"https://hartvaat.nl/mensen/ko-yamamoto/","name":"Ko Yamamoto","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"koichi-inoue","type":"person","url":"https://hartvaat.nl/mensen/koichi-inoue/","name":"Koichi Inoue","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/08/21/lvad-implantatie-voor-destination-therapy-toont-vergelijkbare-uitkomsten-als-bru/","published":"2026-08-29"},{"url":"https://hartvaat.nl/2025/09/01/nierfunctie-en-effectiviteit-van-lva-ablatie-na-pvi-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2021/04/06/pvi-alleen-versus-uitgebreide-ablatie-bij-persisterend-af-meta-analyse/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2016/02/14/kortdurend-antiaritmica-na-katheterablatie-voor-atriumfibrilleren-east-af-trial/","published":"2016-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"koichi-nakao","type":"person","url":"https://hartvaat.nl/mensen/koichi-nakao/","name":"Koichi Nakao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2017/08/01/ldl-cholesterol-streefwaarden-met-pitavastatine-ezetimibe-bij-acs-met-dyslipidem/","published":"2017-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"konstantina-chalkou","type":"person","url":"https://hartvaat.nl/mensen/konstantina-chalkou/","name":"Konstantina Chalkou","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2025/07/08/amulet-versus-watchman-flx-driejaarsresultaten-laa-sluiting/","published":"2025-07-08"},{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","published":"2024-02-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"konstantinos-c-siontis","type":"person","url":"https://hartvaat.nl/mensen/konstantinos-c-siontis/","name":"Konstantinos C Siontis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/03/ice-bij-af-ablatie-veiligheid-en-effectiviteit-meta-analyse/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/04/01/symptomatisch-versus-asymptomatisch-af-en-klinische-uitkomsten-meta-analyse/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2023/08/02/af-ablatie-bij-hypertrofische-cardiomyopathie-meta-analyse/","published":"2023-08-02"},{"url":"https://hartvaat.nl/2017/02/14/doac-s-bij-af-met-kleplijden-excl-significante-mitralisstenose-meta-analyse/","published":"2017-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"konstantinos-d-rizas","type":"person","url":"https://hartvaat.nl/mensen/konstantinos-d-rizas/","name":"Konstantinos D Rizas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2017/07/14/voorspelling-van-plotse-versus-niet-plotse-hartdood-na-mi-met-verminderde-lvef/","published":"2017-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"konstantinos-pamporis","type":"person","url":"https://hartvaat.nl/mensen/konstantinos-pamporis/","name":"Konstantinos Pamporis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/30/linear-trial-lattice-tip-katheter-verslaat-standaard-irrigatie-bij-cti-ablatie-v/","published":"2026-04-19"},{"url":"https://hartvaat.nl/2026/02/03/ice-bij-af-ablatie-veiligheid-en-effectiviteit-meta-analyse/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/03/af-ablatie-timing-naar-af-duur-impact-op-aritmierecidief/","published":"2025-06-03"},{"url":"https://hartvaat.nl/2025/04/01/symptomatisch-versus-asymptomatisch-af-en-klinische-uitkomsten-meta-analyse/","published":"2025-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"konstantinos-prokopidis","type":"person","url":"https://hartvaat.nl/mensen/konstantinos-prokopidis/","name":"Konstantinos Prokopidis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/03/mortaliteit-en-hospitalisaties-bij-hfpef-versus-hfref-vergelijkende-analyse/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/10/01/piek-vo2-en-prognose-bij-hartfalen-meta-analyse/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/08/01/opnameduur-en-eerdere-hf-opnames-bij-frailteit-en-hartfalen-systematische-review/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/10/01/natriuretische-peptiden-en-crp-bij-hartfalen-en-ondervoeding-systematische-revie/","published":"2024-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kumar-balasubramanian","type":"person","url":"https://hartvaat.nl/mensen/kumar-balasubramanian/","name":"Kumar Balasubramanian","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/16/achieve-spironolacton-bij-dialysepatienten-internationale-rct/","published":"2025-08-16"},{"url":"https://hartvaat.nl/2023/10/24/laaos-iii-laa-occlusie-en-anticoagulatiegebruik/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2022/09/15/invictus-rivaroxaban-versus-warfarine-bij-reumatische-hartziekte-en-af/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","published":"2021-06-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kwan-yong-lee","type":"person","url":"https://hartvaat.nl/mensen/kwan-yong-lee/","name":"Kwan Yong Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2024/02/01/talos-ami-dapt-de-escalatie-veilig-bij-mi-met-hoog-ischemisch-risico/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2021/10/09/ongeleide-de-escalatie-van-ticagrelor-naar-clopidogrel-na-mi-met-pci-lancet-talo/","published":"2021-10-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"kyohei-yamaji","type":"person","url":"https://hartvaat.nl/mensen/kyohei-yamaji/","name":"Kyohei Yamaji","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/07/01/lokale-hemodynamische-krachten-en-fenotype-van-coronaire-plaques/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2016/12/01/tienjaarsuitkomsten-van-eerste-generatie-drug-eluting-stents-ses-versus-pes/","published":"2016-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"laine-thomas","type":"person","url":"https://hartvaat.nl/mensen/laine-thomas/","name":"Laine Thomas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2018/03/13/digoxine-en-mortaliteit-bij-patienten-met-atriumfibrilleren/","published":"2018-03-13"},{"url":"https://hartvaat.nl/2016/12/20/off-label-doac-dosering-en-ongunstige-uitkomsten-orbit-af-ii-register/","published":"2016-12-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"laurent-fauchier","type":"person","url":"https://hartvaat.nl/mensen/laurent-fauchier/","name":"Laurent Fauchier","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/06/laminopathieen-natuurlijk-beloop-en-voorspelmodel-voor-hartfalen/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2026/02/03/aanbesteding-van-cardiale-implanteerbare-devices-in-europa-waarde-of-kosten/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2021/12/07/av-junctieablatie-plus-crt-bij-permanent-af-met-smal-qrs-apaf-crt-mortaliteitsan/","published":"2021-12-07"},{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"laurent-m-haegeli","type":"person","url":"https://hartvaat.nl/mensen/laurent-m-haegeli/","name":"Laurent M Haegeli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2016/01/01/gesimuleerde-obstructieve-slaapapneu-bevordert-ritmestoornissen-bij-paroxysmaal-/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"leanne-t-bloedon","type":"person","url":"https://hartvaat.nl/mensen/leanne-t-bloedon/","name":"LeAnne T Bloedon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/03/01/clear-outcomes-bempedoinezuur-vermindert-totale-cv-events-bij-statine-intolerant/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2019/11/12/bempedoinezuur-toegevoegd-aan-statines-bij-hoog-cv-risico-jama-clear-harmony/","published":"2019-11-12"},{"url":"https://hartvaat.nl/2019/03/14/bempedoinezuur-voor-ldl-verlaging-nejm-veiligheid-en-werkzaamheid/","published":"2019-03-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lenore-j-launer","type":"person","url":"https://hartvaat.nl/mensen/lenore-j-launer/","name":"Lenore J Launer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/11/01/bloeddrukvariabiliteit-en-dementie-cognitieve-stoornis-meta-analyse/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"leonhard-bruch","type":"person","url":"https://hartvaat.nl/mensen/leonhard-bruch/","name":"Leonhard Bruch","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"},{"url":"https://hartvaat.nl/2018/09/22/telemedische-interventie-bij-hartfalen-lancet-tim-hf2/","published":"2018-09-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"leslee-j-shaw","type":"person","url":"https://hartvaat.nl/mensen/leslee-j-shaw/","name":"Leslee J Shaw","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2020/05/05/laag-attenuatie-plaque-op-ccta-voorspelt-mi-scot-heart-resultaten/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lewis-a-lipsitz","type":"person","url":"https://hartvaat.nl/mensen/lewis-a-lipsitz/","name":"Lewis A Lipsitz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/01/hypotensieve-episodes-op-24-uurs-abpm-en-cognitieve-functie-sprint-inzichten/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/04/01/lichaamshouding-en-orthostatische-hypotensie-bij-hypertensie-syst-eur-analyse/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2018/10/01/hypertensiebehandeling-en-orthostatische-hypotensie-relatie-met-cv-ziekte/","published":"2018-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lijing-l-yan","type":"person","url":"https://hartvaat.nl/mensen/lijing-l-yan/","name":"Lijing L Yan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/02/barrieres-bij-implementatie-van-lipidenverlagende-therapie-in-de-praktijk/","published":"2026-03-26"},{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2022/05/17/kosteneffectiviteit-van-zoutsubstitutie-ssass-analyse/","published":"2022-05-17"},{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","published":"2021-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"likun-ma","type":"person","url":"https://hartvaat.nl/mensen/likun-ma/","name":"Likun Ma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2024/11/12/recaticimab-monotherapie-bij-niet-familiaire-hypercholesterolemie-fase-3-remain-/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"liping-zhang","type":"person","url":"https://hartvaat.nl/mensen/liping-zhang/","name":"Liping Zhang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/01/intensieve-bloeddrukcontrole-en-cognitieve-functie-gerandomiseerde-trial/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/01/06/esprit-intensieve-bloeddrukcontrole-bij-fragiele-patienten-post-hoc-analyse/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/10/28/esprit-bescheiden-effecten-van-intensieve-bloeddrukverlaging-op-kwaliteit-van-le/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukverlaging-en-retinale-microvasculatuur/","published":"2025-10-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"liqun-zhang","type":"person","url":"https://hartvaat.nl/mensen/liqun-zhang/","name":"Liqun Zhang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"},{"url":"https://hartvaat.nl/2023/06/29/elan-vroege-versus-late-anticoagulatie-na-cva-bij-af-nejm/","published":"2023-06-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lisa-m-wruck","type":"person","url":"https://hartvaat.nl/mensen/lisa-m-wruck/","name":"Lisa M Wruck","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/09/01/aspirinedosering-voor-secundaire-preventie-bij-mannen-versus-vrouwen/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lisheng-liu","type":"person","url":"https://hartvaat.nl/mensen/lisheng-liu/","name":"Lisheng Liu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","published":"2016-05-26"},{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","published":"2016-05-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lluis-serra-majem","type":"person","url":"https://hartvaat.nl/mensen/lluis-serra-majem/","name":"Lluís Serra-Majem","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/07/urinair-wijnzuur-als-biomarker-voor-wijnconsumptie-en-cv-risico-predimed/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2020/12/08/remnant-cholesterol-versus-ldl-en-incident-cv-ziekte/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/02/11/disfunctioneel-hdl-en-incidentie-van-acs-bij-hoog-cardiovasculair-risico/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2017/02/14/mediterraan-dieet-verbetert-hdl-functie-bij-hoog-cardiovasculair-risico-gerandom/","published":"2017-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lorraine-c-nnacheta","type":"person","url":"https://hartvaat.nl/mensen/lorraine-c-nnacheta/","name":"Lorraine C Nnacheta","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/01/18/2021-acc-aha-scai-richtlijn-voor-coronaire-revascularisatie-executive-summary/","published":"2022-01-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"louis-p-perrault","type":"person","url":"https://hartvaat.nl/mensen/louis-p-perrault/","name":"Louis P Perrault","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"luciano-f-drager","type":"person","url":"https://hartvaat.nl/mensen/luciano-f-drager/","name":"Luciano F Drager","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/02/13/bariatrische-chirurgie-en-bloeddruk-na-5-jaar-gerandomiseerde-trial/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2019/03/01/bariatrische-chirurgie-versus-medicamenteus-beleid-op-24-uurs-ambulante-bloeddru/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/04/01/spironolacton-versus-clonidine-als-vierde-middel-bij-resistente-hypertensie-reho/","published":"2018-04-01"},{"url":"https://hartvaat.nl/2018/03/13/bariatrische-chirurgie-bij-obese-patienten-met-hypertensie-gateway-gerandomiseer/","published":"2018-03-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lucio-d-anna","type":"person","url":"https://hartvaat.nl/mensen/lucio-d-anna/","name":"Lucio D'Anna","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"},{"url":"https://hartvaat.nl/2025/03/15/doac-s-versus-geen-anticoagulatie-na-intracraniele-bloeding-bij-af-meta-analyse/","published":"2025-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"luigi-padeletti","type":"person","url":"https://hartvaat.nl/mensen/luigi-padeletti/","name":"Luigi Padeletti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/02/02/thuismonitoring-temporele-trends-en-baseline-risico-voor-hf-voorspelling-bij-icd/","published":"2022-02-02"},{"url":"https://hartvaat.nl/2018/05/01/crt-voordeel-bij-concordant-versus-discordant-linksbundeltakblok-esc-hf-pilot/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/03/07/contractiliteitssensor-geleide-crt-optimalisatie-respond-crt-trial/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2017/02/01/reductie-van-onnodige-ventriculaire-pacing-en-klinische-uitkomsten-bij-behouden-/","published":"2017-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"luis-e-rohde","type":"person","url":"https://hartvaat.nl/mensen/luis-e-rohde/","name":"Luis E Rohde","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/02/01/message-hf-geautomatiseerde-sms-na-hartfalenopname-verbetert-uitkomsten-niet/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2021/12/01/sms-strategie-bij-patienten-na-recente-hf-opname-studieontwerp/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2019/11/21/diureticastaken-bij-stabiel-mild-hf-zonder-vochtretentie/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"luis-manzano","type":"person","url":"https://hartvaat.nl/mensen/luis-manzano/","name":"Luis Manzano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/02/01/clorotic-thiazide-toevoegen-aan-lisdiureticum-bij-acuut-hartfalen/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/06/20/hartfrequentie-en-ritme-en-het-voordeel-van-betablokkers-bij-hartfalen/","published":"2017-06-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lukas-stolz","type":"person","url":"https://hartvaat.nl/mensen/lukas-stolz/","name":"Lukas Stolz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"lynne-t-braun","type":"person","url":"https://hartvaat.nl/mensen/lynne-t-braun/","name":"Lynne T Braun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"m-angelyn-bethel","type":"person","url":"https://hartvaat.nl/mensen/m-angelyn-bethel/","name":"M Angelyn Bethel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/04/28/open-label-drop-in-van-glucoseverlagende-medicatie-en-exscel-uitkomsten/","published":"2020-04-28"},{"url":"https://hartvaat.nl/2017/09/28/exenatide-eenmaal-per-week-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-ne/","published":"2017-09-28"},{"url":"https://hartvaat.nl/2017/09/26/secundaire-cardiovasculaire-preventie-bij-diabetes-type-2-tecos-internationale-i/","published":"2017-09-26"},{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"m-n","type":"person","url":"https://hartvaat.nl/mensen/m-n/","name":"M. N.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/20/hypochloremie-bij-opname-voor-acuut-hartfalen-voorspelt-onafhankelijk-30-daagse-/","published":"2026-07-06"},{"url":"https://hartvaat.nl/2026/03/25/vrouwen-krijgen-een-type-a-aortadissectie-bij-een-kleinere-aortadiameter-door-hu/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/03/10/machine-learning-voorspelt-30-daagse-sterfte-na-een-dotterbehandeling-australisc/","published":"2026-03-10"},{"url":"https://hartvaat.nl/2026/01/30/lager-opleidingsniveau-hangt-samen-met-meer-halsslagaderplaques-los-van-risicofa/","published":"2026-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"madhu-k-natarajan","type":"person","url":"https://hartvaat.nl/mensen/madhu-k-natarajan/","name":"Madhu K Natarajan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/27/intracoronair-lage-dosis-rtpa-bij-primaire-pci-voor-stemi-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","published":"2016-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maja-cikes","type":"person","url":"https://hartvaat.nl/mensen/maja-cikes/","name":"Maja Cikes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","published":"2021-11-11"},{"url":"https://hartvaat.nl/2019/12/10/echocardiografische-kenmerken-bij-hfpef/","published":"2019-12-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"makoto-hibino","type":"person","url":"https://hartvaat.nl/mensen/makoto-hibino/","name":"Makoto Hibino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/06/01/nlr-en-cardiale-remodelling-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/06/01/diabetesduur-beinvloedt-lv-massaregressie-met-empagliflozine/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/04/01/sglt2-remmers-bij-hfref-of-hfpef-meta-analyse/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2022/03/01/bloeddruk-hypertensie-en-risico-op-aortadissectie-j-sch-en-uk-biobank/","published":"2022-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"manas-sinha","type":"person","url":"https://hartvaat.nl/mensen/manas-sinha/","name":"Manas Sinha","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mansoor-husain","type":"person","url":"https://hartvaat.nl/mensen/mansoor-husain/","name":"Mansoor Husain","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/06/01/nierfunctie-en-dapagliflozine-effect-op-gezondheidsstatus-define-hf/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2023/07/18/sglt2-remmers-verbeteren-kwaliteit-van-leven-gelijk-bij-zwarte-en-witte-hartfale/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2020/03/17/liraglutide-cv-uitkomsten-bij-diabetes-met-of-zonder-hartfalen-leader/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/08/29/orale-semaglutide-en-cv-uitkomsten-bij-diabetes-type-2-nejm-pioneer-6/","published":"2019-08-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"manuel-martinez-selles","type":"person","url":"https://hartvaat.nl/mensen/manuel-martinez-selles/","name":"Manuel Martínez-Sellés","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/01/colica-colchicine-bij-acuut-gedecompenseerd-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/12/01/intermitterend-levosimendan-bij-gevorderd-hf-laica-studie/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","published":"2021-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"maoyi-tian","type":"person","url":"https://hartvaat.nl/mensen/maoyi-tian/","name":"Maoyi Tian","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2022/09/26/zoutvervangers-verminderen-cardiovasculaire-events-systematische-review/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2022/05/17/kosteneffectiviteit-van-zoutsubstitutie-ssass-analyse/","published":"2022-05-17"},{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","published":"2021-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marat-v-ezhov","type":"person","url":"https://hartvaat.nl/mensen/marat-v-ezhov/","name":"Marat V Ezhov","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/27/lp-a-verstoort-de-ldl-cholesterolberekening-welke-formule-is-het-meest-betrouwba/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2019/07/01/evolocumab-en-totale-cv-events-bij-cardiovasculaire-ziekte-fourier-analyse/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marc-sapoval","type":"person","url":"https://hartvaat.nl/mensen/marc-sapoval/","name":"Marc Sapoval","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"},{"url":"https://hartvaat.nl/2017/03/01/24-uurs-bloeddrukmonitoring-bij-renale-denervatie-denerhtn-studie/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/09/20/medicatietrouw-en-bloeddrukeffecten-van-renale-denervatie-rsd-pathway-2-analyse/","published":"2016-09-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marc-vanderheyden","type":"person","url":"https://hartvaat.nl/mensen/marc-vanderheyden/","name":"Marc Vanderheyden","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/03/10/mondiale-prevalentie-uitkomsten-en-kosten-van-hartfalen-careme-studie/","published":"2023-03-10"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marc-andre-d-entremont","type":"person","url":"https://hartvaat.nl/mensen/marc-andre-d-entremont/","name":"Marc-André d'Entremont","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marcelle-d-smit","type":"person","url":"https://hartvaat.nl/mensen/marcelle-d-smit/","name":"Marcelle D Smit","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/07/15/race-3-langetermijnresultaten-gerichte-behandeling-bij-vroeg-persisterend-af-en-/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2021/09/08/antiaritmica-bij-vroeg-persisterend-af-met-hf-race-3/","published":"2021-09-08"},{"url":"https://hartvaat.nl/2019/04/01/upstream-therapie-verbetert-qol-bij-persisterend-af-arrest-af/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/08/21/behandeling-van-onderliggende-aandoeningen-verbetert-sinusritme-na-af-arrest-af/","published":"2018-08-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marco-de-carlo","type":"person","url":"https://hartvaat.nl/mensen/marco-de-carlo/","name":"Marco De Carlo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2018/12/01/mitraclip-plus-medicamenteus-versus-medicamenteus-alleen-bij-hf-met-mr-meta-anal/","published":"2018-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marco-trevisan","type":"person","url":"https://hartvaat.nl/mensen/marco-trevisan/","name":"Marco Trevisan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/11/22/cva-risicoscores-bij-af-vergeleken-cha2ds2-vasc-blijft-de-beste/","published":"2022-11-22"},{"url":"https://hartvaat.nl/2017/03/28/edoxaban-bij-af-met-bioprothese-hartkleppen-trombo-emboliepreventie/","published":"2017-03-28"},{"url":"https://hartvaat.nl/2017/03/21/kleplijden-en-edoxaban-versus-warfarine-bij-af-engage-af-timi-48/","published":"2017-03-21"},{"url":"https://hartvaat.nl/2017/03/21/nieuwe-risicovoorspellingsscore-bij-af-voor-netto-klinisch-resultaat-engage-af-t/","published":"2017-03-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marcus-sandri","type":"person","url":"https://hartvaat.nl/mensen/marcus-sandri/","name":"Marcus Sandri","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/01/22/milde-hypothermie-bij-cardiogene-shock-complicerend-mi/","published":"2019-01-22"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marialuisa-zedde","type":"person","url":"https://hartvaat.nl/mensen/marialuisa-zedde/","name":"Marialuisa Zedde","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/05/19/stop-cad-1-op-6-cervicale-arteriedissecties-wordt-aanvankelijk-verkeerd-gediagno/","published":"2026-06-10"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mariama-akodad","type":"person","url":"https://hartvaat.nl/mensen/mariama-akodad/","name":"Mariama Akodad","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/06/27/tavr-bij-patienten-65-jaar-hogere-sterfte-en-heropnames-dan-chirurgie-maar-onvol/","published":"2026-08-04"},{"url":"https://hartvaat.nl/2026/05/22/lge-granulariteit-op-cmr-voorspelt-sterfte-bij-eindstadium-hypertrofische-cardio/","published":"2026-06-06"},{"url":"https://hartvaat.nl/2020/10/01/crp-sst2-en-gdf-15-multimarker-voor-prognostische-stratificatie-bij-stabiel-hf/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/04/01/sst2-voor-hartfalenmanagement-stade-hf-pilotstudie/","published":"2020-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mariana-almudi-souza","type":"person","url":"https://hartvaat.nl/mensen/mariana-almudi-souza/","name":"Mariana Almudi Souza","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"},{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marie-hauguel-moreau","type":"person","url":"https://hartvaat.nl/mensen/marie-hauguel-moreau/","name":"Marie Hauguel-Moreau","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/11/19/afloat-flecainide-voorkomt-af-na-pfo-sluiting-rct/","published":"2024-11-19"},{"url":"https://hartvaat.nl/2021/01/19/residuele-syntax-score-bij-cardiogene-shock/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","published":"2020-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marilyn-borgman","type":"person","url":"https://hartvaat.nl/mensen/marilyn-borgman/","name":"Marilyn Borgman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/10/23/evolocumab-en-coronaire-plaquesamenstelling-glagov-beeldvorming/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/09/01/hdl-mimeticum-met-recombinant-apoa-i-milano-en-coronairlijden-jama-cardiology/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marino-labinaz","type":"person","url":"https://hartvaat.nl/mensen/marino-labinaz/","name":"Marino Labinaz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2025/12/23/korte-anticoagulatie-versus-dapt-na-laa-occlusie-devicetrombosepreventie/","published":"2025-12-23"},{"url":"https://hartvaat.nl/2021/08/05/milrinone-versus-dobutamine-bij-cardiogene-shock-nejm-doremi/","published":"2021-08-05"},{"url":"https://hartvaat.nl/2020/02/01/femorale-versus-radiale-toegang-bij-stemi-jama-cardiology-safari-stemi/","published":"2020-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mariusz-kowalewski","type":"person","url":"https://hartvaat.nl/mensen/mariusz-kowalewski/","name":"Mariusz Kowalewski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/19/salamander-register-95-5-technisch-succes-bij-stand-alone-linker-hartoor-occlusi/","published":"2026-06-10"},{"url":"https://hartvaat.nl/2024/10/03/geisoleerde-versus-hybride-thoracoscopische-ablatie-bij-af-korte-en-langetermijn/","published":"2024-10-03"},{"url":"https://hartvaat.nl/2021/04/01/va-ecls-bij-harttransplantatie-en-vad-centra-meta-analyse/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2018/04/17/uitgangs-ldl-en-mortaliteitsreductie-na-ldl-verlaging-jama-meta-analyse/","published":"2018-04-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mark-a-espeland","type":"person","url":"https://hartvaat.nl/mensen/mark-a-espeland/","name":"Mark A Espeland","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2022/10/01/bloeddruk-in-hogere-versus-lagere-arm-en-cv-uitkomsten-interpress-ipd-meta-analy/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/07/15/fysieke-revalidatie-bij-oudere-gehospitaliseerde-hf-patienten-nejm-rehab-hf/","published":"2021-07-15"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mark-b-effron","type":"person","url":"https://hartvaat.nl/mensen/mark-b-effron/","name":"Mark B Effron","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/09/01/aspirinedosering-voor-secundaire-preventie-bij-mannen-versus-vrouwen/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mark-j-sarnak","type":"person","url":"https://hartvaat.nl/mensen/mark-j-sarnak/","name":"Mark J Sarnak","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/23/clorotic-subanalyse-acute-egfr-daling-door-thiaziden-bij-acuut-hf-is-geen-progno/","published":"2026-04-21"},{"url":"https://hartvaat.nl/2026/03/02/staken-van-ras-remmers-na-acute-egfr-daling-hangt-samen-met-meer-nierfalen-en-st/","published":"2026-03-02"},{"url":"https://hartvaat.nl/2021/03/01/kdigo-2021-bloeddruk-bij-ckd-executive-summary/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2019/11/01/acute-egfr-daling-door-enalapril-en-mortaliteit-bij-hf-met-ckd/","published":"2019-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mark-y-chan","type":"person","url":"https://hartvaat.nl/mensen/mark-y-chan/","name":"Mark Y Chan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/07/09/cangrelor-en-infarctgrootte-bij-stemi-gerandomiseerde-trial/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/05/07/mandibulaire-advancementsplint-versus-cpap-voor-bloeddrukverlaging-bij-osa/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2021/07/01/remote-post-ontslag-behandeling-na-mi-door-paramedici-versus-standaardzorg-jama-/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2018/06/19/cardioprotectieve-therapieen-en-area-at-risk-bij-gereperfuseerd-stemi-cmr-analys/","published":"2018-06-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"markus-meyer","type":"person","url":"https://hartvaat.nl/mensen/markus-meyer/","name":"Markus Meyer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/10/01/gepersonaliseerde-versnelde-pacing-bij-hfpef-klinische-uitkomsten/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/04/01/clip-hfpef-cilostazol-bij-hfpef-gerandomiseerde-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/04/01/betablokkerstaken-verbetert-inspanningscapaciteit-bij-hfpef/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/03/01/gepersonaliseerde-versnelde-pacing-bij-hfpef-met-pacemaker/","published":"2023-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marlene-s-williams","type":"person","url":"https://hartvaat.nl/mensen/marlene-s-williams/","name":"Marlene S Williams","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2022/10/25/2022-acc-aha-datadefinities-voor-pijn-op-de-borst-en-acuut-myocardinfarct/","published":"2022-10-25"},{"url":"https://hartvaat.nl/2020/07/28/evolocumab-op-atherogene-lipoproteinen-in-de-peri-infarctperiode-gerandomiseerde/","published":"2020-07-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marlies-m-kok","type":"person","url":"https://hartvaat.nl/mensen/marlies-m-kok/","name":"Marlies M Kok","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/07/01/uitkomsten-van-des-in-kleine-coronairen-naar-strutdikte-jama-cardiology-meta-ana/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/10/06/resolute-onyx-versus-orsiro-stent-lancet-gerandomiseerde-non-inferioriteitstrial/","published":"2018-10-06"},{"url":"https://hartvaat.nl/2017/03/01/5-jaarsuitkomsten-van-zotarolimus-en-everolimus-eluting-stents-trial-en-real-wor/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/11/26/ultradunne-biodegradeerbare-versus-duurzame-polymer-des-lancet-gerandomiseerde-t/","published":"2016-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"marloes-franssen","type":"person","url":"https://hartvaat.nl/mensen/marloes-franssen/","name":"Marloes Franssen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-bloeddrukcontrole-bij-risicozwangerschap-jama-bump-2/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2019/06/01/kosteneffectiviteit-van-telemonitoring-en-zelfmeting-van-bloeddruk-tasminh4/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2018/03/10/zelfgemeten-bloeddruk-met-of-zonder-telemonitoring-voor-medicatietitratie-lancet/","published":"2018-03-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martha-gulati","type":"person","url":"https://hartvaat.nl/mensen/martha-gulati/","name":"Martha Gulati","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/26/esc-consensus-vrouwenhartcentra-whc-als-nieuw-zorgmodel-in-europa/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2025/01/01/hartfalenpreventie-bewijsgeneratie-trialontwerp-en-regulatoire-trajecten/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-op-een-blik/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2022/10/25/2022-acc-aha-datadefinities-voor-pijn-op-de-borst-en-acuut-myocardinfarct/","published":"2022-10-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-fredriksson","type":"person","url":"https://hartvaat.nl/mensen/martin-fredriksson/","name":"Martin Fredriksson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-frydland","type":"person","url":"https://hartvaat.nl/mensen/martin-frydland/","name":"Martin Frydland","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2022/10/20/box-bloeddrukdoelen-bij-comateuze-overlevenden-van-hartstilstand/","published":"2022-10-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-g-stoel","type":"person","url":"https://hartvaat.nl/mensen/martin-g-stoel/","name":"Martin G Stoel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/12/01/coronairangiografie-na-hartstilstand-zonder-st-elevatie-coact-1-jaarsuitkomsten/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/04/11/coronairangiografie-na-hartstilstand-zonder-st-elevatie-nejm-coact/","published":"2019-04-11"},{"url":"https://hartvaat.nl/2018/10/06/resolute-onyx-versus-orsiro-stent-lancet-gerandomiseerde-non-inferioriteitstrial/","published":"2018-10-06"},{"url":"https://hartvaat.nl/2017/03/01/5-jaarsuitkomsten-van-zotarolimus-en-everolimus-eluting-stents-trial-en-real-wor/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-hadamitzky","type":"person","url":"https://hartvaat.nl/mensen/martin-hadamitzky/","name":"Martin Hadamitzky","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/04/zeer-hoog-vermogen-70w-rf-ablatie-met-flexibele-tip-voor-pvi-bij-af/","published":"2025-08-04"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-hellmich","type":"person","url":"https://hartvaat.nl/mensen/martin-hellmich/","name":"Martin Hellmich","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/07/01/statinoplaaddosis-voor-cabg-gerandomiseerde-trial/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2017/04/01/oscillerende-whole-body-vibratie-verbetert-inspanningscapaciteit-bij-pah/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-m-zenni","type":"person","url":"https://hartvaat.nl/mensen/martin-m-zenni/","name":"Martin M Zenni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/10/13/laaggedoseerd-ticagrelor-versus-standaard-clopidogrel-bij-diabetes-farmacodynami/","published":"2020-10-13"},{"url":"https://hartvaat.nl/2019/04/02/cangrelor-en-gemalen-ticagrelor-bij-stemi-met-primaire-pci/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2016/09/13/prasugrel-versus-ticagrelor-bij-diabetes-type-2-met-coronairlijden-optimus-4-stu/","published":"2016-09-13"},{"url":"https://hartvaat.nl/2016/05/03/gemalen-prasugrel-bij-stemi-met-primaire-pci-de-crush-studie/","published":"2016-05-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-o-donnell","type":"person","url":"https://hartvaat.nl/mensen/martin-o-donnell/","name":"Martin O'Donnell","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/08/25/extracraniale-bloedingen-komen-bij-26-van-af-patienten-op-antistolling-voor-comb/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2024/07/13/convince-langetermijn-colchicine-voor-preventie-van-recidief-niet-cardioembolisc/","published":"2024-07-13"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","published":"2018-01-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-r-cowie","type":"person","url":"https://hartvaat.nl/mensen/martin-r-cowie/","name":"Martin R Cowie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/11/16/sacubitril-valsartan-versus-standaardtherapie-op-nt-probnp-en-inspanningscapacit/","published":"2021-11-16"},{"url":"https://hartvaat.nl/2020/04/01/biomarkers-bij-hf-met-centrale-slaapapneu-serve-hf/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2019/01/05/staken-van-hf-medicatie-bij-herstelde-dilaterende-cardiomyopathie-lancet-tred-hf/","published":"2019-01-05"},{"url":"https://hartvaat.nl/2017/08/07/remote-management-van-hartfalen-met-implanteerbare-devices-overzicht/","published":"2017-08-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martin-s-maron","type":"person","url":"https://hartvaat.nl/mensen/martin-s-maron/","name":"Martin S Maron","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/05/mavacamten-in-de-praktijk-zwarte-patienten-krijgen-55-minder-vaak-toegang-atrium/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/03/05/aficamten-veilig-en-effectief-bij-langdurige-behandeling-van-obstructieve-hcm/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/10/07/nieuwe-inspanningsherstelpatronen-als-maat-voor-cardiale-prestatie/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","published":"2023-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"martina-m-mcgrath","type":"person","url":"https://hartvaat.nl/mensen/martina-m-mcgrath/","name":"Martina M McGrath","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2020/09/29/arni-en-renale-uitkomsten-bij-hfpef-paragon-hf/","published":"2020-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mary-cushman","type":"person","url":"https://hartvaat.nl/mensen/mary-cushman/","name":"Mary Cushman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/20/biomarkers-voorspellen-coronairlijden-bij-atriumfibrilleren-regards/","published":"2026-07-16"},{"url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2020/09/22/sekse-specifieke-cv-risicofactoren-en-biomarkers-bij-incident-hartfalen/","published":"2020-09-22"},{"url":"https://hartvaat.nl/2017/01/03/traditionele-cv-risicofactoren-en-veneuze-trombo-embolie-individuele-patientdata/","published":"2017-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"masaharu-masuda","type":"person","url":"https://hartvaat.nl/mensen/masaharu-masuda/","name":"Masaharu Masuda","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/01/nierfunctie-en-effectiviteit-van-lva-ablatie-na-pvi-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2021/04/06/pvi-alleen-versus-uitgebreide-ablatie-bij-persisterend-af-meta-analyse/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2018/09/01/pace-capture-geleide-ablatie-na-contact-force-pvi-dragon-gerandomiseerde-trial/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2016/02/14/kortdurend-antiaritmica-na-katheterablatie-voor-atriumfibrilleren-east-af-trial/","published":"2016-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"masanori-taniwaki","type":"person","url":"https://hartvaat.nl/mensen/masanori-taniwaki/","name":"Masanori Taniwaki","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neoatherosclerose-na-stemi-secundaire-analyse/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/08/01/biodegradeerbare-versus-duurzame-polymeer-ees-langetermijn-neoatherosclerose/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2019/07/01/lokale-hemodynamische-krachten-en-fenotype-van-coronaire-plaques/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","published":"2019-06-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"masatoshi-koga","type":"person","url":"https://hartvaat.nl/mensen/masatoshi-koga/","name":"Masatoshi Koga","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/03/prasugrel-vs-clopidogrel-invloed-van-patientkenmerken-op-trombocytenremming-bij-/","published":"2026-04-12"},{"url":"https://hartvaat.nl/2025/07/05/optimale-timing-van-anticoagulatie-na-ischemisch-cva-en-af-collaboratief-project/","published":"2025-07-05"},{"url":"https://hartvaat.nl/2024/07/02/vroege-versus-late-doac-na-cva-met-hemorrhagische-transformatie-bij-af/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/06/29/elan-vroege-versus-late-anticoagulatie-na-cva-bij-af-nejm/","published":"2023-06-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"masayuki-fukuzawa","type":"person","url":"https://hartvaat.nl/mensen/masayuki-fukuzawa/","name":"Masayuki Fukuzawa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/19/eldercare-af-post-hoc-edoxaban-spiegel-en-pt-13s-voorspellen-bloedingsrisico-bij/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2022/06/01/edoxaban-15-mg-bij-zeer-oude-patienten-met-atriumfibrilleren-eldercare-subanalys/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2022/03/01/edoxaban-15-mg-naar-nierfunctie-bij-zeer-oude-af-eldercare-subanalyse/","published":"2022-03-01"},{"url":"https://hartvaat.nl/2020/10/29/laaggedoseerd-edoxaban-bij-zeer-oude-af-patienten-nejm-eldercare-af/","published":"2020-10-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"massimo-mancone","type":"person","url":"https://hartvaat.nl/mensen/massimo-mancone/","name":"Massimo Mancone","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/01/sacubitril-valsartan-na-acuut-mi-meta-analyse-van-in-hospital-initiatie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2017/08/08/prasugrel-of-ticagrelor-bij-stemi-met-diabetes/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/07/01/syntax-scores-en-uitkomsten-bij-diabetes-met-multivatenlijden-gepoolde-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/12/21/statines-voor-primaire-preventie-bij-hiv-positieve-patienten-systematische-revie/","published":"2016-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matteo-anselmino","type":"person","url":"https://hartvaat.nl/mensen/matteo-anselmino/","name":"Matteo Anselmino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/06/02/catheterablatie-bij-atriumfibrilleren-in-cardiale-amyloidose-levert-42-ritmievri/","published":"2026-08-11"},{"url":"https://hartvaat.nl/2026/04/20/stopstorm-stereotactische-bestraling-reduceert-refractaire-vt-met-80/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2022/12/09/ideale-blankingperiode-na-af-ablatie-bewijs-voor-herziening/","published":"2022-12-09"},{"url":"https://hartvaat.nl/2016/05/01/katheterablatie-van-af-bij-chronisch-hartfalen-state-of-the-art-en-toekomstpersp/","published":"2016-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matthew-bennett","type":"person","url":"https://hartvaat.nl/mensen/matthew-bennett/","name":"Matthew Bennett","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","published":"2024-02-16"},{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matthew-c-riddle","type":"person","url":"https://hartvaat.nl/mensen/matthew-c-riddle/","name":"Matthew C Riddle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","published":"2019-07-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matthias-bluher","type":"person","url":"https://hartvaat.nl/mensen/matthias-bluher/","name":"Matthias Blüher","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/23/van-internationale-richtlijnen-naar-nationale-implementatie-bij-cardio-renaal-me/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/01/14/glp-1-receptoragonisten-en-de-volgende-generatie-incretinegebaseerde-middelen/","published":"2026-01-14"},{"url":"https://hartvaat.nl/2025/08/14/cagrisema-gecombineerd-cagrilintide-en-semaglutide-bij-overgewicht-nejm/","published":"2025-08-14"},{"url":"https://hartvaat.nl/2018/03/13/leefstijlinterventies-en-mobilisatie-van-vetstapeling-central-mri-gerandomiseerd/","published":"2018-03-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"matthias-gotberg","type":"person","url":"https://hartvaat.nl/mensen/matthias-gotberg/","name":"Matthias Götberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/03/15/5-jaars-ifr-versus-ffr-geleide-pci-define-flair-ifr-swedeheart/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2017/05/11/instantaneous-wave-free-ratio-versus-ffr-voor-pci-indicatie-nejm-ifr-swedeheart/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mattia-arrigo","type":"person","url":"https://hartvaat.nl/mensen/mattia-arrigo/","name":"Mattia Arrigo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/02/01/diureticaresistentie-bij-acuut-hartfalen-prevalentie-en-kenmerken/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","published":"2023-08-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mauro-santos","type":"person","url":"https://hartvaat.nl/mensen/mauro-santos/","name":"Mauro Santos","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/11/28/pop-ht-zelfmanagement-van-bloeddruk-na-hypertensieve-zwangerschap-jama-rct/","published":"2023-11-28"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-bloeddrukcontrole-bij-risicozwangerschap-jama-bump-2/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2018/08/01/zelfmanagement-van-postnatale-hypertensie-de-snap-ht-trial/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"megan-k-yee","type":"person","url":"https://hartvaat.nl/mensen/megan-k-yee/","name":"Megan K Yee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/04/23/implanteerbaar-cardiaal-alertsysteem-voor-vroege-herkenning-van-stemi/","published":"2019-04-23"},{"url":"https://hartvaat.nl/2018/07/10/fatale-of-irreversibele-bloedingen-en-ischemische-events-met-rivaroxaban-bij-acs/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2017/01/24/heropnames-bij-af-patienten-na-stenting-twee-antitromboticastrategieen-vergeleke/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","published":"2016-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"megan-l-neely","type":"person","url":"https://hartvaat.nl/mensen/megan-l-neely/","name":"Megan L Neely","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2017/08/01/voorspelling-van-bloedingsrisico-tijdens-dapt-na-acs/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/08/01/eerder-clopidogrelgebruik-en-uitkomsten-bij-conservatief-behandeld-acs/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"},{"url":"https://hartvaat.nl/2016/03/01/cyp2c19-metaboliseerdersstatus-en-uitkomsten-bij-acs-prasugrel-versus-clopidogre/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mehmet-kanbay","type":"person","url":"https://hartvaat.nl/mensen/mehmet-kanbay/","name":"Mehmet Kanbay","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/08/21/scd-bij-ckd-en-dialyse-heterogene-aritmieen-en-mechanisme-gestuurde-preventie/","published":"2026-08-29"},{"url":"https://hartvaat.nl/2026/03/19/angiotensinogeen-als-nieuw-aangrijppunt-bij-hypertensie-opkomst-van-rna-medicijn/","published":"2026-03-19"},{"url":"https://hartvaat.nl/2026/02/09/communicatie-tussen-nier-en-hart-via-extracellulaire-vesikels/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2025/10/07/relatie-tussen-obesitas-en-ckd-conclusies-van-een-kdigo-conferentie/","published":"2025-10-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mehul-desai","type":"person","url":"https://hartvaat.nl/mensen/mehul-desai/","name":"Mehul Desai","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/07/31/canagliflozine-en-hartfalen-bij-diabetes-type-2-canvas-programma/","published":"2018-07-31"},{"url":"https://hartvaat.nl/2018/01/23/canagliflozine-voor-primaire-en-secundaire-cardiovasculaire-preventie-canvas/","published":"2018-01-23"},{"url":"https://hartvaat.nl/2017/08/17/canagliflozine-en-cardiovasculaire-en-renale-events-bij-diabetes-type-2-nejm-can/","published":"2017-08-17"},{"url":"https://hartvaat.nl/2017/08/08/canagliflozine-en-cardiovasculaire-biomarkers-bij-oudere-diabetespatienten/","published":"2017-08-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"melanie-r-daniels","type":"person","url":"https://hartvaat.nl/mensen/melanie-r-daniels/","name":"Melanie R Daniels","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/10/03/vericiguat-bij-hfref-is-kosteneffectief-victoria-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","published":"2022-08-16"},{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-medicamenteus-bij-af-en-kwaliteit-van-leven-jama-cabana-q/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/11/27/economische-en-qol-uitkomsten-van-nt-probnp-geleide-hf-therapie/","published":"2018-11-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"melissa-a-simon","type":"person","url":"https://hartvaat.nl/mensen/melissa-a-simon/","name":"Melissa A Simon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","published":"2020-11-10"},{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","published":"2017-07-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"melissa-l-magwire","type":"person","url":"https://hartvaat.nl/mensen/melissa-l-magwire/","name":"Melissa L Magwire","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/07/16/interventie-voor-evidence-based-zorg-bij-diabetes-en-cv-risico/","published":"2024-07-16"},{"url":"https://hartvaat.nl/2023/04/18/gecoordineerde-zorg-optimaliseert-cv-preventie-bij-type-2-diabetes-jama-rct/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2020/09/01/2020-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2018/12/18/2018-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","published":"2018-12-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-a-acker","type":"person","url":"https://hartvaat.nl/mensen/michael-a-acker/","name":"Michael A Acker","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-g-silverman","type":"person","url":"https://hartvaat.nl/mensen/michael-g-silverman/","name":"Michael G Silverman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/10/15/triglyceridenverlaging-en-cv-risicoreductie-over-therapeutische-klassen-meta-ana/","published":"2019-10-15"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"},{"url":"https://hartvaat.nl/2016/09/27/ldl-c-verlaging-en-cardiovasculaire-risicoreductie-jama-systematische-review-en-/","published":"2016-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-j-domanski","type":"person","url":"https://hartvaat.nl/mensen/michael-j-domanski/","name":"Michael J Domanski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","published":"2019-02-19"},{"url":"https://hartvaat.nl/2018/12/11/syntax-score-bij-diabetes-met-coronaire-revascularisatie-freedom/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-j-koren","type":"person","url":"https://hartvaat.nl/mensen/michael-j-koren/","name":"Michael J Koren","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/19/evolocumab-en-doorgankelijkheid-van-veneuze-bypasses-na-cabg-newton-cabg-cardiol/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","published":"2025-09-20"},{"url":"https://hartvaat.nl/2025/06/03/pursuit-orale-pcsk9-remmer-voor-hypercholesterolemie-gerandomiseerde-trial/","published":"2025-06-03"},{"url":"https://hartvaat.nl/2019/10/29/langetermijn-werkzaamheid-en-veiligheid-van-evolocumab-bij-hypercholesterolemie/","published":"2019-10-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michael-magro","type":"person","url":"https://hartvaat.nl/mensen/michael-magro/","name":"Michael Magro","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/12/01/thin-cap-fibroatheroom-voorspelt-events-bij-diabetes-met-normale-ffr-combine-oct/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/12/01/coronairangiografie-na-hartstilstand-zonder-st-elevatie-coact-1-jaarsuitkomsten/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/04/11/coronairangiografie-na-hartstilstand-zonder-st-elevatie-nejm-coact/","published":"2019-04-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michel-zeitouni","type":"person","url":"https://hartvaat.nl/mensen/michel-zeitouni/","name":"Michel Zeitouni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2022/02/01/economische-uitkomsten-van-revalidatie-bij-ouderen-met-acuut-hf-rehab-hf/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2021/01/19/residuele-syntax-score-bij-cardiogene-shock/","published":"2021-01-19"},{"url":"https://hartvaat.nl/2020/03/17/klinische-en-farmacologische-effecten-van-apixaban-dosisaanpassing-aristotle/","published":"2020-03-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"michelle-samuel","type":"person","url":"https://hartvaat.nl/mensen/michelle-samuel/","name":"Michelle Samuel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-vasculaire-preventie-meta-analyse-van-lange-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2022/07/15/vt-ablatie-versus-antiaritmica-bij-myocardinfarct-locatie-maakt-uit/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2021/11/01/af-last-en-qol-na-af-ablatie-cabana-substudie/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","published":"2020-11-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"miguel-angel-martinez-gonzalez","type":"person","url":"https://hartvaat.nl/mensen/miguel-angel-martinez-gonzalez/","name":"Miguel Ángel Martínez-González","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/07/urinair-wijnzuur-als-biomarker-voor-wijnconsumptie-en-cv-risico-predimed/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2020/12/08/remnant-cholesterol-versus-ldl-en-incident-cv-ziekte/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/02/11/disfunctioneel-hdl-en-incidentie-van-acs-bij-hoog-cardiovasculair-risico/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2017/02/14/mediterraan-dieet-verbetert-hdl-functie-bij-hoog-cardiovasculair-risico-gerandom/","published":"2017-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mila-menozzi","type":"person","url":"https://hartvaat.nl/mensen/mila-menozzi/","name":"Mila Menozzi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"milos-taborsky","type":"person","url":"https://hartvaat.nl/mensen/milos-taborsky/","name":"Milos Taborsky","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/01/16/watchful-leefstijl-wandelinterventie-bij-hfref/","published":"2024-01-16"},{"url":"https://hartvaat.nl/2022/01/04/4-jaars-laa-sluiting-versus-niet-warfarine-oac-bij-af/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2020/06/30/laa-sluiting-versus-doac-bij-hoogrisico-af-vergelijkende-analyse/","published":"2020-06-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"miodrag-peric","type":"person","url":"https://hartvaat.nl/mensen/miodrag-peric/","name":"Miodrag Peric","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/08/18/c-mic-apparaat-vermindert-hartfalen-ernst-onafhankelijk-van-gdmt-aanpassingen-c-/","published":"2026-08-25"},{"url":"https://hartvaat.nl/2026/03/03/c-mic-ii-hartfunctie-inspanningscapaciteit-en-kwaliteit-van-leven-zijn-verwante-/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2021/04/01/cardio-microstroomdevice-bij-chronisch-hf-eerste-klinische-studie/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/07/14/radiale-arterie-versus-vena-saphena-graft-bij-cabg-jama-langetermijn-meta-analys/","published":"2020-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"miquel-fiol","type":"person","url":"https://hartvaat.nl/mensen/miquel-fiol/","name":"Miquel Fiol","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/07/urinair-wijnzuur-als-biomarker-voor-wijnconsumptie-en-cv-risico-predimed/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2020/12/08/remnant-cholesterol-versus-ldl-en-incident-cv-ziekte/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/02/11/disfunctioneel-hdl-en-incidentie-van-acs-bij-hoog-cardiovasculair-risico/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2017/02/14/mediterraan-dieet-verbetert-hdl-functie-bij-hoog-cardiovasculair-risico-gerandom/","published":"2017-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mirta-diez","type":"person","url":"https://hartvaat.nl/mensen/mirta-diez/","name":"Mirta Diez","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"},{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","published":"2020-01-14"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mitchell-lindsay","type":"person","url":"https://hartvaat.nl/mensen/mitchell-lindsay/","name":"Mitchell Lindsay","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/12/01/post-stenting-ffr-versus-angiografie-voor-pci-optimalisatie-target-ffr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/05/01/pci-versus-medicamenteus-bij-angina-met-ffr-in-de-grijze-zone/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mohammad-kassar","type":"person","url":"https://hartvaat.nl/mensen/mohammad-kassar/","name":"Mohammad Kassar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"molly-szerlip","type":"person","url":"https://hartvaat.nl/mensen/molly-szerlip/","name":"Molly Szerlip","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2024/06/06/smart-zelf-expanderend-versus-ballonexpandeerbaar-tavr-bij-kleine-annulus-nejm/","published":"2024-06-06"},{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","published":"2023-11-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"montserrat-fito","type":"person","url":"https://hartvaat.nl/mensen/montserrat-fito/","name":"Montserrat Fitó","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/07/urinair-wijnzuur-als-biomarker-voor-wijnconsumptie-en-cv-risico-predimed/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2020/12/08/remnant-cholesterol-versus-ldl-en-incident-cv-ziekte/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/02/11/disfunctioneel-hdl-en-incidentie-van-acs-bij-hoog-cardiovasculair-risico/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2017/02/14/mediterraan-dieet-verbetert-hdl-functie-bij-hoog-cardiovasculair-risico-gerandom/","published":"2017-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"morgane-cibotti-sun","type":"person","url":"https://hartvaat.nl/mensen/morgane-cibotti-sun/","name":"Morgane Cibotti-Sun","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/01/richtlijn-volwassenen-met-aangeboren-hartafwijkingen-2025-in-een-oogopslag/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/01/01/richtlijn-acute-longembolie-2026-in-een-oogopslag/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-op-een-blik/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2024/01/02/2023-af-richtlijn-op-een-blik-samenvatting/","published":"2024-01-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"morten-salling-olesen","type":"person","url":"https://hartvaat.nl/mensen/morten-salling-olesen/","name":"Morten Salling Olesen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/15/circadiaanse-patronen-van-af-en-ziekteprogressie-via-implanted-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2023/06/13/loop-substudie-nt-probnp-verbetert-af-screeningsopbrengst/","published":"2023-06-13"},{"url":"https://hartvaat.nl/2023/06/01/genetische-bijdrage-aan-aortastenose-dyslipidemie-inflammatie-en-verkalking/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2022/09/01/bloeddruk-beinvloedt-opbrengst-van-af-screening-loop-substudie/","published":"2022-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"morten-wang-fagerland","type":"person","url":"https://hartvaat.nl/mensen/morten-wang-fagerland/","name":"Morten Wang Fagerland","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","published":"2025-09-13"},{"url":"https://hartvaat.nl/2021/02/09/omega-3-vetzuren-bij-oudere-mi-patienten-omemi-gerandomiseerde-trial/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2016/06/01/preventie-van-cardiale-disfunctie-bij-borstkankerbehandeling-de-prada-trial/","published":"2016-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mustafa-arici","type":"person","url":"https://hartvaat.nl/mensen/mustafa-arici/","name":"Mustafa Arici","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/31/era-s-abcde-raamwerk-voor-preventie-van-nierziekten/","published":"2026-03-31"},{"url":"https://hartvaat.nl/2026/01/24/oproep-tot-actie-europese-trials-nodig-tegen-tsunami-van-nierfalen/","published":"2026-01-24"},{"url":"https://hartvaat.nl/2025/08/16/achieve-spironolacton-bij-dialysepatienten-internationale-rct/","published":"2025-08-16"},{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","published":"2025-03-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"mykela-m-moore","type":"person","url":"https://hartvaat.nl/mensen/mykela-m-moore/","name":"Mykela M. Moore","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/01/richtlijn-volwassenen-met-aangeboren-hartafwijkingen-2025-in-een-oogopslag/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/01/01/richtlijn-acute-longembolie-2026-in-een-oogopslag/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-op-een-blik/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2024/01/02/2023-af-richtlijn-op-een-blik-samenvatting/","published":"2024-01-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"n-m-s-natasja-de-groot","type":"person","url":"https://hartvaat.nl/mensen/n-m-s-natasja-de-groot/","name":"N M S Natasja de Groot","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/02/08/stolling-en-atriumfibrilleren-systematische-review-en-meta-analyse/","published":"2023-02-08"},{"url":"https://hartvaat.nl/2019/01/01/hotspots-van-gefractioneerde-elektrogrammen-in-linker-en-rechter-atrium-bij-af/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"na-li","type":"person","url":"https://hartvaat.nl/mensen/na-li/","name":"Na Li","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/07/09/bempedoinezuur-versus-statines-vergelijking-van-cv-voordelen/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/03/01/clear-outcomes-bempedoinezuur-vermindert-totale-cv-events-bij-statine-intolerant/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","published":"2023-04-13"},{"url":"https://hartvaat.nl/2022/08/01/b-lijnen-geleide-hartfalenbehandeling-verbetert-uitkomsten-na-ontslag/","published":"2022-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nader-rifai","type":"person","url":"https://hartvaat.nl/mensen/nader-rifai/","name":"Nader Rifai","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/05/inflammatie-cholesterol-lp-a-en-30-jaars-cv-uitkomsten-bij-vrouwen/","published":"2024-12-05"},{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","published":"2023-01-21"},{"url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","published":"2022-08-02"},{"url":"https://hartvaat.nl/2020/08/14/il-6-crp-en-ldl-als-biomarkers-van-residueel-risico-vergelijking/","published":"2020-08-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nagwa-khilla","type":"person","url":"https://hartvaat.nl/mensen/nagwa-khilla/","name":"Nagwa Khilla","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/11/01/evinacumab-bij-refractaire-hypercholesterolemie-langetermijn-effectiviteit-en-ve/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2020/12/10/evinacumab-bij-refractaire-hypercholesterolemie-nejm/","published":"2020-12-10"},{"url":"https://hartvaat.nl/2020/08/20/evinacumab-bij-homozygoot-familiaire-hypercholesterolemie-nejm/","published":"2020-08-20"},{"url":"https://hartvaat.nl/2020/07/14/alirocumab-bij-homozygoot-fh-odyssey-hofh/","published":"2020-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nanna-louise-junker-udesen","type":"person","url":"https://hartvaat.nl/mensen/nanna-louise-junker-udesen/","name":"Nanna Louise Junker Udesen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","published":"2026-02-17"},{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","published":"2025-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nanxiang-ouyang","type":"person","url":"https://hartvaat.nl/mensen/nanxiang-ouyang/","name":"Nanxiang Ouyang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2024/09/01/multifactorieel-intensief-bloeddrukmodel-bij-ouderen-en-jongeren/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/03/18/intensieve-bloeddrukinterventie-door-niet-artsen-in-lage-inkomenslanden-lancet-r/","published":"2023-03-18"},{"url":"https://hartvaat.nl/2022/05/21/dorpsarts-geleide-multifacet-interventie-voor-bloeddrukcontrole-in-ruraal-china-/","published":"2022-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"naomi-d-l-fisher","type":"person","url":"https://hartvaat.nl/mensen/naomi-d-l-fisher/","name":"Naomi D L Fisher","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","published":"2018-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nathan-mewton","type":"person","url":"https://hartvaat.nl/mensen/nathan-mewton/","name":"Nathan Mewton","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/05/off-label-dosering-van-sacubitril-valsartan-wijdverspreid-in-de-praktijk/","published":"2026-07-30"},{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2021/11/09/ffr-voor-behandeling-van-multivatencoronairlijden-jacc/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2018/12/13/percutaan-herstel-of-medicamenteuze-therapie-bij-secundaire-mr-nejm-mitra-fr/","published":"2018-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"navdeep-tangri","type":"person","url":"https://hartvaat.nl/mensen/navdeep-tangri/","name":"Navdeep Tangri","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/02/staken-van-ras-remmers-na-acute-egfr-daling-hangt-samen-met-meer-nierfalen-en-st/","published":"2026-03-02"},{"url":"https://hartvaat.nl/2025/12/24/risicovoorspellingsmodellen-voor-ouderen-met-chronische-nierziekte/","published":"2025-12-24"},{"url":"https://hartvaat.nl/2023/03/10/mondiale-prevalentie-uitkomsten-en-kosten-van-hartfalen-careme-studie/","published":"2023-03-10"},{"url":"https://hartvaat.nl/2018/06/12/sglt2-remmers-en-cardiovasculaire-events-de-cvd-real-2-real-world-studie/","published":"2018-06-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nazzareno-galie","type":"person","url":"https://hartvaat.nl/mensen/nazzareno-galie/","name":"Nazzareno Galiè","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/01/02/macitentan-bij-eisenmenger-syndroom/","published":"2019-01-02"},{"url":"https://hartvaat.nl/2018/02/20/morbiditeit-bij-pulmonaal-arteriele-hypertensie-als-prognostische-marker-voor-mo/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/04/14/macitentan-en-hemodynamiek-bij-pah-seraphin-hemodynamische-substudie/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2016/01/01/2015-esc-ers-richtlijn-voor-diagnostiek-en-behandeling-van-pulmonale-hypertensie/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"neil-sulke","type":"person","url":"https://hartvaat.nl/mensen/neil-sulke/","name":"Neil Sulke","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/11/01/nmarq-pvac-en-thoracoscopische-ablatie-bij-paroxysmaal-af-gerandomiseerde-trial/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/01/centrale-iliacale-av-anastomose-bij-ongecontroleerde-hypertensie-rox-control-htn/","published":"2017-12-01"},{"url":"https://hartvaat.nl/2016/07/01/implanteerbare-monitors-als-goudstandaard-voor-af-detectie-gerandomiseerde-verge/","published":"2016-07-01"},{"url":"https://hartvaat.nl/2016/03/01/eerste-trial-met-specifieke-ikach-blokker-toont-geen-reductie-in-af-last-bij-par/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicholas-j-leeper","type":"person","url":"https://hartvaat.nl/mensen/nicholas-j-leeper/","name":"Nicholas J Leeper","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/24/van-biobank-naar-voorspelling-polygenetische-risicoscores-voor-perifeer-vaatlijd/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2025/05/20/plozasiran-en-lipoproteine-deeltjesgrootte-bij-hypertriglyceridemie/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/01/09/plozasiran-bij-persisterende-chylomicronemie-en-pancreatitisrisico-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2024/09/12/plozasiran-sirna-tegen-apoc3-bij-gemengde-hyperlipidemie-nejm/","published":"2024-09-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nicholas-s-peters","type":"person","url":"https://hartvaat.nl/mensen/nicholas-s-peters/","name":"Nicholas S Peters","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/14/tricorder-ai-stethoscoop-voor-triple-cv-ziektedetectie/","published":"2026-02-14"},{"url":"https://hartvaat.nl/2024/06/11/remote-beoordeling-na-acs-gerandomiseerde-trial/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2023/03/30/ablatie-versus-antiaritmica-voor-vermindering-van-ziekenhuisbezoeken-bij-af/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2019/08/01/optimale-laesieset-bij-persisterend-af-ablatie-meta-regressie/","published":"2019-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"niels-vejlstrup","type":"person","url":"https://hartvaat.nl/mensen/niels-vejlstrup/","name":"Niels Vejlstrup","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","published":"2017-06-13"},{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","published":"2016-05-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nikhil-mistry","type":"person","url":"https://hartvaat.nl/mensen/nikhil-mistry/","name":"Nikhil Mistry","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/06/01/igfbp7-en-lv-massaregressie-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2021/12/01/sglt2-remmers-en-cardiale-remodellering-meta-analyse-van-mri-trials/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2019/04/01/restrictieve-versus-liberale-transfusie-bij-hartchirurgie-meta-analyse/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2018/09/27/6-maandsuitkomsten-van-restrictieve-versus-liberale-transfusie-bij-hartchirurgie/","published":"2018-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nikola-jagic","type":"person","url":"https://hartvaat.nl/mensen/nikola-jagic/","name":"Nikola Jagic","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"},{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nikolaos-fragakis","type":"person","url":"https://hartvaat.nl/mensen/nikolaos-fragakis/","name":"Nikolaos Fragakis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/03/ice-bij-af-ablatie-veiligheid-en-effectiviteit-meta-analyse/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/03/af-ablatie-timing-naar-af-duur-impact-op-aritmierecidief/","published":"2025-06-03"},{"url":"https://hartvaat.nl/2025/04/01/symptomatisch-versus-asymptomatisch-af-en-klinische-uitkomsten-meta-analyse/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/01/14/residuele-lekkage-na-laa-occlusie-en-uitkomsten-meta-analyse/","published":"2024-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nikolaos-ostlund-papadogeorgos","type":"person","url":"https://hartvaat.nl/mensen/nikolaos-ostlund-papadogeorgos/","name":"Nikolaos Östlund-Papadogeorgos","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nina-w-van-der-hoeven","type":"person","url":"https://hartvaat.nl/mensen/nina-w-van-der-hoeven/","name":"Nina W van der Hoeven","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/12/01/coronairangiografie-na-hartstilstand-zonder-st-elevatie-coact-1-jaarsuitkomsten/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/08/01/temporele-veranderingen-in-coronaire-hemodynamiek-bij-niet-culprit-vaten-na-stem/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/04/11/coronairangiografie-na-hartstilstand-zonder-st-elevatie-nejm-coact/","published":"2019-04-11"},{"url":"https://hartvaat.nl/2019/01/29/microvasculaire-schade-bij-gerevasculariseerde-stemi-met-ticagrelor-versus-prasu/","published":"2019-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ninian-n-lang","type":"person","url":"https://hartvaat.nl/mensen/ninian-n-lang/","name":"Ninian N Lang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","published":"2023-08-14"},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","published":"2022-12-17"},{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","published":"2021-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"niraj-varma","type":"person","url":"https://hartvaat.nl/mensen/niraj-varma/","name":"Niraj Varma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/09/30/adaptresponse-adaptieve-versus-conventionele-crt-bij-hartfalen-lancet/","published":"2023-09-30"},{"url":"https://hartvaat.nl/2017/11/01/defibrillatie-drempelwaarden-bij-rechtspectorale-icd-en-golfvorm-tuning/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2017/06/07/dagelijkse-telemonitoring-van-icd-s-gepoolde-analyse-van-drie-gerandomiseerde-tr/","published":"2017-06-07"},{"url":"https://hartvaat.nl/2017/05/01/automatische-pacing-timingaanpassingen-en-effectieve-lv-pacing-bij-crt/","published":"2017-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"niteesh-k-choudhry","type":"person","url":"https://hartvaat.nl/mensen/niteesh-k-choudhry/","name":"Niteesh K Choudhry","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/07/01/bestaande-cv-data-benutten-voor-hypertensiedetectie-en-behandeling-vital-trial/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2020/05/01/zelfgerapporteerde-versus-apotheekgeregistreerde-medicatietrouw-compass-analyse/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2020/01/01/p2y12-copay-reductie-en-therapietrouw-aan-andere-secundaire-preventiemiddelen/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/01/01/medicatie-copay-vouchers-en-p2y12-gebruik-en-cv-events-na-mi-jama/","published":"2019-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"norrina-b-allen","type":"person","url":"https://hartvaat.nl/mensen/norrina-b-allen/","name":"Norrina B Allen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/09/22/sekse-specifieke-cv-risicofactoren-en-biomarkers-bij-incident-hartfalen/","published":"2020-09-22"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-systematische-review-circulation/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/06/01/systematische-review-voor-de-2017-acc-aha-hypertensierichtlijn-hypertension-edit/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/05/15/systematische-review-voor-de-2017-acc-aha-hypertensierichtlijn/","published":"2018-05-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nuccia-morici","type":"person","url":"https://hartvaat.nl/mensen/nuccia-morici/","name":"Nuccia Morici","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/29/vroege-iabp-bij-hartfalen-gerelateerde-cardiogene-shock-gerandomiseerde-trial/","published":"2025-04-29"},{"url":"https://hartvaat.nl/2024/07/12/nste-acs-na-cabg-meta-analyse-van-behandelstrategieen/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2024/06/14/invasief-versus-conservatief-bij-ouderen-met-nste-acs-ipd-meta-analyse/","published":"2024-06-14"},{"url":"https://hartvaat.nl/2018/06/05/verlaagde-dosis-prasugrel-versus-standaard-clopidogrel-bij-oudere-acs-patienten/","published":"2018-06-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"nuria-lopez-pajares","type":"person","url":"https://hartvaat.nl/mensen/nuria-lopez-pajares/","name":"Nuria Lopez-Pajares","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"okechukwu-s-ogah","type":"person","url":"https://hartvaat.nl/mensen/okechukwu-s-ogah/","name":"Okechukwu S Ogah","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/10/01/lage-dosis-drievoudige-pil-versus-standaardzorg-bij-hypertensie-in-nigeria/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2022/11/01/antihypertensieve-combinaties-bij-afrikaanse-patienten-creole-secundaire-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2022/09/15/invictus-rivaroxaban-versus-warfarine-bij-reumatische-hartziekte-en-af/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2019/06/20/vergelijking-van-duale-therapieen-voor-bloeddrukverlaging-bij-afrikaanse-afrikan/","published":"2019-06-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"olaf-wendler","type":"person","url":"https://hartvaat.nl/mensen/olaf-wendler/","name":"Olaf Wendler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","published":"2022-01-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ole-ahlehoff","type":"person","url":"https://hartvaat.nl/mensen/ole-ahlehoff/","name":"Ole Ahlehoff","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2022/04/01/icd-bij-niet-ischemisch-systolisch-hf-met-coronaire-atherosclerose-danish/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"olga-bockeria","type":"person","url":"https://hartvaat.nl/mensen/olga-bockeria/","name":"Olga Bockeria","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"olga-castaner","type":"person","url":"https://hartvaat.nl/mensen/olga-castaner/","name":"Olga Castañer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/07/urinair-wijnzuur-als-biomarker-voor-wijnconsumptie-en-cv-risico-predimed/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2020/12/08/remnant-cholesterol-versus-ldl-en-incident-cv-ziekte/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/02/11/disfunctioneel-hdl-en-incidentie-van-acs-bij-hoog-cardiovasculair-risico/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2017/02/14/mediterraan-dieet-verbetert-hdl-functie-bij-hoog-cardiovasculair-risico-gerandom/","published":"2017-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"olga-shestakovska","type":"person","url":"https://hartvaat.nl/mensen/olga-shestakovska/","name":"Olga Shestakovska","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","published":"2021-07-06"},{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","published":"2020-06-09"},{"url":"https://hartvaat.nl/2019/08/13/rivaroxaban-met-of-zonder-aspirine-bij-hf-met-coronair-of-perifeer-vaatlijden/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/05/14/rivaroxaban-plus-aspirine-bij-vaatlijden-met-nierdisfunctie-compass/","published":"2019-05-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"olivier-muller","type":"person","url":"https://hartvaat.nl/mensen/olivier-muller/","name":"Olivier Muller","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/11/25/biodegradeerbare-versus-duurzame-polymeer-des-bij-stemi-langetermijndata/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2019/11/19/evolocumab-voor-vroege-ldl-verlaging-bij-acs-evopacs/","published":"2019-11-19"},{"url":"https://hartvaat.nl/2019/10/05/biodegradeerbare-versus-duurzame-polymer-des-bij-stemi-gerandomiseerde-trial/","published":"2019-10-05"},{"url":"https://hartvaat.nl/2018/09/01/ultradunne-biodegradeerbare-versus-dunne-duurzame-stents-lancet-gerandomiseerde-/","published":"2018-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"olivier-varenne","type":"person","url":"https://hartvaat.nl/mensen/olivier-varenne/","name":"Olivier Varenne","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/01/02/vergelijking-van-twee-ldl-streefwaarden-na-ischemisch-cva-nejm-tst/","published":"2020-01-02"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ota-hlinomaz","type":"person","url":"https://hartvaat.nl/mensen/ota-hlinomaz/","name":"Ota Hlinomaz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2018/01/30/prasugrel-versus-ticagrelor-bij-primaire-pci-voor-mi-1-jaarsuitkomsten/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2016/11/22/prasugrel-versus-ticagrelor-bij-acuut-mi-met-primaire-pci-multicenter-trial/","published":"2016-11-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"otilia-tica","type":"person","url":"https://hartvaat.nl/mensen/otilia-tica/","name":"Otilia Tica","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/03/beeldvorming-bij-atriale-cardiomyopathie-esc-scientific-statement/","published":"2026-03-22"},{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2021/10/16/betablokker-respons-bij-hf-met-sinusritme-en-af-machine-learning-clusteranalyse/","published":"2021-10-16"},{"url":"https://hartvaat.nl/2021/07/01/transformatie-van-klinisch-onderzoek-door-patientbetrokkenheid-rate-af/","published":"2021-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"p-a","type":"person","url":"https://hartvaat.nl/mensen/p-a/","name":"P. A.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/10/zuinig-machine-learningmodel-voorspelt-1-jaarssterfte-en-zinloosheid-na-tavi/","published":"2026-07-23"},{"url":"https://hartvaat.nl/2026/04/29/geisoleerde-secundaire-tricuspidalisinsufficientie-na-linkszijdige-klepchirurgie/","published":"2026-07-12"},{"url":"https://hartvaat.nl/2026/05/26/asymptomatische-matige-ernstige-aortaklepinsufficientie-niet-benigne-meta-analys/","published":"2026-07-03"},{"url":"https://hartvaat.nl/2026/02/12/ct-coronairangiografie-bij-nstemi-uitstekende-diagnostische-nauwkeurigheid-maar-/","published":"2026-02-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pablo-b-nery","type":"person","url":"https://hartvaat.nl/mensen/pablo-b-nery/","name":"Pablo B Nery","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/02/20/vanish2-catheterablatie-versus-antiaritmica-bij-ventriculaire-tachycardie-nejm/","published":"2025-02-20"},{"url":"https://hartvaat.nl/2023/05/01/aware-uitgebreide-ablatie-vermindert-af-recidief-niet-boven-standaard-pvi/","published":"2023-05-01"},{"url":"https://hartvaat.nl/2018/11/21/voortzetten-versus-onderbreken-doac-bij-device-chirurgie-bruise-control-2/","published":"2018-11-21"},{"url":"https://hartvaat.nl/2016/07/14/ablatie-versus-escalatie-van-antiaritmica-bij-ventriculaire-tachycardie-nejm-van/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pam-r-taub","type":"person","url":"https://hartvaat.nl/mensen/pam-r-taub/","name":"Pam R Taub","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/21/glp-1-agonisten-kosten-geen-spiermassa-tijdens-intensieve-hartrevalidatie/","published":"2026-06-09"},{"url":"https://hartvaat.nl/2025/07/22/victorion-initiate-inclisiran-monotherapie-bij-patienten-zonder-ascvd/","published":"2025-07-22"},{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pamela-n-peterson","type":"person","url":"https://hartvaat.nl/mensen/pamela-n-peterson/","name":"Pamela N Peterson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/08/20/fysiologische-versus-rechterkamerpacing-bij-lvef-35/","published":"2019-08-20"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paolo-mulatero","type":"person","url":"https://hartvaat.nl/mensen/paolo-mulatero/","name":"Paolo Mulatero","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":1,"articles":[{"url":"https://hartvaat.nl/2018/08/01/farmacologische-behandeling-van-hypertensie-bij-kinderen-netwerkmeta-analyse/","published":"2018-08-01"}],"videos":[{"url":"https://hartvaat.nl/video/aldosteron-ontregeling-hypertensie-esc/nieuwe-data-in-praktijk-mulatero/","title":"Wat betekent nieuwe data voor de praktijk? — Paolo Mulatero"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paolo-tosi","type":"person","url":"https://hartvaat.nl/mensen/paolo-tosi/","name":"Paolo Tosi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paolo-verdecchia","type":"person","url":"https://hartvaat.nl/mensen/paolo-verdecchia/","name":"Paolo Verdecchia","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/02/01/dabigatran-versus-warfarine-bij-af-met-linkerventrikelhypertrofie-re-ly/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/11/01/gemiddelde-bloeddruk-en-visit-to-visit-variabiliteit-als-gecombineerde-voorspell/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2016/09/01/intensievere-versus-minder-intensieve-bloeddrukverlaging-cumulatief-bewijs-en-tr/","published":"2016-09-01"},{"url":"https://hartvaat.nl/2016/04/01/prognostisch-effect-van-nachtelijke-bloeddrukdaling-bij-hypertensie-de-abc-h-stu/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pascal-defaye","type":"person","url":"https://hartvaat.nl/mensen/pascal-defaye/","name":"Pascal Defaye","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/03/upgrade-van-draadloze-pacemaker-van-enkelvoudig-naar-tweekamersysteem/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/03/multipoint-pacing-vermindert-hf-hospitalisaties-en-sterfte-bij-crt-non-responder/","published":"2025-06-03"},{"url":"https://hartvaat.nl/2024/10/01/draadloos-ultrasound-gebaseerd-crt-systeem-bij-hartfalen/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2016/02/01/rechterkamerseptumpacing-versus-apexpacing-bij-crt-defibrillator-gerandomiseerde/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paschalis-karakasis","type":"person","url":"https://hartvaat.nl/mensen/paschalis-karakasis/","name":"Paschalis Karakasis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/30/linear-trial-lattice-tip-katheter-verslaat-standaard-irrigatie-bij-cti-ablatie-v/","published":"2026-04-19"},{"url":"https://hartvaat.nl/2026/02/03/ice-bij-af-ablatie-veiligheid-en-effectiviteit-meta-analyse/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/03/af-ablatie-timing-naar-af-duur-impact-op-aritmierecidief/","published":"2025-06-03"},{"url":"https://hartvaat.nl/2025/04/01/symptomatisch-versus-asymptomatisch-af-en-klinische-uitkomsten-meta-analyse/","published":"2025-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pascual-bordes","type":"person","url":"https://hartvaat.nl/mensen/pascual-bordes/","name":"Pascual Bordes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/25/amphilimus-versus-zotarolimus-eluting-stent-bij-diabetes-en-coronairlijden/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2022/03/31/amphilimus-versus-zotarolimus-stents-bij-diabetes-sugar-gerandomiseerde-trial/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"},{"url":"https://hartvaat.nl/2019/12/03/magnesium-resorbeerbare-scaffold-versus-metallic-stent-bij-stemi-biosolve-iii/","published":"2019-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-beckers","type":"person","url":"https://hartvaat.nl/mensen/paul-beckers/","name":"Paul Beckers","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/04/01/inspanningstraining-en-hoog-sensitief-troponine-i-bij-hfref/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2021/06/01/inspanningstraining-en-hs-troponine-t-bij-hfref/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2021/02/09/hiit-matig-continu-of-richtlijnadvies-en-piek-vo2-bij-hfref-jama-smartex-hf/","published":"2021-02-09"},{"url":"https://hartvaat.nl/2017/02/28/hoog-intensieve-intervaltraining-bij-hartfalen-met-verminderde-ejectiefractie/","published":"2017-02-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-dendale","type":"person","url":"https://hartvaat.nl/mensen/paul-dendale/","name":"Paul Dendale","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/26/gerichte-patienteneducatie-vermindert-ongeplande-cv-events-bij-af/","published":"2024-12-26"},{"url":"https://hartvaat.nl/2021/12/21/iv-ijzercarboxymaltose-en-cardiale-reverse-remodellering-na-crt-iron-crt/","published":"2021-12-21"},{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","published":"2021-04-07"},{"url":"https://hartvaat.nl/2018/04/21/telemonitoring-verbetert-doac-therapietrouw-bij-af/","published":"2018-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-e-drawz","type":"person","url":"https://hartvaat.nl/mensen/paul-e-drawz/","name":"Paul E Drawz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/01/mhealth-interventie-verbetert-hypertensiezorg-bij-hoogrisicopatienten/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/04/01/hypotensieve-episodes-op-24-uurs-abpm-en-cognitieve-functie-sprint-inzichten/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2020/10/01/intensieve-versus-standaard-bloeddrukbehandeling-op-white-coat-effect-en-gemaske/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2017/01/01/intensieve-versus-standaard-bloeddrukcontrole-op-ambulante-bloeddruk-sprint-resu/","published":"2017-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-o-collinson","type":"person","url":"https://hartvaat.nl/mensen/paul-o-collinson/","name":"Paul O Collinson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-sorajja","type":"person","url":"https://hartvaat.nl/mensen/paul-sorajja/","name":"Paul Sorajja","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/01/zesjaarsuitkomsten-van-transkatheter-versus-chirurgische-aortaklepvervanging-bij/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/06/10/triluminate-tweejaarsresultaten-transcatheter-tr-repair-duurzaam-effectief/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2023/05/18/triluminate-transcatheter-tricuspidaliskleprepair-bij-ernstige-tr-nejm/","published":"2023-05-18"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-zelfexpanderende-klep-bij-laagrisicopatienten-nejm-evolut-low-risk/","published":"2019-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"paul-egbert-reimitz","type":"person","url":"https://hartvaat.nl/mensen/paul-egbert-reimitz/","name":"Paul-Egbert Reimitz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/01/27/periprocedurele-antistolling-bij-eliminate-af-ononderbroken-edoxaban-versus-vka/","published":"2021-01-27"},{"url":"https://hartvaat.nl/2020/12/14/edoxaban-bij-af-met-pci-naar-acute-versus-chronische-coronaire-presentatie-entru/","published":"2020-12-14"},{"url":"https://hartvaat.nl/2019/10/12/edoxaban-versus-vka-gebaseerd-antitrombotisch-regime-na-stenting-bij-af-lancet-e/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/09/21/ononderbroken-edoxaban-versus-vka-bij-af-ablatie-eliminate-af/","published":"2019-09-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pavan-atluri","type":"person","url":"https://hartvaat.nl/mensen/pavan-atluri/","name":"Pavan Atluri","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/03/01/aspirine-en-hemocompatibiliteit-na-lvad-bij-atherosclerotisch-vaatlijden/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pavel-jansa","type":"person","url":"https://hartvaat.nl/mensen/pavel-jansa/","name":"Pavel Jansa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/06/18/sildenafil-dosisvergelijking-bij-pulmonale-arteriele-hypertensie/","published":"2024-06-18"},{"url":"https://hartvaat.nl/2018/02/20/morbiditeit-bij-pulmonaal-arteriele-hypertensie-als-prognostische-marker-voor-mo/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/04/14/macitentan-en-hemodynamiek-bij-pah-seraphin-hemodynamische-substudie/","published":"2017-04-14"},{"url":"https://hartvaat.nl/2017/04/01/hemodynamische-effecten-van-riociguat-bij-inoperabel-cteph/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pawe-e-buszman","type":"person","url":"https://hartvaat.nl/mensen/pawe-e-buszman/","name":"Paweł E Buszman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2016/08/01/cabg-versus-pci-en-risico-op-myocardinfarct-en-revascularisatie-bij-ckd-patiente/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pekka-raatikainen","type":"person","url":"https://hartvaat.nl/mensen/pekka-raatikainen/","name":"Pekka Raatikainen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/10/07/vroege-substraatablatie-versus-antiaritmica-bij-vt-gerandomiseerde-trial/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2019/03/19/katheterablatie-versus-antiaritmica-en-kwaliteit-van-leven-bij-af-jama-captaf/","published":"2019-03-19"},{"url":"https://hartvaat.nl/2018/01/01/supraventriculaire-ectopie-na-af-ablatie-voorspelt-recidief/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/03/01/katheterablatie-als-eerstelijnsbehandeling-bij-paroxysmaal-af-5-jaarsresultaten/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"per-h-nielsen","type":"person","url":"https://hartvaat.nl/mensen/per-h-nielsen/","name":"Per H Nielsen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","published":"2021-12-18"},{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","published":"2020-01-18"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-a-johansson","type":"person","url":"https://hartvaat.nl/mensen/peter-a-johansson/","name":"Peter A Johansson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/01/dapagliflozine-na-mi-naar-ef-cardiometabole-uitkomsten/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","published":"2020-08-25"},{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","published":"2019-05-28"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-boekstegers","type":"person","url":"https://hartvaat.nl/mensen/peter-boekstegers/","name":"Peter Boekstegers","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-j-greasley","type":"person","url":"https://hartvaat.nl/mensen/peter-j-greasley/","name":"Peter J Greasley","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/04/16/sglt2-remming-waterconservatie-domineert-over-osmotische-diurese-bij-hf/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2023/11/25/zenith-ckd-zibotentan-plus-dapagliflozine-bij-ckd-lancet/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","published":"2020-09-15"},{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","published":"2020-04-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-j-schwartz","type":"person","url":"https://hartvaat.nl/mensen/peter-j-schwartz/","name":"Peter J Schwartz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/13/mtmr4-modifier-heeft-tegenovergestelde-invloed-op-aritmierisico-bij-lqt1-en-lqt2/","published":"2026-06-22"},{"url":"https://hartvaat.nl/2026/02/03/plotse-hartstilstand-tijdens-duursporten-tien-jaar-parijse-registerdata/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2016/07/12/nervus-vagus-stimulatie-bij-hartfalen-de-inovate-hf-trial/","published":"2016-07-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-l-thompson","type":"person","url":"https://hartvaat.nl/mensen/peter-l-thompson/","name":"Peter L Thompson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/05/02/determinanten-van-medicatietrouw-na-acs-secundaire-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2021/08/31/colchicine-bij-chronisch-coronairlijden-met-versus-zonder-eerder-acs/","published":"2021-08-31"},{"url":"https://hartvaat.nl/2021/07/21/laaggedoseerd-colchicine-bij-coronairlijden-meta-analyse-van-gerandomiseerde-tri/","published":"2021-07-21"},{"url":"https://hartvaat.nl/2020/08/01/cardiovasculaire-risicovoorspelling-bij-inheemse-australiers/","published":"2020-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-m-rothwell","type":"person","url":"https://hartvaat.nl/mensen/peter-m-rothwell/","name":"Peter M Rothwell","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/24/systemische-inflammatie-en-recidief-na-een-af-gerelateerd-herseninfarct/","published":"2026-03-24"},{"url":"https://hartvaat.nl/2022/10/22/time-avonddosering-antihypertensiva-biedt-geen-voordeel-boven-ochtenddosering/","published":"2022-10-22"},{"url":"https://hartvaat.nl/2020/06/01/arb-versus-calciumantagonist-bloeddrukprofiel-en-klinische-effecten-vergelijking/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2018/09/22/aspirine-voor-primaire-preventie-bij-matig-cv-risico-lancet-arrive/","published":"2018-09-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-w-danse","type":"person","url":"https://hartvaat.nl/mensen/peter-w-danse/","name":"Peter W Danse","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/02/therapietrouw-aan-lipidenverlagende-medicatie-na-pci-in-nederland/","published":"2026-03-28"},{"url":"https://hartvaat.nl/2019/07/01/uitkomsten-van-des-in-kleine-coronairen-naar-strutdikte-jama-cardiology-meta-ana/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/10/06/resolute-onyx-versus-orsiro-stent-lancet-gerandomiseerde-non-inferioriteitstrial/","published":"2018-10-06"},{"url":"https://hartvaat.nl/2016/11/26/ultradunne-biodegradeerbare-versus-duurzame-polymer-des-lancet-gerandomiseerde-t/","published":"2016-11-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"peter-willeit","type":"person","url":"https://hartvaat.nl/mensen/peter-willeit/","name":"Peter Willeit","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/28/lp-a-en-ldl-cholesterol-onafhankelijke-cv-risicopaden/","published":"2025-01-28"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2018/10/13/lp-a-baseline-en-on-statin-voor-cv-eventvoorspelling-lancet-ipd-meta-analyse/","published":"2018-10-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philip-b-adamson","type":"person","url":"https://hartvaat.nl/mensen/philip-b-adamson/","name":"Philip B Adamson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/02/13/implanteerbare-hemodynamische-monitoren-verbeteren-overleving-bij-hfref/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2022/07/14/guide-hf-en-de-impact-van-covid-19-op-hartfalenuitkomsten/","published":"2022-07-14"},{"url":"https://hartvaat.nl/2021/09/11/hemodynamisch-geleid-hf-management-lancet-guide-hf/","published":"2021-09-11"},{"url":"https://hartvaat.nl/2016/01/30/hemodynamische-telemonitoring-bij-chronisch-hartfalen-volledige-champion-resulta/","published":"2016-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philip-j-barter","type":"person","url":"https://hartvaat.nl/mensen/philip-j-barter/","name":"Philip J Barter","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2018/02/01/lipoproteine-a-en-recidiverende-ischemische-events-na-acs-dal-outcomes-analyse/","published":"2018-02-01"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"},{"url":"https://hartvaat.nl/2016/12/06/dalcetrapib-wijzigt-de-relatie-tussen-hdl-cholesterol-en-crp/","published":"2016-12-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philip-m-bath","type":"person","url":"https://hartvaat.nl/mensen/philip-m-bath/","name":"Philip M Bath","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/05/30/right-2-ambulancebloeddrukverlaging-bij-hyperacuut-cva-nejm-vervolgresultaten/","published":"2024-05-30"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"},{"url":"https://hartvaat.nl/2017/05/01/voortzetten-of-tijdelijk-stoppen-van-antihypertensiva-bij-acuut-cva-ipd-meta-ana/","published":"2017-05-01"},{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","published":"2016-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philip-urban","type":"person","url":"https://hartvaat.nl/mensen/philip-urban/","name":"Philip Urban","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/08/01/seksegerelateerde-uitkomsten-bij-hoog-bloedingsrisico-na-pci-leaders-free/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","published":"2019-06-22"},{"url":"https://hartvaat.nl/2017/04/01/polymeervrije-biolimus-stent-bij-hoog-bloedingsrisico-met-acs-leaders-free-subst/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"philipp-blanke","type":"person","url":"https://hartvaat.nl/mensen/philipp-blanke/","name":"Philipp Blanke","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/13/risicofactoren-en-plaquevolume-op-coronaire-ct-angiografie-lessen-uit-het-advanc/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","published":"2023-11-23"},{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","published":"2020-01-09"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-ballonexpandeerbare-klep-bij-laagrisicopatienten-nejm-partner-3/","published":"2019-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"phillip-d-levy","type":"person","url":"https://hartvaat.nl/mensen/phillip-d-levy/","name":"Phillip D Levy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/19/mobiele-screeningseenheid-in-detroit-70-van-inwoners-in-achtergestelde-wijken-he/","published":"2026-06-11"},{"url":"https://hartvaat.nl/2021/02/01/zelfzorginterventie-en-90-daags-uitkomsten-bij-acuut-hf-na-seh-ontslag-jama-card/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"},{"url":"https://hartvaat.nl/2017/08/07/trv027-biased-ligand-van-de-angiotensine-ii-receptor-bij-acuut-hartfalen-gerando/","published":"2017-08-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pierre-deharo","type":"person","url":"https://hartvaat.nl/mensen/pierre-deharo/","name":"Pierre Deharo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2021/08/24/de-escalatie-van-dapt-bij-acs-jacc-review/","published":"2021-08-24"},{"url":"https://hartvaat.nl/2017/11/14/timing-van-angiografie-bij-hoogrisico-nstemi-acuity-analyse/","published":"2017-11-14"},{"url":"https://hartvaat.nl/2017/11/01/switchen-van-dapt-na-acs-de-topic-trial/","published":"2017-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pietro-ameri","type":"person","url":"https://hartvaat.nl/mensen/pietro-ameri/","name":"Pietro Ameri","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/25/pah-met-renaal-diabetische-overlap-komt-vaak-voor-en-geeft-tweemaal-zo-hoog-mort/","published":"2026-06-01"},{"url":"https://hartvaat.nl/2026/05/10/hartfalen-en-infarct-verdrievoudigen-het-risico-op-kanker-vooral-hematologisch/","published":"2026-05-11"},{"url":"https://hartvaat.nl/2026/02/03/rechterhart-hemodynamiek-voor-risicostratificatie-bij-pulmonale-arteriele-hypert/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2021/10/01/sacubitril-valsartan-in-real-life-europese-hfref-meta-analyse/","published":"2021-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"pietro-palmisano","type":"person","url":"https://hartvaat.nl/mensen/pietro-palmisano/","name":"Pietro Palmisano","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/03/pfa-versus-cryoballon-voor-af-ablatie-multielectrode-vergelijking/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2021/12/07/av-junctieablatie-plus-crt-bij-permanent-af-met-smal-qrs-apaf-crt-mortaliteitsan/","published":"2021-12-07"},{"url":"https://hartvaat.nl/2018/12/01/av-junctieablatie-plus-crt-bij-permanent-af-gerandomiseerde-trial/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2017/03/01/vaste-versus-responsieve-pacingfrequentie-bij-permanent-af-met-pacemakerindicati/","published":"2017-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ping-li","type":"person","url":"https://hartvaat.nl/mensen/ping-li/","name":"Ping Li","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/22/werkzaamheid-en-veiligheid-van-finerenon-bij-primair-aldosteronisme/","published":"2026-01-22"},{"url":"https://hartvaat.nl/2025/01/07/dcb-voor-zijtak-bij-provisionale-stenting-gerandomiseerde-trial/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2021/04/01/sarcopenie-bij-hartfalen-systematische-review-en-meta-analyse/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2018/05/15/trombocytenaantal-beinvloedt-werkzaamheid-van-foliumzuur-bij-cva-preventie/","published":"2018-05-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ping-zhang","type":"person","url":"https://hartvaat.nl/mensen/ping-zhang/","name":"Ping Zhang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/12/01/ckd-geassocieerde-jeuk-komt-bij-60-van-dialysepatienten-voor-lage-behandelgraad/","published":"2026-09-04"},{"url":"https://hartvaat.nl/2026/01/06/esprit-intensieve-bloeddrukcontrole-bij-fragiele-patienten-post-hoc-analyse/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2024/06/01/opt-birisk-clopidogrel-monotherapie-bij-acs-met-hoog-ischemisch-en-bloedingsrisi/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2022/11/05/enchanted2-mt-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-is-schadelij/","published":"2022-11-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"piotr-suwalski","type":"person","url":"https://hartvaat.nl/mensen/piotr-suwalski/","name":"Piotr Suwalski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/19/salamander-register-95-5-technisch-succes-bij-stand-alone-linker-hartoor-occlusi/","published":"2026-06-10"},{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2021/04/01/va-ecls-bij-harttransplantatie-en-vad-centra-meta-analyse/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prakriti-gaba","type":"person","url":"https://hartvaat.nl/mensen/prakriti-gaba/","name":"Prakriti Gaba","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","published":"2024-04-23"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","published":"2021-10-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"prithwish-banerjee","type":"person","url":"https://hartvaat.nl/mensen/prithwish-banerjee/","name":"Prithwish Banerjee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/01/economische-ziektelast-van-hartfalen-in-europa-systematische-review/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","published":"2024-04-21"},{"url":"https://hartvaat.nl/2018/08/01/laagfrequente-elektrische-spierstimulatie-en-endotheelfunctie-bij-gevorderd-hart/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"qi-guo","type":"person","url":"https://hartvaat.nl/mensen/qi-guo/","name":"Qi Guo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/12/01/ckd-geassocieerde-jeuk-komt-bij-60-van-dialysepatienten-voor-lage-behandelgraad/","published":"2026-09-04"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","published":"2023-03-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"qi-zhang","type":"person","url":"https://hartvaat.nl/mensen/qi-zhang/","name":"Qi Zhang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/12/gdmt-na-functioneel-complete-revascularisatie-prognostische-impact/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"qi-fang-huang","type":"person","url":"https://hartvaat.nl/mensen/qi-fang-huang/","name":"Qi-Fang Huang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2020/11/10/chinese-kruidenformule-voor-gemaskeerde-hypertensie-gerandomiseerde-placebogecon/","published":"2020-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"qian-h-li","type":"person","url":"https://hartvaat.nl/mensen/qian-h-li/","name":"Qian H Li","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"qiang-lv","type":"person","url":"https://hartvaat.nl/mensen/qiang-lv/","name":"Qiang Lv","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukverlaging-bij-ongediagnosticeerde-hfpef-met-hoog-risico/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/06/13/frailteit-en-intensieve-bloeddrukcontrole-bij-diabetes/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2024/11/12/recaticimab-als-toevoeging-aan-statines-fase-3-remain-2/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","published":"2022-10-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"qirui-song","type":"person","url":"https://hartvaat.nl/mensen/qirui-song/","name":"Qirui Song","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/10/28/step-6-jaarsresultaten-intensieve-bloeddrukcontrole-bij-ouderen-langetermijn/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/08/01/voordeel-en-risico-van-intensieve-bloeddrukcontrole-naar-cv-risico/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/09/01/hypertensieduur-en-effect-van-intensieve-bloeddrukbehandeling/","published":"2024-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rachel-hess","type":"person","url":"https://hartvaat.nl/mensen/rachel-hess/","name":"Rachel Hess","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"},{"url":"https://hartvaat.nl/2021/04/27/patientselectie-voor-intensieve-bloeddrukbehandeling-naar-voordeel-en-bijwerking/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2016/02/09/generaliseerbaarheid-van-sprint-resultaten-naar-de-algemene-bevolking/","published":"2016-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rafael-cavalcante","type":"person","url":"https://hartvaat.nl/mensen/rafael-cavalcante/","name":"Rafael Cavalcante","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/19/paclitaxel-gecoate-ballon-bij-multilayer-in-stent-restenose-agent-ide-subgroep/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2017/09/01/late-trombotische-events-na-bioresorbeerbare-scaffold-meta-analyse-van-gerandomi/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/07/01/syntax-scores-en-uitkomsten-bij-diabetes-met-multivatenlijden-gepoolde-analyse/","published":"2017-07-01"},{"url":"https://hartvaat.nl/2016/09/06/pci-versus-cabg-bij-onbeschermde-hoofdstamziekte-uitkomsten/","published":"2016-09-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rafael-romaguera","type":"person","url":"https://hartvaat.nl/mensen/rafael-romaguera/","name":"Rafael Romaguera","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/25/amphilimus-versus-zotarolimus-eluting-stent-bij-diabetes-en-coronairlijden/","published":"2025-11-25"},{"url":"https://hartvaat.nl/2025/04/10/dapagliflozine-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2025-04-10"},{"url":"https://hartvaat.nl/2022/03/31/amphilimus-versus-zotarolimus-stents-bij-diabetes-sugar-gerandomiseerde-trial/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rafael-de-la-espriella","type":"person","url":"https://hartvaat.nl/mensen/rafael-de-la-espriella/","name":"Rafael de la Espriella","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/03/expertopinie-hierarchische-eindpunten-op-basis-van-verslechterend-hartfalen-voor/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2026/03/01/bij-niervervanging-bescherm-het-hart/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2026/02/03/bio-impedantie-voor-vochtstatusbepaling-en-prognose-bij-chronisch-hartfalen/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2024/04/01/betablokkerstaken-verbetert-inspanningscapaciteit-bij-hfpef/","published":"2024-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ralf-westenfeld","type":"person","url":"https://hartvaat.nl/mensen/ralf-westenfeld/","name":"Ralf Westenfeld","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2023/02/01/nnt-van-nieuwe-antidiabetica-voor-cv-uitkomsten-meta-analyse/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ralph-b-d-agostino","type":"person","url":"https://hartvaat.nl/mensen/ralph-b-d-agostino/","name":"Ralph B D'Agostino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2018/10/27/albiglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-harmony-ou/","published":"2018-10-27"},{"url":"https://hartvaat.nl/2017/05/02/mi-risico-na-stoppen-van-thienopyridine-dapt-studie/","published":"2017-05-02"},{"url":"https://hartvaat.nl/2016/01/21/doodsoorzaken-bij-langdurige-dapt-na-coronaire-stents/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ralph-stephan-von-bardeleben","type":"person","url":"https://hartvaat.nl/mensen/ralph-stephan-von-bardeleben/","name":"Ralph Stephan von Bardeleben","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/05/expanded-bij-73-verbetert-tricuspidalisinsufficientie-binnen-30-dagen-na-m-teer-/","published":"2026-06-26"},{"url":"https://hartvaat.nl/2026/03/16/vroege-linkerventrikel-reverse-remodellering-na-mitralisklep-edge-to-edge-repara/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","published":"2024-11-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ramanathan-parameswaran","type":"person","url":"https://hartvaat.nl/mensen/ramanathan-parameswaran/","name":"Ramanathan Parameswaran","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","published":"2023-09-12"},{"url":"https://hartvaat.nl/2023/07/14/vroege-versus-late-af-ablatie-impact-op-aritmierecidief/","published":"2023-07-14"},{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","published":"2023-01-10"},{"url":"https://hartvaat.nl/2018/07/01/rotorablatie-bij-atriumfibrilleren-systematische-review/","published":"2018-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ramzi-khamis","type":"person","url":"https://hartvaat.nl/mensen/ramzi-khamis/","name":"Ramzi Khamis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2024/06/11/remote-beoordeling-na-acs-gerandomiseerde-trial/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","published":"2024-04-20"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ramon-estruch","type":"person","url":"https://hartvaat.nl/mensen/ramon-estruch/","name":"Ramón Estruch","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/07/urinair-wijnzuur-als-biomarker-voor-wijnconsumptie-en-cv-risico-predimed/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2020/12/08/remnant-cholesterol-versus-ldl-en-incident-cv-ziekte/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/02/11/disfunctioneel-hdl-en-incidentie-van-acs-bij-hoog-cardiovasculair-risico/","published":"2020-02-11"},{"url":"https://hartvaat.nl/2017/02/14/mediterraan-dieet-verbetert-hdl-functie-bij-hoog-cardiovasculair-risico-gerandom/","published":"2017-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rebecca-anthopolos","type":"person","url":"https://hartvaat.nl/mensen/rebecca-anthopolos/","name":"Rebecca Anthopolos","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","published":"2024-09-29"},{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","published":"2023-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rene-j-van-der-schaaf","type":"person","url":"https://hartvaat.nl/mensen/rene-j-van-der-schaaf/","name":"René J van der Schaaf","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2018/09/01/langetermijnimpact-van-cto-rekanalisatie-bij-stemi-patienten/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"},{"url":"https://hartvaat.nl/2016/10/11/pci-van-chronische-totale-occlusie-bij-stemi-met-multivatenlijden-explore-trial/","published":"2016-10-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rianne-a-a-de-heus","type":"person","url":"https://hartvaat.nl/mensen/rianne-a-a-de-heus/","name":"Rianne A A de Heus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/05/01/antihypertensieve-behandeling-en-cerebrale-bloedflow-meta-analyse/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2021/11/01/bloeddrukvariabiliteit-en-dementie-cognitieve-stoornis-meta-analyse/","published":"2021-11-01"},{"url":"https://hartvaat.nl/2019/11/01/bloeddrukvariabiliteit-en-progressie-van-klinische-alzheimer/","published":"2019-11-01"},{"url":"https://hartvaat.nl/2019/08/01/nilvadipine-en-cerebrale-bloedflow-bij-alzheimer-gerandomiseerde-trial/","published":"2019-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"richard-ceska","type":"person","url":"https://hartvaat.nl/mensen/richard-ceska/","name":"Richard Ceška","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2019/07/01/evolocumab-en-totale-cv-events-bij-cardiovasculaire-ziekte-fourier-analyse/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2016/04/19/evolocumab-versus-ezetimibe-bij-statine-intolerante-patienten-de-gauss-3-trial/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"richard-d-weisel","type":"person","url":"https://hartvaat.nl/mensen/richard-d-weisel/","name":"Richard D Weisel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","published":"2016-05-19"},{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","published":"2016-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"richard-troughton","type":"person","url":"https://hartvaat.nl/mensen/richard-troughton/","name":"Richard Troughton","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","published":"2024-10-24"},{"url":"https://hartvaat.nl/2024/02/13/implanteerbare-hemodynamische-monitoren-verbeteren-overleving-bij-hfref/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2022/04/09/natriumreductie-100-mmol-bij-hartfalen-lancet-sodium-hf/","published":"2022-04-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rikke-srensen","type":"person","url":"https://hartvaat.nl/mensen/rikke-srensen/","name":"Rikke Sørensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","published":"2024-12-12"},{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","published":"2020-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-a-fletcher","type":"person","url":"https://hartvaat.nl/mensen/robert-a-fletcher/","name":"Robert A Fletcher","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/27/sglt2-remmers-bij-ernstig-verminderde-nierfunctie-data-uit-credence/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2024/11/26/glp-1-agonisten-alleen-en-met-sglt2-remmers-cv-renale-en-veiligheidsuitkomsten/","published":"2024-11-26"},{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","published":"2024-06-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-j-mcgreevy","type":"person","url":"https://hartvaat.nl/mensen/robert-j-mcgreevy/","name":"Robert J McGreevy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-m-a-van-der-boon","type":"person","url":"https://hartvaat.nl/mensen/robert-m-a-van-der-boon/","name":"Robert M A van der Boon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/28/geen-sekseverschillen-in-werkzaamheid-van-hartfalenmedicatie-meta-analyse-van-13/","published":"2026-05-05"},{"url":"https://hartvaat.nl/2025/08/14/hartfalen-mondiale-economische-ziektelast/","published":"2025-08-14"},{"url":"https://hartvaat.nl/2025/04/01/socio-economische-ongelijkheid-en-hartfalenuitkomsten-systematische-review/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2023/08/14/telemonitoring-bij-hartfalen-meta-analyse-van-alle-strategieen/","published":"2023-08-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-t-gerber","type":"person","url":"https://hartvaat.nl/mensen/robert-t-gerber/","name":"Robert T Gerber","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","published":"2018-01-06"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-vogel","type":"person","url":"https://hartvaat.nl/mensen/robert-vogel/","name":"Robert Vogel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","published":"2020-11-21"},{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","published":"2020-01-21"},{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","published":"2019-07-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"robert-w-mcnutt","type":"person","url":"https://hartvaat.nl/mensen/robert-w-mcnutt/","name":"Robert W McNutt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","published":"2025-08-21"},{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","published":"2023-10-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"roberto-barriales-villa","type":"person","url":"https://hartvaat.nl/mensen/roberto-barriales-villa/","name":"Roberto Barriales-Villa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/05/aficamten-veilig-en-effectief-bij-langdurige-behandeling-van-obstructieve-hcm/","published":"2026-03-21"},{"url":"https://hartvaat.nl/2025/01/01/aficamten-bij-obstructieve-hcm-multidomeinanalyse-van-maple-hcm/","published":"2026-03-14"},{"url":"https://hartvaat.nl/2025/01/01/aficamten-versus-metoprolol-betere-levenskwaliteit-bij-obstructieve-hcm/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","published":"2023-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"roberto-ferrari","type":"person","url":"https://hartvaat.nl/mensen/roberto-ferrari/","name":"Roberto Ferrari","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2020/09/19/trimetazidine-na-pci-lancet-atpci-gerandomiseerde-trial/","published":"2020-09-19"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"roberto-garbo","type":"person","url":"https://hartvaat.nl/mensen/roberto-garbo/","name":"Roberto Garbo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/11/07/stentontwerp-en-dapt-duur-effect-op-ischemie-en-bloedingen-netwerkmeta-analyse/","published":"2017-11-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"roberto-lorusso","type":"person","url":"https://hartvaat.nl/mensen/roberto-lorusso/","name":"Roberto Lorusso","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/06/13/ml-modellen-voorspellen-sterfte-bij-post-cardiotomisch-shock-op-ecmo-elso-regist/","published":"2026-08-10"},{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","published":"2026-06-23"},{"url":"https://hartvaat.nl/2026/05/05/inotropica-bij-low-output-hartfalen-vergelijkbare-hemodynamische-effecten-in-met/","published":"2026-05-24"},{"url":"https://hartvaat.nl/2021/04/01/va-ecls-bij-harttransplantatie-en-vad-centra-meta-analyse/","published":"2021-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"roberto-scarsini","type":"person","url":"https://hartvaat.nl/mensen/roberto-scarsini/","name":"Roberto Scarsini","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","published":"2024-11-09"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rocco-vergallo","type":"person","url":"https://hartvaat.nl/mensen/rocco-vergallo/","name":"Rocco Vergallo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/26/weer-een-stap-vooruit-in-de-verlaging-van-ernstige-hypertriglyceridemie/","published":"2026-02-26"},{"url":"https://hartvaat.nl/2024/08/16/impella-cp-bij-door-mi-gecompliceerde-cardiogene-shock-journal-scan/","published":"2024-08-16"},{"url":"https://hartvaat.nl/2024/08/01/coronaire-microvasculaire-disfunctie-bij-hfpef-meta-analyse/","published":"2024-08-01"},{"url":"https://hartvaat.nl/2022/07/21/permanente-pacemaker-na-tavi-langetermijneffect-op-klinische-uitkomsten/","published":"2022-07-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rogerio-souza","type":"person","url":"https://hartvaat.nl/mensen/rogerio-souza/","name":"Rogério Souza","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/10/23/sotatercept-bij-pah-binnen-het-eerste-jaar-na-diagnose-stellar-subanalyse/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2023/04/20/stellar-sotatercept-bij-pulmonale-arteriele-hypertensie-nejm-fase-3/","published":"2023-04-20"},{"url":"https://hartvaat.nl/2018/02/20/morbiditeit-bij-pulmonaal-arteriele-hypertensie-als-prognostische-marker-voor-mo/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/04/14/macitentan-en-hemodynamiek-bij-pah-seraphin-hemodynamische-substudie/","published":"2017-04-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ron-waksman","type":"person","url":"https://hartvaat.nl/mensen/ron-waksman/","name":"Ron Waksman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2017/10/21/ultradunne-bioresorbeerbare-versus-dunne-duurzame-polymer-stents-lancet-bioscien/","published":"2017-10-21"},{"url":"https://hartvaat.nl/2016/02/16/ticagrelor-versus-clopidogrel-bij-troponine-negatieve-laagrisico-acs-met-ad-hoc-/","published":"2016-02-16"},{"url":"https://hartvaat.nl/2016/02/07/impact-van-pcsk9-remmers-op-lipidenniveaus-en-uitkomsten-netwerkmeta-analyse/","published":"2016-02-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ronak-rajani","type":"person","url":"https://hartvaat.nl/mensen/ronak-rajani/","name":"Ronak Rajani","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/21/evolved-vroege-interventie-bij-asymptomatische-ernstige-aortastenose-met-myocard/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2022/11/24/protecct-ct-bij-verdenking-acs-met-intermediaire-troponinewaarden/","published":"2022-11-24"},{"url":"https://hartvaat.nl/2019/01/05/staken-van-hf-medicatie-bij-herstelde-dilaterende-cardiomyopathie-lancet-tred-hf/","published":"2019-01-05"},{"url":"https://hartvaat.nl/2017/08/01/nauwkeurigheid-van-manchetbloeddrukmeting-systematische-review-en-meta-analyse/","published":"2017-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rong-zhou","type":"person","url":"https://hartvaat.nl/mensen/rong-zhou/","name":"Rong Zhou","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/05/20/plozasiran-en-lipoproteine-deeltjesgrootte-bij-hypertriglyceridemie/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2025/01/09/plozasiran-bij-persisterende-chylomicronemie-en-pancreatitisrisico-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2024/09/12/zodasiran-sirna-tegen-angptl3-bij-gemengde-hyperlipidemie-nejm/","published":"2024-09-12"},{"url":"https://hartvaat.nl/2024/09/12/plozasiran-sirna-tegen-apoc3-bij-gemengde-hyperlipidemie-nejm/","published":"2024-09-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rongjie-huang","type":"person","url":"https://hartvaat.nl/mensen/rongjie-huang/","name":"Rongjie Huang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/11/12/recaticimab-als-toevoeging-aan-statines-fase-3-remain-2/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/12/recaticimab-monotherapie-bij-niet-familiaire-hypercholesterolemie-fase-3-remain-/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2023/12/01/step-trial-diastolische-bloeddruk-beinvloedt-effect-van-intensieve-behandeling/","published":"2023-12-01"},{"url":"https://hartvaat.nl/2023/09/01/step-substudie-intensieve-bloeddrukverlaging-verbetert-lvh-bij-ouderen/","published":"2023-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"roni-nielsen","type":"person","url":"https://hartvaat.nl/mensen/roni-nielsen/","name":"Roni Nielsen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2024/11/12/ketonester-bij-type-2-diabetes-en-hartfalen-cross-over-trial/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/05/07/orale-ketonester-bij-hfref-gerandomiseerde-trial/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2019/04/30/ketonlichaam-3-hydroxybutyraat-bij-chronisch-hartfalen-cardiovasculaire-effecten/","published":"2019-04-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"roopinder-k-sandhu","type":"person","url":"https://hartvaat.nl/mensen/roopinder-k-sandhu/","name":"Roopinder K Sandhu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/07/zorgpaden-na-nieuw-vastgesteld-atriumfibrilleren-rol-van-de-elektrofysioloog-en-/","published":"2026-07-18"},{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2018/11/21/voortzetten-versus-onderbreken-doac-bij-device-chirurgie-bruise-control-2/","published":"2018-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"roos-hesselink","type":"person","url":"https://hartvaat.nl/mensen/roos-hesselink/","name":"Roos-Hesselink","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/10/tweelingzwangerschap-bij-vrouwen-met-een-hartaandoening-geeft-een-hoog-risico-op/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/04/24/sekseverschillen-bij-infectieuze-endocarditis-vrouwen-vaker-conservatief-behande/","published":"2026-07-20"},{"url":"https://hartvaat.nl/2026/04/29/erasmus-mc-linkeratrium-strain-voorspelt-aritmieen-na-chirurgische-correctie-van/","published":"2026-07-11"},{"url":"https://hartvaat.nl/2026/04/24/crt-bij-volwassenen-met-systemische-rechterventrikel-gemengde-uitkomsten-in-inte/","published":"2026-05-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rosa-coppolecchia","type":"person","url":"https://hartvaat.nl/mensen/rosa-coppolecchia/","name":"Rosa Coppolecchia","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2022/10/18/asundexian-factor-xia-remmer-na-acs-fase-2-dosisfindingsstudie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2018/09/22/aspirine-voor-primaire-preventie-bij-matig-cv-risico-lancet-arrive/","published":"2018-09-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rose-crowley","type":"person","url":"https://hartvaat.nl/mensen/rose-crowley/","name":"Rose Crowley","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","published":"2026-01-07"},{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","published":"2023-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rupert-williams","type":"person","url":"https://hartvaat.nl/mensen/rupert-williams/","name":"Rupert Williams","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","published":"2025-05-13"},{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"russell-l-rothman","type":"person","url":"https://hartvaat.nl/mensen/russell-l-rothman/","name":"Russell L Rothman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/09/01/aspirinedosering-voor-secundaire-preventie-bij-mannen-versus-vrouwen/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ruth-frikke-schmidt","type":"person","url":"https://hartvaat.nl/mensen/ruth-frikke-schmidt/","name":"Ruth Frikke-Schmidt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/15/hypokaliemie-en-af-gedetecteerd-door-implanteerbare-loop-recorders/","published":"2025-12-15"},{"url":"https://hartvaat.nl/2023/07/21/vegetarisch-of-veganistisch-dieet-en-bloedlipiden-meta-analyse-van-rct-s/","published":"2023-07-21"},{"url":"https://hartvaat.nl/2023/06/13/loop-substudie-nt-probnp-verbetert-af-screeningsopbrengst/","published":"2023-06-13"},{"url":"https://hartvaat.nl/2022/10/20/box-bloeddrukdoelen-bij-comateuze-overlevenden-van-hartstilstand/","published":"2022-10-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ryota-kakizaki","type":"person","url":"https://hartvaat.nl/mensen/ryota-kakizaki/","name":"Ryota Kakizaki","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","published":"2026-04-09"},{"url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neoatherosclerose-na-stemi-secundaire-analyse/","published":"2026-02-01"},{"url":"https://hartvaat.nl/2025/08/01/biodegradeerbare-versus-duurzame-polymeer-ees-langetermijn-neoatherosclerose/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","published":"2024-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"rudiger-smolnik","type":"person","url":"https://hartvaat.nl/mensen/rudiger-smolnik/","name":"Rüdiger Smolnik","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/01/27/periprocedurele-antistolling-bij-eliminate-af-ononderbroken-edoxaban-versus-vka/","published":"2021-01-27"},{"url":"https://hartvaat.nl/2020/12/14/edoxaban-bij-af-met-pci-naar-acute-versus-chronische-coronaire-presentatie-entru/","published":"2020-12-14"},{"url":"https://hartvaat.nl/2019/10/12/edoxaban-versus-vka-gebaseerd-antitrombotisch-regime-na-stenting-bij-af-lancet-e/","published":"2019-10-12"},{"url":"https://hartvaat.nl/2019/09/21/ononderbroken-edoxaban-versus-vka-bij-af-ablatie-eliminate-af/","published":"2019-09-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"safi-u-khan","type":"person","url":"https://hartvaat.nl/mensen/safi-u-khan/","name":"Safi U Khan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/07/27/veiligheid-van-pcsk9-remmers-systematische-review-en-meta-analyse/","published":"2022-07-27"},{"url":"https://hartvaat.nl/2020/10/13/dapt-na-pci-met-des-netwerkmeta-analyse-van-duur-en-intensiteit/","published":"2020-10-13"},{"url":"https://hartvaat.nl/2020/07/14/vergelijking-van-orale-p2y12-remmers-bij-acs-netwerkmeta-analyse-van-52-816-pati/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2018/06/21/cpap-en-cardiovasculaire-events-bij-obstructieve-slaapapneu-meta-analyse/","published":"2018-06-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"saket-girotra","type":"person","url":"https://hartvaat.nl/mensen/saket-girotra/","name":"Saket Girotra","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/09/01/aspirinedosering-voor-secundaire-preventie-bij-mannen-versus-vrouwen/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"salim-s-hayek","type":"person","url":"https://hartvaat.nl/mensen/salim-s-hayek/","name":"Salim S Hayek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/01/supar-en-uitkomsten-bij-hfpef-topcat-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"samuel-copt","type":"person","url":"https://hartvaat.nl/mensen/samuel-copt/","name":"Samuel Copt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/12/01/post-stenting-ffr-versus-angiografie-voor-pci-optimalisatie-target-ffr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/08/01/seksegerelateerde-uitkomsten-bij-hoog-bloedingsrisico-na-pci-leaders-free/","published":"2020-08-01"},{"url":"https://hartvaat.nl/2017/04/01/polymeervrije-biolimus-stent-bij-hoog-bloedingsrisico-met-acs-leaders-free-subst/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"samuel-s-gidding","type":"person","url":"https://hartvaat.nl/mensen/samuel-s-gidding/","name":"Samuel S Gidding","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/25/eas-consensus-familiaire-hypercholesterolemie-bij-kinderen-en-adolescenten/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2018/11/01/therapieresistente-hypertensie-aha-scientific-statement-over-detectie-evaluatie-/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","published":"2018-10-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sana-shan","type":"person","url":"https://hartvaat.nl/mensen/sana-shan/","name":"Sana Shan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","published":"2026-04-30"},{"url":"https://hartvaat.nl/2026/01/20/voorspelling-van-individuele-corticosteroidrespons-bij-iga-nefropathie-testing-t/","published":"2026-01-20"},{"url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","published":"2021-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sandeep-k-jain","type":"person","url":"https://hartvaat.nl/mensen/sandeep-k-jain/","name":"Sandeep K Jain","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2023/08/02/gerichte-lv-leadplaatsing-bij-crt-meta-analyse-van-beeldvorming-en-elektrisch-ge/","published":"2023-08-02"},{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","published":"2021-05-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sander-van-doorn","type":"person","url":"https://hartvaat.nl/mensen/sander-van-doorn/","name":"Sander van Doorn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/05/nederlandse-huisartsenpost-1-op-20-contacten-voor-benauwdheid-betreft-hartfalen-/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2024/01/23/switchen-van-vka-naar-noac-bij-fragiele-ouderen-met-af-veilig/","published":"2024-01-23"},{"url":"https://hartvaat.nl/2020/08/07/geintegreerd-af-management-in-de-huisartsenpraktijk-all-in-clustergerandomiseerd/","published":"2020-08-07"},{"url":"https://hartvaat.nl/2018/08/01/opportunistische-hf-screening-met-natriuretische-peptiden-bij-af-ipd-meta-analys/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sang-yeub-lee","type":"person","url":"https://hartvaat.nl/mensen/sang-yeub-lee/","name":"Sang Yeub Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/01/intravasculaire-beeldvorming-superieur-aan-angiografie-bij-complexe-pci-5-jaarsr/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","published":"2023-02-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sanghoon-shin","type":"person","url":"https://hartvaat.nl/mensen/sanghoon-shin/","name":"Sanghoon Shin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2023/05/02/korte-versus-standaard-dapt-na-pci-met-moderne-des-meta-analyse/","published":"2023-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sarah-de-ferranti","type":"person","url":"https://hartvaat.nl/mensen/sarah-de-ferranti/","name":"Sarah de Ferranti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","published":"2019-06-18"},{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","published":"2019-06-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sashiananthan-ganesananthan","type":"person","url":"https://hartvaat.nl/mensen/sashiananthan-ganesananthan/","name":"Sashiananthan Ganesananthan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","published":"2023-12-21"},{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","published":"2022-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"satyam-sarma","type":"person","url":"https://hartvaat.nl/mensen/satyam-sarma/","name":"Satyam Sarma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/12/19/synchronisatie-van-voetstap-en-hartfase-bij-crt-patienten/","published":"2023-12-19"},{"url":"https://hartvaat.nl/2023/01/31/hfpef-inspanningsbeperking-niet-alleen-door-hemodynamiek/","published":"2023-01-31"},{"url":"https://hartvaat.nl/2021/09/21/1-jaar-inspanningstraining-keert-lv-stijfheid-om-bij-stadium-b-hf/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2018/04/10/sedentaire-veroudering-omkeren-op-middelbare-leeftijd-gerandomiseerde-trial-voor/","published":"2018-04-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"savitri-e-fedson","type":"person","url":"https://hartvaat.nl/mensen/savitri-e-fedson/","name":"Savitri E Fedson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/10/15/aha-scientific-statement-nierdisfunctie-bij-gevorderd-hartfalen/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sebastiaan-dhont","type":"person","url":"https://hartvaat.nl/mensen/sebastiaan-dhont/","name":"Sebastiaan Dhont","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/09/praise-mr-sacubitril-valsartan-verbetert-inspanningshemodynamica-bij-hfpef-met-a/","published":"2026-07-09"},{"url":"https://hartvaat.nl/2026/05/09/praise-mr-sacubitril-valsartan-verbetert-inspanningshemodynamiek-bij-hfpef-met-a/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/03/25/inspanningsecho-identificeert-hcm-patienten-die-baat-hebben-bij-mavacamten/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","published":"2023-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"seong-wook-park","type":"person","url":"https://hartvaat.nl/mensen/seong-wook-park/","name":"Seong-Wook Park","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/05/01/angiografie-versus-ivus-voor-des-implantatie-gerandomiseerde-trial/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2019/12/03/klinisch-significante-bloedingen-met-ticagrelor-versus-clopidogrel-bij-koreaanse/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2016/04/19/statinebehandeling-en-plaquesamenstelling-dubbelblinde-gerandomiseerde-studie/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sergio-fazio","type":"person","url":"https://hartvaat.nl/mensen/sergio-fazio/","name":"Sergio Fazio","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/26/odyssey-outcomes-post-hoc-hscrp-en-il-6-zijn-complementaire-prognostische-marker/","published":"2026-05-29"},{"url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","published":"2019-03-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"seung-jae-lee","type":"person","url":"https://hartvaat.nl/mensen/seung-jae-lee/","name":"Seung-Jae Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/01/intravasculaire-beeldvorming-superieur-aan-angiografie-bij-complexe-pci-5-jaarsr/","published":"2026-03-13"},{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"seung-whan-lee","type":"person","url":"https://hartvaat.nl/mensen/seung-whan-lee/","name":"Seung-Whan Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/05/01/angiografie-versus-ivus-voor-des-implantatie-gerandomiseerde-trial/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2019/12/03/klinisch-significante-bloedingen-met-ticagrelor-versus-clopidogrel-bij-koreaanse/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2016/04/19/statinebehandeling-en-plaquesamenstelling-dubbelblinde-gerandomiseerde-studie/","published":"2016-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shah","type":"person","url":"https://hartvaat.nl/mensen/shah/","name":"Shah","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/30/etnische-verschillen-in-sterfte-na-acuut-coronair-syndroom-hogere-mortaliteit-bi/","published":"2026-07-11"},{"url":"https://hartvaat.nl/2026/04/24/crt-bij-volwassenen-met-systemische-rechterventrikel-gemengde-uitkomsten-in-inte/","published":"2026-05-09"},{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-myocardinfarct-winratio-analyse-uit-de-cle/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/02/23/regulering-van-ai-in-de-cardiologie-door-de-fda-een-scoping-review/","published":"2026-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shannon-m-dunlay","type":"person","url":"https://hartvaat.nl/mensen/shannon-m-dunlay/","name":"Shannon M Dunlay","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/23/nierbescherming-na-harttransplantatie-risicoreductie-en-therapeutische-mogelijkh/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","published":"2022-05-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sheila-m-hegde","type":"person","url":"https://hartvaat.nl/mensen/sheila-m-hegde/","name":"Sheila M Hegde","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/06/01/invested-griepvaccin-immuunrespons-bij-hoog-risico-cv-patienten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2017/09/12/lichamelijke-activiteit-en-prognose-bij-hfpef-topcat-analyse/","published":"2017-09-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shengxian-tu","type":"person","url":"https://hartvaat.nl/mensen/shengxian-tu/","name":"Shengxian Tu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/12/gdmt-na-functioneel-complete-revascularisatie-prognostische-impact/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/04/26/angiografie-afgeleide-ffr-versus-ivus-bij-pci-gerandomiseerde-trial/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shira-perl","type":"person","url":"https://hartvaat.nl/mensen/shira-perl/","name":"Shira Perl","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/07/baxdrostat-verlaagt-bloeddruk-significant-bij-resistente-hypertensie/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2026/03/07/bax24-baxdrostat-en-ambulante-bloeddruk-bij-resistente-hypertensie/","published":"2026-03-07"},{"url":"https://hartvaat.nl/2025/10/09/baxdrostat-bij-ongecontroleerde-en-resistente-hypertensie-effectiviteit-en-veili/","published":"2025-10-09"},{"url":"https://hartvaat.nl/2024/10/01/amethyst-verinurad-plus-allopurinol-bij-hfpef-negatieve-trial/","published":"2024-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"shubin-qiao","type":"person","url":"https://hartvaat.nl/mensen/shubin-qiao/","name":"Shubin Qiao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/12/gdmt-na-functioneel-complete-revascularisatie-prognostische-impact/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2024/06/01/opt-birisk-clopidogrel-monotherapie-bij-acs-met-hoog-ischemisch-en-bloedingsrisi/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"simon-b-ascher","type":"person","url":"https://hartvaat.nl/mensen/simon-b-ascher/","name":"Simon B Ascher","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/08/20/aangetaste-tubulaire-secretiecapaciteit-verhoogt-cardiovasculaire-sterfte-hunt-s/","published":"2026-08-28"},{"url":"https://hartvaat.nl/2025/04/01/hypotensieve-episodes-op-24-uurs-abpm-en-cognitieve-functie-sprint-inzichten/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/09/01/troponine-nt-probnp-en-cognitieve-uitkomsten-in-sprint/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2022/10/18/intensieve-bloeddrukverlaging-bij-maligne-linkerventrikel-hypertrofie/","published":"2022-10-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"simon-j-walsh","type":"person","url":"https://hartvaat.nl/mensen/simon-j-walsh/","name":"Simon J Walsh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/27/pci-van-natief-coronairvat-versus-veneuze-graft-na-eerdere-cabg-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2024/07/23/anatomische-versus-viabiliteitsgerichte-completeness-van-revascularisatie/","published":"2024-07-23"},{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","published":"2020-01-18"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"simon-kouz","type":"person","url":"https://hartvaat.nl/mensen/simon-kouz/","name":"Simon Kouz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/10/14/dal-gene-farmacogenetica-geleide-dalcetrapib-na-acs/","published":"2022-10-14"},{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","published":"2019-12-26"},{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","published":"2017-05-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sonali-r-gnanenthiran","type":"person","url":"https://hartvaat.nl/mensen/sonali-r-gnanenthiran/","name":"Sonali R Gnanenthiran","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/30/bloeddrukverlagende-effectiviteit-van-antihypertensiva-en-combinaties-uitgebreid/","published":"2025-08-30"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2022/06/01/lage-dosis-drievoudige-combinatietherapie-bij-hypertensie-triumph-secundaire-ana/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2017/12/01/revascularisatie-versus-medicamenteus-beleid-bij-nste-acs-bij-ouderen-meta-analy/","published":"2017-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sondra-m-depalma","type":"person","url":"https://hartvaat.nl/mensen/sondra-m-depalma/","name":"Sondra M DePalma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/10/04/2022-acc-expert-consensus-niet-statine-therapieen-voor-ldl-verlaging-bij-ascvd/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2017/10/03/2017-acc-gerichte-update-niet-statinetherapie-voor-ldl-verlaging/","published":"2017-10-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sophie-degrauwe","type":"person","url":"https://hartvaat.nl/mensen/sophie-degrauwe/","name":"Sophie Degrauwe","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","published":"2025-07-21"},{"url":"https://hartvaat.nl/2023/11/25/biodegradeerbare-versus-duurzame-polymeer-des-bij-stemi-langetermijndata/","published":"2023-11-25"},{"url":"https://hartvaat.nl/2020/12/22/fentanyl-versus-morfine-op-ticagrelor-plaatjesremming-bij-stemi/","published":"2020-12-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"srinath-adusumalli","type":"person","url":"https://hartvaat.nl/mensen/srinath-adusumalli/","name":"Srinath Adusumalli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/05/01/apothekerverwijzingen-voor-statine-start-twee-cluster-rct-s/","published":"2025-05-01"},{"url":"https://hartvaat.nl/2025/03/01/kaliumnitraat-bij-hfpef-gerandomiseerde-trial/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2023/01/01/nudging-verhoogt-statinevoorschrijving-bij-zowel-arts-als-patient/","published":"2023-01-01"},{"url":"https://hartvaat.nl/2021/01/01/passive-choice-en-active-choice-interventies-voor-statinevoorschrijving-jama-car/","published":"2021-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"srinivas-r-dukkipati","type":"person","url":"https://hartvaat.nl/mensen/srinivas-r-dukkipati/","name":"Srinivas R Dukkipati","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/06/01/katheterablatie-of-antiaritmica-als-eerstelijnstherapie-bij-af-jama-cardiology-m/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/12/08/laa-sluiting-versus-oac-bij-af-meta-analyse-van-gerandomiseerde-trials/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2017/10/01/terminatie-van-persisterend-af-tijdens-pvi-inzichten-uit-magic-af/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/05/21/stapsgewijze-ablatie-gestuurd-door-laaggedoseerd-ibutilide-bij-chronisch-af-magi/","published":"2016-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"srinivasan-beddhu","type":"person","url":"https://hartvaat.nl/mensen/srinivasan-beddhu/","name":"Srinivasan Beddhu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","published":"2021-05-20"},{"url":"https://hartvaat.nl/2018/06/01/intensieve-versus-standaard-bloeddruk-naar-tertielen-in-sprint/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2018/01/09/diastolische-bloeddruk-en-intensieve-bloeddrukcontrole-sprint-analyse/","published":"2018-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steen-dalby-kristensen","type":"person","url":"https://hartvaat.nl/mensen/steen-dalby-kristensen/","name":"Steen Dalby Kristensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"},{"url":"https://hartvaat.nl/2020/02/14/danami-2-16-jaarsfollow-up-primaire-pci-versus-fibrinolyse/","published":"2020-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefan-kaab","type":"person","url":"https://hartvaat.nl/mensen/stefan-kaab/","name":"Stefan Kääb","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/03/plotse-hartstilstand-tijdens-duursporten-tien-jaar-parijse-registerdata/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","published":"2018-07-19"},{"url":"https://hartvaat.nl/2017/07/14/voorspelling-van-plotse-versus-niet-plotse-hartdood-na-mi-met-verminderde-lvef/","published":"2017-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefan-osswald","type":"person","url":"https://hartvaat.nl/mensen/stefan-osswald/","name":"Stefan Osswald","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/11/07/drug-coated-balloons-versus-des-bij-kleine-coronairarterien-lancet-basket-small-/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2019/12/17/uitgebreide-vasodilatatie-versus-standaardzorg-bij-acuut-hf-jama-galactic-hf-pil/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/12/01/linkeratriumdimensie-en-cv-uitkomsten-bij-patienten-met-en-zonder-af-meta-analys/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2018/09/08/drug-coated-balloons-bij-kleine-coronairarterien-lancet-basket-small-2/","published":"2018-09-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefano-benenati","type":"person","url":"https://hartvaat.nl/mensen/stefano-benenati/","name":"Stefano Benenati","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/18/cv-effecten-en-verdraagbaarheid-van-glp-1-agonisten-meta-analyse/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","published":"2022-03-07"},{"url":"https://hartvaat.nl/2021/10/01/sacubitril-valsartan-in-real-life-europese-hfref-meta-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2021/04/17/geleide-versus-standaard-antiplaatjestherapie-na-pci-lancet-meta-analyse/","published":"2021-04-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stefano-savonitto","type":"person","url":"https://hartvaat.nl/mensen/stefano-savonitto/","name":"Stefano Savonitto","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/06/14/invasief-versus-conservatief-bij-ouderen-met-nste-acs-ipd-meta-analyse/","published":"2024-06-14"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/06/05/verlaagde-dosis-prasugrel-versus-standaard-clopidogrel-bij-oudere-acs-patienten/","published":"2018-06-05"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephan-achenbach","type":"person","url":"https://hartvaat.nl/mensen/stephan-achenbach/","name":"Stephan Achenbach","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2023/06/01/angiotensinepathways-onder-empagliflozine-bij-chronisch-hartfalen/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2021/12/01/empagliflozine-en-vaatfunctie-bij-chronisch-hf/","published":"2021-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephane-heymans","type":"person","url":"https://hartvaat.nl/mensen/stephane-heymans/","name":"Stephane Heymans","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephen-burgess","type":"person","url":"https://hartvaat.nl/mensen/stephen-burgess/","name":"Stephen Burgess","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/02/01/urinezuur-bloeddruk-en-cv-ziekte-mendeliaanse-randomisatie-en-meta-analyse/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2018/01/01/genetische-associatie-van-lipiden-en-lipide-doelwitten-met-abdominaal-aorta-aneu/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2016/10/04/ldl-cholesterolverlagende-genetische-varianten-en-risico-op-diabetes-type-2-jama/","published":"2016-10-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"stephen-harrap","type":"person","url":"https://hartvaat.nl/mensen/stephen-harrap/","name":"Stephen Harrap","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/03/01/korttermijn-bloeddrukmetingen-voorspellen-langetermijneffect-van-behandeling/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2019/06/01/bloeddrukverlaging-naar-uitgangsdruk-en-cv-risico-bij-diabetes-type-2/","published":"2019-06-01"},{"url":"https://hartvaat.nl/2019/01/01/acute-creatininestijging-bij-start-ace-remmer-en-effecten-van-voortzetting-analy/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2017/08/01/bloeddrukvariabiliteit-en-vasculaire-events-bij-diabetes-type-2/","published":"2017-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"steven-g-terra","type":"person","url":"https://hartvaat.nl/mensen/steven-g-terra/","name":"Steven G Terra","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/05/03/vupanorsen-en-non-hdl-cholesterol-bij-statinebehandelde-patienten-translate-timi/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2021/02/01/sglt2-remmers-en-cv-renale-uitkomsten-bij-diabetes-type-2-jama-cardiology-meta-a/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/12/08/ertugliflozine-en-hf-events-bij-diabetes-met-atherosclerotische-cvd-vertis-cv/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/10/08/ertugliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-vertis-cv/","published":"2020-10-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"susan-j-curry","type":"person","url":"https://hartvaat.nl/mensen/susan-j-curry/","name":"Susan J Curry","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","published":"2017-07-11"},{"url":"https://hartvaat.nl/2016/11/15/statines-voor-primaire-cardiovasculaire-preventie-uspstf-aanbeveling/","published":"2016-11-15"},{"url":"https://hartvaat.nl/2016/08/09/lipidescreening-bij-kinderen-en-adolescenten-uspstf-aanbeveling/","published":"2016-08-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"susan-r-heckbert","type":"person","url":"https://hartvaat.nl/mensen/susan-r-heckbert/","name":"Susan R Heckbert","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/07/25/omega-3-biomarkers-en-incident-af-ipd-analyse/","published":"2023-07-25"},{"url":"https://hartvaat.nl/2018/06/01/gwas-van-pr-interval-bij-hispanic-latino-s-nieuw-locus-bij-id2/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/11/28/schildklierfunctie-en-risico-op-af-subclinische-hypothyreoidie/","published":"2017-11-28"},{"url":"https://hartvaat.nl/2017/01/03/traditionele-cv-risicofactoren-en-veneuze-trombo-embolie-individuele-patientdata/","published":"2017-01-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"susanne-greber-platzer","type":"person","url":"https://hartvaat.nl/mensen/susanne-greber-platzer/","name":"Susanne Greber-Platzer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/25/eas-consensus-familiaire-hypercholesterolemie-bij-kinderen-en-adolescenten/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2025/12/22/evinacumab-bij-kinderen-van-5-17-jaar-met-homozygote-familiaire-hypercholesterol/","published":"2025-12-22"},{"url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2020/10/01/evolocumab-bij-pediatrische-heterozygoot-fh-nejm-hauser-rct/","published":"2020-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"susanne-s-pedersen","type":"person","url":"https://hartvaat.nl/mensen/susanne-s-pedersen/","name":"Susanne S Pedersen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/07/04/cognitieve-gedragstherapie-verbetert-kwaliteit-van-leven-bij-symptomatisch-af/","published":"2023-07-04"},{"url":"https://hartvaat.nl/2022/02/02/remote-monitoring-en-klinische-uitkomsten-bij-europese-hf-met-icd-langetermijn/","published":"2022-02-02"},{"url":"https://hartvaat.nl/2019/09/01/remote-monitoring-en-patientgerapporteerde-uitkomsten-bij-europese-hf-patienten-/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","published":"2019-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"susheel-k-kodali","type":"person","url":"https://hartvaat.nl/mensen/susheel-k-kodali/","name":"Susheel K Kodali","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","published":"2025-03-11"},{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","published":"2025-01-09"},{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","published":"2023-11-23"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-ballonexpandeerbare-klep-bij-laagrisicopatienten-nejm-partner-3/","published":"2019-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"suzanne-de-waha","type":"person","url":"https://hartvaat.nl/mensen/suzanne-de-waha/","name":"Suzanne de Waha","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"},{"url":"https://hartvaat.nl/2017/12/14/mechanische-ondersteuning-bij-cardiogene-shock-systematische-review-en-meta-anal/","published":"2017-12-14"},{"url":"https://hartvaat.nl/2017/08/01/des-versus-bms-bij-acuut-mi-met-cardiogene-shock/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2017/04/18/risicostratificatie-bij-cardiogene-shock-na-acuut-myocardinfarct/","published":"2017-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"sven-mobius-winkler","type":"person","url":"https://hartvaat.nl/mensen/sven-mobius-winkler/","name":"Sven Möbius-Winkler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","published":"2024-04-18"},{"url":"https://hartvaat.nl/2022/07/26/empag-hf-vroege-empagliflozine-bij-acuut-hartfalen-verbetert-diurese/","published":"2022-07-26"},{"url":"https://hartvaat.nl/2020/11/07/drug-coated-balloons-versus-des-bij-kleine-coronairarterien-lancet-basket-small-/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2018/09/08/drug-coated-balloons-bij-kleine-coronairarterien-lancet-basket-small-2/","published":"2018-09-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"soren-lund-kristensen","type":"person","url":"https://hartvaat.nl/mensen/soren-lund-kristensen/","name":"Søren Lund Kristensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/10/poseidon-4-op-10-patienten-met-hartfalen-wereldwijd-heeft-inflammatoir-verhoogd-/","published":"2026-05-11"},{"url":"https://hartvaat.nl/2025/10/01/ambulante-iv-diurese-bij-chronisch-hf-decongest-inzichten/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2017/02/21/diabetesstatus-en-cardiovasculaire-uitkomsten-bij-hfpef-klinische-en-echocardiog/","published":"2017-02-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tae-soo-kang","type":"person","url":"https://hartvaat.nl/mensen/tae-soo-kang/","name":"Tae Soo Kang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","published":"2025-11-08"},{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","published":"2024-02-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tae-hoon-kim","type":"person","url":"https://hartvaat.nl/mensen/tae-hoon-kim/","name":"Tae-Hoon Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/10/14/alone-af-langetermijn-anticoagulatieonthouding-na-af-ablatie-rct/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2024/12/03/ct-gestuurde-atriale-wanddiktemapping-bij-cryoballon-pvi/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2019/05/14/wanneer-doac-stoppen-voor-af-ablatie-multicenter-analyse/","published":"2019-05-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tae-hyun-yang","type":"person","url":"https://hartvaat.nl/mensen/tae-hyun-yang/","name":"Tae-Hyun Yang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","published":"2026-02-09"},{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","published":"2023-04-04"},{"url":"https://hartvaat.nl/2018/04/01/valsartan-en-linkerkamerremodellering-na-mi/","published":"2018-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"takenori-domei","type":"person","url":"https://hartvaat.nl/mensen/takenori-domei/","name":"Takenori Domei","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"takeshi-yamashita","type":"person","url":"https://hartvaat.nl/mensen/takeshi-yamashita/","name":"Takeshi Yamashita","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/19/eldercare-af-post-hoc-edoxaban-spiegel-en-pt-13s-voorspellen-bloedingsrisico-bij/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2022/06/01/edoxaban-15-mg-bij-zeer-oude-patienten-met-atriumfibrilleren-eldercare-subanalys/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2022/03/01/edoxaban-15-mg-naar-nierfunctie-bij-zeer-oude-af-eldercare-subanalyse/","published":"2022-03-01"},{"url":"https://hartvaat.nl/2020/10/29/laaggedoseerd-edoxaban-bij-zeer-oude-af-patienten-nejm-eldercare-af/","published":"2020-10-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"takuya-hayashi","type":"person","url":"https://hartvaat.nl/mensen/takuya-hayashi/","name":"Takuya Hayashi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/19/eldercare-af-post-hoc-edoxaban-spiegel-en-pt-13s-voorspellen-bloedingsrisico-bij/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2022/06/01/edoxaban-15-mg-bij-zeer-oude-patienten-met-atriumfibrilleren-eldercare-subanalys/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2022/03/01/edoxaban-15-mg-naar-nierfunctie-bij-zeer-oude-af-eldercare-subanalyse/","published":"2022-03-01"},{"url":"https://hartvaat.nl/2020/10/29/laaggedoseerd-edoxaban-bij-zeer-oude-af-patienten-nejm-eldercare-af/","published":"2020-10-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tara-mccready","type":"person","url":"https://hartvaat.nl/mensen/tara-mccready/","name":"Tara McCready","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2026/01/27/intracoronair-lage-dosis-rtpa-bij-primaire-pci-voor-stemi-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","published":"2021-01-21"},{"url":"https://hartvaat.nl/2019/10/05/uitgebreide-community-interventie-bij-hypertensie-lancet-hope-4/","published":"2019-10-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tatjana-s-potpara","type":"person","url":"https://hartvaat.nl/mensen/tatjana-s-potpara/","name":"Tatjana S Potpara","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/01/01/weglaten-van-aspirine-bij-gecombineerde-antitrombotische-therapie-voor-af-acs-he/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2018/08/01/2018-ehra-praktische-gids-doac-s-bij-af-europace-editie/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/04/21/2018-ehra-praktische-gids-voor-doac-gebruik-bij-af/","published":"2018-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"taye-h-hamza","type":"person","url":"https://hartvaat.nl/mensen/taye-h-hamza/","name":"Taye H Hamza","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","published":"2019-02-19"},{"url":"https://hartvaat.nl/2018/12/11/syntax-score-bij-diabetes-met-coronaire-revascularisatie-freedom/","published":"2018-12-11"},{"url":"https://hartvaat.nl/2018/02/13/richtlijngetrouwe-medicamenteuze-therapie-in-contemporaine-revascularisatietrial/","published":"2018-02-13"},{"url":"https://hartvaat.nl/2017/01/17/dapt-versus-aspirine-monotherapie-bij-diabetes-met-multivatenlijden-na-cabg-free/","published":"2017-01-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"teguh-santoso","type":"person","url":"https://hartvaat.nl/mensen/teguh-santoso/","name":"Teguh Santoso","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/07/dcb-voor-zijtak-bij-provisionale-stenting-gerandomiseerde-trial/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"theodore-a-bass","type":"person","url":"https://hartvaat.nl/mensen/theodore-a-bass/","name":"Theodore A Bass","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/10/13/laaggedoseerd-ticagrelor-versus-standaard-clopidogrel-bij-diabetes-farmacodynami/","published":"2020-10-13"},{"url":"https://hartvaat.nl/2019/04/02/cangrelor-en-gemalen-ticagrelor-bij-stemi-met-primaire-pci/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2016/09/13/prasugrel-versus-ticagrelor-bij-diabetes-type-2-met-coronairlijden-optimus-4-stu/","published":"2016-09-13"},{"url":"https://hartvaat.nl/2016/05/03/gemalen-prasugrel-bij-stemi-met-primaire-pci-de-crush-studie/","published":"2016-05-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thierry-lefevre","type":"person","url":"https://hartvaat.nl/mensen/thierry-lefevre/","name":"Thierry Lefèvre","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/03/04/stapsgewijze-provisionale-versus-systematische-dualstent-bij-ware-linker-hoofdst/","published":"2025-03-04"},{"url":"https://hartvaat.nl/2021/11/09/ffr-voor-behandeling-van-multivatencoronairlijden-jacc/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2021/10/01/ebc-hoofdstam-stentstudie-provisional-versus-systematisch-dubbel-stenten/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2018/12/13/percutaan-herstel-of-medicamenteuze-therapie-bij-secundaire-mr-nejm-mitra-fr/","published":"2018-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-a-prohaska","type":"person","url":"https://hartvaat.nl/mensen/thomas-a-prohaska/","name":"Thomas A Prohaska","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","published":"2026-01-29"},{"url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","published":"2025-10-02"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-hypertriglyceridemie-en-hoog-cv-risico-nejm/","published":"2024-05-16"},{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-familiaire-chylomicronemie-nejm-fase-3/","published":"2024-05-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-j-wang","type":"person","url":"https://hartvaat.nl/mensen/thomas-j-wang/","name":"Thomas J Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2020/09/22/sekse-specifieke-cv-risicofactoren-en-biomarkers-bij-incident-hartfalen/","published":"2020-09-22"},{"url":"https://hartvaat.nl/2019/09/19/polypil-voor-cv-preventie-bij-onderbehandelde-populatie-nejm/","published":"2019-09-19"},{"url":"https://hartvaat.nl/2019/02/01/genetische-schildklierfunctievoorspellers-en-af-jama-cardiology-mendeliaanse-ran/","published":"2019-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-jon-jensen","type":"person","url":"https://hartvaat.nl/mensen/thomas-jon-jensen/","name":"Thomas Jon Jensen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/10/22/af-en-semaglutide-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-m-maddox","type":"person","url":"https://hartvaat.nl/mensen/thomas-m-maddox/","name":"Thomas M Maddox","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/04/16/2024-acc-expert-consensus-behandeling-van-hfref-beslispad-geactualiseerd/","published":"2024-04-16"},{"url":"https://hartvaat.nl/2021/02/16/2021-acc-hf-behandeloptimalisatie-update-antwoorden-op-10-cruciale-vragen/","published":"2021-02-16"},{"url":"https://hartvaat.nl/2017/02/07/acc-aats-aha-2016-criteria-voor-gepaste-coronaire-revascularisatie-bij-acs-en-st/","published":"2017-02-07"},{"url":"https://hartvaat.nl/2016/04/01/orale-antistolling-bij-atriumfibrilleren-over-het-spectrum-van-beroerterisico-ga/","published":"2016-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-mcandrew","type":"person","url":"https://hartvaat.nl/mensen/thomas-mcandrew/","name":"Thomas McAndrew","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","published":"2018-08-14"},{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","published":"2018-02-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-nestelberger","type":"person","url":"https://hartvaat.nl/mensen/thomas-nestelberger/","name":"Thomas Nestelberger","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2025/01/01/esc-0-1-uur-versus-0-2-of-0-3-uur-hoog-sensitief-troponine-algoritmen-bij-verden/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2019/12/17/uitgebreide-vasodilatatie-versus-standaardzorg-bij-acuut-hf-jama-galactic-hf-pil/","published":"2019-12-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thomas-w-johnson","type":"person","url":"https://hartvaat.nl/mensen/thomas-w-johnson/","name":"Thomas W Johnson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2025/07/15/oct-gebaseerde-post-pci-fysiologiebeoordeling-voorspelt-klinische-uitkomsten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2022/08/30/ripcord-2-routinematige-ffr-meting-versus-conventionele-angiografie/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2017/11/01/switchen-van-dapt-na-acs-de-topic-trial/","published":"2017-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"thor-trovik","type":"person","url":"https://hartvaat.nl/mensen/thor-trovik/","name":"Thor Trovik","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","published":"2020-11-17"},{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","published":"2020-01-18"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"},{"url":"https://hartvaat.nl/2016/09/29/drug-eluting-of-bare-metal-stents-bij-coronairlijden-nejm-norstent-trial/","published":"2016-09-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"timo-makikallio","type":"person","url":"https://hartvaat.nl/mensen/timo-makikallio/","name":"Timo Mäkikallio","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","published":"2020-01-18"},{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","published":"2018-07-24"},{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","published":"2018-03-10"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tobias-reichlin","type":"person","url":"https://hartvaat.nl/mensen/tobias-reichlin/","name":"Tobias Reichlin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/06/02/pulsfield-ablatie-levert-betere-vrijwaring-van-recidief-dan-cryoballoon-bij-paro/","published":"2026-08-12"},{"url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","published":"2026-05-27"},{"url":"https://hartvaat.nl/2025/04/17/pfa-versus-cryoballon-bij-paroxysmaal-af-gerandomiseerde-trial/","published":"2025-04-17"},{"url":"https://hartvaat.nl/2023/02/14/cryoballon-pvi-als-eerstelijnsbehandeling-voor-typisch-atriumflutter/","published":"2023-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tolga-agdirlioglu","type":"person","url":"https://hartvaat.nl/mensen/tolga-agdirlioglu/","name":"Tolga Agdirlioglu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2019/03/01/ambulante-hartfrequentiereductie-na-renale-denervatie-bij-hypertensie-zonder-med/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/10/09/24-uurs-ambulante-bloeddrukreductie-na-renale-denervatie-spyral-htn-off-med/","published":"2018-10-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tom-thuren","type":"person","url":"https://hartvaat.nl/mensen/tom-thuren/","name":"Tom Thuren","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/02/01/il-1-remming-en-bloeddruk-hypertensie-en-residueel-inflammatoir-risico-cantos/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2019/03/05/canakinumab-ter-preventie-van-hartfalen-hospitalisatie-cantos-analyse/","published":"2019-03-05"},{"url":"https://hartvaat.nl/2017/10/21/canakinumab-en-longkankerincidentie-bij-atherosclerose-lancet-cantos-exploratief/","published":"2017-10-21"},{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","published":"2017-09-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tomas-freiberger","type":"person","url":"https://hartvaat.nl/mensen/tomas-freiberger/","name":"Tomas Freiberger","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/18/global-hicc-register-950-hofh-patienten-uit-45-landen-slechts-4-haalt-ldl-doelen/","published":"2026-06-17"},{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/24/eas-consensus-wereldwijde-harmonisatie-van-lipidenklinieken/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/25/eas-consensus-familiaire-hypercholesterolemie-bij-kinderen-en-adolescenten/","published":"2026-06-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tomasz-gasior","type":"person","url":"https://hartvaat.nl/mensen/tomasz-gasior/","name":"Tomasz Gasior","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tomoko-iwata","type":"person","url":"https://hartvaat.nl/mensen/tomoko-iwata/","name":"Tomoko Iwata","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2021/09/28/nt-probnp-prognose-en-empagliflozine-effect-bij-emperor-reduced/","published":"2021-09-28"},{"url":"https://hartvaat.nl/2021/03/23/empagliflozine-bij-hfref-met-volume-overbelasting-emperor-reduced/","published":"2021-03-23"},{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","published":"2021-02-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ton-a-c-m-heestermans","type":"person","url":"https://hartvaat.nl/mensen/ton-a-c-m-heestermans/","name":"Ton A C M Heestermans","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","published":"2023-10-19"},{"url":"https://hartvaat.nl/2020/12/01/coronairangiografie-na-hartstilstand-zonder-st-elevatie-coact-1-jaarsuitkomsten/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2020/04/25/clopidogrel-versus-ticagrelor-of-prasugrel-bij-70-plussers-met-nste-acs-lancet-p/","published":"2020-04-25"},{"url":"https://hartvaat.nl/2019/04/11/coronairangiografie-na-hartstilstand-zonder-st-elevatie-nejm-coact/","published":"2019-04-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"toshiharu-ninomiya","type":"person","url":"https://hartvaat.nl/mensen/toshiharu-ninomiya/","name":"Toshiharu Ninomiya","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2023/07/25/omega-3-biomarkers-en-incident-af-ipd-analyse/","published":"2023-07-25"},{"url":"https://hartvaat.nl/2018/06/01/interarmbloeddrukverschil-en-beroerte-ipd-meta-analyse/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2016/01/30/intensieve-bloeddrukverlaging-en-cardiovasculaire-en-renale-uitkomsten-systemati/","published":"2016-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"traci-turner","type":"person","url":"https://hartvaat.nl/mensen/traci-turner/","name":"Traci Turner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2022/05/03/korte-interfererende-rna-tegen-lp-a-jama-fase-1-dosisstudie/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2020/04/16/inclisiran-bij-heterozygote-familiaire-hypercholesterolemie-nejm-orion-9/","published":"2020-04-16"},{"url":"https://hartvaat.nl/2017/04/13/inclisiran-bij-patienten-met-hoog-cv-risico-en-verhoogd-ldl-nejm-orion-1/","published":"2017-04-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"troels-thim","type":"person","url":"https://hartvaat.nl/mensen/troels-thim/","name":"Troels Thim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","published":"2020-06-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"truls-ramunddal","type":"person","url":"https://hartvaat.nl/mensen/truls-ramunddal/","name":"Truls Råmunddal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","published":"2024-11-09"},{"url":"https://hartvaat.nl/2018/09/01/langetermijnimpact-van-cto-rekanalisatie-bij-stemi-patienten/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","published":"2017-09-21"},{"url":"https://hartvaat.nl/2016/10/11/pci-van-chronische-totale-occlusie-bij-stemi-met-multivatenlijden-explore-trial/","published":"2016-10-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tullio-palmerini","type":"person","url":"https://hartvaat.nl/mensen/tullio-palmerini/","name":"Tullio Palmerini","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","published":"2020-02-18"},{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","published":"2017-04-25"},{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tuvia-ben-gal","type":"person","url":"https://hartvaat.nl/mensen/tuvia-ben-gal/","name":"Tuvia Ben-Gal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","published":"2024-10-22"},{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","published":"2024-09-14"},{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","published":"2024-04-27"},{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","published":"2024-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"tyler-massaro","type":"person","url":"https://hartvaat.nl/mensen/tyler-massaro/","name":"Tyler Massaro","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","published":"2019-12-03"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ulrik-wislff","type":"person","url":"https://hartvaat.nl/mensen/ulrik-wislff/","name":"Ulrik Wisløff","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/06/01/trainingseffect-op-diastolische-functie-bij-hfpef/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2022/10/01/verschillende-trainingsvormen-en-hdl-functie-bij-hfpef-optimex-substudie/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2022/06/01/vijf-jaar-inspanningstraining-verbetert-cardiovasculair-risicoprofiel-bij-oudere/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2021/02/09/hiit-matig-continu-of-richtlijnadvies-en-piek-vo2-bij-hfref-jama-smartex-hf/","published":"2021-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"umberto-barbero","type":"person","url":"https://hartvaat.nl/mensen/umberto-barbero/","name":"Umberto Barbero","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/11/ct-angiografie-of-standaardzorg-na-pci-van-de-linker-hoofdstam/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2017/11/07/stentontwerp-en-dapt-duur-effect-op-ischemie-en-bloedingen-netwerkmeta-analyse/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2017/03/14/drie-arteriele-grafts-verbeteren-langetermijnoverleving-meta-analyse-van-propens/","published":"2017-03-14"},{"url":"https://hartvaat.nl/2016/12/21/statines-voor-primaire-preventie-bij-hiv-positieve-patienten-systematische-revie/","published":"2016-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"urh-groselj","type":"person","url":"https://hartvaat.nl/mensen/urh-groselj/","name":"Urh Groselj","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/24/eas-consensus-wereldwijde-harmonisatie-van-lipidenklinieken/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/25/eas-consensus-familiaire-hypercholesterolemie-bij-kinderen-en-adolescenten/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/02/24/lp-a-spiegels-bij-kinderen-met-hypercholesterolemie-impact-op-ldl-c-interpretati/","published":"2026-02-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"urszula-masiukiewicz","type":"person","url":"https://hartvaat.nl/mensen/urszula-masiukiewicz/","name":"Urszula Masiukiewicz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/02/01/sglt2-remmers-en-cv-renale-uitkomsten-bij-diabetes-type-2-jama-cardiology-meta-a/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/12/08/ertugliflozine-en-hf-events-bij-diabetes-met-atherosclerotische-cvd-vertis-cv/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/10/08/ertugliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-vertis-cv/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","published":"2017-04-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"valerio-lanzilotti","type":"person","url":"https://hartvaat.nl/mensen/valerio-lanzilotti/","name":"Valerio Lanzilotti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"valluvan-jeevanandam","type":"person","url":"https://hartvaat.nl/mensen/valluvan-jeevanandam/","name":"Valluvan Jeevanandam","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/05/23/hemocompatibiliteitsuitkomsten-van-heartmate-3-na-6-maanden-momentum-3/","published":"2017-05-23"},{"url":"https://hartvaat.nl/2017/02/02/intrapericardiale-lvad-bij-gevorderd-hartfalen-nejm/","published":"2017-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vanessa-selak","type":"person","url":"https://hartvaat.nl/mensen/vanessa-selak/","name":"Vanessa Selak","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/06/01/lage-dosis-drievoudige-combinatietherapie-bij-hypertensie-triumph-secundaire-ana/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2020/11/01/lage-dosis-triple-combinatie-en-therapeutische-inertie-bij-hypertensie-jama-card/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2019/01/01/polypil-en-cardiovasculaire-preventie-meta-analyse-van-gerandomiseerde-trials/","published":"2019-01-01"},{"url":"https://hartvaat.nl/2018/08/14/drievoudige-lage-dosis-antihypertensivacombinatie-versus-standaardzorg-jama-gera/","published":"2018-08-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vasilios-papademetriou","type":"person","url":"https://hartvaat.nl/mensen/vasilios-papademetriou/","name":"Vasilios Papademetriou","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2021/04/01/intensieve-versus-standaard-bloeddruk-op-cva-subtypes-sprint/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2018/01/09/diastolische-bloeddruk-en-intensieve-bloeddrukcontrole-sprint-analyse/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","published":"2017-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"veikko-salomaa","type":"person","url":"https://hartvaat.nl/mensen/veikko-salomaa/","name":"Veikko Salomaa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2020/07/01/nieuwe-dna-methyleringsloci-voor-bloeddruk-erfelijkheid-en-genexpressie/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","published":"2019-02-14"},{"url":"https://hartvaat.nl/2018/11/27/metabolome-consequenties-van-pcsk9-remming-versus-statinetherapie/","published":"2018-11-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"veli-pekka-harjola","type":"person","url":"https://hartvaat.nl/mensen/veli-pekka-harjola/","name":"Veli-Pekka Harjola","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/07/10/epinefrine-versus-norepinefrine-bij-cardiogene-shock-na-acuut-mi/","published":"2018-07-10"},{"url":"https://hartvaat.nl/2017/11/28/xenon-inhalatie-vermindert-myocardschade-bij-overlevenden-van-hartstilstand-xe-h/","published":"2017-11-28"},{"url":"https://hartvaat.nl/2017/04/18/risicostratificatie-bij-cardiogene-shock-na-acuut-myocardinfarct/","published":"2017-04-18"},{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","published":"2016-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"victor-aboyans","type":"person","url":"https://hartvaat.nl/mensen/victor-aboyans/","name":"Victor Aboyans","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/10/01/bloeddruk-in-hogere-versus-lagere-arm-en-cv-uitkomsten-interpress-ipd-meta-analy/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/07/01/cv-gevolgen-van-stoppen-met-laaggedoseerd-rivaroxaban-bij-chronisch-vaatlijden/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/01/01/rivaroxaban-plus-aspirine-bij-symptomatisch-pav-compass-subanalyse/","published":"2021-01-01"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vincent-fabien","type":"person","url":"https://hartvaat.nl/mensen/vincent-fabien/","name":"Vincent Fabien","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","published":"2023-05-30"},{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","published":"2021-08-17"},{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","published":"2020-12-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vincent-w-v-jaddoe","type":"person","url":"https://hartvaat.nl/mensen/vincent-w-v-jaddoe/","name":"Vincent W V Jaddoe","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/04/27/genen-voor-bloeddruk-in-de-kindertijd-voorspellen-cardiometabool-risico-op-later/","published":"2026-05-09"},{"url":"https://hartvaat.nl/2023/04/21/cardiometabole-gezondheid-bij-kinderen-geboren-na-ivf/","published":"2023-04-21"},{"url":"https://hartvaat.nl/2019/08/01/hypertensieve-zwangerschapsaandoeningen-en-dna-methylering-bij-pasgeborenen/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/05/07/zwangerschapsgewichtstoename-en-maternale-en-neonatale-uitkomsten-jama-meta-anal/","published":"2019-05-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"virend-k-somers","type":"person","url":"https://hartvaat.nl/mensen/virend-k-somers/","name":"Virend K Somers","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/01/hoog-versus-laag-natrium-oxybaat-en-bloeddruk-bij-narcolepsie/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2021/09/01/slaaprestrictie-en-ambulante-en-slaap-bloeddruk-gerandomiseerde-crossover/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2020/04/01/biomarkers-bij-hf-met-centrale-slaapapneu-serve-hf/","published":"2020-04-01"},{"url":"https://hartvaat.nl/2018/08/01/renale-denervatie-bij-resistente-hypertensie-met-obstructieve-slaapapneu-proof-o/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"vivek-rajagopal","type":"person","url":"https://hartvaat.nl/mensen/vivek-rajagopal/","name":"Vivek Rajagopal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","published":"2020-09-01"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wadea-m-tarhuni","type":"person","url":"https://hartvaat.nl/mensen/wadea-m-tarhuni/","name":"Wadea M Tarhuni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","published":"2025-02-13"},{"url":"https://hartvaat.nl/2022/09/15/invictus-rivaroxaban-versus-warfarine-bij-reumatische-hartziekte-en-af/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2020/08/25/machine-learning-voor-lv-diastolische-functie-op-ecg/","published":"2020-08-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wanda-k-nicholson","type":"person","url":"https://hartvaat.nl/mensen/wanda-k-nicholson/","name":"Wanda K Nicholson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","published":"2023-09-19"},{"url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","published":"2022-07-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wang-soo-lee","type":"person","url":"https://hartvaat.nl/mensen/wang-soo-lee/","name":"Wang Soo Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"},{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","published":"2018-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wataru-shimizu","type":"person","url":"https://hartvaat.nl/mensen/wataru-shimizu/","name":"Wataru Shimizu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/11/07/crrf-peaf-cryoballon-versus-rf-ablatie-bij-persisterend-af/","published":"2025-11-07"},{"url":"https://hartvaat.nl/2022/03/01/edoxaban-15-mg-naar-nierfunctie-bij-zeer-oude-af-eldercare-subanalyse/","published":"2022-03-01"},{"url":"https://hartvaat.nl/2021/10/01/empagliflozine-en-nierprotectie-bij-acuut-mi-met-diabetes-pilot/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2016/02/14/kortdurend-antiaritmica-na-katheterablatie-voor-atriumfibrilleren-east-af-trial/","published":"2016-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wei-wang","type":"person","url":"https://hartvaat.nl/mensen/wei-wang/","name":"Wei Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/12/31/lvh-voorspelt-ongunstige-moeder-en-foetale-uitkomsten-bij-chronische-hypertensie/","published":"2026-08-31"},{"url":"https://hartvaat.nl/2026/03/05/trem-1-remming-vermindert-in-stent-neoatherosclerose-in-diermodel/","published":"2026-04-12"},{"url":"https://hartvaat.nl/2024/04/01/halp-score-hemoglobine-albumine-lymfocyten-trombocyten-en-mortaliteit-bij-hartfa/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","published":"2023-03-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wei-xu","type":"person","url":"https://hartvaat.nl/mensen/wei-xu/","name":"Wei Xu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/12/31/annexine-a1-verergert-activatie-van-eilandjessterrecellen-via-triglyceridenafbra/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/10/28/esprit-bescheiden-effecten-van-intensieve-bloeddrukverlaging-op-kwaliteit-van-le/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/09/01/pvi-met-of-zonder-empirische-svc-isolatie-bij-af-ablatie/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2020/07/01/bloeddruk-en-cognitieve-stoornis-en-dementie-meta-analyse-van-209-studies/","published":"2020-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"weifeng-jiang","type":"person","url":"https://hartvaat.nl/mensen/weifeng-jiang/","name":"Weifeng Jiang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/01/ice-versus-tee-bij-af-ablatie-gerandomiseerde-trial/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/08/12/catheterablatie-versus-rate-control-bij-persisterend-af-en-ouder-hartfalen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2023/05/19/drie-substraatstrategieen-voor-persisterend-af-vergeleken-multicenter-rct/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2021/05/21/extrapulmonale-vein-driver-mapping-bij-persisterend-af-bij-obese-patienten/","published":"2021-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"weiqing-wang","type":"person","url":"https://hartvaat.nl/mensen/weiqing-wang/","name":"Weiqing Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/03/27/intensieve-bloeddrukcontrole-bij-type-2-diabetes-nejm/","published":"2025-03-27"},{"url":"https://hartvaat.nl/2023/08/01/bloeddrukstreefwaarden-bij-type-2-diabetes-netwerk-meta-analyse/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2023/01/01/opleiding-intelligentie-en-cognitie-onafhankelijke-verbanden-met-hypertensie/","published":"2023-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wen-hua-hsieh","type":"person","url":"https://hartvaat.nl/mensen/wen-hua-hsieh/","name":"Wen-Hua Hsieh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2017/05/02/mi-risico-na-stoppen-van-thienopyridine-dapt-studie/","published":"2017-05-02"},{"url":"https://hartvaat.nl/2016/10/04/impact-van-optimale-medicamenteuze-therapie-in-de-dapt-studie/","published":"2016-10-04"},{"url":"https://hartvaat.nl/2016/05/03/diabetes-en-preventie-van-laat-myocardinfarct-na-stenting-dapt-studie/","published":"2016-05-03"},{"url":"https://hartvaat.nl/2016/04/12/protonpompremmers-verminderen-gastro-intestinale-events-ongeacht-aspirinedosis-b/","published":"2016-04-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wen-yi-yang","type":"person","url":"https://hartvaat.nl/mensen/wen-yi-yang/","name":"Wen-Yi Yang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","published":"2025-08-08"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wendimagegn-alemayehu","type":"person","url":"https://hartvaat.nl/mensen/wendimagegn-alemayehu/","name":"Wendimagegn Alemayehu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/01/geografische-variatie-in-hfref-patientkenmerken-en-behandeling/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2022/04/09/natriumreductie-100-mmol-bij-hartfalen-lancet-sodium-hf/","published":"2022-04-09"},{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2019/08/01/hoog-versus-laag-zuurstof-bij-acuut-hartfalen-hilo-hf-pilot/","published":"2019-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wendy-s-post","type":"person","url":"https://hartvaat.nl/mensen/wendy-s-post/","name":"Wendy S Post","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/21/aspirine-lipoproteine-a-en-aortaklepstenose-de-mesa-studie/","published":"2026-02-21"},{"url":"https://hartvaat.nl/2023/06/01/genetische-bijdrage-aan-aortastenose-dyslipidemie-inflammatie-en-verkalking/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2021/06/01/geisoleerde-diastolische-hypertensie-cohort-en-meta-analyse-voor-behandeldrempel/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2018/03/27/hdl-subspecies-met-apoliproteine-c-iii-en-coronairlijden-vier-cohorten/","published":"2018-03-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wengen-zhu","type":"person","url":"https://hartvaat.nl/mensen/wengen-zhu/","name":"Wengen Zhu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/06/01/hypertensie-wijzigt-de-relatie-tussen-lp-a-en-mortaliteit-bij-acuut-gedecompense/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/04/01/copd-en-slechtere-uitkomsten-bij-hfpef-meta-analyse/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/12/01/nt-probnp-voorspelt-nieuw-ontstaan-af-bij-hfpef/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/06/01/s2i2n0-3-score-voorspelt-mortaliteit-bij-hfref-guide-it-subanalyse/","published":"2024-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wessel-ganzevoort","type":"person","url":"https://hartvaat.nl/mensen/wessel-ganzevoort/","name":"Wessel Ganzevoort","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/06/01/amenorroe-duur-bij-start-antihypertensiva-in-de-zwangerschap-chips-secundaire-an/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/11/01/sildenafil-tijdens-de-zwangerschap-preklinische-meta-analyse-over-foetale-groei-/","published":"2017-11-01"},{"url":"https://hartvaat.nl/2016/11/01/chips-trial-is-ernstige-hypertensie-in-de-zwangerschap-meer-dan-alleen-verhoogde/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/01/kostenimplicaties-van-minder-strikte-versus-strikte-bloeddrukcontrole-bij-zwange/","published":"2016-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wilko-reents","type":"person","url":"https://hartvaat.nl/mensen/wilko-reents/","name":"Wilko Reents","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/10/24/laaos-iii-laa-occlusie-en-anticoagulatiegebruik/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2023/07/01/statinoplaaddosis-voor-cabg-gerandomiseerde-trial/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","published":"2021-06-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wilko-spiering","type":"person","url":"https://hartvaat.nl/mensen/wilko-spiering/","name":"Wilko Spiering","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","published":"2024-10-19"},{"url":"https://hartvaat.nl/2022/10/01/smartphone-app-thuisbloeddrukmeting-versus-kantoor-en-ambulante-meting/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2021/01/01/plasmatrogconcentraties-van-antihypertensiva-voor-therapietrouwbeoordeling-meta-/","published":"2021-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"william-e-haley","type":"person","url":"https://hartvaat.nl/mensen/william-e-haley/","name":"William E Haley","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/03/01/orthostatische-hypotensie-cv-uitkomsten-en-adverse-events-sprint-resultaten/","published":"2020-03-01"},{"url":"https://hartvaat.nl/2018/06/01/intensieve-versus-standaard-bloeddruk-naar-tertielen-in-sprint/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/01/01/intensieve-versus-standaard-bloeddrukcontrole-op-ambulante-bloeddruk-sprint-resu/","published":"2017-01-01"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"william-j-kostis","type":"person","url":"https://hartvaat.nl/mensen/william-j-kostis/","name":"William J Kostis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2020/02/01/bloeddrukcontrole-en-diabetes-incidentie-sprint-resultaten/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2018/06/01/intensieve-versus-standaard-bloeddruk-naar-tertielen-in-sprint/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","published":"2017-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"willibald-hochholzer","type":"person","url":"https://hartvaat.nl/mensen/willibald-hochholzer/","name":"Willibald Hochholzer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2023/04/17/in-stent-restenose-tienjaarsuitkomsten-plain-balloon-vs-dcb-vs-des-isar-desire-3/","published":"2023-04-17"},{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","published":"2019-10-17"},{"url":"https://hartvaat.nl/2016/07/19/immatuur-plaatjesaantal-versus-gevestigde-voorspellers-van-plaatjesreactiviteit-/","published":"2016-07-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"winfried-marz","type":"person","url":"https://hartvaat.nl/mensen/winfried-marz/","name":"Winfried März","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/05/24/eas-consensus-wereldwijde-harmonisatie-van-lipidenklinieken/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2021/03/01/genoomwijde-analyse-identificeert-nieuwe-mi-gevoeligheidsloci/","published":"2021-03-01"},{"url":"https://hartvaat.nl/2016/06/01/langetermijneffecten-van-atorvastatine-bij-diabetes-type-2-op-hemodialyse-4d-tri/","published":"2016-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"wouter-ouwerkerk","type":"person","url":"https://hartvaat.nl/mensen/wouter-ouwerkerk/","name":"Wouter Ouwerkerk","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/31/hfpef-fenotype-duidt-op-hogere-sterfte-na-tavi-bij-laagstroom-laaggradient-aorta/","published":"2026-07-27"},{"url":"https://hartvaat.nl/2025/12/16/farmacologische-behandeling-van-hfref-geactualiseerde-systematische-review/","published":"2025-12-16"},{"url":"https://hartvaat.nl/2022/08/01/sekseverschillen-in-effectiviteit-van-hartfalenmedicatie-meta-analyse/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","published":"2022-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xavier-girerd","type":"person","url":"https://hartvaat.nl/mensen/xavier-girerd/","name":"Xavier Girerd","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2021/09/01/normalisatie-van-arteriele-stijfheid-en-cv-events-sparte-studie/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2017/03/01/24-uurs-bloeddrukmonitoring-bij-renale-denervatie-denerhtn-studie/","published":"2017-03-01"},{"url":"https://hartvaat.nl/2016/09/20/medicatietrouw-en-bloeddrukeffecten-van-renale-denervatie-rsd-pathway-2-analyse/","published":"2016-09-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xiang-cheng","type":"person","url":"https://hartvaat.nl/mensen/xiang-cheng/","name":"Xiang Cheng","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/25/explorer-cn-week-78-langetermijneffect-en-veiligheid-van-mavacamten-bij-chinese-/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2026/03/05/nucleair-ago2-verergert-hfpef-via-myocardiale-ketogenese/","published":"2026-04-03"},{"url":"https://hartvaat.nl/2025/01/01/varenicline-vermindert-ventriculaire-ectopie-na-myocardinfarct/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2024/09/24/colchicine-en-coronaire-plaquestabiliteit-na-acs-oct-studie/","published":"2024-09-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xiaofan-guo","type":"person","url":"https://hartvaat.nl/mensen/xiaofan-guo/","name":"Xiaofan Guo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2024/09/01/multifactorieel-intensief-bloeddrukmodel-bij-ouderen-en-jongeren/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/03/18/intensieve-bloeddrukinterventie-door-niet-artsen-in-lage-inkomenslanden-lancet-r/","published":"2023-03-18"},{"url":"https://hartvaat.nl/2022/05/21/dorpsarts-geleide-multifacet-interventie-voor-bloeddrukcontrole-in-ruraal-china-/","published":"2022-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xiaofang-yan","type":"person","url":"https://hartvaat.nl/mensen/xiaofang-yan/","name":"Xiaofang Yan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/06/esprit-intensieve-bloeddrukcontrole-bij-fragiele-patienten-post-hoc-analyse/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukverlaging-en-retinale-microvasculatuur/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukcontrole-en-cva-preventie/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2024/07/20/sbp-120-versus-140-mmhg-bij-hoog-cv-risico-meta-analyse-van-intensieve-behandeli/","published":"2024-07-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xiaoshu-cheng","type":"person","url":"https://hartvaat.nl/mensen/xiaoshu-cheng/","name":"Xiaoshu Cheng","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/01/metabole-score-voor-visceraal-vet-en-risico-op-perifeer-arterieel-vaatlijden-bij/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2018/05/15/trombocytenaantal-beinvloedt-werkzaamheid-van-foliumzuur-bij-cva-preventie/","published":"2018-05-15"},{"url":"https://hartvaat.nl/2017/04/01/optimale-systolische-bloeddruk-voor-primaire-cva-preventie-bij-hypertensie-csppt/","published":"2017-04-01"},{"url":"https://hartvaat.nl/2016/07/01/polsgolfsnelheid-en-bloeddrukcontrole-als-onafhankelijke-voorspellers-van-cva-bi/","published":"2016-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xiaoxia-liu","type":"person","url":"https://hartvaat.nl/mensen/xiaoxia-liu/","name":"Xiaoxia Liu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/09/01/inflammatie-als-risicofactor-krijgt-onvoldoende-ruimte-in-de-ascvd-en-ckd-prakti/","published":"2026-07-26"},{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","published":"2023-03-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xinhua-wang","type":"person","url":"https://hartvaat.nl/mensen/xinhua-wang/","name":"Xinhua Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/16/sluiting-van-het-linker-hartoor-versus-doac-s-na-longembolie/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2025/12/01/ice-versus-tee-bij-af-ablatie-gerandomiseerde-trial/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"},{"url":"https://hartvaat.nl/2023/05/19/drie-substraatstrategieen-voor-persisterend-af-vergeleken-multicenter-rct/","published":"2023-05-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xinyang-hu","type":"person","url":"https://hartvaat.nl/mensen/xinyang-hu/","name":"Xinyang Hu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/01/varenicline-vermindert-ventriculaire-ectopie-na-myocardinfarct/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","published":"2025-08-26"},{"url":"https://hartvaat.nl/2025/04/26/angiografie-afgeleide-ffr-versus-ivus-bij-pci-gerandomiseerde-trial/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","published":"2022-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xinyi-zhang","type":"person","url":"https://hartvaat.nl/mensen/xinyi-zhang/","name":"Xinyi Zhang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/01/01/apolipoproteine-e-genpolymorfismen-en-het-risico-op-coronairlijden/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2022/05/17/kosteneffectiviteit-van-zoutsubstitutie-ssass-analyse/","published":"2022-05-17"},{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","published":"2021-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xue-qiao-zhao","type":"person","url":"https://hartvaat.nl/mensen/xue-qiao-zhao/","name":"Xue-Qiao Zhao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/08/26/dapagliflozin-vermindert-epicardiaal-vetweefsel-onafhankelijk-van-gewichtsverlie/","published":"2026-09-03"},{"url":"https://hartvaat.nl/2025/12/22/evinacumab-bij-kinderen-van-5-17-jaar-met-homozygote-familiaire-hypercholesterol/","published":"2025-12-22"},{"url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2016/02/01/nicotinezuurtherapie-en-het-risico-op-diabetes-meta-analyse-van-gerandomiseerde-/","published":"2016-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"xuejun-yin","type":"person","url":"https://hartvaat.nl/mensen/xuejun-yin/","name":"Xuejun Yin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2022/09/26/zoutvervangers-verminderen-cardiovasculaire-events-systematische-review/","published":"2022-09-26"},{"url":"https://hartvaat.nl/2022/05/17/kosteneffectiviteit-van-zoutsubstitutie-ssass-analyse/","published":"2022-05-17"},{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","published":"2021-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yader-sandoval","type":"person","url":"https://hartvaat.nl/mensen/yader-sandoval/","name":"Yader Sandoval","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/12/01/korte-dapt-na-des-bij-acs-ipd-meta-analyse-bevestigt-veiligheid/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2017/11/21/hoog-sensitief-troponine-i-en-uitkomsten-bij-verdenking-acs-jama-studie/","published":"2017-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yan-wang","type":"person","url":"https://hartvaat.nl/mensen/yan-wang/","name":"Yan Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/05/11/ticagrelor-monotherapie-versus-dapt-na-1-maand-bij-acs-lancet-rct/","published":"2024-05-11"},{"url":"https://hartvaat.nl/2023/06/01/remote-ischemische-conditionering-bij-milde-hypertensie-zonder-medicatie-rct/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","published":"2020-07-14"},{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","published":"2017-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yang-liu","type":"person","url":"https://hartvaat.nl/mensen/yang-liu/","name":"Yang Liu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/01/01/langdurige-blootstelling-aan-bosbranden-pm2-5-en-cardiovasculaire-ziekenhuisopna/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/10/31/herhaalde-in-situ-ablatie-versus-uitgebreide-ablatie-bij-recidief-persisterend-a/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2025/08/12/catheterablatie-versus-rate-control-bij-persisterend-af-en-ouder-hartfalen/","published":"2025-08-12"},{"url":"https://hartvaat.nl/2023/02/01/hartfalenrisicoscores-vergelijking-voor-mortaliteit-en-heropname/","published":"2023-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yanyan-zhao","type":"person","url":"https://hartvaat.nl/mensen/yanyan-zhao/","name":"Yanyan Zhao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/12/gdmt-na-functioneel-complete-revascularisatie-prognostische-impact/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2024/02/01/maggic-score-voor-mortaliteitsvoorspelling-bij-klepziekte/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yared-gurmu","type":"person","url":"https://hartvaat.nl/mensen/yared-gurmu/","name":"Yared Gurmu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2020/02/25/genetische-risicoscore-voorspelt-voordeel-van-evolocumab-fourier/","published":"2020-02-25"},{"url":"https://hartvaat.nl/2019/10/21/cv-biomarkers-bij-acuut-gedecompenseerd-hf-met-sacubitril-valsartan-pioneer-hf/","published":"2019-10-21"},{"url":"https://hartvaat.nl/2019/05/07/sacubitril-valsartan-of-enalapril-bij-acuut-gedecompenseerd-hf-pioneer-hf-klinis/","published":"2019-05-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yasuyuki-egami","type":"person","url":"https://hartvaat.nl/mensen/yasuyuki-egami/","name":"Yasuyuki Egami","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/01/nierfunctie-en-effectiviteit-van-lva-ablatie-na-pvi-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2025/06/01/dapagliflozine-bij-acuut-gedecompenseerd-hartfalen-en-nierfunctie-rct/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2021/04/06/pvi-alleen-versus-uitgebreide-ablatie-bij-persisterend-af-meta-analyse/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2016/02/14/kortdurend-antiaritmica-na-katheterablatie-voor-atriumfibrilleren-east-af-trial/","published":"2016-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yazan-daaboul","type":"person","url":"https://hartvaat.nl/mensen/yazan-daaboul/","name":"Yazan Daaboul","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2017/01/24/heropnames-bij-af-patienten-na-stenting-twee-antitromboticastrategieen-vergeleke/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2016/12/22/preventie-van-bloedingen-bij-af-patienten-die-pci-ondergaan-nejm-pioneer-af-pci/","published":"2016-12-22"},{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","published":"2016-12-13"},{"url":"https://hartvaat.nl/2016/04/21/mtp-131-bij-reperfusieschade-na-stemi-de-embrace-stemi-fase-2a-trial/","published":"2016-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yeonwoo-choi","type":"person","url":"https://hartvaat.nl/mensen/yeonwoo-choi/","name":"Yeonwoo Choi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","published":"2025-09-11"},{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","published":"2023-10-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yi-bang-cheng","type":"person","url":"https://hartvaat.nl/mensen/yi-bang-cheng/","name":"Yi-Bang Cheng","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2020/11/10/chinese-kruidenformule-voor-gemaskeerde-hypertensie-gerandomiseerde-placebogecon/","published":"2020-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yolanda-van-der-graaf","type":"person","url":"https://hartvaat.nl/mensen/yolanda-van-der-graaf/","name":"Yolanda van der Graaf","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2019/12/07/individueel-levenslang-voordeel-en-bloedingsrisico-van-rivaroxaban-plus-aspirine/","published":"2019-12-07"},{"url":"https://hartvaat.nl/2018/10/01/geschat-individueel-levensvoordeel-van-pcsk9-remming-bij-statinebehandelde-cad-p/","published":"2018-10-01"},{"url":"https://hartvaat.nl/2018/01/01/genetische-associatie-van-lipiden-en-lipide-doelwitten-met-abdominaal-aorta-aneu/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2016/11/08/residueel-vasculair-risico-bij-secundaire-preventie-verdeling-van-10-jaarsrisico/","published":"2016-11-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yong-liu","type":"person","url":"https://hartvaat.nl/mensen/yong-liu/","name":"Yong Liu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/02/27/verhoogd-lp-a-en-diabetes-verergeren-samen-de-prognose-bij-coronairlijden/","published":"2026-02-27"},{"url":"https://hartvaat.nl/2026/01/06/esprit-intensieve-bloeddrukcontrole-bij-fragiele-patienten-post-hoc-analyse/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2024/11/12/recaticimab-monotherapie-bij-niet-familiaire-hypercholesterolemie-fase-3-remain-/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2022/05/25/hydratie-ter-preventie-van-nierschade-na-primaire-pci-gerandomiseerde-trial/","published":"2022-05-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yong-hoon-yoon","type":"person","url":"https://hartvaat.nl/mensen/yong-hoon-yoon/","name":"Yong-Hoon Yoon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","published":"2022-09-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yong-un-kim","type":"person","url":"https://hartvaat.nl/mensen/yong-un-kim/","name":"Yong-Un Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","published":"2021-03-16"},{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","published":"2020-11-07"},{"url":"https://hartvaat.nl/2020/05/19/pav-en-vte-na-acs-rol-van-lp-a-en-modificatie-door-alirocumab/","published":"2020-05-19"},{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","published":"2019-12-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yoshihisa-nakagawa","type":"person","url":"https://hartvaat.nl/mensen/yoshihisa-nakagawa/","name":"Yoshihisa Nakagawa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"},{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","published":"2019-06-25"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2018/05/08/hoog-versus-laaggedoseerd-pitavastatine-bij-stabiel-coronairlijden-real-cad/","published":"2018-05-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yu-xu","type":"person","url":"https://hartvaat.nl/mensen/yu-xu/","name":"Yu Xu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/03/27/intensieve-bloeddrukcontrole-bij-type-2-diabetes-nejm/","published":"2025-03-27"},{"url":"https://hartvaat.nl/2023/08/01/bloeddrukstreefwaarden-bij-type-2-diabetes-netwerk-meta-analyse/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2023/01/01/opleiding-intelligentie-en-cognitie-onafhankelijke-verbanden-met-hypertensie/","published":"2023-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yuan-ma","type":"person","url":"https://hartvaat.nl/mensen/yuan-ma/","name":"Yuan Ma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/04/01/hypotensieve-episodes-op-24-uurs-abpm-en-cognitieve-functie-sprint-inzichten/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/11/01/bloeddrukverlagende-medicatie-en-natriumbeperking-gecombineerd-effect/","published":"2024-11-01"},{"url":"https://hartvaat.nl/2024/09/01/troponine-nt-probnp-en-cognitieve-uitkomsten-in-sprint/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2021/11/01/bloeddrukvariabiliteit-en-dementie-cognitieve-stoornis-meta-analyse/","published":"2021-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yue-deng","type":"person","url":"https://hartvaat.nl/mensen/yue-deng/","name":"Yue Deng","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/01/hypertensieduur-en-effect-van-intensieve-bloeddrukbehandeling/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/09/01/step-substudie-intensieve-bloeddrukverlaging-verbetert-lvh-bij-ouderen/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/12/01/klebsiella-pneumoniae-als-mogelijke-oorzaak-van-hypertensie/","published":"2022-12-01"},{"url":"https://hartvaat.nl/2021/09/30/intensieve-bloeddrukcontrole-bij-oudere-patienten-met-hypertensie-nejm-step/","published":"2021-09-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yue-li","type":"person","url":"https://hartvaat.nl/mensen/yue-li/","name":"Yue Li","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/03/darmmicrobioom-bevordert-atriumfibrilleren-bij-chronische-nierziekte-via-nlrp3-i/","published":"2026-04-07"},{"url":"https://hartvaat.nl/2025/01/07/dcb-voor-zijtak-bij-provisionale-stenting-gerandomiseerde-trial/","published":"2025-01-07"},{"url":"https://hartvaat.nl/2024/11/12/recaticimab-als-toevoeging-aan-statines-fase-3-remain-2/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2022/01/18/magnetisch-gecontroleerde-capsule-endoscopie-voor-antiplaatjestherapie-gi-schade/","published":"2022-01-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yufang-bi","type":"person","url":"https://hartvaat.nl/mensen/yufang-bi/","name":"Yufang Bi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/03/27/intensieve-bloeddrukcontrole-bij-type-2-diabetes-nejm/","published":"2025-03-27"},{"url":"https://hartvaat.nl/2023/08/01/bloeddrukstreefwaarden-bij-type-2-diabetes-netwerk-meta-analyse/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2023/01/01/opleiding-intelligentie-en-cognitie-onafhankelijke-verbanden-met-hypertensie/","published":"2023-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yuki-katagiri","type":"person","url":"https://hartvaat.nl/mensen/yuki-katagiri/","name":"Yuki Katagiri","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2018/11/01/ct-coronairangiografie-voor-heart-team-besluitvorming-bij-multivatenlijden/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2018/02/03/sirolimus-eluting-bioabsorbeerbare-stent-versus-everolimus-eluting-stent-na-mi-l/","published":"2018-02-03"},{"url":"https://hartvaat.nl/2017/09/01/late-trombotische-events-na-bioresorbeerbare-scaffold-meta-analyse-van-gerandomi/","published":"2017-09-01"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yuki-obayashi","type":"person","url":"https://hartvaat.nl/mensen/yuki-obayashi/","name":"Yuki Obayashi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","published":"2024-02-20"},{"url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","published":"2022-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yunpeng-zhu","type":"person","url":"https://hartvaat.nl/mensen/yunpeng-zhu/","name":"Yunpeng Zhu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","published":"2023-02-14"},{"url":"https://hartvaat.nl/2022/08/09/ticagrelor-dapt-en-veneuze-graftfalen-na-cabg-systematische-review/","published":"2022-08-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yuri-lopatin","type":"person","url":"https://hartvaat.nl/mensen/yuri-lopatin/","name":"Yuri Lopatin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","published":"2024-06-11"},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","published":"2024-05-21"},{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","published":"2024-04-25"},{"url":"https://hartvaat.nl/2022/12/01/hartfalen-tijdens-de-covid-19-pandemie-klinische-en-organisatorische-dilemma-s/","published":"2022-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"yves-louvard","type":"person","url":"https://hartvaat.nl/mensen/yves-louvard/","name":"Yves Louvard","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","published":"2026-06-19"},{"url":"https://hartvaat.nl/2025/03/04/stapsgewijze-provisionale-versus-systematische-dualstent-bij-ware-linker-hoofdst/","published":"2025-03-04"},{"url":"https://hartvaat.nl/2021/10/01/ebc-hoofdstam-stentstudie-provisional-versus-systematisch-dubbel-stenten/","published":"2021-10-01"},{"url":"https://hartvaat.nl/2018/07/07/revascularisatie-versus-optimale-medicamenteuze-therapie-bij-cto-gerandomiseerde/","published":"2018-07-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zenon-huczek","type":"person","url":"https://hartvaat.nl/mensen/zenon-huczek/","name":"Zenon Huczek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/19/salamander-register-95-5-technisch-succes-bij-stand-alone-linker-hartoor-occlusi/","published":"2026-06-10"},{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zhen-ge","type":"person","url":"https://hartvaat.nl/mensen/zhen-ge/","name":"Zhen Ge","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","published":"2024-09-07"},{"url":"https://hartvaat.nl/2024/05/11/ivus-acs-ivus-geleide-pci-bij-acs-superieur-lancet/","published":"2024-05-11"},{"url":"https://hartvaat.nl/2024/05/11/ticagrelor-monotherapie-versus-dapt-na-1-maand-bij-acs-lancet-rct/","published":"2024-05-11"},{"url":"https://hartvaat.nl/2018/12/18/ivus-versus-angiografie-geleide-des-implantatie-de-ultimate-trial/","published":"2018-12-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zhen-huang","type":"person","url":"https://hartvaat.nl/mensen/zhen-huang/","name":"Zhen Huang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/09/10/tact-2-chelatietherapie-na-mi-bij-diabetes-negatieve-trial/","published":"2024-09-10"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","published":"2016-05-10"},{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","published":"2016-01-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zhen-zhang","type":"person","url":"https://hartvaat.nl/mensen/zhen-zhang/","name":"Zhen Zhang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/03/02/extracellulaire-vesikels-medieren-adipocyt-cardiomyocytcommunicatie-bij-diabetis/","published":"2026-03-31"},{"url":"https://hartvaat.nl/2018/01/30/absorb-bioresorbeerbare-scaffold-3-jaarsresultaten-ipd-meta-analyse/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2017/12/12/3-jaarsresultaten-van-bioresorbeerbare-scaffolds-absorb-iii-trial/","published":"2017-12-12"},{"url":"https://hartvaat.nl/2017/08/19/absorb-bioresorbeerbare-scaffold-lancet-2-jaars-systematische-review-en-meta-ana/","published":"2017-08-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zhipeng-zhou","type":"person","url":"https://hartvaat.nl/mensen/zhipeng-zhou/","name":"Zhipeng Zhou","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","published":"2024-10-15"},{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","published":"2023-10-17"},{"url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","published":"2023-07-11"},{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","published":"2022-11-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zhiyan-wang","type":"person","url":"https://hartvaat.nl/mensen/zhiyan-wang/","name":"Zhiyan Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukverlaging-bij-ongediagnosticeerde-hfpef-met-hoog-risico/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/06/13/frailteit-en-intensieve-bloeddrukcontrole-bij-diabetes/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","published":"2023-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zhuhua-yao","type":"person","url":"https://hartvaat.nl/mensen/zhuhua-yao/","name":"Zhuhua Yao","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/06/26/inclisiran-als-monotherapie-verlaagt-ldl-c-met-47-5-in-chinese-volwassenen-victo/","published":"2026-08-09"},{"url":"https://hartvaat.nl/2025/05/20/angptl3-antilichaam-bij-suboptimaal-gecontroleerde-hyperlipidemie-fase-2/","published":"2025-05-20"},{"url":"https://hartvaat.nl/2024/11/12/recaticimab-als-toevoeging-aan-statines-fase-3-remain-2/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2024/11/12/recaticimab-monotherapie-bij-niet-familiaire-hypercholesterolemie-fase-3-remain-/","published":"2024-11-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zuzana-motovska","type":"person","url":"https://hartvaat.nl/mensen/zuzana-motovska/","name":"Zuzana Motovska","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"},{"url":"https://hartvaat.nl/2018/01/30/prasugrel-versus-ticagrelor-bij-primaire-pci-voor-mi-1-jaarsuitkomsten/","published":"2018-01-30"},{"url":"https://hartvaat.nl/2016/11/22/prasugrel-versus-ticagrelor-bij-acuut-mi-met-primaire-pci-multicenter-trial/","published":"2016-11-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"zeljko-reiner","type":"person","url":"https://hartvaat.nl/mensen/zeljko-reiner/","name":"Željko Reiner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":4,"articles":[{"url":"https://hartvaat.nl/2026/05/24/eas-consensus-wereldwijde-harmonisatie-van-lipidenklinieken/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2022/09/07/prevalentie-van-statine-intolerantie-meta-analyse-nuanceert-het-probleem/","published":"2022-09-07"},{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2016/10/14/2016-esc-eas-richtlijn-voor-het-management-van-dyslipidemieen/","published":"2016-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a-c","type":"person","url":"https://hartvaat.nl/mensen/a-c/","name":"A. C.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/01/21/genetische-test-bij-cardiomyopathie-huidige-britse-criteria-missen-een-op-de-zev/","published":"2026-01-21"},{"url":"https://hartvaat.nl/2026/01/16/nt-probnp-voorspelt-sterfte-na-een-stemi-onafhankelijk-van-de-ejectiefractie/","published":"2026-01-16"},{"url":"https://hartvaat.nl/2026/01/06/machine-learning-algoritme-mi3-helpt-een-infarct-uitsluiten-bij-een-onduidelijke/","published":"2026-01-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a-m","type":"person","url":"https://hartvaat.nl/mensen/a-m/","name":"A. M.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/24/crt-bij-volwassenen-met-systemische-rechterventrikel-gemengde-uitkomsten-in-inte/","published":"2026-05-09"},{"url":"https://hartvaat.nl/2026/04/24/verminderde-nierfunctie-verhoogt-hartfalenrisico-bij-ouderen-aspree-cohort/","published":"2026-05-08"},{"url":"https://hartvaat.nl/2026/03/31/titine-cardiomyopathie-meestal-dcm-of-linksdominante-acm-met-blijvend-ritmestoor/","published":"2026-03-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a-o","type":"person","url":"https://hartvaat.nl/mensen/a-o/","name":"A. O.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/10/risicostratificatie-bij-longembolie-hoe-bruikbaar-zijn-de-huidige-instrumenten/","published":"2026-07-24"},{"url":"https://hartvaat.nl/2026/03/25/vier-klinische-fenotypes-bij-coronairlijden-met-sterk-verschillend-risico-op-nie/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/01/30/lager-opleidingsniveau-hangt-samen-met-meer-halsslagaderplaques-los-van-risicofa/","published":"2026-01-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"a-s","type":"person","url":"https://hartvaat.nl/mensen/a-s/","name":"A. S.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/03/31/titine-cardiomyopathie-meestal-dcm-of-linksdominante-acm-met-blijvend-ritmestoor/","published":"2026-03-31"},{"url":"https://hartvaat.nl/2026/02/06/jonge-patienten-met-een-hartinfarct-meer-leefstijl-en-psychosociale-risicofactor/","published":"2026-02-06"},{"url":"https://hartvaat.nl/2026/01/27/minimaal-invasieve-mitralisklepchirurgie-sneller-herstel-even-veilig-als-de-conv/","published":"2026-01-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aadil-shaukat","type":"person","url":"https://hartvaat.nl/mensen/aadil-shaukat/","name":"Aadil Shaukat","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/12/01/post-stenting-ffr-versus-angiografie-voor-pci-optimalisatie-target-ffr/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2020/05/01/pci-versus-medicamenteus-bij-angina-met-ffr-in-de-grijze-zone/","published":"2020-05-01"},{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","published":"2019-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"abbas-dehghan","type":"person","url":"https://hartvaat.nl/mensen/abbas-dehghan/","name":"Abbas Dehghan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/11/13/bloeddrukverlaging-en-risico-op-diabetes-type-2-lancet-bplttc-ipd-meta-analyse/","published":"2021-11-13"},{"url":"https://hartvaat.nl/2021/02/01/urinezuur-bloeddruk-en-cv-ziekte-mendeliaanse-randomisatie-en-meta-analyse/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2019/08/20/dna-methylering-in-leukocyten-voorspelt-mi-en-coronairlijden/","published":"2019-08-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ad-j-van-boven","type":"person","url":"https://hartvaat.nl/mensen/ad-j-van-boven/","name":"Ad J van Boven","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","published":"2019-11-07"},{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","published":"2019-04-09"},{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","published":"2016-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adam-j-lewandowski","type":"person","url":"https://hartvaat.nl/mensen/adam-j-lewandowski/","name":"Adam J Lewandowski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/11/01/bloeddrukzelfmanagement-en-vasculaire-remodelling-na-hypertensieve-zwangerschap/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/02/13/pop-ht-bloeddrukzelfmanagement-verbetert-cardiale-remodelling-na-hypertensieve-z/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2023/11/28/pop-ht-zelfmanagement-van-bloeddruk-na-hypertensieve-zwangerschap-jama-rct/","published":"2023-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adam-r-glassman","type":"person","url":"https://hartvaat.nl/mensen/adam-r-glassman/","name":"Adam R Glassman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/08/25/aflibercept-versus-bevacizumab-eerst-bij-diabetisch-macula-oedeem/","published":"2022-08-25"},{"url":"https://hartvaat.nl/2020/12/15/aflibercept-versus-vitrectomie-bij-diabetische-glasvochtbloeding-jama-drcr-net-p/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2019/05/21/aflibercept-versus-fotocoagulatie-versus-observatie-bij-diabetisch-maculaoedeem-/","published":"2019-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adam-s-cifu","type":"person","url":"https://hartvaat.nl/mensen/adam-s-cifu/","name":"Adam S Cifu","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/06/08/interventies-bij-secundaire-mitralisklepinsufficientie-jama-klinisch-overzicht/","published":"2021-06-08"},{"url":"https://hartvaat.nl/2021/01/05/management-van-pfo-patienten-met-cva-of-tia-jama-klinisch-overzicht/","published":"2021-01-05"},{"url":"https://hartvaat.nl/2019/03/19/management-van-af-jama-klinisch-overzicht/","published":"2019-03-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adam-stefanski","type":"person","url":"https://hartvaat.nl/mensen/adam-stefanski/","name":"Adam Stefanski","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/12/20/orforglipron-bij-obesitas-nejm-definitieve-fase-3-resultaten/","published":"2025-12-20"},{"url":"https://hartvaat.nl/2025/11/06/orforglipron-voor-obesitasbehandeling-nejm-fase-3/","published":"2025-11-06"},{"url":"https://hartvaat.nl/2024/09/16/tirzepatide-en-bloeddrukverlaging-surmount-1-gestratificeerde-analyse/","published":"2024-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aditya-surapaneni","type":"person","url":"https://hartvaat.nl/mensen/aditya-surapaneni/","name":"Aditya Surapaneni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2021/09/01/albuminurietesting-bij-hypertensie-en-diabetes-ipd-meta-analyse/","published":"2021-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adrian-baranchuk","type":"person","url":"https://hartvaat.nl/mensen/adrian-baranchuk/","name":"Adrian Baranchuk","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/02/16/technieken-om-cardioversiesucces-bij-af-te-verbeteren-meta-analyse/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2021/08/06/orale-antiaritmica-voor-cardioversie-van-recent-onset-af-netwerkmeta-analyse/","published":"2021-08-06"},{"url":"https://hartvaat.nl/2019/08/01/vernakalant-voor-cardioversie-van-recent-onset-af-meta-analyse/","published":"2019-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adrian-ma","type":"person","url":"https://hartvaat.nl/mensen/adrian-ma/","name":"Adrian Ma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"adriana-m-hung","type":"person","url":"https://hartvaat.nl/mensen/adriana-m-hung/","name":"Adriana M Hung","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/08/01/hele-genoomsequencing-onthult-nieuwe-bloeddruk-loci/","published":"2022-08-01"},{"url":"https://hartvaat.nl/2021/05/05/intensieve-bloeddruk-en-aortastijfheid-sprint-heart/","published":"2021-05-05"},{"url":"https://hartvaat.nl/2020/02/01/bloeddrukcontrole-en-diabetes-incidentie-sprint-resultaten/","published":"2020-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aernoud-t-l-fiolet","type":"person","url":"https://hartvaat.nl/mensen/aernoud-t-l-fiolet/","name":"Aernoud T L Fiolet","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","published":"2025-07-07"},{"url":"https://hartvaat.nl/2021/08/31/colchicine-bij-chronisch-coronairlijden-met-versus-zonder-eerder-acs/","published":"2021-08-31"},{"url":"https://hartvaat.nl/2021/07/21/laaggedoseerd-colchicine-bij-coronairlijden-meta-analyse-van-gerandomiseerde-tri/","published":"2021-07-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aeron-m-small","type":"person","url":"https://hartvaat.nl/mensen/aeron-m-small/","name":"Aeron M Small","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2024/04/01/lp-a-en-hscrp-als-cv-risicofactoren-primaire-en-secundaire-preventie/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2023/06/01/genetische-bijdrage-aan-aortastenose-dyslipidemie-inflammatie-en-verkalking/","published":"2023-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ahmad","type":"person","url":"https://hartvaat.nl/mensen/ahmad/","name":"Ahmad","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/17/direct-naar-ct-coronairangiografie-bij-verdenking-angina-snellere-diagnose-en-mi/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/04/10/tweelingzwangerschap-bij-vrouwen-met-een-hartaandoening-geeft-een-hoog-risico-op/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/04/24/relatieve-apicale-sparing-op-strain-echo-voor-cardiale-amyloidose-meta-analyse-v/","published":"2026-07-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ahmed-abdelalim","type":"person","url":"https://hartvaat.nl/mensen/ahmed-abdelalim/","name":"Ahmed Abdelalim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ahmed-elghamaz","type":"person","url":"https://hartvaat.nl/mensen/ahmed-elghamaz/","name":"Ahmed Elghamaz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","published":"2020-11-03"},{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","published":"2020-04-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ahmed-nasreldein","type":"person","url":"https://hartvaat.nl/mensen/ahmed-nasreldein/","name":"Ahmed Nasreldein","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aishwarya-krishnaraj","type":"person","url":"https://hartvaat.nl/mensen/aishwarya-krishnaraj/","name":"Aishwarya Krishnaraj","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/03/09/semaglutide-stimuleert-anti-inflammatoire-stamcelflux-vanuit-beenmerg/","published":"2026-03-09"},{"url":"https://hartvaat.nl/2026/02/19/evolocumab-en-doorgankelijkheid-van-veneuze-bypasses-na-cabg-newton-cabg-cardiol/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aitor-uribarri","type":"person","url":"https://hartvaat.nl/mensen/aitor-uribarri/","name":"Aitor Uribarri","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/03/25/palliatieve-zorg-in-de-cardiologie-een-state-of-the-art-overzicht/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/02/19/delirium-in-de-cardiovasculaire-geneeskunde/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/01/20/es-bempedacs-triple-versus-duale-lipidenbehandeling-na-acs/","published":"2026-01-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ajay-gupta","type":"person","url":"https://hartvaat.nl/mensen/ajay-gupta/","name":"Ajay Gupta","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/07/28/ascot-legacy-atorvastatine-verlaagt-cv-events-over-20-jaar/","published":"2025-07-28"},{"url":"https://hartvaat.nl/2018/09/29/langetermijnmortaliteit-na-bloeddruk-en-lipidenverlaging-bij-hypertensie-ascot-l/","published":"2018-09-29"},{"url":"https://hartvaat.nl/2017/06/24/bijwerkingen-bij-niet-geblindeerde-versus-geblindeerde-statinetherapie-lancet-as/","published":"2017-06-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ajay-m-shah","type":"person","url":"https://hartvaat.nl/mensen/ajay-m-shah/","name":"Ajay M Shah","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/10/13/revived-bcis2-pci-verbetert-overleving-niet-bij-ischemische-lv-disfunctie/","published":"2022-10-13"},{"url":"https://hartvaat.nl/2019/05/21/ijzerisomaltosides-en-skeletspierdenergie-bij-chronisch-hf-met-ijzerdeficientie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2018/03/01/medicamenteuze-behandeling-en-uitkomsten-bij-hfpef-systematische-review-en-meta-/","published":"2018-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"akihiro-sunaga","type":"person","url":"https://hartvaat.nl/mensen/akihiro-sunaga/","name":"Akihiro Sunaga","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/09/01/nierfunctie-en-effectiviteit-van-lva-ablatie-na-pvi-bij-af/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2021/04/06/pvi-alleen-versus-uitgebreide-ablatie-bij-persisterend-af-meta-analyse/","published":"2021-04-06"},{"url":"https://hartvaat.nl/2018/09/01/pace-capture-geleide-ablatie-na-contact-force-pvi-dragon-gerandomiseerde-trial/","published":"2018-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alain-combes","type":"person","url":"https://hartvaat.nl/mensen/alain-combes/","name":"Alain Combes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/02/19/delirium-in-de-cardiovasculaire-geneeskunde/","published":"2026-02-19"},{"url":"https://hartvaat.nl/2026/01/06/levoecmo-levosimendan-bij-ecmo-weaning-bij-cardiogene-shock/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2022/02/01/matige-hypothermie-versus-normothermie-bij-cardiogene-shock-met-va-ecmo-jama-hyp/","published":"2022-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alain-furber","type":"person","url":"https://hartvaat.nl/mensen/alain-furber/","name":"Alain Furber","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","published":"2024-10-10"},{"url":"https://hartvaat.nl/2016/04/26/vroege-aldosteronblokkade-bij-acuut-myocardinfarct-de-albatross-trial/","published":"2016-04-26"},{"url":"https://hartvaat.nl/2016/01/21/stoppen-of-doorgaan-met-clopidogrel-12-maanden-na-drug-eluting-stent-optidual-tr/","published":"2016-01-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alain-g-bertoni","type":"person","url":"https://hartvaat.nl/mensen/alain-g-bertoni/","name":"Alain G Bertoni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2020/12/22/lichaamssamenstelling-en-risico-op-hartfalen-en-mi-prospectieve-analyse/","published":"2020-12-22"},{"url":"https://hartvaat.nl/2020/09/22/sekse-specifieke-cv-risicofactoren-en-biomarkers-bij-incident-hartfalen/","published":"2020-09-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alan-hinderliter","type":"person","url":"https://hartvaat.nl/mensen/alan-hinderliter/","name":"Alan Hinderliter","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/07/27/heeft-deze-volwassene-hypertensie-jama-rational-clinical-examination/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2016/04/05/hartrevalidatie-versterkt-met-stressmanagementtraining-gerandomiseerde-trial/","published":"2016-04-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alan-j-lerner","type":"person","url":"https://hartvaat.nl/mensen/alan-j-lerner/","name":"Alan J Lerner","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2016/08/01/apol1-nierrisicovarianten-en-cerebrale-wittestoflaesies/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alan-s-rigby","type":"person","url":"https://hartvaat.nl/mensen/alan-s-rigby/","name":"Alan S Rigby","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/06/20/hartfrequentie-en-ritme-en-het-voordeel-van-betablokkers-bij-hartfalen/","published":"2017-06-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alastair-j-moss","type":"person","url":"https://hartvaat.nl/mensen/alastair-j-moss/","name":"Alastair J Moss","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2020/05/05/laag-attenuatie-plaque-op-ccta-voorspelt-mi-scot-heart-resultaten/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/01/29/coronaire-plaquekenmerken-en-adverse-uitkomsten-scot-heart/","published":"2019-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"albert-c-van-rossum","type":"person","url":"https://hartvaat.nl/mensen/albert-c-van-rossum/","name":"Albert C van Rossum","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/10/01/trimetazidine-bij-hfpef-gerandomiseerde-cross-over-trial/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2019/01/29/microvasculaire-schade-bij-gerevasculariseerde-stemi-met-ticagrelor-versus-prasu/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2016/10/11/pci-van-chronische-totale-occlusie-bij-stemi-met-multivatenlijden-explore-trial/","published":"2016-10-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alberto-fior","type":"person","url":"https://hartvaat.nl/mensen/alberto-fior/","name":"Alberto Fior","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aldobrando-broccolini","type":"person","url":"https://hartvaat.nl/mensen/aldobrando-broccolini/","name":"Aldobrando Broccolini","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alec-vahanian","type":"person","url":"https://hartvaat.nl/mensen/alec-vahanian/","name":"Alec Vahanian","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","published":"2024-12-10"},{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","published":"2024-11-14"},{"url":"https://hartvaat.nl/2018/12/13/percutaan-herstel-of-medicamenteuze-therapie-bij-secundaire-mr-nejm-mitra-fr/","published":"2018-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aleksander-prejbisz","type":"person","url":"https://hartvaat.nl/mensen/aleksander-prejbisz/","name":"Aleksander Prejbisz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2020/07/01/phactr1-en-fibromusculaire-dysplasie-arcadia-pol-meta-analyse/","published":"2020-07-01"},{"url":"https://hartvaat.nl/2018/08/01/renale-denervatie-bij-resistente-hypertensie-met-obstructieve-slaapapneu-proof-o/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2018/01/01/bijniervenesampling-als-voorkeursmethode-bij-primair-hyperaldosteronisme/","published":"2018-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ales-linhart","type":"person","url":"https://hartvaat.nl/mensen/ales-linhart/","name":"Ales Linhart","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/01/16/watchful-leefstijl-wandelinterventie-bij-hfref/","published":"2024-01-16"},{"url":"https://hartvaat.nl/2023/02/07/ecmo-cs-ecmo-bij-cardiogene-shock-verbetert-overleving-niet/","published":"2023-02-07"},{"url":"https://hartvaat.nl/2020/10/01/accelerometrie-bij-cv-patienten-systematische-review-met-praktische-aanbevelinge/","published":"2020-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alessandro-lupi","type":"person","url":"https://hartvaat.nl/mensen/alessandro-lupi/","name":"Alessandro Lupi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/05/23/stralingsblootstelling-en-vasculaire-toegang-bij-acs-rad-matrix-trial/","published":"2017-05-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alessandro-sticchi","type":"person","url":"https://hartvaat.nl/mensen/alessandro-sticchi/","name":"Alessandro Sticchi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"},{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alessio-gargaro","type":"person","url":"https://hartvaat.nl/mensen/alessio-gargaro/","name":"Alessio Gargaro","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/07/02/closed-loop-stimulatie-vermindert-ahre-s-versus-conventionele-rate-adaptieve-pac/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2022/06/21/timing-van-vt-ablatie-bij-icd-patienten-partita-trial/","published":"2022-06-21"},{"url":"https://hartvaat.nl/2022/02/02/thuismonitoring-temporele-trends-en-baseline-risico-voor-hf-voorspelling-bij-icd/","published":"2022-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alex-r-chang","type":"person","url":"https://hartvaat.nl/mensen/alex-r-chang/","name":"Alex R Chang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/09/01/albuminurietesting-bij-hypertensie-en-diabetes-ipd-meta-analyse/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2021/06/01/dieet-en-natriumreductie-op-cardiale-schade-en-inflammatie-dash-sodium/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2016/02/04/risicoprojectie-voor-nierfalen-bij-levende-nierdonorkandidaten/","published":"2016-02-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexander-c-razavi","type":"person","url":"https://hartvaat.nl/mensen/alexander-c-razavi/","name":"Alexander C Razavi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/22/il-6-sterker-met-hart-en-vaatziekte-geassocieerd-dan-ldl-lp-a-en-crp/","published":"2026-05-22"},{"url":"https://hartvaat.nl/2026/02/21/aspirine-lipoproteine-a-en-aortaklepstenose-de-mesa-studie/","published":"2026-02-21"},{"url":"https://hartvaat.nl/2022/08/01/hele-genoomsequencing-onthult-nieuwe-bloeddruk-loci/","published":"2022-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexander-p-auchus","type":"person","url":"https://hartvaat.nl/mensen/alexander-p-auchus/","name":"Alexander P Auchus","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/04/01/intensieve-versus-standaard-bloeddruk-op-cva-subtypes-sprint/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexander-peikert","type":"person","url":"https://hartvaat.nl/mensen/alexander-peikert/","name":"Alexander Peikert","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2024/06/01/invested-griepvaccin-immuunrespons-bij-hoog-risico-cv-patienten/","published":"2024-06-01"},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","published":"2023-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexander-r-lyon","type":"person","url":"https://hartvaat.nl/mensen/alexander-r-lyon/","name":"Alexander R Lyon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/19/ehj-review-dyslipidemie-bij-kankerpatienten-verhoogd-ascvd-risico-beperkte-data-/","published":"2026-06-14"},{"url":"https://hartvaat.nl/2026/02/03/atriumfibrilleren-bij-kankerpatienten-de-esc-richtlijn-2025-in-de-praktijk/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2016/03/19/serca2a-gentherapie-bij-hartfalen-de-cupid-2-trial/","published":"2016-03-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexander-r-zheutlin","type":"person","url":"https://hartvaat.nl/mensen/alexander-r-zheutlin/","name":"Alexander R Zheutlin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/10/28/prevent-vergelijkingen-voor-intensieve-versus-standaard-bloeddrukcontrole/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2023/08/01/combinatietabletten-voor-intensieve-bloeddrukbehandeling-sprint-analyse/","published":"2023-08-01"},{"url":"https://hartvaat.nl/2023/07/01/leeftijdsbias-draagt-bij-aan-therapeutische-inertie-bij-bloeddrukmanagement/","published":"2023-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexandra-arias-mendoza","type":"person","url":"https://hartvaat.nl/mensen/alexandra-arias-mendoza/","name":"Alexandra Arias-Mendoza","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/08/29/stream-2-halve-dosis-tenecteplase-bij-ouderen-met-stemi/","published":"2023-08-29"},{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","published":"2021-01-14"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexandra-rousseau","type":"person","url":"https://hartvaat.nl/mensen/alexandra-rousseau/","name":"Alexandra Rousseau","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","published":"2022-02-08"},{"url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","published":"2021-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexandra-scrymgeour","type":"person","url":"https://hartvaat.nl/mensen/alexandra-scrymgeour/","name":"Alexandra Scrymgeour","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/12/23/top-liberaal-versus-restrictief-transfusiebeleid-bij-hoogrisico-hartchirurgie/","published":"2025-12-23"},{"url":"https://hartvaat.nl/2024/03/26/grade-cv-uitkomsten-van-glucoseverlagende-middelen-bij-type-2-diabetes/","published":"2024-03-26"},{"url":"https://hartvaat.nl/2019/01/10/endoscopische-versus-open-veneoogst-bij-cabg-nejm-regroup/","published":"2019-01-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexandre-almorad","type":"person","url":"https://hartvaat.nl/mensen/alexandre-almorad/","name":"Alexandre Almorad","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/02/03/varipure-studie-pulsed-field-ablatie-in-de-dagelijkse-af-praktijk/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2024/12/03/pfa-versus-cryoballon-voor-af-ablatie-multielectrode-vergelijking/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2019/08/01/eenvoudige-techniek-voor-pvi-van-linker-longvenen-gerandomiseerde-studie/","published":"2019-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexandre-soeiro","type":"person","url":"https://hartvaat.nl/mensen/alexandre-soeiro/","name":"Alexandre Soeiro","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2019/12/17/uitgebreide-vasodilatatie-versus-standaardzorg-bij-acuut-hf-jama-galactic-hf-pil/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2019/06/11/sonotrombolyse-bij-stemi-behandeld-met-primaire-pci/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2016/05/31/diagnostische-ultrageluidspulsen-verbeteren-microvasculaire-flow-bij-stemi-met-m/","published":"2016-05-31"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alexios-karagiannis","type":"person","url":"https://hartvaat.nl/mensen/alexios-karagiannis/","name":"Alexios Karagiannis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2019/07/01/lokale-hemodynamische-krachten-en-fenotype-van-coronaire-plaques/","published":"2019-07-01"},{"url":"https://hartvaat.nl/2018/08/07/adenosine-en-ticagrelorspiegels-bij-patienten-met-en-zonder-ticagrelor-dyspneu/","published":"2018-08-07"},{"url":"https://hartvaat.nl/2018/03/20/effecten-van-ticagrelor-prasugrel-of-clopidogrel-op-endotheelfunctie/","published":"2018-03-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"alfonso-ielasi","type":"person","url":"https://hartvaat.nl/mensen/alfonso-ielasi/","name":"Alfonso Ielasi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","published":"2026-01-17"},{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","published":"2021-03-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"allan-skanes","type":"person","url":"https://hartvaat.nl/mensen/allan-skanes/","name":"Allan Skanes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","published":"2023-01-12"},{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","published":"2022-06-07"},{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","published":"2021-01-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"allen-jeremias","type":"person","url":"https://hartvaat.nl/mensen/allen-jeremias/","name":"Allen Jeremias","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/07/15/oct-gebaseerde-post-pci-fysiologiebeoordeling-voorspelt-klinische-uitkomsten/","published":"2025-07-15"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"almeida","type":"person","url":"https://hartvaat.nl/mensen/almeida/","name":"Almeida","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/24/bayesiaanse-netwerkmeta-analyse-vergelijkt-revascularisatie-bij-stabiele-ischemi/","published":"2026-05-10"},{"url":"https://hartvaat.nl/2026/01/27/minimaal-invasieve-mitralisklepchirurgie-sneller-herstel-even-veilig-als-de-conv/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2026/01/16/sekseverschillen-na-tavi-vrouwen-lagere-sterfte-bij-intermediair-risico-maar-mee/","published":"2026-01-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amanda-stebbins","type":"person","url":"https://hartvaat.nl/mensen/amanda-stebbins/","name":"Amanda Stebbins","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/09/01/aspirinedosering-voor-secundaire-preventie-bij-mannen-versus-vrouwen/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","published":"2023-11-01"},{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-bij-stabiel-coronairlijden-stability-inzic/","published":"2017-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ameer-kabour","type":"person","url":"https://hartvaat.nl/mensen/ameer-kabour/","name":"Ameer Kabour","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/07/18/bioresorbeerbare-coronaire-scaffolds-vijfjaarsuitkomsten-met-verbeterde-techniek/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2018/10/27/absorb-iv-bioresorbeerbare-scaffold-30-daags-en-1-jaarsresultaten/","published":"2018-10-27"},{"url":"https://hartvaat.nl/2017/12/12/3-jaarsresultaten-van-bioresorbeerbare-scaffolds-absorb-iii-trial/","published":"2017-12-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amil-m-shah","type":"person","url":"https://hartvaat.nl/mensen/amil-m-shah/","name":"Amil M Shah","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","published":"2022-10-04"},{"url":"https://hartvaat.nl/2019/12/10/echocardiografische-kenmerken-bij-hfpef/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2017/09/12/lichamelijke-activiteit-en-prognose-bij-hfpef-topcat-analyse/","published":"2017-09-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amirhossein-sahebkar","type":"person","url":"https://hartvaat.nl/mensen/amirhossein-sahebkar/","name":"Amirhossein Sahebkar","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2026/02/24/lipide-aferese-verlaagt-lp-a-met-60-75-systematische-review-en-meta-analyse/","published":"2026-02-24"},{"url":"https://hartvaat.nl/2022/09/07/prevalentie-van-statine-intolerantie-meta-analyse-nuanceert-het-probleem/","published":"2022-09-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amit-n-vora","type":"person","url":"https://hartvaat.nl/mensen/amit-n-vora/","name":"Amit N Vora","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","published":"2020-03-03"},{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","published":"2019-04-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amra-karegren","type":"person","url":"https://hartvaat.nl/mensen/amra-karegren/","name":"Amra Kåregren","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/03/15/5-jaars-ifr-versus-ffr-geleide-pci-define-flair-ifr-swedeheart/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","published":"2021-11-02"},{"url":"https://hartvaat.nl/2017/05/11/instantaneous-wave-free-ratio-versus-ffr-voor-pci-indicatie-nejm-ifr-swedeheart/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amret-t-hawfield","type":"person","url":"https://hartvaat.nl/mensen/amret-t-hawfield/","name":"Amret T Hawfield","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2020/12/01/intensieve-bloeddrukcontrole-en-alle-hospitalisaties-sprint/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2016/08/01/apol1-nierrisicovarianten-en-cerebrale-wittestoflaesies/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amy-m-pastva","type":"person","url":"https://hartvaat.nl/mensen/amy-m-pastva/","name":"Amy M Pastva","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/02/01/fysieke-revalidatie-bij-fragiele-ouderen-met-acuut-hartfalen/","published":"2023-02-01"},{"url":"https://hartvaat.nl/2022/02/01/economische-uitkomsten-van-revalidatie-bij-ouderen-met-acuut-hf-rehab-hf/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2021/07/15/fysieke-revalidatie-bij-oudere-gehospitaliseerde-hf-patienten-nejm-rehab-hf/","published":"2021-07-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"amy-wohltman","type":"person","url":"https://hartvaat.nl/mensen/amy-wohltman/","name":"Amy Wohltman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/10/07/nieuwe-inspanningsherstelpatronen-als-maat-voor-cardiale-prestatie/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","published":"2023-01-03"},{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","published":"2022-07-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ana-catarina-fonseca","type":"person","url":"https://hartvaat.nl/mensen/ana-catarina-fonseca/","name":"Ana Catarina Fonseca","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ana-catarina-pinho-gomes","type":"person","url":"https://hartvaat.nl/mensen/ana-catarina-pinho-gomes/","name":"Ana-Catarina Pinho-Gomes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/07/27/langetermijneffect-van-antihypertensiva-op-bloeddruk-meta-analyse-op-individueel/","published":"2022-07-27"},{"url":"https://hartvaat.nl/2020/10/01/thuismonitoring-met-technologie-ondersteund-management-bij-chronisch-hf-gerandom/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2018/02/13/richtlijngetrouwe-medicamenteuze-therapie-in-contemporaine-revascularisatietrial/","published":"2018-02-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anand-thiyagarajah","type":"person","url":"https://hartvaat.nl/mensen/anand-thiyagarajah/","name":"Anand Thiyagarajah","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/09/01/af-voorspelt-cognitieve-achteruitgang-meta-analyse-van-2-8-miljoen-personen/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2020/01/01/obesitas-opzettelijk-gewichtsverlies-en-hartfalen-meta-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2018/04/21/subklinisch-device-gedetecteerd-af-en-cva-risico-meta-analyse/","published":"2018-04-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anastase-dzudie","type":"person","url":"https://hartvaat.nl/mensen/anastase-dzudie/","name":"Anastase Dzudie","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2022/11/01/antihypertensieve-combinaties-bij-afrikaanse-patienten-creole-secundaire-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2019/06/20/vergelijking-van-duale-therapieen-voor-bloeddrukverlaging-bij-afrikaanse-afrikan/","published":"2019-06-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anastasios-kollias","type":"person","url":"https://hartvaat.nl/mensen/anastasios-kollias/","name":"Anastasios Kollias","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/01/esh-convenant-polshorloges-bloeddrukmeters-acceptabele-nauwkeurigheid-maar-klini/","published":"2026-09-02"},{"url":"https://hartvaat.nl/2024/07/01/af-screening-tijdens-bloeddrukmeting-diagnostische-nauwkeurigheid/","published":"2024-07-01"},{"url":"https://hartvaat.nl/2016/01/01/centrale-versus-perifere-bloeddruk-en-doelorgaanschade-systematische-review-en-m/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anda-bularga","type":"person","url":"https://hartvaat.nl/mensen/anda-bularga/","name":"Anda Bularga","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/01/01/de-troponine-i-t-ratio-bij-myocardschade-een-multicohort-synthese/","published":"2026-03-02"},{"url":"https://hartvaat.nl/2025/11/11/risicostratificatie-met-hoog-sensitief-troponine-op-de-seh-veiligheidsanalyse/","published":"2025-11-11"},{"url":"https://hartvaat.nl/2022/01/13/risicofactoren-voor-type-1-en-type-2-mi/","published":"2022-01-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anders-sommer","type":"person","url":"https://hartvaat.nl/mensen/anders-sommer/","name":"Anders Sommer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/08/02/gerichte-lv-leadplaatsing-bij-crt-meta-analyse-van-beeldvorming-en-elektrisch-ge/","published":"2023-08-02"},{"url":"https://hartvaat.nl/2022/05/03/multimodaliteitsbeeldvorming-geleide-lv-leadplaatsing-bij-crt-langetermijn/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2019/09/01/elektrisch-versus-beeldvorming-geleide-lv-leadplaatsing-bij-crt-gerandomiseerde-/","published":"2019-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrea-ruzza","type":"person","url":"https://hartvaat.nl/mensen/andrea-ruzza/","name":"Andrea Ruzza","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2020/10/01/evolocumab-bij-pediatrische-heterozygoot-fh-nejm-hauser-rct/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2020/05/12/cognitie-na-ldl-verlaging-met-evolocumab-fourier-follow-up/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2019/10/29/langetermijn-werkzaamheid-en-veiligheid-van-evolocumab-bij-hypercholesterolemie/","published":"2019-10-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrea-scotti","type":"person","url":"https://hartvaat.nl/mensen/andrea-scotti/","name":"Andrea Scotti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/16/pandora-register-supra-versus-intra-annulaire-kleppen-bij-tavr-in-tavr/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","published":"2026-03-23"},{"url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","published":"2023-07-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrea-zini","type":"person","url":"https://hartvaat.nl/mensen/andrea-zini/","name":"Andrea Zini","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andreas-b-gevaert","type":"person","url":"https://hartvaat.nl/mensen/andreas-b-gevaert/","name":"Andreas B Gevaert","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/06/01/trainingseffect-op-diastolische-functie-bij-hfpef/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2021/08/01/klinische-fenotypen-zijn-effectiever-dan-ef-categorieen-voor-hf-uitkomsten/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2021/02/09/hiit-matig-continu-of-richtlijnadvies-en-piek-vo2-bij-hfref-jama-smartex-hf/","published":"2021-02-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andreas-bollmann","type":"person","url":"https://hartvaat.nl/mensen/andreas-bollmann/","name":"Andreas Bollmann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/03/10/mondiale-prevalentie-uitkomsten-en-kosten-van-hartfalen-careme-studie/","published":"2023-03-10"},{"url":"https://hartvaat.nl/2023/02/16/p-golfduur-voorspelt-af-recidief-na-catheterablatie-meta-analyse/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2018/11/01/individueel-aangepaste-versus-gestandaardiseerde-substraatmodificatie-bij-rf-abl/","published":"2018-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andreas-brieke","type":"person","url":"https://hartvaat.nl/mensen/andreas-brieke/","name":"Andreas Brieke","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","published":"2021-03-02"},{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","published":"2018-12-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andreas-fach","type":"person","url":"https://hartvaat.nl/mensen/andreas-fach/","name":"Andreas Fach","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/12/16/gp-iib-iiia-remmers-bij-acuut-mi-en-microvasculaire-obstructie-meta-analyse/","published":"2024-12-16"},{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","published":"2018-11-01"},{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","published":"2017-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andreas-l-birkenfeld","type":"person","url":"https://hartvaat.nl/mensen/andreas-l-birkenfeld/","name":"Andreas L Birkenfeld","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/03/05/finerenon-effectief-bij-type-1-diabetes-met-chronische-nierziekte/","published":"2026-03-12"},{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","published":"2025-06-10"},{"url":"https://hartvaat.nl/2019/08/29/orale-semaglutide-en-cv-uitkomsten-bij-diabetes-type-2-nejm-pioneer-6/","published":"2019-08-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andreas-rieth","type":"person","url":"https://hartvaat.nl/mensen/andreas-rieth/","name":"Andreas Rieth","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/02/03/kenmerken-van-asymptomatische-patienten-met-hartfalen-en-verminderde-ejectiefrac/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/09/25/digitoxine-bij-hfref-gerandomiseerde-trial-nejm/","published":"2025-09-25"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andreas-schuster","type":"person","url":"https://hartvaat.nl/mensen/andreas-schuster/","name":"Andreas Schuster","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/05/reduce-mfa-dzhk25-trial-naar-antifibrotische-therapie-tegen-myocardfibrose-na-ta/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrei-mircea-catarig","type":"person","url":"https://hartvaat.nl/mensen/andrei-mircea-catarig/","name":"Andrei-Mircea Catarig","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/03/05/semaglutide-bij-perifeer-arterieel-vaatlijden-en-diabetes-stride-trial/","published":"2026-03-20"},{"url":"https://hartvaat.nl/2025/11/18/sekseverschillen-in-semaglutide-effect-bij-pad-stride-subanalyse/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2025/05/03/semaglutide-en-loopafstand-bij-perifeer-vaatlijden-en-diabetes/","published":"2025-05-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andres-m-pineda","type":"person","url":"https://hartvaat.nl/mensen/andres-m-pineda/","name":"Andres M Pineda","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/04/12/orbitale-atherectomie-versus-ballonangioplastie-voor-des-bij-ernstig-verkalkte-l/","published":"2025-04-12"},{"url":"https://hartvaat.nl/2020/10/13/laaggedoseerd-ticagrelor-versus-standaard-clopidogrel-bij-diabetes-farmacodynami/","published":"2020-10-13"},{"url":"https://hartvaat.nl/2019/04/02/cangrelor-en-gemalen-ticagrelor-bij-stemi-met-primaire-pci/","published":"2019-04-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-farmer","type":"person","url":"https://hartvaat.nl/mensen/andrew-farmer/","name":"Andrew Farmer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2018/10/18/omega-3-vetzuursupplementen-bij-diabetes-nejm-ascend-omega-3/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2018/10/18/aspirine-voor-primaire-preventie-bij-diabetes-nejm-ascend/","published":"2018-10-18"},{"url":"https://hartvaat.nl/2018/03/10/zelfgemeten-bloeddruk-met-of-zonder-telemonitoring-voor-medicatietitratie-lancet/","published":"2018-03-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-hsieh","type":"person","url":"https://hartvaat.nl/mensen/andrew-hsieh/","name":"Andrew Hsieh","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/25/obicetrapib-verlaagt-naast-ldl-en-apob-ook-lipoproteine-a/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2025/10/07/obicetrapib-en-mace-bij-hoogrisicopatienten-gepoolde-analyse/","published":"2025-10-07"},{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","published":"2025-07-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-j-boyle","type":"person","url":"https://hartvaat.nl/mensen/andrew-j-boyle/","name":"Andrew J Boyle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/07/01/behandeling-van-acuut-coronair-syndroom-in-ruraal-australie-moracs-trial/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2021/07/01/camkii-delta-remming-en-ventriculaire-remodellering-na-mi-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2017/05/23/hemocompatibiliteitsuitkomsten-van-heartmate-3-na-6-maanden-momentum-3/","published":"2017-05-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-j-sauer","type":"person","url":"https://hartvaat.nl/mensen/andrew-j-sauer/","name":"Andrew J Sauer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/06/01/humain-hfpef-nieuwe-metabole-accelerator-bij-obesitas-hfpef-rct/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2025/06/01/nierfunctie-en-dapagliflozine-effect-op-gezondheidsstatus-define-hf/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2021/09/11/hemodynamisch-geleid-hf-management-lancet-guide-hf/","published":"2021-09-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-j-taylor","type":"person","url":"https://hartvaat.nl/mensen/andrew-j-taylor/","name":"Andrew J Taylor","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2020/01/02/alcoholonthouding-bij-drinkers-met-af-nejm-gerandomiseerde-trial/","published":"2020-01-02"},{"url":"https://hartvaat.nl/2017/10/17/katheterablatie-versus-frequentiecontrole-bij-af-met-systolische-disfunctie-came/","published":"2017-10-17"},{"url":"https://hartvaat.nl/2016/03/01/effect-van-aanvullende-zuurstoftoediening-op-myocardschade-bij-stemi/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-kaplan","type":"person","url":"https://hartvaat.nl/mensen/andrew-kaplan/","name":"Andrew Kaplan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","published":"2024-01-11"},{"url":"https://hartvaat.nl/2019/10/22/implanteerbare-monitor-voor-snellere-behandeling-bij-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/04/23/implanteerbaar-cardiaal-alertsysteem-voor-vroege-herkenning-van-stemi/","published":"2019-04-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-lin","type":"person","url":"https://hartvaat.nl/mensen/andrew-lin/","name":"Andrew Lin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/05/uk-biobank-na-ischemisch-cva-of-tia-is-het-risico-op-hartfalen-groter-dan-dat-op/","published":"2026-06-29"},{"url":"https://hartvaat.nl/2026/05/27/sglt2-remmers-verminderen-epicardiaal-vetweefsel-meta-analyse-van-11-studies/","published":"2026-05-28"},{"url":"https://hartvaat.nl/2026/05/13/uk-biobank-na-ischemisch-cva-of-tia-is-het-risico-op-hartfalen-groter-dan-dat-op/","published":"2026-05-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-m-goldsweig","type":"person","url":"https://hartvaat.nl/mensen/andrew-m-goldsweig/","name":"Andrew M Goldsweig","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-maiorana","type":"person","url":"https://hartvaat.nl/mensen/andrew-maiorana/","name":"Andrew Maiorana","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/02/23/pathfinder-trial-betere-naleving-van-hartfalenrichtlijnen-in-de-huisartsenprakti/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/05/02/determinanten-van-medicatietrouw-na-acs-secundaire-analyse/","published":"2025-05-02"},{"url":"https://hartvaat.nl/2022/05/10/sms-voor-medicatietrouw-en-secundaire-preventie-na-acs-textmeds/","published":"2022-05-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-s-levey","type":"person","url":"https://hartvaat.nl/mensen/andrew-s-levey/","name":"Andrew S Levey","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","published":"2025-12-02"},{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","published":"2023-10-03"},{"url":"https://hartvaat.nl/2016/02/04/risicoprojectie-voor-nierfalen-bij-levende-nierdonorkandidaten/","published":"2016-02-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-s-mugglin","type":"person","url":"https://hartvaat.nl/mensen/andrew-s-mugglin/","name":"Andrew S Mugglin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/02/01/pulmonaalvenenstenose-na-pfa-versus-thermale-ablatie-vergelijking/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/11/02/advent-pulsed-field-ablatie-non-inferieur-aan-thermale-ablatie-bij-af-nejm/","published":"2023-11-02"},{"url":"https://hartvaat.nl/2019/05/02/tavr-met-zelfexpanderende-klep-bij-laagrisicopatienten-nejm-evolut-low-risk/","published":"2019-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-sherwood","type":"person","url":"https://hartvaat.nl/mensen/andrew-sherwood/","name":"Andrew Sherwood","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/10/12/leefstijlmodificatie-bij-resistente-hypertensie-triumph-gerandomiseerde-trial/","published":"2021-10-12"},{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","published":"2020-08-18"},{"url":"https://hartvaat.nl/2016/04/05/hartrevalidatie-versterkt-met-stressmanagementtraining-gerandomiseerde-trial/","published":"2016-04-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andrew-whitehouse","type":"person","url":"https://hartvaat.nl/mensen/andrew-whitehouse/","name":"Andrew Whitehouse","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/07/28/ascot-legacy-atorvastatine-verlaagt-cv-events-over-20-jaar/","published":"2025-07-28"},{"url":"https://hartvaat.nl/2018/09/29/langetermijnmortaliteit-na-bloeddruk-en-lipidenverlaging-bij-hypertensie-ascot-l/","published":"2018-09-29"},{"url":"https://hartvaat.nl/2017/06/24/bijwerkingen-bij-niet-geblindeerde-versus-geblindeerde-statinetherapie-lancet-as/","published":"2017-06-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andras-komocsi","type":"person","url":"https://hartvaat.nl/mensen/andras-komocsi/","name":"András Komócsi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","published":"2019-06-21"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andre-rivera","type":"person","url":"https://hartvaat.nl/mensen/andre-rivera/","name":"André Rivera","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/02/27/nieuwe-aldosteronsynthase-remmers-bij-hypertensie-bayesiaanse-meta-analyse/","published":"2026-03-08"},{"url":"https://hartvaat.nl/2025/09/01/sedatie-versus-narcose-bij-af-catheterablatie-meta-analyse/","published":"2025-09-01"},{"url":"https://hartvaat.nl/2024/12/01/korte-dapt-na-des-bij-acs-ipd-meta-analyse-bevestigt-veiligheid/","published":"2024-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"andy-yong","type":"person","url":"https://hartvaat.nl/mensen/andy-yong/","name":"Andy Yong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/07/10/intracoronaire-trombolyse-bij-stemi-meta-analyse/","published":"2024-07-10"},{"url":"https://hartvaat.nl/2021/11/09/colchicine-na-acs-2-jaars-cops-follow-up/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2020/11/17/colchicine-bij-acs-australische-cops-gerandomiseerde-trial/","published":"2020-11-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"angela-m-thompson-paul","type":"person","url":"https://hartvaat.nl/mensen/angela-m-thompson-paul/","name":"Angela M Thompson-Paul","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-systematische-review-circulation/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/06/01/systematische-review-voor-de-2017-acc-aha-hypertensierichtlijn-hypertension-edit/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/05/15/systematische-review-voor-de-2017-acc-aha-hypertensierichtlijn/","published":"2018-05-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"angelo-cascio-rizzo","type":"person","url":"https://hartvaat.nl/mensen/angelo-cascio-rizzo/","name":"Angelo Cascio Rizzo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anique-ducharme","type":"person","url":"https://hartvaat.nl/mensen/anique-ducharme/","name":"Anique Ducharme","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/02/13/implanteerbare-hemodynamische-monitoren-verbeteren-overleving-bij-hfref/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2022/07/14/guide-hf-en-de-impact-van-covid-19-op-hartfalenuitkomsten/","published":"2022-07-14"},{"url":"https://hartvaat.nl/2021/09/11/hemodynamisch-geleid-hf-management-lancet-guide-hf/","published":"2021-09-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anja-sandek","type":"person","url":"https://hartvaat.nl/mensen/anja-sandek/","name":"Anja Sandek","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/02/23/immunoadsorptie-bij-gedilateerde-cardiomyopathie-de-iaso-dcm-trial/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2026/02/03/kenmerken-van-asymptomatische-patienten-met-hartfalen-en-verminderde-ejectiefrac/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2021/12/01/baseline-parameters-en-1-jaars-qol-bij-hf-na-crt-d-esc-hf/","published":"2021-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anja-vogt","type":"person","url":"https://hartvaat.nl/mensen/anja-vogt/","name":"Anja Vogt","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/19/lipoproteine-aferese-blijft-relevant-in-het-tijdperk-van-pcsk9-remmers-en-sirna/","published":"2026-06-12"},{"url":"https://hartvaat.nl/2026/02/21/pelacarsen-vermindert-de-behoefte-aan-lipoproteine-a-aferese-lp-a-frontiers-aphe/","published":"2026-02-21"},{"url":"https://hartvaat.nl/2016/12/21/alirocumab-bij-heterozygoot-fh-met-lipoproteine-aferese-odyssey-escape/","published":"2016-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anjay-rastogi","type":"person","url":"https://hartvaat.nl/mensen/anjay-rastogi/","name":"Anjay Rastogi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/04/01/intensieve-versus-standaard-bloeddruk-op-cva-subtypes-sprint/","published":"2021-04-01"},{"url":"https://hartvaat.nl/2020/02/01/bloeddrukcontrole-en-diabetes-incidentie-sprint-resultaten/","published":"2020-02-01"},{"url":"https://hartvaat.nl/2016/03/01/voorschrijfpatronen-van-thiazidediuretica-in-de-sprint-trial/","published":"2016-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ann-e-kurth","type":"person","url":"https://hartvaat.nl/mensen/ann-e-kurth/","name":"Ann E Kurth","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","published":"2017-07-11"},{"url":"https://hartvaat.nl/2016/11/15/statines-voor-primaire-cardiovasculaire-preventie-uspstf-aanbeveling/","published":"2016-11-15"},{"url":"https://hartvaat.nl/2016/08/09/lipidescreening-bij-kinderen-en-adolescenten-uspstf-aanbeveling/","published":"2016-08-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anna-giczewska","type":"person","url":"https://hartvaat.nl/mensen/anna-giczewska/","name":"Anna Giczewska","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/03/15/leeftijd-en-uitkomsten-van-katheterablatie-versus-medicatie-bij-af-cabana/","published":"2022-03-15"},{"url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/03/17/klinische-en-farmacologische-effecten-van-apixaban-dosisaanpassing-aristotle/","published":"2020-03-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anna-marie-chang","type":"person","url":"https://hartvaat.nl/mensen/anna-marie-chang/","name":"Anna Marie Chang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/10/25/2022-acc-aha-datadefinities-voor-pijn-op-de-borst-en-acuut-myocardinfarct/","published":"2022-10-25"},{"url":"https://hartvaat.nl/2021/02/01/zelfzorginterventie-en-90-daags-uitkomsten-bij-acuut-hf-na-seh-ontslag-jama-card/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2017/11/28/ct-coronairangiografie-en-initiatie-van-cardioprotectieve-medicatie/","published":"2017-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anna-suling","type":"person","url":"https://hartvaat.nl/mensen/anna-suling/","name":"Anna Suling","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","published":"2022-04-05"},{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","published":"2022-03-21"},{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","published":"2020-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anna-maria-langkilde","type":"person","url":"https://hartvaat.nl/mensen/anna-maria-langkilde/","name":"Anna-Maria Langkilde","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2020/10/08/dapagliflozine-bij-chronische-nierziekte-nejm-dapa-ckd/","published":"2020-10-08"},{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","published":"2019-11-21"},{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","published":"2019-01-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"annabelle-frost","type":"person","url":"https://hartvaat.nl/mensen/annabelle-frost/","name":"Annabelle Frost","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/11/01/bloeddrukzelfmanagement-en-vasculaire-remodelling-na-hypertensieve-zwangerschap/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/02/13/pop-ht-bloeddrukzelfmanagement-verbetert-cardiale-remodelling-na-hypertensieve-z/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2023/11/28/pop-ht-zelfmanagement-van-bloeddruk-na-hypertensieve-zwangerschap-jama-rct/","published":"2023-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anne-cruickshank","type":"person","url":"https://hartvaat.nl/mensen/anne-cruickshank/","name":"Anne Cruickshank","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","published":"2022-07-01"},{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","published":"2018-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anne-tybjrg-hansen","type":"person","url":"https://hartvaat.nl/mensen/anne-tybjrg-hansen/","name":"Anne Tybjærg-Hansen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2019/09/17/ldl-cholesterol-en-micro-versus-macrovasculaire-ziekte-mendeliaanse-randomisatie/","published":"2019-09-17"},{"url":"https://hartvaat.nl/2017/07/20/genetische-en-farmacologische-inactivatie-van-angptl3-en-cardiovasculaire-ziekte/","published":"2017-07-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anne-laure-faucon","type":"person","url":"https://hartvaat.nl/mensen/anne-laure-faucon/","name":"Anne-Laure Faucon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/06/30/kfre-aangepast-voor-multimorbiditeit-verbetert-schatting-nierfalenrisico/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2026/02/27/albuminurie-geassocieerd-met-verhoogd-risico-op-abdominaal-aorta-aneurysma/","published":"2026-03-05"},{"url":"https://hartvaat.nl/2026/01/15/populatiegebaseerde-egfr-verdelingen-voor-vroege-identificatie-van-chronische-ni/","published":"2026-01-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"annette-peters","type":"person","url":"https://hartvaat.nl/mensen/annette-peters/","name":"Annette Peters","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2021/05/01/mcp-1-en-cardiovasculaire-mortaliteit-populatie-gebaseerde-meta-analyse/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2019/08/20/dna-methylering-in-leukocyten-voorspelt-mi-en-coronairlijden/","published":"2019-08-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anthony-a-killeen","type":"person","url":"https://hartvaat.nl/mensen/anthony-a-killeen/","name":"Anthony A Killeen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/09/01/troponine-nt-probnp-en-cognitieve-uitkomsten-in-sprint/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2022/10/18/intensieve-bloeddrukverlaging-bij-maligne-linkerventrikel-hypertrofie/","published":"2022-10-18"},{"url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","published":"2021-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antoine-da-costa","type":"person","url":"https://hartvaat.nl/mensen/antoine-da-costa/","name":"Antoine Da Costa","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/06/02/autonoom-remodelling-vormt-onafhankelijk-domein-binnen-atriale-cardiomyopathie/","published":"2026-08-11"},{"url":"https://hartvaat.nl/2024/11/19/afloat-flecainide-voorkomt-af-na-pfo-sluiting-rct/","published":"2024-11-19"},{"url":"https://hartvaat.nl/2023/05/30/complicaties-van-af-ablatie-actueel-overzicht/","published":"2023-05-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antonio-berruezo","type":"person","url":"https://hartvaat.nl/mensen/antonio-berruezo/","name":"Antonio Berruezo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/12/01/lawt-geleide-pvi-bij-persisterend-af-gepersonaliseerde-benadering/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/03/30/qdot-by-lawt-gepersonaliseerde-pvi-gestuurd-door-linkeratriale-wanddikte/","published":"2024-03-30"},{"url":"https://hartvaat.nl/2022/04/19/substraatablatie-versus-antiaritmica-bij-symptomatische-vt/","published":"2022-04-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antonio-de-mase","type":"person","url":"https://hartvaat.nl/mensen/antonio-de-mase/","name":"Antonio De Mase","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antonio-j-vallejo-vaz","type":"person","url":"https://hartvaat.nl/mensen/antonio-j-vallejo-vaz/","name":"Antonio J Vallejo-Vaz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","published":"2026-06-04"},{"url":"https://hartvaat.nl/2020/06/02/prevalentie-van-fh-bij-atherosclerotische-cv-ziekte-meta-analyse/","published":"2020-06-02"},{"url":"https://hartvaat.nl/2017/11/14/ldl-verlaging-voor-primaire-preventie-bij-mannen-met-primaire-ldl-verhoging/","published":"2017-11-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antonio-landi","type":"person","url":"https://hartvaat.nl/mensen/antonio-landi/","name":"Antonio Landi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","published":"2025-08-19"},{"url":"https://hartvaat.nl/2024/01/01/verkorte-dapt-bij-hoog-bloedingsrisico-geen-sekseverschillen/","published":"2024-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antonio-luiz-p-ribeiro","type":"person","url":"https://hartvaat.nl/mensen/antonio-luiz-p-ribeiro/","name":"Antonio Luiz P Ribeiro","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2022/09/01/collaterale-schade-van-covid-19-aan-cardiovasculaire-zorg-meta-analyse/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2019/01/01/implementatie-van-mi-zorgsystemen-in-lage-en-middeninkomenslanden/","published":"2019-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antonis-s-manolis","type":"person","url":"https://hartvaat.nl/mensen/antonis-s-manolis/","name":"Antonis S Manolis","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2019/04/01/pr-interval-en-pacingmodus-en-af-incidentie-bij-tweekamer-pacemaker/","published":"2019-04-01"},{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","published":"2016-11-01"},{"url":"https://hartvaat.nl/2016/10/07/2016-esc-richtlijn-voor-atriumfibrilleren-in-samenwerking-met-eacts/","published":"2016-10-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"antti-jula","type":"person","url":"https://hartvaat.nl/mensen/antti-jula/","name":"Antti Jula","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/09/01/strip-20-jaarsresultaten-van-dieetinterventie-vanaf-de-zuigelingenleeftijd/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2020/11/01/20-jaars-dieetinterventie-vanaf-zuigelingenleeftijd-en-bloeddruk-strip-studie/","published":"2020-11-01"},{"url":"https://hartvaat.nl/2017/08/01/cardiometabole-determinanten-van-carotis-en-aortadistensibiliteit-van-kindertijd/","published":"2017-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"anubha-agarwal","type":"person","url":"https://hartvaat.nl/mensen/anubha-agarwal/","name":"Anubha Agarwal","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","published":"2026-08-03"},{"url":"https://hartvaat.nl/2025/01/01/kwaliteit-van-hartfalenzorg-bij-aziatische-patienten-in-de-vs/","published":"2026-04-08"},{"url":"https://hartvaat.nl/2019/03/01/ziekenhuisgebaseerde-kwaliteitsinterventies-bij-hartfalen-systematische-review/","published":"2019-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"apostolos-tzikas","type":"person","url":"https://hartvaat.nl/mensen/apostolos-tzikas/","name":"Apostolos Tzikas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/04/01/symptomatisch-versus-asymptomatisch-af-en-klinische-uitkomsten-meta-analyse/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2024/01/14/residuele-lekkage-na-laa-occlusie-en-uitkomsten-meta-analyse/","published":"2024-01-14"},{"url":"https://hartvaat.nl/2017/01/01/percutane-linker-hartoorsluiting-munchen-consensusdocument-over-definities-en-ei/","published":"2017-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"arash-arya","type":"person","url":"https://hartvaat.nl/mensen/arash-arya/","name":"Arash Arya","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/02/16/p-golfduur-voorspelt-af-recidief-na-catheterablatie-meta-analyse/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2020/10/01/slokdarmsonde-bij-rf-ablatie-voor-af-opera-prospectieve-gerandomiseerde-trial/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2018/11/01/individueel-aangepaste-versus-gestandaardiseerde-substraatmodificatie-bij-rf-abl/","published":"2018-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"arnaldo-dimagli","type":"person","url":"https://hartvaat.nl/mensen/arnaldo-dimagli/","name":"Arnaldo Dimagli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","published":"2023-10-24"},{"url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","published":"2021-12-28"},{"url":"https://hartvaat.nl/2020/10/06/postoperatief-af-en-langetermijn-cva-risico-na-geisoleerde-cabg/","published":"2020-10-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"arnhild-bakken","type":"person","url":"https://hartvaat.nl/mensen/arnhild-bakken/","name":"Arnhild Bakken","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/25/betami-danblock-is-representatief-betablokker-effect-ook-geldig-in-echte-noorse-/","published":"2026-06-02"},{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","published":"2025-11-13"},{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","published":"2025-09-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"arturo-ausiello","type":"person","url":"https://hartvaat.nl/mensen/arturo-ausiello/","name":"Arturo Ausiello","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","published":"2018-09-08"},{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","published":"2018-03-20"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"arun-krishnamoorthy","type":"person","url":"https://hartvaat.nl/mensen/arun-krishnamoorthy/","name":"Arun Krishnamoorthy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","published":"2019-04-25"},{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","published":"2018-04-12"},{"url":"https://hartvaat.nl/2017/07/18/palliatieve-zorg-bij-hartfalen-de-pal-hf-gerandomiseerde-trial/","published":"2017-07-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aruna-d-pradhan","type":"person","url":"https://hartvaat.nl/mensen/aruna-d-pradhan/","name":"Aruna D Pradhan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/04/15/inflammatie-en-cholesterol-als-cv-voorspellers-onder-statinetherapie-lancet-anal/","published":"2023-04-15"},{"url":"https://hartvaat.nl/2020/05/05/triglyceriderijk-lipoproteinecholesterol-small-dense-ldl-en-cv-events/","published":"2020-05-05"},{"url":"https://hartvaat.nl/2018/07/10/residueel-inflammatoir-risico-bij-pcsk9-remming-plus-statine/","published":"2018-07-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"asbjrn-stylen","type":"person","url":"https://hartvaat.nl/mensen/asbjrn-stylen/","name":"Asbjørn Støylen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/04/01/inspanningstraining-en-hoog-sensitief-troponine-i-bij-hfref/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2022/06/01/vijf-jaar-inspanningstraining-verbetert-cardiovasculair-risicoprofiel-bij-oudere/","published":"2022-06-01"},{"url":"https://hartvaat.nl/2017/02/28/hoog-intensieve-intervaltraining-bij-hartfalen-met-verminderde-ejectiefractie/","published":"2017-02-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"asita-de-silva","type":"person","url":"https://hartvaat.nl/mensen/asita-de-silva/","name":"Asita de Silva","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/07/01/interact3-bundeled-care-bij-acute-intracerebrale-bloeding-lancet/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2023/06/01/lage-dosis-drievoudige-viervoudige-combinatiepil-versus-monotherapie-bij-hyperte/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2020/11/01/lage-dosis-triple-combinatie-en-therapeutische-inertie-bij-hypertensie-jama-card/","published":"2020-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"astin-lee","type":"person","url":"https://hartvaat.nl/mensen/astin-lee/","name":"Astin Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","published":"2022-08-23"},{"url":"https://hartvaat.nl/2021/11/09/colchicine-na-acs-2-jaars-cops-follow-up/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2020/11/17/colchicine-bij-acs-australische-cops-gerandomiseerde-trial/","published":"2020-11-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"atefeh-talebi","type":"person","url":"https://hartvaat.nl/mensen/atefeh-talebi/","name":"Atefeh Talebi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","published":"2025-01-21"},{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","published":"2024-09-21"},{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","published":"2024-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"atsushi-kobori","type":"person","url":"https://hartvaat.nl/mensen/atsushi-kobori/","name":"Atsushi Kobori","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/11/07/crrf-peaf-cryoballon-versus-rf-ablatie-bij-persisterend-af/","published":"2025-11-07"},{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","published":"2019-01-29"},{"url":"https://hartvaat.nl/2016/02/14/kortdurend-antiaritmica-na-katheterablatie-voor-atriumfibrilleren-east-af-trial/","published":"2016-02-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"aurelia-zauli","type":"person","url":"https://hartvaat.nl/mensen/aurelia-zauli/","name":"Aurelia Zauli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"axel-bauer","type":"person","url":"https://hartvaat.nl/mensen/axel-bauer/","name":"Axel Bauer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/08/03/cardiale-shockwave-therapie-bij-cabg-verbetert-myocardfunctie/","published":"2024-08-03"},{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","published":"2022-03-08"},{"url":"https://hartvaat.nl/2017/07/14/voorspelling-van-plotse-versus-niet-plotse-hartdood-na-mi-met-verminderde-lvef/","published":"2017-07-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"axel-schmid","type":"person","url":"https://hartvaat.nl/mensen/axel-schmid/","name":"Axel Schmid","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","published":"2023-11-07"},{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","published":"2020-05-02"},{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","published":"2017-11-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"azmil-h-abdul-rahim","type":"person","url":"https://hartvaat.nl/mensen/azmil-h-abdul-rahim/","name":"Azmil H Abdul-Rahim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/02/01/urinezuur-bloeddruk-en-cv-ziekte-mendeliaanse-randomisatie-en-meta-analyse/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2018/02/20/cva-risico-bij-verminderde-ef-na-mi-zonder-af/","published":"2018-02-20"},{"url":"https://hartvaat.nl/2017/03/07/cva-risico-bij-chronisch-hartfalen-met-behouden-ef-zonder-af-charm-analyse/","published":"2017-03-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"b-daan-westenbrink","type":"person","url":"https://hartvaat.nl/mensen/b-daan-westenbrink/","name":"B Daan Westenbrink","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/22/epicardiaal-vetweefsel-voorspelt-aritmieen-en-hartfalen-events-bij-genotype-posi/","published":"2026-06-06"},{"url":"https://hartvaat.nl/2026/03/03/spierstofwisseling-bij-hfpef-verminderde-oxidatieve-capaciteit-los-van-ijzergebr/","published":"2026-03-03"},{"url":"https://hartvaat.nl/2021/10/05/ketonlichamen-en-functionele-uitkomsten-na-stemi/","published":"2021-10-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"barbara-casolla","type":"person","url":"https://hartvaat.nl/mensen/barbara-casolla/","name":"Barbara Casolla","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"barbara-heude","type":"person","url":"https://hartvaat.nl/mensen/barbara-heude/","name":"Barbara Heude","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/27/genen-voor-bloeddruk-in-de-kindertijd-voorspellen-cardiometabool-risico-op-later/","published":"2026-05-09"},{"url":"https://hartvaat.nl/2023/04/21/cardiometabole-gezondheid-bij-kinderen-geboren-na-ivf/","published":"2023-04-21"},{"url":"https://hartvaat.nl/2019/05/07/zwangerschapsgewichtstoename-en-maternale-en-neonatale-uitkomsten-jama-meta-anal/","published":"2019-05-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"barbara-riegel","type":"person","url":"https://hartvaat.nl/mensen/barbara-riegel/","name":"Barbara Riegel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/08/01/motivational-interviewing-en-zorggebruik-en-mortaliteit-bij-hf-motivate-hf/","published":"2021-08-01"},{"url":"https://hartvaat.nl/2020/06/01/motivational-interviewing-bij-hartfalen-voor-zelfzorg-motivate-hf-gerandomiseerd/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2016/03/22/zelfmanagementinterventies-bij-hartfalen-individuele-patientdata-meta-analyse/","published":"2016-03-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"barbara-s-wiggins","type":"person","url":"https://hartvaat.nl/mensen/barbara-s-wiggins/","name":"Barbara S Wiggins","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/01/02/2023-af-richtlijn-op-een-blik-samenvatting/","published":"2024-01-02"},{"url":"https://hartvaat.nl/2020/08/04/2020-acc-bloedingsmanagement-bij-oac-expert-consensus-decision-pathway/","published":"2020-08-04"},{"url":"https://hartvaat.nl/2016/11/22/management-van-klinisch-significante-geneesmiddelinteracties-met-statines-aha-aa/","published":"2016-11-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"barry-bertolet","type":"person","url":"https://hartvaat.nl/mensen/barry-bertolet/","name":"Barry Bertolet","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/07/18/bioresorbeerbare-coronaire-scaffolds-vijfjaarsuitkomsten-met-verbeterde-techniek/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2018/10/27/absorb-iv-bioresorbeerbare-scaffold-30-daags-en-1-jaarsresultaten/","published":"2018-10-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"barry-i-freedman","type":"person","url":"https://hartvaat.nl/mensen/barry-i-freedman/","name":"Barry I Freedman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2020/12/01/intensieve-bloeddrukcontrole-en-alle-hospitalisaties-sprint/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2018/01/09/diastolische-bloeddruk-en-intensieve-bloeddrukcontrole-sprint-analyse/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2016/08/01/apol1-nierrisicovarianten-en-cerebrale-wittestoflaesies/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"barry-miller","type":"person","url":"https://hartvaat.nl/mensen/barry-miller/","name":"Barry Miller","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/12/cadence-sotatercept-verlaagt-pulmonale-vaatweerstand-bij-gecombineerde-pre-postc/","published":"2026-05-12"},{"url":"https://hartvaat.nl/2025/10/23/sotatercept-bij-pah-binnen-het-eerste-jaar-na-diagnose-stellar-subanalyse/","published":"2025-10-23"},{"url":"https://hartvaat.nl/2023/04/20/stellar-sotatercept-bij-pulmonale-arteriele-hypertensie-nejm-fase-3/","published":"2023-04-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bart-gerritse","type":"person","url":"https://hartvaat.nl/mensen/bart-gerritse/","name":"Bart Gerritse","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/09/30/adaptresponse-adaptieve-versus-conventionele-crt-bij-hartfalen-lancet/","published":"2023-09-30"},{"url":"https://hartvaat.nl/2020/10/01/sekseverschillen-in-kenmerken-en-qol-bij-crt-patienten/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2016/11/01/vochtstatustelemonitoring-bij-hartfalen-gerandomiseerde-trial/","published":"2016-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"beatrice-mariottoni","type":"person","url":"https://hartvaat.nl/mensen/beatrice-mariottoni/","name":"Beatrice Mariottoni","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","published":"2024-09-16"},{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","published":"2021-02-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bei-wang","type":"person","url":"https://hartvaat.nl/mensen/bei-wang/","name":"Bei Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/02/11/langetermijn-evolocumab-bij-ouderen-effectiviteit-en-veiligheid/","published":"2025-02-11"},{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","published":"2023-04-18"},{"url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","published":"2022-10-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"benjamin-blank","type":"person","url":"https://hartvaat.nl/mensen/benjamin-blank/","name":"Benjamin Blank","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","published":"2018-08-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"benjamin-deniau","type":"person","url":"https://hartvaat.nl/mensen/benjamin-deniau/","name":"Benjamin Deniau","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/03/16/natrium-hf-subanalyse-natriuretische-peptiden-lopen-achter-op-de-klinische-ontst/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","published":"2025-06-01"},{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","published":"2024-07-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"benjamin-honton","type":"person","url":"https://hartvaat.nl/mensen/benjamin-honton/","name":"Benjamin Honton","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-laagrisico-acuut-mi/","published":"2025-11-27"},{"url":"https://hartvaat.nl/2025/07/01/calcified-oct-versus-angiografie-bij-pci-van-verkalkte-laesies/","published":"2025-07-01"},{"url":"https://hartvaat.nl/2023/09/26/biodegradeerbare-versus-duurzame-polymeer-stents-bij-hoog-bloedingsrisico/","published":"2023-09-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"benjamin-landau","type":"person","url":"https://hartvaat.nl/mensen/benjamin-landau/","name":"Benjamin Landau","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"benjamin-neely","type":"person","url":"https://hartvaat.nl/mensen/benjamin-neely/","name":"Benjamin Neely","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2017/08/01/voorspelling-van-bloedingsrisico-tijdens-dapt-na-acs/","published":"2017-08-01"},{"url":"https://hartvaat.nl/2016/08/01/eerder-clopidogrelgebruik-en-uitkomsten-bij-conservatief-behandeld-acs/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","published":"2016-03-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bernadette-mazurek-melnyk","type":"person","url":"https://hartvaat.nl/mensen/bernadette-mazurek-melnyk/","name":"Bernadette Mazurek Melnyk","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","published":"2025-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bernard-charbonnel","type":"person","url":"https://hartvaat.nl/mensen/bernard-charbonnel/","name":"Bernard Charbonnel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/02/01/sglt2-remmers-en-cv-renale-uitkomsten-bij-diabetes-type-2-jama-cardiology-meta-a/","published":"2021-02-01"},{"url":"https://hartvaat.nl/2020/12/08/ertugliflozine-en-hf-events-bij-diabetes-met-atherosclerotische-cvd-vertis-cv/","published":"2020-12-08"},{"url":"https://hartvaat.nl/2020/10/08/ertugliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-vertis-cv/","published":"2020-10-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bernardo-antunes","type":"person","url":"https://hartvaat.nl/mensen/bernardo-antunes/","name":"Bernardo Antunes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bernhard-reimers","type":"person","url":"https://hartvaat.nl/mensen/bernhard-reimers/","name":"Bernhard Reimers","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/10/01/mitraclip-bij-secundaire-mitralisklepinsufficientie-meta-analyse-ischemisch-vs-n/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2020/05/09/p2y12-monotherapie-of-aspirine-voor-secundaire-preventie-lancet-meta-analyse/","published":"2020-05-09"},{"url":"https://hartvaat.nl/2018/03/01/doac-plus-antiplaatjestherapie-voor-secundaire-preventie-na-acs-meta-analyse/","published":"2018-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bert-andersson","type":"person","url":"https://hartvaat.nl/mensen/bert-andersson/","name":"Bert Andersson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","published":"2019-12-10"},{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","published":"2018-01-01"},{"url":"https://hartvaat.nl/2017/06/20/hartfrequentie-en-ritme-en-het-voordeel-van-betablokkers-bij-hartfalen/","published":"2017-06-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bert-ferdinande","type":"person","url":"https://hartvaat.nl/mensen/bert-ferdinande/","name":"Bert Ferdinande","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2023/09/26/biodegradeerbare-versus-duurzame-polymeer-stents-bij-hoog-bloedingsrisico/","published":"2023-09-26"},{"url":"https://hartvaat.nl/2020/08/18/optimale-bloeddruk-bij-shock-na-mi-en-hartstilstand/","published":"2020-08-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bert-jan-h-van-den-born","type":"person","url":"https://hartvaat.nl/mensen/bert-jan-h-van-den-born/","name":"Bert-Jan H van den Born","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/10/01/oraal-butyraat-verlaagt-bloeddruk-bij-hypertensie-rct/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2018/12/01/creatininestijging-tijdens-bloeddrukbehandeling-en-uitkomsten-bij-diabetes-type-/","published":"2018-12-01"},{"url":"https://hartvaat.nl/2017/12/05/j-curve-bij-gerandomiseerde-bloeddrukstreefwaarden-sprint-experimentele-analyse/","published":"2017-12-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bin-yang","type":"person","url":"https://hartvaat.nl/mensen/bin-yang/","name":"Bin Yang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/02/16/sluiting-van-het-linker-hartoor-versus-doac-s-na-longembolie/","published":"2026-02-16"},{"url":"https://hartvaat.nl/2025/04/26/angiografie-afgeleide-ffr-versus-ivus-bij-pci-gerandomiseerde-trial/","published":"2025-04-26"},{"url":"https://hartvaat.nl/2023/04/01/sglt2-remmers-raas-remmers-en-arni-vergeleken-bij-hartfalen-meta-analyse/","published":"2023-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bing-han","type":"person","url":"https://hartvaat.nl/mensen/bing-han/","name":"Bing Han","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/12/01/ice-versus-tee-bij-af-ablatie-gerandomiseerde-trial/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2024/11/12/rf-renale-denervatie-bij-ongecontroleerde-hypertensie-in-china-gerandomiseerde-t/","published":"2024-11-12"},{"url":"https://hartvaat.nl/2023/05/19/drie-substraatstrategieen-voor-persisterend-af-vergeleken-multicenter-rct/","published":"2023-05-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bjoern-goebel","type":"person","url":"https://hartvaat.nl/mensen/bjoern-goebel/","name":"Bjoern Goebel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"blanca-fuentes","type":"person","url":"https://hartvaat.nl/mensen/blanca-fuentes/","name":"Blanca Fuentes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bo-norrving","type":"person","url":"https://hartvaat.nl/mensen/bo-norrving/","name":"Bo Norrving","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/07/05/optimale-timing-van-anticoagulatie-na-ischemisch-cva-en-af-collaboratief-project/","published":"2025-07-05"},{"url":"https://hartvaat.nl/2025/03/15/doac-s-versus-geen-anticoagulatie-na-intracraniele-bloeding-bij-af-meta-analyse/","published":"2025-03-15"},{"url":"https://hartvaat.nl/2022/10/04/timing-vroege-versus-late-noac-start-na-ischemisch-cva-bij-af/","published":"2022-10-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bo-zhou","type":"person","url":"https://hartvaat.nl/mensen/bo-zhou/","name":"Bo Zhou","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2022/05/17/kosteneffectiviteit-van-zoutsubstitutie-ssass-analyse/","published":"2022-05-17"},{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","published":"2021-09-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"boaz-hirshberg","type":"person","url":"https://hartvaat.nl/mensen/boaz-hirshberg/","name":"Boaz Hirshberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/03/23/photon-aflibercept-8-mg-bij-diabetisch-macula-oedeem-verlengd-doseerinterval/","published":"2024-03-23"},{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2018/06/30/glp-1-glucagon-duale-agonist-bij-obesitas-met-diabetes-type-2-lancet-fase-2/","published":"2018-06-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bob-weijs","type":"person","url":"https://hartvaat.nl/mensen/bob-weijs/","name":"Bob Weijs","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/07/15/race-3-langetermijnresultaten-gerichte-behandeling-bij-vroeg-persisterend-af-en-/","published":"2022-07-15"},{"url":"https://hartvaat.nl/2021/09/08/antiaritmica-bij-vroeg-persisterend-af-met-hf-race-3/","published":"2021-09-08"},{"url":"https://hartvaat.nl/2019/04/01/upstream-therapie-verbetert-qol-bij-persisterend-af-arrest-af/","published":"2019-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bojan-vrtovec","type":"person","url":"https://hartvaat.nl/mensen/bojan-vrtovec/","name":"Bojan Vrtovec","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/12/01/science-ii-mesenchymale-stamcellen-bij-niet-ischemisch-hartfalen-negatieve-trial/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","published":"2022-09-20"},{"url":"https://hartvaat.nl/2019/02/01/herhaalde-levosimendan-infusies-bij-gevorderd-chronisch-hf-in-de-kwetsbare-postd/","published":"2019-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bongani-mayosi","type":"person","url":"https://hartvaat.nl/mensen/bongani-mayosi/","name":"Bongani Mayosi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/09/15/invictus-rivaroxaban-versus-warfarine-bij-reumatische-hartziekte-en-af/","published":"2022-09-15"},{"url":"https://hartvaat.nl/2019/06/20/vergelijking-van-duale-therapieen-voor-bloeddrukverlaging-bij-afrikaanse-afrikan/","published":"2019-06-20"},{"url":"https://hartvaat.nl/2018/06/09/dabigatran-bij-myocardschade-na-niet-cardiale-chirurgie-lancet-manage-trial/","published":"2018-06-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"borislav-dinov","type":"person","url":"https://hartvaat.nl/mensen/borislav-dinov/","name":"Borislav Dinov","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/02/16/p-golfduur-voorspelt-af-recidief-na-catheterablatie-meta-analyse/","published":"2023-02-16"},{"url":"https://hartvaat.nl/2020/10/01/slokdarmsonde-bij-rf-ablatie-voor-af-opera-prospectieve-gerandomiseerde-trial/","published":"2020-10-01"},{"url":"https://hartvaat.nl/2018/11/01/individueel-aangepaste-versus-gestandaardiseerde-substraatmodificatie-bij-rf-abl/","published":"2018-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brad-sutton","type":"person","url":"https://hartvaat.nl/mensen/brad-sutton/","name":"Brad Sutton","title":"Boston Scientific","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":0,"articles":[],"videos":[{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/market-watch-boston-scientific-laac-pfa/","title":"Market Watch: Boston Scientific over LAAC, PFA en het atriumfibrilleren-traject"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brad-wilson","type":"person","url":"https://hartvaat.nl/mensen/brad-wilson/","name":"Brad Wilson","title":"Boston Scientific","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":0,"articles":[],"videos":[{"url":"https://hartvaat.nl/video/acc26-late-breaking-science/market-watch-boston-scientific-laac-pfa/","title":"Market Watch: Boston Scientific over LAAC, PFA en het atriumfibrilleren-traject"}],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"braden-j-manns","type":"person","url":"https://hartvaat.nl/mensen/braden-j-manns/","name":"Braden J Manns","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/06/17/bedmed-timing-van-antihypertensieve-medicatie-en-cv-events-jama-definitieve-tria/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2023/05/16/afschaffen-eigen-bijdrage-medicatie-vermindert-cardiovasculair-risico-bij-oudere/","published":"2023-05-16"},{"url":"https://hartvaat.nl/2023/05/16/zelfmanagement-via-reclameprincipes-bij-ouderen-met-hoog-cv-risico/","published":"2023-05-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brage-h-amundsen","type":"person","url":"https://hartvaat.nl/mensen/brage-h-amundsen/","name":"Brage H Amundsen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2017/10/01/il-6-remming-en-coronaire-microvasculaire-en-endotheelfunctie-bij-myocardinfarct/","published":"2017-10-01"},{"url":"https://hartvaat.nl/2016/08/07/il-6-receptorantagonist-tocilizumab-bij-nstemi-effect-op-inflammatie-en-troponin/","published":"2016-08-07"},{"url":"https://hartvaat.nl/2016/02/02/aerobe-intervaltraining-vermindert-de-last-van-atriumfibrilleren-gerandomiseerde/","published":"2016-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brenda-r-hemmelgarn","type":"person","url":"https://hartvaat.nl/mensen/brenda-r-hemmelgarn/","name":"Brenda R Hemmelgarn","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/05/16/afschaffen-eigen-bijdrage-medicatie-vermindert-cardiovasculair-risico-bij-oudere/","published":"2023-05-16"},{"url":"https://hartvaat.nl/2023/05/16/zelfmanagement-via-reclameprincipes-bij-ouderen-met-hoog-cv-risico/","published":"2023-05-16"},{"url":"https://hartvaat.nl/2016/06/21/apothekerinterventies-en-cardiovasculair-risico-de-multicenter-rxeach-trial/","published":"2016-06-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brian-olshansky","type":"person","url":"https://hartvaat.nl/mensen/brian-olshansky/","name":"Brian Olshansky","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2020/07/28/langetermijn-icd-uitkomsten-scd-heft/","published":"2020-07-28"},{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","published":"2020-02-04"},{"url":"https://hartvaat.nl/2017/11/01/bloeddrukvariabiliteit-en-uitkomsten-bij-af-affirm-studie/","published":"2017-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"brian-r-ott","type":"person","url":"https://hartvaat.nl/mensen/brian-r-ott/","name":"Brian R Ott","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2020/05/12/cognitie-na-ldl-verlaging-met-evolocumab-fourier-follow-up/","published":"2020-05-12"},{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","published":"2017-10-28"},{"url":"https://hartvaat.nl/2017/08/17/cognitieve-functie-in-de-fourier-trial-met-evolocumab-nejm-ebbinghaus/","published":"2017-08-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bruce-ovbiagele","type":"person","url":"https://hartvaat.nl/mensen/bruce-ovbiagele/","name":"Bruce Ovbiagele","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","published":"2018-10-23"},{"url":"https://hartvaat.nl/2016/12/01/lacunes-in-hypertensierichtlijnen-in-lage-en-middeninkomenslanden-systematische-/","published":"2016-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"bruno-levy","type":"person","url":"https://hartvaat.nl/mensen/bruno-levy/","name":"Bruno Levy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/01/06/levoecmo-levosimendan-bij-ecmo-weaning-bij-cardiogene-shock/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2022/02/01/matige-hypothermie-versus-normothermie-bij-cardiogene-shock-met-va-ecmo-jama-hyp/","published":"2022-02-01"},{"url":"https://hartvaat.nl/2018/07/10/epinefrine-versus-norepinefrine-bij-cardiogene-shock-na-acuut-mi/","published":"2018-07-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c-david-sjostrom","type":"person","url":"https://hartvaat.nl/mensen/c-david-sjostrom/","name":"C David Sjöström","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/10/01/amethyst-verinurad-plus-allopurinol-bij-hfpef-negatieve-trial/","published":"2024-10-01"},{"url":"https://hartvaat.nl/2021/03/31/dapagliflozine-en-mortaliteit-bij-ckd-dapa-ckd-pre-gespecificeerde-analyse/","published":"2021-03-31"},{"url":"https://hartvaat.nl/2020/10/08/dapagliflozine-bij-chronische-nierziekte-nejm-dapa-ckd/","published":"2020-10-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c-m","type":"person","url":"https://hartvaat.nl/mensen/c-m/","name":"C. M.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/24/verminderde-nierfunctie-verhoogt-hartfalenrisico-bij-ouderen-aspree-cohort/","published":"2026-05-08"},{"url":"https://hartvaat.nl/2026/03/25/vrouwen-krijgen-een-type-a-aortadissectie-bij-een-kleinere-aortadiameter-door-hu/","published":"2026-03-25"},{"url":"https://hartvaat.nl/2026/03/10/machine-learning-voorspelt-30-daagse-sterfte-na-een-dotterbehandeling-australisc/","published":"2026-03-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"c-p","type":"person","url":"https://hartvaat.nl/mensen/c-p/","name":"C. P.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/17/niet-invasieve-endotypering-met-stress-mri-verbetert-de-behandeling-van-angina-z/","published":"2026-07-21"},{"url":"https://hartvaat.nl/2026/05/20/klinisch-en-genetisch-risico-op-atriumfibrilleren-versterken-elkaar-additief-13-/","published":"2026-07-06"},{"url":"https://hartvaat.nl/2026/04/24/crt-bij-volwassenen-met-systemische-rechterventrikel-gemengde-uitkomsten-in-inte/","published":"2026-05-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"caio-a-m-tavares","type":"person","url":"https://hartvaat.nl/mensen/caio-a-m-tavares/","name":"Caio A M Tavares","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/03/17/answer-hf-sacubitril-valsartan-versus-enalapril-bij-chagas-hf-primaire-resultate/","published":"2026-03-17"},{"url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","published":"2025-11-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"calvin-yeang","type":"person","url":"https://hartvaat.nl/mensen/calvin-yeang/","name":"Calvin Yeang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/03/22/pelacarsen-op-lp-a-cholesterol-en-gecorrigeerd-ldl-cholesterol/","published":"2022-03-22"},{"url":"https://hartvaat.nl/2021/09/21/pcsk9-remming-en-geoxideerde-fosfolipiden/","published":"2021-09-21"},{"url":"https://hartvaat.nl/2020/06/21/statinetherapie-verhoogt-lipoproteine-a-spiegels/","published":"2020-06-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"campbell","type":"person","url":"https://hartvaat.nl/mensen/campbell/","name":"Campbell","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/17/direct-naar-ct-coronairangiografie-bij-verdenking-angina-snellere-diagnose-en-mi/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/04/10/tweelingzwangerschap-bij-vrouwen-met-een-hartaandoening-geeft-een-hoog-risico-op/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/01/09/hartfalendiagnostiek-na-corona-bijna-niemand-kreeg-de-echo-binnen-de-aanbevolen-/","published":"2026-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"campbell-rogers","type":"person","url":"https://hartvaat.nl/mensen/campbell-rogers/","name":"Campbell Rogers","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/01/13/risicofactoren-en-plaquevolume-op-coronaire-ct-angiografie-lessen-uit-het-advanc/","published":"2026-01-13"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2022/02/01/ccta-afgeleide-ffr-prognostische-waarde-meta-analyse/","published":"2022-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"candace-k-mcclure","type":"person","url":"https://hartvaat.nl/mensen/candace-k-mcclure/","name":"Candace K McClure","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","published":"2024-03-05"},{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","published":"2023-02-28"},{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","published":"2021-06-26"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carl-d-langefeld","type":"person","url":"https://hartvaat.nl/mensen/carl-d-langefeld/","name":"Carl D Langefeld","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2020/12/01/intensieve-bloeddrukcontrole-en-alle-hospitalisaties-sprint/","published":"2020-12-01"},{"url":"https://hartvaat.nl/2016/11/08/onbehandelde-hypertensie-als-risicofactor-voor-lobaire-en-non-lobaire-hersenbloe/","published":"2016-11-08"},{"url":"https://hartvaat.nl/2016/08/01/apol1-nierrisicovarianten-en-cerebrale-wittestoflaesies/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carl-heneghan","type":"person","url":"https://hartvaat.nl/mensen/carl-heneghan/","name":"Carl Heneghan","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2020/05/26/antihypertensieve-medicatiereductie-versus-standaardzorg-bij-ouderen-jama-optimi/","published":"2020-05-26"},{"url":"https://hartvaat.nl/2018/09/01/thuis-versus-praktijkbloeddrukmeting-in-de-zwangerschap/","published":"2018-09-01"},{"url":"https://hartvaat.nl/2018/03/10/zelfgemeten-bloeddruk-met-of-zonder-telemonitoring-voor-medicatietitratie-lancet/","published":"2018-03-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carlo-di-mario","type":"person","url":"https://hartvaat.nl/mensen/carlo-di-mario/","name":"Carlo Di Mario","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/10/01/mitraclip-bij-secundaire-mitralisklepinsufficientie-meta-analyse-ischemisch-vs-n/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","published":"2019-09-01"},{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","published":"2017-05-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carlo-penzo","type":"person","url":"https://hartvaat.nl/mensen/carlo-penzo/","name":"Carlo Penzo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","published":"2020-11-24"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carlo-tumscitz","type":"person","url":"https://hartvaat.nl/mensen/carlo-tumscitz/","name":"Carlo Tumscitz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","published":"2023-09-07"},{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","published":"2019-11-05"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carlos-brotons","type":"person","url":"https://hartvaat.nl/mensen/carlos-brotons/","name":"Carlos Brotons","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2018/09/22/aspirine-voor-primaire-preventie-bij-matig-cv-risico-lancet-arrive/","published":"2018-09-22"},{"url":"https://hartvaat.nl/2016/08/01/2016-europese-richtlijnen-voor-cardiovasculaire-preventie-in-de-klinische-prakti/","published":"2016-08-01"},{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","published":"2016-01-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carlos-hervas","type":"person","url":"https://hartvaat.nl/mensen/carlos-hervas/","name":"Carlos Hervás","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","published":"2026-08-18"},{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","published":"2026-07-17"},{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","published":"2026-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carlos-j-rodriguez","type":"person","url":"https://hartvaat.nl/mensen/carlos-j-rodriguez/","name":"Carlos J Rodriguez","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","published":"2022-09-01"},{"url":"https://hartvaat.nl/2020/06/01/intensieve-bloeddrukverlaging-en-risico-op-af-sprint-analyse/","published":"2020-06-01"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carlos-macaya","type":"person","url":"https://hartvaat.nl/mensen/carlos-macaya/","name":"Carlos Macaya","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/03/31/amphilimus-versus-zotarolimus-stents-bij-diabetes-sugar-gerandomiseerde-trial/","published":"2022-03-31"},{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","published":"2017-07-04"},{"url":"https://hartvaat.nl/2017/01/15/linker-hartoorsluiting-versus-medicamenteuze-behandeling-bij-af-netwerkmeta-anal/","published":"2017-01-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carlos-tajer","type":"person","url":"https://hartvaat.nl/mensen/carlos-tajer/","name":"Carlos Tajer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","published":"2019-06-11"},{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","published":"2018-05-01"},{"url":"https://hartvaat.nl/2017/10/14/multifacet-interventie-voor-oac-gebruik-bij-af-lancet-impact-af/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carmelo-velardo","type":"person","url":"https://hartvaat.nl/mensen/carmelo-velardo/","name":"Carmelo Velardo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-bloeddrukcontrole-bij-risicozwangerschap-jama-bump-2/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2018/08/01/zelfmanagement-van-postnatale-hypertensie-de-snap-ht-trial/","published":"2018-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carmine-pizzi","type":"person","url":"https://hartvaat.nl/mensen/carmine-pizzi/","name":"Carmine Pizzi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/05/cmr-laci-21-identificeert-hoogrisicopatienten-met-hfref-onafhankelijk-van-lvef-e/","published":"2026-06-30"},{"url":"https://hartvaat.nl/2026/01/01/rivaroxaban-discontinueringspercentages-bij-niet-valvulair-af-in-de-italiaanse-p/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2025/03/13/minoca-pathologische-bevindingen-bij-invasieve-beoordeling-meta-analyse/","published":"2025-03-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carole-crawford","type":"person","url":"https://hartvaat.nl/mensen/carole-crawford/","name":"Carole Crawford","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-bloeddrukcontrole-bij-risicozwangerschap-jama-bump-2/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2018/09/01/thuis-versus-praktijkbloeddrukmeting-in-de-zwangerschap/","published":"2018-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"caroline-alsweiler","type":"person","url":"https://hartvaat.nl/mensen/caroline-alsweiler/","name":"Caroline Alsweiler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","published":"2024-12-03"},{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","published":"2024-09-24"},{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"caroline-kistorp","type":"person","url":"https://hartvaat.nl/mensen/caroline-kistorp/","name":"Caroline Kistorp","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/07/01/empagliflozine-en-lv-volumes-en-functie-bij-hfref-jama-cardiology/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2021/06/01/metabole-effecten-van-empagliflozine-bij-hf-empire-hf-metabolic-gerandomiseerde-/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2020/12/08/empagliflozine-en-hemodynamiek-bij-hfref/","published":"2020-12-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"carolyn-h-still","type":"person","url":"https://hartvaat.nl/mensen/carolyn-h-still/","name":"Carolyn H Still","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/01/01/werving-van-zwarte-mannen-met-beroerte-voor-een-gerandomiseerde-klinische-trial/","published":"2026-01-01"},{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"celine-gallagher","type":"person","url":"https://hartvaat.nl/mensen/celine-gallagher/","name":"Celine Gallagher","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2020/01/01/obesitas-opzettelijk-gewichtsverlies-en-hartfalen-meta-analyse/","published":"2020-01-01"},{"url":"https://hartvaat.nl/2019/12/01/geintegreerde-gespecialiseerde-af-poliklinieken-verlagen-totale-mortaliteit-post/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2017/12/01/geintegreerde-zorg-bij-atriumfibrilleren-systematische-review-en-meta-analyse/","published":"2017-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chan-joo-lee","type":"person","url":"https://hartvaat.nl/mensen/chan-joo-lee/","name":"Chan Joo Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/01/lage-dosis-tel-aml-chtd-combinatietablet-versus-standaard-tel-fase-iii/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/06/17/spironolacton-versus-amiloride-bij-resistente-hypertensie-gerandomiseerde-trial/","published":"2025-06-17"},{"url":"https://hartvaat.nl/2023/09/05/optimal-bp-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-jama/","published":"2023-09-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chang","type":"person","url":"https://hartvaat.nl/mensen/chang/","name":"Chang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/10/proteomics-onthult-vier-subgroepen-van-acuut-hfpef-met-eigen-biologische-routes-/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/05/26/acute-bloeddrukverhoging-tijdens-ziekenhuisopname-hoe-te-handelen-bij-asymptomat/","published":"2026-07-04"},{"url":"https://hartvaat.nl/2026/02/23/biologische-versus-mechanische-prothesen-bij-aortaklepvervanging-op-middelbare-l/","published":"2026-02-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chang-hua","type":"person","url":"https://hartvaat.nl/mensen/chang-hua/","name":"Chang Hua","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukverlaging-bij-ongediagnosticeerde-hfpef-met-hoog-risico/","published":"2025-12-01"},{"url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/06/13/frailteit-en-intensieve-bloeddrukcontrole-bij-diabetes/","published":"2025-06-13"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chang-wang","type":"person","url":"https://hartvaat.nl/mensen/chang-wang/","name":"Chang Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2024/09/01/multifactorieel-intensief-bloeddrukmodel-bij-ouderen-en-jongeren/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/03/18/intensieve-bloeddrukinterventie-door-niet-artsen-in-lage-inkomenslanden-lancet-r/","published":"2023-03-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chang-hwan-yoon","type":"person","url":"https://hartvaat.nl/mensen/chang-hwan-yoon/","name":"Chang-Hwan Yoon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","published":"2024-05-01"},{"url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","published":"2023-05-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chang-sheng-ma","type":"person","url":"https://hartvaat.nl/mensen/chang-sheng-ma/","name":"Chang-Sheng Ma","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/06/13/frailteit-en-intensieve-bloeddrukcontrole-bij-diabetes/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","published":"2025-01-02"},{"url":"https://hartvaat.nl/2024/11/12/recaticimab-als-toevoeging-aan-statines-fase-3-remain-2/","published":"2024-11-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chang-sheng-sheng","type":"person","url":"https://hartvaat.nl/mensen/chang-sheng-sheng/","name":"Chang-Sheng Sheng","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","published":"2023-09-01"},{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","published":"2022-05-01"},{"url":"https://hartvaat.nl/2020/11/10/chinese-kruidenformule-voor-gemaskeerde-hypertensie-gerandomiseerde-placebogecon/","published":"2020-11-10"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"charles-a-herzog","type":"person","url":"https://hartvaat.nl/mensen/charles-a-herzog/","name":"Charles A Herzog","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/01/01/dialysaat-kalium-3-0-mmol-l-met-natriumzirconiumcyclosilicaat-bij-dialyse/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","published":"2020-04-23"},{"url":"https://hartvaat.nl/2019/06/04/profylactische-icd-bij-dialysepatienten-ter-preventie-van-plotse-hartdood/","published":"2019-06-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"charles-delagardelle","type":"person","url":"https://hartvaat.nl/mensen/charles-delagardelle/","name":"Charles Delagardelle","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/04/01/inspanningstraining-en-hoog-sensitief-troponine-i-bij-hfref/","published":"2024-04-01"},{"url":"https://hartvaat.nl/2021/06/01/inspanningstraining-en-hs-troponine-t-bij-hfref/","published":"2021-06-01"},{"url":"https://hartvaat.nl/2017/02/28/hoog-intensieve-intervaltraining-bij-hartfalen-met-verminderde-ejectiefractie/","published":"2017-02-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"charles-mondo","type":"person","url":"https://hartvaat.nl/mensen/charles-mondo/","name":"Charles Mondo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","published":"2026-06-28"},{"url":"https://hartvaat.nl/2022/11/01/antihypertensieve-combinaties-bij-afrikaanse-patienten-creole-secundaire-analyse/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2019/06/20/vergelijking-van-duale-therapieen-voor-bloeddrukverlaging-bij-afrikaanse-afrikan/","published":"2019-06-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chengxing-shen","type":"person","url":"https://hartvaat.nl/mensen/chengxing-shen/","name":"Chengxing Shen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/02/05/driejaarsuitkomsten-van-linker-hartoorsluiting-met-of-zonder-ablatie-record-stud/","published":"2026-02-05"},{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","published":"2022-11-29"},{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","published":"2021-12-11"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cheryl-westlake","type":"person","url":"https://hartvaat.nl/mensen/cheryl-westlake/","name":"Cheryl Westlake","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","published":"2017-08-08"},{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","published":"2016-09-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chi-wang","type":"person","url":"https://hartvaat.nl/mensen/chi-wang/","name":"Chi Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","published":"2025-02-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chi-hang-lee","type":"person","url":"https://hartvaat.nl/mensen/chi-hang-lee/","name":"Chi-Hang Lee","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/07/09/cangrelor-en-infarctgrootte-bij-stemi-gerandomiseerde-trial/","published":"2024-07-09"},{"url":"https://hartvaat.nl/2024/05/07/mandibulaire-advancementsplint-versus-cpap-voor-bloeddrukverlaging-bij-osa/","published":"2024-05-07"},{"url":"https://hartvaat.nl/2021/07/01/remote-post-ontslag-behandeling-na-mi-door-paramedici-versus-standaardzorg-jama-/","published":"2021-07-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chinmay-patel","type":"person","url":"https://hartvaat.nl/mensen/chinmay-patel/","name":"Chinmay Patel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/04/03/laa-sluiting-na-af-ablatie-gerandomiseerde-trial-nejm/","published":"2025-04-03"},{"url":"https://hartvaat.nl/2024/02/01/pulmonaalvenenstenose-na-pfa-versus-thermale-ablatie-vergelijking/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/11/02/advent-pulsed-field-ablatie-non-inferieur-aan-thermale-ablatie-bij-af-nejm/","published":"2023-11-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chirag-d-jhaveri","type":"person","url":"https://hartvaat.nl/mensen/chirag-d-jhaveri/","name":"Chirag D Jhaveri","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/08/25/aflibercept-versus-bevacizumab-eerst-bij-diabetisch-macula-oedeem/","published":"2022-08-25"},{"url":"https://hartvaat.nl/2020/12/15/aflibercept-versus-vitrectomie-bij-diabetische-glasvochtbloeding-jama-drcr-net-p/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2019/05/21/aflibercept-versus-fotocoagulatie-versus-observatie-bij-diabetisch-maculaoedeem-/","published":"2019-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chris-hayward","type":"person","url":"https://hartvaat.nl/mensen/chris-hayward/","name":"Chris Hayward","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/08/25/risicogestuurde-af-screening-met-machine-learning-verhoogt-detectiegraad-find-af/","published":"2026-09-01"},{"url":"https://hartvaat.nl/2026/05/21/find-af-biomarker-stratificeert-prognose-bij-hfref-met-atriale-cardiomyopathie-z/","published":"2026-06-08"},{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","published":"2022-05-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chris-watson","type":"person","url":"https://hartvaat.nl/mensen/chris-watson/","name":"Chris Watson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/12/01/sglt2-remming-en-cardiale-reverse-remodelling-bij-hartfalen-systematische-review/","published":"2024-12-01"},{"url":"https://hartvaat.nl/2023/04/01/parable-sacubitril-valsartan-vermindert-linkeratriumvolume-bij-pre-hfpef/","published":"2023-04-01"},{"url":"https://hartvaat.nl/2019/06/01/klinische-predictieregels-voor-diagnostiek-van-chronisch-hartfalen-systematische/","published":"2019-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christersson","type":"person","url":"https://hartvaat.nl/mensen/christersson/","name":"Christersson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/17/langetermijnuitkomsten-na-de-ross-operatie-een-op-de-vier-krijgt-een-heroperatie/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/04/10/tweelingzwangerschap-bij-vrouwen-met-een-hartaandoening-geeft-een-hoog-risico-op/","published":"2026-07-22"},{"url":"https://hartvaat.nl/2026/01/29/verminderde-pompfunctie-na-een-hartinfarct-hoge-symptoomlast-en-slechtere-secund/","published":"2026-01-29"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-delles","type":"person","url":"https://hartvaat.nl/mensen/christian-delles/","name":"Christian Delles","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/11/28/pop-ht-zelfmanagement-van-bloeddruk-na-hypertensieve-zwangerschap-jama-rct/","published":"2023-11-28"},{"url":"https://hartvaat.nl/2018/11/27/metabolome-consequenties-van-pcsk9-remming-versus-statinetherapie/","published":"2018-11-27"},{"url":"https://hartvaat.nl/2017/11/21/sacubitril-valsartan-versus-olmesartan-en-cardiovasculaire-remodellering-bij-hyp/","published":"2017-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-erikstrup","type":"person","url":"https://hartvaat.nl/mensen/christian-erikstrup/","name":"Christian Erikstrup","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/06/13/griepvaccinatie-en-cardiovasculaire-bescherming-inflammatie-heroverwogen-bij-isc/","published":"2025-06-13"},{"url":"https://hartvaat.nl/2023/06/01/genetische-bijdrage-aan-aortastenose-dyslipidemie-inflammatie-en-verkalking/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/03/21/genetische-varianten-geassocieerd-met-syncope-neurale-en-autonome-processen/","published":"2023-03-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-gerdes","type":"person","url":"https://hartvaat.nl/mensen/christian-gerdes/","name":"Christian Gerdes","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/10/21/minimalisatie-van-atriale-pacing-bij-sinusknoopziekte-vermindert-af/","published":"2023-10-21"},{"url":"https://hartvaat.nl/2022/05/03/multimodaliteitsbeeldvorming-geleide-lv-leadplaatsing-bij-crt-langetermijn/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2019/09/01/elektrisch-versus-beeldvorming-geleide-lv-leadplaatsing-bij-crt-gerandomiseerde-/","published":"2019-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-heeger","type":"person","url":"https://hartvaat.nl/mensen/christian-heeger/","name":"Christian Heeger","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/14/ulysses-echogeleide-venapunctie-halveert-toegangscomplicaties-bij-af-ablatie/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2024/12/17/ablatiestrategie-bij-af-recidief-na-duurzame-pvi/","published":"2024-12-17"},{"url":"https://hartvaat.nl/2021/05/21/firm-ablatie-versus-pvi-bij-paroxysmaal-af-gerandomiseerde-resultaten/","published":"2021-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-hengstenberg","type":"person","url":"https://hartvaat.nl/mensen/christian-hengstenberg/","name":"Christian Hengstenberg","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/05/dapa-hd-eerste-gerandomiseerde-studie-naar-dapagliflozin-bij-hemodialyse-patient/","published":"2026-06-29"},{"url":"https://hartvaat.nl/2022/09/21/riociguat-bij-pulmonale-hypertensie-en-hfpef-haemodynamic-trial/","published":"2022-09-21"},{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","published":"2021-12-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-m-matter","type":"person","url":"https://hartvaat.nl/mensen/christian-m-matter/","name":"Christian M Matter","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","published":"2022-05-10"},{"url":"https://hartvaat.nl/2019/11/19/evolocumab-voor-vroege-ldl-verlaging-bij-acs-evopacs/","published":"2019-11-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-m-shaffer","type":"person","url":"https://hartvaat.nl/mensen/christian-m-shaffer/","name":"Christian M Shaffer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/06/01/genetische-bijdrage-aan-aortastenose-dyslipidemie-inflammatie-en-verkalking/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2019/02/01/genetische-schildklierfunctievoorspellers-en-af-jama-cardiology-mendeliaanse-ran/","published":"2019-02-01"},{"url":"https://hartvaat.nl/2018/10/23/lpa-varianten-en-residueel-cv-risico-bij-statinebehandelde-patienten/","published":"2018-10-23"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-templin","type":"person","url":"https://hartvaat.nl/mensen/christian-templin/","name":"Christian Templin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","published":"2023-10-12"},{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","published":"2022-11-08"},{"url":"https://hartvaat.nl/2017/11/07/stentontwerp-en-dapt-duur-effect-op-ischemie-en-bloedingen-netwerkmeta-analyse/","published":"2017-11-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-veltmann","type":"person","url":"https://hartvaat.nl/mensen/christian-veltmann/","name":"Christian Veltmann","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/20/stopstorm-stereotactische-bestraling-reduceert-refractaire-vt-met-80/","published":"2026-05-01"},{"url":"https://hartvaat.nl/2025/09/25/digitoxine-bij-hfref-gerandomiseerde-trial-nejm/","published":"2025-09-25"},{"url":"https://hartvaat.nl/2025/06/01/rv-disfunctie-voorspelt-langetermijnherstel-bij-de-novo-hfref-prolong-ii/","published":"2025-06-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-weber","type":"person","url":"https://hartvaat.nl/mensen/christian-weber/","name":"Christian Weber","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/03/05/microrna-s-in-de-celkern-sturen-hartmetabolisme-bij-hfpef/","published":"2026-04-03"},{"url":"https://hartvaat.nl/2026/03/06/metabool-cardiovasculair-risico-nieuwe-mechanismen-en-therapiekansen/","published":"2026-03-26"},{"url":"https://hartvaat.nl/2025/12/03/galectine-1-herprogrammeert-macrofagen-en-moduleert-t-celimmuniteit-bij-atherosc/","published":"2025-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christian-hendrik-heeger","type":"person","url":"https://hartvaat.nl/mensen/christian-hendrik-heeger/","name":"Christian-Hendrik Heeger","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/06/02/catheterablatie-bij-atriumfibrilleren-in-cardiale-amyloidose-levert-42-ritmievri/","published":"2026-08-11"},{"url":"https://hartvaat.nl/2025/10/31/pfa-versus-thermale-ablatie-periprocedurale-en-middellangetermijneffecten/","published":"2025-10-31"},{"url":"https://hartvaat.nl/2024/05/02/style-af-veneuze-closure-device-versus-figuur-van-acht-hechting-na-af-ablatie/","published":"2024-05-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christina-christersson","type":"person","url":"https://hartvaat.nl/mensen/christina-christersson/","name":"Christina Christersson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/11/volwassenen-met-aangeboren-hartafwijking-hebben-vergelijkbare-overleving-na-hart/","published":"2026-06-24"},{"url":"https://hartvaat.nl/2020/03/17/klinische-en-farmacologische-effecten-van-apixaban-dosisaanpassing-aristotle/","published":"2020-03-17"},{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","published":"2019-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christina-magnussen","type":"person","url":"https://hartvaat.nl/mensen/christina-magnussen/","name":"Christina Magnussen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","published":"2025-09-09"},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","published":"2024-06-03"},{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christoph-herrmann-lingen","type":"person","url":"https://hartvaat.nl/mensen/christoph-herrmann-lingen/","name":"Christoph Herrmann-Lingen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/02/03/kenmerken-van-asymptomatische-patienten-met-hartfalen-en-verminderde-ejectiefrac/","published":"2026-02-03"},{"url":"https://hartvaat.nl/2021/12/01/baseline-parameters-en-1-jaars-qol-bij-hf-na-crt-d-esc-hf/","published":"2021-12-01"},{"url":"https://hartvaat.nl/2018/02/01/hoeveelheid-of-intensiteit-van-inspanning-bij-hfpef/","published":"2018-02-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christoph-pauschinger","type":"person","url":"https://hartvaat.nl/mensen/christoph-pauschinger/","name":"Christoph Pauschinger","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christophe-dubois","type":"person","url":"https://hartvaat.nl/mensen/christophe-dubois/","name":"Christophe Dubois","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","published":"2025-01-30"},{"url":"https://hartvaat.nl/2018/08/01/inhalatie-stikstofoxide-bij-stemi-nomi-gerandomiseerde-trial/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/04/01/polymeervrije-biolimus-stent-bij-hoog-bloedingsrisico-met-acs-leaders-free-subst/","published":"2017-04-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christophe-pouillot","type":"person","url":"https://hartvaat.nl/mensen/christophe-pouillot/","name":"Christophe Pouillot","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/11/09/ffr-voor-behandeling-van-multivatencoronairlijden-jacc/","published":"2021-11-09"},{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","published":"2020-11-28"},{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","published":"2016-10-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christophe-tzourio","type":"person","url":"https://hartvaat.nl/mensen/christophe-tzourio/","name":"Christophe Tzourio","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/04/01/hypotensieve-episodes-op-24-uurs-abpm-en-cognitieve-functie-sprint-inzichten/","published":"2025-04-01"},{"url":"https://hartvaat.nl/2022/12/21/bloeddrukverlaging-en-dementiepreventie-ipd-meta-analyse/","published":"2022-12-21"},{"url":"https://hartvaat.nl/2021/11/01/bloeddrukvariabiliteit-en-dementie-cognitieve-stoornis-meta-analyse/","published":"2021-11-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-b-fordyce","type":"person","url":"https://hartvaat.nl/mensen/christopher-b-fordyce/","name":"Christopher B Fordyce","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","published":"2023-12-28"},{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","published":"2023-10-01"},{"url":"https://hartvaat.nl/2016/07/05/verslechterende-nierfunctie-en-uitkomsten-met-rivaroxaban-versus-warfarine-rocke/","published":"2016-07-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-levi","type":"person","url":"https://hartvaat.nl/mensen/christopher-levi/","name":"Christopher Levi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/11/01/pneumokokkenvaccinatie-en-cv-eventpreventie-ipd-meta-analyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","published":"2019-03-02"},{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","published":"2016-06-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-m-hearon","type":"person","url":"https://hartvaat.nl/mensen/christopher-m-hearon/","name":"Christopher M Hearon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/12/19/synchronisatie-van-voetstap-en-hartfase-bij-crt-patienten/","published":"2023-12-19"},{"url":"https://hartvaat.nl/2023/01/31/hfpef-inspanningsbeperking-niet-alleen-door-hemodynamiek/","published":"2023-01-31"},{"url":"https://hartvaat.nl/2021/09/21/1-jaar-inspanningstraining-keert-lv-stijfheid-om-bij-stadium-b-hf/","published":"2021-09-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-w-schneider","type":"person","url":"https://hartvaat.nl/mensen/christopher-w-schneider/","name":"Christopher W Schneider","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/07/02/pfa-versus-thermale-ablatie-bij-paroxysmaal-af-aritmielastanalyse/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2024/02/01/pulmonaalvenenstenose-na-pfa-versus-thermale-ablatie-vergelijking/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2023/11/02/advent-pulsed-field-ablatie-non-inferieur-aan-thermale-ablatie-bij-af-nejm/","published":"2023-11-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"christopher-x-wong","type":"person","url":"https://hartvaat.nl/mensen/christopher-x-wong/","name":"Christopher X Wong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/01/27/decaf-cafeinehoudende-koffie-en-af-gerandomiseerde-trial/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2024/10/21/dieet-en-af-risico-systematische-review/","published":"2024-10-21"},{"url":"https://hartvaat.nl/2017/12/01/geintegreerde-zorg-bij-atriumfibrilleren-systematische-review-en-meta-analyse/","published":"2017-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chul-soo-park","type":"person","url":"https://hartvaat.nl/mensen/chul-soo-park/","name":"Chul Soo Park","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","published":"2024-03-01"},{"url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","published":"2022-09-08"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chun-chin-chang","type":"person","url":"https://hartvaat.nl/mensen/chun-chin-chang/","name":"Chun Chin Chang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","published":"2019-10-22"},{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","published":"2019-08-14"},{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","published":"2019-03-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chung-shiuan-chen","type":"person","url":"https://hartvaat.nl/mensen/chung-shiuan-chen/","name":"Chung-Shiuan Chen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/03/18/intensieve-bloeddrukinterventie-door-niet-artsen-in-lage-inkomenslanden-lancet-r/","published":"2023-03-18"},{"url":"https://hartvaat.nl/2022/05/21/dorpsarts-geleide-multifacet-interventie-voor-bloeddrukcontrole-in-ruraal-china-/","published":"2022-05-21"},{"url":"https://hartvaat.nl/2017/09/19/community-health-worker-interventie-voor-bloeddrukcontrole-in-argentina-jama-tri/","published":"2017-09-19"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"chuning-shi","type":"person","url":"https://hartvaat.nl/mensen/chuning-shi/","name":"Chuning Shi","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","published":"2025-09-06"},{"url":"https://hartvaat.nl/2024/09/01/multifactorieel-intensief-bloeddrukmodel-bij-ouderen-en-jongeren/","published":"2024-09-01"},{"url":"https://hartvaat.nl/2023/03/18/intensieve-bloeddrukinterventie-door-niet-artsen-in-lage-inkomenslanden-lancet-r/","published":"2023-03-18"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"ciantel-a-blyler","type":"person","url":"https://hartvaat.nl/mensen/ciantel-a-blyler/","name":"Ciantel A Blyler","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","published":"2025-11-04"},{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","published":"2025-09-16"},{"url":"https://hartvaat.nl/2019/01/02/duurzaamheid-van-bloeddrukeffect-van-kapper-interventie/","published":"2019-01-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"claudia-raineri","type":"person","url":"https://hartvaat.nl/mensen/claudia-raineri/","name":"Claudia Raineri","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/05/cmr-laci-21-identificeert-hoogrisicopatienten-met-hfref-onafhankelijk-van-lvef-e/","published":"2026-06-30"},{"url":"https://hartvaat.nl/2026/05/25/pah-met-renaal-diabetische-overlap-komt-vaak-voor-en-geeft-tweemaal-zo-hoog-mort/","published":"2026-06-01"},{"url":"https://hartvaat.nl/2026/02/24/colchicine-bij-chronische-inflammatoire-cardiomyopathie-de-cmp-mythic-trial/","published":"2026-02-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"claudia-s-moy","type":"person","url":"https://hartvaat.nl/mensen/claudia-s-moy/","name":"Claudia S Moy","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","published":"2019-08-13"},{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","published":"2019-02-12"},{"url":"https://hartvaat.nl/2016/09/15/intensieve-bloeddrukverlaging-bij-acute-hersenbloeding-nejm-atach-2-trial/","published":"2016-09-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"claudia-stefanutti","type":"person","url":"https://hartvaat.nl/mensen/claudia-stefanutti/","name":"Claudia Stefanutti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/19/lipoproteine-aferese-blijft-relevant-in-het-tijdperk-van-pcsk9-remmers-en-sirna/","published":"2026-06-12"},{"url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","published":"2024-07-12"},{"url":"https://hartvaat.nl/2020/10/01/evolocumab-bij-pediatrische-heterozygoot-fh-nejm-hauser-rct/","published":"2020-10-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"claudia-torino","type":"person","url":"https://hartvaat.nl/mensen/claudia-torino/","name":"Claudia Torino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/29/cardiovasculaire-ziekte-blijft-leidend-na-niertransplantatie-overzicht-van-uitda/","published":"2026-07-28"},{"url":"https://hartvaat.nl/2026/01/21/patientgerapporteerde-uitkomsten-verbeteren-voorspelling-van-mortaliteit-bij-dia/","published":"2026-01-21"},{"url":"https://hartvaat.nl/2021/12/01/longechogeleide-behandeling-bij-hemodialysepatienten-met-hoog-cv-risico-gerandom/","published":"2021-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"claudio-gimpelewicz","type":"person","url":"https://hartvaat.nl/mensen/claudio-gimpelewicz/","name":"Claudio Gimpelewicz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/01/06/sacubitril-valsartan-versus-enalapril-bij-chagas-hartfalen/","published":"2026-01-06"},{"url":"https://hartvaat.nl/2019/12/01/hepatorenale-disfunctie-identificeert-hoogrisico-acuut-hf-relax-ahf/","published":"2019-12-01"},{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","published":"2019-08-22"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"claudio-laudani","type":"person","url":"https://hartvaat.nl/mensen/claudio-laudani/","name":"Claudio Laudani","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","published":"2026-06-16"},{"url":"https://hartvaat.nl/2025/11/18/cv-effecten-en-verdraagbaarheid-van-glp-1-agonisten-meta-analyse/","published":"2025-11-18"},{"url":"https://hartvaat.nl/2024/04/02/ivus-versus-oct-versus-angiografie-voor-pci-begeleiding-meta-analyse/","published":"2024-04-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"claudio-moretti","type":"person","url":"https://hartvaat.nl/mensen/claudio-moretti/","name":"Claudio Moretti","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2017/11/07/stentontwerp-en-dapt-duur-effect-op-ischemie-en-bloedingen-netwerkmeta-analyse/","published":"2017-11-07"},{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","published":"2017-04-07"},{"url":"https://hartvaat.nl/2016/12/21/statines-voor-primaire-preventie-bij-hiv-positieve-patienten-systematische-revie/","published":"2016-12-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"claudio-passino","type":"person","url":"https://hartvaat.nl/mensen/claudio-passino/","name":"Claudio Passino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2019/04/02/inspanningsrevalidatie-bij-hf-ipd-meta-analyse-van-inspanningscapaciteit-en-qol/","published":"2019-04-02"},{"url":"https://hartvaat.nl/2018/01/16/hoog-sensitief-troponine-t-bij-chronisch-hartfalen-individuele-patientdata-meta-/","published":"2018-01-16"},{"url":"https://hartvaat.nl/2017/09/12/centrale-apneus-gedurende-24-uur-en-prognose-bij-hartfalen/","published":"2017-09-12"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"claudius-jacobshagen","type":"person","url":"https://hartvaat.nl/mensen/claudius-jacobshagen/","name":"Claudius Jacobshagen","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","published":"2021-12-30"},{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","published":"2018-08-01"},{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","published":"2017-10-14"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"clive-rosendorff","type":"person","url":"https://hartvaat.nl/mensen/clive-rosendorff/","name":"Clive Rosendorff","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2018/06/01/intensieve-versus-standaard-bloeddruk-naar-tertielen-in-sprint/","published":"2018-06-01"},{"url":"https://hartvaat.nl/2018/01/09/diastolische-bloeddruk-en-intensieve-bloeddrukcontrole-sprint-analyse/","published":"2018-01-09"},{"url":"https://hartvaat.nl/2016/12/06/comorbiditeiten-bij-hartfalen-hypertensie-obesitas-diabetes-hyperlipidemie-en-me/","published":"2016-12-06"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"colby-ayers","type":"person","url":"https://hartvaat.nl/mensen/colby-ayers/","name":"Colby Ayers","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/05/01/mcp-1-en-cardiovasculaire-mortaliteit-populatie-gebaseerde-meta-analyse/","published":"2021-05-01"},{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","published":"2019-12-17"},{"url":"https://hartvaat.nl/2016/08/01/sedentair-gedrag-en-cardiovasculair-risico-continue-dosis-responsrelatie-in-meta/","published":"2016-08-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"colm-g-hanratty","type":"person","url":"https://hartvaat.nl/mensen/colm-g-hanratty/","name":"Colm G Hanratty","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/01/27/pci-van-natief-coronairvat-versus-veneuze-graft-na-eerdere-cabg-rct/","published":"2026-01-27"},{"url":"https://hartvaat.nl/2022/08/30/ripcord-2-routinematige-ffr-meting-versus-conventionele-angiografie/","published":"2022-08-30"},{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","published":"2016-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"conference-participants","type":"person","url":"https://hartvaat.nl/mensen/conference-participants/","name":"Conference Participants","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/03/06/kdigo-consensusconferentie-uitdagingen-bij-gecombineerd-hartfalen-en-nierziekte/","published":"2026-03-15"},{"url":"https://hartvaat.nl/2026/02/18/groene-dialyse-duurzame-zorg-groei-en-innovatie-kdigo-conferentie/","published":"2026-02-18"},{"url":"https://hartvaat.nl/2025/10/07/relatie-tussen-obesitas-en-ckd-conclusies-van-een-kdigo-conferentie/","published":"2025-10-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"connie-n-hess","type":"person","url":"https://hartvaat.nl/mensen/connie-n-hess/","name":"Connie N Hess","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/06/25/vasculair-zorgteam-versus-educatie-bij-perifeer-arterieel-vaatlijden/","published":"2024-06-25"},{"url":"https://hartvaat.nl/2023/12/12/voyager-pad-rivaroxaban-plus-aspirine-na-endovasculaire-revascularisatie-voor-pa/","published":"2023-12-12"},{"url":"https://hartvaat.nl/2021/02/16/2021-acc-consensus-same-day-ontslag-na-pci/","published":"2021-02-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"conrado-r-hoffmann-filho","type":"person","url":"https://hartvaat.nl/mensen/conrado-r-hoffmann-filho/","name":"Conrado R Hoffmann Filho","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/02/01/message-hf-geautomatiseerde-sms-na-hartfalenopname-verbetert-uitkomsten-niet/","published":"2024-02-01"},{"url":"https://hartvaat.nl/2022/11/01/vip-acs-dubbele-dosis-griepvaccinatie-na-acs-verbetert-uitkomsten-niet/","published":"2022-11-01"},{"url":"https://hartvaat.nl/2021/12/01/sms-strategie-bij-patienten-na-recente-hf-opname-studieontwerp/","published":"2021-12-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"corinne-v-evans","type":"person","url":"https://hartvaat.nl/mensen/corinne-v-evans/","name":"Corinne V Evans","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/07/18/uspstf-evidence-review-lipidescreening-bij-kinderen-geactualiseerd/","published":"2023-07-18"},{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-evidence-update-2021/","published":"2021-04-27"},{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-gezond-dieet-en-beweging-bij-cv-risico-jama-uspstf/","published":"2020-11-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"corrine-y-jurgens","type":"person","url":"https://hartvaat.nl/mensen/corrine-y-jurgens/","name":"Corrine Y Jurgens","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/09/17/2024-acc-aha-kwaliteitsmaatstaven-voor-hartfalen-geactualiseerd/","published":"2024-09-17"},{"url":"https://hartvaat.nl/2021/01/26/2020-acc-aha-kwaliteitsmaten-voor-af-geactualiseerd/","published":"2021-01-26"},{"url":"https://hartvaat.nl/2020/11/24/2020-acc-aha-prestatie-en-kwaliteitsmaten-voor-hartfalen/","published":"2020-11-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cosmo-godino","type":"person","url":"https://hartvaat.nl/mensen/cosmo-godino/","name":"Cosmo Godino","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/10/01/mitraclip-bij-secundaire-mitralisklepinsufficientie-meta-analyse-ischemisch-vs-n/","published":"2022-10-01"},{"url":"https://hartvaat.nl/2020/05/09/p2y12-monotherapie-of-aspirine-voor-secundaire-preventie-lancet-meta-analyse/","published":"2020-05-09"},{"url":"https://hartvaat.nl/2018/03/01/doac-plus-antiplaatjestherapie-voor-secundaire-preventie-na-acs-meta-analyse/","published":"2018-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"costas-thomopoulos","type":"person","url":"https://hartvaat.nl/mensen/costas-thomopoulos/","name":"Costas Thomopoulos","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/08/01/sympathische-overactiviteit-bij-resistente-hypertensie-meta-analyse/","published":"2025-08-01"},{"url":"https://hartvaat.nl/2025/07/14/hartfrequentieverlagende-middelen-en-uitkomsten-bij-hypertensie-cvd-meta-analyse/","published":"2025-07-14"},{"url":"https://hartvaat.nl/2024/05/01/bloeddrukstreefwaarden-en-residueel-risico-systematische-review-en-meta-regressi/","published":"2024-05-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"craig-h-selzman","type":"person","url":"https://hartvaat.nl/mensen/craig-h-selzman/","name":"Craig H Selzman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/03/01/aspirine-en-hemocompatibiliteit-na-lvad-bij-atherosclerotisch-vaatlijden/","published":"2025-03-01"},{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","published":"2019-03-26"},{"url":"https://hartvaat.nl/2017/03/21/plotse-hartdood-bij-ischemisch-hartfalen-na-cabg-stich-resultaten/","published":"2017-03-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cramer","type":"person","url":"https://hartvaat.nl/mensen/cramer/","name":"Cramer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/04/angina-toevoegen-aan-de-h2fpef-score-verbetert-hfpef-diagnose-bij-vrouwen-geen-w/","published":"2026-07-10"},{"url":"https://hartvaat.nl/2026/04/24/crt-bij-volwassenen-met-systemische-rechterventrikel-gemengde-uitkomsten-in-inte/","published":"2026-05-09"},{"url":"https://hartvaat.nl/2026/03/25/vier-klinische-fenotypes-bij-coronairlijden-met-sterk-verschillend-risico-op-nie/","published":"2026-03-25"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cristian-roman","type":"person","url":"https://hartvaat.nl/mensen/cristian-roman/","name":"Cristian Roman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/11/01/bloeddrukzelfmanagement-en-vasculaire-remodelling-na-hypertensieve-zwangerschap/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2024/02/13/pop-ht-bloeddrukzelfmanagement-verbetert-cardiale-remodelling-na-hypertensieve-z/","published":"2024-02-13"},{"url":"https://hartvaat.nl/2023/11/28/pop-ht-zelfmanagement-van-bloeddruk-na-hypertensieve-zwangerschap-jama-rct/","published":"2023-11-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"crystal-c-tyson","type":"person","url":"https://hartvaat.nl/mensen/crystal-c-tyson/","name":"Crystal C Tyson","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/02/01/digitale-interventie-voor-dash-dieet-en-bloeddrukverlaging-bij-vs-volwassenen/","published":"2025-02-01"},{"url":"https://hartvaat.nl/2019/03/01/ambulante-hartfrequentiereductie-na-renale-denervatie-bij-hypertensie-zonder-med/","published":"2019-03-01"},{"url":"https://hartvaat.nl/2018/10/09/24-uurs-ambulante-bloeddrukreductie-na-renale-denervatie-spyral-htn-off-med/","published":"2018-10-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cynthia-r-stockdale","type":"person","url":"https://hartvaat.nl/mensen/cynthia-r-stockdale/","name":"Cynthia R Stockdale","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/08/25/aflibercept-versus-bevacizumab-eerst-bij-diabetisch-macula-oedeem/","published":"2022-08-25"},{"url":"https://hartvaat.nl/2020/12/15/aflibercept-versus-vitrectomie-bij-diabetische-glasvochtbloeding-jama-drcr-net-p/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2019/05/21/aflibercept-versus-fotocoagulatie-versus-observatie-bij-diabetisch-maculaoedeem-/","published":"2019-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"cyril-jean-marie-martel","type":"person","url":"https://hartvaat.nl/mensen/cyril-jean-marie-martel/","name":"Cyril Jean-Marie Martel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/10/28/rsv-vaccin-vermindert-cv-hospitalisaties-bij-ouderen/","published":"2025-10-28"},{"url":"https://hartvaat.nl/2025/01/01/nudge-flu-subanalyse-griepvaccinatie-nudges-bij-mi-langetermijn/","published":"2025-01-01"},{"url":"https://hartvaat.nl/2024/05/27/nudge-flu-elektronische-nudges-verhogen-griepvaccinatie-na-mi/","published":"2024-05-27"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d-s","type":"person","url":"https://hartvaat.nl/mensen/d-s/","name":"D. S.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/24/crt-bij-volwassenen-met-systemische-rechterventrikel-gemengde-uitkomsten-in-inte/","published":"2026-05-09"},{"url":"https://hartvaat.nl/2026/02/25/langetermijnincidentie-van-atriumfibrilleren-en-het-risico-op-beroerte-20-jaar-f/","published":"2026-02-25"},{"url":"https://hartvaat.nl/2026/01/09/endocarditis-van-de-natieve-klep-verschuift-naar-ouderen-chirurgie-blijft-levens/","published":"2026-01-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"d-t","type":"person","url":"https://hartvaat.nl/mensen/d-t/","name":"D. T.","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/05/20/hypochloremie-bij-opname-voor-acuut-hartfalen-voorspelt-onafhankelijk-30-daagse-/","published":"2026-07-06"},{"url":"https://hartvaat.nl/2026/03/10/machine-learning-voorspelt-30-daagse-sterfte-na-een-dotterbehandeling-australisc/","published":"2026-03-10"},{"url":"https://hartvaat.nl/2026/03/02/is-depressie-een-onafhankelijke-risicofactor-voor-sterfte-bij-hart-en-vaatziekte/","published":"2026-03-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daehoon-kim","type":"person","url":"https://hartvaat.nl/mensen/daehoon-kim/","name":"Daehoon Kim","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","published":"2026-02-12"},{"url":"https://hartvaat.nl/2025/10/14/alone-af-langetermijn-anticoagulatieonthouding-na-af-ablatie-rct/","published":"2025-10-14"},{"url":"https://hartvaat.nl/2024/12/03/ct-gestuurde-atriale-wanddiktemapping-bij-cryoballon-pvi/","published":"2024-12-03"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dagmar-m-ouweneel","type":"person","url":"https://hartvaat.nl/mensen/dagmar-m-ouweneel/","name":"Dagmar M Ouweneel","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2017/12/14/mechanische-ondersteuning-bij-cardiogene-shock-systematische-review-en-meta-anal/","published":"2017-12-14"},{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-ondersteuning-versus-iabp-bij-cardiogene-shock-meta-analys/","published":"2017-01-24"},{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-circulatoire-ondersteuning-versus-iabp-bij-cardiogene-shoc/","published":"2017-01-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dalibor-herman","type":"person","url":"https://hartvaat.nl/mensen/dalibor-herman/","name":"Dalibor Herman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/07/08/catheterablatie-versus-leefstijlmodificatie-plus-antiaritmica-bij-af-gerandomise/","published":"2025-07-08"},{"url":"https://hartvaat.nl/2022/01/04/4-jaars-laa-sluiting-versus-niet-warfarine-oac-bij-af/","published":"2022-01-04"},{"url":"https://hartvaat.nl/2020/06/30/laa-sluiting-versus-doac-bij-hoogrisico-af-vergelijkende-analyse/","published":"2020-06-30"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dan-bloomfield","type":"person","url":"https://hartvaat.nl/mensen/dan-bloomfield/","name":"Dan Bloomfield","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","published":"2026-03-01"},{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","published":"2025-11-01"},{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","published":"2025-08-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dan-r-berlowitz","type":"person","url":"https://hartvaat.nl/mensen/dan-r-berlowitz/","name":"Dan R Berlowitz","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/07/01/leeftijdsbias-draagt-bij-aan-therapeutische-inertie-bij-bloeddrukmanagement/","published":"2023-07-01"},{"url":"https://hartvaat.nl/2017/08/24/intensieve-bloeddrukbehandeling-en-patientgerapporteerde-uitkomsten-nejm-sprint-/","published":"2017-08-24"},{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","published":"2016-06-28"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dana-dabelea","type":"person","url":"https://hartvaat.nl/mensen/dana-dabelea/","name":"Dana Dabelea","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/05/31/langetermijneffect-van-metformine-en-leefstijlinterventie-op-cardiovasculaire-ev/","published":"2022-05-31"},{"url":"https://hartvaat.nl/2019/08/01/hypertensieve-zwangerschapsaandoeningen-en-dna-methylering-bij-pasgeborenen/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2017/07/04/langetermijn-metformine-en-leefstijl-en-coronair-calcium-diabetes-prevention-pro/","published":"2017-07-04"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-benjamin-fyenbo","type":"person","url":"https://hartvaat.nl/mensen/daniel-benjamin-fyenbo/","name":"Daniel Benjamin Fyenbo","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/08/02/gerichte-lv-leadplaatsing-bij-crt-meta-analyse-van-beeldvorming-en-elektrisch-ge/","published":"2023-08-02"},{"url":"https://hartvaat.nl/2022/05/03/multimodaliteitsbeeldvorming-geleide-lv-leadplaatsing-bij-crt-langetermijn/","published":"2022-05-03"},{"url":"https://hartvaat.nl/2019/09/01/elektrisch-versus-beeldvorming-geleide-lv-leadplaatsing-bij-crt-gerandomiseerde-/","published":"2019-09-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-duerschmied","type":"person","url":"https://hartvaat.nl/mensen/daniel-duerschmied/","name":"Daniel Duerschmied","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","published":"2024-10-14"},{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","published":"2024-06-04"},{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","published":"2023-10-05"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-e-jonas","type":"person","url":"https://hartvaat.nl/mensen/daniel-e-jonas/","name":"Daniel E Jonas","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-geactualiseerde-evidence-report-2022/","published":"2022-01-25"},{"url":"https://hartvaat.nl/2021/07/27/heeft-deze-volwassene-hypertensie-jama-rational-clinical-examination/","published":"2021-07-27"},{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-evidence-report-en-systematische-review/","published":"2018-08-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-f-martin","type":"person","url":"https://hartvaat.nl/mensen/daniel-f-martin/","name":"Daniel F Martin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/08/25/aflibercept-versus-bevacizumab-eerst-bij-diabetisch-macula-oedeem/","published":"2022-08-25"},{"url":"https://hartvaat.nl/2020/12/15/aflibercept-versus-vitrectomie-bij-diabetische-glasvochtbloeding-jama-drcr-net-p/","published":"2020-12-15"},{"url":"https://hartvaat.nl/2019/05/21/aflibercept-versus-fotocoagulatie-versus-observatie-bij-diabetisch-maculaoedeem-/","published":"2019-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-gras","type":"person","url":"https://hartvaat.nl/mensen/daniel-gras/","name":"Daniel Gras","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2018/03/27/crt-bij-hartfalen-met-smal-qrs-complex/","published":"2018-03-27"},{"url":"https://hartvaat.nl/2017/03/07/lv-global-longitudinal-strain-en-prognose-bij-hartfalen-met-smal-qrs-en-crt/","published":"2017-03-07"},{"url":"https://hartvaat.nl/2016/01/01/persisterende-echocardiografische-dyssynchronie-voorspelt-ongunstige-uitkomsten-/","published":"2016-01-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-h-solomon","type":"person","url":"https://hartvaat.nl/mensen/daniel-h-solomon/","name":"Daniel H Solomon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/02/20/biomarkers-voor-atherosclerotische-events-bij-reumatoide-artritis-lp-a-als-voors/","published":"2026-02-20"},{"url":"https://hartvaat.nl/2019/02/21/laaggedoseerd-methotrexaat-voor-preventie-van-atherosclerotische-events-nejm-cir/","published":"2019-02-21"},{"url":"https://hartvaat.nl/2017/11/21/bloeddrukeffecten-van-ibuprofen-naproxen-en-celecoxib-bij-artritis-precision-abp/","published":"2017-11-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-kalbacher","type":"person","url":"https://hartvaat.nl/mensen/daniel-kalbacher/","name":"Daniel Kalbacher","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","published":"2026-07-14"},{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","published":"2026-06-27"},{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","published":"2026-05-07"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-keene","type":"person","url":"https://hartvaat.nl/mensen/daniel-keene/","name":"Daniel Keene","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/05/19/geleidingssysteempacing-in-europa-inzichten-uit-klinische-praktijk/","published":"2023-05-19"},{"url":"https://hartvaat.nl/2023/03/30/upgrade-van-rv-pacemaker-naar-crt-of-geleidingssysteempacing-meta-analyse/","published":"2023-03-30"},{"url":"https://hartvaat.nl/2023/02/16/catheterablatie-verbetert-cv-uitkomsten-bij-af-en-hartfalen-meta-analyse-van-rct/","published":"2023-02-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-l-lustgarten","type":"person","url":"https://hartvaat.nl/mensen/daniel-l-lustgarten/","name":"Daniel L Lustgarten","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/10/01/gepersonaliseerde-versnelde-pacing-bij-hfpef-klinische-uitkomsten/","published":"2025-10-01"},{"url":"https://hartvaat.nl/2023/03/01/gepersonaliseerde-versnelde-pacing-bij-hfpef-met-pacemaker/","published":"2023-03-01"},{"url":"https://hartvaat.nl/2016/05/17/institutionele-en-operateurvereisten-voor-linker-hartoorocclusie-scai-acc-hrs-st/","published":"2016-05-17"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-p-morin","type":"person","url":"https://hartvaat.nl/mensen/daniel-p-morin/","name":"Daniel P Morin","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/07/01/dubbele-versus-enkele-cardioversie-bij-af-en-obesitas-jama-cardiology-rct/","published":"2024-07-01"},{"url":"https://hartvaat.nl/2018/09/27/draagbare-cardioverter-defibrillator-na-myocardinfarct-nejm-vest/","published":"2018-09-27"},{"url":"https://hartvaat.nl/2016/03/15/voorspelling-van-persisterende-lv-disfunctie-na-myocardinfarct-de-predicts-studi/","published":"2016-03-15"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniel-zimpfer","type":"person","url":"https://hartvaat.nl/mensen/daniel-zimpfer/","name":"Daniel Zimpfer","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/06/13/ml-modellen-voorspellen-sterfte-bij-post-cardiotomisch-shock-op-ecmo-elso-regist/","published":"2026-08-10"},{"url":"https://hartvaat.nl/2026/02/23/aspirinestop-bij-lvad-met-vka-veiligheidsanalyse/","published":"2026-02-23"},{"url":"https://hartvaat.nl/2025/03/01/aspirine-en-hemocompatibiliteit-na-lvad-bij-atherosclerotisch-vaatlijden/","published":"2025-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daniele-giacopelli","type":"person","url":"https://hartvaat.nl/mensen/daniele-giacopelli/","name":"Daniele Giacopelli","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2024/07/02/closed-loop-stimulatie-vermindert-ahre-s-versus-conventionele-rate-adaptieve-pac/","published":"2024-07-02"},{"url":"https://hartvaat.nl/2022/06/21/timing-van-vt-ablatie-bij-icd-patienten-partita-trial/","published":"2022-06-21"},{"url":"https://hartvaat.nl/2022/02/02/thuismonitoring-temporele-trends-en-baseline-risico-voor-hf-voorspelling-bij-icd/","published":"2022-02-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dao-wen-wang","type":"person","url":"https://hartvaat.nl/mensen/dao-wen-wang/","name":"Dao Wen Wang","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2025/01/01/varenicline-vermindert-ventriculaire-ectopie-na-myocardinfarct/","published":"2026-03-16"},{"url":"https://hartvaat.nl/2023/03/18/intensieve-bloeddrukinterventie-door-niet-artsen-in-lage-inkomenslanden-lancet-r/","published":"2023-03-18"},{"url":"https://hartvaat.nl/2022/05/21/dorpsarts-geleide-multifacet-interventie-voor-bloeddrukcontrole-in-ruraal-china-/","published":"2022-05-21"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"daoquan-peng","type":"person","url":"https://hartvaat.nl/mensen/daoquan-peng/","name":"Daoquan Peng","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/06/26/inclisiran-als-monotherapie-verlaagt-ldl-c-met-47-5-in-chinese-volwassenen-victo/","published":"2026-08-09"},{"url":"https://hartvaat.nl/2026/05/25/explorer-cn-week-78-langetermijneffect-en-veiligheid-van-mavacamten-bij-chinese-/","published":"2026-06-03"},{"url":"https://hartvaat.nl/2025/05/20/angptl3-antilichaam-bij-suboptimaal-gecontroleerde-hyperlipidemie-fase-2/","published":"2025-05-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"darlington-o-okonko","type":"person","url":"https://hartvaat.nl/mensen/darlington-o-okonko/","name":"Darlington O Okonko","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2019/08/01/ijzercarboxymaltose-en-plasmavolumestatus-bij-hf-fair-hf-substudie/","published":"2019-08-01"},{"url":"https://hartvaat.nl/2019/05/21/ijzerisomaltosides-en-skeletspierdenergie-bij-chronisch-hf-met-ijzerdeficientie/","published":"2019-05-21"},{"url":"https://hartvaat.nl/2018/03/01/medicamenteuze-behandeling-en-uitkomsten-bij-hfpef-systematische-review-en-meta-/","published":"2018-03-01"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"darryl-p-leong","type":"person","url":"https://hartvaat.nl/mensen/darryl-p-leong/","name":"Darryl P Leong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","published":"2023-10-05"},{"url":"https://hartvaat.nl/2021/07/01/cv-gevolgen-van-stoppen-met-laaggedoseerd-rivaroxaban-bij-chronisch-vaatlijden/","published":"2021-07-01"},{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","published":"2018-01-20"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"dave-l-dixon","type":"person","url":"https://hartvaat.nl/mensen/dave-l-dixon/","name":"Dave L Dixon","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2023/05/09/2023-acc-expert-consensus-management-van-hfpef/","published":"2023-05-09"},{"url":"https://hartvaat.nl/2021/09/01/arts-apotheker-samenwerkingsmodel-en-time-in-target-bloeddruk-post-hoc-analyse/","published":"2021-09-01"},{"url":"https://hartvaat.nl/2021/03/16/systolische-bloeddruk-time-in-target-en-cv-uitkomsten-bij-hypertensie/","published":"2021-03-16"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-a-garcia","type":"person","url":"https://hartvaat.nl/mensen/david-a-garcia/","name":"David A Garcia","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2022/12/06/apixaban-bij-af-op-hemodialyse-eerste-gerandomiseerde-trial/","published":"2022-12-06"},{"url":"https://hartvaat.nl/2020/01/07/nsaid-s-en-oac-bij-af-aristotle-analyse/","published":"2020-01-07"},{"url":"https://hartvaat.nl/2018/10/02/periprocedurele-uitkomsten-van-doac-versus-warfarine-bij-niet-valvulair-af/","published":"2018-10-02"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-a-hess","type":"person","url":"https://hartvaat.nl/mensen/david-a-hess/","name":"David A Hess","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2026/03/09/semaglutide-stimuleert-anti-inflammatoire-stamcelflux-vanuit-beenmerg/","published":"2026-03-09"},{"url":"https://hartvaat.nl/2023/06/01/igfbp7-en-lv-massaregressie-met-empagliflozine-empa-heart-subanalyse/","published":"2023-06-01"},{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","published":"2023-01-24"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-c-grossman","type":"person","url":"https://hartvaat.nl/mensen/david-c-grossman/","name":"David C Grossman","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","published":"2017-07-11"},{"url":"https://hartvaat.nl/2016/11/15/statines-voor-primaire-cardiovasculaire-preventie-uspstf-aanbeveling/","published":"2016-11-15"},{"url":"https://hartvaat.nl/2016/08/09/lipidescreening-bij-kinderen-en-adolescenten-uspstf-aanbeveling/","published":"2016-08-09"}],"videos":[],"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies."},{"id":"david-c-tong","type":"person","url":"https://hartvaat.nl/mensen/david-c-tong/","name":"David C Tong","title":"","dutch_institution":false,"orcid":"","scholar":"","website":"","article_count":3,"articles":[{"url":"https://hartvaat.nl/2021/11/09/colchicine-na-acs-2-jaars-cops-follow-up/","published":"2021-11-09"},{"url":"h